

[illegible]

extraterritorial application of the PRC securities laws. On November 14, 2021, the Cyberspace Administration of China (the “CAC”) published the Security Administration Draft, which provides that data processing operators engaging in data processing activities that affect or may affect national security must be subject to network data security review by the relevant Cyberspace Administration of the PRC. According to the Security Administration Draft, data processing operators who possess personal data of at least one million users or collect data that affects or may affect national security must be subject to network data security review by the relevant Cyberspace Administration of the PRC. The deadline for public comments on the Security Administration Draft was December 13, 2021. The Security Administration Draft has not been fully implemented as of the date of this annual report. Á On December 28, 2021, the CAC, together with 12 other governmental departments of the PRC, jointly promulgated the Cybersecurity Review Measures, which became effective on February 15, 2022. The Cybersecurity Review Measures require that an online platform operator which possesses the personal information of at least one million users must apply for a cybersecurity review by the CAC if it intends to be listed in foreign countries. As confirmed by our PRC counsel, Hebei Changjun Law Firm since we are not an online platform operator that possesses over one million users’ personal information, we are not subject to the cybersecurity review with the CAC under the Cybersecurity Review Measures, and for the same reason, we will not be subject to the network data security review by the CAC if the Draft Regulations on the Network Data Security Administration (Draft for Comments) are enacted as proposed. There remains uncertainty, however, as to how the Cybersecurity Review Measures will be interpreted or implemented and whether the PRC regulatory agencies, including the CAC, may adopt new laws, regulations, rules, or detailed implementation and interpretation related to the Cybersecurity Review Measures. For further details, see ‘Item 3. Key Information’ “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “We may become subject to a variety of laws and regulations in the PRC regarding privacy, data security, cybersecurity, and data protection.” Á In addition, since 2021, the Chinese government has strengthened its anti-monopoly supervision, mainly in three aspects: (1) establishing the National Anti-Monopoly Bureau; (2) revising and promulgating anti-monopoly laws and regulations, including: the Anti-Monopoly Law (draft Amendment published on October 23, 2021 for public opinion; the newly revised Anti-Monopoly Law was promulgated on June 24, 2022, and became effective on August 1, 2022), the anti-monopoly guidelines for various industries, and the detailed Rules for the Implementation of the Fair Competition Review System; and (3) expanding the anti-monopoly law enforcement targeting Internet companies and large enterprises. As of the date of this annual report, the Chinese government’s recent statements and regulatory actions related to anti-monopoly concerns have not impacted our ability to conduct business, accept foreign investments, or list on a U.S. or other foreign exchange, because neither the Company nor its PRC operating entities engage in monopolistic behaviors that are subject to these statements or regulatory actions. Á Á Á On February 17, 2023, the China Securities Regulatory Commission (the “CSRC”) released the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, or the Overseas Listing Trial Measures, and five supporting guidelines, which came into effect on March 31, 2023. The Overseas Listing Trial Measures regulate both direct and indirect overseas offering and listing by PRC domestic companies by adopting a filing-based regulatory regime. Pursuant to the Overseas Listing Trial Measures, domestic companies that seek to offer or list securities overseas, whether directly or indirectly, should fulfill the filing procedures and report relevant information to the CSRC within three working days after submitting listing applications and subsequent amendments. According to the Notice on the Administrative Arrangements for the Filing of the Overseas Securities Offering and Listing by Domestic Companies from the CSRC, or the CSRC Notice, the domestic companies that have already been listed overseas before the effective date of the Overseas Listing Trial Measures (i.e. March 31, 2023) shall be deemed to be existing issuers (the “Existing Issuers”). Existing Issuers are not required to complete the filing procedures immediately, and they shall be required to file with the CSRC for any subsequent offerings. Further, according to the CSRC Notice, domestic companies that have obtained approval from overseas regulatory authorities or securities exchanges (for example, the effectiveness of a registration statement for offering and listing in the U.S. has been obtained) for their overseas offering and listing prior March 31, 2023 but have not yet completed their overseas issuance and listing, are granted a six-month transition period from March 31, 2023 to September 30, 2023. Those that complete their overseas offering and listing within such six-month period are deemed to be Existing Issuers and are not required to file with the CSRC for their overseas offerings and listings. Within such six-month transition period, however, if such domestic companies fail to complete their overseas issuance and listing, they shall complete the filing procedures with the CSRC. Our PRC counsel, Hebei Changjun Law Firm, has advised us that, since we obtained approval from both the SEC and The Nasdaq Capital Market (the “Nasdaq”) to issue and list our ordinary share on the Nasdaq prior to March 31, 2023, we are not required to make the filing with the CSRC pursuant to the Overseas Listing Trial Measures. We shall be required, however, to file with the CSRC for any subsequent offerings. Given the current PRC regulatory environment, it is uncertain whether we or our PRC subsidiaries will be required to obtain approvals from the PRC government to offer securities to foreign investors in the future, and whether we would be able to obtain such approvals. If we are unable to obtain such approvals if required in the future, or inadvertently conclude that such approvals are not required then the value of our ordinary shares may depreciate significantly or become worthless. See ‘Item 3. Key Information’ “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “The PRC government exerts substantial influence over the manner in which we and our PRC subsidiaries must conduct our business activities. We are currently not required to obtain approval from Chinese authorities to list on U.S. exchanges, however, if we or our PRC subsidiaries are required to obtain approval in the future and are denied permission from Chinese authorities to list on U.S. exchanges, we will not be able to continue listing on U.S. exchanges, which would materially affect the interest of the investors.” Á Á Furthermore, we are subject to PRC rules and regulations relating to overseas listing and securities offering, and a substantial extension of the PRC government’s oversight over our business operations or overseas listings may hinder our ability to offer or continue to offer our securities. Under current PRC laws, regulations and regulatory rules, we and our PRC subsidiaries may be required to obtain permissions from the China Securities Regulatory Commission, or the CSRC, and may be required to go through cybersecurity review by the Cyberspace Administration of China, or the CAC, in connection with any future offering and listing on overseas capital markets. Á On June 10, 2021, the Standing Committee of the National People’s Congress of China promulgated the Data Security Law which took effect on September 1, 2021. The Data Security Law provides for data security and privacy obligations of entities and individuals carrying out data activities, prohibits entities and individuals in China from providing any foreign judicial or law enforcement authority with any data stored in China without approval from the competent PRC authority, and sets forth the legal liabilities of entities and individuals found to be in violation of their data protection obligations, including rectification order, warning, fines up to RMB10 million, suspension of relevant business, and revocation of business permits or licenses. The Data Security Law is relatively new, and therefore there are substantial uncertainties with respect to the interpretation and implementation of the law. We may need to adjust our operations to comply with data security requirements from time to time. If we were found to have violations, we may be ordered to rectify and terminate any actions that are deemed illegal by the government authorities and become subject to fines and other government sanctions, which may materially and adversely affect our business, financial condition, and results of operations. Á Á Á On July 6, 2021, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the Opinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law, which took effect on the same day. These opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies. These opinions proposed to take effective measures, such as promoting the construction of relevant regulatory systems, to deal with the risks and incidents facing China-based overseas-listed companies and the demand for cybersecurity and data privacy protection. As of the date of this opinion, no official guidance and related implementation rules have been issued in relation to these recently issued opinions and the interpretation and implementation of these opinions remain unclear at this stage. Á On July 10, 2021, the Cyberspace Administration of China issued the Measures for Cybersecurity Review which took effect on February 15, 2022. The Revised Cybersecurity Measures authorize the relevant government authorities to conduct cybersecurity review on a range of activities that affect or may affect national security, including listings in foreign countries by companies that possess personal data of more than one million users. The PRC National Security Law covers various types of national security, including technology security and information security. Given the nature of our business in China and the fact that we do not have personal information of more than one million users, we do not believe we are an ‘internet platform operator’ that is required to file for a cybersecurity review pursuant to the Measures for Cybersecurity Review. Á On August 20, 2021, the Standing Committee of the National People’s Congress adopted the Personal Information Security Law, which took effect on November 1, 2021. The Personal Information Protection Law includes the basic rules for personal information processing, the rules for cross-border provision of personal information, the rights of individuals in personal information processing activities, the obligations of personal information processors, and the legal responsibilities for illegal collection, processing, and use of personal information. We have access to confidential or personal information in certain of the businesses and have privacy policies and other documentation regarding the protection of personal information; however, we may not be successful in achieving compliance if we fail to comply with these policies and procedures. Á On February 17, 2023, the China Securities Regulatory Commission (the “CSRC”) promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, or the ‘Trial Measures,’ and five supporting guidelines, which came into effect on March 31, 2023. Pursuant to the Trial Measures, domestic companies that seek to offer or list securities overseas, both directly and indirectly, shall complete filing procedures with the CSRC pursuant to the requirements of the Trial Measures within three working days following its submission of initial public offerings or listing application. If a domestic company fails to complete required filing procedures or conceals any material fact or falsifies any major content in its filing documents, such domestic company may be subject to administrative penalties, such as an order to rectify, warnings, fines, and its controlling shareholders, actual controllers, the person directly in charge and other directly liable persons may also be subject to administrative penalties, such as warnings and fines. According to the CSRC Notice, the domestic companies that have already been listed overseas before the effective date of the Trial Measures (namely, March 31, 2023) shall be deemed as existing issuers (the “Existing Issuers”). Existing Issuers are not required to complete the filing procedures immediately, and they shall be required to file with the CSRC for any subsequent offerings. Based on the foregoing, as of the date of this annual report, we are currently not required to complete the filing procedures and submit the relevant information to the CSRC. Á Á Based on PRC laws and regulations effective as of the date of this report and subject to different interpretations of these laws and regulations that may be adopted by PRC authorities, we believe that, as of the date of this report, we, our PRC subsidiaries are not required to obtain any permission from the CSRC, the CAC, or any other PRC authority in connection with the listing or trading of our Ordinary Shares in foreign stock exchanges. As of the date of this annual report, we and our PRC subsidiaries have not received any inquiry, notice, warning or objection in relation to the listing or trading of our securities on Nasdaq from the CSRC, the CAC or any other PRC authorities. If we fail to obtain the relevant approval or complete other review or filing procedures for any future offshore offering or listing, we may face sanctions by the CSRC or other PRC regulatory authorities, which may include fines and penalties on our operations in China, limitations on our operating privileges in China, restrictions on or prohibition of the payments or remittance of dividends by our PRC subsidiaries, restrictions on or delays to our future financing transactions, or other actions that could have a material and adverse effect on our business, financial condition, results of operations, reputation and prospects, as well as the trading price of our ADSs. For more detailed information, see ‘Item 3. Key Information’ “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “In light of recent events indicating greater oversight by the Cyberspace Administration of China, or CAC, over data security, particularly for companies seeking to list on a foreign exchange, we are subject to a variety of laws and other obligations regarding cybersecurity and data protection, and any failure to comply with applicable laws and obligations could have a material and adverse effect on our business, our listing on Nasdaq, financial condition, and results of operations,” and ‘Risk Factors’ “Risks Relating to Doing Business in the People’s Republic of China” “The Opinions, the Trial Measures, and the revised Provisions recently issued by the PRC authorities may subject us to additional compliance requirements in the future.” Á Á Á Holding Foreign Companies Accountable Act (HFCAA) Á Our ADSs may be prohibited from trading on a national exchange or over-the-counter under the Holding Foreign Companies Accountable Act (the “HFCAA”) if the Public Company Accounting Oversight Board (United States) (the “PCAOB”) is unable to inspect our auditors for three consecutive years beginning in 2021. Our auditor, OneStop Assurance PAC (the “OneStop”), is a firm registered with the PCAOB and is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards and is not subject to the determinations announced by the PCAOB on December 16, 2021. If trading in our ADSs is prohibited under the HFCAA in the future because the PCAOB determines that it cannot inspect or fully investigate our auditor at such future time, Nasdaq may determine to delist our ADSs and trading in our ADSs could be prohibited. On December 29, 2022, legislation entitled ‘Consolidated Appropriations Act, 2023’ (the “Consolidated Appropriations Act”) was signed into law by President Biden, which, among other things, amended HFCAA by requiring the SEC to prohibit an issuer’s securities from trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three, thus reducing the time period for triggering the prohibition on trading. Furthermore, our auditor is not among the auditor firms listed on an HFCAA Act Determination List, which includes all of the auditor firms that the PCAOB is not able to inspect. While our auditor is based in the Singapore and is registered with the PCAOB and subject to PCAOB inspection, in the event it is later determined that the PCAOB is unable to inspect or investigate completely our auditor because of a position taken by an authority in a foreign jurisdiction, then such lack of inspection could cause trading in our ADSs to be prohibited under the HFCAA Act, and ultimately result in a determination by a securities exchange to delist our Ordinary Shares. On August 26, 2022, the PCAOB signed a Statement of Protocol (the “SOP”) Agreement with the CSRC and China’s Ministry of Finance. The SOP Agreement, together with two protocol agreements (collectively, ‘SOP Agreements’), governing inspections and investigations of audit firms based in mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. Pursuant to the fact sheet with respect to the Protocol disclosed by the U.S. Securities and Exchange Commission (the “SEC”), the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB’s access in the future, the PCAOB Board will consider the need to issue a new determination. See ‘Item 3. Key Information’ “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Although the audit report included in this annual report is prepared by an auditor who are currently inspected by the PCAOB, there is no guarantee that future audit reports will be prepared by auditors inspected by the PCAOB and, as such, in the future investors may be deprived of the benefits of such inspection. Furthermore, trading in our securities may be prohibited under the HFCAA Act if the SEC subsequently determines our audit work is performed by auditors that the PCAOB is unable to inspect or investigate completely, and as a result, U.S. national securities exchanges, such as Nasdaq, may determine to delist our securities. Furthermore, on December 29, 2022, the Consolidated Appropriations Act, was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things, an identical provision to HFCAA, which reduce the number of consecutive non-inspection years required for triggering the prohibitions under the HFCAA Act from three years to two for more information,” and ‘Item 3. Key Information’ “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “The recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the U.S. Senate and the U.S. House of Representatives, all call for additional and more stringent criteria to be applied to emerging market companies. These developments could add uncertainties to our business operations, share price and reputation.” Á Á Á Cash and Other Assets Transfers within our Organization Á The Company can transfer cash to its subsidiaries through capital contributions and/or intercompany loans, and the Company’s subsidiaries can transfer cash to the Company through dividends or other distributions and/or intercompany loans. Additionally, the Company’s subsidiaries can transfer cash to the VIE through loans, service fees and the VIE can transfer cash to the Company as service fees under the VIE agreements (the “VIE Agreements”) and/or through loans. We intend to settle amounts owed under the VIE Agreements. The aforesaid transactions including capital injection and loans, would be eliminated upon consolidation. Á Our cash primarily consists of cash on hand and cash in banks in the PRC, Hong Kong and USA, which is unrestricted for withdrawal and use and is deposited with banks in China. As of March 31, 2024 and March 31, 2023, we had approximately USD 85.2 and USD 7.9 million of cash in bank, respectively, and the loan due to related parties is USD 2.0 million and USD9.7 million, respectively. Funds are transferred between our subsidiaries, our WFOE, Beijing Hexin Yongheng Technology Development Co., Ltd, Tianjin Haozhongyuan Technology Co., Ltd., Qindao Akso Health Management Co., Limited and Tianjin Akso Enterprise Management Co., Ltd. and the VIE for their daily operation purposes. Á There is no assurance that the PRC government will not intervene or impose restrictions on the ability of us, our subsidiaries and the VIE to transfer cash. For our cash maintained in Renminbi, and the PRC government could

prevent the cash maintained from leaving the PRC, could restrict deployment of the cash into the business of the VIE and its subsidiaries and restrict the ability to pay dividends. For details regarding the restrictions on our ability to transfer cash between us, our subsidiaries and the VIE, see [Item 3. Key Information](#) “D. Risk Factors” “Risks Related to Doing Business in the People’s Republic of China” “We currently do not have cash management policies that dictate how funds are transferred between us, our subsidiaries, and the VIE. For more detailed information, see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” In light of recent events indicating greater oversight by the Cyberspace Administration of China, or CAC, over data security, particularly for companies seeking to list on a foreign exchange, we are subject to a variety of laws and other obligations regarding cybersecurity and data protection, and any failure to comply with applicable laws and obligations could have a material and adverse effect on our business, our listing on Nasdaq, financial condition, and results of operations,” and [Risk Factors](#) “Risks Relating to Doing Business in the People’s Republic of China” “The Opinions, the Trial Measures, and the revised Provisions recently issued by the PRC authorities may subject us to additional compliance requirements in the future.” As of the date of this annual report, our current corporate structure does not contain any variable interest entity in mainland China and we do not have intention establishing any VIEs in mainland China in the future. A Cash may be transferred within our organization in the following manner: (i) we may transfer funds to our subsidiaries, including our PRC subsidiaries, by way of capital contributions or loans, through intermediate holding companies or otherwise; and (ii) our subsidiaries, including our PRC subsidiaries, may make dividends or other distributions to us through intermediate holding companies or otherwise. A 6 A The following table describes transfers among us, our subsidiaries and the former VIEs made during the periods presented: A A Year-End March 31, 2024A A (US\$ in millions)A Capital contributions from us to our offshore subsidiaries(1)A A Loans from us to our offshore subsidiariesA 137.2A Capital contributions from us or our offshore subsidiaries to PRC subsidiariesA A Loans from us or our offshore subsidiaries to PRC subsidiariesA 56.3A Loans from our subsidiaries to the former VIEs, netA A Other amounts paid by our subsidiaries to the former VIEs(2)A A Other amounts paid by former VIEs and their subsidiaries to our subsidiariesA A Notes: A (1) Offshore subsidiaries refer to all of our subsidiaries except our PRC subsidiaries. A (2) Cash paid by one of our Hong Kong subsidiaries to one of our former VIEs for services rendered. A Dividends or Distributions Made to our Company and U.S. Investors and Tax Consequences A Under the Cayman Islands law, we are permitted to provide funding to our subsidiaries through loans or capital contributions without restrictions on the amount of the funds, and we are permitted to pay a dividend out of either profit or share premium amount, provided that in no circumstances may a dividend be paid if this would result in us being unable to pay our debts due in the ordinary course of business. Our board of directors has discretion regarding whether to declare or pay dividends. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. In either case, all dividends are subject to certain restrictions under Cayman Islands law, namely that our company may only pay dividends out of profits or share premium, and provided always that we are able to pay our debts as they fall due in the ordinary course of business. The determination to declare and pay such annual dividend and special dividend and the amount of any dividend in any particular year will be based upon our operations, earnings, financial condition, cash requirements and availability and other factors as our board of directors may deem relevant at such time. See [Item 3. Risk Factors](#) “Risks Related to Our ADS” “We cannot assure you that our existing dividend policy will not change in the future or the amount the dividends that you may receive, and as such, you must rely on price appreciation of our ADSs for return on your investment.” A We Healthy Limited (a We Health HK) is permitted under the laws of Hong Kong to provide funding to Akso Health, the holding company incorporated in Cayman Islands through dividend distribution without restrictions on the amount of the funds. Both Akso Health and We Health HK currently intend to retain all available funds and future earnings, if any, for the operation and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, contractual requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. A According to the Companies Ordinance of Hong Kong, a Hong Kong company may only make a distribution out of profits available for distribution or other distributable reserves. Dividends cannot be paid out from share capital. In addition, there can be no assurance that in the future the PRC government will not intervene or impose restrictions on our Hong Kong subsidiary’s ability to transfer or distribute cash/assets to entities outside of Hong Kong, which could result in an inability or prohibition on making transfers or distributions to Akso Health and adversely affect our business. As of the date of this annual report, there are no restrictions or limitations imposed by the Hong Kong government on the transfer of capital within, into and out of Hong Kong (including funds from Hong Kong to the PRC), except for the transfer of funds involving money laundering and criminal activities. See [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “To the extent cash or assets of our business, or of our PRC or Hong Kong subsidiaries, is in PRC or Hong Kong, such cash or assets may not be available to fund operations or for other use outside of the PRC or Hong Kong, due to interventions in or the imposition of restrictions and limitations by the PRC government to the transfer of cash or assets.” A 7 A On July 19, 2018, our board of directors approved an annual dividend policy. Under this policy, annual dividends will be set at an amount equivalent to approximately 15-25% of our anticipated net income after tax in each year commencing from the fiscal year ended March 31, 2019. On July 19, 2018, our board of directors also approved a special cash dividend of US\$0.13 per ordinary share of our company (or US\$0.13 per ADS), in addition to an annual dividend pursuant to the newly adopted annual dividend policy of US\$0.27 per ordinary share (or US\$0.27 per ADS), for a total dividend of US\$0.40 per ordinary share (or US\$0.40 per ADS). The aggregated dividend payments to shareholders amounted to US\$19,547,532 in the fiscal year ended March 31, 2019. We intend to keep any future earnings to finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future. Subject to the passive foreign investment company (a PFIC) rules, the gross amount of distributions we make to investors with respect to our Ordinary Shares (including the amount of any taxes withheld therefrom) will be taxable as a dividend, to the extent that the distribution is paid out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. A Summary of Risk Factors A Investing in our ADSs involves significant risks. You should carefully consider all of the information in this annual report before making an investment in our ADSs. Below please find a summary of the principal risks we face, organized under relevant headings. These risks are discussed more fully in the section titled [Item 3. Key Information](#) “D. Risk Factors” in this annual report. A RISKS RELATED TO OUR BUSINESS AND INDUSTRY A A — We are no longer engaged in the online microlending business, but we cannot assure you that we would not be penalized under relevant regulations for the previous microlending business. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “We are no longer engaged in the online microlending business, but we cannot assure you that we would not be penalized under relevant regulations for the previous microlending business” on page 15 of this annual report); A A — Any harm to our brand or reputation may materially and adversely affect our business and results of operations. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Any harm to our brand or reputation may materially and adversely affect our business and results of operations” on page 15 of this annual report); A A — If our social e-commerce platform is unable to provide good customer experience, our business and reputation may be materially and adversely affected. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “If our social e-commerce platform is unable to provide good customer experience, our business and reputation may be materially and adversely affected” on page 16 of this annual report); A A — We may incur liability or become subject to administrative penalties for counterfeit or unauthorized merchandise displayed on our platform, or for merchandise displayed on our platform that infringe on third-party intellectual property rights, or for other misconduct. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “We may incur liability or become subject to administrative penalties for counterfeit or unauthorized merchandise displayed on our platform, or for merchandise displayed on our platform that infringe on third-party intellectual property rights, or for other misconduct” on page 17 of this annual report); A A A — We plan to establish and operate cancer therapy and radiation oncology centers that will be majority-owned by us and are subject to significant risks. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “We plan to establish and operate cancer therapy and radiation oncology centers that will be majority-owned by us and are subject to significant risks” on page 17 of this annual report); A A — We may encounter difficulties in successfully introducing new services in a timely and cost-effective manner, which could materially and adversely affect our business and operations. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “We may encounter difficulties in successfully introducing new services in a timely and cost-effective manner, which could materially and adversely affect our business and operations” on page 17 of this annual report); A 8 A A — Our development of new cancer therapy and radiation oncology centers could result in fluctuations in our short-term financial performance, and newly opened cancer therapy and radiation oncology centers and clinics may not achieve timely profitability, or at all. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Our development of new cancer therapy and radiation oncology centers could result in fluctuations in our short-term financial performance, and newly opened cancer therapy and radiation oncology centers and clinics may not achieve timely profitability, or at all” on page 18 of this annual report); A A — Our growth plan includes the construction of cancer therapy and radiation oncology centers. If we cannot identify and seize growth opportunities in fast-changing markets, our future growth will face uncertainties. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Our growth plan includes the construction of cancer therapy and radiation oncology centers. If we cannot identify and seize growth opportunities in fast-changing markets, our future growth will face uncertainties” on page 18 of this annual report); A A — We conduct our business in a heavily regulated industry. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “We conduct our business in a heavily regulated industry” on page 18 of this annual report); A A — We are reliant on our core senior management team. If one or more key executives were unable or unwilling to continue in their present positions, our business and results of operations may be adversely affected. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “We are reliant on our core senior management team. If one or more key executives were unable or unwilling to continue in their present positions, our business and results of operations may be adversely affected” on page 19 of this annual report); A A — We compete for skilled and quality employees, and failure to attract and retain them may adversely affect our business and prevent us from achieving our intended level of growth. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “We compete for skilled and quality employees, and failure to attract and retain them may adversely affect our business and prevent us from achieving our intended level of growth” on page 19 of this annual report); A A — If labor costs in the PRC increase substantially, our business and costs of operations may be adversely affected. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “If labor costs in the PRC increase substantially, our business and costs of operations may be adversely affected” on page 19 of this annual report); A A — Our innovative corporate culture is important to our business, if our culture changes our business and corporate objectives may be adversely affected. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Our innovative corporate culture is important to our business, if our culture changes our business and corporate objectives may be adversely affected” on page 19 of this annual report); A A — We do not have business insurance coverage. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “We do not have business insurance coverage” on page 19 of this annual report); A A — If we do not find available sources of liquidity for capital and financing needs, our business and operations may be materially and adversely affected. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “If we do not find available sources of liquidity for capital and financing needs, our business and operations may be materially and adversely affected” on page 20 of this annual report); A A A — Our business, financial performance and results of operations could be adversely affected by deterioration of the relation between China and the United States. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Our business, financial performance and results of operations could be adversely affected by deterioration of the relation between China and the United States” on page 21 of this annual report); A 9 A A RISKS RELATED TO OUR CORPORATE STRUCTURE A A — PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering and the concurrent private placement to make loans to or make additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering and the concurrent private placement to make loans to or make additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business” on page 21 of this annual report); A RISKS RELATED TO DOING BUSINESS IN THE PEOPLE’S REPUBLIC OF CHINA A A — Although the audit report included in this annual report is prepared by an auditor who are currently inspected by the Public Company Accounting Oversight Board (the PCAOB), there is no guarantee that future audit reports will be prepared by auditors inspected by the PCAOB and, as such, in the future investors may be deprived of the benefits of such inspection. Furthermore, trading in our securities may be prohibited under the Holding Foreign Companies Accountable Act (the HFCA) if the SEC subsequently determines our audit work is performed by auditors that the PCAOB is unable to inspect or investigate completely, and as a result, U.S. national securities exchanges, such as Nasdaq, may determine to delist our securities. Furthermore, on December 29, 2022, the Consolidated Appropriations Act, was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things, an identical provision to AHFCAA, which reduce the number of consecutive non-inspection years required for triggering the prohibitions under the HFCA Act from three years to two. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Although the audit report included in this annual report is prepared by an auditor who are currently inspected by the Public Company Accounting Oversight Board (the PCAOB), there is no guarantee that future audit reports will be prepared by auditors inspected by the PCAOB and, as such, in the future investors may be deprived of the benefits of such inspection. Furthermore, trading in our securities may be prohibited under the Holding Foreign Companies Accountable Act (the HFCA) if the SEC subsequently determines our audit work is performed by auditors that the PCAOB is unable to inspect or investigate completely, and as a result, U.S. national securities exchanges, such as Nasdaq, may determine to delist our securities. Furthermore, on December 29, 2022, the Consolidated Appropriations Act, was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things, an identical provision to AHFCAA, which reduce the number of consecutive non-inspection years required for triggering the prohibitions under the HFCA Act from three years to two” on page 23 of this annual report); A A — The recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the U.S. Senate and the U.S. House of Representatives, all call for additional and more stringent criteria to be applied to emerging market companies. These developments could add uncertainties to our business operations, share price and reputation. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “The recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the U.S. Senate and the U.S. House of Representatives, all call for additional and more stringent criteria to be applied to emerging market companies. These developments could add uncertainties to our business operations, share price and reputation” on page 25 of this annual report); A A A — There may be changes in the regulations of PRC government bodies and agencies relating to VAT collection procedure and ACTCS business. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “There may be changes in the regulations of PRC government bodies and agencies relating to VAT collection procedure and ACTCS business” on page 25 of this annual report); A 10 A A — Failure to comply with laws and regulations applicable to our business could subject us to fines and penalties and could also cause us to lose customers or otherwise harm our business. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Failure to comply with laws and regulations applicable to our business could subject us to fines and penalties and could also cause us to lose customers or otherwise harm our business” on page 26 of this annual report); A A — In light of recent events indicating greater oversight by the Cyberspace Administration of China, or CAC, over data security, particularly for companies seeking to list on a foreign exchange, we are subject to a variety of laws and other obligations regarding cybersecurity and data protection, and any failure to comply with applicable laws and obligations could have a material and adverse effect on our business, our listing on NASDAQ, financial condition, and results of operations. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “In light of recent events indicating greater oversight by the Cyberspace Administration of China, or CAC, over data security, particularly for companies seeking to list on a foreign exchange, we are subject to a variety of laws and other obligations regarding cybersecurity and data protection, and any failure to comply with applicable laws and obligations could have a material and adverse effect on our business, our listing on NASDAQ, financial condition, and results of operations” on page 27 of this annual report); A A — The approval of the China Securities Regulatory Commission, or the CSRC, may be required in connection with an offering under PRC rules, regulations, or policies, and, if required, we cannot predict whether or how soon we will be able to obtain such approval. As a result, both you and us fact uncertainty about future actions by the PRC government that could significantly affect our business, our listing on Nasdaq, financial condition and results of operations. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “The approval of the China Securities Regulatory Commission, or the CSRC, may be required in connection with an offering under PRC rules, regulations, or policies, and, if required, we cannot predict whether or how soon we will be able to obtain such approval. As a result, both you and us fact uncertainty about future actions by the PRC government that could significantly affect our business, our listing on Nasdaq, financial condition and results of operations” on page 28 of this annual report); A A — Changes in the policies of the PRC government could have a significant impact upon our ability to operate profitably in the PRC. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Changes in the policies of the PRC government could have a significant impact upon our ability to operate profitably in the PRC. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Because our business is dependent upon government policies that encourage a market-based economy, change in the political or economic climate in the PRC may impair our ability to operate profitably, if at all. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “Because our business is dependent upon government policies that encourage a market-based economy, change in the political or economic climate in the PRC may impair our ability to operate profitably, if at all” on page 30 of this annual report); A A — PRC laws and regulations governing our current business operations are sometimes vague and uncertain and any changes in such laws and regulations may impair our ability to operate profitably. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “PRC laws and regulations governing our current business operations are sometimes vague and uncertain and any changes in such laws and regulations may impair our ability to operate profitably. (see [Item 3. Key Information](#) “D. Risk Factors” “Risks Relating to Doing Business in the People’s Republic of China” “PRC laws and regulations governing our current business operations

are sometimes vague and uncertain and any changes in such laws and regulations may impair our ability to operate profitably on page 30 of this annual report); Á Á — Changes in China's macroeconomic, socio-political conditions or government policies could have a material adverse effect on our business and results of operations. (see Changes in China's macroeconomic, socio-political conditions or government policies could have a material adverse effect on our business and results of operations on page 31 of this annual report); Á Á — Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted PRC Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations. (see Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted PRC Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations on page 31 of this annual report); Á 11 Á Á — We may be adversely affected by the complexity, uncertainties and changes in PRC regulation of Internet-related businesses and companies, and any lack of requisite approvals, licenses or permits applicable to our business may have a material adverse effect on our business and results of operations. (see We may be adversely affected by the complexity, uncertainties and changes in PRC regulation of Internet-related businesses and companies, and any lack of requisite approvals, licenses or permits applicable to our business may have a material adverse effect on our business and results of operations on page 32 of this annual report); Á Á — Fluctuations in exchange rates could have a material adverse effect on our results of operations and the value of your investment. (see Fluctuations in exchange rates could have a material adverse effect on our results of operations and the value of your investment on page 32 of this annual report); Á Á — Governmental control of currency conversion may limit our ability to utilize our net revenues effectively and affect the value of your investment. (see Governmental control of currency conversion may limit our ability to utilize our net revenues effectively and affect the value of your investment on page 33 of this annual report); Á Á — Failure to make adequate contributions to various employee benefit plans as required by PRC regulations may subject us to penalties. (see Failure to make adequate contributions to various employee benefit plans as required by PRC regulations may subject us to penalties on page 33 of this annual report); Á Á — The M&A Rules and certain other PRC regulations establish complex procedures for some acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China. (see The M&A Rules and certain other PRC regulations establish complex procedures for some acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China on page 33 of this annual report); Á Á — PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiary's ability to increase its registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC law. (see PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiary's ability to increase its registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC law on page 34 of this annual report); Á Á — Any failure to comply with PRC regulations regarding the registration requirements for employee stock incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions. (see Any failure to comply with PRC regulations regarding the registration requirements for employee stock incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions on page 34 of this annual report); Á Á — If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders. (see If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders on page 35 of this annual report); Á Á — We may not be able to obtain certain benefits under relevant tax treaty on dividends paid by our PRC subsidiary to us through our Hong Kong subsidiary. (see We may not be able to obtain certain benefits under relevant tax treaty on dividends paid by our PRC subsidiary to us through our Hong Kong subsidiary on page 35 of this annual report); Á Á — Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential acquisitions we may pursue in the future. (see Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential acquisitions we may pursue in the future on page 36 of this annual report); Á 12 Á Á — Any actions by the Chinese government, including any decision to intervene or influence the operations of the operating entities or to exert control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, may cause us to make material changes to the operations of the PRC operating entities, may limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless. (see Any actions by the Chinese government, including any decision to intervene or influence the operations of the operating entities or to exert control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, may cause us to make material changes to the operations of the PRC operating entities, may limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless on page 36 of this annual report); Á Á — The PRC government exerts substantial influence over the manner in which we and our PRC subsidiaries must conduct our business activities. We are currently not required to obtain approval from Chinese authorities to list on U.S. exchanges, however, if we or our PRC subsidiaries are required to obtain approval in the future and are denied permission from Chinese authorities to list on U.S. exchanges, however, if we or our PRC subsidiaries are required to obtain approval in the future and are denied permission from Chinese authorities to list on U.S. exchanges, we will not be able to continue listing on U.S. exchanges, which would materially affect the interest of the investors on page 37 of this annual report); Á Á — To the extent cash or assets of our business, or of our PRC or Hong Kong subsidiaries, is in PRC or Hong Kong, such cash or assets may not be available to fund operations or for other use outside of the PRC or Hong Kong, due to interventions in or the imposition of restrictions and limitations by the PRC government to the transfer of cash or assets. (see To the extent cash or assets of our business, or of our PRC or Hong Kong subsidiaries, is in PRC or Hong Kong, such cash or assets may not be available to fund operations or for other use outside of the PRC or Hong Kong, due to interventions in or the imposition of restrictions and limitations by the PRC government to the transfer of cash or assets on page 37 of this annual report); Á Á — There are uncertainties regarding the enforcement of laws and rules and regulations in China, which can change quickly with little advance notice, and there is a risk that the Chinese government may intervene or influence our operations at any time, exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, which could materially and adversely affect our business and hinder our ability to offer or continue our operations, and cause the value of our securities to significantly decline or become worthless. (see There are uncertainties regarding the enforcement of laws and rules and regulations in China, which can change quickly with little advance notice, and there is a risk that the Chinese government may intervene or influence our operations at any time, exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, which could materially and adversely affect our business and hinder our ability to offer or continue our operations, and cause the value of our securities to significantly decline or become worthless on page 37 of this annual report); Á RISKS RELATED TO OUR ADSs Á Á — The trading price of our ADSs may be volatile, which could result in substantial losses to investors. (see The trading price of our ADSs may be volatile, which could result in substantial losses to investors on page 38 of this annual report); Á Á — Techniques employed by short sellers may drive down the market price of our ADSs. (see Techniques employed by short sellers may drive down the market price of our ADSs on page 39 of this annual report); Á Á — If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for our ADSs and trading volume could decline. (see If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for our ADSs and trading volume could decline on page 39 of this annual report); Á 13 Á Á — We cannot assure you that our existing dividend policy will not change in the future or the amount the dividends that you may receive, and as such, you must rely on price appreciation of our ADSs for return on your investment. (see We cannot assure you that our existing dividend policy will not change in the future or the amount the dividends that you may receive, and as such, you must rely on price appreciation of our ADSs for return on your investment on page 39 of this annual report); Á Á — Substantial future sales or perceived potential sales of our ADSs in the public market could cause the price of our ADSs to decline. (see Substantial future sales or perceived potential sales of our ADSs in the public market could cause the price of our ADSs to decline on page 40 of this annual report); Á Á — We may be classified as a passive foreign investment company for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. holders of our ADSs or ordinary shares. (see We may be classified as a passive foreign investment company for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. holders of our ADSs or ordinary shares on page 40 of this annual report); Á Á — The amended and restated memorandum and articles of association that we expect to adopt contain anti-takeover provisions that could have a material adverse effect on the rights of holders of our ordinary shares and ADSs. (see The amended and restated memorandum and articles of association that we expect to adopt contain anti-takeover provisions that could have a material adverse effect on the rights of holders of our ordinary shares and ADSs on page 41 of this annual report); Á Á — You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law. (see You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law on page 41 of this annual report); Á Á — Certain judgments obtained against us by our shareholders may not be enforceable. (see Certain judgments obtained against us by our shareholders may not be enforceable on page 42 of this annual report); Á Á — We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions applicable to United States domestic public companies. (see We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions applicable to United States domestic public companies on page 42 of this annual report); Á Á — The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise any right to vote the ordinary shares which are represented by your ADSs. (see The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise any right to vote the ordinary shares which are represented by your ADSs on page 43 of this annual report); Á Á — The depositary for our ADSs will give us a discretionary proxy to vote the ordinary shares represented by your ADSs if you do not give proper or timely voting instructions to the depositary, except in limited circumstances, which could adversely affect your interests. (see The depositary for our ADSs will give us a discretionary proxy to vote the ordinary shares represented by your ADSs if you do not give proper or timely voting instructions to the depositary, except in limited circumstances, which could adversely affect your interests on page 43 of this annual report); Á Á — You may not receive dividends or other distributions on our ordinary shares and you may not receive any value for them if it is illegal or impracticable to make them available to you. (see You may not receive dividends or other distributions on our ordinary shares and you may not receive any value for them if it is illegal or impracticable to make them available to you on page 43 of this annual report); Á Á — You may experience dilution of your holdings due to inability to participate in rights offerings. (see You may experience dilution of your holdings due to inability to participate in rights offerings on page 44 of this annual report); Á Á — You may be subject to limitations on transfer of your ADSs. (see You may be subject to limitations on transfer of your ADSs on page 44 of this annual report); Á Á — We will incur significantly increased costs and devote substantial management time as a result of being a public company. (see We will incur significantly increased costs and devote substantial management time as a result of being a public company on page 44 of this annual report). Á 14 Á Á [Reserved] Á B Capitalization and Indebtedness Á Not applicable. Á C Reasons for the Offer and Use of Proceeds Á Not applicable. Á D Risk Factors Á RISKS RELATED TO OUR BUSINESS AND INDUSTRY Á We are no longer engaged in the online microlending business, but we cannot assure you that we would not be penalized under relevant regulations for the previous microlending business. Á In August 2017, we established Wusu Company, through which we started to conduct our online microlending business. We have engaged in online microlending business since then and have been continuing to contribute resources to our microlending business up to September 30, 2019, since when the principal business scope of Wusu Company has been changed to trading, provision of technological promotion services and import and export. Since May 2019, we have ceased to issue new loans through microlending businesses. The microlending industry is rapidly evolving with significant regulatory uncertainties, and our microlending business may be subject to a variety of laws and regulations in the PRC with ambiguous and inconsistent application and interpretation. As a result, we cannot assure you that our investment and exploration in microlending would not be subject to legal risks. Since the change of Wusu Company's business scope, we cannot carry out any new microlending business without the proper business registration. However, for the loans which were issued prior to the change of the business scope, we are entitled to the credit right over such loans until their maturity. If, however, the authorities were to determine that our historical microlending business was in violation of the relevant PRC laws and regulations, we may be subject to fines and other administrative penalties imposed by the authorities and our business and reputation could be adversely affected. Á Any harm to our brand or reputation may materially and adversely affect our business and results of operations. Á We believe that the recognition and reputation of our brand, Xiaobai Maimai, among our members, users, third-party merchants and service providers have contributed significantly to the growth and success of our business. Maintaining and enhancing the recognition and reputation of our brand are critical to our business and competitiveness. Many factors, some of which are beyond our control, are important to maintaining and enhancing our brand. These factors include our ability to: Á Á — provide a superior shopping experience to our members and users; Á Á — maintain the popularity, attractiveness, diversity, quality and authenticity of product offerings on our platform; Á Á — maintain the efficiency, reliability and quality of the fulfillment and delivery services to our buyers; Á Á — maintain or improve user satisfaction with our services; Á Á — increase brand awareness through marketing and brand promotion activities; and Á Á — preserve our reputation and goodwill in the event of any negative publicity on consumer experience or merchant service, Internet and data security, product quality, price or authenticity, or other issues affecting us or other social e-commerce businesses in China. Á Public perception that non-authentic, counterfeit or defective goods are displayed on our platform or that we or third-party service providers do not provide satisfactory customer service, even if factually incorrect or based on isolated incidents, could damage our reputation, diminish the value of our brand, undermine the trust and credibility we have established and have a negative impact on our ability to attract new users or retain our current users. If we are unable to maintain our reputation, enhance our brand recognition or increase positive awareness of our platform, products and services, it may be difficult to maintain and grow our member and user base, and our business and growth prospects may be materially and adversely affected. Á 15 Á Á If our social e-commerce platform is unable to provide good customer experience, our business and reputation may be materially and adversely affected. Á If our social e-commerce platform does not provide good consumer experience, it could damage our reputation, diminish the value of our brand, undermine the trust and credibility we have established, have a negative impact on our ability to attract new consumers or retain our current consumers, and our business and growth prospects may be materially and adversely affected. Our ability to provide good customer experience depends on a variety of factors. These factors include, among others, our ability to continue to offer authentic products at competitive prices, to source products in response to evolving customer tastes and demands, to ensure the quality of our products and services and to provide flexible payment options. For example, Á If we are unable to develop and maintain good relationships with third-party merchants that would allow us to obtain a sufficient amount and variety of authentic and quality products on acceptable commercial terms, we may be unable to meet customer demands for these products or to offer these products at attractive prices. Á The third-party merchants in our marketplace business rely on a number of contracted third-party delivery logistics service providers to deliver the products to the customers. The products on our platform are supplied by the merchants, who are separately responsible for sourcing and coordinating the delivery of the products with the third-party delivery logistics service providers. As we do not directly control or manage the operations of these third-party logistics service providers, we may not be able to guarantee their performance. Interruptions to or failures in the delivery services could prevent the timely or proper delivery of our products. These interruptions or failures may be due to unforeseen events that are beyond our control or the control of our third-party logistics and delivery service providers, such as inclement weather, health epidemics, natural disasters, transportation disruptions or labor unrest. Delivery of the products could also be affected or interrupted by the merger, acquisition, insolvency or shut-down of the delivery companies the third-party merchants engage to make deliveries, especially those local companies with relatively small business scales. If the products are not delivered on a timely basis or are delivered in a damaged state, customers may refuse to accept the products purchased and have less confidence in our platform, and our business and reputation could suffer. We cannot assure you that our third-party merchants will be able to find alternative cost-effective logistics service providers to offer satisfactory delivery services in a timely manner, or at all, which could cause our business and reputation to suffer or cause third-party merchants to move to other platforms

and have a negative impact on our financial conditions. In addition, if our third-party logistics service providers fail to comply with applicable rules and regulations in China, our delivery services may be materially and adversely affected. Furthermore, the delivery personnel of contracted third-party delivery service providers directly interact with our customers on our behalf. We need to effectively manage these third-party logistics service providers to ensure the quality of customer services. Any failure to provide high-quality delivery services to our customers may negatively impact the shopping experience of our customers, damage our reputation, and cause us to lose customers. Â If our customer service representatives, sales representatives or maintenance engineers and technicians fail to provide satisfactory service, it may compromise our ability to provide effective customer service and enjoyable user engagement, which may in turn cause damage to our reputation, loss of customers or direct economic loss. In addition, any negative publicity or poor feedback regarding our customer service may diminish customer confidence in us and the value of our brand, and in turn cause us to lose customers and market share. Â In addition, we rely on our technology infrastructure to offer a good customer experience and to attract and retain customers on our platform. Any failure to properly upgrade our technology infrastructure to serve the growing number of customers, maintain the satisfactory performance, security and integrity of our social e-commerce platform and systems, may materially and adversely affect our business and reputation. Â 16 Â Â We may incur liability or become subject to administrative penalties for counterfeit or unauthorized merchandise displayed on our platform, or for merchandise displayed on our platform that infringe on third-party intellectual property rights, or for other misconduct. Â Our platform sources merchandise from third-party merchants. Although we have adopted measures to verify the authenticity and authorization of merchandise displayed on our platform and to avoid potential infringement on third-party intellectual property rights in the course of sourcing and selling merchandise, we may not always be successful in these efforts. In the event that any counterfeit, unauthorized or infringing merchandise is displayed on our platform, we could face claims for which we may be held liable. We have not in the past received claims alleging our infringement on third parties' rights, and if we receive such claims in the future irrespective of their validity, we could incur significant costs and efforts in either defending against or settling such claims. If there is a successful claim against us, we might be required to pay substantial damages or refrain from further sale of the relevant merchandise. If we negligently participate or assist in infringement activities associated with counterfeit goods, we may be subject to potential liability under PRC law including injunctions to cease infringing activities, rectification, compensation, administrative penalties, and even criminal liability. Moreover, such third-party claims or administrative penalties could result in negative publicity and our reputation could be severely damaged. Any of these events could have a material and adverse effect on our business, results of operations or financial condition. Â We plan to establish and operate cancer therapy and radiation oncology centers that will be majority-owned by us and are subject to significant risks. Â As part of our growth strategy, we plan to establish and operate cancer therapy and radiation oncology centers that will focus on providing a variety of radiotherapy services as well as catering to cancer patients at varying stages of treatment. This will include specialized radiation therapy centers for radiotherapy (RT), personalized consultation, conventional treatment planning, and other related services for a wide variety of cancer therapy treatments. Â Since we have limited experience in operating our own centers and clinics, or in providing many of the services that we plan to offer in such centers and clinics, we may not be able to provide as high a level of service quality for those treatment options as compared to the other treatments that we offer at our network of centers, which may result in damage to our reputation and growth prospects. Â In addition, we may not be successful in recruiting qualified medical professionals to effectively provide the services that we intend to offer in our own centers and clinics. When we establish our own centers and hospitals under our brand name, we may not be able to immediately gain wide acceptance among patients and, thus, may be unable to attract a sufficient number of patients to our new centers and clinics. Â We may encounter difficulties in successfully introducing new services in a timely and cost-effective manner, which could materially and adversely affect our business and operations. Â Our new cancer therapy and radiation oncology services may not be well received by our clients, and newly introduced services may not achieve expected results. Furthermore, our services will require specialized knowledge of the industry and comprehensive understanding of the market of medical equipment and consumables. We may misjudge the trend of the industry and the market, and may not be able to develop the appropriate solutions for our clients. The efforts to introduce new services may require substantial investments of additional human capital and financial resources. If we fail to improve our existing services or introduce new ones in a timely or cost-effective manner, our ability to attract and retain clients may be impaired, and our results of operations and prospects may be adversely affected. Â 17 Â Â Our development of new cancer therapy and radiation oncology centers could result in fluctuations in our short-term financial performance, and newly opened cancer therapy and radiation oncology centers and clinics may not achieve timely profitability, or at all. Â New cancer therapy and radiation oncology centers generally have lower income and higher operating costs during the initial stages of their operations. We will also incur substantial expenses before opening new cancer therapy and radiation oncology centers such as labor costs, construction expenditures, renovation costs, rental expenses and equipment costs. Based on our research, it generally takes years for new cancer therapy and radiation oncology centers to achieve monthly breakeven and much longer to recover the initial investment. Accordingly, the timing of new cancer therapy and radiation oncology centers openings may have a significant impact on our future profitability. As a result, our results of operations may fluctuate significantly from period to period, which renders the period-to-period comparisons of our results of operations to be not meaningful in predicting our future performance. Â Moreover, we may not be successful in recruiting qualified medical professionals to effectively provide the services that we intend to offer in our new cancer therapy and radiation oncology centers. It could also take significant lead time for newly opened cancer hospitals and clinics to achieve a utilization rate that is profitable, due to factors such as time needed to build patient awareness in the local community. In addition, the opening of new cancer therapy and radiation oncology centers involve regulatory approvals and reviews by various authorities in the U.S., including health authorities. We may not be able to obtain all the required approvals, permits, licenses or certificates in a timely manner or at all. Therefore, we may not be able to immediately utilize or derive revenue from new cancer therapy and radiation oncology centers as anticipated. In addition, the operating results generated from newly opened cancer therapy and radiation oncology centers may not be comparable to the operating results generated from any of our existing businesses. Newly opened cancer therapy and radiation oncology centers may even operate at a loss, which could adversely affect our results of operations. Â Our growth plan includes the construction of cancer therapy and radiation oncology centers. If we cannot identify and seize growth opportunities in fast-changing markets, our future growth will face uncertainties. Â We plan to build cancer therapy and radiation oncology centers on the east coast of the United States, the implementation process of which will be complex, time-consuming and subject to uncertainty. Â We are identifying suitable regions for self-operated cancer therapy and radiation oncology centers by considering a number of factors, including regional market size, existing competition and potential strategic partners. There are uncertainties regarding how successfully we can identify the suitable market, acquire required government approvals in a timely manner and control planned investments. In addition, we may face competition from our existing cancer therapy and radiation oncology centers. Â We conduct our business in a heavily regulated industry. Â The operation of our cancer therapy and radiation oncology centers is subject to laws and regulations issued by a number of government agencies at the national and local levels. These rules and regulations relate mainly to the procurement of large medical equipment, the pricing of medical services, the operation of radiotherapy and diagnostic imaging equipment, the licensing and operation of medical institutions, the licensing of medical staff and the prohibition on non-profit medical institutions from entering into cooperation agreements with third parties to set up for-profit centers that are not independent legal entities. In addition, our cancer therapy and radiation oncology centers will be subject to periodic license or permit renewal requirements and inspections by various government authorities at the provincial and municipal levels. We are also exposed to potential legal liabilities arising from claims relating to medical incidents, patient privacy, anti-corruption and anti-bribery, and environmental protection. Our growth prospects may be constrained by such rules and regulations, particularly those relating to the procurement of large medical equipment. Moreover, new laws and regulations applicable to our operations may be introduced in the future, or the current applicable ones may otherwise be amended or replaced to impose additional supervision and management requirements. Any changes in laws and regulations could require us to obtain additional licenses, permits or approvals, broaden the scope of our potential liabilities, increase our operating costs and expenses, or even result in the invalidation of our existing licenses. Â If we or our future partners fail to comply with such applicable laws and regulations, we could be required to make significant changes to our business or suffer fines or penalties, including the potential loss of our business licenses, the suspension from use of our medical equipment, and the suspension or cessation of operations at cancer therapy and radiation oncology centers in our network. Â 18 Â Â We are reliant on our core senior management team. If one or more key executives were unable or unwilling to continue in their present positions, our business and results of operations may be adversely affected. Â Our business, corporate strategies and future performance depends on our core senior management team comprising our directors, executive officers and other key personnel. If we fail to attract and retain any of our key personnel, or if they are unable or unwilling to continue in their present position due to any reason, we will have to go through a difficult process of replacement. The replacement process will necessarily involve significant time and expenses and may adversely affect our business and results of operations and our business objectives may not be achieved at the pace we expected, or at all. Â We compete for skilled and quality employees, and failure to attract and retain them may adversely affect our business and prevent us from achieving our intended level of growth. Â Competition for our employees including systems engineers, financial officers and marketing professionals is intense. Our business and success relies on the efforts and standard of work of our employees. If we are unable to attract, motivate and retain skilled and trained employees, or if we are unable to continue to provide attractive compensation packages, our business and operations may be adversely affected and our intended levels and rates of growth may be impeded. Â We invest significant time and expense in the training and development of our employees. Failure to retain our existing employees will incur further significant costs to find suitable replacements and a duplication of effort for their training, which may affect our operations and our quality of service to customers and third-party merchants may be compromised, resulting in a material adverse effect on our business and results of operations. Â If labor costs in the PRC increase substantially, our business and costs of operations may be adversely affected. Â In recent years, the Chinese economy has experienced inflationary and labor costs increases. Average wages are projected to continue to increase. Further, under PRC law we are required to pay various statutory employee benefits, including pension, housing fund, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance to designated government agencies for the benefit of our employees. The relevant government agencies may examine whether an employer has made adequate payments to the statutory employee benefits, and those employers who fail to make adequate payments may be subject to late payment fees, fines and/or other penalties. We expect that our labor costs, including wages and employee benefits, will continue to increase. If we are unable to control our labor costs or pass such increased labor costs on to our users by increasing the fees of our services, our financial condition and results of operations may be adversely affected. Â Our innovative corporate culture is important to our business, if our culture changes our business and corporate objectives may be adversely affected. Â Our corporate culture fosters innovation, a collegiate environment of team effort and encourages creativity, which is important to our business and development of our product pipeline and service upgrades. If we fail to maintain these valuable aspects of our culture during the course of our adaptation into a public company and building the relevant infrastructure, our future success and strategic goals may be affected. Furthermore, we may be unable to retain and attract talent, leading to a negative impact on our business and corporate objectives. Â We do not have business insurance coverage. Â Insurance companies in China currently do not offer as extensive an array of insurance products as insurance companies in more developed economies. Currently, we do not have any business liability or disruption insurance to cover our operations. We have determined that the costs of insuring for these risks and the difficulties associated with acquiring such insurance on commercially reasonable terms make it impractical for us to have such insurance. Any uninsured business disruptions may result in our incurring substantial costs and the diversion of resources, which could have an adverse effect on our results of operations and financial condition. Â 19 Â Â If we do not find available sources of liquidity for capital and financing needs, our business and operations may be materially and adversely affected. Â We may experience unexpected changes in business conditions, creating additional capital and financing needs. We believe that our current cash and cash equivalents, anticipated cash flows from operating activities, and the loans from third parties or our related parties will be sufficient to meet our anticipated working capital requirements and capital expenditures in the ordinary course of business for the next 12 months. However, we may need additional sources of liquidity if we find and wish to pursue opportunities for investment, acquisition, capital expenditure or otherwise. If our available cash and cash equivalents on hand are insufficient to cover our expected cash requirements, we may seek to issue equity or debt securities or obtain credit facilities. The issuance and sale of additional equity would result in dilution to our shareholders. We cannot guarantee that financing will be available to us under terms acceptable to us, or at all. Â Â The incurrence of indebtedness would result in increased fixed obligations and could result in covenants restricting our operations. It could further lead to a number of risks that could adversely affect our operations or financial conditions; Â Â default and foreclosure on our assets if our operating revenue is insufficient to repay debt obligations; Â Â acceleration of obligations to repay the indebtedness (or other outstanding indebtedness), even if we make all principal and interest payments when due, if we breach any covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; Â Â our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; Â Â diverting a substantial portion of cash flow to pay principal and interest on such debt, which would reduce the funds available for expenses, capital expenditures, acquisitions, and other general corporate purposes; Â Â creating potential limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; and Â Â loss that might be incurred due to our overseas investment activities. Â If our internal controls over financial reporting are insufficient or ineffective, we may not be able to accurately report our financial results or prevent fraud. Â We are subject to reporting obligations under the U.S. securities laws. Section 404 of the Sarbanes-Oxley Act of 2002 requires that we include a management report on such company's internal control over financial reporting in our annual report on Form 20-F. Our management has concluded that our internal control over financial reporting was effective as of March 31, 2024. See "Item 15. Controls and Procedures." Â During the course of documenting and testing our internal control procedures, in order to satisfy the requirements of Section 404, we may identify weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404. If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of our ADSs. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions. We may also be required to restate our financial statements from prior periods. Â 20 Â Â Our business, financial performance and results of operations could be adversely affected by deterioration of the relation between China and the United States. Â The relation between China and the United States is constantly changing. There was a "trade war" between the two countries in 2019 and tensions exist in other areas such as political, social and health issues, particularly recent disagreements in relation to the COVID-19 pandemic. In light of the recent tensions between China and the United States, there is a risk that our business, the offering and our listing status may be adversely affected by trade restrictions, sanctions and other policies that may be implemented. As we operate in China, any deterioration in political or trade relations might cause a public perception in the United States or elsewhere that might cause our services to become less attractive. The United States lawmakers have introduced several bills intended to protect American investments in Chinese companies. On June 4, 2020, the U.S. President Donald Trump issued PWG, criticizing China's failure to uphold international commitment to transparency and calling for recommendations to protect U.S. investors from China's failure to allow audits of U.S.-listed Chinese companies. PWG may impact U.S.-listed Chinese companies if strict compliance with audit requirements and U.S. law or new listing rules or governance standards were imposed. Changes in political conditions and changes in the state of China-U.S. relations are difficult to predict and could adversely affect our business, operating results and financial condition. We cannot predict what effect any changes in China-U.S. relations may have on our ability to access capital or effectively operate our business in China. Moreover, any political or trade controversies between the United States and China, whether or not directly related to our business, could cause investors to be unwilling to hold or buy our ADSs and consequently cause the trading price of our ADSs to decline. Â RISKS RELATED TO OUR CORPORATE STRUCTURE Â PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering and the concurrent private placement to make loans to or make additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business. Â Under PRC laws and regulations, we are permitted to utilize the proceeds from our initial public offering and

the concurrent private placement to fund our PRC subsidiary by making loans to or additional capital contributions to our PRC subsidiary, subject to applicable government registration and approval requirements. A Any loans to our PRC subsidiary, which are treated as foreign-invested enterprises under PRC laws, are subject to PRC regulations and foreign exchange loan registrations. For example, loans by us to our PRC subsidiary to finance their activities cannot exceed statutory limits and must be registered with the local counterpart of the State Administration of Foreign Exchange, or SAFE. According to the Interim Measures on the Management of Foreign Debts promulgated by SAFE, the Ministry of Finance and the National Development and Reform Commission, or the NDRC, on January4 8,2003, the statutory limit for the total amount of foreign debts of a foreign-invested company is the difference between the amount of total investment as approved by the MOC or its local counterpart and the amount of registered capital of such foreign-invested company, or two times of the net assets provided in the latest audited financial report of such PRC subsidiary, as applicable. According to the Circular of the People’s Bank of China on Matters relating to the Comprehensive Macro-prudential Management of Cross-border Financing issued by the People’s Bank of China in January2017, or Circular9, and Circular of the People’s Bank of China and the State Administration of Foreign Exchange on Adjusting the Macro-prudential Regulation Parameter for Full-covered Cross-border Financing in March2020, or Circular64, the maximum amounts of foreign debt that each company may borrow is determined by reference to its so-called risk-weighted balance of cross-border financing, which may not exceed two times its net assets as indicated in its latest audited financial report. The risk-weighted balance of cross-border financing of a company is calculated based on its outstanding amounts of Renminbi and foreign currency cross-border debt, multiplied by risk conversion factors corresponding to their respective remaining terms, loan categories and currency. However, for a one-year grace period starting from January11,2017, a foreign-invested company such as our PRC subsidiaries may elect to determine the maximum amount of its foreign debt in according with the rules in effect prior to Circular9, or to comply with Circular9. On the other hand, PRC domestic companies such as our consolidated variable interest entities must comply with Circular9. Moreover, according to Notice of the National Development and Reform Commission on Promoting the Administrative Reform of the Recordation and Registration System for Enterprises’ Issuance of Foreign Debts issued by the NDRC in September2015, any loans we extend to our consolidated variable interest entities or other PRC operating companies that are domestic PRC entities for more than one year must be filed with the NDRC or its local counterpart and must also be registered with SAFE or its local branches. 21 A We may also decide to finance our PRC subsidiary by means of capital contributions. These capital contributions must be approved by the MOC or its local counterpart. In addition, SAFE issued a circular in September2008, SAFE Circular142, regulating the conversion by a foreign-invested enterprise of foreign currency registered capital into RMB by restricting how the converted RMB may be used. SAFE Circular142 provides that the RMB capital converted from foreign currency registered capital of a foreign-invested enterprise may only be used for purposes within the business scope approved by the applicable government authority and unless otherwise provided by law, may not be used for equity investments within the PRC. Although on July4,2014, the SAFE issued the Circular of the SAFE on Relevant Issues Concerning the Pilot Reform in Certain Areas of the Administrative Method of the Conversion of Foreign Exchange Funds by Foreign-invested Enterprises, or SAFE Circular36, which launched a pilot reform of the administration of the settlement of the foreign exchange capitals of foreign-invested enterprises in certain designated areas from August4,2014 and some of the restrictions under SAFE Circular142 will not apply to the settlement of the foreign exchange capitals of the foreign-invested enterprises established within the designate areas and such enterprises mainly engaging in investment are allowed to use its RMB capital converted from foreign exchange capitals to make equity investment, our PRC subsidiary is not established within the designated areas. On March30,2015, SAFE promulgated Circular19, to expand the reform nationwide. Circular19 came into force and replaced both Circular142 and Circular36 on June1,2015. Circular19 allows foreign-invested enterprises to make equity investments by using RMB fund converted from foreign exchange capital. However, Circular19 continues to prohibit foreign-invested enterprises from, among other things, using RMB fund converted from its foreign exchange capitals for expenditure beyond its business scope, providing entrusted loans or repaying loans between non-financial enterprises. On June9,2016, the SAFE promulgated Circular16, which expands the application scope from only the capital of the foreign-invested enterprises to the capital, the foreign debt funds and the funds from oversea public offerings. Also, Circular16 allows enterprises to use their foreign exchange capitals under their capital account as stipulated by the relevant laws and regulations. On October23,2019, the SAFE issued the Notice of the State Administration of Foreign Exchange on Further Facilitating Cross-border Trade and Investment, which, among other things, expanded the use of foreign exchange capital to domestic equity investments. Non-investment foreign-funded enterprises are allowed to lawfully make domestic equity investments by using capital funds, subject to the authenticity and compliance with the regulations of such domestic investment projects (including, among others, the compliance of special administrative measures for access of foreign investments (negative list)). If our consolidated variable interest entities need financial support from us or our wholly owned subsidiaries in the future and we find it necessary to use foreign currency-denominated capital to provide such financial support, our ability to fund our consolidated variable interest entities’ operations will be subject to statutory limits and restrictions, including those described above. A In light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans to our PRC subsidiary or future capital contributions by us to our PRC subsidiary. If we fail to complete such registrations or obtain such approvals, our ability to use the proceeds we expect to receive from our initial public offering and the concurrent private placement and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business. 22 A RISKS RELATED TO DOING BUSINESS IN THE PEOPLE’S REPUBLIC OF CHINA A Although the audit report included in this annual report is prepared by an auditor who are currently inspected by the Public Company Accounting Oversight Board (the “PCAOB”), there is no guarantee that future audit reports will be prepared by auditors inspected by the PCAOB and, as such, in the future investors may be deprived of the benefits of such inspection. Furthermore, trading in our securities may be prohibited under the Holding Foreign Companies Accountable Act (the “HFCA Act”) if the SEC subsequently determines our audit work is performed by auditors that the PCAOB is unable to inspect or investigate completely, and as a result, U.S. national securities exchanges, such as Nasdaq, may determine to delist our securities. Furthermore, on December 29, 2022, the Consolidated Appropriations Act, was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things, an identical provision to AHFCAA, which reduce the number of consecutive non-inspection years required for triggering the prohibitions under the HFCA Act from three years to two. A As an auditor of companies that are registered with the SEC and publicly traded in the United States and a firm registered with the PCAOB, our auditor is required under the laws of the United States to undergo regular inspections by the PCAOB to assess their compliance with the laws of the United States and professional standards. A Although we operate part of our business in mainland China, a jurisdiction where the PCAOB is currently unable to conduct inspections without the approval of the Chinese government authorities, our auditor, OneStop Assurance PAC, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess our auditor’s compliance with the applicable professional standards. Inspections of other auditors conducted by the PCAOB outside mainland China have at times identified deficiencies in those auditors’ audit procedures and quality control procedures, which may be addressed as part of the inspection process to improve future audit quality. The lack of PCAOB inspections of audit work undertaken in mainland China prevents the PCAOB from regularly evaluating auditors’ audits and their quality control procedures. As a result, if there is any component of our auditor’s work papers become located in mainland China in the future, such work papers will not be subject to inspection by the PCAOB. As a result, investors would be deprived of such PCAOB inspections, which could result in limitations or restrictions to our access of the U.S. capital markets. A As part of a continued regulatory focus in the United States on access to audit and other information currently protected by national law, in particular mainland China’s, in June 2019, a bipartisan group of lawmakers introduced bills in both houses of the U.S. Congress which, if passed, would require the SEC to maintain a list of issuers for which PCAOB is not able to inspect or investigate the audit work performed by a foreign public accounting firm completely. The proposed Ensuring Quality Information and Transparency for Abroad-Based Listings on our Exchanges (the “EQUITABLE”) Act prescribes increased disclosure requirements for these issuers and, beginning in 2025, the delisting from U.S. national securities exchanges such as Nasdaq of issuers included on the SEC’s list for three consecutive years. It is unclear if this proposed legislation will be enacted. Furthermore, there have been recent deliberations within the U.S. government regarding potentially limiting or restricting China-based companies from accessing U.S. capital markets. On May 20, 2020, the U.S. Senate passed the Holding Foreign Companies Accountable Act (the “HFCA Act”), which includes requirements for the SEC to identify issuers whose audit work is performed by auditors that the PCAOB is unable to inspect or investigate completely because of a restriction imposed by a non-U.S. authority in the auditor’s local jurisdiction. The U.S. House of Representatives passed the HFCA Act on December 2, 2020, and the HFCA Act was signed into law on December 18, 2020. Additionally, in July 2020, the U.S. President’s Working Group on Financial Markets issued recommendations for actions that can be taken by the executive branch, the SEC, the PCAOB or other federal agencies and department with respect to Chinese companies listed on U.S. stock exchanges and their audit firms, in an effort to protect investors in the United States. In response, on November 23, 2020, the SEC issued guidance highlighting certain risks (and their implications to U.S. investors) associated with investments in China-based issuers and summarizing enhanced disclosures the SEC recommends China-based issuers make regarding such risks. On March 24, 2021, the SEC adopted interim final rules relating to the implementation of certain disclosure and documentation requirements of the HFCA Act. We will be required to comply with these rules if the SEC identifies us as having a “non-inspection” year (as defined in the interim final rules) under a process to be subsequently established by the SEC. The SEC is assessing how to implement other requirements of the HFCA Act, including the listing and trading prohibition requirements described above. Under the HFCA Act, our securities may be prohibited from trading on Nasdaq or other U.S. stock exchanges if our auditor is not inspected by the PCAOB for three consecutive years, and this ultimately could result in our Ordinary Shares being delisted. 23 A Furthermore, on June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act (the “AHFCAA”), which, if enacted, would amend the HFCA Act and require the SEC to prohibit an issuer’s securities from trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three and would reduce the time before our securities may be prohibited from trading or delisted. On September 22, 2021, the PCAOB adopted a final rule implementing the AHFCAA, which provides a framework for the PCAOB to use when determining, as contemplated under the AHFCAA, whether the Board is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction. On November 5, 2021, the SEC approved the PCAOB’s Rule 6100, Board Determinations Under the HFCA Act. On December 2, 2021, the SEC issued amendments to finalize rules implementing the submission and disclosure requirements in the HFCA Act. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely because of a position taken by an authority in foreign jurisdictions. On December 16, 2021, the PCAOB issued a Determination Report which found that the PCAOB is unable to inspect or investigate completely registered public accounting firms headquartered in: (1) mainland China of the PRC, and (2) Hong Kong. In addition, the PCAOB’s report identified the specific registered public accounting firms which are subject to these determinations. On December 29, 2022, the Consolidated Appropriations Act, was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things, an identical provision to AHFCAA, which reduce the number of consecutive non-inspection years required for triggering the prohibitions under the HFCA Act from three years to two. Our auditor, OneStop Assurance PAC, is headquartered in Singapore, not mainland China or Hong Kong and was not identified in this report as a firm subject to the PCAOB’s determination. Therefore, our auditor is not currently subject to the determinations announced by the PCAOB on December 16, 2021, and it is currently subject to the PCAOB inspections. A While our auditor is based in the Singapore and is registered with the PCAOB and has been inspected by the PCAOB on a regular basis, in the event it is later determined that the PCAOB is unable to inspect or investigate completely our auditor because of a position taken by an authority in a foreign jurisdiction, then such lack of inspection could cause trading in the our securities to be prohibited under the HFCA Act, and ultimately result in a determination by a securities exchange to delist our securities. In addition, the recent developments would add uncertainties to the listing and trading of our Class A ordinary shares and we cannot assure you whether Nasdaq or regulatory authorities would apply additional and more stringent criteria to us after considering the effectiveness of our auditor’s audit procedures and quality control procedures, adequacy of personnel and training, or sufficiency of resources, geographic reach or experience as it relates to the audit of our financial statements. It remains unclear what the SEC’s implementation process related to the above rules will entail or what further actions the SEC, the PCAOB or Nasdaq will take to address these issues and what impact those actions will have on U.S. companies that have significant operations in the PRC and have securities listed on a U.S. stock exchange (including a national securities exchange or over-the-counter stock market). In addition, the above amendments and any additional actions, proceedings, or new rules resulting from these efforts to increase U.S. regulatory access to audit information could create some uncertainty for investors, the market price of our ADSs could be adversely affected, and we could be delisted if we and our auditor are unable to meet the PCAOB inspection requirement or being required to engage a new audit firm, which would require significant expense and management time. A On August 26, 2022, the PCAOB signed a Statement of Protocol (the “SOP”) Agreements with the CSRC and China’s Ministry of Finance. The SOP Agreement, together with two protocol agreements (collectively, “SOP Agreements”), governs inspections and investigations of audit firms based in mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. Pursuant to the fact sheet with respect to the Protocol disclosed by the SEC, the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB’s access in the future, the PCAOB Board will consider the need to issue a new determination. Delisting of our ADSs would force holders of our ADSs to sell their ADSs. The market price of our ADSs could be adversely affected as a result of anticipated negative impacts of these executive or legislative actions upon, as well as negative investor sentiment towards, companies with significant operations in China that are listed in the United States, regardless of whether these executive or legislative actions are implemented and regardless of our actual operating performance. 24 A The recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the U.S. Senate and the U.S. House of Representatives, all call for additional and more stringent criteria to be applied to emerging market companies. These developments could add uncertainties to our business operations, share price and reputation. A U.S. public companies that have substantially all of their operations in China have been the subject of intense scrutiny, criticism and negative publicity by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and negative publicity has centered on financial and accounting irregularities and mistakes, a lack of effective internal controls over financial accounting, inadequate corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud. A On December7, 2018, the SEC and the PCAOB issued a joint statement highlighting continued challenges faced by the U.S. regulators in their oversight of financial statement audits of U.S.-listed companies with significant operations in China. On April21, 2020, SEC Chairman Jay Clayton and PCAOB Chairman William D. Duhnke III, along with other senior SEC staff, released a joint statement highlighting the risks associated with investing in companies based in or have substantial operations in emerging markets including China, reiterating past SEC and PCAOB statements on matters including the difficulty associated with inspecting accounting firms and audit work papers in China and higher risks of fraud in emerging markets and the difficulty of bringing and enforcing SEC, Department of Justice and other U.S. regulatory actions, including in instances of fraud, in emerging markets generally. A On May18, 2020, Nasdaq filed three proposals with the SEC to (i) apply minimum offering size requirement for companies primarily operating in a “Restrictive Market”, (ii) adopt a new requirement relating to the qualification of management or board of director for Restrictive Market companies, and (iii) apply additional and more stringent criteria to an applicant or listed company based on the qualifications of the company’s auditors. A On May20, 2020, the U.S. Senate passed the Holding Foreign Companies Accountable Act requiring a foreign company to certify it is not owned or controlled by a foreign government if the PCAOB is unable to audit specified reports because the company uses a foreign auditor not subject to PCAOB inspection. If the PCAOB is unable to inspect the company’s auditors for three consecutive years, the issuer’s securities are prohibited to trade on a national exchange. On December2, 2020, the U.S. House of Representatives approved the Holding Foreign Companies Accountable Act. A On May21, 2021, Nasdaq filed three proposals with the SEC to (i) apply minimum offering size requirement for companies primarily

operating in a Restrictive Market, (ii) prohibit Restrictive Market companies from directly listing on Nasdaq Capital Market, and only permit them to list on Nasdaq Global Select or Nasdaq Global Market in connection with a direct listing and (iii) apply additional and more stringent criteria to an applicant or listed company based on the qualifications of the company's auditors. As a result of these scrutiny, criticism and negative publicity, the publicly traded stock of many U.S. listed Chinese companies sharply decreased in value and, in some cases, has become virtually worthless. Many of these companies are now subject to shareholder lawsuits and SEC enforcement actions and are conducting internal and external investigations into the allegations. It is not clear what effect this sector-wide scrutiny, criticism and negative publicity will have on us, our business and our share price. If we become the subject of any unfavorable allegations, whether such allegations are proven to be true or untrue, we will have to expend significant resources to investigate such allegations and/or defend our company. This situation will be costly and time consuming and distract our management from developing our growth. If such allegations are not proven to be groundless, we and our business operations will be severely affected and you could sustain a significant decline in the value of our share. There may be changes in the regulations of PRC government bodies and agencies relating to VAT collection procedure and ACTCS business PRC laws, regulations and policies concerning VAT collection procedures and ACTCS business are evolving and the PRC government authorities may promulgate new laws, regulations and policies in the future. We cannot assure you that our practices would not be deemed to violate any PRC laws, regulations or policies either now or in the future. A Moreover, developments in the ACTCS service industry may lead to changes in PRC laws, regulations and policies or in the interpretation and application of existing laws, regulations and policies, which may limit or restrict the ACTCS hardware and services we offer. Furthermore, we cannot rule out the possibility that the PRC government will institute a new licensing regime covering services we provide in the future. If such a licensing regime were introduced, we cannot assure you that we would be able to obtain any newly required license in a timely manner, or at all, which could materially and adversely affect our business and impede our ability to continue our operations. A Failure to comply with laws and regulations applicable to our business could subject us to fines and penalties and could also cause us to lose customers or otherwise harm our business. A Our business is subject to regulation by various governmental agencies in China, including agencies responsible for monitoring and enforcing compliance with various legal obligations, such as value-added telecommunication laws and regulations, privacy and data protection-related laws and regulations, intellectual property laws, employment and labor laws, workplace safety, environmental laws, consumer protection laws, governmental trade laws, import and export controls, anti-corruption and anti-bribery laws, and tax laws and regulations. In certain jurisdictions, these regulatory requirements may be more stringent than in China. These laws and regulations impose added costs on our business. Noncompliance with applicable regulations or requirements could subject us to: A investigations, enforcement actions, and sanctions; A mandatory changes to our network and products; A disgorgement of profits, fines, and damages; A civil and criminal penalties or injunctions; A claims for damages by our customers or channel partners; A termination of contracts; A loss of intellectual property rights; A failure to obtain, maintain or renew certain licenses, approvals, permits, registrations or filings necessary to conduct our operations; and A temporary or permanent debarment from sales to public service organizations. A If any governmental sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations, and financial condition could be adversely affected. In addition, responding to any action will likely result in a significant diversion of our management's attention and resources and an increase in professional fees. Enforcement actions and sanctions could materially harm our business, results of operations, and financial condition. A Additionally, companies in the technology industry have recently experienced increased regulatory scrutiny. Any reviews by regulatory agencies or legislatures may result in substantial regulatory fines, changes to our business practices, and other penalties, which could negatively affect our business and results of operations. Changes in social, political, and regulatory conditions or in laws and policies governing a wide range of topics may cause us to change our business practices. Further, our expansion into a variety of new fields also could raise a number of new regulatory issues. These factors could negatively affect our business and results of operations in material ways. A Moreover, we are exposed to the risk of misconduct, errors and failure to functions by our management, employees and parties that we collaborate with, who may from time to time be subject to litigation and regulatory investigations and proceedings or otherwise face potential liability and penalties in relation to noncompliance with applicable laws and regulations, which could harm our reputation and business. A In light of recent events indicating greater oversight by the Cyberspace Administration of China, or CAC, over data security, particularly for companies seeking to list on a foreign exchange, we are subject to a variety of laws and other obligations regarding cybersecurity and data protection, and any failure to comply with applicable laws and obligations could have a material and adverse effect on our business, our listing on NASDAQ, financial condition, and results of operations. A We are subject relating various risks and costs associated with to the collection, use, sharing, retention, security, and transfer of confidential and private information, such as personal information and other data. This data is wide ranging and relates to our customers and any other third parties. Our compliance obligations include those relating to the Data Protection Act (As Revised) of the Cayman Islands and the relevant PRC laws in this regard. These PRC laws apply not only to third-party transactions, but also to transfers of information among us and our PRC subsidiaries, and other parties with which we have commercial relations. These laws continue to develop, and the PRC government may adopt other rules and restrictions in the future. Non-compliance could result in penalties or other significant legal liabilities. A Pursuant to the PRC Cybersecurity Law, which was promulgated by the Standing Committee of the National People's Congress on November 7, 2016 and took effect on June 1, 2017, personal information and important data collected and generated by a critical information infrastructure operator in the course of its operations in China must be stored in China, and if a critical information infrastructure operator purchases internet products and services that affects or may affect national security, it should be subject to cybersecurity review by the CAC. Due to the lack of further interpretations, the exact scope of critical information infrastructure operator remains unclear. On December 28, 2021, the CAC and other relevant PRC governmental authorities jointly promulgated the Cybersecurity Review Measures (the "new Cybersecurity Review Measures") to replace the original Cybersecurity Review Measures. The new Cybersecurity Review Measures took effect on February 15, 2022. Pursuant to the new Cybersecurity Review Measures, if critical information infrastructure operators purchase network products and services, or network platform operators conduct data processing activities that affect or may affect national security, they will be subject to cybersecurity review. A network platform operator holding more than one million users' individual information also shall be subject to cybersecurity review before listing abroad. The cybersecurity review will evaluate, among others, the risk of critical information infrastructure, core data, important data, or a large amount of personal information being influenced, controlled or maliciously used by foreign governments and risk of network data security after going public overseas. In the opinion of our PRC counsel, Hebei Changjun Law Firm we are not subject to cybersecurity review, because: (i) we do not collect or maintain personal information in our business operations and (ii) data processed in our business does not have a bearing on national security and thus may not be classified as core or important data by the authorities. However, Hebei Changjun Law Firm has also advised us that since the regulatory authorities have discretion in this regard, whether an entity is subject to cybersecurity review shall still subject to the regulatory authorities' view. In addition, we currently do not have over one million users' personal information and do not anticipate to collect over one million users' personal information in the foreseeable future. If we ever became subject to the cybersecurity review of CAC in the future as the applicable rules, regulations, policies or the interpretation thereof change, during such review, we may be required to suspend our operation or experience other disruptions to our operations. Cybersecurity review could also result in negative publicity with respect to our company and diversion of our managerial and financial resources. A Furthermore, if we were found to be in violation of applicable laws and regulations in China during such review, we could be subject to administrative penalties, such as warnings, fines, or service suspension. Therefore, cybersecurity review could materially and adversely affect our business, financial condition, and results of operations. A 27 A In addition, the PRC Data Security Law, which was promulgated by the Standing Committee of the National People's Congress on June 10, 2021 and took effect on September 1, 2021, requires data collection to be conducted in a legitimate and proper manner, and stipulates that, for the purpose of data protection, data processing activities must be conducted based on data classification and hierarchical protection system for data security. As the Data Security Law was recently promulgated, we may be required to make further adjustments to our business practices to comply with this law. If our data processing activities were found to be not in compliance with this law, we could be ordered to make "corrections, and under certain serious circumstances, such as severe data divulgence, we could be subject to penalties, including the revocation of our business licenses or other permits. Furthermore, the recently issued Opinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law require (i) speeding up the revision of the provisions on strengthening the confidentiality and archives management relating to overseas issuance and listing of securities and (ii) improving the laws and regulations relating to data security, cross-border data flow, and management of confidential information. As there remain uncertainties regarding the further interpretation and implementation of those laws and regulations, we cannot assure you that we will be compliant such new regulations in all respects, and we may be ordered to rectify and terminate any actions that are deemed illegal by the regulatory authorities and become subject to fines and other sanctions. As a result, we may be required to suspend our relevant businesses, shut down our website, take down our operating applications, or face other penalties, which may materially and adversely affect our business, financial condition, and results of operations. A On August 20, 2021, the Standing Committee of the National People's Congress of China promulgated the PIPL, which took effect in November 2021. As the first systematic and comprehensive law specifically for the protection of personal information in the PRC, the PIPL provides, among others, that (i) an individual's consent shall be obtained to use sensitive personal information, such as biometric characteristics and individual location tracking, (ii) personal information operators using sensitive personal information shall notify individuals of the necessity of such use and impact on the individual's rights, and (iii) where personal information operators reject an individual's request to exercise his or her rights, the individual may file a lawsuit with a People's Court. As uncertainties remain regarding the interpretation and implementation of the PIPL, we cannot assure you that we will comply with the PIPL in all respects, we may become subject to fines and/or other penalties which may have material adverse effect on our business, operations and financial condition. A While we take measures to comply with all applicable data privacy and protection laws and regulations, we cannot guarantee the effectiveness of the measures undertaken by us. However, compliance with any additional laws could be expensive, and may place restrictions on our business operations and the manner in which we interact with our users. In addition, any failure to comply with applicable cybersecurity, privacy, and data protection laws and regulations could result in proceedings against us by government authorities or others, including notification for rectification, confiscation of illegal earnings, fines, or other penalties and legal liabilities against us, which could materially and adversely affect our business, financial condition, results of operations and the value of our ADSs. In addition, any negative publicity on our website or platform's safety or privacy protection mechanism and policy could harm our public image and reputation and materially and adversely affect our business, financial condition, and results of operations. A The approval of the China Securities Regulatory Commission, or the CSRC, may be required in connection with an offering under PRC rules, regulations, or policies, and, if required, we cannot predict whether or how soon we will be able to obtain such approval. As a result, both you and us face uncertainty about future actions by the PRC government that could significantly affect our business, our listing on Nasdaq, financial condition and results of operations. A On August 8, 2006, six PRC regulatory agencies, including the MOFCOM, the State-Owned Assets Supervision and Administration Commission, or the SASAC, the SAT, the State Administration for Industry and Commerce, or the SAIC, the CSRC, and the State Administration of Foreign Exchange, or the SAFE, jointly adopted the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&A Rules, which came into effect on September 8, 2006 and were amended on June 22, 2009. The M&A Rules include, among other things, provisions that purport to require that an offshore special purpose vehicle that is controlled by PRC domestic companies or individuals and that has been formed for the purpose of an overseas listing of securities through acquisitions of PRC domestic companies or assets to obtain the approval of the CSRC prior to the listing and trading of such special purpose vehicle's securities on an overseas stock exchange. On September 21, 2006, the CSRC published on its official website procedures regarding its approval of overseas listings by special purpose vehicles. However, substantial uncertainty remains regarding the scope and applicability of the M&A Rules to offshore special purpose vehicles. A 28 A While the application of the M&A Rules remains unclear, we believe, based on the advice of our PRC legal counsel, Hebei Changjun Law Firm that the CSRC approval is not required for the listing and trading our ADSs on the Nasdaq Capital Market because Qingdao Akso Health Management Co., Ltd., or our WFOE was incorporated as a foreign-invested enterprise by means of foreign direct investments rather than by merger with or acquisition of any PRC domestic companies as defined under the M&A Rules. There can be no assurance that the relevant PRC government agencies, including the CSRC, would reach the same conclusion as our PRC legal counsel. If the CSRC or other PRC regulatory body subsequently determines that we need to obtain the CSRC's approval for our offering or if the CSRC or any other PRC government authorities promulgates any interpretation or implements rules that would require us to obtain CSRC or other governmental approvals for our offering, we may face adverse actions or sanctions by the CSRC or other PRC regulatory agencies. In any such event, these regulatory agencies may impose fines and penalties on our operations in China, limit our operating privileges in China, delay or restrict the repatriation of the proceeds from our offerings into the PRC, restrictions on or prohibition of the payments or remittance of dividends by our subsidiaries in China, or other actions that could have a material and adverse effect on our business, reputation, financial condition, results of operations, prospects, as well as the trading price of the ADSs. The CSRC or other PRC regulatory agencies may also take actions requiring us, or making it advisable for us, to halt our offering before settlement and delivery of the Ordinary Shares that we are offering. Consequently, if you engage in market trading or other activities in anticipation of and prior to settlement and delivery, you would be doing so at the risk that the settlement and delivery may not occur. In addition, if the CSRC or other regulatory agencies later promulgate new rules or explanations requiring us to obtain their approvals for our offering, we may be unable to obtain waivers of such approval requirements. Any uncertainties or negative publicity regarding such approval requirements could materially and adversely affect the trading price of our ADSs. A As of the date of this annual report, as advised by our PRC counsel, Hebei Changjun Law Firm, we and our subsidiaries, (1) currently are not required to obtain permissions from any PRC authorities to list or trade our ADSs in foreign stock exchanges, (2) are not subject to permission requirements from the CSRC, CAC or any other entity that is required to approve of our PRC subsidiaries' operations, and (3) have not received or were denied such permissions by any PRC authorities. Nevertheless, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the "Opinions on Severely Cracking Down on Illegal Securities Activities According to Law," or the Opinions, which were made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal securities activities, and the need to strengthen the supervision over overseas listings by Chinese companies. Given the current PRC regulatory environment, it is uncertain when and whether we or our PRC subsidiaries, will be required to obtain permission from the PRC government to list on U.S. exchanges in the future, and even when such permission is obtained, whether it will be denied or rescinded. We have been closely monitoring regulatory developments in China regarding any necessary approvals from the CSRC or other PRC governmental authorities required for overseas listings. As of the date of this annual report, we have not received any inquiry, notice, warning, sanctions or regulatory objection to this offering from the CSRC or other PRC governmental authorities. However, there remains significant uncertainty as to the enactment, interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities. A On February 17, 2023, the CSRC promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the "Trial Measures"), which took effect on March 31, 2023. The Trial Measures clarified and emphasized several aspects, which include but are not limited to: (1) comprehensive determination of the indirect overseas offering and listing by PRC domestic companies in compliance with the principle of substance over form and particularly, an issuer will be required to go through the filing procedures under the Trial Measures if the following criteria are met at the same time: a) 50% or more of the issuer's operating revenue, total profit, total assets or net assets as documented in its audited consolidated financial statements for the most recent accounting year is accounted for by PRC domestic companies, and b) the main parts of the issuer's business activities are conducted in mainland China, or its main places of business are located in mainland China, or the senior managers in charge of its business operation and management are mostly Chinese citizens or domiciled in mainland China; (2) exemptions from immediate filing requirements for issuers that a) have already been listed or registered but not yet listed in foreign securities markets, including U.S. markets, prior to the effective date of the Trial Measures, and b) are not required to re-perform the regulatory procedures with the relevant overseas regulatory authority or the overseas stock exchange, c) whose such overseas securities offering or listing shall be completed before September 30, 2023, provided however that such issuers shall carry out filing procedures as required if they conduct refinancing or are involved in other circumstances that require filing with the CSRC; (3) a negative list of types of issuers banned from listing or offering overseas, such as (a) issuers whose listing or offering overseas have been recognized by the State Council of the PRC as possible threats to national security, (b) issuers whose affiliates have been recently convicted of bribery and corruption, (c) issuers under ongoing criminal investigations, and (d) issuers under major disputes regarding equity ownership; (4)

issuersâ€™ compliance with web security, data security, and other national security laws and regulations; (5) issuersâ€™ filing and reporting obligations, such as obligation to file with the CSRC after it submits an application for initial public offering to overseas regulators, and obligation after offering or listing overseas to report to the CSRC material events including change of control or voluntary or forced delisting of the issuer; and (6) the CSRCâ€™s authority to fine both issuers and their shareholders between 1 and 10 million RMB for failure to comply with the Trial Measures, including failure to comply with filing obligations or committing fraud and misrepresentation. A 29 A Changes in the policies of the PRC government could have a significant impact upon our ability to operate profitably in the PRC. A We conduct all of our operations and all of our revenue is generated in the PRC. Accordingly, economic, political and legal developments in the PRC will significantly affect our business, financial condition, results of operations and prospects. Policies of the PRC government can have significant effects on economic conditions in the PRC and the ability of businesses to operate profitably. Our ability to operate profitably in the PRC may be adversely affected by changes in policies by the PRC government, including changes in laws, regulations or their interpretation, particularly those dealing with the Internet, including censorship and other restriction on material which can be transmitted over the Internet, security, intellectual property, money laundering, taxation and other laws that affect our ability to operate our website. A Because our business is dependent upon government policies that encourage a market-based economy, change in the political or economic climate in the PRC may impair our ability to operate profitably, if at all. A Although the PRC government has been pursuing a number of economic reform policies for more than two decades, the PRC government continues to exercise significant control over economic growth in the PRC. Because of the nature of our business, we are dependent upon the PRC government pursuing policies that encourage private ownership of businesses. Restrictions on private ownership of businesses would affect the VAT filing and collection in general and businesses using ACTCS in particular. We cannot assure you that the PRC government will pursue policies favoring a market-oriented economy or that existing policies will not be significantly altered, especially in the event of a change in leadership, social or political disruption, or other circumstances affecting political, economic and social life in the PRC. A PRC laws and regulations governing our current business operations are sometimes vague and uncertain and any changes in such laws and regulations may impair our ability to operate profitably. A There are substantial uncertainties regarding the interpretation and application of PRC laws and regulations including, but not limited to, the laws and regulations governing our business and the enforcement and performance of our arrangements with customers in certain circumstances. The laws and regulations are sometimes vague and may be subject to future changes, and their official interpretation and enforcement may involve substantial uncertainty. The effectiveness and interpretation of newly enacted laws or regulations, including amendments to existing laws and regulations, may be delayed, and our business may be affected if we rely on laws and regulations which are subsequently adopted or interpreted in a manner different from our understanding of these laws and regulations. New laws and regulations that affect existing and proposed future businesses may also be applied retroactively. We have substantially operations conducted by our VIEs in China, which are governed by PRC laws, rules and regulations. Our PRC subsidiaries and the VIEs are subject to laws and regulations applicable to foreign investment in China. We cannot predict what effect the interpretation of existing or new PRC laws or regulations may have on our business. A The PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions under the civil law system may be cited for reference but have limited precedential value. Since these laws and regulations are relatively new and the PRC legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and the enforcement of these laws, regulations and rules involves uncertainties. A In 1979, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The overall effect of legislation over the past three decades has significantly enhanced the protections afforded to various forms of foreign investments in China. However, China has not developed a fully integrated legal system, and recently enacted laws and regulations may not sufficiently cover all aspects of economic activities in China. In particular, the interpretation and enforcement of these laws and regulations involve uncertainties. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory provisions and contractual terms, it may be difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy. These uncertainties may affect our judgment on the relevance of legal requirements and our ability to enforce our contractual rights or tort claims. In addition, the regulatory uncertainties may be exploited through unmerited or frivolous legal actions or threats in attempts to extract payments or benefits from us. A Furthermore, the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all and may have retroactive effect. As a result, we may not be aware of our violation of any of these policies and rules until sometime after the violation. In addition, any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. A 30 A From time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. However, since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. Furthermore, the PRC legal system is based in part on government policies and internal rules (some of which are not published in a timely manner or at all) that may have retroactive effect. As a result, we may not be aware of our violation of these policies and rules until sometime after the violation. Such uncertainties, including uncertainty over the scope and effect of our contractual, property (including intellectual property) and procedural rights, and any failure to respond to changes in the regulatory environment in China could materially and adversely affect our business and impede our ability to continue our operations. A Recently, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the â€œOpinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law,â€ or the Opinions, which was made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal securities activities, and the need to strengthen the supervision over overseas listings by Chinese companies. Effective measures, such as promoting the construction of relevant regulatory systems will be taken to deal with the risks and incidents of China-concept overseas listed companies, and cybersecurity and data privacy protection requirements and similar matters. The Opinions and any related implementing rules to be enacted may subject us to compliance requirement in the future. A Changes in Chinaâ€™s macroeconomic, socio-political conditions or government policies could have a material adverse effect on our business and results of operations. A All of our operations are located in China. Accordingly, our business, prospects, financial condition and results of operations are affected significantly by the political, economic and social climate in China and continuously by the economic performance of China as a whole. A The Chinese economy is unique from the economies of most developed countries in many respects, the more salient aspects include the amount of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. Although the Chinese government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in China is still state-owned. In addition, the Chinese government continues to play a significant role in regulating industry development by imposing industrial policies. The Chinese government also exercises significant control over Chinaâ€™s economic growth through allocating resources, controlling payment of foreign currency-denominated obligations, setting the monetary policy, and determining the different levels of treatment accorded to different industries and companies in accordance with its national development policy. A While the Chinese economy has experienced significant growth over the past decades, the growth rate has had sporadic bursts, across geographically and among various sectors and industries. The Chinese government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall Chinese economy, but may have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations. In addition, in the past the Chinese government has implemented certain measures, including interest rate increases, to control the pace of economic growth. These measures may cause decreased economic activity in China, and since 2012, Chinaâ€™s economic growth has slowed down. Any prolonged slowdown in the Chinese economy may reduce the demand for our products and services and materially and adversely affect our business and results of operations. A Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted PRC Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations. A On MarchA 15,A 2019, the National Peopleâ€™s Congress approved the Foreign Investment Law, which came into effect on JanuaryA 1,A 2020 and replaced the trio of existing laws regulating foreign investment in China, namely, the Sino-foreign Equity Joint Venture Enterprise Law, the Sino-foreign Cooperative Joint Venture Enterprise Law and the Wholly Foreign-invested Enterprise Law, together with their implementation rulesA and ancillary regulations. The Foreign Investment Law embodies an expected PRC regulatory trend to rationalize its foreign investment regulatory regime in line with prevailing international practice and the legislative efforts to unify the corporate legal requirements for both foreign and domestic investments. However, since the Foreign Investment Law is relatively new, uncertainties still exist in relation to its interpretation and implementation. For instance, under the Foreign Investment Law, â€œforeign investmentâ€ refers to the investment activities directly or indirectly conducted by foreign individuals, enterprises or other entities in China. Although it does not explicitly classify contractual arrangements as a form of foreign investment, there is no assurance that foreign investment via contractual arrangement would not be interpreted as a type of indirect foreign investment activities under the definition in the future. In addition, the definition contains a catch-all provision which includes investments made by foreign investors through means stipulated in laws or administrative regulations or other methods prescribed by the State Council. Therefore, it still leaves leeway for future laws, administrative regulations or provisions promulgated by the State Council to provide for contractual arrangements as a form of foreign investment. In any of these cases, it will be uncertain whether our contractual arrangements will be deemed to be in violation of the market access requirements for foreign investment under the PRC laws and regulations. Furthermore, if future laws, administrative regulations or provisions prescribed by the State Council mandate further actions to be taken by companies with respect to existing contractual arrangements, we may face substantial uncertainties as to whether we can complete such actions in a timely manner, or at all. Failure to take timely and appropriate measures to cope with any of these or similar regulatory compliance challenges could materially and adversely affect our current corporate structure, corporate governance and business operations. A 31 A We may be adversely affected by the complexity, uncertainties and changes in PRC regulation of Internet-related businesses and companies, and any lack of requisite approvals, licenses or permits applicable to our business may have a material adverse effect on our business and results ofA operations. A The PRC government extensively regulates the Internet industry, including foreign ownership of, and the licensing and permit requirements pertaining to, companies in the Internet industry. These Internet-related laws and regulations are relatively new and evolving, and their interpretation and enforcement involve significant uncertainties. As a result, in certain circumstances it may be difficult to determine what actions or omissions may be deemed to be in violation of applicable laws and regulations. A We have only contractual control over our website. We do not directly own the website due to the restriction of foreign investment in businesses providing value-added telecommunication services in China, including Internet information provision services. This may significantly disrupt our business, subject us to sanctions, compromise enforceability of related contractual arrangements, or have other harmful effects onA us. A The evolving PRC regulatory system for the Internet industry may lead to the establishment of new regulatory agencies. For example, in MayA 2011, the State Council announced the establishment of a new department, the State Internet Information Office (with the involvement of the State Council Information Office, the Ministry of Industry and Information Technology, or the MIIT, and the Ministry of Public Security). The primary role of this new agency is to facilitate the policy-making and legislative development in this field, to direct and coordinate with the relevant departments in connection with online content administration and to deal with cross-ministry regulatory matters in relation to the Internet industry. A Fluctuations in exchange rates could have a material adverse effect on our results of operations and the value of your investment. A A portion of our revenues and expenditures are denominated in RMB, and the functional currency for our PRC subsidiary and consolidated variable interest entities is RMB, whereas our reporting currency is the U.S.A dollar. Any significant revaluation of RMB may materially and adversely affect our cash flows, revenues, earnings and financial position, and the value of, and any dividends payable on, our ADSs in U.S. dollars. For example, to the extent that we need to convert U.S.A dollars we receive from our initial public offering into RMB to pay our operating expenses, appreciation of the RMB against the U.S.A dollar would have an adverse effect on the RMB amount we would receive from the conversion. If we decide to convert our RMB into U.S.A dollars for the purpose of making payments for dividends on our ordinary shares or for other business purposes, appreciation of the U.S.A dollar against the RMB would have a negative effect on the U.S.A dollar amount available to us. Moreover, a significant depreciation of the RMB against the U.S. dollar may significantly reduce our earnings translated in the U.S. dollars, which in turn could adversely affect the price of our ADSs. Furthermore, fluctuations in currencies relative to the periods in which the earnings are generated may make it more difficult to perform period-to-period comparisons of our reported results ofA operations. A The value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in Chinaâ€™s political and economic conditions and foreign exchange policies. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future. In the year ended March 31, 2022, the value of the RMB appreciated approximately by 3.2% against of the U.S dollar. In the year ended March 31, 2023, the value of the RMB depreciated by approximately 8.3% against the U.S. dollar. And in the year ended March 31, 2024, the value of the RMB depreciated by approximately 5.1% against the U.S. dollar. With the development of the foreign exchange market and progress towards interest rate liberalization and RMB internationalization, the PRC government may in the future announce further changes to the exchange rate system and there is no guarantee that the RMB will not appreciate or depreciate significantly in value against the U.S. dollar in the future. A 32 A A Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert RMB into foreign currency. As a result, fluctuations in exchange rates may have a material adverse effect on your investment. A Governmental control of currency conversion may limit our ability to utilize our net revenues effectively and affect the value of your investment. A The PRC government imposes controls on the convertibility of the RMB into foreign currencies and, in certain cases, the remittance of currency out of China. We receive substantially all of our net revenues in RMB. Under our current corporate structure, our company in the Cayman Islands relies on dividend payments from our PRC subsidiary to fund any cash and financing requirements we may have. Under existing PRC foreign exchange regulations, payments of current account items, such as profit distributions and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval from SAFE by complying with certain procedural requirements. Therefore, our PRC subsidiary is able to pay dividends in foreign currencies to us without prior approval from SAFE, subject to the condition that the remittance of such dividends outside of the PRCA complies with certain procedures under PRC foreign exchange regulation, such as the overseas investment registrations by the beneficial owners of our company who are PRC residents. However, approval from or registration with appropriate government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may also at its discretion restrict access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies to our shareholders, including holders of ourA ADSs. A Failure to make adequate contributions to various employee benefit plans as required by PRC regulations may subject us toA penalties. A We are required under PRC laws and regulations to participate in various government sponsored employee benefit plans, including certain social insurance, housing funds and other welfare-oriented payment obligations, and contribute to the plans in amounts equal to certain percentages of salaries, including bonuses and allowances, of our employees up to a maximum amount specified by the local government from time to time at locations where we operate our businesses. The requirement of employee benefit plans has not been implemented consistently by the local governments in China given the different levels of economic development in different locations. We have not made adequate employee benefit payments. We may be required to make up the contributions for these plans as well as to pay late fees and fines. If we are subject to late fees or fines in relation to the underpaid employee benefits, our financial condition and results of operations may be adversely affected. A The M&A RulesA and certain other PRC regulations establish complex procedures for some acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions inA China. A The Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors, or the M&A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009, and some other regulations and rulesA concerning mergers and acquisitions established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex, including requirements in some instances that the MOC be notified in advance of any

change-of-control transaction in which a foreign investor takes control of a PRC domestic enterprise. Moreover, the Anti-Monopoly Law requires that the MOC shall be notified in advance of any concentration of undertaking if certain thresholds are triggered. In addition, the security review rules issued by the MOC that became effective in September 2011 specify that mergers and acquisitions by foreign investors that raise national security concerns and mergers and acquisitions through which foreign investors may acquire de facto control over domestic enterprises that raise national security concerns are subject to strict review by the MOC, and the rules prohibit any activities attempting to bypass a security review, including by structuring the transaction through a proxy or contractual control arrangement. In the future, we may grow our business by acquiring complementary businesses. Complying with the requirements of the above-mentioned regulations and other relevant rules to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval from the MOC or its local counterparts may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share. A 33 A PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiary's ability to increase its registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC law. A SAFE promulgated the Circular on Relevant Issues Relating to Domestic Resident's Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37, in July 2014 that requires PRC residents or entities to register with SAFE or its local branch in connection with their establishment or control of an offshore entity established for the purpose of overseas investment or financing. In addition, such PRC residents or entities must update their SAFE registrations when the offshore special purpose vehicle undergoes material events relating to any change of basic information (including change of such PRC citizens or residents, name and operation term), increases or decreases in investment amount, transfers or exchanges of shares, or mergers or divisions. SAFE Circular 37 is issued to replace the Notice on Relevant Issues Concerning Foreign Exchange Administration for PRC Residents Engaging in Financing and Roundtrip Investments via Overseas Special Purpose Vehicles, or SAFE Circular 75. SAFE promulgated the Notice on Further Simplifying and Improving the Administration of the Foreign Exchange Concerning Direct Investment in February 2015, which took effect on June 1, 2015. This notice has amended SAFE Circular 37 requiring PRC residents or entities to register with qualified banks rather than SAFE or its local branch in connection with their establishment or control of an offshore entity established for the purpose of overseas investment or financing. A If our shareholders who are PRC residents or entities do not complete their registration as required, our PRC subsidiary may be prohibited from distributing its profits and proceeds from any reduction in capital, share transfer or liquidation to us, and we may be restricted in our ability to contribute additional capital to our PRC subsidiary. Moreover, failure to comply with the SAFE registration described above could result in liability under PRC laws for evasion of applicable foreign exchange restrictions. A All of our shareholders who directly or indirectly hold shares in our Cayman Islands holding company and who are known to us as being PRC residents have completed the foreign exchange registrations required in connection with our recent corporate restructuring. A However, we may not be informed of the identities of all the PRC residents or entities holding direct or indirect interest in our company, nor can we compel our beneficial owners to comply with SAFE registration requirements. As a result, we cannot assure you that all of our shareholders or beneficial owners who are PRC residents or entities have complied with, and will in the future make or obtain any applicable registrations or approvals required by, SAFE regulations. Failure by such shareholders or beneficial owners to comply with SAFE regulations, or failure by us to amend the foreign exchange registrations of our PRC subsidiary, could subject us to fines or legal sanctions, restrict our overseas or cross-border investment activities, limit our PRC subsidiary's ability to make distributions or pay dividends to us or affect our ownership structure, which could adversely affect our business and prospects. A Any failure to comply with PRC regulations regarding the registration requirements for employee stock incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions. A In February 2012, SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plan of Overseas Publicly-Listed Company, replacing earlier rules promulgated in March 2007. Pursuant to these rules, PRC citizens and non-PRC citizens who reside in China for a continuous period of not less than one year who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be the PRC subsidiary of such overseas listed company, and complete certain other procedures. In addition, an overseas entrusted institution must be retained to handle matters in connection with the exercise or sale of stock options and the purchase or sale of shares and interests. We and our executive officers and other employees who are PRC citizens or who have resided in the PRC for a continuous period of not less than one year and who have been granted options or other awards are subject to these regulations. Failure to complete the SAFE registrations may subject them to fines and legal sanctions and may also limit our ability to contribute additional capital into our PRC subsidiary and limit our PRC subsidiary's ability to distribute dividends to us. We also face regulatory uncertainties that could restrict our ability to adopt additional incentive plans for our directors, executive officers and employees under PRC law. See Item 4. A Information on the Company-B. A Business Overview-Regulation-Regulations Relating to Foreign Exchange - Regulations on Stock Incentive Plans. A 34 A A If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders. A Under the EIT Law and its implementation rules, an enterprise established outside of the PRC with a de facto management body within the PRC is considered a resident enterprise and will be subject to the enterprise income tax on its global income at the rate of 25%. The implementation rules define the term de facto management body as the body that exercises full and substantial control over and overall management of the business, productions, personnel, accounts and properties of an enterprise. In April 2009, the State Administration of Taxation, or the SAT, issued a circular, known as Circular 82, which provides certain specific criteria for determining whether the de facto management body of a PRC-controlled enterprise that is incorporated offshore is located in China. Although this circular only applies to offshore enterprise groups controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners like us, the criteria set forth in Circular 82 may reflect the SAT's general position on how the de facto management body test should be applied in determining the tax resident status of all offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its de facto management body in China and will be subject to PRC enterprise income tax on its global income only if all of the following conditions are met: (i) the primary location of the day-to-day operational management is in the PRC; (ii) decisions relating to the enterprise's financial and human resource matters are made or are subject to approval by organizations or personnel in the PRC; (iii) the enterprise's primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in the PRC; and (iv) at least 50% of voting board members or senior executives habitually reside in the PRC. A We believe none of our entities outside of China is a PRC resident enterprise for PRC tax purposes. See Item 10. A Additional Information-E. A Taxation-People's Republic of China Taxation. A However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term de facto management body. A As substantially all of our management members are based in China, it remains unclear how the tax residency rule will apply to our case. If the PRC tax authorities determine that we or any of our subsidiaries outside of China is a PRC resident enterprise for PRC enterprise income tax purposes, then we or such subsidiary could be subject to PRC tax at a rate of 25% on its world-wide income, which could materially reduce our net income. In addition, we will also be subject to PRC enterprise income tax reporting obligations. Furthermore, if the PRC tax authorities determine that we are a PRC resident enterprise for enterprise income tax purposes, dividends we pay to non-PRC holders may be subject to PRC withholding tax, and gains realized on the sale or other disposition of ADSs or ordinary shares may be subject to PRC tax, at a rate of 10% in the case of non-PRC enterprises or 20% in the case of non-PRC individuals (in each case, subject to the provisions of any applicable tax treaty), if such dividends or gains are deemed to be from PRC sources. It is unclear whether non-PRC shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. Any such tax may reduce the returns on your investment in the ADSs. A We may not be able to obtain certain benefits under relevant tax treaty on dividends paid by our PRC subsidiary to us through our Hong Kong subsidiary. A We are a holding company incorporated under the laws of the Cayman Islands and as such rely on dividends and other distributions on equity from our PRC subsidiary to satisfy part of our liquidity requirements. Pursuant to the EIT Law, a withholding tax rate of 10% currently applies to dividends paid by a PRC resident enterprise to a foreign enterprise investor, unless any such foreign investor's jurisdiction of incorporation has a tax treaty with China that provides for preferential tax treatment. Pursuant to the Arrangement between the Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, or the Double Tax Avoidance Arrangement, such withholding tax rate may be lowered to 5% if a Hong Kong resident enterprise owns at least 25% of a PRC enterprise. Pursuant to the Notice of the State Administration of Taxation on the Issues concerning the Application of the Dividend Clauses of Tax Agreements, or Circular 81, the 5% withholding tax rate does not automatically apply and certain requirements must be satisfied, including without limitation that (a) the Hong Kong enterprise must be the beneficial owner of the relevant dividends; and (b) the Hong Kong enterprise must directly hold at least 25% share ownership in the PRC enterprise during the 12 consecutive months preceding its receipt of the dividends. However, a transaction or arrangement entered into for the primary purpose of enjoying a favorable tax treatment should not be a reason for the application of the favorable tax treatment under the Double Tax Avoidance Arrangement. If a taxpayer inappropriately is entitled to such favorable tax treatment, the competent tax authority has the power to make appropriate adjustments. A 35 A In August 2015, the State Administration of Taxation promulgated the Administrative Measures for Non-Resident Taxpayers to Enjoy Treatments under Tax Treaties, or Circular 60, which became effective on November 1, 2015. Circular 60 provides that non-resident enterprises are not required to obtain pre-approval from the relevant tax authority in order to enjoy the reduced withholding tax rate. Instead, non-resident enterprises and their withholding agents may, by self-assessment and on confirmation that the prescribed criteria to enjoy the tax treaty benefits are met, directly apply the reduced withholding tax rate, and file necessary forms and supporting documents when performing tax filings, which will be subject to post-tax filing examinations by the relevant tax authorities. However, if a competent tax authority finds out that it is necessary to apply the general anti-tax avoidance rules, it may start general investigation procedures for anti-tax avoidance and adopt corresponding measures for subsequent administration. Accordingly, Hexindai Hong Kong Limited, or Hexindai HK, our Hong Kong subsidiary, may be able to enjoy the 5% withholding tax rate for the dividends they receive from Hexin Yongheng, our PRC subsidiary, if it satisfies the conditions prescribed under Circular 81 and other relevant tax rules and regulations. However, according to Circular 81 and Circular 60, if the relevant tax authorities consider the transactions or arrangements we have are for the primary purpose of enjoying a favorable tax treatment, the relevant tax authorities may adjust the favorable withholding tax in the future. A Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential acquisitions we may pursue in the future. A In connection with the EIT Law, the SAT issued the Circular on Strengthening the Administration of Enterprise Income Tax on Non-resident Enterprises' Equity Transfer Income, or Circular 698, which became effective as of January 1, 2008, the Notice on Issues Concerning Process of Enterprise Income Tax in Enterprise Restructuring Business, or Circular 59 on April 30, 2009, and the Announcement of the State Administration of Taxation on Several Issues concerning the Enterprise Income Tax on the Indirect Transfers of Properties by Non-Resident Enterprises, or the SAT Announcement 7, on February 3, 2015. By promulgating and implementing the above, the PRC tax authorities have strengthened their scrutiny over the direct or indirect transfer of equity interest in a PRC resident enterprise by a non-PRC resident enterprise. Pursuant to SAT Announcement 7, if a non-resident enterprise, or referred to as a transferor, transfers its equity in an offshore enterprise which directly or indirectly owns PRC taxable assets, including ownership interest in PRC resident companies, or the Taxable Properties, without a reasonable commercial purpose, such transfer shall be deemed as a direct transfer of such Taxable Properties. The payer, or referred as a transferee, in such transfer shall be the withholding agent, and is obligated to withhold and remit the enterprise income tax to the relevant PRC tax authority. If a transferor fails to declare for payment timely or in full of the tax due on proceeds from indirect transfer of PRC taxable assets and the withholding agent also fails to withhold such tax, the tax authority shall, in addition to supplementary collection of such tax, also charge for interest on a daily basis from the transferor according to the EIT Law and its implementation rules. Factors that may be taken into consideration when determining whether there is a reasonable commercial purpose include, among other factors, the value of the transferred equity, offshore taxable situation of the transaction, the offshore structure's economic essence and duration and trading fungibility. If an equity transfer transaction satisfies all the requirements mentioned above, such transaction will be considered an arrangement with reasonable commercial purpose. On October 17, 2017, the SAT issued the Bulletin of SAT on Issues Concerning the Withholding of Non-resident Enterprise Income Tax at Source, or Bulletin 37, which came into effect on December 1, 2017 and was amended in June 2018, which, among others, repeals certain rules stipulated in Circular 7. Bulletin 37 further details and clarifies the tax withholding methods in respect of the income of non-resident enterprises. A Accordingly, we and non-resident enterprise investors face uncertainties on the reporting and consequences on future private equity-financing transactions, share exchange or other transactions involving the transfer of shares in our company by investors that are non-PRC resident enterprises. The PRC tax authorities may pursue such non-resident enterprises with respect to a filing or the transferees with respect to withholding obligation, and request our PRC subsidiaries to assist in the filing. As a result, we and non-resident enterprises in such transactions may become at risk of being subject to filing obligations or being taxed, under Circular 59, Circular 698, the SAT Announcement 7 and Bulletin 37, and we may be required to expend valuable resources to comply with Circular 59, Circular 698, the SAT Announcement 7 and Bulletin 37 or to establish that we and our non-resident enterprises should not be taxed under these circulars, which may have a material adverse effect on our financial condition and results of operations. A Additionally, the PRC tax authorities have the discretion under SAT Circular 59, Circular 698, the SAT Announcement 7 and Bulletin 37 to make adjustments to the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. Although we currently have no plans to pursue any acquisitions in China or elsewhere in the world, we may pursue acquisitions in the future that may involve complex corporate structures. If we are considered a non-resident enterprise under the EIT Law and if the PRC tax authorities make adjustments to the taxable income of the transactions under SAT Circular 59, Circular 698, the SAT Announcement 7 and Bulletin 37, our income tax costs associated with such potential acquisitions will be increased, which may have an adverse effect on our financial condition and results of operations. A Any actions by the Chinese government, including any decision to intervene or influence the operations of the operating entities or to exert control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, may cause us to make material changes to the operations of the PRC operating entities, may limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless. A We are a Cayman Islands holding company and are not a Chinese company. As a holding company with no material operations of our own, we conduct all of our operations through our PRC operating entities in China. As such, our corporate structure involves unique risks to investors. There are legal and operational risks associated with having operations in mainland China, and the Chinese regulatory authorities could disallow this ownership structure, which would likely result in a material change in our operations and/or a material change in the value of the securities we are registering for sale, including that it could cause the value of such securities to significantly decline or become worthless. A In the meeting of the Political Bureau of the CPC Central Committee held on July 30, 2021, the improvement of the regulatory system for overseas listing of enterprises was first proposed. On February 17, 2023, the CSRC released the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, or the Overseas Listing Trial Measures, and five supporting guidelines, which came into effect on March 31, 2023. Pursuant to the Overseas Listing Trial Measures, domestic companies that seek to offer or list securities overseas, whether directly or indirectly, should fulfill the filing procedures and submit relevant information to the CSRC. A 36 A Although the detailed implementations are still unclear, the supervision of overseas listing of Chinese stocks may continue to tighten. The Chinese government has exercised, and continues to exercise, substantial control over virtually every sector of the Chinese economy through regulation and state ownership. The ability of our operating entities to operate in China may be impaired by changes in its laws and regulations, including those relating to taxation, environmental regulations, land use rights, foreign investment limitations, and other matters. The central or local governments of China may impose new, stricter regulations or interpretations of existing regulations that would require additional expenditures and efforts on our part to our compliance with such regulations or interpretations. As such, we may be subject to various government and regulatory interference in the provinces in which we operate. We could be subject to regulation by various political and regulatory entities, including various local and municipal agencies and government sub-divisions. We may incur increased costs necessary to comply with existing and newly adopted laws and regulations or penalties for any failure to comply. A Furthermore, it is uncertain when and whether we will be required to obtain permission from the PRC government to list on U.S.A exchanges in the future, and even when such permission is obtained, whether it will be denied or rescinded. Although we believe that we are currently not required to obtain

permission from any Chinese authorities and have not received any notice of denial of permission to list on the U.S. exchange, our operations could be adversely affected, directly or indirectly, by existing or future laws and regulations relating to the PRC operating entities’ business or industry, particularly in the event permission to list on U.S.A exchanges may be later required, or withheld or rescinded once given. A Accordingly, government actions in the future, including any decision to intervene or influence our operations at any time or to exert control over an offering of securities conducted overseas and/or foreign investment in China-based issuers, may cause us to make material changes to our operations, may limit or completely hinder our ability to offer or continue to offer securities to investors, and/or may cause the value of such securities to significantly decline or be worthless. A There are uncertainties regarding the enforcement of laws and rules and regulations in China, which can change quickly with little advance notice, and there is a risk that the Chinese government may intervene or influence our operations at any time, exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, which could materially and adversely affect our business and hinder our ability to offer or continue our operations, and cause the value of our securities to significantly decline or become worthless. A There are substantial uncertainties regarding the interpretation and application of PRC laws and regulations including, but not limited to, the laws and regulations related to our business and the enforcement and performance of our arrangements with customers in certain circumstances. The laws and regulations are sometimes vague and may be subject to future changes, and their official interpretation and enforcement may involve substantial uncertainty. The effectiveness and interpretation of newly enacted laws or regulations, including amendments to existing laws and regulations, may be delayed, and our business may be affected if we rely on laws and regulations which are subsequently adopted or interpreted in a manner different from our understanding of these laws and regulations. New laws and regulations that affect existing and proposed future businesses may also be applied retroactively. We cannot predict what effect the interpretation of existing or new PRC laws or regulations may have on our business. The uncertainties regarding the enforcement of laws and the fact that rules and regulations in mainland China can change quickly with little advance notice could result in a material change in our operations, financial performance and/or cause the value of our securities to significantly decline or become worthless and/or impair our ability to raise money. A The Chinese government may exercise significant oversight and discretion over the conduct of business in the PRC and may intervene in or influence our operations at any time, which could result in a material change in our operations and/or the value of our securities. We are also currently not required to obtain approval from Chinese authorities to list on U.S. exchanges, however, if we are required to obtain approval in the future and are denied permission from Chinese authorities to list on U.S. exchanges, we will not be able to continue listing on U.S. exchange, which would materially affect the interest of the investors. The PRC government may intervene or influence our business operations at any time or may exert more control over offerings conducted overseas and foreign investment in China-based issuers, which could result in a material change in our business operations or the value of our securities. Additionally, the governmental and regulatory interference could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. A To the extent cash or assets of our business, or of our PRC or Hong Kong subsidiaries, is in mainland China or Hong Kong, such cash or assets may not be available to fund operations or for other use outside of the PRC or Hong Kong, due to interventions in or the imposition of restrictions and limitations by the PRC government to the transfer of cash or assets. A The transfer of funds and assets among the Company, its Hong Kong and PRC subsidiaries is subject to governmental control and restriction. The competent PRC government imposes controls on the conversion of the RMB into foreign currencies and the remittance of currencies out of mainland China. In addition, the PRC EIT Law and its implementation rules provide that a withholding tax at a rate of 10% will be applicable to dividends payable by Chinese companies to enterprises that are not mainland China resident enterprises, unless reduced under treaties or arrangements between the PRC central government and the governments of other countries or regions where the enterprises that are not mainland China resident enterprises are tax resident. A As of the date of this report, there are no restrictions or limitations imposed by the Hong Kong government on the transfer of capital within, into and out of Hong Kong (including funds from Hong Kong to the PRC), except for the transfer of funds involving money laundering and criminal activities. However, there is no guarantee that the Hong Kong government will not promulgate new laws or regulations that may impose such restrictions in the future. A As a result of the above, to the extent cash or assets of our business, or of our PRC or Hong Kong subsidiaries, is in mainland China or Hong Kong, such funds or assets may not be available to fund operations or for other use outside of the PRC or Hong Kong, due to interventions in or the imposition of restrictions and limitations by the competent government to the transfer of cash or assets. A 37 A RISK RELATED TO OUR ADSs A The trading price of our ADSs may be volatile, which could result in substantial losses to A investors. A The trading price of our ADSs has ranged from US\$0.25 to US\$2.90 per ADS A in fiscal year 2024. The trading prices of our ADSs are likely to be volatile and could fluctuate widely due to factors beyond our control. This may happen because of broad market and industry factors, like the performance and fluctuation in the market prices or the underperformance or deteriorating financial results of Internet or other companies based in China that have listed their securities in the United States in recent years. The securities of some of these companies have experienced significant volatility since their initial public offerings, including, in some cases, substantial decline in their trading prices. The trading performances of other Chinese companies’ securities after their offerings may affect the attitudes of investors toward Chinese companies listed in the United States, which consequently may impact the trading performance of our ADSs, regardless of our actual operating performance. In addition, any negative news or perceptions about inadequate corporate governance practices or fraudulent accounting, corporate structure or other matters of us or other Chinese companies may also negatively affect the attitudes of investors towards Chinese companies in general, including us, regardless of whether we have conducted any inappropriate activities. In addition, securities markets may from time to time experience significant price and volume fluctuations that are not related to our operating performance, such as the large decline in share prices in the United States, China and other jurisdictions in late 2008, early 2009, the second half of 2011, the third quarter of 2015 and the first quarter of 2016, which may have a material adverse effect on the market price of our ADSs. A In addition to market and industry factors, the price and trading volume for our ADSs may be highly volatile for factors specific to our own operations, including the following: A A regulatory developments affecting us, our customers or our industry; A A announcements of studies and reports relating to our products and service offerings or those of our competitors; A A changes in the economic performance or market valuations of other social e-commerce platforms; A A actual or anticipated fluctuations in our quarterly results of operations and changes or revisions of our expected results; A A changes in financial estimates by securities research analysts; A A conditions in the Internet and unsecured consumer finance industries; A A announcements of new product, service and expansions by us or our competitors; A A replacement of existing third-party service providers; A A additions to or departures of our senior management; A A detrimental negative publicity about us, our management or our industry; A A fluctuations of exchange rates between the RMB and the U.S. dollar; A A release or expiry of lock-up or other transfer restrictions on our outstanding ordinary shares or ADSs; and A A sales or perceived potential sales of additional ordinary shares or ADSs. A Any of these factors may result in large and sudden changes in the volume and price at which our ADSs will trade. A 38 A Techniques employed by short sellers may drive down the market price of our ADSs. A Short selling is the practice of selling securities that the seller does not own but rather has borrowed from a third party with the intention of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from a decline in the value of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects to pay less in that purchase than it received in the sale. As it is in the short seller’s interest for the price of the security to decline, many short sellers publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects in order to create negative market momentum and generate profits for themselves after selling a security short. These short attacks have, in the past, led to selling of shares in the market. A We have been the subject of short selling, and it is not clear what long-term effect such negative publicity could have on us. We may also be subject to short seller attacks from time to time in the future. If we were to become the subject of any unfavourable allegations, whether such allegations are proven to be true or untrue, we may have to expend a significant amount of resources to investigate such allegations and/or defend ourselves. While we would strongly defend against any such short seller attacks, we may be constrained in the manner in which we can proceed against the relevant short sellers by principles of freedom of speech, applicable state law or issues of commercial confidentiality. Such a situation could be costly and time-consuming, and could divert management’s attention from the day-to-day operations of our company. Even if such allegations are ultimately proven to be groundless, allegations against us could severely impact the market price of our ADSs and our business operations. A If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for our ADSs and trading volume could decline. A The trading market for our ADSs will depend in part on the research and reports that securities or industry analysts publish about us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who cover us downgrade our ADSs or publish inaccurate or unfavourable research about our business, the market price for our ADSs would likely decline. If one or more of these analysts’ cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume of our ADSs to decline. A We cannot assure you that our existing dividend policy will not change in the future or the amount the dividends that you may receive, and as such, you must rely on price appreciation of our ADSs for return on your investment. A On July 19, 2018, our board of directors approved an annual dividend policy. Under this policy, annual dividends will be set at an amount equivalent to approximately 15-25% of our anticipated net income after tax in each year commencing from the fiscal year ended March 31, 2019. On July 19, 2018, our board of directors also approved a special cash dividend of US\$0.13 per ordinary share of our company (or US\$0.13 per ADS), in addition to an annual dividend pursuant to the newly adopted annual dividend policy of US\$0.27 per ordinary share (or US\$0.27 per ADS), for a total dividend of US\$0.40 per ordinary share (or US\$0.40 per ADS). No dividends have been declared or distributed since August 2018. A Our annual dividend policy is subject to change at any time at the discretion of our board of directors, and our board of directors has complete discretion as to whether to distribute dividends in the future. If our board of directors decides to continue to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. As such, the amount of dividends that you will receive is subject to change. In addition, there can be no assurance that we will not adjust our dividend policy in the future. Accordingly, you should not rely on an investment in our ADSs as a source for any future dividend income, and the return on your investment in our ADSs will likely depend entirely upon any future price appreciation of our ADSs. There is no guarantee that our ADSs will appreciate in value or even maintain the price at which you purchased the ADSs. You may not realize a return on your investment in our ADSs and you may even lose your entire investment. A Any declaration and payment, as well as the amount, of dividends will be subject to our constitutional documents and applicable Chinese and U.S.A state and federal laws and regulations, including the approval from the shareholders of each subsidiary which intends to declare such dividends, if applicable. A 39 A Substantial future sales or perceived potential sales of our ADSs in the public market could cause the price of our ADSs to decline. A Sales of our ADSs in the public market, or the perception that these sales could occur, could cause the market price of our ADSs to decline. As of March 31, 2024, we had 437,170,960 ordinary shares outstanding. Among these shares, 42,341,432 ordinary shares are in the form of ADSs. All our ADSs are freely transferable without restriction or additional registration under the Securities Act. The remaining ordinary shares outstanding are available for sale, subject to volume and other restrictions as applicable under Rules 144 and 701 under the Securities Act. To the extent shares are sold into the market, the market price of our ADSs could decline. A Certain holders of our ordinary shares may cause us to register under the Securities Act the sale of their shares. Registration of these shares under the Securities Act would result in ADSs representing these shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. Sales of these registered shares in the form of ADSs in the public market could cause the price of our ADSs to decline. A We have adopted our 2023 Equity Incentive Plan which was approved by our shareholders at our 2023 annual general meeting of shareholders held on June 19, 2023, under which we have the discretion to grant a broad range of equity-based awards to eligible participants. See 6. Directors, Senior Management and Employees B. Compensation Share Incentive Plan. We have registered certain ordinary shares that we may issue under our share incentive plans and intend to register all ordinary shares that we may issue under our share incentive plans. Once we register these ordinary shares, they can be freely sold in the public market in the form of ADSs upon issuance, subject to volume limitations applicable to affiliates and relevant lock-up agreements. If a large number of our ordinary shares or securities convertible into our ordinary shares are sold in the public market in the form of ADSs after they become eligible for sale, the sales could reduce the trading price of our ADSs and impede our ability to raise future capital. In addition, any ordinary shares that we issue under our share incentive plans would dilute the percentage ownership held by the investors who purchased ADSs. A We may be classified as a passive foreign investment company for U.S.A federal income tax purposes, which could result in adverse U.S.A federal income tax consequences to U.S.A Holders of our ADSs or ordinary shares. A Depending upon the value of our assets, which is determined in part by the market value of our ADSs or ordinary shares, and the composition of our assets and income over time, we could be classified as a passive foreign investment company, or PFIC, for U.S.A federal income tax purposes. Based on the projected composition of our assets and income, we do not believe that we were a PFIC for our taxable year ended March 31, 2024 and we do not anticipate becoming a PFIC in the foreseeable future. While we do not anticipate becoming a PFIC, fluctuations in the market price of our ADSs or ordinary shares may cause us to become a PFIC for the current or any subsequent taxable year. A non-U.S.A corporation, such as our company, will be classified as a PFIC for U.S.A federal income tax purposes for any taxable year, if either (i) 75% or more of its gross income for such year consists of certain types of 6 passive income or (ii) 50% or more of the value of its assets (determined on the basis of a quarterly average) during such year produce or are held for the production of passive income. Whether we are a PFIC is a factual determination and we must make a separate determination each taxable year as to whether we are a PFIC (after the close of each taxable year). Accordingly, we cannot assure you that we will not be a PFIC for our taxable year ending March 31, 2024 or any future taxable year. A If we were to be classified as a PFIC for any taxable year during which a U.S.A Holder (as defined in 10. Additional Information E.A Taxation U.S.A Federal Income Tax Considerations) holds an ADS or an ordinary share, such U.S.A Holder would generally be subject to reporting requirements and might incur significantly increased U.S.A federal income tax on gain recognized on the sale or other disposition of the ADSs or ordinary shares and on the receipt of distributions on the ADSs or ordinary shares to the extent such gain or distribution is treated as an 6 excess distribution under the applicable U.S.A federal income tax rules. Further, if we were to be classified as a PFIC for any year during which a U.S.A Holder holds our ADSs or ordinary shares, we generally would continue to be treated as a PFIC for all succeeding years during which such U.S.A Holder holds our ADSs or ordinary shares even if we cease to qualify as a PFIC under the rules set forth above. You are urged to consult your tax advisor concerning the U.S.A federal income tax consequences of acquiring, holding, and disposing of ADSs or ordinary shares if we were to be classified as a PFIC. For more information, see 10. Additional Information E.A Taxation U.S.A Federal Income Tax Considerations PFIC Rules. A 40 A The amended and restated memorandum and articles of association that we expect to adopt contain anti-takeover provisions that could have a material adverse effect on the rights of holders of our ordinary shares and ADSs. A We have adopted an amended and restated memorandum and articles of association. Our amended and restated memorandum and articles of association contains provisions to limit the ability of others to acquire control of our company or cause us to engage in change-of-control transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to obtain control of our company in a tender offer or similar transaction. In addition, our board of directors has the authority, without further action by our shareholders, to issue preferred shares in one or more series and to fix their designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares underlying the ADSs. Preferred shares could be issued quickly with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. If our board of directors decides to issue preferred shares, the price of our ADSs may fall and the voting and other rights of the holders of our ordinary shares underlying the ADSs may be materially and adversely affected. A You may face difficulties in protecting your interests, and your ability to protect your rights through U.S.A courts may be limited, because we are incorporated under Cayman Islands law. A We are an exempted company incorporated under the laws of the Cayman Islands with limited liability. Our corporate affairs are governed by our memorandum and articles of association, the Companies Act (As Revised) of the Cayman Islands and the common law of the Cayman Islands. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary duties of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the

Cayman Islands as well as from the common law of England, the decisions of whose courts are not persuasive authority, but are not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States. Some U.S.A. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have standing to initiate a shareholder derivative action in a federal court of the United States. A Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to obtain copies of register of members of these companies. Our directors have discretion under our articles of association to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxyÅ contest. A Certain corporate governance practices in the Cayman Islands, which is our home country, differ significantly from requirements for companies incorporated in other jurisdictions such as the U.S.A Currently, we rely on home country practices with respect to certain corporate governance matters, please see Åœœtem 16.GÅœ Corporate Governance.Åœ As a result, our shareholders may be afforded less protection than they otherwise would under rulesÅ and regulations applicable to U.S.A domestic issuers. A As a result of all of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken by our management, members of the board of directors or controlling shareholders than they would as public shareholders of a company incorporated in the United States. A 41 A Certain judgments obtained against us by our shareholders may not beÅ enforceable. A We are a Cayman Islands exempted company and substantially all of our assets are located outside of the United States. Substantially all of our current operations are conducted in China. In addition, a majority of our current directors and officers are nationals and residents of countries other than the United States. Substantially all of the assets of these persons are located outside the United States. As a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the United States in the event that you believe that your rights have been infringed under the U.S.A federal securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands and of China may render you unable to enforce a judgment against our assets or the assets of our directors and officers. A There is no statutory enforcement in the Cayman Islands of judgments obtained in the federal or state courts of the United States (and the Cayman Islands are not a party to any treaties for the reciprocal enforcement or recognition of such judgments), a judgment obtained in such jurisdiction will be recognized and enforced in the courts of the Cayman Islands at common law, without any re-examination of the merits of the underlying dispute, by an action commenced on the foreign judgment debt in the Grand Court of the Cayman Islands, provided such judgment (a)Å is given by a foreign court of competent jurisdiction, (b)Å imposes on the judgment debtor a liability to pay a liquidated sum for which the judgment has been given, (c)Å is final, (d)Å is not in respect of taxes, a fine or a penalty, and (e)Å was not obtained in a manner and is not of a kind the enforcement of which is contrary to natural justice or the public policy of the Cayman Islands. However, the Cayman Islands courts are unlikely to enforce a judgment obtained from the U.S. courts under civil liability provisions of the U.S. federal securities law if such judgment is determined by the courts of the Cayman Islands to give rise to obligations to make payments that are penal or punitive in nature. Because such a determination has not yet been made by a court of the Cayman Islands, it is uncertain whether such civil liability judgments from U.S. courts would be enforceable in the Cayman Islands. A The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties or other forms of reciprocity with the United States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or our director and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security or public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States. A We are a foreign private issuer within the meaning of the rulesÅ under the Exchange Act, and as such we are exempt from certain provisions applicable to United States domestic public companies. A Because we are a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the securities rulesÅ and regulations in the United States that are applicable to U.S.A domestic issuers, including: A A — the rulesÅ under the Exchange Act requiring the filing of quarterly reports on FormÅ 10-Q orÅ current reports on FormÅ 8-K with the SEC; A A — the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act; A A — the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time;Å and A A — the selective disclosure rulesÅ by issuers of material non-public information under RegulationÅ FD. A We are required to file an annual report on FormÅ 20-F within four months of the end of each fiscal year. In addition, we intend to publish our results periodically through press releases, distributed pursuant to the rulesÅ and regulations of the NASDAQ Global Market. Press releases relating to financial results and material events will also be furnished to the SEC on FormÅ 6-K. However, the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S.A domestic issuers. As a result, you may not be afforded the same protections or information, which could be made available to you, were you investing in a U.S.A domestic issuer. A 42 A A The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise any right to vote the ordinary shares which are represented by yourÅ ADSs. A As a holder of our ADSs, you will only be able to direct the exercise of the voting rights attaching to the ordinary shares which are represented by your ADSs in accordance with the provisions of the deposit agreement. Under the deposit agreement, you must vote by giving voting instructions to the depository. Upon receipt of your voting instructions, the depository will use its best endeavors to vote the ordinary shares which are represented by your ADSs in accordance with your instructions. You will not be able to directly exercise any right to vote with respect to the shares represented by your ADSs unless you withdraw the shares from the ADR facility prior to the applicable share record date. Under our amended and restated memorandum and articles of association, the minimum notice period required for convening a general meeting is ten calendar days. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholdersÅ™ annual general meetings. Our amended and restated memorandum and articles of association provide that we may, but are not obliged to, in each year hold a general meeting as our annual general meeting. When a general meeting is convened, you may not receive sufficient advance notice to withdraw the underlying shares represented by your ADSs to allow you to vote with respect to any specific resolution or matter to be considered and voted upon at such general meeting. If we give notice to our shareholders of any general meeting, the depository will notify you of the upcoming vote and will arrange to deliver our voting materials to you. We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depository to vote the underlying shares represented by your ADSs. In addition, the depository and its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out your voting instructions. This means that you may not be able to exercise your right to vote and you may have no legal remedy if the underlying shares represented by your ADSs are not voted as youÅ requested. A The depository for our ADSs will give us a discretionary proxy to vote the ordinary shares represented by your ADSs if you do not give proper or timely voting instructions to the depository, except in limited circumstances, which could adversely affect yourÅ interests. A Under the deposit agreement for the ADSs, if you do not give proper or timely voting instructions to the depository, the depository will give us a discretionary proxy to vote the ordinary shares represented by your ADSs at shareholdersÅ™ meetings unless: A A — we have failed to timely provide the depository with notice of meeting and related voting materials; A A — we have instructed the depository that we do not wish a discretionary proxy to beÅ given; A A — we have informed the depository that there is substantial opposition as to a matter to be voted on at theÅ meeting; A A — a matter to be voted on at the meeting would have a material adverse impact on shareholders;Å or A A — the voting at the meeting is to be made on a show of hands. A The effect of the foregoing is that if you do not give proper or timely voting instructions to the depository as to how to vote at shareholdersÅ™ meetings, a discretionary proxy to vote the ordinary shares represented by your ADSs will be given to a person designated by us, except under the circumstances described above. This may make it more difficult for shareholders and holders of ADSs to influence the management of our company. Holders of our ordinary shares are not subject to this discretionary proxy. A You may not receive dividends or other distributions on our ordinary shares and you may not receive any value for them if it is illegal or impracticable to make them available toÅ you. A The depository of our ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities which are represented by your ADSs, after deducting its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depository is not responsible if it decides that it is unlawful or impracticable to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act but that are not properly registered or distributed under an applicable exemption from registration. The depository may also determine that it is not practicable to distribute certain property through the mail. Additionally, the value of certain distributions may be less than the cost of mailing them. In these cases, the depository may determine not to distribute such property. We have no obligation to register under U.S.A securities laws any ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that you may not receive distributions we make on our ordinary shares or any value for them if it is illegal or impracticable for us to make them available to you. These restrictions may cause a material decline in the value of ourÅ ADSs. A 43 A A You may experience dilution of your holdings due to inability to participate in rights offerings. A We may, from time to time, distribute rights to our shareholders, including rights to acquire securities. Under the deposit agreement, the depository will not distribute rights to holders of ADSs unless the distribution and sale of rights and the securities to which these rights relate are either exempt from registration under the Securities Act with respect to all holders of ADSs, or are registered under the provisions of the Securities Act. The depository may, but is not required to, attempt to sell these undistributed rights to third parties, and may allow the rights to lapse. We may be unable to establish an exemption from registration under the Securities Act, and we are under no obligation to fileÅ a registration statement with respect to these rights or underlying securities or to endeavour to have a registration statement declared effective. Accordingly, holders of ADSs may be unable to participate in our rights offerings and may experience dilution of their holdings as a result. A You may be subject to limitations on transfer of your ADSs. A Your ADSs are transferable on the books of the depository. However, the depository may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depository may close its books from time to time for a number of reasons, including in connection with corporate events such as a rights offering, during which time the depository needs to maintain an exact number of ADS holders on its books for a specified period. The depository may also close its books in emergencies, or on weekends and public holidays. The depository may refuse to deliver, transfer or register transfers of our ADSs generally when our share register or the books of the depository are closed, or at any time if we or the depository thinks it is advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any otherÅ reason. A We will incur significantly increased costs and devote substantial management time as a result of being a public company. A As a public company, we incur additional legal, accounting and other expenses as a public reporting company. For example, we will be required to comply with additional requirements of the rulesÅ and regulations of the SEC and requirements of the NASDAQ Global Market, including applicable corporate governance practices. We expect that compliance with these requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costlier. In addition, we expect that our management and other personnel will need to divert attention from operational and other business matters to devote substantial time to these public company requirements. We cannot predict or estimate the amount of additional costs we may incur or the timing of suchÅ costs. A In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of managementÅ™ s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may also initiate legal proceedings against us and our business may be adversely affected. A In the past, shareholders of public companies have often brought securities class action suits against those companies following periods of instability in the market price of their securities. If we were involved in a class action suit, it could divert a significant amount of our managementÅ™ s attention and other resources from our business and operations and require us to incur significant expenses to defend the suit, which could harm our results of operations. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and results ofÅ operations. A 44 A A ITEM 4. INFORMATION ON THE COMPANY A A History and Development of the Company A In April 2016, Hexindai Inc. was incorporated in Cayman Islands as a holding company. We provided online microlending business and P2P marketplace business from 2017 to 2019. As part of our major business restructuring and disposition of our P2P marketplace business in and around December 2020, which is described in greater detail below, we changed our name from Hexindai Inc. to Xiaobai Maimai Inc. to reflect our business that was built upon our social e-commerce platform. On December 3, 2021, we changed our name from Xiaobai Maimai Inc. to Akso Health Group in recognition of our focus on our new business development in the health sector. As of the date of this annual report, we are no longer engaged in the P2P marketplace businesses and are not making any new loans under the microlending business, and are solely focused on our social e-commerce platform business, cancer therapy and radiotherapy oncology service provider business, and the sale of COVID-19 Rapid Antigen Tests. A In MarchÅ 2014, our founders Mr.Å Xiaobo An and Mr.Å Xiaoning An, along with Mr.Å Xiaobin Zhai, established Hexin E-Commerce Co. Ltd in China, or Hexin E-Commerce, which at the time of its inception was not under our control and jointly owned by the individuals named above. A In order to obtain control of Hexin E-Commerce, in NovemberÅ 2016, we entered into a series of contractual arrangements with HexinÅ E-Commerce and its then-shareholders and became Hexin E-commerceÅ™ s primary beneficiary. Prior to our disposal of HexinÅ E-Commerce in DecemberÅ 2020, we conducted our P2P marketplace businesses primarily through HexinÅ E-Commerce. A In MayÅ 2016, we established a wholly-owned subsidiary in Hong Kong, Hexindai HK, and further established Beijing Hexin Yongheng Technology Development Co. Ltd., or Hexin Yongheng, which to this date remains Hexindai HKÅ™ s wholly-owned subsidiary in China, in AugustÅ 2016. A In AugustÅ 2017, we established Wusu Company to conduct online microlending business. At the time of Wusu CompanyÅ™ s inception, HexinÅ E-Commerce, Mr.Å Ming Jia and Mr.Å Shiwei Wu were the shareholders of Wusu Company. On JanuaryÅ 1, 2018, Hexin Yongheng, Wusu Company, Hexin E-Commerce, Mr.Å Ming Jia and Mr.Å Shiwei Wu entered into a series of agreements (the Åœœ2018

technological services as its principal business, was acquired by Hexin Jinke from an independent third party, and Hexin Digital had minimal activities before being acquired by us. We obtained control and became the primary beneficiary of Hexin Digital in August 2019 by entering into a series of contractual arrangements with Hexin Digital and Hexin Jinke. Hexin Digital is 100% owned by Hexin Jinke. Hexin Digital holds the requisite licenses necessary to conduct our online marketplace business which is subject to restrictions under current PRC laws and regulations. We operate our newly launched social e-commerce platform Xiaobai Maimai through Hexin Digital. Á On September 30, 2019, we changed Wusu Company’s principal businesses from micro-lending to trading, provision of technological promotion services, and import and export. Á On July 15, 2020, we incorporated Hexin Investment Private Limited in Singapore with a view to engage in future investment activities. Á As part of our corporate restructurings prior to our disposal of Hexin E-Commerce in December 2020, Mr. Á Ming Jia and Mr. Á Shiwei Wu transferred their equity interests of Wusu Company to Hexin E-Commerce, and therefore, Hexin E-Commerce became the sole shareholder of Wusu Company on November 20, 2020. On November 20, 2020, Hexin Yongheng, Wusu Company, Hexin E-Commerce, Mr. Á Ming Jia and Mr. Á Shiwei Wu entered into a VIE termination agreement, which terminated all rights and obligations with respect to each party thereto under the 2018 Wusu VIE Agreements. On December 1, 2020, Wusu Company and its shareholder, Hexin E-Commerce, entered into a new series of contractual arrangements with Hexin Yongheng, and as a result of which, Hexin Yongheng remains the primary beneficiary of and controls Wusu Company. Á On December 16, 2020, Hexin Yongheng and Kuaihangche, a company not directly associated with the Company but controlled by Mr. Á Xiaobo An, and Hexin E-Commerce entered into an assignment and assumption agreement. Pursuant to the Agreement, Hexin Yongheng agreed to assign and transfer to Kuaihangche the control over Hexin E-Commerce, in exchange for cash consideration of RMB5.0 million (US\$726,781). Á On July 8, 2021, we incorporated WE HEALTH LIMITED in New York. Á On December 15, 2021, we established We Healthy Limited in Hong Kong. WE HEALTH LIMITED owns 51% equity of We Healthy Limited. Á On December 30, 2021, we incorporated Akso Health Treatment Center Inc. in the State of Massachusetts, and on January 10, 2022 we changed the name from Akso Health Treatment Center Inc. to Akso First Health Treatment Center Inc. Á On January 3, 2022, we incorporated Akso Remote Medical Consultation Center Inc. in Wyoming. Á On January 26, 2022, we established Qingdao Akso Health Management Co., Ltd, which is a wholly-owned subsidiary of We Healthy Limited (Akso Qingdao Akso). Á On January 4, 2022, we incorporated Akso Online Meditech Co., Ltd. (Akso Online Meditech) in Wyoming. Á Akso First Health Treatment Center Inc., Akso Remote Medical Consultation Center Inc. and Akso Online Meditech Co., Ltd. are 100% owned by We Health Limited. Á On November 15, 2023, we established Akso Medical Cloud Limited in British Virgin Island, which is 100% owned by Akso Health Group. Á On December 4, 2023, we established Akso Medi-care Limited in Hong Kong, China, which is 100% owned by Akso Medical Cloud Limited. Á On January 16, 2024, we established Tianjin Akso Enterprise Management Co., Ltd. in Tianjin Province, China, which is owned by Akso Medi-care Limited. Á On March 5, 2024, Tianjin Akso Enterprise Management Co., Ltd., our PRC subsidiary, entered into certain securities purchase agreements with four shareholders of Tianjin Wangyi Cloud Co., Ltd. and acquired 50% of the equity interests of Tianjin Wangyi Cloud Co., Ltd. The transaction closed on April 15, 2024. Tianjin Wangyi Cloud Co., Ltd. engages in the business of providing online hospital services including health consultancy services and online sales of medicines and health products through its two wholly owned PRC subsidiaries, Tian Jin Deyihui Online Hospital Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd. Á On April 30, 2024, the shareholders of the Company approved and adopted an amended and restated memorandum and articles of association (the Amended M&A), which changed the authorized issued share capital of the Company from US\$500,000 divided into 5,000,000 ordinary shares, par value US\$0.0001 each, to US\$500,000 divided into 4,500,000 Class A ordinary shares, par value US\$0.0001 each and 500,000,000 Class B ordinary shares, par value US\$0.0001 each (the Re-Designation of the Authorized Capital). Each Class A ordinary share is entitled to one (1) vote and each Class B ordinary share is entitled to twenty (20) votes. In connection with the Re-Designation of the Authorized Capital, 7,980,800 ordinary shares owned by Webao Limited then and 492,019,200 authorized but unissued ordinary shares were converted into Class B ordinary shares on a one-for-one basis. 4,500,000,000 authorized ordinary shares (including 320,770,660 issued and outstanding ordinary shares held by all shareholders other than Webao Limited) were converted into Class A ordinary shares on a one-for-one basis. Á 46 Á Á Business Restructuring and Disposition Á Prior to our disposition of Hexin E-Commerce, on November 20, 2020, Mr. Á Ming Jia and Mr. Á Shiwei Wu transferred their equity interest in Wusu Company to Hexin E-Commerce, which resulted in Wusu Company becoming a wholly-owned entity of Hexin E-Commerce. On November 20, 2020, Hexin Yongheng, Wusu Company, Hexin E-Commerce, Mr. Á Ming Jia and Mr. Á Shiwei Wu entered into a VIE termination agreement, which terminated all rights and obligations with respect to each party thereto under the 2018 Wusu VIE Agreements. Á On December 1, 2020, Hexin Yongheng, our wholly-owned subsidiary, entered into a new series of contractual arrangements with Wusu Company and Hexin E-Commerce whereby Hexin Yongheng retained its interests as the primary beneficiary to Wusu Company. Á On December 16, 2020, Hexin Yongheng, Kuaihangche, Hexin E-Commerce, Xiaobo An, Xiaoning An, and Xiaobin Zhai entered into an assignment and assumption agreement. Pursuant to this agreement, Hexin Yongheng has agreed to assign and transfer to Kuaihangche the control over Hexin E-Commerce, in exchange for cash consideration of RMB 5 million. Upon the closing of the disposition, Kuaihangche became the primary beneficiary of and obtained control of Hexin E-Commerce, and as a result, assume all assets and liabilities of Hexin E-Commerce and subsidiaries owned or controlled by Hexin E-Commerce, excluding any rights, titles, interests or claims that Hexin E-Commerce had in Wusu Company, which remained a consolidated variable interest entity of the Hexin Yongheng by way of the December 1, 2020 contractual arrangements. We closed the disposition of Hexin E-Commerce on December 30, 2020. As a result of the disposition, we are no longer conducting the P2P marketplace business and instead are focusing on developing and investing resources into our social e-commerce platform, Xiaobai Maimai. Á On December 16, 2020, our shareholders approved our name change from Hexindai Inc. to Akso Xiaobai Maimai Inc. to reflect our business transition. Á On January 1, 2021, Hexin Yongheng, our wholly-owned subsidiary, obtained control and became the primary beneficiary of Hexin Jinding by entering into a series of contractual arrangements with Hexin Jinding and Hexin Fengze, the shareholder of Hexin Jinding and a wholly-owned subsidiary of Hexin Jinke. Á On December 3, 2021, our shareholders approved our name change from Akso Xiaobai Maimai Inc. to Akso Akso Health Group to reflect our business transition. Á On May 10, 2023, the Company, HX Asia, HX China, and Hexindai HK (together with HX Asia and HX China, the Targets), and Umbrella Capital Investment Co., Ltd, a British Virgin Islands company which is not affiliate of the Company of any of its directors or officers (the Purchaser) entered into certain share purchase agreement (the Disposition SPA). Pursuant to the Disposition SPA, the Purchaser agreed to purchase the Targets in exchange for cash consideration of US\$215,000 (the Purchase Price). The Disposition closed on May 19, 2023. Upon the closing of the Disposition, the Buyer became the sole shareholder of the Targets and as a result, assume all assets and liabilities of the Targets and subsidiaries owned or controlled by the Target. Á On March 5, 2024, Tianjin Akso Enterprise Management Co., Ltd., our PRC subsidiary, entered into certain securities purchase agreements with four shareholders of Tianjin Wangyi Cloud Co., Ltd. and acquired 50% of the equity interests of Tianjin Wangyi Cloud Co., Ltd. The transaction closed on April 15, 2024. Tianjin Wangyi Cloud Co., Ltd. engages in the business of providing online hospital services including health consultancy services and online sales of medicines and health products through its two wholly owned PRC subsidiaries, Tian Jin Deyihui Online Hospital Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd. Á Corporate Information Á Our principal executive offices are located at Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building, No. 44, Moscow Road, QianwanBonded Port Area, Qingdao Pilot Free Trade Zone, China (Shandong). Our telephone number at this address is +86 152 1005 4919. Our registered office in the Cayman Islands is located at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104. Our agent for service of process in the United States is Law Debenture Corporate Services Inc., located at 801, 2nd Avenue, Suite 403, New York, NY 10017. Á 47 Á Á B. Business Overview Á Historically, the Company generated revenues primarily from our loan facilitation services, post-origination services, and other related services (the P2P Business). On December 30, 2020, we completed the disposal of the P2P Business and transitioned into a social e-commerce platform operator in China, offering high-quality and affordable branded products. Since the fourth quarter of 2021, the Company started exploring healthcare equipment and product trading and related healthcare services business. On January 4, 2022, we incorporated Akso Online Meditech in the State of Wyoming and have been engaged in the sale of COVID-19 Rapid Antigen test kits through Akso Online Meditech. In February 2022, Akso Online Meditech entered into a supply agreement to purchase Akso Health branded COVID-19 Rapid Antigen test kits from its supplier and sells these test kits to distributors in the United States. On January 26, 2022, we incorporated Qingdao Akso in Shandong Province, China and started the sales of medical devices through Qingdao Akso since April 2022. Qingdao Akso has entered into supply agreements to purchase medical devices such as defibrillators, anesthesia laryngoscope from its supplier and sells these devices to distributors or end-users in China. In May 2023, the Company completed the disposition of its social e-commerce business. The Company has since then focused on exploring other area of healthcare sector other than the medical devices and supplies. Á Recently, we begun exploring online hospital and chain pharmacies segments in China. We plan to acquire online hospital(s) in certain cities of China which provides online medical consultations for initial diagnosis, follow-up consultations, and management of chronic diseases, providing patients with an efficient and convenient solution to manage their health online through their smartphones or computers. Typically, the online hospitals are closely connected with and supported by traditional hospitals and outpatient clinics, and their main sources of revenue are from fees charged to patients for both online and offline consultations and the marketing and sales of a variety of health products including medicine, medical equipment and supplements. Á In addition to our plan to acquire online hospital(s), we believe that traditional independent pharmacies in China currently face serious competition and bottlenecks in sales growth, which is why we also plan to acquire multiple independent pharmacies nationwide throughout China, integrating and operating the pharmacies as a chain using our extensive offline resources and IT solutions. We plan to build a new type of pharmacy operation and management system, as well as digital operation and sales solutions for our pharmacies, thereby enhancing our competitiveness and overcoming the current difficulties in the industry. Á On March 5, 2024, Tianjin Akso Enterprise Management Co., Ltd., our PRC subsidiary, entered into certain securities purchase agreements with four shareholders of Tianjin Wangyi Cloud Co., Ltd. and acquired 50% of the equity interests of Tianjin Wangyi Cloud Co., Ltd. The transaction closed on April 15, 2024. Tianjin Wangyi Cloud Co., Ltd. engages in the business of providing online hospital services including health consultancy services and online sales of medicines and health products through its two wholly owned PRC subsidiaries, Tian Jin Deyihui Online Hospital Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd. Á The social e-commerce industry Á We were formally known as Hexindai Inc., and used to be engaged in the business of providing online facilitation related services via our consumer lending marketplace in China, facilitating loans to meet the increasing consumption demand of the emerging middle class in China from 2017 to 2019. Hexindai Inc. was a mobile e-commerce and consumer lending platform in China until it disposed of Hexin E-Commerce in December 2020 and changed its name to Xiaobai Maimai Inc. As part of its transition into the social e-commerce platform business, in May 2020, we launched a new form of social e-commerce mobile platform, Xiaobai Maimai App, offering high-quality and affordable branded products. Xiaobai Maimai leverages its cooperation with major domestic e-commerce platforms and services marketplaces as part of its integrated buyer resources to select and source the most desirable goods and services. Xiaobai Maimai rewards customers with a small commission for every purchase, share or recommendation of a product made to friends. Á In August 2020, Xiaobai Maimai underwent an upgrade to offer an even wider variety of high-quality products covering food and beverage, wine, cosmetic products, fashion and apparel, entertainment, houseware, home appliances and cost-saving promotions at petrol gas stations nationwide. On Xiaobai Maimai App, customers can easily compare superior products at competitive prices without having to change their shopping preferences or switch between different online merchants. It is also a convenient, one-stop platform for customers to not only save big on daily necessities when they shop online, but also stay informed of the latest promotions with attractive discounts, coupons and rebates on the application. As of June 30, 2022, Xiaobai Maimai had approximately 288,858 active customer accounts (an active customer account refers to a customer account that has made at least one purchase) since its launch. In May 2023, the Company entered into a Disposition SPA to dispose the social e-commerce business and the disposal was completed May 19, 2023. Á Healthcare equipment and products trading and radiation oncology service business Á Sales of medical devices Á Through our operating subsidiaries, Akso Online Meditech and Qingdao Akso, we are mainly specialized in the sales of medical devices both in China and in the United States. Á On January 4, 2022, we incorporated Akso Online Meditech in the State of Wyoming and have begun the sale of COVID-19 Rapid Antigen test kits through Akso Online Meditech since March, 2022. Akso Online Meditech has entered into a supply agreement to purchase Akso Health branded COVID-19 Rapid Antigen test kits from its supplier in Hong Kong and sells these test kits to distributors in the United States. Á 48 Á Á Since April 2022, the Company has engaged in the sale of medical devices such as defibrillators and anesthesia laryngoscope through its subsidiary, Qingdao Akso, in China. Qingdao Akso purchases these medical devices in bulk from its suppliers and distributes the products to downstream distributors and end-users. Á Pursuant to the Regulation on the Supervision and Administration of Medical Devices (2021 Revision) promulgated on January 4, 2020 and came into effect on June 1, 2014 (the Supervision and Administration of Medical Devices), which was latest amended on February 9, 2021 and came into effect on June 1, 2021, medical devices are classified into the following three categories based on the degree of risk. Á Á Á Á Class I medical devices means the medical devices with low risks, whose safety and effectiveness can be ensured through routine administration. As of the date of this annual report, we and our subsidiaries do not sell Class I medical devices. Á Á Á Á Class II medical devices means the medical devices with moderate risks, which shall be strictly controlled and administered to ensure their safety and effectiveness. For example, the anesthesia laryngoscope that Qingdao Akso currently may sell are Class II medical devices. Á Á Á Á Class III medical devices means the medical devices with relatively high risks, which shall be strictly controlled and administered through special measures to ensure their safety and effectiveness. For example, the defibrillators Qingdao Akso currently may sell are Class III medical devices. Á Á Pursuant to the Administrative Measures on the Operation Supervision of Medical Devices, filing and licensing are not required for the operation of Class I medical devices. Operators engaged in the operation of Class II medical devices are subject to filing administration and will receive a Class II Medical Device Selling Record Certificate upon satisfaction of filing requirement and no pre-approval of authorities is needed. Operators engaged in the operation of Class III medical devices are subject to pre-approval licensing administration and will receive a Class III Medical Device Operation License upon the authorities’ approval. A Class II Medical Device Selling Record Certificate will be effective in the long term until it is revoked or canceled by the issuing authorities. A Class III Medical Device Operation License is valid for five years and may be renewed six months prior to its expiration date. Á As of the date of this annual report, Qingdao Akso has received from the PRC authorities all requisite licenses, permissions or approvals needed to engage in the resale of medical devices businesses currently conducted in China, and no permission or approval has been denied. Such licenses and permissions include business licenses, a Class II Medical Device Selling Record Certificate and a Class III Medical Device Operation License (as defined below). Pursuant to the Administrative Measures on the Operation Supervision of Medical Devices, filing and licensing are not required for the operation of Class I medical devices. Operators engaged in the resale of Class II medical devices are subject to filing administration and will receive a Class II medical device selling record certificate upon satisfaction of filing requirement and no pre-approval of the authorities is needed (the Class II Medical Device Selling Record Certificate). Operators engaged in the resale or distribution of Class III medical devices are subject to pre-approval licensing administration and will receive medical device operation license upon the authorities’ approval (the Class III Medical Device Operation License). A Class III Medical Device Operation License is valid for five years and may be renewed six months prior to its expiration date. A Class II Medical Device Selling Record Certificate will be effective in the long term until it is revoked or canceled by the issuing authorities. Qingdao Akso obtained a Class II Medical Device Selling Record Certificate on February 25, 2022, and a Class III Medical Device Operation License, and such license expired on March 2, 2022. Á Revenue attributable to the sales of medical equipment for the fiscal year ended March 31, 2024 was \$2.4 million, representing 100% of the Company’s total revenue. Á Akso Health’s radiation oncology services business Á On September 24, 2021, the Board of Directors approved our new business plan to enter the radiation oncology services market in the U.S. On September 26, 2021, we signed a product purchase agreement with a third-party supplier to purchase equipment for the new cancer therapy and radiation oncology business. The total price of the equipment was approximately US\$12.7 million. We prepaid 80% of the purchase price and planned to pay the balance after the equipment was received and installed. In February 2022, affected by the continuous influence of COVID-19 and the global chip shortage, we terminated the purchase agreement and the prepayment for equipment purchase has been refunded. We intend to keep pursuing business opportunities in this sector under the guidance of Dr. Yingxian Liu. Á Akso Health’s radiation oncology services and Covid-19 research business model Currently, the Company is engaged in the sale of COVID-19 Rapid Antigen test kits. In the future, the Company will develop its the cancer therapy and radiation oncology market in the U.S. We plan to open 2 vaccine research centers for AIDS and Covid-19 and 100 radiation oncology centers on the east coast of the U.S. catering to cancer patients at varying stages of treatment. This will include specialized radiation therapy centers for radiotherapy (RT), personalized consultation, conventional treatment planning, and other related services for a wide variety of cancer therapy treatments. On October 22, 2021, we announced the appointment of Dr. Yingxian Liu as the medical consultant to the Company. Dr. Liu has extensive experience, and is highly respected in the pathology field. We believe Dr. Liu’s insights and guidance will support our mission in

assembling the necessary team and infrastructure to build a best-in-class practice thatâ€™s scalable and delivers safe and high-quality cancer treatments for our patients.â€ 49 A Our Suppliers A Our subsidiaries source the medical devices, such as COVID-19 Rapid Antigen test kits, defibrillators and anesthesia laryngoscope, from its supplier in mainland China and Hong Kong. A Our subsidiaries enter into purchase agreements with the supplier in the ordinary course of business. Prices vary depending on the specific items they purchase in each purchase agreement. None of our subsidiaries have long-term agreements that obligate their supplier to continue supplying it with medical devices over the long term. Relationships with suppliers are subject to change from time to time. Changes in relationships with suppliers in the future could positively or negatively impact our subsidiariesâ€™ net sales and operating profits. We believe our subsidiaries can be successful in mitigating negative effects resulting from unfavorable changes in the relationships with suppliers through, among other things, the development of new or expanded supplier relationships. A We currently have one significant supplier, Qingdao Yongbaoyun Technology Co., Ltd.,s which represents 100.0% of our total purchases for the fiscal year ended March 31, 2024. A Our Customers A Our medical devices business which includes the sale of COVID-19 Rapid Antigen test kits, defibrillators and anesthesia laryngoscopes primarily target medical product dealers and end-users such as hospitals. We do not currently have any long-term sale contracts with our customers. Our three main customers are Xiâ€™s an Nazi Hengsheng Medical Equipment Co., Ltd, Xuzhou Bowei Medical Equipment Co., Ltd. and Sichuan Nazi Tongchuang Medical Equipment Co., Ltd, which represented approximately 34.8%, 36.3% and 28.0% of our total revenues for the fiscal year ended March 31, 2024. A Competition A Radiation Oncology and Cancer Therapy Center Business A The oncology healthcare service market in the United States is fragmented and competition is intense. Our planned radiation oncology service and cancer therapy centers would compete primarily on a regional or local basis with government-owned and private hospitals that offer radiotherapy, diagnostic imaging and other oncology healthcare services either directly or in conjunction with third parties. A We would primarily compete with our competitors based on the range of services provided, the reputation of our cancer therapy and radiation oncology centers among doctors and patients in the U.S. and level of patient service and satisfaction. A In addition, we would compete with those who offer other types of available treatment methods that we do not offer, such as chemotherapy, surgery, different forms of radiotherapy that we do not offer, other alternative treatment methods commercialized in recent years and certain treatments that are currently in the experimental stage. These treatments may be more effective or less costly, or both, compared to the treatment methods that our cancer therapy and radiation oncology centers will provide. A iHealth COVID-19 Test Kit Business in the United States A The diagnostic testing industry, especially for COVID-19, is highly competitive, and given the significant interest and growth in COVID-19 related diagnostic tests, we expect ongoing intense competition from different sources, including from manufacturers and producers of diagnostic tests, vaccines and therapeutic treatments. In diagnostic testing, we anticipate facing competition from companies that have or are developing molecular tests (including centralized laboratory and POC tests) as well as antigen and antibody tests to detect SARS-CoV-2. In addition, we face competition from companies developing COVID-19, tests. We face potential competition from many sources, including academic institutions, public and private research institutions and governmental agencies. A In addition to competition from diagnostic testing companies, there are companies developing vaccines and therapeutic treatments for COVID-19. In December 2020 and February 2021, for example, the FDA issued Emergency Use Authorizations for three COVID-19 vaccines. If existing or future vaccines are widely distributed and compliantly administered or if therapeutic treatments are identified and become widely used, our COVID-19 testing opportunities and the market as a whole may shrink or disappear. A 50 A A We believe the following factors affect our ability to compete successfully: A â€test accuracy; A â€timeliness in delivery of test results; A â€user experience; A â€cost control; A â€pricing; A â€manufacturing capability; and A â€access to market. A Sales of Medical Devices A The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. We compete or plan to compete with manufacturers and distributors of medical devices. Some of these competitors are large, well-capitalized companies with significantly greater market share and resources than we have. As a consequence, they are able to spend more on product development, marketing, sales and other product initiatives than we can. We also compete with smaller medical device companies that have single products or a limited range of products. A We believe that the principal competitive factors in our industry are: A A â€ pricing; A A A â€ name recognition; A A A A â€ product quality and selection; A A A A â€ product functionality, reliability and compatibility; A A A A â€ relations with healthcare professionals and customers; A A A A â€ distribution networks; A A A A â€ financial and human resources for sales and marketing; and A A A A â€ additional lines of products and the ability to offer rebates or bundle products to offer greater discounts or other incentives. A Intellectual Property A We have registered a website at <http://www.ahgtop.com/en/index.html>. A To date, we have not experienced a material misappropriation of our intellectual property.Â Despite our efforts to protect our proprietary rights, third parties may attempt to use, copy or otherwise obtain and market or distribute our proprietary technology or develop a platform that is similar to our marketplace. We cannot be certain that the steps we have taken or will take in the future will prevent misappropriations of our technology and intellectual property rights. For a description of the risks related to our intellectual property rights, please see â€œItem 3. Key Informationâ€D. Risk Factorsâ€Risks Related to Our Business and Industryâ€We may be unable to protect our proprietary intellectual property rights from unauthorized use, such that our brand, reputation and business may be negatively impacted.â€ 51 A A Regulation A PRC Regulations A This section sets forth a summary of the most significant rulesA and regulations that affect our business activities in China. A Regulations Relating to Microlending A The Guidance on the Pilot Establishment of Microlending Companies jointly promulgated by the CBRC and the PBOC in MayA 2008 allows provincial governments to approve the establishment of microlending companies on a test basis. Based on this guidance, many provincial governments in China, including the Xinjiang Uygur Autonomous Region, promulgated local implementation rulesA on the administration of microlending companies. For example, Xinjiang Financial Service Office, the regulatory authority for microlending companies in the Xinjiang Uygur Autonomous Region, promulgated the Interim Measures for the Administration of Microlending Companies in Xinjiang Uygur Autonomous Region in AugustA 2017, to impose management duties upon the relevant regulatory authorities and to specify more detailed requirements on microlending companies, including, among others, (i)A microlending companies are prohibited from engaging in the receipt of deposits from the public and illegal fund-raising; (ii)A the modification of certain company registration issues shall be subject to the approval by the relevant regulatory authorities; and (iii)A the microlending company shall engage in the loan business in the place of registration and also in or around the surrounding counties within the same municipality as the place of registration, and the loan balance for the borrowers in the county of registration shall not be less than the 80% of the aggregate loan balance. A In NovemberA 2017, the Internet Finance National Rectification Office issued the Notice on the Immediate Suspension of Approvals for the Establishment of Online Microlending Companies, which took effect immediately, and provides that the relevant regulatory authorities of microlending companies at all levels shall suspend the approval of the establishment of online microlending companies and the approval of any microlending business conducted across provincial lines. A On DecemberA 1, 2017, the Internet Finance National Rectification Office and the Online Lending National Rectification Office jointly issued Circular 141, which suspends approval of new network microlending companies and further imposes measures to strengthen the regulation of network microlending companies. A On DecemberA 8, 2017, the Online Lending National Rectification Office promulgated the Implementation Plan of Specific Rectification for Risks in Microlending Companies and Online Microlending Companies, or the Rectification Implementation Plans of Online Microlending Companies. Pursuant to the Rectification Implementation Plans of Online Microlending Companies, â€œonline microlending loansâ€ are defined as microlending loans provided through the Internet by online microlending companies controlled by Internet enterprises. The features of online microlending loans include online borrower acquisition, credit assessment based on the online information collected from the Internet enterpriseâ€™s business operations and the borrowerâ€™s Internet usage, as well as online loan application, approval and funding. A Consistent with the Guidance on the Pilot Establishment of Microlending Companies and Circular 141, the Rectification Implementation Plans of Online Microlending Companies emphasize several aspects where inspection and rectification measures must be carried out for the online microlending loans industry, which include, among others, (i)A the online microlending companies shall be approved by the competent authorities in accordance with the applicable regulations promulgated by the State Council, and the approved online microlending companies subsequently in violation of any regulatory requirements shall be re-examined; (ii)A qualification requirements to conduct online micro-loan business (including the qualification of sponsor shareholders, the sources of borrowers, the Internet scenario and the digital risk-management technology); (iii)A whether the qualification and funding source of the shareholders of online microlending companies are in compliance with the applicable laws and regulations; (iv)A whether the â€œintegrated actual interestâ€ (namely the aggregated borrowing costs charged to borrowers in the form of interest and various fees) are annualized and subject to the limit on the interest rate of private lending set forth in the Private Lending Judicial Interpretations issued by the Supreme Peopleâ€™s Court and, whether any interest, handling fee, management fee or deposit are deducted from the principal of loans provided to the borrowers in advance, prior to the repayment of the loan; (v)A whether campus loans or online microlending loans with no specific scenario or designated use of loan proceeds are granted; (vi)A with respect to the loan business conducted in cooperation with third-party institutions, whether the online microlending companies outsource the core business (including the credit assessment and risk control), or accept any credit enhancement service (whether or not in a disguised form) provided by any third-party institutions with no approval to provide financing guarantee and whether any applicable third-party institution collects any interest or fees from the borrowers; and (vii)A entities that conduct online microlending loans business without relevant approval or license for lending business shall be shut down and banned. A 52 A A The Rectification Implementation Plans of Online Microlending Companies also sets forth that all related institutions shall be subject to inspection and investigation. Depending on the results, different measures shall be implemented: (i)A for institutions holding online microlending licenses but do not meet the qualification requirements to conduct online micro-loan business, their online microlending licenses shall be revoked and such institutions will be prohibited from conducting loan business outside the administrative jurisdiction of their respective approving authorities; and (ii)A for institutions holding online microlending licenses that meet the qualification requirements to conduct online micro-loan business but were found not in compliance with other requirements, such as the requirements on the integrated actual interest rate, the scope of loan and the cooperation with third-party institutions, such institutions shall take rectification measures in a period to be separately specified by authorities, and in the event that the rectification does not meet the authoritiesâ€™ requirements, such institutions shall be subject to several sanctions, including revocation of license and an order to cease business operations. A On September 7, 2020, CBIRC issued the Circular on Strengthening the Supervision and Administration of Microlending Companies (â€œMicrolending Circularâ€). The Microlending Circular provides that the microlending companies shall mainly operate the lending business and shall act in accordance with the requirements regarding the loan concentration, loan purposes, fund management, debt collection and disclosure. Local authorities shall enhance supervision and administration of the establishment of the microlending companies and suspend newly-incorporated microlending companies from engaging in the Internet microlending business and other inter-provincial business. A On November 2, 2020, CBIRC and PBOC published the Interim Administrative Measures for Online Microlending Business (Draft for Comment) (â€œDraft Interim Administrative Measuresâ€), for public review and comments. Pursuant to the Draft Interim Administrative Measures, â€œonline microlending businessâ€ refers to any microlending business engaged in by a microlending company through using big data, cloud computing, mobile internet and other technical means, utilizing internally generated data and information on customer operation, online consumption, online transaction, etc., accumulated via internet platforms as well as other data and information obtained through legitimate channels to analyze and appraise the credit risk of borrowing customers, determine the mode and quota of loans, and complete such processes as loan application, risk review, loan approval, loan granting and loan recovery online. Online microlending business engaged in by a microlending company shall mainly be carried out in the provincial-level administrative region to which its place of registration belongs. Without the approval of the banking regulator under the State Council, no microlending company may carry out online microlending business across provincial-level administrative regions. The registered capital of a microlending company which engages in online microlending business shall not be less than CNY1 billion and shall be one-off paid-up monetary capital. The registered capital of a microlending company which engages in online microlending business across provincial-level administrative regions shall not be less than CNY5 billion and shall be one-off paid-up monetary capital. In principle, the balance of single-account online microlending loans granted to a natural person shall not exceed CNY300,000 or one-third of its average annual income in the last three years, between which the lower one shall be the maximum loan amount; and in principle, the balance of single-account online microlending loans granted to a legal person or any other organization and its related parties shall not exceed CNY1 million. The Draft Interim Administrative Measures was released for public comment only, there remains substantial uncertainty regarding the Draft Interim Administrative Measures, including with respect to its final content, adoption timeline or effective date. A We engage in online microlending businesses through our subsidiary Wusu Company, which has owned the business scope of microlending. However, we have ceased new microlending business as the principal business scope of Wusu Company has been changed to trading, provision of technological promotion services and import and export since SeptemberA 30, 2019, yet still entitled to the credit right over the loans issued prior to the change of the business scope. A Regulations Relating to Foreign Investment A PRC Foreign Investment Law A The Foreign Investment Law was formally adopted by the second session of the 13th National Peopleâ€™s Congress on MarchA 15, 2019, which has become effective on JanuaryA 1, 2020 and, together with their implementation rulesA and ancillary regulations, has replaced the trio of existing laws regulating foreign investment in China, namely, the Sino-foreign Equity Joint Venture Enterprise Law, the Sino-foreign Cooperative Joint Venture Enterprise Law and the Wholly Foreign-invested Enterprise Law. Meanwhile, the Regulations for the Implementation of the Foreign Investment Law has come into effect as of JanuaryA 1, 2020, which clarified and elaborated the relevant provisions of the Foreign Investment Law. The organization form, organization and activities of foreign-invested enterprises shall be governed, among others, by the laws of the Company Law of the Peopleâ€™s Republic of China and the Partnership Enterprise Law of the Peopleâ€™s Republic of China. Foreign-invested enterprises established before the implementation of this Law may retain the original business organization and so on within five years after the implementation of this Law. A 53 A A The Foreign Investment Law is formulated to further expand opening-up, vigorously promote foreign investment and protect the legitimate rights and interests of foreign investors. According to the Foreign Investment Law, foreign investments are entitled to pre-entry national treatment and are subject to negative list management system. The pre-entry national treatment means that the treatment given to foreign investors and their investments at the stage of investment access shall not be less favorable than that of domestic investors and their investments. The negative list management system means that the state implements special administrative measures for access of foreign investment in specific fields. The Foreign Investment Law does not mention the relevant concept and regulatory regime of VIE structures. See â€œItem 3. Key Informationâ€D. Risk Factorsâ€Risks Related to Doing Business in the Peopleâ€™s Republic of Chinaâ€Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted PRC Foreign Investment law and how it may impact the viability of our current corporate structure, corporate governance and business operations.â€ A Foreign investorsâ€™ investment, earnings and other legitimate rights and interests within the territory of the PRC shall be protected in accordance with the law, and all national policies on supporting the development of enterprises shall equally apply to foreign-invested enterprises. Among others, the state guarantees that foreign invested enterprises participate in the formulation of standards in an equal manner and that foreign-invested enterprises participate in government procurement activities through fair competition in accordance with the law. Further, the state shall not expropriate any foreign investment except under special circumstances. Under special circumstances, the state may levy or expropriate the investment of foreign investors in accordance with the law for the needs of the public interest. The expropriation and requisition shall be conducted in accordance with legal procedures and timely and reasonable compensation shall be given. In carrying out business activities, foreign invested enterprises shall comply with relevant provisions on labor protection, social insurance, tax, accounting, foreign exchange and other matters stipulated in laws and regulations. A According to the Measures for the Security Review of Foreign Investment promulgated by National Development and Reform Commission, the NDRC, and Ministry of Commerce of the Peopleâ€™s Republic of China, the MOC, on DecemberA 19, 2020 and became effective on JanuaryA 18, 2021, the NDRC and the MOC will establish a working mechanism office in charge of the security review of foreign investment. Such measures define foreign investment as direct or indirect investment by foreign investors in the PRC, which includes (i)A investment in new onshore projects or establishment of wholly foreign owned onshore companies or joint ventures with foreign investors; (ii)A acquiring equity or asset of onshore companies by merger and acquisition; and (iii)A onshore investment by and through any other means. Investment in certain key areas with bearing on national security, such as important cultural products and services, important information technology and Internet services and products, key technologies, and other important areas with bearing on national security which results in the acquisition of de facto control of investee companies, shall be filed with a specifically established office before such investment is carried out. What may constitute â€œonshore investment by and through any other meansâ€ or â€œde facto controlâ€ could be broadly interpreted under such measures. It is likely that control through contractual arrangement be regarded as de facto control based on provisions applied to security review of foreign investment in the free trade zone. Failure to make such filing may

subject such foreign investor to rectification within prescribed period, and will be recorded as negative credit information of such foreign investor in the relevant national credit information system, which would then subject such investors to joint punishment as provided by relevant rules. If such investor fails to or refuses to undertake such rectification, it would be ordered to dispose of the equity or asset and to take any other necessary measures so as to return to the status quo and to erase the impact to national security. A Industry Catalog Relating to Foreign Investment A Investment activities in the PRC by foreign investors are principally governed by the Catalog of Industries for Encouraging Foreign Investment, or the Catalog, which became effective on January 27, 2021, and the Special Administrative Measures (Negative List) for Foreign Investment Access, or the Negative List promulgated by the MOC, which became effective on July 23, 2020 and has been amended from time to time by the MOC and the National Development and Reform Commission. It sets out the industries in which foreign investments are prohibited or restricted. Foreign investors will not make investments in prohibited industries, while must satisfy certain conditions stipulated in the Negative List for investment in restricted industries. According to the Negative List, the proportion of foreign investment in entities engaged in value-added telecommunication services (excluding e-commerce, domestic multi-party communications services, store-and-forward services, and call center services) shall not exceed 50%. The most updated Negative List, issued on 27 December, 2021 and became effective on 1 January, 2022, stipulates that any PRC domestic enterprise engaging in the fields prohibited by the negative list shall obtain the consent of the relevant competent PRC authorities for overseas listing, and the foreign investors shall not participate in the operation and management of such enterprise, and the shareholding percentage of the foreign investors in such enterprise shall be subject to the relevant administrative provisions of PRC domestic securities investment by foreign investors. Such negative list does not further elaborate whether existing overseas listed enterprise will be subject to such requirements. The staff of the NDRC addressed in an interview on 27 December, 2021 that certain existing overseas listed enterprises whose foreign investors’ shareholding percentage exceed the aforementioned threshold are not required to make adjustment or deduction. A 54 A Foreign Investment in Value-Added Telecommunication Services A The Provisions on Administration of Foreign Invested Telecommunications Enterprises promulgated by the State Council in December 2001 and subsequently amended in September 2008 and 2016 prohibit a foreign investor from owning more than 50% of the total equity interest in any value-added telecommunications service business in China and require the major foreign investor in any value-added telecommunications service business in China to have a good and profitable record and operating experience in this industry. The Catalog and the Foreign Investment Negative List allow a foreign investor to own more than 50% of the total equity interest in an e-commerce business. A In July 2006, the Ministry of Information Industry, the predecessor of the MIIT, issued the Circular on Strengthening the Administration of Foreign Investment in the Operation of Value-added Telecommunications Business, pursuant to which a domestic PRC company that holds an operating license for value-added telecommunications business, which we refer to as a VATS License, is prohibited from leasing, transferring or selling the VATS License to foreign investors in any form and from providing any assistance, including resources, sites or facilities, to foreign investors that conduct a value-added telecommunications business illegally in China. Further, the domain names and registered trademarks used by an operating company providing value-added telecommunications services must be legally owned by that company or its shareholders. In addition, the VATS License holder must have the necessary facilities for its approved business operations and to maintain the facilities in the regions covered by its VATSA License. A In light of the above restrictions and requirements, we operate our website through Hexin Digital, which has received the VATS License necessary to provide online information service and other value-added telecommunications services in China. A Anti-money Laundering Regulations A The PRC Anti-money Laundering Law, which became effective in January 2007, sets forth the principal anti-money laundering requirements applicable to financial institutions as well as non-financial institutions with anti-money laundering obligations, including the adoption of precautionary and supervisory measures, establishment of various systems for client identification, retention of clients’ identification information and transactions records, and reports on large transactions and suspicious transactions. According to the PRC Anti-money Laundering Law, financial institutions subject to the PRC Anti-money Laundering Law include banks, credit unions, trust investment companies, stock brokerage companies, futures brokerage companies, insurance companies and other financial institutions as listed and published by the State Council, while the list of the non-financial institutions with anti-money laundering obligations will be published by the State Council. The PBOC and other governmental authorities issued a series of administrative rules and regulations to specify the anti-money laundering obligations of financial institutions and certain non-financial institutions, such as payment institutions. A In July 2018, the PBOC issued the Notice on Strengthening Supervision on Anti-money Laundering by Certain Non-financial Institutions, stipulating that the following non-financial institutions shall undertake the responsibilities of anti-money laundering and anti-terrorist financing during certain of their respective business operations: (i) A real estate development enterprises and real estate agencies while selling real estates and providing service for real estate transactions; (ii) A precious metal traders and precious metals trading platforms while conducting or providing service for precious metal spot trading; (iii) A accounting firms, law firms and notary offices while conducting real estate transactions, asset management, bank account and securities account management, fund-raising for establishment or operation of enterprises and business entities transactions on behalf of their clients; and (iv) A company service providers providing service for establishment, operation and management of companies. A On October 10, 2018, the PBOC, the CBIRC and CSRC together promulgated the Measures for the Anti-money Laundering and Anti-terrorist Finance of Internet Finance, which further specified that, any Internet finance institutions incorporated upon approval or upon record-filing by applicable regulatory authority, shall report any forms of cash receipts and payments whose transaction value reaches or exceeds RMB 50,000 or foreign currency equivalent of US\$10,000 on a per-transaction or cumulative basis on a given day, within five working days from the date when such transaction takes place. A 55 A Regulations on Value-Added Telecommunication Services A The Telecommunications Regulations promulgated by the State Council and its related implementation rules, including the Catalog of Classification of Telecommunications Business issued by the MIIT, amended in 2019 categorize various types of telecommunications and telecommunications-related activities into basic or value-added telecommunications services, and Internet information services, or ICP services, and on-line data processing and transaction processing services, are classified as value-added telecommunications businesses. In 2009, the MIIT promulgated the Administrative Measures on Telecommunications Business Operating Licenses, amended in July 2017, which set forth more specific provisions regarding the types of licenses required to operate value-added telecommunications services, the qualifications and procedures for obtaining such licenses and the administration and supervision of such licenses. Under these regulations, a commercial operator of value-added telecommunications services must first obtain a license for value-added telecommunications business, or VATS License, from the MIIT or its provincial level counterparts. A In September 2000, the State Council also issued the Administrative Measures on Internet Information Services, which was amended in January 2011. Pursuant to these measures, A Internet information services A refer to provision of Internet information to online users, and are divided into A e-commerce Internet information services A and A non-commercial Internet information services. A A commercial Internet information services operator must obtain a VATS License for Internet information services, or ICP License, from the relevant government authorities before engaging in any commercial Internet information services operations in China. The ICP License has a term of five years and can be renewed within 90 days before expiration. A We operate our social e-commerce platform Xiaobai Maimai which was launched in May 2020 through Hexin Digital. Xiaobai Maimai is a form of social e-commerce mobile platform offering high-quality and affordable branded products. Xiaobai Maimai leverages our integrated buyer resources to select and source goods globally, and rewards users with a small commission for every purchase, share or recommendation of a product made to friends. Hexin Digital has obtained its EDI License and ICP License for e-commerce business, which is qualified for providing online transactions between consumers and third-party merchants. A Regulations Relating to Product Quality and Consumer Rights Protection A Pursuant to the Product Quality Law of PRC promulgated by the Standing Committee of the National People’s Congress in February 1993, and as amended in July 2000, August 2009 and December 2018 respectively, or the Product Quality Law, a seller must establish and practise a check-for-acceptance system for replenishment of its stock, and examine the quality certificates and other marks and must also adopt measures to keep the products for sale in good quality. Violation of the Product Quality Law could result in various penalties, including the imposition of fines, suspension of business operations, revocation of business licenses or criminal liabilities. Where a defective product causes physical injury to a person or damage to another person’s property, the victim may claim compensation from the manufacturer or from the seller of the product. If the seller pays compensation and it is the manufacturer that should bear the liability, the seller has a right of recourse against the manufacturer. Similarly, if the manufacturer pays compensation and it is the seller that should bear the liability, the manufacturer has a right of recourse against the seller. A The PRC Consumer Rights and Interests Protection Law, as amended and effective as of March 15, 2014, the Online Transactions Measures and the E-Commerce Law, have provided stringent requirements and obligations on business operators, including Internet business operators and platform service providers. For example, consumers are entitled to return goods purchased online, subject to certain exceptions, within seven days upon receipt of such goods without stating a reason for such return. To ensure that sellers and service providers comply with these laws and regulations, the platform operators are required to implement rules governing transactions on the platform, monitor the information posted by sellers and service providers, and report any violations by such sellers or service providers to the relevant authorities. In addition, online marketplace platform providers may, pursuant to the relevant PRC consumer protection laws, be exposed to liabilities if the lawful rights and interests of consumers are infringed upon in connection with consumers’ purchase of goods or acceptance of services on online marketplace platforms and the online marketplace platform providers fail to provide consumers with the contact information of the seller or manufacturer. In addition, online marketplace platform providers may be jointly and severally liable with sellers and manufacturers if they are aware or should be aware that any seller or manufacturer is using the online platform to infringe upon the lawful rights and interests of consumers and fail to take measures necessary to prevent or stop such activity. A 56 A The Civil Code of the PRC, effective on January 1, 2021, also provides that if an online service provider is aware that an online user is committing infringing activities, such as selling counterfeit products, through its Internet services and fails to take necessary measures, it shall be jointly liable with the said online user for such infringement. If the online service provider receives any notice from the infringed party on any infringing activities, the online service provider shall take necessary measures, including deleting, blocking, and unlinking the infringing content, in a timely manner. Otherwise, it will be jointly liable with the relevant online user for extended damages. A We are subject to these laws and regulations as an online supplier of commodities and a provider of an online marketplace platform. Failure to comply with the PRC Consumer Rights and Interests Protection Law and other laws and regulations mentioned above may subject us to civil liabilities such as refunding purchase prices, replacement of commodities, repairing or ceasing damages, compensation, and restoring reputation, and could subject us or the responsible individuals to criminal penalties when personal damages are involved or if the circumstances are severe. A Regulation and Classification of Medical Devices A Pursuant to the Regulations on the Supervision and Administration of Medical Devices promulgated on January 4, 2000 and came into effect on June 1, 2014 (the A Supervision and Administration of Medical Devices A), which was latest amended on February 9, 2021 and came into effect on June 1, 2021, the National Medical Products Administration shall be responsible for the national administration and supervision of medical devices and its local counterparts are responsible for the local administration and supervision of medical devices. A Under this regulation, medical devices have been classified into three categories based on the degree of risk. Class I medical devices shall refer to those devices with low level of risks and whose safety and effectiveness can be ensured through routine administration. Class II medical devices shall refer to those devices with moderate risks that must be strictly controlled and regulated to ensure their safety and effectiveness. Class III medical devices shall refer to those devices with relatively high risks that must be strictly controlled and regulated through special measures to ensure their safety and effectiveness. A Operation of Medical Devices A Pursuant to the Supervision and Administration of Medical Devices, and the Administrative Measures on the Operation Supervision of Medical Devices, promulgated on July 30, 2014, and came into effect on October 1, 2014, then amended on March 10, 2022, and came into effect on May 1, 2022, filing and licensing are not required for the operation of Class I medical devices. Operators engaged in the operation of Class II medical devices are subject to filing administration and will receive a Class II Medical Device Selling Record Certificate upon satisfaction of filing requirement and no pre-approval of the authorities is needed. In addition, the operators are required to guarantee the safety and effectiveness of Class II medical devices, or the record-filing shall be canceled, and an announcement shall be made. While operators engaged in the operation of Class III medical devices are subject to pre-approval licensing administration and will receive a Class III Medical Device Operation License upon the authorities’ approval. A Class III Medical Device Operation License is valid for five years and may be renewed six months prior to its expiration date. A Class II Medical Device Selling Record Certificate will be effective in the long term until it is revoked or canceled by the issuing authorities. A To engage in business operations of medical devices, the following requirements shall be met (a qualifying enterprise must have): A A A quality control institution or staff corresponding to the business scope and scale, and the staff shall have relevant education or professional titles certified by the state. A A A operation and storage premise corresponding to the business scope and scale. A A A Storage conditions corresponding to the business scope and scale; warehouses are not required if all storage is commissioned to other operators of medical devices. A A A quality control system corresponding to the medical devices concerned. A A A Capability for professional guidance, technical training and after-sale service corresponding to the medical devices it operates; or it has come into an agreement on technical support with a relevant institution. A An enterprise to be engaged in business operations of Class III medical devices shall also have a computerized information management system compliant with quality standards to ensure traceability of products. An enterprise to be engaged in business operations of Class I or Class II medical devices is encouraged to set up such a system. A 57 A Advertisements of Medical Devices A Pursuant to the Regulations on Tentative Measures for the Censorship of Advertisement for Drugs, Medical Devices, Dietary Supplements, Food Formula for Special Medical Purpose promulgated by SAMR on December 24, 2019 and came into effect on March 1, 2020, the State Administration for Market Regulation is responsible for organizing and guiding the review of advertisements for drugs, medical devices, health foods and formula foods for special medical purposes. The administrations for market regulation and drug administrations of all provinces, autonomous regions and centrally administered municipalities shall be responsible for the review of advertisements for drugs, medical devices, health food and formula food for special medical purposes, and may entrust other administrative authorities to implement review of advertisements pursuant to the law. A The validity period of the advertisement approval number for drugs, medical devices, health food and formula food for special medical purposes shall be consistent with the shortest validity period of the product registration certificate, filing certificate or production license. If no valid period is prescribed in the product registration certificate, filing certificate or production license, the valid period of the advertisement approval number shall be two years. A Advertisements for drugs, medical devices, health food and formula food for special medical purposes shall be true and legitimate and shall not contain any false or misleading contents. Advertisers shall be responsible for the veracity and legitimacy of the contents of advertisements for drugs, medical devices, health food and formula food for special medical purposes. A Regulation on Intellectual Property Rights A The PRC has adopted comprehensive legislation governing intellectual property rights, including trademarks. The PRC Trademark Law and its implementation rules protect registered trademarks. The PRC Trademark Law has adopted a A first-to-file A principle with respect to trademark registration. The Trademark Office under the State Administration of Industry and Commerce is responsible for the registration and administration of trademarks throughout the PRC, and grants a term of ten years to registered trademarks and another ten years if requested upon expiry of the initial or extended term. Trademark license agreements must be filed with the Trademark Office for record. As of the date of this annual report on Form 20-F, we have no registered trademarks. A Regulations Relating to Indirect Transfers and Dividend Withholding Tax A Pursuant to the EIT Law and its implementation rules, if a non-resident enterprise has not set up an organization or establishment in the PRC, or has set up an organization or establishment but the income derived has no actual connection with such organization or establishment, it will be subject to a withholding tax on its PRC-sourced income at a rate of 10%. In connection with the EIT Law, the SAT issued Circular 698, which became effective as of January 1, 2008, Circular 59 on April 30, 2009, and the SAT Announcement 7, on February 3, 2015. By promulgating and implementing the above, the PRC tax authorities have strengthened their scrutiny over the direct or indirect transfer of equity interest in a PRC resident enterprise by a non-PRC resident enterprise. Pursuant to SAT Announcement 7, if a non-resident enterprise, or referred to as a transferor, transfers its equity in an offshore enterprise which directly or indirectly owns PRC taxable assets, including ownership interest in PRC resident companies, or the Taxable Properties, without a A reasonable commercial purpose A, such transfer shall be deemed as a direct transfer of such Taxable Properties. The payer, or referred as a transferee, in such transfer shall be the withholding agent, and is obligated to withhold and remit the enterprise income tax to the relevant PRC tax authority. If a transferor fails to declare for payment timely or in full of the tax due on proceeds from indirect transfer of PRC taxable assets and the withholding agent also fails to withhold such tax, the tax authority shall, in addition to supplementary collection of such tax, also charge for interest on a daily basis from the transferor according to the EIT Law and its implementation rules. Factors that may be taken into consideration when determining whether there is a reasonable commercial purpose include, among other factors, the value of the transferred equity,

offshore taxable situation of the transaction, the offshore structure’s economic essence and duration and trading fungibility. If an equity transfer transaction satisfies all the requirements mentioned above, such transaction will be considered an arrangement with reasonable commercial purpose. On October 17, 2017, the SAT issued Bulletin 37, which came into effect on December 1, 2017 and amended in June 2018, which, among others, repeals certain rules stipulated in Circular 7. Bulletin 37 further details and clarifies the tax withholding methods in respect of income of non-resident enterprises. A 58 Å Pursuant to the Double Taxation Avoidance Arrangement, the withholding tax rate in respect to the payment of dividends by a PRC enterprise to a Hong Kong enterprise is reduced to 5% from a standard rate of 10% if the Hong Kong enterprise directly holds at least 25% of the PRC enterprise. Pursuant to Circular 81, a Hong Kong resident enterprise must meet the following conditions, among others, in order to enjoy the reduced withholding tax: (i) Å it must be the beneficial owners of the relevant dividends; and (ii) Å it must have directly owned at least 25% of the PRC resident enterprise throughout the 12 Å months prior to receiving the dividends. However, a transaction or arrangement entered into for the primary purpose of enjoying a favorable tax treatment should not be a reason for the application of the favorable tax treatment under the Double Taxation Avoidance Arrangement. If a taxpayer inappropriately is entitled to such favorable tax treatment, the competent tax authority has the power to make appropriate adjustments. In August 2015, the State Administration of Taxation promulgated Circular 60, which became effective on November 1, 2015. Circular 60 provides that non-resident enterprises are not required to obtain pre-approval from the relevant tax authority in order to enjoy the reduced withholding tax rate. Instead, non-resident enterprises and their withholding agents may, by self-assessment and on confirmation that the prescribed criteria to enjoy the tax treaty benefits are met, directly apply the reduced withholding tax rate, and file necessary forms and supporting documents when performing tax filings, which will be subject to post-tax filing examinations by the relevant tax authorities. On October 14, 2019, the State Administration of Taxation promulgated a new Administrative Measures for Non-Resident Taxpayers to Enjoy Treaty Benefits, or Circular 35, which became effective on January 1, 2020 and replaced and repealed Circular 60. However, Circular 35 sets forth similar rules Å that non-resident enterprises and their withholding agents shall enjoy treaty benefit by means of Å self-judgment of eligibility, declaration of entitlement, and retention of relevant materials for future reference. Accordingly, Hexindai HK, our Hong Kong subsidiary, may be able to enjoy the 5% withholding tax rate for the dividends they receive from Hexin Yongheng, our PRC subsidiary, if it satisfies the conditions prescribed under Circular 81 and other relevant tax rules Å and regulations. However, according to Circular 81 and Circular 35, if the relevant tax authorities consider the transactions or arrangements we have are for the primary purpose of enjoying a favorable tax treatment, the relevant tax authorities may adjust the favorable withholding tax in the future. Å According to the Circular on Several Issues regarding the Å beneficial owner Å in Tax Treaties, which was issued on February 3, 2018 by the SAT and has taken effect from April 1, 2018, or Circular 9, when determining the applicant’s status of the Å beneficial owner Å regarding tax treatments in connection with dividends, interests or royalties in the tax treaties, several factors, including without limitation whether the applicant is obligated to pay more than 50% of his or her income in 12 months to residents in a third country or region, whether the business operated by the applicant constitutes the actual business activities, and whether the counterparty country or region to Å the tax treaties levies any tax or grants tax exemption on relevant incomes or levies tax at an extremely low rate, will be taken into account, and such determination will be analyzed according to the actual circumstances of the specific cases. Circular 9 further provides that applicants who intend to prove his or her status of the Å beneficial owner Å shall submit the relevant documents to the relevant tax authority according to Circular 35. Based on Circular 35, non-resident enterprises are not required to file supporting documents when submitting one necessary form to the relevant tax authority in order to enjoy the reduced withholding tax rate. Instead, non-resident enterprises and their withholding agents may, by self-assessment and on confirmation that the prescribed criteria to enjoy the tax treaty benefits are met, directly apply the reduced withholding tax rate, and preserve the supporting documents for post-tax filing examinations by the relevant tax authorities. However, if a competent tax authority finds out that it is necessary to apply the general anti-tax avoidance rules, it may start general investigation procedures for anti-tax avoidance and adopt corresponding measures for subsequent administration. Å Regulations Relating to Foreign Exchange Å Regulation on Foreign Currency Exchange Å The principal regulations governing foreign currency exchange in China are the Foreign Exchange Administration Regulations, most recently amended in August 2008. Under the PRC foreign exchange regulations, payments of current account items, such as profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval from SAFE by complying with certain procedural requirements. By contrast, approval from or registration with appropriate government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital account items, such as direct investments, repayment of foreign currency-denominated loans, repatriation of investments and investments in securities outside of China. Å 59 Å In November 2012, SAFE promulgated the Circular of Further Improving and Adjusting Foreign Exchange Administration Policies on Foreign Direct Investment, mostly recently amended in December 2019, which substantially amends and simplifies the current foreign exchange procedure. Pursuant to this circular, the opening of various special purpose foreign exchange accounts, such as pre-establishment expenses accounts, foreign exchange capital accounts and guarantee accounts, the reinvestment of RMB proceeds derived by foreign investors in the PRC, and remittance of foreign exchange profits and dividends by a foreign-invested enterprise to its foreign shareholders no longer require the approval or verification of SAFE, and multiple capital accounts for the same entity may be opened in different provinces, which was not possible previously. In addition, SAFE promulgated another circular in May 2013, which specifies that the administration by SAFE or its local branches over direct investment by foreign investors in the PRC must be conducted by way of registration and banks must process foreign exchange business relating to the direct investment in the PRC based on the registration information provided by SAFE and its Å branches. On February 13, 2015, the SAFE promulgated the Notice on Further Simplifying and Improving the Administration of the Foreign Exchange Concerning Direct Investment, or SAFE Notice 13. After SAFE Notice 13 became effective on June 1, 2015, instead of applying for approvals regarding foreign exchange registrations of foreign direct investment and overseas direct investment from SAFE, entities and individuals will be required to apply for such foreign exchange registrations from qualified banks. The qualified banks, under the supervision of the SAFE, will directly examine the applications and conduct the registration. Å On March 30, 2015, the SAFE promulgated Circular 19, to expand the pilot reform of the administration of the settlement of the foreign exchange capitals of foreign-invested enterprises nationwide. Circular 19 allows foreign-invested enterprises to make equity investments by using RMB fund converted from foreign exchange capital. However, Circular 19 continues to, prohibit foreign-invested enterprises from, among other things, using RMB fund converted from its foreign exchange capitals for expenditure beyond its business scope, providing entrusted loans or repaying loans between non-financial enterprises. Å On June 9, 2016, the SAFE promulgated Circular 16, which expands the application scope from only the capital of the foreign-invested enterprises to the capital, the foreign debt fund and the fund from overseas public offering. Also, Circular 16 allows the enterprises to use their foreign exchange capitals under capital account allowed by the relevant laws and regulations. Å On October 23, 2019, the SAFE promulgated the Notice of the Administration of Foreign Exchange on Further Promoting the Convenience of Cross-Border Trade and Investment, which, among other things, non-investment foreign-invested entities may use foreign exchange capital or Renminbi funds converted from the foreign exchange capital to make domestic equity investments, provided that such investments should comply with relevant PRC laws and regulations. Å Regulations on Foreign Exchange Registration of Overseas Investment by PRC Residents Å SAFE issued the SAFE Circular on Relevant Issues Relating to Domestic Resident’s Å Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37, that became effective Å in July 2014, replacing the previous SAFE Circular 75. SAFE Circular 37 regulates foreign exchange matters in relation to the use of special purpose vehicles, or SPVs, by PRC residents or entities to seek offshore investment and financing or conduct round trip investment in China. Under SAFE Circular 37, a SPV refers to an offshore entity established or controlled, directly or indirectly, by PRC residents or entities for the purpose of seeking offshore financing or making offshore investment, using legitimate onshore or offshore assets or interests, while Å round trip investment Å refers to direct investment in China by PRC residents or entities through SPVs, namely, establishing foreign-invested enterprises to obtain the ownership, control rights and management rights. SAFE Circular 37 provides that, before making contribution into an SPV, PRC residents or entities are required to complete foreign exchange registration with SAFE or its local branch. SAFE promulgated the Notice on Further Simplifying and Improving the Administration of the Foreign Exchange Concerning Direct Investment in February 2015, which took effect on June 1, 2015 and was further amended on December 30, 2019. This notice has amended SAFE Circular 37 requiring PRC residents or entities to register with qualified banks rather than SAFE or its local branch in connection with their establishment or control of an offshore entity established for the purpose of overseas investment or Å financing. Å 60 Å A PRC residents or entities who had contributed legitimate onshore or offshore interests or assets to SPVs but had not obtained registration as required before the implementation of the SAFE Circular 37 must register their ownership interests or control in the SPVs with qualified banks. An amendment to the registration is required if there is a material change with respect to the SPV registered, such as any change of basic information (including change of the PRC residents, name and operation term), increases or decreases in investment amount, transfers or exchanges of shares, and mergers or divisions. Failure to comply with the registration procedures set forth in SAFE Circular 37 and Å the subsequent notice, or making misrepresentation on or failure to disclose controllers of the foreign-invested enterprise that is established through round-trip investment, may result in restrictions being imposed on the foreign exchange activities of the relevant foreign-invested enterprise, including payment of dividends and other distributions, such as proceeds from any reduction in capital, share transfer or liquidation, to its offshore parent or affiliate, and the capital inflow from the offshore parent, and may also subject relevant PRC residents or entities to penalties under PRC foreign exchange administration regulations. Å We are aware that our PRC resident beneficial owners subject to these registration requirements have registered with the Beijing SAFE branch. Å Regulations on Stock Incentive Plans Å SAFE promulgated the Stock Option Rules Å in February 2012, replacing the previous rules Å issued by SAFE in March 2007. Under the Stock Option Rules Å and other relevant rules Å and regulations, PRC residents who participate in stock incentive plan in an overseas publicly-listed company are required to register with SAFE or its local branches and complete certain other procedures. Participants of a stock incentive plan who are PRC residents must retain a qualified PRC agent, which could be a PRC subsidiary of the overseas publicly listed company or another qualified institution selected by the PRC subsidiary, to conduct the SAFE registration and other procedures with respect to the stock incentive plan on behalf of the participants. In addition, the PRC agent is required to amend the SAFE registration with respect to the stock incentive plan if there is any material change to the stock incentive plan, the PRC agent or other material changes. The PRC agent must, on behalf of the PRC residents who have the right to exercise the employee share options, apply to SAFE or its local branches for an annual quota for the payment of foreign currencies in connection with the PRC residents’ Å exercise of the employee share options. The foreign exchange proceeds received by the PRC residents from the sale of shares under the stock incentive plans granted and dividends distributed by the overseas listed companies must be remitted into the bank accounts in the PRC opened by the PRC agents before distribution to such PRC residents. Å We have adopted a share incentive plan, under which we have the discretion to grant a broad range of equity-based awards to eligible participants. See Å Item 6. Directors, Senior Management and Employees Å “B. Compensation Å “Share Incentive Plan. Å However, any failure to complete the registration pursuant to the Stock Option Rules Å and other foreign exchange requirements may subject these PRC individuals to fines and legal sanctions and may also limit our ability to contribute additional capital to our PRC subsidiary, limit our PRC subsidiary’s Å ability to distribute dividends to us or otherwise materially adversely affect our business. Å Regulations on Dividend Distribution Å Under our current corporate structure, our Cayman Islands holding company may rely on dividend payments from Hexin Yongheng, which is a wholly foreign-owned enterprise incorporated in China, to fund any cash and financing requirements we may have. The principal regulations governing distribution of dividends of Å foreign-invested enterprises include the Company Law and Foreign Investment Law and its implementation rules. Under these laws and regulations, wholly foreign-owned enterprises in China may pay dividends only out of their accumulated after-tax profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, wholly foreign-owned enterprises in China are required to allocate at least 10% of their respective accumulated profits each year, if any, to fund certain reserve funds until these reserves have reached 50% of the registered capital of the enterprises. Wholly foreign-owned companies may, at their discretion, allocate a portion of their after-tax profits based on PRC accounting standards to staff welfare and bonus funds. These reserves are not distributable as cash Å dividends. Å Regulations Relating to Employment Å The PRC Labor Law and the Labor Contract Law require that employers must execute written employment contracts with full-time employees. If an employer fails to enter into a written employment contract with an employee within one year from the date on which the employment relationship is established, the employer must rectify the situation by entering into a written employment contract with the employee and pay the employee twice the employee’s Å salary for the period from the day following the lapse of one month from the date of establishment of the employment relationship to the day prior to the execution of the written employment contract. All employers must compensate their employees with wages equal to at least the local minimum wage standards. Violations of the PRC Labor Law and the Labor Contract Law may result in the imposition of fines and other administrative sanctions, and serious violations may result in criminal liabilities. Å 61 Å Enterprises in China are required by PRC laws and regulations to participate in certain employee benefit plans, including social insurance funds, namely a pension plan, a medical insurance plan, an unemployment insurance plan, a work-related injury insurance plan and a maternity insurance plan, and a housing provident fund, and contribute to the plans or funds in amounts equal to certain percentages of salaries, including bonuses and allowances, of the employees as specified by the local government from time to time at locations where they operate their businesses or where they are located. Failure to make adequate contributions to various employee benefit plans may be subject to fines and other administrative sanctions. Also, enterprises in China are required by PRC laws and regulations to serve as the individual income tax withholding agents and withhold individual income tax from their employees accordingly. Å We have not made adequate contributions to employee benefit plans, as required by applicable PRC laws and regulations. See Å Item 3. Key Information Å “D. Risk Factors Å “Risks Related to Doing Business in the People’s Å Republic of China Å “Failure to make adequate contributions to various employee benefit plans as required by PRC regulations may subject us to penalties. Å Å M Å Rules and Regulations Relating to Overseas Listing Å On August 8, 2006, six PRC regulatory agencies, including the CSRC, MOFCOM, the State-owned Assets Supervision and Administration Commission, the SAT, the State Administration of Industry and Commerce and SAFE, adopted the M Å Rules, which became effective on September 8, 2006, and were amended on June 22, 2009. Foreign investors shall comply with the M Å Rules when they purchase equity interests of a domestic company or subscribe the increased capital of a domestic company, and thus changing the nature of the domestic company into a foreign-invested enterprise, when the foreign investors establish a foreign-invested enterprise in the PRC, purchase the assets of a domestic company and operate the assets, or when the foreign investors purchase the assets of a domestic company, establish a foreign-invested enterprise by injecting such assets, and operate the assets. As for merger and acquisition of a domestic company with a related party relationship by a domestic company, enterprise or natural person in the name of an overseas company legitimately incorporated or controlled by the domestic company, enterprise of natural person, such merger and acquisition shall be subject to examination and approval of MOFCOM. The parties involved shall not use domestic investment by foreign investment enterprises or other methods to circumvent the requirement of examination and approval. Å Pursuant to the Manual of Guidance on Administration for Foreign Investment Access, which was issued and became effective on December 18, 2008 by MOFCOM, notwithstanding the fact that (i) the domestic shareholder is connected with the foreign investor or not, or (ii) the foreign investor is the existing shareholder or the new investor, the M Å Rules shall not apply to the transfer of an equity interest in an incorporated foreign-invested enterprise from the domestic shareholder to the foreign investor. Å On July 6, 2021, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the Opinions. The Opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies. The Opinions proposed to take effective measures, such as promoting the construction of relevant regulatory systems, to deal with the risks and incidents facing China-based overseas-listed companies and the demand for cybersecurity and data privacy protection. Å On February 17, 2023, the CSRC promulgated the Trial Measures and five supporting guidelines, which came into effect on March 31, 2023. Pursuant to the Trial Measures, domestic companies that seek to offer or list securities overseas, both directly and indirectly, shall complete filing procedures with the CSRC pursuant to the requirements of the Trial Measures within three working days following its submission of initial public offerings or listing application. If a domestic company fails to complete required filing procedures or conceals any material fact or falsifies any major content in its filing documents, such domestic company may be subject to administrative penalties, such as an order to rectify, warnings, fines, and its controlling shareholders, actual controllers, the person directly in charge and other directly liable persons may also be subject to administrative penalties, such as warnings and fines. Å The Trial Measures establish a list outlining the circumstances where a PRC enterprise is prohibited from offering and listing securities overseas, and the CSRC has the authority to block offshore listings that: (i) are explicitly prohibited by laws; (ii) may endanger national security as determined by relevant competent departments under the State Council; (iii) involve criminal offenses that disrupting PRC economy such as corruption, bribery,

embezzlement, or misappropriation of property by the issuer, the controlling shareholder, and/or actual controller in the recent three years; (iv) involve the issuer under investigations for suspicion of criminal offenses or major violations of laws and regulations; or (v) involve material ownership disputes over the shares held by the controlling shareholder or by other shareholders that are controlled by the controlling shareholder and/or actual controller. An issuer seeking direct or indirect overseas listings is also required to undergo national security review or obtain clearance from relevant authorities if necessary before making any application with overseas regulator or listing venue. Where an overseas securities regulator investigates and collects evidence relating to the overseas offering and listing of a PRC enterprise and related activities, and requests the CSRC for cooperation in accordance with the cross-border supervision and management cooperation mechanism, the CSRC may provide necessary assistance according to law and based on the principle of reciprocity. Our application for listing in Nasdaq does not fall under the circumstance that such overseas listing is prohibited by the Trial Measures, nor do we need to go through the review such as security review or clearance approval from relevant authorities. A 62 A According to the CSRC Notice, the domestic companies that have already been listed overseas before the effective date of the Trial Measures (namely, March 31, 2023) shall be deemed as Existing Issuers. Existing Issuers are not required to complete the filing procedures immediately, and they shall be required to file with the CSRC for any subsequent offerings. Further, according to the CSRC Notice, domestic companies that have obtained approval from overseas regulatory authorities or securities exchanges (for example, the effectiveness of a registration statement for offering and listing in the U.S. has been obtained) for their indirect overseas offering and listing prior to March 31, 2023 but have not yet completed their indirect overseas issuance and listing, are granted a six-month transition period from March 31, 2023 to September 30, 2023. Those that complete their indirect overseas offering and listing within such six-month period are deemed as Existing Issuers and are not required to file with the CSRC for their indirect overseas offerings and listings. Within such six-month transition period, however, if such domestic companies fail to complete their indirect overseas issuance and listing, they shall complete the filing procedures with the CSRC. A Based on the foregoing, we are currently not required to complete the filing procedures pursuant to the Trial Measures. However, in the event that we undertake new offerings or fundraising activities in the future, we may be required to complete the filing procedures. A On February 24, 2023, the CSRC, together with the MOF, National Administration of State Secrets Protection and National Archives Administration of China, revised the Provisions issued by the CSRC and National Administration of State Secrets Protection and National Archives Administration of China in 2009. The revised Provisions were issued under the title the “Provisions on Strengthening Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies,” and came into effect on March 31, 2023 together with the Trial Measures. One of the major revisions to the revised Provisions is expanding their application to cover indirect overseas offering and listing, as is consistent with the Trial Measures. The revised Provisions require that, among other things, (a) a domestic company that plans to, either directly or indirectly through its overseas listed entity, publicly disclose or provide to relevant individuals or entities, including securities companies, securities service providers, and overseas regulators, any documents and materials that contain state secrets or working secrets of government agencies, shall first obtain approval from competent authorities according to law, and file with the secrecy administrative department at the same level; and (b) a domestic company that plans to, either directly or indirectly through its overseas listed entity, publicly disclose or provide to relevant individuals and entities, including securities companies, securities service providers, and overseas regulators, any other documents and materials that, if leaked, will be detrimental to national security or public interest, shall strictly fulfill relevant procedures stipulated by applicable national regulations. Any failure or perceived failure by our Company, our subsidiaries, or the VIEs to comply with the above confidentiality and archives administration requirements under the revised Provisions and other PRC laws and regulations may result in the relevant entities being held legally liable by competent authorities, and referred to the judicial organ to be investigated for criminal liability if suspected of committing a crime. A U.S. Regulations A This section sets forth a summary of the most significant rules and regulations that affect our business activities in the United States. A The levels of revenues and profitability of companies involved in the health services industry, such as the Company, may be affected by the continuing efforts of governmental and third-party payors to contain or reduce the costs of health care through various means. Although the Company does not believe that its business activities will be materially affected in the foreseeable future, it is not possible to predict the long term effect of recent and future changes in the regulatory environment, or the responses of federal, state or private payors for healthcare goods and services in response to healthcare proposals or legislation. A In March 2010, significant reforms to the healthcare system were adopted in the form of the Patient Protection and Affordable Care Act (the “PPACA”). The PPACA includes provisions that, among other things, reduce and/or limit Medicare reimbursement to certain providers, require all individuals to have health insurance (with limited exceptions) and impose new and/or increased taxes. The Company cannot predict the effects these changes may have on its business, and no assurance can be given that any such changes will not have a material adverse effect on the Company. A In addition, the provision of medical services in the United States is dependent on the availability of reimbursement to consumers from third party payors, such as government and private insurance companies. Although patients are ultimately responsible for services rendered, the Company expects that the majority of its revenues will be derived from reimbursements by third party payors. Medicare has authorized reimbursement for certain forms of cancer treatment. Over the last several years, such third-party payors are increasingly challenging the cost effectiveness of medical products and services and taking other cost containment measures. A 63 A In the future, the Company may establish additional radiation oncology and cancer therapy services. Completion of future centers would require approvals and arrangements with hospitals, health care organizations, or other third parties, including certain regulatory authorities. In addition, many states require hospitals to obtain a Certificate of Need (“CON”) before they can acquire a significant piece of medical equipment. Should the Company enter into future ventures such as the one described above, but it can have no assurance that CONs will be granted. A Regulation of Medical Devices in the United States A Our COVID-19 self-test kits and operations are subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act and its implementing regulations, collectively referred to as the FDCA, as well as other federal and state regulatory bodies in the United States. The laws and regulations govern, among other things, product design and development, pre-clinical and clinical testing, manufacturing, packaging, labeling, storage, record keeping and reporting, clearance or approval, marketing, distribution, promotion, import and export and post-marketing surveillance. A The FDA regulates the development, design, pre-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, import, export, adverse event reporting, advertising, promotion, marketing and distribution of medical devices in the United States to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA. Failure to comply with applicable requirements may subject a device and/or its manufacturer to a variety of administrative sanctions, such as FDA refusal to approve pending premarket applications, issuance of warning letters, mandatory product recalls, import detentions, civil monetary penalties, and/or judicial sanctions, such as product seizures, injunctions and criminal prosecution. A FDA Premarket Clearance and Approval Requirements A Unless an exemption applies, each medical device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, approval of a premarket approval, or PMA, or grant of a de novo request for classification. During public emergencies, FDA also may grant emergency use authorizations to allow commercial distribution of devices intended to address the public health emergency. Under the FDCA, medical devices are classified into one of three classes—Class I, Class II or Class III—depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to provide reasonable assurance of its safety and effectiveness. Classification of a device is important because the class to which a device is assigned determines, among other things, the necessity and type of FDA review required prior to marketing the device. A Class I devices include those with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to the FDA’s “general controls” for medical devices, which include compliance with the applicable portions of the FDA’s Quality System Regulation, or QSR, facility registration and product listing, reporting of adverse medical events and malfunctions through the submission of Medical Device Reports, or MDRs, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. Some Class I or low risk devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below. A Class II devices are moderate risk devices subject to the FDA’s “general controls,” and any other “special controls” deemed necessary by the FDA to ensure the safety and effectiveness of the device, such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process, though certain Class II devices are exempt from this premarket review process. When required, the manufacturer must submit to the FDA a premarket notification, or 510(k), submission demonstrating that the device is “substantially equivalent” to a legally marketed predicate device, which in some cases may require submission of clinical data. Unless a specific exemption applies, 510(k) premarket notification submissions are subject to user fees. If the FDA determines that the device, or its intended use, is not substantially equivalent to a legally marketed device, the FDA will place the device, or the particular use of the device, into Class III, and the device sponsor must then fulfill more rigorous premarketing requirements. A Class III devices include devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices and devices deemed not substantially equivalent to a predicate device following a 510(k) submission. The safety and effectiveness of Class III devices cannot be reasonably assured solely by general or special controls. Submission and FDA approval of a PMA application is required before marketing of a Class III device can proceed. As with 510(k) submissions, unless an exemption applies, PMA submissions are subject to user fees. The PMA process is much more demanding than the 510(k) premarket notification process. A PMA application, which is intended to demonstrate that the device is reasonably safe and effective for its intended use and must be supported by extensive data, typically including data from pre-clinical studies and clinical trials. A 64 A Emergency Use Authorization A In emergency situations, such as a pandemic, the FDA has the authority to allow unapproved medical products or unapproved uses of cleared or approved medical products to be used in an emergency to diagnose, treat or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear warfare threat agents when there are no adequate, approved, and available alternatives. A Under this authority, the FDA may issue an EUA for an unapproved device if the following four statutory criteria have been met: (1) a serious or life-threatening condition exists; (2) evidence of effectiveness of the device exists; (3) a risk-benefit analysis shows that the benefits of the product outweigh the risks; and (4) no other alternatives exist for diagnosing, preventing or treating the disease or condition. Evidence of effectiveness includes medical devices that “may be effective” to prevent, diagnose, or treat the disease or condition identified in a declaration of emergency issued by the Secretary of HHS. The “may be effective” standard for EUAs requires a lower level of evidence than the “effectiveness” standard that FDA uses for product clearances or approvals in non-emergency situations. The FDA assesses the potential effectiveness of a possible EUA product on a case-by-case basis using a risk-benefit analysis. In determining whether the known and potential benefits of the product outweigh the known and potential risks, the FDA examines the totality of the scientific evidence to make an overall risk-benefit determination. Such evidence, which could arise from a variety of sources, may include (but is not limited to) results of domestic and foreign clinical trials, in vivo efficacy data from animal models, in vitro data, as well as the quality and quantity of the available evidence. A Once granted, an EUA will remain in effect and generally terminate on the earlier of (1) the determination by the Secretary of HHS that the public health emergency has ceased or (2) a change in the approval status of the product such that the authorized use(s) of the product are no longer unapproved. After the EUA is no longer valid, the product is no longer considered to be legally marketed and one of the FDA’s “non-emergency premarket pathways” would be necessary to resume or continue distribution of the subject product. A The FDA also may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect the public health or safety. A On January 31, 2020, the Secretary of HHS issued a declaration of a public health emergency related to COVID-19. On February 4, 2020, HHS determined that COVID-19 represents a public health emergency that has a significant potential to affect national security or the health and security of U.S. citizens living abroad and, subsequently, declared on March 24, 2020, that circumstances exist to justify the authorization of emergency use of medical devices, including alternative products used as medical devices, during the COVID-19 pandemic, subject to the terms of any authorization as issued by the FDA. On February 29, 2020, the FDA issued an immediately in effect guidance with policy specific to development of in vitro diagnostic tests during the COVID-19 public health emergency, as periodically updated thereafter. A 510(k) Clearance Marketing Pathway A Our current products are class II and, but for the immediate ability to seek an EUA, would be subject to premarket notification and clearance under section 510(k) of the FDCA. To obtain 510(k) clearance for a medical device, an applicant must submit to the FDA a 510(k) submission demonstrating that the proposed device is “substantially equivalent” to a legally marketed device, known as a “predicate device.” A legally marketed predicate device may include a device that was legally marketed prior to May 28, 1976 (a pre-amendment device), a device that has been reclassified from Class III to Class II or Class I, or a device that was found substantially equivalent through the 510(k) process. A device is substantially equivalent if, with respect to the predicate device, it has the same intended use and has either (1) the same technological characteristics, or (2i) different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does not raise new questions of safety and effectiveness and is at least as safe and effective as the predicate device. A showing of substantial equivalence sometimes, but not always, requires clinical data. Once the 510(k) submission is accepted for review, by regulation, the FDA has 90 calendar days to review and issue a determination. As a practical matter, clearance may take and often takes longer. Upon review, the FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and annual fees and for medical device establishments. A 65 A Before the FDA will accept a 510(k) submission for substantive review, the FDA will first assess whether the submission satisfies a minimum threshold of acceptability. If the FDA determines that the 510(k) submission is incomplete, the FDA will issue a “Refuse to Accept” letter which generally outlines the information the FDA believes is necessary to permit a substantive review and to reach a determination regarding substantial equivalence. An applicant must submit the requested information within 180 days before the FDA will proceed with additional review of the submission. A If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is “not substantially equivalent” to a previously cleared device, for example, due to a finding of a lack of a predicate device, that the device has a new intended use or different technological characteristics that raise different questions of safety or effectiveness when the device is compared to the cited predicate device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the “de novo” process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. If the FDA determines that the information provided in a 510(k) submission is insufficient to demonstrate substantial equivalence to the predicate device, the FDA generally identifies the specific information that needs to be provided so that the FDA may complete its evaluation of substantial equivalence, and such information may be provided within the time allotted by the FDA or in a new 510(k) submission should the original 510(k) submission have been withdrawn. A After a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) marketing clearance or, depending on the modification, PMA approval. The determination as to whether or not a modification could significantly affect the device’s safety or effectiveness is initially left to the manufacturer using available FDA guidance. Many minor modifications today are accomplished by a “letter to file” in which the manufacturer documents the rationale for the change and why a new 510(k) submission is not required. However, the FDA may review such letters to file to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) marketing clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties. A PMA Approval Pathway A Class III devices require PMA approval before they can be marketed although some pre-amendment Class III devices for which FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is generally more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is reasonably safe and effective, and the PMA must be supported by extensive data, including data from pre-clinical studies and clinical trials. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing, and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FDCA to complete its review of a PMA, although in practice, the FDA’s review may take and often takes significantly longer, and can take up to several years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel’s recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the applicant or its third-party manufacturers’ or suppliers’ manufacturing facility or facilities

to ensure compliance with the QSR. The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical trial that supported PMA approval or requirements to conduct additional clinical trials post-approval. The FDA may also condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.

66 Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, that affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness. None of our test kits are currently approved under a PMA. However, we may in the future develop devices which will require the approval of a PMA.

De novo Classification Medical device types that the FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk they pose. To market low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, a manufacturer may request a de novo down-classification. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. A medical device may be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent or a manufacturer may request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. The FDA is required to classify the device within 120 calendar days following receipt of the de novo application, although in practice, the FDA's review may take significantly longer. During the pendency of the FDA's review, the FDA may issue an additional information letter, which places the de novo request on hold and stops the review clock pending receipt of the additional information requested. In the event the de novo requestor does not provide the requested information within 180 calendar days, the FDA will consider the de novo request to be withdrawn. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the de novo request for classification if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed. In the event the FDA determines the data and information submitted demonstrate that general controls or general and special controls are adequate to provide reasonable assurance of safety and effectiveness, the FDA will grant the de novo request for classification. When the FDA grants a de novo request for classification, the device is granted marketing authorization and further can serve as a predicate for future devices of that type, through a 510(k) premarket notification.

Post-market Regulation After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:

- Establishment registration and device listing with the FDA;
- QSR requirements, which require manufacturers and contract manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;
- Labeling regulations and FDA prohibitions against the promotion of investigational products, or cleared or approved products;
- Requirements related to promotional activities;
- Clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices;
- Medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;
- Correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections, product removals or recalls if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;
- The FDA's recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and
- Post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.

Advertising and promotion of medical devices, in addition to being regulated by the FDA, are also regulated by the Federal Trade Commission and by state regulatory and enforcement authorities. Recently, promotional activities for FDA-regulated products have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. In addition, under the federal Lanham Act and similar state laws, competitors and others can initiate litigation relating to advertising claims. In general, if the FDA determines that our promotional materials or training constitutes promotion of an unapproved or unclear use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved or unclear use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:

- Untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
- Unanticipated expenditures to address or defend such actions;
- Customer notification requirements for repair, replacement, refunds;
- Recall, withdrawal, administrative detention or seizure of our test kits;
- Operating restrictions or partial suspension or total shutdown of production;
- Refusal of or delay in granting our requests for 510(k) clearance or PMA approval of new test kits or modified test kits;
- Operating restrictions, partial suspension or total shutdown of production;
- Withdrawing 510(k) clearance or PMA approvals that are already granted;
- Refusal to grant export approval for our test kits; or
- Criminal prosecution.

68 Health Insurance Portability and Accountability Act and Other Privacy Laws The federal Health Insurance Portability and Accountability Act of 1996, as amended by the Healthcare Information Technology for Economic and Clinical Health Act of 2009, or collectively HIPAA, among other things, established federal protection for the privacy and security of protected health information, or PHI. Under HIPAA, the HHS has issued regulations to protect the privacy and security of PHI used or disclosed by covered entities, including certain healthcare providers, health plans and healthcare clearinghouses, and their respective business associates and their covered subcontractors that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and certain healthcare providers. The HIPAA privacy regulations protect PHI by limiting its use and disclosure, giving patients the right to access certain information about them, and limiting most disclosures of PHI to the minimum amount necessary to accomplish an intended purpose. The HIPAA security standards require the adoption of administrative, physical and technical safeguards and the adoption of written security policies and procedures. In addition, HIPAA requires covered entities to execute business associate agreements with their business associates and subcontractors, who provide services for or on behalf of covered entities. Business associates have a corresponding obligation to maintain appropriate business associate agreements with downstream subcontractors under HIPAA.

In addition, various states, such as California and Massachusetts, have implemented similar data privacy and security laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California's patient privacy laws, for example, provide for penalties of up to \$250,000 and permit injured parties to sue for damages. Additionally, we are subject to other data privacy and security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards related to data privacy and security. Such obligations may include the Federal Trade Commission Act, the California Consumer Privacy Act of 2018, or the CCPA, the Canadian Personal Data Protection and Electronic Documents Act, and the Payment Card Industry Data Security Standard, or PCI DSS. In addition, states within the United States have enacted or proposed data privacy laws. For example, Virginia passed the Consumer Data Protection Act and Colorado passed the Colorado Privacy Act. For example, the CCPA, which increases privacy rights for California residents and imposes obligations on companies that process their personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. In addition, it is anticipated that the California Privacy Rights Act of 2020, or the CPRA, effective January 1, 2023, will expand the CCPA. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues and potentially exposing us to additional expense, adverse publicity and liability. The compliance requirements of these laws, including additional breach reporting requirements, and the penalties for violation vary widely, and new data privacy and security laws in this area are evolving. Requirements of these laws and penalties for violations vary widely. If we or our operations are found to be in violation of HIPAA, or its implementing regulations, and similar state laws, we may be subject to significant penalties, including civil, criminal and administrative penalties, fines, imprisonment and exclusion from participation in federal or state healthcare programs, and the curtailment or restructuring of our operations. HIPAA has four tiers of civil monetary penalties, as well as criminal penalties, both of which may be applied to business associates as well as covered entities, and state attorneys have authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys' fees and costs associated with pursuing federal civil actions. Federal, state, local, and foreign data privacy and security obligations also may include penalties for noncompliance, as well as a private right of action.

69 C.A. Organizational Structure The following diagram illustrates our corporate structure, including our subsidiaries and consolidated affiliated entities as of the date of this annual report on Form 20-F:

A. Property, Plant and Equipment Our headquarters are located in Qingdao. We lease our premises from unrelated third parties free of charge. We believe that we will be able to obtain adequate facilities, principally through leasing, to accommodate our future expansion plans.

4A. UNRESOLVED STAFF COMMENTS None.

5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes included elsewhere in this annual report on Form 20-F. This discussion and analysis may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Item 3. Key Information.

D. Risk Factors or in other parts of this annual report on Form 20-F.

70 A.A. Operating Results Overview Our Business Historically, we generated revenues primarily from our loan facilitation services, post-origination services, and other related services. On December 30, 2020, we completed the disposal of P2P Business, which historically operated our loan facilitation services, post-origination services, and other related services. Since August 2017, the Company started its microlending business and lent funds to borrowers up to their approved credit through its consolidated VIE, and since May 2019, the Company has ceased to issue new loans. Interest income was recognized based on the contractual interest rates of the loan. As of March 31, 2022, the outstanding balance of loan receivable, net of allowance was nil. We launched our social e-commerce platform in May 2020 as a new business line for business transition, and we had developed and invested in our social e-commerce platform to take advantage of China's fast-growing e-commerce industry. Our social e-commerce platform offered high-quality and affordable products to consumers in China. We cooperated with major domestic e-commerce platforms and services marketplaces to select and source goods and services, and rewarded users with a small commission for every purchase, share or recommendation of a product made to friends. In May 2023, to fully utilize the Company's existing funds and resources and maximize the shareholders' interest, the Company completed the disposition of its social e-commerce business. The Company has since then focused on exploring other area of healthcare sector other than the medical devices and supplies.

A. On January 4, 2022, we incorporated Akso Online Meditech in the State of Wyoming and have begun the sale of COVID-19 Rapid Antigen test kits through Akso Online Meditech as of the date of this report. Akso Online Meditech has entered into a supply agreement to purchase Health branded COVID-19 Rapid Antigen test kits from its supplier and sells these test kits to distributors in the United States.

On January 26, 2022, we incorporated Qingdao Akso in Shandong Province, China and have begun the sales of medical devices through Qingdao Akso since April 2022. Qingdao Akso has entered into supply agreements to purchase medical devices such as defibrillators, anesthesia laryngoscope from its supplier and sells these devices to distributors or end-users in China.

Our net revenues were US\$6.0 million, US\$13.2 million, and US\$2.4 million for the fiscal years ended March 31, 2022, 2023, and 2024 respectively. We had net losses of US\$16.8 million, net losses of US\$1.2 million and net losses of 9.5 million for the years ended March 31, 2022, 2023, and 2024, respectively. Recently, we begun exploring online hospital and chain pharmacies segments in China. We plan to acquire online hospital(s) in certain cities of China which provides online medical consultations for initial diagnosis, follow-up consultations, and management of chronic diseases, providing patients with an efficient and convenient solution to manage their health online through their smartphones or computers. Typically, the online hospitals are closely connected with and supported by traditional hospitals and outpatient clinics, and their main sources of revenue are from fees charged to patients for both online and offline consultations and the marketing and sales of a variety of health products including medicine, medical equipment and supplements.

In addition to our plan to acquire online hospital(s), we believe that traditional independent pharmacies in China currently face serious competition and bottlenecks in sales growth, which is why we also plan to acquire multiple independent pharmacies nationwide throughout China, integrating and operating the pharmacies as a chain using our extensive offline resources and IT solutions. We plan to build a new type of pharmacy operation and management system, as well as digital operation and sales solutions for our pharmacies, thereby enhancing our competitiveness and overcoming the current difficulties in the industry.

On March 5, 2024, Tianjin Akso Enterprise Management Co., Ltd., our PRC subsidiary, entered into certain securities purchase agreements with four shareholders of Tianjin Wangyi Cloud Co., Ltd. and acquired 50% of the equity interests of Tianjin Wangyi Cloud Co., Ltd. The transaction closed on April 15, 2024. Tianjin Wangyi Cloud Co., Ltd. engages in the business of providing online hospital services including health consultancy services and online sales of medicines and health products through its two wholly owned PRC subsidiaries, Tian Jin Deyihui Online Hospital Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd.

Discontinued Operations According to ASC 205, the effect of discontinued operations of commission service from social from social E-commerce business and interest income from microlending business and other related services for the fiscal years ended March 31, 2022 and 2023 and 2024 has been accounted for retroactively in the consolidated statement of operations for all the periods presented. Results from these discontinued operations, net of income tax, were losses of USD 12.7 million, income of USD 11.8 million, and losses of USD 0.4 million for the fiscal years ended March 31, 2022, 2023 and 2024, respectively.

71 Key Components of Results of Operations Revenues Revenues are from the sale of medical devices business. The following table sets forth the components of our revenues by amounts and percentages of our total revenues for the periods presented:

	2022	2023	2024
Sale of medical devices	6,000,000	13,186,525	2,416,797
Sale of medical devices	100.0 %	100.0 %	100.0 %
Business and sales related taxes	4,964	2,459	1,181,561
Sale of medical devices	99.9 %	99.9 %	99.9 %

Starting in February 2022, through its subsidiary Akso Online MediTech, the Company engaged in the sale of Covid-19 Antigen Rapid Tests in US market. Akso Online MediTech purchases medical devices in quantity and distributes products primarily to medical products dealers. Since April 2022, through its subsidiary

Qingdao Akso Health Management Co., Ltd. the company started its sales of medical devices business in China domestic market. Qingdao Akso also purchases medical devices in quantity and distribute products primarily to medical products dealers or end-users such as hospitals. The deliveries may take one day or longer depending on the customers' location. Revenue from sales of merchandise to non-retail customers is recognized when the merchandise is transferred to customers. There was no sales return since the start of the business. Cost of goods sold Cost of goods sold consist primarily of purchase price of COVID-19 Antigen Test kit, defibrillators and anesthesia laryngoscope related to the sale of medical devices. Operating expenses Our operating expenses primarily consist of sales and marketing expenses, general and administrative expenses, finance cost and share-based compensation. The following table sets forth a breakdown of our operating costs and expenses for the periods indicated:

	For the Fiscal Years Ended March 31, 2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	

[illegible]

(Jerry) T. Neal satisfies the independence requirements of the listing rules of NASDAQ. The nominating and corporate governance committee assists the board of directors in selecting individuals qualified to become our directors and in determining the composition of the board of directors and its committees. The nominating and corporate governance committee is responsible for, among other things:

- A – recommending nominees to the board of directors for election or re-election to the board of directors, or for appointment to fill any vacancy on the board of directors;
- B – reviewing annually with the board of directors the current composition of the board of directors with regards to characteristics such as independence, age, skills, experience and availability of service to us;
- C – selecting and recommending to the board of directors the names of directors to serve as members of the audit committee and the compensation committee, as well as of the nominating and corporate governance committee itself;
- D – monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.

Duties of Directors

Under Cayman Islands law, our directors owe fiduciary duties to our company, including a duty to act honestly, and a duty to act in what they consider in good faith to be in our best interests. Our directors must also exercise their powers only for a proper purpose. Our directors also owe to our company a duty to act with skills they actually possess and exercise such care and diligence that a reasonably prudent person would exercise in comparable circumstances. It was previously considered that a director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands. In fulfilling their duty of care to our company, our directors must ensure compliance with our memorandum and articles of association, as amended and restated from time to time, and the rights vested thereunder in the holders of the shares. Our directors owe their fiduciary duties to our company and not to our company's individual shareholders, and it is our company which has the right to seek damages if a duty owed by our directors is breached. In limited exceptional circumstances, a shareholder may have the right to seek damages in our name if a duty owed by our directors is breached.

Terms of Directors and Officers

Pursuant to our amended and restated memorandum and articles of association, subject to the approval of our shareholders, our board of directors has the power from time to time and at any time to appoint any person as a director to fill a casual vacancy on the board or as an addition to the existing board (subject to the maximum size limit). Our directors are not subject to a term of office and will hold their offices until such time as they are removed from office by an ordinary resolution of our shareholders.

In addition, the office of any of our directors shall be vacated if the director:

- (A) becomes bankrupt or makes any arrangement or composition with his creditors;
- (B) dies or becomes of unsound mind;
- (C) resigns his office by notice in writing to our company;
- (D) without special leave of absence from our board of directors, is absent from meetings of the board for three consecutive meetings and the board of directors resolves that his office be vacated;
- (E) is prohibited by law or designated stock exchange rules from being a director; or
- (F) is removed from office pursuant to our memorandum and articles of association.

Our officers are elected by and serve at the discretion of the board of directors. Our senior executive officers are employed for a specified time period. We may terminate employment for cause, at any time, without advance notice or remuneration, for certain acts of the senior executive officers, such as the officer's fraudulent or illegal conduct that is materially detrimental to our business, the officer's unsecured material breach of our confidentiality agreement or the officer's unsecured material breach of the applicable employment agreement. We may also terminate a senior executive officer's employment without cause with advance written notice. Each senior executive officer may terminate employment at any time with advance written notice at the election of such officer.

Employment Agreements and Confidentiality Agreements

We have entered into employment agreements and confidentiality agreements with each of our executive officers. Under these agreements, each of our executive officers is employed for a specified period of time. The employment agreements provide that the employment can be terminated pursuant to the PRC Employment Contract Law and relevant regulations. Under such law and regulations, we may terminate employment with an employee:

- (i) for cause, at any time, without advance notice or remuneration, including for certain acts of the employee, such as conviction of a crime, malpractices which caused significant damage to us, or violation of our internal policies; or
- (ii) without cause by paying severance compensation to the employee.

According to the confidentiality agreements entered into with our executive officers, our executive officers may resign at any time with a 30-day advance written notice. Each executive officer has agreed, both during and within two years after the termination or expiry of his or her employment agreement to:

- (i) hold, in strict confidence and not to use any of our confidential information or trade secrets, any confidential information or trade secrets of our users, or the confidential or proprietary information of any third party received by us and for which we have confidential obligations; and
- (ii) be bound by non-competition restrictions.

Each executive officer has agreed not to, without our express consent, assume employment by, or provide direct or indirect services to, any of our competitors, whether as a shareholder, partner, executive, supervisor, consultant or otherwise, or to engage in any business that is similar to our business. Each executive officer has agreed to indemnify us against any actual loss incurred by us as a result of his or her breach of the confidentiality and non-competition obligations.

83 A We have entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of our company.

D Employees

We had 42, 12 and 9 full-time employees as of March 31, 2022, 2023 and 2024, respectively. None of our employees are represented by a labor union. We have not experienced any work stoppages, and we consider our relations with our employees to be good.

We invest significant resources in the recruitment of employees in support of our business operations. We have established comprehensive training programs, including orientation programs and on-the-job-training, to enhance performance and service quality.

As required by PRC Laws and regulations, we participate in various government statutory employee benefit plans, including a pension contribution plan, a medical insurance plan, an unemployment insurance plan, a work-related injury insurance plan, a maternity insurance plan and a housing provident fund. We are required under PRC law to contribute to employee benefit plans at specified percentages of the salaries, bonuses and certain allowances of our employees up to a maximum amount specified by the local government from time to time.

We enter into standard labor contracts with our employees. We also enter into standard confidentiality and non-compete agreements with our executive officers.

7. Major Shareholders and Related Party Transactions

"B. Compensation"

Employment Agreements and Confidentiality Agreements

A F Share Ownership

Please refer to **6. Directors, Senior Management and Employees**

"C. Board Practices"

Employment Agreements and Confidentiality Agreements

"Share Incentive Plan"

A E Disclosure of a registrant's action to recover erroneously awarded compensation.

A Not applicable.

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A A Major Shareholders

The following table presents information regarding the beneficial ownership of our ordinary shares as of the date of this annual report by:

- A – each person or entity that we know beneficially owns or will beneficially own more than 5% of our outstanding ordinary shares;
- A – each director or executive officer who beneficially owns or will beneficially own more than 1% of our outstanding ordinary shares; and
- A – all of our directors and executive officers as a group.

The calculations in the table below assume there are 722,595,220 ordinary shares (including 714,614,420 Class A ordinary shares and 7,980,800 Class B ordinary shares) outstanding as of the date of this annual report.

A Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of that person, we have included ordinary shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant, or other right or the conversion of any other security. These ordinary shares, however, are not included in the computation of the percentage ownership of any other person.

84 A A A Ordinary shares beneficially owned

A A Class A ordinary shares

A A Class B ordinary shares

A Total ordinary shares on as-converted basis

A % of total ordinary shares on as-converted basis

(2) A % of aggregate voting power

(3) Directors and Executive Officers

(1): A A A A A A A A A A A A Yilin (Linda) Wang (4) A A A A A A A A A A A A A A A A A A A A A A Stephen P. Brown (5) A A A A A A A A A A A A A A A A A A A A A A Zhe Liu (6) A A A A A A A A A A A A A A A A A A A A A A Gerald (Jerry) T. Neal (7) A A A A A A A A A A A A A A A A A A A A A A Rui (Kerrie) Zhang (8) A A A A A A A A A A A A A A A A A A A A A A Wenjuan (Vivian) Liu (9) A A A A A A A A A A A A A A A A A A A A A A All directors and executive officers as a group

A A A A A A A A A A A A A A A A A A A A A A Principal Shareholders

A A A A A A A A A A A A A A A A A A A A A A Webao Limited (8) A A A A A A A A A A A A A A A A A A A A A A Notes:

- (1) Less than 1% of our total outstanding ordinary shares.
- (1) Except for Mr. Stephen P. Brown and Mr. Gerald (Jerry) T. Neal, the business address of our directors and executive officers is Room 515, Floor 5, Jia No. 92-4 to 24 Jianguo Road Chaoyang District, Beijing 100020, People's Republic of China.
- (2) For each person and group included in this column, percentage ownership is calculated by dividing the number of Class A and Class B ordinary shares beneficially owned by such person or group by the sum of the total number of Class A and Class B ordinary shares outstanding, which is 722,595,220 ordinary shares (including 714,614,420 Class A ordinary shares and 7,980,800 Class B ordinary shares) as of the date of this annual report, plus the number of Class A and Class B ordinary shares such person or group has the right to acquire upon the exercise of options, warrants or other rights within 60 days after as of the date of this annual report. We use the conversion rate of 1:1 for the incentive shares for the purpose of calculating the beneficial ownership of our ordinary shares. Vested incentive shares convert to ordinary shares of our company at a 1:1 conversion rate, subject to payment of the reserve amount, which was calculated by us to be our good faith estimate of the fair market value of our ordinary shares (or equivalent thereof) at the time of the grant of such incentive shares.
- (3) For each person or group included in this column, the percentage of total voting power represents voting power based on both Class A and Class B ordinary shares held by such person or group as of the date of this annual report with respect to all of our outstanding Class A and Class B ordinary shares as one class as of the date of this annual report. Each holder of Class A ordinary shares is entitled to one vote per share, subject to the limitations set forth in **Additional Information**

"B. Memorandum and Articles of Association"

Ordinary Shares

Each holder of our Class B ordinary shares is entitled to 20 votes per share on all matters subject to a shareholder's vote. Our Class B ordinary shares are convertible at any time by the holder into Class A ordinary shares on a one-for-one basis, whereas Class A ordinary shares are not convertible into Class B ordinary shares under any circumstances. The total voting power of the Class B Holders is limited. See **Additional Information**

"B. Memorandum and Articles of Association"

Ordinary Shares

A A (4) Ms. Yilin (Linda) Wang does not hold any ordinary share in our company.

(5) The business address of Mr. Stephen P. Brown is 9 Bent Oak Coto de Caza, CA 92679.

(6) The business address of Mr. Zhe Liu is 101, Unit 2, Building 3, Block C, No. 35, Beicheng Road, Xinhua District, Shijiazhuang, Hebei Province, People's Republic of China.

(7) The business address of Mr. Gerald (Jerry) T. Neal is 3085 Middlecott Lane Florence, SC 29506.

(8) Represents 7,980,800 Class B ordinary shares held by Webao Limited. The registered office address of Webao Limited is 12 / F, Santai building, 137-139 Connaught Road Central, Hong Kong.

To our knowledge, on the same basis of calculation as above, approximately 6.17% of our total outstanding Class A ordinary shares were held by one record shareholder in the United States, namely, Citibank, N.A., which held 44,056,049 Class A ordinary shares represented by 14,685,350 ADSs. The number of beneficial owners of our ADSs in the United States is likely to be much larger than the number of record holders of our ordinary shares in the United States.

A None of our shareholders has informed us that it is affiliated with a registered broker-dealer or is in the business of underwriting securities. None of our existing shareholders will have different voting rights from other shareholders, except with respect to the differences in voting rights afforded to holders of Class A ordinary shares and Class B ordinary shares. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.

85 A B A Related Party Transactions

A Contractual Arrangements and Corporate Structure

A Akso Health Group, formerly known as Xiaobai Maimai Inc., is a limited company incorporated under the laws of the Cayman Islands and currently conducts substantially all of our business operations in the PRC through our wholly foreign owned entities (collectively referred to as "WFOEs") incorporated in the PRC and certain business operations through the PRC consolidated variable interest entity (collectively referred to as "VIEs"). Due to PRC legal restrictions on foreign ownership and investment in the value-added telecommunications market, we rely on a series of contractual arrangements among the VIE and its shareholders to operate our online and mobile platforms in China. These contractual arrangements entered into with the VIE allow us to:

 - (i) exercise effective control over the VIE,
 - (ii) receive substantially all of the economic benefits of the VIE, and
 - (iii) have an exclusive option to purchase all or part of the equity interests in the VIE when and to the extent permitted by PRC law.

These contractual arrangements include an exclusive business cooperation agreement, exclusive option agreement, equity interest pledge agreement, and a power of attorney. As a result of these contractual arrangements, we exert effective control over, and are considered the primary beneficiary of, the VIE and consolidate its operating results in our financial statements under U.S. GAAP. As used in this annual report, unless otherwise indicated, **we**, **our**, **us**, **the Company**, **we**, **our**, **us**, **the Company**, **we**, **our**, **us**, **the Company**,

conditions are met: (i)Â information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements and (ii)Â the range of loss can be reasonably estimated.Â In January 2019, we were attacked by a short seller, alleging fraud in our financial reporting system. We conducted an internal investigation, with the assistance of forensic accountant, to evaluate these allegations. Based on the information reasonably available and reviewed as part of the investigation, the investigation did not identify any conclusive proof of fraud. In addition, two law firms launched investigations in connection with the short seller attack, though no securities lawsuits have been initiated, nor has there been any additional investigation notices as of the date of this annual report on FormÂ 20-F.Â A Dividend PolicyÂ A Our board of directors has discretion regarding whether to declare or pay dividends. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. In either case, all dividends are subject to certain restrictions under Cayman Islands law, namely that our company may only pay dividends out of profits or share premium, and provided always that we are able to pay our debts as they fall due in the ordinary course of business. On July 19, 2018, our board of directors approved an annual dividend policy. Under this policy, annual dividends will be set at an amount equivalent to approximately 15-25% of our anticipated net income after tax in each year commencing from the fiscal year ended March 31, 2019. On July 19, 2018, our board of directors also approved a special cash dividend of US\$0.13 per ordinary share of our company (or US\$0.13 per ADS), in addition to an annual dividend pursuant to the newly adopted annual dividend policy of US\$0.27 per ordinary share (or US\$0.27 per ADS), for a total dividend of US\$0.40 per ordinary share (or US\$0.40 per ADS). The aggregated dividend payments to shareholders amounted to US\$19,547,532 in the fiscal year ended March 31, 2019 and no dividends have been paid in following years. The determination to declare and pay such annual dividend and special dividend and the amount of any dividend in any particular year will be based upon our operations, earnings, financial condition, cash requirements and availability and other factors as our board of directors may deem relevant at such time.Â We are a holding company incorporated in the Cayman Islands. We may rely on dividends from our subsidiaries in China for our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us. See Æœitem 3. Key InformationÆœD. Risk FactorsÆœRisks Related to Our Corporate StructureÆœWe rely on dividends and other distributions on equity paid by our PRC subsidiary to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiary to make payments to us could have a material adverse effect on our ability to conduct our businessÆœ and Æœitem 3. Key InformationÆœD. Risk FactorsÆœRisks Related to Doing Business in the PeopleÆœs Republic of ChinaÆœEnhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential acquisitions we may pursue in the future.ÆœÂ 88Â A If we pay any dividends, we will pay such dividends on the shares represented by ADSs to the depositary, and the depositary will pay such dividends to our ADS holders to the same extent as holders of our ordinary shares, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. See Æœitem 12. Description of Securities other than Equity SecuritiesÆœD. American Depositary Shares.Æœ Cash dividends on our ordinary shares, if any, will be paid in U.S.Â dollars.Â B. Significant ChangesÂ A We have not experienced any significant changes since the date of our audited consolidated financial statements included in this annual report on FormÂ 20-F.Â A ITEM 9. THE OFFER AND LISTINGÂ A A. Offering and Listing DetailsÂ A Our ADSs, each representing three ordinary shares, have been listed on the NASDAQ since NovemberÂ 3, 2017. The ratio of ADS representing its ordinary shares was amended from one (1)Â ADS representing one (1)Â ordinary share to one (1)Â ADS representing three (3)Â ordinary shares with effect from AugustÂ 24, 2020. Our ADSs trade under the symbol ÆœæAHLÆœ.Â A On April 30, 2024, our 2024 annual general meeting of shareholders approved the amendment to our authorized share capital. Upon effective of the amendment May 7, 2024, our ADSs, each represents three Class A ordinary shares.Â B. Plan of DistributionÂ A Not applicable.Â C. MarketsÂ A See Æœitem 9. The Offer and ListingÆœA. Offering and Listing Details.ÆœÂ D. Selling ShareholdersÂ A Not applicable.Â E. DilutionÂ A Not applicable.Â F. Expenses of the IssueÂ A Not applicable.Â A ITEM 10. ADDITIONAL INFORMATIONÂ A A. Share CapitalÂ A Not applicable.Â B. Memorandum and Articles of AssociationÂ AÂ A We are a Cayman Islands exempted company with limited liability and our affairs are governed by our memorandum and articles of association, as amended and restated from time to time and the Companies Act of the Cayman Islands, which is referred to as the Companies Act below, and the common law of the CaymanÂ Islands.Â A The following are summaries of the material provisions of our amended and restated memorandum and articles of association and the Companies Act insofar as they relate to the material terms of our ordinary shares. This summary is not complete, and you should read our amended and restated memorandum and articles of association, which has been filed as ExhibitÂ 3.2 to our FormÂ F-1 (File No.Â 333-220720), as amended, filed with the SEC on OctoberÂ 25, 2017.Â A 89Â A Registered Office and ObjectsÂ A Our registered office in the Cayman Islands is located at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104. As set forth in article 3 of our amended and restated memorandum of association, the objects for which our company is established are unrestricted.Â A Board of DirectorsÂ A See Æœitem 6. Directors, Senior Management and EmployeesÆœC. Board PracticesÆœCommittees of the Board of DirectorsÆœ and Æœitem 6. Directors, Senior Management and EmployeesÆœC. Board PracticesÆœTerms of Directors and Officers.ÆœÂ A Ordinary SharesÂ A General Our authorized share capital is US\$500,000 divided into 5,000,000,000 ordinary shares of a par value of US\$0.0001 each, comprising (i) 4,500,000,000 Class A ordinary shares of a par value of US\$0.0001 each and (ii) 500,000,000 Class B ordinary shares of a par value of US\$0.0001 each. All of our issued and outstanding ordinary shares are fully paid and non-assessable. Our ordinary shares are issued in registered form, and are issued when registered in our register of members. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their ordinary shares. Under our amended and restated memorandum and articles of association, our company may issue only non-negotiable shares and may not issue bearer shares.Â A Dividends The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, our company may declare and pay a dividend only out of funds legally available therefor, namely out of either profit or our share premium account, provided that in no circumstances may we pay a dividend if this would result in our company being unable to pay its debts as they fall due in the ordinary course ofÂ business.Â A Voting Rights The holders of Class A Ordinary Shares and Class B Ordinary Shares shall at all times vote together as one class on all resolutions submitted to a vote by the Members. Subject to any rights or restrictions as to voting attached to any shares, unless any share carries special voting rights, on a show of hands every shareholder who is present in person and every person representing a shareholder by proxy shall have one vote per Class A Ordinary Share and one vote per Class B Ordinary Share. On a poll, every shareholder who is present in person and every person representing a shareholder by proxy shall have one vote for each Class A Ordinary Share and twenty votes per Class B Ordinary Share of which he or the person represented by proxy is the holder. Votes may be given either personally or by proxy.Â A At any general meeting a resolution put to the vote of the meeting shall be decided by a show of hands unless a poll is demanded. A poll may be demanded by the chairman of such meeting or any one or more shareholders who together hold not less than 10% of the votes attaching to all issued and outstanding shares of our company entitled to vote at general meetings.Â A An ordinary resolution to be passed by the shareholders requires the affirmative vote of a simple majority of the votes attached to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting, while a special resolution requires the affirmative vote of no less than two-thirds of the votes attached to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting. A special resolution is required for important matters such as a change of name or any amendment to our memorandum and articles of association. Holders of our ordinary shares may effect certain changes by ordinary resolution, including increasing the amount of our authorized share capital, consolidating all or any of our share capital into shares of larger amount than our existing shares, sub-dividing our shares or any of them into shares of an amount smaller than that fixed by our memorandum, and cancelling any unissued shares. Both ordinary resolution and special resolution may also be passed by a unanimous written resolution signed by all the shareholders of our company, as permitted by the Companies Act and our amended and restated memorandum and articles of association.Â A Appointment and Removal of Directors Our board of directors may, by the affirmative vote of a simple majority of the directors present and voting at a board meeting, appoint any person as a director, to fill a casual vacancy on the board or as an addition to the existing board. Directors may be removed by ordinary resolution of our shareholders.Â A General Meetings of Shareholders and Shareholder Proposals As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholdersÆœ annual general meetings. Our amended and restated memorandum and articles of association provide that we may, but are not obliged to, in each year hold a general meeting as our annual general meeting in which case we shall specify the meeting as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by ourÂ directors.Â A 90Â A ShareholdersÆœ annual general meetings and any other general meetings of our shareholders may be convened by a majority of our board of directors or the chairman of the board. Advance notice of at least ten calendar days is required for the convening of our annual general shareholdersÆœ meeting and any other general meeting of our shareholders. A quorum required for a general meeting of shareholders consists of one or more shareholders present in person or by proxy or, if a corporation or other non-natural person, by its duly authorized representative, who hold in aggregate not less than one-third of the votes attaching to all issued and outstanding shares of our company entitled to vote at general meetings.Â A Cayman Islands law provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a companyÆœ articles of association. Our amended and restated memorandum and articles of association allow any two or more of our shareholders holding in the aggregate not less than one-third of the votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings, to requisition an extraordinary general meeting of the shareholders, in which case our directors are obliged to call such meeting and to put the resolutions so requisitioned to a vote at such meeting; however, our amended and restated memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders.Â A Transfer of Shares Subject to the restrictions of our amended and restated memorandum and articles of association set out below, as applicable, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or ordinary form or any other form approved by our board ofÂ directors.Â A Our board of directors may, in its sole discretion, decline to register any transfer of any ordinary share which is not fully paid up. Our directors may also decline to register any transfer of any ordinary share unless (a)Â the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer; (b)Â the instrument of transfer is properly stamped, if required; (c)Â in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be transferred does not exceed four; (d)Â the share to be transferred is free of any lien in favor of us; (e)Â a fee of such maximum sum as NASDAQ may determine to be payable, or such lesser sum as our board of directors may from time to time require, is paid to us in respect thereof; and (f)Â the instrument of transfer is in respect of only one class of shares.Â A If our directors refuse to register a transfer they shall, within two months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal. The registration of transfers may, after compliance with any notice required of NASDAQ, be suspended and our register of members closed at such times and for such periods as our board of directors may from time to time determine, provided, however, that the registration of transfers shall not be suspended nor the register of members closed for more than 30Â days in any year as our board of directors mayÂ determine.Â A Conversion Rights Each Class B Ordinary Share is convertible into one (1) Class A Ordinary Share at any time at the option of the holder thereof. The right to convert shall be exercisable by the holder of the Class B Ordinary Share delivering a written notice to the Company that such holder elects to convert a specified number of Class B Ordinary Shares into Class A Ordinary Shares. In no event shall Class A Ordinary Shares be convertible into Class B Ordinary Shares.Â A All conversions of Class B Ordinary Shares to Class A Ordinary Shares shall be effected by way of the re-designation of each relevant Class B Ordinary Share as a Class A Ordinary Share.Â A Liquidation On a winding up of our company, if the assets available for distribution among our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed among our shareholders on a proÂ rata basis in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay all of the paid-up capital, the assets will be distributed so that the losses are borne by our shareholders in proportion to the par value of the shares held byÂ them.Â A The liquidator may, with the sanction of a special resolution of our shareholders, divide amongst the shareholders inÂ a species or in kind the whole or any part of the assets of our company and may for that purpose value any assets and determine how the division shall be carried out as between our shareholders or different classes of shareholders.Â A We are an exempted company with limited liability incorporated under the Companies Act, and under the Companies Act, the liability of our members is limited to the amount, if any, unpaid on the shares respectively held by them. Our memorandum of association contains a declaration that the liability of our members is soÂ limited.Â A Calls on Shares and Forfeiture of Shares Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their ordinary shares in a notice served to such shareholders at least 14 calendar days prior to the specified time and place of payment. The ordinary shares that have been called upon and remain unpaid on the specified time are subject toÂ forfeiture.Â A 91Â A Redemption, Repurchase and Surrender of Shares We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders, on such terms and in such manner as may be determined by our board of directors, before the issue of such shares, or by a special resolution of our shareholders. Our company may also repurchase any of our shares provided that the manner and terms of such purchase have been approved by our board of directors or by ordinary resolution of our shareholders, or are otherwise authorized by our memorandum and articles of association. Under the Companies Act, the redemption or repurchase of any share may be paid out of our companyÆœ profits or out of the proceeds of a fresh issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if the company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a)Â unless it is fully paid up, (b)Â if such redemption or repurchase would result in there being no shares outstanding, or (c)Â if the company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.Â A Variations of Rights of Shares If at any time, our share capital is divided into different classes of shares, all or any of the special rights attached to any class of shares may be varied either with the written consent of the holders of two-thirds in nominal value of the issued shares of that class, or with the sanction of a special resolution passed at a separate general meeting of the holders of shares of that class. The rights conferred upon the holders of the shares of any class issued with preferred or other rights will not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking pariÂ passu with such existing class ofÂ shares.Â A Inspection of Books and Records Holders of our ordinary shares will have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, at the discretion of our board of directors, we intend to provide our shareholders with annual audited financial statements.Â A Changes in Capital Our shareholders may from time to time by ordinary resolution:Â AÂ A â— increase our share capital by such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe;Â AÂ A â— consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares;Â AÂ A â— sub-divide our existing shares, or any of them into shares of a smaller amount, provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; orÂ AÂ A â— cancel any shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares soÂ cancelled.Â A Our shareholders may, by special resolution and subject to confirmation by the Grand Court of the Cayman Islands on an application by our company for an order confirming such reduction, reduce our share capital and any capital redemption reserve in any manner authorized byÂ law.Â A Issuance of Additional Shares Our amended and restated memorandum and articles of association authorizes our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine, to the extent there are available authorized but unissued shares.Â A Our amended and restated memorandum and articles of association authorizes our board of directors to establish from time to time one or more series of convertible redeemable preferred shares and to determine, with respect to any series of convertible redeemable preferred shares, the terms and rights of that series, including:Â AÂ A â— designation of the series;Â AÂ A â— the number of shares of the series;Â AÂ A â— the dividend rights, conversion rights and voting rights; andÂ AÂ A â— the rights and terms of redemption and liquidation preferences.Â A 92Â A The issuance of convertible redeemable preferred shares may be used as an anti-takeover device without further action on the part of the shareholders. Issuance of these shares may dilute the voting power of holders of ordinary shares.Â A Anti-Takeover Provisions Some provisions of our memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisionsÂ that:Â AÂ A â— authorize our board of directors to issue

preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our shareholders; and

Â – limit the ability of shareholders to requisition and convene general meetings of shareholders.

However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our amended and restated memorandum and articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company.

C. Material Contracts

The following descriptions of the material provisions of the referenced agreements do not purport to be complete and are subject to, and qualified in their entirety by reference to the agreements which have been filed as exhibits to this report.

May 2023 Disposition SPA

On May 10, 2023, the Company (the “Seller”), HX Asia Investment Limited, a British Virgin Islands company (the “HX Asia”), HX China Investment Limited, a British Virgin Islands company (the “HX China”), and Hexindai Hong Kong Limited, a Hong Kong company (the “Hexindai”) and together with HX Asia and HX China, the “Targets”), and Umbrella Capital Investment Co., Ltd., a British Virgin Islands company which is not affiliate of the Company of any of its directors or officers (the “Purchaser”) entered into certain share purchase agreement (the “Disposition SPA”). Pursuant to the Disposition SPA, the Purchaser agreed to purchase the Targets in exchange for cash consideration of US\$215,000 (the “Purchase Price”). Upon the closing of the transaction (the “Disposition”) contemplated by the Disposition SPA, the Buyer will become the sole shareholder of the Targets and as a result, assume all assets and liabilities of the Targets and subsidiaries owned or controlled by the Target.

The closing of the Disposition is subject to the satisfaction or waiver of certain closing conditions including the payment of the Purchase Price, the receipt of a fairness opinion from an independent firm, and all consents required to be obtained from or made with any governmental authorities. The Disposition closed on May 19, 2023.

The form of the securities purchase agreement is filed as Exhibit 99.1 to the Current Report on Form 6-K filed with the Commission on May 25, 2023.

The foregoing is only a brief description of the material terms of the share purchase agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibits.

October 2023 Private Placement

On October 2, 2023, the Company entered into certain securities purchase agreement (the “SPA”) with certain non-U.S. Persons (the “Purchasers”) as defined in Regulation S of the Securities Act of 1933, as amended (the “Securities Act”) pursuant to which the Company agreed to sell an aggregate of 35,739,270 units (the “Units”), each Unit consisting of one Ordinary Share of the Company, par value \$0.0001 per share (the “Share”) and a warrant to purchase one Share (the “Warrant”) with an initial exercise price of \$0.4875, or approximately \$1.47 per American depositary share of the Company (the “ADS”), at a price of \$0.391 per Unit, or approximately \$1.17 per ADS for an aggregate purchase price of approximately \$14 million (the “Offering”). The net proceeds to the Company from such Offering will be approximately \$14 million and shall be used by the Company for working capital and general corporate purposes.

93 A

The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.4875, or approximately \$1.47 per ADS, for cash (the “Warrant Shares”). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.

The parties to the SPA have each made customary representations, warranties and covenants, including, among other things, (a) the Purchasers are non-U.S. Persons as defined in Regulation S and are acquiring the Shares for the purpose of investment, (d) the absence of any undisclosed material adverse effects, and (e) the absence of legal proceedings that affect the completion of the transaction contemplated by the SPA.

The SPA is subject to various conditions to closing, including, among other things, (a) Nasdaq’s approval of the supplemental listing application for the Units and (b) accuracy of the parties’ representations and warranties.

On October 17, 2023, the transaction contemplated by the SPA consummated when all the closing conditions of the SPA have been satisfied and the Company issued the Units to the Purchasers pursuant to the SPA.

The forms of the securities purchase agreement and warrant are filed as Exhibit 99.1 and 99.2 to the Current Report on Form 6-K filed with the Commission on October 2, 2023.

The foregoing is only a brief description of the material terms of the share purchase agreement and warrant, and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibits.

November 2023 Private Placement

On November 16, 2023, the Company entered into certain securities purchase agreement (the “SPA”) with certain non-U.S. Persons (the “Purchasers”) as defined in Regulation S of the Securities Act of 1933, as amended (the “Securities Act”) pursuant to which the Company agreed to sell up to an aggregate of 53,608,910 units (the “Units”), each Unit consisting of one Ordinary Share of the Company, par value \$0.0001 per share (the “Share”) and a warrant to purchase one Share (the “Warrant”) with an initial exercise price of \$0.52875, or approximately \$1.59 per American depositary share of the Company (the “ADS”), at a price of \$0.423 per Unit, or approximately \$1.27 per ADS for an aggregate purchase price of approximately \$22.68 million (the “Offering”). The net proceeds to the Company from such Offering will be approximately \$22.6 million and shall be used by the Company for working capital and general corporate purposes.

The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.423, or approximately \$1.59 per ADS, for cash (the “Warrant Shares”). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.

The parties to the SPA have each made customary representations, warranties and covenants, including, among other things, (a) the Purchasers are non-U.S. Persons as defined in Regulation S and are acquiring the Shares for the purpose of investment, (d) the absence of any undisclosed material adverse effects, and (e) the absence of legal proceedings that affect the completion of the transaction contemplated by the SPA.

The SPA is subject to various conditions to closing, including, among other things, (a) Nasdaq’s approval of the supplemental listing application for the Units and (b) accuracy of the parties’ representations and warranties.

On November 21, 2023, the transaction contemplated by the SPA consummated when all the closing conditions of the SPA have been satisfied and the Company issued the Units to the Purchasers pursuant to the SPA.

The forms of the securities purchase agreement and warrant are filed as Exhibit 99.1 and 99.2 to the Current Report on Form 6-K filed with the Commission on November 17, 2023.

The foregoing is only a brief description of the material terms of the share purchase agreement and warrant, and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibits.

January 2024 Private Placement

On January 17, 2024, the Company entered into certain securities purchase agreement (the “SPA”) with certain non-U.S. Persons (the “Purchasers”) as defined in Regulation S of the Securities Act of 1933, as amended (the “Securities Act”) pursuant to which the Company agreed to sell up to an aggregate of 160,826,730 units (the “Units”), each Unit consisting of one Ordinary Share of the Company, par value \$0.0001 per share (the “Share”) and a warrant to purchase one Share (the “Warrant”) with an initial exercise price of \$0.4146, or approximately \$1.2438 per American depositary share of the Company (the “ADS”), at a price of \$0.3317 per Unit, or approximately \$0.9951 per ADS for an aggregate purchase price of approximately \$53.35 million (the “Offering”). The net proceeds to the Company from such Offering shall be used by the Company for working capital and general corporate purposes.

The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.4146, or approximately \$1.2438 per ADS, for cash (the “Warrant Shares”). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.

The parties to the SPA have each made customary representations, warranties and covenants, including, among other things, (a) the Purchasers are non-U.S. Persons as defined in Regulation S and are acquiring the Shares for the purpose of investment, (d) the absence of any undisclosed material adverse effects, and (e) the absence of legal proceedings that affect the completion of the transaction contemplated by the SPA.

The SPA is subject to various conditions to closing, including, among other things, (a) Nasdaq’s approval of the supplemental listing application for the Units and (b) accuracy of the parties’ representations and warranties.

On January 26, 2024, the transaction contemplated by the SPA consummated when all the closing conditions of the SPA have been satisfied and the Company issued the Units to the Purchasers pursuant to the SPA.

The forms of the securities purchase agreement and warrant are filed as Exhibit 99.1 and 99.2 to the Current Report on Form 6-K filed with the Commission on January 22, 2024.

The foregoing is only a brief description of the material terms of the share purchase agreement and warrant, and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibits.

March 2024 Registered Direct Offering

On March 5, 2024 Akso Health Group (the “Company”) entered into certain securities purchase agreement (the “Purchase Agreement”) with certain non-affiliated institutional investors (the “Purchasers”) pursuant to which the Company agreed to sell 37,100,000 of its American Depositary Shares (the “ADSs”) representing 111,300,000 ordinary shares, par value \$0.0001 per share (the “Ordinary Shares”), in a registered direct offering, and warrants (the “Warrants”) to purchase 222,600,000 Ordinary Shares in a concurrent private placement for gross proceeds of approximately \$49.34 million (the “Offering”).

The warrants are exercisable immediately as of the date of issuance at an exercise price of \$0.4933 per ordinary share, or \$1.48 per ADS and expire five years from the date of issuance. The purchase price for each ADS and the corresponding Warrants is \$1.33. Each Warrant is subject to anti-dilution provisions to reflect stock dividends and splits, subsequent rights offerings or other similar transactions, but not as a result of future securities offerings at lower prices. Upon the occurrence of a Fundamental Transaction (as defined in the Warrants), the Warrants are subject to mandatory redemption for cash consideration equal to the Black Scholes Value (as defined in the Warrants) of such portion of such Warrant to be redeemed.

The Warrants and the Ordinary Shares issuable upon the exercise of the Warrants are being offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.

The Company currently intends to use the net proceeds from the Offering for working capital and general corporate use. The Offering closed on March 7, 2024.

The forms of the securities purchase agreement and warrant are filed as Exhibit 99.1 and 99.2 to the Current Report on Form 6-K filed with the Commission on March 8, 2024.

The foregoing is only a brief description of the material terms of the share purchase agreement and warrants, and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibits.

95 A

D. Exchange Controls

There is no exchange control legislation under Cayman Islands law, and accordingly, there are no exchange control regulations imposed under Cayman Islands law. See also Item 4. Information on the Company’s “B. Business Overview.”

Regulations Relating to Foreign Exchange

Regulations on Foreign Exchange Registration of Overseas Investment by PRC Residents

Item 4. Information on the Company’s “B. Business Overview.”

Regulations Relating to Foreign Exchange

Regulation on Foreign Currency Exchange

Item 4. Information on the Company’s “B. Business Overview.”

Regulations on Dividend Distribution

E. Taxation

The following summary of the material Cayman Islands, PRC and U.S. federal income tax consequences of an investment in our ADSs or ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this registration statement, all of which are subject to change. This summary does not deal with all possible tax consequences relating to an investment in our ADSs or ordinary shares, such as the tax consequences under U.S. state and local tax laws or under the tax laws of jurisdictions other than the Cayman Islands, PRC and the United States.

A Cayman Islands Taxation

The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or after execution brought within the jurisdiction of the Cayman Islands. The Cayman Islands is not party to any double tax treaties that are applicable to any payments made to or by our company. There are no exchange control regulations or currency restrictions in the Cayman Islands.

A Payments of dividends and capital in respect of the ordinary shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of the ordinary shares, nor will gains derived from the disposal of the ordinary shares be subject to Cayman Islands income or corporation tax.

A People’s Republic of China Taxation

PRC Enterprise Income Tax Law

Under the EIT Law, which became effective on January 1, 2008 and amended by the PRC National People’s Congress in December 2018, an enterprise established outside the PRC with a de facto management bodies within the PRC is considered a PRC resident enterprise for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. In 2009, the SAT issued SAT Circular 82, which provides certain specific criteria for determining whether the de facto management body of a PRC controlled enterprise that is incorporated offshore is located in China. In 2011, the SAT issued SAT Bulletin 45 to provide more guidance on the implementation of SAT Circular 82.

A According to SAT Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be considered a PRC resident enterprise by virtue of having its de facto management body in China and will be subject to PRC enterprise income tax on its worldwide income only if all of the following conditions are met: (a) the senior management and core management departments in charge of its daily operations function have their presence mainly in the PRC; (b) its financial and human resources decisions are subject to determination or approval by persons or bodies in the PRC; (c) its major assets, accounting books, company seals, and minutes and files of its board and shareholders’ meetings are located or kept in the PRC; and (d) more than half of the enterprise’s directors or senior management with voting rights habitually reside in the PRC.

Although SAT Circular 82 and SAT Bulletin 45 only apply to offshore incorporated enterprises controlled by PRC enterprises or PRC enterprise groups and not those controlled by PRC individuals or foreigners, the determination criteria set forth therein may reflect the SAT’s general position on how the term de facto management body could be applied

SAT Announcement 7A extends its tax jurisdiction to not only indirect transfers set forth under SAT CircularA 698 but also transactions involving transfer of other taxable assets through offshore transfer of a foreign intermediate holding company. In addition, SAT Announcement 7A provides clearer criteria than SAT CircularA 698 for assessment of reasonable commercial purposes and has introduced safe harbors for internal group restructurings and the purchase and sale of equity through a public securities market. SAT Announcement 7A also brings challenges to both foreign transferor and transferee (orA other person who is obligated to pay for the transfer) of taxable assets. Where a non-resident enterprise transfers taxable assets indirectly by disposing of the equity interests of an overseas holding company, which is an indirect transfer, the non-resident enterprise as either transferor or transferee, or the PRC entity that directly owns the taxable assets, may report such indirect transfer to the relevant tax authority. Using a A substance over formA principle, the PRC tax authority may disregard the existence of the overseas holding company if it lacks a A reasonable commercial purposeA and was established for the purpose of reducing, avoiding or deferring PRC tax. Factors that may be taken into consideration when determining whether there is a reasonable commercial purpose include, among other factors, the value of the transferred equity, offshore taxable situation of the transaction, the offshore structureA's economic essence and duration and trading fungibility. If an equity transfer transaction satisfies all the requirements mentioned above, such transaction will be considered an arrangement with reasonable commercial purpose. If an overseas holding company lacks a reasonable commercial purpose, gains derived from an indirect transfer may be subject to PRC enterprise income tax, and the transferee or other person who is obligated to pay for the transfer is obligated to withhold the applicable taxes, currently at a rate of 10% for the transfer of equity interests in a PRC resident enterprise. Both the transferor and the transferee may be subject to penalties under PRC tax laws if the transferee fails to withhold the taxes and the transferor fails to pay the taxes. A Accordingly, if we sell all or a part of our company and if the PRC tax authorities determine that we are a holding company that lacks a A reasonable commercial purposeA, such sale may be considered an indirect transfer under CircularA 59, CircularA 698, the SAT Announcement 7 and Bulletin 37 and subject non-PRC holders of our ordinary shares and ADSs to a PRC enterprise income tax, currently at a rate of 10%, on any gains derived by non-PRC holders on such sale. Additionally, a purchaser of all or a part of our company may determine that, under CircularA 59, CircularA 698, the SAT Announcement 7 and Bulletin 37, it is required to withhold the potentially applicable PRC tax rate of 10% from any consideration paid to non-PRC holders of our ordinary shares andA ADSs. A 97 A A U.S. Federal Income Tax ConsiderationsA The following is a discussion of the material U.S.A federal income tax considerations relevant to the acquisition, ownership, and disposition of our ADSs or ordinary shares by U.S.A Holders (asA defined below) that will hold our ADSs or ordinary shares as A capital assetsA (generally, property held for investment) under the U.S.A Internal Revenue Code of 1986, as amended, or the Code. This discussion is based upon applicable provisions of the Code, U.S.A Treasury regulations promulgated thereunder, pertinent judicial decisions, interpretive rulings of the Internal Revenue Service, or the IRS, and such other authorities as we have considered relevant, all of which are subject to change, possibly with retroactive effect. This discussion does not address all aspects of U.S.A federal income taxation that may be important to particular investors in light of their individual investment circumstances, including investors subject to special tax rulesA (forA example, certain financial institutions; insurance companies; broker-dealers; pension plans; regulated investment companies; real estate investment trusts; tax-exempt organizations (including private foundations); U.S.A expatriates; holders who own (directly, indirectly, or constructively) 10% or more of our stock (by vote or value); investors that will hold their ADSs or ordinary shares as part of a straddle, hedge, conversion, constructive sale, or other integrated transaction for U.S.A federal income tax purposes; investors required to accelerate the recognition of any item of gross income with respect to our ADSs or ordinary shares as a result of such income being recognized on an A applicable financial statementA (as defined in section 451 of the Code); investors that are traders in securities that have elected the mark-to-market method of accounting; or investors that have a functional currency other than the U.S.A dollar), all of whom may be subject to tax rulesA that differ significantly from those discussed below. A In addition, this discussion does not address tax considerations relevant to U.S.A Holders under any non-U.S., state or local tax laws, the Medicare tax on net investment income, U.S.A federal estate or gift tax, or the alternative minimum tax. Each U.S.A Holder is urged to consult its tax advisors regarding the U.S.A federal, state, local, and non-U.S.A income and other tax considerations of an investment in ADSs or ordinary shares. A The discussion below of U.S.A federal income tax consequences applies to you if you are a A U.S.A Holder.A You are a U.S.A Holder if you are a beneficial owner of our ADSs or ordinary shares and you are: (i)A an individual who is a citizen or resident of the UnitedA States for U.S.A federal income tax purposes; (ii)A a corporation, or other entity treated as a corporation for U.S.A federal income tax purposes, created in, or organized under the law of the UnitedA States, any state thereof or the District of Columbia; (iii)A an estate the income of which is includible in gross income for U.S.A federal income tax purposes regardless of its source; or (iv)A a trust (A)A the administration of which is subject to the primary supervision of a U.S.A court and which has one or more U.S.A persons who have the authority to control all substantial decisions of the trust or (B)A that has otherwise validly elected to be treated as a U.S.A person under theA Code. A If you are a partner in a partnership (including any entity or arrangement treated as a partnership for U.S.A federal income tax purposes) that holds our ADSs or ordinary shares, your tax treatment generally will depend on your status and the activities of the partnership. Partners in a partnership holding our ADSs or ordinary shares should consult their tax advisors regarding the tax consequences of an investment in the ADSs or ordinary shares. A Except as described in A PFIC RulesA below, this discussion assumes that we are not, and will not become, a passive foreign investment company, or PFIC, for any taxableA year. A ADSs A If you hold ADSs, for U.S. federal income tax purposes, you generally will be treated as the owner of the underlying ordinary shares that are represented by such ADSs. Accordingly, deposits or withdrawals of ordinary shares for ADSs will not be subject to U.S. federal income tax. A 98 A A DividendsA Subject to the PFIC rulesA discussed below, any cash distributions (including the amount of any PRC tax withheld) paid on our ADSs or ordinary shares out of our current or accumulated earnings and profits, as determined under U.S.A federal income tax principles, will generally be includible in your gross income as dividend income on the day actually or constructively received by you, in the case of ordinary shares, or by the depositary, in the case of ADSs. Because we do not intend to determine our earnings and profits under U.S.A federal income tax principles, any distribution paid will generally be treated as a dividend for U.S.A federal income tax purposes. Dividends received on our ADSs or ordinary shares will not be eligible for the dividends received deduction allowed to corporations under theA Code. A A non-corporate recipient will be subject to tax at preferential tax rates applicable to A qualified dividend income,A provided that certain conditions are satisfied, including that (1)A our stock (orA ADSs representing such stock) is readily tradable on an established securities market in the UnitedA States, or, in the event that we are deemed to be a PRC tax resident enterprise under the PRC tax law, we are eligible for the benefit of the UnitedA States-PRC income tax treaty, or the Treaty, (2)A we are neither a PFIC nor treated as such with respect to a U.S.A Holder (asA discussed below) for the taxable year in which the dividend was paid and the preceding taxable year, and (3)A certain holding period requirements areA met. The ADSs are readily tradable on the NASDAQ Global Market, and as such, we believe that dividends paid on the ADSs constitute qualified dividend income. There can be no assurance that our ADSs will continue to be considered readily tradable on an established securities market in later years. Our ordinary shares are not traded on an established securities market in the United States. Accordingly, we do not believe that dividends paid on our ordinary shares that are not backed by ADSs currently meet the conditions required for the reduced tax rate. A In the event that we are deemed to be a PRC tax resident enterprise under PRC tax law, you may be subject to PRC withholding taxes on dividends paid on our ADSs or ordinary shares, as described under A TaxationA "PeopleA's Republic of China Taxation.A If we are deemed to be a PRC tax resident enterprise, we may, however, be eligible for the benefits of the Treaty. If we are eligible for such benefits, dividends we pay on our ordinary shares, regardless of whether such shares are represented by our ADSs, may be eligible for the reduced rates of taxation applicable to qualified dividend income, as discussed above. A For U.S.A foreign tax credit purposes, dividends generally will be treated as income from foreign sources and generally will constitute passive category income. Depending on your particular circumstances, you may be eligible, subject to a number of complex limitations, to claim a foreign tax credit in respect of any foreign withholding taxes imposed on dividends received on our ADSs or ordinary shares. If you do not elect to claim a foreign tax credit for foreign tax withheld, you may instead claim a deduction, for U.S.A federal income tax purposes, for the foreign tax withheld, but only for a year in which you elect to do so for all creditable foreign income taxes. The rulesA governing the foreign tax credit are complex. You are urged to consult your tax advisor regarding the availability of the foreign tax credit under your particular circumstances. A Sale or Other Disposition of ADSs or Ordinary SharesA Subject to the PFIC rulesA discussed below, you generally will recognize capital gain or loss upon the sale or other disposition of our ADSs or ordinary shares in an amount equal to the difference, if any, between the amount realized upon the disposition and your adjusted tax basis in such ADSs or ordinary shares. Any capital gain or loss will be long-term capital gain or loss if you have held the ADSs or ordinary shares for more than one year, and will generally be U.S.-source gain or loss for U.S.A foreign tax credit purposes. The deductibility of a capital loss may be subject to limitations. In the event that we are deemed to be a PRC tax resident enterprise under PRC tax law, gain from the disposition of the ADSs or ordinary shares may be subject to tax in the PRC, as described under A TaxationA "PeopleA's Republic of China Taxation.A If we are treated as a PRC resident enterprise and PRC tax were imposed on any gain from your disposition of the ADSs or ordinary shares, you would be able to elect to treat the gain as PRC source income for foreign tax credit purposes if you are eligible for the benefits of the Treaty. You are urged to consult your tax advisor regarding the tax consequences if a foreign tax is imposed on a disposition of our ADSs or ordinary shares, including the availability of the foreign tax credit under your particular circumstances. A 99 A A PFIC RulesA A non-U.S.A corporation, such as our company, will be classified as a PFIC for U.S.A federal income tax purposes for any taxable year, if either (i)A 75% or more of its gross income for such year consists of certain types of A passiveA income or (ii)A 50% or more of the value of its assets (determined on the basis of a quarterly average) during such year produce or are held for the production of passive income. Passive income generally includes dividends, interest, royalties, rents, annuities, net gains from the sale or exchange of property producing such income and net foreign currency gains. For this purpose, cash is categorized as a passive asset and the companyA's goodwill associated with active business activity is taken into account as a non-passive asset. We will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other corporation in which we own, directly or indirectly, more than 25% (byA value) of theA stock. A Based on the projected composition of our assets and income, we do not believe that we were a PFIC for our taxable year ended MarchA 31, 2023 and we do not anticipate becoming a PFIC for our taxable year ending MarchA 31, 2024. While we do not anticipate becoming a PFIC, because the value of our assets for purposes of the PFIC asset test will generally be determined by reference to the market price of our ADSs or ordinary shares, fluctuations in the market price of our ADSs or ordinary shares may cause us to become a PFIC for the current or any subsequent taxable year. The determination of whether we will become a PFIC will also depend, in part, on the composition of our income and assets, which will be affected by how, and how quickly, we use our liquid assets and the cash raised in our initial public offering. Additionally, although the law in this regard is unclear, we treat our VIE as being owned by us for U.S.A federal income tax purposes, not only because we exercise effective control over the operation of such entity but also because we are entitled to substantially all of its economic benefits, and, as a result, we consolidate their results of operation in our combined and consolidated financial statements. Whether we are a PFIC is a factual determination and we must make a separate determination each taxable year as to whether we are a PFIC (after the close of each taxable year). Accordingly, we cannot assure you that we will not be a PFIC for our taxable year ending MarchA 31, 2024 or any future taxable year. If we are classified as a PFIC for any taxable year during which you hold our ADSs or ordinary shares, we generally will continue to be treated as a PFIC, unless you make certain elections, for all succeeding years during which you hold our ADSs or ordinary shares even if we cease to qualify as a PFIC under the rulesA set forth above. If we are a PFIC for any taxable year during which you hold our ADSs or ordinary shares, you will be subject to special tax rulesA with respect to any A excess distributionA that you receive and any gain you realize from a sale or other disposition (including a pledge) of our ADSs or ordinary shares, unless you make a A mark-to-marketA election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable years or your holding period for the ADSs or ordinary shares will be treated as an excess distribution. Under these special tax rules: A A A A the excess distribution or gain will be allocated ratably over your holding period for the ADSs or ordinary shares; A A A A amounts allocated to the current taxable year and any taxable years in your holding period prior to the first taxable year in which we are classified as a PFIC, or a pre-PFIC year, will be taxable as ordinary income;A and A A A A amounts allocated to each prior taxable year, other than the current taxable year or a pre-PFIC year, will be subject to tax at the highest tax rate in effect applicable to you for that year, and such amounts will be increased by an additional tax equal to interest on the resulting tax deemed deferred with respect to suchA years. A A A A If we are a PFIC for any taxable year during which you hold our ADSs or ordinary shares and any of our non-U.S.A subsidiaries is also a PFIC, you will be treated as owning a proportionate amount (byA value) of the shares of each such non-U.S.A subsidiary classified as a PFIC for purposes of the application of theseA rules. A 100 A A U.S.A Holder of A marketable stockA (asA defined below) in a PFIC may make a mark-to-market election for such stock of a PFIC to elect out of the tax treatment discussed in the two preceding paragraphs. If you make a valid mark-to-market election for the ADSs, you will include in income each year an amount equal to the excess, if any, of the fair market value of the ADSs as of the close of your taxable year over your adjusted basis in such ADSs. You will be allowed a deduction for the excess, if any, of the adjusted basis of the ADSs over their fair market value as of the close of the taxable year. However, deductions will be allowable only to the extent of any net mark-to-market gains on the ADSs included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition of the ADSs, will be treated as ordinary income. Ordinary loss treatment will also apply to the deductible portion of any mark-to-market loss on the ADSs, as well as to any loss realized on the actual sale or disposition of the ordinary shares, to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such ADSs. Your basis in the ADSs will be adjusted to reflect any such income or loss amounts. If you make a mark-to-market election, tax rulesA that apply to distributions by corporations which are not PFICs (described above in A "DividendsA") would apply to distributions by us (except that the preferential rates for qualified dividend income would notA apply). A The mark-to-market election is available only for A marketable stockA which is stock that is traded in other than de minimis quantities on at least 15A days during each calendar quarter (A regularly tradedA) on a qualified exchange or other market, as defined in applicable U.S.A Treasury regulations. We expect that the ADSs will be listed on the NASDAQ Global Market, which is a qualified exchange for these purposes. If the ADSs are regularly traded, and the ADSs qualify as A marketable stockA for purposes of the mark-to-market rules, then the mark-to-market election might be available to you if we were to become a PFIC. A Because, as a technical matter, a mark-to-market election cannot be made for any lower-tier PFICs that we may own, you may continue to be subject to the PFIC rulesA with respect to your indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S.A federal income tax purposes. We do not currently intend to provide information necessary for U.S.A Holders to make qualified electing fund elections, which, if available, would result in tax treatment different from the general tax treatment for PFICs described above. A If you own our ADSs or ordinary shares during any taxable year that we are a PFIC, you must file an annual report on IRS FormA 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with the IRS, generally with your federal income tax returns for such year, subject to certain exceptions based on the value of the ADSs or ordinary shares held. A failure to fileA a required annual report will suspend the statute of limitations with respect to any tax return, event, or period to which such report relates (potentially including with respect to items that do not relate to your investment in the ADSs or ordinary shares). You are urged to consult your tax advisor concerning the U.S.A federal income tax consequences of purchasing, holding, and disposing of our ADSs or ordinary shares if we are or become a PFIC, including the possibility of making a mark-to-market election. A Information with Respect to Specified Foreign Financial AssetsA You may be required to submit to the IRS certain information with respect to your beneficial ownership of our ADSs or ordinary shares, if such ADSs or ordinary shares are not held on your behalf by certain financial institutions. Penalties also may be imposed if you are required to submit such information to the IRS and fail to doA so. A Information Reporting and Backup WithholdingA Dividend payments with respect to ADSs or ordinary shares and proceeds from the sale, exchange or redemption of ADSs or ordinary shares may be subject to information reporting to the IRS and possible U.S.A backup withholding. Backup withholding will not apply, however, to a U.S.A Holder who furnishes a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from backup withholding. U.S.A Holders who are required to establish their exempt status generally must provide such certification on IRS FormA W-9 orA an acceptable substituteA form. A Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S.A federal income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rulesA by timely filing the appropriate claim for refund with the IRS and furnishing any required information. You are urged to consult your tax advisors regarding the application of the U.S.A information reporting and backup withholding rules. A 101 A A F. Dividends and Paying AgentsA Not applicable. A G. Statements by ExpertsA Not applicable. A H. Documents on DisplayA We previously filed with the SEC our registration statement on FormA F-1, as amended, to register our ordinary shares in relation to our initial public offering. We have also filed with the SEC a related registration statement on F-6 (Registration No.A 333-

09666) to register the ADSs. As we are subject to periodic reporting and other information requirements of the Securities Exchange Act of 1934, as amended, or the "Exchange Act," Under the Exchange Act, we are required to file reports and other information with the SEC, including filing annually a Form 20-F within four months after the end of each fiscal year, which is March 31. Copies of reports and other information, when so filed, may be inspected without charge and may be obtained at prescribed rates at the public reference facilities maintained by the Securities and Exchange Commission at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. The public may obtain information regarding the Washington, D.C. Public Reference Room by calling the Commission at 1-800-SEC-0330. The SEC also maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of quarterly reports and proxy statements, and officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. We will furnish Citibank, N.A., the depositary of our ADSs, with our annual reports, which will include a review of operations and annual audited consolidated financial statements prepared in conformity with U.S. GAAP, and all notices of shareholders' meeting and other reports and communications that are made generally available to our shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, upon our written request, will mail to all record holders of ADSs the information contained in any notice of a shareholders' meeting received by the depositary from us. 1. Subsidiary Information A. Not applicable. A. ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK A. Foreign Exchange Risk Substantially all of our revenue and substantially all of our expenses are denominated in RMB. In our consolidated financial statements, our financial information that uses RMB as the functional currency has been translated into U.S. dollars. Due to foreign currency translation adjustments, we had a foreign exchange translation gain of US\$ 1.5 million for the fiscal year ended March 31, 2022, a foreign exchange translation loss of US\$2.2 million for the fiscal year ended March 31, 2023, and a foreign exchange loss of US\$0.2 million for the fiscal year ended March 31, 2024. Appreciation or depreciation in the value of the RMB relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations. A. The conversion of RMB into foreign currencies, including U.S. dollars, is based on rates set by the PBOC. In fiscal year 2022, the value of RMB appreciated by approximately 3.2% against U.S. dollar. In fiscal year 2023, the value of RMB depreciated by approximately 8.3% against U.S. dollar. In fiscal year 2024, the value of RMB depreciated by approximately 5.1% against U.S. dollar. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future. A. 102 A. To the extent that we need to convert U.S. dollars into RMB for our operations, appreciation of the RMB against the U.S. dollar would have an adverse effect on the RMB amount we receive from the conversion. Conversely, if we decide to convert RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amounts available to us. A. It is difficult to predict how market forces, including the volatile market conditions arising from the COVID-19 pandemic, or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future. A. See also Item 3. Key Information A. D. Risk Factors A. Risks Related to Doing Business in the People's Republic of China A. Fluctuations in exchange rates could have a material adverse effect on our results of operations and the value of your investment. A. Interest Risk A. We have not been exposed to material risks due to changes in market interest rates, and we have not used any derivative financial instruments to manage our interest risk exposure. However, we cannot provide assurance that we will not be exposed to material risks due to changes in market interest rate in the future. Our future interest income may fall short of expectations due to changes in market interest rates. A. ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES A. Debt Securities A. Not applicable. A. B. Warrants and Rights A. Not applicable. A. C. Other Securities A. Not applicable. A. 103 A. D. American Depositary Shares A. Fees and Charges Our ADS Holders May Have to Pay A. As an ADS holder, you will be required to pay the following service fees to the depositary and certain taxes and governmental charges (in addition to any applicable fees, expenses, taxes and other governmental charges payable on the deposited securities represented by any of your ADSs): A. Service A. Fees (1) Issuance of ADSs (e.g., an issuance upon a deposit of Shares, upon a change in ADS(s)-to-Share(s) ratio, or for any other reason), excluding issuances as a result of distributions described in paragraph (4) below. A. Up to U.S. \$5.00 per 100 ADSs (or fraction thereof) issued. A. A. (2) Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited Shares, upon a change in the ADS(s)-to-Shares(s) ratio, or for any other reason). A. Up to U.S. \$5.00 per 100 ADSs (or fraction thereof) cancelled. A. A. A. (3) Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements). A. Up to U.S. \$5.00 per 100 ADSs (or fraction thereof) held. A. A. A. (4) Distribution of ADSs pursuant to (i) stock dividends or other free stock distributions, or (ii) an exercise of rights to purchase additional ADSs. A. Up to U.S. \$5.00 per 100 ADSs (or fraction thereof) held. A. A. A. (5) Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., spin-off shares). A. Up to U.S. \$5.00 per 100 ADSs (or fraction thereof) held. A. A. A. (6) ADS Services. A. Up to U.S. \$5.00 per 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the depositary. A. As an ADS holder, you will also be responsible to pay certain fees and expenses incurred by the depositary and certain taxes and governmental charges (in addition to any applicable fees, expenses, taxes and other governmental charges payable on the deposited securities represented by any of your ADSs) such as the following: A. A. a. Fees for the transfer and registration of ordinary shares charged by the registrar and transfer agent for the ordinary shares in Cayman Islands (i.e., upon deposit and withdrawal of ordinary shares). A. A. a. Expenses incurred for converting foreign currency into U.S. dollars. A. A. a. Expenses for cable, telex, fax and electronic transmissions and for delivery of securities. A. A. a. Taxes and duties upon the transfer of securities, including any applicable stamp duties, any stock transfer charges or withholding taxes (i.e., when ordinary shares are deposited or withdrawn from a deposit). A. A. a. Fees and expenses incurred in connection with the delivery of ordinary shares on deposit or the servicing of ordinary shares, deposited securities and/or ADSs. A. A. a. Fees and expenses incurred in connection with complying with exchange control regulations and other regulatory requirements applicable to ordinary shares, deposited securities, ADSs and ADRs. A. 104 A. A. ADS fees and charges payable upon (i) a deposit of the ordinary shares against issuance of ADSs and (ii) a surrender of ADSs for cancellation and withdrawal of the ordinary shares are charged to the person to whom the ADSs are delivered (in the case of ADS issuances) and to the person who delivers the ADSs for cancellation (in the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC or presented to the depositary bank via DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC and may be charged to the DTC participant(s) receiving the ADSs or the DTC participant(s) surrendering the ADSs for cancellation, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account(s) of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participant(s) as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges, and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC and may be charged to the DTC participants, in accordance with the procedures and practices prescribed by DTC, and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. In the event of refusal to pay the depositary bank fees, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS holder. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary bank. You will receive prior notice of such changes. A. Citibank, N.A. and/or its agent may act as principal for such conversion of foreign currency. A. The charges described above may be amended from time to time by agreement between us and the depositary. A. Fees and Other Payments Made by the Depositary to Us A. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary bank agree from time to time. A. 105 A. A. PART II A. ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES A. None. A. ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS A. Material Modifications to the Rights of Security Holders A. See also Item 10. Additional Information A. B. Memorandum and Articles of Association A. Ordinary Shares A. For a description of the rights of securities holders, which remain unchanged. A. Use of Proceeds A. The following use of proceeds information relates to (i) the registration statement on Form F-1, as amended (File Number: 333-220720) in relation to our initial public offering of 5,036,950 ADSs representing 5,036,950 ordinary shares, at an initial offering price of US\$10.00 per ADS. A. Our initial public offering closed on November 3, 2017. Network 1 Financial Services, Inc. was the representative of the underwriters for our initial public offering. As a result of our initial public offering, we raised an aggregate of approximately US\$43.3 million in net proceeds, after deducting related costs and expenses. A. As of the date of this annual report, we had used all the net proceeds received from our initial public offering. A. ITEM 15. CONTROLS AND PROCEDURES A. Evaluation of Disclosure Controls and Procedures A. Our management, with the participation of our chief executive officer and our chief financial officer, has performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(a) and 15d-15(e) promulgated under the Exchange Act) as of the end of the period covered by this annual report on Form 20-F, as required by Rule 13a-15(b) under the Exchange Act. A. Based on that evaluation, our management concluded that, as of March 31, 2024, our disclosure controls and procedures were effective in ensuring that the information required to be disclosed by us in the reports that we file and furnish under the Exchange Act was recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, to allow timely decisions regarding required disclosure. A. A. Management A. Our Annual Report on Internal Control over Financial Reporting A. Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. Our management evaluated the effectiveness of our internal control over financial reporting, as required by Rule 13a-15(c) of the Exchange Act, based on criteria established in the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management has concluded that the material weaknesses identified during the fiscal year ended March 31, 2018 have been remediated, and our internal control over financial reporting was effective as of March 31, 2024. A. A. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness of our internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate. A. 106 A. A. Attestation Report of the Independent Registered Public Accounting Firm A. We did not include an attestation report of the Company's registered public accounting firm due to rules of the SEC where domestic and foreign registrants that are non-accelerated filers, which we are, are not required to provide the auditor attestation report. A. Changes in Internal Control over Financial Reporting A. There were no changes in our internal control over financial reporting that occurred during the fiscal year ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. A. ITEM 16. [Reserved] A. ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT A. Our audit committee consists of three members and is chaired by Mr. Stephen P. Brown. Each of Mr. Stephen P. Brown, Mr. Zhe Liu and Mr. Gerald (Jerry) T. Neal satisfies the independence requirements of the listing rules of NASDAQ and meet the independence standards under Rule 10A-3 under the Exchange Act. We have determined that each of Mr. Stephen P. Brown qualifies as an audit committee financial expert. A. ITEM 16B. CODE OF ETHICS A. Our board of directors adopted a code of business conduct and ethics that applies to our directors, officers, employees and advisors, which became effective in November 2017. We have posted a copy of our code of business conduct and ethics on our website at xiaoobaaimai.com. A. ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES A. The following table sets forth the aggregate fees by the categories specified in connection with certain professional services rendered by OneStop Assurance PAC. We did not pay any other fees to our auditor during the periods indicated below. A. A. Year ended March 31, A. A. 2024 A. A. 2023 A. Audit fees (1) A. \$220,000 A. Audit-related fees (2) A. A. A. Tax fees (3) A. A. A. All other fees A. A. A. Total A. \$220,000 A. \$300,000 A. (1) Audit fees represent the aggregate fees for professional services rendered by our principal auditors for the review of our interim consolidated financial statements, the audit of our annual consolidated financial statements and/or services that are normally provided by the auditors in connection with statutory and regulatory filings or engagements. A. Tax fees represent the aggregate fees for professional services rendered by our principal auditors for tax compliance, tax advice and tax planning. A. (2) Audit-related fees means the aggregate fees billed for related services by our principal accountant that are reasonably related to the performance of the audit or review of our financial statements and are not reported under Audit fees. A. (3) Tax fees means the aggregated fees billed for professional services rendered by our independent registered public accounting firm for tax compliance, tax advice, and tax planning. A. The policy of our audit committee is to pre-approve all audit and non-audit services to be provided by OneStop, including audit services, audit-related services, tax services and other services as are described above, other than those for de minimis services which are approved by the audit committee prior to the completion of the audit. A. 107 A. A. ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES A. Not

Factors“Risks Related to Our ADSs“We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions applicable to United States domestic public companies.Â ITEM 16H. MINE SAFETY DISCLOSURE A Not applicable.Â ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS A Not applicable.Â ITEM 16J. INSIDER TRADING POLICY A We will be required to comply with disclosure requirements under this Item 16J for the fiscal year ending on March 31, 2025.Â ITEM 16K. CYBERSECURITY A Risk Management and Strategy A We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. We have implemented cybersecurity measures and protocols for assessing, identifying, and managing material risks from cybersecurity threats, which are integrated into our overall risk management framework. We aim to ensure a comprehensive and proactive approach to safeguarding our assets and operations.Â As of the date of this annual report, we have not experienced any material cybersecurity incidents or identified any material cybersecurity threats that have affected or are reasonably likely to materially affect us, our business strategy, results of operations or financial condition.Â A Governance A Our board of directors is responsible for overseeing risks related to cybersecurity. Our board of directors shall (i) maintain oversight of the disclosure related to cybersecurity matters in current reports or periodic reports of our company, (ii) review updates to the status of any material cybersecurity incidents or material risks from cybersecurity threats to our company, and the disclosure issues, if any, presented by our management on a quarterly basis, and (iii) review disclosure concerning cybersecurity matters in our annual report on Form 20-F presented by our management.Â At the management level, our CEO, CFO and the head of the departments in connection with cybersecurity-related matters are responsible for assessing, identifying and managing cybersecurity risks and monitoring the prevention, detection, mitigation, and remediation of cybersecurity incidents. Our CEO and CFO report to our board of directors (i) timely updates to the status of any material cybersecurity incidents or material risks from cybersecurity threats to our company, and the disclosure issues, if any, and (ii) in connection with disclosure concerning cybersecurity matters in our annual report on Form 20-F.Â If a cybersecurity incident occurs, our cybersecurity-related departments will promptly organize personnel for internal assessment. If it is further determined that the incident could potentially be a material cybersecurity event, the cybersecurity-related departments will promptly report the incident and assessment results to our CEO and CFO, and, to the extent appropriate, seek advice from external experts and legal counsels. If it is determined that the incident could potentially be a material cybersecurity event, our CEO and CFO will decide on relevant response measures and management shall promptly prepare disclosure material on the cybersecurity incident for review and approval by our board of directors before it is disseminated to the public.Â 109 A A PARTA III A ITEM 17. FINANCIAL STATEMENTS A We have elected to provide financial statements pursuant to Item 18.Â ITEM 18. FINANCIAL STATEMENTS A VIE Financial Information A Set forth below is selected consolidated statements of operations and cash flows for the fiscal years ended March 31, 2024, 2023, 2022 and 2021, and selected balance sheet information as of March 31, 2024, 2023 and 2022 showing financial information for the parent company Akso Health Group, the WFOE (as defined below) and WFOE’s subsidiaries (as defined below), the VIE and VIE’s subsidiaries, eliminating entries and consolidated information (in dollars). In the tables below, the column headings correspond to the following entities in the organizational diagram on page 70. See also VIE and consolidated financial information in Note 3 of our financial statements.Â For the purposes of this section: A A – æœParent companyæœ refers to Akso Health Group; A A A – æœWFOEæœ refers to Beijing Hexin Yongheng Technology Development Co., Ltd., Tianjin Haohong Trading Co., Ltd. and Qindao Akso Health Management Co., Limited, Tianjin Akso Enterprise Management Co., Ltd. A A – æœVIEæœ refers to Wusu Hexin Yongheng Trade Co., Ltd, Hexin Digital Technology Co., Ltd., Beijing Hexin Jiuding Technology Co., Ltd. A A – æœOther subsidiariesæœ refers to HX Asia Investment Limited, HX China Investment Limited, We Health Limited, We Healthy Limited, Akso Online MediTech Co., Ltd, Akso Medical Cloud Limited and Akso Medi-care Limited A Selected Condensed Consolidation Schedule of Balance Sheet A A As of March 31, 2024 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries (1) A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Cash and cash equivalents A 2,279 A A 74,791,108 A A 10,530,935 A A 880,073 A A (1,030,378) A A 85,174,017 A Intercompany receivables (1) A 141,456,064 A A A A A 20,383,406 A A (161,839,470) A A Total current assets A 141,458,343 A A 75,194,606 A A 73,158,083 A A 25,636,634 A A (173,429,549) A A 142,018,117 A Total Assets A 141,458,343 A A 85,195,260 A A 73,158,419 A A 25,661,413 A A (183,455,318) A A 142,018,117 A Intercompany payables (1) A A A 121,749,699 A A 60,538,415 A A A A (182,288,114) A A Total Liabilities A 3,090,959 A A 122,266,987 A A 67,354,488 A A 17,647 A A (189,136,158) A A (189,136,158) A A Total Shareholders’ Equity A 138,367,384 A A (37,128,537) A A 5,803,931 A A 25,643,766 A A 5,680,840 A A 138,367,384 A Non-controlling interests A A A 56,810 A A A 56,810 A A A 56,810 A A A 56,810 A Total Liabilities and Equity A 141,458,343 A A 85,195,260 A A 73,158,419 A A 25,661,413 A A (183,455,318) A A 142,018,117 A A As of March 31, 2023 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries (1) A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Cash and cash equivalents A 4,472 A A 43,321 A A 4,466,219 A A 678,691 A A (1,268,235) A A 7,924,468 A Intercompany receivables (1) A 11,303,978 A A A A A 26,206,288 A A (37,510,266) A A Total current assets A 11,314,245 A A 12,030,429 A A 26,967,518 A A (47,510,918) A A 20,460,299 A A 12,030,076 A A 26,938,820 A A (37,481,213) A A 20,460,299 A Total Assets A 11,314,245 A A 17,659,025 A A 12,030,429 A A 26,967,518 A A (47,510,918) A A 20,460,299 A Intercompany payables (1) A A A 39,340,009 A A 4,915,930 A A A A (44,255,939) A A Total Liabilities A 2,588,941 A A 47,468,686 A A 5,798,567 A A 19,806 A A (44,255,217) A A 11,620,783 A Total Shareholders’ Equity A 8,725,304 A A (29,923,873) A A 6,231,862 A A 26,947,712 A A (3,255,701) A A 8,725,304 A Non-controlling interests A A A 114,212 A A A A A 114,212 A Total Liabilities and Equity A 11,314,245 A A 17,659,025 A A 12,030,429 A A 26,967,518 A A (47,510,918) A A 20,460,299 A A 110 A A A As of March 31, 2022 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries (1) A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Cash and cash equivalents A 4,472 A A 8,075,355 A A 11,450,608 A A 2,394,869 A A (3,495,317) A A 18,429,987 A Intercompany receivables (1) A 14,333,994 A A A A A 27,139,795 A A (41,473,789) A A Total current assets A 14,344,280 A A 46,043,013 A A 12,004,330 A A 29,605,775 A A (39,190,890) A A 62,806,508 A Total Assets A 14,344,280 A A 46,043,013 A A 12,005,875 A A 29,659,663 A A (39,246,323) A A 62,806,508 A Intercompany payables (1) A A A 42,054,570 A A 4,074,729 A A A A (46,129,299) A A Total current liabilities A 2,060,675 A A 42,112,594 A A 4,758,851 A A 89,205 A A 1,499,601 A A 50,520,926 A Total Shareholders’ Equity A 12,283,605 A A 3,928,443 A A 7,247,024 A A 29,570,458 A A (40,745,924) A A 12,813,606 A Non-controlling interests A A A 1,976 A A A A A 1,976 A Total Liabilities and Equity A 14,344,280 A A 46,043,013 A A 12,005,875 A A 29,659,663 A A (39,246,323) A A 62,806,508 A (1) Elimination of intercompany balances among parent company, other subsidiaries, WFOE and VIEs and their subsidiaries that we consolidate and reclassification of retroactive adjustment for discontinued operations. A Selected Condensed Consolidated Statements of Operations Data A A For the year ended March 31, 2024 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries (2) A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Total revenue, net A A A 2,414,338 A A 694 A A (694) A A 2,414,338 A Total costs and expenses (benefits) A 2,122,139 A A 7,391,678 A A 2,532,589 A A (11,798) A A (982,230) A A 11,052,378 A Loss from subsidiaries and VIEs A 7,394,438 A A A A A A (7,394,438) A A Total other income, net A A A 128,983 A A 18,809 A A 5 A A (601,548) A A (453,751) (Loss) income from continuing operations before income tax expenses A (9,116,779) A (7,262,066) A (124,431) A 12,497 A A 7,374,000 A A (9,116,779) Total gain (loss) from discontinued operations A A A A A A (399,798) A (399,798) Net (loss) income A (9,116,779) A (7,262,066) A (124,431) A 12,497 A A 6,974,202 A A (9,516,577) A A For the year ended March 31, 2023 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries (2) A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Total revenue, net A A A 9,181,274 A A 4,000,288 A A 24,995 A A (24,996) A A 13,181,561 A Total costs and expenses A 160,427 A A 17,414,712 A A 10,570,774 A A 37,019 A A (1,073,518) A A 27,448,414 A Loss from subsidiaries and VIEs A 1,086,999 A A A A A A (1,086,999) A A Total other income, net A A A 14,049,229 A A 34,051 A A 2,218 A A (12,885,134) A A 1,200,364 (Loss) income from continuing operations before income tax expenses A (1,247,426) A 5,815,791 A A (6,536,435) A (348,806) A (10,749,613) A (13,066,489) Less: income tax expense A A A 50 A A A 17,499 A A A A A A 17,549 A Net (loss) income from continuing operations A (1,247,426) A 5,815,741 A A (6,553,934) A (348,806) A (10,749,613) A (13,084,038) Total gain (loss) from discontinued operations A A A A A A (399,798) A A A A A A 11,836,612 A A 11,836,612 A Net (loss) income A (1,247,426) A 5,815,741 A A (6,553,934) A (348,806) A 1,086,999 A A (1,247,426) A 111 A A A For the year ended March 31, 2022 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries (2) A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Total revenue, net A A A 6,000,000 A A A A 6,000,000 A A A A 311,092 A A (311,092) A 6,000,000 A Total costs and expenses A 3,129,090 A A 6,134,383 A A 1,158,637 A A 11,826,736 A A (12,988,383) A A 9,260,463 A Loss from subsidiaries and VIEs A 13,720,643 A A A A A A (13,720,643) A A Total other income (loss), net A A A A (750,744) A A (56,471) A A 26,669 A A (747,818) A Loss from continuing operations before income tax expenses A (16,849,733) A (885,127) A (1,215,108) A (11,488,975) A 26,430,662 A A (4,008,281) Less: income tax (benefit) expense A A A 54,199 A A A 38,613 A A A 92,816 A Net (loss) income from continuing operations A (16,849,733) A (939,326) A (1,215,112) A (11,527,588) A 26,430,662 A A (4,101,097) Total gain (loss) from discontinued operations A A A A A A (12,748,636) A (12,748,636) Net (loss) A (16,849,733) A (939,326) A (1,215,112) A (11,527,588) A 13,682,026 A A (16,849,733) A A For the year ended March 31, 2021 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries (2) A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Total revenue, net A A A 2,300,653 A A (2,300,653) A A Total costs and expenses A 4,293,327 A A A A A A A A 1,143,272 A A 35,304,848 A A (36,500,198) A A 4,241,249.00 A Loss from subsidiaries and VIEs A 30,533,662 A A A A A A (30,533,662) A A Total other income (expense), net A A A A 533,510 A A 398,836 A A (984,424) A A (52,078) A Loss from continuing operations before income tax expenses A (34,826,989) A A A (609,762) A A (32,605,359) A 63,748,783 A A (4,293,327) Less: income tax (benefit) expense A A A A 1,929 A A 481,413 A A (483,342) A A Net (loss) income from continuing operations A (34,826,989) A A A (611,691) A (33,086,772) A 64,232,125 A A (4,293,327) Total (loss) from discontinued operations A A A A A A (30,533,662) A (30,533,662) Net (loss) A (34,826,989) A A A (611,691) A (33,086,772) A 33,698,463 A A (34,826,989) A (2) Reclassification of retroactive adjustment for discontinued operations A 112 A A Selected Condensed Consolidation Schedule of Cash Flows A A For the year ended March 31, 2024 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Net cash provided by (used in) operating activities A (1,614,326) A 260,838 A 2,692,231 A A 12,497 A A A 1,351,240 A Net cash provided by (used in) investing activities A A A 1,528,918 A A (56,250,000) A A A A (54,721,082) A Net cash provided by (used in) financing activities A 1,612,133 A A 74,230,195 A A 55,622,485 A A 188,884 A A A 131,653,697 A Intercompany A receive A A A A A A A A 138,042,067 A A A A For the year ended March 31, 2023 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Net cash provided by (used in) operating activities A (3,158,498) A (7,125,619) A (3,957,655) A 5,613,401 A A (8,628,371) A Net cash provided by (used in) investing activities A A A (20,000,000) A A 1,491,687 A A (1,455,547) A A A (19,963,860) A Net cash provided by (used in) financing activities A 1,679,505 A A 35,200,000 A A 11,105,170 A A (13,203,558) A A A 34,781,117 A Intercompany A receive A A A A A A 337,695 A A A A A A (337,695) A A A A For the year ended March 31, 2021 A A Parent Company A Other Subsidiaries A WFOE and WFOE’s Subsidiary A VIE and VIE’s Subsidiary A Elimination Entries and Reclassification Entries A Consolidated Total A A (US\$) A A (US\$) A A (US\$) A A (US\$) A Net cash (used in) provided by operating activities A (6,547,518) A A (10,184) A (4,785,527) A 21,401,699 A A A 10,058,470 A Net cash (used in) provided by investing activities A A A A (408,081) A 407,419 A A A (662) A Net cash provided by (used in) financing activities A 6,321,854 A A 10,184 A A (2,241,562) A A (13,127,699) A A A (9,037,223) A Intercompany A receive A A A A A A A A 11,327,745 A A A A Intercompany payment A A A A A A (11,327,745) A A The consolidated financial statements of Akso Health Group, its subsidiaries and its consolidated former variable interest entities are included at the end of this annual report on Form 20-F. A 113 A A ITEM 19. EXHIBITS A EXHIBIT INDEX A Exhibit Number A Description A Document A A 1.1 A Amended and Restated Memorandum and Articles of Association of the Registrant (incorporated herein by reference to Exhibit 3.2 to the registration statement on Form F-1 (File No. A 333-220720), as amended, initially filed with the Securities and Exchange Commission on September 29, 2017) A A 1.2* A Amended and Restated Memorandum and Articles of Association of the Registrant effective on May 7, 2024 A A 2.1 A Registrant’s Specimen American Depositary Receipt (included in Exhibit 2.3) A A 2.2 A Registrant’s Specimen Certificate for Ordinary Shares (incorporated herein by reference to Exhibit 4.2 to the registration statement on Form F-1 (File No. A 333-220720), initially filed with the Securities and Exchange Commission on September 29, 2017) A A 2.3 A Deposit Agreement by and among the Registrant, the Depository, and the Holders and Beneficial Owners of the American Depositary Shares, dated as of November 2, 2017 (incorporated herein by reference to Exhibit (a)(i) to the Post-Effective Amendment No. 1 to Form F-6 registration statement (File No. A 333-220966), initially filed with the Securities and Exchange Commission on August 10, 2020) A A 2.4 A Form of Amendment No. 1 to the Deposit Agreement by and among the Registrant, the Depository, and the Holders and Beneficial Owners of the American Depositary Shares, and Form of American Depositary Receipt (incorporated herein by reference to Exhibit (a)(i) to the Post-Effective Amendment No. 1 to Form F-6 registration statement (File No. A 333-220966), initially filed with the Securities and Exchange Commission on August 10, 2020) A A 2.5 A Description of securities of the Registrant registered under Section 12 of the Securities Exchange Act of 1934 (incorporated herein by reference to Exhibit 2.5 to the annual report on Form 20-F filed with the SEC on August 14, 2020) A A 4.1 A Amended and Restated 2016 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.17 to the registration statement on Form F-1 (File No. A 333-220720), as amended, initially filed with the Securities and Exchange Commission on September 29, 2017) A A 4.2 A Form of Option Agreement (incorporated herein by reference to Exhibit 10.18 to the registration statement on Form F-1 (File No. A 333-220720), as amended, initially filed with the Securities and Exchange Commission on September 29, 2017) A A 4.3 A Form of Indemnification Agreement with Executive Officers and Directors (incorporated herein by reference to Exhibit 10.19 to the registration statement on Form F-1 (File No. A 333-220720), as amended, initially filed with the Securities and Exchange Commission on September 29, 2017) A A 4.4 A Form of Escrow Agreement (incorporated herein by reference to Exhibit 10.20 to the registration statement on Form F-1 (File No. A 333-220720), as amended, initially filed with the Securities and Exchange Commission on September 29, 2017) A A 4.5 A Form of Subscription Agreement (incorporated herein by reference to Exhibit 10.21 to the registration statement on Form F-1 (File No. A 333-220720), as amended, initially filed with the Securities and Exchange Commission on September 29, 2017) A A 4.6 A Share Purchase Agreement by and among Umbrella Capital Investment Co., Ltd, HX Asia Investment Limited, a British Virgin Islands company, HX China Investment Limited, Hexindai Hong Kong Limited, and Akso Health Group (incorporated herein by reference to Exhibit 99.1 to the current report on Form 6-K filed on May 25, 2023). A A 4.7* A Unofficial English translation of the form of the

securities purchase agreements, by and between Tianjin Akso Enterprise Management Co., Ltd. and each of the four shareholders of Tianjin Wangyi Cloud Co., Ltd. Á Á Á 4.8 Á Form of Share Purchase Agreement, dated October 2, 2023 (incorporated herein by reference to Exhibit 99.1 to the current report on Form 6-K filed on October 2, 2023) Á Á Á 4.9 Á Form of Warrant, dated October 2, 2023 (incorporated herein by reference to Exhibit 99.2 to the current report on Form 6-K filed on October 2, 2023) Á 114 Á Á 4.10 Á Form of Share Purchase Agreement, dated November 16, 2023 (incorporated herein by reference to Exhibit 99.1 to the current report on Form 6-K filed on November 17, 2023) Á Á Á 4.11 Á Form of Warrant, dated November 16, 2023 (incorporated herein by reference to Exhibit 99.2 to the current report on Form 6-K filed on November 17, 2023) Á Á Á 4.12 Á Form of Share Purchase Agreement, dated January 17, 2024 (incorporated herein by reference to Exhibit 99.1 to the current report on Form 6-K filed on January 22, 2024) Á Á Á 4.13 Á Form of Warrant, dated January 17, 2024 (incorporated herein by reference to Exhibit 99.2 to the current report on Form 6-K filed on January 22, 2024) Á Á Á 4.14 Á Form of Share Purchase Agreement, dated March 5, 2024 (incorporated herein by reference to Exhibit 99.1 to the current report on Form 6-K filed on March 8, 2024) Á Á Á 4.15 Á Form of Warrant, dated March 5, 2024 (incorporated herein by reference to Exhibit 99.2 to the current report on Form 6-K filed on March 8, 2024) Á Á Á 8.1* Á List of Subsidiaries of the Registrant Á Á 11.1 Á Code of Business Conduct and Ethics of the Registrant (incorporated herein by reference to Exhibit 99.1 to the registration statement on Form F-1 (File No. Á 333-220720), as amended, initially filed with the Securities and Exchange Commission on September 29, 2017) Á Á Á 12.1* Á Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Á Á Á 12.2* Á Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Á Á Á 13.1** Á Certification by Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Á Á Á 15.1* Á Consent of Onestop Assurance PAC, an independent registered public accounting firm Á Á Á 15.2* Á Consent of Hebei Changjun Law Firm Á Á Á 97 Á Policy relating to recovery of erroneously awarded compensation, as required by applicable listing standards adopted pursuant to 17 CFR 240.10D-1 Á Á Á 101.INS* Á Inline XBRL Instance Document Á Á Á 101.SCH* Á Inline XBRL Taxonomy Extension Schema Document Á Á Á 101.CAL* Á Inline XBRL Taxonomy Extension Calculation Linkbase Document Á Á Á 101.DEF* Á Inline XBRL Taxonomy Extension Definition Linkbase Document Á Á Á 101.LAB* Á Inline XBRL Taxonomy Extension Label Linkbase Document Á Á Á 101.PRE* Á Inline XBRL Taxonomy Extension Presentation Linkbase Document Á Á Á 104* Á Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith Á ** Furnished herewith Á 115 Á Á SIGNATURES Á The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F, and that it has duly caused and authorized the undersigned to sign this annual report on its behalf. Á Á Akso Health Group Á Á Á By: /s/ Yilin (Linda) Wang Á Á Name: Yilin (Linda) Wang Á Á Title: Chairwoman and Chief Executive Officer Á Date: July 30, 2024 Á 116 Á Á AKSO HEALTH GROUP AND SUBSIDIARIES Á TABLE OF CONTENTS Á Á Page Consolidated Financial Statements Á Report of Independent Registered Public Accounting Firm (OneStop Assurance PAC, PCAOB ID: 6732) F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations and Comprehensive (Loss) F-4 Consolidated Statements of Changes in Shareholders' Equity F-5 Consolidated Statements of Cash Flows F-6 Notes to the Consolidated Financial Statements F-7 Á F-29 Schedule 1 Á Additional information of the Parent Company F-30 Á F-32 Á F-1 Á REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Á To the shareholders and the board of directors of Akso Health Group and subsidiaries Á Opinion on the Financial Statements Á We have audited the accompanying consolidated balance sheets of Akso Health Group and subsidiaries (collectively, the "Company") as of March 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, shareholders' equity, and cash flows for each of the years in the three-year period ended March 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial positions of the Company as of March 31, 2024 and 2023, and the consolidated results of its operations and its cash flows for each of the years in the three-year period ended March 31, 2024, in conformity with accounting principles generally accepted in the United States of America. Á Going Concern Uncertainty Á The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company had a net loss of approximately \$9.5 million from operations for the year ended March 31, 2024 and approximately \$1.2 million for the year ended March 31, 2023. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Á Basis for Opinion Á These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. Á We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Á Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. Á Critical Audit Matter Á Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters. Á Emphasis of Matter Á The Company has significant transactions with related parties, which are described in Note 12 to the financial statements. Transactions involving related parties cannot be presumed to be carried out on an arm's length basis, as the requisite conditions of competitive, free market dealings may not exist. Á /s/ ONESTOP ASSURANCE PAC Á Á ONESTOP ASSURANCE PAC (id# 6732) Á We have served as the Company's auditor since 2022. Singapore Á July 30, 2024 Á Á F-2 Á Á AKSO HEALTH GROUP AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Á Á Notes Á As of March 31, 2024 Á Á As of March 31, 2023 Á Á Á USD Á USD Á ASSETS Á Á Á Á Á CURRENT ASSETS: Á Á Á Á Á Cash and cash equivalents Á \$85,174,017 Á \$7,924,468 Á Accounts receivable, net Á 5,411,901 Á 7,696,983 Á Prepayments and other assets Á 6,412,899 Á 272,129 Á Inventories Á 7,191,201 Á 1,686,449 Á Current assets held for sale - discontinued operation Á 4,135,352 Á 1,351,352 Á Loan receivables Á 8,152,918 Á 1,528,918 Á Prepaid consideration Á 9,562,500 Á 562,000 Á TOTAL CURRENT ASSETS Á 142,018,117 Á 20,460,299 Á TOTAL ASSETS Á 142,018,117 Á 20,460,299 Á Á Á Á Á LIABILITIES AND SHAREHOLDERS' EQUITY Á Á Á Á Á CURRENT LIABILITIES: Á Á Á Á Á Accrued expenses and other current liabilities Á 11,104,812 Á \$938,767 Á Contract liabilities Á 4,510,020 Á 194,376 Á Taxes payable Á 74,091 Á 96,005 Á Amount due to related parties Á 2,000,000 Á 9,686,152 Á Current liabilities held for sale - discontinued operation Á 4,135,483 Á TOTAL CURRENT LIABILITIES Á 13,593,923 Á 11,620,783 Á TOTAL LIABILITIES Á 13,593,923 Á 11,620,783 Á Á Á Á Á COMMITMENTS AND CONTINGENCIES (Note 20) Á Á Á Á Á SHAREHOLDERS' EQUITY: Á Á Á Á Á Ordinary share (\$0.0001 par value, 5,000,000 shares authorized, 438,336,843 and 69,763,933 shares issued, 437,170,960 and 68,598,050 shares outstanding as of March 31, 2024 and 2023, respectively) Á 17,438,344 Á 6,977 Á Additional paid-in capital Á 210,324,890 Á 71,021,898 Á Treasury stock (1,165,883 shares as of March 31, 2024 and 2023, respectively) Á 18 Á (3,988,370) Á (3,988,370) Á Accumulated deficit Á (63,926,383) Á (54,467,600) Á Accumulated other comprehensive loss Á (4,086,587) Á (3,847,601) Á TOTAL SHAREHOLDERS' EQUITY Á 138,367,384 Á 8,725,304 Á Non-controlling interest Á 56,810 Á 114,212 Á TOTAL EQUITY Á 138,424,194 Á 8,839,516 Á Á Á Á Á TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Á 142,018,117 Á 20,460,299 Á The accompanying notes are an integral part of these consolidated financial statements. Á F-3 Á AKSO HEALTH GROUP AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) Á Á For the years ended March 31, Á Á 2024 Á 2023 Á Á USD Á USD Á USD Á REVENUES Á Á Á Á Á Sale of medical devices Á \$2,416,797 Á \$13,186,525 Á \$6,000,000 Á Tax and surcharges Á (2,459) Á (4,964) Á - Á Net Revenues Á 2,414,338 Á 13,181,561 Á 6,000,000 Á Á Á Á Á Cost of goods sold Á 2,292,206 Á 11,912,571 Á 5,394,866 Á Á Á Á Á Gross Profit Á 122,132 Á 1,268,990 Á 605,134 Á Á Á Á Á OPERATING EXPENSES Á Á Á Á Á Sales and marketing Á 168,421 Á 6,661 Á - Á General and administrative Á 8,591,751 Á 15,529,182 Á 2,669,834 Á Finance cost Á - Á - Á 804,138 Á Share-based compensation Á 391,625 Á Total Operating Expenses Á 8,760,172 Á 15,535,843 Á 3,865,597 Á Á Á Á Á LOSS FROM CONTINUING OPERATIONS Á (8,638,040) Á (14,266,853) Á (3,260,463) Á Á Á Á Á OTHER INCOME (EXPENSE) Á 252,408 Á 395,668 Á 5,103 Á Other expenses Á (114,168) Á (338,310) Á (4,419) Á Exchange (loss) gain Á (591,991) Á 1,143,006 Á (748,502) Total Other (Expense) Income, net Á (453,751) Á 1,200,364 Á (747,818) Á Á Á Á Á (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Á (9,091,791) Á (13,066,489) Á (4,008,281) Á Á Á Á Á PROVISION FOR INCOME TAXES Á 24,988 Á 17,549 Á 92,816 Á NET (LOSS) FROM CONTINUING OPERATIONS Á (9,116,779) Á (13,084,038) Á (4,101,097) Net (loss) gain income from discontinued operations, net of income taxes Á (3,884) Á 11,836,612 Á (12,748,636) Loss from disposal of discontinued operations, net of income taxes Á (395,914) Á - Á - Á Total (loss) gain from discontinued operations Á (399,798) Á 11,836,612 Á (12,748,636) Á Á Á Á Á NET (LOSS) Á (9,516,577) Á (1,247,426) Á (16,849,733) Less: net (loss) income attributable to non-controlling interest Á (57,793) Á 112,497 Á 1,331 Á NET (LOSS) ATTRIBUTABLE TO AKSO'S SHAREHOLDERS Á (9,458,784) Á (1,359,923) Á (16,851,064) Á COMPREHENSIVE (LOSS) Á Á Á Á Á Foreign currency translation adjustment Á (238,594) Á (2,198,640) Á 1,454,336 Á COMPREHENSIVE (LOSS) Á (9,575,171) Á (3,446,066) Á (15,395,397) Less: comprehensive income (loss) attributable to non-controlling interest Á 391 Á (261) Á 17 Á COMPREHENSIVE (LOSS) ATTRIBUTABLE TO AKSO'S SHAREHOLDERS Á (9,755,562) Á (3,445,805) Á (15,395,414) Á Á Á Á Á Net (loss) per share Á Á Á Á Á Continuing operations Á Á Á Á Á Basic Á (0.07) Á (0.20) Á (0.07) Diluted Á (0.07) Á (0.20) Á (0.07) Á Á Á Á Á Discontinued operations Á Á Á Á Á Basic Á \$0.18 Á \$(0.21) Diluted Á \$0.18 Á \$(0.21) Á Á Á Á Á Weighted average shares Á Á Á Á Á Basic Á 141,516,777 Á 68,598,050 Á 59,612,152 Á Diluted Á 141,516,777 Á 68,598,050 Á 59,612,152 Á The accompanying notes are an integral part of these consolidated financial statements. Á F-4 Á AKSO HEALTH GROUP AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Á Á Ordinary Shares Á Additional Treasury stock Á Á Accumulated Other Á Non- Á Á Number of Á Á Paid-in Á Number of Á Á (Accumulated Á Comprehensive Á controlling Á Á Shares Á Amount Á Capital Á Shares Á Amount Á Deficit) Á (Loss) Á Interest Á Total Á Á USD Á USD Á USD Á USD Á USD Á USD Á April 30, 2021 Á 50,016,457 Á \$5,002 Á \$60,615,048 Á (1,165,883) Á (3,988,370) Á (36,256,612) Á (3,103,543) Á \$17,271,525 Á Private placement Á 19,020,000 Á 1,902 Á 10,015,298 Á - Á - Á - Á 10,017,200 Á Share-based compensation Á - Á - Á 391,625 Á - Á - Á - Á 391,625 Á Exercise of RSUs Á 727,476 Á 73 Á (73) Á - Á - Á - Á - Á - Á - Á Capital contribution from non-controlling interest (áNCLá) Á - Á - Á - Á - Á - Á 628 Á 628 Á Net loss Á - Á - Á - Á - Á - Á - Á - Á (16,851,064) Á - Á 1,331 Á (16,849,733) Foreign currency translation adjustment Á - Á - Á - Á - Á - Á - Á 1,454,320 Á 17 Á 1,454,336 Á March 31, 2022 Á 69,763,933 Á \$6,977 Á \$71,021,898 Á (1,165,883) Á (3,988,370) Á (\$53,107,676) Á (\$1,649,223) Á \$1,976 Á \$12,285,582 Á Net (loss) income Á - Á - Á - Á - Á - Á - Á (1,359,923) Á - Á 112,497 Á (1,247,426) Foreign currency translation adjustment Á - Á - Á - Á - Á - Á - Á - Á - Á - Á (2,198,379) Á (261) Á (2,198,640) March 31, 2023 Á 69,763,933 Á \$6,977 Á \$71,021,898 Á (1,165,883) Á (3,988,370) Á (\$54,467,599) Á (\$3,847,602) Á \$114,212 Á \$8,839,516 Á Private placement Á 361,474,910 Á 36,147 Á 139,303,702 Á - Á - Á - Á - Á 139,339,849 Á Exercise of warrants Á 7,098,000 Á 710 Á (710) Á - Á - Á - Á - Á - Á - Á Net (loss) income Á - Á - Á - Á - Á - Á - Á (9,458,784) Á - Á (57,793) Á (9,516,577) Foreign currency translation adjustment Á - Á - Á - Á - Á - Á - Á (238,985) Á 391 Á (238,594) March 31, 2024 Á 438,336,843 Á \$43,834 Á \$210,324,890 Á (1,165,883) Á (3,988,370) Á (\$63,926,383) Á (\$4,086,587) Á \$56,810 Á \$138,424,194 Á The accompanying notes are an integral part of these consolidated financial statements. Á F-5 Á AKSO HEALTH GROUP AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS Á Á For the years ended March 31, Á Á 2024 Á 2023 Á Á USD Á USD Á USD Á CASH FLOWS FROM OPERATING ACTIVITIES: Á Á Á Á Á Net (loss) from continuing operations Á (9,116,779) Á (13,084,038) Á (4,101,097) Adjustments to reconcile net (loss) to net cash provided by (used in) operating activities: Á Á Á Á Á Loss from disposal of discontinued operations Á 395,914 Á - Á - Á Share-based compensation Á - Á - Á 391,625 Á Provision for doubtful accounts Á 7,369,797 Á 8,274,526 Á - Á Changes in operating assets and liabilities: Á Á Á Á Á Accounts receivable and contract assets Á 327,186 Á (8,097,742) Á - Á Prepayments and other assets Á (130,770) Á (95,151) Á (16,530) Inventories Á 1,495,248 Á 6,109,372 Á (7,795,822) Accounts payable, accrued expenses and other current liabilities Á 166,045 Á 712,885 Á 148,540 Á Contract liabilities Á 220,644 Á 194,376 Á - Á Taxes payable Á (21,914) Á 3,190 Á 92,816 Á Net cash provided by (used in) operating activities from continuing operations Á 705,371 Á (5,982,582) Á (11,280,468) Net cash provided by operating activities from discontinued operations Á 645,869 Á 2,729,242 Á 2,652,097 Á NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES Á 1,351,240 Á (3,253,340) Á (8,628,371) CASH FLOWS FROM INVESTING ACTIVITIES: Á Á Á Á Á Cash paid for loan originations Á - Á (1,528,918) Á (20,000,000) Cash received from loan repayments Á 1,528,918 Á 20,000,000 Á - Á Prepaid consideration Á (56,250,000) Á - Á - Á Net cash (used in) provided by investing activities from continuing operations Á (54,721,082) Á 18,471,082 Á (20,000,000) Net cash provided by investing activities from discontinued operations Á - Á - Á 36,140 Á NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES Á (54,721,082) Á 18,471,082 Á (19,963,860) CASH FLOWS FROM FINANCING ACTIVITIES: Á Á Á Á Á Repayments of loans due to related parties Á (7,686,152) Á (27,513,848) Á - Á Proceeds from private placement, net of offering costs Á 139,339,849 Á - Á - Á 10,017,200 Á Repayments of unsecured senior notes Á - Á - Á (10,000,000) Amounts due to (from) related parties Á - Á - Á 9,086,804 Á Net cash provided by (used in) financing activities from continuing operations Á 131,653,697 Á (27,513,848) Á 9,104,004 Á Net cash provided by financing activities from discontinued operations Á - Á - Á 25,677,113 Á NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES Á 131,653,697 Á (27,513,848) Á 9,348,117 Á EFFECT OF EXCHANGE RATE CHANGE ON CASH Á (1,272,164) Á (436,513) Á 607,717 Á NET INCREASE (DECREASE) IN CASH Á 77,011,691 Á (12,732,619) Á 6,796,603 Á CASH AND CASH EQUIVALENTS Á beginning of year Á 9,192,703 Á 21,925,322 Á 15,128,791 Á CASH AND CASH EQUIVALENTS Á end of year Á 86,204,394 Á \$9,192,703 Á 21,925,322 Á Less: cash and cash equivalents of discontinued operations at end of period Á 1,030,377 Á 1,268,235 Á 4,395,335 Á Cash and cash equivalents of continuing operations, at end of period Á \$85,174,017 Á \$7,924,468 Á \$18,429,987 Á SUPPLEMENTAL CASH FLOW DISCLOSURES: Á Á Á Á Á Cash paid for income tax Á 24,988 Á \$17,549 Á \$92,816 Á Cash paid for interest Á \$11,563 Á \$336,593 Á \$676,894 Á The accompanying notes are an integral part of these consolidated financial statements. Á F-6 Á AKSO HEALTH GROUP AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS Á Note 1 - BUSINESS DESCRIPTION Á Organization and description of business Á Akso Health Group, formerly known as Xiaobai Maimai Inc., is a limited company incorporated under the laws of the Cayman Islands on April 25, 2016. Akso Health Group (áAkso Healthá or the áCompanyá), its subsidiaries, and consolidated variable interest entities (áVIEsá) (collectively the áCompanyá), previously operated an online Peer (áP2Pá) marketplace business and micro-lending business in the People's Republic of China (the áPRCá). Since May 2019, the Company has ceased to issue new loans through its micro-lending business and since October 2019, the Company has ceased to conduct its P2P business. On December 30, 2020, the Company completed the disposition transaction of its P2P business. Á In May 2020, the Company launched its social e-

commerce platform to offer high-quality and affordable branded products through online and offline channels. The Company is in the process of developing a new business as a cancer therapy and radiotherapy oncology service provider with operations in the U.S. The Company plans to open 2 vaccine research centers and 100 radiation oncology centers to be located on the east coast serving cancer patients in need of varying stages of treatment, including specialized radiation therapy centers for radiotherapy (RT), personalized consultation, conventional treatment planning, and other cancer related treatment services. On December 3, 2021, the shareholders approved the Company's plan to change its name to "Akso Health Group". In January 2022, three centers were established in US and the Company started its business of sales of medical devices in US market. In April 2022, the Company started its sales of medical devices in China market through its subsidiary Qindao Akso Health Management Co., Ltd. In May 2023, the Company disposed its social E-commerce business and would focus on healthcare business in the future. As of March 31, 2024, the Company's principal subsidiaries are as follows:

- Date of incorporation / acquisition
- Place of incorporation
- Percentage of legal ownership
- Principal activities
- Wholly owned subsidiaries
- We Health Limited (We Health) July 8, 2021
- New York 100%
- Investment holding Akso Medical Cloud Limited (Akso Medical Cloud) November 15, 2023
- BVIA 100%
- Investment holding We Healthy Limited (We Healthy) December 15, 2021
- Hong Kong 51%
- Investment holding Akso Medi-care Limited (Akso Medi-care) December 4, 2023
- Hong Kong 100%
- Investment holding Akso Remote Medical Consultation Center Inc. (Akso Remote Medical) January 3, 2022
- Wyoming 100%
- Provision of health treatment services Akso Online MediTech Co., Ltd. (Akso Online MediTech) January 4, 2022
- Wyoming 100%
- Sales of medical devices Akso First Health Treatment Center Inc. (Akso First Health) January 4, 2022
- Massachusetts 100%
- Provision of health treatment services Tianjin Akso Enterprise Management Co., Limited. (Wholly Owned Foreign Enterprise, WOFE) January 16, 2024
- PRCA 100%
- Provision of consultancy support Qindao Akso Health Management Co., Limited. January 26, 2022
- PRCA 51%
- Provision of health treatment services F-7
- NOTE 2 - GOING CONCERN

As indicated in the accompanying consolidated financial statements, the Company had a net loss of approximately \$9.5 million for the year ended March 31, 2024 and approximately \$1.2 million for the year ended March 31, 2023. The net cash provided by operating activities from continuing operation was US\$0.7 million for the year ended March 31, 2024 and the net cash used in operating activities was US\$3.3 million for the year ended March 31, 2023. Management of the Company has considered whether there is substantial doubt about its ability to continue as a going concern due to the Company's healthcare business as well as its planned new business as a cancer therapy and radiotherapy oncology service provider, and evaluated its available cash balance against its working capital requirements and investment to the cancer centers over the next twelve months. A While management cannot accurately predict the prospects and regulatory environment of the healthcare service industry, the management believes that the Company would have sufficient funds to meet its working capital requirements for fiscal year 2025, and that its capital resources are currently sufficient to maintain its business operations for the next twelve months. A The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and/or classification of the recorded asset amounts and/or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A Basis of presentation A The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP) and have been consistently applied. Certain prior year balances in the consolidated statements of operations and comprehensive (loss) and cash flows have been reclassified to the current year's presentation. A Basis of consolidation A The accompanying consolidated financial statements include the financial statements of the Company, its subsidiaries, its consolidated VIEs and VIEs' subsidiaries for which the Company is the primary beneficiary. All inter-company transactions and balances have been eliminated upon consolidation. A Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce Business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented. Assets and liabilities of the social E-commerce business were reclassified separately from other assets and liabilities of the Company on the consolidated balance sheets. Refer to Note 1 and Note 4. A Consolidated VIEs A VIE arrangements A In order to comply with the PRC laws and regulations which prohibit or restrict foreign investments into companies involved in restricted businesses, the Company operates its marketplace and restricted businesses in the PRC through certain PRC domestic companies, whose equity interests are held by certain management members of the Company or onshore nominees of the Company (Nominee Shareholders). The Company obtained control over these PRC domestic companies by entering into a series of contractual arrangements with these PRC domestic companies and their respective Nominee Shareholders. These contractual agreements cannot be unilaterally terminated by the Nominee Shareholders or the PRC domestic companies. As a result, the Company maintains the ability to control these PRC domestic companies and is entitled to substantially all of the economic benefits from these PRC domestic companies. Management concluded that these PRC domestic companies are VIEs of the Company, of which the Company is the ultimate primary beneficiary. As such, the Company consolidated financial results of these PRC domestic companies and their subsidiaries in the Group's consolidated financial statements. The principal terms of the agreements entered into amongst the VIEs, their respective shareholders and the WOFE are further described below.

F-8 A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) A Basis of consolidation - continued A Consolidated VIEs (Continued) A Exclusive Business Cooperation Agreements A The Exclusive Business Cooperation Agreements enable the WOFE to receive substantially all of the assets and business of the VIEs in the PRC. Under these Agreements, the WOFE has the exclusive right to provide the VIEs with comprehensive technical support, consulting services and other services during the term of these Agreements, including but not limited to software licensing; development, maintenance and update of software, network systems, hardware and database; technical support and training for employees; consultancy on technology and market information; business management consultation; marketing and promotion services, etc. The WOFE has the right to determine the fees associated with the services it provides based on the technical difficulty and complexity of the services, the actual labor costs it incurs for providing the services and some other factors during the relevant period. This Agreements remain effective unless otherwise terminated in writing by WOFE. A Equity Interest Pledge Agreements A Pursuant to the Equity Interest Pledge Agreements, each Shareholder of the VIEs agreed to pledge their equity interest in the VIEs to the WOFE to secure the performance of the VIEs' obligations under the Exclusive Business Cooperation Agreements and any such agreements to be entered into in the future. Shareholders of the VIEs agreed not to transfer, sell, pledge, dispose of or otherwise create any encumbrance on their equity interests in the VIEs without the prior written consent of the WOFE. The Pledges became effective on such date when the pledge of the Equity Interest contemplated herein were registered with the relevant administration for industry and commerce (the AIC) and remain effective until all contract obligations have been fully performed and all secured indebtedness has been fully paid. A Exclusive Option Agreements A Pursuant to the Exclusive Option Agreements, each of the Shareholders of the VIE irrevocably grant the WOFE an irrevocable and exclusive right to purchase, or designate one or more persons (including individuals, corporations, partnerships, partners, enterprises, trusts or non-corporate organizations) to purchase the equity interests in the VIEs then held by such Shareholder of the VIEs once or at multiple times at any time in part or in whole at the WOFE's sole and absolute discretion to the extent permitted by Chinese laws at the price of RMB 1 or at the price of the minimum amount of consideration permitted by the applicable PRC law at the time when such purchase occurs. These three Agreements remain effective until all equity interests held by the shareholders of the VIEs in the VIEs have been transferred or assigned to the WOFE and/or its designees. A Loan Agreements A Pursuant to the three Loan Agreements, the WOFE agreed to lend each of the Shareholders of VIEs a loan only to subscribe to the registered capital of the VIEs. The repayment of the loan shall be made by permitting the WOFE to execute its exclusive right to purchase shares from the shareholders of the VIEs under the Exclusive Option Agreement as the repayment is equivalent to the consideration of the purchased shares. The term of these loans is 10A years, which may be extended upon mutual written consent of all parties. A Power of Attorney A Each Shareholder of the VIEs, executed a Power of Attorney agreement with the WOFE and the VIEs, whereby Shareholders of the VIEs irrevocably appoint and constitute the WOFE as their attorney-in-fact to exercise on the shareholders' behalf any and all rights that Shareholders of the VIEs have in respect of their equity interests in the VIEs. These three Power of Attorney documents remain irrevocable and continuously effective and valid as long as the original shareholders of the VIEs remain as the Shareholders of the VIEs.

F-9 A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) A Basis of consolidation - continued A Consolidated VIEs (Continued) A Risks in relation to the VIE structure A The Company believes that the contractual arrangements with its VIEs and their respective shareholders are in compliance with the PRC laws and regulations and are legally enforceable. However, uncertainties in the PRC legal system could limit the Company's ability to enforce the contractual arrangements. If the legal structure and contractual arrangements were found to be in violation of the PRC laws and regulations, the PRC government could:

- revoke the business and operating licenses of the Company's PRC subsidiary and VIEs;
- discontinue or restrict the operations of any related-party transactions between the Company's PRC subsidiary and VIEs;
- limit the Company's business expansion in the PRC by way of entering into contractual arrangements;
- impose fines or other requirements with which the Company's PRC subsidiary and VIEs may not be able to comply;
- require the Company or the Company's PRC subsidiary and VIEs to restructure the relevant ownership structure or operations; and/or
- restrict or prohibit the Company's use of the proceeds of the additional public offering to finance the Company's business and operations in the PRC.

A The Company's ability to conduct its Online Marketplace business may be negatively affected if the PRC government were to carry out any of the aforementioned actions. As a result, the Company may not be able to consolidate its VIEs in its consolidated financial statements as it may lose the ability to exert effective control over the VIEs and their respective shareholders and it may lose the ability to receive economic benefits from the VIEs. The Company, however, does not believe such actions would result in the liquidation or dissolution of the Company, its PRC subsidiary and VIEs. A The interests of the shareholders of VIEs may diverge from that of the Company and that may potentially increase the risk that they would seek to act contrary to the contractual terms, for example by influencing the VIEs not to pay the service fees when required to do so. The Company cannot assure that when conflicts of interest arise, shareholders of the VIEs will act in the best interests of the Company or that conflicts of interests will be resolved in the Company's favor. Currently, the Company does not have existing arrangements to address potential conflicts of interest the shareholders of the VIEs may encounter in their capacity as beneficial owners and directors of the VIEs, on the one hand, and as beneficial owners and directors of the Company, on the other hand. The Company believes the shareholders of VIEs will not act contrary to any of the contractual arrangements and the exclusive option agreements provide the Company with a mechanism to remove the current shareholders of the VIEs should they act to the detriment of the Company. The Company relies on certain current shareholders of the VIEs to fulfill their fiduciary duties and abide by laws of the PRC and act in the best interest of the Company. If the Company cannot resolve any conflicts of interest or disputes between the Company and the shareholders of the VIEs, the Company would have to rely on legal proceedings, which could result in disruption of its business, and there is substantial uncertainty as to the outcome of any such legal proceedings. A In May 2023, the Company completed the disposal of its social E-commerce business. After that, no VIEs or its subsidiaries were included in the consolidated financial statement of the Company. As a result, the Company's results of operations, revenues, costs and expenses related to the social E-commerce Business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented. Assets and liabilities of the social E-commerce business were reclassified separately from other assets and liabilities of the Company on the consolidated balance sheets. Refer to Note 1 and Note 4.

F-10 A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) A Basis of consolidation - continued A Consolidated VIEs (Continued) A The following financial statement amounts and balances of the consolidated VIEs were included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income:

As of March 31, 2024	As of March 31, 2023	USD A										
Current Assets:												
Cash and cash equivalents	678,691	A										
Accounts receivable and contract assets, net	10,062	A										
Prepayments and other assets	43,779	A										
Amounts due from related parties	26,206,288	A										
Total Current Assets	26,938,820	A										
Property, equipment and software, net	28,698	A										
Total Assets	26,967,518	A										
Current Liabilities												
Accrued expenses and other current liabilities	32,430	A										
Taxes (benefit) payable	(12,624)	A										
Total Current Liabilities	19,806	A										
Total Liabilities	19,806	A										
Year ended A Year ended A Year ended A	March 31, 2024	March 31, 2023	March 31, 2022									
USD A USD A USD A	USD A	USD A	USD A									
Net revenues	694	A	27,324	A	311,725	A	(12,479)	A	(348,806)	A	(11,527,588)	A
Year ended A Year ended A Year ended A	March 31, 2024	March 31, 2023	March 31, 2022									
USD A USD A USD A	USD A	USD A	USD A									
Net cash provided by (used in) operating activities	14,297	A	(559,973)	A	5,613,401	A	Net cash (used in) investing activities					

sale of medical devices. In May 2020, the Company launched its social e-commerce platform and built collaboration with domestic mainstream E-commerce marketplaces, which was discontinued in fiscal year 2023 and disposed in May 2023. The Company provides recommendation services by referring certain interested users to those marketplaces for high-quality and affordable branded products. Prior to business transformation, the Company through its P2P business offered online consumer lending-related service in fiscal year 2020, which was discontinued in fiscal year 2021 and disposed on December 30, 2020. The Company presents value added taxes (â€œVATâ€) as a reduction of revenues. A Revenues generated are accounted under Accounting Standards Update (ASU) 2014-09, â€œRevenue from contracts with Customersâ€ (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following steps: A Step 1: Identify the contract (s)A with a customer A Step 2: Identify the performance obligations in the contract A Step 3: Determine the transaction price A Step 4: Allocate the transaction price to the performance obligations in the contract A Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation A Online marketplace services A â€” Commission revenue A The commission services revenue primarily consists of commission fees charged to the online E-commerce marketplace for recommending users to purchase on their marketplaces, where the Company generally is acting as an agent and its performance obligation is to provide recommendation services for purchasing specified goods or services by those third-party sellers, is not responsible for fulfilling the promise to provide the specified goods or services, and does not have the ability to control the related shipping services when utilized by the third-party sellers. Upon successful sales, the Company will charge the online E-commerce companies a negotiated amount or a fixed rate commission fee based on the sales amount. Commission services revenues are recognized on a net basis at the point of receipt of products, net of a return allowance and incentives to consumers or channels. A In order to promote its online marketplace and attract more registered consumers, the Company at its own discretion offers incentives to consumers. Consumers are not customers of the Company, therefore incentives offered to consumers are not considered payments to customers. Such incentives offered to consumers were as a reward for purchasing by themselves or their sharing through our platform. Incentives provided to consumers are specific to any merchant and are recognized as a reduction of commission service revenue. For the years ended March 31, 2024, 2023, 2022, the total amount of incentives was nil, nil and US\$96,332, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income. A â€” Interest income A Started in August 2017, the Company lent funds to borrowers up to their approved credit through its consolidated VIE, and since May 2019, the Company has ceased to issue new loans through its microlending business. Interest income on loans receivable is recognized monthly based on the contractual interest rates of the loan. Accrual of interest is generally discontinued when reasonable doubt exists as to the full, timely collection of interest or principal. When a loan is discontinued from interest accrual, the Company stops accruing interest and reverses all accrued but unpaid interest as of such date. Interest income was nil, nil, US\$215,393 for the years ended March 31, 2024, 2023 and 2022, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income. A F-13 A A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES â€” (Continued) A Revenue recognition - continued A â€” Sales of medical devices A Started in February 2022, through its subsidiary Akso Online MediTech, the Company engaged in the sale of Covid-19 Antigen Rapid Tests in US market. For the years ended March 31, 2024, 2023 and 2022, revenue generated from sale of Covid-19 Antigen Rapid Tests was nil, \$9,181,274 and \$6,000,000. Akso Online MediTech purchases medical devices in quantity and distributes products primarily to medical products dealers. The deliveries may take one day or longer depending on the customersâ€™ location. Revenue from sales of merchandise to non-retail customers is recognized when the merchandise is transferred to customers. There was no sales return since the start the business. A â€” Disaggregation of revenue A All of the Companyâ€™s revenue for the years ended March 31, 2024 was generated from PRC and revenue for the year ended March 31, 2023 were generated from US and PRC, and for the year ended March 31, 2022 were generated from US. The following table illustrates the disaggregation of revenue: A A Year endedA Year endedA A Year endedA A MarchA 31, 2024A A MarchA 31, 2023A A MarchA 31, 2022A A A US\$A A US\$A A US\$A A Revenue from medical devices-USA A-A A \$9,181,274A A \$6,000,000A Revenue from medical devices-PRCA A 2,416,797A A 4,005,251A A A -A Total revenuesA A 2,416,797A A 13,186,525A A A 6,000,000A Tax and surchargesA A 2,459A A 4,964A A A -A Net RevenuesA A 2,414,338A A 13,181,561A A 6,000,000A A Cash and cash equivalentsA Cash and cash equivalents represent cash on hand, unrestricted demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash. A Accounts receivable and allowance for uncollectible accounts A Accounts receivable are mainly receivables from online E-commerce marketplaces and recommendation services, which are stated at the historical carrying amount net of allowance for uncollectible accounts. The Company establishes an allowance for uncollectible accounts receivable based on estimates, historical experience and other factors surrounding the credit risk of specific customers. Uncollectible accounts receivables are written off when a settlement is reached for an amount that is less than the outstanding historical balance or when the Company has determined that it is not probable for the balance to be collected. Beginning on April 1, 2020, the Company evaluates its accounts receivable for expected credit losses on a regular basis. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. The Company uses the length of time a balance has been outstanding, the payment history, creditworthiness and financial conditions of the customers and industry trend as credit quality indicators to monitor the Companyâ€™s receivables within the scope of expected credit losses model and use these as a basis to develop the Companyâ€™s expected loss estimates. The Company adjusts the allowance percentage periodically when there are significant differences between estimated bad debts and actual bad debts. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Company also makes a specific allowance in the period in which a loss is determined to be probable. Accounts receivable balances are written off after all collection efforts have been exhausted. As of March 31, 2024 and 2023, the allowance for uncollectible accounts receivable balance was US\$ 7,369,797 and US\$ 400,759, respectively. A Inventories A Inventories are comprised of finished goods, which are defibrillators and anesthesia laryngoscope, and are stated at the lower of cost or net realizable value using first in first out (FIFO) method. Management reviews inventories for obsolescence and cost in excess of net realizable value periodically when appropriate and records a reserve against the inventory when the carrying value exceeds net realizable value. As of March 31, 2024, the Company determined that no allowance was necessary. A F-14 A A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES â€” (Continued) A Property and equipment, net A Property and equipment are stated at cost. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives: A A Useful life Office equipment A 3-5A years A The Company eliminates the cost and related accumulated depreciation and amortization of assets sold or otherwise retired from the accounts and includes any gains or losses from disposal of property, equipment, and software in other income. The Company charges maintenance, repairs, and minor renewals directly to expense as incurred; major additions and betterments to equipment are capitalized. For the disposal of social E-commerce business, property and equipment, net was recorded in discontinued operations. A Impairment of long-lived assets A The carrying value of the long-lived assets are reviewed for impairment, whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of assets to future undiscounted net cash flows expected to be generated by the assets. Such assets are considered to be impaired if the sum of the expected undiscounted cash flows is less than carrying amount of the assets. The impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets. No impairment loss was recognized for the years ended March 31, 2024, 2023 and 2022. A Advertising and promotion expenses A The Company recognizes its advertising and promotion expenses as sales and marketing expense. Advertising expenses represent expenses for placing advertisements on television, radio and in newspapers, as well as on internet websites and search engines. Advertising and promotion costs are expensed as incurred. For the years ended MarchA 31, 2024, 2023 and 2022, the advertising and promotion expenses were US\$ 168,421, US\$ 6,661, nil, respectively. A Lease A Upon the adoption of FASB ASC 842 on April 1, 2019 using the modified retrospective method, the Company determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (â€œROUâ€) assets and operating lease liabilities, in the Companyâ€™s consolidated balance sheets. The Company does not have any finance leases as of the adoption date or March 31, 2022. A ROU represents the Companyâ€™s right to use an underlying asset for the lease term and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Companyâ€™s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which it calculates based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. A For operating lease with a term of one year or less, the Company has elected to not recognize a lease liability or lease right of use asset on its consolidated balance sheets. Instead, it recognizes the lease payment as expense on a straight-line basis over the lease term. Short-term lease costs are immaterial to its consolidated statements of operations and comprehensive (loss). The Company has operating lease agreements with insignificant non-lease components and have elected the practical expedient to combine and account for lease and non-lease components as single lease component. A F-15 A A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES â€” (Continued) A Warrants A The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (â€œFASBâ€) ASC 480 â€œDistinguishing Liabilities from Equityâ€ (â€œASC 480Aâ€) and ASC 815, Derivatives and Hedging (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common stock and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annually period end date while the warrants are outstanding. A For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations (Note 17). A Share-based compensation A Under the Amended and Restated 2016 Equity Incentive Plan, the Company grants share options to the Companyâ€™s selected employees, and directors. Awards granted to employees with service conditions attached are measured at the fair value on the grant date and are recognized as an expense using straight-line method, net of estimated forfeitures, over the requisite service period, which is generally the vesting period. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share-based compensation expense to be recognized in future periods. A Awards granted to employees with performance conditions attached are measured at fair value on the grant date and are recognized as compensation expense in the period and thereafter when the performance goal becomes probable toA achieve. Awards granted to employees with market conditions attached are measured at fair value on the grant date and are recognized as compensation expense over the estimated requisite service period, regardless of whether the market condition has been satisfied if the requisite service period isA fulfilled. A Binomial option-pricing models are adopted to measure the value of awards at each grant date or measurement date. The determination of fair value is affected by assumptions relating to a number of complex and subjective variables, including but not limited to the expected share price volatility, actual and projected employee share option exercise behavior, risk-free interest rates and expected dividends. The use of the option-pricing model requires extensive actual employee exercise behavior data for the relative probability estimation purpose, and a number of complex assumptions. A Treasury stock A Treasury stock represents ordinary shares repurchased by the Company that are no longer outstanding and are held by the Company. The repurchase of ordinary shares is accounted for under the cost method whereby the entire cost of the acquired shares are recorded as treasury stock. The cost of treasury stock is transferred to â€œadditional paid-in capitalâ€ when it is re-issued for the purpose of share options exercised and share awards. A F-16 A A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES â€” (Continued) A Income taxes A The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date. A The Company accounts for income tax under the asset and liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Under this method, deferred income taxes will be recognized if significant temporary differences between tax and financial statements occur. A valuation allowance is established against net deferred tax assets when it is more likely that some portion or all of the net deferred tax asset will not be realized. For the years ended March 31, 2024, 2023 and 2022, the Company provided a full valuation allowance on the net deferred tax assets. A The Company may be subject to challenges from taxing authorities regarding the amounts of taxes due. These challenges may alter the timing or amount of taxable income or deductions. Management determines whether the benefits of its tax positions are more-likely-than-not of being sustained upon audit based on the technical merits of the tax position. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. A An uncertain tax position is recognized as a benefit only if it is â€œmore likely than notâ€ that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. For tax positions not meeting the â€œmore likely than notâ€ test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income taxes are classified as income tax expense in the period incurred. The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measures the unrecognized benefits associated with the tax positions. As of March 31, 2024 and 2023, the Company did not have any significant unrecognized uncertain tax positions. The Company does not believe that its unrecognized tax benefits will change over the next twelve months. A Noncontrolling interests A Noncontrolling interest consists of 49% of the equity interest of We Healthy held by other investors. Excess of contribution received from noncontrolling shareholders over carrying value of the entity is recorded in additional paid in capital. The noncontrolling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Noncontrolling interests in the results of the Company are presented on the face of the consolidated statement of operations as an allocation of the total income or loss for the year between non-controlling interest holders and the shareholders of the Company. A Noncontrolling interest consist of the following: A A DecemberA 31, 2024A A DecemberA 31, 2023A A A US\$A A US\$A A We HealthyA A \$6,810A A \$114,212A A Earnings (loss) per share A The Company computes earnings per share (â€œEPSâ€) in accordance with FASB ASC 260, â€œEarnings per Shareâ€ (â€œASC 260â€). ASC 260 requires public companies with capital structures to present basic and diluted EPS. Basic EPS is measured as net income (loss) attributed to ordinary shareholders divided by the weighted average number of ordinary shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential ordinary shares (e.g., A convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., A those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. A F-17 A A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES â€” (Continued) A Foreign currency translation A The functional currency of the Company is United States Dollar. The Companyâ€™s subsidiaries with operations in mainland China, the Hong Kong Special Administrative Region of the PRC (â€œHong Kongâ€ or â€œHong Kong S.A.R.â€), the United States generally use their respective local currencies as their functional currencies. The Companyâ€™s financial statements have been translated into the reporting currency, the United States Dollar (â€œUSDâ€). Assets and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated at the average exchange rate during the reporting period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss). Transactions denominated in currencies other than functional currency are translated into the functional currency at the exchange rates quoted by authoritative banks prevailing at the dates of the transactions. Exchange gains and losses resulting from those foreign currency transactions denominated in a currency other than the functional currency are recorded in â€œother income (expense)â€ in the consolidated statements of operations and comprehensive income. The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take

place through authorized institutions. No representation is made that any RMB amounts could have been, or could be, converted, realized or settled into USD at the rates used in translation. A Spot exchange rates and average exchange rates were used in the translation of the consolidated financial statements. A A A Fiscal year 2024A A Fiscal year 2023A A Fiscal year 2022A US Exchange RateA A A A A A Year-end RMBA A 7.2203A A 6.8676A A A 6.3393A Year average RMB A 7.1671A A A 6.8516A A A 6.4180A A Significant risks and uncertainties A Foreign currency risk A RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the PeopleleA s Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. The CompanyA s cash and cash equivalents denominated in RMB amounted to US\$10,380,711 and US\$7,876,767 as at March 31, 2024 and 2023, respectively. A Concentration of credit risk A Financial instruments that potentially expose the Company to significant concentration of credit risk primarily included in the financial lines of cash and cash equivalents, accounts receivable, other receivables and prepayments and other assets. As of March 31, 2024, substantially all of the CompanyA s cash and cash equivalents were held by major financial institutions located worldwide, including mainland China and Unite State. According to the China Bank Deposit Insurance Ordinance, the deposits at each bank is covered by insurance with an upper limit of RMB 500,000 (approximately US\$69,249) at each bank. As of March 31, 2024, the total amount not covered by issuance in the PRC was US\$ 10,310,077. The Hong Kong Deposit Protection Board pays compensation up to a limit of HKD 500,000 (approximately US\$ 63,890) if the bank with which an individual/a company hold its eligible deposit fails. As of March 31, 2024, no cash balance maintained at financial institutions in Hong Kong was subject to credit risk. In the US, the insurance coverage of each bank is \$250,000. As of March 31, 2024, no cash balance maintained at financial institutions in US was subject to credit risk. If the financial institutions could become insolvent, the Company could lose some or all of the value of its investments. To limit exposure to credit risk relating to deposits, the Company primarily place cash and cash equivalent deposits with large financial institutions which management believes are of high credit quality and management also continually monitors the financial institutionsA credit worthiness. A Accounts receivable is typically unsecured and are derived from revenue earned from customers in the PRC. The risk with respect to accounts receivable is mitigated by credit evaluations the Company performs on its customers and its ongoing monitoring process of outstanding balances. A F-18 A A Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A (Continued) A Significant risks and uncertainties A (continued) A Customer concentration risk A For the year ended March 31, 2024, three customers accounted for 36.3%, 34.8% and 28.0% for the CompanyA s total revenue from sales of medical devices business. For the year ended March 31, 2023, three customers accounted for 59.5%, 11.1% and 10.1% for the CompanyA s total revenue from sales of medical devices business. For the year ended March 31, 2022, one customer accounted for 95.1% of the CompanyA s total revenues. There was no customer of the Company that accounted for more than 10% of the CompanyA s carrying amount of account receivables as of March 31, 2024 and there was one customer of the Company that accounted for 100% of the CompanyA s carrying amount of accounts receivable as of March 31 2023. A Vendor concentration risk A For the year ended March 31, 2024, one vendor accounted for 100% of the CompanyA s purchase of medical devices business. For the year ended March 31, 2023, one vendor accounted for 97.3% of the CompanyA s purchase of medical devices business. For the year ended March 31, 2022, one vendor accounted for 100% of the CompanyA s purchase of medical devices business. There was no vendor of the Company that accounted for greater than 10% of the CompanyA s carrying amount of accounts payable as of March 31, 2024 and 2023. A Recent Accounting Pronouncements A In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). ASU No. 2023-09 requires disaggregated information about a reporting entityA s effective tax rate reconciliation as well as additional information on income taxes paid. The guidance is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Company does not expect to adopt ASU No. 2023-09 early and is currently evaluating the impact of adopting this standard on its consolidated financial statements. A The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated balance sheets, consolidated statements of operations and comprehensive loss (income) and consolidated statements of cash flows. A F-19 A A NOTE 4 - DISCONTINUED OPERATION A On DecemberA 16, 2020, Beijing Hexin Yongheng Technology Development Co.,A Ltd. (AHexin YonghengA), a wholly-owned subsidiary of the Company, Kuaihangche Automobile Leasing Co.,A Ltd. (AHexinKuaihangcheA), a company not directly associated with the Company, Hexin E-Commerce Company Limited (AHexin E-CommerceA), and individual shareholders of Hexin E-Commerce entered into an assignment and assumption agreement (the AAgreementA). Pursuant to the Agreement, Hexin Yongheng agreed to assign and transfer to Kuaihangche the control over Hexin E-Commerce, in exchange for cash consideration of RMB 5 million (US\$726,781) (the ADispositionA). Upon the closing of the Disposition, Kuaihangche will become the primary beneficiary of and have control of Hexin E-Commerce, and as a result, assume all assets and liabilities of Hexin E-Commerce and subsidiaries owned or controlled by Hexin E-Commerce, excluding any rights, titles, interests or claims that Hexin E-Commerce may have in Wusu Hexin Yongheng Commercial and Trading Co.,A Ltd. (AWusu CompanyA), shall remain as a consolidated variable interest entity of the Company. As a result of the Disposition, the Company will cease to conduct its P2P business and focus on developing and investing resources into its social e-commerce platform, Xiaohai Maimai. A On May 10, 2023, Akso Health Group (the ACompanyA or the ASellerA), HX Asia Investment Limited, a British Virgin Islands company (AHX AsiaA), HX China Investment Limited, a British Virgin Islands company (AHX ChinaA), and Hexindai Hong Kong Limited, a Hong Kong company (AHexindaiA and together with HX Asia and HX China, the ATargetsA), and Umbrella Capital Investment Co., Ltd, a British Virgin Islands company which is not affiliate of the Company of any of its directors or officers (the APurchaserA) entered into certain share purchase agreement (the ADisposition SPAA). Pursuant to the Disposition SPA, the Purchaser agreed to purchase the Targets in exchange for cash consideration of US\$215,000 (the APurchase PriceA). Upon the closing of the transaction (the ADispositionA) contemplated by the Disposition SPA, the Buyer will become the sole shareholder of the Targets and as a result, assume all assets and liabilities of the Targets and subsidiaries owned or controlled by the Target. As a result of the Disposition, the Company will cease to conduct its social E-commerce business and focus on developing and investing resources into its medical devices business. A The discontinued operation represents a strategic shift that has a major effect on the CompanyA s operations and financial results, which trigger discontinued operations accounting in accordance with FASB ASC 205-40. The assets and liabilities related to the discontinued operations are classified as assets/liabilities of discontinued operations as of March 31, 2024 and 2023, while results of operations related to the discontinued operations for the years ended March 31, 2024, 2023 and 2022, were reported as income (loss) from discontinued operations. A The results of discontinued operations for years ended March 31, 2024, 2023 and 2022 are as follows: A A For the years ended March 31,A A A 2024A A 2023A A 2022A A A USDA A USDA A USDA Net RevenuesA A 694A A 24,995A A 311,092A Operating costs and developmentA A 4,551A A 1,073,518A A 12,988,383A (Loss) income from discontinued operationsA A (3,857)A A (1,048,522)A A (12,677,291) Other income (expense), netA A (27)A A 12,885,134A A (32,728) (Loss) income before taxA A (3,884)A A 11,836,612A A (12,710,019) Income tax provisionA A A A A A 38,617A Net (loss) income from discontinued operationsA A (3,884)A A 11,836,612A A (12,748,636) Loss on sale of discontinued operations, net of taxesA A (395,914)A A A A A Net income (loss) from discontinued operationA A (399,798)A A 11,836,612A A (12,748,636) A F-20 A A NOTE 4 - DISCONTINUED OPERATION A (Continued) A Assets and liabilities of the discontinued operations as of March 31, 2024 and 2023 are as follows: A A March 31,A A March 31,A A A 2024A A 2023A A A USDA A USDA A USDA Cash and cash equivalentsA A A 1,268,235A Accounts receivable, netA A A A 10,062A Prepayments and other assetsA A A A 44,004A Property, equipment and software, netA A A A 29,051A Current assets held for sale-discontinued operationA A A A 1,351,352A A A A A Accrued expenses and other current liabilitiesA A A A 737,693A Tax (benefit) payableA A A A (32,210) Amount due to related partyA A A A Total liabilities held for sale-discontinued operationA A A A 705,483A A The calculation of loss on sale of discontinued operations, net of taxes illustrated as below: A A May 19, 2023A A A USDA Cash and cash equivalentsA A 1,030,377A Accounts receivable, netA A 9,508A Prepayments and other assetsA A 241,025A Property, plant and equipment, netA A 24,998A Total assetsA A 1,305,908A A A A Account payableA A 662,648A Accrued expenses and other current liabilitiesA A 32,346A Total liabilitiesA A 694,994A A A A Net assetsA A 610,914A Consideration receivedA A 215,000A Loss on sale of discontinued operations, net of taxesA A (395,914) A Note 5 - ACCOUNTS RECEIVABLE, NET A A As ofA A As ofA A MarchA 31, 2024A A MarchA 31, 2023A A A USDA A USDA Accounts receivableA A 7,770,556A A 8,097,742A Allowance for uncollectible accounts receivableA A (7,770,556)A A (400,759) Accounts receivable, netA A A A 7,696,983A A A Note 6 - PREPAYMENTS AND OTHER ASSETS, NET A A As ofA A As ofA A MarchA 31, 2024A A MarchA 31, 2023A A A USDA A USDA A A A A Prepayments to suppliers and othersA A 409,322A A 272,129A AllowanceA A (6,423)A A A Total prepayments and other assets,netA A 402,899A A 272,129A A Note 7 - INVENTORIES A As of March 31, 2024 and 2023, inventory consisted of finished goods, which were medical devices such as defibrillators and anesthesia laryngoscope, valued at US\$191,201 and US\$ 1,686,449; respectively. The Company constantly monitors its potential obsolete products. Any loss on damaged items is immaterial and will be recognized immediately. As a result, no reserves were made for inventory for the years ended March 31, 2024, 2023. A F-21 A A Note 8 - LOAN RECEIVABLES A A As ofA A As ofA A MarchA 31, 2024A A MarchA 31, 2023A A A USDA A USDA A A A A Loan receivablesA A A A A A A A A 1,528,918A Allowance for uncollectible loan receivablesA A A A A Loan receivables, netA A A A 1,528,918A Loan receivables A currentA A A A 1,528,918A Loan receivables A non-currentA A A A A In March 2023, the Company lent a total of US\$1.5 million (RMB10.5 million) to two third party companies. The loan term for each loan was one year with an annual interest of 2%. In July 2023, the Company received the total loan principle and all accrued interests from the two third party companies. A NOTE 9 - PREPAID CONSIDERATION A In March 2024, the Company, through Tianjin Akso Enterprise Management Co., Ltd., one of its PRC subsidiaries, entered into Share Purchase Agreements (the ASPA) with four non-affiliated individual shareholders (the ASellersA) of Tianjin Wangyi Cloud Technology Co., Ltd. (the ATargetA). Pursuant to the SPA, the Company acquired 50% of the equity interest in the Target held by the four Sellers, each of which held 12.5% equity interest, respectively. The total consideration for the transaction was US\$75.0 million. As of March 31, 2024, the Company has paid US\$56.25 million, which was recorded as prepaid consideration. The transaction closed on April 15, 2024. Upon closing, Tianjin Akso Enterprise Management Co., Ltd. acquired 50% equity interest of Tianjin Wangyi Cloud Co., Ltd. At the completion of the transaction, the Company determined that no provision needed to be made for the prepaid consideration as of March 31, 2024. A NOTE 10 - RIGHT OF USE LEASE ASSETS A The Company had several operating leases for offices in the PRC. The related lease agreements do not contain any material residual value guarantees or material restrictive covenants. A Effective April 1, 2019, the Company adopted the new lease accounting standard using a modified retrospective transition method which allowed the Company not to recast comparative periods presented in its consolidated financial statements. In addition, the Company elected the package of practical expedients, which allowed the Company to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Company has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. The Company combines the lease and non-lease components in determining the ROU assets and the related lease obligation. Adoption of this standard resulted in the recording of operating lease ROU assets and corresponding operating lease liabilities as disclosed below and had no impact on our accumulated deficit as of March 31, 2020. ROU assets and related lease obligations are recognized at commencement date based on the present value of remaining lease payments over the lease term. A As of April 1, 2019, the Company recorded a ROU asset and lease liability of US\$ 2,559,646. A The CompanyA s operating leases primarily include leases for office space. The current portion of operating lease liabilities and the non-current portion of operating lease liabilities are presented on the consolidated balance sheets. For operating lease with a term of one year or less, the Company has elected to not recognize a lease liability or lease right of use asset on its consolidated balance sheets. Instead, it recognizes the lease payment as expense on a straight-line basis over the lease term. For the Social E-commerce disposal and retroactive adjustment to its financial statement, the total lease expense amounted to nil, nil, and nil for the years ended March 31, 2024, 2023 and 2022, respectively. For the year ended March 31, 2024, the Company leased premises and warehouse from third parties for free of charge. A Note 11 - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES A A As of MarchA 31, 2024A A As of MarchA 31, 2023A A A USDA A USDA Accrued payroll and benefitsA A 1,092,629A A 588,342A Professional fees, other payable and accrued expensesA A 2,733A A 245,340A Interest payableA A 9,450A A 105,085A A A 1,104,812A A 938,767A A F-22 A A Note 12 - RELATED PARTY BALANCES AND TRANSACTIONS A On August 26, 2021, the Company entered into a loan agreement with Webao Limited, the majority shareholder of the Company, for a loan of US\$2.0 million with a 0% annual interest rate. The loan term is 1 year. On August 26, 2022, both the Company and Webao Limited entered into a Deferred Repayment Agreement to extend the loan term one more year to August 27, 2023 and the annual interest rate remained 0%. On August 26, 2023, the loan agreement was extended one more year to August 27, 2024 and the annual interest rate remained 0%. As of March 31, 2024, the balance of amount due to related parties was US\$2.0 million. A On January 24, 2022, the Company entered into a loan agreement with SOS Information Technology New York, Inc. (A SOS NYA), one of our senior management was the related party of SOS Limited, for a loan of US\$35,200,000 with a 2% annual interest rate. The loan term was 1 year. For the fiscal year ended March 31, 2022, interest expense pertaining to the loan amounted to US\$127,244. On July 27, 2022, the Company and SOS NY entered into an amendment and supplemental agreement to the loan agreement, pursuant to which the Company shall make a repayment in advance to SOS NY of US\$27,513,849 of the principal amount together with all accrued but unpaid interest of US\$358,751. The Company made a payment of US\$27,872,600 for the above principal and interest on July 28, 2022. In November 2023, the Company made a payment of US\$7,686,151 of principal amount together with all accrued but unpaid interest of US\$196,681 to SOS NY. As of March 31, 2024, the outstanding balance of unpaid principal and interest was nil and nil, respectively. A Note 13 - EMPLOYEE BENEFITS A A A A A The Company has made the required employee benefit contributions in accordance with relevant rules and regulations in the PRC. Such contributions include funding for retirement insurance, unemployment insurance, medical insurance, work injury insurance, maternity insurance and housing fund. The Company recorded the contributions in salary and employee charges at specified percentages of the salaries, bonuses and certain allowances of its employees, up to a maximum amount specified by the local government. The contributions made by the Company were US\$7,390, nil and nil for the years ended MarchA 31, 2024, 2023 and 2022, respectively. A Note 14 - TAXES PAYABLE A A As of March 31, 2024A A As of March 31, 2023A A A USDA A USDA Income taxes payableA A 92,816A A 95,888A Other taxes (recovery) payableA A (18,725)A A 117A Total taxes payableA A 74,091A A 96,005A A F-23 A A Note 15 - INCOME TAXES A Cayman Islands A Akso Health was incorporated in the Cayman Islands and is not subject to income taxes or capital gain under current laws of Cayman Islands. A Hong Kong A We Healthy Limited and Akso Medi-care Limited are investment holding companies registered in Hong Kong and exempted from income tax on its foreign-derived income. A United States A The CompanyA s subsidiaries established in the U.S. are incorporated in the U.S. and is subject to both federal and state income taxes for its business operation in the U.S. The applicable tax rate is 21% for federal, 6.5% for We Health established in New York, 0% for Akso Remote Medical and Akso Online MediTech established in Wyoming and 8% for Akso First Health established in Massachusetts. All U.S. entities had no taxable income for the year ended March 31, 2024. A PRC A The CompanyA s subsidiaries established in the PRC are subject to the PRC statutory income tax rate of 25%, according to the PRC Enterprise Income Tax (A EIT lawA). A i) A The components of income tax expenses are as follows: A A Year ended MarchA 31, 2024A A Year ended MarchA 31, 2023A A Year ended MarchA 31, 2022A A A USDA A USDA CurrentA A 24,988A A 17,549A A 92,816A DeferredA A A A A A A A TotalA A 24,988A A 17,549A A 92,816A A All income taxes are related to income derived in the U.S. and PRC during the years ended March 31, 2024, 2023 and 2022. A F-24 A A Note 15 - INCOME TAXES A (Continued) A PRC A (Continued) A The net income before taxes for the PRC entities was US\$83,103, US\$ 165,429 and US\$ 2,717 for the years ended MarchA 31, 2024, 2023 and 2022, respectively. The net (loss) income before taxes for the U.S. entities was US\$(3,366,893), US\$ 634,709 and US\$441,981 for the years ended MarchA 31, 2024, 2023 and 2022, respectively. A The following table reconciles the PRC statutory rates to the CompanyA s effective tax rate for the years ended MarchA 31, 2024, 2023 and 2022. A A Year ended MarchA 31, 2024A A Year ended MarchA 31, 2023A A Year ended MarchA 31, 2022A PRC Income tax statutory rateA A (25.0)%A A (25.0)%A A (25)% Effect of tax holiday and preferential tax rateA A 4.0)% A 4.0)% A 4.0A Non-deductible foreign lossesA A 5.8)% A 0.7)% A 19.5% Change in valuation allowanceA A 20.3)% A 24.8)% A 0.8% Non-deductible expenses and othersA A (5.4)%A A (4.6)%A A -% Effective tax rateA A (0.3)%A A (0.1)%A A (2.3)% A A According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of income taxes is due to computational errors made by the taxpayer. The statute of limitations will be extended to five years under special circumstances, which are not clearly defined, but an underpayment of income tax liability exceeding US\$15,263 (RMB 100,000) is specifically listed as a special circumstance. In the case of a transfer pricing related adjustment, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. A Aggregate undistributed earnings of the CompanyA s PRC subsidiaries that are available for distribution was approximately negative US\$124,358 and US\$232,059 as of March 31, 2024 and 2023, respectively. A In accordance with the EIT Law, dividends, which

arise from profits of foreign invested enterprises (the “PTIE”) earned after January 1, 2008, are subject to a 10% withholding income tax. In addition, under the tax treaty between the PRC and Hong Kong, if the foreign investor is incorporated in Hong Kong and qualifies as the beneficial owner, the applicable withholding tax rate is reduced to 5%, if the investor holds at least 25% in the FIE, or 10%, if the investor holds less than 25% in the FIE. On July 19, 2018, the board of directors approved an annual dividend policy. Under this policy, annual dividends will be set at an amount equivalent to approximately 15-25% of the Company’s anticipated net income after tax in each year commencing from fiscal year ended March 31, 2019, which will be derived from the earnings of the Company’s PRC entities. The board of directors did not declare any annual dividend for the fiscal years ended March 31, 2024, 2023 and 2022. A deferred tax liability should be recognized for the undistributed profits of PRC subsidiaries unless the Company has sufficient evidence to demonstrate that the undistributed dividends will be reinvested and the remittance of the dividends will be postponed indefinitely. The Company plans to indefinitely reinvest undistributed profits earned from its China subsidiaries in its operations in the PRC. Therefore, no withholding income taxes for undistributed profits of the Company’s subsidiaries have been provided as of March 31, 2024 and 2023. Under applicable accounting principles, a deferred tax liability should be recorded for taxable temporary differences attributable to the excess of the financial reporting basis over the tax basis in a domestic subsidiary. However, recognition is not required in situations where the tax law provides a means by which the reported amount of that investment can be recovered tax-free and the enterprise expects that it will ultimately use that means. The Company completed its feasibility analysis on a method, which the Company will ultimately execute if necessary to repatriate the undistributed earnings of the subsidiary without significant tax costs. As such, the Company does not accrue deferred tax liabilities on the earnings of the subsidiary given that the Company will ultimately use the means.

F-25 A Note 16 - EARNINGS (LOSS) PER SHARE A Basic earnings (loss) per share is the amount of net earnings available to each share of ordinary shares outstanding during the reporting period. Diluted EPS is the amount of net earnings available to each share of ordinary shares outstanding during the reporting period adjusted to include the effect of potentially dilutive ordinary shares. The following table details the outstanding shares for basic and diluted net earnings per share: A Year ended March 31, 2024A Year ended March 31, 2023A Year ended March 31, 2022A A USD\$ A USD\$ A USD\$ Numerator: A Net loss from continuing operation attributable to Akso Health Group’s shareholders A Net loss from continuing operation attributable to Akso Health Group’s shareholders A (9,058,986) A (13,196,535) A (4,102,428) Net income (loss) from discontinued operation attributable to Akso Health Group’s shareholders A (399,798) A 11,836,612A (12,748,636) Net loss attributable to Akso Health Group’s shareholders A (9,458,784) A (1,359,923) A (16,851,064) A Denominator: A Weighted average number of ordinary shares outstanding-basic A 141,516,777A 68,598,050A 59,612,152A Weighted average number of dilutive potential ordinary shares from share options A A A Weighted average number of ordinary shares outstanding-diluted A 141,516,777A 68,598,050A 59,612,152A Basic (loss) per common share A (0.07) A (0.02) A (0.28) Diluted (loss) per common share A (0.07) A (0.02) A (0.28) A Note 17 - SHAREHOLDERS’ EQUITY A Akso Health was established under the laws of the Cayman Islands on April 25, 2016. The authorized number of ordinary shares is 500,000,000 shares with par value of US\$0.0001 each. On August 24, 2020, the Company amended the ratio of ADS representing its ordinary shares from one (1) ADS representing one (1) ordinary share to one (1) ADS representing three (3) ordinary shares. The change in the ADS ratio has the same effect as a one-for-three reverse ADS split. There was no change to our ordinary shares in connection with the change of the ADS ratio. On June 19, 2023, the Company increased its authorized shares from US\$50,000 divided into 500,000,000 ordinary shares of a par value of US\$0.0001 each to US\$500,000 divided into 5,000,000,000 ordinary shares of a par value of US\$0.0001 by the creation of an additional 4,500,000,000 ordinary shares of a par value of US\$0.0001. As of March 31, 2024 and 2023, the Company’s outstanding ordinary shares were 437,170,960 and 68,598,050, respectively. A Private Placement A On August 9, 2021, the Company entered into a certain securities purchase agreement (the “SPA”) with certain non-U.S. Persons pursuant to which the Company agreed to sell an aggregate of 6,340,000 units at a price of US\$1.58 per unit, each unit consisting of three ordinary shares of the Company, par value \$0.0001 per share (the “Share”) and a warrant to purchase three Shares with an initial exercise price of US\$3.00, for an aggregate purchase price of approximately US\$10.02 million (the “Offering”). On September 17, 2021, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$10.0 million from such Offering will be used by the Company for working capital and general corporate purposes. The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$3.00, or for cash (the “Warrant Shares”). The Warrants may also be exercised on a cashless basis if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions. During the year ended March 31, 2024, a total of 3,380,000 warrants (each warrant to purchase 3 ordinary shares) were exercised on cashless basis, resulting issuance of 7,098,000 ordinary shares. A Note 17 - SHAREHOLDERS’ EQUITY (Continued) A On October 2, 2023, the Company entered into a certain securities purchase agreement (the “SPA”) with certain non-U.S. Persons pursuant to which the Company agreed to sell an aggregate of 35,739,270 units at a price of US\$0.391 per unit, each unit consisting of one ordinary shares of the Company, par value \$0.0001 per share (the “Share”) and a warrant to purchase one Share with an initial exercise price of US\$0.48875, for an aggregate purchase price of approximately US\$14.0 million (the “Offering”). On October 17, 2023, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$14.0 million from such Offering will be used by the Company for working capital and general corporate purposes. The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.48875, or approximately \$1.47 per ADS, for cash (the “Warrant Shares”). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions. A On November 16, 2023, the Company entered into a certain securities purchase agreement (the “SPA”) with certain non-U.S. Persons pursuant to which the Company agreed to sell an aggregate of 53,608,910 units at a price of US\$0.423 per unit, each unit consisting of one ordinary shares of the Company, par value \$0.0001 per share (the “Share”) and a warrant to purchase one Share with an initial exercise price of US\$0.52875, for an aggregate purchase price of approximately US\$22.68 million (the “Offering”). On November 21, 2023, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$22.68 million from such Offering will be used by the Company for working capital and general corporate purposes. A The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.52875, or approximately \$1.59 per ADS, for cash (the “Warrant Shares”). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions. A On January 17, 2024, the Company entered into a certain securities purchase agreement (the “SPA”) with certain non-U.S. Persons pursuant to which the Company agreed to sell an aggregate of 160,826,730 units at a price of US\$0.3317 per unit, each unit consisting of one ordinary shares of the Company, par value \$0.0001 per share (the “Share”) and a warrant to purchase one Share with an initial exercise price of US\$0.4146, for an aggregate purchase price of approximately US\$53.35 million (the “Offering”). On January 26, 2024, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$53.35 million from such offering will be used by the Company for working capital and general corporate purposes. A The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.4146, or approximately \$1.2438 per ADS, for cash (the “Warrant Shares”). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions. A On March 5, 2024, the Company entered into a certain securities purchase agreement (the “SPA”) with certain non-affiliated institutional investors (the “Purchasers”) pursuant to which the Company agreed to sell an aggregate of 37,100,000 of its American Depositary Shares (“ADS”) representing 111,300,000 ordinary shares, par value \$0.0001 per share (the “Ordinary Shares”), in a registered direct offering, and warrants (the “Warrants”) to purchase 222,600,000 Ordinary Shares in a concurrent private placement for gross proceeds of approximately \$49.34 million (the “Offering”). A The warrants are exercisable immediately as of the date of issuance at an exercise price of \$0.4933 per ordinary share, or \$1.48 per ADS and expire five years from the date of issuance. The purchase price for each ADS and the corresponding Warrants is \$1.33. Each Warrant is subject to anti-dilution provisions to reflect stock dividends and splits, subsequent rights offerings or other similar transactions, but not as a result of future securities offerings at lower prices. Upon the occurrence of a Fundamental Transaction (as defined in the Warrants), the Warrants are subject to mandatory redemption for cash consideration equal to the Black Scholes Value (as defined in the Warrants) of such portion of such Warrant to be redeemed. The Company intended to use the net proceeds from the Offering for working capital and general corporate use. The Offering closed on March 7, 2024. A F-27 A Note 17 - SHAREHOLDERS’ EQUITY (Continued) A Warrants A As the warrants contained in the placement above are indexed to the Company’s ordinary share (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Warrants as additional paid-in capital on the Company’s consolidated balance sheet. The Company accounts for the warrants issued in connection with the private placement in accordance with the guidance contained in ASC 815-40. The Company’s management has examined the warrants and determined that these warrants qualify for equity treatment in the Company’s financial statements. A The warrants contained in the private placements above shall expire five years from its date of issuance. The warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions. A During the year ended March 31, 2024, 3,380,000 warrants were exercised on cashless basis, leading to an insurance of 7,098,000 ordinary shares. During the year ended March 31, 2023, no warrants were exercised. A As of March 31, 2024, the Company had 290,234,910 warrants outstanding to purchase 481,654,910 ordinary shares with weighted average exercise price of US\$ 0.48 per warrant. As of March 31, 2023, the Company had 6,340,000 warrants outstanding to purchase 19,020,000 ordinary shares. A Following is a summary of the status of warrants outstanding and exercisable as of March 31, 2024: A Warrants A Weighted Average Exercise Price A Aggregate Intrinsic Value A Warrants outstanding, as of March 31, 2022 A \$0.42 A \$0.42 A Issued A 6,340,000 A \$3.00 A Exercised A \$0.42 A Expired A \$0.42 A A Warrants outstanding, as of March 31, 2023 A 6,340,000 A \$3.00 A A Issued A 287,274,910 A 0.46 A Exercised A 3,380,000 A A A A \$0.42 A A A Expired A \$0.42 A A Warrants outstanding, as of March 31, 2024 A 290,234,910 A 0.48 A A Warrants exercisable in ordinary shares A Weighted Average Exercise Price A Average Remaining Contractual Life August 9, 2021 warrants A 8,880,000 A \$1.00 A 2.4 years October 2, 2023 warrants A 35,739,270 A 0.4888 A 4.6 years November 16, 2023 warrants A 53,608,910 A 0.5288 A 4.7 years January 17, 2024 warrants A 160,826,730 A 0.4146 A 4.8 years March 5, 2024 warrants A 222,600,000 A 0.4933 A 4.9 years A Note 18 - TREASURY STOCK A On December 10, 2018, the Company announced that its board of directors authorized a share repurchase program under which the Company may repurchase up to US\$25 million of its ordinary shares in the form of American depositary shares (“ADS”) over the next 12 months. The Company repurchased an aggregate of 1,165,883 ADSs from the open market for a total consideration of US\$3,988,370, which was recorded as treasury stock. A F-28 A Note 19 - RESTRICTED NET ASSETS A Restricted Net Assets A As a result of the PRC laws and regulations and the requirement that distributions by the PRC entities can only be paid out of distributable profits computed in accordance with the PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Company. The restricted net assets consist of paid in capital, capital reserve and statutory reserves of the Company’s PRC entities. As of March 31, 2024 and 2023

of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the most recent fiscal year were transferred to the parent company by subsidiaries in the form of loans, advances, or cash dividends without the consent of a third party. The condensed parent company financial statements have been prepared in accordance with RuleA 12-04, ScheduleA I of Regulation S-X as the restricted net assets of the Companyâ€™s PRC subsidiaries and VIEs exceed 25% of the consolidated net assets of the Company. A The condensed financial information of the parent company has been prepared in accordance with SEC Regulation S-X Rule 5-04 and Rule 12-04, using the same accounting policies as set out in the Companyâ€™s consolidated financial statements, except that the Company uses the equity method to account for investments in its subsidiaries, VIEs and VIEsâ€™ subsidiaries. The footnote disclosures generally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. The footnote disclosures contain supplemental information relating to the operations of the Company, as such, these statements are not the general-purpose financial statements of the reporting entity and should be read in conjunction with the notes to the consolidated financial statements of the Company. A CONDENSED BALANCE SHEETS A A As of MarchA 31 2024A A As of MarchA 31 2023A A USD\$A USD\$ ASSETS:A A A A A CashA \$ 2,279A A A 4,472A Prepayment and other assetsA \$ A A A A A 5,795A Investments in subsidiaries, VIEs and VIEsâ€™ subsidiariesA \$ 141,456,064A A \$ 11,303,978A TOTAL ASSETS\$ 141,458,343A A \$ 11,314,245A A A A A A LIABILITIES:A A A A A Accrued expenses and other current liabilitiesA \$ 1,090,959A A \$ 588,941A Due to related partyA \$ 2,000,000A A \$ 2,000,000A TOTAL LIABILITIES\$ 3,090,959A A \$ 2,588,941A A A A A A SHAREHOLDERSâ€™ EQUITY:A A A A A Ordinary share (\$0.0001 par value, 5,000,000 shares authorized, 438,336,843 and 69,763,933 shares issued, 437,170,960 and 68,598,050 shares outstanding as of March 31, 2024 and 2023, respectively)A \$ 43,834A A \$ 6,977A Additional paid-in capitalA \$ 210,324,890A A \$ 71,021,898A Treasury stockA \$ (3,988,370)A A \$ (3,988,370) Accumulated deficitA \$ (63,926,383)A A \$ (54,467,600) Accumulated other comprehensive lossA \$ (4,086,587)A A \$ (3,847,601) TOTAL SHAREHOLDERSâ€™ EQUITYA \$ 138,367,384A A \$ 8,725,304A TOTAL LIABILITIES AND SHEREHOLDERSâ€™ EQUITYA \$ 141,458,343A A \$ 11,314,245A F-30 A A AKSO HEALTH GROUP INC. AND SUBSIDIARIES Schedule I - CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY (Continued) A CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME A A Years Ended MarchA 31 A A 2024A A 2023A A USD\$A USD\$ Equity in (loss) earnings of subsidiariesA \$ (7,394,438)A A \$ (1,086,999)A A \$ (13,720,643) General administrative expense and othersA \$ (2,122,139)A A \$ (160,427)A A \$ (3,129,090) NET (LOSS)A \$ (9,516,577)A A \$ (1,247,426)A A \$ (16,849,733) A A A A A OTHER COMPREHENSIVE INCOME (LOSS)A A A A A Foreign currency translation adjustmentA \$ (238,985)A A \$ (2,198,379)A A \$ 1,454,319A COMPREHENSIVE (LOSS)A \$ (9,755,562)A A \$ (3,445,805)A A CONDENSED STATEMENTS OF CASH FLOWS A A For The Years Ended MarchA 31 A A 2024A A 2023A A USD\$A USD\$ CASH FLOWS FROM OPERATING ACTIVITIES:A A A A A Net (loss)A \$ (9,516,577)A A \$ (1,247,426)A A \$ (16,851,064) Adjustments to reconcile net income to net cash provided by (used in) operating activities:A A A A A Provision for doubts accountsA \$ 5,795A A A A A Equity in loss of subsidiariesA \$ 7,394,438A A \$ 1,147,003A A \$ 13,721,974 Share-based compensationA A A A A \$ 391,625A Changes in operating assets and liabilitiesA A A A A A A A A A A Prepayments and other assetsA A A A A \$ 154,654A Accrued expenses and other current liabilitiesA \$ 502,018A A \$ 528,266A A \$ 101,207A Interest payments on unsecured senior notes and short-term bank loanA A A A A \$ (676,894) NET CASH (USED IN) OPERATING ACTIVITIESA \$ (1,614,326)A A \$ 427,843A A \$ (3,158,498) A A A A A CASH FLOWS FROM FINANCING ACTIVITIES:A A A A A Proceeds from private placement offering, net of offering costsA \$ 139,339,849A A A A A \$ 10,017,200A Principal payments on unsecured senior notesA A A A A \$ (10,000,000) Loan to subsidiaries, VIEs and VIEsâ€™ subsidiariesA \$ (137,727,716)A A \$ (427,862)A A \$ (337,695) Proceeds from related partyA A A A A \$ 2,000,000A NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIESA \$ 1,612,133A A \$ (427,862)A A \$ 1,679,505A NET (DECREASE) IN CASH A A \$ (2,193)A A \$ (19)A A \$ (1,478,993) CASH-beginning of yearA \$ 4,472A A \$ 4,491A A \$ 1,483,484A CASH-end of yearA \$ 2,279A A \$ 4,472A A \$ 4,491A SUPPLEMENTAL CASH FLOW DISCLOSURES:A A A A A Cash paid for income tax A \$ 24,988A A \$ 17,549A A \$ 92,816A Cash paid for interestA \$ 111,563A A \$ 336,593A A \$ 676,894A F-31 A A AKSO HEALTH GROUP INC. AND SUBSIDIARIES Schedule I - CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY (Continued) A Notes to condensed financial statements A 1.Akso Health, formerly known as Xiaobai Maimai Inc., was founded on AprilA 25, 2016 in the Cayman Islands. The condensed full year results of the Company have been prepared assuming the Reorganization (see Note 1 in the consolidated financial statements) was in effect from November 1, 2016. A 2. The condensed financial statements of Akso Health have been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in subsidiaries, VIEs and subsidiaries of VIEs. Such investment in subsidiaries and VIEs are presented on the balance sheets as interests in subsidiaries and VIEs and the income (loss) of the subsidiaries and VIEs is presented as equity in (loss) earnings of subsidiaries and VIEs on the statement of operations. A 3. As of March 31, 2023 and 2022, there were no material contingencies, significant provisions of long-term obligations of the Company, except for those which have been separately disclosed in the consolidated financial statements. A 4. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The notes to consolidated financial statements disclosed certain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the accompanying Consolidated Financial Statements. A F-32 A A 500000000 500000000 PIY false FY 10020 10020

0001702318	true	0001702318	2023-04-01	2024-03-31	0001702318	dei:BusinessContactMember	2023-04-01	2024-03-31	0001702318
ahg:	AmericanDepositaryShares	AmericanDepositaryShareRepresentingThreeOrdinarySharesParValueUS000001PerShareMember	2023-04-01	2024-03-31	0001702318				
ahg:	OrdinarySharesParValueUS000001PerShareMember	2023-04-01	2024-03-31	0001702318	2023-03-31	0001702318	us-gaap:RelatedPartyMember	2024-03-31	0001702318
0001702318	us-gaap:RelatedPartyMember	2023-03-31	0001702318	ahg:	SaleOfMedicalDevicesMember	2023-04-01	2024-03-31	0001702318	ahg:SaleOfMedicalDevicesMember
2022-04-01	2023-03-31	0001702318	ahg:	SaleOfMedicalDevicesMember	2022-04-01	2023-03-31	0001702318	ahg:	TaxAndSurchargesMember
2022-04-01	2023-03-31	0001702318	ahg:	TaxAndSurchargesMember	2022-04-01	2023-03-31	0001702318	2022-04-01	2023-03-31
0001702318	2021-04-01	2022-03-31	0001702318	2021-04-01	2022-03-31	0001702318	2021-04-01	2022-03-31	0001702318
2021-04-01	2022-03-31	0001702318	2021-04-01	2022-03-31	0001702318	2021-04-01	2022-03-31	0001702318	2021-04-01
2022-03-31	0001702318	us-gaap:CommonStockMember	2021-04-30	0001702318	us-gaap:AdditionalPaidInCapitalMember	2021-04-30	0001702318	us-gaap:TreasuryStockCommonMember	2021-04-30
0001702318	us-gaap:RetainedEarningsMember	2021-04-30	0001702318	us-gaap:AccumulatedOtherComprehensiveIncomeMember	2021-04-30	0001702318	us-gaap:NoncontrollingInterestMember	2021-04-30	0001702318
us-gaap:AdditionalPaidInCapitalMember	2021-05-01	2022-03-31	0001702318	us-gaap:TreasuryStockCommonMember	2021-05-01	2022-03-31	0001702318	us-gaap:RetainedEarningsMember	2021-05-01
2022-03-31	0001702318	us-gaap:AccumulatedOtherComprehensiveIncomeMember	2021-05-01	2022-03-31	0001702318	us-gaap:NoncontrollingInterestMember	2021-05-01	2022-03-31	0001702318

[illegible]

the other. The Company may also pay such brokerage as may be lawful on any issue of Shares. 8 A 11. The Directors may refuse to accept any application for Shares, and may accept any application in whole or in part, for any reason or for no reason. A CLASS A ORDINARY SHARES AND CLASS B ORDINARY SHARES 12. Holders of Class A Ordinary Shares and Class B Ordinary Shares shall at all times vote together as one class on all resolutions submitted to a vote by the Members. Each Class A Ordinary Share shall entitle the holder thereof to one (1) vote on all matters subject to vote at general meetings of the Company, and each Class B Ordinary Share shall entitle the holder thereof to twenty (20) votes on all matters subject to vote at general meetings of the Company. 13. Each Class B Ordinary Share is convertible into one (1) Class A Ordinary Share at any time at the option of the holder thereof. The right to convert shall be exercisable by the holder of the Class B Ordinary Share delivering a written notice to the Company that such holder elects to convert a specified number of Class B Ordinary Shares into Class A Ordinary Shares. In no event shall Class A Ordinary Shares be convertible into Class B Ordinary Shares. 14. Any conversion of Class B Ordinary Shares into Class A Ordinary Shares pursuant to these Articles shall be effected by means of the re-designation of each relevant Class B Ordinary Share as a Class A Ordinary Share. Such conversion shall become effective (i) in the case of any conversion effected pursuant to Article 13, forthwith upon the receipt by the Company of the written notice delivered to the Company as described in Article 13 (or at such later date as may be specified in such notice), or (ii) in the case of any automatic conversion effected pursuant to Article 15, forthwith upon occurrence of the event specified in Article 15 which triggers such automatic conversion, and the Company shall make entries in the Register to record the re-designation of the relevant Class B Ordinary Shares as Class A Ordinary Shares. 15. Upon any direct or indirect sale, transfer, assignment or disposition of the legal and beneficial title to any Class B Ordinary Share by the holder thereof or the direct or indirect transfer or assignment of the voting power attached to such number of Class B Ordinary Shares through voting proxy or otherwise to any person that is neither an Affiliate of such holder nor another holder of Class B Ordinary Shares or an Affiliate of such another holder, such Class B Ordinary Share shall be automatically and immediately converted into the same number of Class A Ordinary Share. For the avoidance of doubt, (i) a sale, transfer, assignment or disposition shall be effective upon the Company's registration of such sale, transfer, assignment or disposition in its Register; and (ii) the creation of any pledge, charge, encumbrance or other third party right of whatever description on any Class B Ordinary Shares to secure a holder's contractual or legal obligations shall not be deemed as a sale, transfer, assignment or disposition, or a change of ultimate beneficial ownership, unless and until any such pledge, charge, encumbrance or other third party right is enforced and results in the third party holding legal title to the relevant Class B Ordinary Shares, in which case all the related Class B Ordinary Shares shall be automatically converted into the same number of Class A Ordinary Shares. For the purposes of this Article 15, beneficial ownership shall have the meaning set forth in Rule 13d-3 under the United States Securities Exchange Act of 1934, as amended. 9 A 16. Save and except for voting rights and conversion rights as set out in Articles 12 to 15 (inclusive), the Class A Ordinary Shares and the Class B Ordinary Shares shall rank *pari passu* with one another and shall have the same rights, preferences, privileges and restrictions. A MODIFICATION OF RIGHTS 17. If at any time the capital of the Company is divided into different Classes, all or any of the rights attached to any such Class may, subject to any rights or restrictions for the time being attached to any Class, varied with the consent in writing of two-thirds of the holders of the issued Shares of that Class or with the sanction of a Special Resolution passed at a separate meeting of the holders of the Shares of that Class. To every such separate meeting all the provisions of these Articles relating to general meetings of the Company or to the proceedings thereat shall, *mutatis mutandis*, apply, except that the necessary quorum shall be one or more Persons holding or representing by proxy at least one-third (1/3) in nominal or par value amount of the issued Shares of the relevant Class (but so that if at any adjourned meeting of such holders a quorum as above defined is not Present, those Shareholders who are Present shall form a quorum) and that, subject to any rights or restrictions for the time being attached to the Shares of that Class, every Shareholder of the Class shall on a poll have one vote for each Share of the Class held by him. For the purposes of this Article the Directors may treat all the Classes or any two or more Classes as forming one Class if they consider that all such Classes would be affected in the same way by the proposals under consideration, but in any other case shall treat them as separate Classes. 18. The rights conferred upon the holders of the Shares of any Class issued with preferred or other rights shall not, subject to any rights or restrictions for the time being attached to the Shares of that Class, be deemed to be varied by, *inter alia*, the creation, allotment or issue of further Shares ranking *pari passu* with or subsequent to the Shares of that Class or the redemption or purchase of any Shares of any Class by the Company. The rights of the holders of Shares shall not be deemed to be varied by the creation or issue of Shares with preferred or other rights including, without limitation, the creation of Shares with enhanced or weighted voting rights. A CERTIFICATES 19. Every Person whose name is entered as a Member in the Register may, without payment and upon its written request, request a certificate within two calendar months after allotment or lodgment of transfer (or within such other period as the conditions of issue shall provide) in the form determined by the Directors. All certificates shall specify the Share or Shares held by that Person, provided that in respect of a Share or Shares held jointly by several Persons the Company shall not be bound to issue more than one certificate, and delivery of a certificate for a Share to one of several joint holders shall be sufficient delivery to all. All certificates for Shares shall be delivered personally or sent through the post addressed to the Member entitled thereto at the Members registered address as appearing in the Register. 10 A 20. Every share certificate of the Company shall bear legends required under the applicable laws, including the Securities Act. 21. Any two or more certificates representing Shares of any one Class held by any Member may at the Member's request be cancelled and a single new certificate for such Shares issued in lieu on payment (if the Directors shall so require) of one dollar (US\$1.00) or such smaller sum as the Directors shall determine. 22. If a share certificate shall be damaged or defaced or alleged to have been lost, stolen or destroyed, a new certificate representing the same Shares may be issued to the relevant Member upon request, subject to delivery up of the old certificate or (if alleged to have been lost, stolen or destroyed) compliance with such conditions as to evidence and indemnity and the payment of out-of-pocket expenses of the Company in connection with the request as the Directors may think fit. 23. In the event that Shares are held jointly by several Persons, any request may be made by any one of the joint holders and if so made shall be binding on all of the joint holders. A FRACTIONAL SHARES 24. The Directors may issue fractions of a Share and, if so issued, a fraction of a Share shall be subject to and carry the corresponding fraction of liabilities (whether with respect to nominal or par value, premium, contributions, calls or otherwise), limitations, preferences, privileges, qualifications, restrictions, rights (including, without prejudice to the generality of the foregoing, voting and participation rights) and other attributes of a whole Share. If more than one fraction of a Share of the same Class is issued to or acquired by the same Shareholder such fractions shall be accumulated. A LIEN 25. The Company has a first and paramount lien on every Share (whether or not fully paid) for all amounts (whether presently payable or not) payable at a fixed time or called in respect of that Share. The Company also has a first and paramount lien on every Share registered in the name of a Person indebted or under liability to the Company (whether he is the sole registered holder of a Share or one of two or more joint holders) for all amounts owing by him or his estate to the Company (whether or not presently payable). The Directors may at any time declare a Share to be wholly or in part exempt from the provisions of this Article. The Company's lien on a Share extends to any amount payable in respect of it, including but not limited to dividends. 26. The Company may sell, in such manner as the Directors in their absolute discretion think fit, any Share on which the Company has a lien, but no sale shall be made unless an amount in respect of which the lien exists is presently payable nor until the expiration of fourteen (14) calendar days after a notice in writing, demanding payment of such part of the amount in respect of which the lien exists as is presently payable, has been given to the registered holder for the time being of the Share, or the Persons entitled thereto by reason of his death or bankruptcy. 27. For giving effect to any such sale the Directors may authorise a Person to transfer the Shares sold to the purchaser thereof. The purchaser shall be registered as the holder of the Shares comprised in any such transfer and he shall not be bound to see to the application of the purchase money, nor shall his title to the Shares be affected by any irregularity or invalidity in the proceedings in reference to the sale. 11 A 28. The proceeds of the sale after deduction of expenses, fees and commission incurred by the Company shall be received by the Company and applied in payment of such part of the amount in respect of which the lien exists as is presently payable, and the residue shall (subject to a like lien for sums not presently payable as existed upon the Shares prior to the sale) be paid to the Person entitled to the Shares immediately prior to the sale. A CALLS ON SHARES 29. Subject to the terms of the allotment, the Directors may from time to time make calls upon the Shareholders in respect of any moneys unpaid on their Shares, and each Shareholder shall (subject to receiving at least fourteen (14) calendar days' notice specifying the time or times of payment) pay to the Company at the time or times so specified the amount called on such Shares. A call shall be deemed to have been made at the time when the resolution of the Directors authorising such call was passed. 30. The joint holders of a Share shall be jointly and severally liable to pay calls in respect thereof. 31. If a sum called in respect of a Share is not paid before or on the day appointed for payment thereof, the Person from whom the sum is due shall pay interest upon the sum at the rate of eight percent per annum from the day appointed for the payment thereof to the time of the actual payment, but the Directors shall be at liberty to waive payment of that interest wholly or in part. 32. The provisions of these Articles as to the liability of joint holders and as to payment of interest shall apply in the case of non-payment of any sum which, by the terms of issue of a Share, becomes payable at a fixed time, whether on account of the amount of the Share, or by way of premium, as if the same had become payable by virtue of a call duly made and notified. 33. The Directors may make arrangements with respect to the issue of partly paid Shares for a difference between the Shareholders, or the particular Shares, in the amount of calls to be paid and in the times of payment. 34. The Directors may, if they think fit, receive from any Shareholder willing to advance the same all or any part of the moneys uncalled and unpaid upon any partly paid Shares held by him, and upon all or any of the moneys so advanced may (until the same would, but for such advance, become presently payable) pay interest at such rate (not exceeding without the sanction of an Ordinary Resolution, eight percent per annum) as may be agreed upon between the Shareholder paying the sum in advance and the Directors. No such sum paid in advance of calls shall entitle the Member paying such sum to any portion of a dividend declared in respect of any period prior to the date upon which such sum would, but for such payment, become presently payable. 12 A 35. If a Shareholder fails to pay any call or instalment of a call in respect of partly paid Shares on the day appointed for payment, the Directors may, at any time thereafter during such time as any part of such call or instalment remains unpaid, serve a notice on him requiring payment of so much of the call or instalment as is unpaid, together with any interest which may have accrued. 36. The notice shall name a further day (not earlier than the expiration of fourteen (14) calendar days from the date of the notice) on or before which the payment required by the notice is to be made, and shall state that in the event of non-payment at or before the time appointed, the Shares in respect of which the call was made will be liable to be forfeited. 37. If the requirements of any such notice as aforesaid are not complied with, any Share in respect of which the notice has been given may at any time thereafter, before the payment required by notice has been made, be forfeited by a resolution of the Directors to that effect. 38. A forfeited Share may be sold or otherwise disposed of on such terms and in such manner as the Directors think fit, and at any time before a sale or disposition the forfeiture may be cancelled on such terms as the Directors think fit. 39. A Person whose Shares have been forfeited shall cease to be a Shareholder in respect of the forfeited Shares, but shall, notwithstanding, remain liable to pay to the Company all moneys which at the date of forfeiture were payable by him to the Company in respect of the Shares forfeited, but his liability shall cease if and when the Company receives payment in full of the amount unpaid on the Shares forfeited. 40. A certificate in writing under the hand of a Director that a Share has been duly forfeited on a date stated in the certificate shall be conclusive evidence of the facts in the declaration as against all Persons claiming to be entitled to the Share. 41. The Company may receive the consideration, if any, given for a Share on any sale or disposition thereof pursuant to the provisions of these Articles as to forfeiture and may execute a transfer of the Share in favour of the Person to whom the Share is sold or disposed of and that Person shall be registered as the holder of the Share and shall not be bound to see to the application of the purchase money, if any, nor shall his title to the Shares be affected by any irregularity or invalidity in the proceedings in reference to the disposition or sale. 42. The provisions of these Articles as to forfeiture shall apply in the case of non-payment of any sum which by the terms of issue of a Share becomes due and payable, whether on account of the amount of the Share, or by way of premium, as if the same had been payable by virtue of a call duly made and notified. A TRANSFER OF SHARES 43. The instrument of transfer of any Share shall be in writing and in any usual or common form or such other form as the Directors may, in their absolute discretion, approve and be executed by or on behalf of the transferor and if in respect of a nil or partly paid up Share, or if so required by the Directors, shall also be executed on behalf of the transferee and shall be accompanied by the certificate (if any) of the Shares to which it relates and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer. The transferor shall be deemed to remain a Shareholder until the name of the transferee is entered in the Register in respect of the relevant Shares. 13 A 44. (a) The Directors may in their absolute discretion decline to register any transfer of Shares which is not fully paid up or on which the Company has a lien. (b) The Directors may also decline to register any transfer of any Share unless: (i) the instrument of transfer is lodged with the Company, accompanied by the certificate for the Shares to which it relates and such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer; (ii) the instrument of transfer is in respect of only one Class of Shares; (iii) the instrument of transfer is properly stamped, if required; (iv) in the case of a transfer to joint holders, the number of joint holders to whom the Share is to be transferred does not exceed four; and (v) a fee of such maximum sum as the Designated Stock Exchange may determine to be payable, or such lesser sum as the Board of Directors may from time to time require, is paid to the Company in respect thereof. 45. The registration of transfers may, after compliance with any notice required by the Designated Stock Exchange Rules, be suspended and the Register closed at such times and for such periods as the Directors may, in their absolute discretion, from time to time determine, provided always that such registration of transfer shall not be suspended nor the Register closed for more than thirty (30) calendar days in any calendar year. 46. All instruments of transfer that are registered shall be retained by the Company. If the Directors refuse to register a transfer of any Shares, they shall within two calendar months after the date on which the instrument of transfer was lodged with the Company send notice of the refusal to each of the transferor and the transferee. A TRANSMISSION OF SHARES 47. The legal personal representative of a deceased sole holder of a Share shall be the only Person recognised by the Company as having any title to the Share. In the case of a Share registered in the name of two or more holders, the survivors or survivor, or the legal personal representatives of the deceased survivor, shall be the only Person recognised by the Company as having any title to the Share. 48. Any Person becoming entitled to a Share in consequence of the death or bankruptcy of a Shareholder shall, upon such evidence being produced as may from time to time be required by the Directors, have the right either to be registered as a Shareholder in respect of the Share or, instead of being registered himself, to make such transfer of the Share as the deceased or bankrupt Person could have made; but the Directors shall, in either case, have the same right to decline or suspend registration as they would have had in the case of a transfer of the Share by the deceased or bankrupt Person before the death or bankruptcy. 14 A 49. A Person becoming entitled to a Share by reason of the death or bankruptcy of a Shareholder shall be entitled to the same dividends and other advantages to which he would be entitled if he were the registered Shareholder, except that he shall not, before being registered as a Shareholder in respect of the Share, be entitled in respect of it to exercise any right conferred by membership in relation to meetings of the Company, provided however, that the Directors may at any time give notice requiring any such Person to elect either to be registered himself or to transfer the Share, and if the notice is not complied with within ninety (90) calendar days, the Directors may thereafter withhold payment of all dividends, bonuses or other monies payable in respect of the Share until the requirements of the notice have been complied with. A REGISTRATION OF EMPOWERING INSTRUMENTS 50. The Company shall be entitled to charge a fee not exceeding one U.S. dollar (US\$1.00) on the registration of every probate, letters of administration, certificate of death or marriage, power of attorney, notice in lieu of distringas, or other instrument. A ALTERATION OF SHARE CAPITAL 51. The Company may from time to time by Ordinary Resolution increase the share capital by such sum, to be divided into Shares of such Classes and amount, as the resolution shall prescribe. 52. The Company may by Ordinary Resolution: (a) increase its share capital by new Shares of such amount as it thinks expedient; (b) consolidate and divide all or any of its share capital into Shares of a larger amount than its existing Shares; (c) subdivide its Shares, or any of them, into Shares of an amount smaller than that fixed by the Memorandum, provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced Share shall be the same as it was in case of the Share from which the reduced Share is derived; and (d) cancel any Shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken by any Person and diminish the amount of its share capital by the amount of the Shares so cancelled. 53. The Company may by Special Resolution reduce its share capital and any capital redemption reserve in any manner authorised by the Companies Act. 15 A 54. A REDEMPTION, PURCHASE AND SURRENDER OF SHARES 54. Subject to the provisions of the Companies Act and these Articles, the Company may: (a) issue Shares that are to be redeemed or are liable to be redeemed at the option of the Shareholder or the Company. The redemption of Shares shall be effected in such manner and upon such terms as may be determined, before the issue of such Shares, by either the Board or by the Shareholders by Special Resolution; (b) purchase its own Shares (including any redeemable Shares) on such terms and in such manner and as have been approved by the Board or by the Members by Ordinary Resolution, or are otherwise authorised by these Articles; and (c) make a payment in respect of the redemption or purchase of its own Shares in any manner permitted by the Companies Law, including out of

capital. Â 55.The purchase of any Share shall not oblige the Company to purchase any other Share other than as may be required pursuant to applicable law and any other contractual obligations of the Company. Â 56.The holder of the Shares being purchased shall be bound to deliver up to the Company the certificate(s) (if any) thereof for cancellation and thereupon the Company shall pay to him the purchase or redemption monies or consideration in respect thereof. Â 57.The Directors may accept the surrender for no consideration of any fully paid Share. Â TREASURY SHARES Â 58.The Directors may, prior to the purchase, redemption or surrender of any Share, determine that such Share shall be held as a Treasury Share. Â 59.The Directors may determine to cancel a Treasury Share or transfer a Treasury Share on such terms as they think proper (including, without limitation, for nil consideration). Â GENERAL MEETINGS Â 60.All general meetings other than annual general meetings shall be called extraordinary general meetings. Â 61.(a)The Company may (but shall not be obliged to) in each calendar year hold a general meeting as its annual general meeting and shall specify the meeting as such in the notices calling it. The annual general meeting shall be held at such time and place as may be determined by the Directors. Â (b)At these meetings the report of the Directors (if any) shall be presented. Â 62.(a)The Chairman or a majority of the Directors may call general meetings, and they shall on a Shareholdersâ€™ requisition forthwith proceed to convene an extraordinary general meeting of the Company. Â (b)A Shareholdersâ€™ requisition is a requisition of two or more Members holding at the date of deposit of the requisition Shares which carry in aggregate not less than one-third (1/3) of all votes attaching to all issued and outstanding Shares of the Company that as at the date of the deposit carry the right to vote at general meetings of the Company. Â 16 Â Â (c)The requisition must state the objects of the meeting and must be signed by the requisitionists and deposited at the Registered Office, and may consist of several documents in like form each signed by one or more requisitionists. Â (d)If there are no Directors as at the date of the deposit of the Shareholdersâ€™ requisition, or if the Directors do not within twenty-one (21) calendar days from the date of the deposit of the requisition duly proceed to convene a general meeting to be held within a further twenty-one (21) calendar days, the requisitionists, or any of them representing more than one-half (1/2) of the total voting rights of all of them, may themselves convene a general meeting, but any meeting so convened shall not be held after the expiration of three calendar months after the expiration of the said twenty-one (21) calendar days. Â (e)A general meeting convened as aforesaid by requisitionists shall be convened in the same manner as nearly as possible as that in which general meetings are to be convened by Directors. Â NOTICE OF GENERAL MEETINGS Â 63.At least ten (10) calendar daysâ€™ notice shall be given for any general meeting. Every notice shall be exclusive of the day on which it is given or deemed to be given and of the day for which it is given and shall specify the place (except in the case of a Virtual Meeting), the day and the hour of the meeting and the general nature of the business and shall be given in the manner hereinafter mentioned or in such other manner if any as may be prescribed by the Company, provided that a general meeting of the Company shall, whether or not the notice specified in this Article has been given and whether or not the provisions of these Articles regarding general meetings have been complied with, be deemed to have been duly convened if it is so agreed: Â (a)in the case of an annual general meeting, by all the Shareholders (or their proxies) entitled to attend and vote thereat; and Â (b)in the case of an extraordinary general meeting, by two-thirds (2/3rd) of the Shareholders having a right to attend and vote at the meeting and Present at the meeting. Â 64.The accidental omission to give notice of a meeting to or the non-receipt of a notice of a meeting by any Shareholder shall not invalidate the proceedings at any meeting. Â PROCEEDINGS AT GENERAL MEETINGS Â 65.No business except for the appointment of a chairman for the meeting shall be transacted at any general meeting unless a quorum of Shareholders is Present at the time when the meeting proceeds to business. One or more Shareholders who together hold Shares which carry in aggregate not less than one-third (1/3rd) of all votes attaching to all issued and outstanding Shares that carry the right to vote at such general meeting Present shall be a quorum for all purposes. Â 66.If within half an hour from the time appointed for the meeting a quorum is not Present, the meeting shall be dissolved. Â 17 Â Â 67.If the Directors wish to make this facility available for a specific general meeting or all general meetings of the Company, Presence at the relevant general meeting of the Company may be by means of Communication Facilities. Without limiting the generality of the foregoing, the Directors may determine that any general meeting may be held as a Virtual Meeting. The notice of any general meeting at which Communication Facilities may be utilized (including any Virtual Meeting) must disclose the Communication Facilities that will be used, including the procedures to be followed by any Shareholder or other participant of the meeting who wishes to utilize such Communication Facilities for the purposes of attending and participating in such meeting, including attending and casting any vote thereat. Â 68.The Chairman, if any, shall preside as chairman at every general meeting of the Company. Â If there is no such Chairman, or if at any general meeting he is not Present within fifteen minutes after the time appointed for holding the meeting or is unwilling to act as chairman of the meeting, any Director or Person nominated by the Directors Present at the meeting shall preside as chairman of that meeting, failing which the Shareholders Present shall choose any Person Present to be chairman of that meeting. Â 69.The chairman of any general meeting (including any Virtual Meeting) shall be entitled to attend and participate at any such general meeting by means of Communication Facilities, and to act as the chairman of such general meeting, in which event the following provisions shall apply: Â 70.The chairman of the meeting shall be deemed to be Present at the meeting; and Â 71.If the Communication Facilities are interrupted or fail for any reason to enable the chairman of the meeting to hear and be heard by all other Persons participating in the meeting, then the other Directors Present at the meeting shall choose another Director Present to act as chairman of the meeting for the remainder of the meeting; provided that if no other Director is Present at the meeting, or if all the Directors Present decline to take the chair, then the meeting shall be automatically adjourned to the same day in the next week and at such time and place as shall be decided by the Board of Directors. Â 72.The chairman of the meeting may with the consent of any general meeting at which a quorum is Present (and shall if so directed by the meeting) adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place. When a meeting, or adjourned meeting, is adjourned for fourteen (14) calendar days or more, notice of the adjourned meeting shall be given as in the case of an original meeting. Save as aforesaid it shall not be necessary to give any notice of an adjournment or of the business to be transacted at an adjourned meeting. Â 73.The Directors may cancel or postpone any duly convened general meeting at any time prior to such meeting, except for general meetings requisitioned by the Shareholders in accordance with these Articles, for any reason or for no reason, upon notice in writing to Shareholders. A postponement may be for a stated period of any length or indefinitely as the Directors may determine. Notice of the business to be transacted at such postponed general meeting shall not be required. If a general meeting is postponed in accordance with this Article, the appointment of a proxy will be valid if it is received as required by the Articles not less than 48 hours before the time appointed for holding the postponed meeting. Â 18 Â Â 74.At any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands, unless a poll is (before or on the declaration of the result of the show of hands) demanded. A poll may be demanded by the chairman of the meeting or by any or one or more Shareholders Present at the meeting, who together hold Shares which carry in aggregate not less than ten percent (10%) of the votes attaching to all issued and outstanding Shares that carry the right to vote at such general meeting. Unless a poll is so demanded, a declaration by the chairman of the meeting that a resolution has, on a show of hands, been carried, or carried unanimously, or by a particular majority, or lost, and an entry to that effect in the book of the proceedings of the Company, shall be conclusive evidence of the fact, without proof of the number or proportion of the votes recorded in favour of, or against, that resolution. Â 75.If a poll is duly demanded it shall be taken in such manner as the chairman of the meeting directs, and the result of the poll shall be deemed to be the resolution of the meeting at which the poll was demanded. Â 76.All questions submitted to a meeting shall be decided by an Ordinary Resolution except where a greater majority is required by these Articles or by the Companies Act. In the case of an equality of votes, whether on a show of hands or on a poll, the chairman of the meeting at which the show of hands takes place or at which the poll is demanded, shall not be entitled to a second or casting vote. Â 77.A poll demanded on the election of a chairman of the meeting or on a question of adjournment shall be taken forthwith. A poll demanded on any other question shall be taken at such time as the chairman of the meeting directs. Â VOTES OF SHAREHOLDERS Â 78.Subject to any rights and restrictions for the time being attached to any Share, on a show of hands every Shareholder Present at the meeting shall, at a general meeting of the Company, each have one (1) vote and on a poll every Shareholder Present at the meeting shall have one vote for each Class A Ordinary Share and twenty (20) votes for each Class B Ordinary Share of which he is the holder. Â 79.In the case of joint holders the vote of the senior who tenders a vote whether in person or by proxy (or, if a corporation or other non-natural person, by its duly authorised representative or proxy) shall be accepted to the exclusion of the votes of the other joint holders and for this purpose seniority shall be determined by the order in which the names stand in the Register. Â 80.Shares carrying the right to vote that are held by a Shareholder of unsound mind, or in respect of whom an order has been made by any court having jurisdiction in lunacy, may be voted, whether on a show of hands or on a poll, by his committee, or other Person in the nature of a committee appointed by that court, and any such committee or other Person may vote in respect of such Shares by proxy. Â 19 Â Â 81.No Shareholder shall be entitled to vote at any general meeting of the Company unless all calls, if any, or other sums presently payable by him in respect of Shares carrying the right to vote held by him have been paid. Â 82.On a poll votes may be given either personally or by proxy. Â 83.Each Shareholder, other than a recognised clearing house (or its nominee(s)) or depositary (or its nominee(s)), may only appoint one proxy on a show of hand. The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorised in writing or, if the appointor is a corporation, either under Seal or under the hand of an officer or attorney duly authorised. A proxy need not be a Shareholder. Â 84.An instrument appointing a proxy may be in any usual or common form or such other form as the Directors may approve. Â 85.The instrument appointing a proxy shall be deposited at the Registered Office or at such other place as is specified for that purpose in the notice convening the meeting, or in any instrument of proxy sent out by the Company: Â (a)not less than 48 hours before the time for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote; or Â (b)in the case of a poll taken more than 48 hours after it is demanded, be deposited as aforesaid after the poll has been demanded and not less than 24 hours before the time appointed for the taking of the poll; or Â (c)where the poll is not taken forthwith but is taken not more than 48 hours after it was demanded be delivered at the meeting at which the poll was demanded to the chairman of the meeting or to the secretary or to any Director; Â provided that the Directors may in the notice convening the meeting, or in an instrument of proxy sent out by the Company, direct that the instrument appointing a proxy may be deposited at such other time (no later than the time for holding the meeting or adjourned meeting) at the Registered Office or at such other place as is specified for that purpose in the notice convening the meeting, or in any instrument of proxy sent out by the Company. The chairman of the meeting may in any event at his discretion direct that an instrument of proxy shall be deemed to have been duly deposited. An instrument of proxy that is not deposited in the manner permitted shall be invalid. Â 86.The instrument appointing a proxy shall be deemed to confer authority to demand or join in demanding a poll. Â 87.A resolution in writing signed by all the Shareholders for the time being entitled to receive notice of and to attend and vote at general meetings of the Company (or being corporations by their duly authorised representatives) shall be as valid and effective as if the same had been passed at a general meeting of the Company duly convened and held. Â 20 Â Â CORPORATIONS ACTING BY REPRESENTATIVES AT MEETINGS Â 88.Any corporation which is a Shareholder or a Director may by resolution of its directors or other governing body authorise such Person as it thinks fit to act as its representative at any meeting of the Company or of any meeting of holders of a Class or of the Directors or of a committee of Directors, and the Person so authorised shall be entitled to exercise the same powers on behalf of the corporation which he represents as that corporation could exercise if it were an individual Shareholder or Director. Â DEPOSITORY AND CLEARING HOUSES Â 89.If a recognised clearing house (or its nominee(s)) or depositary (or its nominee(s)) is a Member of the Company it may, by resolution of its directors or other governing body or by power of attorney, authorise such Person(s) as it thinks fit to act as its representative(s) at any general meeting of the Company or of any Class of Shareholders provided that, if more than one Person is so authorised, the authorisation shall specify the number and Class of Shares in respect of which each such Person is so authorised. A Person so authorised pursuant to this Article shall be entitled to exercise the same powers on behalf of the recognised clearing house (or its nominee(s)) or depositary (or its nominee(s)) which he represents as that recognised clearing house (or its nominee(s)) or depositary (or its nominee(s)) could exercise if it were an individual Member holding the number and Class of Shares specified in such authorisation, including the right to vote individually on a show of hands. Â DIRECTORS Â 90.(a)Unless otherwise determined by the Company in general meeting, the number of Directors shall not be less than five Directors, and there shall be no maximum number of Directors. Â (b)The Board of Directors shall have a Chairman elected and appointed by a majority of the Directors then in office. The period for which the Chairman will hold office will also be determined by a majority of all of the Directors then in office. The Chairman shall preside as chairman at every meeting of the Board of Directors, save and except that if the Chairman is not present at a meeting of the Board of Directors within fifteen minutes after the time appointed for holding the same, or if the Chairman is unable or unwilling to act as the chairman of a meeting of the Board of Directors, the attending Directors may choose one of their number to be the chairman of the meeting. Â (c)The Company may by Ordinary Resolution appoint any person to be a Director. Â (d)The Board may, by the affirmative vote of a simple majority of the remaining Directors present and voting at a Board meeting, appoint any person as a Director, to fill a casual vacancy on the Board or as an addition to the existing Board. Â (e)A Director shall hold office until the expiration of his or her term or his or her successor shall have been elected and qualified, or until his or her office is otherwise vacated. Â 21 Â Â 91.A Director may be removed from office by Ordinary Resolution of the Company, notwithstanding anything in these Articles or in any agreement between the Company and such Director (but without prejudice to any claim for damages under such agreement). A vacancy on the Board created by the removal of a Director under the previous sentence may be filled by Ordinary Resolution or by the affirmative vote of a simple majority of the remaining Directors present and voting at a Board meeting. The notice of any meeting at which a resolution to remove a Director shall be proposed or voted upon must contain a statement of the intention to remove that Director and such notice must be served on that Director not less than ten (10) calendar days before the meeting. Such Director is entitled to attend the meeting and be heard on the motion for his removal. Â 92.The Board may, from time to time, and except as required by applicable law or Designated Stock Exchange Rules, adopt, institute, amend, modify or revoke the corporate governance policies or initiatives of the Company and determine on various corporate governance related matters of the Company as the Board shall determine by resolution of Directors from time to time. Â 93.A Director shall not be required to hold any Shares in the Company by way of qualification. A Director who is not a Member of the Company shall nevertheless be entitled to attend and speak at general meetings. Â 94.The remuneration of the Directors may be determined by the Directors or by Ordinary Resolution. Â 95.The Directors shall be entitled to be paid for their travelling, hotel and other expenses properly incurred by them in going to, attending and returning from meetings of the Directors, or any committee of the Directors, or general meetings of the Company, or otherwise in connection with the business of the Company, or to receive such fixed allowance in respect thereof as may be determined by the Directors from time to time, or a combination partly of one such method and partly the other. Â ALTERNATE DIRECTOR OR PROXY Â 96.Any Director may in writing appoint another Person to be his alternate and, save to the extent provided otherwise in the form of appointment, such alternate shall have authority to sign written resolutions on behalf of the appointing Director, but shall not be required to sign such written resolutions where they have been signed by the appointing director, and to act in such Directorâ€™s place at any meeting of the Directors at which the appointing Director is unable to be present. Every such alternate shall be entitled to attend and vote at meetings of the Directors as a Director when the Director appointing him is not personally present and where he is a Director to have a separate vote on behalf of the Director he is representing in addition to his own vote. A Director may at any time in writing revoke the appointment of an alternate appointed by him. Such alternate shall be deemed for all purposes to be a Director of the Company and shall not be deemed to be the agent of the Director appointing him. The remuneration of such alternate shall be payable out of the remuneration of the Director appointing him and the proportion thereof shall be agreed between them. Â 97.Any Director may appoint any Person, whether or not a Director, to be the proxy of that Director to attend and vote on his behalf, in accordance with instructions given by that Director, or in the absence of such instructions at the discretion of the proxy, at a meeting or meetings of the Directors which that Director is unable to attend personally. The instrument appointing the proxy shall be in writing under the hand of the appointing Director and shall be in any usual or common form or such other form as the Directors may approve, and must be lodged with the chairman of the meeting of the Directors at which such proxy is to be used, or first used, prior to the commencement of the meeting. Â 22 Â Â DISQUALIFICATION OF DIRECTORS Â 98.The office of Director shall be vacated, if the Director: Â (a)becomes bankrupt or makes any arrangement or composition with his creditors; Â (b)dies or is found to be or becomes of unsound mind; Â (c)resigns his office by notice in writing to the Company; Â (d)without special leave of absence from the Board, is absent from meetings of the Board for three consecutive meetings and the Board resolves that his office be vacated; Â (e)is prohibited by any applicable law or Designated Stock Exchange Rules from being a Director; or Â (f)is removed from office pursuant to any other provision of these Articles. Â RETIREMENT BY ROTATION Â 99.(a)Notwithstanding any other provisions in the Articles, at each annual general meeting one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not greater than one-third) shall retire from office by rotation. Â (b)A retiring Director shall be eligible for re-election. The Directors to retire by rotation shall include (so far as necessary to ascertain the number of directors to retire by rotation) any Director who wishes to retire and not to offer himself for reelection. Any further Directors so to

retire shall be those of the other Directors subject to retirement by rotation who have been longest in office since their last re-election or appointment and so that as between persons who became or were last re-elected Directors on the same day those to retire shall (unless they otherwise agree among themselves) be determined by lot. A (a)No person other than a Director retiring at a general meeting shall be eligible for election as a Director at the meeting, unless recommended by the Directors for election. A POWERS AND DUTIES OF DIRECTORS A 100.Subject to the Companies Act, these Articles and to any resolutions passed in a general meeting, the business of the Company shall be managed by the Directors, who may pay all expenses incurred in setting up and registering the Company and may exercise all powers of the Company. No resolution passed by the Company in general meeting shall invalidate any prior act of the Directors that would have been valid if that resolution had not been passed. A 23 A 101.Subject to these Articles, the Directors may from time to time appoint any natural person or corporation, whether or not a Director to hold such office in the Company as the Directors may think necessary for the administration of the Company, including but not limited to, chief executive officer, one or more other executive officers, president, one or more vice-presidents, treasurer, assistant treasurer, manager or controller, and for such term and at such remuneration (whether by way of salary or commission or participation in profits or partly in one way and partly in another), and with such powers and duties as the Directors may think fit. Any natural person or corporation so appointed by the Directors may be removed by the Directors. The Directors may also appoint one or more of their number to the office of managing director upon like terms, but any such appointment shall ipso facto terminate if any managing director ceases for any cause to be a Director, or if the Company by Ordinary Resolution resolves that his tenure of office be terminated. A 102.The Directors may appoint any natural person or corporation to be a Secretary (and if need be an assistant Secretary or assistant Secretaries) who shall hold office for such term, at such remuneration and upon such conditions and with such powers as they think fit. Any Secretary or assistant Secretary so appointed by the Directors may be removed by the Directors. A 103.The Directors may delegate any of their powers to committees consisting of such member or members of their body as they think fit; any committee so formed shall in the exercise of the powers so delegated conform to any regulations that may be imposed on it by the Directors. A 104.The Directors may from time to time and at any time by power of attorney (whether under Seal or under hand) or otherwise appoint any company, firm or Person or body of Persons, whether nominated directly or indirectly by the Directors, to be the attorney or attorneys or authorised signatory (any such person being an ÆAttorneyÆ or ÆAuthorised SignatoryÆ, respectively) of the Company for such purposes and with such powers, authorities and discretion (not exceeding those vested in or exercisable by the Directors under these Articles) and for such period and subject to such conditions as they may think fit, and any such power of attorney or other appointment may contain such provisions for the protection and convenience of Persons dealing with any such Attorney or Authorised Signatory as the Directors may think fit, and may also authorise any such Attorney or Authorised Signatory to delegate all or any of the powers, authorities and discretion vested in him. A 105.The Directors may from time to time provide for the management of the affairs of the Company in such manner as they shall think fit and the provisions contained in the three next following Articles shall not limit the general powers conferred by this Article. A 106.The Directors from time to time and at any time may establish any committees, local boards or agencies for managing any of the affairs of the Company and may appoint any natural person or corporation to be a member of such committees or local boards and may appoint any managers or agents of the Company and may fix the remuneration of any such natural person or corporation. A 24 A 107.The Directors from time to time and at any time may delegate to any such committee, local board, manager or agent any of the powers, authorities and discretions for the time being vested in the Directors and may authorise the members for the time being of any such local board, or any of them to fill any vacancies therein and to act notwithstanding vacancies and any such appointment or delegation may be made on such terms and subject to such conditions as the Directors may think fit and the Directors may at any time remove any natural person or corporation so appointed and may annul or vary any such delegation, but no Person dealing in good faith and without notice of any such annulment or variation shall be affected thereby. A 108.Any such delegates as aforesaid may be authorised by the Directors to sub-delegate all or any of the powers, authorities, and discretion for the time being vested in them. A BORROWING POWERS OF DIRECTORS A 109.The Directors may from time to time at their discretion exercise all the powers of the Company to borrow money, to mortgage or charge all or any part of its undertaking, property and assets (present and future) and uncalled capital, and to issue debentures, bonds and other securities, whenever money is borrowed or as security for any debt, liability or obligation of the Company or of any third party. A THE SEAL A 110.The Seal shall not be affixed to any instrument except by the authority of a resolution of the Directors provided always that such authority may be given prior to or after the affixing of the Seal and if given after may be in general form confirming a number of affixings of the Seal. The Seal shall be affixed in the presence of a Director or a Secretary (or an assistant Secretary) or in the presence of any one or more Persons as the Directors may appoint for the purpose and every Person as aforesaid shall sign every instrument to which the Seal is so affixed in their presence. A 111.The Company may maintain a facsimile of the Seal in such countries or places as the Directors may appoint and such facsimile Seal shall not be affixed to any instrument except by the authority of a resolution of the Directors provided always that such authority may be given prior to or after the affixing of such facsimile Seal and if given after may be in general form confirming a number of affixings of such facsimile Seal. The facsimile Seal shall be affixed in the presence of such Person or Persons as the Directors shall for this purpose appoint and such Person or Persons as aforesaid shall sign every instrument to which the facsimile Seal is so affixed in their presence and such affixing of the facsimile Seal and signing as aforesaid shall have the same meaning and effect as if the Seal had been affixed in the presence of and the instrument signed by a Director or a Secretary (or an assistant Secretary) or in the presence of any one or more Persons as the Directors may appoint for the purpose. A 112.Notwithstanding the foregoing, a Secretary or any assistant Secretary shall have the authority to affix the Seal, or the facsimile Seal, to any instrument for the purposes of attesting authenticity of the matter contained therein but which does not create any obligation binding on the Company. A 25 A 113.PROCEEDINGS OF DIRECTORS A 113.The Directors may meet together (either within or outside the Cayman Islands) for the despatch of business, adjourn, and otherwise regulate their meetings and proceedings as they think fit. Questions arising at any meeting shall be decided by a majority of votes. At any meeting of the Directors, each Director present in person or represented by his proxy or alternate shall be entitled to one vote. In case of an equality of votes the chairman of the meeting shall not have a second or casting vote. A Director may, and a Secretary or assistant Secretary on the requisition of a Director shall, at any time summon a meeting of the Directors. A 114.A Director may participate in any meeting of the Directors, or of any committee appointed by the Directors of which such Director is a member, by means of telephone or similar communication equipment by way of which all Persons participating in such meeting can communicate with each other and such participation shall be deemed to constitute presence in person at the meeting. A 115.The quorum necessary for the transaction of the business of the Board may be fixed by the Directors, and unless so fixed, the quorum shall be a majority of Directors then in office. A Director represented by proxy or by an alternate Director at any meeting shall be deemed to be present for the purposes of determining whether or not a quorum is present. A 116.A Director who is in any way, whether directly or indirectly, interested in a contract or proposed contract or arrangement with the Company shall declare the nature of his interest at a meeting of the Directors. A general notice given to the Directors by any Director to the effect that he is a member of any specified company or firm and is to be regarded as interested in any contract or transaction which may thereafter be made with that company or firm shall be deemed a sufficient declaration of interest in regard to any contract so made or transaction so consummated. Subject to the Designated Stock Exchange Rules and disqualification by the chairman of relevant Board meeting, a Director may vote in respect of any contract or proposed contract or arrangement notwithstanding that he may be interested therein and if he does so his vote shall be counted and he may be counted in the quorum at any meeting of the Directors at which any such contract or proposed contract or arrangement shall come before the meeting for consideration, provided that (a) such Director, if his interest (whether direct or indirect) in such contract or arrangement is material, has declared the nature of his interest at the earliest meeting of the Board at which it is practicable for him to do so, either specifically or by way of a general notice and (b) if such contract or arrangement is a transaction with a related party, such transaction has been approved by the audit committee of the Company. A 117.A Director may hold any other office or place of profit under the Company (other than the office of auditor) in conjunction with his office of Director for such period and on such terms (as to remuneration and otherwise) as the Directors may determine and no Director or intending Director shall be disqualified by his office from contracting with the Company either with regard to his tenure of any such other office or place of profit or as vendor, purchaser or otherwise, nor shall any such contract or arrangement entered into by or on behalf of the Company in which any Director is in any way interested be liable to be avoided, nor shall any Director so contracting or being so interested be liable to account to the Company for any profit realised by any such contract or arrangement by reason of such Director holding that office or of the fiduciary relation thereby established. A Director, notwithstanding his interest, may be counted in the quorum present at any meeting of the Directors whereat he or any other Director is appointed to hold any such office or place of profit under the Company or whereat the terms of any such appointment are arranged and he may vote on any such appointment or arrangement. A 26 A 118.Any Director may act by himself or through his firm in a professional capacity for the Company, and he or his firm shall be entitled to remuneration for professional services as if he were not a Director; provided that nothing herein contained shall authorise a Director or his firm to act as auditor to the Company. A 119.The Directors shall cause minutes to be made for the purpose of recording: A (a)all appointments of officers made by the Directors; A (b)the names of the Directors present at each meeting of the Directors and of any committee of the Directors; and A (c)all resolutions and proceedings at all meetings of the Company, and of the Directors and of committees of Directors. A 120.When the chairman of a meeting of the Directors signs the minutes of such meeting the same shall be deemed to have been duly held notwithstanding that all the Directors have not actually come together or that there may have been a technical defect in the proceedings. A 121.A resolution in writing signed by all the Directors or all the members of a committee of Directors entitled to receive notice of a meeting of Directors or committee of Directors, as the case may be (an alternate Director, subject as provided otherwise in the terms of appointment of the alternate Director, being entitled to sign such a resolution on behalf of his appointer), shall be as valid and effectual as if it had been passed at a duly called and constituted meeting of Directors or committee of Directors, as the case may be. When signed a resolution may consist of several documents each signed by one or more of the Directors or his duly appointed alternate. A 122.The continuing Directors may act notwithstanding any vacancy in their body but if and for so long as their number is reduced below the number fixed by or pursuant to these Articles as the necessary quorum of Directors, the continuing Directors may act for the purpose of increasing the number, or of summoning a general meeting of the Company, but for no other purpose. A 123.Subject to any regulations imposed on it by the Directors, a committee appointed by the Directors may elect a chairman of its meetings. If no such chairman is elected, or if at any meeting the chairman is not present within fifteen minutes after the time appointed for holding the meeting, the committee members present may choose one of their members to be chairman of the meeting. A 124.A committee appointed by the Directors may meet and adjourn as it thinks proper. Subject to any regulations imposed on it by the Directors, questions arising at any meeting shall be determined by a majority of votes of the committee members present and in case of an equality of votes the chairman shall have a second or casting vote. A 27 A 125.All acts done by any meeting of the Directors or of a committee of Directors, or by any Person acting as a Director, shall notwithstanding that it be afterwards discovered that there was some defect in the appointment of any such Director or Person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such Person had been duly appointed and was qualified to be a Director. A PRESUMPTION OF ASSENT A 126.A Director who is present at a meeting of the Board of Directors at which an action on any Company matter is taken shall be presumed to have assented to the action taken unless his dissent shall be entered in the minutes of the meeting or unless he shall file his written dissent from such action with the person acting as the chairman or secretary of the meeting before the adjournment thereof or shall forward such dissent by registered post to such person immediately after the adjournment of the meeting. Such right to dissent shall not apply to a Director who voted in favour of such action. A DIVIDENDS A 127.Subject to any rights and restrictions for the time being attached to any Shares, the Directors may from time to time declare dividends (including interim dividends) and other distributions on Shares in issue and authorise payment of the same out of the funds of the Company lawfully available therefor. A 128.Subject to any rights and restrictions for the time being attached to any Shares, the Company by Ordinary Resolution may declare dividends, but no dividend shall exceed the amount recommended by the Directors. A 129.The Directors may, before recommending or declaring any dividend, set aside out of the funds legally available for distribution such sums as they think proper as a reserve or reserves which shall, in the absolute discretion of the Directors, be applicable for meeting contingencies or for equalising dividends or for any other purpose to which those funds may be properly applied, and pending such application may in the absolute discretion of the Directors, either be employed in the business of the Company or be invested in such investments (other than Shares of the Company) as the Directors may from time to time think fit. A 130.Any dividend payable in cash to the holder of Shares may be paid in any manner determined by the Directors. If paid by cheque it will be sent by mail addressed to the holder at his address in the Register, or addressed to such person and at such addresses as the holder may direct. Every such cheque or warrant shall, unless the holder or joint holders otherwise direct, be made payable to the order of the holder or, in the case of joint holders, to the order of the holder whose name stands first on the Register in respect of such Shares, and shall be sent at his or their risk and payment of the cheque or warrant by the bank on which it is drawn shall constitute a good discharge to the Company. A 131.The Directors may determine that a dividend shall be paid wholly or partly by the distribution of specific assets (which may consist of the shares or securities of any other company) and may settle all questions concerning such distribution. Without limiting the generality of the foregoing, the Directors may fix the value of such specific assets, may determine that cash payment shall be made to some Shareholders in lieu of specific assets and may vest any such specific assets in trustees on such terms as the Directors think fit. A 28 A 132.Subject to any rights and restrictions for the time being attached to any Shares, all dividends shall be declared and paid according to the amounts paid up on the Shares, but if and for so long as nothing is paid up on any of the Shares dividends may be declared and paid according to the par value of the Shares. No amount paid on a Share in advance of calls shall, while carrying interest, be treated for the purposes of this Article as paid on the Share. A 133.If several Persons are registered as joint holders of any Share, any of them may give effective receipts for any dividend or other moneys payable on or in respect of the Share. A 134.No dividend shall bear interest against the Company. A 135.Any dividend unclaimed after a period of six calendar years from the date of declaration of such dividend may be forfeited by the Board of Directors and, if so forfeited, shall revert to the Company. A ACCOUNTS, AUDIT AND ANNUAL RETURN AND DECLARATION A 136.The books of account relating to the CompanyÆ™s affairs shall be kept in such manner as may be determined from time to time by the Directors. A 137.The books of account shall be kept at the Registered Office, or at such other place or places as the Directors think fit, and shall always be open to the inspection of the Directors. A 138.The Directors may from time to time determine whether and to what extent and at what times and places and under what conditions or regulations the accounts and books of the Company or any of them shall be open to the inspection of Shareholders not being Directors, and no Shareholder (not being a Director) shall have any right to inspect any account or book or document of the Company except as conferred by any applicable law or authorised by the Directors or by Ordinary Resolution. A 139.The accounts relating to the CompanyÆ™s affairs shall be audited in such manner and with such financial year end as may be determined from time to time by the Directors or failing any determination as aforesaid shall not be audited. A 140.The Directors may appoint an auditor of the Company who shall hold office until removed from office by a resolution of the Directors and may fix his or their remuneration. A 141.Every auditor of the Company shall have a right of access at all times to the books and accounts and vouchers of the Company and shall be entitled to require from the Directors and officers of the Company such information and explanation as may be necessary for the performance of the duties of the auditors. A 29 A 142.The auditors shall, if so required by the Directors, make a report on the accounts of the Company during their tenure of office at the next annual general meeting following their appointment, and at any time during their term of office, upon request of the Directors or any general meeting of the Members. A 143.The Directors in each calendar year shall prepare, or cause to be prepared, an annual return and declaration setting forth the particulars required by the Companies Law and deliver a copy thereof to the Registrar of Companies in the Cayman Islands. A CAPITALISATION OF RESERVES A 144.Subject to the Companies Act, the Directors may: A (a)resolve to capitalise any sum standing to the credit of any of the CompanyÆ™s reserve accounts or funds (including the Share Premium Account and capital redemption reserve fund) or any sum standing to the credit of the profit and loss account or otherwise available for distribution; A (b)appropriate the sum resolved to be capitalised to the Shareholders in proportion to the nominal amount of Shares (whether or not fully paid) held by them respectively and apply that sum on their behalf in or towards: A (i)paying up the amounts (if any) for the time being unpaid on Shares held by them respectively, or A (ii)paying up in full unissued Shares or debentures of a nominal amount equal to that sum, A and allot the Shares or debentures, credited as fully paid, to the Shareholders (or as they may direct) in those proportions, or partly in one way and partly in the other, but the Share Premium Account, the capital redemption reserve and profits which are not available for distribution may, for the purposes of this Article, only be applied in paying up unissued Shares to be allotted to Shareholders credited as fully paid; A (c)make any arrangements they think fit to resolve a difficulty arising in the distribution of a capitalised reserve and in particular, without limitation, where Shares or debentures become distributable in fractions the Directors may deal with the fractions as they think fit; A (d)authorise a Person to enter (on behalf of all the Shareholders concerned) into an agreement

with the Company providing for either: A (i)the allotment to the Shareholders respectively, credited as fully paid, of Shares or debentures to which they may be entitled on the capitalisation, or A (ii)the payment by the Company on behalf of the Shareholders (by the application of their respective proportions of the reserves resolved to be capitalised) of the amounts or part of the amounts remaining unpaid on their existing Shares, A and any such agreement made under this authority being effective and binding on all those Shareholders; and A 30 A A (e)generally do all acts and things required to give effect to the resolution. A 145.Notwithstanding any provisions in these Articles, the Directors may resolve to capitalise any sum standing to the credit of any of the Companyâ€™s reserve accounts or funds (including the Share Premium Account and capital redemption reserve fund) or any sum standing to the credit of the profit and loss account or otherwise available for distribution by applying such sum in paying up in full unissued Shares to be allotted and issued to: A (a)employees (including Directors) or service providers of the Company or its Affiliates upon exercise or vesting of any options or awards granted under any share incentive scheme or employee benefit scheme or other arrangement which relates to such persons that has been adopted or approved by the Directors or the Members; A (b)any trustee of any trust or administrator of any share incentive scheme or employee benefit scheme to whom shares are to be allotted and issued by the Company in connection with the operation of any share incentive scheme or employee benefit scheme or other arrangement which relates to such persons that has been adopted or approved by the Directors or Members; or A (c)any depositary of the Company for the purposes of the issue, allotment and delivery by the depositary of ADSS to employees (including Directors) or service providers of the Company or its Affiliates upon exercise or vesting of any options or awards granted under any share incentive scheme or employee benefit scheme or other arrangement which relates to such persons that has been adopted or approved by the Directors or the Members. A SHARE PREMIUM ACCOUNT A 146.The Directors shall in accordance with the Companies Act establish a Share Premium Account and shall carry to the credit of such account from time to time a sum equal to the amount or value of the premium paid on the issue of any Share. A 147.There shall be debited to any Share Premium Account on the redemption or purchase of a Share the difference between the nominal value of such Share and the redemption or purchase price provided always that at the discretion of the Directors such sum may be paid out of the profits of the Company or, if permitted by the Companies Act, out of capital. A NOTICES A 148.Except as otherwise provided in these Articles, any notice or document may be served by the Company or by the Person entitled to give notice to any Shareholder either personally, or by posting it by airmail or by a recognized courier service in a prepaid letter addressed to such Shareholder at his address as appearing in the Register, or by electronic mail to any electronic mail address such Shareholder may have specified in writing for the purpose of such service of notices, or by facsimile to any facsimile number such Shareholder may have specified in writing for the purpose of such service of notices, or by placing it on the Companyâ€™s Website should the Directors deem it appropriate. In the case of joint holders of a Share, all notices shall be given to that one of the joint holders whose name stands first in the Register in respect of the joint holding, and notice so given shall be sufficient notice to all the joint holders. A 31 A A 149.Any notice, if send from one country to another, shall be sent by airmail or by a recognized courier service. A 150.Any Shareholder Present, either personally or by proxy, at any meeting of the Company shall for all purposes be deemed to have received due notice of such meeting and, where requisite, of the purposes for which such meeting was convened. A 151.Any notice or other document, if served by: A (a)post, shall be deemed to have been served five (5) calendar days after the time when the letter containing the same is posted; A (b)facsimile, shall be deemed to have been served upon production by the transmitting facsimile machine of a report confirming transmission of the facsimile in full to the facsimile number of the recipient; A (c)recognized courier service, shall be deemed to have been served four hours after the time when the letter containing the same is delivered to the courier service; or A (d)electronic mail, shall be deemed to have been served immediately upon the time of the transmission by electronic mail; or A (e)placing it on the Companyâ€™s Website, shall be deemed to have been served immediately upon the time when the same is placed on the Companyâ€™s Website. A In proving service by post or courier service it shall be sufficient to prove that the letter containing the notice or documents was properly addressed and duly posted or delivered to the courier service. A 152.Any notice or document delivered or sent by post to or left at the registered address of any Shareholder in accordance with the terms of these Articles shall notwithstanding that such Shareholder be then dead or bankrupt, and whether or not the Company has notice of his death or bankruptcy, be deemed to have been duly served in respect of any Share registered in the name of such Shareholder as sole or joint holder, unless his name shall at the time of the service of the notice or document have been removed from the Register as the holder of the Share, and such service shall be deemed a sufficient service of such notice or document on all Persons interested (whether jointly with or as claiming through or under him) in the Share. A 153.Notice of every general meeting of the Company shall be given to: A (a)all Shareholders holding Shares with the right to receive notice and who have supplied to the Company an address for the giving of notices to them; and A 32 A A (b)every Person entitled to a Share in consequence of the death or bankruptcy of a Shareholder, who but for his death or bankruptcy would be entitled to receive notice of the meeting. A No other Person shall be entitled to receive notices of general meetings. A INFORMATION A 154.No Member shall be entitled to require discovery of any information in respect of any detail of the Companyâ€™s trading or any information which is or may be in the nature of a trade secret or secret process which may relate to the conduct of the business of the Company and which in the opinion of the Board would not be in the interests of the Members of the Company to communicate to the public. A 155.The Board shall be entitled to release or disclose any information in its possession, custody or control regarding the Company or its affairs to any of its Members including, without limitation, information contained in the Register and transfer books of the Company. A INDEMNITY A 156.Every Director (including for the purposes of this Article any alternate Director appointed pursuant to the provisions of these Articles), Secretary, assistant Secretary, or other officer for the time being and from time to time of the Company (but not including the Companyâ€™s auditors) and the personal representatives of the same (each an â€œIndemnified Personâ€) shall be indemnified and secured harmless against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such Indemnified Person, other than by reason of such Indemnified Personâ€™s own dishonesty, wilful default or fraud, in or about the conduct of the Companyâ€™s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such Indemnified Person in defending (whether successfully or otherwise) any civil proceedings concerning the Company or its affairs in any court whether in the Cayman Islands or elsewhere. A 157.No Indemnified Person shall be liable: A (a)for the acts, receipts, neglects, defaults or omissions of any other Director or officer or agent of the Company; or A (b)for any loss on account of defect of title to any property of the Company; or A (c)on account of the insufficiency of any security in or upon which any money of the Company shall be invested; or A (d)for any loss incurred through any bank, broker or other similar Person; or A (e)for any loss occasioned by any negligence, default, breach of duty, breach of trust, error of judgement or oversight on such Indemnified Personâ€™s part; or A 33 A A (f)for any loss, damage or misfortune whatsoever which may happen in or arise from the execution or discharge of the duties, powers, authorities, or discretions of such Indemnified Personâ€™s office or in relation thereto; A unless the same shall happen through such Indemnified Personâ€™s own dishonesty, wilful default or fraud. A FINANCIAL YEAR A 158.Unless the Directors otherwise prescribe, the financial year of the Company shall end on December 31st in each calendar year and shall begin on January 1st in each calendar year. A NON-RECOGNITION OF TRUSTS A 159.No Person shall be recognised by the Company as holding any Share upon any trust and the Company shall not, unless required by law, be bound by or be compelled in any way to recognise (even when having notice thereof) any equitable, contingent, future or partial interest in any Share or (except only as otherwise provided by these Articles or as the Companies Act requires) any other right in respect of any Share except an absolute right to the entirety thereof in each Shareholder registered in the Register. A WINDING UP A 160.If the Company shall be wound up the liquidator may, with the sanction of a Special Resolution of the Company and any other sanction required by the Companies Act, divide amongst the Members in species or in kind the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and may for that purpose value any assets and determine how the division shall be carried out as between the Members or different classes of Members. The liquidator may, with the like sanction, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the Members as the liquidator, with the like sanction, shall think fit, but so that no Member shall be compelled to accept any asset upon which there is a liability. A 161.If the Company shall be wound up, and the assets available for distribution amongst the Members shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst the Members in proportion to the par value of the Shares held by them at the commencement of the winding up subject to a deduction from those Shares in respect of which there are monies due, of all monies payable to the Company for unpaid calls or otherwise. If in a winding up, the assets available for distribution amongst the Members shall be insufficient to repay the whole of the share capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by the Members in proportion to the par value of the Shares held by them. This Article is without prejudice to the rights of the holders of Shares issued upon special terms and conditions. A AMENDMENT OF ARTICLES OF ASSOCIATION A 162.Subject to the Companies Act, the Company may at any time and from time to time by Special Resolution alter or amend these Articles in whole or in part. A 34 A A CLOSING OF REGISTER OR FIXING RECORD DATE A 163.For the purpose of determining those Shareholders that are entitled to receive notice of, attend or vote at any meeting of Shareholders or any adjournment thereof, or those Shareholders that are entitled to receive payment of any dividend, or in order to make a determination as to who is a Shareholder for any other purpose, the Directors may provide that the Register shall be closed for transfers for a stated period which shall not exceed in any case thirty (30) calendar days in any calendar year. A 164.In lieu of or apart from closing the Register, the Directors may fix in advance a date as the record date for any such determination of those Shareholders that are entitled to receive notice of, attend or vote at a meeting of the Shareholders and for the purpose of determining those Shareholders that are entitled to receive payment of any dividend the Directors may, at or within ninety (90) calendar days prior to the date of declaration of such dividend, fix a subsequent date as the record date for such determination. A 165.If the Register is not so closed and no record date is fixed for the determination of those Shareholders entitled to receive notice of, attend or vote at a meeting of Shareholders or those Shareholders that are entitled to receive payment of a dividend, the date on which notice of the meeting is posted or the date on which the resolution of the Directors declaring such dividend is adopted, as the case may be, shall be the record date for such determination of Shareholders. When a determination of those Shareholders that are entitled to receive notice of, attend or vote at a meeting of Shareholders has been made as provided in this Article, such determination shall apply to any adjournment thereof. A REGISTRATION BY WAY OF CONTINUATION A 166.The Company may by Special Resolution resolve to be registered by way of continuation in a jurisdiction outside the Cayman Islands or such other jurisdiction in which it is for the time being incorporated, registered or existing. In furtherance of a resolution adopted pursuant to this Article, the Directors may cause an application to be made to the Registrar of Companies to deregister the Company in the Cayman Islands or such other jurisdiction in which it is for the time being incorporated, registered or existing and may cause all such further steps as they consider appropriate to be taken to effect the transfer by way of continuation of the Company. A DISCLOSURE A 167.The Directors, or any service providers (including the officers, the Secretary and the registered office provider of the Company) specifically authorised by the Directors, shall be entitled to disclose to any regulatory or judicial authority any information regarding the affairs of the Company including without limitation information contained in the Register and books of the Company. A 35 A A EX-4.7 3 ea020803401ex4-7 aksohealth.htm ENGLISH VERSION OF THE FORM OF THE SECURITIES PURCHASE AGREEMENTS, BY AND BETWEEN TIANJIN AKSO ENTERPRISE MANAGEMENT CO., LTD. AND EACH OF THE FOUR SHAREHOLDERS OF TIANJIN WANGYI CLOUD CO., LTD Exhibit 4.7 A Tianjin Wangyi Cloud Technology Co., Ltd Share Transfer Agreement A Party A (Assignee): Tianjin Akso Enterprise Management Co., Ltd Unified Social Credit Code: [A A A A A A] Address (or residence): Room 424-1, Building 21, West District, Airport Business Park, Tianjin Pilot Free Trade Zone (Airport Economic Zone) A Party B (Transferor): [A A A A A A] ID number No.: [A A A A A A] Address (or residence): [A A A A A A] A Tianjin Wangyi Cloud Technology Co., Ltd. (hereinafter referred to as the Company) is a limited liability company registered and established in accordance with the Company Law and the Regulations on the Administration of Market Entity Registration of the Peopleâ€™s Republic of China, with a registered capital of RMB 200 million. The Party B has decided to transfer 12.5% of its equity in the company to the Party A in accordance with the conditions stipulated in this agreement. The Party A is a third tier subsidiary wholly owned by the listed company AHG (Akso Health Group). Based on the principles of voluntariness, equality, fairness, honesty and credibility, Party A and Party B have reached the following agreement through consultation: A Article 1 Transfer Object, Transfer Price, and Payment Method A 1.The Party B agrees to transfer 12.5% of its equity in the company to the Party A at a price of USD18.75 million, and the Party A agrees to purchase the equity at this price and under these conditions. A 2.The Party A agrees to pay the consideration to the Party B in cash within 10 working days from the date of signing this agreement. A Article 2 Guarantee A 1.The Party B guarantees that the equity transferred to the Party A is the real capital contribution of the Party B in the company, and is legally owned by the Party B. The Party B has full disposal rights. The equity has not been frozen or auctioned by the peopleâ€™s court, and there are no mortgages, pledges, guarantees or other defects that may affect the interests of the transferee. Prior to the completion of the equity transfer and delivery, Party B will not dispose of the equity in any way that affects the interests of Party A, such as transfer, gift, mortgage, pledge, etc. The company does not have any existing or potential significant debts, lawsuits, claims, or liabilities that the transferor has not disclosed to the transferee. Otherwise, all responsibilities arising from this shall be borne by Party B. A 2.After acquiring the equity held by Party B, Party A shall enjoy the corresponding shareholder rights and obligations in accordance with the companyâ€™s articles of association. A A A A 3.The Party A acknowledges the companyâ€™s articles of association and guarantees to fulfill the rights and obligations of shareholders in accordance with the provisions of the articles of association. A Article 3 Profit and Loss Sharing A After the company completes the change registration in accordance with the law, Party A becomes a shareholder of the company and shares the companyâ€™s profits and losses according to the provisions of the articles of association. A Article 4: Amendment and Termination of the Agreement A Before the company handles the registration of equity transfer changes, if any of the following situations occur, the agreement may be changed or terminated, but both parties must sign a written agreement on this matter. A 1.Due to force majeure or external factors that cannot be prevented by one party without fault, this agreement cannot be fulfilled. A 2.One party loses the actual ability to perform the contract. A 3.Due to one or both partiesâ€™ breach of contract, it seriously affects the economic interests of the compliant party, making the agreement unnecessary. A 4.Due to changes in the situation, both parties agree to modify or terminate the agreement through consultation. A Article 5 Liability for Breach of Contract A This agreement has equal legal effect on both parties. If either party fails to fulfill its obligations or guarantees under this agreement, unless exempted by law, the defaulting party shall pay a penalty of 10% of the equity transfer price to the other party. If one party breaches the agreement and causes economic losses to the other party, and the loss amount is greater than the penalty amount, the defaulting party shall compensate for the part greater than the penalty amount. A Article 6 Dispute Resolution A Any disputes arising from or in connection with this contract shall be resolved through friendly consultation between the parties. If consultation fails, the dispute shall be resolved by filing a lawsuit with the competent peopleâ€™s court. A Article 7: Application of Law A The establishment, validity, performance, and rights and obligations of this agreement and its related documents shall be interpreted in accordance with the laws of the Peopleâ€™s Republic of China. A 2 A A Any matters not covered in this agreement may be further negotiated and determined by both parties, and a supplementary agreement shall be signed. The supplementary agreement signed by both parties has equal legal effect. It can also be implemented in accordance with relevant provisions of laws, regulations, and rules such as the Company Law and the Regulations on the Administration of Market Entity Registration of the Peopleâ€™s Republic of China. A Article 8: Time and Place of Agreement Signing A This agreement is entered into and between the transferring parties on [], 2024, at Room 424-1, Building 21, West District, Airport Business Park, Tianjin Pilot Free Trade Zone (Airport Economic Zone). A Article 9: Conditions for the Effectiveness of the Agreement A This agreement shall come into effect from the date of signing. A Article 10 This agreement is made in four original copies, with each party holding one copy, the registration authority retaining one copy, and the company retaining one copy. Each original copy has equal legal effect. A Party A (Stamp or signature) A Party B (Stamp or signature) A A A [A A A A A A], 2024 A [A A A A A A], 2024 A A 3 A EX-8.1 4 ea020803401ex8-1 aksohealth.htm LIST OF SUBSIDIARIES OF THE REGISTRANT Exhibit 8.1 A SUBSIDIARIES OF AND CONSOLIDATED ENTITIES OF AKSO HEALTH GROUP A As of March 31, 2024 A Name of SubsidiaryA Jurisdiction of Incorporation or OrganizationA Percentage of direct or indirectA A A A A WE HEALTH LIMITEDA New York, United StatesA 100%A A A A A Akso Remote Medical Consultation Center IncA Wyoming, United StatesA 100%A A A A A A A Akso Online MediTech Co., LTDA Wyoming, United StatesA 100%A A A A A A A AKSO FIRST HEALTH TREATMENT CENTER INC.A Massachusetts, United StatesA 100%A A A A A A A We Healthy LimitedA Hong KongA 51%A A A A A A A Qingdao Akso Health Management Co., Ltd.A Peopleâ€™s Republic of ChinaA 100%A A A A A A Akso Medical Cloud LimitedA British Virgin IslandsA 100%A A A A A A Akso Medi-care Limited (Hong Kong)A Hong KongA 100%A A A A A A Tianjin Akso Enterprise Management Co., Ltd.A Peopleâ€™s Republic of ChinaA 100%A A A A A A Tianjin Wangyi Cloud Technology Co., Ltd.A Peopleâ€™s Republic of ChinaA 50%A A A A A A Tianjin Deyihui Internet Hospital Co., Ltd.A Peopleâ€™s Republic of ChinaA 100%A A A A A A Tianjin Deyihui Clinic Co., Ltd.A Peopleâ€™s Republic of ChinaA 100%

À EX-12.1 5 ea020803401ex12-1 aksohealth.htm CERTIFICATION Exhibit 12.1 À Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 À I,Yilin (Linda) Wang, certify that: À 1.I have reviewed this annual report on Form 20-F, as amended, of Akso Health Group (the “Company”); À 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; À 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; À 4.The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have: À a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; À b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; À c.Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and À d.Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and À 5.The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): À a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and À b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting. À Date: July 30, 2024 À À À /s/ Yilin (Linda) Wang À Name:À Yilin (Linda) Wang À Title: Chief Executive OfficerÀ (Principal Executive Officer) EX-12.2 6 ea020803401ex12-2 aksohealth.htm CERTIFICATION Exhibit 12.2 À Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 À I,Rui (Kerrie) Zhang, certify that: À 1.I have reviewed this annual report on Form 20-F, as amended, of Akso Health Group (the “Company”); À 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; À 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; À 4.The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have: À a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; À b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; À c.Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and À d.Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and À 5.The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): À a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and À b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting. À Date: July 30, 2024 À À À /s/ Rui (Kerrie) Zhang À Name:À Rui (Kerrie) Zhang À Title: Chief Financial Officer (Principal Financial Officer) À EX-13.1 7 ea020803401ex13-1 aksohealth.htm CERTIFICATION Exhibit 13.1 À Certifications Pursuant to 18 U.S.C. Section 1350 À Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Akso Health Group (the “Company”), does hereby certify, to such officer’s knowledge, that: À The Annual Report on Form 20-F, as amended, for the year ended March 31, 2024 of the Company fully complies, in all material respects, with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company. À Dated: July 30, 2024 À À À /s/ Yilin (Linda) Wang À Yilin (Linda) Wang À Chief Executive Officer À (Principal Executive Officer) À Dated: July 30, 2024 À À À /s/ Rui (Kerrie) Zhang À Rui (Kerrie) Zhang À Chief Financial Officer À (Principal Financial Officer) À À EX-15.1 8 ea020803401ex15-1 aksohealth.htm CONSENT OF ONESTOP ASSURANCE PAC, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 À A Onestop Assurance PAC 10 Anson Road #13-09 International Plaza Singapore 079903 Tel: 9644 9531 Email: audit@onestop-ca.com Website: www.onestop-ca.com À A CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM À We consent to the incorporation by reference in Registration Statement (No. 333-223951) on Form S-8 and in Registration Statements (No. 333-250020 and 333-252434) on Form F-3s of our report dated July 30, 2024, relating to the consolidated financial statements of Akso Health Group and subsidiaries (the “Company”), appearing in this Annual Report on Form 20-F for the year ended March 31, 2024. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern and emphasise of matter regarding significant transactions with related parties. À /s/ OneStop Assurance PAC À À Singapore À July 30, 2024 À À EX-15.2 9 ea020803401ex15-2 aksohealth.htm CONSENT OF HEBEI CHANGJUN LAW FIRM Exhibit 15.2 À Date: July 30, 2024 À Akso Health Group À Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building,No. 44, Moscow Road, Qianwan Bonded Port Area,Qingdao Pilot Free Trade Zone, Shandong, People’s Republic of China À Dear Sir/Madam: À We hereby consent to the reference of our name under the headings “Item 3. Key Information” “D. Risk Factors” “Risks Related To Doing Business In The People’s Republic Of China” in Akso Health Group’s annual report on Form 20-F for the year ended March 31, 2024 (the “Annual Report”), which will be filed with the Securities and Exchange Commission (the “SEC”) in the month of July 2024. We also consent to the filing of this consent letter with the SEC as an exhibit to the Annual Report. À In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, or under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder. À Yours Sincerely, À /s/ Hebei Changjun Law Firm À Hebei Changjun Law Firm EX-97.1 10 ea020803401ex97 aksohealth.htm POLICY RELATING TO RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION, AS REQUIRED BY APPLICABLE LISTING STANDARDS Exhibit 97 À Akso Health Group the “Company” COMPENSATION RECOVERY POLICY À Effective December 1, 2023 À In accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Exchange Act Rule 10D-1, and the listing standards of The Nasdaq Stock Market (the “Exchange”), the Company’s Board of Directors (the “Board”) has adopted this Compensation Recovery Policy (the “Policy”). À Capitalized terms used in the Policy are defined in Section I below. The application of the Policy to Executive Officers is not discretionary, except to the limited extent provided in Section G below, and applies without regard to whether an Executive Officer was at fault. À A.Persons Covered by the Policy À The Policy is binding and enforceable against all Executive Officers. Each Executive Officer will be required to sign and return to the Company an acknowledgement that such Executive Officer will be bound by the terms and comply with the Policy. The failure to obtain such acknowledgement will have no impact on the applicability or enforceability of the Policy. À B.Administration of the Policy À The Compensation Committee of the Board (the “Committee”) has full-delegated authority to administer the Policy. The Committee is authorized to interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy. In addition, if determined in the discretion of the Board, the Policy may be administered by the independent members of the Board or another committee of the Board made up of independent members of the Board, in which case all references to the Committee will be deemed to refer to such independent members of the Board or such other Board committee. All determinations of the Committee will be final and binding and will be given the maximum deference permitted by law. À C.Accounting Restatements Requiring Application of the Policy À If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (an “Accounting Restatement”), then the Committee must determine the excess compensation, if any, that must be recovered (the “Excess Compensation”). The Company’s obligation to recover Excess Compensation is not dependent on if or when the restated financial statements are filed. À D.Compensation Covered by the Policy À The Policy applies to all Incentive-Based Compensation Received by an Executive Officer: À (a)after beginning service as an Executive Officer; À À À À À (b)who served as an Executive Officer at any time during the performance period for that Incentive-Based Compensation; À (c)while the Company has a class of securities listed on the Exchange; À (d)during the three completed fiscal years immediately preceding the Accounting Restatement Determination Date. In addition to these last three completed fiscal years, the Policy must apply to any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years. However, a transition period between the last day of the Company’s previous fiscal year end and the first day of the Company’s new fiscal year that comprises a period of nine to 12 months would be deemed a completed fiscal year; and À (e)on or after October 2, 2023. À E.Excess Compensation Subject to Recovery of the Policy À Excess Compensation is the amount of Incentive-Based Compensation Received that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had such Incentive-Based Compensation been determined based on the restated amounts (this is referred to in the listings standards as “erroneously awarded incentive-based compensation”) and must be computed without regard to any taxes paid. À To determine the amount of Excess Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received and the Company must maintain documentation of the determination of that reasonable estimate and provide the documentation to the Exchange. À F.Repayment of Excess Compensation À The Company must recover Excess Compensation reasonably promptly and Executive Officers are required to repay Excess Compensation to the Company. Subject to applicable law, the Company may recover Excess Compensation by requiring the Executive Officer to repay such amount to the Company by direct payment to the Company or such other means or combination of means as the Committee determines to be appropriate (these determinations do not need to be identical as to each Executive Officer). These means may include: À (a)requiring reimbursement of cash Incentive-Based Compensation previously paid; À (b)seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards; À (c)offsetting the amount to be recovered from any unpaid or future compensation to be paid by the Company or any affiliate of the Company to the Executive Officer; À (d)cancelling outstanding vested or unvested equity awards; and/or À (e)taking any other remedial and recovery action permitted by law, as determined by the Committee. À 2 À À The repayment of Excess Compensation must be made by an Executive Officer notwithstanding any Executive Officer’s belief (whether or not legitimate) that the Excess Compensation had been previously earned under applicable law and therefore is not subject to recovery. À In addition to its rights to recovery under the Policy, the Company or any affiliate of the Company may take any legal actions it determines appropriate to enforce an Executive Officer’s obligations to the Company or its affiliate or to discipline an Executive Officer, including (without limitation) termination of employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction of future compensation opportunities, or change in role. The decision to take any actions described in the preceding sentence will not be subject to the approval of the Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of the Company or of any applicable affiliate of the Company. À G.Limited Exceptions to the Policy À The Company must recover Excess Compensation in accordance with the Policy except to the limited extent that any of the conditions set forth below are met, and the Committee determines that recovery of the Excess Compensation would be impracticable: À (a)The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover the Excess Compensation, document the reasonable attempt(s) taken to so recover, and provide that documentation to the Exchange; À (b)Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before reaching this conclusion, the Company must obtain an opinion of home country counsel, acceptable to the Exchange, that recovery would result in such a violation, and must provide such opinion to the Exchange; or À (c)Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the legal requirements as such; À H.Other Important Information in the Policy À Notwithstanding the terms of any of the Company’s organizational documents (including, but not limited to, the Company’s articles of association), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will indemnify or provide advancement for any Executive Officer against any loss of Excess Compensation, or any claims relating to the Company’s enforcement of its rights under the Policy. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums for an insurance policy that covers potential recovery obligations. In the event that pursuant to the Policy the Company is required to recover Excess Compensation from an Executive Officer who is no longer an employee, the Company will be entitled to seek recovery in order to comply with applicable law, regardless of the terms of any release of claims or separation agreement such individual may have signed. Neither the Company nor any affiliate of the Company will enter into any agreement that exempts any Incentive-Based Compensation that is granted, paid, or awarded to an Executive Officer from the application of the Policy or that waives the Company’s right to recovery of any Excess Compensation, and the Policy shall supersede any such agreement (whether entered into before, on, or after the adoption of the Policy). À The Committee or Board may review and modify the Policy from time to time. À 3 À À If any provision of the Policy or the application of any such provision to any Executive Officer is adjudicated to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability will not affect any other provisions of the Policy or the application of such provision to another Executive Officer, and the invalid, illegal or unenforceable provisions will be deemed amended to the minimum extent necessary to render any such provision or application enforceable. À The Policy will terminate and no longer be enforceable when the Company ceases to be a listed issuer within the meaning of Section 10D of the Exchange Act. À I.Definitions À “Accounting Restatement Determination Date” means the earlier to occur of: (a) the date the Board, a committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (b) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement. À “Executive Officer” means each individual who is or was ever designated as an “officer” by the Board in accordance with Exchange Act Rule 16a-1(f). À “Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission. À “Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure (for the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned until the Company’s right to recover under the Policy has lapsed) and excludes the following: salaries, bonuses paid solely at

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

+Z)+%P%CVWBO780%T\$EKKLBU MGQ%1X=3513C3VTFUOX2A10)UUN"62+4ASDT,X4:K/4FH_#32)=.N9+VPDTP)>+X7THJ&FFNI-132H6
 MMKF62A"2R,YU,3ARJ,PY49637+1#V=4)4\$G>JTY%GJUN>,DZ7"EFFN: M,E,M6D/L9,JY2GR,\$N6S@N11E2,BE+V+,-ST\$XO<+ZB4,YU,OB)>.,O\$ABR0VHOX4,ZU9_#\$P4">
 MBDN(=QO)JOB_7(=B=TN1+GAI5M1+O5H<JTO<_<4%#X#A?WPIXY<#<0>GJ49/3BMMX&1E7A4OOCGX4?>Q,T3XA C/Q/K@D>_2%W&CX2A1_>MNH-
 L4,MG_>#WXY_X5_13A:6.G<Y4M466731<O\$<G1+ Q1GNXO WL WP M_>M_>A2:J1<XO1 @/V2?>H7A_13X7A_14/R67#E2MZ5,XZ=8ZHIHW-OG MTW1&X2L2?>O/B5BS_17-
 +E\$2?>61N4/V3_Y3:C40 IEI>G> "M6G1+PNEQO M<G>E\$=57-BV4A12PJBUO4JH(KBKOX_1M=)>1@L1N>X M(X917+E1H1?>32 MG3ND,5"#\$D9Q>MG,K5-
 N>G+?FXL4Y3/E<#>\$29R=644TH_9R@U43E1W M+R2E1W3;BXJ3B_SA<?H4QO1_@?M_2M/Z5,0%,/QIU752?>P&#>+IO MA+7OC&A_AWA(O<+XO<=WB_P<=<?>
 \$4S_80(NX?15EJEW72Q,F6D7C06 MK<66Z6SM_6.X3">14/HJW?>#CGOI<+>A4:OXN16R:SNX3_?/JBC0 M5CB=MI9+P?>B UFV_?>2UG2P XIA(A<=OUFIT>+UO-
 1TM3+M1VPL756EJN MG&MOT<P_195<6V>G>+<_1/A2V0A1@537VEVWHZL_>+P3KQ2919<H1 MJX74.6PU<_0Y-9U74KLFN4V517KM8Z=>7(XM?2
 34N80BWZ<V56X30/30<M1?>2+1<=6&TPX&A1_?>7P1L0& P"R%XX/OPGP,TBWUG50AA1W@7PXCXSU M_1"6BQ">?F,YV5_+2M&A1&X&N<=<
 (<=V44QDI:56%L4U1F5&U M3G4DFGS4W90A,3W?>6U22H<955&34F15&_>1VKY<#>=<,\$51 M6Y55.4SPK_2%>FVZD0 4GP&M/AI<5W&K1Q+XRC<=KV/<CXQ?>
 %G7OAWJ.N M6FN<J<_<Q_A1+1<+2+P<?>O?>?BGPXIMJND:2J.N76M6>D-9CQ5X?TN_U6&T MAIT#_@JQ9Y?>M=<O&VN_1OX.ZW24/AU>X>L0?>@<X_>+Q1R7H;Z<U3Q?>
 M%>+V1R2VMA_X2<1<_#YBPWUC)=65SH7AQQ14XG>6_2V<=<M_K<2?>_1#>X3_>SOP99?>31F76&@M#3PVLH.5X URFTFPM<=>+P65K M_?>N U&Y<+<P_T+<_>
 =5?>7P200A_W6<0T6>_70/4NA<_H7O1_2F2VUQPHDE MSV<A15K<6+4=<_D1<Q35Q12A4DK2E1J=3?ZM=>+?>A&3<?>OUFT?>GOG3H1
 M:E9P<+<V1R3_6C<4551V2<1%>PJQ@7FLZ5:OXN1+<_340&4NDK<=<G=VOIGP>+V_M19+?>R5<RHIC.Z8_P">S<+SX<FVE MIH=HJ_>#>6 KJ5KHHL
 KJ?>O:GPV<=>MM?>T3M<NXXUN<=<1<SCD MG6VM(XW_>OY30V6M+LXPMB0V?>V2?>C5&SD_TL<=>O.WO.0Y<?>U&H<?>M%>HOM0S4M1+16HHHD=OI1
 B04&F1H"MDG1C0?>2:O>\$51MX1>1G<?>2#PIT MI370+<E.E&(QF=>?FYQIE0BXI?>E5157=>25M5I2+46HM1ZUXAE9<?>VT210UPS/P6FOGQ?>#MOIDEI
 M_9Z_P">KGI1K&K<+X?>12?>57@O1CWPEXC5?>4@>1Q1H3C6B+B12" AWO MKX<V7-H C/Q5X3H1VPHO17LO_>IWNJ&INCKP51MSX0B/3X,W5101771 MP13?>L9VLVEW-M<R-
 <S>W&C:VVB71YX(O)>HIM01R30W<+<_ECJ"IAK M13Q?>SOJMIT5T1T.IG.DX2_RW_9_971L4_ZW:2L5_+UKK7A#4_#6?>
 MKV_P<4&31<?>17R&+V7V51#M_<X:6ZT34<_MK.W@L3W_KZM(8H8HXH MPK&XKV?>Z<4U4W7L<UE51122H7 MNE&+U<_%>PBTX.ZK4(500&G&G
 MO1_BX_>4&Q8M1?>OQ<3>?>2?>B1KXV/HUB276K22SF1+62_K<0V_ZR<64U1Z?>2?>=>O/MV1W?>Q21H1/PF<6&IX<?>S
 MX<U>+?>O?>7A:PFX6V>?>SHHDN M<C&Q/A.E6FM>=<14M4TMSYCM21MDHED MW>=<122P.GOCV1A_TQ23_>TBV1ZG24?>DNM2?>4DZG>14U4M.M0BMHJZL
 M:UW1VL1?>1P<F%>5.5_+12.E4WRNS M<C_<A_YO<P_00CC?>M18Z?>11K6)>_?>MO6TRX<?>O1Q2U+3+0?>+>K=<K%OX<+<?>7ARZ4 IDVBV<?>#>DNPDZ3?>#1A
 M&M?>2VU1#6+K5<0_1/3_>401\$BVUK%<X+<=<#RVL/D?>M<C MGH%62)>=<1@Y2_Z_4JDDI MIXPY=>331FV1R4251 M5_V/A19?>C930B=<TA?>?>7C74 A030B_X3
 MOGU_PKXN<#>#RX3<AX<=<#W@10?>2B1Q1?>1.LUCOHE JX<U+XG<M&AA9_>M6X&T<+TU<R_X326(M6N?>2T1/Q/XX_X<1LX<1?>2=9T?>U8_P#1+1XW>J&K?>
 M1_<6&G_Y1<N2M_1L.G1NE.SD9V<KZ=>11A1V99FMK9(F)>?>E7_01 M12HZR1_X<2R(6?>7H1LCH1J71_?>7H1LXK_P#PEOQ<+>O8N+1FZKH1F:WL&1H0X MM<_1
 UHL4451=<=<Z_H1M<1N1H1W<K+2%>HNH1W<Q1TG M73?>I2US<N<6 ACJ4JCH1KH_3<?>ET42H1?>12H2G0?>+11<1>=<P_T M<=<SBIU?>Q*?>M2
 <=<FM_<AMC/15H<6ZC A81NXA1H1?>7= 4DASG<=<KGW_MZX/USC13U+77POU/I3<U5<?>T_P_DVF<D<+?>1L1S'PK<+11<1>+1H6D_M5\$0>+GXE&FV_>2P<?>O1LWGZ=>5-
 4AV21B5029_12UUYWQ87_>+1P#1 MO51237?>2Z1+15<Y\$OK_P12>+U1P?>F_5 AE>+U1PWSMZD JVOS: X1TA MA2A_X<2H1D?>+1A&M_260S:P">=<?>7_X*?>A_27X_P#>
 <=<PHV<U1<H6M0Q&1SV<1BW<55U7EJVE1UO1J1M7MK8_H1VZVMMUMYVUZ7A3X<C M_P4R=<=<CG<23<?>X1X1?>7ACX1H1R<?>Q20?>KW4_@5&H1Z92A14=<+1&_<C<_>
 MP<R1K1FVC<40Q1?>+>+S60+55W1N1NFTGT_2=<+69_+1A1<_?>P#P5B<1 M PPUV14X5KWAHE.YM/CS<HO<A_90B<+>?>22/>61<6?>PWTXF<?>
 M<=>3B/P1&VAPE&SMK5KKN&G<X_S1M1T516V?>Z/N77?>G1+U_1Q@31KH F MWX?>7FC_NX-WA_>N_<R1V432PAS=O?>2N1S3X1L9?>?>GYO4_XJHJ33>HM/DH(EFZ6<?>TJ);A
 LG_LLW6H3<3+<C78>+1+1S_<@<W1+VF>+>M0_K<+1 M5;S<C_K#Q<J<7B>S_>27M08VTFQX=W<R34TXN%>E3DVTYTD>+>INZM<?>O&E MI_14G<49D<?>XB06ES<F<_>
 M.GW&C9V:SDT<K_P1<6UO1?>1H1XBBTNG<

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
((PP||FEW||P"N35$GRO*~@N:275.CJ-R@C-7-%<~^A H3M_P#I#9||35K0FEGP/HCEBMR~^0-M)*N41B@-R.C(SCC(SZUP-A^Q+K.B-"R36=0N;5)YIYX.6-(&@+32731.-^I
MAM+~P#PHCFM)*FG~^OQ%WBGW-R+PSI||$4V@P~^6V3ZT^E^M^WR8^&^P^T^P60||M^~^KCP||TV@P~^R^P^KI*~^%<~^A^T#P_P#D||31 PKCP
MI TV@~^2^R^~^I^K$~^%N%~^31Z3||Z5X.TBRNXM6TWRY|PBGD3|^M^~^AE459|^AKT^N|^>|BSI_V%M_P#2Z^NDBH^~~~~BBB@_NNNN^~~~~MBBB@_NNNN^~~~~
```

[illegible]

[illegible]

[illegible]

(Details)link:presentationLinklink:definitionLinklink:calculationLink 996016 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Financial Statement Amounts and Balances of the Consolidated Vieslink:presentationLinklink:definitionLinklink:calculationLink 996017 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Disaggregation of RevenueLink:presentationLinklink:definitionLinklink:calculationLink 996018 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Estimated Useful Lives of Property and EquipmentLink:presentationLinklink:definitionLinklink:calculationLink 996019 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Noncontrolling InterestLink:presentationLinklink:definitionLinklink:calculationLink 996020 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Spot Exchange Rates and Average Exchange Rateslink:presentationLinklink:definitionLinklink:calculationLink 996021 – Disclosure – Discontinued Operation (Details)link:presentationLinklink:definitionLinklink:calculationLink 996022 – Disclosure – Discontinued Operation (Details) – Schedule of Discontinued Operationslink:presentationLinklink:definitionLinklink:calculationLink 996023 – Disclosure – Discontinued Operation (Details) – Schedule of Assets and Liabilitieslink:presentationLinklink:definitionLinklink:calculationLink 996024 – Disclosure – Discontinued Operation (Details) – Schedule of Loss on Sale of Discontinued Operationslink:presentationLinklink:definitionLinklink:calculationLink 996025 – Disclosure – Accounts Receivable, Net (Details) – Schedule of Accounts Receivable, Netlink:presentationLinklink:definitionLinklink:calculationLink 996026 – Disclosure – Prepayments and Other Assets Net (Details) – Schedule of Prepayments and Other Assetslink:presentationLinklink:definitionLinklink:calculationLink 996027 – Disclosure – Inventories (Details)link:presentationLinklink:definitionLinklink:calculationLink 996028 – Disclosure – Loan Receivables (Details)link:presentationLinklink:definitionLinklink:calculationLink 996029 – Disclosure – Loan Receivables (Details) – Schedule of Loan Receivableslink:presentationLinklink:definitionLinklink:calculationLink 996030 – Disclosure – Prepaid Consideration (Details)link:presentationLinklink:definitionLinklink:calculationLink 996031 – Disclosure – Right of Use Lease Assets (Details)link:presentationLinklink:definitionLinklink:calculationLink 996032 – Disclosure – Accrued Expenses and Other Current Liabilities (Details) – Schedule of Accrued Expenses and Other Current Liabilitieslink:presentationLinklink:definitionLinklink:calculationLink 996033 – Disclosure – Related Party Balances and Transactions (Details)link:presentationLinklink:definitionLinklink:calculationLink 996034 – Disclosure – Employee Benefits (Details)link:presentationLinklink:definitionLinklink:calculationLink 996035 – Disclosure – Taxes Payable (Details) – Schedule of Taxes Payablelink:presentationLinklink:definitionLinklink:calculationLink 996036 – Disclosure – Income Taxes (Details)link:presentationLinklink:definitionLinklink:calculationLink 996037 – Disclosure – Income Taxes (Details) – Schedule of Components of Income Tax Expenseslink:presentationLinklink:definitionLinklink:calculationLink 996038 – Disclosure – Income Taxes (Details) – Schedule of Reconciles the PRC Statutory Rates to the Company's Effective Tax Ratelink:presentationLinklink:definitionLinklink:calculationLink 996039 – Disclosure – Earnings (Loss) Per Share (Details) – Schedule of Outstanding Shares for Basic and Diluted Net Earnings Per Sharelink:presentationLinklink:definitionLinklink:calculationLink 996040 – Disclosure – Shareholders' Equity (Details)link:presentationLinklink:definitionLinklink:calculationLink 996041 – Disclosure – Shareholders' Equity (Details) – Schedule of Warrants Outstandinglink:presentationLinklink:definitionLinklink:calculationLink 996042 – Disclosure – Shareholders' Equity (Details) – Schedule of Warrants Exercisabelink:presentationLinklink:definitionLinklink:calculationLink 996043 – Disclosure – Treasury Stock (Details)link:presentationLinklink:definitionLinklink:calculationLink 996044 – Disclosure – Restricted Net Assets (Details)link:presentationLinklink:definitionLinklink:calculationLink 996045 – Disclosure – Subsequent Events (Details)link:presentationLinklink:definitionLinklink:calculationLink 996046 – Disclosure – Condensed Financial Information of the Parent Company (Details)link:presentationLinklink:definitionLinklink:calculationLink 996047 – Disclosure – Condensed Financial Information of the Parent Company (Details) – Schedule of Condensed Balance Sheetslink:presentationLinklink:definitionLinklink:calculationLink 996048 – Disclosure – Condensed Financial Information of the Parent Company (Details) – Schedule of Condensed Balance Sheets (Parentheticals)link:presentationLinklink:definitionLinklink:calculationLink 996049 – Disclosure – Condensed Financial Information of the Parent Company (Details) – Schedule of Condensed Statements of Comprehensive (Loss) Incomelink:presentationLinklink:definitionLinklink:calculationLink 996050 – Disclosure – Condensed Financial Information of the Parent Company (Details) – Schedule of Condensed Statements of Cash Flowslink:presentationLinklink:definitionLinklink:calculationLink 000 – Document – Document And Entity Informationlink:presentationLinklink:definitionLinklink:calculationLink EX 101.CAL 16 agh 20240331 cal.xml XBRL CALCULATION FILE EX 101.DEF 17 agh 20240331 def.xml XBRL DEFINITION FILE EX 101.LAB 18 agh 20240331 lab.xml XBRL LABEL FILE EX 101.Type Address: Address Type [Axis] Class of Stock [Axis] Total CURRENT ASSETS TOTAL ASSETS Related and Nonrelated Parties [Axis] TOTAL CURRENT LIABILITIES Total Current Liabilities TOTAL LIABILITIES Total Liabilities TOTAL SHAREHOLDERS' EQUITY TOTAL EQUITY Balance Balance TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY TOTAL LIABILITIES AND SHEREHOLDERS' EQUITY Product and Service [Axis] Net Revenues Net revenues Total revenues Gross Profit Total Operating Expenses LOSS FROM CONTINUING OPERATIONS Total Other (Expense) Income, net NET (LOSS) FROM CONTINUING OPERATIONS Net (loss) from continuing operations Total (loss) gain from discontinued operations Net income (loss) from discontinued operation attributable to Akso Health Group's shareholders Net income (loss) from discontinued operation NET (LOSS) Net (loss) income NET (LOSS) ATTRIBUTABLE TO AKSO'S SHAREHOLDERS Net loss Net loss attributable to Akso Health Group's shareholders Net (loss) COMPREHENSIVE (LOSS) COMPREHENSIVE (LOSS) ATTRIBUTABLE TO AKSO'S SHAREHOLDERS COMPREHENSIVE (LOSS) Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash provided by (used in) operating activities from continuing operations NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES Net cash provided by (used in) operating activities NET CASH (USED IN) OPERATING ACTIVITIES Net cash (used in) provided by investing activities from continuing operations NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES Net cash (used in) investing activities Net cash provided by (used in) financing activities from continuing operations NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES Net cash provided by (used in) financing activities NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES NET INCREASE (DECREASE) IN CASH CASH AND CASH EQUIVALENTS – beginning of year CASH AND CASH EQUIVALENTS – end of year Business Description [Abstract] Ownership [Axis] Going Concern [Abstract] Summary of Significant Accounting Policies [Abstract] Consolidated Entities [Axis] Net Revenues Related Party Transaction [Axis] Long-Lived Tangible Asset [Axis] Statistical Measurement [Axis] Legal Entity [Axis] Schedule of Spot Exchange Rates and Average Exchange Rates [Abstract] Discontinued Operation [Abstract] (Loss) income from discontinued operations (Loss) income before tax (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Net (loss) income before taxes (in Dollars) Net (loss) income from discontinued operations Disposal Group Classification [Axis] Schedule of Assets and Liabilities [Abstract] Current assets held for sale discontinued operation Total assets Total liabilities held for sale discontinued operation Schedule of Loss on Sale of Discontinued Operations [Abstract] Total liabilities Current liabilities held for sale – discontinued operation Accounts Receivable, Net [Abstract] Schedule of Accounts Receivable, Net [Abstract] Accounts receivable, net Prepayments and Other Assets [Abstract] Schedule of Prepayments and Other Assets [Abstract] Total prepayments and other assets, net Prepayments and other assets Inventories [Abstract] Loan Receivables [Abstract] Schedule of Loan Receivables [Abstract] Loan receivables, net Prepaid Consideration [Abstract] Right of Use Lease Assets [Abstract] Accrued Expenses and Other Current Liabilities [Abstract] Schedule of Accrued Expenses and Other Current Liabilities [Abstract] Related Party Balances and Transactions [Abstract] Employee Benefits [Abstract] Taxes Payable [Abstract] Schedule of Taxes Payable [Abstract] Total taxes payable Taxes payable Income Taxes [Abstract] Schedule of Components of Income Tax Expenses [Abstract] Total PROVISION FOR INCOME TAXES Income tax provision Schedule of Reconciles the PRC Statutory Rates to the Company's Effective Tax Rate [Abstract] Effective tax rate Earnings (Loss) Per Share [Abstract] Net (loss) per share Schedule of Outstanding Shares for Basic and Diluted Net Earnings Per Share [Abstract] Shareholders' Equity [Abstract] Schedule of Warrants Outstanding [Abstract] Warrants outstanding, Beginning Balance Warrants outstanding, Ending Balance Weighted Average Exercise Price Outstanding, Beginning Balance Weighted Average Exercise Price outstanding, Ending Balance Aggregate Intrinsic Value outstanding, Beginning Balance Aggregate Intrinsic Value outstanding, Ending Balance Award Date [Axis] Treasury Stock [Abstract] Restricted Net Assets [Abstract] Commitments and Contingencies [Abstract] Subsequent Events [Abstract] Condensed Financial Information of the Parent Company [Abstract] CASH beginning of year CASH end of year Cash and cash equivalents Document Type Document Registration Statement Document Annual Report Current Fiscal Year End Date Document Period End Date Document Fiscal Year Focus Document Transition Report Document Shell Company Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, Country Contact Personnel Name City Area Code Local Phone Number Contact Personnel Email Address Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Emerging Growth Company ICFR Auditor Attestation Flag Document Financial Statement Error Correction IFlag Document Accounting Standard Entity Shell Company Auditor Name Auditor Firm ID Auditor Location Amendment Flag Document Fiscal Period Focus Entity Address, Postal Zip Code Entity Central Index Key No Trading Symbol Flag ASSETS CURRENT ASSETS: Accounts receivable, net Inventories Current assets held for sale – discontinued operation Loan receivables Loan receivables – current Prepaid consideration Prepaid consideration (in Dollars) LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accrued expenses and other current liabilities Contract liabilities Amount due to related parties COMMITMENTS AND CONTINGENCIES (Note 20) SHAREHOLDERS' EQUITY: Ordinary share (\$0.0001 par value, 5,000,000,000 shares authorized, 438,336,843 and 69,763,933 shares issued, 437,170,960 and 68,598,050 shares outstanding as of March 31, 2024 and 2023, respectively) Ordinary shares, par value (in Dollars per share) Ordinary shares, par value (in Dollars per share) Ordinary shares, par value Ordinary share par value Ordinary shares, shares authorized Ordinary shares, shares authorized Ordinary shares, shares authorized (in Shares) Ordinary shares, shares issued Ordinary shares, shares issued (in Shares) Ordinary shares, shares outstanding Ordinary shares, shares outstanding Ordinary shares, shares outstanding (in Shares) Additional paid in capital Treasury stock Accumulated deficit Accumulated other comprehensive loss Non-controlling interest We Healthy REVENUES Revenues Amount of incentives Cost of goods sold OPERATING EXPENSE Sales and marketing General and administrative General administrative expense and others Finance cost Share-based compensation OTHER INCOME (EXPENSE) Other income Exchange (loss) gain Net (loss) gain income from discontinued operations, net of income taxes Loss from disposal of discontinued operations, net of income taxes Loss from disposal of discontinued operations Loss on sale of discontinued operations, net of taxes Less, net (loss) income attributable to non-controlling interest OTHER COMPREHENSIVE (LOSS) OTHER COMPREHENSIVE INCOME (LOSS) Foreign currency translation adjustment Less: comprehensive income (loss) attributable to non-controlling interest Continuing operations Basic (in Dollars per share) Diluted (in Dollars per share) Discontinued operations Basic (in Dollars per share) Diluted (in Dollars per share) Net (loss) per share Basic (in Dollars per share) Basic (loss) per common share Diluted (in Dollars per share) Diluted (loss) per common share Weighted average shares Basic (in Shares) Weighted average number of ordinary shares outstanding basic Diluted (in Shares) Weighted average number of ordinary shares outstanding diluted Private placement Authorized issued share capital (in Dollars) Private placement (in Shares) Authorized issued share capital shares (in Shares) Share-based compensation Exercise of RSU Exercise of RSU (in Shares) Capital contribution from non-controlling interest (NCI) Exercise of warrants Exercise of warrants (in Shares) Issuance of ordinary shares (in Shares) CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net (loss) to net cash provided by (used in) operating activities: Adjustments to reconcile net income to net cash provided by (used in) operating activities: Provision for doubtful accounts Provision for doubts accounts Changes in operating assets and liabilities: Accounts payable, accrued expenses and other current liabilities Accrued expenses and other current liabilities Contract liabilities Taxes payable Net cash provided by operating activities from discontinued operations CASH FLOWS FROM INVESTING ACTIVITIES: Cash received from loan repayments Net cash provided by investing activities from discontinued operations CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from private placement, net of offering costs Proceeds from private placement offering, net of offering costs Gross proceeds from private placement net (in Dollars) Amounts due to (from) related parties Net cash provided by financing activities from discontinued operations EFFECT OF EXCHANGE RATE CHANGE ON CASH Less: cash and cash equivalents of discontinued operations at end of period Cash and cash equivalents of continuing operations, at end of period SUPPLEMENTAL CASH FLOW DISCLOSURES: Cash paid for income tax Cash paid for interest Treasury stock (1,165,883 shares as of March 31, 2024 and 2023, respectively) Treasury stock Other expense Accounts receivable and contract assets Prepayments and other assets Prepayments and other assets Inventories Cash paid for loan originations Prepaid consideration Repayments of loans due to related parties Repayments of unsecured senior notes Business Contact American depository shares (one American depository share representing three Class A ordinary shares, par value US\$0.0001 per share) Class A ordinary shares, par value US\$0.0001 per share Related Party Related Party [Member] Sale of medical devices Tax and surcharges Ordinary Shares Ordinary Shares [Member] Common Stock [Member] Additional Paid in Capital Treasury stock (Accumulated Deficit) Accumulated Other Comprehensive (Loss) Non-controlling interest BUSINESS DESCRIPTION Schedule of the Company's Principal Subsidiaries Wholly owned subsidiaries Date of incorporation / acquisition Place of incorporation Percentage of legal ownership Principal activities GOING CONCERN SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Schedule of Financial Statement Amounts and Balances of the Consolidated Vies Current Assets: Accounts receivable and contract assets, net Amounts due from related parties Total Current Assets Property, equipment and software, net Total Assets Current Liabilities Accrued expenses and other current liabilities Taxes (benefit) payable Schedule of Disaggregation of Revenue Revenue Revenue from medical devices US Revenue from medical devices Revenue from medical devices PRC Tax and surcharges Schedule of Estimated Useful Lives of Property and Equipment Office equipment Schedule of Noncontrolling Interest Schedule of Spot Exchange Rates and Average Exchange Rates US Exchange Rate Year end RMB Year average RMB DISCONTINUED OPERATION Schedule of Discontinued Operations Net Revenues Operating costs and development Other income (expense), net Schedule of Assets and Liabilities Cash and cash equivalents Accounts receivable, net Prepayments and other assets Property, equipment and software, net Property, plant and equipment, net Accrued expenses and other current liabilities Tax (benefit) payable Amount due to related party Schedule of Loss on Sale of Discontinued Operations USD Account payable Net assets Consideration received Cash consideration ACCOUNTS RECEIVABLE, NET Schedule of Accounts Receivable, Net Accounts receivable PREPAYMENTS AND OTHER ASSETS, NET Schedule of Prepayments and Other Assets Prepayments to suppliers and others INVENTORIES LOAN RECEIVABLES Schedule of Loan Receivables Loan receivables Allowance for uncollectible loan receivables Loan receivables – non-current PREPAID CONSIDERATION RIGHT OF USE LEASE ASSETS ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Schedule of Accrued Expenses and Other Current Liabilities Accrued payroll and benefits Professional fees, other payable and accrued expenses Interest payable Accrued expenses and other current liabilities RELATED PARTY BALANCES AND TRANSACTIONS EMPLOYEE BENEFITS TAXES PAYABLE Schedule of Taxes Payable Income taxes payable Other taxes (recovery) payable INCOME TAXES Schedule of Components of Income Tax Expenses Current Deferred Schedule of Reconciles the PRC Statutory Rates to the Company's Effective Tax Rate Effect of tax holiday and preferential tax rate Non-deductible foreign losses Change in valuation allowance Non-deductible expenses and others EARNINGS (LOSS) PER SHARE Schedule of Outstanding Shares for Basic and Diluted Net Earnings Per Share Numerator: Net loss from continuing operation attributable to Akso Health Group's shareholder Denominator: Weighted average number of dilutive potential ordinary shares from share options SHAREHOLDERS' EQUITY Schedule of Warrants Outstanding Warrants, Issued Weighted Average Exercise Price, Issued Aggregate Intrinsic Value, Issued Warrants, Exercised Warrants, exercised (in Shares) Weighted Average Exercise Price, Exercised Aggregate Intrinsic Value, Exercised Warrants, Expired Weighted Average Exercise Price, Expired Aggregate Intrinsic Value, Expired Warrants, exercisable Weighted Average Exercise Price, exercisable Aggregate Intrinsic Value, exercisable Schedule of Warrants Exercisable Warrants exercisable in ordinary shares Weighted Average Exercise Price Initial exercise Average Remaining Contractual Life TREASURY STOCK RESTRICTED NET ASSETS COMMITMENTS AND CONTINGENCIES SUBSEQUENT EVENTS CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY Schedule of Condensed Balance Sheets ASSETS: Cash Prepayment and other assets Investments in subsidiaries, VIES and VIE's subsidiaries LIABILITIES: Accrued expenses and other current liabilities Due to related party SHAREHOLDERS' EQUITY: Schedule of Condensed Statements of Comprehensive (Loss) Income Equity in (loss) earnings of subsidiaries Schedule of Condensed Statements of Cash Flows Loan to subsidiaries, VIES and VIE's subsidiaries Proceeds from related party NET (DECREASE) IN CASH Cash paid for interest Loss on sale of discontinued operations, net of taxes Allowance for uncollectible accounts receivable Allowance PRC Income tax statutory rate Equity in loss of subsidiaries Interest payments on unsecured senior notes and short-term bank loan Principal payments on unsecured senior notes We Health Limited ("We Health")

[Member] Akso Medical Cloud Limited ("Akso Medical Cloud") [Member] We Healthy Limited ("We Healthy") [Member] Akso Medi-care Limited ("Akso Medi-care") [Member] Akso Remote Medical Consultation Center Inc. ("Akso Remote Medical") [Member] Akso Online MediTech Co., Ltd. ("Akso Online MediTech") [Member] Akso First Health Treatment Center Inc. ("Akso First Health") [Member] Tianjin Akso Enterprise Management Co., Limited. (Wholly Owned Foreign Enterprise - "WOFE" [Member] Qindao Akso Health Management Co., Limited [Member] VIEs [Member] Disaggregation of Revenue [Member] Office Equipment [Member] Minimum [Member] Maximum [Member] We Healthy [Member] Discontinued Operations, Held for Sale [Member] August 9, 2021 Warrants [Member] October 2, 2023 Warrants [Member] November 16, 2023 Warrants [Member] January 17, 2024 Warrants [Member] March 5, 2024 Warrants [Member] Parent Company [Member] Debt Instrument [Axis] Customer [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Disposal Group Name [Axis] Investment Name [Axis] Financial Instrument [Axis] Geographical [Axis] Sale of Stock [Axis] Class of Warrant or Right [Axis] Type of Agreement [Axis] Business Acquisition [Axis] Subsequent Event Type [Axis] Scenario [Axis] Net loss Net cash provided by operating activities Minimum amount (in Yuan Renminbi) Number of loan agreements Term of the loan Allowance for uncollectable accounts receivable Impairment loss Advertising and promotion expense Operating lease term of contract Equity interest Annual interest rate Cash and cash equivalents Deposits covered by insurance Amount not covered by issuance Maximum compensation Insurance coverage upper limit Concentration of credit risk Number of customers (in customers) Concentration risk percentage Total revenues percentage Number of vendor (in vendors) Vendor percentage Vendor concentration risk percentage Inventory cost of finished goods Inventory Total loan receivables Percentage of annual interest Equity interest Total consideration (in Dollars) ROU asset and lease liability Operating lease term Total lease expense Loan amount Loan term Principal amount Unpaid interest Payment of principal and interest Unpaid principal amount Amount of contributions Applicable tax rate Statutory income tax rate Income tax liability Undistributed earnings available for distribution (in Dollars) Withholding income tax percentage Withholding tax rate Investor holding percentage Annual dividends Reverse ADS split ratio Increased its authorized shares value (in Dollars) Divided into ordinary shares (in Shares) Divided shares value (in Dollars) Additional ordinary shares (in Shares) Additional shares par value Sale of units (in Shares) Sell an aggregate shares (in Shares) Sale of units price per share Sell an aggregate price per share Aggregate purchase price (in Dollars) Net proceeds (in Dollars) Term of warrants Number of ordinary shares (in Shares) Number of warrants share (in Shares) Purchase of warrants (in Shares) Purchase price per share Warrants outstanding (in Dollars) Number of shares to purchase warrants (in Shares) Weighted average exercise price of warrants Warrants outstanding (in Shares) Number of shares to be repurchased Term of repurchase Repurchase of ordinary shares (in Shares) Total consideration on repurchase of shares Restricted net assets Annual basis percentage Registered capital percentage Statutory reserve Registered capital percentage Equity interest rate Total consideration (in Dollars) Cash consideration (in Dollars) Ordinary shares par value Issuance of ordinary shares (in Shares) Warrants to purchase price per share Aggregate purchase price (in Dollars) Net proceeds (in Dollars) Warrants to purchase price per share Warrants to purchase price per share Interest rate (in Dollars) Net assets percentage Basis of presentation Basis of consolidation Consolidated VIEs Revenue recognition Uses of estimates Fair value of financial instruments Discontinued Operations Cash and cash equivalents Accounts receivable and allowance for uncollectable accounts Inventories Property and equipment, net Impairment of long-lived assets Advertising and promotion expenses Lease Warrants Share-based compensation Treasury stock Income taxes Noncontrolling interests Earnings (loss) per share Foreign currency translation Significant risks and uncertainties Recent Accounting Pronouncements Commission Revenue [Member] Commission Services [Member] Interest income [Member] Other Investors [Member] We Healthy Limited [Member] Customers One [Member] Accounts Receivable [Member] One Customer Concentration Risk [Member] Customers Two [Member] Two Customer Concentration Risk [Member] Customers Three [Member] Three Customer Concentration Risk [Member] Vendor [Member] Hexin E-Commerce Company Limited [Member] Disposition SPA [Member] Tianjin Akso Enterprise Management Co., Ltd [Member] Tianjin Wangyi Cloud Technology Co., Ltd [Member] Tianjin Akso Enterprise Management Co., Ltd One [Member] Webao Ltd [Member] Commercial Loan [Member] U.S. [Member] We Health [Member] Akso Remote Medical [Member] Akso Online MediTech [Member] PRC [Member] Private Placement [Member] Warrant Shares [Member] Warrant [Member] Securities Purchase Agreement [Member] American Depository Shares [Member] American Depository Member American Depository Shares [Member] Subsequent Event [Member] Class A Ordinary Shares [Member] Common Class A [Member] Class B Ordinary Shares [Member] Webao Limited [Member] Forecast [Member] PRC [Member] Related and Nonrelated Parties [Domain] Statement [Table] Statement [Line Items] Product and Service [Domain] Equity Component [Domain] Ownership [Domain] Subsidiary of LLC or LP [Table] Subsidiary of Limited Liability Company or Limited Partnership [Line Items] Consolidated Entities [Domain] Variable Interest Entity [Table] Variable Interest Entity [Line Items] Related Party Transaction [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Long-Lived Tangible Asset [Domain] Statistical Measurement [Domain] Summary of Significant Accounting Policies (Details) Schedule of Estimated Useful Lives of Property and Equipment [Table] Summary of Significant Accounting Policies (Details) Schedule of Estimated Useful Lives of Property and Equipment [Line Items] Entity [Domain] Summary of Significant Accounting Policies (Details) Schedule of Noncontrolling Interest [Table] Summary of Significant Accounting Policies (Details) Schedule of Noncontrolling Interest [Line Items] Disposal Group Classification [Domain] Disposal Groups, Including Discontinued Operations [Table] Schedule of Discontinued Operations [Line Items] Discontinued Operation (Details) Schedule of Loss on Sale of Discontinued Operations [Table] Discontinued Operation (Details) Schedule of Loss on Sale of Discontinued Operations [Line Items] Award Date [Domain] Class of Warrant or Right [Table] Schedule of Warrants Exercisable [Line Items] Condensed Balance Sheet Statement [Table] Condensed Balance Sheet Statements, Captions [Line Items] Condensed Statement of Comprehensive Income [Table] Condensed Statement of Income Captions [Line Items] Condensed Cash Flow Statement [Table] Condensed Cash Flow Statements, Captions [Line Items] Customer [Domain] Concentration Risk Type [Domain] Concentration Risk Benchmark [Domain] Debt Instrument Name [Domain] Summary of Significant Accounting Policies (Details) [Table] Summary of Significant Accounting Policies [Line Items] Disposal Group Name [Domain] Discontinued Operation (Details) [Table] Discontinued Operation [Line Items] Investment Name [Domain] Prepaid Consideration (Details) [Table] Prepaid Consideration [Line Items] Financial Instruments [Domain] Related Party Balances and Transactions (Details) [Table] Related Party Balances and Transactions [Line Items] Geographical [Domain] Income Taxes (Details) [Table] Income Taxes [Line Items] Sale of Stock [Domain] Type of Agreement [Domain] Class of Warrant or Right [Domain] Shareholders' Equity (Details) [Table] Shareholders' Equity [Line Items] Class of Stock [Domain] Treasury Stock (Details) [Table] Treasury Stock [Line Items] Scenario [Domain] Subsequent Event Type [Domain] Business Acquisition, Acquiree [Domain] Subsequent Events (Details) [Table] Subsequent Events [Line Items] Condensed Financial Information of the Parent Company (Details) [Table] Condensed Financial Information of the Parent Company [Line Items] Accounts receivable and contract assets, net Accrued expenses and other current liabilities Number of additional ordinary shares Number of additional share par value The disclosure of advertising and promotion expenses Amount of aggregate purchase price Amount not covered by issuance in pre-Average remaining contractual life Amount of cash and cash equivalents and cash and cash equivalents restricted to withdrawal or usage attributable to disposal group including but not limited to discontinued operations Cash includes but is not limited to currency on hand demand deposits with banks or financial institutions and other accounts with general characteristics of demand deposits Cash equivalents include but are not limited to short-term highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates Exercise price per share or per unit of warrants or rights outstanding For an entity that discloses a concentration risk in relation to quantitative amount which serves as the "benchmark" (or denominator) in the equation this concept represents the concentration percentage derived from the division Debt instrument accrued interest payment It represents outstanding balance of unpaid principal amount Deposits covered by insurance upper limit The amount of net assets It represents a reduction in the amount of tax which is disposal group including discontinued operation tax (benefit) payable Represent the amount of divided shares value Number of divided into ordinary shares Percentage of domestic federal statutory tax rate applicable to pretax income (loss) Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to holiday and preferential statutory income tax rate Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign losses Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses and others Income tax liability maximum amount of underpayment Represent the amount of increased authorized shares value Insurance coverage upper limit Ownership percentage of the FIE by foreign investors to qualify for withholding tax rate limit for dividends paid by an FIE in China to its immediate holding company in Hong Kong Maximum compensation limit by hong kong deposit protection board Minimum amount the amount of net proceeds Represent the amount of net proceeds from private placement The disclosure of noncontrolling interests policy text block Number of customers Number of loan agreements Number of vendor Number of ordinary shares Number of warrants share Percentage of annual interest Represents information pertaining to dividend as a percentage of the Company's anticipated net income after tax The amount of prepaid consideration Purchase of Warrant Shares Purchase price per share of warrant Registered capital percentage Represents the minimum percentage of net income from subsidiaries required to be appropriated towards the statutory reserve fund for entities incorporated in the People's Republic of China until the reserve balance reaches 50 percent of registered capital Reserve reaches of its registered capital The amount of revenue from medical devices PRC The amount of revenue from medical devices U.S The entire disclosure right of use lease assets Tabular disclosure of schedule of current taxes payable table text block Tabular disclosure of the foreign exchange rates used in the preparation of the financial statements Tabular disclosure of noncontrolling interest Tabular disclosure of the depreciation recognized in the consolidated statements of comprehensive income Tabular disclosure of loss on sale of discontinued operation Tabular disclosure of the warrants outstanding The number of equity-based payment instruments excluding stock (or unit) options that were warrants exercised during the reporting period The number of equity-based payment instruments excluding stock (or unit) options that were warrants expired during the reporting period The number of equity-based payment instruments excluding stock (or unit) options that were warrants issued during the reporting period The number of outstanding equity-based payment instruments excluding stock (or unit) options that validly exist and are outstanding as of the balance sheet date Per share or unit weighted average fair value of exercisable award under share-based payment arrangement Excludes share and unit options Per share or unit weighted average fair value of exercised award under share-based payment arrangement Excludes share and unit options Per share or unit weighted average fair value of issued award under share-based payment arrangement Excludes share and unit options Per share or unit weighted average fair value of warrants outstanding award under share-based payment arrangement Excludes share and unit options Intrinsic value of exercised award under share-based payment arrangement Excludes share and unit options Share-Based Compensation Arrangement by Share-Based Payment Award Equity Instruments Other than Options Aggregate Intrinsic Value Expired Intrinsic value of issued award under share-based payment arrangement Excludes share and unit options Share-Based Compensation Arrangement by Share-Based Payment Award Equity Instruments Other than Options Aggregate Intrinsic Value Exercisable Disclosure of accounting policy for significant risks and uncertainties Statutory reserve Number of shares in exercise of warrants Represent the amount of exercise of warrants Amount of tax and surcharges The entire disclosure taxes payable current disclosure text block The term of loan agreements among affiliated parties in "PnYnMnDnTnMnS" format for example "P1Y5M13D" represents the reported fact of one year five months and thirteen days The disclosure of treasury stock policy text block Amount of undistributed earnings available for distribution Vendor concentration risk percentage Percentage of remaining performance obligation to total remaining performance obligation not recognized as vendor Represents the weighted average exercise price of warrants Represents the rate of withholding tax for dividends paid by an FIE in China to its immediate holding company in Hong Kong under specified conditions Represents the percentage of withholding income tax rate on dividends distributed by the Foreign Invested Enterprise to its immediate holding company Address Type [Domain] Other Accounts Payable and Accrued Liabilities Stockholders' Equity Reverse Stock Split Commission Services Member Assets [Abstract] Disposal Group Including Discontinued Operation Consideration Disposal Group Including Discontinued Operation Accounts Payable and Accrued Liabilities Current Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Earnings Per Share Diluted Derivatives Policy [Policy Text Block] Retained Earnings [Member] Proceeds from (Repayments of) Related Party Debt Accounts Payable Accrued Liabilities and Other Liabilities Disclosure Current [Text Block] Akso Remote Medical Member Common Class B [Member] Akso Online Medi-Tech Member Weighted Average Number of Shares Outstanding Basic Accrued Professional Fees Current Required Percentage Of Net Income Allocated To Statutory Surplus Reserves Schedule of Variable Interest Entities [Table Text Block] Continuing Operations Abstract Other Nonoperating Income (Expense) Deposits Covered By Insurance Upper Limit Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries Cash Provided by (Used in) Operating Activities Discontinued Operations Disposal Group Including Discontinued Operation Liabilities Local Phone Number Condensed Statement of Comprehensive Income [Table Text Block] Webao Limited Member Revenue Abstract Auditor Name Hexin E-Commerce Company Limited Member Stock Issued During Period Shares New Issues Revenue Remaining Performance Obligation Percentage Entity Common Stock Shares Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options Warrants Issued Document Registration Statement Disposal Groups Including Discontinued Operations Disclosure [Text Block] Ordinary Shares Par Value US\$00001 Per Share Member PRC Member Title of 12(b) Security Other Assets Noncurrent Customers One Member Share-Based Compensation Arrangement by Share-Based Payment Award Equity Instruments Other than Options Aggregate Intrinsic Value Outstanding Entity Well-known Seasoned Issuer Additional Paid-in Capital Operating Expenses [Abstract] Noncontrolling Interest Increase from Subsidiary Equity Issuance Disposition SPAMember Document Accounting Standard Income (Loss) from Subsidiaries Net of Tax Insurance Coverage Upper Limit Earnings Per Share Basic Other Disclosure [Abstract] Supplemental Cash Flow Information [Abstract] Warrants and Rights Outstanding Accounts Payable and Other Accrued Liabilities Current Net Cash Provided by (Used in) Operating Activities [Abstract] Long-Term Debt Term Equity Attributable to Parent [Abstract] Disposal Group Including Discontinued Operation Accounts Payable Current Prepaid Expense Current Security Exchange Name Forecast [Member] Minimum [Member] Schedule of Stockholders' Equity Note Warrants or Rights [Table Text Block] Common Stock Shares Outstanding Customer Concentration Risk One Member Schedule Of Condensed Balance Sheets Abstract American Depository Shares Member Retained Earnings (Accumulated Deficit) Sharebased Compensations Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable VIEs Member Net Cash Provided by (Used in) Investing Activities Additional Share Par Value Other Liabilities Inventory Finished Goods Gross Number of Ordinary Shares Comprehensive Income (Loss) Net of Tax Attributable to Parent [Abstract] Unlabeled Abstract11 Business Description and Basis of Presentation [Text Block] Unlabeled Abstract12 Disaggregation Of Revenue Member Purchase Of Warrant Shares Unlabeled Abstract10 Percentage Of Annual Interest Unlabeled Abstract15 We Healthy Member Unlabeled Abstract16 Unlabeled Abstract13 Unlabeled Abstract14 Share-Based Payment Arrangement [Policy Text Block] Unlabeled Abstract19 Withholding Tax Rate On Dividend Distributed By Foreign Invested Enterprise To Its Immediate Holding Company Dividendo Ordinary Shares Interest Paid Excluding Capitalized Interest Operating Activities Unlabeled Abstract17 Unlabeled Abstract18 Akso First Health Treatment Center Inc Akso First Health Member Maximum Compensation Limit By Hong Kong Deposit Protection Board Stock Issued During Period Value Exercise Of Warrants Treasury Stock Common [Member] Inventory Disclosure [Text Block] Accrued Income Taxes Current Prepaid Expense and Other Assets Current Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options Warrants Exercised Effective Income Tax Rate Reconciliation Nondeductible Expense Foreign Losses Percent Maximum [Member] Income Tax Policy [Policy Text Block] March52024 Warrants Member Entity Address Address Line One Unlabeled Abstract22 UNITED STATES Common Stock Shares Authorized Unlabeled Abstract23 Treasury Stock [Text Block] Unlabeled Abstract20 Schedule Of Warrants Exercisable Abstract Entity Incorporation State or Country Code Entity Address Address Line Two Effective Income Tax Rate Reconciliation Effect Of Tax Holiday And Preferential Statutory Income Tax Rate Unlabeled Abstract21 Right of Use Asset Obtained in Exchange for Operating Lease Liability Tianjin Akso Enterprise Management Co Ltd Member Entity Address Address Line Three Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations Net of Tax Per Diluted Share Revenue from Contract with Customer Including Assessed Tax

Accounts Receivable [Policy Text Block] Schedule Of Discontinued Operations Abstract Additional Number Of Ordinary Shares Other Investors Member Increase (Decrease) in Operating Capital [Abstract] Also Online Medi Tech Co Ltd Also Online Medi Tech Member Net Cash Provided by (Used in) Financing Activities [Abstract] January 172024 Warrants Member Additional Paid in Capital [Member] Accounts and Other Receivables, Not Current Disposal Group Including Discontinued Operation, Cash and Cash Equivalents Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Expired Class of Warrant or Right, Number of Securities Called by Warrants or Rights Allowance for Credit Loss, Receivable, Other, Current Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Net Cash Provided by (Used in) Investing Activities [Abstract] Disposal Group, Including Discontinued Operation, Revenue Denominator Abstract Income (Loss) from Continuing Operations, Per Basic Share Contact Personnel Name Net Cash Provided by (Used in) Financing Activities, Continuing Operations Stock Issued During Period, Shares, Restricted Stock Award, Gross Sale Of Medical Devices Member Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Significant Accounting Policies [Table Text Block] Schedule Of Sale Of Discontinued Operation Table Text Block Increase (Decrease) in Other Operating Assets Unlabeled Abstract2 Unlabeled Abstract5 Net Cash Provided by (Used in) Operating Activities, Continuing Operations Unlabeled Abstract4 AQCI Attributable to Parent [Member] Unlabeled Abstract1 Unlabeled Abstract6 Property, Plant and Equipment, Useful Life Schedule Of Noncontrolling Interest Abstract Also Medical Cloud Limited Also Medical Cloud Member Document Shell Company Report Unlabeled Abstract7 Unlabeled Abstract6 Foreign Currency Exchange Rate, Translation Proceeds from Related Party Debt Comprehensive Income (Loss), Net of Tax Attributable to Parent Unlabeled Abstract9 Unlabeled Abstract8 Income (Loss) from Continuing Operations, Per Diluted Share Derivative, Average Exchange Rate Floor Cash Provided by (Used in) Investing Activities, Discontinued Operations Related Party Transactions Disclosure [Text Block] Interest Income (Expense), Operating Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Accounts Receivable, Allowance for Credit Loss [Table Text Block] Net Cash Provided by (Used in) Operating Activities Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised Usd Abstract Debt Instrument Agreement Of Unpaid Principal Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Outstanding Accrued Payroll Taxes, Current Warrant, Exercise Price, Increase Stock Issued During Period Shares Exercise Of Warrants Increased Authorized Shares Value Office Equipment [Member] We Health Limited We Health Member Warrants Weighted Average Exercise Price Substantial Doubt about Going Concern [Text Block] Proceeds from Collection of Loans Receivable Revenue From Medical Devices PRC Equity, Attributable to Parent Average Remaining Contractual Life Effective Income Tax Rate Reconciliation Nondeductible Expenses And Others Percent Accumulated Other Comprehensive Income (Loss), Net of Tax Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Exercisable Condensed Cash Flow Statement [Table Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Tax And Surcharges Member Asset Acquisition, Consideration Transferred Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Cash and Cash Equivalents, Policy [Policy Text Block] Number of Warrants Share Unlabeled Abstract Us Exchange Rate Abstract Current Fiscal Year End Date Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Cash Provided by (Used in) Financing Activities, Discontinued Operations Entity Address, Postal Zip Code Document Fiscal Period Focus Prepaid Expense and Other Assets Other Assets Deferred Income Tax Expense (Benefit) Schedule Of Estimated Useful Lives Of Property And Equipment Abstract Net Income (Loss) Attributable to Noncontrolling Interest Interest Paid, Including Capitalized Interest, Operating and Investing Activities Customer Concentration Risk Three Member Disposal Group, Including Discontinued Operation, Operating Income (Loss) Disposal Group, Including Discontinued Operation, Liabilities, Current Equity, Including Portion Attributable to Noncontrolling Interest Schedule Of Condensed Statements Of Cash Flows Abstract Shareholders Equity Abstract0 Disposal Groups, Including Discontinued Operations [Table Text Block] Equity [Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Share Repurchase Program, Period in Force Sale of Stock, Number of Shares Issued in Transaction Business Contact [Member] Schedule Of Current Taxes Payable Table Text Block Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Operating Expenses Defined Contribution Plan, Cost Statement of Financial Position [Abstract] Cash and Cash Equivalents, at Carrying Value Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Continued Operations Securities Purchase Agreement Member Other Current Assets [Text Block] Shares Issued, Price Per Share Entity File Number Schedule Of Warrants Outstanding Table Text Block Warrant Shares Member Repayments of Senior Debt Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Exercisable Lessor, Operating Lease, Term of Contract Document Type Discontinued Operations, Policy [Policy Text Block] Document Period End Date Entity Interactive Data Current Also Remote Medical Consultation Center Inc Also Remote Medical Member Registered Capital Percentage Condensed Balance Sheet [Table Text Block] Accrued Expenses And Other Current Liabilities Equity Attributable to Noncontrolling Interest Weighted Average Number of Shares Outstanding, Diluted, Adjustment Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Other Nonoperating Income Liabilities [Abstract] Prepaid Supplies Share Based Payment Arrangement, Noncash Expense Reserve Reaches Of Its Registered Capital Debt Instrument, Interest Rate During Period Trading Symbol Disposal Group Including Discontinued Operation Tax Benefit Payable Numerator Abstract Minimum Amount Inventory, Net Entity Address, City or Town Use of Estimates, Policy [Policy Text Block] Commitments and Contingencies Nonoperating Income (Expense) [Abstract] Common Stock, Value, Issued City Area Code Net Cash Provided by (Used in) Investing Activities, Continuing Operations Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Noncontrolling Interest [Member] Share Repurchase Program, Authorized, Amount Accounts Receivable, after Allowance for Credit Loss Net Investment in Lease, before Allowance for Credit Loss Lessee, Leases [Policy Text Block] Entity Voluntary Filers Document Financial Statement Error Correction [Flag] Other Nonoperating Expense Increase (Decrease) in Prepaid Expense and Other Assets Inventory, Gross Commercial Loan [Member] Discontinued Operations, Held for Sale [Member] Noncontrolling Interests Policy Text Block Stock Issued During Period, Value, New Issues Customers Two Member Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Cost of Goods and Services Sold Statement of Stockholders' Equity [Abstract] Basis of Accounting, Policy [Policy Text Block] Parent Company [Member] Schedule Of Condensed Statements Of Comprehensive Loss Income Abstract Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Subsidiary of Limited Liability Company or Limited Partnership, State Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Issued Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations Income Tax Expense (Benefit) Income Statement [Abstract] Payments to Acquire Loans Receivable Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expired New Accounting Pronouncements, Policy [Policy Text Block] Taxes Payable Loans Receivable, Fair Value Disclosure APIC, Share Based Payment Arrangement, Increase for Cost Recognition November 162023 Warrants Member Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Earnings Per Share, Basic Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Accounts Receivable, before Allowance for Credit Loss, Current Revenues [Abstract] Treasury Stock, Value Assets Liabilities Type of Agreement Axis Proceeds from (Payments for) Other Financing Activities Accounts Receivable [Member] Schedule Of The Companies Principal Subsidiaries Abstract Entity Shell Company Subsequent Events [Text Block] Asset, Held for Sale, Not Part of Disposal Group, Other, Current Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Outstanding Derivative, Net Assets, Percentage Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Significant Risks And Uncertainties Policy Policy Text Block Schedule Of Disaggregation Of Revenue Abstract Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Issued Increase (Decrease) in Inventories No Trading Symbol Flag Accounts Receivable, Allowance for Credit Loss, Current Gain (Loss), Foreign Currency Transaction, before Tax Discontinued Operations Abstract Treasury Stock Policy Text Block Inventory, Policy [Policy Text Block] Restricted Assets Disclosure [Text Block] China, Yuan Renminbi Customers Three Member Warrants and Rights Outstanding, Term Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block] Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest Repayments of Related Party Debt Customer Concentration Risk Two Member Concentration Risk Percentage Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Disposal Group, Including Discontinued Operation, Assets, Current Accounts Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Noncurrent Asset Acquisition, Consideration Transferred, Other Assets Subsequent Event [Member] Warrant [Member] Payments for (Proceeds from) Previous Acquisition Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Amendment Flag Aggregate Purchase Price Accrual for Taxes Other than Income Taxes, Current Entity Address, Country Accounts Receivable, Credit Loss Expense (Reversal) Disposal Group Including Discontinued Operation Net Assets Taxes Payable Current Disclosure Text Block Sale of Stock, Consideration Received on Transaction Tianjin Also Enterprise Management Co Limited Wholly Owned Foreign Enterprise WOFEMember Effective Income Tax Rate Reconciliation, Tax Credit, Percent Disposal Group, Including Discontinued Operation, Other Liabilities, Current Entity Central Index Key Current Liabilities Abstract0 Foreign Currency Transactions and Translations Policy [Policy Text Block] Operating Income (Loss) Auditor Location Selling and Marketing Expense Vendor Member Repayments of Long-Term Debt Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Accounts Receivable, Allowance for Credit Loss Accounts Receivable And Contract Assets Current Schedule Of Foreign Exchange Rates Table Text Block Common Class A [Member] Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates Percent Accrued Liabilities and Other Liabilities Investment Owned, Balance, Principal Amount Income (Loss) from Equity Method Investments Sale of Stock, Price Per Share American Depository Shares Member Taxes Payable, Current Common Stock [Member] Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Document Annual Report Entity Registrant Name Investor Holding Percentage Subsidiary of Limited Liability Company or Limited Partnership, Date Statement of Cash Flows [Abstract] Interest Expense, Operating and Nonoperating Class of Warrant or Right, Outstanding Income Tax Disclosure [Text Block] October 2023 Warrants Member Number Of Vendor Equity Method Investment, Ownership Percentage Compensation and Employee Benefit Plans [Text Block] Other Receivables, Gross, Current Condensed Financial Information of Parent Company Only Disclosure [Text Block] Schedule Of Financial Statement Amounts And Balances Of The Consolidated Vies Abstract Liabilities, Current [Abstract] Also Medicare Limited Also Medicare Member Withholding Tax Rate Schedule Of Property Equipment And Software Depreciation Recognized Table Text Block Treasury Stock, Value, Acquired, Cost Method Interest Income1 Member Other Assets, Current Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Prepaid Consideration Accounts and Nontrade Receivable [Text Block] Right Of Use Lease Asset Text Block We Healthy Limited Member Statutory Reserve Tianjin Wangyi Cloud Technology Co Ltd Member Divided Shares Value Operating Lease, Weighted Average Remaining Lease Term Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Other Assets Disclosure [Text Block] Number Of Loan Agreements Amount Not Covered By Issuance In Pre Increase (Decrease) in Accounts Payable and Accrued Liabilities Vendor Remaining Performance Obligation Percentage Earnings Per Share [Text Block] Vendor Concentration Risk Percentatge Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Revenues Interest Payable, Current Marketing and Advertising Expense Treasury Stock, Common, Shares Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Accrued Taxes Payable Assets Abstract0 Wholly Owned Subsidiaries Abstract Other Receivables, Net, Current Income Tax Liability Maximum Amount Of Underpayment August 2021 Warrants Member General and Administrative Expense Noncontrolling Interest in Variable Interest Entity Retirement Benefits [Abstract] Concentration Risk, Percentage Commission Revenue Member Revenue [Policy Text Block] Qindao Also Health Management Co Limited Member Contract with Customer, Liability, Current Document Fiscal Year Focus ICFR Auditor Attestation Flag Current Assets Abstract0 Discontinued Operation, Tax Effect of Discontinued Operation Related Party Transaction, Amounts of Transaction Earnings Per Share, Policy [Policy Text Block] Entity Current Reporting Status Common Stock, Shares, Issued Proceeds from Issuance of Private Placement Entity Emerging Growth Company American Depository Sharesone American Depository Share Representing Three Ordinary Shares Par Value US00001 Per Share Member Other Liabilities, Current Weighted Average Number of Shares Outstanding, Diluted Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Webao Ltd Member Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Exercised Gross Profit Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Expired Operating Lease, Expense Contact Personnel Email Address Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Auditor Firm ID Private Placement [Member] Accounts Receivable, after Allowance for Credit Loss, Current Undistributed Earnings Available For Distribution Document Transition Report Net Loss Per Share Abstract Related Party [Member] Net Income (Loss) Attributable to Parent Disaggregation of Revenue [Table Text Block] We Healthy Limited We Healthy Member Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Stock Issued During Period, Value, Restricted Stock Award, Gross Debt Instrument, Face Amount Receivables, Net, Current Increase (Decrease) in Accounts and Other Receivables Assets, Current [Abstract] Debt Instrument Accrued Interest Payment Advertising And Promotion Expenses Policy Text Block Cash Number Of Customers Other Receivable, after Allowance for Credit Loss, Noncurrent Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Liabilities, Current Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Tianjin Also Enterprise Management Co Ltd One Member Net Proceeds From the Private Placement Term Of Loan Agreements With Affiliated Parties Consolidation, Policy [Policy Text Block] Liabilities and Equity [Abstract] Shares, Outstanding Commitments and Contingencies Disclosure [Text Block] We Health Member Disposal Group, Including Discontinued Operation, Operating Expense Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Cash Equivalents, at Carrying Value Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Tax And Surcharges Entity Filer Category Treasury Stock, Shares, Acquired, Warrant, Exercise Price, Decrease Class of Warrant or Right, Exercise Price of Warrants or Rights Income Taxes Paid Percentage Of Dividend Revenue From Medical Devices US Impairment, Long-Lived Asset, Held-for-Use Liabilities and Equity Current Income Tax Expense (Benefit) Schedule Of Noncontrolling Interest Table Text Block Purchase Price Per Share Share Revenues, Net of Interest Expense Net Proceeds Consolidation, Variable Interest Entity, Policy [Policy Text Block] Excess Stock, Shares Issued Assets, Current Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest EX-101.PRE 19 aq-

Document And Entity Information12 Months Ended

Mar. 31, 2024
shares

Document Information Line Items Entity Registrant Name Also Health Group Document Type 20 F Current Fiscal Year End Date 03-31 Entity Common Stock, Shares Outstanding 437,170,960 Amendment Flag false Entity Central Index Key 0001702318 Entity Current Reporting Status Yes Entity Voluntary Filers No Entity Filer Category Non-accelerated Filer Entity Well-known Seasoned Issuer No Document Period End Date Mar. 31, 2024 Document Fiscal Year Focus 2024 Document Fiscal Period Focus FY Entity Emerging Growth Company false Entity Shell Company false ICFR Auditor Attestation Flag false Document Registration Statement false Document Annual Report true Document Transition Report false Document Shell Company Report false Entity File Number 001-38245 Entity Incorporation, State or Country Code E9 Entity Address, Address Line One Room 8201-4 4(A), 2nd Floor, Qiantongyuan Building Entity Address, Address Line Two No. 44, Moscow Road Entity Address, Address Line Three Qianwan Bonded Port Area Entity Address, City or Town Qingdao Entity Address, Country CN Entity Interactive Data

[Current](#)[Yes](#)[Document Financial Statement Error Correction \[Flag\]](#)[false](#)[Document Accounting Standard](#)[U.S. GAAP](#)[Auditor Name](#)[ONESTOP ASSURANCE PAC](#)[Auditor Firm ID](#)[6732](#)[Auditor Location](#)[Singapore](#)[Entity Address, Postal Zip Code](#)[100020](#)[Business Contact](#)[Document Information Line Items](#)[Entity Address, Address Line One](#)[Room](#)[#201-4-4\(A\)](#)[2nd Floor](#)[Qiantongyuan Building](#)[Entity Address, Address Line Two](#)[No. 44](#)[Moscow Road](#)[Entity Address, Address Line Three](#)[Qianwan Bonded Port Area](#)[Entity Address, City or Town](#)[Qingdao](#)[Entity Address, Country](#)[CN](#)[Contact Personnel Name](#)[Rui \(Kerrie\) Zhang](#)[City Area Code](#)[+86](#)[Local Phone Number](#)[152 1005 4919](#)[Contact Personnel Email Address](#)[ir@ahgtop.com](#)[Entity Address, Postal Zip Code](#)[100020](#)[American depository shares \(one American depository share representing three Class A ordinary shares, par value US\\$0.0001 per share\)](#)[Document Information Line Items](#)[Trading Symbol](#)[AHG](#)[Title of 12\(b\) Security](#)[American depository shares \(one American depository share representing three Class A ordinary shares, par value US\\$0.0001 per share\)](#)[Security Exchange Name](#)[NASDAQ](#)[Class A ordinary shares, par value US\\$0.0001 per share](#)[Document Information Line Items](#)[Title of 12\(b\) Security](#)[Class A ordinary shares, par value US\\$0.0001 per share](#)[Security Exchange Name](#)[NASDAQ](#)[No Trading Symbol Flag](#)[true](#)

[XML 22 R2.htm IDEA](#)[XBRL DOCUMENT](#)

Consolidated Balance Sheets - USD (\$)	Mar. 31, 2024	Mar. 31, 2023
CURRENT ASSETS:		
Cash and cash equivalents	\$ 85,174,017	\$ 7,924,468
Accounts receivable, net		7,696,983
Prepayments and other assets	402,899	272,129
Inventories	191,201	1,686,449
Current assets held for sale - discontinued operation		1,351,352
Loan receivables		1,528,918
Prepaid consideration	56,250,000	
TOTAL CURRENT ASSETS	142,018,117	20,460,299
TOTAL ASSETS	142,018,117	20,460,299
CURRENT LIABILITIES:		
Accrued expenses and other current liabilities	1,104,812	938,767
Contract liabilities	415,020	194,376
Taxes payable	74,091	96,005
Current liabilities held for sale - discontinued operation		705,483
TOTAL CURRENT LIABILITIES	3,593,923	11,620,783
TOTAL LIABILITIES	3,593,923	11,620,783
COMMITMENTS AND CONTINGENCIES (Note 20)		
SHAREHOLDERS' EQUITY:		
Ordinary share (\$0.0001 par value, 5,000,000,000 shares authorized, 438,336,843 and 69,763,933 shares issued, 437,170,960 and 68,598,050 shares outstanding as of March 31, 2024 and 2023, respectively)	43,834	6,977
Additional paid-in capital	210,324,890	71,021,898
Treasury stock (1,165,883 shares as of March 31, 2024 and 2023, respectively)	(3,988,370)	(3,988,370)
Accumulated deficit	(63,926,383)	(54,467,600)
Accumulated other comprehensive loss	(4,086,587)	(3,847,601)
TOTAL SHAREHOLDERS' EQUITY	138,367,384	8,725,304
Non-controlling interest	56,810	114,212
TOTAL EQUITY	138,424,194	8,839,516
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	142,018,117	20,460,299
Related Party		
CURRENT LIABILITIES:		
Amount due to related parties	\$ 2,000,000	\$ 9,686,152

[XML 23 R3.htm IDEA](#)[XBRL DOCUMENT](#)

Consolidated Balance Sheets	Mar. 31, 2024	Mar. 31, 2023	
(Parenteticals) - \$ / shares			
Statement of Financial Position [Abstract]			
Ordinary shares, par value (in Dollars per share)	\$ 0.0001	\$ 0.0001	
Ordinary shares, shares authorized	500,000,000	500,000,000	
Ordinary shares, shares issued	438,336,843	69,763,933	
Ordinary shares, shares outstanding	437,170,960	68,598,050	
Treasury stock	1,165,883	1,165,883	
XML 24 R4.htm IDEA XBRL DOCUMENT			
Consolidated Statements of Operations and Comprehensive (Loss) - USD (\$)	12 Months Ended		
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
REVENUES			
Net Revenues	\$ 2,414,338	\$ 13,181,561	\$ 6,000,000
Cost of goods sold	2,292,206	11,912,571	5,394,866
Gross Profit	122,132	1,268,990	605,134
OPERATING EXPENSE			
Sales and marketing	168,421	6,661	
General and administrative	8,591,751	15,529,182	2,669,834
Finance cost			804,138
Share-based compensation			391,625
Total Operating Expenses	8,760,172	15,535,843	3,865,597
LOSS FROM CONTINUING OPERATIONS	(8,638,040)	(14,266,853)	(3,260,463)
OTHER INCOME (EXPENSE)			
Other income	252,408	395,668	5,103
Other expense	(114,168)	(338,310)	(4,419)
Exchange (loss) gain	(591,991)	1,143,006	(748,502)
Total Other (Expense) Income, net	(453,751)	1,200,364	(747,818)
(LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(9,091,791)	(13,066,489)	(4,008,281)
PROVISION FOR INCOME TAXES	24,988	17,549	92,816
NET (LOSS) FROM CONTINUING OPERATIONS	(9,116,779)	(13,084,038)	(4,101,097)
Net (loss) gain income from discontinued operations, net of income taxes	(3,884)	11,836,612	(12,748,636)
Loss from disposal of discontinued operations, net of income taxes	(395,914)		
Total (loss) gain from discontinued operations	(399,798)	11,836,612	(12,748,636)
NET (LOSS)	(9,516,577)	(1,247,426)	(16,849,733)
Less: net (loss) income attributable to non-controlling interest	(57,793)	112,497	1,331
NET (LOSS) ATTRIBUTABLE TO AKSO'S SHAREHOLDERS	(9,458,784)	(1,359,923)	(16,851,064)
OTHER COMPREHENSIVE (LOSS)			
Foreign currency translation adjustment	(238,594)	(2,198,640)	1,454,336
COMPREHENSIVE (LOSS)	(9,755,171)	(3,446,066)	(15,395,397)
Less: comprehensive income (loss) attributable to non-controlling interest	391	(261)	17
COMPREHENSIVE (LOSS) ATTRIBUTABLE TO AKSO'S SHAREHOLDERS	\$ (9,755,562)	\$ (3,445,805)	\$ (15,395,414)
Continuing operations			
Basic (in Dollars per share)	\$ (0.07)	\$ (0.2)	\$ (0.07)
Diluted (in Dollars per share)	(0.07)	(0.2)	(0.07)
Discontinued operations			
Basic (in Dollars per share)		0.18	(0.21)
Diluted (in Dollars per share)		0.18	(0.21)
Net (loss) per share			
Basic (in Dollars per share)	(0.07)	(0.02)	(0.28)

Diluted (in Dollars per share)	\$ (0.07)	\$ (0.02)	\$ (0.28)
Weighted average shares			
Basic (in Shares)	141,516,777	68,598,050	59,612,152
Diluted (in Shares)	141,516,777	68,598,050	59,612,152
Sale of medical devices			
REVENUES			
Revenues	\$ 2,416,797	\$ 13,186,525	\$ 6,000,000
Tax and surcharges			
REVENUES			
Revenues	\$ (2,459)	\$ (4,964)	

~~XML 25 R5.htm IDEA XBRL DOCUMENT~~

Consolidated Statements of Changes in Shareholders' Equity - USD (\$)	Ordinary Shares	Additional Paid-in Capital	Treasury stock	(Accumulated Deficit)	Accumulated Other Comprehensive (Loss)	Non- controlling interest	Total
Balance at Apr. 30, 2021	\$ 5,002	\$ 60,615,048	\$ (3,988,370)	\$ (36,256,612)	\$ (3,103,543)		\$ 17,271,525
Balance (in Shares) at Apr. 30, 2021	50,016,457		(1,165,883)				
Private placement	\$ 1,902	10,015,298					10,017,200
Private placement (in Shares)	19,020,000						
Share-based compensation		391,625					391,625
Exercise of RSU	\$ 73	(73)					
Exercise of RSU (in Shares)	727,476						
Capital contribution from non-controlling interest ("NCI")						628	628
Net (loss) income				(16,851,064)		1,331	(16,849,733)
Foreign currency translation adjustment					1,454,320	17	1,454,336
Balance at Mar. 31, 2022	\$ 6,977	71,021,898	\$ (3,988,370)	(53,107,676)	(1,649,223)	1,976	12,285,582
Balance (in Shares) at Mar. 31, 2022	69,763,933		(1,165,883)				
Net (loss) income				(1,359,923)		112,497	(1,247,426)
Foreign currency translation adjustment					(2,198,379)	(261)	(2,198,640)
Balance at Mar. 31, 2023	\$ 6,977	71,021,898	\$ (3,988,370)	(54,467,599)	(3,847,602)	114,212	8,839,516
Balance (in Shares) at Mar. 31, 2023	69,763,933		(1,165,883)				
Private placement	\$ 36,147	139,303,702					139,339,849
Private placement (in Shares)	361,474,910						
Exercise of warrants	\$ 710	(710)					
Exercise of warrants (in Shares)	7,098,000						
Net (loss) income				(9,458,784)		(57,793)	(9,516,577)
Foreign currency translation adjustment					(238,985)	391	(238,594)
Balance at Mar. 31, 2024	\$ 43,834	\$ 210,324,890	\$ (3,988,370)	\$ (63,926,383)	\$ (4,086,587)	\$ 56,810	\$ 138,424,194
Balance (in Shares) at Mar. 31, 2024	438,336,843		(1,165,883)				

~~XML 26 R6.htm IDEA XBRL DOCUMENT~~

Consolidated Statements of Cash Flows - USD (\$)	12 Months Ended		
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net (loss) from continuing operations		\$ (9,116,779)	\$ (13,084,038)
Adjustments to reconcile net (loss) to net cash provided by (used in) operating activities:			\$ (4,101,097)
Loss from disposal of discontinued operations		395,914	
Share-based compensation			391,625
Provision for doubtful accounts		7,369,797	8,274,526
Changes in operating assets and liabilities:			
Accounts receivable and contract assets		327,186	(8,097,742)
Prepayments and other assets		(130,770)	(95,151)
Inventories		1,495,248	6,109,372
Accounts payable, accrued expenses and other current liabilities		166,045	712,885
Contract liabilities		220,644	194,376
Taxes payable		(21,914)	3,190
Net cash provided by (used in) operating activities from continuing operations		705,371	(5,982,582)
Net cash provided by operating activities from discontinued operations		645,869	2,729,242
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES		1,351,240	(3,253,340)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Cash paid for loan originations			(1,528,918)
Cash received from loan repayments		1,528,918	20,000,000
Prepaid consideration		(56,250,000)	
Net cash (used in) provided by investing activities from continuing operations		(54,721,082)	18,471,082
Net cash provided by investing activities from discontinued operations			36,140
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES		(54,721,082)	18,471,082
CASH FLOWS FROM FINANCING ACTIVITIES:			
Repayments of loans due to related parties		(7,686,152)	(27,513,848)
Proceeds from private placement, net of offering costs		139,339,849	10,017,200
Repayments of unsecured senior notes			(10,000,000)
Amounts due to (from) related parties			9,086,804
Net cash provided by (used in) financing activities from continuing operations		131,653,697	(27,513,848)
Net cash provided by financing activities from discontinued operations			9,104,004
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES		131,653,697	(27,513,848)
EFFECT OF EXCHANGE RATE CHANGE ON CASH		(1,272,164)	(436,513)
NET INCREASE (DECREASE) IN CASH		77,011,691	(12,732,619)
CASH AND CASH EQUIVALENTS - beginning of year		9,192,703	21,925,322
CASH AND CASH EQUIVALENTS - end of year		86,204,394	9,192,703
Less: cash and cash equivalents of discontinued operations at end of period		1,030,377	1,268,235
Cash and cash equivalents of continuing operations, at end of period		85,174,017	7,924,468
SUPPLEMENTAL CASH FLOW DISCLOSURES:			
Cash paid for income tax		24,988	17,549
Cash paid for interest		\$ 111,563	\$ 336,593

~~XML 27 R7.htm IDEA XBRL DOCUMENT~~

Business Description	12 Months Ended Mar. 31, 2024
Business Description	
[Abstract]	
BUSINESS DESCRIPTION	
NOTE 1 - BUSINESS DESCRIPTION	
Organization and description of business	

Akso Health Group, formerly known as Xiaobai Maimai Inc., is a limited company incorporated under the laws of the Cayman Islands on April 25, 2016. Akso Health Group ("Akso Health" or the "Company"), its subsidiaries, and consolidated variable interest entities ("VIEs") (collectively the "Company"), previously operated an online Peer to Peer ("P2P") marketplace business and micro-lending business in the People's Republic of China (the "PRC"). Since May 2019, the Company has ceased to issue new loans through its micro-lending business and since October 2019, the Company has ceased to conduct its P2P business. On December 30, 2020, the Company completed the disposition transaction of its P2P business.

In May 2020, the Company launched its social e-commerce platform to offer high-quality and affordable branded products through collaboration with online and offline merchants. In addition, the Company is in the process of developing a new business as a cancer therapy and radiotherapy oncology service provider with operations in the U.S. The Company plans to open 2 vaccine research centers and 100 radiation oncology centers to be located on the east coast serving cancer patients in need of varying stages of treatment, including specialized radiation therapy centers for radiotherapy (RT), personalized consultation, conventional treatment planning, and other cancer related treatment services. On December 3, 2021, the shareholders approved the Company's plan to change its name to "Akso Health Group". In January 2022, three centers were established in US and the Company started its business of sales of medical devices in US market. In April 2022, the Company started its sales of medical devices in China market through its subsidiary Qingdao Akso Health Management Co., Ltd. In May 2023, the Company disposed its social E-commerce business and would focus on healthcare business in the future.

As of March 31, 2024, the Company's principal subsidiaries are as follows:

	Date of incorporation / acquisition	Place of incorporation	Percentage of legal ownership	Principal activities
Wholly owned subsidiaries				
We Health Limited ("We Health")	July 8, 2021	New York	100%	Investment holding
Akso Medical Cloud Limited ("Akso Medical Cloud")	November 15, 2023	BVI	100%	Investment holding
We Healthy Limited ("We Healthy")	December 15, 2021	Hong Kong	51%	Investment holding
Akso Medi-care Limited ("Akso Medi-care")	December 4, 2023	Hong Kong	100%	Investment holding
Akso Remote Medical Consultation Center Inc. ("Akso Remote Medical")	January 3, 2022	Wyoming	100%	Provision of health treatment services
Akso Online MediTech Co., Ltd.("Akso Online MediTech")	January 4, 2022	Wyoming	100%	Sales of medical devices
Akso First Health Treatment Center Inc. ("Akso First Health")	January 4, 2022	Massachusetts	100%	Provision of health treatment services
Tianjin Akso Enterprise Management Co., Limited. (Wholly Owned Foreign Enterprise,"WOFE"	January 16, 2024	PRC	100%	Provision of consultancy support
Qindao Akso Health Management Co., Limited	January 26, 2022	PRC	51%	Provision of health treatment services

~~[XML 28 R8.htm IDEA XBRL DOCUMENT](#)~~

Going Concern

**12 Months Ended
Mar. 31, 2024**

[Going Concern](#)
[\[Abstract\]](#)
[GOING CONCERN](#)

NOTE 2 - GOING CONCERN

As indicated in the accompanying consolidated financial statements, the Company had a net loss of approximately \$9.5 million for the year ended March 31, 2024 and approximately \$1.2 million for the year ended March 31, 2023. The net cash provided by operating activities from continuing operation was US\$0.7 million for the year ended March 31, 2024 and the net cash used in operating activities was US\$3.3 million for the year ended March 31, 2023. Management of the Company has considered whether there is substantial doubt about its ability to continue as a going concern due to the Company's healthcare business as well as its planned new business as a cancer therapy and radiotherapy oncology service provider, and evaluated its available cash balance against its working capital requirements and investment to the cancer centers over the next twelve months.

While management cannot accurately predict the prospects and regulatory environment of the healthcare service industry, the management believes that the Company would have sufficient funds to meet its working capital requirements for fiscal year 2025, and that its capital resources are currently sufficient to maintain its business operations for the next twelve months.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and/or classification of the recorded asset amounts and/or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

~~[XML 29 R9.htm IDEA XBRL DOCUMENT](#)~~

**Summary of
Significant
Accounting Policies**

**12 Months Ended
Mar. 31, 2024**

[Summary of
Significant
Accounting Policies](#)
[\[Abstract\]](#)
[SUMMARY OF
SIGNIFICANT
ACCOUNTING
POLICIES](#)

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and have been consistently applied. Certain prior year balances in the consolidated statements of operations and comprehensive (loss) and cash flows have been reclassified to the current year's presentation.

Basis of consolidation

The accompanying consolidated financial statements include the financial statements of the Company, its subsidiaries, its consolidated VIEs and VIE's subsidiaries for which the Company is the primary beneficiary. All inter-company transactions and balances have been eliminated upon consolidation.

Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce Business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented. Assets and liabilities of the social E-commerce business were reclassified separately from other assets and liabilities of the Company on the consolidated balance sheets. Refer to Note 1 and Note 4.

Consolidated VIEs

VIE arrangements

In order to comply with the PRC laws and regulations which prohibit or restrict foreign investments into companies involved in restricted businesses, the Company operates its marketplace and restricted businesses in the PRC through certain PRC domestic companies, whose equity interests are held by certain management members of the Company or onshore nominees of the Company ("Nominee Shareholders"). The Company obtained control over these PRC domestic companies by entering into a series of contractual arrangements with these PRC domestic companies and their respective Nominee Shareholders. These contractual agreements cannot be unilaterally terminated by the Nominee Shareholders or the PRC domestic companies. As a result, the Company maintains the ability to control these PRC domestic companies and is entitled to substantially all of the economic benefits from these PRC domestic companies. Management concluded that these PRC domestic companies are VIEs of the Company, of which the Company is the ultimate primary beneficiary. As such, the Company consolidated financial results of these PRC domestic companies and their subsidiaries in the Group's consolidated financial statements. The principal terms of the agreements entered into amongst the VIEs, their respective shareholders and the WFOE are further described below.

Exclusive Business Cooperation Agreements

The Exclusive Business Cooperation Agreements enable the WOFE to receive substantially all of the assets and business of the VIEs in the PRC. Under these Agreements, the WOFE has the exclusive right to provide the VIEs with comprehensive technical support, consulting services and other services during the term of these Agreements, including but not limited to software licensing; development, maintenance and update of software, network systems, hardware and database; technical support and training for employees; consultancy on technology and market information; business management consultation; marketing and promotion services, etc. The WOFE has the right to determine the fees associated with the services it provides based on the technical difficulty and complexity of the services, the actual labor costs it incurs for providing the services and some other factors during the relevant period. This Agreements remain effective unless otherwise terminated in writing by WOFE.

Equity Interest Pledge Agreements

Pursuant to the Equity Interest Pledge Agreements, each Shareholder of the VIEs agreed to pledge their equity interest in the VIEs to the WOFE to secure the performance of the VIEs' obligations under the Exclusive Business Cooperation Agreements and any such agreements to be entered into in the future. Shareholders of the VIEs agreed not to transfer, sell, pledge, dispose of or otherwise create any encumbrance on their equity interests in the VIEs without the prior written consent of the WOFE. The Pledges became effective on such date when the pledge of the Equity Interest contemplated herein were registered with the relevant administration for industry and commerce (the "AIC") and remain effective until all contract obligations have been fully performed and all secured indebtedness has been fully paid.

Exclusive Option Agreements

Pursuant to the Exclusive Option Agreements, each of the Shareholders of the VIE irrevocably grant the WOFE an irrevocable and exclusive right to purchase, or designate one or more persons (including individuals, corporations, partnerships, partners, enterprises, trusts or non-corporate organizations) to purchase the equity interests in the VIEs then held by such Shareholder of the VIEs once or at multiple times at any time in part or in whole at the WOFE's sole and absolute discretion to the extent permitted by Chinese laws at the price of RMB 1 or at the price of the minimum amount of consideration permitted by the applicable PRC law at the time when such purchase occurs. These three Agreements remain effective until all equity interests held by the shareholders of the VIEs in the VIEs have been transferred or assigned to the WOFE and/or its designees.

Loan Agreements

Pursuant to the three Loan Agreements, the WOFE agreed to lend each of the Shareholders of VIEs a loan only to subscribe to the registered capital of the VIEs. The repayment of the loan shall be made by permitting the WOFE to execute its exclusive right to purchase shares from the shareholders of the VIEs under the Exclusive Option Agreement as the repayment is equivalent to the consideration of the purchased shares. The term of these loans is 10 years, which may be extended upon mutual written consent of all parties.

Power of Attorney

Each Shareholder of the VIEs, executed a Power of Attorney agreement with the WOFE and the VIEs, whereby Shareholders of the VIEs irrevocably appoint and constitute the WOFE as their attorney-in-fact to exercise on the shareholders' behalf any and all rights that Shareholders of the VIEs have in respect of their equity interests in the VIEs. These three Power of Attorney documents remain irrevocable and continuously effective and valid as long as the original shareholders of the VIEs remain as the Shareholders of the VIEs.

Risks in relation to the VIE structure

The Company believes that the contractual arrangements with its VIEs and their respective shareholders are in compliance with the PRC laws and regulations and are legally enforceable. However, uncertainties in the PRC legal system could limit the Company's ability to enforce the contractual arrangements. If the legal structure and contractual arrangements were found to be in violation of the PRC laws and regulations, the PRC government could:

- revoke the business and operating licenses of the Company's PRC subsidiary and VIEs;
- discontinue or restrict the operations of any related-party transactions between the Company's PRC subsidiary and VIEs;
- limit the Company's business expansion in the PRC by way of entering into contractual arrangements;

- impose fines or other requirements with which the Company's PRC subsidiary and VIEs may not be able to comply;
- require the Company or the Company's PRC subsidiary and VIEs to restructure the relevant ownership structure or operations; and/or
- restrict or prohibit the Company's use of the proceeds of the additional public offering to finance the Company's business and operations in the PRC.

The Company's ability to conduct its Online Marketplace business may be negatively affected if the PRC government were to carry out any of the aforementioned actions. As a result, the Company may not be able to consolidate its VIEs in its consolidated financial statements as it may lose the ability to exert effective control over the VIEs and their respective shareholders and it may lose the ability to receive economic benefits from the VIEs. The Company, however, does not believe such actions would result in the liquidation or dissolution of the Company, its PRC subsidiary and VIEs.

The interests of the shareholders of VIEs may diverge from that of the Company and that may potentially increase the risk that they would seek to act contrary to the contractual terms, for example by influencing the VIEs not to pay the service fees when required to do so. The Company cannot assure that when conflicts of interest arise, shareholders of the VIEs will act in the best interests of the Company or that conflicts of interests will be resolved in the Company's favor. Currently, the Company does not have existing arrangements to address potential conflicts of interest the shareholders of the VIEs may encounter in their capacity as beneficial owners and directors of the VIEs, on the one hand, and as beneficial owners and directors of the Company, on the other hand. The Company believes the shareholders of VIEs will not act contrary to any of the contractual arrangements and the exclusive option agreements provide the Company with a mechanism to remove the current shareholders of the VIEs should they act to the detriment of the Company. The Company relies on certain current shareholders of the VIEs to fulfill their fiduciary duties and abide by laws of the PRC and act in the best interest of the Company. If the Company cannot resolve any conflicts of interest or disputes between the Company and the shareholders of the VIEs, the Company would have to rely on legal proceedings, which could result in disruption of its business, and there is substantial uncertainty as to the outcome of any such legal proceedings.

In May 2023, the Company completed the disposal of its social E-commerce business. After that, no VIEs or its subsidiaries were included in the consolidated financial statement of the Company. As a result, the Company's results of operations, revenues, costs and expenses related to the social E-commerce Business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented. Assets and liabilities of the social E-commerce business were reclassified separately from other assets and liabilities of the Company on the consolidated balance sheets. Refer to Note 1 and Note 4.

The following financial statement amounts and balances of the consolidated VIEs were included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Current Assets:		
Cash and cash equivalents	—	678,691
Accounts receivable and contract assets, net	—	10,062
Prepayments and other assets	—	43,779
Amounts due from related parties	—	26,206,288
Total Current Assets	—	26,938,820
Property, equipment and software, net	—	28,698
Total Assets	—	26,967,518
Current Liabilities		
Accrued expenses and other current liabilities	—	32,430
Taxes (benefit) payable	—	(12,624)
Total Current Liabilities	—	19,806
Total Liabilities	—	19,806

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
	USD	USD	USD
Net revenues	694	27,324	311,725
Net loss	(12,479)	(348,806)	(11,527,588)
	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	USD	USD	USD
Net cash provided by (used in) operating activities	12,497	(559,973)	5,613,401
Net cash (used in) investing activities	-	-	(1,455,547)
Net cash provided by (used in) financing activities	213,879	(1,156,948)	(13,203,558)

Uses of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during each reporting period. Actual results could differ from such estimates. Significant accounting estimates reflected in the Company's consolidated financial statements include estimates and judgments applied in allocation of revenue with various performance obligations, allowance for accounts receivable and contract assets, impairment on long-term investments, valuation allowance for deferred tax assets, valuation of share-based compensation and allowance for loans receivable and other receivable.

Fair value of financial instruments

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurement or assumptions that market participants would use when pricing the asset or liability.

The Company follows the provisions of Financial Accounting Standards Board ("FASB"), Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3 - Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts reported in the balance sheets for cash, receivables, prepayments and other assets, loan principal and interest receivable, approximate their fair value based on the short-term maturity of these instruments. The Company did not transfer any assets or liabilities in or out of level 3 during the years ended March 31, 2023, 2022 and 2021.

The Company's long-term investments consist of equity securities and available-for-sale investments. For long-term investments without readily determinable fair value, the Company is not able to estimate fair value, hence, the Company uses the cost minus impairment method as alternative.

Discontinued Operations

A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity's financial results and operations. Included in the consolidated statements of operations and comprehensive (loss) income, result from discontinued operations have been reported separately from the income and expenses from continuing operations and prior periods have been presented on a reclassified comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.

Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented.

Revenue recognition

In February 2022, the Company started its business in the US market for the sale of medical devices. In May 2020, the Company launched its social e-commerce platform and built collaboration with domestic mainstream E-commerce marketplaces, which was discontinued in fiscal year 2023 and disposed in May 2023. The Company provides recommendation services by referring certain interested users to those marketplaces for high-quality and affordable branded products. Prior to business transformation, the Company through its P2P business offered online consumer lending-related service in fiscal year 2020, which was discontinued in fiscal year 2021 and disposed on December 30, 2020. The Company presents value added taxes ("VAT") as a reduction of revenues.

Revenues generated are accounted under Accounting Standards Update (ASU) 2014-09, "Revenue from contracts with Customers" (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following steps:

Step 1: Identify the contract (s) with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation

Online marketplace services

● Commission revenue

The commission services revenue primarily consists of commission fees charged to the online E-commerce marketplace for recommending users to purchase on their marketplaces, where the

Company generally is acting as an agent and its performance obligation is to provide recommendation services for purchasing specified goods or services by those third-party sellers, is not responsible for fulfilling the promise to provide the specified goods or services, and does not have the ability to control the related shipping services when utilized by the third-party sellers. Upon successful sales, the Company will charge the online E-commerce companies a negotiated amount or a fixed rate commission fee based on the sales amount. Commission services revenues are recognized on a net basis at the point of receipt of products, net of a return allowance and incentives to consumers or channels.

In order to promote its online marketplace and attract more registered consumers, the Company at its own discretion offers incentives to consumers. Consumers are not customers of the Company, therefore incentives offered to consumers are not considered payments to customers. Such incentives offered to consumers were as a reward for purchasing by themselves or their sharing through our platform. Incentives provided to consumers are specific to any merchant and are recognized as a reduction of commission service revenue. For the years ended March 31, 2024, 2023, 2022, the total amount of incentives was nil, nil and US\$96,332, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

● **Interest income**

Started in August 2017, the Company lent funds to borrowers up to their approved credit through its consolidated VIE, and since May 2019, the Company has ceased to issue new loans through its microlending business. Interest income on loans receivable is recognized monthly based on the contractual interest rates of the loan. Accrual of interest is generally discontinued when reasonable doubt exists as to the full, timely collection of interest or principal. When a loan is discontinued from interest accrual, the Company stops accruing interest and reverses all accrued but unpaid interest as of such date. Interest income was nil, nil, US\$215,393 for the years ended March 31, 2024, 2023 and 2022, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

● **Sales of medical devices**

Started in February 2022, through its subsidiary Akso Online MediTech, the Company engaged in the sale of Covid-19 Antigen Rapid Tests in US market. For the years ended March 31, 2024, 2023 and 2022, revenue generated from sale of Covid-19 Antigen Rapid Tests was nil, \$9,181,274 and \$6,000,000. Akso Online MediTech purchases medical devices in quantity and distributes products primarily to medical products dealers. The deliveries may take one day or longer depending on the customers’ location. Revenue from sales of merchandise to non-retail customers is recognized when the merchandise is transferred to customers. There was no sales return since the start the business.

● **Disaggregation of revenue**

All of the Company’s revenue for the years ended March 31, 2024 was generated from PRC and revenue for the year ended March 31, 2023 were generated from US and PRC, and for the year ended March 31, 2022 were generated from US. The following table illustrates the disaggregation of revenue:

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
	USD	USD	USD
Revenue			
Revenue from medical devices-US	-	9,181,274	6,000,000
Revenue from medical devices-PRC	2,416,797	4,005,251	-
Total revenues	2,416,797	13,186,525	6,000,000
Tax and surcharges	2,459	4,964	-
Net Revenues	2,414,338	13,181,561	6,000,000

Cash and cash equivalents

Cash and cash equivalents represent cash on hand, unrestricted demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash.

Accounts receivable and allowance for uncollectible accounts

Accounts receivable are mainly receivables from online E-commerce marketplaces and recommendation services, which are stated at the historical carrying amount net of allowance for uncollectible accounts. The Company establishes an allowance for uncollectible accounts receivable based on estimates, historical experience and other factors surrounding the credit risk of specific customers. Uncollectible accounts receivables are written off when a settlement is reached for an amount that is less than the outstanding historical balance or when the Company has determined that is not probable for the balance to be collected. Beginning on April 1, 2020, the Company evaluates its accounts receivable for expected credit losses on a regular basis. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. The Company uses the length of time a balance has been outstanding, the payment history, creditworthiness and financial conditions of the customers and industry trend as credit quality indicators to monitor the Company’s receivables within the scope of expected credit losses model and use these as a basis to develop the Company’s expected loss estimates. The Company adjusts the allowance percentage periodically when there are significant differences between estimated bad debts and actual bad debts. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Company also makes a specific allowance in the period in which a loss is determined to be probable. Accounts receivable balances are written off after all collection efforts have been exhausted. As of March 31, 2024 and 2023, the allowance for uncollectible accounts receivable balance was US\$ 7,369,797 and US\$ 400,759, respectively.

Inventories

Inventories are comprised of finished goods, which are defibrillators and anesthesia laryngoscope, and are stated at the lower of cost or net realizable value using first in first out (FIFO) method. Management reviews inventories for obsolescence and cost in excess of net realizable value periodically when appropriate and records a reserve against the inventory when the carrying value exceeds net realizable value. As of March 31, 2024, the Company determined that no allowance was necessary.

Property and equipment, net

Property and equipment are stated at cost. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives:

	Useful life
Office equipment	3-5 years

The Company eliminates the cost and related accumulated depreciation and amortization of assets sold or otherwise retired from the accounts and includes any gains or losses from disposal of property, equipment, and software in other income. The Company charges maintenance, repairs, and minor renewals directly to expense as incurred; major additions and betterments to equipment are capitalized. For the disposal of social E-commerce business, property and equipment, net was recorded in discontinued operations.

Impairment of long-lived assets

The carrying value of the long-lived assets are reviewed for impairment, whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of assets to future undiscounted net cash flows expected to be generated by the assets. Such assets are considered to be impaired if the sum of the expected undiscounted cash flows is less than carrying amount of the assets. The impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets. No impairment loss was recognized for the years ended March 31, 2024, 2023 and 2022.

Advertising and promotion expenses

The Company recognizes its advertising and promotion expenses as sales and marketing expense. Advertising expenses represent expenses for placing advertisements on television, radio and in newspapers, as well as on internet websites and search engines. Advertising and promotion costs are expensed as incurred. For the years ended March 31, 2024, 2023 and 2022, the advertising and promotion expenses were US\$ 168,421, US\$ 6,661, nil, respectively.

Lease

Upon the adoption of FASB ASC 842 on April 1, 2019 using the modified retrospective method, the Company determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities, in the Company’s consolidated balance sheets. The Company does not have any finance leases as of the adoption date or March 31, 2022.

ROU represents the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which it calculates based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease.

For operating lease with a term of one year or less, the Company has elected to not recognize a lease liability or lease right of use asset on its consolidated balance sheets. Instead, it recognizes the lease payment as expense on a straight-line basis over the lease term. Short-term lease costs are immaterial to its consolidated statements of operations and comprehensive (loss). The Company has operating lease agreements with insignificant non-lease components and have elected the practical expedient to combine and account for lease and non-lease components as single lease component.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annually period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations (Note 17).

Share-based compensation

Under the Amended and Restated 2016 Equity Incentive Plan, the Company grants share options to the Company’s selected employees, and directors. Awards granted to employees with service conditions attached are measured at the fair value on the grant date and are recognized as an expense using straight-line method, net of estimated forfeitures, over the requisite service period, which is generally the vesting period. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share-based compensation expense to be recognized in future periods.

Awards granted to employees with performance conditions attached are measured at fair value on the grant date and are recognized as compensation expense in the period and thereafter when the performance goal becomes probable to achieve. Awards granted to employees with market conditions attached are measured at fair value on the grant date and are recognized as compensation expense over the estimated requisite service period, regardless of whether the market condition has been satisfied if the requisite service period is fulfilled.

Binomial option-pricing models are adopted to measure the value of awards at each grant date or measurement date. The determination of fair value is affected by assumptions relating to a number

of complex and subjective variables, including but not limited to the expected share price volatility, actual and projected employee share option exercise behavior, risk-free interest rates and expected dividends. The use of the option-pricing model requires extensive actual employee exercise behavior data for the relative probability estimation purpose, and a number of complex assumptions.

Treasury stock

Treasury stock represents ordinary shares repurchased by the Company that are no longer outstanding and are held by the Company. The repurchase of ordinary shares is accounted for under the cost method whereby the entire cost of the acquired shares are recorded as treasury stock. The cost of treasury stock is transferred to “additional paid-in capital” when it is re-issued for the purpose of share options exercised and share awards.

Income taxes

The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

The Company accounts for income tax under the asset and liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Under this method, deferred income taxes will be recognized if significant temporary differences between tax and financial statements occur. A valuation allowance is established against net deferred tax assets when it is more likely that some portion or all of the net deferred tax asset will not be realized. For the years ended March 31, 2024, 2023 and 2022, the Company provided a full valuation allowance on the net deferred tax assets.

The Company may be subject to challenges from taxing authorities regarding the amounts of taxes due. These challenges may alter the timing or amount of taxable income or deductions. Management determines whether the benefits of its tax positions are more-likely-than-not of being sustained upon audit based on the technical merits of the tax position. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated.

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income taxes are classified as income tax expense in the period incurred. The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measures the unrecognized benefits associated with the tax positions. As of March 31, 2024 and 2023, the Company did not have any significant unrecognized uncertain tax positions. The Company does not believe that its unrecognized tax benefits will change over the next twelve months.

Noncontrolling interests

Noncontrolling interest consists of 49% of the equity interest of We Healthy held by other investors. Excess of contribution received from noncontrolling shareholders over carrying value of the entity is recorded in additional paid in capital. The noncontrolling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Noncontrolling interests in the results of the Company are presented on the face of the consolidated statement of operations as an allocation of the total income or loss for the year between non-controlling interest holders and the shareholders of the Company.

Noncontrolling interest consist of the following:

	December 31, 2024 USD	December 31, 2023 USD
We Healthy	56,810	114,212

Earnings (loss) per share

The Company computes earnings per share (“EPS”) in accordance with FASB ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires public companies with capital structures to present basic and diluted EPS. Basic EPS is measured as net income (loss) attributed to ordinary shareholders divided by the weighted average number of ordinary shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

Foreign currency translation

The functional currency of the Company is United States Dollar. The Company’s subsidiaries with operations in mainland China, the Hong Kong Special Administrative Region of the PRC (“Hong Kong” or “Hong Kong S.A.R.”), the United States generally use their respective local currencies as their functional currencies. The Company’s financial statements have been translated into the reporting currency, the United States Dollar (“USD”). Assets and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated at the average exchange rate during the reporting period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss). Transactions denominated in currencies other than functional currency are translated into the functional currency at the exchange rates quoted by authoritative banks prevailing at the dates of the transactions. Exchange gains and losses resulting from those foreign currency transactions denominated in a currency other than the functional currency are recorded in “other income (expense)” in the consolidated statements of operations and comprehensive income. The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that any RMB amounts could have been, or could be, converted, realized or settled into USD at the rates used in translation.

Spot exchange rates and average exchange rates were used in the translation of the consolidated financial statements.

	Fiscal year 2024	Fiscal year 2023	Fiscal year 2022
US Exchange Rate			
Year-end RMB	7.2203	6.8676	6.3393
Year average RMB	7.1671	6.8516	6.4180

Significant risks and uncertainties

Foreign currency risk

RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. The Company’s cash and cash equivalents denominated in RMB amounted to US\$10,380,711 and US\$7,876,767 as at March 31, 2024 and 2023, respectively.

Concentration of credit risk

Financial instruments that potentially expose the Company to significant concentration of credit risk primarily included in the financial lines of cash and cash equivalents, accounts receivable, other receivables and prepayments and other assets. As of March 31, 2024, substantially all of the Company’s cash and cash equivalents were held by major financial institutions located worldwide, including mainland China and Unite State. According to the China Bank Deposit Insurance Ordinance, the deposits at each bank is covered by insurance with an upper limit of RMB 500,000 (approximately US\$69,249) at each bank. As of March 31, 2024, the total amount not covered by issuance in the PRC was US\$ 10,310,077. The Hong Kong Deposit Protection Board pays compensation up to a limit of HKD 500,000 (approximately US\$ 63,890) if the bank with which an individual/a company hold its eligible deposit fails. As of March 31, 2024, no cash balance maintained at financial institutions in Hong Kong was subject to credit risk. In the US, the insurance coverage of each bank is \$250,000. As of March 31, 2024, no cash balance maintained at financial institutions in US was subject to credit risk. If the financial institutions could become insolvent, the Company could lose some or all of the value of its investments. To limit exposure to credit risk relating to deposits, the Company primarily place cash and cash equivalent deposits with large financial institutions which management believes are of high credit quality and management also continually monitors the financial institutions’ credit worthiness.

Accounts receivable is typically unsecured and are derived from revenue earned from customers in the PRC. The risk with respect to accounts receivable is mitigated by credit evaluations the Company performs on its customers and its ongoing monitoring process of outstanding balances.

Customer concentration risk

For the year ended March 31, 2024, three customers accounted for 36.3%, 34.8% and 28.0% for the Company’s total revenue from sales of medical devices business. For the year ended March 31, 2023, three customers accounted for 59.5%, 11.1% and 10.1% for the Company’s total revenue from sales of medical devices business. For the year ended March 31, 2022, one customer accounted for 95.1% of the Company’s total revenues. There was no customer of the Company that accounted for more than 10% of the Company’s carrying amount of account receivables as of March 31, 2024 and there was one customer of the Company that accounted for 100% of the Company’s carrying amount of accounts receivable as of March 31 2023.

Vendor concentration risk

For the year ended March 31, 2024, one vendor accounted for 100% of the Company’s purchase of medical devices business. For the year ended March 31, 2023, one vendor accounted for 97.3% of the Company’s purchase of medical devices business. For the year ended March 31, 2022, one vendor accounted for 100% of the Company’s purchase of medical devices business. There was no vendor of the Company that accounted for greater than 10% of the Company’s carrying amount of accounts payable as of March 31, 2024 and 2023.

Recent Accounting Pronouncements

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). ASU No. 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The guidance is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Company does not expect to adopt ASU No. 2023-09 early and is currently evaluating the impact of adopting this standard on its consolidated financial statements.

The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated balance sheets, consolidated statements of operations and comprehensive loss (income) and consolidated statements of cash flows.

[XML 30 R10.htm IDEA: XBRL DOCUMENT](#)

Discontinued
Operation
[Discontinued
Operation \[Abstract\]](#)
[DISCONTINUED
OPERATION](#)

12 Months Ended
Mar. 31, 2024

NOTE 4 - DISCONTINUED OPERATION

On December 16, 2020, Beijing Hexin Yongheng Technology Development Co., Ltd. (“Hexin Yongheng”), a wholly-owned subsidiary of the Company, Kuaishangche Automobile Leasing Co., Ltd. (“Kuaishangche”), a company not directly associated with the Company, Hexin E-Commerce Company Limited (“Hexin E-Commerce”), and individual shareholders of Hexin E-Commerce entered into an assignment and assumption agreement (the “Agreement”). Pursuant to the Agreement, Hexin Yongheng agreed to assign and transfer to Kuaishangche the control over Hexin E-Commerce, in exchange for cash consideration of RMB 5 million (US\$726,781) (the “Disposition”). Upon the closing of the Disposition, Kuaishangche will become the primary beneficiary of and have control of Hexin E-Commerce, and as a result, assume all assets and liabilities of Hexin E-Commerce and subsidiaries owned or controlled by Hexin E-Commerce, excluding any rights, titles, interests or claims that Hexin E-Commerce may have in Wusu Hexin Yongheng Commercial and Trading Co., Ltd. (“Wusu Company”), shall remain as a consolidated variable interest entity of the Company. As a result of the Disposition, the Company will cease to conduct its P2P business and focus on developing and investing resources into its social e-commerce platform, Xiaobai Maimai.

On May 10, 2023, Akso Health Group (the “Company” or the “Seller”), HX Asia Investment Limited, a British Virgin Islands company (“HX Asia”), HX China Investment Limited, a British Virgin Islands company (“HX China”), and Hexindai Hong Kong Limited, a Hong Kong company (“Hexindai” and together with HX Asia and HX China, the “Targets”), and Umbrella Capital Investment Co., Ltd, a British Virgin Islands company which is not affiliate of the Company of any of its directors or officers (the “Purchaser”) entered into certain share purchase agreement (the “Disposition SPA”).

Pursuant to the Disposition SPA, the Purchaser agreed to purchase the Targets in exchange for cash consideration of US\$215,000 (the "Purchase Price"). Upon the closing of the transaction (the "Disposition") contemplated by the Disposition SPA, the Buyer will become the sole shareholder of the Targets and as a result, assume all assets and liabilities of the Targets and subsidiaries owned or controlled by the Target. As a result of the Disposition, the Company will cease to conduct its social E-commerce business and focus on developing and investing resources into its medical devices business.

The discontinued operation represents a strategic shift that has a major effect on the Company's operations and financial results, which trigger discontinued operations accounting in accordance with FASB ASC 205-20-45. The assets and liabilities related to the discontinued operations are classified as assets/liabilities of discontinued operations as of March 31, 2024 and 2023, while results of operations related to the discontinued operations for the years ended March 31, 2024, 2023 and 2022, were reported as income (loss) from discontinued operations.

The results of discontinued operations for years ended March 31, 2024, 2023 and 2022 are as follows:

	For the years ended March 31,		
	2024	2023	2022
	USD	USD	USD
Net Revenues	694	24,995	311,092
Operating costs and development	4,551	1,073,518	12,988,383
(Loss) income from discontinued operations	(3,857)	(1,048,522)	(12,677,291)
Other income (expense), net	(27)	12,885,134	(32,728)
(Loss) income before tax	(3,884)	11,836,612	(12,710,019)
Income tax provision	-	-	38,617
Net (loss) income from discontinued operations	(3,884)	11,836,612	(12,748,636)
Loss on sale of discontinued operations, net of taxes	(395,914)	-	-
Net income (loss) from discontinued operation	(399,798)	11,836,612	(12,748,636)

Assets and liabilities of the discontinued operations as of March 31, 2024 and 2023 are as follows:

	March 31,	March 31,
	2024	2023
	USD	USD
Cash and cash equivalents	-	1,268,235
Accounts receivable, net	-	10,062
Prepayments and other assets	-	44,004
Property, equipment and software, net	-	29,051
Current assets held for sale-discontinued operation	-	1,351,352
Accrued expenses and other current liabilities	-	737,693
Tax (benefit) payable	-	(32,210)
Amount due to related party	-	-
Total liabilities held for sale-discontinued operation	-	705,483

The calculation of loss on sale of discontinued operations, net of taxes illustrated as below:

	May 19,
	2023
	USD
Cash and cash equivalents	1,030,377
Accounts receivable, net	9,508
Prepayments and other assets	241,025
Property, plant and equipment, net	24,998
Total assets	1,305,908
Account payable	662,648
Accrued expenses and other current liabilities	32,346
Total liabilities	694,994
Net assets	610,914
Consideration received	215,000
Loss on sale of discontinued operations, net of taxes	(395,914)

~~[XML 31 R11.htm IDEA XBRL DOCUMENT](#)~~

Accounts Receivable, Net 12 Months Ended Mar. 31, 2024

[Accounts Receivable, Net \[Abstract\]](#)

[ACCOUNTS RECEIVABLE, NET](#)

NOTE 5 - ACCOUNTS RECEIVABLE, NET

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Accounts receivable	7,770,556	8,097,742
Allowance for uncollectible accounts receivable	(7,770,556)	(400,759)
Accounts receivable, net	-	7,696,983

~~[XML 32 R12.htm IDEA XBRL DOCUMENT](#)~~

Prepayments and Other Assets,Net 12 Months Ended Mar. 31, 2024

[Prepayments and Other Assets \[Abstract\]](#)

[PREPAYMENTS AND OTHER ASSETS,NET](#)

NOTE 6 - PREPAYMENTS AND OTHER ASSETS,NET

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Prepayments to suppliers and others	409,322	272,129
Allowance	(6,423)	-
Total prepayments and other assets,net	402,899	272,129

~~[XML 33 R13.htm IDEA XBRL DOCUMENT](#)~~

Inventories 12 Months Ended Mar. 31, 2024

[Inventories \[Abstract\]](#)

[INVENTORIES](#)

NOTE 7 - INVENTORIES

As of March 31, 2024 and 2023, inventory consisted of finished goods, which were medical devices such as defibrillators and anesthesia laryngoscope, valued at US\$191,201 and US\$ 1,686,449; respectively. The Company constantly monitors its potential obsolete products. Any loss on damaged items is immaterial and will be recognized immediately. As a result, no reserves were made for inventory for the years ended March 31, 2024, 2023.

~~[XML 34 R14.htm IDEA XBRL DOCUMENT](#)~~

Loan Receivables 12 Months Ended Mar. 31, 2024

[Loan Receivables](#)

[\[Abstract\]](#)

[LOAN RECEIVABLES](#)

NOTE 8 - LOAN RECEIVABLES

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Loan receivables	-	1,528,918
Allowance for uncollectible loan receivables	-	-
Loan receivables, net	-	1,528,918
Loan receivables - current	-	1,528,918
Loan receivables - non-current	-	-

In March 2023, the Company lent a total of US\$1.5 million (RMB10.5 million) to two third party companies. The loan term for each loan was one year with an annual interest of 2%. In July 2023, the Company received the total loan principle and all accrued interests from the two third party companies.

~~[XML 35 R15.htm IDEA XBRL DOCUMENT](#)~~

Prepaid Consideration 12 Months Ended Mar. 31, 2024

[Prepaid](#)

NOTE 9 - PREPAID CONSIDERATION

In March 2024, the Company, through Tianjin Akso Enterprise Management Co, Ltd., one of its PRC subsidiaries, entered into Share Purchase Agreements (the “SPA”) with four non-affiliated individual shareholders (the “Sellers”) of Tianjin Wangyi Cloud Technology Co., Ltd. (the “Target”). Pursuant to the SPA, the Company acquired 50% of the equity interest in the Target held by the four Sellers, each of which held 12.5% equity interest, respectively. The total consideration for the transaction was US\$75.0 million. As of March 31, 2024, the Company has paid US\$56.25 million, which was recorded as prepaid consideration. The transaction closed on April 15, 2024. Upon closing, Tianjin Akso Enterprise Management Co., Ltd. acquired 50% equity interest of Tianjin Wangyi Cloud Co., Ltd. At the completion of the transaction, the Company determined that no provision needed to be made for the prepaid consideration as of March 31, 2024.

~~XML 36 R16.htm IDEA- XBRL DOCUMENT~~

Right of Use Lease
Assets

12 Months Ended
Mar. 31, 2024

Right of Use Lease
Assets [Abstract]
RIGHT OF USE LEASE
ASSETS

NOTE 10 - RIGHT OF USE LEASE ASSETS

The Company had several operating leases for offices in the PRC. The related lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Effective April 1, 2019, the Company adopted the new lease accounting standard using a modified retrospective transition method which allowed the Company not to recast comparative periods presented in its consolidated financial statements. In addition, the Company elected the package of practical expedients, which allowed the Company to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Company has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. The Company combines the lease and non-lease components in determining the ROU assets and the related lease obligation. Adoption of this standard resulted in the recording of operating lease ROU assets and corresponding operating lease liabilities as disclosed below and had no impact on our accumulated deficit as of March 31, 2020. ROU assets and related lease obligations are recognized at commencement date based on the present value of remaining lease payments over the lease term. As of April 1, 2019, the Company recorded a ROU asset and lease liability of US\$ 2,559,646.

The Company’s operating leases primarily include leases for office space. The current portion of operating lease liabilities and the non-current portion of operating lease liabilities are presented on the consolidated balance sheets. For operating lease with a term of one year or less, the Company has elected to not recognize a lease liability or lease right of use asset on its consolidated balance sheets. Instead, it recognizes the lease payment as expense on a straight-line basis over the lease term. For the Social E-commerce disposal and retroactive adjustment to its financial statement, the total lease expense amounted to nil, nil, and nil for the years ended March 31, 2024, 2023 and 2022, respectively. For the year ended March 31, 2024, the Company leased premises and warehouse from third parties for free of charge.

~~XML 37 R17.htm IDEA- XBRL DOCUMENT~~

Accrued Expenses
and Other Current
Liabilities

12 Months Ended
Mar. 31, 2024

Accrued Expenses and Other Current Liabilities [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

NOTE 11 - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Accrued payroll and benefits	1,092,629	588,342
Professional fees, other payable and accrued expenses	2,733	245,340
Interest payable	9,450	105,085
	1,104,812	938,767

~~XML 38 R18.htm IDEA- XBRL DOCUMENT~~

Related Party
Balances and
Transactions

12 Months Ended
Mar. 31, 2024

Related Party
Balances and
Transactions
[Abstract]
RELATED PARTY
BALANCES AND
TRANSACTIONS

NOTE 12 - RELATED PARTY BALANCES AND TRANSACTIONS

On August 26, 2021, the Company entered into a loan agreement with Webao Limited, the majority shareholder of the Company, for a loan of US\$2.0 million with a 0% annual interest rate. The loan term is 1 year. On Augustst 26, 2022, both the Company and Webao Limited entered into a Deferred Repayment Agreement to extend the loan term one more year to August 27, 2023 and the annual interest rate remained 0%. On August 26, 2023, the loan agreement was extended one more year to August 27, 2024 and the annual interest rate remained 0%. As of March 31, 2024, the balance of amount due to related parties was US\$2.0 million.

On January 24, 2022, the Company entered into a loan agreement with SOS Information Technology New York, Inc. (“SOS NY”), one of our senior management was the related party of SOS Limited, for a loan of US\$35,200,000 with a 2% annual interest rate. The loan term was 1 year. For the fiscal year ended March 31, 2022, interest expense pertaining to the loan amounted to US\$127,244. On July 27, 2022, the Company and SOS NY entered into an amendment and supplemental agreement to the loan agreement, pursuant to which the Company shall make a repayment in advance to SOS NY of US\$27,513,849 of the principal amount together with all accrued but unpaid interest of US\$358,751. The Company made a payment of US\$27,872,600 for the above principal and interest on July 28, 2022. In November 2023, the Company made a payment of US\$7,686,151 of principal amount together with all accrued but unpaid interest of US\$196,681 to SOS NY. As of March 31, 2024, the outstanding balance of unpaid principal and interest was nil and nil, respectively.

~~XML 39 R19.htm IDEA- XBRL DOCUMENT~~

Employee Benefits

Employee Benefits
[Abstract]
EMPLOYEE BENEFITS

12 Months Ended
Mar. 31, 2024

NOTE 13 - EMPLOYEE BENEFITS

The Company has made the required employee benefit contributions in accordance with relevant rules and regulations in the PRC. Such contributions include funding for retirement insurance, unemployment insurance, medical insurance, work injury insurance, maternity insurance and housing fund. The Company recorded the contributions in salary and employee charges at specified percentages of the salaries, bonuses and certain allowances of its employees, up to a maximum amount specified by the local government. The contributions made by the Company were US\$7,390, nil and nil for the years ended March 31, 2024, 2023 and 2022, respectively.

~~XML 40 R20.htm IDEA- XBRL DOCUMENT~~

Taxes Payable

Taxes Payable [Abstract]
TAXES PAYABLE

12 Months Ended
Mar. 31, 2024

NOTE 14 - TAXES PAYABLE

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Income taxes payable	92,816	95,888
Other taxes (recovery) payable	(18,725)	117
Total taxes payable	74,091	96,005

~~XML 41 R21.htm IDEA- XBRL DOCUMENT~~

Income Taxes

Income Taxes
[Abstract]
INCOME TAXES

12 Months Ended
Mar. 31, 2024

NOTE 15 - INCOME TAXES

Cayman Islands

Akso Health was incorporated in the Cayman Islands and is not subject to income taxes or capital gain under current laws of Cayman Islands.

Hong Kong

We Healthy Limited and Akso Medi-care Limited are investment holding companies registered in Hong Kong and exempted from income tax on its foreign-derived income.

United States

The Company’s subsidiaries established in the U.S. are incorporated in the U.S. and is subject to both federal and state income taxes for its business operation in the U.S. The applicable tax rate is 21% for federal, 6.5% for We Health established in New York, 0% for Akso Remote Medical and Akso Online MediTech established in Wyoming and 8% for Akso First Health established in Massachusetts. All U.S. entities had no taxable income for the year ended March 31, 2024.

PRC

The Company’s subsidiaries established in the PRC are subject to the PRC statutory income tax rate of 25%, according to the PRC Enterprise Income Tax (“EIT”) law.

i) The components of income tax expenses are as follows:

	March 31, 2024	March 31, 2023	March 31, 2022
	USD	USD	USD
Current	24,988	17,549	92,816
Deferred	-	-	-
Total	24,988	17,549	92,816

All income taxes are related to income derived in the U.S. and PRC during the years ended March 31, 2024, 2023 and 2022.

The net income before taxes for the PRC entities was US\$83,103, US\$ 165,429 and US\$ 2,717 for the years ended March 31, 2024, 2023 and 2022, respectively. The net (loss) income before taxes for the U.S. entities was US\$(3,366,893), US\$ 634,709 and US\$441,981 for the years ended March 31, 2024, 2023 and 2022, respectively.

The following table reconciles the PRC statutory rates to the Company’s effective tax rate for the years ended March 31, 2024, 2023 and 2022.

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
PRC Income tax statutory rate	(25.0)%	(25.0)%	(25)%
Effect of tax holiday and preferential tax rate	4.0%	4.0%	4.0
Non-deductible foreign losses	5.8%	0.7%	19.5%
Change in valuation allowance	20.3%	24.8%	0.8%
Non-deductible expenses and others	(5.4)%	(4.6)%	-%
Effective tax rate	(0.3)%	(0.1)%	(2.3)%

According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of income taxes is due to computational errors made by the taxpayer. The statute of limitations will be extended to five years under special circumstances, which are not clearly defined, but an underpayment of income tax liability exceeding US\$15,263 (RMB 100,000) is specifically listed as a special circumstance. In the case of a transfer pricing related adjustment, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. Aggregate undistributed earnings of the Company’s PRC subsidiaries that are available for distribution was approximately negative US\$124,358 and US\$232,059 as of March 31, 2024 and 2023, respectively.

In accordance with the EIT Law, dividends, which arise from profits of foreign invested enterprises (“FIEs”) earned after January 1, 2008, are subject to a 10% withholding income tax. In addition, under the tax treaty between the PRC and Hong Kong, if the foreign investor is incorporated in Hong Kong and qualifies as the beneficial owner, the applicable withholding tax rate is reduced to 5%, if the investor holds at least 25% in the FIE, or 10%, if the investor holds less than 25% in the FIE. On July 19, 2018, the board of directors approved an annual dividend policy. Under this policy, annual dividends will be set at an amount equivalent to approximately 15-25% of the Company’s anticipated net income after tax in each year commencing from fiscal year ended March 31, 2019, which will be derived from the earnings of the Company’s PRC entities. The board of directors did not declare any annual dividend for the fiscal years ended March 31, 2024, 2023 and 2022.

A deferred tax liability should be recognized for the undistributed profits of PRC subsidiaries unless the Company has sufficient evidence to demonstrate that the undistributed dividends will be reinvested and the remittance of the dividends will be postponed indefinitely. The Company plans to indefinitely reinvest undistributed profits earned from its China subsidiaries in its operations in the PRC. Therefore, no withholding income taxes for undistributed profits of the Company’s subsidiaries have been provided as of March 31, 2024 and 2023. Under applicable accounting principles, a deferred tax liability should be recorded for taxable temporary differences attributable to the excess of the financial reporting basis over the tax basis in a domestic subsidiary. However, recognition is not required in situations where the tax law provides a means by which the reported amount of that investment can be recovered tax-free and the enterprise expects that it will ultimately use that means. The Company completed its feasibility analysis on a method, which the Company will ultimately execute if necessary to repatriate the undistributed earnings of the subsidiary without significant tax costs. As such, the Company does not accrue deferred tax liabilities on the earnings of the subsidiary given that the Company will ultimately use the means.

[XML 42 R22.htm IDEA- XBRL DOCUMENT](#)

Earnings (Loss) Per Share

Earnings (Loss) Per Share [Abstract]

EARNINGS (LOSS) PER SHARE

12 Months Ended Mar. 31, 2024

NOTE 16 - EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is the amount of net earnings available to each share of ordinary shares outstanding during the reporting period. Diluted EPS is the amount of net earnings available to each share of ordinary shares outstanding during the reporting period adjusted to include the effect of potentially dilutive ordinary shares. The following table details the outstanding shares for basic and diluted net earnings per share:

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
	USD	USD	USD
Numerator:			
Net loss from continuing operation attributable to Akso Health Group’s shareholder	(9,058,986)	(13,196,535)	(4,102,428)
Net income (loss) from discontinued operation attributable to Akso Health Group’s shareholders	(399,798)	11,836,612	(12,748,636)
Net loss attributable to Akso Health Group’s shareholders	(9,458,784)	(1,359,923)	(16,851,064)
Denominator:			
Weighted average number of ordinary shares outstanding-basic	141,516,777	68,598,050	59,612,152
Weighted average number of dilutive potential ordinary shares from share options	-	-	-
Weighted average number of ordinary shares outstanding-diluted	141,516,777	68,598,050	59,612,152
Basic (loss) per common share	(0.07)	(0.02)	(0.28)
Diluted (loss) per common share	(0.07)	(0.02)	(0.28)

[XML 43 R23.htm IDEA- XBRL DOCUMENT](#)

Shareholders' Equity

Shareholders' Equity [Abstract]

SHAREHOLDERS' EQUITY

12 Months Ended Mar. 31, 2024

NOTE 17 - SHAREHOLDERS’ EQUITY

Akso Health was established under the laws of the Cayman Islands on April 25, 2016. The authorized number of ordinary shares is 500,000,000 shares with par value of US\$0.0001 each. On August 24, 2020, the Company amended the ratio of ADS representing its ordinary shares from one (1) ADS representing one (1) ordinary share to one (1) ADS representing three (3) ordinary shares. The change in the ADS ratio has the same effect as a one-for-three reverse ADS split. There was no change to our ordinary shares in connection with the change of the ADS ratio. On June 19, 2023, the Company increased its authorized shares from US\$50,000 divided into 500,000,000 ordinary shares of a par value of US\$0.0001 each to US\$500,000 divided into 5,000,000,000 ordinary shares of a par value of US\$0.0001 by the creation of an additional 4,500,000,000 ordinary shares of a par value of US\$0.0001. As of March 31, 2024 and 2023, the Company’s outstanding ordinary shares were 437,170,960 and 68,598,050, respectively.

Private Placement

On August 9, 2021, the Company entered into a certain securities purchase agreement (the “SPA”) with certain “non-U.S. Persons” pursuant to which the Company agreed to sell an aggregate of 6,340,000 units at a price of US\$1.58 per unit, each unit consisting of three ordinary shares of the Company, par value \$0.0001 per share (“Share”) and a warrant to purchase three Shares with an initial exercise price of US\$3.00, for an aggregate purchase price of approximately US\$10.02 million (the “Offering”). On September 17, 2021, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$10.0 million from such Offering will be used by the Company for working capital and general corporate purposes.

The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$3.00, or for cash (the “Warrant Shares”). The Warrants may also be exercised on a cashless basis if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions. During the year ended March 31, 2024, a total of 3,380,000 warrants (each warrant to purchase 3 ordinary shares) were exercised on cashless basis, resulting issuance of 7,098,000 ordinary shares.

On October 2, 2023, the Company entered into a certain securities purchase agreement (the “SPA”) with certain “non-U.S. Persons” pursuant to which the Company agreed to sell an aggregate of 35,739,270 units at a price of US\$0.391 per unit, each unit consisting of one ordinary shares of the Company, par value \$0.0001 per share (“Share”) and a warrant to purchase one Shares with an initial exercise price of US\$0.48875, for an aggregate purchase price of approximately US\$14.0 million (the “Offering”). On October 17, 2023, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$14.0 million from such Offering will be used by the Company for working capital and general corporate purposes.

The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.48875, or approximately \$1.47 per ADS, for cash (the “Warrant Shares”). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.

On November 16, 2023, the Company entered into a certain securities purchase agreement (the “SPA”) with certain “non-U.S. Persons” pursuant to which the Company agreed to sell an aggregate of 53,608,910 units at a price of US\$0.423 per unit, each unit consisting of one ordinary shares of the Company, par value \$0.0001 per share (“Share”) and a warrant to purchase one Shares with an initial exercise price of US\$0.52875, for an aggregate purchase price of approximately US\$22.68 million (the “Offering”). On November 21, 2023, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$22.68 million from such Offering will be used by the Company for working capital and general corporate purposes.

The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.52875, or approximately \$1.59 per ADS, for cash (the “Warrant Shares”). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.

On January 17, 2024, the Company entered into a certain securities purchase agreement (the “SPA”) with certain “non-U.S. Persons” pursuant to which the Company agreed to sell an aggregate of 160,826,730 units at a price of US\$0.3317 per unit, each unit consisting of one ordinary shares of the Company, par value \$0.0001 per share (“Share”) and a warrant to purchase one Shares with an initial exercise price of US\$0.4146, for an aggregate purchase price of approximately US\$53.35 million (the “Offering”). On January 26, 2024, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$53.35 million from such Offering will be used by the Company for working capital and general corporate purposes.

The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.4146, or approximately \$1.2438 per ADS, for cash (the “Warrant Shares”). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.

On March 5, 2024, the Company entered into a certain securities purchase agreement (the “SPA”) with certain non-affiliated institutional investors (the “Purchasers”) pursuant to which the Company agreed to sell an aggregate of 37,100,000 of its American Depositary Shares (“ADSs”) representing 111,300,000 ordinary shares, par value \$0.0001 per share (“Ordinary Shares”), in a registered direct offering, and warrants (“Warrants”) to purchase 222,600,000 Ordinary Shares in a concurrent private placement for gross proceeds of approximately \$49.34 million (the “Offering”).

The warrants are exercisable immediately as of the date of issuance at an exercise price of \$0.4933 per ordinary share, or \$1.48 per ADS and expire five years from the date of issuance. The purchase price for each ADS and the corresponding Warrants is \$1.33. Each Warrant is subject to anti-dilution provisions to reflect stock dividends and splits, subsequent rights offerings or other similar transactions, but not as a result of future securities offerings at lower prices. Upon the occurrence of a Fundamental Transaction (as defined in the Warrants), the Warrants are subject to mandatory redemption for cash consideration equal to the Black Scholes Value (as defined in the Warrants) of such portion of such Warrant to be redeemed. The Company intended to use the net proceeds from the Offering for working capital and general corporate use. The Offering closed on March 7, 2024.

Warrants

As the warrants contained in the placement above are indexed to the Company’s ordinary share (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Warrants as additional paid-in capital on the Company’s consolidated balance .The Company accounts for the warrants issued in connection with the private placement in accordance with the guidance contained in ASC 815-40. The Company’s management has examined the warrants and determined that these warrants qualify for equity treatment in the Company’s financial statements.

The warrants contained in the private placements above shall expire five years from its date of issuance. The warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar as transactions.

During the year ended March 31, 2024, 3,380,000 warrants were exercised on cashless basis, leading to an insurance of 7,098,000 ordinary shares. During the year ended March 31, 2023, no warrants were exercised.

As of March 31, 2024, the Company had 290,234,910 warrants outstanding to purchase 481,654,910 ordinary shares with weighted average exercise price of US\$ 0.48 per warrant. As of March 31, 2023, the Company had 6,340,000 warrants outstanding to purchase 19,020,000 ordinary shares.

Following is a summary of the status of warrants outstanding and exercisable as of March 31, 2024:

	Warrants	Weighted Average Exercise Price	Aggregate Intrinsic Value
Warrants outstanding, as of March 31, 2022	—	—	—
Issued	6,340,000	\$ 3.0	—
Exercised	—	—	—
Expired	—	—	—
Warrants outstanding, as of March 31, 2023	6,340,000	\$ 3.0	—
Issued	287,274,910	0.46	—
Exercised	3,380,000	—	—
Expired	—	—	—
Warrants outstanding, as of March 31, 2024	290,234,910	0.48	—
Warrants exercisable, as of March 31, 2024	290,234,910	0.48	—

	Warrants exercisable in ordinary shares	Weighted Average Exercise Price	Average Remaining Contractual Life
August 9, 2021 warrants	8,880,000	\$ 1.0	2.4 years
October 2, 2023 warrants	35,739,270	0.4888	4.6 years
November 16, 2023 warrants	53,608,910	0.5288	4.7 years
January 17, 2024 warrants	160,826,730	0.4146	4.8 years
March 5, 2024 warrants	222,600,000	0.4933	4.9 years

~~XML 44 R24.htm IDEA XBRL DOCUMENT~~

Treasury Stock

Treasury Stock

[Abstract]

TREASURY STOCK

12 Months Ended
Mar. 31, 2024

NOTE 18 - TREASURY STOCK

On December 10, 2018, the Company announced that its board of directors authorized a share repurchase program under which the Company may repurchase up to US\$25 million of its ordinary shares in the form of American depositary shares (“ADS”) over the next 12 months. The Company repurchased an aggregate of 1,165,883 ADSs from the open market for a total consideration of US\$3,988,370, which was recorded as treasury stock.

~~XML 45 R25.htm IDEA XBRL DOCUMENT~~

Restricted Net Assets

Restricted Net Assets

[Abstract]

RESTRICTED NET ASSETS

12 Months Ended
Mar. 31, 2024

NOTE 19 - RESTRICTED NET ASSETS

Restricted Net Assets

As a result of the PRC laws and regulations and the requirement that distributions by the PRC entities can only be paid out of distributable profits computed in accordance with the PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Company. The restricted net assets consist of paid in capital, capital reserve and statutory reserves of the Company’s PRC entities. As of March 31, 2024 and 2023, the restricted net assets that are not available for distribution amounted to approximately US\$89.5 and US\$89.5 million, respectively, which was included in the additional paid-in capital on the consolidated balance sheets.

Statutory Reserve

Pursuant to the Company Law of the PRC, each of the PRC entities is required to appropriate 10% of its net income to the statutory reserve on an annual basis until the aggregated amount of the reserve reaches 50% of its registered capital. The statutory reserve is not distributable. Subject to the approval of the shareholders, the statutory reserve may be used to offset accumulated losses or converted into capital of the company. As of March 31, 2024 and 2023, the statutory reserves amounted to nil and nil, respectively.

~~XML 46 R26.htm IDEA XBRL DOCUMENT~~

Commitments and Contingencies

Commitments and Contingencies

[Abstract]

COMMITMENTS AND CONTINGENCIES

12 Months Ended
Mar. 31, 2024

NOTE 20 - COMMITMENTS AND CONTINGENCIES

Contingencies

In the ordinary course of business, the Company may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records contingent liabilities resulting from such claims, when a loss is assessed to be probable and the amount of the loss is reasonably estimable. As of March 31, 2024 and 2023, no such contingent liabilities are assessed as probable.

~~XML 47 R27.htm IDEA XBRL DOCUMENT~~

Subsequent Events

Subsequent Events

[Abstract]

SUBSEQUENT EVENTS

12 Months Ended
Mar. 31, 2024

NOTE 21 - SUBSEQUENT EVENTS

In March 2024, the Company, through Tianjin Akso Enterprise Management Co, Ltd., one of its subsidiary in China, entered into Share Purchase Agreements (the “SPA”) with four non-affiliated individual shareholders (the “Sellers”) of Tianjin Wangyi Cloud Technology Co., Ltd (the “Target”). Pursuant to the SPA, the Company will acquire 50% of the equity interest in the Target held by the four Sellers, each of which held 12.5% equity interest, respectively. The total consideration for the transaction was US\$75.0 million. As of March 31, 2024, the Company has paid US\$56.25 million. In April 2024, the Company paid the remaining US\$18.75 million consideration and the transaction was closed.

In the Company’s Annual General Meeting held on April 30, 2024, the Company’s authorized issued share capital is approved to change from US\$500,000 divided into 5,000,000,000 ordinary shares, par value US\$0.0001 each, to US\$500,000 divided into 4,500,000,000 Class A ordinary shares, par value US\$0.0001 each and 500,000,000 Class B ordinary shares, par value US\$0.0001 each. And 7,980,800 issued and outstanding ordinary shares of the Company held by Webao Limited were re-designated and re-classified as Class B Ordinary Shares par value US\$0.0001 each on a 1:1 basis and all other issued and outstanding Ordinary Shares as class A ordinary shares, par value US\$0.0001 each (the “Class A Ordinary Shares”) on a 1:1 basis.

On June 17, 2024, the warrants issued in the October 2023 and November 2023 private placements (see Note 17) were fully exercised on a cashless basis, resulting in the issuance of 25,017,480 and 37,256,230 Class A ordinary shares, respectively.

On June 27, 2024, the Company entered into a certain securities purchase agreement (the “June SPA”) with certain “non-U.S. Persons” pursuant to which the Company agreed to sell an aggregate of 220,000,050 units at a price of US\$0.2844 per unit, each unit consisting of one Class A ordinary share of the Company, par value \$0.0001 per share (“Share”) and three warrants to purchase one Share each with an initial exercise price of US\$0.3555, for an aggregate purchase price of approximately US\$62.6 million (the “June Offering”). On July 2, 2023, the June Offering was consummated when all the closing conditions of the June SPA were satisfied. The net proceeds of approximately US\$62.6 million from the June Offering will be used by the Company for working capital and general corporate purposes.

The warrants issued in the June Offering (the “June Warrants”) are exercisable immediately upon the date of issuance at an initial exercise price of \$0.3555, or approximately \$1.0665 per ADS, for cash. The June Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the warrant shares underlying the June Warrants. The June Warrants shall expire five years from its date of issuance and are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.

~~XML 48 R28.htm IDEA XBRL DOCUMENT~~

Schedule I - CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY

The Company's subsidiaries and VIEs established in the PRC are restricted in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China. The Company's subsidiaries and its VIEs are also required to set aside at least 10% of its after-tax profit based on the PRC accounting standards each year to its statutory reserves account until the accumulative amount of such reserves reaches 50% of its respective registered capital. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends.

In addition, the Company's operations and revenues are conducted and generated in China, all of the Company's revenues being earned and currency received are denominated in RMB. RMB is subject to the foreign exchange control regulation in China, and, as a result, the Company may be unable to distribute any dividends outside of China due to the PRC foreign exchange control regulations that restrict the Company's ability to convert RMB into US Dollars.

Regulation S-X requires the condensed financial information of a registrant shall be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the registrant's proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances, or cash dividends without the consent of a third party. The condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X as the restricted net assets of the Company's PRC subsidiaries and VIEs exceed 25% of the consolidated net assets of the Company.

The condensed financial information of the parent company has been prepared in accordance with SEC Regulation S-X Rule 5-04 and Rule 12-04, using the same accounting policies as set out in the Company's consolidated financial statements, except that the Company uses the equity method to account for investments in its subsidiaries, VIEs and VIEs' subsidiaries. The footnote disclosures generally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. The footnote disclosures contain supplemental information relating to the operations of the Company, as such, these statements are not the general-purpose financial statements of the reporting entity and should be read in conjunction with the notes to the consolidated financial statements of the Company.

CONDENSED BALANCE SHEETS

	As of March 31 2024 USD	As of March 31 2023 USD
ASSETS:		
Cash	2,279	4,472
Prepayment and other assets	—	5,795
Investments in subsidiaries, VIEs and VIEs' subsidiaries	141,456,064	11,303,978
TOTAL ASSETS	141,458,343	11,314,245
LIABILITIES:		
Accrued expenses and other current liabilities	1,090,959	588,941
Due to related party	2,000,000	2,000,000
TOTAL LIABILITIES	3,090,959	2,588,941
SHAREHOLDERS' EQUITY:		
Ordinary share (\$0.0001 par value, 5,000,000,000 shares authorized, 438,336,843 and 69,763,933 shares issued, 437,170,960 and 68,598,050 shares outstanding as of March 31, 2024 and 2023, respectively)	43,834	6,977
Additional paid-in capital	210,324,890	71,021,898
Treasury stock	(3,988,370)	(3,988,370)
Accumulated deficit	(63,926,383)	(54,467,600)
Accumulated other comprehensive loss	(4,086,587)	(3,847,601)
TOTAL SHAREHOLDERS' EQUITY	138,367,384	8,725,304
TOTAL LIABILITIES AND SHEREHOLDERS' EQUITY	141,458,343	11,314,245

CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

	Years Ended March 31,		
	2024 USD	2023 USD	2022 USD
Equity in (loss) earnings of subsidiaries	(7,394,438)	(1,086,999)	(13,720,643)
General administrative expense and others	(2,122,139)	(160,427)	(3,129,090)
NET (LOSS)	(9,516,577)	(1,247,426)	(16,849,733)
OTHER COMPREHENSIVE INCOME (LOSS)			
Foreign currency translation adjustment	(238,985)	(2,198,379)	1,454,319
COMPREHENSIVE (LOSS)	(9,755,562)	(3,445,805)	(15,395,414)

CONDENSED STATEMENTS OF CASH FLOWS

	For The Years Ended March 31,		
	2024 USD	2023 USD	2022 USD
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net (loss)	(9,516,577)	(1,247,426)	(16,851,064)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:			
Provision for doubts accounts	5,795	-	-
Equity in loss of subsidiaries	7,394,438	1,147,003	13,721,974
Share-based compensation	-	-	391,625
Changes in operating assets and liabilities:			
Prepayments and other assets	-	-	154,654
Accrued expenses and other current liabilities	502,018	528,266	101,207
Interest payments on unsecured senior notes and short-term bank loan	-	-	(676,894)
NET CASH (USED IN) OPERATING ACTIVITIES	(1,614,326)	427,843	(3,158,490)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Proceeds from private placement offering, net of offering costs	139,339,849	-	10,017,200
Principal payments on unsecured senior notes	-	-	(10,000,000)
Loan to subsidiaries, VIEs and VIE's subsidiaries	(137,727,716)	(427,862)	(337,695)
Proceeds from related party	-	-	2,000,000
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	1,612,133	(427,862)	1,679,505
NET (DECREASE) IN CASH	(2,193)	(19)	(1,478,993)
CASH-beginning of year	4,472	4,491	1,483,484
CASH-end of year	2,279	4,472	4,491
SUPPLEMENTAL CASH FLOW DISCLOSURES:			
Cash paid for income tax	24,988	17,549	92,816
Cash paid for interest	111,563	336,593	676,894

Notes to condensed financial statements

- Akso Health, formerly known as Xiaobai Maimai Inc., was founded on April 25, 2016 in the Cayman Islands. The condensed full year results of the Company have been prepared assuming the Reorganization (see Note 1 in the consolidated financial statements) was in effect from November 1, 2016.
- The condensed financial statements of Akso Health have been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in subsidiaries, VIEs and subsidiaries of VIEs. Such investment in subsidiaries and VIEs are presented on the balance sheets as interests in subsidiaries and VIEs and the income (loss) of the subsidiaries and VIEs is presented as equity in (loss) earnings of subsidiaries and VIEs on the statement of operations.
- As of March 31, 2023 and 2022, there were no material contingencies, significant provisions of long-term obligations of the Company, except for those which have been separately disclosed in the consolidated financial statements.
- Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The notes to consolidated financial statements disclosed certain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the accompanying Consolidated Financial Statements.

~~XML 49 R29.htm IDEA XBRL DOCUMENT~~

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and have been consistently applied. Certain prior year balances in the consolidated statements of operations and comprehensive (loss) and cash flows have been reclassified to the current year's presentation.

Consolidated VIEs

The accompanying consolidated financial statements include the financial statements of the Company, its subsidiaries, its consolidated VIEs and VIE's subsidiaries for which the Company is the primary beneficiary. All inter-company transactions and balances have been eliminated upon consolidation.

VIE arrangements. In order to comply with the PRC laws and regulations which prohibit or restrict foreign investments into companies involved in restricted businesses, the Company operates its marketplace and restricted businesses in the PRC through certain PRC domestic companies, whose equity interests are held by certain management members of the Company or onshore nominees of the Company ("Nominee Shareholders"). The Company obtained control over these PRC domestic companies by entering into a series of contractual arrangements with these PRC domestic companies and their respective Nominee Shareholders. These contractual agreements cannot be unilaterally terminated by the Nominee Shareholders or the PRC domestic companies. As a result, the Company maintains the ability to control these PRC domestic companies and is entitled to substantially all of the economic benefits from these PRC domestic companies. Management concluded that these PRC domestic companies are VIEs of the Company, of which the Company is the ultimate primary beneficiary. As such, the Company consolidated financial results of these PRC domestic companies and their subsidiaries in the Group's consolidated financial statements. The principal terms of the agreements entered into amongst the VIEs, their respective shareholders and the WFOE are further described below.

The Exclusive Business Cooperation Agreements enable the WOFE to receive substantially all of the assets and business of the VIEs in the PRC. Under these Agreements, the WOFE has the exclusive right to provide the VIEs with comprehensive technical support, consulting services and other services during the term of these Agreements, including but not limited to software licensing; development, maintenance and update of software, network systems, hardware and database; technical support and training for employees; consultancy on technology and market information; business management consultation; marketing and promotion services, etc. The WOFE has the right to determine the fees associated with the services it provides based on the technical difficulty and complexity of the services, the actual labor costs it incurs for providing the services and some other factors during the relevant period. This Agreements remain effective unless otherwise terminated in writing by WOFE.

Pursuant to the Equity Interest Pledge Agreements, each Shareholder of the VIEs agreed to pledge their equity interest in the VIEs to the WOFE to secure the performance of the VIEs' obligations under the Exclusive Business Cooperation Agreements and any such agreements to be entered into in the future. Shareholders of the VIEs agreed not to transfer, sell, pledge, dispose of or otherwise create any encumbrance on their equity interests in the VIEs without the prior written consent of the WOFE. The Pledges became effective on such date when the pledge of the Equity Interest contemplated herein were registered with the relevant administration for industry and commerce (the "AIC") and remain effective until all contract obligations have been fully performed and all secured indebtedness has been fully paid.

Pursuant to the Exclusive Option Agreements, each of the Shareholders of the VIE irrevocably grant the WFOE an irrevocable and exclusive right to purchase, or designate one or more persons (including individuals, corporations, partnerships, partners, enterprises, trusts or non-corporate organizations) to purchase the equity interests in the VIEs then held by such Shareholder of the VIEs once or at multiple times at any time in part or in whole at the WFOE's sole and absolute discretion to the extent permitted by Chinese laws at the price of RMB 1 or at the price of the minimum amount of consideration permitted by the applicable PRC law at the time when such purchase occurs. These three Agreements remain effective until all equity interests held by the shareholders of the VIEs in the VIEs have been transferred or assigned to the WFOE and/or its designees.

Pursuant to the three Loan Agreements, the WOFIE agreed to lend each of the Shareholders of VIEs a loan only to subscribe to the registered capital of the VIEs. The repayment of the loan shall be made by permitting the WOFIE to execute its exclusive right to purchase shares from the shareholders of the VIEs under the Exclusive Option Agreement as the repayment is equivalent to the consideration of the purchased shares. The term of these loans is 10 years, which may be extended upon mutual written consent of all parties.

Each Shareholder of the VIEs, executed a Power of Attorney agreement with the WFOE and the VIEs, whereby Shareholders of the VIEs irrevocably appoint and constitute the WFOE as their attorney-in-fact to exercise on the shareholders' behalf any and all rights that Shareholders of the VIEs have in respect of their equity interests in the VIEs. These three Power of Attorney documents remain irrevocable and continuously effective and valid as long as the original shareholders of the VIEs remain as the Shareholders of the VIEs.

The Company believes that the contractual arrangements with its VIEs and their respective shareholders are in compliance with the PRC laws and regulations and are legally enforceable. However, uncertainties in the PRC legal system could limit the Company's ability to enforce the contractual arrangements. If the legal structure and contractual arrangements were found to be in violation of the PRC laws and regulations, the PRC government could:

- revoke the business and operating licenses of the Company's PRC subsidiary and VIEs;
- discontinue or restrict the operations of any related-party transactions between the Company's PRC subsidiary and VIEs;
- limit the Company's business expansion in the PRC by way of entering into contractual arrangements;
- impose fines or other requirements with which the Company's PRC subsidiary and VIEs may not be able to comply;
- require the Company or the Company's PRC subsidiary and VIEs to restructure the relevant ownership structure or operations; and/or
- restrict or prohibit the Company's use of the proceeds of the additional public offering to finance the Company's business and operations in the PRC.

The Company's ability to conduct its Online Marketplace business may be negatively affected if the PRC government were to carry out any of the aforementioned actions. As a result, the Company may not be able to consolidate its VIEs in its consolidated financial statements as it may lose the ability to exert effective control over the VIEs and their respective shareholders and it may lose the ability to receive economic benefits from the VIEs. The Company, however, does not believe such actions would result in the liquidation or dissolution of the Company, its PRC subsidiary and VIEs.

The interests of the shareholders of VIEs may diverge from that of the Company and that may potentially increase the risk that they would seek to act contrary to the contractual terms, for example by influencing the VIEs not to pay the service fees when required to do so. The Company cannot assure that when conflicts of interest arise, shareholders of the VIEs will act in the best interests of the Company or that conflicts of interests will be resolved in the Company's favor. Currently, the Company does not have existing arrangements to address potential conflicts of interest the shareholders of the VIEs may encounter in their capacity as beneficial owners and directors of the VIEs, on the one hand, and as beneficial owners and directors of the Company, on the other hand. The Company believes the shareholders of VIEs will not act contrary to any of the contractual arrangements and the exclusive option agreements provide the Company with a mechanism to remove the current shareholders of the VIEs should they act to the detriment of the Company. The Company relies on certain current shareholders of the VIEs to fulfill their fiduciary duties and abide by laws of the PRC and act in the best interest of the Company. If the Company cannot resolve any conflicts of interest or disputes between the Company and the shareholders of the VIEs, the Company would have to rely on legal proceedings, which could result in disruption of its business, and there is substantial uncertainty as to the outcome of any such legal proceedings.

In May 2023, the Company completed the disposal of its social E-commerce business. After that, no VIEs or its subsidiaries were included in the consolidated financial statement of the Company. As a result, the Company's results of operations, revenues, costs and expenses related to the social E-commerce Business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented. Assets and liabilities of the social E-commerce business were reclassified separately from other assets and liabilities of the Company on the consolidated balance sheets. Refer to Note 1 and Note 4.

The following financial statement amounts and balances of the consolidated VIEs were included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Current Assets:		
Cash and cash equivalents	—	678,691
Accounts receivable and contract assets, net	—	10,062
Prepayments and other assets	—	43,779
Amounts due from related parties	—	26,206,288
Total Current Assets	—	26,938,820
Property, equipment and software, net	—	28,698
Total Assets		26,967,518
Current Liabilities		
Accrued expenses and other current liabilities	—	32,430
Taxes (benefit) payable	—	(12,624)
Total Current Liabilities	—	19,806
Total Liabilities	—	19,806

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
	USD	USD	USD
Net revenues	694	27,324	311,725
Net loss	(12,479)	(348,806)	(11,527,588)
	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	USD	USD	USD
Net cash provided by (used in) operating activities	12,497	(559,973)	5,613,401
Net cash (used in) investing activities	-	-	(1,455,547)
Net cash provided by (used in) financing activities	213,879	(1,156,948)	(13,203,558)

[illegible]

	2022	USD	USD	USD	USD
Net revenues	694,327,524	311,725	Net loss	(12,479)	(346,606)
					(11,327,566)
	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021		
	USD	USD	USD		
Net cash provided by (used in) operating activities	12,497	(559,973)	5,613,401		
Net cash (used in) investing activities	-	-	(1,455,547)		
Net cash provided by (used in) financing activities	213,879	(1,156,948)	(13,203,558)		

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during each reporting period. Actual results could differ from such estimates. Significant accounting estimates reflected in the Company's consolidated financial statements include estimates and judgments applied in allocation of revenue with various performance obligations, allowance for accounts receivable and contract assets, impairment on long-term investments, valuation allowance for deferred tax assets, valuation of share-based compensation and allowance for loans receivable and other receivable.

Fair value of financial instruments

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurement or assumptions that market participants would use when pricing the asset or liability.

The Company follows the provisions of Financial Accounting Standards Board ("FASB"), Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other

than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3 - Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts reported in the balance sheets for cash, receivables, prepayments and other assets, loan principal and interest receivable, approximate their fair value based on the short-term maturity of these instruments. The Company did not transfer any assets or liabilities in or out of level 3 during the years ended March 31, 2023, 2022 and 2021.

The Company's long-term investments consist of equity securities and available-for-sale investments. For long-term investments without readily determinable fair value, the Company is not able to estimate fair value, hence, the Company uses the cost minus impairment method as alternative.

Discontinued Operations

A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity's financial results and operations. Included in the consolidated statements of operations and comprehensive (loss) income, result from discontinued operations have been reported separately from the income and expenses from continuing operations and prior periods have been presented on a reclassified comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.

Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented.

Revenue recognition

In February 2022, the Company started its business in the US market for the sale of medical devices. In May 2020, the Company launched its social e-commerce platform and built collaboration with domestic mainstream E-commerce marketplaces, which was discontinued in fiscal year 2023 and disposed in May 2023. The Company provides recommendation services by referring certain interested users to those marketplaces for high-quality and affordable branded products. Prior to business transformation, the Company through its P2P business offered online consumer lending-related service in fiscal year 2020, which was discontinued in fiscal year 2021 and disposed on December 30, 2020. The Company presents value added taxes ("VAT") as a reduction of revenues.

Revenues generated are accounted under Accounting Standards Update (ASU) 2014-09, "Revenue from contracts with Customers" (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following steps:

Step 1: Identify the contract (s) with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation

Online marketplace services

● **Commission revenue**

The commission services revenue primarily consists of commission fees charged to the online E-commerce marketplace for recommending users to purchase on their marketplaces, where the Company generally is acting as an agent and its performance obligation is to provide recommendation services for purchasing specified goods or services by those third-party sellers, is not responsible for fulfilling the promise to provide the specified goods or services, and does not have the ability to control the related shipping services when utilized by the third-party sellers. Upon successful sales, the Company will charge the online E-commerce companies a negotiated amount or a fixed rate commission fee based on the sales amount. Commission services revenues are recognized on a net basis at the point of receipt of products, net of a return allowance and incentives to consumers or channels.

In order to promote its online marketplace and attract more registered consumers, the Company at its own discretion offers incentives to consumers. Consumers are not customers of the Company, therefore incentives offered to consumers are not considered payments to customers. Such incentives offered to consumers were as a reward for purchasing by themselves or their sharing through our platform. Incentives provided to consumers are specific to any merchant and are recognized as a reduction of commission service revenue. For the years ended March 31, 2024, 2023, 2022, the total amount of incentives was nil, nil and US\$96,332, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

● **Interest income**

Started in August 2017, the Company lent funds to borrowers up to their approved credit through its consolidated VIE, and since May 2019, the Company has ceased to issue new loans through its microlending business. Interest income on loans receivable is recognized monthly based on the contractual interest rates of the loan. Accrual of interest is generally discontinued when reasonable doubt exists as to the full, timely collection of interest or principal. When a loan is discontinued from interest accrual, the Company stops accruing interest and reverses all accrued but unpaid interest as of such date. Interest income was nil, nil, US\$215,393 for the years ended March 31, 2024, 2023 and 2022, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

● **Sales of medical devices**

Started in February 2022, through its subsidiary Akso Online MediTech, the Company engaged in the sale of Covid-19 Antigen Rapid Tests in US market. For the years ended March 31, 2024, 2023 and 2022, revenue generated from sale of Covid-19 Antigen Rapid Tests was nil, \$9,181,274 and \$6,000,000. Akso Online MediTech purchases medical devices in quantity and distributes products primarily to medical products dealers. The deliveries may take one day or longer depending on the customers' location. Revenue from sales of merchandise to non-retail customers is recognized when the merchandise is transferred to customers. There was no sales return since the start the business.

● **Disaggregation of revenue**

All of the Company's revenue for the years ended March 31, 2024 was generated from PRC and revenue for the year ended March 31, 2023 were generated from US and PRC, and for the year ended March 31, 2022 were generated from US. The following table illustrates the disaggregation of revenue:

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
	USD	USD	USD
Revenue			
Revenue from medical devices-US	-	9,181,274	6,000,000
Revenue from medical devices-PRC	2,416,797	4,005,251	-
Total revenues	2,416,797	13,186,525	6,000,000
Tax and surcharges	2,459	4,964	-
Net Revenues	2,414,338	13,181,561	6,000,000

[Uses of estimates](#)

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during each reporting period. Actual results could differ from such estimates. Significant accounting estimates reflected in the Company's consolidated financial statements include estimates and judgments applied in allocation of revenue with various performance obligations, allowance for accounts receivable and contract assets, impairment on long-term investments, valuation allowance for deferred tax assets, valuation of share-based compensation and allowance for loans receivable and other receivable.

Fair value of financial instruments

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurement or assumptions that market participants would use when pricing the asset or liability.

The Company follows the provisions of Financial Accounting Standards Board ("FASB"), Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3 - Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts reported in the balance sheets for cash, receivables, prepayments and other assets, loan principal and interest receivable, approximate their fair value based on the short-term maturity of these instruments. The Company did not transfer any assets or liabilities in or out of level 3 during the years ended March 31, 2023, 2022 and 2021.

The Company's long-term investments consist of equity securities and available-for-sale investments. For long-term investments without readily determinable fair value, the Company is not able to estimate fair value, hence, the Company uses the cost minus impairment method as alternative.

[Discontinued Operations](#)

Discontinued Operations

A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity's financial results and operations. Included in the consolidated statements of operations and comprehensive (loss) income, result from discontinued operations have been reported separately from the income and expenses from continuing operations and prior periods have been presented on a reclassified comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.

Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented.

[Cash and cash equivalents](#)

Cash and cash equivalents

Cash and cash equivalents represent cash on hand, unrestricted demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash.

[Accounts receivable and allowance for uncollectible accounts](#)

Accounts receivable and allowance for uncollectible accounts

Accounts receivable are mainly receivables from online E-commerce marketplaces and recommendation services, which are stated at the historical carrying amount net of allowance for uncollectible accounts. The Company establishes an allowance for uncollectible accounts receivable based on estimates, historical experience and other factors surrounding the credit risk of specific customers. Uncollectible accounts receivables are written off when a settlement is reached for an amount that is less than the outstanding historical balance or when the Company has determined that is not probable for the balance to be collected. Beginning on April 1, 2020, the Company evaluates its accounts receivable for expected credit losses on a regular basis. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. The Company uses the length of time a balance has been outstanding, the payment history, creditworthiness and financial conditions of the customers and industry trend as credit quality indicators to monitor the Company's receivables within the scope of expected credit losses model and use these as a basis to develop the Company's expected loss estimates. The Company adjusts the allowance percentage periodically when there are significant differences between estimated bad debts and actual bad debts. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Company also makes a specific allowance in the period in which a loss is determined to be probable. Accounts receivable balances are written off after all collection efforts have been exhausted. As of March 31, 2024 and 2023, the allowance for uncollectible accounts receivable balance was US\$ 7,369,797 and US\$ 400,759, respectively.

[Inventories](#)

Inventories

Inventories are comprised of finished goods, which are defibrillators and anesthesia laryngoscope, and are stated at the lower of cost or net realizable value using first in first out (FIFO) method. Management reviews inventories for obsolescence and cost in excess of net realizable value periodically when appropriate and records a reserve against the inventory when the carrying value exceeds net realizable value. As of March 31, 2024, the Company determined that no allowance was necessary.

[Property and equipment, net](#)

Property and equipment, net

Property and equipment are stated at cost. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives:

	Useful life
Office equipment	3-5 years

The Company eliminates the cost and related accumulated depreciation and amortization of assets sold or otherwise retired from the accounts and includes any gains or losses from disposal of property, equipment, and software in other income. The Company charges maintenance, repairs, and minor renewals directly to expense as incurred; major additions and betterments to equipment are capitalized. For the disposal of social E-commerce business, property and equipment, net was recorded in discontinued operations.

[Impairment of long-lived assets](#)

Impairment of long-lived assets

The carrying value of the long-lived assets are reviewed for impairment, whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Recoverability

of assets to be held and used is evaluated by a comparison of the carrying amount of assets to future undiscounted net cash flows expected to be generated by the assets. Such assets are considered to be impaired if the sum of the expected undiscounted cash flows is less than carrying amount of the assets. The impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets. No impairment loss was recognized for the years ended March 31, 2024, 2023 and 2022.

Advertising and promotion expenses

Advertising and promotion expenses

The Company recognizes its advertising and promotion expenses as sales and marketing expense. Advertising expenses represent expenses for placing advertisements on television, radio and in newspapers, as well as on internet websites and search engines. Advertising and promotion costs are expensed as incurred. For the years ended March 31, 2024, 2023 and 2022, the advertising and promotion expenses were US\$ 168,421, US\$ 6,661, nil, respectively.

Lease

Lease

Upon the adoption of FASB ASC 842 on April 1, 2019 using the modified retrospective method, the Company determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets and operating lease liabilities, in the Company's consolidated balance sheets. The Company does not have any finance leases as of the adoption date or March 31, 2022.

ROU represents the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which it calculates based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease.

For operating lease with a term of one year or less, the Company has elected to not recognize a lease liability or lease right of use asset on its consolidated balance sheets. Instead, it recognizes the lease payment as expense on a straight-line basis over the lease term. Short-term lease costs are immaterial to its consolidated statements of operations and comprehensive (loss). The Company has operating lease agreements with insignificant non-lease components and have elected the practical expedient to combine and account for lease and non-lease components as single lease component.

Warrants

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in Financial Accounting Standards Board ("FASB") ASC 480 "Distinguishing Liabilities from Equity" ("ASC 480") and ASC 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common stock and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annually period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations (Note 17).

Share-based compensation

Share-based compensation

Under the Amended and Restated 2016 Equity Incentive Plan, the Company grants share options to the Company's selected employees, and directors. Awards granted to employees with service conditions attached are measured at the fair value on the grant date and are recognized as an expense using straight-line method, net of estimated forfeitures, over the requisite service period, which is generally the vesting period. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share-based compensation expense to be recognized in future periods.

Awards granted to employees with performance conditions attached are measured at fair value on the grant date and are recognized as compensation expense in the period and thereafter when the performance goal becomes probable to achieve. Awards granted to employees with market conditions attached are measured at fair value on the grant date and are recognized as compensation expense over the estimated requisite service period, regardless of whether the market condition has been satisfied if the requisite service period is fulfilled.

Binomial option-pricing models are adopted to measure the value of awards at each grant date or measurement date. The determination of fair value is affected by assumptions relating to a number of complex and subjective variables, including but not limited to the expected share price volatility, actual and projected employee share option exercise behavior, risk-free interest rates and expected dividends. The use of the option-pricing model requires extensive actual employee exercise behavior data for the relative probability estimation purpose, and a number of complex assumptions.

Treasury stock

Treasury stock

Treasury stock represents ordinary shares repurchased by the Company that are no longer outstanding and are held by the Company. The repurchase of ordinary shares is accounted for under the cost method whereby the entire cost of the acquired shares are recorded as treasury stock. The cost of treasury stock is transferred to "additional paid-in capital" when it is re-issued for the purpose of share options exercised and share awards.

Income taxes

Income taxes

The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

The Company accounts for income tax under the asset and liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Under this method, deferred income taxes will be recognized if significant temporary differences between tax and financial statements occur. A valuation allowance is established against net deferred tax assets when it is more likely that some portion or all of the net deferred tax asset will not be realized. For the years ended March 31, 2024, 2023 and 2022, the Company provided a full valuation allowance on the net deferred tax assets.

The Company may be subject to challenges from taxing authorities regarding the amounts of taxes due. These challenges may alter the timing or amount of taxable income or deductions. Management determines whether the benefits of its tax positions are more-likely-than-not of being sustained upon audit based on the technical merits of the tax position. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated.

An uncertain tax position is recognized as a benefit only if it is "more likely than not" that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. For tax positions not meeting the "more likely than not" test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income taxes are classified as income tax expense in the period incurred. The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measures the unrecognized benefits associated with the tax positions. As of March 31, 2024 and 2023, the Company did not have any significant unrecognized uncertain tax positions. The Company does not believe that its unrecognized tax benefits will change over the next twelve months.

Noncontrolling interests

Noncontrolling interests

Noncontrolling interest consists of 49% of the equity interest of We Healthy held by other investors. Excess of contribution received from noncontrolling shareholders over carrying value of the entity is recorded in additional paid in capital. The noncontrolling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Noncontrolling interests in the results of the Company are presented on the face of the consolidated statement of operations as an allocation of the total income or loss for the year between non-controlling interest holders and the shareholders of the Company.

Noncontrolling interest consist of the following:

	December 31, 2024 USD	December 31, 2023 USD
We Healthy	56,810	114,212

Earnings (loss) per share

Earnings (loss) per share

The Company computes earnings per share ("EPS") in accordance with FASB ASC 260, "Earnings per Share" ("ASC 260"). ASC 260 requires public companies with capital structures to present basic and diluted EPS. Basic EPS is measured as net income (loss) attributed to ordinary shareholders divided by the weighted average number of ordinary shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

Foreign currency translation

Foreign currency translation

The functional currency of the Company is United States Dollar. The Company's subsidiaries with operations in mainland China, the Hong Kong Special Administrative Region of the PRC ("Hong Kong" or "Hong Kong S.A.R."), the United States generally use their respective local currencies as their functional currencies. The Company's financial statements have been translated into the reporting currency, the United States Dollar ("USD"). Assets and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated at the average exchange rate during the reporting period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss). Transactions denominated in currencies other than functional currency are translated into the functional currency at the exchange rates quoted by authoritative banks prevailing at the dates of the transactions. Exchange gains and losses resulting from those foreign currency transactions denominated in a currency other than the functional currency are recorded in "other income (expense)" in the consolidated statements of operations and comprehensive income. The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that any RMB amounts could have been, or could be, converted, realized or settled into USD at the rates used in translation.

Spot exchange rates and average exchange rates were used in the translation of the consolidated financial statements.

	Fiscal year 2024	Fiscal year 2023	Fiscal year 2022
US Exchange Rate			
Year-end RMB	7.2203	6.8676	6.3393
Year average RMB	7.1671	6.8516	6.4180

Significant risks and uncertainties

Significant risks and uncertainties

Foreign currency risk

RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People's Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. The Company's cash and cash equivalents denominated in RMB amounted to US\$10,380,711 and US\$7,876,767 as at March 31, 2024 and 2023, respectively.

Concentration of credit risk

Financial instruments that potentially expose the Company to significant concentration of credit risk primarily included in the financial lines of cash and cash equivalents, accounts receivable, other receivables and prepayments and other assets. As of March 31, 2024, substantially all of the Company's cash and cash equivalents were held by major financial institutions located worldwide, including mainland China and Unite State. According to the China Bank Deposit Insurance Ordinance, the deposits at each bank is covered by insurance with an upper limit of RMB 500,000 (approximately US\$69,249) at each bank. As of March 31, 2024, the total amount not covered by issuance in the PRC was US\$ 10,310,077. The Hong Kong Deposit Protection Board pays compensation up to a limit of HKD 500,000 (approximately US\$ 63,890) if the bank with which an individual/a company hold its eligible deposit fails. As of March 31, 2024, no cash balance maintained at financial institutions in Hong Kong was subject to credit risk. In the US, the insurance coverage of each bank is \$250,000. As of March 31, 2024, no cash balance maintained at financial institutions in US was subject to credit risk. If the financial institutions could become insolvent, the Company could lose some or all of the value of its investments. To limit exposure to credit risk relating to deposits, the Company primarily place cash and cash equivalent deposits with large financial institutions which management believes are of high credit quality and management also continually monitors the financial institutions' credit worthiness.

Accounts receivable is typically unsecured and are derived from revenue earned from customers in the PRC. The risk with respect to accounts receivable is mitigated by credit evaluations the Company performs on its customers and its ongoing monitoring process of outstanding balances.

Customer concentration risk

For the year ended March 31, 2024, three customers accounted for 36.3%, 34.8% and 28.0% for the Company's total revenue from sales of medical devices business. For the year ended March 31, 2023, three customers accounted for 59.5%, 11.1% and 10.1% for the Company's total revenue from sales of medical devices business. For the year ended March 31, 2022, one customer accounted for 95.1% of the Company's total revenues. There was no customer of the Company that accounted for more than 10% of the Company's carrying amount of account receivables as of March 31, 2024 and there was one customer of the Company that accounted for 100% of the Company's carrying amount of accounts receivable as of March 31 2023.

Vendor concentration risk

For the year ended March 31, 2024, one vendor accounted for 100% of the Company's purchase of medical devices business. For the year ended March 31, 2023, one vendor accounted for 97.3% of the Company's purchase of medical devices business. For the year ended March 31, 2022, one vendor accounted for 100% of the Company's purchase of medical devices business. There was no vendor of the Company that accounted for greater than 10% of the Company's carrying amount of accounts payable as of March 31, 2024 and 2023.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). ASU No. 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as additional information on income taxes paid. The guidance is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Company does not expect to adopt ASU No. 2023-09 early and is currently evaluating the impact of adopting this standard on its consolidated financial statements.

The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated balance sheets, consolidated statements of operations and comprehensive loss (income) and consolidated statements of cash flows.

As of March 31, 2024, the Company’s principal subsidiaries are as follows:

	Date of incorporation / acquisition	Place of incorporation	Percentage of legal ownership	Principal activities
Wholly owned subsidiaries				
We Health Limited (“We Health”)	July 8, 2021	New York	100%	Investment holding
Akso Medical Cloud Limited (“Akso Medical Cloud”)	November 15, 2023	BVI	100%	Investment holding
We Healthy Limited (“We Healthy”)	December 15, 2021	Hong Kong	51%	Investment holding
Akso Medi-care Limited (“Akso Medi-care”)	December 4, 2023	Hong Kong	100%	Investment holding
Akso Remote Medical Consultation Center Inc. (“Akso Remote Medical”)	January 3, 2022	Wyoming	100%	Provision of health treatment services
Akso Online MediTech Co., Ltd. (“Akso Online MediTech”)	January 4, 2022	Wyoming	100%	Sales of medical devices
Akso First Health Treatment Center Inc. (“Akso First Health”)	January 4, 2022	Massachusetts	100%	Provision of health treatment services
Tianjin Akso Enterprise Management Co., Limited. (Wholly Owned Foreign Enterprise, “WOFE”)	January 16, 2024	PRC	100%	Provision of consultancy support
Qindao Akso Health Management Co., Limited	January 26, 2022	PRC	51%	Provision of health treatment services

[XML 51 R31.htm IDEA XBRL DOCUMENT](#)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies [Abstract]

Schedule of Financial Statement Amounts and Balances of the Consolidated Vies

12 Months Ended

Mar. 31, 2024

The following financial statement amounts and balances of the consolidated VIEs were included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Current Assets:		
Cash and cash equivalents	—	678,691
Accounts receivable and contract assets, net	—	10,062
Prepayments and other assets	—	43,779
Amounts due from related parties	—	26,206,288
Total Current Assets	—	26,938,820
Property, equipment and software, net	—	28,698
Total Assets	—	26,967,518
Current Liabilities		
Accrued expenses and other current liabilities	—	32,430
Taxes (benefit) payable	—	(12,624)
Total Current Liabilities	—	19,806
Total Liabilities	—	19,806
	Year ended March 31, 2024	Year ended March 31, 2023
	USD	USD
Net revenues	694	27,324
Net loss	(12,479)	(348,806)
	Year ended March 31, 2023	Year ended March 31, 2022
	USD	USD
Net cash provided by (used in) operating activities	12,497	(559,973)
Net cash (used in) investing activities	-	-
Net cash provided by (used in) financing activities	213,879	(1,156,948)

Schedule of Disaggregation of Revenue

The following table illustrates the disaggregation of revenue:

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
	USD	USD	USD
Revenue			
Revenue from medical devices-US	-	9,181,274	6,000,000
Revenue from medical devices-PRC	2,416,797	4,005,251	-
Total revenues	2,416,797	13,186,525	6,000,000
Tax and surcharges	2,459	4,964	-
Net Revenues	2,414,338	13,181,561	6,000,000

Schedule of Estimated Useful Lives of Property and Equipment

Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives:

	Useful life
Office equipment	3-5 years

Schedule of Noncontrolling Interest

Noncontrolling interest consist of the following:

	December 31, 2024	December 31, 2023
	USD	USD
We Healthy	56,810	114,212

Schedule of Spot Exchange Rates and Average Exchange Rates

Spot exchange rates and average exchange rates were used in the translation of the consolidated financial statements.

	Fiscal year 2024	Fiscal year 2023	Fiscal year 2022
US Exchange Rate			
Year-end RMB	7.2203	6.8676	6.3393
Year average RMB	7.1671	6.8516	6.4180

[XML 52 R32.htm IDEA XBRL DOCUMENT](#)

Discontinued Operation (Tables)

Discontinued Operation [Abstract]

Schedule of Discontinued Operations

12 Months Ended

Mar. 31, 2024

The results of discontinued operations for years ended March 31, 2024, 2023 and 2022 are as follows:

	For the years ended March 31,		
	2024	2023	2022
	USD	USD	USD
Net Revenues	694	24,995	311,092
Operating costs and development	4,551	1,073,518	12,988,383
(Loss) income from discontinued operations	(3,857)	(1,048,522)	(12,677,291)
Other income (expense), net	(27)	12,885,134	(32,728)
(Loss) income before tax	(3,884)	11,836,612	(12,710,019)
Income tax provision	-	-	38,617
Net (loss) income from discontinued operations	(3,884)	11,836,612	(12,748,636)
Loss on sale of discontinued operations, net of taxes	(395,914)	-	-
Net income (loss) from discontinued operation	(399,798)	11,836,612	(12,748,636)

Schedule of Assets and Liabilities

Assets and liabilities of the discontinued operations as of March 31, 2024 and 2023 are as follows:

	March 31, 2024	March 31, 2023
	USD	USD
Cash and cash equivalents	-	1,268,235
Accounts receivable, net	-	10,062
Prepayments and other assets	-	44,004
Property, equipment and software, net	-	29,051
Current assets held for sale-discontinued operation	-	1,351,352
Accrued expenses and other current liabilities	-	737,693
Tax (benefit) payable	-	(32,210)
Amount due to related party	-	-
Total liabilities held for sale-discontinued operation	-	705,483

Schedule of Loss on Sale of Discontinued Operations

The calculation of loss on sale of discontinued operations, net of taxes illustrated as below:

May 19, 2023

	USD
Cash and cash equivalents	1,030,377
Accounts receivable, net	9,508
Prepayments and other assets	241,025
Property, plant and equipment, net	24,998
Total assets	1,305,908
Account payable	662,648
Accrued expenses and other current liabilities	32,346
Total liabilities	694,994
Net assets	610,914
Consideration received	215,000
Loss on sale of discontinued operations, net of taxes	(395,914)

[XML 53 R33.htm IDEA- XBRL DOCUMENT](#)

Accounts Receivable, Net (Tables)

**12 Months Ended
Mar. 31, 2024**

[Accounts Receivable, Net \[Abstract\]](#)
[Schedule of Accounts Receivable, Net](#)

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Accounts receivable	7,770,556	8,097,742
Allowance for uncollectible accounts receivable	(7,770,556)	(400,759)
Accounts receivable, net	-	7,696,983

[XML 54 R34.htm IDEA- XBRL DOCUMENT](#)

Prepayments and Other Assets,Net (Tables)

**12 Months Ended
Mar. 31, 2024**

[Prepayments and Other Assets \[Abstract\]](#)
[Schedule of Prepayments and Other Assets](#)

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Prepayments to suppliers and others	409,322	272,129
Allowance	(6,423)	-
Total prepayments and other assets,net	402,899	272,129

[XML 55 R35.htm IDEA- XBRL DOCUMENT](#)

Loan Receivables (Tables)

**12 Months Ended
Mar. 31, 2024**

[Loan Receivables \[Abstract\]](#)
[Schedule of Loan Receivables](#)

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Loan receivables	-	1,528,918
Allowance for uncollectible loan receivables	-	-
Loan receivables, net	-	1,528,918
Loan receivables - current	-	1,528,918
Loan receivables - non-current	-	-

[XML 56 R36.htm IDEA- XBRL DOCUMENT](#)

Accrued Expenses and Other Current Liabilities (Tables)

**12 Months Ended
Mar. 31, 2024**

[Accrued Expenses and Other Current Liabilities \[Abstract\]](#)
[Schedule of Accrued Expenses and Other Current Liabilities](#)

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Accrued payroll and benefits	1,092,629	588,342
Professional fees, other payable and accrued expenses	2,733	245,340
Interest payable	9,450	105,085
	1,104,812	938,767

[XML 57 R37.htm IDEA- XBRL DOCUMENT](#)

Taxes Payable (Tables)

**12 Months Ended
Mar. 31, 2024**

[Taxes Payable \[Abstract\]](#)
[Schedule of Taxes Payable](#)

	As of March 31, 2024	As of March 31, 2023
	USD	USD
Income taxes payable	92,816	95,888
Other taxes (recovery) payable	(18,725)	117
Total taxes payable	74,091	96,005

[XML 58 R38.htm IDEA- XBRL DOCUMENT](#)

Income Taxes (Tables)

**12 Months Ended
Mar. 31, 2024**

[Income Taxes \[Abstract\]](#)
[Schedule of Components of Income Tax Expenses](#)

i) The components of income tax expenses are as follows:

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
	USD	USD	USD
Current	24,988	17,549	92,816
Deferred	-	-	-
Total	24,988	17,549	92,816

[Schedule of Reconciles the PRC Statutory Rates to the Company's
Effective Tax Rate](#)

The following table reconciles the PRC statutory rates to the Company's effective tax rate for the years ended March 31, 2024, 2023 and 2022.

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
PRC Income tax statutory rate	(25.0)%	(25.0)%	(25)%
Effect of tax holiday and preferential tax rate	4.0%	4.0%	4.0
Non-deductible foreign losses	5.8%	0.7%	19.5%
Change in valuation allowance	20.3%	24.8%	0.8%
Non-deductible expenses and others	(5.4)%	(4.6)%	-%
Effective tax rate	(0.3)%	(0.1)%	(2.3)%

[XML 59 R39.htm IDEA- XBRL DOCUMENT](#)

Earnings (Loss) Per Share (Tables)

**12 Months Ended
Mar. 31, 2024**

[Earnings \(Loss\) Per Share \[Abstract\]](#)
[Schedule of Outstanding Shares for Basic and Diluted Net Earnings Per
Share](#)

The following table details the outstanding shares for basic and diluted net earnings per share:

	Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
	USD	USD	USD
Numerator:			
Net loss from continuing operation attributable to Akso Health Group's shareholder	(9,058,986)	(13,196,535)	(4,102,428)

Net income (loss) from discontinued operation attributable to Akso Health Group's shareholders	(399,798)	11,836,612	(12,748,636)
Net loss attributable to Akso Health Group's shareholders	(9,458,784)	(1,359,923)	(16,851,064)
Denominator:			
Weighted average number of ordinary shares outstanding-basic	141,516,777	68,598,050	59,612,152
Weighted average number of dilutive potential ordinary shares from share options	-	-	-
Weighted average number of ordinary shares outstanding-diluted	141,516,777	68,598,050	59,612,152
Basic (loss) per common share	(0.07)	(0.02)	(0.28)
Diluted (loss) per common share	(0.07)	(0.02)	(0.28)

[XML 60 R40.htm IDEA XBRL DOCUMENT](#)

Shareholders' Equity
(Tables)

Shareholders' Equity [Abstract]

[Schedule of Warrants Outstanding](#)
Following is a summary of the status of warrants outstanding and exercisable as of March 31, 2024:

	Warrants	Weighted Average Exercise Price	Aggregate Intrinsic Value
Warrants outstanding, as of March 31, 2022	—	—	—
Issued	6,340,000	\$ 3.0	—
Exercised	—	—	—
Expired	—	—	—
Warrants outstanding, as of March 31, 2023	6,340,000	\$ 3.0	—
Issued	287,274,910	0.46	—
Exercised	3,380,000	—	—
Expired	—	—	—
Warrants outstanding, as of March 31, 2024	290,234,910	0.48	—
Warrants exercisable, as of March 31, 2024	290,234,910	0.48	—
	Warrants exercisable in ordinary shares	Weighted Average Exercise Price	Average Remaining Contractual Life
August 9, 2021 warrants	8,880,000	\$ 1.0	2.4 years
October 2, 2023 warrants	35,739,270	0.4888	4.6 years
November 16, 2023 warrants	53,608,910	0.5288	4.7 years
January 17, 2024 warrants	160,826,730	0.4146	4.8 years
March 5, 2024 warrants	222,600,000	0.4933	4.9 years

[XML 61 R41.htm IDEA XBRL DOCUMENT](#)

**Condensed Financial
Information of the
Parent Company**
(Tables)

**Condensed Financial Information of the Parent
Company [Abstract]**

[Schedule of Condensed Balance Sheets](#)

CONDENSED BALANCE SHEETS

	As of March 31 2024 USD	As of March 31 2023 USD
ASSETS:		
Cash	2,279	4,472
Prepayment and other assets	—	5,795
Investments in subsidiaries, VIEs and VIEs' subsidiaries	141,456,064	11,303,978
TOTAL ASSETS	141,458,343	11,314,245
LIABILITIES:		
Accrued expenses and other current liabilities	1,090,959	588,941
Due to related party	2,000,000	2,000,000
TOTAL LIABILITIES	3,090,959	2,588,941
SHAREHOLDERS' EQUITY:		
Ordinary share (\$0.0001 par value, 5,000,000,000 shares authorized, 438,336,843 and 69,763,933 shares issued, 437,170,960 and 68,598,050 shares outstanding as of March 31, 2024 and 2023, respectively)	43,834	6,977
Additional paid-in capital	210,324,890	71,021,898
Treasury stock	(3,988,370)	(3,988,370)
Accumulated deficit	(63,926,383)	(54,467,600)
Accumulated other comprehensive loss	(4,086,587)	(3,847,601)
TOTAL SHAREHOLDERS' EQUITY	138,367,384	8,725,304
TOTAL LIABILITIES AND SHEREHOLDERS' EQUITY	141,458,343	11,314,245

[Schedule of Condensed Statements of
Comprehensive \(Loss\) Income](#)

CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

	Years Ended March 31,		
	2024 USD	2023 USD	2022 USD
Equity in (loss) earnings of subsidiaries	(7,394,438)	(1,086,999)	(13,720,643)
General administrative expense and others	(2,122,139)	(160,427)	(3,129,090)
NET (LOSS)	(9,516,577)	(1,247,426)	(16,849,733)
OTHER COMPREHENSIVE INCOME (LOSS)			
Foreign currency translation adjustment	(238,985)	(2,198,379)	1,454,319
COMPREHENSIVE (LOSS)	(9,755,562)	(3,445,805)	(15,395,414)

[Schedule of Condensed Statements of Cash Flows](#)

CONDENSED STATEMENTS OF CASH FLOWS

	For The Years Ended March 31,		
	2024 USD	2023 USD	2022 USD
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net (loss)	(9,516,577)	(1,247,426)	(16,851,064)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:			
Provision for doubts accounts	5,795	-	-
Equity in loss of subsidiaries	7,394,438	1,147,003	13,721,974
Share-based compensation	-	-	391,625
Changes in operating assets and liabilities:			
Prepayments and other assets	-	-	154,654
Accrued expenses and other current liabilities	502,018	528,266	101,207
Interest payments on unsecured senior notes and short-term bank loan	-	-	(676,894)
NET CASH (USED IN) OPERATING ACTIVITIES	(1,614,326)	427,843	(3,158,498)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Proceeds from private placement offering, net of offering costs	139,339,849	-	10,017,200
Principal payments on unsecured senior notes	-	-	(10,000,000)
Loan to subsidiaries, VIEs and VIE's subsidiaries	(137,727,716)	(427,862)	(337,695)
Proceeds from related party	-	-	2,000,000
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	1,612,133	(427,862)	1,679,505
NET (DECREASE) IN CASH	(2,193)	(19)	(1,478,993)
CASH-beginning of year	4,472	4,491	1,483,484
CASH-end of year	2,279	4,472	4,491
SUPPLEMENTAL CASH FLOW DISCLOSURES:			
Cash paid for income tax	24,988	17,549	92,816
Cash paid for interest	111,563	336,593	676,894

[XML 62 R42.htm IDEA XBRL DOCUMENT](#)

Business Description
(Details) - Schedule
of the Company's
Principal Subsidiaries

[We Health Limited \("We Health"\) \[Member\]](#)

[Wholly owned subsidiaries](#)

[Date of incorporation / acquisition](#)

[Place of incorporation](#)

[Percentage of legal ownership](#)

12 Months Ended

Mar. 31, 2024

Jul. 08, 2021

New York

100.00%

Principal activities	Investment holding				
Akso Medical Cloud Limited ("Akso Medical Cloud") [Member]					
Wholly owned subsidiaries					
Date of incorporation / acquisition	Nov. 15, 2023				
Place of incorporation	BVI				
Percentage of legal ownership	100.00%				
Principal activities	Investment holding				
We Healthy Limited ("We Healthy") [Member]					
Wholly owned subsidiaries					
Date of incorporation / acquisition	Dec. 15, 2021				
Place of incorporation	Hong Kong				
Percentage of legal ownership	51.00%				
Principal activities	Investment holding				
Akso Medi-care Limited ("Akso Medi-care") [Member]					
Wholly owned subsidiaries					
Date of incorporation / acquisition	Dec. 04, 2023				
Place of incorporation	Hong Kong				
Percentage of legal ownership	100.00%				
Principal activities	Investment holding				
Akso Remote Medical Consultation Center Inc. ("Akso Remote Medical") [Member]					
Wholly owned subsidiaries					
Date of incorporation / acquisition	Jan. 03, 2022				
Place of incorporation	Wyoming				
Percentage of legal ownership	100.00%				
Principal activities	Provision of health treatment services				
Akso Online MediTech Co., Ltd.("Akso Online MediTech") [Member]					
Wholly owned subsidiaries					
Date of incorporation / acquisition	Jan. 04, 2022				
Place of incorporation	Wyoming				
Percentage of legal ownership	100.00%				
Principal activities	Sales of medical devices				
Akso First Health Treatment Center Inc. ("Akso First Health") [Member]					
Wholly owned subsidiaries					
Date of incorporation / acquisition	Jan. 04, 2022				
Place of incorporation	Massachusetts				
Percentage of legal ownership	100.00%				
Principal activities	Provision of health treatment services				
Tianjin Akso Enterprise Management Co., Limited. (Wholly Owned Foreign Enterprise . "WOFE" [Member]					
Wholly owned subsidiaries					
Date of incorporation / acquisition	Jan. 16, 2024				
Place of incorporation	PRC				
Percentage of legal ownership	100.00%				
Principal activities	Provision of consultancy support				
Qindao Akso Health Management Co., Limited [Member]					
Wholly owned subsidiaries					
Date of incorporation / acquisition	Jan. 26, 2022				
Place of incorporation	PRC				
Percentage of legal ownership	51.00%				
Principal activities	Provision of health treatment services				
~~XML 63 R43.htm IDEA XBRL DOCUMENT~~					
Going Concern (Details) - USD (\$)	12 Months Ended				
\$ in Millions	Mar. 31, 2024	Mar. 31, 2023			
Going Concern [Abstract]					
Net loss	\$ 9.5	\$ 1.2			
Net cash provided by operating activities	\$ 0.7	\$ 3.3			
~~XML 64 R44.htm IDEA XBRL DOCUMENT~~					
Summary of Significant Accounting Policies (Details)	12 Months Ended				
	Mar. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2024
	USD (\$)	CNY (¥)	USD (\$)	USD (\$)	CNY (¥)
Summary of Significant Accounting Policies [Line Items]	customers vendors				
Minimum amount (in Yuan Renminbi) ¥	¥ 1				
Number of loan agreements	3			3	3
Term of the loan	10 years	10 years			
Revenue from medical devices			\$ 9,181,274	\$ 6,000,000	
Allowance for uncollectible accounts receivable	7,369,797		400,759		
Impairment loss					
Advertising and promotion expense	\$ 168,421		6,661		
Operating lease, term of contract	1 year			1 year	1 year
Cash and cash equivalents	\$ 10,380,711		7,876,767		
Deposits covered by insurance	69,249			¥ 500,000	
Amount not covered by issuance	\$ 10,310,077				
Maximum compensation			63,890		\$ 500,000
Insurance coverage upper limit			\$ 250,000		
Number of customers (in customers) customers			3		
Number of vendor (in vendors) vendors			1		
Vendor percentage			97.30%		
Vendor concentration risk percentage	10.00%	10.00%	10.00%		
We Healthy Limited [Member] Other Investors [Member]					
Summary of Significant Accounting Policies [Line Items]					
Equity interest	49.00%	49.00%			
One Customer Concentration Risk [Member] Accounts Receivable [Member]					
Summary of Significant Accounting Policies [Line Items]					
Concentration risk, percentage			59.50%		
Two Customer Concentration Risk [Member] Accounts Receivable [Member]					
Summary of Significant Accounting Policies [Line Items]					
Concentration risk, percentage			11.10%		
Three Customer Concentration Risk [Member] Accounts Receivable [Member]					
Summary of Significant Accounting Policies [Line Items]					
Concentration risk, percentage			10.10%		
Customers One [Member] Accounts Receivable [Member]					
Summary of Significant Accounting Policies [Line Items]					
Concentration risk, percentage			100.00%		
Vendor [Member] Accounts Receivable [Member]					
Summary of Significant Accounting Policies [Line Items]					
Concentration of credit risk	100.00%	100.00%		100.00%	

Commission Revenue [Member]			
Summary of Significant Accounting Policies [Line Items]			
Amount of incentives			\$ 96,332
Commission Services [Member]			
Summary of Significant Accounting Policies [Line Items]			
Amount of incentives			
Interest income [Member]			
Summary of Significant Accounting Policies [Line Items]			
Amount of incentives			\$ 215,393
Customers One [Member]			
Summary of Significant Accounting Policies [Line Items]			
Total revenues percentage			95.10%
Customers One [Member] One Customer Concentration Risk [Member] Accounts Receivable [Member]			
Summary of Significant Accounting Policies [Line Items]			
Concentration of credit risk	36.30%	36.30%	
Customers Two [Member] Two Customer Concentration Risk [Member] Accounts Receivable [Member]			
Summary of Significant Accounting Policies [Line Items]			
Concentration of credit risk	34.80%	34.80%	
Customers Three [Member] Three Customer Concentration Risk [Member] Accounts Receivable [Member]			
Summary of Significant Accounting Policies [Line Items]			
Concentration of credit risk	28.00%	28.00%	

~~XML 65 R45.htm IDEA XBRL DOCUMENT~~				
Summary of Significant Accounting Policies (Details) - Schedule of Financial Statement Amounts and Balances of the Consolidated Vies - VIEs [Member] - USD (\$)	12 Months Ended			
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Current Assets:				
Cash and cash equivalents		\$ 678,691		
Accounts receivable and contract assets, net		10,062		
Prepayments and other assets		43,779		
Amounts due from related parties		26,206,288		
Total Current Assets		26,938,820		
Property, equipment and software, net		28,698		
Total Assets		26,967,518		
Current Liabilities				
Accrued expenses and other current liabilities		32,430		
Taxes (benefit) payable		(12,624)		
Total Current Liabilities		19,806		
Total Liabilities		19,806		
Net revenues	694	27,324	\$ 311,725	
Net loss	\$ (12,479)	(348,806)	(11,527,588)	
Net cash provided by (used in) operating activities		12,497	(559,973)	\$ 5,613,401
Net cash (used in) investing activities				(1,455,547)
Net cash provided by (used in) financing activities		\$ 213,879	\$ (1,156,948)	\$ (13,203,558)

~~XML 66 R46.htm IDEA XBRL DOCUMENT~~				
Summary of Significant Accounting Policies (Details) - Schedule of Disaggregation of Revenue - Disaggregation of Revenue [Member] - USD (\$)	12 Months Ended			
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022	
Revenue				
Revenue from medical devices-US	\$ 9,181,274	\$ 6,000,000		
Revenue from medical devices-PRC	2,416,797	4,005,251		
Total revenues	2,416,797	13,186,525	6,000,000	
Tax and surcharges	2,459	4,964		
Net Revenues	\$ 2,414,338	\$ 13,181,561	\$ 6,000,000	

~~XML 67 R47.htm IDEA XBRL DOCUMENT~~				
Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property and Equipment [Member]				Mar. 31, 2024
Minimum [Member]				
Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property and Equipment [Line Items]				
Office equipment				3 years
Maximum [Member]				
Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property and Equipment [Line Items]				
Office equipment				5 years

~~XML 69 R49.htm IDEA XBRL DOCUMENT~~				
Summary of Significant Accounting Policies (Details) - Schedule of Noncontrolling Interest - USD (\$)			Mar. 31, 2024	Mar. 31, 2023
We Healthy [Member]				
Summary of Significant Accounting Policies (Details) - Schedule of Noncontrolling Interest [Line Items]				
We Healthy		\$ 56,810	\$ 114,212	

~~XML 69 R49.htm IDEA XBRL DOCUMENT~~				
Summary of Significant Accounting Policies (Details) - Schedule of Spot Exchange Rates and Average Exchange Rates			Mar. 31, 2024	Mar. 31, 2023
Schedule of Spot Exchange Rates and Average Exchange Rates [Abstract]				
Year-end RMB	7.2203	6.8676	6.3393	

[XML 70 R50.htm IDEA: XBRL DOCUMENT](#)

Discontinued Operation (Details) - Discontinued Operations, Held-for- Sale [Member] ¥ in Millions	May 10, 2023	Dec. 16, 2020	Dec. 16, 2020
	USD (\$)	USD (\$)	CNY (¥)

[Hexin E Commerce Company Limited \[Member\]](#)[Discontinued Operation \[Line Items\]](#)

Cash consideration	\$ 726,781	¥ 5

[Disposition SPA \[Member\]](#)[Discontinued Operation \[Line Items\]](#)

Cash consideration	\$ 215,000

[XML 71 R51.htm IDEA: XBRL DOCUMENT](#)

Discontinued Operation (Details) - Schedule of Discontinued Operations - Discontinued Operations, Held-for- Sale [Member] - USD (\$)	12 Months Ended		
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022

[Schedule of Discontinued Operations \[Line Items\]](#)

Net Revenues	\$ 694	\$ 24,995	\$ 311,092
Operating costs and development	4,551	1,073,518	12,988,383
(Loss) income from discontinued operations	(3,857)	(1,048,522)	(12,677,291)
Other income (expense), net	(27)	12,885,134	(32,728)
(Loss) income before tax	(3,884)	11,836,612	(12,710,019)
Income tax provision			38,617
Net (loss) income from discontinued operations	(3,884)	11,836,612	(12,748,636)
Loss on sale of discontinued operations, net of taxes	(395,914)		
Net income (loss) from discontinued operation	\$ (399,798)	\$ 11,836,612	\$ (12,748,636)

[XML 72 R52.htm IDEA: XBRL DOCUMENT](#)

Discontinued Operation (Details) - Schedule of Assets and Liabilities - USD (\$)	Mar. 31, 2024	Mar. 31, 2023

[Schedule of Assets and Liabilities \[Abstract\]](#)

Cash and cash equivalents	\$ 1,268,235
Accounts receivable, net	10,062
Prepayments and other assets	44,004
Property, equipment and software, net	29,051
Current assets held for sale-discontinued operation	1,351,352
Accrued expenses and other current liabilities	737,693
Tax (benefit) payable	(32,210)
Amount due to related party	
Total liabilities held for sale-discontinued operation	\$ 705,483

[XML 73 R53.htm IDEA: XBRL DOCUMENT](#)

Discontinued Operation (Details) - Schedule of Loss on Sale of Discontinued Operations - Discontinued Operations, Held-for- Sale [Member]	May 19, 2023
	USD (\$)

[USD](#)

Cash and cash equivalents	\$ 1,030,377
Accounts receivable, net	9,508
Prepayments and other assets	241,025
Property, plant and equipment, net	24,998
Total assets	1,305,908
Account payable	662,648
Accrued expenses and other current liabilities	32,346
Total liabilities	694,994
Net assets	610,914
Consideration received	215,000
Loss on sale of discontinued operations, net of taxes	\$ (395,914)

[XML 74 R54.htm IDEA: XBRL DOCUMENT](#)

Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net - USD (\$)	Mar. 31, 2024	Mar. 31, 2023

[Schedule of Accounts Receivable, Net \[Abstract\]](#)

Accounts receivable	\$ 7,770,556	\$ 8,097,742
Allowance for uncollectible accounts receivable	(7,770,556)	(400,759)
Accounts receivable, net		\$ 7,696,983

[XML 75 R55.htm IDEA: XBRL DOCUMENT](#)

Prepayments and Other Assets, Net (Details) - Schedule of Prepayments and Other Assets - USD (\$)	Mar. 31, 2024	Mar. 31, 2023

[Schedule of Prepayments and Other Assets \[Abstract\]](#)

Prepayments to suppliers and others	\$ 409,322	\$ 272,129
Allowance	(6,423)	
Total prepayments and other assets, net	\$ 402,899	\$ 272,129

[XML 76 R56.htm IDEA: XBRL DOCUMENT](#)

Inventories (Details) - USD (\$)	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022

[Inventories \[Abstract\]](#)

Inventory, cost of finished goods	\$ 191,201	\$ 1,686,449

[Inventory](#)[XML 77 R57.htm IDEA: XBRL DOCUMENT](#)

Loan Receivables (Details) ¥ in Millions, \$ in Millions	12 Months Ended Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2023
		USD (\$)	CNY (¥)

[Loan Receivables \[Abstract\]](#)

Total loan receivables \$ 1.5 ¥ 10.5

Percentage of annual interest 2.00%

[XML 78 R58.htm IDEA XBRL DOCUMENT](#)

Loan Receivables
(Details) - Schedule
of Loan Receivables - Mar. 31, 2024 Mar. 31, 2023
USD (\$)

[Schedule of Loan Receivables \[Abstract\]](#)

Loan receivables \$ 1,528,918
Allowance for uncollectible loan receivables
Loan receivables, net 1,528,918
Loan receivables - current 1,528,918
Loan receivables - non-current

[XML 79 R59.htm IDEA XBRL DOCUMENT](#)

Prepaid 12 Months Ended
Consideration
(Details) - USD (\$) Mar. 31, 2024 Mar. 31, 2023

[Prepaid Consideration \[Line Items\]](#)

Total consideration (in Dollars) \$ 75,000,000
Prepaid consideration (in Dollars) \$ 56,250,000
Tianjin Akso Enterprise Management Co. Ltd [Member]

[Prepaid Consideration \[Line Items\]](#)

Equity interest 50.00%
Tianjin Wangyi Cloud Technology Co., Ltd [Member]

[Prepaid Consideration \[Line Items\]](#)

Equity interest 12.50%
Tianjin Akso Enterprise Management Co. Ltd One [Member]

[Prepaid Consideration \[Line Items\]](#)

Equity interest 50.00%

[XML 80 R60.htm IDEA XBRL DOCUMENT](#)

Right of Use Lease 12 Months Ended
Assets (Details) - USD Apr. 01, 2019 Mar. 31, 2024 Mar. 31, 2023 Mar. 31, 2022
(\$)

[Right of Use Lease Assets \[Abstract\]](#)

ROU asset and lease liability \$ 2,559,646
Operating lease term 1 year
Total lease expense

[XML 81 R61.htm IDEA XBRL DOCUMENT](#)

Accrued Expenses
and Other Current
Liabilities (Details) -
Schedule of Accrued
Expenses and Other
Current Liabilities -
USD (\$) Mar. 31, 2024 Mar. 31, 2023

[Schedule of Accrued Expenses and Other Current Liabilities \[Abstract\]](#)

Accrued payroll and benefits \$ 1,092,629 \$ 588,342
Professional fees, other payable and accrued expenses 2,733 245,340
Interest payable 9,450 105,085
Accrued expenses and other current liabilities \$ 1,104,812 \$ 938,767

[XML 82 R62.htm IDEA XBRL DOCUMENT](#)

Related Party
Balances and
Transactions (Details) Nov. 30, Aug. 27, Aug. 26, Jul. 28, Jul. 27, Jan. 24, Aug. 26, 12 Months
- USD (\$) 2023 2023 2023 2022 2022 2022 2021 Ended
Mar. 31, 2024 Mar. 31, 2023 Mar. 31, 2022

[Related Party Balances and Transactions
\[Line Items\]](#)

Loan amount \$ 35,200,000 \$ 127,244
Loan term 1 year 1 year
Principal amount \$ 27,513,849
Unpaid interest \$ 196,681 \$ 358,751
Payment of principal and interest \$ 7,686,151 \$ 27,872,600

Unpaid principal amount

Related Party [Member]

[Related Party Balances and Transactions
\[Line Items\]](#)

Amount due to related parties \$ 2,000,000 \$ 9,686,152
Webao Ltd [Member]

[Related Party Balances and Transactions
\[Line Items\]](#)

Annual interest rate 0.00% 0.00% 2.00%
Loan term 1 year
Commercial Loan [Member] | Webao Ltd [Member]

[Related Party Balances and Transactions
\[Line Items\]](#)

Loan amount \$ 2,000,000
Annual interest rate 0.00%

[XML 83 R63.htm IDEA XBRL DOCUMENT](#)

Employee Benefits 12 Months Ended
(Details) - USD (\$) Mar. 31, 2024 Mar. 31, 2023 Mar. 31, 2022

[Retirement Benefits \[Abstract\]](#)

Amount of contributions \$ 7,390

[XML 84 R64.htm IDEA XBRL DOCUMENT](#)

Taxes Payable
(Details) - Schedule
of Taxes Payable -
USD (\$) Mar. 31, 2024 Mar. 31, 2023

[Schedule of Taxes Payables \[Abstract\]](#)

Income taxes payable \$ 92,816 \$ 95,888
Other taxes (recovery) payable (18,725) 117
Total taxes payable \$ 74,091 \$ 96,005

[XML 85 R65.htm IDEA XBRL DOCUMENT](#)

Income Taxes 12 Months Ended
(Details) Jan. 01, 2008 Mar. 31, 2024 Mar. 31, 2024 Mar. 31, 2023 Mar. 31, 2022 Mar. 31, 2019
USD (\$) CNY (¥) USD (\$) USD (\$) USD (\$)

[Income Taxes \[Line Items\]](#)

Net (loss) income before taxes (in Dollars) \$ (9,091,791) \$ (13,066,489) \$ (4,008,281)
Income tax liability 15,263 ¥ 100,000

Undistributed earnings available for distribution (in Dollars)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																								

Gross proceeds from private placemnet (in Dollars)	\$ 139,339,849	\$ 10,017,200
Warrants outstanding (in Dollars)	\$ 290,234,910	
Warrants outstanding (in Shares)		6,340,000

Warrant [Member]
Shareholders' Equity [Line Items]

Warrants, exercised (in Shares)	3,380,000	
Issuance of ordinary shares (in Shares)	7,098,000	
Number of shares to purchase warrants (in Shares)	481,654,910	19,020,000
Weighted average exercise price of warrants	\$ 0.48	

Securities Purchase Agreement [Member]
Shareholders' Equity [Line Items]

Ordinary shares, par value	\$ 0.0001	\$ 0.0001	\$ 0.0001	\$ 0.0001
Sale of units (in Shares)	37,100,000	160,826,730	53,608,910	35,739,270
Sale of units price per share		\$ 0.3317	\$ 0.423	\$ 0.391
Initial exercise		\$ 0.4146	\$ 0.52875	\$ 0.48875
Aggregate purchase price (in Dollars)		\$ 53,350,000	\$ 22,680,000	\$ 14,000,000
Net proceeds (in Dollars)	\$ 53,350,000	\$ 22,680,000	\$ 14,000,000	
Number of ordinary shares (in Shares)		1	1	1
Number of warrants share (in Shares)		1	1	1
Purchase of warrants (in Shares)	222,600,000			
Gross proceeds from private placemnet (in Dollars)	\$ 49,340,000			

Common Stock [Member]
Shareholders' Equity [Line Items]

Ordinary shares, par value			\$ 0.0001	
Divided into ordinary shares (in Shares)			5,000,000,000	
Additional ordinary shares (in Shares)			4,500,000,000	
Additional shares par value			\$ 0.0001	
Issuance of ordinary shares (in Shares)				7,098,000

American Depositary Shares [Member]
Shareholders' Equity [Line Items]

Initial exercise	\$ 1.48	\$ 1.2438	\$ 1.59	\$ 1.47
Purchase price per share	\$ 1.33			

American Depositary Shares [Member].
Securities Purchase Agreement [Member]

Shareholders' Equity [Line Items]

Sale of units (in Shares)	111,300,000
Private Placement [Member]	

Shareholders' Equity [Line Items]

Ordinary shares, par value	\$ 0.0001
Sale of units (in Shares)	6,340,000
Initial exercise	\$ 3
Aggregate purchase price (in Dollars)	\$ 10,020,000.00
Net proceeds (in Dollars)	\$ 10,000,000
Term of warrants	5 years

Private Placement [Member] | Warrant Shares [Member]

Shareholders' Equity [Line Items]

Initial exercise	\$ 3

~~XML 99 R70.htm IDEA XBRL DOCUMENT~~

Shareholders' Equity (Details) - Schedule of Warrants Outstanding - USD (\$)	12 Months Ended
	Mar. 31, 2024 Mar. 31, 2023

Schedule of Warrants Outstanding [Abstract]

Warrants outstanding, Beginning Balance	6,340,000	
Weighted Average Exercise Price Outstanding, Beginning Balance	\$ 3	
Aggregate Intrinsic Value outstanding, Beginning Balance		
Warrants, Issued	287,274,910	6,340,000
Weighted Average Exercise Price, Issued	\$ 0.46	\$ 3
Aggregate Intrinsic Value, Issued		
Warrants, Exercised	3,380,000	
Weighted Average Exercise Price, Exercised		
Aggregate Intrinsic Value, Exercised		

Warrants, Expired		
Weighted Average Exercise Price, Expired		
Aggregate Intrinsic Value, Expired		
Warrants outstanding, Ending Balance	290,234,910	6,340,000
Weighted Average Exercise Price outstanding, Ending Balance	\$ 0.48	\$ 3
Aggregate Intrinsic Value outstanding, Ending Balance		
Warrants, exercisable	290,234,910	
Weighted Average Exercise Price, exercisable	\$ 0.48	
Aggregate Intrinsic Value, exercisable		

~~[XML 91 R71.htm IDEA XBRL DOCUMENT](#)~~

Shareholders' Equity	12 Months Ended
(Details) - Schedule	Mar. 31, 2024
of Warrants	\$ / shares
Exercisable	shares

[August 9, 2021 Warrants \[Member\]](#)

[Schedule of Warrants Exercisable \[Line Items\]](#)

Warrants exercisable in ordinary shares shares	8,880,000
Weighted Average Exercise Price \$ / shares	\$ 1
Average Remaining Contractual Life	2 years 4 months 24 days

[October 2, 2023 Warrants \[Member\]](#)

[Schedule of Warrants Exercisable \[Line Items\]](#)

Warrants exercisable in ordinary shares shares	35,739,270
Weighted Average Exercise Price \$ / shares	\$ 0.4888
Average Remaining Contractual Life	4 years 7 months 6 days

[November 16, 2023 Warrants \[Member\]](#)

[Schedule of Warrants Exercisable \[Line Items\]](#)

Warrants exercisable in ordinary shares shares	53,608,910
Weighted Average Exercise Price \$ / shares	\$ 0.5288
Average Remaining Contractual Life	4 years 8 months 12 days

[January 17, 2024 Warrants \[Member\]](#)

[Schedule of Warrants Exercisable \[Line Items\]](#)

Warrants exercisable in ordinary shares shares	160,826,730
Weighted Average Exercise Price \$ / shares	\$ 0.4146
Average Remaining Contractual Life	4 years 9 months 18 days

[March 5, 2024 Warrants \[Member\]](#)

[Schedule of Warrants Exercisable \[Line Items\]](#)

Warrants exercisable in ordinary shares shares	222,600,000
Weighted Average Exercise Price \$ / shares	\$ 0.4933
Average Remaining Contractual Life	4 years 10 months 24 days

~~[XML 92 R72.htm IDEA XBRL DOCUMENT](#)~~

Treasury Stock	Dec. 10, 2018
(Details)	USD (\$)
	shares

[Treasury Stock \[Line Items\]](#)

Number of shares to be repurchased	\$ 25,000,000
Term of repurchase	12 months

[American Depository Shares \[Member\]](#)

[Treasury Stock \[Line Items\]](#)

Repurchase of ordinary shares (in Shares) shares	1,165,883
Total consideration on repurchase of shares	\$ 3,988,370

~~[XML 93 R73.htm IDEA XBRL DOCUMENT](#)~~

Restricted Net Assets	12 Months Ended
(Details) - USD (\$)	
\$ in Millions	Mar. 31, 2024 Mar. 31, 2023

[Restricted Net Assets \[Abstract\]](#)

Restricted net assets	\$ 89.5	\$ 89.5
Annual basis, percentage	10.00%	
Registered capital, percentage	50.00%	
Statutory reserve		

~~[XML 94 R74.htm IDEA XBRL DOCUMENT](#)~~

Subsequent Events					11 Months Ended	12 Months Ended				
(Details) - USD (\$)	Jun. 27, 2024	Apr. 30, 2024	Mar. 31, 2024	Aug. 09, 2021	Mar. 31, 2022	Mar. 31, 2024	Nov. 30, 2023	Oct. 31, 2023	Jun. 19, 2023	Mar. 31, 2023

[Subsequent Events \[Line Items\]](#)

Registered capital percentage						50.00%				
Total consideration (in Dollars)			\$ 75,000,000			\$ 56,250,000				
Cash consideration (in Dollars)						18,750,000				
Authorized issued share capital (in Dollars)					\$ 10,017,200	\$ 139,339,849				
Ordinary shares, shares issued (in Shares)			438,336,843			438,336,843				69,763,933
Ordinary shares, shares outstanding (in Shares)			437,170,960			437,170,960				68,598,050
Issuance of ordinary shares (in Shares)							25,017,480			
Sell an aggregate price per share				\$ 1.58						
Ordinary share par value			\$ 0.0001			\$ 0.0001			\$ 0.0001	\$ 0.0001
Net proceeds (in Dollars)						\$ 62,600,000				

[Minimum \[Member\]](#)

[Subsequent Events \[Line Items\]](#)

Warrants to purchase price per share						\$ 0.3555				
Maximum [Member]										
Subsequent Events [Line Items]										
Warrants to purchase price per share						\$ 1.0665				
Ordinary Shares [Member]										
Subsequent Events [Line Items]										
Authorized issued share capital (in Dollars)					\$ 1,902	\$ 36,147				
Authorized issued share capital shares (in Shares)					19,020,000	361,474,910				
Ordinary share par value									\$ 0.0001	

[Tianjin Wangyi Cloud Technology Co., Ltd \[Member\]](#)

[Subsequent Events \[Line Items\]](#)

Equity interest rate			12.50%			12.50%				
Subsequent Event [Member] Ordinary Shares [Member]										
Subsequent Events [Line Items]										
Authorized issued share capital (in Dollars)			\$ 500,000							
Authorized issued share capital shares (in Shares)			5,000,000,000							
Ordinary shares, par value			\$ 0.0001							

[Subsequent Event \[Member\] | Webao Limited \[Member\]](#)

[Subsequent Events \[Line Items\]](#)

Ordinary shares, shares issued (in Shares)	7,980,800
Ordinary shares, shares outstanding (in Shares)	7,980,800
Common Class A [Member] Subsequent Event [Member]	
Subsequent Events [Line Items]	
Authorized issued share capital (in Dollars)	\$ 500,000
Authorized issued share capital shares (in Shares)	4,500,000,000
Ordinary shares, par value	\$ 0.0001
Common Class A [Member] Subsequent Event [Member] Webao Limited [Member]	

[Subsequent Events \[Line Items\]](#)

Ordinary shares, par value	\$ 0.0001
Class B Ordinary Shares [Member] Subsequent Event [Member]	

[Subsequent Events \[Line Items\]](#)

Authorized issued share capital shares (in Shares)	500,000,000
Ordinary shares, par value	\$ 0.0001
Class B Ordinary Shares [Member] Subsequent Event [Member] Webao Limited [Member]	

[Subsequent Events \[Line Items\]](#)

Ordinary shares, par value	\$ 0.0001
Forecast [Member]	

[Subsequent Events \[Line Items\]](#)

Sell an aggregate shares (in Shares)	220,000,050
Ordinary share par value	\$ 0.0001
Aggregate purchase price (in Dollars)	\$
	62,600,000

[Forecast \[Member\] | Warrant \[Member\]](#)

[Subsequent Events \[Line Items\]](#)

Warrants to purchase price per share	\$ 0.3555
Forecast [Member] Common Class A [Member]	

[Subsequent Events \[Line Items\]](#)

Sell an aggregate price per share	\$ 0.2844
Private Placement [Member]	

[Subsequent Events \[Line Items\]](#)

Issuance of ordinary shares (in Shares)		37,256,230
Sell an aggregate shares (in Shares)	6,340,000	
Ordinary share par value	\$ 0.0001	

~~XML 95-R75.htm IDEA XBRL DOCUMENT~~

Condensed Financial Information of the Parent Company (Details)	12 Months Ended
	Mar. 31, 2024
	USD (\$)

[Condensed Financial Information of the Parent Company \[Line Items\]](#)

Interest rate (in Dollars)	\$ 10
Registered capital percentage	50.00%
Net assets percentage	25.00%
PRC [Member]	

[Condensed Financial Information of the Parent Company \[Line Items\]](#)

Net assets percentage	25.00%

~~XML 96-R76.htm IDEA XBRL DOCUMENT~~

Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Balance Sheets - Parent Company [Member] - USD (\$)	Mar. 31, 2024	Mar. 31, 2023

ASSETS:

Cash	\$ 2,279	\$ 4,472
Prepayment and other assets		5,795
Investments in subsidiaries, VIEs and VIEs' subsidiaries	141,456,064	11,303,978
TOTAL ASSETS	141,458,343	11,314,245

LIABILITIES:

Accrued expenses and other current liabilities	1,090,959	588,941
TOTAL LIABILITIES	3,090,959	2,588,941

SHAREHOLDERS' EQUITY:

Ordinary share (\$0.0001 par value, 5,000,000,000 shares authorized, 438,336,843 and 69,763,933 shares issued, 437,170,960 and 68,598,050 shares outstanding as of March 31,2024 and 2023, respectively)	43,834	6,977
Additional paid-in capital	210,324,890	71,021,898
Treasury stock	(3,988,370)	(3,988,370)
Accumulated deficit	(63,926,383)	(54,467,600)
Accumulated other comprehensive loss	(4,086,587)	(3,847,601)
TOTAL SHAREHOLDERS' EQUITY	138,367,384	8,725,304
TOTAL LIABILITIES AND SHEREHOLDERS' EQUITY	141,458,343	11,314,245

[Related Party \[Member\]](#)

LIABILITIES:

Due to related party	\$ 2,000,000	\$ 2,000,000

~~XML 97-R77.htm IDEA XBRL DOCUMENT~~

Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Balance Sheets (Parentheticals) - Parent Company [Member] - \$ / shares	Mar. 31, 2024	Mar. 31, 2023

[Condensed Balance Sheet Statements, Captions \[Line Items\]](#)

Ordinary shares , par value (in Dollars per share)	\$ 0.0001	\$ 0.0001
Ordinary shares , shares authorized	5,000,000,000	5,000,000,000
Ordinary shares , shares issued	438,336,843	69,763,933
Ordinary shares , shares outstanding	437,170,960	68,598,050

~~XML 98-R78.htm IDEA XBRL DOCUMENT~~

Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Statements of Comprehensive (Loss)	12 Months Ended		
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022

[illegible]

4140LQC%<05H@/UNL1TFL0E1Q0-437A-E%<@C8J1VC%-4SM.M141ROR>|C7631NUFV|D"PB88X8H&Q-2S.(Q24SF7Q/1-7N/XDITZ1Y5M1+8S-A)JF-
1112127QQRWAAUHVY1Y1_6L@7E7*MPRSD>V58RZD@M1DY3JLUFPLLA1L-@<Z2ANZ71+7MLXN.LM-@F.BEHEH1H&+D7OC1+PWP1JF-E8T.KTDHMIQ.3S(OW%>=D/L.YXLGS
M4M.VL31LGMHFI.ML1138>P.VSTRYH|H@C@C1T.L8WAOE@C393KXA.M-@<84>40.C6G\$Q0<0ZH@SE@>XBJW0D0203YVDHWM5.M13RUD7.016-M.R1.LX36P#64
3.4W=>3&-<CM92.B.M6ZWMYHJCNFI<@<=8.A.LG1.MLID.C.O19&S*N%V3V4521.V61+>31.LY.M5.8K1+VL#.#8ZOV7W1>1.98B^SH4G%=>SSHUWA0%#<172-R#.#3Z.MON#1+>+>
+>Z12Z%XXH1L.B3JRHO20Y1(WOCKH1.O5N.K.NRBJ011.CT.MB.WO3>31.RA5E1SEG>3.QP1SL1-NWJ+31VD-8M30J1V1T+>@TJ57Y.M1L.#8R4EB1+AH0T
MSZJ1+M&XZD4RC.X1=S.(D842Q810W1.F1DN5.N2P31.MC01+PZ=>OMR.H70LDPD8HW>9IG7.G.GIN#<S#<W18/C3J1<8TPN.VY#9-0.#64I.G.M.#O(FA.<8>10%QO2L10Y.5B1Z1J9S?
A5B183SNE1L15%04E.A5T7N#>4.M1MUE+51)2IHPH#>2D0TC#H1<L.N1O.V.G<J22.#QO.BEY9>MGS<C2D45>X6<C.G@H3.V5.T.L1W.2J5X1.KE127D9DW1CPL8L%>+0U
M8H1H@<N#K.#E17E1KZP1VU14<@<GOMQ.D0P>0UG.3F2Z(DP1+41>3V.M.CW.N47K.LN.62@.Q9A04<@<X1L#E5.#1WHPF>YX.AYK4K<@<0JCP.SVU.MPZ+Z7BKSE01==>
=>Q1R.2%M.#M#QO81KZ7A8V1F4ENR@<B1AX.L1+>1.WO.Y2Z+QY.V16.H.\$50.L2P0>T2ZHC#<W12P>64.#69JKOY.D122+>1.M.M66R9P83X1JX1D10.1X@<Y125N3KZR-8-
-RN1^>H02P.\$%>@.MN<#<62=>#C0#<0.1@<ID.X#<W.WJK&UL.M15EK.INX&OVN7T%<X+Q8H1>6Y&>1>=>O0VY.8(FV>W%Q2U.2I3.K21Z22E.M.O7I0TJVG.LNBD
(8LDSAS.V5S#<3U1F.H1GBB6.SL=>R81S.MOLV06H1H1M48L8E1.W/BBSA15E47^<7&5.M&ON.K9OUM&ON#2#RBIG1H1W/WTE3Q4#<8-1>X1F65#F3WZD1WRD7A71\$2K.M%>
363228U.WO@A.K101-X7&MOJ>01=>F1#>YF7F8WZ2SYD772781%VX.MPCFW.>G"IDGX%\$.P13T2R#>114.0(PCGR1.@XB>NGUD4^<SLAKT#>Z\$MFCB13^5?>
QO9H#<F>1XWZZD7610.ROUS%NSY1&#<8C.CC<HJG7V1U.H10N.M01-1>@<0AGE1+W%\$S>2I2L.U1O-L1OJ.R3^<2-1.N.S1NB1GS<^>B058F8^<ZV.M#H2WKF071MMSZQ1YFS.ZA10A.XO12
O1E#<H.C#Z1\$1.MO42#10N#>POL8Y>DDNSXVD<0LOF31J3641V82147V.91C<#<L8.D.MN2B184347UFW1651ZU@B41EMKNZRIHS9N8+>78.81YE11J1<0C1+41N2P
R19KNDUEIM1(L.R.1C2.<6N9FA6C#<2.U.M61L1+G#E.F.P.AD631O1QO.#81@<1.9F03D1L1K50.#73<1+1#UE14101#<W.MKV&X1<CX.U6.FC132>01#>2051B1E1V1CJX.OOY6V.CF
<53&6H0UC1M1007B.W.K3.9U51E1^11821V1+1RVPV#>XV1>11.H.X&U1#<TSA&S1.8H6.M73C<NTXYZQZPLK8MB&W1>H1K2Z.<106B.4.6FINEC%<012H14.591.M0.5<9@8Y1+<
1^#1+1+1+1#141X1CD3621F1<161+>#Z1P3&.<+C>N=>812161^4.EBO.2.M.T^<C.OPEPU+EU.LP.G1F#<D.6H2>21V.3^K1P1#5UA3E2#*N.XD%<L<1^1M.MN^9QF2
^#3D@<1K5E50P>QOS<4SB>8.D.UVKV1J1M<1.L41L1+041F15N.MODT71CWS1UN<783>S.RKV1M1-2^R1.V61+>WDL41.#HJ5D1501Y1@T.M1.#PVO1P1^<4<1.6NP2
JBSWAY2V#<K@<#1.<8.U1L1.C8H1F1>@.7U1V.M.L1.#E9.OQ.#1.A.W=30./B1>7&CLU161<1&1^71.C12P107^31H1+JUN=V>+M1%<1.S21UOL1V11T1>31P>1K731LKB1C+G5RNC?
51+19EM3V1U1>B>8&K1.H.M.W.#P%L1.#82123X558./SOTGT2PB1336V.DH9KPM1A4Q.O0>V&KCU8C.M1XQ1.M321V>3N.M1+>X2=>1.O&MRS1V>.6W151+V7.6Z.21W.831).ACB1=Y43Y1
M1>1W>Q1.207SD38M122.DCF#>1.#1ANN1.NLS1^P1PX.#001L1+>1.RTIU1<M121\$1+110F24W81C1^3Y1V1>55MB1AOVDCX&A03HD25S.G15151.63.WH.M.#<2<
1V2XNV15D1<00>P1.F@<AXP2SGC1<N15>1=>OOZL1.F6NF#<HND.M1&A.O1@<#<V%<81C2>T1^11GXTBKRCCY<B1M1#1&C1X1U1APP0R1U1GX2.M1%>Z<#<6S1#1W
B.PAP17D5<011140.H21.W1M.#MCFU1P.4A#>4.9<41<@<0433P1T.H5OSBN.OG1#<CYD0.314-W.6WABT.P.M.FKN1A1X.01C1T3>1W1V12F4&#<7#14W5<25S.NK121#NN.<1/T1&
<#<151DL516Y5V1J1X@<F12WV1#<1@<O1Q%W31Z1G1+>+PRV16>2MEV1.BBL189.M5<#<2T@106BB7.G0FKE71L1J1K1R1F&W1=>#D14YS.RX3<123GBMESQ8Q
M7H0Q.85V2B1>1JPK#<1+VO<1U.V1NGXT1.Z0@<171XX-W.87T#<P^<3E15.MS1.KP#<9K105175N&P.L8J151#K1R1D1&.>J1<N.S8QZ@UV14&L&OW1.7MBP10WU1^<1U91E.L1JZ.K#<
H1W1V10J1<1^1V25101.MP.W27>POP.MB7L.O#<W1+1.A.10.2P5.IAVCX2JEGM4&4E1.F7D154.C.2P1C6S1>1ME1KF1UW1&891W&M1101+1B.EBA@G#<P1J89>9>#PO.M=V1R.W
H96571W21322F#<2.121L1.N=>S91A91U1+EW1DF.M=N.U1.A.0UT74&D1V1E1>YX1Q.W7B1N1416X#1#<SH1@ED1+>23F5RG41@1E1W1H1.L1#Y1T1L1GA1E1F7JRU1J1
MHAL+ZE1H1X4081G1C.N1X.11.#21L1.CV0UVH1Z1@<1@<S&R10W&15T1^1.MP1LUN128YK>7N<+1#>VTL1D50%31LAY1BN501EN#41H1011B31Z1D1MSR11.M1U810
F#<2J01.71HPZ31LKH123C1ULSA1&G1HN.W1#<N.ZN9V>3&8M1MXPD1138<1.8\$>1+>N21^<ST72>87L1GKBK<#1+1LH1&1<C>1K1<
M#<14R7K#<T1BRM11K1F&H2>555K1&9OZ1J1V1>0<88&#<P.O=V1R.W1H96571E1O1GHM1F21>1^>N1#<NKE1L1H1S&B1S7R3.FHN#<ST51U.6.M.FEFG.K21SP1M.#<V.6YB591U1X5R
W1#85%2131#EN1L<=<#V1.3#M1+1C1P18.31U1.#91W1Y1R8H1F2PX.YK1L10W1K1AL<#<7PK11L9&S&18D>@<0.#1\$1L1&C1+>DRW1Y1XW1YX.W1A1U1+1L12.OOQ.9.MRL1NEOL9KNF5
N1N14VG@O#2WD1H1MG6T8N1J1J5ZP155.5K0O2Y51.L1MP1&K1101#101W14.5C41^1T.8.TTS.ONJ1=>B1F8N15%1Q1.3T55<351M1E56&B&X1%1E#>6\$1791A1OM

[illegible]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

%-75S>?%^@B\N; M*W0SGIZ:IV;??Z#QY&IV,+N;31J/-MOV%+^ZJBK,M@:D?!\#N@T"CJ-
MNBC: ^C'1V""N3)59F*!;/JXET+M@%J. 6\$0>TG\$Y'-YY\D2WJ3)4P%AL;0!-RSH/X&,\$BE\$*WB!_S+AZ(@'%E M-
HE=9E.7P=R.@AU,@E5,@M6:37-):K;.0MM%?K)=PFQ0STNV,"TJ&O-PYEXZ
MF+9C5I*KI9UJ1\$C%S/^/QTFV#'-JBY88%LV(ILL8;UKR^UBH^@MP\$#-16RI56%JC23^29QT%
<=UCC1'6P14\V(4S#BM*!.;QH_BXG>Z^5<_YD M'^<0^"@.Z#.+FMN)TV5:Z#.9V%.R 5:R5TDH16-
A&J:=W2)8P)*+MT1JH18 MK>\$^D&Y=:!7)W@OZ*T*0LLZ\$5\$!9JQ:W4C#TOW4(!LA=9?VR?V^~9OIT+^N4 M9.%Z%I:
(AJOM1F5'AL2JK0\$*.ZQAHMD-4SD)E;1"G<6" GU0V,*?E5Y\$X6E0>RA45V8 M5!%U; X-9JB
LJ2UV/C0/N%B=CY^GKQCGX!;!?->W"GT=RNHAUR6DILW"H>ML:SS&Y6J5)! HZ>(*=-J\$!99CB!M5BR%>|S)K-
!Z+PI\7 &QJUI= F MCIXID /5I/H/RE9=7(IW:AJVB:8U9%VI? &O!#!L-8(-#=-1HIIT=*1U)UT% M!K>Q?
UNE,,,MRO@2^K':.=U+8R09DD6H4ACJNFTY#2H1E\ (9MROGPTI*60B%Y\$/L)5 MB:XXI=Q5(!?7I3-
I38I20>-6*:E.H:-W-PIS%VI_ U3V<25E3KW(+4RPKE>S MH6I8D VJB+!;U1JR@93JEK2K6PGYR)U.;J?CQ?08(&
<\$J%"1NHKLPT:NBDEE MABOIU#4:&?;0V0MW""C4I*1=D\KAIY?L.8ACV?UA)7AE_%4"JFM%PIH)%8_*MRL%50
K=:0QU8I|@FD@I/\$FL.SP.*FK6Y#4)ILA=G414UC5I;P*JSV\AS!* M!4?:OYTNI?SR^G5I/IN?
(D*#@83;.XOVU01*333Z>=1G.;BG;(:*DR M2?OGT^PT8\$;#/-O@!?:9D;XH:33J"0)"MIK+4IAAVZRI(5=AYI#AWEIWB*C4
M>*1=XU41Y3LN)1ZS|BT78VQ:M694M|URZPV+5=AIJSR#/-B""6/F9'1QE M*QGS4Y'B:7&<-|X.L2K/S_&)FQ_*E6'R_1
(KFD+OXBAD*PBI?%;A:&E^D);? MB&23'40M\$SR&2*+M<;JS5I;K|ZL\$%|N1KZ@./P<_0M02P_*Q%3@ N(#^M6*!;867 P
EQH T IX; "IS="EL9?N>+ULW5GM;MHP%V5%*Y65IH; MDJP60%10ZHT;9LJM3 YKS+5 40.QQS3P=YG+(GFV|
<0J"^E/;2A948M^_M<^|QI8V-U4\$I5YS>SBF5UC+E63FTYU(6'QRGC.YI2LJ+O""9\B2Y2(E473%S MRD)0\$I<
2KGCI7J;DQ*6V;-!MDBO4UE:TWR1R:'M^HW-TK?/L;(&|VU+|XWS MF |M^f.W/Q.YO^ICZ?O)NY.3WOWYU;
HK*NE#FRHO1\X?1 M1R/J;. #J/(-T5/ R \;7"G""SLF0?RYS&=QKIP&?IM;'X%MH#(S4^78^+O9D!)VA\;J?Z+&
MT2#)L\WB &L#&%1TDE+K@?^A/2;.<300#5\$)2QE?:fC%AFO-<6%*M2DJ;"Y;R MEW;
fN@<+5LV3LBP756P=07I/ZL=W'-L>"&2<P(16QM&@X)(245VK3K5PY7Q MDK0BF<")RO4MI
ZAN*L@D\$S\$5FT727IM&TX3D"/8; YWF1<..*7. M4I6(&9GE&:DTK!%U0I%.*>>WL)I_3I:XETEKE7JLW-&N:2E#=U#2Z
-QM-LW= MHO5Z+^*U"O.0RT+~9RLZD.UT!M!\$!L^LND\$8"QNS@|*0J^~LC9+\$N!OS! M
4<#LL99\URP7RH:E;I4&BPK0IH4J!+9G@FKT;OZW>9I1 MC K"VZ)5I|SEE^LV I?2W*UJNP*-FJL?
Z\$=NiC+|H@;NB"R S7H!>OL?I% M?>PBNY#)-!56I>N>=(+L@TNN"2+!+&KNP*X9=V!7#XJP5G?
fW2B4O223#C=YE?/QS0A"RIO&N?0WK2 MTI@MTIAYZ@8243^U;7^!X;E!-

!0VIN=&5N=%!4>7!E&ULS=K? M3MLP% ;P5ZERBQK7_S=\$N0%N-R!V EYRVD9-8LLVK+SIG!20-K\$*5*1!-XU:
MV^<A!9% ^5!WZ!10H+0Y# /Z9UMO<:E375!>T<0!H7MP=RL^!^ZBM2G:G%SW#AEK2L70M!U M+I=U!CBV?
Z4LGO!JDW9=2!=E0!7>3)A6_AWP? !H!78M;2X=S%>CK8!&+T!FYW# =/_G9 M^7.94X%EYWWT(96)1?IXW,M(IM/+4
H!S-W!5WQ+*7!7C^+!MU2^!^!L;+2!H20?K@*Y1& M4\$3E**1R%%,Y"JH<156.PB!<96CP,!H9!4HL@H4606*K
%5H\$BJT"15:#!(M*E!D2BR^A19)8JL\$D56B2*K1!)55HL@!J4625*+!)%%DEBJP215:%(JM"D56A
MR*I09%4HLBH4616*K!%5H4BJT*15:/(JE%DU2BR:A19-8JL&D56C2*K1!%5 MH!BJ460U*+(!%%D-BJP&15:#!
(JM!D=6@R&I09#4HLAH462V*K!9%5HLBJT61 MU:+(E%DM2BR6A19+8JL!G_*M!/_2?"S!Z<-WXDL_F?U!?
_P902P\$"% ,4 M " "X@/Y8!T%-8H\$ "Q \$ @ \$ 9&!G4!)O M<!,087!P+GAM;%!+ 0(4 Q0 (-+B_EBJXB<8!P "L" 1 M " :!
!D:V-0&UL4\$L! A0#% @ N(#^6!/@H!"V!P L2< !@ ("! M#@@ 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @
MN(#^6!&^!VW"0 1S0 !@ ("!RAD 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ N(#^6*2=\$C0#"0 ,1@ !D ("!
M>6T 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% M @ N(#^6)?#BM?B @ !P4 !D ("!)P 'AL+W=O&PO=VJR:W-
H965T&UL4\$L! A0#% @ N(#^6!^RYG,C P Y 8 !D M ("!)10 'AL+W=O&PO=VJR M:W-H965T&UL M4\$L! A0#% @
N(#^6*00,RO) P O D !D ("!)J0 M 'AL+W=O&PO=VJR:W-H965T) #P , % & 9 M " @6ZT !X;"!W;W)K&UL4\$L! A0#% @
MN(#^6!;:!=&PO=VJR:W-H965T&UL4\$L! A0#% @ N(#^6#^S>3Z:#0 ME"(!D ("!X<8 'AL+W=O&PO=VJR:W-
H965T&UL4\$L! A0#% @ N(#^6\$AJ!S!@ +A !D M ("!)1 ! 'AL+W=O&PO=VJR:W-H M965T&UL4\$L! M A0#% @
N(#^6.9EB^1U @ BP4 !D ("!)K!X! 'AL M+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ N(#^ M6+1; %Y7 @ .04 !D
("!)O28! 'AL+W=O&PO=VJR:W-H965TF@, 'P(9 " @? L 0!X;"!W;W)K M&UL4\$L! A0#% @ N(#^6 N5)M5O P *@D M !D
("!)P3 ! 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ N(#^6*G(%YQ @ /08 !D M ("!)U4('AL+W=O&PO=VJR:W-
H965T M 9 M " @!A1 0!X;"!W;W)K&UL4\$L! A0# M% @ N(#^6&F) MTL P ; H !D ("!)58! 'AL+W=O M&PO=VJR:W-
H965TU< M 0!X;"!W;W)K&UL4\$L! A0#% @ N(#^6)OH MCGV @ %0< !D ("!)=%! ! 'AL+W=O&PO=VJR:W-
H965T&UL4\$L! A0#% @ N(#^6*#*PBIO P ,OP !D M ("!)9FD! 'AL+W=O&PO M=VJR:W-H965T&UL4\$L! A0#% @
N(#^6%&QR;M @ R 8 !D ("!) M; ! 'AL+W=O>V\$ (" @!P &0 @('N=0\$ >&PO=VJR:W-H965T&UL4\$L! A0#% M @
N(#^6#4VW!/*& @ R @ !D ("!)0! ! 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ N(#^6"X?_VK\$ M @ K0< !D
("!)BH0! 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ N(#^6+ !=C!D @ 708 !D M ("!)E! ! 'AL+W=O&PO=VJR M:W-
H965T&UL M4\$L! A0#% @ N(#^6)^FZ.9M P P !D ("!)A9T! M 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @
MN(#^6&E**8@! 0!4 !D ("!)8! 'AL+W=O&UL4\$L! A0#% @ N(#^6,,!D:6F @ M% @ !D ("!)F\$! 'AL+W=O&PO=VJR:W-
H965T&UL4\$L! A0#% @ N(#^6!%2CQ D!0 !(!D M ("!)\$J8! 'AL+W=O&PO=VJR:W-H M965T 0!X;"!W;W)K&UL4\$L! M
A0#% @ N(#^6+RVVK3 !@ ("!)T !D ("!)B>(! 'AL M+W=O&PO=PO7W)E; ,O=VJR:V)O;VLN>&UL+G)E M;-'02P\$"% ,4 "
"X@/Y8W2=K"Q@" "%+0 \$P @ &U L!@ \$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 5P!7 -@7 #^ ^ \$! end XML 101
Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange
Commission. Data and content created by government employees within the scope of their employment are not
subject to domestic copyright protection. 17 U.S.C. 105. var Show=
{Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(e.style){}else if(e.style.display){}else{var
d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerHTML=p+a.innerHTML.substring(1)}} XML 102 report.css
IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */.report table.authRefData{
background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }.report table.authRefData a
{ display: block; font-weight: bold; }.report table.authRefData p { margin-top: 0px; }.report table.authRefData
.hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }.report table.authRefData .hide
a: hover { background-color: #2F4497; }.report table.authRefData .body { height: 150px; overflow: auto; width:
400px; }.report table.authRefData table { font-size: 1em; } /* Report Styles */.pl a,.pl a:visited { color: black; text-
decoration: none; } /* table */.report { background-color: white; border: 2px solid #acf; clear: both; color: black;
font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; }.report hr { border: 1px solid #acf; } /* Top labels
*/.report th { background-color: #acf; color: black; font-weight: bold; text-align: center; }.report th.void {
background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; }.report
.pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap:
break-word; */ }.report td.pl a a { cursor: pointer; display: block; width: 200px; overflow: hidden; }.report td.pl
div a { width: 200px; }.report td.pl a: hover { background-color: #ffc; } /* Header rows... */.report tr.rh {
background-color: #acf; color: black; font-weight: bold; } /* Calendars... */.report .rc { background-color: #f0f0f0; }
/* Even rows... */.report .re,.report .reu { background-color: #def; }.report .reu td { border-bottom: 1px solid black;
} /* Odd rows... */.report .ro,.report .rou { background-color: white; }.report .rou td { border-bottom: 1px solid
black; }.report .rou table td,.report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */
.report .fn { white-space: nowrap; } /* styles for numeric types */.report .num,.report .nump { text-align: right;
white-space: nowrap; }.report .nump { padding-left: 2em; }.report .nump { padding: 0px 0.4em 0px 2em; } /* styles
for text types */.report .text { text-align: left; white-space: normal; }.report .text .big { margin-bottom: 1em; width:
17em; }.report .text .more { display: none; }.report .text .note { font-style: italic; font-weight: bold; }.report .text
.small { width: 10em; }.report sup { font-style: italic; }.report .outerFootnotes { font-size: 1em; } XML 104
FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 htm! 215 392 1 false 74 0 false 8 false false R1.htm 000 -
Document - Document And Entity Information Sheet
http://www.aksohealthgroup.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1
false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet
http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets Statements 2 false
false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet
http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet Parentheticals Consolidated Balance Sheets
(Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and
Comprehensive (Loss) Sheet http://www.aksohealthgroup.com/role/ConsolidatedIncomeStatement Consolidated
Statements of Operations and Comprehensive (Loss) Statements 4 false false R5.htm 004 - Statement - Consolidated
Statements of Changes in Shareholders??? Equity Sheet
http://www.aksohealthgroup.com/role/ShareholdersEquityType2or3 Consolidated Statements of Changes in
Shareholders??? Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows
Sheet http://www.aksohealthgroup.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows
Statements 6 false false R7.htm 006 - Disclosure - Business Description Sheet

<http://www.akshealthgroup.com/role/BusinessDescription> Business Description Notes 7 false false R8.htm 007-
 Disclosure - Going Concern Sheet <http://www.akshealthgroup.com/role/GoingConcern> Going Concern Notes 8 false
 false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet
<http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPolicies> Summary of Significant Accounting
 Policies Notes 9 false false R10.htm 009 - Disclosure - Discontinued Operation Sheet
<http://www.akshealthgroup.com/role/DiscontinuedOperation> Discontinued Operation Notes 10 false false R11.htm
 010 - Disclosure - Accounts Receivable, Net Sheet <http://www.akshealthgroup.com/role/AccountsReceivableNet>
 Accounts Receivable, Net Notes 11 false false R12.htm 011 - Disclosure - Prepayments and Other Assets, Net Sheet
<http://www.akshealthgroup.com/role/PrepaymentsandOtherAssetsNet> Prepayments and Other Assets, Net Notes 12
 false false R13.htm 012 - Disclosure - Inventories Sheet <http://www.akshealthgroup.com/role/Inventories>
 Inventories Notes 13 false false R14.htm 013 - Disclosure - Loan Receivables Sheet
<http://www.akshealthgroup.com/role/LoanReceivables> Loan Receivables Notes 14 false false R15.htm 014-
 Disclosure - Prepaid Consideration Sheet <http://www.akshealthgroup.com/role/PrepaidConsideration> Prepaid
 Consideration Notes 15 false false R16.htm 015 - Disclosure - Right of Use Lease Assets Sheet
<http://www.akshealthgroup.com/role/RightofUseLeaseAssets> Right of Use Lease Assets Notes 16 false false R17.htm
 016 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet
<http://www.akshealthgroup.com/role/AccruedExpensesandOtherCurrentLiabilities> Accrued Expenses and Other
 Current Liabilities Notes 17 false false R18.htm 017 - Disclosure - Related Party Balances and Transactions Sheet
<http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactions> Related Party Balances and
 Transactions Notes 18 false false R19.htm 018 - Disclosure - Employee Benefits Sheet
<http://www.akshealthgroup.com/role/EmployeeBenefits> Employee Benefits Notes 19 false false R20.htm 019-
 Disclosure - Taxes Payable Sheet <http://www.akshealthgroup.com/role/TaxesPayable> Taxes Payable Notes 20 false
 false R21.htm 020 - Disclosure - Income Taxes Sheet <http://www.akshealthgroup.com/role/IncomeTaxes> Income
 Taxes Notes 21 false false R22.htm 021 - Disclosure - Earnings (Loss) Per Share Sheet
<http://www.akshealthgroup.com/role/EarningsLossPerShare> Earnings (Loss) Per Share Notes 22 false false R23.htm
 022 - Disclosure - Shareholders' Equity Sheet <http://www.akshealthgroup.com/role/ShareholdersEquity>
 Shareholders' Equity Notes 23 false false R24.htm 023 - Disclosure - Treasury Stock Sheet
<http://www.akshealthgroup.com/role/TreasuryStock> Treasury Stock Notes 24 false false R25.htm 024 - Disclosure -
 Restricted Net Assets Sheet <http://www.akshealthgroup.com/role/RestrictedNetAssets> Restricted Net Assets Notes
 25 false false R26.htm 025 - Disclosure - Commitments and Contingencies Sheet
<http://www.akshealthgroup.com/role/CommitmentsandContingencies> Commitments and Contingencies Notes 26
 false false R27.htm 026 - Disclosure - Subsequent Events Sheet
<http://www.akshealthgroup.com/role/SubsequentEvents> Subsequent Events Notes 27 false false R28.htm 027-
 Disclosure - Condensed Financial Information of the Parent Company Sheet
<http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompany> Condensed Financial
 Information of the Parent Company Notes 28 false false R29.htm 996000 - Disclosure - Accounting Policies, by
 Policy (Policies) Sheet <http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy> Accounting Policies, by
 Policy (Policies) Policies <http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPolicies> 29 false
 false R30.htm 996001 - Disclosure - Business Description (Tables) Sheet
<http://www.akshealthgroup.com/role/BusinessDescriptionTables> Business Description (Tables) Tables
<http://www.akshealthgroup.com/role/BusinessDescription> 30 false false R31.htm 996002 - Disclosure - Summary of
 Significant Accounting Policies (Tables) Sheet
<http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables> Summary of Significant
 Accounting Policies (Tables) Tables <http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPolicies>
 31 false false R32.htm 996003 - Disclosure - Discontinued Operation (Tables) Sheet
<http://www.akshealthgroup.com/role/DiscontinuedOperationTables> Discontinued Operation (Tables) Tables
<http://www.akshealthgroup.com/role/DiscontinuedOperation> 32 false false R33.htm 996004 - Disclosure - Accounts
 Receivable, Net (Tables) Sheet <http://www.akshealthgroup.com/role/AccountsReceivableNetTables> Accounts
 Receivable, Net (Tables) Tables <http://www.akshealthgroup.com/role/AccountsReceivableNet> 33 false false R34.htm
 996005 - Disclosure - Prepayments and Other Assets, Net (Tables) Sheet
<http://www.akshealthgroup.com/role/PrepaymentsandOtherAssetsNetTables> Prepayments and Other Assets, Net
 (Tables) Tables <http://www.akshealthgroup.com/role/PrepaymentsandOtherAssetsNet> 34 false false R35.htm
 996006 - Disclosure - Loan Receivables (Tables) Sheet <http://www.akshealthgroup.com/role/LoanReceivablesTables>
 Loan Receivables (Tables) Tables <http://www.akshealthgroup.com/role/LoanReceivables> 35 false false R36.htm
 996007 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet
<http://www.akshealthgroup.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables> Accrued Expenses and
 Other Current Liabilities (Tables) Tables
<http://www.akshealthgroup.com/role/AccruedExpensesandOtherCurrentLiabilities> 36 false false R37.htm 996008 -
 Disclosure - Taxes Payable (Tables) Sheet <http://www.akshealthgroup.com/role/TaxesPayableTables> Taxes Payable
 (Tables) Tables <http://www.akshealthgroup.com/role/TaxesPayable> 37 false false R38.htm 996009 - Disclosure -
 Income Taxes (Tables) Sheet <http://www.akshealthgroup.com/role/IncomeTaxesTables> Income Taxes (Tables)
 Tables <http://www.akshealthgroup.com/role/IncomeTaxes> 38 false false R39.htm 996010 - Disclosure - Earnings
 (Loss) Per Share (Tables) Sheet <http://www.akshealthgroup.com/role/EarningsLossPerShareTables> Earnings (Loss)
 Per Share (Tables) Tables <http://www.akshealthgroup.com/role/EarningsLossPerShare> 39 false false R40.htm
 996011 - Disclosure - Shareholders' Equity (Tables) Sheet
<http://www.akshealthgroup.com/role/ShareholdersEquityTables> Shareholders' Equity (Tables) Tables
<http://www.akshealthgroup.com/role/ShareholdersEquity> 40 false false R41.htm 996012 - Disclosure - Condensed
 Financial Information of the Parent Company (Tables) Sheet
<http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyTables> Condensed
 Financial Information of the Parent Company (Tables) Tables
<http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompany> 41 false false R42.htm
 996013 - Disclosure - Business Description (Details) - ???Schedule of the Company's Principal Subsidiaries Sheet
<http://www.akshealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable> Business Description
 (Details) - ???Schedule of the Company's Principal Subsidiaries Details
<http://www.akshealthgroup.com/role/BusinessDescriptionTables> 42 false false R43.htm 996014 - Disclosure - Going
 Concern (Details) Sheet <http://www.akshealthgroup.com/role/GoingConcernDetails> Going Concern (Details) Details
<http://www.akshealthgroup.com/role/GoingConcern> 43 false false R44.htm 996015 - Disclosure - Summary of
 Significant Accounting Policies (Details) Sheet

<http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails> Summary of Significant Accounting Policies (Details) Details

<http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables> 44 false false R45.htm 996016 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Financial Statement Amounts and Balances of the Consolidated Vies Sheet

<http://www.aksohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTable> Summary of Significant Accounting Policies (Details) – Schedule of Financial Statement Amounts and Balances of the Consolidated Vies Details

<http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables> 45 false false R46.htm 996017 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Disaggregation of Revenue Sheet

<http://www.aksohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable> Summary of Significant Accounting Policies (Details) – Schedule of Disaggregation of Revenue Details

<http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables> 46 false false R47.htm 996018 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Estimated Useful Lives of Property and Equipment Sheet

<http://www.aksohealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable> Summary of Significant Accounting Policies (Details) – Schedule of Estimated Useful Lives of Property and Equipment Details

<http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables> 47 false false R48.htm 996019 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Noncontrolling Interest Sheet

<http://www.aksohealthgroup.com/role/ScheduleofNoncontrollingInterestTable> Summary of Significant Accounting Policies (Details) – Schedule of Noncontrolling Interest Details

<http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables> 48 false false R49.htm 996020 – Disclosure – Summary of Significant Accounting Policies (Details) – Schedule of Spot Exchange Rates and Average Exchange Rates Sheet

<http://www.aksohealthgroup.com/role/ScheduleofSpotExchangeRatesandAverageExchangeRatesTable> Summary of Significant Accounting Policies (Details) – Schedule of Spot Exchange Rates and Average Exchange Rates Details

<http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables> 49 false false R50.htm 996021 – Disclosure – Discontinued Operation (Details) Sheet

<http://www.aksohealthgroup.com/role/DiscontinuedOperationDetails> Discontinued Operation (Details) Details

<http://www.aksohealthgroup.com/role/DiscontinuedOperationTables> 50 false false R51.htm 996022 – Disclosure – Discontinued Operation (Details) – ???Schedule of Discontinued Operations Sheet

<http://www.aksohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable> Discontinued Operation (Details) – ???Schedule of Discontinued Operations Details

<http://www.aksohealthgroup.com/role/DiscontinuedOperationTables> 51 false false R52.htm 996023 – Disclosure – Discontinued Operation (Details) – ???Schedule of Assets and Liabilities Sheet

<http://www.aksohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable> Discontinued Operation (Details) – ???Schedule of Assets and Liabilities Details

<http://www.aksohealthgroup.com/role/DiscontinuedOperationTables> 52 false false R53.htm 996024 – Disclosure – Discontinued Operation (Details) – Schedule of Loss on Sale of Discontinued Operations Sheet

<http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable> Discontinued Operation (Details) – Schedule of Loss on Sale of Discontinued Operations Details

<http://www.aksohealthgroup.com/role/DiscontinuedOperationTables> 53 false false R54.htm 996025 – Disclosure – Accounts Receivable, Net (Details) – ???Schedule of Accounts Receivable, Net Sheet

<http://www.aksohealthgroup.com/role/ScheduleofAccountsReceivableNetTable> Accounts Receivable, Net (Details) – ???Schedule of Accounts Receivable, Net Details

<http://www.aksohealthgroup.com/role/AccountsReceivableNetTables> 54 false false R55.htm 996026 – Disclosure – Prepayments and Other Assets, Net (Details) – ???Schedule of Prepayments and Other Assets Sheet

<http://www.aksohealthgroup.com/role/ScheduleofPrepaymentsandOtherAssetsTable> Prepayments and Other Assets, Net (Details) – ???Schedule of Prepayments and Other Assets Details

<http://www.aksohealthgroup.com/role/PrepaymentsandOtherAssetsNetTables> 55 false false R56.htm 996027 – Disclosure – Inventories (Details) Sheet

<http://www.aksohealthgroup.com/role/InventoriesDetails> Inventories (Details) Details

<http://www.aksohealthgroup.com/role/Inventories> 56 false false R57.htm 996028 – Disclosure – Loan Receivables (Details) Sheet

<http://www.aksohealthgroup.com/role/LoanReceivablesDetails> Loan Receivables (Details) Details

<http://www.aksohealthgroup.com/role/LoanReceivablesTables> 57 false false R58.htm 996029 – Disclosure – Loan Receivables (Details) – Schedule of Loan Receivables Sheet

<http://www.aksohealthgroup.com/role/ScheduleofLoanReceivablesTable> Loan Receivables (Details) – Schedule of Loan Receivables Details

<http://www.aksohealthgroup.com/role/LoanReceivablesTables> 58 false false R59.htm 996030 – Disclosure – Prepaid Consideration (Details) Sheet

<http://www.aksohealthgroup.com/role/PrepaidConsiderationDetails> Prepaid Consideration (Details) Details

<http://www.aksohealthgroup.com/role/PrepaidConsideration> 59 false false R60.htm 996031 – Disclosure – Right of Use Lease Assets (Details) Sheet

<http://www.aksohealthgroup.com/role/RightofUseLeaseAssetsDetails> Right of Use Lease Assets (Details) Details

<http://www.aksohealthgroup.com/role/RightofUseLeaseAssets> 60 false false R61.htm 996032 – Disclosure – Accrued Expenses and Other Current Liabilities (Details) – ???Schedule of Accrued Expenses and Other Current Liabilities Sheet

<http://www.aksohealthgroup.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable> Accrued Expenses and Other Current Liabilities (Details) – ???Schedule of Accrued Expenses and Other Current Liabilities Details

<http://www.aksohealthgroup.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables> 61 false false R62.htm 996033 – Disclosure – Related Party Balances and Transactions (Details) Sheet

<http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails> Related Party Balances and Transactions (Details) Details

<http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactions> 62 false false R63.htm 996034 – Disclosure – Employee Benefits (Details) Sheet

<http://www.aksohealthgroup.com/role/EmployeeBenefitsDetails> Employee Benefits (Details) Details

<http://www.aksohealthgroup.com/role/EmployeeBenefits> 63 false false R64.htm 996035 – Disclosure – Taxes Payable (Details) – Schedule of Taxes Payable Sheet

<http://www.aksohealthgroup.com/role/ScheduleofTaxesPayableTable> Taxes Payable (Details) – Schedule of Taxes Payable Details

<http://www.aksohealthgroup.com/role/TaxesPayableTables> 64 false false R65.htm 996036 – Disclosure – Income Taxes (Details) Sheet

<http://www.aksohealthgroup.com/role/IncomeTaxesDetails> Income Taxes (Details) Details

<http://www.aksohealthgroup.com/role/IncomeTaxesTables> 65 false false R66.htm 996037 – Disclosure – Income Taxes (Details) – Schedule of Components of Income Tax Expenses Sheet

<http://www.aksohealthgroup.com/role/ScheduleofComponentsofIncomeTaxExpensesTable> Income Taxes (Details) –

[Schedule of Components of Income Tax Expenses Details](http://www.akshealthgroup.com/role/IncomeTaxTables) <http://www.akshealthgroup.com/role/IncomeTaxTables> 66 false false R67.htm 996038 - Disclosure - Income Taxes (Details) - Schedule of Reconciles the PRC Statutory Rates to the Company???'s Effective Tax Rate Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 67 false false R68.htm 996039 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Outstanding Shares for Basic and Diluted Net Earnings Per Share Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 68 false false R69.htm 996040 - Disclosure - Shareholders' Equity (Details) Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 69 false false R70.htm 996041 - Disclosure - Shareholders' Equity (Details) - ???Schedule of Warrants Outstanding Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 70 false false R71.htm 996042 - Disclosure - Shareholders' Equity (Details) - Schedule of Warrants Exercisable Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 71 false false R72.htm 996043 - Disclosure - Treasury Stock (Details) Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 72 false false R73.htm 996044 - Disclosure - Restricted Net Assets (Details) Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 73 false false R74.htm 996045 - Disclosure - Subsequent Events (Details) Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 74 false false R75.htm 996046 - Disclosure - Condensed Financial Information of the Parent Company (Details) Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 75 false false R76.htm 996047 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Balance Sheets Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 76 false false R77.htm 996048 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Balance Sheets (Parentheticals) Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 77 false false R78.htm 996049 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Statements of Comprehensive (Loss) Income Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 78 false false R79.htm 996050 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Statements of Cash Flows Sheet <http://www.akshealthgroup.com/role/IncomeTaxTables> 79 false false All Reports Book All Reports ahg-20240331.xsd ahg-20240331-cal.xml ahg-20240331-def.xml ahg-20240331-lab.xml ahg-20240331-pre.xml ea0208034-20f_akshealth.htm image_001.jpg image_002.jpg image_003.jpg <http://fasb.org/srt/2024> <http://fasb.org/us-gaap/2024> <http://xbrl.sec.gov/dei/2024> true true JSON 107 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0208034-20f_akshealth.htm": { "nsprefix": "ahg", "nsuri": "http://www.akshealthgroup.com/20240331", "dts": { "schema": { "local": { "ahg-20240331.xsd" } }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } }, "calculationLink": { "local": { "ahg-20240331-cal.xml" } }, "definitionLink": { "local": { "ahg-20240331-def.xml" } }, "labelLink": { "local": { "ahg-20240331-lab.xml" } }, "presentationLink": { "local": { "ahg-20240331-pre.xml" } }, "inline": { "local": { "ea0208034-20f_akshealth.htm" } } }, "keyStandard": 310, "keyCustom": 82, "axisStandard": 26, "axisCustom": 1, "memberStandard": 23, "memberCustom": 48, "hidden": { "total": 197, "http://fasb.org/us-gaap/2024": 156, "http://www.akshealthgroup.com/20240331": 35, "http://xbrl.sec.gov/dei/2024": 6 }, "contextCount": 215, "entityCount": 1, "segmentCount": 74, "elementCount": 632, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 916, "http://xbrl.sec.gov/dei/2024": 50, "http://fasb.org/srt/2024": 4 }, "report": { "R1": { "role": "http://www.akshealthgroup.com/role/DocumentAndEntityInformation", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "td",

"tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R2": { "role": "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R3": { "role": "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["div", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R4": { "role": "http://www.aksohealthgroup.com/role/ConsolidatedIncomeStatement", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive (Loss)", "shortName": "Consolidated Statements of Operations and Comprehensive (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R5": { "role": "http://www.aksohealthgroup.com/role/ShareholdersEquityType2or3", "longName": "004 - Statement - Consolidated Statements of Changes in Shareholders' Equity", "shortName": "Consolidated Statements of Changes in Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c16", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c16", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R6": { "role": "http://www.aksohealthgroup.com/role/ConsolidatedCashFlow", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ProvisionForDoubtfulAccounts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R7": { "role": "http://www.aksohealthgroup.com/role/BusinessDescription", "longName": "006 - Disclosure - Business Description", "shortName": "Business Description", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R8": { "role": "http://www.aksohealthgroup.com/role/GoingConcern", "longName": "007 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R9": { "role": "http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPolicies", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R10": { "role": "http://www.aksohealthgroup.com/role/DiscontinuedOperation", "longName": "009 - Disclosure - Discontinued Operation", "shortName": "Discontinued Operation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DiscontinuedOperationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DiscontinuedOperationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }

"c0", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.akshealthgroup.com/role/AccountsReceivableNet", "longName": "010 - Disclosure - Accounts Receivable, Net", "shortName": "Accounts Receivable, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.akshealthgroup.com/role/PrepaymentsandOtherAssetsNet", "longName": "011 - Disclosure - Prepayments and Other Assets, Net", "shortName": "Prepayments and Other Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.akshealthgroup.com/role/Inventories", "longName": "012 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.akshealthgroup.com/role/LoanReceivables", "longName": "013 - Disclosure - Loan Receivables", "shortName": "Loan Receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.akshealthgroup.com/role/PrepaidConsideration", "longName": "014 - Disclosure - Prepaid Consideration", "shortName": "Prepaid Consideration", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.akshealthgroup.com/role/RightofUseLeaseAssets", "longName": "015 - Disclosure - Right of Use Lease Assets", "shortName": "Right of Use Lease Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "ahg:RightOfUseLeaseAssetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ahg:RightOfUseLeaseAssetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.akshealthgroup.com/role/AccruedExpensesandOtherCurrentLiabilities", "longName": "016 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactions", "longName": "017 - Disclosure - Related Party Balances and Transactions", "shortName": "Related Party Balances and Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.akshealthgroup.com/role/EmployeeBenefits", "longName": "018 - Disclosure - Employee Benefits", "shortName": "Employee Benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-

20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R20": { "role": "http://www.aksohealthgroup.com/role/TaxesPayable", "longName": "019 - Disclosure - Taxes Payable", "shortName": "Taxes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "ahg:TaxesPayableCurrentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R21": { "role": "http://www.aksohealthgroup.com/role/IncomeTaxes", "longName": "020 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R22": { "role": "http://www.aksohealthgroup.com/role/EarningsLossPerShare", "longName": "021 - Disclosure - Earnings (Loss) Per Share", "shortName": "Earnings (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R23": { "role": "http://www.aksohealthgroup.com/role/ShareholdersEquity", "longName": "022 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R24": { "role": "http://www.aksohealthgroup.com/role/TreasuryStock", "longName": "023 - Disclosure - Treasury Stock", "shortName": "Treasury Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R25": { "role": "http://www.aksohealthgroup.com/role/RestrictedNetAssets", "longName": "024 - Disclosure - Restricted Net Assets", "shortName": "Restricted Net Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RestrictedAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RestrictedAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R26": { "role": "http://www.aksohealthgroup.com/role/CommitmentsandContingencies", "longName": "025 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R27": { "role": "http://www.aksohealthgroup.com/role/SubsequentEvents", "longName": "026 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R28": { "role": "http://www.aksohealthgroup.com/role/CondensedFinancialInformationoftheParentCompany", "longName": "027 - Disclosure - Condensed Financial Information of the Parent Company", "shortName": "Condensed Financial Information of the Parent Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "R29": { "role":

"http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy", "longName": "996000 – Disclosure – Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.akshealthgroup.com/role/BusinessDescriptionTables", "longName": "996001 – Disclosure – Business Description (Tables)", "shortName": "Business Description (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "996002 – Disclosure – Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.akshealthgroup.com/role/DiscontinuedOperationTables", "longName": "996003 – Disclosure – Discontinued Operation (Tables)", "shortName": "Discontinued Operation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisc", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisc", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.akshealthgroup.com/role/AccountsReceivableNetTables", "longName": "996004 – Disclosure – Accounts Receivable, Net (Tables)", "shortName": "Accounts Receivable, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.akshealthgroup.com/role/PrepaymentsandOtherAssetsNetTables", "longName": "996005 – Disclosure – Prepayments and Other Assets, Net (Tables)", "shortName": "Prepayments and Other Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.akshealthgroup.com/role/LoanReceivablesTables", "longName": "996006 – Disclosure – Loan Receivables (Tables)", "shortName": "Loan Receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.akshealthgroup.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "longName": "996007 – Disclosure – Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure",

"subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.aksohealthgroup.com/role/TaxesPayableTables", "longName": "996008 - Disclosure - Taxes Payable (Tables)", "shortName": "Taxes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "ahg:ScheduleOfCurrentTaxesPayableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ahg:TaxesPayableCurrentDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ahg:ScheduleOfCurrentTaxesPayableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ahg:TaxesPayableCurrentDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.aksohealthgroup.com/role/IncomeTaxesTables", "longName": "996009 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.aksohealthgroup.com/role/EarningsLossPerShareTables", "longName": "996010 - Disclosure - Earnings (Loss) Per Share (Tables)", "shortName": "Earnings (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.aksohealthgroup.com/role/ShareholdersEquityTables", "longName": "996011 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c0", "name": "ahg:ScheduleOfWarrantsOutstandingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ahg:ScheduleOfWarrantsOutstandingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.aksohealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyTables", "longName": "996012 - Disclosure - Condensed Financial Information of the Parent Company (Tables)", "shortName": "Condensed Financial Information of the Parent Company (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c0", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.aksohealthgroup.com/role/ScheduleoftheCompanysPrincipalSubsidiariesTable", "longName": "996013 - Disclosure - Business Description (Details) - \u200bSchedule of the Company's Principal Subsidiaries", "shortName": "Business Description (Details) - \u200bSchedule of the Company's Principal Subsidiaries", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c62", "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c62", "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.aksohealthgroup.com/role/GoingConcernDetails", "longName": "996014 - Disclosure - Going Concern (Details)", "shortName": "Going Concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:NetInvestmentInLease", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:NetInvestmentInLease", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef":

"ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R44": { "role":
"http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "996015-
Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant
Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c0", "name": "ahg:MinimumAmount", "unitRef":
"cny", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "ix:continuation", "div",
"body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c0", "name": "ahg:MinimumAmount", "unitRef": "cny", "xsiNil": "false", "lang":
null, "decimals": "0", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1,
"baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R45": { "role":
"http://www.aksohealthgroup.com/role/ScheduleofFinancialStatementAmountsAndBalancesoftheConsolidatedViesTab
"longName": "996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Financial
Statement Amounts and Balances of the Consolidated Vies", "shortName": "Summary of Significant Accounting
Policies (Details) - Schedule of Financial Statement Amounts and Balances of the Consolidated Vies", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": {
"contextRef": "c89", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false",
"lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation",
"div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c89", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef":
"usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation",
"ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-
20f_aksohealth.htm", "first": true, "unique": true } }, "R46": { "role":
"http://www.aksohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable", "longName": "996017-
Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Disaggregation of Revenue",
"shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Disaggregation of Revenue",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46",
"firstAnchor": { "contextRef": "c95", "name": "ahg:RevenueFromMedicalDevicesUS", "unitRef": "usd", "xsiNil":
"false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation",
"ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "c95", "name": "ahg:RevenueFromMedicalDevicesUS", "unitRef":
"usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation",
"ix:continuation", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-
20f_aksohealth.htm", "first": true, "unique": true } }, "R47": { "role":
"http://www.aksohealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable",
"longName": "996018 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated
Useful Lives of Property and Equipment", "shortName": "Summary of Significant Accounting Policies (Details)-
Schedule of Estimated Useful Lives of Property and Equipment", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c97", "name": "us-
gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": ["span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"
"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c97", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "ix:continuation", "ix:continuation",
"ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true,
"unique": true } }, "R48": { "role": "http://www.aksohealthgroup.com/role/ScheduleofNoncontrollingInterestTable",
"longName": "996019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of
Noncontrolling Interest", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of
Noncontrolling Interest", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "48", "firstAnchor": { "contextRef": "c99", "name": "us-gaap:MinorityInterest", "unitRef": "usd",
"xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation",
"ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "c99", "name": "us-gaap:MinorityInterest", "unitRef": "usd",
"xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation",
"ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true,
"unique": true } }, "R49": { "role":
"http://www.aksohealthgroup.com/role/ScheduleofSpotExchangeRatesandAverageExchangeRatesTable",
"longName": "996020 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Spot
Exchange Rates and Average Exchange Rates", "shortName": "Summary of Significant Accounting Policies (Details)
- Schedule of Spot Exchange Rates and Average Exchange Rates", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c4", "name": "us-
gaap:ForeignCurrencyExchangeRateTranslation1", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4",
"ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"] },
"reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c4", "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1", "unitRef": "pure", "xsiNil":
"false", "lang": null, "decimals": "4", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation",
"ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true,
"unique": true } }, "R50": { "role": "http://www.aksohealthgroup.com/role/DiscontinuedOperationDetails",
"longName": "996021 - Disclosure - Discontinued Operation (Details)", "shortName": "Discontinued Operation
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"50", "firstAnchor": { "contextRef": "c101", "name": "us-
gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "usd", "xsiNil": "false", "lang": null,
"decimals": "0", "ancestors": ["p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
"div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c101", "name": "us-
gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "usd", "xsiNil": "false", "lang": null,
"decimals": "0", "ancestors": ["p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
"div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }
" }, "R51": { "role": "http://www.aksohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable", "longName":

"996022 - Disclosure - Discontinued Operation (Details) - \u200bSchedule of Discontinued Operations",
"shortName": "Discontinued Operation (Details) - \u200bSchedule of Discontinued Operations", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": {
"contextRef": "c103", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd",
"xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-
gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html"], "reportCount":
1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"c103", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil":
"false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-
gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html"], "reportCount":
1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R52": { "role":
"http://www.akshealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable", "longName": "996023 - Disclosure -
Discontinued Operation (Details) - \u200bSchedule of Assets and Liabilities", "shortName": "Discontinued Operation
(Details) - \u200bSchedule of Assets and Liabilities", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c5", "name": "us-
gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false",
"lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body",
"html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } },
"uniqueAnchor": { "contextRef": "c5", "name": "us-
gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false",
"lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body",
"html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R53": {
"role": "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable", "longName":
"996024 - Disclosure - Discontinued Operation (Details) - Schedule of Loss on Sale of Discontinued Operations",
"shortName": "Discontinued Operation (Details) - Schedule of Loss on Sale of Discontinued Operations", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": {
"contextRef": "c106", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
"unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation",
"ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "c106", "name": "us-
gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false",
"lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body",
"html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R54": {
"role": "http://www.akshealthgroup.com/role/ScheduleofAccountsReceivableNetTable", "longName": "996025 -
Disclosure - Accounts Receivable, Net (Details) - \u200bSchedule of Accounts Receivable, Net", "shortName":
"Accounts Receivable, Net (Details) - \u200bSchedule of Accounts Receivable, Net", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": {
"contextRef": "c4", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang":
null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-
gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-
gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-
20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-
gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors":
["td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-
gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-
20f_akshealth.htm", "first": true, "unique": true } }, "R55": { "role":
"http://www.akshealthgroup.com/role/ScheduleofPrepaymentsandOtherAssetsTable", "longName": "996026 -
Disclosure - Prepayments and Other Assets, Net (Details) - \u200bSchedule of Prepayments and Other Assets",
"shortName": "Prepayments and Other Assets, Net (Details) - \u200bSchedule of Prepayments and Other Assets",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55",
"firstAnchor": { "contextRef": "c4", "name": "us-gaap:Supplies", "unitRef": "usd", "xsiNil": "false", "lang": null,
"decimals": "0", "ancestors": ["td", "tr", "table", "us-
gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-
gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-
20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-
gaap:Supplies", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-
gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-
gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-
20f_akshealth.htm", "first": true, "unique": true } }, "R56": { "role":
"http://www.akshealthgroup.com/role/InventoriesDetails", "longName": "996027 - Disclosure - Inventories
(Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c4", "name": "us-
gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p",
"us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-
20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-
gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p",
"us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-
20f_akshealth.htm", "first": true, "unique": true } }, "R57": { "role":
"http://www.akshealthgroup.com/role/LoanReceivablesDetails", "longName": "996028 - Disclosure - Loan
Receivables (Details)", "shortName": "Loan Receivables (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c5", "name": "us-
gaap:LoansReceivableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "5",
"ancestors": ["p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html"],
"reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c5", "name": "us-gaap:LoansReceivableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang":
null, "decimals": "5", "ancestors": ["p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
"div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }
}, "R58": { "role": "http://www.akshealthgroup.com/role/ScheduleofLoanReceivablesTable", "longName": "996029 -

Disclosure - Loan Receivables (Details) - Schedule of Loan Receivables", "shortName": "Loan Receivables (Details) - Schedule of Loan Receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:OtherReceivablesGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c5", "name": "us-gaap:OtherReceivablesGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails", "longName": "996030 - Disclosure - Prepaid Consideration (Details)", "shortName": "Prepaid Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": ["p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": ["p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.akshealthgroup.com/role/RightofUseLeaseAssetsDetails", "longName": "996031 - Disclosure - Right of Use Lease Assets (Details)", "shortName": "Right of Use Lease Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c111", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ahg:RightOfUseLeaseAssetTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c111", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ahg:RightOfUseLeaseAssetTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.akshealthgroup.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable", "longName": "996032 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - u200bSchedule of Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities (Details) - u200bSchedule of Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:AccruedPayrollTaxesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:AccruedPayrollTaxesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails", "longName": "996033 - Disclosure - Related Party Balances and Transactions (Details)", "shortName": "Related Party Balances and Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c118", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c118", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.akshealthgroup.com/role/EmployeeBenefitsDetails", "longName": "996034 - Disclosure - Employee Benefits (Details)", "shortName": "Employee Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.akshealthgroup.com/role/ScheduleofTaxesPayableTable", "longName": "996035 - Disclosure - Taxes Payable (Details) - Schedule of Taxes Payable", "shortName": "Taxes Payable (Details) - Schedule of Taxes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:AccruedIncomeTaxesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ahg:ScheduleOfCurrentTaxesPayableTableTextBlock", "ahg:TaxesPayableCurrentDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:AccruedIncomeTaxesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ahg:ScheduleOfCurrentTaxesPayableTableTextBlock", "ahg:TaxesPayableCurrentDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0208034-20f_akshealth.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.akshealthgroup.com/role/IncomeTaxesDetails", "longName": "996036 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",

"unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ahg:IncomeTaxLiabilityMaximumAmountOfUnderpayment", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "unique": true } }, "R66": { "role": "http://www.aksohealthgroup.com/role/ScheduleofComponentsofIncomeTaxExpensesTable", "longName": "996037 - Disclosure - Income Taxes (Details) - Schedule of Components of Income Tax Expenses", "shortName": "Income Taxes (Details) - Schedule of Components of Income Tax Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.aksohealthgroup.com/role/ScheduleofReconcilethePRCStatutoryRatestotheCompany'sEffectiveTaxRateTable", "longName": "996038 - Disclosure - Income Taxes (Details) - Schedule of Reconciles the PRC Statutory Rates to the Company's Effective Tax Rate", "shortName": "Income Taxes (Details) - Schedule of Reconciles the PRC Statutory Rates to the Company's Effective Tax Rate", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.aksohealthgroup.com/role/ScheduleofOutstandingSharesforBasicandDilutedNetEarningsPerShareTable", "longName": "996039 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Outstanding Shares for Basic and Diluted Net Earnings Per Share", "shortName": "Earnings (Loss) Per Share (Details) - Schedule of Outstanding Shares for Basic and Diluted Net Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.aksohealthgroup.com/role/ShareholdersEquityDetails", "longName": "996040 - Disclosure - Shareholders' Equity (Details)", "shortName": "Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c140", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "unique": true } }, "R70": { "role": "http://www.aksohealthgroup.com/role/ScheduleofWarrantsOutstandingTable", "longName": "996041 - Disclosure - Shareholders' Equity (Details) - u200bSchedule of Warrants Outstanding", "shortName": "Shareholders' Equity (Details) - u200bSchedule of Warrants Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c5", "name": "ahg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrants", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ahg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrants", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "unique": true } }, "R71": { "role": "http://www.aksohealthgroup.com/role/ScheduleofWarrantsExercisableTable", "longName": "996042 - Disclosure - Shareholders' Equity (Details) - Schedule of Warrants Exercisable", "shortName": "Shareholders' Equity (Details) - Schedule of Warrants Exercisable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c173", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c173", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.aksohealthgroup.com/role/TreasuryStockDetails", "longName": "996043 - Disclosure - Treasury Stock (Details)", "shortName": "Treasury Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c183", "name":

"srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:TreasuryStockTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c183", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:TreasuryStockTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.aksohealthgroup.com/role/RestrictedNetAssetsDetails", "longName": "996044 - Disclosure - Restricted Net Assets (Details)", "shortName": "Restricted Net Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:RestrictedAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:RestrictedAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.aksohealthgroup.com/role/SubsequentEventsDetails", "longName": "996045 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c0", "name": "ahg:RegisteredCapitalPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true }, "uniqueAnchor": { "contextRef": "c187", "name": "us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "unique": true } }, "R75": { "role": "http://www.aksohealthgroup.com/role/CondensedFinancialInformationOfTheParentCompanyDetails", "longName": "996046 - Disclosure - Condensed Financial Information of the Parent Company (Details)", "shortName": "Condensed Financial Information of the Parent Company (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:NoncontrollingInterestInVariableInterestEntity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:NoncontrollingInterestInVariableInterestEntity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.aksohealthgroup.com/role/ScheduleOfCondensedBalanceSheetsTable", "longName": "996047 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Balance Sheets", "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Balance Sheets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c206", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c206", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.aksohealthgroup.com/role/ScheduleOfCondensedBalanceSheetsTable_Parentheticals", "longName": "996048 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Balance Sheets (Parentheticals)", "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c206", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c206", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.aksohealthgroup.com/role/ScheduleOfCondensedStatementsofComprehensiveLossIncomeTable", "longName": "996049 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Statements of Comprehensive (Loss) Income", "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Statements of Comprehensive (Loss) Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c210", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c210", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0208034-20f_aksohealth.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.aksohealthgroup.com/role/ScheduleOfCondensedStatementsofCashFlowsTable", "longName": "996050 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Statements of Cash Flows", "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c210", "name": "us-

```

gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": { "tr": { "table": { "ix:continuation": { "ix:continuation": { "div": { "body": { "html": { "reportCount": 1, "baseRef": "ea0208034-20f-aksohealth.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c210", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": { "tr": { "table": { "ix:continuation": { "ix:continuation": { "div": { "body": { "html": { "reportCount": 1, "baseRef": "ea0208034-20f-aksohealth.htm", "first": true, "unique": true } } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": { } }, "us-gaap_AccountsAndNontradeReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndNontradeReceivableTextBlock", "presentation": { "http://www.aksohealthgroup.com/role/AccountsReceivableNet": { "lang": { "en-us": { "role": { "terseLabel": "ACCOUNTS RECEIVABLE, NET", "label": "Accounts and Nontrade Receivable [Text Block]", "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable." } } }, "auth_ref": { "r312", "r351" } }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet": { "http://www.aksohealthgroup.com/role/ScheduleofLoanReceivablesTable": { "lang": { "en-us": { "role": { "terseLabel": "Loan receivables", "verboseLabel": "Loan receivables \u2013 2013 current", "label": "Accounts and Other Receivables, Net, Current", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { } }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": { "http://www.aksohealthgroup.com/role/AccruedExpensesAndOtherCurrentLiabilities": { "lang": { "en-us": { "role": { "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": { "r452" } }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities [Abstract]" } } }, "auth_ref": { } }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": { } }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": { "http://www.aksohealthgroup.com/role/AccountsReceivableNetTables": { "lang": { "en-us": { "role": { "terseLabel": "\u2013 200b Schedule of Accounts Receivable, Net", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": { "r955" } }, "ahg_AccountsReceivableAndContractAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "AccountsReceivableAndContractAssetsCurrent", "crdr": "debit", "calculation": { "http://www.aksohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and contract assets, net", "documentation": "Accounts receivable and contract assets, net.", "label": "Accounts Receivable And Contract Assets Current" } } }, "auth_ref": { } }, "us-gaap_AccountsReceivableExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent", "crdr": "debit", "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofLoanReceivablesTable": { "lang": { "en-us": { "role": { "terseLabel": "Loan receivables \u2013 2013 non-current", "label": "Accounts Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount excluding accrued interest, after allowance for credit loss, of accounts receivable classified as noncurrent." } } }, "auth_ref": { "r954" } }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.aksohealthgroup.com/role/ScheduleofAccountsReceivableNetTable": { "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofAccountsReceivableNetTable": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": { "r226", "r314", "r801" } }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": { "http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Member]", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": { "r782" } }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "calculation": { "http://www.aksohealthgroup.com/role/ScheduleofAccountsReceivableNetTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {

```

["http://www.aksohealthgroup.com/role/ScheduleofAccountsReceivableNetTable"](http://www.aksohealthgroup.com/role/ScheduleofAccountsReceivableNetTable)], "lang": { "en-us": { "role": { "totalLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": { "r716", "r781", "r869", "r1038", "r1039" } }, "us-gaap_AccountsReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetAbstract", "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net [Abstract]" } } }, "auth_ref": { } }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": { "r945" } }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.aksohealthgroup.com/role/ScheduleofTaxesPayableTable": { "parentTag": "us-gaap_TaxesPayableCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofTaxesPayableTable": { "lang": { "en-us": { "role": { "terseLabel": "Other taxes (recovery) payable", "label": "Accrual for Taxes Other than Income Taxes, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r92", "r804", "r999" } }, "ahg_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.aksohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities" } } }, "auth_ref": { } }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.aksohealthgroup.com/role/ScheduleofTaxesPayableTable": { "parentTag": "us-gaap_TaxesPayableCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofTaxesPayableTable": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": { "r92", "r152" } }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": { } }, "us-gaap_AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": { "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and benefits", "label": "Accrued Payroll Taxes, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r92" } }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": { "lang": { "en-us": { "role": { "terseLabel": "Professional fees, other payable and accrued expenses", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r92" } }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 }, "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet": { "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": { "r22", "r23", "r108", "r228", "r628", "r659", "r660" } }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.aksohealthgroup.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "u200bAccumulated Other Comprehensive (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity

from transactions resulting from investments by owners and distributions to owners." } }], "auth_ref": ["r3", "r15", "r23", "r498", "r501", "r535", "r655", "r656", "r917", "r918", "r919", "r932", "r933", "r934", "r936"] }, "ahg_AdditionalNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "AdditionalNumberOfOrdinaryShares", "presentation": ["http://www.akshealthgroup.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional ordinary shares (in Shares)", "documentation": "Number of additional ordinary shares.", "label": "Additional NumberOf Ordinary Shares" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r102", "r848", "r1074"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.akshealthgroup.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r676", "r932", "r933", "r934", "r936", "r1012", "r1075"] }, "ahg_AdditionalShareParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "AdditionalShareParValue", "presentation": ["http://www.akshealthgroup.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional shares par value", "documentation": "Number of additional share par value.", "label": "Additional Share Par Value" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": ["http://www.akshealthgroup.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "crdr": "debit", "presentation": ["http://www.akshealthgroup.com/role/GoingConcernDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net cash provided by operating activities", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "documentation": "The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities." } } }, "auth_ref": ["r923"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.akshealthgroup.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r43", "r44", "r438"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.akshealthgroup.com/role/ConsolidatedCashFlow", "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net (loss) to net cash provided by (used in) operating activities:", "verboseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ahg_AdvertisingAndPromotionExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "AdvertisingAndPromotionExpensesPolicyTextBlock", "presentation": ["http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Advertising and promotion expenses", "documentation": "The disclosure of advertising and promotion expenses.", "label": "Advertising And Promotion Expenses Policy Text Block" } } }, "auth_ref": [] }, "ahg_AggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "AggregatePurchasePrice", "crdr": "credit", "presentation": ["http://www.akshealthgroup.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate purchase price (in Dollars)", "documentation": "Amount of aggregate purchase price.", "label": "Aggregate Purchase Price" } } }, "auth_ref": [] }, "ahg_AksoFirstHealthTreatmentCenterIncAksoFirstHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "AksoFirstHealthTreatmentCenterIncAksoFirstHealthMember", "presentation": ["http://www.akshealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable"], "lang": { "en-us": { "role": { "terseLabel": "Akso First Health Treatment Center Inc. (u201cAkso First Health\u201d) [Member]", "label": "Akso First Health Treatment Center Inc Akso First Health Member" } } }, "auth_ref": [] }, "ahg_AksoMedicalCloudLimitedAksoMedicalCloudMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "AksoMedicalCloudLimitedAksoMedicalCloudMember", "presentation": ["http://www.akshealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable"], "lang": { "en-us": { "role": { "terseLabel": "Akso Medical Cloud Limited (u201cAkso Medical Cloud\u201d)"

[Member]", "label": "Akso Medical Cloud Limited Akso Medical Cloud Member" } }], "auth_ref": [] },
 "ahg_AksoMedicareLimitedAksoMedicareMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.aksohealthgroup.com/20240331", "localname": "AksoMedicareLimitedAksoMedicareMember",
 "presentation": { "http://www.aksohealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable" },
 "lang": { "en-us": { "role": { "terseLabel": "Akso Medi-care Limited (u201cAkso Medi-care u201d) [Member]",
 "label": "Akso Medicare Limited Akso Medicare Member" } } }, "auth_ref": [] },
 "ahg_AksoOnlineMediTechCoLtdAksoOnlineMediTechMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.aksohealthgroup.com/20240331", "localname":
 "AksoOnlineMediTechCoLtdAksoOnlineMediTechMember", "presentation": {
 "http://www.aksohealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable" }, "lang": { "en-us": {
 "role": { "terseLabel": "Akso Online Medi Tech Co., Ltd. (u201cAkso Online Medi Tech u201d) [Member]", "label":
 "Akso Online Medi Tech Co Ltd Akso Online Medi Tech Member" } } }, "auth_ref": [] },
 "ahg_AksoOnlineMediTechMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.aksohealthgroup.com/20240331", "localname": "AksoOnlineMediTechMember", "presentation": {
 "http://www.aksohealthgroup.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Akso
 Online Medi Tech [Member]", "label": "Akso Online Medi Tech Member" } } }, "auth_ref": [] },
 "ahg_AksoRemoteMedicalConsultationCenterIncAksoRemoteMedicalMember": { "xbrltype": "domainItemType",
 "nsuri": "http://www.aksohealthgroup.com/20240331", "localname":
 "AksoRemoteMedicalConsultationCenterIncAksoRemoteMedicalMember", "presentation": {
 "http://www.aksohealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable" }, "lang": { "en-us": {
 "role": { "terseLabel": "Akso Remote Medical Consultation Center Inc. (u201cAkso Remote Medical u201d)
 [Member]", "label": "Akso Remote Medical Consultation Center Inc Akso Remote Medical Member" } } }, "auth_ref":
 [] }, "ahg_AksoRemoteMedicalMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.aksohealthgroup.com/20240331", "localname": "AksoRemoteMedicalMember", "presentation": {
 "http://www.aksohealthgroup.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Akso
 Remote Medical [Member]", "label": "Akso Remote Medical Member" } } }, "auth_ref": [] }, "us-
 gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "calculation": {
 "http://www.aksohealthgroup.com/role/ScheduleofAccountsReceivableNetTable": { "parentTag": "us-
 gaap_AccountsReceivableNet", "weight": -1.0, "order": 2.0 } }, "presentation": {
 "http://www.aksohealthgroup.com/role/ScheduleofAccountsReceivableNetTable" }, "lang": { "en-us": { "role": {
 "negatedLabel": "Allowance for uncollectible accounts receivable", "label": "Accounts Receivable, Allowance for
 Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": {
 "r229", "r315", "r354", "r357", "r359", "r1039" } }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": {
 "http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Allowance for uncollectible accounts receivable", "label": "Accounts Receivable, Allowance
 for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified
 as current." } } }, "auth_ref": { "r229", "r315", "r354" } }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent":
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AllowanceForDoubtfulOtherReceivablesCurrent", "crdr": "credit", "calculation": {
 "http://www.aksohealthgroup.com/role/ScheduleofPrepaymentsandOtherAssetsTable": { "parentTag": "us-
 gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": {
 "http://www.aksohealthgroup.com/role/ScheduleofPrepaymentsandOtherAssetsTable" }, "lang": { "en-us": { "role": {
 "negatedLabel": "Allowance", "label": "Allowance for Credit Loss, Receivable, Other, Current", "documentation":
 "Amount of allowance for credit loss on receivable, classified as other and current." } } }, "auth_ref": { "r227" } },
 "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
 "AmendmentFlag", "presentation": { "http://www.aksohealthgroup.com/role/DocumentAndEntityInformation" },
 "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation":
 "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref":
 [] }, "ahg_AmericanDepositorySharesMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.aksohealthgroup.com/20240331", "localname": "AmericanDepositorySharesMember", "presentation": {
 "http://www.aksohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "American Depository Shares [Member]", "label": "American Depository Shares Member" } } }, "auth_ref": [] },
 "ahg_AmericanDepositorySharesoneAmericanDepositoryShareRepresentingThreeOrdinarySharesParValueUS00001Pe
 f": { "xbrltype": "domainItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname":
 "AmericanDepositorySharesoneAmericanDepositoryShareRepresentingThreeOrdinarySharesParValueUS00001PerSha
 re", "presentation": { "http://www.aksohealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": {
 "role": { "terseLabel": "American depository shares (one American depository share representing three Class A
 ordinary shares, par value US\$0.0001 per share)", "label": "American Depository Sharesone American Depository
 Share Representing Three Ordinary Shares Par Value US00001 Per Share Member" } } }, "auth_ref": [] },
 "ahg_AmericanDepositorySharesMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.aksohealthgroup.com/20240331", "localname": "AmericanDepositorySharesMember", "presentation": {
 "http://www.aksohealthgroup.com/role/TreasuryStockDetails" }, "lang": { "en-us": { "role": { "terseLabel": "American
 Depository Member", "verboseLabel": "American Depository Shares [Member]", "label": "American Depository
 Shares Member" } } }, "auth_ref": [] }, "ahg_AmountNotCoveredByIssuanceInPrc": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname":
 "AmountNotCoveredByIssuanceInPrc", "crdr": "debit", "presentation": {
 "http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Amount not covered by issuance", "documentation": "Amount not covered by issuance in
 prc", "label": "Amount Not Covered By Issuance In Prc" } } }, "auth_ref": [] }, "us-
 gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries", "crdr": "debit", "presentation": {
 "http://www.aksohealthgroup.com/role/RestrictedNetAssetsDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Restricted net assets", "label": "Amount of Restricted Net Assets for Consolidated and Unconsolidated
 Subsidiaries", "documentation": "Amount of restricted net assets of consolidated and unconsolidated subsidiaries as

of the end of the most recently completed fiscal year." } } }, "auth_ref": { "r257" } }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash consideration (in Dollars)", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": { "r833", "r1009", "r1010", "r1011" } }, "us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredOtherAssets", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails", "lang": { "en-us": { "role": { "terseLabel": "Total consideration (in Dollars)", "label": "Asset Acquisition, Consideration Transferred, Other Assets", "documentation": "Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash." } } }, "auth_ref": { "r1009", "r1010", "r1011" } }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable", "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r150", "r165", "r222", "r258", "r294", "r298", "r306", "r307", "r350", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r491", "r495", "r510", "r622", "r721", "r811", "r812", "r848", "r876", "r966", "r967", "r1027" } }, "ahg_AssetsAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "AssetsAbstract0", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable", "lang": { "en-us": { "role": { "terseLabel": "ASSETS:", "label": "Assets Abstract0" } } }, "auth_ref": { "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT ASSETS", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r217", "r234", "r258", "r350", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r491", "r495", "r510", "r848", "r966", "r967", "r1027" } }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": { "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Current assets held for sale - discontinued operation", "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Other, Current", "documentation": "Amount of other assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": { "r129" } }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "parentTag": "ahg_DisposalGroupIncludingDiscontinuedOperationNetAssets", "weight": 1.0, "order": 1.0 }, "http://www.akshealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable", "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable", "lang": { "en-us": { "role": { "totalLabel": "Current assets held for sale-discontinued operation", "terseLabel": "Total assets", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r2", "r71", "r85", "r130", "r132", "r215", "r216" } }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Assets and Liabilities [Abstract]" } } }, "auth_ref": { "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation", "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": { "r881", "r882", "r883" } }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation", "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": { "r881", "r882", "r883" } }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation", "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": { "r881", "r882", "r883" } } }, "ahg_August92021WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "August92021WarrantsMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsExercisableTable", "lang": { "en-us": { "role": { "terseLabel": "August 9, 2021 Warrants [Member]", "label": "August92021 Warrants Member" } } }, "auth_ref": { "ahg_AverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "AverageRemainingContractualLife", "presentation": {

["http://www.akohealthgroup.com/role/ScheduleofWarrantsExercisableTable"](http://www.akohealthgroup.com/role/ScheduleofWarrantsExercisableTable)], "lang": { "en-us": { "role": { "terseLabel": "Average Remaining Contractual Life", "documentation": "Average remaining contractual life.", "label": "Average Remaining Contractual Life" } } }, "auth_ref": [] }, "us-gaap-AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": { "http://www.akohealthgroup.com/role/ScheduleofWarrantsExercisableTable"], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998"] }, "us-gaap-BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": { "http://www.akohealthgroup.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap-BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": { "http://www.akohealthgroup.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r371", "r372", "r373", "r374", "r375", "r487", "r829", "r830"] }, "us-gaap-BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": { "http://www.akohealthgroup.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r45", "r46", "r371", "r372", "r373", "r374", "r375", "r487", "r829", "r830"] }, "us-gaap-BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "presentation": { "http://www.akohealthgroup.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity interest rate", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination." } } }, "auth_ref": [] }, "dei-BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": { "http://www.akohealthgroup.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": ["r882", "r883"] }, "ahg-BusinessDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname": "BusinessDescriptionAbstract", "lang": { "en-us": { "role": { "label": "Business Description [Abstract]" } } }, "auth_ref": [] }, "us-gaap-BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": { "http://www.akohealthgroup.com/role/BusinessDescription"], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS DESCRIPTION", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r69", "r125", "r126"] }, "currency-CNY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "CNY", "presentation": { "http://www.akohealthgroup.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "PRC [Member]", "label": "China, Yuan Renminbi" } } }, "auth_ref": [] }, "us-gaap-Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.akohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r171", "r626", "r687", "r715", "r848", "r876", "r911"] }, "us-gaap-CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.akohealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab { "parentTag": "us-gaap-OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akohealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.akohealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable", "http://www.akohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab"], "lang": { "en-us": { "role": { "periodStartLabel": "CASH-beginning of year", "periodEndLabel": "CASH-end of year", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r28", "r220", "r799"] }, "us-gaap-CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://www.akohealthgroup.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel":

"Cash and cash equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": { "r29" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "periodStartLabel": "CASH AND CASH EQUIVALENTS \u2013 beginning of year", "periodEndLabel": "CASH AND CASH EQUIVALENTS \u2013 end of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r28", "r121", "r254" } } }, "ahg_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingContinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingContinuedOperations", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents of continuing operations, at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Continued Operations" } } }, "auth_ref": { "r28", "r121", "r254" } } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Less: cash and cash equivalents of discontinued operations at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r28", "r121", "r254" } } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRate", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" }, "lang": { "en-us": { "role": { "totalLabel": "NET (DECREASE) IN CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r1", "r121" } } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRate", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "totalLabel": "NET INCREASE (DECREASE) IN CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r1", "r121" } } }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": {

"role": { "terseLabel": "Cash and cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } }, "auth_ref": { "r911", "r1037" } }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Net cash provided by financing activities from discontinued operations", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } }, "auth_ref": { "r121" } }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Net cash provided by investing activities from discontinued operations", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } } }, "auth_ref": { "r84", "r121" } }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Net cash provided by operating activities from discontinued operations", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } } }, "auth_ref": { "r84", "r121" } }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } } }, "auth_ref": { } }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails": { "http://www.akshealthgroup.com/role/TreasuryStockDetails": { "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } } }, "auth_ref": { "r181", "r223", "r224", "r225", "r258", "r283", "r284", "r286", "r288", "r296", "r297", "r350", "r383", "r385", "r386", "r387", "r390", "r391", "r410", "r411", "r414", "r417", "r424", "r510", "r665", "r666", "r667", "r668", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r688", "r707", "r730", "r753", "r773", "r774", "r775", "r776", "r777", "r888", "r926", "r937" } }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails": { "lang": { "en-us": { "role": { "label": "Shareholders' Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": { "r223", "r224", "r225", "r296", "r410", "r411", "r412", "r414", "r417", "r422", "r424", "r665", "r666", "r667", "r668", "r821", "r888", "r926" } }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails": { "http://www.akshealthgroup.com/role/WarrantOrRightAxis": { "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } } }, "auth_ref": { "r42" } }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails": { "http://www.akshealthgroup.com/role/WarrantOrRightDomain": { "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } } }, "auth_ref": { } }, "ahg_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase price per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights" } } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": { "http://www.akshealthgroup.com/role/ScheduleOfWarrantsExercisableTable":

<http://www.aksohealthgroup.com/role/ShareholdersEquityDetails>], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "verboseLabel": "Initial exercise", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": { "r425" } }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofWarrantsExercisableTable" }, "lang": { "en-us": { "role": { "label": "Schedule of Warrants Exercisable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofWarrantsExercisableTable" }, "lang": { "en-us": { "role": { "terseLabel": "Warrants exercisable in ordinary shares", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://www.aksohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of shares to purchase warrants (in Shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": { "r425" } }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": { "http://www.aksohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Warrants outstanding (in Shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofWarrantsExercisableTable" }, "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": { "r42" } }, "us-gaap_CommercialLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialLoanMember", "presentation": { "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Commercial Loan [Member]", "label": "Commercial Loan [Member]", "documentation": "A loan, whether secured or unsecured, to a company for purposes such as seasonal working capital needs, inventory financing, equipment purchases and acquisitions." } } }, "auth_ref": { } }, "ahg_CommissionRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "CommissionRevenueMember", "presentation": { "http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Commission Revenue [Member]", "label": "Commission Revenue Member" } } }, "auth_ref": { } }, "ahg_CommissionServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "CommissionServicesMember", "presentation": { "http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Commission Services [Member]", "label": "Commission Services Member" } } }, "auth_ref": { } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 20)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r97", "r155", "r625", "r706" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": { } }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://www.aksohealthgroup.com/role/CommitmentsandContingencies" }, "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r135", "r377", "r378", "r783", "r957", "r962" } }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": { "http://www.aksohealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Class A Ordinary Shares [Member]", "verboseLabel": "Common Class A [Member]", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": { "r1075" } }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": { "http://www.aksohealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Class B Ordinary Shares [Member]", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": { "r1075" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://www.aksohealthgroup.com/role/ShareholdersEquityDetails", "http://www.aksohealthgroup.com/role/ShareholdersEquityType2or3",

["http://www.aksohealthgroup.com/role/SubsequentEventsDetails"](http://www.aksohealthgroup.com/role/SubsequentEventsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "verboseLabel": "Ordinary Shares [Member]", "netLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r866", "r867", "r868", "r870", "r871", "r872", "r873", "r932", "r933", "r936", "r1012", "r1071", "r1075" } }, "us-gaap-CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable_Parentheticals", "<http://www.aksohealthgroup.com/role/ShareholdersEquityDetails>", "[http://www.aksohealthgroup.com/role/SubsequentEventsDetails"](http://www.aksohealthgroup.com/role/SubsequentEventsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, par value (in Dollars per share)", "verboseLabel": "Ordinary shares, par value (in Dollars per share)", "netLabel": "Ordinary shares, par value", "label": "Ordinary share par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r100" } }, "us-gaap-CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable_Parentheticals", "[http://www.aksohealthgroup.com/role/ShareholdersEquityDetails"](http://www.aksohealthgroup.com/role/ShareholdersEquityDetails)], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares authorized", "verboseLabel": "Ordinary shares, shares authorized", "netLabel": "Ordinary shares, shares authorized (in Shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r100", "r707" } }, "us-gaap-CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "CommonStockSharesIssued", "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable_Parentheticals", "[http://www.aksohealthgroup.com/role/SubsequentEventsDetails"](http://www.aksohealthgroup.com/role/SubsequentEventsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares issued", "verboseLabel": "Ordinary shares, shares issued", "netLabel": "Ordinary shares, shares issued (in Shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r100" } }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable_Parentheticals", "<http://www.aksohealthgroup.com/role/ShareholdersEquityDetails>", "[http://www.aksohealthgroup.com/role/SubsequentEventsDetails"](http://www.aksohealthgroup.com/role/SubsequentEventsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares outstanding", "verboseLabel": "Ordinary shares, shares outstanding", "netLabel": "Ordinary shares, shares outstanding (in Shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r16", "r100", "r707", "r727", "r1075", "r1076" } }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "<http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet>": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 1.0 }, "<http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable>": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "<http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet>", "[http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable"](http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable)], "lang": { "en-us": { "role": { "terseLabel": "Ordinary share (\$0.0001 par value, 5,000,000,000 shares authorized, 438,336,843 and 69,763,933 shares issued, 437,170,960 and 68,598,050 shares outstanding as of March 31, 2024 and 2023, respectively)", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r100", "r627", "r848" } }, "us-gaap-CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": { "[http://www.aksohealthgroup.com/role/EmployeeBenefits"](http://www.aksohealthgroup.com/role/EmployeeBenefits)], "lang": { "en-us": { "role": { "terseLabel": "EMPLOYEE BENEFITS", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": { "r140", "r141", "r142", "r143" } }, "us-gaap-CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": { "r140", "r141", "r142", "r143" } }, "us-gaap-ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "<http://www.aksohealthgroup.com/role/ConsolidatedIncomeStatement>": { "parentTag": null, "weight": null, "order": null, "root": true }, "<http://www.aksohealthgroup.com/role/ScheduleofCondensedStatementsOfComprehensiveLossIncomeTable>": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "<http://www.aksohealthgroup.com/role/ConsolidatedIncomeStatement>", "[http://www.aksohealthgroup.com/role/ScheduleofCondensedStatementsOfComprehensiveLossIncomeTable"](http://www.aksohealthgroup.com/role/ScheduleofCondensedStatementsOfComprehensiveLossIncomeTable)], "lang": { "en-us": { "role": { "totalLabel": "COMPREHENSIVE (LOSS) ATTRIBUTABLE TO AKSO\u00202019S SHAREHOLDERS", "terseLabel": "COMPREHENSIVE (LOSS)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": {

"r24", "r236", "r238", "r245", "r618", "r642", "r643" | }, "us-gaap-ComprehensiveIncomeNetOfTaxAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ComprehensiveIncomeNetOfTaxAbstract", "presentation": {
 "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement",
 "http://www.akohealthgroup.com/role/ScheduleOfCondensedStatementsofComprehensiveLossIncomeTable" | },
 "lang": { "en-us": { "role": { "terseLabel": "OTHER COMPREHENSIVE (LOSS)", "verboseLabel": "OTHER
 COMPREHENSIVE INCOME (LOSS)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent
 [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap-ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
 "calculation": { "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-
 gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 | }, "presentation": {
 "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement" | }, "lang": { "en-us": { "role": { "totalLabel":
 "COMPREHENSIVE (LOSS)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to
 Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and
 other events and circumstances from net income and other comprehensive income. Excludes changes in equity
 resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r61", "r145", "r236", "r238",
 "r244", "r617", "r642" |], "us-gaap-ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": {
 "http://www.akohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" | }, "lang": { "en-us": {
 "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of
 a disclosed concentration risk percentage." } } }, "auth_ref": ["r33", "r34", "r66", "r67", "r311", "r782" |], "us-
 gaap-ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": {
 "http://www.akohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" | }, "lang": { "en-us": {
 "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of
 concentration risk." } } }, "auth_ref": ["r33", "r34", "r66", "r67", "r311", "r662", "r782" |], "us-
 gaap-ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "ConcentrationRiskByTypeAxis", "presentation": {
 "http://www.akohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" | }, "lang": { "en-us": {
 "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for
 example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } },
 "auth_ref": ["r33", "r34", "r66", "r67", "r311", "r782", "r897" |], "ahg-ConcentrationRiskPercentage": { "xbrltype":
 "percentItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname":
 "ConcentrationRiskPercentage", "presentation": {
 "http://www.akohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" | }, "lang": { "en-us": {
 "role": { "terseLabel": "Concentration risk, percentage", "documentation": "For an entity that discloses a
 concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the
 equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration
 Risk Percentage" } } }, "auth_ref": [] }, "us-gaap-ConcentrationRiskPercentage1": { "xbrltype": "percentItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": {
 "http://www.akohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" | }, "lang": { "en-us": {
 "role": { "terseLabel": "Concentration of credit risk", "label": "Concentration Risk, Percentage", "documentation":
 "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the
 \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from
 the division." } } }, "auth_ref": ["r33", "r34", "r66", "r67", "r311" |], "us-gaap-ConcentrationRiskTypeDomain": {
 "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ConcentrationRiskTypeDomain", "presentation": {
 "http://www.akohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" | }, "lang": { "en-us": {
 "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a
 concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset,
 liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [
 "r33", "r34", "r66", "r67", "r311", "r782" |], "srt-CondensedBalanceSheetStatementTable": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedBalanceSheetStatementTable",
 "presentation": { "http://www.akohealthgroup.com/role/ScheduleOfCondensedBalanceSheetsTable",
 "http://www.akohealthgroup.com/role/ScheduleOfCondensedBalanceSheetsTable_Parentheticals" | }, "lang": { "en-
 us": { "role": { "label": "Condensed Balance Sheet Statement [Table]", "documentation": "Disclosure of information
 about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and
 consolidation eliminations." } } }, "auth_ref": ["r182", "r263", "r893" |],
 "srt-CondensedBalanceSheetStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/srt/2024", "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "presentation": {
 "http://www.akohealthgroup.com/role/ScheduleOfCondensedBalanceSheetsTable",
 "http://www.akohealthgroup.com/role/ScheduleOfCondensedBalanceSheetsTable_Parentheticals" | }, "lang": { "en-
 us": { "role": { "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "documentation": "Line items
 represent financial concepts included in a table. These concepts are used to disclose reportable information
 associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r182", "r263", "r893"
 |], "srt-CondensedCashFlowStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
 "localname": "CondensedCashFlowStatementTable", "presentation": {
 "http://www.akohealthgroup.com/role/ScheduleOfCondensedStatementsofCashFlowsTable" | }, "lang": { "en-us": {
 "role": { "label": "Condensed Cash Flow Statement [Table]", "documentation": "Disclosure of information about
 condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and
 consolidation eliminations." } } }, "auth_ref": ["r182", "r263", "r893" |],
 "srt-CondensedCashFlowStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/srt/2024", "localname": "CondensedCashFlowStatementsCaptionsLineItems", "presentation": {
 "http://www.akohealthgroup.com/role/ScheduleOfCondensedStatementsofCashFlowsTable" | }, "lang": { "en-us": {
 "role": { "label": "Condensed Cash Flow Statements, Captions [Line Items]", "documentation": "Line items represent
 financial concepts included in a table. These concepts are used to disclose reportable information associated with

domain members defined in one or many axes to the table." } } }, "auth_ref": { "r182", "r263", "r893" } }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Condensed Financial Information of the Parent Company [Abstract]" } } }, "auth_ref": { "r182", "r263", "r893" } }, "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompany", "lang": { "en-us": { "role": { "terseLabel": "CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY", "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]", "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document." } } }, "auth_ref": { "r263", "r893" } }, "ahg_CondensedFinancialInformationoftheParentCompanyDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CondensedFinancialInformationoftheParentCompanyDetailsLineItems", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyDetails", "lang": { "en-us": { "role": { "label": "Condensed Financial Information of the Parent Company [Line Items]" } } }, "auth_ref": { "r263", "r893" } }, "ahg_CondensedFinancialInformationoftheParentCompanyDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CondensedFinancialInformationoftheParentCompanyDetailsTable", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyDetails", "lang": { "en-us": { "role": { "label": "Condensed Financial Information of the Parent Company (Details) [Table]" } } }, "auth_ref": { "r263", "r893" } }, "srt_CondensedStatementOfComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedStatementOfComprehensiveIncomeTable", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofComprehensiveLossIncomeTable", "lang": { "en-us": { "role": { "label": "Condensed Statement of Comprehensive Income [Table]", "documentation": "Disclosure of information about condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations." } } }, "auth_ref": { "r182", "r263", "r893" } }, "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Condensed Statements of Comprehensive (Loss) Income", "label": "Condensed Statement of Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations." } } }, "auth_ref": { "r906", "r931" } }, "srt_CondensedStatementOfIncomeCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedStatementOfIncomeCaptionsLineItems", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofComprehensiveLossIncomeTable", "lang": { "en-us": { "role": { "label": "Condensed Statement of Income Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r182", "r263", "r893" } }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyDetails", "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable", "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable_Parentheticals", "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable", "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofComprehensiveLossIncomeTable", "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab", "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": { "r182", "r202", "r263", "r491", "r492", "r495", "r496", "r544", "r788", "r907", "r908", "r909", "r965", "r968", "r969" } }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyDetails", "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": { "r182", "r202", "r263", "r491", "r492", "r495", "r496", "r544", "r788", "r907", "r908", "r909", "r965", "r968", "r969" } }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel": "Basis of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": { "r51", "r805" } }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel": "Consolidated VIEs", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the

entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } }], "auth_ref": ["r47", "r54", "r56"] }, "dei_ContractPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContractPersonnelEmailAddress", "presentation": ["http://www.akshealthgroup.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Email Address", "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContractPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContractPersonnelName", "presentation": ["http://www.akshealthgroup.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel." } } }, "auth_ref": [] }, "ahg_ContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ContinuingOperationsAbstract", "presentation": ["http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Continuing operations", "label": "Continuing Operations Abstract" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer Liability Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r427", "r428", "r431"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r114", "r115", "r585"] }, "ahg_CurrentAssetsAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CurrentAssetsAbstract0", "presentation": ["http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab"], "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Current Assets Abstract0" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.akshealthgroup.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofComponentsofIncomeTaxExpensesTable": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.akshealthgroup.com/role/ScheduleofComponentsofIncomeTaxExpensesTable"], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": ["r470", "r929"] }, "ahg_CurrentLiabilitiesAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CurrentLiabilitiesAbstract0", "presentation": ["http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab"], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities", "label": "Current Liabilities Abstract0" } } }, "auth_ref": [] }, "ahg_CustomerConcentrationRiskOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CustomerConcentrationRiskOneMember", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "One Customer Concentration Risk [Member]", "label": "Customer Concentration Risk One Member" } } }, "auth_ref": [] }, "ahg_CustomerConcentrationRiskThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CustomerConcentrationRiskThreeMember", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Three Customer Concentration Risk [Member]", "label": "Customer Concentration Risk Three Member" } } }, "auth_ref": [] }, "ahg_CustomerConcentrationRiskTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CustomerConcentrationRiskTwoMember", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Two Customer Concentration Risk [Member]", "label": "Customer Concentration Risk Two Member" } } }, "auth_ref": [] }, "ahg_CustomersOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CustomersOneMember", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customers One [Member]", "label": "Customers One Member" } } }, "auth_ref": [] }, "ahg_CustomersThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CustomersThreeMember", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customers Three [Member]", "label": "Customers Three Member" } } }, "auth_ref": [] }, "ahg_CustomersTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "CustomersTwoMember", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customers Two [Member]", "label": "Customers Two Member" } } }, "auth_ref": [] }, "ahg_DebtInstrumentAccruedInterestPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DebtInstrumentAccruedInterestPayment", "crdr":

"debit", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unpaid interest", "documentation": "Debt instrument accrued interest payment", "label": "Debt Instrument Accrued Interest Payment" } } }, "auth_ref": { } }, "ahg_DebtInstrumentAgreementOfUnpaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DebtInstrumentAgreementOfUnpaidPrincipal", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unpaid principal amount", "documentation": "It represents outstanding balance of unpaid principal amount.", "label": "Debt Instrument Agreement Of Unpaid Principal" } } }, "auth_ref": { } }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": { "r19", "r91", "r92", "r151", "r154", "r263", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r816", "r817", "r818", "r819", "r820", "r846", "r927", "r958", "r959", "r960", "r1022", "r1023" } }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loan amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": { "r392", "r525", "r526", "r817", "r818", "r846" } }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Equity interest", "verboseLabel": "Annual interest rate", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": { "r94", "r404", "r1022" } }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": { "r19", "r263", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r816", "r817", "r818", "r819", "r820", "r846", "r927", "r958", "r959", "r960", "r1022", "r1023" } }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": { "http://www.akshealthgroup.com/role/PrepaymentsandOtherAssetsNetTables" }, "lang": { "en-us": { "role": { "terseLabel": "u200bSchedule of Prepayments and Other Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet, and other deferred costs." } } }, "auth_ref": { } }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofComponentsofIncomeTaxExpensesTable": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofComponentsofIncomeTaxExpensesTable" }, "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": { "r10", "r179", "r929" } }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/EmployeeBenefitsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Amount of contributions", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": { "r434" } }, "ahg_DenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DenominatorAbstract", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofOutstandingSharesforBasicandDilutedNetEarningsPerShareTable" }, "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Denominator Abstract" } } }, "auth_ref": { } }, "ahg_DepositsCoveredByInsuranceUpperLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DepositsCoveredByInsuranceUpperLimit", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Deposits covered by insurance", "documentation": "Deposits covered by insurance upper limit.", "label": "Deposits Covered By Insurance Upper Limit" } } }, "auth_ref": { } }, "us-gaap_DerivativeAverageExchangeRateFloor1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAverageExchangeRateFloor1", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofSpotExchangeRatesandAverageExchangeRatesTable" }, "lang": { "en-us": { "role": { "terseLabel": "Year average RMB", "label": "Derivative, Average Exchange Rate Floor", "documentation": "Average floor rate on a group of foreign currency derivatives for example, but not limited to, floors or collars." } } }, "auth_ref": { } }, "us-gaap_DerivativeNetAssetsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNetAssetsPercentage", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net assets percentage", "label": "Derivative, Net Assets, Percentage", "documentation": "Percentage of value of derivative contract to net assets." } } }, "auth_ref": { "r691", "r693", "r694", "r695", "r868", "r1072" } }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": {

"http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": { "r17", "r62", "r63", "r64", "r65", "r262", "r277" } }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": { "http://www.akshealthgroup.com/role/ScheduleOfDisaggregationOfRevenueTable"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r430", "r822", "r823", "r824", "r825", "r826", "r827", "r828" } }, "ahg_DisaggregationOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DisaggregationOfRevenueMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleOfDisaggregationOfRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Member]", "label": "Disaggregation Of Revenue Member" } } }, "auth_ref": { } }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": { "http://www.akshealthgroup.com/role/ScheduleOfDisaggregationOfRevenueTable"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r430", "r822", "r823", "r824", "r825", "r826", "r827", "r828" } }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": { "http://www.akshealthgroup.com/role/SummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r972" } }, "ahg_DiscontinuedOperationDetailsScheduleOfLossOnSaleOfDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DiscontinuedOperationDetailsScheduleOfLossOnSaleOfDiscontinuedOperationsLineItems", "presentation": { "http://www.akshealthgroup.com/role/ScheduleOfLossOnSaleOfDiscontinuedOperationsTable"], "lang": { "en-us": { "role": { "label": "Discontinued Operation (Details) - Schedule of Loss on Sale of Discontinued Operations [Line Items]" } } }, "auth_ref": { } }, "ahg_DiscontinuedOperationDetailsScheduleOfLossOnSaleOfDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DiscontinuedOperationDetailsScheduleOfLossOnSaleOfDiscontinuedOperationsTable", "presentation": { "http://www.akshealthgroup.com/role/ScheduleOfLossOnSaleOfDiscontinuedOperationsTable"], "lang": { "en-us": { "role": { "label": "Discontinued Operation (Details) - Schedule of Loss on Sale of Discontinued Operations [Table]" } } }, "auth_ref": { } }, "ahg_DiscontinuedOperationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DiscontinuedOperationDetailsTable", "presentation": { "http://www.akshealthgroup.com/role/DiscontinuedOperationDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operation (Details) [Table]" } } }, "auth_ref": { } }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow", "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement", "http://www.akshealthgroup.com/role/ScheduleOfLossOnSaleOfDiscontinuedOperationsTable"], "lang": { "en-us": { "role": { "terseLabel": "Loss from disposal of discontinued operations, net of income taxes", "negatedLabel": "Loss from disposal of discontinued operations", "verboseLabel": "Loss on sale of discontinued operations, net of taxes", "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": { "r72", "r74", "r76", "r87" } }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleOfDiscontinuedOperationsTable": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleOfDiscontinuedOperationsTable"], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income from discontinued operations", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": { "r72", "r73", "r74", "r75", "r76", "r82", "r113", "r1040" } }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) gain income from discontinued operations, net of income taxes", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax", "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal." } } }, "auth_ref": { "r72", "r73", "r87" } }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri":

["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "lang": { "en-us": { "role": { "negatedLabel": "Loss on sale of discontinued operations, net of taxes", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": { "r73", "r74", "r75", "r76", "r82", "r87", "r456", "r475", "r477" } }, "ahg_DiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DiscontinuedOperationsAbstract", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations", "label": "Discontinued Operations Abstract" } } }, "auth_ref": { } }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operation [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": { "http://www.akshealthgroup.com/role/DiscontinuedOperationDetails": { "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Held-for-Sale [Member]", "label": "Discontinued Operations, Held-for-Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": { "r6", "r7", "r215" } }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy": { "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Discontinued Operations, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": { "r13", "r21" } }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": { "http://www.akshealthgroup.com/role/DiscontinuedOperationDetails": { "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": { "r215" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 }, "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r2", "r71", "r85", "r132" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 }, "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current", "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r2", "r71", "r85", "r130", "r132" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "lang": { "en-us": { "role": { "terseLabel": "Account payable", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r2", "r71", "r85", "r130", "r132" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "calculation": {

"http://www.aksohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 },
"http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 }},
"presentation": { "http://www.aksohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable",
"http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable" }, "lang": { "en-us": {
"role": { "terseLabel": "Cash and cash equivalents", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r2", "r71", "r85", "r132" } }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr":
"debit", "presentation": { "http://www.aksohealthgroup.com/role/DiscontinuedOperationDetails",
"http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable" }, "lang": { "en-us": {
"role": { "terseLabel": "Consideration received", "verboseLabel": "Cash consideration", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": { }
"ahg_DisposalGroupIncludingDiscontinuedOperationNetAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.aksohealthgroup.com/20240331", "localname":
"DisposalGroupIncludingDiscontinuedOperationNetAssets", "crdr": "debit", "calculation": {
"http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": {
"http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable" }, "lang": { "en-us": {
"role": { "totalLabel": "Net assets", "documentation": "The amount of net assets.", "label": "Disposal Group Including Discontinued Operation Net Assets" } } }, "auth_ref": { }
us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
"crdr": "debit", "calculation": { "http://www.aksohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": {
"parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0,
"order": 2.0 } }, "presentation": { "http://www.aksohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable" },
"lang": { "en-us": { "role": { "terseLabel": "Operating costs and development", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r83" } }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.aksohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.aksohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable" }, "lang": { "en-us": { "role": {
"totalLabel": "(Loss) income from discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r83" } }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "crdr": "credit", "calculation": {
"http://www.aksohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "parentTag": "us-
gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.aksohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable" }, "lang": { "en-us": { "role": {
"terseLabel": "Amount due to related party", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r2", "r71", "r85", "r130", "r132" } }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "calculation": {
"http://www.aksohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "parentTag": "us-
gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 3.0 },
"http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "parentTag": "us-
gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 3.0 } },
"presentation": { "http://www.aksohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable",
"http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable" }, "lang": { "en-us": {
"role": { "terseLabel": "Prepayments and other assets", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r2", "r71", "r85", "r130", "r132" } }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "calculation": {
"http://www.aksohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "parentTag": "us-
gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 4.0 },
"http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "parentTag": "us-
gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 4.0 } },
"presentation": { "http://www.aksohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable",
"http://www.aksohealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable" }, "lang": { "en-us": {
"role": { "terseLabel": "Property, equipment and software, net", "verboseLabel": "Property, plant and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": {

["r2", "r71", "r85", "r130", "r132"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "en-us": { "role": { "terseLabel": "Net Revenues", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r83", "r216"] }, "ahg_DisposalGroupIncludingDiscontinuedOperationTaxBenefitPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DisposalGroupIncludingDiscontinuedOperationTaxBenefitPayable", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": { "en-us": { "role": { "terseLabel": "Tax (benefit) payable", "documentation": "It represents a reduction in the amount of tax which is disposal group including discontinued operation tax (benefit) payable.", "label": "Disposal Group Including Discontinued Operation Tax Benefit Payable" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": { "http://www.akshealthgroup.com/role/DiscontinuedOperation": { "en-us": { "role": { "terseLabel": "DISCONTINUED OPERATION", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r70", "r128"] }, "ahg_DispositionSPAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DispositionSPAMember", "presentation": { "http://www.akshealthgroup.com/role/DiscontinuedOperationDetails": { "en-us": { "role": { "terseLabel": "Disposition SPA [Member]", "label": "Disposition SPAMember" } } }, "auth_ref": [] }, "ahg_DividedSharesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DividedSharesValue", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails": { "en-us": { "role": { "terseLabel": "Divided shares value (in Dollars)", "documentation": "Represent the amount of divided shares value.", "label": "Divided Shares Value" } } }, "auth_ref": [] }, "ahg_DividedintoOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DividedintoOrdinaryShares", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails": { "en-us": { "role": { "terseLabel": "Divided into ordinary shares (in Shares)", "documentation": "Number of divided into ordinary shares.", "label": "Dividedinto Ordinary Shares" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing. This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other.'" } } }, "auth_ref": ["r882"] }, "ahg_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r881", "r882", "r883"] }, "dei_DocumentFinStmntErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmntErrorCorrectionFlag", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r881", "r882", "r883", "r885"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype":

"dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": {
 "http://www.akohealthgroup.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel":
 "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission
 types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of
 Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format
 of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype":
 "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement",
 "presentation": { "http://www.akohealthgroup.com/role/DocumentAndEntityInformation": { "lang": { "en-us": {
 "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement",
 "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [
 "r877"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri":
 "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": {
 "http://www.akohealthgroup.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel":
 "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that
 is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r882"]
 }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
 "localname": "DocumentTransitionReport", "presentation": {
 "http://www.akohealthgroup.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel":
 "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true
 only for a form used as a transition report." } } }, "auth_ref": ["r884"] }, "dei_DocumentType": { "xbrltype":
 "submissionItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": {
 "http://www.akohealthgroup.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel":
 "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K,
 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the
 word 'Other.'" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label":
 "Earnings (Loss) Per Share [Abstract]", "terseLabel": "Net (loss) per share" } } }, "auth_ref": [] }, "us-
 gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "EarningsPerShareBasic", "presentation": {
 "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement",
 "http://www.akohealthgroup.com/role/ScheduleOfOutstandingSharesforBasicandDilutedNetEarningsPerShareTable"
 }, "lang": { "en-us": { "role": { "terseLabel": "Basic (in Dollars per share)", "verboseLabel": "Basic (loss) per common
 share", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per
 each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r246", "r269",
 "r270", "r271", "r272", "r273", "r274", "r280", "r283", "r286", "r287", "r288", "r293", "r485", "r489", "r506", "r507",
 "r619", "r644", "r808"] }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EarningsPerShareBasicOtherDisclosuresAbstract", "presentation": {
 "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel":
 "Weighted average shares", "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]" } } }, "auth_ref": [] },
 "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "EarningsPerShareDiluted", "presentation": {
 "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement",
 "http://www.akohealthgroup.com/role/ScheduleOfOutstandingSharesforBasicandDilutedNetEarningsPerShareTable"
 }, "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Dollars per share)", "verboseLabel": "Diluted (loss) per
 common share", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the
 period available to each share of common stock or common unit outstanding during the reporting period and to
 each share or unit that would have been outstanding assuming the issuance of common shares or units for all
 dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r246",
 "r269", "r270", "r271", "r272", "r273", "r274", "r283", "r286", "r287", "r288", "r293", "r485", "r489", "r506", "r507",
 "r619", "r644", "r808"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": {
 "http://www.akohealthgroup.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel":
 "Earnings (loss) per share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure
 of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and
 participating security. Addresses all significant policy factors, including any antidilutive items that have been
 excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the
 balance sheet date of the latest reporting period but before the issuance of the financial statements." } } },
 "auth_ref": ["r31", "r32", "r290"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": {
 "http://www.akohealthgroup.com/role/EarningsLossPerShare", "lang": { "en-us": { "role": { "terseLabel":
 "EARNINGS (LOSS) PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire
 disclosure for earnings per share." } } }, "auth_ref": ["r279", "r289", "r291", "r292"] }, "us-
 gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposal6
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroup
 "crdr": "debit", "calculation": { "http://www.akohealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeR
 "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.akohealthgroup.com/role/ConsolidatedCashFlow": {
 "lang": { "en-us": { "role": { "terseLabel": "EFFECT OF EXCHANGE RATE CHANGE ON CASH", "label": "Effect of
 Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal
 Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate
 changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in
 foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is
 not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with
 general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly
 liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they
 present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1021"] },

"us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype":
 "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits", "weight": 1.0, "order": 5.0 } },
 "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "lang": { "en-us": { "role": { "negatedLabel": "PRC Income tax statutory rate", "label": "Effective Income Tax Rate
 Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal
 statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": { "r259", "r457", "r473", "r832" } },
 "ahg_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatesPercent": { "xbrltype":
 "percentItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRatesPercent", "presentation": {
 "http://www.akshealthgroup.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statutory
 income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income
 (loss)", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates Percent" } } },
 "auth_ref": { } }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
 "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits", "weight": 1.0, "order": 3.0 } },
 "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "lang": { "en-us": { "role": { "terseLabel": "Change in valuation allowance", "label": "Effective Income Tax Rate
 Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the
 difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by
 applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations
 attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": { "r460", "r832", "r930",
 "r1000" } },
 "ahg_EffectiveIncomeTaxRateReconciliationEffectOfTaxHolidayAndPreferentialStatutoryIncomeTaxRate": {
 "xbrltype": "percentItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "EffectiveIncomeTaxRateReconciliationEffectOfTaxHolidayAndPreferentialStatutoryIncomeTaxRate", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits", "weight": 1.0, "order": 1.0 } },
 "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "lang": { "en-us": { "role": { "terseLabel": "Effect of tax holiday and preferential tax rate", "documentation":
 "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense
 (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from
 continuing operations attributable to holiday and preferential statutory income tax rate.", "label": "Effective Income
 Tax Rate Reconciliation Effect Of Tax Holiday And Preferential Statutory Income Tax Rate" } } }, "auth_ref": { } },
 "ahg_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignLossesPercent": { "xbrltype":
 "percentItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignLossesPercent", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits", "weight": 1.0, "order": 2.0 } },
 "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "lang": { "en-us": { "role": { "terseLabel": "Non-deductible foreign losses", "documentation": "Percentage of the
 difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by
 applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations
 attributable to foreign losses.", "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Foreign
 Losses Percent" } } }, "auth_ref": { } },
 "ahg_EffectiveIncomeTaxRateReconciliationNondeductibleExpensesAndOthersPercent": { "xbrltype":
 "percentItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "EffectiveIncomeTaxRateReconciliationNondeductibleExpensesAndOthersPercent", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits", "weight": 1.0, "order": 4.0 } },
 "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "lang": { "en-us": { "role": { "terseLabel": "Non-deductible expenses and others", "documentation": "Percentage of
 the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed
 by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations
 attributable to nondeductible expenses and others.", "label": "Effective Income Tax Rate Reconciliation
 Nondeductible Expenses And Others Percent" } } }, "auth_ref": { } }, "us-
 gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofReconcilesthePRCStatutoryRatetotheCompanysEffectiveTaxRateT: {
 "lang": { "en-us": { "role": { "totalLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation,
 Tax Credit, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit)
 and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to
 pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research
 credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": { "r459", "r461", "r930",
 "r1000" } }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": { "xbrltype": "percentItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",

presentation": { "http://www.akshealthgroup.com/role/IncomeTaxDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Applicable tax rate", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits." } } }, "auth_ref": { "r832", "r930", "r1000", "r1001" } }, "us-gaap-EmployeeTrustAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeTrustAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefits [Abstract]" } } }, "auth_ref": { "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": { "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Three", "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": { "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://www.akshealthgroup.com/role/IncomeTaxDetails", "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate the filer category of the filer." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation": "Indicate the filing date of the document." } } }, "auth_ref": { "dei_EntityFilingDate": { "xbrltype": "filingDateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilingDate", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filing Date", "label": "Entity Filing Date", "documentation":

"Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r879" } },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { "r879" } }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r886" } }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r879" } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r879" } }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": { "r887" } }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-E, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": { "r887" } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails", "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3", "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r16", "r213", "r240", "r241", "r242", "r264", "r265", "r266", "r268", "r273", "r275", "r277", "r295", "r352", "r353", "r376", "r426", "r471", "r472", "r482", "r483", "r484", "r486", "r488", "r489", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r516", "r517", "r518", "r519", "r520", "r521", "r527", "r529", "r535", "r640", "r655", "r656", "r657", "r676", "r753" } }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": { "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails" }, "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": { "r347", "r348", "r349", "r481", "r890", "r891", "r892", "r1005", "r1006", "r1007", "r1008" } }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": { "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Equity interest", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": { "r347" } }, "us-gaap_ExcessStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExcessStockSharesIssued", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares (in Shares)", "label": "Excess Stock, Shares Issued", "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders." } } }, "auth_ref": { "r347" } }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": { "r12" } }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r355", "r356", "r360", "r361", "r362", "r363", "r364", "r365", "r408", "r422", "r503", "r509", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r565", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r641", "r814", "r836", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r849", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r949", "r950", "r951", "r952", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018" } }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyExchangeRateTranslation1", "presentation": {

<http://www.akshealthgroup.com/role/ScheduleofSpotExchangeRatesandAverageExchangeRatesTable>], "lang": { "en-us": { "role": { "terseLabel": "Year-end RMB", "label": "Foreign Currency Exchange Rate, Translation", "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency." } } }, "auth_ref": { "r522", "r523" } }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "en-us": { "role": { "terseLabel": "Exchange (loss) gain", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": { "r512", "r513", "r514", "r515", "r750" } }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": { "r511" } }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofComprehensiveLossIncomeTable": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofComprehensiveLossIncomeTable": { "en-us": { "role": { "terseLabel": "General and administrative", "negatedLabel": "General administrative expense and others", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": { "r118", "r732" } }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "en-us": { "role": { "totalLabel": "Gross Profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": { "r109", "r116", "r164", "r258", "r350", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r510", "r810", "r811", "r939", "r940", "r941", "r942", "r943", "r966" } }, "ahg_HexinECommerceCompanyLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "HexinECommerceCompanyLimitedMember", "presentation": { "http://www.akshealthgroup.com/role/DiscontinuedOperationDetails": { "en-us": { "role": { "terseLabel": "Hexin E Commerce Company Limited [Member]", "label": "Hexin ECommerce Company Limited Member" } } }, "auth_ref": { } }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": { "r881", "r882", "r883" } }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails": { "en-us": { "role": { "terseLabel": "Impairment loss", "label": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": { "r10", "r38", "r131", "r837" } }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": { "r0", "r134" } }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 }, "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "en-us": { "role": { "totalLabel": "NET (LOSS) FROM CONTINUING OPERATIONS", "terseLabel": "Net (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": { "r50", "r112", "r124", "r269", "r270", "r271", "r272", "r273", "r285", "r288", "r489" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr":

"credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": "http://www.akshealthgroup.com/role/IncomeTaxesDetails", "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before tax", "terseLabel": "(LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES", "verboseLabel": "Net (loss) income before taxes (in Dollars)", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": { "r110", "r159", "r164", "r620", "r635", "r810", "r811", "r939", "r940", "r941", "r942", "r943" } }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Basic (in Dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r112", "r160", "r246", "r267", "r269", "r270", "r271", "r272", "r273", "r283", "r286", "r287", "r485", "r489", "r507", "r619", "r1041" } }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r112", "r246", "r267", "r269", "r270", "r271", "r272", "r273", "r283", "r286", "r287", "r288", "r489", "r507", "r619", "r1041" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable", "http://www.akshealthgroup.com/role/ScheduleofOutstandingSharesforBasicandDilutedNetEarningsPerShareTable": { "lang": { "en-us": { "role": { "totalLabel": "Total (loss) gain from discontinued operations", "terseLabel": "Net income (loss) from discontinued operation attributable to Akso Health Group's 2019s shareholders", "verboseLabel": "Net income (loss) from discontinued operation", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": { "r72", "r73", "r74", "r75", "r76", "r87", "r216", "r478", "r636" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Basic (in Dollars per share)", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": { "r113", "r246", "r284", "r286", "r287", "r1035", "r1041" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Dollars per share)", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": { "r148", "r284", "r286", "r287" } }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfComprehensiveLossIncomeTable": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfComprehensiveLossIncomeTable": { "lang": { "en-us": { "role": { "terseLabel": "Equity in (loss) earnings of subsidiaries", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": { "r10", "r111", "r158", "r294", "r302", "r307", "r346", "r634" } }, "us-gaap_IncomeLossFromSubsidiariesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromSubsidiariesNetOfTax", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable": { "lang": { "en-us": { "role": { "negatedLabel": "Equity in loss of subsidiaries", "label": "Income (Loss) from Subsidiaries, Net of Tax", "documentation": "Amount after tax of income (loss) of subsidiary attributable to the parent entity." } } }, "auth_ref": { } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement

[Abstract]" } }], "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": ["http://www.akohealthgroup.com/role/DiscontinuedOperationDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r829", "r830"] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItem": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItem", "presentation": ["http://www.akohealthgroup.com/role/DiscontinuedOperationDetails", "http://www.akohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable"], "lang": { "en-us": { "role": { "label": "200bSchedule of Discontinued Operations [Line Items]", "terseLabel": "Discontinued Operation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": ["http://www.akohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r13", "r18", "r20", "r71", "r77", "r78", "r79", "r80", "r81", "r86", "r88", "r89", "r133"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.akohealthgroup.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r259", "r453", "r457", "r462", "r463", "r464", "r465", "r468", "r474", "r476", "r479", "r480", "r670", "r832"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": ["http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 3.0 }, "http://www.akohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": -1.0, "order": 2.0 }, "http://www.akohealthgroup.com/role/ScheduleofComponentsofIncomeTaxExpensesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement", "http://www.akohealthgroup.com/role/ScheduleofComponentsofIncomeTaxExpensesTable", "http://www.akohealthgroup.com/role/ScheduleofDiscontinuedOperationsTable"], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "PROVISION FOR INCOME TAXES", "verboseLabel": "Income tax provision", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r170", "r180", "r276", "r277", "r294", "r303", "r307", "r456", "r457", "r475", "r645", "r832"] }, "ahg_IncomeTaxLiabilityMaximumAmountOfUnderpayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname": "IncomeTaxLiabilityMaximumAmountOfUnderpayment", "crdr": "credit", "presentation": ["http://www.akohealthgroup.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income tax liability", "documentation": "Income tax liability, maximum amount of underpayment.", "label": "Income Tax Liability Maximum Amount Of Underpayment" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.akohealthgroup.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r239", "r454", "r455", "r465", "r466", "r467", "r469", "r664"] }, "ahg_IncomeTaxesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname": "IncomeTaxesDetailsTable", "presentation": ["http://www.akohealthgroup.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "auth_ref": [] }, "ahg_IncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname": "IncomeTaxesLineItems", "presentation": ["http://www.akohealthgroup.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Income Taxes [Line Items]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": ["http://www.akohealthgroup.com/role/ConsolidatedCashFlow", "http://www.akohealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income tax", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r30", "r123", "r925", "r1002", "r1003"] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": ["http://www.akohealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.akohealthgroup.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable and contract assets", "label": "Increase (Decrease) in Accounts and Other Receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from

customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } }
 }, "auth_ref": { "r9" } }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 },
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow":
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" }, "lang": { "en-us": {
 "role": { "terseLabel": "Accounts payable, accrued expenses and other current liabilities", "verboseLabel": "Accrued
 expenses and other current liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
 "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods
 and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": { "r9" } },
 "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "IncreaseDecreaseInAccruedTaxesPayable", "crdr": "debit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } },
 "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
 "terseLabel": "Taxes payable", "label": "Increase (Decrease) in Accrued Taxes Payable", "documentation": "The
 increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other
 taxes." } } }, "auth_ref": { "r922" } }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } },
 "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
 "terseLabel": "Contract liabilities", "label": "Increase (Decrease) in Contract with Customer Liability",
 "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which
 consideration has been received or is receivable." } } }, "auth_ref": { "r583", "r922" } }, "us-
 gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 10.0 } },
 "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
 "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase
 (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity,
 associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": { "r9" } }, "us-
 gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow":
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" }, "lang": { "en-us": {
 "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating
 Capital [Abstract]", "documentation": "Amount of increase (decrease) in operating capital." } } }, "auth_ref": { } }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" }, "lang": { "en-us": {
 "role": { "negatedLabel": "Interest payments on unsecured senior notes and short-term bank loan", "label":
 "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating
 assets classified as other." } } }, "auth_ref": { "r9" } }, "us-
 gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr":
 "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable":
 { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } },
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 9.0 } },
 "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow":
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" }, "lang": { "en-us": {
 "role": { "negatedLabel": "Prepayments and other assets", "negatedTerseLabel": "Prepayments and other assets",
 "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase
 (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": { "r9" } },
 "ahg_IncreasedAuthorizedSharesValue": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "IncreasedAuthorizedSharesValue", "crdr": "credit",
 "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Increased its authorized shares value (in Dollars)", "documentation": "Represent the amount of
 increased authorized shares value.", "label": "Increased Authorized Shares Value" } } }, "auth_ref": { } },
 "ahg_InsuranceCoverageUpperLimit": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "InsuranceCoverageUpperLimit", "crdr": "debit",
 "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang":
 { "en-us": { "role": { "terseLabel": "Insurance coverage upper limit", "documentation": "Insurance coverage upper
 limit.", "label": "Insurance Coverage Upper Limit" } } }, "auth_ref": { } }, "us-gaap_InterestExpense": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit",
 "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-
 gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel":
 "Finance cost", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest

expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": { "r294", "r298", "r301", "r304", "r307", "r524", "r811", "r812" } }, "ahg_InterestIncome1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "InterestIncome1Member", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest income [Member]", "label": "Interest Income1 Member" } } }, "auth_ref": { } }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofDiscontinuedOperationsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Interest Income (Expense), Operating", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": { "r616", "r940" } }, "us-gaap_InterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaid", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities." } } }, "auth_ref": { "r924" } }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r249", "r252", "r253" } }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" }, "lang": { "en-us": { "role": { "terseLabel": "Interest payable", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r92" } }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventories [Abstract]" } } }, "auth_ref": { } }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": { "http://www.akshealthgroup.com/role/Inventories" }, "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": { "r366" } }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/InventoriesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Inventory, cost of finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": { "r914" } }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryGross", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/InventoriesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Inventory, label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": { "r915" } }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r231", "r800", "r848" } }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": { "r172", "r219", "r230", "r366", "r367", "r368", "r584", "r806" } }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Investment Owned, Balance, Principal Amount", "documentation": "Amount of principal of investment owned." } } }, "auth_ref": { "r689", "r696", "r762", "r768", "r771", "r868" } }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Investments in subsidiaries, VIEs and VIEs\u2019 subsidiaries", "label": "Investments in and Advance

to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": { "r913" } },
"ahg_InvestorHoldingPercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.akssohealthgroup.com/20240331", "localname": "InvestorHoldingPercentage", "presentation": {
"http://www.akssohealthgroup.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investor
holding percentage", "documentation": "Ownership percentage of the FIE by foreign investors to qualify for
withholding tax rate limit for dividends paid by an FIE in China to its immediate holding company in Hong Kong.",
"label": "Investor Holding Percentage" } } }, "auth_ref": { } }, "ahg_January172024WarrantsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.akssohealthgroup.com/20240331", "localname":
"January172024WarrantsMember", "presentation": {
"http://www.akssohealthgroup.com/role/ScheduleofWarrantsExercisableTable" }, "lang": { "en-us": { "role": {
"terseLabel": "January 17, 2024 Warrants [Member]", "label": "January172024 Warrants Member" } } }, "auth_ref":
{ } }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"LegalEntityAxis", "presentation": { "http://www.akssohealthgroup.com/role/IncomeTaxesDetails",
"http://www.akssohealthgroup.com/role/ScheduleofNoncontrollingInterestTable",
"http://www.akssohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": {
"role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } },
"auth_ref": { } }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": {
"http://www.akssohealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel":
"Lease", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing
arrangement entered into by lessee." } } }, "auth_ref": { "r530" } }, "us-
gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LessorOperatingLeaseTermOfContract", "presentation": {
"http://www.akssohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Operating lease, term of contract", "label": "Lessor, Operating Lease, Term of Contract",
"documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r1025" } }, "us-
gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"Liabilities", "crdr": "credit", "calculation": { "http://www.akssohealthgroup.com/role/ConsolidatedBalanceSheet": {
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 },
"http://www.akssohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 },
"http://www.akssohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.akssohealthgroup.com/role/ConsolidatedBalanceSheet",
"http://www.akssohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable",
"http://www.akssohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab
, "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "terseLabel": "Total Liabilities", "label":
"Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise
providing economic benefit to others." } } }, "auth_ref": { "r19", "r91", "r92", "r93", "r95", "r96", "r97", "r98", "r258",
"r350", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r492", "r495", "r496", "r510", "r705",
"r809", "r876", "r966", "r1027", "r1028" } }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": {
"http://www.akssohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" }, "lang": { "en-us": { "role": {
"terseLabel": "LIABILITIES:", "label": "Liabilities [Abstract]" } } }, "auth_ref": { } }, "us-
gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {
"http://www.akssohealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null,
"root": true }, "http://www.akssohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag":
null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.akssohealthgroup.com/role/ConsolidatedBalanceSheet",
"http://www.akssohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" }, "lang": { "en-us": { "role": {
"totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS'2019 EQUITY", "terseLabel": "TOTAL LIABILITIES AND
SHEREHOLDERS'2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and
equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": {
"r106", "r157", "r631", "r848", "r928", "r953", "r1020" } }, "us-gaap_LiabilitiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit",
"calculation": { "http://www.akssohealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-
gaap_Liabilities", "weight": 1.0, "order": 1.0 },
"http://www.akssohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab
{ "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.akssohealthgroup.com/role/ConsolidatedBalanceSheet",
"http://www.akssohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab
, "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT LIABILITIES", "terseLabel": "Total Current
Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations
that are expected to be paid during the following twelve months or within one business cycle, if longer." } } },
"auth_ref": { "r93", "r218", "r258", "r350", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391",
"r492", "r495", "r496", "r510", "r848", "r966", "r1027", "r1028" } }, "us-gaap_LiabilitiesCurrentAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract",
"presentation": { "http://www.akssohealthgroup.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": {
"terseLabel": "CURRENT LIABILITIES:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": { } }, "us-
gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr":
"credit", "calculation": { "http://www.akssohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.akssohealthgroup.com/role/ScheduleofAssetsandLiabilitiesTable" }, "lang": { "en-us": { "role": {
"totalLabel": "Total liabilities held for sale-discontinued operation", "label": "Disposal Group, Including

Discontinued Operation, Liabilities, "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r2", "r71", "r85", "r132", "r215", "r216"] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable": { "parentTag": "ahg_DisposalGroupIncludingDiscontinuedOperationNetAssets", "weight": -1.0, "order": 2.0 }, "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.akshealthgroup.com/role/ScheduleofLossonSaleofDiscontinuedOperationsTable" }, "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "Current liabilities held for sale - discontinued operation", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r71", "r85", "r130", "r132", "r215", "r216"] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": { "http://www.akshealthgroup.com/role/LoanReceivables" }, "lang": { "en-us": { "role": { "terseLabel": "LOAN RECEIVABLES", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": ["r525", "r944"] }, "us-gaap_LoansReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansReceivableFairValueDisclosure", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/LoanReceivablesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Total loan receivables", "label": "Loans Receivable, Fair Value Disclosure", "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts." } } }, "auth_ref": ["r1019"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTerm", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loan term", "label": "Long-Term Debt, Term", "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1014", "r1015", "r1016"] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": ["r311", "r824", "r859", "r863", "r972", "r1042", "r1043", "r1044", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070"] }, "ahg_March52024WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "March52024WarrantsMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsExerciseTable" }, "lang": { "en-us": { "role": { "terseLabel": "March 5, 2024 Warrants [Member]", "label": "March52024 Warrants Member" } } }, "auth_ref": [] }, "us-gaap_MarketingAndAdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Advertising and promotion expense", "label": "Marketing and Advertising Expense", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." } } }, "auth_ref": ["r118"] }, "ahg_MaximumCompensationLimitByHongKongDepositProtectionBoard": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "MaximumCompensationLimitByHongKongDepositProtectionBoard", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum compensation", "documentation": "Maximum compensation limit by hong kong deposit protection board.", "label": "Maximum Compensation Limit By Hong Kong Deposit Protection Board" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.akshealthgroup.com/role/IncomeTaxesDetails", "http://www.akshealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable", "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r183", "r185", "r187", "r188", "r190", "r211", "r212", "r379", "r380", "r381", "r382", "r435", "r451", "r508", "r582", "r653", "r654", "r661", "r697", "r698", "r761", "r764", "r766", "r767", "r770", "r794", "r795", "r813", "r821", "r831", "r839", "r840", "r844", "r845", "r860", "r970", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034"] }, "ahg_MinimumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "MinimumAmount", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Minimum amount (in Yuan Renminbi)", "documentation": "Minimum amount.", "label": "Minimum Amount" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.akshealthgroup.com/role/IncomeTaxesDetails", "http://www.akshealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable", "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r183", "r185", "r187", "r188", "r190", "r211", "r212", "r379", "r380", "r381", "r382", "r435", "r451", "r508", "r582", "r653", "r654", "r661", "r697", "r698", "r761", "r764", "r766", "r767", "r770", "r794", "r795", "r813"] }

"r821", "r831", "r839", "r840", "r844", "r860", "r970", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034" | }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.akshealthgroup.com/role/ScheduleofNoncontrollingInterestTable" | }, "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest", "verboseLabel": "We Healthy", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": { "r105", "r156", "r258", "r350", "r383", "r385", "r386", "r387", "r390", "r391", "r510", "r630", "r709" | }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" | }, "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": { "r311", "r824", "r859", "r863", "r972", "r1042", "r1043", "r1044", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070" | }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchange", "weight": 1.0, "order": 2.0 }, "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchange", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow", "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable", "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab" | }, "lang": { "en-us": { "role": { "totalLabel": "NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES", "terseLabel": "Net cash provided by (used in) financing activities", "verboseLabel": "NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r251" | }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow", "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" | }, "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" | } }, "auth_ref": { } }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" | }, "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities from continuing operations", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r921" | }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchange", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow", "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab" | }, "lang": { "en-us": { "role": { "totalLabel": "NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES", "terseLabel": "Net cash (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r251" | }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" | }, "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" | } }, "auth_ref": { } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" | }, "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities from continuing operations", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r921" | }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"NetCashProvidedByUsedInOperatingActivities", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeF
 weight": 1.0, "order": 1.0 },
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable": { "parentTag": "us-
 gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeF
 weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow",
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable",
 "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab
 l", "lang": { "en-us": { "role": { "totalLabel": "NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES",
 "terseLabel": "Net cash provided by (used in) operating activities", "verboseLabel": "NET CASH (USED IN)
 OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount
 of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows
 include transactions, adjustments, and changes in value not defined as investing or financing activities." } } },
 "auth_ref": { "r121", "r122", "r124" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow",
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" }, "lang": { "en-us": {
 "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in)
 Operating Activities [Abstract]" } } }, "auth_ref": { } }, "us-
 gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "totalLabel": "Net cash
 provided by (used in) operating activities from continuing operations", "label": "Net Cash Provided by (Used in)
 Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating
 activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and
 changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r121", "r122", "r124" } }, "us-
 gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "NetIncomeLoss", "crdr": "credit", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 },
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order":
 null, "root": true } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement",
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable",
 "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab
 l", "http://www.akshealthgroup.com/role/ScheduleofOutstandingSharesforBasicandDilutedNetEarningsPerShareTable"
 l, "lang": { "en-us": { "role": { "totalLabel": "NET (LOSS) ATTRIBUTABLE TO AKSO\u2019S SHAREHOLDERS",
 "terseLabel": "Net loss", "verboseLabel": "Net loss attributable to Akso Health Group\u2019s shareholders",
 "netLabel": "Net (loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit
 or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r117", "r124",
 "r161", "r216", "r235", "r237", "r242", "r258", "r267", "r269", "r270", "r271", "r272", "r273", "r276", "r277", "r285",
 "r350", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r485", "r489", "r507", "r510", "r639",
 "r729", "r751", "r752", "r874", "r966" } }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss",
 "weight": -1.0, "order": 2.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel":
 "Less: net (loss) income attributable to non-controlling interest", "label": "Net Income (Loss) Attributable to
 Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." }
 } }, "auth_ref": { "r60", "r147", "r235", "r237", "r273", "r276", "r277", "r638", "r919" } }, "us-
 gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "presentation":
 {
 "http://www.akshealthgroup.com/role/ScheduleofOutstandingSharesforBasicandDilutedNetEarningsPerShareTable"
 l, "lang": { "en-us": { "role": { "terseLabel": "Net loss from continuing operation attributable to Akso Health
 Group\u2019s shareholder", "label": "Net Income (Loss) from Continuing Operations Available to Common
 Shareholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on
 preferred stock and participating securities, of income (loss) from continuing operations available to common
 shareholders." } } }, "auth_ref": { "r281", "r288" } }, "us-gaap_NetInvestmentInLease": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentInLease", "crdr": "debit",
 "presentation": { "http://www.akshealthgroup.com/role/GoingConcernDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Net loss", "label": "Net Investment in Lease, before Allowance for Credit Loss", "documentation":
 "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases." } } },
 "auth_ref": { "r169", "r360", "r534", "r954" } }, "ahg_NetLossPerShareAbstract": { "xbrltype": "stringItemType",
 "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NetLossPerShareAbstract", "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel":
 "Net (loss) per share", "label": "Net Loss Per Share Abstract" } } }, "auth_ref": { } }, "ahg_NetProceeds": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NetProceeds", "crdr":
 "credit", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Net proceeds (in Dollars)", "documentation": "the amount of net proceeds.", "label": "Net
 Proceeds" } } }, "auth_ref": { } }, "ahg_NetProceedsFromthePrivatePlacement": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NetProceedsFromthePrivatePlacement", "crdr":

"credit": "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net proceeds (in Dollars)", "documentation": "Represent the amount of net proceeds from private placement.", "label": "Net Proceeds From the Private Placement" } } }, "auth_ref": { } }, "us-gaap_NewAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyTextBlock", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "No Trading Symbol Flag", "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": { }, "us-gaap_NoncontrollingInterestInVariableInterestEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestInVariableInterestEntity", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest rate (in Dollars)", "label": "Noncontrolling Interest in Variable Interest Entity", "documentation": "Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest)." } } }, "auth_ref": { }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel": "Capital contribution from non-controlling interest (u201cNCIu201d)", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": { "r14", "r39", "r146" }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel": "u200bNon-controlling interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": { "r48", "r426", "r932", "r933", "r934", "r936", "r1075" }, "ahg_NoncontrollingInterestsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NoncontrollingInterestsPolicyTextBlock", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "documentation": "The disclosure of noncontrolling interests policy text block.", "label": "Noncontrolling Interests Policy Text Block" } } }, "auth_ref": { }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "OTHER INCOME (EXPENSE)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": { }, "ahg_November162023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "November162023WarrantsMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsExercisableTable" }, "lang": { "en-us": { "role": { "terseLabel": "November 16, 2023 Warrants [Member]", "label": "November162023 Warrants Member" } } }, "auth_ref": { }, "ahg_NumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NumberOfCustomers", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of customers (in customers)", "documentation": "Number of customers.", "label": "Number Of Customers" } } }, "auth_ref": { }, "ahg_NumberOfLoanAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NumberOfLoanAgreements", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of loan agreements", "documentation": "Number of loan agreements.", "label": "Number Of Loan Agreements" } } }, "auth_ref": { }, "ahg_NumberOfVendor": { "xbrltype": "integerItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NumberOfVendor", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of vendor (in vendors)", "documentation": "Number of vendor.", "label": "Number Of Vendor" } } }, "auth_ref": { }, "ahg_NumberofOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NumberofOrdinaryShares", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of ordinary shares (in Shares)", "documentation": "Number of ordinary shares.", "label": "Numberof Ordinary Shares" } } }, "auth_ref": { }, "ahg_NumberofWarrantsShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NumberofWarrantsShare", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of warrants share (in Shares)", "documentation": "Number of warrants share.", "label": "Numberof Warrants Share" } } }, "auth_ref": { }, "ahg_NumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "NumeratorAbstract", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofOutstandingSharesforBasicandDilutedNetEarningsPerShareTable" }, "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Numerator Abstract" } } }, "auth_ref": { }, "ahg_October22023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "October22023WarrantsMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsExercisableTable" }, "lang": { "en-us": { "role": { "terseLabel": "October 2, 2023 Warrants [Member]", "label": "October22023 Warrants Member" } } }, "auth_ref": { }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable" }, "lang": { "en-us": { "role": { "terseLabel": "Office Equipment [Member]", "label": "Office Equipment [Member]",

"documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "totalLabel": "Total Operating Expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "OPERATING EXPENSE", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "totalLabel": "LOSS FROM CONTINUING OPERATIONS", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r164", "r810", "r939", "r940", "r941", "r942", "r943"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": { "http://www.akshealthgroup.com/role/RightofUseLeaseAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r1024"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://www.akshealthgroup.com/role/RightofUseLeaseAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r532", "r847"] }, "ahg_OrdinarySharesParValueUS00001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "OrdinarySharesParValueUS00001PerShareMember", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Class A ordinary shares, par value US\$0.0001 per share", "label": "Ordinary Shares Par Value US00001 Per Share Member" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Other Accounts Payable and Accrued Liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": ["r149", "r221", "r621", "r812", "r876"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r233", "r848"] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsDisclosureTextBlock", "presentation": { "http://www.akshealthgroup.com/role/PrepaymentsandOtherAssetsNet": { "lang": { "en-us": { "role": { "terseLabel": "PREPAYMENTS AND OTHER ASSETS, NET", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "lang": { "en-us": { "role": { "terseLabel": "Property, equipment and software, net", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r221"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-

```

"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfComprehensiveLossIncomeTable": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement", "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfComprehensiveLossIncomeTable", "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r4", "r640" } }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Less: comprehensive income (loss) attributable to non-controlling interest", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": { "r8", "r15", "r145" } }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": { "http://www.akshealthgroup.com/role/PrepaidConsideration" }, "lang": { "en-us": { "role": { "terseLabel": "PREPAID CONSIDERATION", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": { } }, "ahg_OtherInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "OtherInvestorsMember", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other Investors [Member]", "label": "Other Investors Member" } } }, "auth_ref": { } }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Due to related party", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": { "r153", "r623", "r701", "r702", "r876", "r1036", "r1073" } }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Amount due to related parties", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r92", "r848" } }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "negatedLabel": "Other expense", "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": { "r119" } }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": { "r248" } }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Total Other (Expense) Income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": { "r119" } }, "us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivableAfterAllowanceForCreditLossNoncurrent", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofLoanReceivablesTable": { "parentTag": "us-gaap_ReceivablesNetCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofLoanReceivablesTable" }, "lang": { "en-us": { "role": { "terseLabel": "Allowance for uncollectible loan receivables", "label": "Other Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of receivable classified as other and noncurrent." } } }, "auth_ref": { "r912" } }, "us-gaap_OtherReceivablesGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesGrossCurrent", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofLoanReceivablesTable": { "parentTag": "us-gaap_ReceivablesNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofLoanReceivablesTable" }, "lang": { "en-us": { "role": { "terseLabel": "Loan receivables", "label": "Other Receivables, Gross, Current", "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref":

```


["r227"] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab": { "lang": { "en-us": { "role": { "terseLabel": "Amounts due from related parties", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherRestrictedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestrictedAssetsAbstract", "lang": { "en-us": { "role": { "label": "Restricted Net Assets [Abstract]" } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": { "http://www.akshealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable": { "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "ahg_PRCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "PRCMember", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyDetails": { "lang": { "en-us": { "role": { "terseLabel": "PRC [Member]", "label": "PRCMember" } } }, "auth_ref": [] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ParentCompanyMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable_Parentheticals": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofComprehensiveLossIncomeTable": { "lang": { "en-us": { "role": { "terseLabel": "Parent Company [Member]", "label": "Parent Company [Member]", "documentation": "Registrant with controlling financial interest in one or more subsidiaries. Controlling interest in subsidiary includes, but is not limited to, primary beneficiary of variable interest entity (VIE). Controlling interest in subsidiary excludes broker-dealer with controlling financial interest in subsidiary but control is likely to be temporary." } } }, "auth_ref": ["r182", "r263"] }, "us-gaap_PaymentsForProceedsFromPreviousAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromPreviousAcquisition", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate purchase price (in Dollars)", "label": "Payments for (Proceeds from) Previous Acquisition", "documentation": "The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireLoansReceivable", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "negatedLabel": "Cash paid for loan originations", "label": "Payments to Acquire Loans Receivable", "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services." } } }, "auth_ref": ["r26"] }, "ahg_PercentageOfAnnualInterest": { "xbrltype": "percentItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "PercentageOfAnnualInterest", "presentation": { "http://www.akshealthgroup.com/role/LoanReceivablesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of annual interest", "documentation": "Percentage of annual interest.", "label": "Percentage Of Annual Interest" } } }, "auth_ref": [] }, "ahg_PercentageOfDividend": { "xbrltype": "percentItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "PercentageOfDividend", "presentation": { "http://www.akshealthgroup.com/role/IncomeTaxesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Annual dividends", "documentation": "Represents information pertaining to dividend as a percentage of the Company's anticipated net income after tax.", "label": "Percentage Of Dividend" } } }, "auth_ref": [] }, "ahg_PrepaidConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "PrepaidConsideration", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid consideration", "documentation": "The amount of prepaid consideration.", "label": "Prepaid Consideration" } } }, "auth_ref": [] }, "ahg_PrepaidConsiderationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "PrepaidConsiderationAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Consideration [Abstract]" } } }, "auth_ref": [] }, "ahg_PrepaidConsiderationDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "PrepaidConsiderationDetailsLineItems", "presentation": { "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails": { "lang": { "en-us": { "role": { "label": "Prepaid Consideration [Line Items]" } } }, "auth_ref": [] }, "ahg_PrepaidConsiderationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "PrepaidConsiderationDetailsTable", "presentation": { "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails": { "lang": { "en-us": { "role": { "label": "Prepaid Consideration (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "lang": { "en-us": { "role": { "terseLabel": "Prepayment and other assets", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent",

"weight": 1.0, "order": 3.0 },
 "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab
 { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 },
 "http://www.akshealthgroup.com/role/ScheduleofPrepaymentsandOtherAssetsTable": { "parentTag": null, "weight":
 null, "order": null, "root": true } }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet",
 "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab
 "http://www.akshealthgroup.com/role/ScheduleofPrepaymentsandOtherAssetsTable" }, "lang": { "en-us": { "role": {
 "totalLabel": "Total prepayments and other assets, net", "terseLabel": "Prepayments and other assets", "label":
 "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in
 advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to
 be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r916" } }, "us-
 gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent",
 "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet",
 "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Prepaid consideration", "verboseLabel": "Prepaid consideration (in Dollars)", "label": "Prepaid Expense, Current",
 "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits
 within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r232", "r369",
 "r370", "r802" } }, "ahg_PrepaymentsAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "PrepaymentsAndOtherAssetsAbstract", "lang": { "en-
 us": { "role": { "label": "Prepayments and Other Assets [Abstract]" } } }, "auth_ref": { } }, "us-
 gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "PrivatePlacementMember", "presentation": {
 "http://www.akshealthgroup.com/role/ShareholdersEquityDetails",
 "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Private Placement [Member]", "label": "Private Placement [Member]", "documentation": "A private placement is a
 direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension
 funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": { } }, "us-
 gaap_ProceedsFromCollectionOfLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ProceedsFromCollectionOfLoansReceivable", "crdr": "debit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } },
 "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
 "terseLabel": "Cash received from loan repayments", "label": "Proceeds from Collection of Loans Receivable",
 "documentation": "The cash inflow associated with the collection, including prepayments, of loans receivable issued
 for financing of goods and services." } } }, "auth_ref": { "r25" } }, "us-
 gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 },
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow",
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable",
 "http://www.akshealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Proceeds from private placement, net of offering costs", "verboseLabel": "Proceeds from private placement offering,
 net of offering costs", "netLabel": "Gross proceeds from private placement (in Dollars)", "label": "Proceeds from
 Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from
 entity's raising of capital via private rather than public placement." } } }, "auth_ref": { "r5" } }, "us-
 gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit",
 "calculation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } },
 "presentation": { "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable" },
 "lang": { "en-us": { "role": { "terseLabel": "Loan to subsidiaries, VIEs and VIE subsidiaries", "label":
 "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from
 financing activities classified as other." } } }, "auth_ref": { "r895", "r920" } }, "us-
 gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable" }, "lang": { "en-us": {
 "role": { "terseLabel": "Proceeds from related party", "label": "Proceeds from Related Party Debt", "documentation":
 "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or
 significant influence over another party, including affiliates, owners or officers and their immediate families,
 pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": { "r27" }
 }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "crdr": "debit",
 "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } },
 "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
 "terseLabel": "Amounts due to (from) related parties", "label": "Proceeds from (Repayments of) Related Party Debt",
 "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include,
 but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts." } } },
 "auth_ref": { } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
 "localname": "ProductOrServiceAxis", "presentation": {

<http://www.aksohealthgroup.com/role/ConsolidatedIncomeStatement>,
<http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails>], "lang": { "en-us": {
"role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of
similar products and similar services." } } }, "auth_ref": { "r192", "r193", "r194", "r195", "r196", "r197", "r209",
"r308", "r585", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r797", "r822", "r858", "r860", "r861", "r864",
"r865", "r910", "r963", "r964", "r972", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049",
"r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062",
"r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070" } }, "srt_ProductsAndServicesDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain",
"presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedIncomeStatement",
"http://www.aksohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": {
"role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar
products or similar services." } } }, "auth_ref": { "r192", "r193", "r194", "r195", "r196", "r197", "r209", "r308",
"r585", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r797", "r822", "r858", "r860", "r861", "r864", "r865",
"r910", "r963", "r964", "r972", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050",
"r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063",
"r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070" } }, "us-gaap_ProfitLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit",
"calculation": { "http://www.aksohealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order":
1.0 }, "http://www.aksohealthgroup.com/role/ScheduleofCondensedStatementsOfComprehensiveLossIncomeTable": {
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.aksohealthgroup.com/role/ConsolidatedIncomeStatement",
"http://www.aksohealthgroup.com/role/ScheduleofCondensedStatementsOfComprehensiveLossIncomeTable",
"http://www.aksohealthgroup.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel":
"NET (LOSS)", "terseLabel": "Net (loss) income", "label": "Net Income (Loss), Including Portion Attributable to
Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes,
including the portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r216", "r235", "r237", "r250",
"r258", "r267", "r273", "r276", "r277", "r350", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391",
"r485", "r489", "r490", "r493", "r494", "r507", "r510", "r620", "r637", "r675", "r729", "r751", "r752", "r834", "r835",
"r875", "r919", "r966" } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": {
"http://www.aksohealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable" }, "lang": {
"en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived,
physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r11", "r533" } },
"us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": {
"http://www.aksohealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel":
"Property and equipment, net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
"documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business
and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset
classified as collections." } } }, "auth_ref": { "r11", "r175", "r178", "r633" } }, "us-
gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": {
"http://www.aksohealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable" }, "lang": {
"en-us": { "role": { "terseLabel": "Office equipment", "label": "Property, Plant and Equipment, Useful Life",
"documentation": "Useful life of long-lived, physical assets used in the normal conduct of business and not intended
for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five
months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office
equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": { } }, "us-
gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": {
"http://www.aksohealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 },
"http://www.aksohealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } },
"presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedCashFlow",
"http://www.aksohealthgroup.com/role/ScheduleofCondensedStatementsOfCashFlowsTable" }, "lang": { "en-us": {
"role": { "terseLabel": "Provision for doubtful accounts", "verboseLabel": "Provision for doubts accounts", "label":
"Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense)
for expected credit loss on accounts receivable." } } }, "auth_ref": { "r247", "r358" } },
"ahg_PurchaseOfWarrantShares": { "xbrltype": "sharesItemType", "nsuri":
"http://www.aksohealthgroup.com/20240331", "localname": "PurchaseOfWarrantShares", "presentation": {
"http://www.aksohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Purchase of warrants (in Shares)", "documentation": "Purchase of Warrant Shares.", "label": "Purchase Of Warrant
Shares" } } }, "auth_ref": { } }, "ahg_PurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri":
"http://www.aksohealthgroup.com/20240331", "localname": "PurchasePricePerShare", "presentation": {
"http://www.aksohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Purchase price per share", "documentation": "Purchase price per share of warrant.", "label": "Purchase Price Per
Share" } } }, "auth_ref": { } }, "ahg_QindaoAksoHealthManagementCoLimitedMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname":
"QindaoAksoHealthManagementCoLimitedMember", "presentation": {
"http://www.aksohealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable" }, "lang": { "en-us": {
"role": { "terseLabel": "Qindao Akso Health Management Co., Limited [Member]", "label": "Qindao Akso Health
Management Co Limited Member" } } }, "auth_ref": { } }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": {
"http://www.aksohealthgroup.com/role/IncomeTaxesDetails",
"http://www.aksohealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable",

```

http://www.aksohealthgroup.com/role/SubsequentEventsDetails] , "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } } , "auth_ref": [ "r183", "r185", "r187", "r188", "r190", "r211", "r212", "r379", "r380", "r381", "r382", "r432", "r435", "r443", "r444", "r445", "r451", "r508", "r554", "r566", "r582", "r653", "r654", "r661", "r697", "r698", "r761", "r764", "r766", "r767", "r770", "r794", "r795", "r813", "r821", "r831", "r839", "r840", "r844", "r845", "r860", "r868", "r961", "r970", "r1015", "r1030", "r1031", "r1032", "r1033", "r1034" ] } , "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.aksohealthgroup.com/role/IncomeTaxesDetails", "http://www.aksohealthgroup.com/role/SubsequentEventsDetails" ] , "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } } , "auth_ref": [ "r183", "r185", "r187", "r188", "r190", "r211", "r212", "r379", "r380", "r381", "r382", "r432", "r435", "r443", "r444", "r445", "r451", "r508", "r554", "r566", "r582", "r653", "r654", "r661", "r697", "r698", "r761", "r764", "r766", "r767", "r770", "r794", "r795", "r813", "r821", "r831", "r839", "r840", "r844", "r845", "r860", "r868", "r961", "r970", "r1015", "r1030", "r1031", "r1032", "r1033", "r1034" ] } , "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Loan Receivables [Abstract]", "documentation": "Information by type of loan receivable. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } } , "auth_ref": [ ] , "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.aksohealthgroup.com/role/ScheduleofLoanReceivablesTable": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": [ "http://www.aksohealthgroup.com/role/ScheduleofLoanReceivablesTable" ] , "lang": { "en-us": { "role": { "totalLabel": "Loan receivables, net", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } } , "auth_ref": [ "r848" ] } , "ahg_RegisteredCapitalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "RegisteredCapitalPercentage", "presentation": [ "http://www.aksohealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyDetails", "http://www.aksohealthgroup.com/role/SubsequentEventsDetails" ] , "lang": { "en-us": { "role": { "terseLabel": "Registered capital percentage", "documentation": "Registered capital percentage." , "label": "Registered Capital Percentage" } } } , "auth_ref": [ ] } , "ahg_RelatedPartyBalancesandTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "RelatedPartyBalancesandTransactionsDetailsTable", "presentation": [ "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions (Details) [Table]", "documentation": "Information by type of related party transaction." } } } , "auth_ref": [ ] , "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails", "http://www.aksohealthgroup.com/role/SubsequentEventsDetails" ] , "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } } , "auth_ref": [ "r313", "r433", "r539", "r540", "r624", "r632", "r700", "r701", "r702", "r703", "r704", "r726", "r728", "r760" ] } , "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails", "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" ] , "lang": { "en-us": { "role": { "terseLabel": "Related Party", "verboseLabel": "Related Party [Member]", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } } , "auth_ref": [ "r260", "r261", "r539", "r540", "r541", "r542", "r624", "r632", "r700", "r701", "r702", "r703", "r704", "r726", "r728", "r760" ] } , "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" ] , "lang": { "en-us": { "role": { "terseLabel": "Payment of principal and interest", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } } , "auth_ref": [ "r68", "r539" ] } , "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable", "http://www.aksohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable" ] , "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } } , "auth_ref": [ "r539", "r540", "r1026" ] } , "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.aksohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" ] , "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } } , "auth_ref": [ ] } , "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [ "r313", "r733", "r734", "r737" ] } , "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [Abstract]", "documentation": "Information by type of related party transaction." } } } , "auth_ref": [ ] } , "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [By Related Party Axis]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [ "r313", "r733", "r734", "r737" ] } , "us-gaap_RelatedPartyTransactionsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDomain", "presentation": [ "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [Domain]", "documentation": "Transaction between related party." } } } , "auth_ref": [ ] } , "us-gaap_RelatedPartyTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsLineItems", "presentation": [ "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [ "r313", "r733", "r734", "r737" ] } , "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [Abstract]", "documentation": "Information by type of related party transaction." } } } , "auth_ref": [ ] } , "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [By Related Party Axis]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [ "r313", "r733", "r734", "r737" ] } , "us-gaap_RelatedPartyTransactionsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDomain", "presentation": [ "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [Domain]", "documentation": "Transaction between related party." } } } , "auth_ref": [ ] } , "us-gaap_RelatedPartyTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsLineItems", "presentation": [ "http://www.aksohealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [ "r313", "r733", "r734", "r737" ] } , "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Balances and Transactions [Abstract]", "documentation": "Information by type of related party transaction." } } } , "auth_ref": [ ] } , "us-gaap_Related
```

"RelatedPartyTransactionsByRelatedPartyAxis", "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet",
 "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails",
 "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "label": "Related
and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party
includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method,
trust for benefit of employee, principal owner, management, and member of immediate family, and other party that
may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } },
 "auth_ref": { "r313", "r433", "r539", "r540", "r624", "r632", "r700", "r701", "r702", "r703", "r704", "r726",
 "r728", "r760", "r1026" } }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "RelatedPartyTransactionsDisclosureTextBlock", "presentation": {
 "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactions" }, "lang": { "en-us": { "role": {
 "terseLabel": "RELATED PARTY BALANCES AND TRANSACTIONS", "label": "Related Party Transactions Disclosure
[Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party
transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common
parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": { "r536", "r537", "r538", "r540",
 "r543", "r671", "r672", "r673", "r735", "r736", "r737", "r757", "r759" } }, "us-gaap_RepaymentsOfLongTermDebt": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": {
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" }, "lang": { "en-us": {
 "role": { "negatedLabel": "Principal payments on unsecured senior notes", "label": "Repayments of Long-Term Debt",
 "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal
operating cycle, if longer." } } }, "auth_ref": { "r120", "r668" } }, "us-gaap_RepaymentsOfRelatedPartyDebt": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 3.0 } },
 "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
 "negatedLabel": "Repayments of loans due to related parties", "label": "Repayments of Related Party Debt",
 "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one
party can exercise control or significant influence over another party; including affiliates, owners or officers and
their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }
 }, "auth_ref": { "r120" } }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } },
 "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
 "negatedLabel": "Repayments of unsecured senior notes", "label": "Repayments of Senior Debt", "documentation":
 "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of
bankruptcy or liquidation during the period." } } }, "auth_ref": { "r120" } },
 "ahg_RequiredPercentageOfNetIncomeAllocatedToStatutorySurplusReserves": { "xbrltype": "percentItemType",
 "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "RequiredPercentageOfNetIncomeAllocatedToStatutorySurplusReserves", "presentation": {
 "http://www.akshealthgroup.com/role/RestrictedNetAssetsDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Annual basis, percentage", "documentation": "Represents the minimum percentage of net income from subsidiaries
required to be appropriated towards the statutory reserve fund for entities incorporated in the People's Republic of
China until the reserve balance reaches 50 percent of registered capital.", "label": "Required Percentage Of Net
Income Allocated To Statutory Surplus Reserves" } } }, "auth_ref": { } },
 "ahg_ReserveReachesOfItsRegisteredCapital": { "xbrltype": "percentItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "ReserveReachesOfItsRegisteredCapital",
 "presentation": { "http://www.akshealthgroup.com/role/RestrictedNetAssetsDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Registered capital, percentage", "documentation": "Reserve reaches of its registered capital.", "label":
 "Reserve Reaches Of Its Registered Capital" } } }, "auth_ref": { } }, "us-gaap_RestrictedAssetsDisclosureTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "RestrictedAssetsDisclosureTextBlock", "presentation": {
 "http://www.akshealthgroup.com/role/RestrictedNetAssets" }, "lang": { "en-us": { "role": { "terseLabel":
 "RESTRICTED NET ASSETS", "label": "Restricted Assets Disclosure [Text Block]", "documentation": "The entire
disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory
requirements. This would include, but not limited to, a description of the restricted assets and the terms of the
restriction." } } }, "auth_ref": { } }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit",
 "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag":
 "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } },
 "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-
 gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet",
 "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" }, "lang": { "en-us": { "role": {
 "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount
of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r103", "r137", "r629", "r658", "r660", "r669",
 "r708", "r848" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "RetainedEarningsMember", "presentation": {
 "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel":
 "(Accumulated Deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed
earnings (deficit)." } } }, "auth_ref": { "r213", "r264", "r265", "r266", "r268", "r273", "r275", "r277", "r352", "r353",
 "r376", "r471", "r472", "r482", "r483", "r484", "r486", "r488", "r489", "r497", "r499", "r500", "r502", "r505", "r527",

"r529", "r655", "r657", "r676", "r1075" }], "ahg_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname": "RevenueAbstract", "presentation": { "http://www.akohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable" }, "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Abstract" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement", "http://www.akohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Amount of incentives", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r162", "r163", "r294", "r299", "r300", "r305", "r307", "r308", "r309", "r311", "r429", "r430", "r585"] }, "ahg_RevenueFromMedicalDevicesPRC": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname": "RevenueFromMedicalDevicesPRC", "crdr": "credit", "calculation": { "http://www.akohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable" }, "lang": { "en-us": { "role": { "terseLabel": "Revenue from medical devices-PRC", "documentation": "The amount of revenue from medical devices-PRC.", "label": "Revenue From Medical Devices PRC" } } }, "auth_ref": [] }, "ahg_RevenueFromMedicalDevicesUS": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname": "RevenueFromMedicalDevicesUS", "crdr": "credit", "calculation": { "http://www.akohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable", "http://www.akohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Revenue from medical devices-US", "verboseLabel": "Revenue from medical devices", "documentation": "The amount of evenue from medical devices-US.", "label": "Revenue From Medical Devices US" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": { "http://www.akohealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r731", "r796", "r807"] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": { "http://www.akohealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Total revenues percentage", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": ["r896"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "http://www.akohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable": { "parentTag": "us-gaap_RevenuesNetOfInterestExpense", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement", "http://www.akohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable", "http://www.akohealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab l", "lang": { "en-us": { "role": { "totalLabel": "Net Revenues", "label": "Net revenues", "verboseLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r162", "r163", "r243", "r258", "r294", "r299", "r300", "r305", "r307", "r308", "r309", "r311", "r350", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r510", "r620", "r811", "r966"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": { "http://www.akohealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "REVENUES", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenuesNetOfInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesNetOfInterestExpense", "crdr": "credit", "calculation": { "http://www.akohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.akohealthgroup.com/role/ScheduleofDisaggregationofRevenueTable" }, "lang": { "en-us": { "role": { "totalLabel": "Net Revenues", "label": "Revenues, Net of Interest Expense", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income after deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r162", "r163", "r294", "r299", "r300", "r305", "r307", "r308", "r309", "r311"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": { "http://www.akohealthgroup.com/role/RightofUseLeaseAssetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "ROU asset and lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r531", "r847"] }, "ahg_RightOfUseLeaseAssetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname": "RightOfUseLeaseAssetTextBlock", "presentation": { "http://www.akohealthgroup.com/role/RightofUseLeaseAssets"

1, "lang": { "en-us": { "role": { "terseLabel": "RIGHT OF USE LEASE ASSETS", "documentation": "The entire disclosure right of use lease assets.", "label": "Right Of Use Lease Asset Text Block" } } }, "auth_ref": { } }, "ahg_RightOfUseLeaseAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "RightOfUseLeaseAssetsAbstract", "lang": { "en-us": { "role": { "label": "Right of Use Lease Assets [Abstract]" } } }, "auth_ref": { } }, "ahg_SaleOfMedicalDevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "SaleOfMedicalDevicesMember", "presentation": { "http://www.aksohealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Sale of medical devices", "label": "Sale Of Medical Devices Member" } } }, "auth_ref": { } }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": { "http://www.aksohealthgroup.com/role/PrepaidConsiderationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Total consideration (in Dollars)", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": { } }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://www.aksohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": { } }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": { "http://www.aksohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Sale of units (in Shares)", "verboseLabel": "Sell an aggregate shares (in Shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": { } }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": { "http://www.aksohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Sale of units price per share", "verboseLabel": "Sell an aggregate price per share", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": { } }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": { "http://www.aksohealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": { "r436", "r905", "r935" } }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": { "http://www.aksohealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": { "r210", "r278", "r436", "r889", "r935" } }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": { "http://www.aksohealthgroup.com/role/LoanReceivablesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loan Receivables", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": { "r101", "r107" } }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": { "http://www.aksohealthgroup.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "u200bSchedule of Accrued Expenses and Other Current Liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": { } }, "ahg_ScheduleOfAccountsReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "ScheduleOfAccountsReceivableNetAbstract", "lang": { "en-us": { "role": { "label": "u200bSchedule of Accounts Receivable, Net [Abstract]" } } }, "auth_ref": { } }, "ahg_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aksohealthgroup.com/20240331", "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "u200bSchedule of Accrued Expenses and Other Current Liabilities [Abstract]" } } }, "auth_ref": { } }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": { "http://www.aksohealthgroup.com/role/IncomeTaxesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Tax Expenses", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-

the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": { "r1004" } }, "ahg_ScheduleOfComponentsOfIncomeTaxExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfComponentsOfIncomeTaxExpensesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expenses [Abstract]" } } }, "auth_ref": { } }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Condensed Balance Sheets", "label": "Condensed Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": { "r906", "r931" } }, "ahg_ScheduleOfCondensedBalanceSheetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfCondensedBalanceSheetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Condensed Balance Sheets Abstract" } } }, "auth_ref": { } }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "presentation": { "http://www.akshealthgroup.com/role/CondensedFinancialInformationoftheParentCompanyTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Condensed Statements of Cash Flows", "label": "Condensed Cash Flow Statement [Table Text Block]", "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": { "r906", "r931" } }, "ahg_ScheduleOfCondensedStatementsOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfCondensedStatementsOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Condensed Statements Of Cash Flows Abstract" } } }, "auth_ref": { } }, "ahg_ScheduleOfCondensedStatementsOfComprehensiveLossIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfCondensedStatementsOfComprehensiveLossIncomeAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Condensed Statements Of Comprehensive Loss Income Abstract" } } }, "auth_ref": { } }, "ahg_ScheduleOfCurrentTaxesPayableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfCurrentTaxesPayableTableTextBlock", "presentation": { "http://www.akshealthgroup.com/role/TaxesPayableTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Taxes Payable", "documentation": "Tabular disclosure of schedule of current taxes payable table text block.", "label": "Schedule Of Current Taxes Payable Table Text Block" } } }, "auth_ref": { } }, "ahg_ScheduleOfDisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfDisaggregationOfRevenueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Disaggregation Of Revenue Abstract" } } }, "auth_ref": { } }, "ahg_ScheduleOfDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfDiscontinuedOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Discontinued Operations Abstract" } } }, "auth_ref": { } }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosures": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosures", "presentation": { "http://www.akshealthgroup.com/role/DiscontinuedOperationTables", "lang": { "en-us": { "role": { "terseLabel": "200b Schedule of Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": { "r13", "r18", "r20", "r71", "r77", "r78", "r79", "r80", "r81", "r86", "r88", "r89", "r133" } }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://www.akshealthgroup.com/role/EarningsLossPerShareTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Shares for Basic and Diluted Net Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": { "r938" } }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": { "http://www.akshealthgroup.com/role/IncomeTaxesTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciles the PRC Statutory Rates to the Company's 2019s Effective Tax Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": { "r458", "r832", "r1000" } }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": { "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails", "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": { "r347", "r348", "r349", "r481", "r890", "r891", "r892", "r1005", "r1006", "r1007", "r1008" } }, "ahg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Estimated Useful Lives Of Property And Equipment Abstract" } } }, "auth_ref": { } }, "ahg_ScheduleOfFinancialStatementAmountsAndBalancesOfTheConsolidatedViesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfFinancialStatementAmountsAndBalancesOfTheConsolidatedViesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Financial Statement Amounts And Balances Of The Consolidated Vies Abstract" } } }, "auth_ref": { } },

"auth_ref": [] }, "ahg_ScheduleOffForeignExchangeRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOffForeignExchangeRatesTableTextBlock", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Spot Exchange Rates and Average Exchange Rates", "documentation": "Tabular disclosure of the foreign exchange rates used in the preparation of the financial statements.", "label": "Schedule Of Foreign Exchange Rates Table Text Block" } } }, "auth_ref": [] }, "ahg_ScheduleOfLoanReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfLoanReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Loan Receivables [Abstract]" } } }, "auth_ref": [] }, "ahg_ScheduleOfLossOnSaleOfDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfLossOnSaleOfDiscontinuedOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Loss on Sale of Discontinued Operations [Abstract]" } } }, "auth_ref": [] }, "ahg_ScheduleOfNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfNoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Noncontrolling Interest Abstract" } } }, "auth_ref": [] }, "ahg_ScheduleOfNoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfNoncontrollingInterestTableTextBlock", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Noncontrolling Interest", "documentation": "Tabular disclosure of noncontrolling interest.", "label": "Schedule Of Noncontrolling Interest Table Text Block" } } }, "auth_ref": [] }, "ahg_ScheduleOfOutstandingSharesForBasicAndDilutedNetEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfOutstandingSharesForBasicAndDilutedNetEarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Outstanding Shares for Basic and Diluted Net Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "ahg_ScheduleOfPrepaymentsAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfPrepaymentsAndOtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Prepayments and Other Assets [Abstract]" } } }, "auth_ref": [] }, "ahg_ScheduleOfPropertyEquipmentAndSoftwareDepreciationRecognizedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfPropertyEquipmentAndSoftwareDepreciationRecognizedTableTextBlock", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment", "documentation": "Tabular disclosure of the depreciation recognized in the consolidated statements of comprehensive income.", "label": "Schedule Of Property Equipment And Software Depreciation Recognized Table Text Block" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": ["http://www.akshealthgroup.com/role/DiscontinuedOperationTables"], "lang": { "en-us": { "role": { "terseLabel": "u200bSchedule of Assets and Liabilities", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": ["r144"] }, "ahg_ScheduleOfReconcilesThePRCStatutoryRatesToTheCompanysEffectiveTaxRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfReconcilesThePRCStatutoryRatesToTheCompanysEffectiveTaxRateAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Reconciles the PRC Statutory Rates to the Company's Effective Tax Rate [Abstract]" } } }, "auth_ref": [] }, "ahg_ScheduleOfSaleOfDiscontinuedOperationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfSaleOfDiscontinuedOperationTableTextBlock", "presentation": ["http://www.akshealthgroup.com/role/DiscontinuedOperationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loss on Sale of Discontinued Operations", "documentation": "Tabular disclosure of loss on sale of discontinued operation.", "label": "Schedule Of Sale Of Discontinued Operation Table Text Block" } } }, "auth_ref": [] }, "ahg_ScheduleOfSpotExchangeRatesAndAverageExchangeRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfSpotExchangeRatesAndAverageExchangeRatesAbstract", "lang": { "en-us": { "role": { "label": "u200bSchedule of Spot Exchange Rates and Average Exchange Rates [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.akshealthgroup.com/role/ShareholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants Exercisable", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r42"] }, "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "presentation": ["http://www.akshealthgroup.com/role/BusinessDescriptionTables"], "lang": { "en-us": { "role": { "terseLabel": "u200bSchedule of the Company's Principal Subsidiaries", "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]", "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited

partnership." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable", "presentation": { "http://www.akshealthgroup.com/role/ScheduleoftheCompanysPrincipalSubsidiariesTable" }, "lang": { "en-us": { "role": { "label": "Subsidiary of LLC or LP [Table]", "documentation": "Disclosure of information about subsidiary of limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": { } }, "ahg_ScheduleOfTheCompanysPrincipalSubsidiariesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfTheCompanysPrincipalSubsidiariesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of The Companys Principal Subsidiaries Abstract" } } }, "auth_ref": { } }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab", "lang": { "en-us": { "role": { "label": "Variable Interest Entity [Table]", "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements." } } }, "auth_ref": { "r52", "r53", "r55", "r57", "r58", "r491", "r492", "r495", "r496", "r562", "r563", "r564" } }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Statement Amounts and Balances of the Consolidated Vies", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": { "r52", "r53", "r55", "r57", "r58" } }, "ahg_ScheduleOfWarrantsExercisableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfWarrantsExercisableAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrants Exercisable Abstract" } } }, "auth_ref": { } }, "ahg_ScheduleOfWarrantsOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "ScheduleOfWarrantsOutstandingTableTextBlock", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "u200bSchedule of Warrants Outstanding", "label": "Schedule Of Warrants Outstanding Table Text Block" } } }, "auth_ref": { } }, "ahg_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "SecuritiesPurchaseAgreementMember", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Securities Purchase Agreement [Member]", "label": "Securities Purchase Agreement Member" } } }, "auth_ref": { } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r878" } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r880" } }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": { "http://www.akshealthgroup.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": { "r184", "r186", "r189", "r191", "r198", "r199", "r200", "r201", "r203", "r204", "r205", "r206", "r207", "r208", "r309", "r310", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r690", "r692", "r694", "r763", "r765", "r769", "r772", "r780", "r784", "r785", "r786", "r787", "r789", "r790", "r791", "r792", "r793", "r798", "r823", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r862", "r868", "r972", "r1042", "r1043", "r1044", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070" } }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-

gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel":
 "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of
 expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": { } }, "us-
 gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 },
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 },
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-
 gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedCashFlow",
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement",
 "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable" }, "lang": { "en-us": {
 "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash
 Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": {
 "r9" } } },
 "ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarra
 f "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsE
 "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsOutstandingTable" }, "lang": { "en-us":
 { "role": { "terseLabel": "Warrants, exercisable", "documentation": "The number of equity-based payment
 instruments, excluding stock (or unit) options, that were warrants exercisable during the reporting period.", "label":
 "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options
 Warrants Exercisable" } } }, "auth_ref": { } },
 "ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarra
 f "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsE
 "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsOutstandingTable",
 "http://www.akshealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Warrants, Exercised", "verboseLabel": "Warrants, exercised (in Shares)", "documentation": "The number of equity-
 based payment instruments, excluding stock (or unit) options, that were warrants exercised during the reporting
 period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments
 Other Than Options Warrants Exercised" } } }, "auth_ref": { } },
 "ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarra
 f "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsE
 "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsOutstandingTable" }, "lang": { "en-us":
 { "role": { "terseLabel": "Warrants, Expired", "documentation": "The number of equity-based payment instruments,
 excluding stock (or unit) options, that were warrants expired during the reporting period.", "label": "Share Based
 Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants
 Expired" } } }, "auth_ref": { } },
 "ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarra
 f "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIs
 "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsOutstandingTable" }, "lang": { "en-us":
 { "role": { "terseLabel": "Warrants, Issued", "documentation": "The number of equity-based payment instruments,
 excluding stock (or unit) options, that were warrants issued during the reporting period.", "label": "Share Based
 Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants
 Issued" } } }, "auth_ref": { } },
 "ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarra
 f "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsO
 "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsOutstandingTable" }, "lang": { "en-us":
 { "role": { "periodStartLabel": "Warrants outstanding, Beginning Balance", "periodEndLabel": "Warrants
 outstanding, Ending Balance", "documentation": "The number of outstanding equity-based payment instruments,
 excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label":
 "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options
 Warrants Outstanding" } } }, "auth_ref": { } },
 "ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeigh
 f "xbrltype": "perShareItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedA
 "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsOutstandingTable" }, "lang": { "en-us":
 { "role": { "terseLabel": "Weighted Average Exercise Price, exercisable", "documentation": "Per share or unit
 weighted-average fair value of exercisable award under share-based payment arrangement. Excludes share and unit
 options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments
 Other Than Options Weighted Average Exercise Price Exercisable" } } }, "auth_ref": { } },
 "ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeigh
 f "xbrltype": "perShareItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedA
 "presentation": { "http://www.akshealthgroup.com/role/ScheduleofWarrantsOutstandingTable" }, "lang": { "en-us":
 { "role": { "terseLabel": "Weighted Average Exercise Price, Exercised", "documentation": "Per share or unit
 weighted-average fair value of exercised award under share-based payment arrangement. Excludes share and unit
 options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments
 Other Than Options Weighted Average Exercise Price Exercised" } } }, "auth_ref": { } },
 "ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeigh
 f "xbrltype": "perShareItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":

~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedA~~
~~"presentation": { "http://www.akohealthgroup.com/role/ScheduleofWarrantsOutstandingTable" }, "lang": { "en-us":~~
~~{ "role": { "terseLabel": "Weighted Average Exercise Price, Expired", "documentation": "Per share or unit weighted-~~
~~average fair value of expired award under share-based payment arrangement. Excludes share and unit options.",~~
~~"label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than~~
~~Options Weighted Average Exercise Price Expired" } } }, "auth_ref": [] },~~
~~"ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeigh~~
~~{ "xbrltype": "perShareItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname":~~
~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedA~~
~~"presentation": { "http://www.akohealthgroup.com/role/ScheduleofWarrantsOutstandingTable" }, "lang": { "en-us":~~
~~{ "role": { "terseLabel": "Weighted Average Exercise Price, Issued", "documentation": "Per share or unit weighted-~~
~~average fair value of issued award under share-based payment arrangement. Excludes share and unit options.",~~
~~"label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than~~
~~Options Weighted Average Exercise Price Issued" } } }, "auth_ref": [] },~~
~~"ahg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeigh~~
~~{ "xbrltype": "perShareItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname":~~
~~"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedA~~
~~"presentation": { "http://www.akohealthgroup.com/role/ScheduleofWarrantsOutstandingTable" }, "lang": { "en-us":~~
~~{ "role": { "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning Balance",~~
~~"periodEndLabel": "Weighted Average Exercise Price outstanding, Ending Balance", "documentation": "Per share or~~
~~unit weighted-average fair value of warrants outstanding award under share-based payment arrangement. Excludes~~
~~share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity~~
~~Instruments Other Than Options Weighted Average Exercise Price Outstanding" } } }, "auth_ref": [] }, "us-~~
~~gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri":~~
~~"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",~~
~~"presentation": { "http://www.akohealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": {~~
~~"terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]",~~
~~"documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but~~
~~is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r437", "r439", "r440",~~
~~"r441", "r442", "r443", "r446", "r447", "r448", "r449", "r450"] },~~
~~"ahg_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggreg~~
~~{ "xbrltype": "monetaryItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname":~~
~~"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateI~~
~~"crdr": "debit", "presentation": { "http://www.akohealthgroup.com/role/ScheduleofWarrantsOutstandingTable" },~~
~~"lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercised", "documentation": "Intrinsic value~~
~~of exercised award under share-based payment arrangement. Excludes share and unit options.", "label":~~
~~"Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options~~
~~Aggregate Intrinsic Value Exercised" } } }, "auth_ref": [] },~~
~~"ahg_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggreg~~
~~{ "xbrltype": "monetaryItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname":~~
~~"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateI~~
~~"crdr": "debit", "presentation": { "http://www.akohealthgroup.com/role/ScheduleofWarrantsOutstandingTable" },~~
~~"lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Expired", "documentation": "Share-Based~~
~~Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate~~
~~Intrinsic Value, Expired", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity~~
~~Instruments Other Than Options Aggregate Intrinsic Value Expired" } } }, "auth_ref": [] },~~
~~"ahg_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggreg~~
~~{ "xbrltype": "monetaryItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname":~~
~~"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateI~~
~~"crdr": "debit", "presentation": { "http://www.akohealthgroup.com/role/ScheduleofWarrantsOutstandingTable" },~~
~~"lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Issued", "documentation": "Intrinsic value of~~
~~issued award under share-based payment arrangement. Excludes share and unit options.", "label": "Sharebased~~
~~Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate~~
~~Intrinsic Value Issued" } } }, "auth_ref": [] }, "us-~~
~~gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggreg~~
~~{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":~~
~~"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateI~~
~~"crdr": "debit", "presentation": { "http://www.akohealthgroup.com/role/ScheduleofWarrantsOutstandingTable" },~~
~~"lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value outstanding, Beginning Balance",~~
~~"periodEndLabel": "Aggregate Intrinsic Value outstanding, Ending Balance", "label": "Share-Based Compensation~~
~~Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value,~~
~~Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement.~~
~~Excludes share and unit options." } } }, "auth_ref": [] },~~
~~"ahg_SharebasedCompensationsArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggre~~
~~{ "xbrltype": "monetaryItemType", "nsuri": "http://www.akohealthgroup.com/20240331", "localname":~~
~~"SharebasedCompensationsArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregate~~
~~"crdr": "credit", "presentation": { "http://www.akohealthgroup.com/role/ScheduleofWarrantsOutstandingTable" },~~
~~"lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, exercisable", "documentation": "Share-Based~~
~~Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate~~
~~Intrinsic Value, Exercisable.", "label": "Sharebased Compensations Arrangement By Sharebased Payment Award~~
~~Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable" } } }, "auth_ref": [] },~~
~~"ahg_ShareholdersEquityAbstract0": { "xbrltype": "stringItemType", "nsuri":~~
~~"http://www.akohealthgroup.com/20240331", "localname": "ShareholdersEquityAbstract0", "presentation": {~~
~~"http://www.akohealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" }, "lang": { "en-us": { "role": {~~
~~"terseLabel": "SHAREHOLDERS\u2019 EQUITY", "label": "Shareholders Equity Abstract0" } } }, "auth_ref": [] },~~
~~"ahg_ShareholdersEquityDetailsTable": { "xbrltype": "stringItemType", "nsuri":~~
~~"http://www.akohealthgroup.com/20240331", "localname": "ShareholdersEquityDetailsTable", "presentation": {~~
~~"http://www.akohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "label":~~

"Shareholders' Equity (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, par value", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://www.akshealthgroup.com/role/SummaryOfSignificantAccountingPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r125", "r255"] }, "ahg_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "SignificantRisksAndUncertaintiesPolicyPolicyTextBlock", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Significant risks and uncertainties", "documentation": "Disclosure of accounting policy for significant risks and uncertainties." }, "label": "Significant Risks and Uncertainties Policy Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation", "http://www.akshealthgroup.com/role/SubsequentEventsDetails", "http://www.akshealthgroup.com/role/TreasuryStockDetails" }, "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r181", "r223", "r224", "r225", "r258", "r283", "r284", "r286", "r288", "r296", "r297", "r350", "r383", "r385", "r386", "r387", "r390", "r391", "r410", "r411", "r414", "r417", "r424", "r510", "r665", "r666", "r667", "r668", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r688", "r707", "r730", "r753", "r773", "r774", "r775", "r776", "r777", "r888", "r926", "r937"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails", "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3", "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r16", "r100", "r104", "r105", "r213", "r240", "r241", "r242", "r264", "r265", "r266", "r268", "r273", "r275", "r277", "r295", "r352", "r353", "r376", "r426", "r471", "r472", "r482", "r483", "r484", "r486", "r488", "r489", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r516", "r517", "r518", "r519", "r520", "r521", "r527", "r529", "r535", "r640", "r655", "r656", "r657", "r676", "r753"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://www.akshealthgroup.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": ["r184", "r186", "r189", "r191", "r198", "r199", "r200", "r201", "r203", "r204", "r205", "r206", "r207", "r208", "r309", "r310", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r690", "r692", "r694", "r763", "r765", "r769", "r772", "r780", "r784", "r785", "r786", "r787", "r789", "r790", "r791", "r792", "r793", "r798", "r823", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r862", "r868", "r972", "r1042", "r1043", "r1044", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement", "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r264", "r265", "r266", "r295", "r529", "r585", "r663", "r688", "r699", "r700", "r701", "r702", "r703", "r704", "r707", "r710", "r711", "r712", "r713", "r714", "r717", "r718", "r719", "r720", "r722", "r723", "r724", "r725", "r726", "r728", "r731", "r732", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r753", "r869"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": ["r210", "r278", "r436", "r889", "r894", "r935"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement", "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income,"

income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r264", "r265", "r266", "r295", "r313", "r529", "r585", "r663", "r688", "r699", "r700", "r701", "r702", "r703", "r704", "r707", "r710", "r711", "r712", "r713", "r714", "r717", "r718", "r719", "r720", "r722", "r723", "r724", "r725", "r726", "r728", "r731", "r732", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r753", "r869" } }, "ahg_StatutoryReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "StatutoryReserve", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/RestrictedNetAssetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statutory reserve", "documentation": "Statutory reserve.", "label": "Statutory Reserve" } } }, "auth_ref": { } }, "ahg_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails", "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants (in Shares)", "verboseLabel": "Issuance of ordinary shares (in Shares)", "documentation": "Number of shares in exercise of warrants.", "label": "Stock Issued During Period Shares Exercise Of Warrants" } } }, "auth_ref": { } }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3", "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Private placement (in Shares)", "verboseLabel": "Authorized issued share capital shares (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": { "r16", "r99", "r100", "r137", "r665", "r753", "r774" } }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel": "Exercise of RSU (in Shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": { "r16", "r137" } }, "ahg_StockIssuedDuringPeriodValueExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants", "documentation": "Represent the amount of exercise of warrants.", "label": "Stock Issued During Period Value Exercise Of Warrants" } } }, "auth_ref": { } }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3", "http://www.akshealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Private placement", "verboseLabel": "Authorized issued share capital (in Dollars)", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": { "r16", "r99", "r100", "r137", "r676", "r753", "r774", "r875" } }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel": "Exercise of RSU", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": { "r16", "r99", "r100", "r137" } }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": { "http://www.akshealthgroup.com/role/TreasuryStockDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of shares to be repurchased", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": { "r971" } }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramPeriodInForce1", "presentation": { "http://www.akshealthgroup.com/role/TreasuryStockDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Term of repurchase", "label": "Share Repurchase Program, Period in Force", "documentation": "Period share may be purchased under authorized share repurchase plan, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": { } }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet", "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" }, "lang": { "en-us": { "role": { "totalLabel": "TOTAL SHAREHOLDERS' 2019 EQUITY", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r100", "r104", "r105", "r127", "r709", "r727", "r754", "r755", "r848", "r876", "r928", "r953", "r1020", "r1075" } }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS' 2019 EQUITY", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": { } }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": {

"http://www.aksohealthgroup.com/role/ConsolidatedBalanceSheet",
"http://www.aksohealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "totalLabel":
"TOTAL EQUITY", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Including Portion
Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and
noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": { "r48", "r49", "r59", "r213", "r214", "r241",
"r264", "r265", "r266", "r268", "r273", "r275", "r352", "r353", "r376", "r426", "r471", "r472", "r482", "r483", "r484",
"r486", "r488", "r489", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r516", "r517", "r521", "r528", "r535",
"r656", "r657", "r674", "r709", "r727", "r754", "r755", "r778", "r875", "r928", "r953", "r1020", "r1075" } }, "us-
gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Shareholders' Equity
[Abstract]" } } }, "auth_ref": { } }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteDisclosureTextBlock", "presentation": {
"http://www.aksohealthgroup.com/role/ShareholdersEquity" }, "lang": { "en-us": { "role": { "terseLabel":
"SHAREHOLDERS\2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for
equity." } } }, "auth_ref": { "r136", "r256", "r409", "r411", "r413", "r414", "r415", "r416", "r417", "r418", "r419",
"r420", "r421", "r423", "r426", "r504", "r756", "r758", "r779" } }, "us-gaap_StockholdersEquityReverseStockSplit": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityReverseStockSplit", "presentation": {
"http://www.aksohealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Reverse ADS split ratio", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the
reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the
balance sheet date but before the release of financial statements." } } }, "auth_ref": { "r138" } }, "us-
gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventLineItems", "presentation": {
"http://www.aksohealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "label":
"Subsequent Events [Line Items]", "documentation": "Detail information of subsequent event by type. User is
expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure,
which is further associated with dimension and member elements pertaining to a subsequent event." } } },
"auth_ref": { "r522", "r546" } }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": {
"http://www.aksohealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that
occurred after the balance sheet date but before financial statements are issued or available to be issued." } } },
"auth_ref": { "r522", "r546" } }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": {
"http://www.aksohealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "label":
"Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date
but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r522", "r546" } }, "us-
gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventTypeDomain", "presentation": {
"http://www.aksohealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "label":
"Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before
financial statements are issued or available to be issued." } } }, "auth_ref": { "r522", "r546" } }, "us-
gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }
}, "auth_ref": { } }, "ahg_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.aksohealthgroup.com/20240331", "localname": "SubsequentEventsDetailsTable", "presentation": {
"http://www.aksohealthgroup.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "label":
"Subsequent Events (Details) [Table]" } } }, "auth_ref": { } }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock",
"presentation": { "http://www.aksohealthgroup.com/role/SubsequentEvents" }, "lang": { "en-us": { "role": {
"terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire
disclosure for significant events or transactions that occurred after the balance sheet date through the date the
financial statements were issued or the date the financial statements were available to be issued. Examples include:
the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant
foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of
business." } } }, "auth_ref": { "r545", "r547" } }, "us-
gaap_SubsiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose", "presentation": {
"http://www.aksohealthgroup.com/role/ScheduleoftheCompanysPrincipalSubsidiariesTable" }, "lang": { "en-us": {
"role": { "terseLabel": "Principal activities", "label": "Subsidiary of Limited Liability Company or Limited
Partnership, Business Purpose", "documentation": "Description of business purpose of the subsidiary of the limited
liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a
holding or operating company." } } }, "auth_ref": { } }, "us-
gaap_SubsiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate": { "xbrltype": "dateItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate",
"presentation": { "http://www.aksohealthgroup.com/role/ScheduleoftheCompanysPrincipalSubsidiariesTable" },
"lang": { "en-us": { "role": { "terseLabel": "Date of incorporation / acquisition", "label": "Subsidiary of Limited
Liability Company or Limited Partnership, Date", "documentation": "Date the subsidiary of the limited liability
company (LLC) or limited partnership (LP) was formed, in YYYY-MM-DD format." } } }, "auth_ref": { } }, "us-
gaap_SubsiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname":
"SubsiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems", "presentation": {
"http://www.aksohealthgroup.com/role/ScheduleoftheCompanysPrincipalSubsidiariesTable" }, "lang": { "en-us": {
"role": { "label": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]", "documentation":
"Line items represent financial concepts included in a table. These concepts are used to disclose reportable

information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest", "presentation": ["http://www.akshealthgroup.com/role/ScheduleoftheCompanysPrincipalSubsidiariesTable"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of legal ownership", "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest", "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership." } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState", "presentation": ["http://www.akshealthgroup.com/role/ScheduleoftheCompanysPrincipalSubsidiariesTable"], "lang": { "en-us": { "role": { "terseLabel": "Place of incorporation", "label": "Subsidiary of Limited Liability Company or Limited Partnership, State", "documentation": "State in which the subsidiary of the limited liability company or limited partnership was organized." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.akshealthgroup.com/role/ShareholdersEquityDetails", "http://www.akshealthgroup.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": ["http://www.akshealthgroup.com/role/GoingConcern"], "lang": { "en-us": { "role": { "terseLabel": "GOING CONCERN", "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": ["r90"] }, "ahg_SummaryofSignificantAccountingPoliciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "ahg_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyandEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyandEquipmentLineItems", "presentation": ["http://www.akshealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property and Equipment [Line Items]" } } }, "auth_ref": [] }, "ahg_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable", "presentation": ["http://www.akshealthgroup.com/role/ScheduleofEstimatedUsefulLivesofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property and Equipment [Table]" } } }, "auth_ref": [] }, "ahg_SummaryofSignificantAccountingPoliciesDetailsScheduleofNoncontrollingInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofNoncontrollingInterestLineItems", "presentation": ["http://www.akshealthgroup.com/role/ScheduleofNoncontrollingInterestTable"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of Noncontrolling Interest [Line Items]" } } }, "auth_ref": [] }, "ahg_SummaryofSignificantAccountingPoliciesDetailsScheduleofNoncontrollingInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofNoncontrollingInterestTable", "presentation": ["http://www.akshealthgroup.com/role/ScheduleofNoncontrollingInterestTable"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of Noncontrolling Interest [Table]" } } }, "auth_ref": [] }, "ahg_SummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "presentation": ["http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.akshealthgroup.com/role/ConsolidatedCashFlow", "http://www.akshealthgroup.com/role/ScheduleofCondensedStatementsofCashFlowsTable"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Supplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Supplies", "crdr": "debit", "calculation": ["http://www.akshealthgroup.com/role/ScheduleofPrepaymentsandOtherAssetsTable"], "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.akshealthgroup.com/role/ScheduleofPrepaymentsandOtherAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Prepayments to suppliers and others", "label": "Prepaid Supplies", "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r803", "r815", "r956"] }, "ahg_TaxAndSurcharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TaxAndSurcharges", "crdr": "debit", "calculation": ["http://www.akshealthgroup.com/role/ScheduleofDisaggregationofRevenueTable"], "parentTag": "us-gaap_RevenuesNetOfInterestExpense", "weight": -1.0, "order": 2.0 }, "presentation": ["http://www.akshealthgroup.com/role/ScheduleofDisaggregationofRevenueTable"], "lang": { "en-us": { "role": {

"terseLabel": "Tax and surcharges", "documentation": "Amount of tax and surcharges.", "label": "Tax And Surcharges" } }], "auth_ref": [] }, "ahg_TaxAndSurchargesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TaxAndSurchargesMember", "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Tax and surcharges", "label": "Tax And Surcharges Member" } } }, "auth_ref": [] }, "ahg_TaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TaxesPayable", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab { "lang": { "en-us": { "role": { "terseLabel": "Taxes (benefit) payable", "label": "Taxes Payable" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.akshealthgroup.com/role/ScheduleofTaxesPayableTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "http://www.akshealthgroup.com/role/ScheduleofTaxesPayableTable": { "lang": { "en-us": { "role": { "totalLabel": "Total taxes payable", "terseLabel": "Taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r91", "r92"] }, "us-gaap_TaxesPayableCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Taxes Payables [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "label": "Taxes Payable [Abstract]" } } }, "auth_ref": [] }, "ahg_TaxesPayableCurrentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TaxesPayableCurrentDisclosureTextBlock", "presentation": { "http://www.akshealthgroup.com/role/TaxesPayable": { "lang": { "en-us": { "role": { "terseLabel": "TAXES PAYABLE", "documentation": "The entire disclosure taxes payable current disclosure text block.", "label": "Taxes Payable Current Disclosure Text Block" } } }, "auth_ref": [] }, "ahg_TermOfLoanAgreementsWithAffiliatedParties": { "xbrltype": "durationItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TermOfLoanAgreementsWithAffiliatedParties", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Term of the loan", "documentation": "The term of loan agreements among affiliated parties, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term Of Loan Agreements With Affiliated Parties" } } }, "auth_ref": [] }, "ahg_TianjinAksoEnterpriseManagementCoLimitedWhollyOwnedForeignEnterpriseWOFEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TianjinAksoEnterpriseManagementCoLimitedWhollyOwnedForeignEnterpriseWOFEMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable": { "lang": { "en-us": { "role": { "terseLabel": "Tianjin Akso Enterprise Management Co., Limited. (Wholly Owned Foreign Enterprise \u201cWOFEMember\u201d)", "label": "Tianjin Akso Enterprise Management Co Limited Wholly Owned Foreign Enterprise WOFEMember" } } }, "auth_ref": [] }, "ahg_TianjinAksoEnterpriseManagementCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TianjinAksoEnterpriseManagementCoLtdMember", "presentation": { "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Tianjin Akso Enterprise Management Co, Ltd [Member]", "label": "Tianjin Akso Enterprise Management Co Ltd Member" } } }, "auth_ref": [] }, "ahg_TianjinAksoEnterpriseManagementCoLtdOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TianjinAksoEnterpriseManagementCoLtdOneMember", "presentation": { "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Tianjin Akso Enterprise Management Co, Ltd One [Member]", "label": "Tianjin Akso Enterprise Management Co Ltd One Member" } } }, "auth_ref": [] }, "ahg_TianjinWangyiCloudTechnologyCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TianjinWangyiCloudTechnologyCoLtdMember", "presentation": { "http://www.akshealthgroup.com/role/PrepaidConsiderationDetails": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Tianjin Wangyi Cloud Technology Co., Ltd [Member]", "label": "Tianjin Wangyi Cloud Technology Co Ltd Member" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": { "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and allowance for uncollectible accounts", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": ["r166", "r167", "r168", "r946", "r947", "r948"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://www.akshealthgroup.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": { "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails": { "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r316", "r317", "r318", "r319",

"r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334",
 "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r408", "r422", "r503", "r509",
 "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r565",
 "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581",
 "r641", "r836", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r849", "r898", "r899", "r900", "r901",
 "r902", "r903", "r904", "r949", "r950", "r951", "r952", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018" } }, "us-
 gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "TreasuryStockCommonMember", "presentation": {
 "http://www.akshealthgroup.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel":
 "Treasury stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common
 shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": { "r40" } }, "us-
 gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "TreasuryStockCommonShares", "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet_Parentheticals" }, "lang": { "en-us": { "role": {
 "terseLabel": "Treasury stock", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously
 issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": { "r40" } },
 "ahg_TreasuryStockDetailsLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "TreasuryStockDetailsLineItems", "presentation": {
 "http://www.akshealthgroup.com/role/TreasuryStockDetails" }, "lang": { "en-us": { "role": { "label": "Treasury Stock
 [Line Items]" } } }, "auth_ref": { } }, "ahg_TreasuryStockDetailsTable": { "xbrltype": "stringItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "TreasuryStockDetailsTable", "presentation": {
 "http://www.akshealthgroup.com/role/TreasuryStockDetails" }, "lang": { "en-us": { "role": { "label": "Treasury Stock
 (Details) [Table]" } } }, "auth_ref": { } }, "us-
 gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract",
 "lang": { "en-us": { "role": { "label": "Treasury Stock [Abstract]" } } }, "auth_ref": { } },
 "ahg_TreasuryStockPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "TreasuryStockPolicyTextBlock", "presentation": {
 "http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel":
 "Treasury stock", "documentation": "The disclosure of treasury stock policy text block.", "label": "Treasury Stock
 Policy Text Block" } } }, "auth_ref": { } }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": {
 "http://www.akshealthgroup.com/role/TreasuryStockDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Repurchase of ordinary shares (in Shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number
 of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": { "r16",
 "r100", "r137" } }, "us-gaap_TreasuryStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockTextBlock", "presentation": {
 "http://www.akshealthgroup.com/role/TreasuryStock" }, "lang": { "en-us": { "role": { "terseLabel": "TREASURY
 STOCK", "label": "Treasury Stock [Text Block]", "documentation": "The entire disclosure for treasury stock,
 including, but not limited to, average cost per share, description of share repurchase program, shares repurchased,
 shares held for each class of treasury stock." } } }, "auth_ref": { "r139" } }, "us-gaap_TreasuryStockValue": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr":
 "debit", "calculation": { "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-
 gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 },
 "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable": { "parentTag": "us-
 gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedBalanceSheet",
 "http://www.akshealthgroup.com/role/ScheduleofCondensedBalanceSheetsTable" }, "lang": { "en-us": { "role": {
 "negatedLabel": "Treasury stock (1,165,883 shares as of March 31, 2024 and 2023, respectively)",
 "negatedTerseLabel": "Treasury stock", "label": "Treasury Stock, Value", "documentation": "The amount allocated to
 treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the
 entity, and are held in its treasury." } } }, "auth_ref": { "r40", "r41", "r100", "r104" } }, "us-
 gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": {
 "http://www.akshealthgroup.com/role/TreasuryStockDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Total
 consideration on repurchase of shares", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation":
 "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using
 the cost method." } } }, "auth_ref": { "r16", "r40", "r137" } }, "ahg_TypeofAgreementAxis": { "xbrltype":
 "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "TypeofAgreementAxis",
 "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Type of Agreement [Axis]", "label": "Typeof Agreement Axis" } } }, "auth_ref": { } },
 "ahg_TypeofAgreementDomainDomain": { "xbrltype": "domainItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "TypeofAgreementDomainDomain", "presentation": {
 "http://www.akshealthgroup.com/role/ShareholdersEquityDetails" }, "lang": { "en-us": { "role": { "label":
 "TypeofAgreementDomain [Domain]" } } }, "auth_ref": { } }, "country_US": { "xbrltype": "domainItemType", "nsuri":
 "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": {
 "http://www.akshealthgroup.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "U.S.
 [Member]", "label": "UNITED STATES" } } }, "auth_ref": { } }, "ahg_UndistributedEarningsAvailableForDistribution":
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "UndistributedEarningsAvailableForDistribution", "crdr": "credit", "presentation": {
 "http://www.akshealthgroup.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel":
 "Undistributed earnings available for distribution (in Dollars)", "documentation": "Amount of undistributed
 earnings available for distribution.", "label": "Undistributed Earnings Available For Distribution" } } }, "auth_ref": { } },
 "ahg_UsdAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.akshealthgroup.com/20240331",
 "localname": "UsdAbstract", "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofLossorSaleofDiscontinuedOperationsTable" }, "lang": { "en-us": {
 "role": { "terseLabel": "USD", "label": "Usd Abstract" } } }, "auth_ref": { } }, "us-gaap_UseOfEstimates": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": {

["http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy"](http://www.akshealthgroup.com/role/AccountingPoliciesByPolicy)], "lang": { "en-us": { "role": { "terseLabel": "Uses of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r35", "r36", "r37", "r173", "r174", "r176", "r177" } }, "ahg_VIEsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "VIEsMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab", "lang": { "en-us": { "role": { "terseLabel": "VIEs [Member]", "label": "VIEs Member" } } }, "auth_ref": { } }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityLineItems", "presentation": { "http://www.akshealthgroup.com/role/ScheduleofFinancialStatementAmountsandBalancesoftheConsolidatedViesTab", "lang": { "en-us": { "role": { "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r491", "r492", "r495", "r496", "r562", "r563", "r564" } }, "ahg_VendorConcentrationRiskPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "VendorConcentrationRiskPercentage", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vendor concentration risk percentage", "documentation": "Vendor concentration risk percentage.", "label": "Vendor Concentration Risk Percentage" } } }, "auth_ref": { } }, "ahg_VendorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "VendorMember", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vendor [Member]", "label": "Vendor Member" } } }, "auth_ref": { } }, "ahg_VendorRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "VendorRemainingPerformanceObligationPercentage", "presentation": { "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vendor percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as vendor.", "label": "Vendor Remaining Performance Obligation Percentage" } } }, "auth_ref": { } }, "us-gaap_WarrantExercisePriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantExercisePriceDecrease", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase price per share", "label": "Warrant, Exercise Price, Decrease", "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": { "r425" } }, "us-gaap_WarrantExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantExercisePriceIncrease", "presentation": { "http://www.akshealthgroup.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase price per share", "label": "Warrant, Exercise Price, Increase", "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": { "r425" } }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails", "http://www.akshealthgroup.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": { "r866", "r867", "r870", "r871", "r872", "r873" } }, "ahg_WarrantSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "WarrantSharesMember", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant Shares [Member]", "label": "Warrant Shares Member" } } }, "auth_ref": { } }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": { "en-us": { "role": { "label": "u200bSchedule of Warrants Outstanding [Abstract]" } } }, "auth_ref": { } }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "credit": "credit", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants outstanding (in Dollars)", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": { "r1014", "r1015", "r1016" } }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term of warrants", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r1014", "r1015", "r1016" } }, "ahg_WarrantsWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "WarrantsWeightedAverageExercisePrice", "presentation": { "http://www.akshealthgroup.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of warrants", "documentation": "Represents the weighted average exercise price of warrants.", "label": "Warrants Weighted Average Exercise Price" } } }, "auth_ref": { } }, "ahg_WeHealthLimitedWeHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "WeHealthLimitedWeHealthMember", "presentation": { "http://www.akshealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable"], "lang": { "en-us": { "role": { "terseLabel": "We Health Limited (u201cWe Health\u201d) [Member]", "label": "We Health Limited We Health Member" } } }, "auth_ref": { } }, "ahg_WeHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname": "WeHealthMember", "presentation": { "http://www.akshealthgroup.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "We Health [Member]", "label": "We Health Member" } } }, "auth_ref": { } }, "ahg_WeHealthLimitedMember": { "xbrltype":

"domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "WeHealthyLimitedMember", "presentation": {
 "http://www.akshealthgroup.com/role/SummaryofSignificantAccountingPoliciesDetails": { "lang": { "en-us": {
 "role": { "terseLabel": "We Healthy Limited [Member]", "label": "We Healthy Limited Member" } } }, "auth_ref": { } },
 "ahg_WeHealthyLimitedWeHealthyMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "WeHealthyLimitedWeHealthyMember", "presentation":
 { "http://www.akshealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable": { "lang": { "en-us": {
 "role": { "terseLabel": "We Healthy Limited (u201cWe Healthyu201d) [Member]", "label": "We Healthy Limited We
 Healthy Member" } } }, "auth_ref": { } }, "ahg_WeHealthyMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "WeHealthyMember", "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofNoncontrollingInterestTable": { "lang": { "en-us": { "role": {
 "terseLabel": "We Healthy [Member]", "label": "We Healthy Member" } } }, "auth_ref": { } },
 "ahg_WebaoLimitedMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "WebaoLimitedMember", "presentation": {
 "http://www.akshealthgroup.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel":
 "Webao Limited [Member]", "label": "Webao Limited Member" } } }, "auth_ref": { } }, "ahg_WebaoLtdMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "WebaoLtdMember", "presentation": {
 "http://www.akshealthgroup.com/role/RelatedPartyBalancesandTransactionsDetails": { "lang": { "en-us": { "role": {
 "terseLabel": "Webao Ltd [Member]", "label": "Webao Ltd Member" } } }, "auth_ref": { } }, "us-
 gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
 "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleofOutstandingSharesforBasicandDilutedNetEarningsPerShareTable"
 }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of dilutive potential ordinary shares from
 share options", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation":
 "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit
 computation." } } }, "auth_ref": { "r938" } }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
 "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement",
 "http://www.akshealthgroup.com/role/ScheduleofOutstandingSharesforBasicandDilutedNetEarningsPerShareTable"
 }, "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Shares)", "verboseLabel": "Weighted average number of
 ordinary shares outstanding-diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted",
 "documentation": "The average number of shares or units issued and outstanding that are used in calculating
 diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the
 period." } } }, "auth_ref": { "r282", "r288" } }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
 "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": {
 "http://www.akshealthgroup.com/role/ConsolidatedIncomeStatement",
 "http://www.akshealthgroup.com/role/ScheduleofOutstandingSharesforBasicandDilutedNetEarningsPerShareTable"
 }, "lang": { "en-us": { "role": { "terseLabel": "Basic (in Shares)", "verboseLabel": "Weighted average number of
 ordinary shares outstanding-basic", "label": "Weighted Average Number of Shares Outstanding, Basic",
 "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and
 other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period
 that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r280",
 "r288" } }, "ahg_WhollyOwnedSubsidiariesAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "WhollyOwnedSubsidiariesAbstract", "presentation": {
 "http://www.akshealthgroup.com/role/ScheduleoftheCompanyPrincipalSubsidiariesTable": { "lang": { "en-us": {
 "role": { "terseLabel": "Wholly owned subsidiaries", "label": "Wholly Owned Subsidiaries Abstract" } } }, "auth_ref":
 { } }, "ahg_WithholdingTaxRate": { "xbrltype": "percentItemType", "nsuri":
 "http://www.akshealthgroup.com/20240331", "localname": "WithholdingTaxRate", "presentation": {
 "http://www.akshealthgroup.com/role/IncomeTaxesDetails": { "lang": { "en-us": { "role": { "terseLabel":
 "Withholding tax rate", "documentation": "Represents the rate of withholding tax for dividends paid by an FIE in
 China to its immediate holding company in Hong Kong under specified conditions.", "label": "Withholding Tax Rate"
 } } }, "auth_ref": { } },
 "ahg_WithholdingTaxRateOnDividendDistributedByForeignInvestedEnterpriseToItsImmediateHoldingCompany": {
 "xbrltype": "percentItemType", "nsuri": "http://www.akshealthgroup.com/20240331", "localname":
 "WithholdingTaxRateOnDividendDistributedByForeignInvestedEnterpriseToItsImmediateHoldingCompany",
 "presentation": { "http://www.akshealthgroup.com/role/IncomeTaxesDetails": { "lang": { "en-us": { "role": {
 "terseLabel": "Withholding income tax, percentage", "documentation": "Represents the percentage of withholding
 income tax rate on dividends distributed by the Foreign Invested Enterprise to its immediate holding company.",
 "label": "Withholding Tax Rate On Dividend Distributed By Foreign Invested Enterprise To Its Immediate Holding
 Company" } } }, "auth_ref": { } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
 "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role":
 "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45",
 "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10",
 "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-
 10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
 "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A",
 "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14",

[illegible]

[illegible]

[illegible]

[illegible]

Standards Codification, "**Section**": "45", "**Paragraph**": "25", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147482740/230-10-45-25](\"https://asc.fasb.org/1943274/2147482740/230-10-45-25\")" }, "**r123**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "230", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "45", "**Paragraph**": "25", "**Subparagraph**": "(f)", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147482740/230-10-45-25](\"https://asc.fasb.org/1943274/2147482740/230-10-45-25\")" }, "**r124**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "230", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "45", "**Paragraph**": "28", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147482740/230-10-45-28](\"https://asc.fasb.org/1943274/2147482740/230-10-45-28\")" }, "**r125**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "235", "**Name**": "Accounting Standards Codification", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/235/tableOfContent](\"https://asc.fasb.org/235/tableOfContent\")" }, "**r126**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "275", "**Name**": "Accounting Standards Codification", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/275/tableOfContent](\"https://asc.fasb.org/275/tableOfContent\")" }, "**r127**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "310", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "S99", "**Paragraph**": "2", "**Subparagraph**": "(SAB Topic 4.E)", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147480418/310-10-S99-2](\"https://asc.fasb.org/1943274/2147480418/310-10-S99-2\")" }, "**r128**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "360", "**Name**": "Accounting Standards Codification", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/360/tableOfContent](\"https://asc.fasb.org/360/tableOfContent\")" }, "**r129**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "360", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "15", "**Paragraph**": "4", "**Subparagraph**": "(b)(2)", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147482309/360-10-15-4](\"https://asc.fasb.org/1943274/2147482309/360-10-15-4\")" }, "**r130**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "360", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "45", "**Paragraph**": "9", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147482130/360-10-45-9](\"https://asc.fasb.org/1943274/2147482130/360-10-45-9\")" }, "**r131**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "360", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "50", "**Paragraph**": "2", "**Subparagraph**": "(b)", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147482099/360-10-50-2](\"https://asc.fasb.org/1943274/2147482099/360-10-50-2\")" }, "**r132**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "360", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "50", "**Paragraph**": "3", "**Subparagraph**": "(e)", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147482099/360-10-50-3](\"https://asc.fasb.org/1943274/2147482099/360-10-50-3\")" }, "**r133**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "360", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "50", "**Paragraph**": "3A", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147482099/360-10-50-3A](\"https://asc.fasb.org/1943274/2147482099/360-10-50-3A\")" }, "**r134**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "360", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "S99", "**Paragraph**": "2", "**Subparagraph**": "(SAB Topic 5.CC)", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147480091/360-10-S99-2](\"https://asc.fasb.org/1943274/2147480091/360-10-S99-2\")" }, "**r135**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "440", "**Name**": "Accounting Standards Codification", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/440/tableOfContent](\"https://asc.fasb.org/440/tableOfContent\")" }, "**r136**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "505", "**Name**": "Accounting Standards Codification", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/505/tableOfContent](\"https://asc.fasb.org/505/tableOfContent\")" }, "**r137**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "505", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "S99", "**Paragraph**": "1", "**Subparagraph**": "(SX 210.3-04)", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147480008/505-10-S99-1](\"https://asc.fasb.org/1943274/2147480008/505-10-S99-1\")" }, "**r138**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "505", "**SubTopic**": "10", "**Name**": "Accounting Standards Codification", "**Section**": "S99", "**Paragraph**": "4", "**Subparagraph**": "(SAB Topic 4.C)", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/1943274/2147480008/505-10-S99-4](\"https://asc.fasb.org/1943274/2147480008/505-10-S99-4\")" }, "**r139**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "505", "**SubTopic**": "30", "**Name**": "Accounting Standards Codification", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/505-30/tableOfContent](\"https://asc.fasb.org/505-30/tableOfContent\")" }, "**r140**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "710", "**Name**": "Accounting Standards Codification", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/710/tableOfContent](\"https://asc.fasb.org/710/tableOfContent\")" }, "**r141**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "712", "**Name**": "Accounting Standards Codification", "**Publisher**": "FASB", "**URI**": "[https://asc.fasb.org/712/tableOfContent](\"https://asc.fasb.org/712/tableOfContent\")" }, "**r142**": { "**role**": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "**Topic**": "715", "**Name**": "Accounting Standards Codification", "**Publisher**": "FASB

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

**Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147477891/740-270-50-1> }, "r480": { "role":

<https://asc.fasb.org/1943274/2147482603/740-30-50-2> }, "r481": { "role":

<https://asc.fasb.org/1943274/2147478758/740-323-25-1> }, "r482": { "role":

<https://asc.fasb.org/1943274/2147478666/740-323-65-2> }, "r483": { "role":

<https://asc.fasb.org/1943274/2147478666/740-323-65-2> }, "r484": { "role":

<https://asc.fasb.org/1943274/2147478666/740-323-65-2> }, "r485": { "role":

<https://asc.fasb.org/1943274/2147478666/740-323-65-2> }, "r486": { "role":

<https://asc.fasb.org/1943274/2147478666/740-323-65-2> }, "r487": { "role":

<https://asc.fasb.org/1943274/2147479907/805-20-50-5> }, "r488": { "role":

<https://asc.fasb.org/1943274/2147476176/805-60-65-1> }, "r489": { "role":

<https://asc.fasb.org/1943274/2147476176/805-60-65-1> }, "r490": { "role":

<https://asc.fasb.org/1943274/2147481231/810-10-45-19> }, "r491": { "role":

<https://asc.fasb.org/1943274/2147481231/810-10-45-25> }, "r492": { "role":

<https://asc.fasb.org/1943274/2147481231/810-10-45-25> }, "r493": { "role":

<https://asc.fasb.org/1943274/2147481203/810-10-50-1A> }, "r494": { "role":

<https://asc.fasb.org/1943274/2147481203/810-10-50-1A> }, "r495": { "role":

<https://asc.fasb.org/1943274/2147481203/810-10-50-3> }, "r496": { "role":

<https://asc.fasb.org/1943274/2147481203/810-10-50-3> }, "r497": { "role":

<https://asc.fasb.org/1943274/2147480528/815-20-65-6> }, "r498": { "role":

<https://asc.fasb.org/1943274/2147480528/815-20-65-6> }, "r499": { "role":

<https://asc.fasb.org/1943274/2147480528/815-20-65-6> }, "r500": { "role":

<https://asc.fasb.org/1943274/2147480528/815-20-65-6> }, "r501": { "role":

<https://asc.fasb.org/1943274/2147480528/815-20-65-6> }, "r502": { "role":

<https://asc.fasb.org/1943274/2147480528/815-20-65-6> }, "r503": { "role":

<https://asc.fasb.org/1943274/2147480237/815-40-50-5> }, "r504": { "role":

<https://asc.fasb.org/1943274/2147480237/815-40-50-6> }, "r505": { "role":**

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"Codification": "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",

"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477271/946-320-S99-1](\"https://asc.fasb.org/1943274/2147477271/946-320-S99-1\")", "r871": { "role": "

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2)))",

"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477271/946-320-S99-2](\"https://asc.fasb.org/1943274/2147477271/946-320-S99-2\")", "r872": { "role": "

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1(a)))",

"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477271/946-320-S99-3](\"https://asc.fasb.org/1943274/2147477271/946-320-S99-3\")", "r873": { "role": "

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2)))",

"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477271/946-320-S99-6](\"https://asc.fasb.org/1943274/2147477271/946-320-S99-6\")", "r874": { "role": "

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479168/946-830-55-10", "r875": { "role": "

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479168/946-830-55-11", "r876": { "role": "

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479168/946-830-55-12", "r877": { "role": "

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240",

"Section": "12", "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":

"Exchange Act", "Number": "240", "Section": "12", "Subsection": "b", "r879": { "role": "

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240",

"Section": "12", "Subsection": "b-2", "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":

"SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1", "r881": { "role": "

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249",

"Section": "310", "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name:

"Form 20-F", "Number": "249", "Section": "220", "Subsection": "f", "r883": { "role": "

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249",

"Section": "240", "Subsection": "f", "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":

"SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1", "r885": { "role": "

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",

"Section": "402", "Subsection": "w", "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":

"SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405", "r887": { "role": "

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230",

"Section": "405", "r888": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher":

"FASB", "URI": "[https://asc.fasb.org/1943274/2147483014/272-10-45-3](\"https://asc.fasb.org/1943274/2147483014/272-10-45-3\")", "r889": { "role": "

"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483076/450-20-50-10", "r890": { "role": "

"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB",

"URI": "[https://asc.fasb.org/1943274/2147478156/740-323-50-2](\"https://asc.fasb.org/1943274/2147478156/740-323-50-2\")", "r891": { "role": "

"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB",

"URI": "[https://asc.fasb.org/1943274/2147478156/740-323-50-2](\"https://asc.fasb.org/1943274/2147478156/740-323-50-2\")", "r892": { "role": "

"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB",

"URI": "[https://asc.fasb.org/1943274/2147478156/740-323-50-2](\"https://asc.fasb.org/1943274/2147478156/740-323-50-2\")", "r893": { "role": "

"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481231/810-10-45-11", "r894": { "role": "

"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483399/855-10-50-3", "r895": { "role": "

"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45",

"Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482740/230-10-45-15", "r896": { "role": "

"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479806/606-10-50-13", "r897": { "role": "

"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477351/944-825-50-1B", "r898": { "role": "

"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section":

"1402", "Paragraph": "a", "Publisher": "SEC", "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",

"Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)",

"Publisher": "SEC", "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K

(SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC", "r901": {

"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229",

"Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC", "r902": { "role": "

"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "2

"1402": { "Paragraph": "c", "Publisher": "(2)(iii)", "SEC": "SEC", "r905": { "role": "

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-599-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-599-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3" } } ZIP 108 0001013762-24-002658-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001013762-24-002658-xbrl.zip M4\$L#!0 (+B-ECX KE=Z!P "1E 0 0 86AG+3(P,C0P,S,Q+GAS M9.U=77;N-'_SX%\$S\$3Z_3.K8D.X{3}:U9MBJ.\$0Q2IQ+IW-#D9#\$,T7H M %*VIM, /+BDG@A*,L6W+ S;6,1 ^+72QV% XOENW^3^UK#A#V8/^J_5J M=|L"@0=+QB_WJYVNY>| <{.MOIYP.)^>O< VIO6+R R Z!;PT75@L.9U>. M9UTC.+CB*6S^TKI;V 0G#Y=N=G20I^U<.:8,=#P\$,^0 3'^PMK?)@.F0 M/03H@&^MZPA8GR+?ZNO;K3=O6P=OHO6S77;N^V|^N/HUIP&^Q.P%3VP(^ MF((@/'60/08C_+ #IUM_1+;OC3S@;EF\$KH"TI>%VN)@! 'XKP32R? 51..= MI-\$.'7+'FTT!N&%/05X9CL@ZT")L.L_PG #;#R=C!*9I8'UVNUT6NFK7'^X M*W1Z&^*?O.FJNJ09H8^'^@9AP>N_7V'M6X='A|NL*=I4WLRKHTEPC*ZTR<) MV0D:+)@"+=V_07E_(K->.:6T.6&62LF2LI<.TJ1LB|920!SL4|071WMJM M;^'^1TS:>8B*| (=YX("M#19/ED4%P@X"&-HAD6 J53|1R6(-SV9>.(?DI (MCW12WZ;N 0CBTWS6PKD_1;VIC.?LH?]-D%@|'Z+S/QV.K.^?;P%8&8MK"1 M@Z /U" SX(EH6ANS'-M=K+(.YWQ_-&J0!-M>TVHL_-M;B|/*K45&|P' PQ|SZ7*^|CVZ9J^F@+| E(? G,M|0I)YWS(36P*0F\$#T1Q MD6WHBH@9VR3(O_C6DE>_#6Q\$9F("0H^@PSJL*W>YX&I;GY/6S!7!_RI@ M; <-7"5_/B-TW!=E,RWA9;B8DK|# CHJ|V0-LP9'5GU'KDG3#EAVXS,+\$8 (" ML,VH?2,YQ\$*6-JNUR- 6K"5D%\$^B|Q*X_ ^2/RP@4=HPU1)|I41:L//&D%CNH M<|0WL8,OP)876/D7_M _OFFW#OYAO2|NEJG^,NW9>' +JPWO9^LR> # ^!MA!WHO'R'-*|+AR!WO^-^/L8<>'. \$*_)& M8N6&\$?F84V.-;|+Q@3.7<*O"D\OU=G90Y@;K;R4#.*JL8F^*IE,;+>#H MRAL'WHB8:4'8=1P8!2&9Q00100IQ5@KIE%X?K8*7'M3YEHR+%5PN8&MY<*+'A M>KX7E08_-4Y5K.1B#D3(JSH\$'U_KE@_-2ZL M\$>.^= L! W=9*/ '|.8GID. &)G;P7D)JNW\$?7/ @'2,YF;7(/\$A7V/E MU3^B51_-5@1VVEP (3_57^3'K U;BML(KY^A|97(73N'OM^X4\$\$.|@H0MK; M8MT;NZK20L8A|AOBHEZ 4."C"AY7G&VN1#^E9E MFG\$1@N415CQ\$83YH2X")|BGGH|<|IVS|+Z|4*|@_.P@F(4QEI"IP=+*K9 M/K6Z5B|W+D*0Q<+*WF'E7D(C>^0U5OP>*WE1XQ9IG<#FDA.:%NQ?"|SOK*B5 M>F4>'K|>W94=Q^&S&?Y. |^|S0UH_IS|*RH;HJDSNZZYXR9Y(Y5OQ5C'N5>B M+^_KYW@X21HLP|ZN48|VOUJH|&6MY|TP|^4C)| (;52E('_5S;IV2L9, MSKL3YR0UC^M49A+/.%4S+<9Q+J L5:E'R3;TQXGFT5F'GW+N854;4L8 M5TREX5DH;|AFC)^8SEW1L6DAD>KI@ (E6BMKEJ^E7.2Z^4_-Q2X7"39ZW@ MJ3).S5C'G3H7#CK5&V'#& (&9)H_-J'6NN).H?_H.V6|HBC4)Y^BE;5FQNZ? M|B|H^VT|^.? =9.6|=5D;#4N23X@7G9LV+NZP#;|S|4&J-SJ^|S|E8)=.'|@C.SVS?7JY+>F>C5)CL|'F;W;5V4|YY^YQ@/48A+;G M8UK'BMY2W+X@W(F632D0"Z" _3DHA67E;3=B@UEW<9;)E5W+3QSKJG OQ%.|F M+GG;<&A-P7;| |^IUK^H6X>^6U(F=* G=L%NHHK+L,*L"TV9R,"EOXM-<|40O M+TM&2% K|4>.J:7>|7D)|06%=LMI^Z5AL*R5D2|G;8TL=S|&7)5-+DMH)& M(2"1YAGC|<(C|+|Q+;01 !A5@I>U1;A%S<:@T24X1\$?TE-9*#@+PDG./2F M= W=8#^*_ -O3M7#("YFMR+C_IE;|H:%<)>1=Q M)??. (A)2DL@8QH1"M%(S% MT#^ID< L/6H|H-422@0.CI)=I17"7ZN1Y9,TSLQ*-B7/&J5"5W70V0^XFS A5 MI|3F<2I&G^B|N CI ^B LO^VE+RYM7JG/ME# USV.\$3&E77*EO."ID.#UJ M@|&5Q=+*U^VL\$8? D;QMI\$1>B@6BSRG&H@T8TO,I FCTHT0,RJM7P?S| M)7FJ885*^*FUC|>R'AI RJ^'^15|O<#+A19G9^H%>-5_8DJf%&@36"^YY6 M&^UWW2>^/3X,VZG^N#GIW:WX MFS_!Q2AT>X2W4|M8/_Z'1P.CJH:00XWZ MX^S.FIN'R;|^M7_HJ1Y^'.S)|@PY.JW^YILP.ZQGN.5YX?+GW_C|6|^J2 M? E!L#>M"5,U0H.94S71T68>+I+I+(&8*|7&E\$ 6<4I;K-|0Z7'1/6A|1R;N& M=3*OKL9U!JFG5V>.:N^OPX4 ZIZ'J/0)'UV1L1&HFB4919I|OY>6BN>BB)IU M&J02VAI>JXHVA@K:U*M|FX'U?L3G&647/Q*J<;Z:U+AH7>D2E.3= MJ*H)V3|31C^- MS66|KU&(40+EC02 MPMQUC)/1"! #9\$XY39JL/1H^K(#A? MTY*=);3XLLIES|K0)4DT(W&#C^+RCNDURL*_ M3+&0/69_?GBX|***YX28W2SK&F6T|0I8^+Q2IU:4U6|' M8/5"GEPI;6&(4|H|@Z^IU=SNSFS6KF.L_#VK;A)931E3W#1ME37N0FI/%D9 M# \$G5QQ|9T?D F8#1,0>@0JKBTCY?

Y:(L,%TYY'9*R?BV,4VXU* X M-\$ <?*!P:~U?BHY5SM|^%WADNDA,"V&LIG-
*N+0B=BI5T"IR0(O7"18TY+N=I_ S6GLT0G7R8_Q3\$, "8DE0IOR_ M>M,91*5\$V%
9I8#"AQI&"+%43CG?;N;F?'"V@|TR&+9%,K7/H<.&4W2A M?VVG_ ;I3INMIG:G|>H:INULI'U9!08D>VK@VBK3?
*BA&AZRX2'9*YQF3< MJHX 2;MV>OSG< ;V/6-I=H?XFR8;2K3:G/AAFB'CD%';6I3BCHM.9ZJGNQO MG
'1D(I/L_!SOIQ0FR-J|J* >5;M;F 4; &'TBO'NR.8HT"4= ^25&,YW ML.2H@'@"WI+HO*AY*?
#C4E+TK>^WTGVH/IJN'k';8">(0V0YA :7I_19IJ?>6 MOM2"1IG9M:B"V++LI-7IKI!%Y.^XU0P@#
IK7K)\;H40K/YIOTPTX;8O)VX@R MC>C37ZAZ3U_BD>&7V_L*D;.\E|SO+1/6798)2UY9+!-FX,0GA:=&2N6F^JG M%;
G(JI,5E*-75-2IGQ5UZN:*.ADX!2N UY\$!<=\$B ^FO *I#*U>_IRNN MPV, @I;6A|WS06!;#B2@4&DE!;5(2YU?OLPH-
+XCN&J|SUJ%L"HIE"0RD6HVS MVA+*77C0%FI@&TAK-5;ME5RZAI25WD,R< KJ8Z16-4;AX&4JU|JK&=QW-Y M.BN
ZJAO01RP+PLKFSP#>=>#7\$8'"N&EXI,5;_! =8H?1N H*_-0:0QV/2;HY MKNFN>>AW:IU^RSP"6K4(:)M'0+L6
1WS".C4(F#//+V;A&P;QX!/@4(>T> M:JK\$7!;@'@\$'M0AX8QX!;VH1<&@> 8?U-C(#M^+6KM37Z<6Q+1P B&\$EPM
MHAH7K2D3#&I;L+1R<V2 P.MIE9;RI<+&_8_ S6@;0V2X;BT1 ^V_5D2?*"KZM M@>9?;T^* W8"?
7_1OP^("VOBZ6H5/M5161)R*P8@-|M2F#L|JDM PWTUKY| M;Y=&/HWA41";E"&F'2P+CX_%HH3SOVO&\$""!56-
%&.COM5|+PUL4+0OAT6E M3'GZ# '126PO0B3MMH|&Q@";.M# 'QI\$'.D2(5-7Q6U#?3IVW+?
MGV|KH;/E8+IU2P'++=BH\$;C## MA7 5H2V;:D#_2U73W/8!2P'#2=\$^J;N,4?FL"EAHHA8)
YI&IA"=U7H79I@8R41.H=#??J_VTL-W-/GSAJA2%-I>0(.+ M|3CFD;T;FW4Y?
@^Q_(R1^!>P5%3VR%8S!;#P/\$8<%IYE"#\$X\$(CL"K114I.^ M8E; P&+PK&@!UDCI/(4(\$GDOR!M)MD:
<+7N;C00AA.O*YJG9S?V#;@ZM6; M27HU6OUL_G+3%3C;IKD8K->&XBR|8U(C;GH'/OX#)=!KKQ-0@03\$+>0=!GG-2
M'NGYZI@.D'KQES-2V@K#H"/B56_A?R.L?VC!<?5(FDX);CC*?>N>J-!&K; M+S_!NJQ8)+JH#3;V,Y=U+
IF%_8SQ!+=.V\$!\$1-1GQ2WL>0B6FSA/ ?YS M+V DEX"/&SB)>3Y2GT#%\$%2L,RQ=G?7'K%EWQNUZIF%:1H1))
<2!XCH|)%|& M;IY(>A15-M6;IU)6)D/FSV?;?L>V8TX)5^+RH.>9M^O3#@QI9#;<%P8!(T"=Q*3X\$ _N6-M5&&0?
*R#+A|2IGDC'4)FTK;=-YI0: ^7N0%IINA*W.D|DBB'M"K%DxN?F+T
M)&H3|Q2SE@4M7OR4!92H2JK0K(PC&P.75F<@W=FP71K1&|VIXMEDT%5YUZ9@6?S@VBK'I6K-B(@(^_&Q\$6W>
<\$L4 M/IU%8?89YV;G1;Z^\$C9?@JGM!V?>Z/2A*9;_9FOPE1 5.CF.B?T MIAWSK@!^33-ASHGMBK!ENND+D9IH-
(T_%V.NE5.\$J3-0+Z+I\$"#Z)00IZ!(E M\$)>.+A+F!2\$8_2LNY,\$E^(:D#3\$4U(N*SFC>CC_3!G)3 MP QB+|0I2)0;<(^H?
B>XB/#(:;Q8%_<#D QA'M?Q8,MQ&LW56X%21_L1_HDL|O_6R;CA8?83#^3/Z;3.H P9>Y,+(^)+-W|BY6)D@
MQ21E8L3FEVSY+V MJ# KBB|QI=B+< BG *UI8Z^C_%QDZH6_0QHJ8D#12GK%_M;D=.(10/!%"A4T;<4RI_P8#"R*#V)\$
DFD<8;-B;LQD^UDCGH#WTO_B2< M0=RI"5>5NQ;|06&W'1IK;JA8HVIDA5-IKC/V!5+R\$OBIO;I(ORU!^XUV?
QS:P;4;_M=9'+|!#;!.%Q&GY++F^DZ2)5YOK26NB5;=S%_5/KS^Z";AH99_F?3%3(*= M;F5D2;7&1LMD"!4;CTI*#;
<1!51Q2%*R7U3ZKRXM&F*07M)>)&Y@|E3B2(O MF#V|3GAD,+X> '%?MA1%3MB8VH38N|B>Z"B
M'AER^:1;%HDO5U8\$+5#XZ|=EZ_=X^8:C19*H?Q;B18FKZ3Z>.(8!#*|A M68C/IE-"#NGI,1XK^0SZQA?
9\$Y.G;@ "IUH#9T(=UZ'S_%%"KT'NJ|R9HLYD MSBE(N;IQ0H2@%/0%VIE8XRDR!8TCI)?
A_|Z2XI)=GM=A5R)27M;GJO88;*A5 ME9LO+98'W&X43B"B%<'B*JGLM-?LW58%7!D#H9).5F8(^XC|Z\$H|KGYQ#TY
MM&IZ7@;!!&15"!#KDI>1\$6T_CEW"D6DLJT2HR)+ (NK*FQ^DN<@JN8LR8\$I.MI?DB U;D|,88<;F#*HG5I
|@T39;5X|BF%)7;F\$ M;ZHDQW3I(521F?%AHK*A-K ESEQ9V<4^J|TXLU98#DV=&PXHNZ\$3N3M.\$GHEL;\$&3H?
>PI#%\$|A;./P;#";7+0QIX M!^@A#%#;2@V^_.K1;3CHO2)H58HUZ9#4*>|Y,')90BKQ)\$H_&T;I/E85X^/F M"" C(&
8I2J.RM@=:=X/?+*F;:=KX\$QZ|#QT^9^-H;<_VGJ4&TJBWN*!|%;8 M@E2^88 C/V1("FN^T,H8>E?'KHBPOPOJB)B->
<4O;E"THJ ?+&1;|DWCAP|+%7A\$CAG;5JO2;^4>0HH4FU=-) M(6G0-HX^S)S1#)=4 ^C@A"5U3PA3UL\$IS8N-
1;NU@O/#883(IJ N@ M#|<+X|A;B5*QN7XI.S%#=#6 R)@25!^BFKI%+EG8 N0J00D%L06S;I
MZ@0&9<&HL6D09105^K"- "AQ)0"D71;E+|K>1!)71*;H9F\$E'A5JH!4;*\$=\$ M \$AJBL5M#>F/2V 4*_ DHPEX
_#X&V\$>=J|K=3?|M;M&M4A4W*AUPU/7/R7X6@ M%;4;+6_C.&*|IRJ6|MQK29!_NC#^V;Q9E2H2JJQ4T3;_NL'@G%8;.
(PT M-3KHQ&2+TOW1_08!@9T9QJG3)BSH!;0F5=O/+&4*T5K9E|WISB;9%4
M&4+5UWFRSKE/A<9V^"E\$1S;VG"ZM"~33FD 7(\$SK*J51;0-GX9&\$;:SA"6IS; MX.L)&%SVEO2*;
6R;TA^30XK<5;2+*DP9;|K8;.^<\$ _=*?0\$M(C_4^9+= M|C|F+K1 IL|NQU")";S-|79KOW_4\$L#!0 (-+B_E@P*HC?
KQ8 &5(M 0 4 86AG+3(P,C0P,S;07V-A;"YX;6SM76|SVSC.2I^?PI?GS?;C3?_M-LVVTJZ-
8R>MTS1QI23=|N9FAY%#H6QN9/OOYXG=F&J6@YYMW?XZV!> Q/#,2TR>K=W-VBV!NUN=^? M_VHT?
GGICV;S|X33)&'S<#;0_%V)M;I835N*2+NT*&3QOI2D_IK-|MCSYN^ MV=|>GKZU6#?<0V+8M?
QJ8%=-D&CV60#+H=L4P'?_X17^CTK<;QP>-PI_? M')Z^_3EJW-
VV&T<^1|M_N27M|9%A^0BQN;.^~^VXM0>GZ@J|;.>T?'1P< M|F^N+?XYIMG_L^JY^.@V!?
OGH>C_X|>JKKIT13;LX?ZGZX&OAA4;_B MKH>(P0FXUALW^/#*;9_72#*3KX;P&_Q?S>77FORCYN%1|_CPUV?
7W%O(K=%X M2QT;|&P\$7#^QIM|A;LIUYL;_D #XX7(C_P/^!/^F2; M(C;YC6R;7_!FR^40&8XR|O08?^*I?
W9@>G2=,4;V-QY1QYIR#/?YI_:%P^P' MC\$)SVF6J;<\$#C_T|P;0;L|LC;7Z!>6TC=WQA.T|EF#P-P;4)P|I77-.WL3+_ML
C#RD+V2@*MB>;3ST5DB;K#+TQCK)S;V'W% CUP8KFF!\$86|J0U.QW+1;1 MQ;-@T3K#|YAXN-RC|LBVOM)*|1P1?
1E>_ZSID@%0!(3L^G+6-B-\$P@J79QP;V9IS;_29*(B;> MJ46X2&<_JT#%\$U@ (KK5)|@X&S2(N>L=M# M?
X|Q<0M*VR)H54L7C;OPS99|B_3S5Z_ MS?=-WW/HO;IV4|=S@NUU;D5D|IX|A|CPK|EGC/^VW'Q+SU8A#>9)F%S@&^YI
M;6#%8|+K9TAKY3*Y"|VB>P^9R+DF1204;F)4U)*5X;7(2;_1N*6;OC;&! M;_W@TWVBK\$?3H(6#(RVA 1?
08PXXG=;|P4;ZU'6(C;*'IVZ_"L;6#| MW9|O-D<3?|>#;QMGI@&HH'FO|H.B;#V'*(W(<@P_S<)|#L(|MSUU^\$H 2
M)(IAKJW\$QR;=(S;R;J)T;I;1)|#;R;V-E|X)=XMN MS@Y18D>^S&F 90!>_B-?>?3(+1FA;3M;7?
#ZDSR4#/_Y+ARR%@"N9%2,Q|JLK4\$JY!_0TO/XNNF MU+;S7*61\$%7Y I_-L^Y+35)R(5ZO-;@IEVM8@.*8%%C)
1R"25_"K52-C;4 M&+4ZR%>LH+8%NNWM%A5H)\$FLI1<3"!8RC GMG)K#(ZV%0^F=SDM3OR8I\$D
MF5%YL8K4L%"\$!"/(L|8GGCMN|ZS@33)) (HK+6KOG_D2D889!61?; NE=LY\$94=,6=" (0EBL;(|YU;LT"6&I?;2
MHL0S2^7;_""N=@39TD(716XE-4=FK79A3+@4.6@#CS>|PI-AQ4Y5E@;PXL MZP0"9;+|SF3BD&!)8G|
|>&U;H<8FTT?95LDP"K2;DV+4;%/LL@#"GW|Y8+;_#AY9A06|I|\$@3U M^HURX,C(=#=2-C| (G*6-<^I%&3<_I;
|&W@TO0H\$HW-1UYR%EQ@>44*>#|P M2S%R?3I7MND\$-@1NYM1Y+RGC
MQ6X,104>J;XK;+ "RQW0Z8_5L"6"PG";(Z8)24GR99K|>(W|SX3W;O^X1YTA>!@9'5DK! E33\$
AUS"*U0#Q;_HNKUN*01B@@"<@&B;.(SQ-P1GHQC!*>H6U3;A_-M@9R<91+!
(1W1,7G9'6V=|5>UI\$0IZ|_X1<|ZP0%&W(C_4B2XTGD;|K8I^H<-+ MBI"=37|4V-
\$,8B4#L18&4^2P&"|I@N'LE'"\$A%C'KSFP);_M-IOWR")<4=LE;A8|KU M-K+;(UG\$9|36|WDL%&+U6@!VSY^93|YX|
BB|RZ;L5O)|9E*3K5NZ15_D@;_M1#V(VODY50LE8WE"GFJE3ZWRE;9;I+9#-05;@B@#?8MQ|;<;\$P^?+152T
M.REEP\$T0&G|J=Y;IY!>M%)5-3?JXZ1BZ^;T>H9C*I# M\$A;K9-
#DM"JJ_6IO@XW1\$AE81A\$W9'D3X";YF;@J=2D_4|H3M4KTIP VP+?4 M%EDU!K"&!'VR"MH8
X|WV|JS|3J@('!7;_VX\$+!U;_#2K&H;G3JPZ?9)U_ M|1=7PLND(BSZBUB;O)*16W^Y;L>K_I4Y/XJ8E)K)K
"M5&%K<4)9DI7;OR ML>2V)ZPSAP;M(A?2T;86P+@R2;XX M#ZGOXRE7A'3|YSESBU^X&>4\$U60*UST6;XJ5G^;YD|
=;*H!>|NOYP"U^|4 M&%Y@.^%3^&*<0;5<(CXI7Y"DFT?SR5R"GI\$/G?E2\$?/EK>P4;_*4YNEJ%<
M|;28^/=13DL0I5X#7.Q*|%LG= '%7% "E-;|C^&9)?9EP.@I2T_6UIQ-UO M
@6GYZ4T!|J|CE>DLMH;^P2O&B|;BSG\$Z4!_VQI=(*MSJN'4Y7)!EIO!^
MQ@(@;&)MAVMNV<7IV?|TO8VT;H//THK>4>EU-!MO*<NXJ95#_%+H=#8/G+SO: ^CQ|H-
7QCM-.#1*;!>.^&=UW\$8* M@ "6BX(J5DF>M>T-NI.V8P(LVCU>>EQU9ZK(>8PX0*O\$8+RR"

MB%\$3CU&6&1"/L>NZ/F 4/3/L4;7>;AG(V/CW5 %F,*T,H>C>?4\$)' +F"9N MP!O!49)IMK,NO)N;81!;17S7I?
S#GY0B7\$JV9IFN8% 3I=XVNO !5ZIK0Q< M"4! *\$2E4(R/IF51'&!B.50Q?A\$B!/?0W@7"+ "C->=%+!41MYKK6Y#+L#;(Y
M0EHM*@@D\$G6C1%DC(5U+0\$2)TJ" !M(<&;X WF?@!FRN;GILY"&6D982MB
MYN8'D6!NWDV(Y>%5T;GXTQ(B/<9WO. ^7" (#?IK?4ARKIO;TX-5L9.T%-/U
M(D"Y%\$2&@ TBP"S3" H>IX*EFY&4S1M22B#1MJ K9K#L+RK9?VLPH1>#6@.0 M4GKY*JM-S#&V/1MI
S#98OL59>?UB0HJ4/(\$/VSS"YSM,X^@%OWNVN&^C MQX50'8\$BQ5H*6Y-O\$BCIS#-8M^!O.?M(Z9SAKZ2'KQ1-
W> "'W"<=L,EQ >0 MS>0'@!M:T?59+*<=7C%(T;G\$410<@VE/.*6#D5UB<6::M;_ #57=
M>Z+GM;""%3)J8H'MC*!LTWZH> ^7M/YK- MQG^ ^?+H ^>] _C" F_O-7#C_NSYK/WU8&8.Z+=/PV00" _!HWGG
M^!I/Y"Y^M!IO+M\$Q _!HG0!V^GPI/7 WMX=08-.?N!E) !6WIL%GAIPI MW7X;/1RJ?>XWIF>/GXE^/5-
!KT!WOM6>??AXZW/Y-FY_O^P=T9N/UW<?7YG7_ S1F5_C.;SOXWKH!Q.CK M-WS:ZPP.V!>.K!OIF+@L?
OM>MS%4^1GT(W\$S8M)MP.#EJ0W@TD M%GC:7VM?
ITE=AS.G#%1%1G7JDUV^7\$2S_<[W7?7*+9@Q<\$?2@H?>H?>*K?>YI>I MI&JCFXFF"R-?FN8!P/L6^!08(SJ2!L!B?
Z+9T9(580)TA2 J5;2#)9P.*F M:QQ81(QX@RH!M9DIG"AB<'W5"K!\$U!R8#NG"6.XFR! Y\$;A8R"! 5K0Z.DE_-:
=2!"#T@?XX&D/HWANH;&L:T M!/- 69B):KFUA!6+B!ZO8!C)YT+!HE:A#MNC3FS!ISODMCI41B;Z6G)\$Q*J*7
M"S*!\$&0=8S7"7"48"?>BK#2UQ%I"78D" 3^Z!TCE%:I@O";"!IP1K2Q#RYK, M:1<+30VWWA&"C_-@>=;
<[M>F1S*PP4, LIR%!;-55-E"<4U8M2F0NE B4MZ MU2N0PWTFYCT:\$8!QQ^WDE-
!8J8\$297#VTYVKV9B)*Y)+ED#EFIVZ>JE!.*@W MPS)!3;00J#Q.UJ4>K9"^E=SEI4 \$2>'QNH0<#+(
-4Q!R1=REAI^YI6@O(! MJY R#7)E\$E7>@@MKK7>;1V!!"?M:KSR!!!ASED@(!6)!WDBEYR13^04_V2
M*WK)%;WDBEYR1350H9=?X\$^0HJV6(RB.EV M35+!V! /&4*#; 07LFWGB;_U>.'0CN;_>?/2
GM_!DJ,J8\$4GG\$)*684A.N MW\$%)*%8-4P.TD3104!U;_ ^2!LUGX\$^G-OS!YFI8!9J>I"HWJ F AOA)*VG M!-
*RW&N<"EVI5%+!J3!5 MN;2'>7J8+&;XM8:^BQ-1E9812N4UJ.Y.I0W@!Z RW;S\$KJ_*KT17T
MG+T>%F!5PW!&;=UF*T,(&ST>_L0&?";&AYC1,ZM!*8M:#9!&D<(H4VKIOTC* M313SH!+9S&7D!G17K_-617X3
GFO%>/ZSE!>YK)%)&YN!B5;&M'2!>ZY+E5L2?8 T2F+P^U *(96ROP;3F MX4!OXS?
%M4@96H(BU*!RZIC0@5V)4YK5!4!6.+B!H=*K\$G+N!;H)PC4HD% MR>)H9S3H).HJWI=17)<"!W#)W'
MX\$/JM8'B\$ _OH_:E2UK#86"" ML#OP^US+M!"UV%;ENHX12;IXN70LXMYVSK_L4O.BC""UN-R4A&9) 8-V!Z^X
M^5^ADZ!(\$2055!>V,WZ!#!+.?C'DAML\$EDQ+DD0U!8 H:QA7KD8>(!Q:'9L M-J3+KYMY<^C:NCB!;F=
SE3BD&!);VJMX?7JAEB;#.TT=3RD UM+ 54M+M2JRH^#^JBU#P5GI>Z9@J\$
M6H53Q:E7!M&BING9;H5NB;BYWAHM86/VU&KA, MGZ!H!X%6)<P-W;_2/Y"20%;%DW-BSD.F!BMC5!LH
UJWF/"SP?XI79S8A'+ M!2@-WQE>=7 #!2F+FM;P*QV<3\$!'MKI+<'<4>8!HE#00%PDA;*.ZUP""+!CT
M!S2LYUA471KS6XJ(BXQ 3,0_ A4*S?S+7ROA13@J8E+KDLRI *IPTGN")=G3 M0.[XPG:>5%\$X!>
V/!L_6/KPI*R:UXP"EBQ'P&_+1R M!;!5N^A1Q *A=K0.H)^*E(D\$=QS33"G"YCOC6A26I"QK?NH;BK(QXC74CN M(?
JO5*\$?2\$%O/HJIT\$XGNN"ID*!H0T-.8H("QTX5%\$#\$TQ\$Y)A LK*QOL7LSI!%KQ@+3GHV.(#J!%=<^%EB-
9565.0WW+FI40+&X.M2/;""!8 M*!\$L\$O7ZF!>Z/0.! NA*B1JX+C=*OX^#0_4>HMZ!@Q!4+M<8J!HHD<:%""#M M:E
LGPRI&9XY9#1+;83!5@)R=32KY,\$22R!>Q5ZH2&L;C5D*;/78!;E+ ML&^Y@>1;_8PM?BQWJ:'0 !66!E4
M:5&ULL;UK<IQ&T;Z27^% M5N2+.;&AD62_H!GOF>C>9-14R2!T*2=V=AP@\$!U-RPTP.&8007:Q4RNW4"C M!LA\$
1+?>"OB"QGP1A MO/KYY8?5XO;X /SE _S W OXK !X!^>O7B'8E)ZN4D>'&_?7&<;!YN_?#% M7>K%V3))-
R_ ^WWSS _JUX!6*=YPI_? WZRYR!C+RC?;?G!@/K_ MY?ORM] _!/-/KM_W?
UJ%O)^D0!H07>G!QZZ_)OGL5QEGN03XCD(5_S!H? M7B2^EY=(^OEZ(?P-!K=7S: ^!8C!Z!?:!5!^ _%W!
MXTN&UXL7_TB3B-R0Y8MRBG_/MP_DYY=9N'F(&_?ES!8!62!TENO7C&DWWO? MD2!Z !^3W! 3N(LB<*
B>C(B!B;_!>\$Y"!L(\$_W)QWYN!ISI(A!)!04J3 MXH\$)^S7!O=?"85Z7FH#)Z>_77DKB?SWRT!>B#
(COPU%QYG%.U^*&W;_TSQM* M;0#OAR-1?@%XO5U3%-9)%%+T-6)0-5R (#>^QEZ!H M^3(
T=10KV%6VE&1A3!)LA-2^6GXP.R(<7>1\$>#T!EU" P4*#&J24!8ZGP! M7K'9>.DV6=Z&JSARS&^*3!-&
!C!BEL>WGCP&XG5*KPM;VJ9P=7U"2!G MBRPC>6;J70H**F?QX^40)*JV2!25#X+A(OOWD&E*7#KX%L82F(&#F-
@SL M%@9W""#V;L+5.D^6'S)R0:B35NF((7_!2 7;DI-PNG3 XDSLE/GXR)E;LM% MZ-
V'49B;ZZ#^N&!3N2\$1VV^IPY5O;Q>;T2U/'9!Y&J.O<;(0*IR2G!SV1)R M1 !.R!82WJ?@Z%ZYSV1!-
K;LG5KR%3G4YCMO)/RX&-C>+^2S!P3KTF!CM^ M=I%DV35)2^_45*!]
(8"4JN!M#W:WP;_W.WJYLG_F=3Q>H"471#>#;;_!!3J;2VIN16(!_U4V\$!3;29^1_Q24PBGS1GN8="* M5JE!&+S*CH-
6+&L_""<5!TPZ#2DC#U!\$O.TP"+VT6>_F(C(<'9KEX8;I!"\$CRR^Z"!A9 MA=I0GVL?
\$MQ91;@4\$!;@JF=*!E=9G\$S^DX!&O5N=Q3E)Z=I!XV)!J8T/S?
M/B3Y29_!NBQ^8;BR!1^!4C!X!7!_C8C;RH0!U!VKK?=_ (3DDY)K20*I>9 M8G;HPEES+QX1!"SFF23QK8\$!X^"FD-
2S!J M(H\$VNUT8(*OL=DK6!_240#%?LS'>(#+3IH2JCI1TNZB1/*V4C WD4!5S+4!C MIH7&VL<;_1!PK3LR!F-
Q@8"G'O^LN-?A1" J\$=EYP!H"@!&S8!2<8!/!. M!""MT(Y-V4@PO')3#.V8E0X%EZBC3;NSY%Y_8*+K8.T/3NV1;.@7
?:6H+> M^&"Q!HUF.66(!P'R/QW.0_96JW\$!>LUU#PH"@PB0'Z6&V7@!_"%C5 M-
+SRM)N\$)1\$(!^TD!8ORUB;_3JDSDF!E\$T=&ME0C89H;_+J^#19/FD;V6_M_*&<0Q!NV.DAB5!%9.D54?IR14VFS?
MNC#.#.7!-/7M>_!K>;TO(!;+PP MMF;U^GJ_&C&87=-A4K^X)Z!VA.WXY0W0TEH4@\$M@7FW(YIZDANAV/MU9\$
PN MO2@RX XU!L_ (ZFD8AVQ=75#;-0?LUP;^S^W.CSSEA)JEX.5.7!IRE/B=7XK8 M(^@D;Z,O'L2_?
RRR%ZM/_AHT!F+))SND?LSY<63/KI9?>EU.OOW!-1K M\$N59!Y2 JA!;PU6"2W!C*E?&!D_N;.<2#+)K&#QQ#-
@RR6CIO M9;MGJ!#>URX_FGC>MOP?) EUG.5#+&F0B2%!A<="V8C@^K!6Z<+!IR9@J M#+
8^#1VJWIT*>AY"P)DU(O!1@SL!H4>+>E_6&SGT8O8>7^1'WMIN@WCU4KKRTL*O%!AWT!M!KM99(S-^2*9>
^))D7O6/1EIK94A-0? 4S#MOY\$OI6SP;86L3_ M!7YJ;6QPLY!>[SH>Y>Q9*>?P4YNOC(LN3#4D; MZEL2HAY!_-
M*?.T'3#C2XE% NVF E@X7?@WWP\$84Y?I%-XHB M*G.R?4*DT)V+@T/O>>Q!7M=Q\$T:QQ^@4&F).C!R;/X-
>B+=!+KTL;#U_@E M6%K+3O5<+!/#GY-/K!_OL'+O=(&)S^Q!Y#F'L!L"1\$5%SOU29"\$2*%6;#L3HX!;8D#AX^ZO.F70!
M3EDG05/F8>'!Q;8HT!>.*\$9^"+V;!!T&!K#J&U0M2%5U%_D95&XJ+6D%Y0%BWSL) M*PPAI#@-
FZLQ(DZ#P<^KFD?0Q M!CEN!0KZ;4L;J!H\$0B'G7)M"C\$6T^YNBU)Y*JUH9?HU*/2@YXR-Y!9*BT^H MU.P ?AXH&C(
X%>J8EA0G!2;*&P+QJ2IC(@=6R8T_JK!;O2<#B">D;""_1E\$N M!NOF7!E2!P^W_-003?HXH!)^1EGD/278!?
#9^ROZ_P!E;_!<ZD!)2CNC;_M_4!LU%5QC+2BIA*%T!I>&SCY.GKG?>4G0M!RW200?SQ,2FKI-DV&\$S\$PUZ
MEI(FLFFR!;J&H!>=P!*_!>B23L2K!O!3TCXNIC_-L)M4#A*04"HFW)+R M8IVNM?>^IFT*\$;_B!2\$W^T-I4IV
DD2J+!#NZMZ1F'(849J+8\$.Q8=ROGF\$X M,E)1FXF@E*!AE6QLTE-PI_XNE-K9B20'BY(SUO+ZX@CCX!\$;BLIJ;J6:/PA
MXQ-Q>9!M9L8\$(&GD\$@/M^!C!_31R"RV>;TZ/!0W^<78^?2HN TR!Y(&U8 M-)IOV0GA.HF3+L&F8B"."ZRF-
X<3N09JZM=U PHE!E#KOP!%;2"7T5;67KT\$ M'F!8GG&/(!3)23CT+!";C(&!82T5F2DG!55TKPVP77W!\$L+!D8)Z_H+
M'2!VH3S#Q68\$+>8T4!#B1UJ&76).CT*0!O)P4<(6L-WL.LV!0Q@7E/NJ\$FM M-ZU^?Z=/_J4F3#VTFVY4X_R(
3TZF8E&E!409JH8E)5;?^M.EBA^T;B+>OKG0AW0U+H;3%K3+598??H(V>_YM9>1JR*_M)FF8!\$@OLU%8G+Q*X
A&_2H.3(D;_!_!NJ;E97_!K!XIMJ8_S6#VSLH!OE M+!JUE!K*G;_!JOG;O+!&RD'50H&JL!XCGM@;>P9)KPI
+;D\$;!6!D)?E> MX_ZI_YC3=[B ^FK9">F;0XE34[K#""!9G\$Z.4"C642P/2\$X%6!;XET%);#
M<09F3@NX1FZ2"RSK2)^@5!\$X%+F(@_)O4;D=+H(_BJPL78GD8" QZ2Y89+!4
M>H%#!&\$A5B.037_"A7F@N9N!9PLNCL8FB;JHH4T2997+857MY>V(=D?%B4-M M0%IVNI9(*2.49J2228!G-
Y;0G23%J5G08#7QV\$;R7J'5!Q!R7!H)Y^LS55/ MO+FLA5T&ZACW-4F/O"ST.8HZE5)WL5QT5=+LYN 52R/2HN1DS
J5!BB;#BXN2\$9*)=1&CITUP5_M*(J\$^Y2(D6*JH;C/8;ID;P6SL'7 "QB<2KM94.Q:/=#-;DMJV;M]

MB6\$(S6@I%:F5YK>E;8@SDE45<-%V6A"+Q9I2=QF6Q!*X&&I=JXU6LK3DJ5.I M_XXB_%V2?
O^R@WB|8NESP\$+G@|78|4M|7%3*R:X\$DKCL/*E9O=1&+EQ:6&(" MJ&BJ"19."M,!+?WBIB9^O)
<&UNE)6N+42#=\$|KA|?)Y1P\$9>67K53"*DXJ7D* M*QBM JCVN29-L7E><4I(^OP.*Z1JV0=!#7Z4XJ@-'4\$?
4|11R&DY#.)I2T6| M%G?"PLZ"*?/!(A|Q;G|H|V| 412X"(K.P8R* 4-Y2;-3RQ%#L MYG3=7>7JVSJ\$'5:C-C6YN\$DM*(3DK*
|3L|9?)X5+6|+0|BS|W|/R*>G:" MVFL_ JF J6: A|S|<K+C+5J|JKU<=>RV2.92?#2 *E_!2X):\$.S1E(20| MHIO
NJ5ZHPLND.B|1C"&B_?'"\$I8|B'E)IP1-?+ "E|P8M2P8H?| -W'972*(S91< MW1^6UKTAU&?*PIS4W0RJ&=P0/UE5
BBU\$#S^AGHP M*\$M1/M>JF\$NM"LV: ^|BE*:0E-#%3^=K=QX^|;'T6)5|>=F|O)?\$-RL6Z6C;C M8R5^2TD-V?
M(SL:GZ_!QI\$ <;3|DK%7|K@W#@|LKZD8H +/+=@H%IV%.)S_!*
M_:!D#/. *+N6^ ^|*R|XEN6I07..NR|DNRSZF1X23I+C/ET6T
M/AVDZ%V20)REQ:3<1C|&DJX<#9W41ENGL0S.G)#JORV^ZU@|DN|@0'@2&06:
M+H\$)GDBI|T6&CVB)_HR%\$5F(2/+&<(X4A@O-OHFN^7(Y2T^R6*3D%).SK ME#QX87!"EB1-2="T1*JY6F09 3??
EDPX|2AA:|'E|HXT^SN:~K-2-|QA MA:=I^44B|4 (J:1;:NO2VS:R7MN|3(1.%%Z-V^4>E'G&:T|4Q|1;+6 UVG M43..\$K
X\$^<^4YBOCZG|21W-M&%EBRY|_767WABTW|4X|U.(P=84|:RHURM M@E.L|1|H-KTFT7\$QQ.H?
T(TC!_4'.C.G|190W)\$20#5YXM?8 |:&8;Q.X%Y_ M4Q4&8HYCZ|7UTYD-^\$K7NXZEAQ0L.RMD+F_390Q|#:;
I4H"52;)6T6|OV^OP M^_ |PI1<)%Z<|8,ZT!%P%3F7" |5>ZSL1;B6B:;%\$RRKE|2%#?>X4<1*1.LL)4^ MO^Y_+K.S-
^P#I6&3EP+|'"3\$XS%OL.3D(R|K^\$D) 48Y67'#24|*L_ |.GE#RH|U|U|Z;T_ (/:1. M|:3H0GS|EU|Y|FDKF&+=?21\$/T:1*J+
M+TH1GK8^W9(X3%+D5=DB.D" >OLK_ +O_ &|IAK/G=%M|C.K_|/7<#KFXMG(M%#PG|W2Y)#
|E^/3)7W0QBMS0.5S%C" _V|U;|X-+V-:T+XC!_F\$1|T7M|YS M5_RQ>>CSCCV^IE^_8B0F.%09G=|G@-
=.NR6>K.W>93V)JAA_!V&KGEH;K@|! MA.UN1.9G|_C" |13^|N;X.F,25UFYEO-0#S1A-DCO;HJM_QLVWC.XY+/(@?
MWXZ|_A-GHY%R<@EJW|MX|H|5FLA_2Q|B)D8G4+|/HUIB2:91*6M#0|O|5|H2|Q
M|:7SHF;ZY_ \$R23=5^2.D|D6:5&=4U\$_.R\$;6XKMR^RH^|_:%\$+H3|_H;HV_ MFP5G?+YUY6Z|L|J'F'_>L"
VOEF|*#29\$RPI*=W=/9'*=S/ MP_ILP8 3?=>48%N_.;#5NE@#6BC,@|)#Z#ZHQ M74=-
'WB=EP68*_*VV&R|=)LL;|5""Y#G_)=/SHOFSE%H=^ZWN%M4Y;M|@XH
M8|4"%|_R|2XEPPEM1>D1=5R02BG4SB+1Q%'+?T9'MP8C@U@|4_S*HD-WI
M'6N|F%*WCG=VQU_ \$N=A|J9B+E&"M|_L_P<6&K_0<'&@=)PO7\$UE5'VK|A_ MYV"8EH:0NS&AV6@Z75|1-T
M|D: =4P|5|U(-U|D)>=1L+7EY6O|RR2GYT*V|7+JF.(KO1T|E>#1.KM56_) M|S0<4&%A4&K1*2VP-
2Q\$7T^R>^I^B'E|UO_-ZM (*+D(V>I^1|_2H"6Z|/K M3:A_Y|GR0T8N6"YBM_CQ;(>&854^W4POC^ZRK^W;U_-
&U_@O|H|3<#^UH*Z MR>918.#8XZ@K4I8UHUG>GOWH<G|N|38^|B#T)9^N|U5P1^|_O|H9A0=GW>T|_V|Z6|_Z_|?
3S4.4_ DY(C\$="I?_Y|H M1K|+BPQKH^/3L-S*VLV>|J|\$0.>:&A>T|XD1:8|WPRL\$# M97&UAVXVY_+"Q4=U
+7)VAU|...K|PWN&4AS((<:RK_YF2D"Y^KVX==C?T M|4_|H
BW#V)*0SH'0Z*=_L@(>7Z|D\$H_Y3@4GZ_EX:A_ \$J8VT\$KTE;MG@\$ M|1DT!)K|L3P>\$1G;(.SA@%AZ+J;C|1#6&2FR=0@-
B|_R_|9*=_1)I^C+V7&|? MN@|JP?4V|H|L4&-7+.%AOW>3\$|S^N%|?&M_ 'Z=%T^0|>1<?"C51|_U|<3=ZQ"
M0I^N2Y:AUT9G_|N"07RU+)=DUGK.2EG?0X.5+QK\$BOVZZI|#6D0"(BY?7\$|I
MOKVB1#@_ZOYK>O|AF686*RSU+);HOZ1M"LCL^F|M@ (2U;5^IPP#%BJ6J*3MTK
M+;)%YXZ<;&+KUMHX3S2;.FX34JOK BL2*=T66\$VSL2Y3TY7UL%|XN""4|=CHY6M\$_-9L@3V|_ MF"|>^70%O0<(Y-
@X|HEM-HI>D0GD>BE^>Y<%T>K=*3(XG6 MW>2&4)>V8_|UDU4%>|24|_T_K30\$=_L<1&;|R8_M.F.FC4-0-/
V&|_YH7|1R|J2*OZT7E.V2K*F_B*=.CZ?("(PT04FA@J_|+ # M597|_7MZ_.VN>%M|/?O%1E#L MIQ|^"1': ML#
?_V|L\$;_=-G\$(O@D6|F+%.9ZS\$;K))&&C>V.ID+G/(0P^G+|C%|" M_|J5U0:A>5_4D9>?C+T1:;%%U(|H1-2-
G.F|QC|9"LDXZ=H|14|OU_ M^OGDSP|J+3:"@UZ<89|A_0E_OLU\$ "IVP09RH_|WOIR:4KMQ9V%:+2%KA ?>7?V2?
&DOGR8Q_:/60=|N&O6F/R<\$A'_L6W\$+\$L|MPRC|B7SG%(\$G+;7\$ZOE95B_=F|_(PSB_>ZP\$W/PVQK M94|Y3AN5\$:
(XB<8G8>;M5BE9U_|ZB2^_!S^+WHTYW_XT_10F8%L? S8J4|S M0_|N|F*7N|6VRS+_0T^@)>4B)'Y_|U;F9?Y))F#^V0".V
QNOJ^AU4E9MA<_M|VXT0_1_ TY_@=J@I\$Q1MA=3'40X??+77KPB-RPQ=X^0(-;W4K3@4@CDQG5 M?
^2F>RK=1;CDW^<NY>->_ \$;M|JL;B|UVKW;L|>V;.\$&:2%T%OBMB+6D5B|W4
M|6;@=&T#M)9T(G7=BC|_#='CO|)P|&|Y&>|JL_C4?TC|W^).7?@L*\$S9RAP00
M/V&XFW=34W|9J=|6#O^N;KUZD0AV'30O07|4EW|> &E;@ZCVU4=XXMYM.(KB M77P|_6OWHRZB*/G"-@3J2!
|3Y10FK# M|FVU9_+|K9EY3UM3G)V&>67|_8&# MN|_OQ';|NIF:5U|H(W15'V_|@|5CW2AW_/9.U|!| M?U'5TK%|S^G-J
H|Z*QBV53S+(D)A5F_80W7N%W4|_ "B|Y|L|UKB|B;5>3TR|_5.2C79B9<3&;GE06 M_.\$^M|Q=2GNZ|&W-
U7SET^PPX'L&\$;_|S1_:/A|A:I&2YWWC|J|V74.4C0>O&CW M7K*YZ@_.GUJ^QZ0S)><43.@RZ8/9
7"@|5CH^Q&J|UHS#QW?'P|+RF7Z9^ M<4|>T9^RS3_|0('73^_.3^32/^;BV8DW*C@A1-/2+>UMI(Y%70X7V_NW*U
MKH=M.W_P|_B_PN|O|L_!%QYZOR0|UJ-X@_ MUTD4:=G\$@J9_Q_|7|UV=G6K+|B@_@XMN#0E#HZKL>V4N^'^&<>
EC_-R?K<M_ZXZ?+|C_M'2ZE0LH M@_ HAF8|'#"R00#X_)?@B0#E3+*)*&=>@ I^Y_|(4T'.4C#)>%5L;":7CH
MX_EHAV(-_VRFSM0|2IN_CGM>8%FS|!_FWH_G<)>0;S0_ '%SHMJ_|P1XL|F|SZ M*SC+|\$\$X45075+R=(^6"EV2FO%>?
U-'2NY_0<|_0|*1BB@M6|+DN2E>74^C6IN_* M9?|ZT|'H|*"OOYRT@_ -|&DHEX1:=-4N28XC*0FA|3=|_ ^G(-O-
|^E0Q%PW MPF4R TGPEX6|H|_0&>Q+|^&)H47#7>M;BYB)"_:=GC5#Q8(G#(C?L;#;4B|J_|IT&
<'&J^H|L%)YP*AWQYX=|_?0P&;3MXPBX_|U MFCR&_0F.MA_HF.=QW319(&& M'(#*GS*_OO;)7=|<#X&8?>
|HH.NM*Z2N|XNK&5*H_|DL;S2;J.8ER5DCI3HX4EW-(JDKY3;Z+O_-5B_ MG_9UWS@AH=,L#S?_9?
J0D641782|f#W>=9K0XV2^|>? Y?T^|_HJ2J)\$OKU" MBLW&2|?|C9"&2VMHXX|_
PWAUG42ASW+S2>Z%46;#L" #4Q&|:=AXS5FD) MZ/QOPEEN@|H_V.5&&72|94;2K).WC#=>O") CQ?
W8|EZK3C^0FR>=+5PA/7R M=X/S#O_V8AJA^IWRZ6)|SI@&M22'8 GR&O\$0T0=|3_4P1A@>^'Y42U4JXC
MK^RBNULN1|L|^CE""% ^HL/2|&YLD9\$X<)|S"4DSPB@7|_#H41PD|2RX*#_-.' MEAS;8(^?C6@#YWH'E(A|
<'>+&\$%0_"_>Z*PI+;|H(CJNQ(FKS;X-R%PPW_ M4.W_ M&_|L6_|4|*\$CK>J\$|1V9MB_-\$((V\$X;W6ZGS9|0<>)>P"
<1'6+5|!%LG\$K#D M.S="<%>);_O_H(\$Q@)|@5@%&3>49&\$R42F?TP&% PM|OR_J+JB1>=I6RZ8S\$|H9BW_|
MEFA;@VAMWN|OL_|2_ ^|Y|Z"1@:H|JY.C6N7&_?+|FQ>D^+NR&\$^=/_D(OO/M0Y*2/OEK=@_H4<'5IAW|4A2
M_|T4Z/Y9|T|9NY+XZ?)"J|9^ ^0=+D@;%M|METO=*5ZD>QOVX_7::A1F3GR%G@5_MZ5)UE&LW7;CM%:0-
4J^H2DPX2.E|S|<?|H%29)"U>_HKOX|^AHM<#5NDX; MYQ\$=_ _YA7)"@?I2:Q"CERJOGV|O_Z76Y|_
LU(2PHLPB|Q#BB6|T75G; MTK|))D7O6A9W2(|_CHL7G6A""&*R|8W)NGZ;+SR3&&|&QN';QW-"|PK?-
MT&@X>P19(29X|C+LM+I17H(J;+FNNK|R;@X)&L7|!#_01L-NBBY\$VIZSG+\$ M#->\$IO30HD3;M_|3)O1DZ#|K
D.""!&I%FV.J?B%1,\$R22E|/KF89E+4HNK@ MK&ALG_XD|8?F."M2OB'4CT(P%Z@> TX?
Z3IV|VSDA=;ESX"9704HG|=70SAQ M;#3FHTQ|^6\$52;1A"JV.WD|E7%:%FJ%N<4K^=>X;X^P*DJU+|E|2Z|LB(9EO
MUL:(D<+5+|7EA8^?% KRQ2"GB_ M|FHL|U<_5'_8|8%5|^LS0\$3*TH=52YHO|+)?S* |EX!@JIN3AF|9-EF)3
MEFV%|*KXTRG+AL")_R/2W|^C;2*A6DU^4GC? (^0F5^V"O#AH|3J_2|Q|T*FH ME*M&|WS_|J|B)G\$-UFH_ANSW
VY*W%Z;|H(M_GZ<1H:A_-LRBC^2E:A6P^6_MFLZ?ETF59'61>|&K#2A|_|.6-Y=Q/_=J|2_|E+H9|CS6S4G";<?Q96|0Y)S
MC9)"_ZTMHQ&@D>D\$|_H6?2|AZH%ISZ8L%_N^RG/AF?TOSY&T=YAL@%|I^ ^7 MQ=Y;|SODQ>JPR|ZCT(D)K_A7<|
(ENJ_9X9FJHX9K|OLG?=4Q|_#U^XD.&OYK M48SA_&M<.>|G5NBT|QTUNT+<\$ BK4|M(&2DO#VP5|S7%:_|_F|_
QM>F+/_R MT+@<&"OLRP+527SKV3|/L|H(^W|Z+Z75G/7B|/+=\$9BF55D|*#9TRI_ TAN|_M@V;HK1GY^|?S|RE*
S|^OGH?3>SY%=LH/F2! M05V8|F^|_NN\$|@UU(|_SIP?Z<| "F#AP%=I^Y)|RZ;+G4|5CE_ D_>\$YF\$ "M
JQ>#_PB>_X@F%0&_+1N0^0|_M?A#3XM?IS M3L?^0F;Q SQ|?R8%ZLX;C*4FGN'H
AUKA91|S)H2>=O^#S<79#SLYP=D# MA/3ZS41IDC@+_|17E'9LS-U4'X"J?+P&%F_-1^?_ IM7<|.MX.\$ETMM'(*8F M|_</p></div>

JH8-!\$@:3UL|=XRUBI%)TPE2*Q;X;/9>:5)5IOBRB/BO0XM,CZLY9&2)34!1 MWM-ON45?> 4EQ.SDQ(=*L^;="!M.&?
S>LH@F>S??"H!CM3H\$>Q&W*WV&?5H MMG X-VJJS:B5W^V6\$M>4;4)ZM!(W@12OZ M6E^U86RQKCPU*\$X
:2J9::JWG%2!>VXI6MM86!T!&:L-1C2&f:9RN,X0 MCRJ24E,P7@KY=%K&2V%#VX@.R"Z6.5U3+>MYG)
(@S%EL@15X^>BRX2M:1 MD*TFER%@JVM,4U<=9V7R;,@^W!B(3 "2QK%FRFSV=7&\$)>S5FM,TT8T>I: M!
(!T!UB+Z^)^FW*KKHPL1#<,>V:.\$88!)19LB.%CQGS.<12Z^T7 JC!EO M:W.P\$)>@&V0W"W0ZF6TKKTMJV%=5KE&
IPB0JXW2&M!BPV(9!8!78:FFFR M)!EIR^1%9P1;@)B\$SA@@H1A"G2PZW&\$J.F @F(N/=V0"0G@A"M7EP5BM%(
M#L,X.FK1_2HJP,FCIN"#Y*N0'4S&*T3VZ/CUM_6\$9IR-&O!CIWO350-RT. MG5H9_O'??FUZ;|_O?_XP_YW_+?
RB>_A7_|%/PYX^JWIMXPIG09=W/Z8_M_?C;=WHN-MFT8^/_HOHE_SU_DM^?7"/|_360!C?_OLI+O;WUX_/AT=
M_^O-8W"/_OOIC+1/!YY^G)2IYW/P67WRZ_OSA5^|_O7SWOZ;|~7!H MI-LU>3SZMY=LSY1^~.FK_|^?O/0/IPY>I?
JZ/Y?6WK7_|K=2IW_H/|^G%I57Q^4VT.CG_VEI>?#Y_CU_5_N=P^/_G M7Y^*3XGWK^_??OCKFR_=?
3GV^C!;S_GQ?>M>O7CDKF*_A_YQ=G;=O>+==
MC"/_U!T%)B:L;NU%XC!J\$718NMA&A)IPXS_TX#/:6I>X@TEQ.5G.BD1 MQ!GF(8G9J5NR;SG@U!#:N!%
!0E?I0E;10CTIAQ@NVKQC=-Q2D%L B=+(PFV MEX0*1^7F8Y6@3):\$D@W&D9Z*FNLSB+7LE#B!#+?8IB&^\$GL
MAQ)J/IR?7/N@:55!FV-UY.?Y:0G!+I>_ \$VJ_HWA8!LONQ?;>H/5MW'+;N MDCLQ6U8;&2! =O;LR=QK"1&Z;"ZM5??
D;82Y)HQUOGEX'7(P1^N-X@&K4 M7M<@X@).@6<3U^&KZ<)&_&7) H#;fN(@^N4I2W4PH5ZZL5=39C4OSI50A<7
M!+V+K^7"/_!2VU!GJWW/H\$9E\$J_|)%#V/D=3O'52M!4F;W#>K0/H"0.W%* H+C8M+?ZE***WHI45E3IMD-2IG
EWSO.O'&YYIE(\$KV)D\$!&>OKOJPE<2<)N:EQH M4(L?"^+A:DV96SQ2G5@IJAMTHE?+:@ZM26!7&:TG0E9HJ?M%6.
0%0&^X7 MM0+V66D\$?Q19OH%/G+!E8I8UD\$7*4U=H'.BCL99OT+JSOI@#%K 8C#1,MD/ MMPD,XINGX>80H"D@
2Q8+RD/R=6*@"R'AHH!_H2&CMX)O(1.9.7IAY+6MDO M6=@ U_YNU(2HHW?
#+\$C9^8*=8.BT"U&;CQU:1J>J@MW=IZ=9&135)G%6W M%X\$@JFQ,>+3= _IU541E!<5+R!K!<?
8!IK2+LK+*+BWxzJ\$!PG&\$HA-!&Y4? MDTZ(I3(U!X:1)08;1T&>0'=;WTBJ1!FY#H-?3(9-
=3D!5DUK22+DOE:O67FVIC(YJ8!5\$!QOR4XP!;U3L_>LBZ;R5.?%6.GGF";=3#4= M<#9;K70A1:WDG*D8S!K;9F5-8U_>
<^,F^C5=>|@7E!QE54^E1.+/\$EU.+P M63%MQ*K1B&L&V!6QGKIA;KXJZDB8&LW")F5*=YO!0YBZ-IH'O(Q_?
SA=TW@H M)F7WLTDF=2P3T#Q-/A!5D8S<;JLLS5,OG0BQT4FP_O2C'M3Z M!|=;X549/9^6TDFRGL+(D.)B=|_DYDH
MJS/^OI(I?#1Q-AHJ?<=<|F9@BS^55J*BS)/SG.R@7Y>I"!F MGP?+?
BNOTAQ9G"N=J!*.O,3W)=4H+2E#J!LE<4!UZS0fUJW/+S.R8G! MR>;8%6AE2_>\$/4!_"J%UK3LV8L!Q3;|_>*>O*
(J38K9&WDM067=6)\$!N!M=LP-E9/2J)O!H!X=T7-JH!5="2E0!7W!B@-W"@|>'H\$OK!#3!RR+?3!5=\$ M.0SN#
!8A\$CF72R*59'E!U&LWC;Z N.#R-OY,3?NG.R!&NW<8DIX76;D;N MRL!3.OAWE-!WOO!*G99;UR!L&S*X,^_RV?
1R6_Y_N_6J\$!_QABJL'9OFL MM3K9&J!JQ<77KH^R.#T!ADV==NKST5,\$NGKCJ\$.2A!<&E @'5_C#?YTH@f.WA
VQS!>L>)\$+!7 M>-%%N-2)9*I<_.FFZC-"" U9S,3CR(E:4W9-2*!L/&*B'5F: M_|ZEPLH'EJ\$?;J&J\$*I15)".VS(#1&!
!\$V!%TOQ00HB:C'2<_)F!_71\$!M(I)E:T0:M!\$A0TN)9F65!9P\$!W%>M0+4C!ZJQ<@?&NF(KPP<&FIP2W@B,;
MEXG(Z4<3+632"28ZB";J!%,%@:Q13A9Z\$48ATG#0801A9:48;3_N&1(S: MM9?FVSOJG&34SV#
P%IWR"BA!308%DP+;IS7!@*2*O#;KDX)A'HUK+CH@6!)HRIE VVVC2GPZL%#_N?#"H&fT?3JJ+@ "AEF*REVA
M00T)R\$!"ZOCY2*JZK=EYO@<NRT8<+LM!K,P"+V4G8R"+/+GU*6?DWHO#_2 M7R!2 BVY8;RXJ>;I(=;!\$*,57D59??
MU-K/Y15!Y!Z%W3Q6@C"S@U,KD M47"PZT#)@PL8;+!30*^3!;V!K!\$!Z\$?1RT+!D!LHK="9;"E86)+*8
M>!9MCR\$T\$;IRGB@N!4;P7Z!9^CL7KK4C7^JMRLEAT+9UVY!98A#HA03=>4J MVR-
CU8@I3_S!Y8L@Z./CX?".V@2H:USJNR!@A/%70!B8_77=,CU'E,=23, MO0AZNQ90<=AISDP<0IAT K4VD@!HAN.57-
+1*EX!^BGS!ZG M::3*FI8A==PSI>ZJZ8V!%30%%2FSNESW";!Y<%(WE\$K#M"% MI23G8G5AA"X6.J4372>*UO?
N*Y)OI>M) I<^<KL<^HLY+)Y3IUI3IUI3IUI M3IUI3IVUOI=Y3A5K SINJE@K!\$<)7Z6EL0S\$\$\$?
30A\$O"!JDZ.3=)Y0'K04I M3D(BW35&791Y.LD#?;S;Q JHS3GXX!40:R07X!HKP4+O,@Z!52^&H!I=XJ"
MDA9>!SPI;|;KQ. X_S#7!L+_/#/:15C=;|PD|<06M9'Q@IUI/O-+K)EC8 @H5A;1.Q*3 MU(L6<;(-A0T=K>?TPVP?
BH#>+d5-LX?.@N-EDM2,I= "C.55Y;.,*V:N!R0DPORE,Z2E(2K^+A(MZ1HK=HMQT'YMZAJTA!452F&BE=#
(E)=X!M#)9/!_%@K'P7L!(HCF)=9BK M:R0%3^>Q@MSZ+DBZ(OH'4TKAE 1#PF?7(6ISJC).#Q1 %Q%Q#B'/(QH
M(!>!'0%&\$UO#0X7/!@4#-P*%=8@%CAK!77,'S&K-5@PX/IT;.@5# \$;Z=4Z965_)(7:6ML MMP7,
f/7!0!MM\$"|@OW+U.;fITE-X3ZA'X8D0!EN!3M6D5AT75I!LNUC",N MV!8!K3#K8!C<@K,D!4F*^WQ91-O?3PKX2R I*
<=>Q_7V\$%06X+V2%=>^!>); M2*\$L#8(N.V&)&T=V%\$*8O/!4_+/+6\$#\$93VFL00KPA4*6)\$W)*;5!+9EP;C-UX5<IGf@
M8!T!T!2E!Z(K;MBDRP_H5=##ET)M(CXBH!_#W2L;L;)CN!3>H<58^EZA;
M'QU:SGO0">"S./H\$^HN6"ICX&L+EDK!UL@V ML(R?^(0\$Y0F//8-C;
fNEM=I^\$AG=IUYJFO:X\$C*3I\$)QE>U5@1!Q3+70! MXJXWU!W6ZIGR6L56 MSV\$=<5GJ4^<9*H%?
G5EXHQ7L;W2;G2!\$REL+XYF!O'J!6^O#fCSMREKVT_MEJU/^J!C A/L_8!YM&+&/_WA*!@Z;?
5Q.@YN_N#UFI>DS1DKVFZ!H(C3)S!J MV-MU^H>U%Z_(#87E=+DD!G!XS+OO"^W7XF'C9+&#%->D9Z*UP;.%Q2;--U2
M9E"JF&O1G(??%(.#40Q7;XN&A2J+UHL:0GL?+)U43PIP3N6Z5&>Z;- MJKJ J?
VHJWW1#)6LAWESGL NE.S;*B^_6OH%DHX70;XYRDU+2C2*(UM\$OI M-T@*;7@TKP_0WKZ!2UC8/(EJDL8GK(!
fM%ZOY;|=7%X9!E.O!>W!DZ3%=>^!9IU"/3F#XFVIR!>.PI2X>6_\$ M PJCI-
JEMR%7RPXUL(>XK'Q#A+*5XJB#6R@ET"_O!42 ODK;"_Y>.PZ0 M@=8S1XMU0#V+H/#SJ_26H(^A3X!.\$W=8.-T?
R3;QL8)_%J1*10S5(3@WF2+MQW9HFF0Z>(-!#Q2\$MJA".B#F22\$9^9ID!S WV'O0O@L9!27Y=&2^"/_AJM
M!^AGNH;Y#)\$0FG.MDL+29RW?CV2C*^_1LBO!8E1!-0(E8FICAM@B1\$A5
MS^A!RLJ)"807EZ;39B*N@(-2_7Y"5%Y5E&I8**Y@1 R^KY\$U_J2" #77AR! ML;N!4@U M,OHR-
EM.UMUB9@&GV59B#Z?5Q!\$=;13S0-1L0! M:S-4;V;25+!@S#W,W?- MOU2OQ098_FP1UOXG\DOY"F-!\$6!G 3:P
H^=+1B;f4&SA%L!0X6;VG4!X4 MF!6&G>8T@.S^O@;,"O">*XF#JL_B&8'+@K'/C)Y6)%30ZGZ2!79,&'K05_M#G
1J#Q'\$:(%<Z)/!S->+Y3*;PJ;23N!A(%<6^F.Y<-#@A&_&5J!YCH(MS2HB42>Z?\$_(6&CVI?XKE"RHC2_P_@2^K;
<##^_@PG!4&HZY3X-%VY+4>; MDX#.*#HA973XPZW&0I5!7?+*45&>;%L%0Z/HN0+*P!Z;&QC_E6/63!N!P8
MT782*H1=@89@:Y0/LRHMLGCPPK3J/LO*2%Z\$CR2H*C_0J*!08!O)""LWY MJJR&V#H+^%C*!KV7?B;EZ_DX6-2/A.
fD65GLJZR!RQ4!&O8;&JX*SE^#?@ M%7H!HJ7TV!K;51^6W-
Q@TL20Y"LS!"FH!;R_Gf+;A!S27:SPGL1TRF^<8G?^!J-J-7-525,YRW-'4+&H(FW)R0AR0+!^PXH4:>
M%:A^E2DS%7!\$ MIAF@TSB;: TS7R!ZE&2"QGB!>YGD>)U 7O6:V40Q^VU^HZ_L;_5^M+_=IDA.?_?M1
MXJ6!AJRLAYZW\$.T1:0K#M28YR#6Z!H4*&IE9@EE7!_9YU BTPA"DO\ALR&
M.C7L!Y3Z6V@70T9JSK+3PI(1H"3L8GM!M+N8-K@;VG!S9^@%*#18 U4RKA*U MA<+527>0?#UW_*7(-)*0A#
(&W/3<\$#;_ZBA6UO=E?8?NHW!5!B*2\$-0MCS;U M^3H/UG@W"/&R-797S9F#fZ@fE?3E3;^Y!>
YJ@&MUM5DK3*V"AV*#7 MB!#NA5K%@< @>f!R&1CS#9DIPE1(Q=92A!F4>"3,&/%54-J<C,ZKISHU"^W M;ZPJ-
+Y\$5.7V_7A.3EW4103L.+&14A"(EV=&6_H6>%KWH">fVUWP<-D6
MU0!&OPP=N=6R88R>J6@U:/@:48>^6^6K,+D:H1G34,L7C08)0/&\$DIMU6 ML-
%>@_U6+!CB1*N=8L0+7LD'2RY&*3T@J0DOIFKN7#C:R@VK#(4=/_!5*NPU
MR6\$%B!G!\$5HIV@X_OY&79:7!7LH#H2I0@AJ25N#M1TKXH\$M%:;!#&WS&X!;I MP24K&*2GRIKB0Z^BHJ2-
:ZN%,G196 A!@A@A)BU^<4A?&I'Q'#HA/LIM:+ MMZ9/US0<5HM8:"SVIP=;!">%%8<5_B=7N!T!8*!S.#S5A9,'
W%WGXG# MTJ&724HG@U. 1Y>JPVH.VMOV@8W30W.T>>*2J3)*!@JZFD!/*,S9F@3ODB2 M#T-RB;BL&0AMFZXD
+35@/GFAI=;fE;_*K!>YAMC*H47'=N9FI@JZ_O_P M+!W9).#L'2&:%1%6<1DDK=>
(9UZ8EIGW>P\$#.Z!T*&'2X37>5VD@1HJTF MQ^<3%*Z6BS@NO*AY_*)QM)@f!_H*_!63=NU0;E.R8,7!AW_=";JE

B(J?0! M0)D*Z QC==R6C*Q!H:X< C'&R.W!P+Z3E65. R^"#=U>EDIK5N?NCI%1-
VF5;1^3?)T\$^_!O_9!2PL00"TT!Y%W>U&MJIA-4!%A2"/T?Q01!.O#j2#@ MJ+L*E-8WXOZ)R!>:T)S!Z=-V4;S;1-
%C@B9(*=,NQc?8V3_S/'=ZKXSFA.G67>G'F^0@W.M.V.TG;T7LA6M(C1H2!;FORFYA/BC4!C7DM1@).^_UVT;---
N%KGR?)#1LHZ M1E6%,>#;L;(@(-S=4""3F%VN4?F^?4! ?MQSRZIL;"/44IX^60JHK_*
M>JU23Q>A=Q!U&9"AIJ<.,+H@9:64#NO2H>@C7JUB7WB3_-2;"HZC'LGO;M MBGQ!UT@P)N_N;BQM;VA1?%
NFS@5##DTW"S/0V4TV%-0JF_@+HUD;BI(KVM M.UPR+PY;/@W;.>N><(N:X\$(\$X,Y50<HJD0?/=U!%-
_1O!Q6;17=ODZR(4JC MWI(T.SL+8!I=R*XH\$1LLBZ@@RE+KML12FIM63@@@6GYCR=V2GK-W?2NIC;U; MGC/I/*
!00%G#?W4E>9^A6!=M#8"5ORS4!ORU!H3B.T9XDAW\$!Z/ M!#)SA4VT4;H! ?RU! P!V! "Z&)Q^TYN
MD&30WA(+7/KL;_O^%P139T#8;2H1@ \$T 5DS+C!(T""6D4/ ^2-B<^T6B4W;_M0.+
(!MPP'J3CT"!RT;3!Q!L!1GD!P";D+1;C.AD@!F6!Q/Y.XSRNXY^.#M MBVS-MJV'D!2YD;F?=-.3\$WL+@;+;7!);.18
1*^J6JN;!"KT2^ IUYOF\$URI6 MV)=ND7?ZS<_ JV&""^TI_7;G(33Y?*L&*!> MO=L(IX^_3L*^2TS;VG>9"N\$);-
)@Q!1F=-^;.*"ET2C6!AGUO<!)I+*!K/FI?>Z 2K?IP.%C;6HK;WGH3!;-2&&8N M0M"!1=TS% C_Z5RD!5+ODGM-
*_/!!KAJM\$%=N!;..SJ!7RT_Q"R"=;?;S=>;_M>*AY^!5FZ"@;NV)F4)UN'DD2!@1B>E X'FIK;/EKLL8;/!>D#Q,2SS0!^"8
M4!YT8!>D;..IE>?POF#4KNFF=YQ0)Y_XR2H..R3PAR4=FBZW*0NQ=PI-6f#J MW?1T+.'SK\SHA4XRN-C1KASD!;..
!L(0FIU3""U(F!;\$05(9N469X;IAP/R#79C^6R%8.F(!;..! MS6YT_3MM'6!R,90>A<|>F@B52..6!\$(_A\$%%"#H(G.N N
!Q_!9WGIMB.M;6AW/&>E.CC+KD'T8.88AXWWWA.L)DWQ)@EJ=;0?E39_S3= _O!A5F.IKW^Y M_K3^RQ!UE
_LD;TCJ!C_U/;03;_?+>U= _^?GSY+QTPZU^OT;S_UH*\$S/9R+ MZ*0^HIV)(S1S^41^*2.*!BF!G0^\$DP1!=-
=2N8OK3DAJKNF;\$*?2322JG>*)*3!ZJ5-ER2?P! M?_2!DP5+^6*7%!\$?1F%Y.4)_>)Q290*L3!@!OB2RX3 M17Y&6_6HB
7T"M;H//+65U=36.A05*;IH3!;46K9U;1NTBRI(S;[KCJ);Q.4XM&
MD9\$R0=3&GNPXY96T!@!D54XRQVA5!^TTIC.QINF."UPT4@!-9<_)1%F51H" M"4ZIE-
6ERA;/7AB5/3B2!^3YYUX>&UHCBA4>&AKK;V8\$2&0ZUG..8\$'3YY*?7&_JNTI_B!X!2)Z5\$!2C M@-
UV@'RTL(HRLA*025ORB594LSN^2YE(@PV'E3\$/8(%/;MZ0-/2!^(0))%F8_ML!@;_!U_R_3Q<^0#N*N!UJ0872L;)%|=I+
MKI(RSAA!J***7).T9_)2\$**4!B!M(28X?5@;(DVPD;W)!^F=2;<1#%\$(G_M<_M0G(!
@M+!#3":58Y%6GK&HL%_7U3HOE49CRU<_X.ZWTDI!44T?)5^Z2N,*MZ)R2JSJA0B*J;?<
XVXDC+9DT2N)S3<L!F3D?_2R&;X(K3VME><^!9!_@**?N M19<%XSA9&JNN*IRM_4PJ!);!\$O;=-.75>=15!;7;>%;!<
((P8Y!U!5_M>99!4MCQCXM\$E-?_HP:5.31Z;E:N//J7D09YE!7UNO*?91N1GO+2LL.R
M>2!1U1;.*RGH8JUNA_2F9FH#C!H_Q*>9!;-Y)P!29^2F9VUC50!K!G;_MFSPE#W_QGW8-
P*"J=6;K2K54!6!JEONTR>MX*OP!QRX!V90;>&6G;U_X M+TE^G28^(4YSCI?D!_!PVIH-0:9=HQ#%XE&
G""!8.H.NL.5RVGEL."T/)) M26X6D5!U;(W)_O4E)O;\$00(=_KC.TY6!9H<?>_4C=G67SQTJ_*FK6;^97% M3>
!67GSU4!8T;*;3&%J=IX)C!26!GDNDV_MR_*%*LK7VK53N5L?VHHK^G+*IU3IC)MK10"X0=N19';*!<^!6LH!;X"!..2VB
M\$!>B3SHBGG+FL SE^;BU;EZ(XE MIQ3T+;6F EF@J'Q6PAFI!Y?L6;T>_!NGHIPQ=00CM_M456/%M;CT\$-
Y3*%PAITFX!^<^>IVY#P^2U*?_M0.2!;)&ID;J5.98! MGEA%;7%/ _^!YT+=#8!FM%>6&""
"ZRPZ\$#;.F6>+M...6N*BV^B.H/27"7!H! MW1;10U1D="XD?>2ZFAY.PFE^HK;T8="*YK58!0SUA3>I(YSRFY59BQ?<
CO! ML?<0!EYD)46-85R&G0T!0;_M#*=9Y4?5H!J9T(" _^!EL8;Y/5O;1,E!C_6!O_MZ2)E=4PKR#?(B;.
(ZX_4D>2!4!>Y4.CW7Y ICE6S\$S824 E@)Y&_M2B<!Q/W< _!JQ*2&JH(UWW@N??< _^!YIX#._^!4(5OZ^N/6^!ATW-
1HFL7_ME9%NWKB(=V^@AE""#_!AMY)63>)#G#T0/UR&)-"W>BD";=V5"U7J78!^8A1 M@;X'E9+3;U_#Q.#\$5_V7!|!=
!V!>"<_85T1CF<*_Z7\$NU4B;;D@E)PIC91)R?^8<_M*A!|VW949&%.LBH'(;NP@;=M(BISLVU"M)17_U"RJ)=(
<&RVRHVW!7Q_LI_%A_MM%/BLDT012!7"V"/!133R2'@W%::Z!(!;JB=/ON\$P.VC0#H.#2*T;#";??:
MY=JX.V;(&)&ZIE;^!;..;QK)Y;&3^W.GYN9;0!2W3#R!L!79+NOT);">"7HJW9_MJTNKVY&KWY1)!T1VBXI+SM!M-
!TZ"YU0!0>XP#Q%U=&6!@R=X7!Z#2X10 MN!^QH4^CID8;WD#@N1?Q.U*RIBP^H>U(5!CBH_K_OY;
A#=#G7;ET1W?70_MTOFC920U"D(=T/LP+OL"W>;DH_4030!@QEJ6G^_T1R0>L'2S02Q-7^;P\$M_I
ME&7RXB5F6@QPXKFA)16R6AYQ#R2E"IM69VJDD!K!V\$QEXY.*W@!L;C3H>_M\$)Y)RWVYRB&4*4*NEE7N^RW
20+REV2+^6_P=5Z=^T&ATSD*F@CKH(" MK(HYCB5!0Z+SV59U450GRMF*L=69&!5_M!#;.\$RF!"IUZM#_*2;_
EXLND-E M/HM(B)-&.@;09!;NQZW;@6A-R(3T@!O.8QV)B.X&Y%"%PC8_X!J2(C(S\$!6??"B
MK20Z;G"ONO;2H3;1J^_"4@BTJ\$X&Z!/"!Y&=%#A#A9IY5X.=!K5!;MD\W!W_MR5!;H_/2O@W>Z&>YV2QS
IVC<=P(Q@/!<@ATF6#;2_MAL^6W;X)GE#66;M7HIZACW9M<_"!JJ)=>9T&>\$)!UE8#>@;2DIF_!;H!K
M)"6..D!)Z3P>34H!40.6TAZQ1DKB(!F.2/C)Y(3;F=A;\$7^Z\$7G;-_5Q\$M0\$T&\$D#Q*H
M@=4DE@SN!^6N2CMEHD!Z+BO!U6TH86JN_RX2UX!HIX_125_ODIX!>&C*3U_RDY!0+!#!;\$A!_VPC8_M/I!%;C+P-
>8!HK@R>EDBL(G_Z!U!JE8^\$AV?7304D#EM;S<1R"M_P6F.B6_-MT0ZX)XE?);=^\$5>!P;8U6!DQUD2W
A+!WMI!#2XHG;4B/!7U;)(YU16&D4 M_<>D90#&JLEP8B<<=>P-MO\$S7;FJ!8;HK1Y+LD^(_W^L;.*AHYQF#2!&
MZ#D_?3?ZW_%BB#2>.T"HI%?)9TMVVIO700!;LS>FRM_G!8QMUJ9U\$;LS<ML;ZUTH\$'_&\$4(JBHC15;C'T1W-2S%)?<
V1KL.3"">Y=*2VR!)P)Y8'_'\$ M9G!L;+/8T*_'!4GY""Z!DRW59Y;4E;!/T0Q!HOL;E&!K.RH7F<><
!YZE(\$;F/+!%)\$%NZ=3<&5H_!%7;WO!7P3J6QL"J;@X3)_D;GPXI>P%CI2SRA@FB.KCHSRV;&=<
(#XF41&SP_19&)\$40@*(YH_?3_T'E";(=!M2>&8!NJK)(4P.JWOYK2!B"A2AML"_DG\$D6_QIEJ?J*K")!^W_#\$6=@><
1@;+W<'(+!_79S1G!DIFOR..8=-5XB'_MONO;8=A7XH9&OSWJ#;_C\$DC43VBM=X+3#4E7U+=ZER9?G6=M
P##G7Z@_M1XJ*^O&KG1!NUW3@<_^_!P<+V!8UW!J9@G_O+=%\$\$(?W719Z3+^Y&AQ0_MD
P!BTU7!HOZ>R0G;>Y#*BJG=9L2!^!_D>3BA"G34#U!M;*(X!+J@;W_MB!PZ!YH\$^X!T4
>OC=72FPVD\$E"H"X!P;=E^KW,6ENLB#P/P@VU!H8*!;_ML+/8#V2P-&*S4?81S^JEL0!;ZL%F_WH>@!1KVT-
L!XO"3E\$ITOI<<)T6< MIIOC)(#(3I"/X-I0_NF1D+2>^!IF<#U?QB;P'\$PAMU-L+@0M*(._%DW*?W_M'8H(OINS"+
!BP"L_K;_WODS1+XIA\$@Q.U MN0;_'_&\$_WFH&=@MHP6*?\$&NYV=@;8?9>!.NTDGA*D!S<_2-@5PCJ)(OY4
MO<%F<;#J0!#_#MV/5PMIW0&46VP0;U'9^Y;)&AR9!H_%5C9@1OB5^D=&6!M_>|^+LP/LCO#38+K>|^#T;.
_FZSL!^;@S9(IX_PV25X0#>@Q!R M^_XK-2!K3K5<7S93@UXI\$=7JWOLWR?G1FIW_\$X!%)99Q*#6ZW^L+/8^62P-&*
O>FM_M!Y4;P_M<68!=6?B#;9PC9);!_"^3*^!(!W!XA_00%8!_P>@2BCOL+(R'#)9&#K"GV;ND_MW)TL?<
#&V!>+@L7B09TV5VLN_K;/UXS"O=>1MBZ_!H02P;\$@_N(#^_M6&GD5_Y_0X0_#P4+!0!A:&W/;.+@O_M_<^3X;
!>VDK!;_!L_D9G=OR<;1-)*<!S6UA1-0A(W_*DA*^<;3W! M!\$^!24#;
!JVI9QP;C;ZOT9WH!IE_W>_<!!QA&N#_!9NS;T^="W_M!^UW_W!JY;Q8K_8CL??+^_?_?_D+_UZ<
=!"H15#!JSMPP3"XWRYL%RQ#_MRX!607@/GL7WS!\$+L(GC!O!O7W!YN5;&!6);#>\$4;+!1CA7X_7+!^_V9##_M\$.(?<
P#+!00_!3QP<0K.WOOP!OJ'5^?@=CD\$YZ?GWR5=_N5-8%LOV3>;SU,\$/G=)H0K_M.B%>&+<
!\$ _5_Z<(VW'D_R#DIR!CY>Y\$ _IKV^L.^A! W#+V_F8N;_W!&23BIU_MTKES!<
(5*Q!9Z=DYQ?^!G(09AW)Q'_!QH'N;R_=_N!P"0%QW!^/UAB7H_'MVHOD_1_M(HV0%4!VW7P!(!A)_T?B'%_@'LCD"0Z><
!D_U#B=Y.O'PCL\$;_R17^!)MW_MYQ!@;!@&0G!|!>+;_Z6=)YKY/L1X!@G_BKO_Z2S+GWT!H(8.PO/=6;=&4
MH1!5!V>&D^2!1MXQ>E1;W"XZ&W\$@U_OI<&SBUZL+60!VR)&7!X!H.A_M9T71+=+6(_MS_W965G!UIP.D@<
(>G&4_>_!9Y2K3W!H5&AA(LU L_*DM814Y&GCS#;_&!5%CYA*3<#D>&190;#X5;<-89>?><
=ERP026V^Y2VWYAS(&T\$^OT_M?IQM-ORTQ5%1+&+U&!&E"8F_O=>^WUL#WNFJ@_1/C?UM^4T);_IY;"0
MM+N1);8)/=MX^CW'3+P.S>X.O.8_-?J9""_K!7!P7ST?GIS_9HO_ORG_<=G_MKW!\$HU!NQ!M?B!<
P8W>S&%8VN*G+53;UZN_-?>O;X0N!61!B?6L0QZ!IMXNM_M.P!N_Z1JHK7\$;%%HM/781U!IC+!6F3HBJ@>9)<
(!&!L<(DREJ&A!)>F;IM2_MPA!B\$D6UCA@&S4Q!"MBUJGT!544QK_-PL#9V?>T7_#PP;6;H!SN8#Z\$F0"
M^M=!'C""U>*69LW.^_33IL3YG+;N>9PU@J2!)1@4W!6VN=AX@/ZN.Q!6(N==&\$01\$F4KMN_V2W%DWO!RPMP_N4-

:(*)26=IX MA0-%1E>7HLJZ19'WR+;902XA7I4^3%3'U^_M5&C@65>D+;PVRYB9E)Y_ M13C0%ZAX79T/ABSCX|/>
(*3UA8G'##%WITL1!<2''' 8N;Z6(IKN?3#V XG2S' MDIOOYIV8SD;SP7(AG2Q_ P@ M>#Y%?F#NX)G:=/G(.EY GOH^
P18VD)5\|H|JD>4#J-2)R&/AH^IV:(85R MX'S'E &OBI'WB37_ ^K|JF^PQ,=)8EMHS M#W5\#O>
300'X*|LU&7')_..E555J)E/AD>K'9'P,;_4.LS7DMH/0C5F-'I9V@;>T M R7R2?
#BK\$M>5;Y^/+AG^N@/#%PGI/>XUL*9!'4H!^Y\$S-9-M/OCB#ZO&OJ MM/L7.EX *W'J|...G76CR6+|<411+PV@N"= <%;^# /O:VO24/AQOI7X6I2V.. M-1)P5=/EC@Q8DB U\$J#;0-1-Y6N0+D^>!)QIWF0/%;#HNDNQOG(L+CI^\$.Q
MC|_30XKFIS152AB?=OHH CQS?9#T;M..3E4>NM 75S'7Z;8BQ4;)9S'111 M?
E+;W.+CR_ (=)'1'D^"/P3/J_ ^5M2Y=*1'\$Z*\$E2&-- 6'MD;3HDGQCYK@ MBKGT%MH;A"&5K29A<&#ZT#G!&GZ-
6\$IRY+;%Y9("S+PS5QM#3507F10<|A(D4KWUV4 A^&S)9WJW)1 M9C;V61SU)I"D5'Y&D|^CA9/0>7BX\$-
O)>DXTQS|7K6|Y|&>S*#%'(Y@.\$'59SB*RRP9^T0T028 *2ALRF=WLZ4V8V M|F\$<|4>@YA"Y'D|^D^\$.3.)TY.%##
|S&=S@SR%|PB-%VQ'9\$+PP)H<(@T1| MATCO<^5^I%Y1|4|W@2_ #|U?5@>?
B6;X|TN|"U8^C@/PO| R+0LL9NH> M^W8(K0A>P>2_>4S4Z'>(;_ "N17#T6H%|1Z|HNH*1';L\$=|AR;RJ@H+;DPD
MV>E%4JKU3TV|>WC;IHO9;B"#%4*9|@%"N"?62=3=;0\$&8*1(DLZ?>L&?H M|N/;-2-
N^THQVMY/#VU*6OS.E'0MZ&4#1.=SY6Z|UDBU_IBVB3*"M>6|_Y!
M'+#P("SW7(Y'0F2\$6)E"_CE=I1;7Y>51@1%=.+3/I4)33IC1#NAF)7Y M,< JSQ #)F2)1/9N+K\$32EI5V=;V>*K&-
AYL...Z_4.S6_C'K|0)TS4<>J M/0^>_ "H8F%SL|N^M<\$|J|HKWUYVMN7'X#_ .R 8R?XZ*|14^_)?)+/|'D M/N 9.J3N-
!ZVfy.5.;0&S'F9UE|A>8@;VAT2%Z\$/ID)S%VLJE.BRY!_ DIE M3R3|25C)G_ ^00MT>|=G%^\$U!
(W62E\$@;65C\$|N'NZ%24V..0?L=J4*'L33I/OF\$ M+&T96RQ1C'1D#WR 5K0+B;5R!'Z&VK9G&DYY2;(<=:#
|VPV<6QY1CH|VT?0 M_G8=+/Q\$01*VHA!_ *6-I<.THS+^M9QJT2)W1OF^6?C;6=9;Y*W9K#<6%O MH+/SX'2UV
9Q)8H.5YP;L_ #06L/RK|6= R2T&UX\$=B0R@.(0Q-DXO?2LS&)=8U M&AED8P R"*DIE8Y>_ 1/=Y;MM6X/C;RIW7*+6WB
Z(DXT;3H#|L@LCR2'JPO MMY#L|H5;DGB&& OC@+R88X P2T14-285'9*45TOC9C'35_)Z+^*2DMB|?_ MMB.8@?IG-
X54J<(HRLT@O0/L5(#?<C|H;R;M/BSJ_ A*L@3).2+;U'&(T>T=<7 MA(A"JR/8W@?;ENNN7|;@6H8_KCHP.8N01|*FA
7|H52S;7P/D9|M M2Y6T6A(MUJBQ%@VX"%U/YR,<_ #G|_ ++P=|'OC;8FIWL=B8JK#JM'T5-
QC|5S7)3M@Z%E11\$)%>KJ2;|H-8T1- RELGPGI ME>2>| ^5^QW|S|A|BG(V EU@)\$|M6BZDC
XA|LPA|^<5T|7>X)T|GZUH9U MY57P82>3\$+?UC6O=N5X6|%/S|)F("NL;0*7HL6|VU<1W<33?@Y%)'5R68%N
MR5^!E7P\$&^@Y)VP (T-7S25;S;3)|D;MU!"89J|K0CF;9=2;15)@|XFJ*N M>|>MI;MA4-\$;OJ;J9LR&K-
+55"N=570<)|+B043)|+6B*TA^UH6UC+;#U M-O47%OZ9<;^H\$F4A;S&MWPJ| EHI'@P@"PJ|S^
_TN^OC"*>1Y7P^DD-Q| MY4ADU8^D'S6T+34F=-&6-(N|Z/Z|'
MA'Q>4MX3#;MB;'MWJGPJ**.&TOPLL|5;6=3LQD'4FNW3(M+.W6;I6*)CD5%N#DPIBT2L7E5J-4;F&FSD*XM?)4WS?
F<8;&"9^(@DOU#R& MK@#_1DH8L"CT(|<>I&=V#6(Z@8;4FS(1(|83K4^P+N C;YK^ER*JD"H>8O+P M;GB224--
=J|;1/60"5PG?7A=GJ;2-X3(C;2;PJ0Q?4E;"N(# @BDQN/D_)Y
M..2YJS";RH|=Q3;E|PKG37X'0<|)HOH'JZ"@RRK1%U2^73M4=F;C_@X ^O_>^ M 2_KW=L;MIX;VEIX<4AA"\$LAY'E?
%'^@/E %3>|JA5?H|QTZ|Y>)"DFT.GB MH/0Q|NX#;\$J|N6;X6'T M^HW+)|MI=&WLG6NBMA2%Q=OQ>-
%7Z+J=;50J>+|E(B)*IX8LV^ESB>&8'DL MLX4;QG5PFC+722|Q9#TPK.Y;G2\;(GA^%)H MB;>K6V1;X;SZTFX5?
GHJ5P<_ECYQG??+Z@7H|TXWA+&-#B'9;)H7W|_ M|I/V6
SAY|JV>Z@4|@S|3EP7H\$"_ 2E29C*E!*_ 7EIH3_.*5J+HU'E|O&D FWP4@CL MC*(O;W2_18(|A.MP%_6E"-
#GT'C44PE@X"EK"RZA#U M|5@W|CP_/_S;X|QW|;O7I5(X6GUYI\$5)8MUR4;R0J3|CP=@LCPN8DYJ1U0/ M2-
HD^G|GY%CD\$"+@?RT|48A\$F0 CF#5P>%'&;9_&'5_O=SDFYS&?00GU'^K5L|&F|Y'YH5 U7|>R9-%_%;PEA7L63 MI#
<|6LR'@TGPPIX-BKUN2025|21A<+|?P%@|MOH/E5KN* TAL1'_)OX5(C M\$U_#N|@?QU0=O#Y&-
<76G"Y|LP1W|<6H47E85;CLB|95IG%Q|M&|BT|;RR>|_ :0|&OW|R22I%M;20 MJ4Q%"C78AL&#&Q778#|903IK?
7XGLH!^J1C/_+T6 M"VO+WT=)<7CW 9_" ZITF'|A/E|+ Z3|<^6#;KJ+H|CR<3H;G1T'8275N3;I/" MXNA@W9|&-OT-
1; M3F5\$26M'X|!^5|@D1\$12?5"YB"1#NDL)%|+EB;) (HQ|P;_7UL0|XH*R* M+>+ _KP|>))5Q&;IX/L;QTOJ;YA;
IU4XGQ@6NO'JYW^&V#Z\$>01#V2 M|T-BI"R*7X%M4+WU F2%|H96|F2;QPA\$>N?<+|\$1%9=>18(C2)1SEF Y9\$K%Q
M|H@U %ODC/LOK;T3U#(S\$2'N MKIG^VGZ|^MU"-=6#;=^+I^Y-H?+6_ /@W;^ZA+J4?P<(|H|AS;RWR5E'
MD/<\$I*NH^6;"^78\$7T')M6>;K3W<;G"/RF-9..VD%_0TZXS|+YR/@*N*CP4(M\$5J|J2J/EL35=(U(G9PERW
9<)|1%6Y;*A9IS35&Z4\$D/45J6L%RU#;\$6| M<\$|N62;|^SL83E?)^1V<\$;\$.2)>|B3YXN/MZ--^%;;V/5%N0RHK?3H<\$9;PC
M"E7I B&EATYMIHULH (U&Q|9&|PTC|UQC) +FT>UQ*F)D?LN8D|N\$H\$D|) M<;&(M^8-
:)%)>\$)WS|VZDG(X_ ^C;+HQZOT;6FUNO@)2BC54;JC &"<4I MC7)\$ E0 T6\$RF^6J|A<|XB^/L.S31Z(-
/U%7#FD;GX&1P8J;R9N#1+WI M<M1G14;_Z-%;Z%<1<%;8(G;Z#GZDXUZZ/+|7L|;^%@COB6TSZ;
|@<61|ZV>+B%&X1X);V^<=WW<"W9^>_)00>M M\$'4L5 |6|U_SP68JH3;Z1KU@3@-B84-9.8T93UR#MS"R;M;D?G"#
|@L1Z GXT20WLG\$*6/K/;5B;U31 H=)|Y+|L@X+^LBA+VNMM@(|'O M|ROO#K=|V U82@-
J;T18%#3A(FD+DL9FSHHF;E1Q4%N>_ %M;|0R;NL;F0>6 M|RM2;9#ZA&|66H&_..AN8<\$BA*6(|^FGD-8
=|70>1NS|PJFEB4(8;|V#;" M89;IU;V:01^QARJ&(@B1\$23A\$@;U|%(2\$)065(5\$?4%2IK|Q<\$;L+I&O^%=
MDHO#H#JFOLQ""J;D%_4#J2#*4_=@#M51-"6JN-6+6FM.&YXB|61#K6'VJ" F
MM;PJ(8TV1MZ^JDR8;C@8|'D9'42%MCDT%AOH>_D#LD-D4(8U='S4*6D|^F1 M>Z6/ QIL-
E41PEBOP\$R|E;WWE^|'DS""UH;HS;89CA4YV4A>ES.G;9/7CB77?3H&D#JC5O'11P;YH2W C9D;AQ-
"A4AB")P60US\$=P/ Z<+|/#'-P/+D%|M)2ZGB1.A">(T X|S;_ M/T40V@B4(&'T-IRY/LX#|@*EO
M7/9PV%1&")VO)W6+DO|>;G|1LY5;+|SAP21LY%_7+> T8N>L'Q7%Y\$Q M(Y@GC"7A&S)5\$TXNNL+)\$/TX#9?|9%|
|E|3&U.L/8U A"!'<>LIN(N1>\$S! MYE!Q45FIHCNL/&2BV72(B71 Q3X/O1&|O4;5"@S8!;S03-P5Y6|V&+H;^8T9-WF*
_H'J'5VJHM#;0S MG*8X;8O/Y\$'_2J6J&|V408Z9VMU^4H!_3?H+|YL\$ _A>="EK@VGV4E;G9S"7 M-
_DW1%X\$5D*L\$OGG;)|3WB0R M1#C&\$O*UE2MJ? MHIT(D;<|IY9N|+63^+7|;N'ZORL1KX;SCX^>S|V=US
MD/AR"046&S+V4U>F'26H472|^_OIP*O%_+|^D5-Z6YF2^OK20?&ED3H;C M|GC&UOI'6GI&HT=|@14M;J0-
JU=H%+!>_ :5-0=;6L;_XT;UBZXMKXU# M|H|Q?<2@?TY>8LOEK|*U(G#J|N'69)+Z9G_1.\$C6<9&4#"KV-F TBS"PI M
1HW0R44)AGZ\$_2|G_W@B|^%M) H#..HETG00^LD'6|LZ>;N|B+&MMTB|=FNK-BJE%YO%6U#'=@\$;NBD-
78YUP*+^5P<@| M;O@<C5'7@VM&Z#3BPRN;9T4Q#_#3'9XR@;V|J|?#BGJ\$9GEE
MZMK&Z;Z\$;R1 WH7|EWB3|OIV@_#ZN#10-3AT+&G=0=0%GROTV|1JRN54&2#L M12O=B8SM53C8;2|ZZR".<^0<#3?
M6>ULY\$YPVK64-F4_) R'E|/O=H#%+H MW;>4_&AF4X;2A06V>B^&S;G|>|2&03@;T;ED=P(5@>%_O15BD|3I"Q+9I2-
MZ-9D&' 8!_P3CV0F%9<<7^N/SK|TNK9NFWCL(U\$_-8=*W0Z-1=E6\$;C;J4 M-#YESWN
K;LQ/%|D'DGO=UN;NX&=N!\$87YGG;_G/*SPM+*7=-X|#>+ VT 5O|&T7K96 M)F|@;|;F|K'V/<*>
TNK4;M6;"SW""JUN5OSR2YD^W.#>+MUE;LLYGGI6T M<|96UM(RIP/22D);5(UQE|B|;R1U5(T;P*4B;);:6%L1H5A
^C^AY0;KK M|>"|S"R(8LO|A|OMZ*4O=5@CMY@T2@1?1R1|_I4?N|N8L;MV5CDM'22^M>V5^=0|>|Y<^*UH+V_E|_
%F"!;_ MF*PRQ&50'1>T|!"\$S\$>V M 6'>YP3;#9RD;CPL2CIG4K5_@;|^|@43!#NT8=HZ@|19;>^&"PO!*"
(AG5AA;5U=NM TBRWL7|KMMBBQ2 M&ZV7; C.GDA2_#2F3K;1&W@8-"59!"_0\$+P CA09D|7#CH@V.*PXOTT
M|;TH8;1^LE08ON#<>|:56_3%A&Q9^0_#GU"S|ANIC/G"V <%H;%HU27*6= MF8#A7=1>VAE=|K|_7_ ^TYOSL?<
@5T-U?TJV76J;\$_ /OKBU7&?T MB(MOPWX\$ GT.W2<8E0K&YYZV;8BYD>O4SB #&.+RJ8@9|C*|IVL?2;5;YUEA|_
RLW&W/A%;5'XBU62|VZY_0(?N^T|_R'=W>G%Q1KX| M>A^=|BF5 L;W9H;MW'W%|&000=FVO'M;I=S8Y?
4|B;|1S>|A|>X7)=|XG MU;Y;PM|HO/V|H8ZEFX|E^&|^|68#"Y HOW@_GH_?3F;C1?S"W@|8|@|I;OM
M>/FK40\$NR_BB;)'(55-H#|)OYV6SD2Z=0(V*0T;UP+HC'I=FYG&P%\$ _M>9 MM*..

(M65L44V24Q5C4&.E9OKIS;@<6/PM/A/SBI!#;@/\$)N MC\$JL6X)%:&KS*O#I"%KA).TV8+L)?C#K9)1S M#0@X
/3E4IK?K%1LOD-A5H>OX);)H\IDVGHN#Y.)A7A)& @V?I\ ?;T/0. MZR#@ ?<I
+1.T&R7MDP6VBS=I/Z/X/G1/PW<6;DXN+IT->?!=I;K+7OWYZI M_O/BY.W%1=::QO3T->?
G^M^Q\$INCMFY/35_FXP2'++BG%CU M+6/E/R?)KW0#Q_VSTV""[+05)6&-8YT N"9%4Y#I#E#>
M(2//8\$ARJO6?>.;.1ORK F0)@3I.Z."^>"D#MC1.6CPW&Z08#D#>-P-ZEI? M%K@^\$R2-
=IE681Z0XMY7QIS3#E7_NB.1X#TPZZIX.=IS.MZ+Q9+?@/X<IY&HJ)5WN(%>0^CN%:S.9.7.9U(@>NC6-
TK2%V\!:"K"HRJ^ ^ I9TZJ4/BMI B=D36>\$"TG&>ZY45IQM\PY4HAKPU. M.FDBD#THED-5421(0@21D;4(N!' .B&)5
MA/?@*\$1NA2@IN4MES5? F6.0PQ629&1Q12;@B 5R2R:U\$T!Q"N8!@QC1PK8H;_4E7K>@YC MR_6A;
D"PPFO&#;N_L=B5BI@BO7=KN.OA"84'L&FV;:V&'-64/@)"W-ZH'B M["Q"2W#I;1+A'\$8D@84X^W\$(-I"/WN#SO)V8V
MI:A4 "-.7I<1S@!9'Y^-J.*\$UDMOE6)(V@?7#I*L'!&NA:%M>%U1Q-5 M"6#F;_-?X.P6:%
/Z^UNVMSTJ0&+/46T4)=HY\$TQC1*!1?L)@?0?N* J53V M;:>WNJ?9^4/3BQ"_\$R?_D"?_PE\$B)5>1WAAGYW1-@Y">-
C/RNK3B2)AE2_76::ZPO*Y\$ICX&K M*B8OK**3V6@^P&^%P>COLI%D,3*.;J")9.7D=REJMY5+2#Q/Z+X8.5?H:%
M3NYSIK8-I\VRWTMM@_HK5'1+OH(I0Z&:!!ZI
MZ/IL8D=B^Z@=#3;/I/E(#/OPTI;T(GJQ2/Z/"2)"515B)K+^/R*HUOJAJR1B: MHR#G3*E3EF#KD%K.OWU\I.K);=-
GYV6I/EU)=W8"J42&A7\$GY=@AL(/(M;*H;C_*=1/J*U+6(W#8S*4500??:/AFDJS*ND0I\$GTAQ;0"6%I#ICQBSO<
MFL0.9.U-/MIGLZND.K"7*AD!0#5I7JE8G*.6YROGH#%>^K(3.XJNG(=?*" MR.+-+D)#(IQL9^7U;U\$D\(/NDRB=?=
(CH2<700-)D*F&ZEB^126IT=S.M.)X.IQI&X%GJ5S">9T>8IT5A+I8%RM'4)+L/D?7?BK&+.;27-9I82&)Q!>Z
MI(EI_#3PJL6DK%(9:Q+T.+J1XVUCW>6:Z/HQ\$OX0JUZ3I\$ M069F\$YB2H(I5//C1WJ!_0_
_1Z1^I\VO4SVP.JP*WBPB4W9)NDJV^5E%Y7AM6 M>5X_97G=:/%I\3W?6_"B/?&;DFR? R#>-C'S35G>I*E0)G&9%
@IAZS@T MAMKD:A>BDVJY09.NM=I78.@&3DJI7HA4?N#GCY6P0J.AW"Q:\$HU(H"IQJ)@*
M&9&JM6F(%VX;6XIF<IWWB.IG)2Y)LO(X=;IV.2Z'M0PFB-K#DI*>'MC*SZ_=4I\$FD;4.P2CZ@0BH
MU!A)M1ZK."2N1N0WO^4U<0&@I32A8#25K8K@E-I>9Y)P)XNHT1F-).KOXDL MIGW4MM0O\$ZCS32#X:45N78?
Q>1D9JY.69FB7FC)J%,-^ARBCC23PI0.35?BNA\$@OI(M#_*+5OE7.G28UK0D:WR.I<"/MBGF.S&=.*' 4ZJ32.3H2P
M;B9%I-/7TH10T@+I_6EN2KD;S\I:VXB^0':VI-&0+/SI4U-P00C*"LY*^\$
MRL;J=7YQ2"B.=P\PH&5;2&O<_8S5MC"UI75\B&Y>#.SU&DGP RR2'0C"1I0_A(I5)L9I:M_HDIH5WIWJJ.EYWO.7
MFIUBXOTK@Y:VJM10"?..QYXBHLV\$3W.H8?V>9<:/f"GRP73A4(72M32F; M[MF%>;U9)*.N>;VY:?
NV862WLR5R0X1MCZ_/8A.TE9Y6;VT:8JQ2I#>#QJ M@NYZ@A)025M89I'=3CDN5"7&I4#
I@IHV+8U<&NE/YI#OSXD8DIH-Y<=;< M^?2GLNU;B)OL;LC'-G=W)PNJK5T.W#D);.VX"XD2*PT?:K%58V(&>4V%V4
M_);8B"V7H(>M6WRCGADV'P<I.@4N*14\$(9VIT;..B7XFMPC+9IQ5="S3
M;G_W*X*8L^N_LY.D4."K3LX@5_(7JNWRXVIX%\$Q2)T.23.+0? MKI'B"K6?9L/K^QD3.8AF^EE(8"V^"?O\$B3!NUL-
TNW@2A^P<2*RX9(A\$AP+V M;FOYI9^GZ5N*_IG7N"R M5(1(I4S7&2L#Y,M)5/>55/JS^O M.S=R8YA6Z4O(FT;
I6/MD%" +R.I9"O9.K^U*_IP6IUG@P=;SJ@F/Q0I/" O4O ME* =0S&\$4AZZ;1+<;O#%"IUW81#I!78-
!R1+L"(GE)EV&H:V&Y%8//%K5D7 M6RL8B"JH_!U2IKAQCS+&#&XB0GLTL1J=8A!^\$E11%V@6V;UV!4@HN:3&OAU"
M=\$@;..%I[BYR'=<JR-T1L1I3"(NM-4QJ%L08JADB2*YK"=@J=)I15I\$G & M%i+IDY5" CS\Y->G)^?
_C@9CL6I9S;CJH#Z9*290V6ZR4L)%W1&02+KZ M9(6AA90L@?
MIRO'U^2GEB1.0S%_2ID;I#>KRP(\$%/9#H1(5I\W"3+FB#H% MI@)I\$D"CNICTIY\HAK0!>-P-
TNGO4J21YO3*9#3M_NT_EIEM_%X3& ^M;#;+M@P?7@<I[E_A;9I[-+UH^L&W=GPO44^*A!@(:Y)GDJ6HC980 ?7-I
/'W_I MGWX A+V@^%R_'&'(I6/QAUMZLCHI* 5F7#5*^2KXK\CR;=>#I2RXXR\ L MT'LA4;M5WL+;#EW7?YYE
M;T'6CY5/_-1N7<IABO3I=LEMWK0_04NS/I:#05ZC8>^K(Q*:_3I%WL*S%+, MZD#FB=S OPI'JV\W%ZJ\WVL"V@UW-
3&HMZIE3F7_X\OAB!@2D7<J"(&3=D(X M3GH9CDL18681C8T;8"(
H(DHFERBL"6B;N5KX\$H;RR9S)5W\Y+I%P9)Z2WM2_MJ'0F-I*(2) XE@%*#M!&Z'0K'FY1!#\$.?
S=XKG7G>I6#SDQV%DCV5Y*QR&R3 M>IZARB9^&?6'B@#D@A;V3I/9Q\$=IF5;AVN.'C7'A3S9@_Z@13E?
S_EUR#SN3#=#@A M*9;?G1OY.T2& C0PFRV?>I BCC_L1S+7 HYB\FF#5.IET3SV\ Z:0I^SX.DX=T=1-8 M?C2'-G0?>E
J1&25;L;+\$L8;I0*.AR7(I@&I GP":@<H@04#F;JP+E2,+EYRNTN?=L^QU=X; M\IV=20U?? J2Q+I%)YT0";ZMOY\$H<-
>.15VM(I6!80&0I@5^_2PEIV"E# MM^6"Y#NS7FIHJLY- TSLP*X_T5O.OSZ;.:T#7\$6=;!<
IY1_46@YIFUOAW\Y(8"W061YZ)#=;5\$/+5_8\$2S(1&YUXZMFO9FOAX_MEVIZ#49_'IX?3-Z-P'RP'(TY^D\$8;O>
M\$UH\W0;\$A+;.%;3!#8RB'Y+C'X?)D1_@809L.S.;2&#%.+(NA6N(.&CNF@
M\$.WXXFH.^OBH4FRB\PJ'3=I^36!)D)T9S30LRS>+2KK I;S.O&%S>\$_?UJ M?ENO%YC9DWR-
I7@/++++CWB\K(I3;U%WP9^ZL@O>C\W1C)3JK_N1A8H2Q_MLD+>SF8WHP^CR7)P_)K*G
U@QOIH0;>>E>RDP6!"EVES*%26Q-BU"(Y)5G M&BOI=EW7L#JZ
76L0@)\VF\I\WESO>S=L/5X%+6K;IRIUZ.NKT_5GLC2;^&! M)K#I\W?ET8V_H42"
(B2/H8C)'F<*0.AOC95("OQ*/4NW).L-WTDI9.T*5V MEUIKK;&+FX>(B&L;/FT(8AP2_#LI.3L^UGNS%UOLYA;AQ-
B8IFZ4RSQ;GVZ=IH5\AE3IFV M8=OL=IMWU;2TX23P\CX4?)XKN;/F3E-9IJD^+?.HH7Q19/FV9M"PP=I\$|>*<
M6.\$NLYTJR\AOB.PG.NDAPE7?ZV;.W'T\$0#2B2XK\$IO?;8=XTL?&S%X)"_WC M>I O@_*Q9ZNL?
5)75ZLSS7".N>M'\$A1>8U?@I\QH:@\$+/I2%=ZP;.;914U*GFAZ0);H_U1=_ C6'D?0^ZB# MCN0AQ;F.0A85"&*(G\$*+
(WLM3V\$<'U55Q;0VF;IQID;I@O.S\$>\$/I9.YJN M+P.1&-70)20GX>I44.L6;M^?)D'03Y6PIV(I0)Q32F:?
2<(BVQ772JQ)"MBT%JMZXDI)KQP2*H.X1IL M#6DS#1M>G;IQ5R>NN=8U"Q0"Q;EFB\$#H
MZ(I@%B.Y+\$QO1\$+!LX+!0LW\IA"BI0=@5M@I3F#B2Z*0(H6F'E\$YI%*R MD:0C\8C&^<^QD@:BR=,ECR('N;Y>
IR/5A%.%I>H;P(9L;!*>P1-5Y_-8E@P"-K"1+&9L(Z&YF\.(HSC62P00.\$VK420=D3PCSO;Q2GZ?V?
B\I@@@!S+_C9I.Y.2#&U("A9Z/9E M M2"#V?P@D\$D#MXO_>_HMI@X'4"5_-U1MRQS<_W2_#D=59;+>?M.3WJ.^#
M;AUJ7T_YO#? KQJR%-49@^J<:-"HJ;(UB8P14"_3@93@4UL'M+2Y%46FS-E M#96Z+A-
/Y^FDT+SRI3T&_TP;_IOL\$Y\VVZT2Z4#*<%D>G*X^0<=IHXO%6M M(V%1S^FLN40CDQ!6Y"OJ@*W#^Z0+4GJ
(Z/UU\HYD9=.XZ16P2Y86H\#WUD@_MGB"QOI9_*C\H<&=#+8;5O)15R4-S<5YL_?HHS=G;4I.Y" &P?UIX)-@J5Z;
MW/KX^E/IUFA@A3%EVERBZQAU;3+Y4GI815U8Q\MP&E+I8-VV%9VF;.:0(9*2U73-(0D);4?
7Y2NS6HDBRX^*+;O#P=QC/ZUETHNHX\JE MH'AAQOF<^L#1"=7K@^2+N9H;+.;5W=N)V*%&#
IY>GJ>_#B\$62)HH300>(+=#XWZ6F39GWI5)/;IL) M@I\$Z<QIX*&_KK/GTHRHSYV%G*;IOT08H M>R.R.^XK&-
FANR7/LWWGTHK<"*=)%)=B)#!K"1_C2S36YX\AID" 4U.GDI6
M".3M8CP9+1;@:K08SL>SY7@Z.8U&=0P4;JX1;JZW<+>0&>'O;&+W5WD.JX5_MJ>K&_?>C0\UY?98'EO^?AJF?
I^N>QIQ>^N"W3VA>U^.#0_UX6PI?=V93X MJ@="K"=_ _6-HA^C.L='W;W2*S;.:?(-1I;UBLH2QDV>E
(2C*G3QMT.VG M7YI*7N0&/2_.I3*C.02I=UH-U#" F_0">X&(BHJ_5IR"/(EN^T06;B2;6* M4I18=RV36U\B<.>0;K\$.D.
(_89&*T2\$VR)N@R.D\JC7H&I\?V2Q@('6#JL&O*RK&Q\BH M(3ID%NUQH+Y.EGYC;E>DLSX&B A&JMB;?!\$>7"-
%.LCZF03&=8VD#CX/IHJ M580RXWJY0Y*KIT0X'1'U=;Z)"N7_-Y69C7FH.F#SNXL%=L(O?I4DR4QN&-3EJQ""N-
WD_U>#B8+.%@).S>3DCYIIGT9CP+M#HYITP<=L@5I=C4I'D@4)W+8OMIC2@2;IS71BBC4U2\$64.QE.IIS&C
MH_T^E0R6&-7DL8@:2V#N4=I_%W/<I&SUZ;\$ZRR%WB&3R\#_23_(N.DLZ90" M_)<83#2/I4^D.UJ+ M38I
W4A22(^9I<582EDN"VM)9=F+;YF'F".AND%0_U(KB"VO\$3TB\$F)1P+E M\^P(D.(4.PT+;="BDO%P.%?<
V"C.842P5*E@5S+?PC#>GY"2/UNB.9/7?L\$J M_F*(L')P&89+G7\$.Q%36W8DXZ0\KG2_\$0GAPI<:128L&IK?(Z7'KDWI
J)=MSUX)*+;T7AH=Z@P2&I\PU^5B;L\IY9ILE.B%*ANN33SUSAA7@8"7.5VMN0S4JC MI<%P+70Q9G<I*%BP#
(7JFK%AKLIEW*>#I\X^EY@1*SB6WK@W8;K8\BSNG\6E M*";=3DI0X-&@9."&E>-EP825V""U;I XY<^<GOV8E0/BT-Q

YH=1;4?W 4\X\#OY.-I+A8\$4I7A=53?&-49 BZ6 2\=-25'CJS-5;F M9F:FJO);L_!@;&HF/NBK4+;?
TI&NTVM^X3@T,+GHV\ZO3R*=L," #6-K;2MJEJ4(<@ MB,RI/0#M: ^ ^P=T> (H^/9=C=Y-IIAAV1\F #3"*
M80>>W>>1G"U\|"- ^Y"\$X623\$Z#F%!C^*DY?O(C-E-UNN6JH;C;YS+/(Q#D1 M"6\NW%7GU9L\$9C00@2Y
%BOYX6Jf%#H#79G)9Q<2\^R5;)\O:0+ M(F)6:\$.#-72BE1.0EN5AP-AD)7AU=M:E.G0#VM#KUKX,0NFM_I(CT^"-Y^C8
MB5H 3JF X8R=M;V,YT^%ML#@QAD0P R\GE, A#@TQ8, RGRY\11X7 =@X);IB+U M;J\B\H(>/\$9"W2X2.AD;+TNRL
PZ%G@IWM^L"G2)U00JFY DWAH"IC"Y.=.T%0=@UY\$1F.*# "Y#% 1NPTA/... DV%FZAA).5& MVR"RO'=AL-
M&8]_V=@Y2V\^OL1+G^COH3+=IZ<|(\J8+HEW8YS5L.W*TB\,V M%+/2P(P7PRE^?
7<|N@+3V6@^*^6B,W.3V@E2*I>|L3>O30*87&.4HB3)&YJ_ M/DL?G"TV\$&G^Y\F^T"QAJ=_ ^E9@-
+^=MF6*9\|KS@T.DYO-7&..V2WBGKY MULEOR" KFL X"Q0R^|VH,YYYGHGOBP-TIC_XZS0T
MTAQL:Y285=GDB&7=%&3-@!U\$Z3-T\5"8"XQ>='6(\$T644->OA<*6N9.3 R(= M% F1CN',G\$8\5EF4L(!
(8KE=TA@|2\,IGY??=1D 8\;BNCBKK@37?JPWSIV M<\$AE0N=1#J\$3K(9HG_Y30%Q0A3M\OEAWJ)=U0IS\3:K<+,\$-
>^DZ&)R*4^ M@S\$C8CJ\H=H4910>'LH@:M\,NX,0EB\EC\DK#100J-I A6::FDS
MERE_K%L\IP85Z\ZP93B)R.XL8JL 20(F85P;|E.JLBOSSP@75&E.SM\$1W0S M\TF@+GMLX19?DEK5/)'_ L&
(P\$CQ4VG<4_5<%5)4,((C^!;::#LN%6P)O^I M2<-R\% ^/&+B4OR"!+>|:V\6H\IWQ\$FA/O_XPV>*>!"(Y8/Z+\$=D-
5DHJ44\4 M\KU(J\^EE_%,=|B50QWQ>QP%N(1NLL33J\QZ3\!(%5XKQ(U2&R"/6/B66 MT7%ND^,6G0H8;&G6B7)
I7FN!\$%+Z,\$RR4LBGF^EU? ZLOOG.BN3Q2ERXZ"4C=O-HUA=ZA1 MO7?G9IU2\$-
R%@J96&L\% ^J47V")CVKJW9\PA0+/L6Z"*.*I# "80B&\$YMYA M2:.
L AQ+;N<4W@7>1H\42RRG-/Q*X^,K_%U951@ZR^D8>G54\U/55_-JU MDC7\VKPU-?
D6_-O.TQD+\$2-7ULAO/3\#C3B>929-9_-7BOA8Z<+ 93B0 M6PBS-TK" I(UY8?;F20BS-W" I(TR-R5P-
(\$Q+4=16W_\$85B=\$294B>3\$1I2N M2X_7\UHG18+H;PE;9+2"L @ZRM47G\2\$X4NQ4ACJ>M)P=4%F(^&H_"P>7-Z
1,1DNC,)7CT*5A,@.0XE/\$"MF8,B"""/.\$#^\$'EL_-I8_*-&@K=/_Y:DZ/_=7I+BL4/I&KX M?O)XN%
(&T\$BJK&X@5,ZCU<&NMGE\O-MNO>ZC0?)A35@|V>0"KT/B_\$1)Z\ 0 MF&>XV&25)Z7'M<6U*=-LG8_+|+3|
(\T+;NY4)M#;!(XB\F/D(SIAL_/OR%0A M&1G&E9,6-"06&4+D=1UY;K?5)G0FJ_K5M/O'EAH-)D"G1"D#C3?3P;3@BS\$-
MR59_*&)5?8<407P(12H\B64H/FO71^9T;Z_|M\YV(82@SDUI(D5BD&S_(*O MYECRU2DCA)X;0VWG6FAZU8^H\W-
=RH3XI='\$\$O*8A2&-I2;LZ4;N%>S\DK M5L9E9\$*|3\=(\CKKB@_UIB).A"/J%")LMUF'4#JR_\$_|/_:L8N&+IX+
M\>9A^*4.#G\$%MTXQNT/=K3EZ3*KT\=&6?HO\$WCOFKHCN)IM0!!D0VP;^GL M\(\$?@!_Z+M*OI8,,>@,9WT;??
|+9Z1WKR)&ZL7GWZC\D,27Z-3Q6_O@*#*3 MQ?BJFEK=G-K;IUY;-76K%*2VEUOXNGJ(FTVM")(1I5YR@J0%".
R;|NC|O<DJ^@A;B2ETM7+7H4\U;7#M87#F1"CZN\;\$ M2C\=-O%1I29C\OJ9@GL^*(YKB8Q^OML_%E.BA>9PIOY?
#19@IOOX')|,UZ; M=|#V@SC;|=WAGG?H'^.JPM>4B%:1%*.5(>3IE8IM(LDE1L7D\$LEI;8J\$XTP^ MJPXGOC=-M
MF7\5B_@LO!S6_R3,WRY7PP60R&V#&Y M,I2\?X782\H2)E;=P\|Z",F0Q_Q9;BQ?#YC\$)M;O_A GCENW
M,0';LO#_P0,,IV;3^*ISO(9^19U1)*DH^EX9\,9RLP\&S9;S'PH08?*0@3;R_9G<8 M\$ _K\91QIO-1_..X5\AO?
D@<#K'R.0DT\<-S4<J^#C\&/A5-UXE=ZW(M5\$F;Z0K\I7W@N8ZU' @X^07Z@-%1X%I>SL#2(
(NOCYGUYN=O|>5L&Y6R&CX MDT*F\|@D Y(KZVUA2/+L/RMZ/9L;L;8Y@6MFPT*CR-\$2)H\$OH.^>2Q8'H0
M7@'ICN\;\$B6=E6,Z1\|<^N.FK@G\A7\$U>3 M?2\$YH.0VE-%+YL(<,-8A5JD*F&J'R0.FCY>V22I?
L'5S;EK7U&EWT(1 M;)|)2D8 K@|>LBI_RJ085<ZPE=1/^MCCQ40>E6_ZOQ=8H8#I3Z7UDOBSL@6
M.TGI,8,&JOAT#H^VIPE\4ULX\$=6Z+O^&@^WV%CIW=BPYS%@F3).85D(@_ED M/'FW_,INIHO%
M+L827\|O2(H*LVXA&5(%/\$+371S%2&RB,0\$9,(O5,BP1)RF^_X"";_*#9 MD\;FP=P220P/D/O>JSA_)KM\7,TA""4*(-;
|Z+RXIE+ J&S=C^8.XF9.YR= MJ/3%*-I#HT\D.9JQX7;-R\@F53P0E@Z500X\F8\HYM2\PHX'@.\$"I'OH\$&1C
RN_0_=N%Y_0+2>FGF\H4\$Y@5QWOC'8_'RG'W.B^8Q5J2JWW^".*\$.
M0LD#D@MKB(I9.QBFVE,B9\;ASH'S\UT4WW*IA0\I7I%4\NRRT8"5#=#|
M,AY6\QT\K\I#W09Q>D<5A&A0*JPGIUAZ(*)?T5E8+69NY%K":?B(=9FHY6M MW1B9">D1;I\Y\9\G-
^V_X\I7I7EUJW;"E+\$,6.Q>3^D\N1K-%ZD2\D_-W(Z7 MOY\A2S+Z)+Y*;4G:@K4P<3\9(6AA4,4#VAO\42I>31#3Y0;"1-
A)0-5228 MF#-M%3A92ZIDMCNJS^%2SPFNW%)XN(EG7\$;L4R-WAR;SI-S(X(L5.@GXQS\2
M0W;D\DG^I&":'\$<9V>.,HVD%!'BZ2-&LB;I:%TO-2\N=@*29J1M\W4C+/R2= MVZ\B8?5(8%F-&CW""T'8C;
M=&Q\#9IE,W\MSJ3;NM1G?"I")H^/OLP_4Z+|WU+BV1G4\ M;VG,IVP =_JTIC(C.H_"1L?I77
T0#OE(@UF3<\$SUT_C0Y_%W4;N^+HX#;B MI1D)&2%\$X5=T;HBL5\I7VHQPQ_RGVGPD9C.Q*Z=@D(UJMM\$
P0YP166\DJ?(& M(54 ?;U&(?_3+O;I\I\$Q&@5X&0^OI-D*JPS>P M2\7%NWJ4_R?HW>R\W133CNZH+_L)
<9S6D2C>|WJ^GJ""^N(=7\X/L5'M5L MJ&EWD>?<.+C;TV8GGOF/5I#&K^=#%ENPJFI.^.^.*N;#M.FM?2.Q\$--Y8CZ
M\3B)9C\DG7V#6M5%YM/R))8\J^?/5)=P>|2&+?Y>3\YT(YU@|5;B3)T_ M;4TE&D52.2O\X9&?..H,(!?
(RMX\H4<=>E84Y<^TJ&3)Y&(#FEO0F*(M4C0+|^22S_%QY?02C)(C9*F*J96|<(<=5%<-);,;MTQJ*VH86
M63KV79)S((LK-5M_PSA#5<|T^|C#N\ M%V7=N"L1.D\I+VY MIQNH85EC\I93(NX%"/X
|FO+#+#O(C,Y1\$EJ^HXBU#;\$6|<\$^TRKZ,%8D^BT0 M.B&L;K;ST6\Q_+5+);3X<|F*R/SF524-
)P%*(@)D#I&1\=K8I492)>LH#|H MHP\$|7H_L9C7XQ7(^N*N")/1\$@P6BY'92ML2/"V7?;?; 67%.KB_ =TDZG6C@
M.TGVN#7T;3^IX\ZR\J;6;C\ M35L;^H>QURKSU%^A6Y#JAFRLC)U6BR0&?U\7@R0))Q<_/&D^OI_@.9Y; MP/0;+
^/P&PPOZA&\$G4VF/Q\7G9V\JNR0.UFER55SRB,2^524R(N+O\7YEAL M(%0HTHL&+7P.Z%^3T%^/GV EZ9-
J\N@.I(AP#QD;B(<9%9F@JVN\X^E2(MSINE\ST5\;.%4>NB\;_S?*0\$/%8_9VQ\FC@_*M15MJ\$5;H^/?&0VNM)
MXN5EQOQ?ZDJE;3\5+=ATF&=\$M^LO,0KBU7">M6Y.5K4E0TC*GN5.9N\$CA<0 M^E"HB8.A8^
17J8UEA\$.%E\$3^J8RLRC/TTF"3QC<|^8+4BE9)@A/5_UWM M\$F\|K)K\I%\$ _\4N\I\$35;DI7H&M'BVZ?1"MJ&9
MC(DOLZ/"6"?@XWB4 ME/#"/V1Y?8M-S\$J^3H4\W\#>ZHCL*YB+I#ZV6ZCLY2_YJCH*YS7%A\40 M5;_#C6O=(?3@J
AZ+876HHLV@W;%B\$(\$@_IWX\^E^&+|^I^*Z\|F<%A3%\$2 ML\;60I<V^:X@TYQY/14+?RJ8Y"(S;G?
G21\$%N&2OI2;DP">Q=B#PGP#H.8 M;#D>%|f\$G_@&*5XS\|P\&L;T(DP03%<|4DDJA)Z%XYRV5AC038HG\$6RP8-")
MXG&FFBWU^*5);QGO%Z&TG;1*=%N@+)|#19? M;O_94GJ=P5FSM;-G;6YBW81(P&+1OLMKW?
HIG0KPNEBSMV\ZO-JU&(*,I MY>_/XZ2WQ?&LIPV;|GOG#V%5_*X\D5P+J&JE"GR\7\DR^F\PW@1.P8S0
MW%|D;J=^?5J+|E9=;(-.W^>>021,"IJC""|3,X>?7:7G3JB>R.I2M;|W,E M;|K<28%B7&WB6Y1K+_B22S8=-^%
DOJ_#F\|L,T9B48&M>_BCNAT7\GBEQDOJRXZ41"->1%T121\$T\$6S">HXY3R>A8\$-H4\J_05 M=G0=A,3N3R.#_/Z
CMV\EPWLK/KUW8D*61Y\|+Q\X?H77H9PX50LRW(=RIS\$0\L EB1@|D79""OW27I&8\ M\$;_JLBHJU>_L#G^X?UN,?
+^C\|_ O\AX#OE7Q1;SF#H8K7?QJ\VX\5_ M_CMZM+T=KK6)?MC@3\AS1_IHM8*=W\IED\KZ\SR(+8\>|TK9^Q(^
_LZO1 M\$+|G&ST^XPD8#A;OS3YM+0+;CB89LZHZC\|C^XE71,K,@540 C?M8\BI\8TC91+95Y*&@;.."?/B;0F6YA2+?
EI9C JKI MBOKWCB&B1D.7.L;|!T^2;CD\|D1"M3^XZ0!>Z#R\$HL=*?0P199Z0B^S#& M?X^M1\,^P59P*>)7?
1^5%9F\YP5?<0\4KZO@MU=O_IY_IL_=D0PVQ")WEH& MNO:Q(&*3F@&S&^LJ)"L_Q&..H/_
^QSL5)>JQT\$*139Z,850;D6%|*""Q'? MHDZ\2;S#PP31_FTT8\;ULS_U\$&A4TX-7RB*W"Y"8B\;C5!&8R*"U>(CUC)
M1+;|)9+P7)\$-+Z&#A+*G;N\I\8^U+CEE":47=9\BV.V;I;C8CY;Kf@Q M4@("BK""I
YR0TJR(T")B +0;2T4UN7RE60Q/GT'DK;9>KWWID\86>RQ_** MJ6\|O;T\LNXY59^R\WC+|N^FID\H8(M2J;_V"?
2/M6%_7403(\$)\$S6C"H@1 MQWQUD\|C+('TN1@ROG1_A5(K(VHJ@|R(MU@_B+PYV@1A_+UN0=WE0\9P=;R
MC8=C2"B E;1C5/6&N;9\QHNKH)/42\5P/MPL;0P(0Q8MS,L&%QU56\I3 M@*#IVXNX@+V3\ 0P)5>"NG=I?Z\T\I
MEQAF'E"0M)I+_W\XV>G_Z8_X7\^<^S^Y^"?R4C_,E;47(A;V=5\|VZH\&(/ M/D?!!^BXMN4-O6#GI*-7?RT,
(+GQM*8\|D*&,91*COB\|M#4CS&LSJ3=AXTYU1 M0877>;X%Z>U3BQ*^<+VOXPO+<-8(^C-3H
39.8V\|EV\YH@?"7(LZHD\XV) M0H#K 8HAK*\$SA HBC#>_JG\9N9X_O\;_2%Q)4RA-

A>0H9#K944 M3'UYOIN0VM/+0FS0\^6%8 MD(R+ 7C2EC%<IG0TXK\$3P!3!W6!^%47KU\$>)
<,MH,T9!C>Q4 ^U%,AE1C0A M;B7HXT\$Y:0^R#@C+WYX--:W>Q66O&DL 'X*C" ""C9G526R!>N&,6)-H'S
M79,7,Z6/HM! "JL^ VNVEM6HY &7-,LZ7P\MO@MMC!>(JL=+(HH5MQ=%;-+MZ5K^OUT?#SK"\$VQ#-X(?+
J*BI^A+RA5G3>Y^VGV7WSH7 3 (+T0S!PF" <5!E8 M3!||MZ/0\$^19FB&2;E=4E"?4L=82P5&NMTCQZF96"/#HU
="*2JCHY0MS)H-"
M>M6P ^EJA8M& /YSMUA,T.#1/B\5=0!MR;EH5#"0D!0%>6.CCAZ)>SG+16;5GQ14DC*TJ^MY=300OKO +I
(+Q;XA=8Q MJ &2?&H<<78(T4LJBM=U"!%N^F+"OV*NZ=9O;5&EW#HH+E8";MP=L3@+N MO&*Y>3=" (R)RES!WR6K6Y!2. S3".1KT0AH)G,YZW4YL0EB60!(G!X7^#A MH!T0S3S)\$ &P;@7/T21X(W/OE="!+>
I5A\JQ06;H2T"SCI7@06FE\$APID, M%XV+5SPV?K+IG17NSUYCQDN#@J=;IW4!AQ08&.M(>X.PU <=W/"!HAH8 6S)D
M-*U;Z2+!Z)S!TH)\$!RNEAV7+ #J8=BEJ#EXU(D\$S\$)H8D:& NUJ5!)"EHN=
MN2=HH^K2,1GSLYZ)D)8@;6I8J6Q@2-.R8*U/M4->GY*_-2@.=JB=.7ATNW!S M1HF@AV/#HX"!30'+4\$4-
P.\$E^"=N:TR!_90R2RD+U(QH J6ZH!.\$162W"/M/C113#1Z+6N#=#G!T&+ GYR5K"AM0^&J=LQ0XQ27Z<^"IF M;O3YQ
-C=-U;H RQ\$03-2S\$%+L!W _DW6HH,I&H39"GE+<+
MS5NA^ -2,082==, #KWPFT!C*!"!\$^0%>YQ!B\J!2J6UMTH8D>>>+M9K'OC. MP"%XNO@VB"SO71CLMA\$:(DGV1_?
<I@!(341KQ;+>;%0%L@X M@ P\$)M9!_1,OE_1""SKKB3.TL\$RRRVGD:=7K:C_%D+U(Y4T%;3: FJVE+9
M6!WA&1F"MDH(Z\$>G\$"Q0U3OR=-,XM;7JF-&L6S78T@PP&YO+6QV=1-W"M M*\$JY;U:RK7/I_<
X&Z!#_-O"SNZID&W-L?<*+10(#)<5FAM\$AQ)UOP3.5TMXL#NP_1FSZ/"*=(ZOB3IK+EI0!\$G'2R+.B0.\$O6-6+._2L
M*)JNTGN!3AWUYL^3B+V/IAPZ2#94 CJA@W:0!0A(#T.OJ+NHEY)7N:NW*E M1X3H!^JL XAI.LO!>
E%ZG;_H!>+Y6"?>)>^WM:L MRPZ_DC;_Z5(7\$ MY2YR?1A\$ QLIQ!\$Q!^L0\$;Q9_"NK##(8 ,E:@T+S(SE=&KA6E
Y!_2MG!+! M%QOIA^VH!L_1>O+5LE!1CH&2QE)>_2,JCI!0L!A654=82VXG7VSL*%0
MA6!0M6U3&E<3!)@\$.M")DU;A>-S*B9,K6%?*KF)S ^.% & @W.B=JQN*!. MH5!X_!BE,\$.4G;-8SS>--42XP%Z;J?
R^R0;_P>' =Z%SN;R/HC/U#2MV^:D7V1J;)DGUI+8;#<)>L4>TJ^ M ^?J,K,Z.OP96WMJTI8B>H5@J!*J\$G"J3"/I-GC8-!7&-%P-
KMJ<;#5Z;NN\$Y MJ44:@6>N#W!=63Z80 _>I>_ZD;G<=RUI;F&PIV>\$00)P;VO)S4U!\$ M@&=TU!W232>#)6%
(8VS)XWSQP,K;FWL^O_+/+2?O4JECQ@G: ^_JLF-X/5 MBE3K2?J3UHY^NB=>"RISX.\$Z6(Y?7!Q_5S6;0,-EA=0XE;N 9+;
D5U7;P\$ ME!X^6>RY#2CX4@3^QU1RDZRCQ=PY;*HUO+?#?WD11&N'\$?H)/4VL^O;M!
MMYV;G6)S&BC#*D(7\$S@DJUNQ3TT\$3LGM!3W)!P;BE+R@Q5^AD0^QV%4#Q") MW8@4"MY"OW.8-4QF0
(R*6OD-#400^87W?Z\$MPZ2?65^(&\$N+!*/8!55!M=P@C.*#C4#"(E^3X^P8X?+;STNT"\$VK/;J%,\$^ME>.YE!""?
\$Q^GRI^=IC,J MU<+Y6P2;X&:T>_Y1?C.4E2#"M?RN=B&;BF2WCN!"=J#A^H=T%7+ #JE^4B^OI!G\$?E3&T3! 'SSV+
(&U^T D3>F(\$R0@FXP!62*0 MNJR _#_SUS^A_*4!G8!C+US@7P96Z
A@1WEHO!2);,AF;==&_WX%VB^LZ!5;Y4)JOM'D%"S^*Q>P<="ZRXU!ODW:<!"NY MC^*K2U>Z%,XNF?4(!)1
(<^I@(<@H;L _IMK^6)JLC_92!2@IGOU>O_!AJ5 ME;R!C@^I>;UU,YY#BI#GCS_Z\$!#_.YDI20IXDB&A;=*)TE:M6<.
IRW73QQ MJR^QX?6!YSD^ (6+*RT/EOD9! =ORD)(2NF)(@M#X3)6!\$5? _;T7>%TD
ME>U1252;"L*/T^<.#03.H2#YA=FY=D;#Z8^THR<2LF/Q3/)V^E4WNOJD518
MFHHO+^FN)G7H=WD;M1K6LL1QJ0HE;">G#IQH@;^_) *60+;H5(6C7^-(IMH;N
M")SNWI!)S\$0!D8EA).4B#0^08""8GR K=)"N8(WIE;ZPXO.NG/6*N6IE_+IMB_ "(H+!G@VL-LRO.WP<T^C4;
(ZC/_ZREA<# P=;%0-5KRPW);>8699#9;I>XM6W"!E\$)"> (=40>9+J.KJZC2!Y MV#&IBRW7Q^<C1X_V!FTX?
G)4#I>^<:T!UT-?4=?N!A:4.%?F6A#+/!>@LL M!/:).C+X47:=4=:D+C^*
MEJ^3%K28A.YONUO+ZT5!B,UIYGJGD2Z6!RUK51!)@D,H_MA4C-)#. #<^EO+=2C06K6_11)GSN\$M
MDN^R%9VW<^AE27CV!2!@L)HNNK<28SLPG+3((^9G%6PAY!5;_IR"Z?@D0C M\$7?2C)"!VIGMGE^D<
7!60^JZ2KYHG.9*2_1V\$!4!DB.++M2W!7#0LX1H9 MO!R_(UH8!NML.^+))JPIW8DN_0MZ#" (8IS,Z%ZI7!L5?H+W
)_J4OK\$>F!C2R+K=>JZ-XOY_#V6DV08 F<+)"2N5!7W2%YH M8KDL,ML@OH;XOLS#6=AW.(J!U#A*;WD%SN@N9!<
YC=(<RL;?I8)J8ZX5QW5 MF@_Z^H^I^Z0)=JZ8!O/Q!MNPI,%U^*KA)449TJ!IC %@.@BPLE%(5EJG_XC.\$4W%)6XG\$%1?
N/4H(BS,6!^#Y=+M3L7GU+IR=\$79B(-LS@LM@^?C^WND!Y.Q M<+&(*R!+8+=G C0-N.MW-8P/I#H04_@/"W6_17H
5CVV6C8?Y57AG6RE+X, MO8^!ZO,+X(IF=G^*1P/*D).! =G+25F3SK37M->^M06E>+ M,' <(8P!C_8S^6W^0?
0WI(+ +9>-156^<^!R@1E-A)0WD!6*NTW:@<'5_D2X
M^2"AUF;O!B7X6@H;%!P%74!V;\$ACEES!KMX\$X38_!S86(B9E+2U+!#;P#-
M#@8.*6R/0M0X(RB5MX3!^0K>_!JZ6:>?G^#_*L*#H;FS5!P0(9AXZS;)B& MZ#^X/#L96.1RE-E7ZVTHBPI6OMFD;/Y-
#T^0!LCP@9&1!#8&C\$;_Y+>?W(6W M@H.0@:/<18#6;&MZ>\$\$*BL(DLFK;!* GHX1A-8ZW4(UU8,>4?(M?
P0S3U6#G@H3S4+7AC,8DHGZDRKE:4Q*D!(E0M)BBWM@_VH"N^!&)5U#S5 M5VU<\$-1(\$OOHV=QXTOR0_I.)
(+MR@RO;F!D PKHB!2.VHW)ZADL!3% P32 MUBD6&!\$%^EN4<+F1^X_L:LE9H>XCH0-H1=(U+B#1HP
8_06384C(\$2&\$1W M=MQ&BE@9Q&_P*QL>-2-4\$,<9UJ>_4J>HIX^H1&O='(TW,>0:P(S\$Q\$!(>F
MQLC9@HJCRVK%;G65&4RZ1H2(G/W:#0WH5N!.)H:'D>CA"."\$D;=IU%02TU
M1FK>M;.Y4=5)%=PX.#A@N,>?"3QWA*)2;/T.ME5)F))_D3_#CND\$7YVBC4*>Y#;ZB,\$XB;^=PF^N3_L.30PWS2VL-
"R))Q&Q*+_.5N^29"E\$0M#%S#L 3#!^Y&Q9L_LYG8XVY.NGC+TFG.(7Z!2;I M9)C4J@NB;5%*/^7?C%8G>=MZU0K?
J^F!_U:ZHTHWFCNAF M^MAL5.#C@AED7*/^EX!14!1^EUNJHC)G#I-OK?B %=&09*89>*0C=)9!GOIH
ML0NWWBY"/P0>@ZK/44FL-TVM++?J!9T5N="2Y,KIB;N;MZ63G5!ZPI@/_ MH65O8#1=C6,TYMJ-
<.);9VAMW5@H;00_K=BB(D,25HU@!824,Z!4G+ _G MQ00PST?/KIZUS _FIWCI_ZK!XZ?IQ^6/^Z!V^O=F_>00!?
00!Y_~WRWD MO7ZP SCU?HI?Q@OXTQ+O+SX GMDW!>D_KJ/%S^?B^YZ^N LPGH6\$WB
M3_7/T97OW_Y>/^S?-HOGV)^OB?_QDV4!Q=Z=2GVYQE\N/R%>S^CZ!>
MS;_Q_#TE!""_+!Q_K!IS_/G^!FFP_ ^K#M!QY/4OTS=I>WCV!TW/_W! M>O5Z.?JE^_5^=V7LIM?YO#CHV/I
L_O(P^_6.S_AGV7DX_7ER>_UO9_*_MHL_-G,27IH/V?GJ#UJ_@*IG5XNSX44P&H^O?HOININGSU_N5>+.8ICZ?
M>NNK!>WGQWGC;O;NX=-^/8\$ _CV_!_W_.CS_Y2)R_#E!Y?G*_JE7N!CU810_@_II
MUR=FZ""&6V*!1>3A8)*3(JL5_/93(P!V5!^U\$Y).W&EW0.A8*=J9BP^QE.7 MP^E.3IUMHO(G0"@7:G07R+;N^FO\$
M2;_AD)0^&6OC&^!44I^E%*JJ#^<^Z!1AL;7FUY" F=4?VIM!95^5_M0=7EM^OZ5!)>5S#)&HJQ%.%9?
#1\$Y6@IW>XR7^4!@""000^AQ9MY^PGK09L MX5,="<
I8R@KXN;%4YVH2MTBHX8VL2^>0>))0KK!^<^D_6J&+;I9DOQGYL100 M.T;Y.2ZO:YRY#&38A=N\$KM2HP_E_8,
M=5QR.!H8\$O(")\$R_3DA^I9+O#;MO\$5.U4L<039=#6P;P_BBB^!Y!K!YAN MX6_!B?
L!OJVS6Q2(>I0J0Q!\$8Z)S73883Y@PTAPV>L^(-+MZ+B6Z^_J#T/ M0L6%BWL%'7WSU<);,\$YM2/0"&ZF-6@#GW!H;_<
IC5Z^Q25?A?>J;HL;+P^?P?W!_+OIX#X#N MS7(4FM- MAX1NGAQA9;WR:@'^^AN!GL9#<+>GVPENAG^W
\$!0%CK7ZE(!;08"BQ).P6_NOT8>"/IS!@#P9?Q^X)_#)JE4H_J#?N48XX9FG3?!B-+?9, "EXYBK M<*K"\$S/A4^G-
453Z;B""_+S!D4!J2C>3/H%(8<!:M9(6Z/GL_ "OBK^K:8FJ_M+KL^C^1O/QUI(MVWGVQ2&H(F#0=M-/.*B#\$PHNBj4<
>0EWBQ+K#X!Z!+_+. MEFV!Q_T7R>SC^("0T+582^!EU4*%>U!9>H9*6+P2)_N!%#+_HQEVFQM@8/;
M.TV(C5)+1E=2!2FOA^!L;RV^Q*\$E=X@!O(BW;=Y>_AA;P96;&AH^R1 3!BIVFV70K1 WTL)_ MLW_<
_R^ (HN=FB!)=.K^42\$!@I>HJ^7400G?M#W=A^"TT+Z58MGDEAVI4.2? MGHY@#^4Z#(0J=+^*AM^Q@_V.B"
(#T.85M5;XZ,41M1JXU22?Z+9W)5K(Q+M!D;?HR11-00C^QTX;F;>RA_!N-J/9V52&39D8>Q0(@^TI677\$XD!E^VS Y<
MSU^JO\$TMCO4_)X#1,&?H#WM!;2UZ_E9I>1-BW+);,*#L#_"H4!Y+--R<
M5A4*!>C^ENEEHLHN+JWHPA)ZC0P_0\$!L0\$)">KIU;9R""""^60E:PVRMP3_M3#KIRI2M4L/^YXF<
..M4M&@/ORY@^.#;.%)>?2:6KYA(*+J;V9^UK_??YZH M!C!4(4!9K\$HU@!+.=.PN.1F/KV?WKMF*@U-"0:6M6U?3*

X#/+S"GA\$50<\$91+?NWT@1 M2U- B3K#.\$H>Y^%\$>(. ^J J=A.U3LA%R6+;.\\$B?+H9.9DR6?O_%D02V/
MYV2H77M9"DOK&OAH.)KSB#(AR:T(O\&2%0R-F&K:CG7!%%0/(O==)J6 M-
*)01N>U08H&U175)4EJAF6K)!L1Y(C\ZG4DB)>+D!4&K,0X&H1#)I& M/5%P1WV\$OA.\$PH@I=?MD"A.SL! TN0(,FT?
=0CD^40%5^V/THS).09E@%<="I4=(7DN1W) M>;68#83Q0NVF4U>@<#\$.VH(U\;CM4>@*O&W/N,Y8"
(HEO*IRX^D\HJ0H.R.;CN%21XFY.O*-M=A4D2\HJ9TF)LDH\$1*K/#OS&A1?>WM/TJW-G6EJ\;X"15L%W+NPDL
MOY>K\H4\G+HT.C@1&@E30%N; HH\$F%6.8TT8Z6R*"&W@.'^~10G;\$Q\$T/YV
M'3R13\LCD\$C_<4\#82AM%\$""5DY>K\=?O<-JIO,N9EA78%\U86V2\$=>V-*M1A=G;PJU.0H93=O?EQ-
2U4\G^1S>!\\$Z,QV7-ORA+G)ZJGU^I-!"MV FMH M27.0MC<;R' @3RQ#F>EBI>B>,BICWY+AL0FA!3SJ5TU?I0L.G@
2-J#K(I MPU>=\$T40.)EN2X2F2ZNO%%ZZ=;@ZB3PDUB\LDQZ'+L\<15.L;J5"WO=+Q>!\\$%Y M;(E8(50<"36-
94AE.%N;>1\%A="+YY IP6O1VL0\@1%;A?>_,8>I^&-Y# M>@;>JP-91Y#W-*Z"W.J?_,MM^JYL
I#/%S\BM(KDBM<"JY1#0,H-.OSR>% M91VDG<%"A%", \$T6T@'/\$F-Q:5Z_FEJ\,'+2%2'4 @Q)E"""">H&D@SG_@1!/ M&-
"@K;HK>X\AG=!\&TZ<?"K*"K>I\=:ZU+4Q; THKKK!\^+4'1X.P^:G@R9D3395FA4N=2#2 MD\(^84-
WG8'=HYMM';>1>RBFXUVT)&H&%O*-&T3@WOUQ9YZ\JLX6<;-/ G8 MF2>_A9UY\$K103BPIH(&QWIKVY_HJOZ#L)H:\
^!\@?R)#2*OM\ITP)+P_NCGVN\OZ9YPK;_55(U+V?E8Y(5 M1\ZT#1\XA4LI-1S7XQ%8T0QY0PI#^;DL*OE/Z
C6V5\;\$YI@(%O;YZA>V-I(MNY+13X*H1^84WB_OV-LY\$H\$YND0 MLXRB\CSKZ"7I;_U:L\H /E\&(-
OQ"@*>%MHVQQ\ADRKHH^DY_/9%6KJHR MW6\0-/5\2A5X=-V;/3/KHIP+0FG\$.P%Q.%IOS:D\T_=P6ZXN>=);7\N?F=
M;P^8J3-"V2ME@5;>*>B79B_<62+KNOP_15CN\MR5MX_\$JB7\I.&>I5S^! MRNGT)0+;+O.U8.KY0_9TM+-C2!'MQ\A\Y
9V15HMX72P2%^="2;.#JA0MWV@_MZ3ZGFQX\!+(T2ZJ7S4Y:'CYFR5V6RZ65%"^;2OX"M%9:"?>+M.'B@V=\$T"
=QI\$>I>Q365.VN U\$JXMKPJ9*J1L>CF?64NZ.H^2*H-C6B&Y
MJV\KEJA_BKJ\1DY\ANHENOQ#601^WNME68H\TR;WZ_4 ZPH\F)O\56Y>W\ M&N+3V#.4R8O-?
*=&6'.\ZJOM1\9S\?Z>9^K?S;J_MSQM_"/-2<(&X>'@G_MHO4ROL_VGS\B%<,#1=9;5R?U11>1%"?"=K'?
T&K>F\U/(\#/'76.08 M#.T1-WBWW\$ATZBO*2_L_V(%LJO=1EZ/X=B(OP=S?2EM2_O5.C;JRS MT;TX+I>X?
*+L3+QBLFS610K6ZR?N%66=7^5B#/DBKK\$P8\$26-?>Q+;I?? MV4UYRWZ>@3ZVKFMJ<%G\$66X3IK>?
H\PF\;F6"C#7C-13;@#X\%\$Z-0030_+M9QU.1*QN."D)YK4^TJZQ_/\-PSH_P.0H\5#W>/\SXFU4NYTXK;H5\H0@H
M6"UHDV1YK=Z6Y>ZH15+0O=-WM<JA4=-E3"S'1U^!8K3+GO>(&!\&G5X7%D_M-?7RC\%9JE=DUFO:R@&O-
W(\;D\HH8!_#J\$&\$2PH<"OU&#X<!\?7\B\H7X_M2\JE-
#;::Y7DYZ;\H\N;V>3(RO\N#PM;_LO0\$F\LK1\JOU\#X;49O\0UCCO_MJT"A3+\$N0G5C?^FTMA\$A1%(K)\NVP"-
I08UJXK&I;)D0_-0_PS&W=9-(P' M1O!>66E#262-S?73YVI=C*W-/8_VOD(?IL*5<"I_0\4U2_#V&H\3Y/KQT-M!
<@S_@B\H>MTP0NQ%?9>DK_/_^N&I_M\I+UP>M6\RH#_XN-H12XPU;3;16\$.R(IWU8UG797&3P-^#;VQ;P<@C?
@_1 M*G+4@=MO4\^LC\X&,\$BEDFGNTXN'&QGV6OLL:TZIA'GI=9-I\&C#6.*^>/X
MWT2S?Q\Z;@RG3!_49WE=7;13IS_-/SL?Z;5.D9NTA?Q; Q\X;ES7XN@W& M%UH1;18\ML8S)
H\H&9&)M=ED^,&1L=A)Q?E=9_-\$%V M;JD;_F5%>*>Q_A_7M\?SV803?I\12F@B_UGO4S'<<1&!)O;0+L>9<^;
MG'^#4HHUS\M9@O%_VMOZE\GHQ\J3E9K2HJ;I_N;CIKE3T_U?@4-I")@_/9T M5=&3R*Z\$IR5VH*T(F:NATZFEL
>8QY8BIMZ?9H33>S';38#);_=\$SF#&WN_M.JQ71-&*_@0X9\6\$K5&+W;GZ8MOM?0W;I
&I_@#M'V3(6Q\A'8\CG\$+2Z
MJ6/R+M'N<&07(O_/86CA>40PD2SF9OLZ^J'(9_#OG\$#QC1GK7D5P@4MO0GJ8*BTYMRZGY-' MNME\2OY95J?
/NF&G9W4TN"8\;17L'4(MN4E&T4.Q@^&;5.W#P>4C"&C;H MA-O@JM_?;7<;->74;_Z'.OGT==#P)="/19BD\@8
H\Q63<_T%HW(GM\B M^_"85+_B+*?AY^*NJ<%HPA=6VW&Q\LRK\XE9A+'W;IK>M=<%G53\>&6A'Q
M=>*M;9_1A%>R#<+F>6?-2==^1;.#'4M;1;IYZP=0NOF>6+9Z40Q_J66=HAJY M(SMF#LMO*1?
L\%R00SP+DS\F>3\>OCRO;6'S\WCX2EV">SPF9^U6_H3AK3_M77P1LZIW2<\\$-9MJHLBF+FE?W-TOPJSQX(;#
M1C(W#T?0+/\SNL=A=-\$0\=S&-GD&S9=RNX;P;I-1=5_M19^2+*#UE;S\+YUUX7A*(J4*^L5CKQO%NI-
?>=>\$A7W>A\J061_T\I\QJPG;_#M4UZD06304F)"1C-IY<2.4)LZ4P_K9O1>G/'-J\Z\>Y0UYU*\$AYBH<<JRV(NJH@V94-
M2TB;_7OL9ZTA6_HPMW_MWB6M5Q\ORF>=%*E69&"JP7HJ1<0K?;+0@J\+*H<\$%GY\48A_9;^=9G=YS_M)#
<;J;)2\<*B\+Q6K1-D92%T-4BIN9_GR-Y)0\J+\$;DD_>I.V0"5_"J\I;L;L MC\IF=H&@!QL=C=-N?U5A\$"^=FVU@
^B5HWT#L?F#)=P&KSK(MYLX5/9JQ_9_M)H"9AP@W\WK=^KZBW_O")K6E?\$LD;W(@=,ASAH?T\? M;L;L-
<)875\^3=ZU3Z0Z;@7"S\AI_J;0BT

2KK_R*B\Z(4U\9:B.L_((X&V%WW&O948Q?P,? M6J<_@,DK;\$&\$&N>L&8X7^?'63*O>3?I'T &61Z/P'<7+4?
5M4^/6\$<6G/E_MMN)U_%!\\$6EWC;TOTC5C'8!_297MY8R\KA5L!=8W#;WZZF1YGC';1;.*<3=
M'R\HW#F.L"41'0TY>#Y<"V)\6TRVG&H\519^6HG^@VVV4T/9\EW\$H;SW)N_M&X(56\$VT7T#FKW=F6K.YD\<
<#+&O\NYK^_>SN?/KUF3V?X=W"A\ZSBLV22J_M/>\$=I'F_48Q\IOMGKV=" @MR_D7
M;BE=C\J'^1D6?OY\EHV%.MG4\U"ED\$+Z_%F5\||^;XPTR&E,F'2@N^HP7O_M\ EKOF@5XE%?L8P;
EQ503B'4\Y;XS2B\ZDQX^V_%.2PZ@2099(MNLO)'3_"HE\GWJ&RG9)..^;4P\$AWX\Z\H\<Q'7=U+R3<_TNHX;(&
ISNZC_MK(BTW/(\;#X;PJ0N?U=W2\H\FVV\H_W(>F2K;_NJYI4Y_N*QBX+7%242\5
M2X)'_8(-2;^RH)\$H\DK@0;9"B(D\ZC\9Y_-9A3PR1.\$=&QSV7O
M#+;ILY_WCW>T*G>.*F7G2/7"-7_6B1.MX;I-6@JDE%U)S?O^(>*KR,??)J" MY!!AA\7CXN-
@)E/2;ZGDZ%SP9Y2BKR#_W_\$/NL_ICGPX^VT=VB\FGX)E6_M359GQ3W;Q5>;E1;JAW-D5U>;NFWYH0IA+_9N;6Z2-
IFZ\$N9JBERX^D\T6Y_M\0WC;J\I7(C;IK.T(^^^_N*WB<-O6*4'Y*;7E79UKJSUHIP%-Y4_W(D^S(
MIH\UC*AB&#D9S8F#WP@'&Y?GY*H6RIT/3DY;*NJY"29B&U%<';UFI(0(;#O"S:4Y)Y>4S_6LPVL_YIDG_-=O8-
M(KHQ95SV;_5PU\I<3MM@V#/BINCT;R\$"_H5@';&OX;5CL&J?175_W;_LW_M
K>;G;/V@M>V@H+1C*Z1@)Q7_Z;0\$.G+^RX^T^;J^ZGIUVQ=J;1HB1?ML^8AK9*O7&LD^YK)^H(TK
6=_N&O^18HU2A;_W#N%=L=|N1KPAKQ0^!/'O_M\;D5OUY;OVRY>D/L\!<=*;UZ)O5H^BP;%\@3J8#XP%1I"M
_9*2MDH;L8" M#)K<)<6O-0QZUYH>I\J)NLF;O\2GC">J#RCO>T8\$/*3M\8371*F.IMCOH_M:O
A.6)=>G+T8Q@S@U'75^452..47U11CU^>+ME;FNF1C+NL(H)\LZ\@0;3_M9J1
188'1QB2B@2\5@*D+=)A8\RD(P;S11WR;ZF@HE\6;.#9FP"8SZ_MZ;/9LJR>T\$C;7L;RM\932743^A=AO.FW#MN=|H\D?
\$S_MZZLJW]=^7G&*I-PW=<.-6-!-S_4V0QBCY3);H!\\$F?PA)?<6&">WOK6K%!9NS_MA#V)V)6)XU1H&UB&Q\X-
WH&\$G2_4YT/ #=IK\B^E3K"_HS.5AJ?*"W(MM@^DIM4S4*FYM?@_K4OF_>Z4R#9XI_D#?M^2HORD9WV35F\!?
+0FAW.B8@9_M;H892(GFGU9'H&"9G\X3RVWC&3%Q\26_N\99H\H^=26<1TX*;01"36S_+M&R24;
<I\T>H05P8\SH76\@E;U/L^IN'+\$SOP/H*.;MIW4K/6W_*J;E#?Z'D_M1CP50_@;3UJH3-#WGE\$_-)B?
J;2R>0R;2;MPI"@RN\$6SQ_VA\O1W_V64(O\ M+WRLMFW\$_8
W65PJH@!O_IK\I^N>Z*T\TGVI^F^2;U*28\;M1_K'=O=&H8N6\A4O./Y_\$D>L((LLO+C&&?
Z9T1X>UR^IBNU>H8K(944)#. MO\O#7U&APR_YG;_K)_20Z#Z9KE5_<K\$CGT79+WU\'=TV
M6J7=;I=)0Z\I<)SE&>^V;BXH_3F_\$H9Z_"EUC6CZ&://7097X'+*.8 @D_M.T&3U(HH/R+!H\;D;2\Z<|VRJS*-
M^)\M;H_-184_A^FU4I^X1939<(\$>?CH4N_M*=%FLV_+^;LS1YX7Y3NJ.0)H+9>_M;8L*^L;_TME\U;_Y2"E:2H)J^/'!
M5Q(L*NEZUFYFL/O"3I?>ENQ73_M&/&P8E_@JN??MB\QC2"W\MK6MS"4R_L4_MZ;V_9;X\$\$(4#K5.Q;H\OXW3-
S>M1.SG3_A#GR\$^DNNP;_W("2+ ME\+9?2&1+V)Q_6_V5\;"4&1G\$EJHDYOS*F>LR^F+;?2RD9H_Q+_WRYPIQ"
MEYPA6+5>_42-/?'VA:6187\KFH\K8)L7SXEW\+^+;.(9@+*EL\3V\P&6W_MFE0@LN*/I^VN-WK\&*^_B=Q/PNF<(+
((VS48)* TT7>^;A\+*_N<@HT6F_MJ)&D);<4'X;4/L>>429;JDY9O;PMGUX?<*M%V\$6P"NG&6X_AR\&?#PS:<^

ML5A4+BHKIM6#/=+O>M|+=@1_I|Z8YK>?E27I|#!S4PTS2KJ7/(<IV.)<1M\NE!?!+
S9_!YY+!6|JPBK0GWUL\$U7W#:.64%.!(B_7K@(.H>'VF:06=%:2NS MNEC+'TOV|_!N^Z\$<^(O#
(M|QTG#.0X0!^HIY2!!CUW7. @).RJ5+;PI^!^!OI@G+2V0P_P&S|!O\GX|T@!EV2)7=-YH78*X@_MAE-!F\$"QWPZ?LJ*
!Y:US*AJ-W.GH^ZPWV!@QZP@:YV?%4SJEM+4.KJO1G!3 M)DCHBEU<0^%.F0>X%J|A@_X;UBHADR&/-
E2E_IN4_MTH8N\X).@2)X4 MR9AWB9IAOQPY171T5#OW#%.CZ^S_EOIE7IT?RLJ.)KXW08@H\$H@:1H+<_M
(&7EE_8S;Q=-/>T/UR9: MG1G\XWYF%KDC>"&*D'WYXLO*\$E>C47'^?#1^H;=Y\$5SHD9?U8/0V@1M8Q%9' MNQ?
!9KH23>YV/H;_!W\$<S(5/0X+.'Z2Q9^W>M=XF|G_QTCP5EYC"%ZB_+398>ZK6C77ZAW<_MC_<
T<5NYF(D>1>SR\$^!^OP^VXO.R|H5^RC%L;V^((QXV)DYLHC>PBWUM7-/!MK(9!^SU-GK(FR?
T^D^X+V8H^VNT03_(3H;RIS*_KZY>4XY^G.H7T6?:"/ _S_M.N>XBC2I+=M(LYMHJ93O(0V:9VP&7/5P:3I^DW7_.M?
N:V|XJ_ =W|!#3.DBJC_M%(@1@8ZP1V/NZU^MO_2D67/-EPJ2^?A)I48\$|GMF?8_+BV>J9KQ3/9M63V5_M52+^7_0B(2V?
_5V>6%8PMO%KK8LYRT579725M%D^!^H_NDIQO_T_MJD;+^H?2.C\$CM?N_18^B-8?OY:3-EF=PD9_(-=;%#8M|5?\$.
D2/<6\$TT_M^C3|_!1M/9A;.&^%9UKL^9C-/&45T2F\$^RNJJ^N3;TT4H0\$.?H2!^4D^M;2>4_!V1M/DD^4R+J2=4!?:F|
!HU3XYJ9+S&^!M^DKV2IA17@U:9AAR9&O_9^5W^SRH/LZW6A(6|AV!S|KPM@R?Y/(D^GZK1H_MX;+
(X1+83BIDP6(?^QVXY_1Z.?!^X2SWJ|;7=P6^??+R3|_@@5<_1;G8;|!(*+\$|V)>SE\$&;MLQDN^FPM
MM!OC5069",T+H^H|<="/(KTI=PU|^?=(S>.%N1>0|Q.?'%Q#G>^B&3S6J_*8N_MR:K_#@96G@D&#|EN<_<
+H^QD71IH40.ZDGA6QXRL_)X4I6OH_/3;RX27)N_M^3?B\$"%7S_MA*Q;H1LGG2F^?)70@6Z(&^Y5:T40.44WYWQ|<
F9#;0!Y6KTIQE_@OM;@_M7_HLOK?L&) @H5(HRN!?:Q51+N!D^12J50_D5_(V|+^OC!8>C3L5HG>*O_M
_P;"HM^FKJ_1V@KG1\$-6N>_VX5.1Z\$)Z\$L_WW:&P>(3.\$UBG^9|(\$K_>X_MQ#G_1;X_OL1XDI>GT.HD1!
!>2=^!#/^F>HJ8-/REK4_|HU|T5X>82D) #GU!MO^C^G.19FK^PIEG=<(P+^F^D?2NIU5-012?4#Y0V).U#^?WNUKTV0?
B+!H0Z_M2D|H@((C7C;_RDH/O3|@?27JE_!ST^!ODN^!1_((D).EC_CMX+YU@O@A_*_M0Q_9!&DX^!V/YR;^"
(B/P>:0Q09\$S|+A=-V_P@;H@IB^7?;Y/8M;*Y6P2_M45YG@_Q;114;2E|G?
RN7K|.MITOXAF;0SQN7VMK_+OL#>PG%?!7_/Y7JT!E9QIH\XO;ZW'2P'O_.\$G|P|J30_25|LB_Q1;) \PR?LFCB
M;|8|/HWD_ENJP9?%DT%91VW'\$_0^!^HF_>GQ11H^Y<|Q^G|D)#_I=CXQN" M?^P=|U>/(B*B#0G0|_1VA?6=">
M|SD(N\$7(>1^6>J_E;_UL^Z;G".0T5J;+U7LD&&5#"|3KJ|WGUA##(*H%>C#H_MD?B-
3*&_U4/@+@!SWCDSO4/11%@_NDU(62VRQ^0^*K#20%>WC6#<8Q7S;_M3N-
T/%TS!!7A\$6D>9N^N^Q^E%);A|Y0N8T(MK;_IU-0V)OS-OD^F5<@;JBZ_MMZ/\$K^OU;^&J|ML^4>^I(O/#23
S&\$;_2JTS(|NE(29C_#1^*56_XW6_2J_M8F|MZT^G8^2NIDT^>^CD;IU8CVU0N_.F;#O3>2BHQ9713(NXO#T61YI8&|!43-
"B_MRAU-SY_*D%#K|7_2Y7!_7935F2IU9@M27;OUSSIRA|Z)\$%9:6?GF34/3>)
M^>%4SI!K0%)+&COBH>A(MGI/_JR7N^/0-^KD>3D;_M3EB@*)_WH!C5-7T4*_1L-/SB8X/_FQZ?
L(TM7BAK_E2)'RI8>P!HV_M)8!8>EL69;_#023U"/P^VM2^RLR|#J9)/O65\$|H5|A|/(REBDHA*BJE?8|^*M+^F+H0%|4D-
8^DYEN)C0|!K>_>IT3Z9+EX9#^9D4#^O%?;\$|UFNXOR_M".TTBQU_-9;<_-8MLD4^NZ^FM^5E_M4U^JN9*%
"7&?_!RZ8;_ZHMf4_9(C%FZ|_K;6P9|5*.\$NY+^#9-TXO3+2L^5_M6A=7W_/C56?#OP2//>Z6|7L"Y
CWC_E7^2B3&GVCW6;LN51W|D)F9R7<^*K_-M0T5W0LHU\$S_7<4VW?|@OG_^3I6.B_O|^!^L|^L?
OM7L)S3_(->ZTVFBPT0_MB>GE(=H1;\$A^\$4W_3Z2WH^AL^*LC|W=@VZ2Z|Y^=YD3_@/LRU<.\$I@|2Z_M2-E|CU-
5=%GA|5^<^05|2))<^N^*)\$T^G%NDLG_ZA_U4U^O|+QSS2W(<A_M1^*M;.*H|(K;J^2_.\$S5_N+ZVL=Y5&_.\$%A120-
PIL03B5^<_T\$+DU3%RPV)ZD!\$CVC|3C86AK>CFU74PXX#|=-K_M.W8E)UOK?A"MR"^JW?^?)NN3|8S;M;A-
7^#>S^CS3<-B9D>0_5.7^Z;^0>)&_M%+O1D1N3(US1(YS@BK0DB4Z3M\$17|S'FCH9N^KB#R^Z=-M@#CAU;->(8?
(Q:A_'2QGU^M?N6-4G:FS+?(GN.W^4S9QI;W5OKL2^B#_E%_FG:4#\$.9RM3Q@/6(P+D0_*;
M0G1JYZ1TOSM4;+NBEI\$AUAV%3<.)OFI&#ZV|_E^*NJW%*.UE^SY9K^*Q)9Z
ML|NFN8K+>#FC=-9ZL;*_J%OSIB/!KJ;W1%(AG_P!;I\$G*)1=TY1_.\$Q7N\$W)P_MXXVN.W8^JLDPC68@N5X-@")%ELMF|I
L-H^-(DJ;M|4FDB!!)_MA73)*H(0T2BM^*<5U|_SB6W3GIDA-VP|!*XUIBGM^#>N)_D%|5K-E!;A=R/0
M;YSTBJ0VNOFRW/=>2;_Y=8Y1G-;T_Q5=HL7V;7;\$D2!_--FF)D|N2=&E|DCY1
M^XAX>BZQ%#=#RKNLTLS|E50;HJ2HW-BXK1\$<R3R!%0BD^*C(U2>23)5!E|AMH&_07?F(HUL^P_MT2JZ&
/HE;Z|FY?V^N|NLL5>HX+|\$.^_|#V_NWA+5+9;Y23CLX2UD9@O322|P_M|/|@W|C/CQ1UH*5%1>_L5Z=I^#R<9.F"
/C%SBF1.Y/%% ^|H|VE5;PK/4=VV_M))MB^8?Q>.3#P|^&V+\$%|J1H(|JFHNHFF_Y|<>PP\$6<(J-=+J200(<\$_+3
MGVF>_W=1?BUN:%*7!4WYPI_Z"DE+\$O1Z|RMT(ZJ?L;_.\$K|H&3);CYS1M8)*-(
MO>_76B6ZF\$4HHS!U9NC(j0FW7470";&MHLW8YC^L5|>_L^0X@|A0RI=L8_MP!=YWK(-^9YVSSU*;8Y!-
SPP8F^3/_!^NY2L^1K|?Y\$C^!_!^RO4LY\$)88_M?CS<7^W=JK^6EK2-
X|4OF(8^U(WM|^"%&BBCY|HM;G<#B@C39;RVWJX+47UB_M;KM7-B_O#9^_1;_<
(N+J8UG^05V7@>^XV>QNDV^V.5#)&|!#W|>#TRH1WG4>V_M,1)Q8T#1+|J;J%#!(|GHVM0%GLR0W
>D=70I^*K/OG(Y+>P_SR2XA#^6')_#5^<\$>?^EF/_0@7K/0U^U_@%V4^A^R%%(QD@)G)O_MM\$S,DB#N+^#
U^*!%RG>\$_@L(X_00-?*&_>|H/EH+Q73Q3EJ@7Y<>RN(22AP_*M|W_!TXN^W?
0@/"DK0C|_6HVZ7#@IADP,Q>|OH!7IY0U!-;*(#"C|FFA\$*_MCDBDW^UB9|RH;GC\$!)O!W^YU>_W?;
(SVJR!FXV;2=8B;.%J\$23NV_@|3^*UTV_M5N;|1=6D)9:5L_M^JX|
!LA%"B8^R^BF^29M3&^!+TOG@V^N3=E^EL"E;^*T_DRE<_D@PKG)P+Q1_M8>C@(\$32ZTJ@KR4L_5)4HIVUH;%Z:<1
K).18ZT^>ZV3?^!@N:0%(@@_<8BP\$XOFSA|_M;7K8%-D@_E2S99YMDT+BL4J^);Y|_DNI%NFXJ721^%+^!>A
@@/^YY!8@SNLNV|HJ6XZHE;|3.1/9^&UGC|?GNBU^D)UUAEC@NM7#_J6_M|=Q!?:77&D=-^
PLAK8|KOW>QL7VL0;=&*T^9J29&1W|9<!)8NK^3Y?GGKI^
MT&)|R^OD&Z8P^D;H||EM|3D^N>L_G9#L!/Z|E|+FMXL=S1K_!P0OG55B
M6)!&71PIWITJN|2J4^6Q^R^SMLVZC5;_QLS_2^UR|8F_@QUL^WC^QXE+BYQPV@.)@JT%A_HN\$|A0.%7^9_M>A3VM_B-6-
9.GQ_L1LTPV;%A_!T|^!|HJK|_KWMV&J;DJYMK_O8;_SACK%R_MANIB|G7|!U>UV>TWE89^YNLBQ1"BNO-
|HH|>)3X;=>UXZB1#12/;"0\$X_M_MHY_?%/+= "&8-L|<44;<2Q|F!^4|R|E+^_Q|Z0_VV1#V;)/>C#;#4_V!_PIZ_M|RT3F
Y5Z^|L1_93G;^T@_@6T>KABAAZ2FFYWTEKK5+=4<9^!|#!4N;@&>_M_P^#F3OY1+*BCG?=-Q;D^<6QUITYN^51D-<)?
=;EW^OOIH_MITZ9^H/GVOD8K6@/QUOCM?^<_VG^JOI3RM3(\$+!2CRG?YZP60^G_7Z9_H_7-T?2GI^;+!2CFR=-XO
MV^<^CR_?^\$V3IQ^7(HH|^V?XQ1A^N\$=|XHUZEESPV^GNF5TS4|5699JL7;RF_M";=,W8OW98T/0>U!G^*GL;7C;U
MY>_C33/6^T=I2Q8%L;GOVE?T;UDS@NV13\$|5EHGT^HD^DOXGZ_ND^#S6U+P^6_M78V
R^&H2BLQU;H7%>Y(2T.82D13\$>69T53AOF4M_X.MQ^<B96H/YVMKFT&X%25(R\$U%BXF7_PB++7B9^24|<
MA/CT^S=|4@_MBH@:Y%|F7^U_6<|5|Q?_U?>7Z++|ZP39_G4YLOVK7|9_19;M^M>ZO_BJNA&&_M@|N^*)@WHT;
<4MA/3^@<-W^82;.\$QX;VDR(2U!(BB^YN;FT4WK_R3PW_<^Y\$F_MV|1_2KY!\$|_<C.#
(6R_4^8#NTUEU4\$F;@5RE^\$<0|&S_F-2I3R<
MHYJVVJ^<^662VC|^XDFJ?P^A\$NI<4XXR51HH&GZ;|PLAK;_*BPZD8&33-4;|5)=5U_MF=JR|=&+2|8CB|;X_EH-

A@SS=>#O+Y;@<*M@H7EN;5:PJ3D>499_0S)\$VG M>|:L+J=R&TI+*P17TUK&?MA-I 8;VH4A#./I
{Y#>AIK#3)G(O;=4<> XP77'M%-EPI1U-.C 4;(YT(IYT'LP>^?*.CMFC#U;? PLGB,E4|<0+EV2 :JRVU(H
M3^|B|+HVGLS*L8M_I-#(3XRYAS|YH'WZ|OSFOAR|:(HBVXX M*CH9.M|U|6X'.=
DY&NFZ1\$XT=)#FN0" T6*1/TR(H/RPG C*#_X(R@^8 M\$91&LZQ7T^M;HQ>5@6=FO&N)CH"-)
I^"8DOY;3^+|+G-GRP9#X;@.M;V"F MX<48YD#EN>@@:CM! PH RAL:QW@^0D#H".6GBQB|Y/J\$@/PK@15@|E00
M|J9)&GHJE)/3.K7B6|OG0: OBO#> \$@K*1 @>OP#.30_&@(\$ HB|KCM(6-I M1#A?;|=?
RP6^WCZ8)|+*.)Y%F(U%&TX%L2/99ZERT0.MNF*AG!;0@OY;<*>3?2/D_ K0WK+MO/.E.H6BB)&OC:H1Y/1R:(IBKZ9X
M%##QR1(P7K=S:8E|6MQ62;K7'N55UIB23K-GL)&XTI#;4G5=|>C/HH9-X|! MLU4W6#+;2V2&(=)(LRR17I(H9?
M<(AGPHINV9;LEX%LFP&1P;)0\$@UBY MHT5>G@8JIT%-!R#%QH.=#@.-#9,"WJSPIT?D?
I>5)V^A+JVC>|GYD&/Q2X MG4%O1G|>2,BC^UTLPR0=I7J%=1(&|4C;=@;|>@,)#*!.!90WCJ8;R+-%L9TD
M,32L/8LWA3L_033;-;NGW@#^+OCP/R6G<4 CT(=)&F_O!SLN00KJ|+Y' M1|N;.)SRTCWTFQ9_?N^|^\$QZSV
MNMCM5K\$WHI.3X2;T.HV<1M>J0X"H<5G<4IUS<3:(21ZQ^|JN8;I9G&V4).MODRD4_0B&8;H05S|N60J6)\$B7?
M|HS+JM|I<,K>,W+H@+HV3%2X>S!C0-M"27NX61FHX<(-J.U'4;SB?+C@M3S69W0|2|B|NLITF>@TX|K\$|N
M.T\$Y6?|*<1I5>|D8U:O#I2YX(^O!F&)>\$CZW;'@BTR%Z%*DC:ZYY7GZ% M)G+(EGS4|8W>E*4PK<8XM1&,*9JH-
TV5 M&6(I>=,*D)U*78ROONR,-7X9M?*.VSDUUAU>-WHX|&:TO9\$OGCD2&-X7|Z6X
M"#N/H0KG@78>4 W2I=-MY"%88.?QRA(U!G'"EBX|Z|=|TF"<>=ZN@.?.ST MQ(@'%\$R+|C\$KP"?NV|E:T|&
|%QL8>#SLX=%JY0P9B\$R/-3H5L|Z60.=OJ(5 MU'-.3@WXZFCUPK@=@=
(O3&P5N+2|TR|N /UPK4(089B0(-83AL)7%1E"714'S MS|FC=1)E6I(V)M Z8A:*.?#Z#+@97\$;I=(-
|O+1\$CNAV6JFW7M1WQF"-;#W;R&*%Y|BPLO4VVM9V(%5%6)-Z'F** (R69J374C| MZWGB,"V\$0P2+%=-60/
6>.,W27YB&GIESR>7A|HPH|B.P4W3%IYV1D:23P MC+KWW@ ZR";
|+P!\$XC*%A+% =1E;HKC> FL/1LIUD6J5|MGO|H0;N7^P%; MVSC\$Z#Y'N2Q*(DJA0<8>*|C4B/T=^X1|
<3\$CLD>5GW,60,46(#E:XPB9^ MH;ILD7ZB_@^TEN+\$&D9'M24V5,(59#*!\$BK!L?HKD8NNMY5(O K PAO|L-I#
MHG;.(M3T0B|M7AQ/>A5CB_LLQIT'H^D|PDI?3)R R^XGRKZ0(NZ3=CE+R ! MP2ALOMN7VRHIZF0K|XWQ?
^7"XY3^ZIF'225E^8H<5ODZ(C6MSM>|KW|AFH&5^*)79;+4E M0XTJ6A+O#/?N05<"6(JW89@;SA|VHAOH=-
#8WGMX%6:8P365Y00(%3B^DP M6\$9X&W2\$|C |.|B-DCXW\$/-XZ-R0|P!|^8P(NR)(\$&P P&E>P\$|K=-VE)
M@O77N_3^M/68FMT#JG7&R;BDG^A@S;@<*98-B>).YH2\$<3"J#_<4G|SE|!
M_8_H^XZH/O?7MRT=3V:O.D56Q.+FZ\$96;N?K;E.OJ7C|W%>19R_3-6 MC<%GT^03M;)Y^+9XOZ1MX0<>Q_WGI^
6?Q=D@3K|ZW|*OV483<.NT;:EZL< M| 4%#_E^ BL/NX|V^ OCMK^#JBN*(I-P\$LFdz;8.D< MB##|F7\$
V'|ESMK;)Z#DI04+|?TJ:SLD92R!^%=B.Q#1*GB'54=@DW/H8DNB_5NORM&T?IF?U=C:994(E.D MW/*?KHOT?Y=9T?
S\$FNE2+YIEJB\$T(JUU^LP17MB+J_O*BNC?69'N2R+5 M@G^J*_%+E9Q@*#;2^!@R2;?P6-P?
AW(IN#YV@\$(8EO9E* &K 5H-"LB9VO5G M1\$;T6^0H.YIDTL5.EAF6ZX0^R.S^>W=UD|+OU M_7U%
|F1Q6ZX*BOJ/M3DN|;7#LW|N%=&/#AW6SX>-K\$;G2&!\$ MW"D9N=;5GG;#(6:WR3<- E|GH
M0607POLL!+34RHSE3>)D'?GM*=\$R>VM#I0';YD+V60WV|ZJ%9X@Z'2Z.3|/B MEP|B+K(+|/\$B-
L;XMI|X5C@FB<;4S9P&10Q3|&|N@G2_UO\$E5BRE=|Y'N ML@(|H&3\$TKJ3;E+BV% ^FZJ=GC'6-
JS6Z6A0.3(@#D8V^SVP\$00 J<|H2EXXV|M0#)#ME(G-DX'Z8#SL\$KHG|_V1)GGS(|U3 =DO^9\$M&L#=#;N?C*T<;>
M|4Z6A|L@@"T"%MU\$KH41-NYU **>|3|>+)=>CV0F6""IOW/X.E/0F2W(. M9|/^*?_#R74)P015(4?5J;C0#@)D@-
PHD0265)X#+!)M.NJGRPIO+/1;T ME&G^E/N;[N/95)H#HJPL-B_.1?R:3^04|,\$3A(24M2@5@F|*O|Y
M=7UJ.R15|7CH- +9/VB&=UJFQ_)H4!=I^1.LX2+C%SJAS M7@#R0_ET5*TSUKQM;|F#QI"PA" MS.C645*Q_8"*6*?
\$&8_8^0WE>(^@O9JTL_9%2BG;|Y/5<\$4<>1*6A=P! M41 ^Z\$N-# F P32C62X4UD/GWV*UG2Y"U*B#U_\$@R&>1?
5D@#-\$M3%KGUM TS|V#UL4GC5K;)#GA9F5-JTA| MGFP?^FVME|WL2L#PC5&OV--L)Q,Z^)(PD=/XQL7=P^|++G>
S>DH;*&_Z*,ME)CGY=8XM>%BPGJ>B855MO\$;=:NZ1FE&G?OG'YE_+;|S|&)T;|@-R\$|MLS^:I6HTYJ%
<+4QAQG'K&G%131%E&EC)SHM4^N1+7H0V054;^A\$6""W2*>V79>AJ>VCVNL0M(*4U<R+@|X+|S+KI
M6A|1>5W*%>C#)J8CUIG(4|<C)CM4^M2!RQ2RK:2/4|DXW4649|E-N87H/#P#;HE M1;+VODQVV|) ...|/\$;Q1UG*O#
(UR++!\$1KH1=L/7TRVD^H07=97;<8ME-M#Z)0: V-|LVLN0|K)EF(T@: 1F; 39_7C29(C7%8CLZTW.^7RT+T=LP#H
M9Y!'!Z6?/L8 H/J6:%?V@)&)%WRC"W|W3)3^YH!%/ MKI1EKD^3IXSIW*.;NVRD875QOE=-9>LMNUL5:U47|+K3*
WX=W|FWDPS2\$N^&A&2X1S:P*|O) *NLD_M_Z\$JIT_M?C#; IK=T|T\$5K5-4B6R.8RN35H0W\$_%
0Y>@14#;FY7\$4<>;J5N.TBG:H M5V7%(R<#-=053TKW*^D6B"0Z6>|:1|!*\$-8\$K?U"%/H|@V#I(M714;
M6<|Z5@:21(L\$G\$BP@/=C%SS;4>(|5Z&T|+|O';G>?Q(G" X;R|WB|REIS4
MNZC8>E/QR1CQ|F9.1|B8QKY^FC72.^ZJHW72UTHG8UG20YX(>/%*.;SK M-.6AB4G>H4?77NIR7RFI_5K)\$G%>
(C3I8Y&GE;<\$?1-Q|PD@(|(\$4C%M+)\$AL? 3HLXA8'L?=-EDD%N';>0.*C2>+(M6UVR_\$=8|HL>B;:(M(HG;2* M<*+
<9J|H|B/B|@GO22)N'?|H_'B|HAK^L3S#0""I+RODD?A|H|TL+DKV*6N=-M%9%DUW4FLO=*N;VS@G_*D0.+
EBT|M@T6|OW016%A|>@T|D:X\$.MEEH96+ ML"92)F*O1XGL&V'=*LQ#'?|S*GGAA_#H)#9N&-W_*B-C
M.14BR9#AK;8;|Z>78<=3-4Q6BRH"=T)W9=5!*^(WO1E153M)/JY9(IT_4T MLUMHN3ARQ|^LQ690T"|H|?
H*PKI|'9|Y3G#AG94S@B%OV&-AVJ|.IES? M-C&P"@S;Z@^+ICMT7*7#;LL6".0CGY9U
U@HIP6X|1T14M"9Z+UY C8D MH:QO21|K%DBI\$)EHDU5D-6|4WFEH6&SDR'127Y5BK16L^4;)% (SD7|Q|)+Z
MCLM\$TOM/L&G_)V;6OV\$6|FYA7O2)U\$AP/SLC1FT6|0ID>WG8GJ37Y1-6-G M6DR8Y?Z#*%
TR/6FCXBRZDPDPMQOQ/J"VP(C MB:P)G&T1@L\$|YZ?L'4J>R+^&= MEQ/=9E3?<9FB@DQ94L6^AY6
9*NY8^:RVF)4N>CZLLM=X1C4|RV0PIZ;M<@9I(|TEG|BK-35+\$9C)6S+-7FO(\$&4?
3R(56X)>WG2<.TNP<)%M4X=/GX ME&05#VJH5-P|5 (M|@&X*17NU_7=\$<+"ANT-2*|=FIQ_XX3E*|F|;^JYTC\$ MM
_F2Q;S|;97-3M&RSZXB#ML0&|O0|V7_4X9L;+6#C&=>I=V|MAWK:DQ MCC(NW(DK;M+*)&90Z_|I*
<L0>H*,U6UBYZT+<=A#+3H|8*TX0|SNK-|A+""P\$O|E(50FN(D<=TWG-53;A3_-M7@;|#C<%6
M6"\$S66W,\$K|H7CBCH(4A(*WGE;FURIYH M1\$2KB,CRO=\$.K=|&5I#;W1 RVZ3;Q+I6.98AB"%>2%9.#RTI*QR5";>,(= (M9'C@2Y=1#L=>P+ #6.K*I^BV#>.7CAJ->3@#%J;P O(-947VN'I=3UR|G(W7*/M8<0.KH=9 M5BXY97_=5+?
E5^L385BL|7J|0CZQ-TL#!A=BM; >\$5QC*FPJGQ|S+C)%MPI(C/KGA9;AXE|ZR+R+25.<3,K|V?
<+4=HG+Q)NN9)4|H|PYLEV|;6*|+B&UA5-7!72^"4+C88%T9"O M67VLP|MUS
=Z@1|3H;RVX\$-7|&Y>*J|N*H2V@D|S R^W\$+AIR@"_1H81
MQ(V;Y.F_HL T2ZJ7S>YCONY#FBH_QPN8A9."*8/R/U=)U12TJA^R)P4"=K6O MV-/GA+;4N?;4T&F#4-Y(?
(+H"BK7VH?69\$6(TU^)ZIA_2B2,CM"CC<J#|W M|V;ANFOVKED#?%09 !NOFG,PIQG,TL-5/%R|@SH5=C&H)
(V0=7|H20_4;\$ MBBNW#N"(8JR;LL3Z^A+;+;G;?9.&R#^J")L'C.&FCM"VA(F-H;C*/A6_FQ M*/<>_A\$C:(T(L>M|U|6
8EC'DS||\$BN#V1(I?#;37V)DL'=0^IBN!-=M|6^V5,UUFJGLT-^|QD%ZSP00_*@YOU314XKFF8-8S#R,>UD3_39G((
CD4 MDQ?3-V57.\$%Y/J*|YJ|J#;C;BU3@F^&3\$N<5;.(15F(|;5B-E"EKX<@T#UX|X/H4?BISME69M@|
(*)5=A14>A;8U\$3\$RH9U-I%0J+;P3XG87\$1GX|)T&KDYQD7?KN|;/BS|M"1H^J M"MH6:O4FY|RB1MXH>F_A0E=
(f)5TKRT="SYXA|_K>KXX8P0(L >Q M087 M,O,*>FV8K3D TCQE+X4ZR3U5F*T0&4#A?2|QCI=5&4_8L
Q1JR;)FN2E)! M* KIE+ :PFHQ>*/&^|8(8U*=KJEA00=395X736@|BYB|AS_0K_XU5 M)>="50&B7HAWZPIG-
\$2#R\$_Z(#Z-OIMP 6&7IZ|OOY9AQ>AKPIJ.X3.BE9|O M1C|<)C;>\$+<\$W'LU% "L(1Z|5>)>H?
JP2P8V24C5M;\$DW;F"73RQW9GVL8_-IW;^5//H6-#NJ0NO?L M.Q5I8#_/GGF).!&T:SZI&3U^G_W_?O^:E|A|@YH\$=-
E+;_Y7I6P|N3JZ MXN<9>X-56'2XSRS>#SAZP|0^G^N2)&O:L|"EAR%3DZ1KA;|)CS0V1C5\$4/
M%\$9VM>=Y89Y|R;I6@"TG'MOV?(A@C|KBP8)&.39:&/<|X\$|W608|_7|?470

M&4>74&62G9%.;L2IBHGYOI=&.3 W6S\$ W9HI\V:L <:TF.B\WC3\CHZHNY M+GX\E^8\$Y !\N\1XL\I4>
K+Z3#;.LGB+ZHI ?T^<=%XM0U;Z6+G\160\$C M<=0D!X %/2;Q1G9YNX#2XB,^+<
\$/=I9IS_E)5D%:MM7Z7\D.;\L*LI)H&8;E MK2A736?T. !?ZOELWUED;KQLSSZA\5EZB\6VYWK*#IJ+<
<(IY^Q6(5D"JRF) MI,DC. 0P\CGO\AUH\$B0.U2\;F.L1.;<S805D.;QH,0ZQYB.ZFMQ;%^B9<
M%5\UXWE5%NR06V\$;F^1M@)B+CA#14UJHWV\$JZ8S;9X\4"PE9\$;PW7S(C4 M\VVW&^& (^U?Z7\!CKE<
QB+N7U0725;OK=O%#SB#,7K98=!9!KE=IR6\$7#CY ML\97!\$@%T62;P<6#EI&F&1R\27Z59.EE(7%.S0?<
+67=YTU5\$8@B)@KOEUY M7W J3F"6]=7EZ8IX,7W;@:'>>P8Q'H'8FO8KRT\TQ+"F2],*,?RF3M\$W _9 MO0B_5\I6.?<
1G8>I^N"G3\X#D7+,SVL\Y;AX*>P*" ^^^,6,VXGRFS6;^;A/ M">4-4'E+0"@VFQO'/<
1G";.FF^BNRDJH\).KLT\I18(>)S\HGB)RQ\5PGE0% M\$W7_3@D%49YMK05U9&,(+!9G^HKP#E\$-9T863!\AX!7Y=<
<'TX5W6?)3Y\;8 M>YZMK>VSHVR?&.;0EE6CY6.@B.B !CRER5\9THALX.NA7XT*7RX\$XD#GV*B' M!;@(<==*NZ3-<
E9Z>W\I(EJMY (S;P3; (VLX9)-V"KZO7OIHAF8C2K7LH2\& MUM7'PS=)VL8D\N.Y2THUGC/#E-T8YX4U<
5"LI&2TU#0(TL\?R+M% YPN\DPX MS\NYFY=8<38'MB\ +\I7G.;JZH^N.;?;RI#;INNKF/S^Y3D;7RAH6!<
M4&Q\,%&DG.SI(PN(7V>D5/@I>YTK8D2C%K\RROR)'@>I3Y(=7@#\$H@N"J %&VT%QKN; FO\H+S9VX;HE?<
NPY\$1##G\T.* MPS;R8CIS\7SC6DVXY@^X%NPR\N2.SV4#@=V;72\04%H(^&WM?;(.<\$!X?C;+MFP><
A3#*DY;.&U.B/8TFB<'<CIHA3D8,6G%R9#J\$,6!>J\J2)Z#*V;#;:@&< *P=7-E/X\DP6 M*600\$+>H'1E<
*E75(D6""X\IZ N4F;K GVA+ 6(I1"Y&I>)@.>-E;F7W1;+ MMNS\$N.J\7P\$XPN35\4D60%Q?VM\$F3&>M"<
&. #7"R)\$>/167YP"ZBG 3S\ MZ\$2?+F#GO9,FEDE"=,3)N=1'7,>M'!;.\$MR\ A\;S@^Q3@)Y+&HC+- Z=Q M_%X/\$1"6<
>;UE\J;W3\T-%T_T\TK=G.?? +P1;/RS;4@N*(9V*T=(Y!)"&B/A M@QSGA/Y^M%WOW"<
JOX'K\#N\;@ "HY\>;X)"Q"QUC.R+NSDRJ05\8@!X9P"<
M>IOGLE>#W86F KDD .KR\%K'PTLW#UH3;1RAYO,4@\$I%V5U5N\IOFMT^SLX<
MYD0\$30@%BF&I\WT6XU77"H\$N&Q0\90@R J;+LT*X3CKW_1T81Y.>B6 MC+DT32LT;(/O)#VB"!*-8AO^Q8A%?<
2%.8-HTIY-EAI>M8XZ;|<6 6:*231HU<
MMJ+C9FBHBH2PCODZHH=//;ZZ^1%B"X*0=C\$SBBOQ.AZCN\$!@*)69B"DAGO.MX@;!^85N\A&GH6ZMXXH4!??<
Z^B3 MAXM>/F TFZ R+RHH\+7@+ML\F?X?TO8ER.)V4*TCC<;F(29-7V2T=7@ELD3 M.<"7,WKGR*Y2?6!MR%Y^E\I<
(N.;F7GQZRH^OC'LW,H)>04V"P\;=1VUP M>1G2Z\H=W).";Y%T.#MK-HW.)PPT?^IH(TH&2.B\@VC%"V)-<
AYV0T"SZF MD9\F.F,2'=ZH?+AC\6MZ4*5Z&K\$1*N;M %AM5 M#M2??-;T7D%PG_Y I2KMNODE'&-OR;XY;JKY.<
I% (&ID'RXBU\I"8G)W7 M\$JW1? "JTXB\)-E(3.;SY"B9@EMA\3B6BB>J*PY\$6"C\TMF?^C%.=6@ "W*VL<
M.=LO.NMQ0DI#+5G\U57VU7Q-F *QBF8>0V*FA7+4R4"VXX@1# +YW3QHP54I<
M\$1/7CF.E1.N9F".1XQ5RH'R119;1< S\FQPI^U6UA_/O #7. ;G\I\7P0-P M#<)5.2,6H?T2D9\J7^0KDL#77-<
*\$W3>CFH>.+#_C@GJ-<+\$(._P1&\$;P\T MQC3WFEVO8NES;|ZHC3ZHB&I-S"<
(K17I42;N=6B;LS\$(+U<)DCRPAU;K3.M0+>-8)@-<
N8R;VT86;"8V"ZIQ7#1N;L@9;XFBHY\K<^1@ODU3==4;.\$^HJ@X'@*M99PI=G MT-<
2HI\$^(F%T.48LZ+4=Z?;AM\JE\IA%7;05Z1LO<=\$97PV\47\2".;I.* M4UC)K@CGMM\$PLAD\I M+DW6EWV%E;0PC-<
Z^TK10\$AD\IV3J<5ZOH;9AJK26JB M.&NEUBI82E\$BP6?P \PCIHOPC%3^2Q;I\$^C;"I>ED4=3GLK8Q7SYBU\0I<
MB\OFR(83B;A>K0=9!SO E#D6VH\HM6<=J 4ED*#& Z^W\AQOEHFO\@E9<ME6.2VT+T72YH063W&9)\<
<^L6\I;E^=@5GZ\IH^2HI\$!>?EC)8\;.>L\I2 M(\$XLE0E;7?;?Q?G;B.4 J\SY"N(^D^Q\9"&AGOL4CH<
(VY4WKU7TOXL8^ MJMQ&!\ KS IF.8<@))=00H&R60\#5\$7)6 !>"6(M_%/?(F"8 TYDQ1X3(BO0\$ M%8,_M.1--<
D";/DYT@GBT;J07\EP\7\$8QB,X)8^T8+KGWRD/X^+*UH0W)ZO\I%(W<.GKS"!?<
(E;1U/%\$J^S<I^P\INT)QUO\TFIW#."+& MQ4^T2.O*.;@6;4;L<
<@7MC\2X0TIY@+W2M9SJSZ6(ETW/*\>KR#+OV\D7V<%\ H\WF4%!\N&OJDA88HK#H1UWA9\!5E\IAD!5M<
MHA%?2\$?%CQML@0G%)P >3GW\$@ID<87;/(2C32CC>!"\MX/@08X#B\;7Q?& MJ\&I/4%*>Z=0C8?<
7H*=4&9ICY*BPATNG*,9\$5\$A55%+*QN@HCF2BB\F MKP.G4&E;H\!IP%(V0\HNSV\LEJL,*M\$5^2X6;<
(\3CA+\$HVG;)\@@=|\Z4M\I)R%L0CZ\ M M\J\T&\ +>5R#6>IE4>4K4Y @&HW(@8)7HG+5@J+AG73P-C\QF1S6P+=J<
MHOVO(U%C@^42=0QB/ OLW@BB0R<8P7Y\I(*2K>RS\JD\$@4(\D_96=F+ M=-V\$ _&L#*!#Z&\D)TNC=%B<
9(W\;\$#8%#="I").(L 4,HS>M?BN3B+9,|=3@ M.|\;A.8BGQ-"9Q\4_)EM->4<
GC\8VK\$(3+XR3B2I7\9&9L(8\A6CY\&R+XB MA@O=UE\1"17>QJHA;V9*\$95H,1YT)Q""CLW++B\ZLBV*?Y?LH*<
IL6#BR+1&- MB6@=.;G/;/BA@IC.'I\OUS6\SR#>IF@^X\I6;IR,Z>H;\$V@=4TD\O@+R-"U9U056+L,<(Y+W(+Z\29/"6<
M@(\GL+3B?!)KW@FWNR>ZJHU=D.U6&G@G&^@_ET6I?A#;J#%@R6Q<,G"-ZQH# MA\%F)P%G-A6\11^4<
G>3;/&=L("EN"=2\I\8KCW&0_#F?'=0R0-?LL M>SY;@&;1_%S>*C;Q;+ %FGNPF6)<
<.)ROK9B3?F\8O6D&TA6@7+9BB\IR44\$W.H\IZ<
M9C=&6P!\W)H<+HM2;6\$E\$8S*SI\DH*60MME<.N4C/"Y R\H72\$UK07=9<<
ML2FKO;=%K\@UZ%*"I"D">SG"IH4YBV&^1F.#1='INGQ2P W/>T+)%0SE.)B0YYC;NR>A2H3OV%N?9Z.*0%<
M7N00\$Q2UEC\I1.-.*C7@GQK#H\$/>)6Z*"OR8"&9M^J19^*14*6D4*0H_IZ M^V86P1H0="/#-.BKX?;! K1%F6Y2Y<
MP#UCM; U>=+|\DJ;8 Z.EK@8IZ&=.=.AYV>TX\8&T6ZA.L\$SPSQ<I8V\C7D S6M3V)M99MY%.*Q MR(<"M_&&?<
JM=56\+;E\@#?@D.W\3;EKOK\I/Z-/%=UF"LJO"U7=Z5HCZ M\FD PB\SI1FB?X=T'W*DC>!/Z?<
\$D9K_5CC;7J\$;67HCGZY)\3V5&(0>#B8% M*UB8\OB-7GWE4K73%<=<5N;7V+J_2\$|FNZ\<-F@!AFHU\$^P-<
HWWW)M\TJV MCGRU<=<^CBJP,HB*Q)XWAJG5GVG#W@)MRM;G21U MMFVCJ0.#_LWQ@2+AI4Q*W>V=BL-<
M^SX; T\)\4X.#UZUL \$|=G=6+G/M L03(BL31%<
Z;9J.*HC7;QPOG)6YQ\I8L&.;FU+1EIL@(\ \$EH@)V7VKZD6DOE!_R7J6?>P*.GW4C<
MO)^XUTPZ//VYIPH4);Y.YR(7HK;S.'H M1>S@Q\$Q0024)7\.;5L_V5+VX5HVC/HV'0QZ\.(T.H5UUTJ.XY^9^%ZRTIS<
MH=T^U"4>7G_1R4;!\(PXF9)\JT\$^<V\$D>=L54;2(I\$5;8O(N\G(+09D,Y-WXZ)PE\PG;6?3 M<
+=M60APMC;&3X;"RFB,L1\F\$R@#*H0F-T2A7HH9!M>1H)^JVI %V;".IY<
MDC\$MAH.%C;CQ+Y*LXD>.YK^+JFX@E>\$L+6"@|.HL#%J9<#Z5H".R6"@D< MPK=I)70QC;M'Y@EPX8<
MO3%;.@R00&&DS<I\7)K?E(<.'E\$&R+),CKK<7\$YRY/%95HPOYP(5)_9 MO%JT\@JS"PE9G5XW-K J+&I\P_<7YE^<
M0 *)4_930ZI"/.4/6MF.L7#C3M7JAOE*2"<=4*.RK7J@.'5\;V,F7>)UXI+^QF<
MX2G'=;XLSNB.5A6\$V7T3;B18(T\I.E<)B/ OE+SX&I\Z+Z^&K-2WVBOVB_6 J MY3\!E'.M I-G"W&U09EPINZL;>H\?<
NHYZL;A&D"^@Q@!W;)4+XQ%* S6-\$. M>1@3(<./>^AB%U-W;(LA@5J;LG=)D\7^FE!=2BNS7?I1G6AXLR#FRO3?(3<
M(5ZPM81OY(I.T AKT6Z@%;P<#^ED%3?P@YHAHU>9;Q+Y\JPO MH\W\$W4-B-XQ?E*RAZ\A! 0)<
#V;1.;+^\$R;Z7@9K.-"=&(\U8WD8-YU.PI M^0IM\Z=;R;?L0ZV1BG=43>)X MN(I\B LS\$7Q_S\2-<
QWWX\I\I)0SK8,5Y"S"96)C8W2MN/E%CJ\X@190E8F_ MK1ZS@.@.O@Z%'>UZ9-H_LA^9>LA W-VK*XYW_1W<
;AUHZXYD>T74.D MPL-0,7*RBN\LDO >/(2 ASA\G?=\$X@L+_/RXW X^82 MQ^OZQ(DQ+@D\$2"<
MXJ>D8/OQD8/R!>5D"(\("J0(\T-GK\FS=3\$WC#?IO ZWT\$0A8=I.G.9ECQ7% M;X\W<
G;\$N6\F3\ING\$#A1"CJ.=.%TDB3_TV\ "83JY>KK>LDVA/H0'B/&(>?M@P%I KQ\ (MPL;G+I;Y;<
H\;/3+63<.>)ESWN.@3;U6\$R\;+R*J\$*T/@4Y1 M++QN/H92IW&;Y;50.<
(AAS@L%_I@<)X9Y_"/=RL\$E;C2).0T\$<@1YB)\$E3<1Z MYEB2;G@2)B=H3\V)?%7,DH/HCA H+@S?<
TWS1%;4>KFM\$O;W?+WKX".W>RT MG\DU;Z"U^=B^G778=7B\T*N5??SN%;""1R;=7") L.=SV&(^ K;1SB)0Q<
MNXB0YX""4Y\4T(M&RO-?%*YDP^8)%953A;/5)=VXN\K'T.1@ MO&;/I2IRL;M57Y\TV2HW@*<
L.UQ@WH)@)H242=FS N35.U13XX;I=MX/V<

M\$+YG& >JOS*GL:B (+GV%)IB.BD"EI\$KWUKY.5\CG8QDP.I56V38HS=GK6 M69-
4+V(GEP6U_.H:T)%K"LKF->U#1>FF2K.BI<@4&8XC>7F. :?1^J&I'CI MY:=(IRW2CH-8?TOTL1
<*&)&HX"2V"/DEH<P8LI^>*2*(08>:1 MW9,1FFE<#L\$=QV6J!\$!^?B.F@=*,>RF>9PE/\$Q;OP+18-??_NFRV.9I&(?
1\$%2 ML#<7#07L5#0!>=>D2D6=2@TIC\KMPJ)L7GBR.*#1^G+ZVV64W9 MBV+;_B.U0KIRI8M_E/3J16HC
I0109T<'>#(D)J#9=5%8(A\$CG\$,TZA& M1O@XVW^F\$6.*T 1<+DN8L7@ZBFJ
(B1I(\RZSW\$FQ#1)O+.%H8W6=.R/F\$&, M\GI%M2.#J,^/4%1E^CGBHI(E^).5P\$02^*(QX1HK\$?CCW<6TIV|@<<>'!
M48&C.1%.Z>(-@L(C4FVS16MZK(H:'I^F&3Y.DW9-ZS^"IF'M)T(IT5DMUC^ M"Q"2PA=\$5D_\$D6>DU?
+KNULH\ZZ:ILKMIPW.3FE)6 M)HZY:~P2_.V@4+DA!1G<)N+K'JIM):#4R%%T(I07T2%VN1PS&V8GD9UA3-.2LD?T3!
>XVT+=*B;>9)= T"N"IT*(M\ #LBZ:,DX_F@O9OILC%L&FB_+"R!J*5)(I.CG*8J.&+IS&XR&=69VI M7SI*?
_6(D#9ZI"5#&!\VB\$XJ%RC:)VZ?2/\$-4\$4*!><11)HJ?0DB%-Q:XZR"C M2*)%IMI8&-XK:E;Q<!)I!>0!V3Y0!J
>_K(1"1M!S;ZVH.%A)*=-W**FO;3 M1=MUMYNQOEHO"G"TE4<.-+3?X38.<4UJ;+XIO1@&+!UE/???#IXW09S+N<>+
M2>0&M9M#K9/I^XH*+=3-N9UA16I7Z>+&YUE;XN:H9Q?8%G.TN0"04/GH>K M7X&Q_?DDH/GZ+?8WBX&GO& H2
I(->.T<#RNR>I2L IGY:KK9@SDG*U.I MZ.64K!<@L\$>2?PSIXKHP2QCZ&HD\PK3LKM?=(0H(>0RNB9^6X^AX
M/_4UA4?!%J(^H!6WHG,OC\5\&323H<3M*1%K@U_G2PIHJ:D6@BIR-B3MW-DZ,^!>->J: M8 +66P#*6Y2G02"6WQH-
W^ACG61#F'HID. =L7.1^A\B\U=3!N<3A,E1PJ MM(S(/U7)J!Z;AFC<J+.%8A8F3".8NW<(D9>I13B1*K@9R!|!
(UTD+H^N# MO,<%1@SA;OBX")<(G61NAVQ-NH5XZX\$/53ZW&M##I&Q+)>&I\I(D):"CNH
MR2C\,FJ5KDE<#V=QCLQ0 4^2^L\$;H.!^%QNJAW!=&AUPT;J>:7"UQ7N24"Q MOI9IO!
G_-J16=0.%N\S87#EK\GV;H+|V*.#SA+0R0B=.@C-H\$A|@9\$XB\$*??P/S@'GI.<|C@Q9>Z&7W P8OT'6DMA(Q^;
MF.O!=YMRRL 0F5 @3WE>OVP'YX'T01.I\$/'SW\$D(C:UJ=?FID MHO'C&%MD^&C4>;_H!7
EKPU&Y6%/_'LH\0>SSE.5U;2'A=JDFI(#/'&)M'#8CLP0+9A^DEA0EE&?
I.XGGX6)TA,\$0+M).B=8P:=MZ:P&F,)/V5&D! M?&1?%VY/C!@Y#VLCNT*@/_ V&ZT>_SO("U_?5Y2/H 8D"-
R)9TN=#T_JW;V6(636YTB(_J)S!>9Y9_)! M?>0&
I@H<#^M:=1H@2#1F04@S/!:\$0T_1MG<"ZO:/2VV;"UT)50"CK&6"M|= M/3JD(T1^6=21-
H5UR\$W77B8=2IEK&=@O&M\B\I=IN,+.W\0,ZE\$TP5K8)GOI MLMJGFVVI/A1%?)EVV>'(CG0'FN6,*(I2#S'6QO5;?(-
'NE0Y85M?U!\$N:GJ M@J90#(^CY39E|=)K;\$7?5*2521!_V+G%I4I^19*&R"0\A/#3FWYJ-C\I1\$D M9EHT1YL(I)
&S0RTDZ3JGIARYD\SKK,?7VS'5L JJ>(\H\G_S9;.=<2 M&U;7_G?BPOIME1KB;CGADJS%RA".=@#0%VP15*?LD+JG
M\X\YJW):JQM 1KP\UR3IY0STM;1%;L:J>_#Z198=YQ1)RN@+7D%V&F/RJ
M7VPEQ<&2Z=#Q2@!3J9"/7CW;/^52LC\^I_ 5+1=1Q153"N!" #HY,T^&7 *I1 M\31/ZGJSDV;5-< SM@;??O+6OZV?F
HSDQR#F4/4A9\$=YE.'E:FIM5\$>= MR%F",&J\AR6*_7M P.PVS/K>=@IUCB,2I&=:IE/D0>7Q*L@K>-.#R+.X_9L\T%N\
(M#Y>|M"BZN"/I_MRNK=UJH&EOI"F+3>!:.%RP=3\$?/YTP+B M-#4?
8^S9I7\$SQZ,8P<\EXD?VTO:C4IH01V0U"IC4K.IRHDC>SZ-JYBY63+ MJ\$%%" (/G_I0-|SNXZ2/. VLUESMK47-DAI5^>
<5M/5(35T!D5OU_-I.OEA9P+9H#TCCZD8)F9Q'S). M2LW15-34>IR-JD^+7M/NCB4X\$UT
M4:6QB\JG1C^_IXW\$P\JM.5S89BZ_:FD7PIBOR\YZ1B!&2&RGH3YDH|=OS!_R M:7>)2I?L7 +A\$& M!0 !A:&KU?
=F/#TX>? MQ^).F=TH76W9:E6-I_:F8T\T5F6:6:16IXJ?7\J9O)HXI'DLP#29\JO7@3 MIE:+!) (I%('I/T
I_14CB6<:G_YNV?WGSSB@I_ZN.%@|=O/MY^N\I@MO.SYQ\IU>O_Z_N-
Q_^W;_U^D)P&)G(1XK^IWKTH#W<.M2U =14X0K\H\^I_ M)+O_>K;5ILD>?CKZ|=?OGSYD\M^)W9H!
(PC5P2\Q^| ^O9;K \$>1H1#0"O MK^Y2\NKGU" UW9M7;_RUJ<_ /7I=Z\^WTV^>O?FW7_FG_S'WWP;?+YW8O**
MT1W\$?_ ^F@NGI/O+_%\$;_U^>O/GN=?F+W^2_ ^=JUMW2W;_MS2(\$R=P.8*8_C7.?G@5NDZ2<7*0KE>=
MOI_ JFWY;J_R'WW\IMVWW\WTFU/L?9/SI=6KOT6A3V\(^E5&^5^3_0Y^<S'Y_R)X_.%W&X) M2;YYQ0%_O+FL+
<'Y(=;XOC)=A.%Z0.7X6O^>Z\I'P;S."+5)Z6\K(R)!LB4) M=1T_!B*!="7..B\9%MNI\X3I><>P&=#>A.3H!:#U=LNXL
U\COF&W^G-G? M,1#OPN@I15)! +VVH*58?WQ?7T\$?GWB?7RK9? M#_ ,Q%5\$'IP\VJQ\$WA+9I*C11R3)%:GM!<4E-
(C)09U/TXB\+524N:<^3=1U4\XNV%)NB_ /6^9P?O"!>_XLIN\$ MXW*YQ>
B*0JIRSWPSWA)RP^I'_.*FM)ZW_PKMXY3R1>.7N^;Q6)JGT*D2CS3E4E)P(!!1M;IG8W08\WN\8+3U. MH_UM\$KJ?
516K\BT4134>_#BD*3OWPS4\H_ (+ M.PI%.8?J'E&%#L/LIM7C9)_J297'D!@ A!;E/D0%BG@544;(@^S;Y
ZU(G%:XJ(D7H0"IV>N\I8=G MF\4N_ *8*2O#%@5MQV>)7XT7:X@6F@O)W\$VFXAL"i6Z(>SJD!\$S-?8"A=2.
MISBA_ZFCS%9I_X5?>0L7\$4A\I&2>_KMP /G-5FRU+.%RVKZS#@_ B.#QH: M7 8)B=C5V6Q-23"AZ;H")S)W?
KL&OS#>_C5_G%(_.#Z3V8L5J6&I\N094 M=;_MY\LNJ0\FM)!REYGQK.G":5/?#1&<^=P5"8-QY8@9.#>1D5-G;>R/OE
MTPT2SJ\$!8.N\GYDM8@(\L!1UKW\H.%\$H #)QDM;N:B3JH+&@8JW;G?9:VI"@ M#2UW><.
JYVX/ES\2M29\$2\YH:2%8HK_Q_G)A?3&Y.N8>?)F&TS\I) *SX M^>?K-7\$3YD_QOQB_FJW7&+\$_BS3A*T=Y
MIZ|=H4988+3!@|^5'D_#6LT&6VP\$Z_-JD_?R*1RZXTQD:E\$Z_-Z@^Q@VIB ML:%AZ88);Q\
I<9DEG6JAL+;Z0Q@@SNUV1+;LY\Q <5^S_-X@_I/&9%4;:U04 M29Y06MD#&\BCJN9:G\H_02H\I7E(7\0STJ
M!0"@:&M<-O3HZP_""^:82"O4(I/\$@RMPA1#6)H0<EZ@RFY6E2+P\8Z\$&K MD;G1W87%_O/@J6H 4+;>>A\3/!
(ZX0"9_UK.FAZ-0A\0J_P#MGSDBRKV\6=6CZ0)4_ MSM\$F\U_IL_KIE='!0=@6%Q86SMY2@CC:58;^1^<27_S0I?
V&SZOR@RC\Q? MN2?^W\H\XV\WCO/PV\%U7OY?2%=A3#G9BWNV.=A)4NJUO\QNN';-^ZVZHY5?KZ-
PIZ=F2=@MSS;B M1UY1J18@ MR\BV\ZK25.\$AC*2-17T6\AP:6!H@0!@ZJK=Y=@2XX5 GS#!*AIS*M0/Y#=
M/8DLRJ^+SD4?_?R.EI?9\KEIV355_77PIF(K#541V\9_U)>X?2?IE^=Q^P5HDITX4I6F^=7Q M4VA?
4@XG\H>JA5J4HR\$S\$S*6KM2E'3K_UZ:=APCY@I\7.S"X4T5\$F64 M2N4BM6-32C^S(5-8CB\$1+5D\ND?
GBVW040\$Y70_-H R\(&>B8FMLZ.0CC? MX5C2C.:?B.I=A!/_R:P.\$^YQ+GEJYD,8_ YI^LDJ^I7IEA701XT"3-I(WN;J
ML+90A0\T50:34I4T(I472NO":S_-F>QK2086,OX>9*\$%65T\C9S7,%\8I^F;=A02ZSB0\$8>9@-*>C(H)(6;S=4 MTX-
H^K+JXQ*8\$VKD>12U H=;3%XT+T;;DA,BC1\4 \KN\@MD>1K>35\@G;86B1ASB.G#IE<""5.\8C:E)IYJ80Q
M\Z&"0U!.MG7G&EW_NHZUD:Q_KJ6U_KFVQ#202X\HY W@EEKI?;EH==\$\$=F>I
M,4TDKZQ7+V<@HK%;4H02X&OI>M;2ZWM1#3J;=?I4*_V#+=G>L_CHLY(+ MT@2/*ZLA76WNNCIGH.(
6C\$AS\LRBAU_Y5#O,CAU\BBSP="AGPXL^(Z^BN0Z M>86;V5&K&K*QV00(YB4X\$8+.XXG2-
TE2WEZHVLH@KYGD#0VN2+;D77S@ MX^U^V+!=5B53K,I9L\$LIJ_C KW8F=@(76A\FF1JBT)QYU#K>U"+J^F4C2AN
M6ST/E(ZSSM4_J\$A\$7C6K?0@.NP36#2U\&S4JA0N4)>I\T#+=+IYJVE7E
M_DOY>%>@AW%M&66XO.R2=1R892OVTXEQ*E94L79;BIEP:2/&H;V\<^_B3;;_ M/_B#>/8DW<(T\$5NI+^
V\#^"2"!2O8SCU+Y\$"RR3N:V8RK/D&EP."8@P*TU(M;4NTBNK9B+7&/S&9Z;:P_CX%(^1018\S#7@10=7JHF
MHC7@6_)N\ 8."@O'8W\$"+M8!"66YBI"X.E.)WP"CT4C=A3CB)JE+9/L4 ML6\K\F%_JF\$^Q\$G-E6JY\N\HS?
5:I"2Q0YR*FY;L_R0E& \M'.D.ZV)"/ MB"?U?D)H;.EM.OU!^+Q\$,@9R>"*.(H)>R/V?(SD\APLV).\$|=IX3%VL; MN(?
A):/L_SWXO(="C#EW*73_BFK<14S;ZIU\$ _UCVL(ZI\$NMA\$V\I2&\I2/=@^_!\$GTF%ONA_ (M5S)\^3@*W\$9I0MO!T-
*%1%T'MH1YI#V&8CTD&V 789 MUH5OYVE8=N38A\YL2Y5U^(_DGJO&W#HGS@J1G#_FE\$Q\$MS0M)H1 MH6
3U\LMB\ CYWF9REN"FL"631LJ)=C\8 M254PQ?*(FIRAB#XN" L'0D M=1T&89VFLBNOG>O\+YYQ\$HD^97,FS0^;9-
)_1&L""+49IQ6XUP!&Q#/O6 MT"+_CIO9B0;5M.*(TN2FT%FKJB/+BS B=%_TR'&K0U;>_S3@1\068=I.COT
M6X,*YEGN7R768C>8IS V(^WL.C+D^R2DL6\N<-XJWZZ?>X\A6;BFC|= @
MJI#RJS7\>R>V5\$8T#9QHGS>HU3:V:1T^A%ZJW(RJ+T%>(OYD%SLB&+>L17U
M:6H/C\I4Q" @5\$Q)KBWL;H9F,/H9H9M<&6R.H(5=DN\DRWAE,TXO7_6R<:D^>N6(C25P#8AM7&5&*!;/_MKE;
(GB1%4)HS.*_W53ME6X%L=79R9NQG*8)N2G!%IV-SIGNO=I&F=HBUY M2Y:(Q(SD*6RK5GS8@KBPWP)

IV#&!OFW0U.W H0<72&GG=%('S'W^OGW#EB1< M2=|BZ^V(MFR(\$E2IL;1%9;W;H)3
3!BP_1K/%LTBL;^74Z61&+VSJRB|+G9O-MA<7409|/62K|ZRI%=@=3\$=?CA8T6B\$R>FKHTF@JK8<<0LH|AJCTD-
GF*6L\$H1 M>T;|-\$>F@K4* . #!/A/WQHZ66B%|J-327B/YZ9 M5J\$#QV#+Z;3NVXHEXSV*BHQFR-
4H03\$2UK7\$EGE7TQ1&\$*%X|%RL8-FIOIR MLJYVM*8(XV*%N?CE(1E%@1X|XIQ8\$1@!W2NNJOEROQ(KL6-I
MH1G(H<- @U|90FW*0E|<60MAG\$;6.EBHX9|%ZYHB.TL;BY1K|G0S9;IX.*1 M'<8;^D\$/L5.
MX\$|J9KDON/%VR;GF+U|A0/|@L=CN\$V46V.Y+8BOPXD.S.N7:P"G%BN9V&!'VO;L;2>="1H2|M>.79
M"3B#2K.MEB"/|SXJL>U%-YFHB*^)^QAFTM3-.L&FLO'Y2CDKH68AC5GNT@TV5 M'G>36,X|&9_7H/9-2YZ#UDS
49ME!AZD|;#XU;+@\$M*%&#;+1;6;CR; MJ5X^_K9H+Y\$!SX977Y.OV;_ Q|5D<Y'K'+Y5!*I7(H T4I9%07/A@8J;@PKA-
JLDC) M=D+\$|;.*|Y-K+|&#79(VX>%GT&|<%<'>C/+|9G?&|*|Q|@FI!C&E* RAKCA
M)LB@9(H.'EJW3.XD+FR|YX|!B<%'DZ"IP1MVQ8BHRY.R^&|MOCB1E|V=&M\$|
M|'9AUG|G\$|^APE6'\$ADO1@B8A|'OK>Y;+&^IO'P+P2U"HI_!BVM|Z#U>> 91S;H71XQ1_4S^D!%ROJ M
M=.%MD5\$F/3|;@#GW|;2+4R?>70CAEY|><D-1*%K>JN'E0+&A4SZAP>' M*6%R2YC3+S+X#P;
<&.A\$>:4&ME;QH\$3.5%ZY%ZH|6C.HM1.UV|#"H%SOCL MWB2:0QZ0NCG4XI\$|F|BXU">U5K5W(C.ZYL\$+B-((ZDN;\$CI
P'RY>ACU84RZ; M.IKBN_@5^|92UY-P|QY+|NFTJ' 4 M.;VM36JIE(L@K|I@>X+01Q|AE.Z1C* .5JX@|.0| M*V@P
|6Q" _BF(?&Y|S\$H%YOH+5\$CNV PD)AM.4R>&2;"B,Z@LVHXGI6L|Q M4>.8L"OBTCZMG#TW6DPEV4|B=L^YHLX|H3-
+3SHI>(9Z44.ZUQ"|@-IW%G\$)(4*S=4W&H=*|489|.% M|WDI@9"K<)F0=M>1GB#;21F7M=14X;G";-
&29;78OD;!=WB_6&S-)I'M M(JDTAES"/6;D-I-KCQ;&V)TSD#8BPY2^74JQDSRZ"/@>21Y|+(8*N%>|H7#
MV9>%1^Z_4QJ|J|)XF|;#?K%8P@=&|N;7WR&U%XU|GF*|="D"74*|(@/9|TF6 M;M<6Q;)-8DQFHH
L@W'&+1714YX;R189"=ZVA56^PLIF+ "TQ&P CBL/ M;S|H"POS|&Y71 6NP|77V34_*;F>5P1A1PU
M*..S>\$6|H(3N(A7Q#X"GL<56L92%8)5V>|U|X|H+|S7|H0|+^I2LG2O9GY|Y; M^KVHL|B|I=&O=EO'S=|S|U|;X9EQ?
=R08K8?24A*|I|Q.U6W># 'L0?H|%"\$6 MPZB-V*M;:>DL"&D;6=WL%R23O#_!O.H_|+ME5?
E&M.O2;|')\$&66*>@|4PE8?|VZ*52(-<+1(@SPM|X.@GTQBN&9P)F%@V9,<.^P|I4I+18O.F?NT|QX(%
M5;_FK+9PU(Y(-_RT>VS1EIH,D)\$XNB9/23%GYP;.<+W4&8U; ^3("*-5@#?K
M.M;=>K|5(59N|;:>0U"ONWC;|_4^AZC^_Q4\$VBI.P.8IF\$J;V&% MIT/Z*LSK&HF0.1R|8|FD5#GS) ^MIC;IPX.?
L|5^\$3;BN^LDTNI^6;P/>9 MJ4.7L|@;?+JL;7C?8DC6E XOB.Q&Y\$'Z|YV.WFM"H*) LMNI"AZ#O;|WW
M(I'P#MQ8AKS|(QMC=AI C^Y M).K9%YJV=1EMG(|MP^D5%W|I*=%UQ_(-S8"O|88F?;?PGC?Y3AC4
MK|I;XCY;DZH;_U|>2XL150G;FID?%L|OX;&_|WJ;IG|MP_4MW01T35V MP*)/2S8EP*=NY6FWM;&U>A>WP-OJ0-R-
2=@@=A^3K.T;_38J9?#8JUM)DE. MSN040(G;M^HY#L;|+@QJ|V-I|MBU+U|U>_10Y3/XS3B-C;2L;DH;9*M-
'6FT3';4|ZS.0W+&F7|M_*C1YJ&PN1V#T".W#|I;5_I_76<*H|<|T"W"FI+T.*\$0==YROK+7(<)N^;R
MLU|00|W^#M&C 7OK|,BYNF4T&3P?_ZJC*Y#A;A*!5G6JNCXW|Z?RR;=)|AY8
M=;8Z;.\$M&4\$TIXAW;&K66CW#=#ULDW#|D>'C>=3UR0RF?E0&?D KJ#@=|K MI\$6*
'9HMS1^_9;BLU<;0>6/PN%+5I5%Z.M#E?>8A.*I@E QY#Z6NF7IL|N M9\$F% LU7ER;J%HRB* |Z'C\$%T38#DL!\$8?
M8QDHEBBH;26RF3P#5=L'G#@^ M|QO"C0+S0X/8<6NYOF|WGR/&*AIK%Z\$!=-J>7A=D^YG*K|'^.1Y=|<-DBEM
#^@;8 /<+S334*\$KPMERN+C2ZKSE-@+8V13<>Y|Q| M(<'5.LET.VLF%_R;I&WH.V)C7E5ZGA
(DAHFSFU;#S=RO;M9|HR|L;AHD| MY\$|XY|BEGC+R+B6*RW|S|ED6M|Q3CEIM_6;KJ;I"OT|T|B9;K;_&E<)P
M1O>1@;B94.DZ.^&EL;FZT#"?(=|D#VU9W7QR#P#-2|M U3MQ DC
MEKX759CG^4Y<^CVTZP#"#8/8T3VZ*3\$6@|P2W|Q|@|>;C;T;1.8.H@FO(MT%L\$IVNG*|@6#5S6@P1JN
T&X,K@L1B85D&.Z15JZ4(C8JW\$Z-EXBKSL EOP| M93#.>2HL>&"N"=1;9YT. ".5X%6 _@N_Q7C0>Y"TZY9N|W|K-
D<3\$S_@YAX MAZKU2M^5<_W.L%7&.2YRY03=80G5;1)'R6^|N?>K&N)EX&M6*#L.%7UD?SOJ M(A 1)KT+M;_';|S;_*
<*YK<&J5/T0!)#23 Q"NVS^9) |H7?O?V4^X&H6.PW M|9^LM3&20XK|E*76L\$&6D|C-V&H-7^Q*N1?
50&3;S56<^="VGYU(LIS# MS&NC@9S|;:DQ|;TKPJDE6;^>LJKX;--0.WOY&%|JK. M\$OR#FVJF(^|;5FNS^.\$L<?&br/>&Y0 SAJOJ&W|H;9@5|C'YZ<^AT;.^GY*) MH3+@)&29E\$F*U97#B?N(X;4"6Y6,A;HS|_0.=A<2L?NT97#N><)"W)Q4+2
MYHWM;RIO#UZ<)"W)Q4+2;AWC;|70I;9\$5JRW;XY25J2BX6D ML?K&M%RU"|&|C3C0S|K"Z6554(\$S\$8->_@EV92|-%
M?NI1D|C|&|&|VKMVT|T#|PVS.191V6-QN;X*|@T522QS*2SO;1T2YF2_17AL
M.G75X"J|;|Z9VM*8SX#EO;K#7<@96W87Z%4%8=V1(L;9;')5)@%_#M5K|T28 MCN4M+BQOYCY
<|H501P5&9)|\$+DZ(Q'S_)F.VQ?G|L|S2?>W.\$|P"=,PKUKINRPGV;_0>:6=ULNU@%_190;|H77HLY|NRF==6 M\$M<-
|LL3| F\$4+4M-K=24/8YG/H#?ME*|YE\$GK/2^"-T\$>9|&MIX^J|A1 MY8 Q|J/QQQV. "WR|R+D7.H*B-
Y;FC|F9YD<^U2AP;|YL\$JES0O.M|W<_ MLM;D6"E2X_ "2CA6X)E|BXO"@/W1)96W;+N;7QG|O%)OU+E;*@-0?&K4;AW
MD-WNEOB|3Y9KGGU"/6H\$ MJPZ;7ZRNZHFQE>6^S";/BG_@;28")I@M M2;ARRE9QCA4;YS4U9)|9I+^+S>X<6B?F7E
\$>5\$6; VASBJ(Y7D>>|DIQ MJP/;OL A'9%|5 1;+LG#P;^<|JMP MG7QAW#<CC""790076=) _\$|/|<#<07&SAD|HCRD-
S%*# XTB^_POEH@|3-63RP MJS|O|Y3@2&41;#E 0) 2X;V664X|!%5K8-7C%698#UY"(7/B MG|VPY;_6*
(WYS9^;|IDL|!&_>O@=DL(PD6GI>5'3E^I<^6?<|ZO;4@&W* MH?Y+<C60AK>FARY3)WAF\$EE(=51+^Z;
|2/0148AC|YCY S M"%Q;<\$7;NG|*K5/LMHXC3;|=D8;260;25M;25
MGQ7R.0WC) #YU'FCB^/RH7>6C1^OH|+>T.B8'98M)R|B>&FW*^9F4S5&?P^? M;'H=0^8T?SHSY1&-IM6G|&G)
|228| M@M;R3_E53*)MZU;?T|S|B|AJD3;APG3(K)DT9M_N3ID;6 3;S6*>'9S^XYZ
M40X2;G)0+|8R#&U^_R4>#67>665;7Z63KV93_-K2#W"CRD|=SM=KXO+^S0/E_#69Q^B9^W3P6@VH+YH
MD(+L|FBK|7H1X|K|J|T6|).Q&"NB9QN;D2ANYX?>8^G4@4|.%#G|B\$Z3."\$GA|A<'8AH9|<9 ?2;G\$
M(=CK@DG|CG|AQ5\$ W2SM3A 1YN.N6@%=>GX;XHSN|_# 9|Y5-X;_J#;J@
MH9I^|N|_#*Q4#|=|SF;2CP6G(=Q*|7(1|QOU|S/83^N7)>-4;+Y(O;\$=% M-%F/E877H=6|@?%WXY&(&
(S*\$)E;DD>@R7NV;U.%20+3OV")_ \$JHHOM M#XY_*\$@N|WYW M'|CMX-X%7(-
+A|T"S;KK%\$E7T.5\$&5Q4IM\$QSR27; M1= C5(S)08G;ZV| T*X"A8+J'W6^3ID#M|;+P4)BR*U?ZPD5A6(
MD|H32BQ|F<+R;F@49SD|HSWXTYX8*2F9I5?4)*?|N|>HVZ3_*M|285)XZ
MP>|TX2=AKZ_YZOV RBX=AU_ M+PXEX8U.\$*| M(&2G|D"S%&PZGY)B_(&GA/R111ZVEZ
M;SE84WQB%7@!-1X06<4O('+'K? M%71C'L<-JAFO'H*_'H"BN9F5|TA9J'V5-'LN^HDX|!_ T|O@B^2FP|@J^?<
MGJ&9^>^TJ"3G|0DLS*JA0<1^G<4CZPPG@BAJA)U+_W22T|O 90QT@/;>32")>%KNL5MD)RJRZN\$@B
M">+0IQH+>17WBDCG00MC@053^AU@K022LRFQ6=>=8EMYT*TH|5=U5^J|O6 MU05H;4/8;_
|4%C19L9T|6(*3AIC=2TE14#Y|V@IQ\$ZD=K&E035#C;-GN/Q MZ^5Y+!W3J_PR6E+
D(IQ'E<7|7NWG(>.2=MCD/'_DKZ5K1J|/2.A>OX>8 MDI\$|KA\$N|;7(7&|YW9><3_PPNA'AV?
E_XODE.GBO8TV/SJ^"FT\$R*%^|&&8Q|WCYS2C%-KA CXYD.XHJC0&Q26)'H#V(IKDY93@\$+9%
M7W@V=V'GH|N;P.2;3">W+\$PAF|J|4Z*2|Z.RD*^?/2|+^|?SZ M_+|PZV5Y@I%AA&U6*9.D6?
UU1%=MB.OU9%>E|H=>8\$/#P\$'9+|L2#H|K.\$H MO|'08T|&4|XV0D8@WVN*X;C0\$CF Q9Y%J>\$;_'UF".SJTI(=?
Q;N);S|+| MZK|G*%0U+&%D)2F9T29T M;=>K&A&O'9;9H_0K5PS;86;J(LH-I;Z;2W_N^Q;T|2"LI^+ \$X"Z|U#28;+M?
FZ<^@DM.H>G)@AKI|=.*NB@_E6;7|U%\$U2SL@C=4G|5;=>^|*Q;2*1/0=M
M|T*QDM0ZB5K=G|JPGW^_&=@MVKY*_|B|_ "WYU! M&55=K(QP\$E"P/%"PI%"@%O1_*|_ KQ=SLGVH?
K6(H)Z)H=9@Q8GF-@|TJ M|E+27Q&\$H?ZL3'K^U8|B&*5MTZ51VA)1P6-0)/F)\$G_9V5C8;2;N1;C-O
MG&|;#@(|HQC|H0BFQ'-3|ET6;%Z-7;7+|VA =^E.%+?2DF\$='F(3MI9BEAQO MK|@G1)
1XCS;LKKX&Y^LKI8KH.V7E54OD57OL_#3_LTY|I?O<0C|>|B/6 M;3>Z|5;2P^@-^PY|VO&"W*@27ZOJM02""@9K4K;
(U;C8&86?"|P&>L<;T M|_4C*+Y);+|30TK;U|!%|F;S|7T|@9BI\$0!^9 W1C2&ET+Q.NS09R-V97C) M5N1% C\$TKRC(

J2(B@3IX\$,#?4C'B92(*1@A*C*\$&#T"(J2A:|H=7K|8A1#8|M0G^I(AO'SO,+!^X",7' M D?7I.O\K.(->%X|E@X0R+LV8-
N.2%+IL_+|= @ M&A)F#ZH>A:M-/YI:HU=+,1E^@\$NH#J_!@<:A!'3!TL=?EO@9QIWE3RMJIYN
MFYOZVZCY/C_B6^/M0YBAQ-J3VXR%_5|_::6%?B+*%K M^_.*P+4#_.!6:-(-Q O""Y 42 MT4=&RB,1+/#"#_!.(6@=D,*)|_!:-
(5:P"F:XQ7\A(.!BGOBLK_!+#6NEJ, M3;?TD:UCHQBE7PBC)YQ4*!,LY"?B>_!LP8A0+RZ@@
MU\$0**W:YB|S:YNMBBSPN MH(OPMYIDIOY=U33U_2B*?T4T#)HIG2Q: C5D)MBAI'G?V=4TZ("0#72-UIM
M1G&QWTY(0_4CEJVL6!7R4Y"K03,U^|S:%*BWANJJ&|X:|TIL 8D2(-JKYB M,P8F6(-C.8F2T@BWT3K-
7&3CN#_&HX2,-7;NXT!::?1^/"7-D"WOZ@^%U= M8RBO/?*&"? 63PGUWUS4)%1H4|_
<@O&RFI(1|XPI>L_!9")9R<<<3!81 M9>_PY0PI8>Z#I0X_(A^.%0'Q(O)-5!#W(X'DZW*_76+";HFFL81RN.5U
MF"= 785.4)ET"1^G@J4-RZ*KH RTD.=L:PEF6.YOAC2Z&HPKSWH>M>OIPP MIP4I+.*C+'8"BC= V==^<
Z+*CO&K|_BR?B|Z/\$%.VIF(AFPV/I8KETQ:8_? MFO.1A|8'WUDBJL^!I6D"3742+.%3ONQ:|IRGXEU"?
L"E\$7C42!LZIBO&77> MD4H>A|OXVE&3GT;I2T0_KMX:8#Y& M4)T_%X3!K:-
=JA7_!C1+C.TH'6\$"F#5784VM%;EOR(W^WT'0(QBVTI5XVP MX*OH"925_+"6X+4-(A*JHRC>RFCF_5VL7":C=QSZ6/I
M*:A#U=^>N2R%^2XU;LSHW?HE0Z)/900Z/M44AY?ANGE-|ISZ@)"B|I"M-(M48!3GW%R\$;0FYZW;0K?;S3(
M7V++976|OEJJ7P4B:K*.*C'RX#:O.8=E.Y0+3HXV&Y;+V-&B\$LK2:8?DDGO M0 LP,R"Q)>|I
!EZ|H>4O&KW_@'N8;|T+7P_._(+VB_"Z"Q,IY-UZK=IAI:R M"%T\$9P&XI9DI930T??|IAM#?|)\$<:!,O,'<@=7'XN,>_F-
=*AE#QA|F|F MO18|CQAVAO94T-7?3+3.MF%|HVL|E;?KPX_,GI| XMLP:5%4E?|C%M3W=9\$Y
MS59PW(RV"!\$%S#.5L1)S00LO1'.V0MLT4UNC)=O&8SH#JF6Y*5X"=>L=KRJ
M|R>HZ*Z=DZV|1+,@.00Q#^Q1K;EN+|1>5/B6<\$|U5W0SS34<^'^B6?GG_0_3C#|_|^_WCW3|V?
WAT_WCC_YR|3FDSW_|M-WGH?N5?+F7Q<7|VY>?WX=>+ZSS>|WFWTKP_KZ^03^<?G>_^U|I^=IRG_OA??
+C+ROR>|O)IQ?|GW_7|WIR|W_|RP_JNYM_|SX M#:OI+V| N.&_/KG/Y|^_03+7?SI7|O3?_^|>A/&
|=V W.WQ/GGO|@/H/MZ??A:O+U:Q/O|I+K|_|^?ZG7|_B|IME^OF-OSFI M_/CY:QOTRSO_'S|G5ZM/SG=>|%_AR=W-
V>E|J?G|Z?D_NOIYC_??_|^KT MIN;::7L7#O@,#+:U\$5_Z(3O^X+DB)TLR.1(ULY>|9C/YLJ8.T<|\$\$*HC6\$V9C3W:R
M\$7/B5DE7%*Y)|%>_F"V!9Q|S+T&_VHI+LXBCWDJ|K3|5C_._Y!|>|S@_NYB
MC%AOB78@0B8|U\$;T00KO.S#B"DR&ZB0YDL.4'4C%BF_'UI>|JV*PVZ^|)#Y-V MX/;@.H*UD|I(@5XD+NW2LA/<
J*^(7N|K_#.8PRFK(-?|=U@G'D*H<8MT.Y MCIPE&0KG^0_9(N&|I?7B:(LA1P"#LF.<9B=AKN',. OK>&Z.=W.3C^U(9E
M&Z/6'5).HJ85+(0|SMB|63HESXEY56WRQ_7X3)&M9+Q"X3C"D(&Z|SKRWB M028B=Z+X.@=G @AV2*!SR1:|I(6X8N-
0G.7_!5C>G?I9R0I?^_|DI&1E@3EM2V8E|ULGV+!?'*UP|DMYVO.OCL_F MSPZU,IR&4)F1W9AD"UO M&_J_|#CC
|HUA:.(0V LZ|UJ6L8#CXC02=B7BY"W/>4BKD"O(SX)? M'_ULV1(63.#.AC ENR?H&FZL 20=JES=>(|U#|:6QL33.J%
M,K=(7GB_IW&R@T^BTJ5BAIH@PUOL;H\$.%>XB?IQCT(D=)S)F9@VZ60EY4.L% MM|KGEPU|+|!;C|03HP=3
\$M9P:05:%6EJ558L'RR#1E=F".?L 8L>_DR>* M')|S=#06@!&^@|D|JL#"|H8;KFPB\$|_N^6<=&@7RS"V^")95)Z?
|+A^RN*Y"&3'IS M5'JPMJ>F+O&M_|+|_W|O|Q+1T+M-G"C|HK8L+K;N=|P_DP^C<(|,TN>9>M|GZ8\$??*C%AL-
E&67G<9)|\$-F#/&TPNZE=N|92CF M4E#KB30VP"289G"3\$N^|B=CV0AR7<9PV/7TDIZ,@Y<52IX@)+--
L GK8'R7O15T5Q_DXZ5_-A.4|1-25%H&RNFHLA1+"9BY.OO_7SRRTZ#1_@2 U&
M">:|)K4M*+AC!1Q9Y#8R+J'47AB|J"=1@?J2A&H|Y@BAK, YQ)#\$: MC,R?_+!O';%_A6W00:#V;M33"= MRUX|K-
T>0(|H\$ZFWR:9ELD|W(=|P|H'8P|K?&65I/%%=@74\$6RJU^?L: M2(I'_.#^JK+;0;/3 TH/&DV:IQ<:/R-7IE068:7WC
"/5F.9/CBZO=5D)XX/ MD)=1FEW|H&Q\$DZ4PCR&5"=M#|S:P.0H7=OE%"Q6C/X'K'K9^#|A@6< MF24ZXUVSGBBT
_NPL;V4X6U7FUI2YPN(@%3DLT@W:9S|R'CZMM2S#X27 TM8 MK^YO40I7H:IOGO>L%:D7T)-0H;_2/I.V7V|WR,|
|HES#?>K'Z"UR'COD% M;_ ^L)87>SW\$*6*H7_)*,?#W:"U(GV;W_@#%860M_7F*E(G1+H72|@Q#YI
M_G|@BH^K|7|SD^Q3^).IGT0^X)2Q0@|MRMZ|H5_3_7*71>\$*ZH^\$QRX6^_&_+|=0
MG\$\$.L*TG D+8_|QJE.6.1MKTA.X?RABR|B2B_4:>_?T77,N'+(0BSV>R#K(I T M",>9NAAXO"V|=^+XO*7_|9:09&CQ,|M|
+M* X213H=2E6+&F7KQ>;Z*B(|#O6* @6|E/+>2 M=ZJ/+X/%>IT-62/Q:7H?4X|Z\$??
BTL8V/&W9V9UZ3+P9|5S;I4%DA5|2Y9^J4W:|M|/(689BE
MMJ++M|PYK|H RM!5""M.B.J/H+>@%\$|Y:YM13GV8;M|E@4JDMW4)=Y6QR_!6|H%X&3-4HVVYK0WD8"%K09
MD&I2ZV02U^&E(|F|B#AQ&NVM|2|!@IG(2|0:#0_ QUQ405;@YIT)LU157ST2 MA|EPKQOEQ05S7=)=F8?
XSLJ8NA;Z|22!\$N5I8#M|/5:U"!K4UL?L)@%"+_M1U0L0S M@PIOM5N%:3PM|*Q+=!#=5)-U\$-
M8FZ"-5!_-844V2*::4L2ZCK^D24O&::O
M&::O&::O&::3C"Z|9_R^9.RVHTBS4%&IQ###_@DS#2"@3WS+*R/2RR\$0YS=I> M<+03XV3E+>==2C%5?V-TS
8WD7U&4|Q(DVT8T3_Y|KW89KW1.*7AW_YL3#R M%8V;@YI?Y_9_3_ M824XR<_2>8#22M|_0'+|+@+|
(@J"0#;C7U.N:|H|P\$>#N+8...#DY2*N1 M PELTPD:.*ALR|~7T|1N|!M4\$%AM""4NRLXOUH M0/G9F3"5+DJ-
@&4^A&U*AY&"K>9J\$LU9.C|ZE5U&X|EY716|Q5@/|S#PK M"* *8.RCD9"LE:(H'EEE-DIEHIS9#.#5)2_(2;
(|@4=G1D)UV\$\$.&X#1E M5_5NK>H_|+* ^_DPO_3_ \$ROE")FB4C,(A.%|=8|K\$@+FO/H(<=XUF=^?H
MO>P#3BW\$ "U,Z|2;"#|_|=O2#C\$R6:_%CD2V09OD^|)3O|J4H=(K|VDU2
MDD&4H2CJ8&M2WZ7(@("\$I5YBB1*FNW|CCA(^?D=OL0.C513P3(#Q MU/\$7F MUW#RV,7YD7J|^?<
A'1Q|ELP@_|P|L;XWVTV5-"@X|)H#<|(|@_NY&K0AG) MQTL|O/KL+%|NNGOA8:(J_S2D-
XA7)|@87P2/E|X+KPA;ABXU""^#2U IQM&E@C>A @CQJ;B0U_MZ.(P6.LS?;O VS60.Y+ M|*PHL^&)2=\$?
\$\$HMJ;OH4*=\$ZT 48+BIZI9P4= M8|27U20"111WS|HZB"=L;CJB;_HS*E.|RMEGHYX#K|T;T+K*2|'QK%1&
MCN|W(93J"17.%AZBXQ|9(5+L"PJT0H@Y;J|R>B D0 TH 4|9^QJF' 7N.8' M2A.N.; PUQLO_U'P|+?>R&S#?0C-
PY1+B9?>E7H_(!^6ZU5\$|G*5HC M9LN^Y;V|)64^* 1W3R_4)<5AT|MO8Y|Z^R".X'H_UMW9^0>ODI?QI4
M1Q%&UMTL|T|Z>_T54E11AE#HQ@F1.WO QVW\$ 5_7ZXC&F5*)_4(U2_ \$YT^NG_)^!^P/6R?
8D!O&O?/UFL#7@XQ+/-*M M1'_3-H>GC2EH@Y0>X|FQ7(CU@PID71GM%KI3V_%ZYN#1=&B3!5?W YT.F M9X.G
H:"W|Z8.+*Y'IP'YJ_LZ<.#GQWY9?!.HQV M;_ MQ+MDLS+J|4+|<%T>=XQ|_GZ6S_8F@VO^L7O'97#%G78;Z>U-%,BV
M\$%016GGQ+7|BFLM*|MTUVUS,E&3GMG%NG;T4>%@RL;UL|HF3|_8|PLEG;G MNYT3|:7(M7@?N-
3S)D@|@)HKA|\$@/PP;B|K2W=|L?MA.8U2*(Y^&O4%PY5;JC#_ M5Q)X822|)VJ_CML|7HK5|>7IER:872\$|0G^I(AO'^^?
=5_<#|G_W#|JPL?7 M|*O+2LY7E^L MF=?ZB?R493GLK^B.)L23MB\$='TZ095U+! Q%_ =W*3TC@;MEV_#S.U;R_|IG=
MSQN|U#"TH" _H+&N;DWT4WNBY4^G|A-CEH9@;(*2IQ#7\$)?>2J)M|'7CYW MJHT&M<> CF"Z&885Y2|XZ7,ET&
<1'G/4|I@304(LXM|;I94Q#?LAG?&RL M4|S7.P8RTXT|N|NQ6WF|59EDY 2+ M342(8)RQ4 H='Z*J#
(61A<7D&Z3O(M3DYA/-DN UFOJTI'W2ZMN1B@G>5AS
M_|)"Z2FP"R=E|=BM*TN;X3UZF&N>)=IS.LN@|V50M+C@73W9_WOP??MU*)CG MEC;B.58;S0JQ'XC'5NV?
D2S^<_MQ%;Q^WJ>0NSEAWY(NBDDK<""|X=?>&M% MP4"0X|ITYGW8+7LFEA'NV=EV3U5A/28>2^<=V#0Z_12"
|OR7A%'XF7-VK^B?@> M6|1^|H.9QSI945.006"41^A^_M92R&M;L1#|+@'6O LARMU""Y2K|=N|S?8XVW&(I?M
MF<<5.1|EY""&Q*LSLO3_V|G^_N1Z:6S43.V M?5_/P+6RX|22!"S7&#RH|ASQG_
Z'OQ.P>J|BFK^7F_|TM|0|2T=?X#^VGO M"@^@QV_FN?;_R'_%_!C5K70N5,|)"32|_4|9=+/+CU)*%&AXM7BAO#4G?S&
M0\$Y:7.8|GVZR;CNDB#4\$Y|TKD'A96Y7>H'O A(OY;F=2)*AK3X8+YG7/E M10#;0S?JY51ZF|*GX\$|MG|U1?
*J_*W.L(*9U 7<<30XB8),^V#_U5Q*=<4 MW+|H M9|IV WYLE/B%
<|X\$6"/ZTPOP@1|Q_ \$ _H%=FAW_/2?_5K=65>S*YU\$? M'V5|M@|_|!RH<_A>?_+XW.+<;@E)LL=
CW)\$L6):^XD&=Q>AYV|?50EK(MPL|0RW?&EZF8=3@=@BN'YG%|HX3QYD_G|G|0DWC #;_ ^)^6/4|D&T2C57V1
M"12|H2RFS*CV4|L2Q6W)(L6UO2#J.FX U4_/8 Z/>B:|:3AG;R'Z2^1@< MZA5_L6D|5#8FMAR
MX.C7\$3UI?7R9S2Q,7AA|+).2F&*F^H|O&^6|HDPZ|;I<#94BL3|H5|_#82V4"

(<8A.E5HZ^SY6/V9X%RIZZ#8)00'7UP.MX(U,EJ_ %@ M-2YVDE&!;#1-2@=D8)H0)LEWFJ<V.2^32?8?2+(-O>-
XX/9/'>'=HX#& M-IFAOW')9;=9.1(C.,P4Q15M;*+)K!93P.(^850>R'4O)#7#3IO'9'G>IW
M&BS8Z7?.S^6'B.,D@O.P1YJ3>1I>)*O=@(K.,)/D')1X1M6CZ:=/H8YH+R=7+W/T:5U1JG/C#CTPX4!)2@>C11.;T5X
M)KP&S^1TY,Z791(7PKO%GFY_:LZ="(KJP71DIUCU062G4&8N;F5FGUT! M/C\$.C^/14)S^-GP0-
W6+IR#ORS10(RC'G8^K^6.67P7/Z*NXX/V2#3J1ML2SO9!^P5""j7F16-QHF6+U<3*=:2U<+H*BR&\$>0+2D?
\$\$#1A_E+16_M9P_U84\$IC/4V9=6>=S(J? NHYTAXP6\$MR1ZI'X1;Y9K_9GQ'0,7B_)RDPAM4-(PDX,'DM5/6#%3/-
K:C.8BAX!T5J@HA"N0D(6IB3F\$&FGZFN;V_9CE
MGJ%M81/O\$QL0YK8IHG<.TIOR(T/L*MW^WG77!WNK;_++SI95_ %@ME20(QS_M

=PE6;/%,Y6#%NQ,@>#YR,+>GXL%(MS\+D7+6R+32ZYH7BM<.Q@O'):.*QE\>504-GQF=#E4S,E
ML9TIERXL<IR&G1P#R1J24+TL^9M1YA7.P8L;H0^,^48E<_YR6>=7AE+I+? M3S*YES=B/ZX;I3R1)#1.5LY^UJ_ '7-
W)."%W?RTZ.+8"S+P%C*,E"OVNPWQ5MZW3E/MOI-M%>!'Z#?
5C4G946QS13;_K.M+(\$Q);1E_.U4M.PRY:5RO"N33R#18/G+*4%:VM6'.X>T_"3>0;.*G+KBY
#0Z8>_8Q0%5/S0QZ&8)0H>)1A'9-.D:ZT10#1NQM,<&04AY\$UL%WXN_51A?13=Q5:XO'2S4J19_C1#?KLC&M1<^#A
ZF;11B8%_E\$F!_.#)2!M%_25.OG#="&VP.1TY"8.V29CY_4_8KQ1 MVE0RO;Y8L1363^2GS.572/6J?8_5S11@4W-
9@.WHI%G+U'IWK9UU@Q3NYS1HCS!OZ&KO)LKZ^8KCC<8JF41R!;\$A1U&HTM5X3-Z&/MY\$ 5S^OBH?C
I3!-6,9^>J(H4F;J<&;1%519_E<+JB*W!@--X? MJ(EWID2!>U"1>>&3N3S.*(HS.RGINY9<)Y:8&;Y)R4V0)3D;G)YILMZ/YX
5_M)1R.*;/U"/9L_R2),IHY?035_FF77.#UUD1+)+I<I9@SPH^*8=5C&B5_M"9G;)0#KFCZD'+Y#19L;J9,6@J?_
W&3%1E<J2;R_3#SM1Z+ULVW*\$;.=WP> M;ARGU:29=Q&NX;D.\$UMY>0/(U%WL3BD)IN@--"MALF\$!IU;H8;;8A@1
UV790FSMZRG=R#Z.YVB1JBC1SA7/F.F^5166G_T8\$M1H_M22!:=,+((<#D:^^)7+I<1_(86!NROL0T;V8L+96-
I6.E^AB\$DT1T>=NH\$63&0_M8ARX'HJ\$ K>'K;389-Z"B#=#0#(/_ECK+UF'CVS15#DO8)"&Z?LQWRX1231O
MR8L=B:CK!&?D(8O1PFTWMP*Q?I9/P1<#T%6*\$-WVQ^N?+73*M1_MLDHC=LG(Y0H1\$W+,PDRBK1!
1J4CQ41A<;%-6\$&7E_MDE&/0L9=;%N'O<!"QV\W%"_YG=U_(B1!>12.8>1@D
M^W'OACQRVY1002YZOXM\$@"9=%DG_.E(0TNK^=MB!ZU@R64*HA16M(/AHXJZ%_M:;F
_3W5HNV>1SEO'AZY8YYN%;6_D\$0F.I/@(89@12TTC81DAS\$>1W1%=
M7TY6W0N&"Y;\$^B^M\$R3.\$"GE5J^!)41361ZH&G;G&.(U4C%)/9JPE&UV_M1J>_OLLXSIHNVYMCK(1ZVEZ#^C<+J?
^ (U_"Z0NPJHJZM"W(GFMFM_M;E1B^_M-I5%&L1?^C;6.2\$7OX01CXU_CM&*V/@S3.OVSKL;A4C9\$'MRPVFXAL>.)>
M1::942CC'HD_G+;7VK'8DO>C15"N2;.*0I<0+ZL@3K;DF3XI(0D)O)?/*M**4T;D2C1?#"QSWG>
1;BC5F8=#2(N+7\$'FVE6(=N>HV.Y%>)/RLUDR=4(O)_M%.YD?_R58H#(XHL3>7D8M#+#. ^L>U>BPHZ1Y??N1?
5X>WY7Y_2=12Y#1'T6(T18!5?42#ZL;K_DL\$0)&:%-+7S14F5B^/JO/U;U@W1CA4@9K9*(4QVTN1&7O&;DG))1(O
(=Z"71J<#;G%="5.LA28_MJ5MH.5Z4D@*(Z<#M<(OOS4/H)N1;RK.M%"Q_AHW5-D1W/#4N99=4OF81'8AJ
M*.I/MJE(1MY+1F1<9@9%UOJ3V1\$BOHN\$5%7MG%1H1?*"U9P"2"WM5J3DJMJ/M"-400VA75@;.+2NL?C=E17;5+-ELO-
""@W3&#FX;80>_1>0Y%8EQ&958A4!_MJBX18Q5"WA;.*FMH<ZL""41@LR1L=QJPDPR!;NM7214(C_MS=_?
+H1;_O=#J8%_D2UB->9B_T81+*KQ)H1CC1LMGRDD=IXORWP;G'H4X17+1/H14<^DN7P@T/_
M21AX#9>*Q15F)DC4KI1W8%@H@#TEE14ZH;DH+;JVMC_KOO"SCXAW%OI&_M21VFT8.?_
QFR1)J42I(P1H%1;_+X41*6_(A*J0@3!F>0/E;_BF7A?H4)\$KE5#8^F8L4VFN=A3?#_M;3LS!@S&^2-
/X1UR9701Y5=QV1H8T85&.5-8S1/L1%IG^NW5*E#17AT@69B_M_6T&M1EZGP9E&17;@#Q>WVY?9UC(B1VT7A#
(G2E1S(GXF5.Q_2ESD16LYA_M1(OW1NV36\$W21#6<_X^(8A@HO6MEO2\$O9P!_#125DV10\$?@_B1N'1-B2=O
MA8;DTPD;9S_-ZN)!/_U;_7IUKL+FDR1=)U;P89+<;@!&.4>4.=WD1E+@X.M/M1%VYP9S;30NQ1NW\$LZS=CI-?
65^E#/'S^X@R;H)Y<51_/_A.U.IG=B6_MVLG;179BJ3VX49B(31>P%&P089FZASW(08_I%1%BLQ>Z,2#^&
M50WX5NR>&?F@1^_1_1(@1L1&AD54JO6A3O1#3XYP693_T1P>Z(NPU"/1SL_M31_KQ)_B9>%-
/62S.%UQK>\$1HC<R<*E7@N1QR;1Z+Q8.1)BG%?"2L54_MX-1^NVVC(J\$15;1@_HE955_NH919_Q\$HWPBNXH
RD_N\$1\$>Y#DAY'_M16M_F3J_-W5<-TK;_W_OKK1CG@I@1XCS1LKX&;Y*LKZ18;G8>6)^DKV1>N*)S.CPM7*/1M)U
*PEW1K1BDA-WIS8>Z>1AG?;A/R4(GZEW,-/EQD2'MBSE1%)_MV.9)1BM@98_9.3;_(E^Q?X9P<9G/A52;*REN2A?FJ>
M47AU@_J1=_(HFXBG=1+1M'_82DKBZ#BO*NS;U.G;U\$1^_S'4/L^1&D1N^M8U5IM/>15<_RIWW9R2F-
V#1_1)67^>5HDK0PPESW6?_197<^V1NQ^1N_MNEZ?FWSX.F_961V@N(K(PW3;N\$1_1960#R2R).*.
1\$F1JN(9HD)6\$2V13Z_MVS.PIK7%&4P%1W@1+/9Y;?>?9F&TL1S@^G@EN1Y&8PFSP.JMN-6VYF>AH%1IAX%51P
IX1CEG4,Z6V?L"#2=5HAKWM@=QOS8G%/M;K:(R?3YV1%1%B=U1:720+0F.#C#%_M_Z71->1<>*>HS(FPH/
&B432Q1X;JP1B%1Q.FIT#%XY@+X1J0T-(TH@KXFE<1<_)ONQ8>=M"X79LMWA+@_#
115#1/0VU;C=J>&?^36212=0K#N1_MJFRZN8+3^!H0#4K&&5/EDE6+>H=-5)UB1;IUOK/5N&QY=RX3MF(JM#FL>Y
MTUB1?EF^X;E3Z^C@);/61YY^H7T/<)+;Z_Q&E%G8>V3).=<-7VVA+*+?\$_-M>0@C'C?CD9D4(FC1_7@>NZB?_
_IMUD\$VU;^AGP81Z'E1?08/0%9-B+:/5"UV_MZ#>7AM14&26GS)_9A!&\$T:O#FY>;T._%5#V1KF@^\$=_0B_!+?>\$X4)7E;Z
M;1.AZH<1+W%UL>@FMTXE%_N(^1!&#&D.DYWB=NV_M@G*=
<=;#E5HLB24B<1PX+M0#=#B8>11CP\$K1=0^H1@TK;S)=)(J_%)BR'_OT?X_M_U?RK>1;+((@=?P18_(BL1K
67D4=5;4PD\$)2AQ>PGAWLJP_"J"\$6D#GMIW: M7"F%1!1DT)9510P%E)81\$R.K#1E1&(OK\$)_71?W@10*97)N)9-I.*4Q
M>B3BO\$C<_&(<Q#P-TR)1J>A1Y\$>U1_jf>4%*.*4(DU9IEU1;_XXH+@#T"##AA?6=#6-6UC?84%_M\$;
P%81^<_RN@N_F"6L=1&4XO)P)%23B1+FC3E1^A@_1J.YO(QU840;1A W&);P&9RBVTSHQ0?CVJF-
RDYSN'^H5%1;5-<#S_M/W1>5.*_0>-IRP6^*F\$=00;1=W1'\$L#E""1A_E&_";5\$1B^1*\$DY?W*W
M2;Z1;O!#B+0U_-BE(RB^&K%18'Y?R2;Z-59?2@.\$@6*1HWY5J1;_Y'\$=8L/+D6_TIA0*0JF\$415V&<_/_Z_MZ
/0(ZL01\$RL5A1CRL+8T;_*UV&M)X&QNR;"_Q?_3;B+4C(0<=<\$16Z+^134G_MY-Z)"?_P=02P.\$%_@_N(^#6(\$W=0"@0
N3;A1P1E83_R_#@P.M.S0M.C1F7V%KH(NC#XN_Z*VIR915)5*0N!+L1C_MS7-...@%1>JO1_MO51_1^5?_
91ZXD%1A<=J=1W_12(8-A_/*R3_1HEK=3K_1^>1_1'WM1_MXJ_9.0FT1/1R_WB<1C_Q-D1D5LB6F2S1^?1Y8+1I#>"8>
M>10;PS0;RA@_#M1KE6)&QOZ*?20/U1>^Z+Q_FWCU=L71?1)KOR4.1@_1.M^%1D_H\$1UIU_O\$>H?
1+0ZGT063Z20\$TSF1XCG^8'Z01A&SO\$Y73Y@??%_W_M;_>#7POD1^T/V_1%>X1;91VG5M1^F_M=1HO1O9?6YN%)
11MV"E^/71C11^HPSVL1L/Z\$GX_?H;_PW<=WYZH1B^+M>1OZ=1T3>YQ1&14N^P%
1<1IG1MX*)+W_5^MAP>)_PDR>F.MWCL_"=+XB6^?1^>_1=R'B9.G+?SP9PY-016_-GHB^Y.Q)4+
MT0UG;E#C#VJB)R-O_(1^A01Q_1^M<+(11KN1_@K=B".^4T3LQ'W10!;\$(<^M1(?*E7YN1;
M^OLG1_1OQH01H1V%#V1QE"UL1N^CN1B41>CU11#PF9(CGE_WS@OPK#OQ_MU8V4P3EV9YZ_?O9&^U;VL=-
_3)X_6TFV1?1U^L1_N?)1W1A;_7;GWM_M=OJ=1L1GAZ+1K1GY1G1NB=2E2Z?7ZYR=/LO1_1H1?>1W01B-
_1GN/O&1.X.W_M@1KW1C@*_1/8^7^P=@\$@1>O(>U*^37Y1GEG1?>1/O-RG71SH_MFW.6R&<1?
11+1+1)9U;_31Y;W8^RY1^1?1>95A.1#B1>#8HX>211PX_MS&X^123-
Z^_CMX5D=SIMC1V>OUNLP1L6Y#D^M(^180SK1W>UR1171F@.23_MMXV1X-GXJR+Y6_7TY\$_U;_9!
(ADP;-5A^_KPY/KAVUNA(N>A\$M-9M1J&_M'B&;11\$16E)1_@M3UNW(>1@5*?ZDH_>4H3=31V/XMN^_RLNX;_#XFZ
M7SP=0#J_A%(HR<9"K%V(N'KB^6THV\$#\$9R)*YQ@R/@Q'LS>&*"1H;1N1S6"1T?M8'0_1M?Z;LGUT&GK)^1!_M
^GXK111*3;9>PNKOL92?P29Q_U1M4OPZ.5M60^ZN/5@.5@F2G;B&12F/_M%"WP4'5QT2&Y5\$N;)>2+&+&\$%C%D=
(\$O\$51V=A/_9Z_9F=>_MC/D;SMCS10C2V41&;Z1N_K6#Q\$N6)_#4_HGNX/GKP_XM1?^UP1&+52-KV_M2=*)88QOQVW>;N
_XFR%@1=P=47;+&\$S@\$__#718*C_26VHK;"JB8X.01HWYS\$ MIO_VY+WX)8GTZA;4#VM1F_MGK;_N1.CE0_1R.4KC
_-=RZ(T1.1)>(+PD%L1&P%\$S1R613%*VQG/_W<

MZ(V7(^D='SO@TNGS9@YH@6VD\$WL4SPECRI_5^O#QJOWL6,25Z0A*(=3'PO MGCY:9+FRMH0996_E_)&RB14'E|>
<|D;H, PCT%ZR>%;+VZ%(YOO';H8_M,JZVW"4*3IP|<\$HOOI|YHY,4C;ZCOV+;5H01_-\$;S_T+_O.P)_"(P
M/GVGZN.EIE1I9NC423C6/WGLQ?(1E1I.WSROAN&_'Z-2IHVCAUG-7\$0 MC,2)'X913?S+ YX4I-E"D2I(?
5IU*)60/6,R/|>|P^>, />X/X\$DO!)#B@*=@VTEFIIT2UY^OTZ|7|JB_KA
M(EOQ^27N.9B,W+1^7N^6\$B3B(L=5),7_#<Y-Z:D7I8\$2_A6F1#0X%3_M>=A>@84UJ8*5PQ=>/>U/@W\$_0SWI2+3
&[SO2^M^+I>OQ2-%P=H\$KP01V|_M*|EBIT.*|DM_3*/0(1X<|<7|KLKTV|O*^Z)CD)CO\$PGVC&1TLA%
M=>\$;L'.912'02#|O)&(9/;I\$GJB;>_RBCRY#/OOX%85J6%-*28W\$"|5W_M#5=|1A<<_32^!K0DYU_@,9OI)_G#0_X"
|/#FO,>(AO'GR'NARA7<>7/(2#5_M,8)3XIEH#|Y7Z#XLA#V3SC\$|LSU_.L<8_&Z/>*\$^2WW'GRWHO^;W%:TPE-;
|M1\$>P_9GX#=>/>K^<0=QMXL|OCY|+2_MDE3\$3B>*>|B)EBE(S|D%KMSB.Q'QV,W(3
^4SW+^3|/;&\$T>K>H0;Q9/42\$LPD;Y28@V''P0B,74_M&TY_&43/WSL9/IQ)Z_5;I\$X
2>#>#>=<+T5_15JM=LG)WF:_M%CV:'A'^@J_MB.+^R|;|@C14C_00|HJXT2)+#82;
|#Y\$Q<_'GBJ0MR73P%/4"1_1ZS+>_1MYIAG8Z_RUD);(9H@|>_XLI5J<\$^1N'#15|J00;_MU_?W|Q8N'LC?4L4<=CB
MX_<AB|NZ4L4*F|/8|_EJ|_2YZ>|/L|M,8|_%L,2I0_<LFH*_*|L*ZZSXF%J_MP-V=NO'(^60%F%BY@PEU(W91L_?_
MA@EB#Y88X"4Q"!_0#/?EYC7_\$0W+F<"M++QD2A:P#UHB/.AH@WBI^@_.PB=..F|WCYK|*"%0GX|S"G3S|H"
|NW#_GQ>16_MG1?WC4BOZJ9PQ*6.1H>|_%VTOTW/!;A18'J5FW-WV=KO_/C6N\$E)F5AV>UX#X_M1O'?
G3L1B_21,9.)CN0+>J,7^U00+>PG3EMSP;O_M90ET"/+7VYW9;ND(=M6Q;L%V^S6BIG6_\$D9(8F4J@_98'Z8)-A|D!
|6_M.MG+J=53+XY3&9D;./+|U_#18|'BOV&LUF(^|P"3KBQ9IE#XRE_H>JNQV&
M%Z1U#9;TJ4L=-11+KM^5;K7N|'E'3|!\$&GHSUX_1:1S>I(OZ@2*G5\$&|E;_MN&DR#2,0'B/E%=%D26L#"*F?|
(^O!|?2DV3OBYJ7\$CRM8:C"N_MY3RCE2EFSS_|<?6?_?BS^C.D5.?G^\$|^%A&_CB<2B|^_4WX?&-1%D%>%JR
MS@X(TIZW?P|Y5N#&K72#%LNOZ1"1L%UAAPU%QM/I"N8RX59T'_M.M|5KXL?-(JZ?
@)VJ.=PU,"\$)=EPRW#91)Y;^|4%QNV1SB6W/VC841VKV)I|'_M_O;/UTVDX?8E-
90*Q%"_TT0)|:5O5&|6Y^|/0T*#\$;G"6Q52B:5Q_JK?._MT8S,04>@J@T\$|H0&WRR\$6T@U0.PZ/5Q2RC<\$|_
4%#2#FAC)H21H|\$@J|H6_M|/R%|="2CU,PY&,0=T#16H,IFY2I(B%&Z^2_U8|>\$92Z*G|H\$@93_0-/!_MG|
#?)X>A1A%&H=;_P1.^3G12#=.!%O|E7(7<9W2AC7)P#5=|RK?1Y8V9<6_MZ.#PR7L@MR(AK)(?D"722T4?B8-H
Q@S|Q)4AZ0/F|_%2KL_A(18;TT%|_M@XKAA13';N**\$^>_*>K)UK#9M"VMNW*2J|+8WEY?;5C>?5.'!P>U.\$)UM4|
M|JZ>8_7T);0D?I26&|&#(C)^MN,\$8%T'WH*BASP!'%4\$<%T"(\$^J#|N"#3|\$M"UD-1\$&40.4S*/T4%)5@K^2+\$+
Y|3|9A'(B)E&X2*_*JC#)B3KLIZNJ45_MQ_<_WJ_L|H@?=>UXIQ|>4|_CT) /;FY?D)K4(W#@9|HJLV;*|IEUA
M%CTH>ABV|^#17(ZAPG1PVI@*>0<_G<7M.LV&2^V2WM_-COR_L,D^+>4@_D_MV?+U,=+&,1*+H5IM?
NSCZA=SC6NTZIV33_Q^\$X'DI8^%KOU<7'90.+M|JYLD*_N2!HAX"|;YJ_UI3%
|W@%T=MUE|K^C&U*R'WWN+W\$#|'(\$8|3@6|B_M>>%'1|;H0TY=17S=7H&_MN3Z\$|!|<
/W_I4^TPI\$W|B)!=';_%JP'_L%NK\$;_W>=M'0_5&G+S;+|@WA|MH|NZ8|DB?|+C5.<.\$+D3XEW*
<.;!|"ONG7WWY9*1.\$|;+XA/MNKB_MU<%+K/AZIC\$JEV8U|\$46A@Z|@'C;=.;^5F.0DF.;8R|L,<&M35FW(-,\$+*=
MX3AJXD0"J)D=|8G03O(R|M7;|OX/V1XX8D9&T@BCC?;XZ;_DOCS,ED_M|'H:WT+)"4UW@|ZR2QI(P0M_|H+P|4*S:C!
(HF^CV,7_+M#)|E5C_MH84HQ#Z;(PKY)R48+&AAU_7&JPZ<%Q=8Q<5D*6LRT"E">"IO:Q"@2EV-
EDPLZ|@Z|/F|>*>|H|+(NM=>=M7SAFY<%|H5E8L\$|T;3F)VZ2DZL9QQY_N%BD<6=+N_W+-%|;_#R?P=
M@R5;Y|RSTS=/WAN#|89;@U<'M|H#BMBR'T>S.EV1H+(T;D)H%UF5%N|>?_M%7U&#+K\$;|6-UA)KTY5N=TI*3X?
|VIC=CK|/S|_G7W^K7T;?Q\$?FJ>_>=K^>|UM_B//N6:O=/NZ2*N>|2FB_Z@I0_!O|H|M2\$A|T)'YC_MS,E=
M%>MS#|H2G)|;BK,=T^%62YU_%%+N^<2R|,1HG9WVVZ?|GE6=|>|H(X.?*=*
MGE=;463P=.#_:/P>'KVL&+1%|6"QU+PXSH6^*3HGL>%TOC5"M_"_W_Z/1_M9%MT4YSVNV?7VE@F3EVEXW>ZP#?
6>|91E?MAXS&+/DJUMW=GC>)<6KC*\$O_M+L>@U9N^|D^O'GG>QL9?E=M|H0?3X|^Q4L-
C#IX),OS10SEVTQE5OF)|<5)ZDXR/G%)MM&7G>|/9YAYT'_MS#D:%>.H&,>C9QQ;:/9Z;>_B\$9==
(|*N|T_|#IRL>=;K05/^OVX&?MTYX9_M5WQIGC8_MK_(Z)Y>BR;Q|H>NUNKY(U%;MYH_"7-3%;UV#^X;*K4ZV)%9S
M4<.<|+NBEX?DQ>O|J\$4M_|L>>|H6|O|7IKDK;N82|5<@GTCU;/>+EU_MYV)8%|^V_W@D;I2*B5L,I&
(B6QW40\$SDJ&XS\$'_AXDTK;OY|W3/W;_GORI_MJ_B_@O|OTO_KI=-_LRZ^GG;:/4ZS_SOEY
3)_PNG#>P8;_:/WN|WKW2Y%5MY_M7_3K;R9NMLY45=G)VWNZ|4G^XDC|=)Y|1YVNHT/XMN|^|=^W?Z|+Q|UD-'
MR.XQFNT=QZO|BL54+;_OLYC&EG(O+1;SLGYYZ*;|Y?SSV1_M|NXQF"UJ,J|
M|E,QF\$?/8+;;^X|H,YE4=V.D_@;GT/C6H|4GGX^Q@C92K?|N8G1&|Q#^4/T_MN|W37L/R9>|/S|S>WJ\$<57RFXC_/GL|L-
266^_SKNF4=|7(TY_7KB00KZ|A_O_MZ6|UAY5(^TV=PBV<(X*;Q6=;\$CG|N'.DO|U|OWY3J1\$5+WGT0.06TEKWZZ)Y_M2-
Q|U6"%8DMV<<^K8B>BU6U|^|H(2S@#NZ8+QDWS5+3_|15+;;(O=Y|^|%;<
MH8+^|7*E1\$=;O.K>Q_|*B|@KZQTOEV|>;|RB#G#2_|JYWZN|2?;
M%M8>BV;WVYVYFQ_;"X|C_NG|IK;_NTM90"OV(+%?2/F"UL/_NS<82I\$UV
M%R.;7|Z;R>=%GDB>|C;%2,>W<|'3_V>93A(>P\$BZ|I#(KH_J5SWC05>_MH7^4/_.@^<^FTJNV>?>SHYO-4^1O|B1?
X/F8#N_2/D_RWGV9S>%D7_M_P_0>KOf6_OX_JU|BG|547P%>_E^VG/39>_NNB^?6XTZ=ZTTZ_WVY;B9#8
M(J?KQC|0R;E^PW|XY0\$VT^";+S|@*K_9G|?ZG3FL7?Z*|^OH'S'9WT^<
MXLM6'8S|_#HCF-3<8ON=+1LO3^H"Z|WT8QNGOW;_T&1Z0|@7.I&Z>|42KW>UW3OZ@%E7&_M^JA8PZ7\$=3_H|_
(^|X|+W\$*&X|N|Z%SLGHU00<0^|^_WA^0_!HR?_P%E(*7W;J_M%LFC"=#L'J.Z?W+6;7<^GHI_?NUV>L>=ELI_M3LB_-
N^S=L^|DYI=;T;JG4_MK>(5%;|XU+SB-O(^_XF3,J=8RQ;|C|)39R??>|L;_U2Q0_JZ^|Q|B=,1?_MZZ+UOX=V5U
MRSB;MIV;ZX|VJH_U3_BTD%KZN;/_O4<_IAOYOTOXM9_R^P9SB3YT/G9VD_M|Z|A3|W(\$OW_|R|B|>_
|H|Q_+L_C\$N|MLJ_8N='\$@_?@H_NW2_202Y|H_MKJ";_?|7701_|V)=\$T_ZH|?BW)W(=[#;7ZD_A@#GX3MQ-D^|_(C?
XEM|^=<_T4T47L|G;Z#)Y/?A#@|X|X0\$^P_,"T2#N,>7^U;|Q;|&8322D?GL_M@P^\$(OKU|^|+|2IT9.5PPC";_Z5SJ35?
0Q0|H8^R50\$178YZ)|Y)WH+>P_M|<_A0D;TNG?BU)U)/KG3\$;_#LW_X7/^23@J|WIS1NC;_1+|MC>0XS""=>=T_M(S;
+TL_QK_U3|E"A_S|UK|B|5GN=?2*|S1|Y|@C\$T;61#K_MN56Z&+S08_N5XZM;OP^N#N;7'<_M_2Z3B"2J1<+PA2H*)
(SL_H\$6\$@3H"LMQ_<^WDE-I(\$OXUB\$R51&^R^6CA>_@#LGI-7CO*+_DUF;I?_OK@8/I=|H@7TU;|QPWDG|A(DPC
MT9S|SX;PJA@?;PE;K04)=0EG)7N<"K"15A_/?@+5^1N#&#_QZE@2LAS(MGL|KKZ2'W(H24F%Z;_7GL6-T|46D'_|*
&5P10<|H_>;<.;|ZXHOKS5Q/M?2L4>?2_%Y|B_1W60004*U7<9U0?>Q;FYB5O_Z(O03V=>\$*8QO"Q*ATD;
M@?;B|B_0;JPA)=B(4S,40IQ)LE#UL0@*U|WP6>|H|MC&9'40^BB|VFR|;
MS8_=@O8S#&=S=\$5H7|2A8L\$U|S0Z"MTKM|YMI%Y"|JWQF=E?JOSKNM_M2'
M+|JE";Q;%2O&HBOGZ0"t&=3N;T;ICPJ6_M%|_HW".MO5@R1OHMN@9LJW|0)O_JW#CIG?_QR21\$5CF@;ITE);&E!;!
|TM_M|/%G;|X5_E=;2&THL6GZ<1&#|P\$7_H8;_M;+;%E_"_&Z;1EW@2>0%170B&2"N7N#GR.Z'83#VHADY<418'&-
|>:ZFO\$;KQ*X0^|X@|H|D;|O|H|VK^_M2C1C4\$S_D_#0^(@H/*(PO^|V_7GP/_MH2E_H_F9*G=TN-
RQH)9C;EBA()2R=Q(Y9H|?UMO|Z_MOI|0<|P#PR7;R_YH2,\$P'(0@G\$FA"R_\$SUD|Z_M|2*5Y)5-
7;)*Z_|B89<+EE\$A5Y|1YG+>;9Q|*)|SKJW1B-T<#L_4B"68_MB#XB=B;3|/Q(72C487A%8;O-
H;K9|=BYPC|TOQ9IX76G;2X|?YTIYPX";_<XT3?>ZJ|_|+0DTP97Z34|K2J3_MIB*YW2;K|V_U30)Z(|_JO;H8A;
|O1K'^3@N|OQCGNCPD|>B5Y)^<^C7PL*R=M**SR|5<\$LN_\$M3@?&PV\$POX|68V|3SR@B\$V_XK%1_@Z?
L4P|I*_M_@|176_M5UA_S|^>TG_<2==/H41@|^|82Y/N69Y/A'5R|8*6V'EU0E*"6*4Z'C7"<8_MU|_5P
H|AKN<\$3FI5V.WEC";AY%KT5C+7<(>12?&CB=L;_O?FO'A^9X|^'PO_M6=|/|*#&^|AX_|2UD42+5_2P52*T-3+X5G|*
|8;^R8|ZV24O_H'|@A"NBI#&=MQ-|N|+YMN;_<R_#6IG?LGC&1HH|LVH|6LOT_"NSAE0_'KP""M#='|R7L,I0W2Y
NP78A';(<|H|A|^9JL8|NJE63F'BQE6(I6-X)'LVTB" M|_VC_(-%VUPE|^|6O?+|+5|?

GLE0& P%\$=""TSI_3APOLCB>VZ,"D)E;N8 M84D#ZEYB&SEU\2EC/4R_K'#K;50?I2_28>/H10!6,,8N1>,
MO*%JP17#%DI1W*X<_)%> HW\$2X!#M"B;I-!50?& M>\$AOI/VM4=?Y_8TN7TZ6 (.P545 K%IWICGS#
BTG260M1JZ<9F1Q3#PGI M#.'&@S""I3U #L@R.&Q"? M,W*K-N3SV8GSS4@+JP\$?XBSJ7J_!<4&.UF1JH5=-
YS"RB;Q0V1KG>&?PA<9 M4-.361?MOU)0E!PO+BP&QY^\$1\$XD4=%;1P)E57N;D_X&B48;0.&I<.RM6P MP'X;
<*>TJJA8!WNI.G3&)NNXC_9-@EWA.QD04;^<2&I.J.L/0<)C.4H; M.^>AV_0" E@QP=#C#35UPSA<5AJAI
<*!C8>BDBIF/,%FE(UQJXH).I09PI.NAL;7FY2^R&IX-169;A363RH!;\$V.I/X-N4S6 MF)TNQ;\$0"-H(2/C
N'+,5S%P%P%)*: C6(@94 F#"V_9+;"XJY9CX(*Q; MTVI>(<#*&9 K_DZ1=^ZB8@Q8!UP>KL6QZ!OR|ZRL\$|
(8Y!)6C>C^LOXQ2\$ M*/0%?D.;V0H18>O!-L.;#T"IG_6B'^F(
0;KVS^E61=X^BP&JV^AG^V\$1U45;G(DF@CP6C3=Q7M3% M^V\$J"\$JLCRPB;^E-M=YR";@021!\$*DKGH.T&;J?@9
M^U/Q4Q=-&IS%._%>I09T4D#0M.;E3R^Z;+I|CI'#3"XF<#Z7MP^2L+Q_ Q M+GSO&YJ>2;BR%)A9
*CK/RQ%"Q/&"K/L&KFD L<>6.R@;^&N0=;3M=7%I U*I M0Z#0C;JW48/^T\$X5%-0PR\$BA\P)5
M.SH1TJ_<15@C=- 8!A&A/TKLZ9.^;I5OC*6F9241123L;P-P92C@SZ;JBO M.K)QP81H ZQ;XURN;E!5#N0=
<""C6YD2NK[[V]L(IU7AQ@IC=OECE3PPOM=1 MUIVE5L;JU:2\$FY?X;D%L87"QA@<4B8;N65 M>[L5\$=(N2J81+,%
MR@8/5&R1POAIA_&(S9%48;*I-U?I2/CQ3_X&H)EJ;M%3<0ICFRBOR93#I/Q/
M=.TOO8RG>"0Z^\$VF.WX5T*/9N"KZOED5^EE1DD5-BO;@NXJR*LK;6A|PTI-!>|T>B_O^&V0QAA=X5 M>M!#I_8UP|&
<,U3G>29;YWBQ!4;GLN@AEI_&9!*6E5@A=(?1.(K0;Q^EL MSK\$JBG+Z2!*GE>9.@1U*Z-&I>"\$PH!
>^:F9T3L;R/Y=B@6E4&&HD@9.NRDY M;)=AZF"X#XBNP-#RBEZOGR/C?_@|G@C@5FG;H?Y8)TZ";^4Z7E
MLL5%"85>_ \$V.W6\$21K\$SIN^A!<.<@*="I1U.SCR LBU_E,M>=I;@NNOC;_ \$YM M78=2^U_8@);-33!0?
I^Z>#P7DH*HJN<#O@3K5RY" _P*W)(,++PD)-Z@|> 6! M^&P@FDC.?DW@-JB\$TE.IE5Z""=.4)A9I QXZSY9D-J(SS:2(VI
(>6;Y=

=;"W79W&4K8L-6=I_/CN%I=DC8MNZRI MY1SIBO)4K).ATHK|^I|=>F#2J1&VS8FFPK1BSCXI&<.;2!@-F10.PJ;H&W8
M=*WDU9_6D*(B>._V2-4AT'.XV!;=.;/?^PT6Y_H2"Y_6NDJ-@LZAN%=5#(M8U>BC&B%ISNTPBQ;X?X.K?
#O@U8(?;6MTF10%50S!CM7*!KFADNFQ|HDTCL M("L;)SH(-\$H(.7>(>Q7(L7@";.&@\$O.96LJU&;C@?I"D0A2A?
4EG;|X(RZ_|M)AK71-X_??70@Y|<#" \$O7B^RNQRYTQ-#HC28982AG*16#R+V&TP(MHJ?L2 M+AG4)-
^9IGXODG"!|DZJPFA(K_43O.XODA%<=IP M0M@Y;A&5R)K&+N%CB(+&F_ |DH;\$!NDF(&.34&-
F5&+H6_20U)BB;7^XJ8 M8(I"M2D;5\3O1>66BC#% 5#=#!\$4!U_ ^1.HN6XYB3LH<)0^T94B0C^G/_U43_ M-G&"G@4?
7Z_0+S2=AS7 JX\$B?W6|^Z+ZBP|DT9TUY^J%DDAD| @'_ :\$.R%U=OI? \$B^V5^RLB|K_ ^Y")LY"C#<6.47(.TTI0*JB-4-H
M=V#N01(!6?^<13_7@_ M!#1B|XN;U2O(EJ0HH5)YO4"YW/=;|#>.|R|")9ADYQ1^1/_&AK
/43_ J|FV|IWB|AV(BT0Y;\$WNSRKU/ MF"C=;=,/*R@*\$L?3JCE_ S;I4FZ<\$2#_UH37;S8F;F_*C6GF37X_G9 M^)^HR|48G!
:&%U.X#HK41Z%"_01YA0*!V3*P%R K%"BD_H37&3MF%*C M^B MR2-V27|34F5X"N98+ _\$C_)R2TWRL
M="EJ">+Z6RG8\$G&I/%AG;GJ>ZJ|6|38/(!#;3=>2^P4*L89_&'R W-^T M;P"8B5I;+.902DBH^0*!@I^K5%(D
B*2D&20CP=|D2@%U3^L;X@B|X@E;_ MC#5)C.8;JDM<8/%1QSRH.2)XV8/(9DY#W8S=43>)6XL7P LR&@DX4%&6)T4
MXL;H38-N_4>.50<=%@L|08IV#I#J4G|A@.2I&^&#1&D_O;.#DGL2 MGDJH3DZ|32/%!F_?35P7J>CY"ACJ?
A:&Y!;IP(ENM'7_F#J#0W/3X8_T
MHT(=M"LOE!5)UB+0F0|LA!"M"TO=I@0=I!|\$RZC_ER0A9E0#&PZ*Z&B|>O\$>/4P|PA<*+K^0--5X^<I4+/
MRZ?I66Y#&H/%=T09^1Z%ZJ;LXG' CUG%NVD\$E;_#8ZY|T/2<I;Q_>>ADH MO*G)*;/EQ
L_(1EYJ3+BW13DG06OF|F+RNW>C|P|IG>;1PNP.?D60-70C/I M\$OH9%5&C@;.#@I?Z;.W/485&
(_42HHQC8(HY"=4=;4715;PHN(+*A2PX7PS MTWI_J_2(LJH|I%?LB_5U*|C\$|98?
QEIHZ;DY<5EV1C;Q(W\$YS&^'=84@@-M0!KY!N%_#8Q&FPBWIT3Q^6!%EF5NBIXE@@6_1>S(M&9-A|3Y(V;)/0V|Z\$*
L|EF#;FT;36L&V^T(CU_TM)DUL7PU5HL%>*2U M?VP4*W|OC;M1YGP-O)071&+GKA4|I1WHB01S;/*_IZ6?
JZ<|R;AN29"KE|_R M91399/*D/SK2>M8P0|L\$^G|I(Q?|R4HS@VF=<*;IEG^M^ACH;3?QD8*K\$1 M.#PB-S?
0HC% %LUAY|WOR2)(0DK960S0325A8IN?;%_D(I^I287;&>\$4>P%)MF=I93;-;HK|BS^ MC!M#1W=-@G=
NR^HD3M@JGU2#OI|P2X/YN#?I#>P7|4#OI6N^0!4BXJ6L#T M<-0J(I|F"P":3_*
ND2_*;1"SQ=9(CHDX25=A@!\$;M5=E\$W7_ %WT;+NO.P184YVY0_4 I+|5<< MC0M;=E=|R4Q8MM-OA/0D@9;N>!
I_39(%A#WPLWLA8*G M%8=-8C%8D|G;GH*Z8&M(26EP1PRE&/1C#VVJ479EBDP13I%;+@U;4Z/V#6#
M4.J.N^16_"N\$K_8;!!4*+MUFT|P;3I2FI?>(IQW;+JB.A#_ KVS)=6D<9 MW.\$.)=RP+5G78 M2)E|LHHNP;600_63RTM|
MU2A;+=R1YSF>HITVROTO;C;<#7+YIG;(*R>. MU6D#;?QH-(W3K;LHFH9-L/U.3H#?26*CWG;Z;|T*|1AXXDMM
EE9@WEA*% M^R9/T(=1_1SNDG0%-X)=AS6MIDIE=UE621Q7")P6!*\$O6;3*BM8XTM^Z>X4^M%FEV@@%.-
;R7AA#E1HU^NTO;.:2MC^W8@8;.I7NX=;\$W|?0IY@6/LJX7SC MKF;J3^U(8?Z%78&)0>FB<)=VKXRY6+
^KP4N**AMZK_*;4|M3Z@S4PWR0|4X MQM"A>96|B2;I5D+;C|"EH_#\$M_2P>|6%#|>K-G/L7_SPX ^X41>UC G?MJ9;
M"E(>;5X5M8F;M.XX"W|7^C5G0_H_XS1^-!B5"E:>895S9TY M8S#QZ2UN8E_8YJB|ADH>G|X(+&|XQ"Y.)&\$O1?
R9|VW|^)FKNYM|L\$?963Z M20T_!J*|S1R9^H6K3UDJM190TAYB4I|D%I0#"^_VS3YFMKK7=^;6|3/32PT M|I^C-
IGBQW%<<^" HT<#SIPI==8V_30Z&2/&>A8EAOC.TC0KM=B20#T?S\$M)#H2I)ANCI8W^H37=9-N=RI9^V"
|XRSBH9+W/#53EVUL%#T+4 M2Q;O-2XOAP)O>B8\$^W=3KCWLEWGQCB&^ORM6^J5#B;RI^1L5_LDB/J_G32
M;BLR13PFBE*9_)E0@R@;C|JXK04R")SS740"S;8;ZMF#6!K\$R#|ZJ|MO M@BUVNL6^<+(-;3(&_"G\$QA8ND?
SGI06|3TM+X\$ZB7=YB-RH="BTGDGEHT; M!@O;BW3 M^2K\$5K\$G|JYH|WL"|
OXI3ST@QWDXP^4VP8YR9MA_+Z;Z<8*4= 72P!G#^RM M8)!<2Z;C0X*=3Z4&V^*_|J;K_5A-ID<
MH@OM=KE_|FJ^X^*- (4XJT%L3+2!(04Y_14R_*#;DK>/\$8|A EMM \$;% M;=#&X)I2)=_EK4^>W8!<
M_HQM)TL&"XGN&19(>_?JGSU=5M38 M.&?
*%W0A_9>XEGBX<.>F9I|EB7!%YQ=WW+CE6#00#IW6+1S^@)FW^9E"->CQ-M%W6QU;K|YW6/>D)-
<7HH_)!4\$PP4C^PQ21?#|P3S)#EF*;R2U7-ENP|P6<_M
#8;Q@2;Y1BR9NI+O#5JR3#;C4*CHP6TFGYA6W*-1H5(M%@#"+&ASS)>| M=0&>BY
FSV;F)"X8A!QS6R;CMYR|@B6!@|H.(SK)/9\$F)OD^N@!7W;0" PQT_8!8|^! M+A&Y|HA;-MP;JTSIU;9>NBW/HNB?
39UMPZ?^4/+SP^>IYD#7X_X/FK M^U-/U%Z6_Z(QQV8#"I AWL<< ^3H@GL4G>BV/GA;L3+K);30P83Q1L(N%PL*
M%>A0KL6|55+Y!0&8I@3;H0H_X'?'^+K|RTF#P-G;9=GRS0;G8M&Y|M<
MVR<0")4^02G58.3E;@_3^&WKB^4)X5&M^H6R><8IF)16P_DT9#3D8+0|HPY+ MVB D-MHA\$3J^98BH|B26VID-
&^#0!_"K>2N)JHW&_9;WHA50<*FE%YD|R|3 MN+<5R!9\$O@V.BFX/7IL?I2ZX\$NOVI&3.T>DR-ZP(7-|Y|*&40@?
MJ2I*085 MYL6)+%D5S<|B4)O&E7E;0V=TDZ|=-|U(^SFR41T")H#|+A6=Q=T>\$3(+W MA;%Y3!42|Y|Y|BUDNH?
MHDUB=H21.F"/_;"N.I?LCM|8@_R;|614?NJF M AJD)Z&4!H0++!7)^UYM>8;J|0WR918T1Z=- (/)!=(Q|E4|6N*
&BPIEK?MMV)=S=2I\$ZQ61.HQDB>^4_Q0+Z0#^+&P9C^ (IDIR%E4!8ZKEA=*9\$>AL;G MTK)1Q<9VZ|N^X!&=-I=I
<9V>O6(C%V)INC SA|NZ5Q3J|_ \$ 457N\$;0GC&V|*!S|4-G4G(9B6_*X5WU\$;7 M_L_?>HCA5|C|+Z?K-%Z?@R"@K|
;M"-5;PZ0Z> MI*8;|H&ZPW3|+G9F8^TFC^|M?79R7<>OC<;L_G^#X#R+M_\$.;U/Q^DNS
M08L*O\$D@I20G4.%_&UV4RC^IL7_|POS0H70K&%IUL7&>5F|WR4\$J7&CEV(M6E+B8HFJX^Y-O9WV^<*>+1VSJ|
(EC@?;3>D@TC^ME|U<I=M(NXD|_K*P M#OP3^XW/VZ+OV62;HQB|Y|SK@2^9_-P>C\$B^0N(P88^N> M-|@5S#(O?
L_B\$4WGT_#%|!^I7UE?>D;5IB3X9LT8<&P1G8!G&>FJ|+Q3AX7 M)"KU+68|K)C#;I;
;6!Z\$ER#;DAHL0=|RRWDMFEU>_I+NMJ*WQ*!@> M3.YEO-#1^N4;+K;_-9Y2RPFK@HE&'VS)Y0_2X177;I6T
M>DM&Y;>^/D(6J#O#QXOK6O*9;7;4:@FGR|0N^X0P>ES1)K-3OEUBW.X&7GJ M7D(ORY* DX\$-!K*V;\$-?=>+ZD<4I

:22A)%CA=XB\ N+FX+TSA6JM7FYN^0 M&SJ!>D8ESW!D#4?/G_YB7GL4V53VYA.RVR7WMWC'.ZH30*J2N!\$6!;E
@5F@1 MD?0%WK'GX/A.1KD>_JC8(X5EJ4_/J&VELB<(YDC:HL-XEI#9BSXM6"-_GK? MTWY W;8 _&KCOJIS\$
N.250JL+ /IW* @EK09PIFIEJ071.&#ROW".E3@1E/A MN=|V?|\$5.A51P.>25DN4XH&L-?'/0P.,NJ#<+
MZ9"IT\$TPHGF,*9RO#B/BQMTG;VH2^4\$C.ZIF#U*\$2.GVY3 + (ON<(4-#W2 M*-8V)_%#R85-
AM4)E.PU+UDTTH'SBL;H!#1DZK0? JV2P_7(\$.PPJ MMV2 B&WCGF*1KN>33TR'S21>2+DG0;4J(6I7MBXJ0?
RY\$!F!WI(N7.\$^\$BCAD)GH8T:F)D:63(V. MMKTV760\&#%#(\$69W0\IS) %_.:QA2V5@E(X-KE9+B9EU_/JUT\$X/_HZV-<)
MH"+N9A0.[23/PKXE(V\ 'HQ?>HJF956 "-",Z #13.5BM4F248KLM@_#KN|+7(M(W06>!--P-R-/1-K_!J7LJA;0J&8-
LBAX@_YUGPX3GJ#"\$45\$Z)+\$S3&BUDB" M#T,\$>-GFW#5-!4!X=-!P-^W0W:7ZH?P7>2T@M^F&K7&-4)LV;NW-
DWB)7(MNUG-1E:DD^+LK@5K:Y14^#29NK^XWR-!9AQ9Y&ID1K|=9(Y'MG+@HM'H(2 M-2_5@H;U=ZSPJHVBWNW6*
!MO\$L*RY08!"^Z.%YH\$V? (5G5ZL0N4_ '(V+O.HY M\$K8J&HD8<>ZD5XZDX;"P.U\&
MVB60G#^&TMX!)YTRYQ4)Z\$CB<[7FAKYJMR40&>>CDI90<7PSJ>"A!U712 MVV&A!8Q#J L+WS[<|.K0!>4
NJGZ/PRS-2I.Om>9DHQ/G_!A9-!> 5*66G!ARQ;O)M_ ATB;4_ V8<ID)PIANW*5P M^V!["#NDH*LZ&)6QH!)GYB67?
!FA<8;WU'S85D1.B!MIV?@OO:Z'IVJ>O/B M#5;_T2N29M8_=YWI^B.IU)=8M:*&@!@BW;ZSO
RDDP.W(8UCH"F8=\$D*ZA M;_>H79?_1Q0HV"6&38BLX HV3RY10L8 KO05AA9CT0N%E+ BZ9HRBG28_Z@^P MQ@!-
^;W4CK_ AD3#+P'3J?9W.FV?)LOP!N97(<\$9=Z//D"/^7W/Q 6Z""S"^H)8/O(PA(" TW+C=\$4>;Y3V4X40AD@QY
YJ62D\$P?KO<3UZ'I&-" M\$5MXI7U^L_3"M:49TQHJ9*.;PV\$1#G>E.@CB^UFL>#^Z/L'C'PILM;7U" MS#-PZL?YQ?
HF1:AA4C.@VOX\N?>P#>| KYJ2^='(ZS9AJ &+5EZNB-%&E8:70MCI=4Q6VY;IL MKQ:9#NIA!HQ_S
0^"@=-M;|!S^+@^!UP|+!\$!9'!&N80U1T67.;):.4A) M"Z%LAU\$-
J6*7KKS!CE#M>7(U^VJQB;1W)LWCIU77%VFN459S'DLRZXV^1V MI"1H2Z4AYJ^WZB\$O"JGMG^9%(^ (D*KI#
G)."T"K&H0T+&1^GFI?>@X_ H60K? MMP247F8PCU<JUMAOLX!7FOT6\I+0%_A#)*UX)\$W>J".2ZH0'@ X4V=-6QK
M.M!-U9\$RK;&K8:XU+1YZ"[9K ?D":.0WN.CPBXFP0*@I%&.!DUI"BT33=@NQ MP_ "JIKY.8;|)WF>)LP11UIA#U!HKQ/W
E=DH0?D'T1^!\$E3J)V%(1(#Y&|T=EG+N0LC%,&A=94R"% MN)%#%(083 M!\$B_Q-M'D1-P29'5O
SHW8D),P'1K"W#+WAA*\$ GLG!4HYS2JS4EQFX0<+*M/RQE!?)&K.V0;O-
30D^M)GR'RY40V(S: ^SLM%IX"5CJ&E05@XIC\$+ _D'1^1"3 OF.!.*"ISY.LI+* 67I3P)N9JHMP-)HEB
MJ3>)C:40PORG>SJM\$>\$VW)40;_<19A1\ D\U2X0+B.OD=(7281S%:XEA3Q5<
MDSE?"72'/XT8(N8LT>0I')#JN>E(I^*M34MN?2"% (A;_<1\$3.V4VXAK9F;6 M4X*AG_97R/27 ZA%P1#H&" V>
<\$45>2QYM=.00J!_.\$@<:Y1% (H)O_7Y" M8F08&>88TZA8YS85\$AEV0LSYVY1"D1")% ^C73'
M+IOXZY=\$A8A\$AES<7NF\$-00CC#Z&\$S/XXT.S 80,1N9LA\$CYFMMOHE,LO8\N'F<6;0J^!RBV^%=-..?Z1EN
MG0>|_2KG=X86D(M0K^@!1@;T3<_JL.S3L:9!B)4M+ M+_V^<;8=WDA+\$\$T!5YXK!12):U1OBTI@_0L#(B7-
E,2)DRS>&M=AH2#2R1\$A MXT+W^YH7RZRLS|WJ?;8+Q4+4BY&KV2*AAO=%-S<9|BB=D86G32|25M*D:(J
M/+X8V97IB!>5QX|D NXH"(L5(0HNYQ2-XNG@S\$\$(B'/(LRVYI0*F!)>J\$7E M8H.C# HRIWQND\O.RDJED^O?C7-
L(Q*?<< 2U6!%:08MBZ00Q% "E=O&3)K MI?3^|M-1FQP2.V/6CY?KBDPW7&=-!OI0Q.3H6B'(3"H!K<>AOPP'7
B)PNQE M*?:S77LKK^_1U;-I Z3PU.S.H N27'-Y#|I3>0/4CEL;|LP4A(CXOT2U?G2-5. MQ+_Z_I_?'
48P767M.M#A<22#2=FKI4R# M\J2B\$F.5.&A_V=E*+7N/LK?1%5I2J8U;|1HJ0R!)_Z\$X3;3OBM^V9/%4
MK>%M(SE=E MANGBG'37U/K")ITL*\$V<-AD5T=R^/?SW*Y1;40BE@.4#>6F
MYLHJA&G8)\$V";.1=1/5_.RHY" N!&I4 T(2:6#B@9|>X'A;" 1G%|VS;%| MF2?|3*91(%H^ ^HIS_!%PN;%#I/RTT^X+2(
MI^N;|7N9F|ZT>RR0K|T*|1ZWFA15T*+2DF,70D)&C;OCFISU&77RSD/T?7+NWBD(M;*_
<4!YF* @6B=GO/PC;|S.+)IQW7_9T!UO6V45\$!T'T9P|_#3^6U?#& M+VOYN1G++
|F)Y1=N (^T W: ^RJ_6Y A|2>16H_WB&U/ZIE^9<|H*=- ?OOR MY&|GR=L7/QZ_>_ \$!>??
W36^I2JF53J:=^ZK|UYZB"\$3QO%EC%"Y;H/YM MDK@ "ZP;T<9G/!-=L;JZL6|+%.YFYB"K>@MK96|@KZA-
O#N^31QN7^ (U#F#PY M84NV;|Z^?W!_M%#O#/ACT?|3P|P-(V?3>2RX361E?G401656Q4M8HBWV-GN MZ.#H
4>3HY&VT5"(IM)6K1;T?GDI;(\$H@O\$&E.TNV\$;=B(P&|>8)BHYYJ1#K\$3Z3?T"LU|B.|\$K8QN7;F@>LM#FA;\$H#
<0K MK+<)(8QB(L-36%V:K C"%EALQ&4O@Z)Z\$SKBJY?K_-+U=|B=V/QZ\$6V9>I M;0BJM
K9??'2.GG=Q*SLR4DE94W1& 5|H&R6!HOKOCN(4!H6'FTP7D4<'V#
MOBX9|."U!^C>LR4,\$_|>*&%G*YP&M&G0JQ7!7S590^Q+!H)JP^ITLO;=R|=V MV(89|&WXM=;^A-7T6
(==7GSS6DG=@>V11H76.1'/UI7I?E/M(^/A1ZMM#ABK"YX/ (^ (Q0T:U3VM|O*+3Q2H>HPEPSGKXG-
%# @R!>C!F:E@5Q M";6'4TE.IN:D.9>=+*1)76A41W0E^VH1|!023.A)TCR-M24\$OI?DUH^!)\$ M=^5)
(*52NSLOX\$B!W#4=NW;(X1P0&%1Z+7IU_-'AE/G|B1B0!5M3|_<Q|)
MN!6|HU_-Y+CAPG3C"Y/KEPIM(BNJ2X6U;I^A47E>G)W#"?_W_:KV_+O)T@FB MY'L9OJPBL\$OH?4?24".Q!?
STIUNY81VSCN5EN<5KJ;|^|W">OZ.30<@6^O_ M#Q.LH>X|_!CY^&L.C\$4'9WZ3.. MR>3WESE<1?6&IQ9|
(>E%0@:HUO*=("S\$|T' J>AK?HCB8N(T*!DO#O9O%.R MF1EB.L;GP2|2S":G8N<+BJ|66TF:H0/
ZNXZ4Y42YB|&FE|J36S.1A.&2B|R2HD4JTSR/2%W*7+7!"HH_HNG21N0>7+|2|X)76EV%YU_+J*Y(?*UW=P% M^?7
R^47D,PHHT=4M=:T-^2F|_+G31S3F7"2|R;9B>:;|!3\$8E;=U3EZH/ MFZ(A0MRR7KS?ZS;(OD69WHGP3H0-
MQY"P=4@_Q!%)9VCM)7|<890>\$9(IV^!@_DOH#4C\$|PHPKF0:P;9R@#;7U;J:T5K4 |&>;MB%B7_V3H8|X",
MA^"5H-&=2F@1)KZ4BM3,H'Z6BR^T92*).)^EX4FG8;|7APL;B8^BCK!%@14 M%|I/=Z(&UC4N=;_F?@94-
#ELOVMCG\$-|!&?&?P6H@*?A>G3;\$F>6EW'K.LR M; &F"V//4MW3(VBY-2H;CRW-59?0^!\$L=6E@H7Z7AIK&R!72?
MQI4;9&M\$R^A+DUA_ HP@=X13C@IN,RT<=>Y!9!2?K.CNJ M8.(;>_OLYA"."K*<1@U2D)V3&KJ!;"OB/1&K)K-9
"55BV\$C;AQJP_>B521 M*RP|R+&I2V#62;C33YE=\$NL=-B;#ZDB *!;00BN^F#;O2|L3F)O#9=9^0 M=NA",
(Q_1//GX_@139X/*GO=C*52?"OZ5AK+;_L&YQ|9Z*HJ79% M=2|02(K5Q%8B#7G)2)YR&XO360.B0650:2P=6>-
>.TVTR&2"7S2%;Q-&E^Z MSR\$|HFUI7WT+%"#;@B^CW@6F:X932!785TS _PK=LP%QAQ\$)^5U39 AY"/#R-MJ!?
6+@&A14F,F9DM'=1|8Z|H=%")%9M@5V)O7D@&R-JBRN+*OS\$0W;=N94 MB|S-J;1&S<#I GA?
^F1.R8B'W7E!T?25J8""2++E7_12+1 ^V?R?6%|;_0 M:\$^U&-2/X&UH.B.XB#@G#;|*)A" V-
/OKRO;./XVC0/30#^\$V0KKIQ5TEO M_XO#_!^I-K"*+RO"/VG\$ 2\;MM>^"HMIAOI&.I?+7#+N.UN98;K3G6-1**5.#
ME*7>FQ*+*E 6*JP?*H% H2A+;5JU7C-2O|KTE\$3XUC?L_*/%MQ'TSWG<(E M31\$HR+;6F|FV|KGVA;LQ90S%
(|JBWYF(6+CB+M7"!S.CMA7=%5|@CYZ M-KQ\$8J|DJZ5"J"AMY>BO_?G_/2#%=ULX!%;DIA4U>\$">?
%_ZRY1RTDN7N MU/+D@%L3M&'3|&3|>\$3SNB?UEC2GVXJ\$6,>D2XS.5?AI+";.GVIE<*)M!; |H(9X<_.|HX= _|&7^
MIK(X:Y@S8)OH20&V0<4Q3P#%4DT'&2J5@OBC%"ST=)TY_0E#6Z(M36#OM1QE!^!I_5HZ|B_'D^S
|!_LO#H7;\$|);./D|?|L_# M7?6@:YZ/Y9OIY_ ^6RS,XQ*BSLX;./RRQ:WAQVG=\$PH&|Z^/^# \$2=)'C_ %BC6
M6S"\$UW10IK;7%6WL@V.TB'6X)2W/5&T'(OW5C;_!A|CQ8%|3Z7V-DIS&5W% MZMX3@ZONJA&
<5!AYC7856W)WKNE!Q>QX8P;|L?UR4*T4)#|Z40'"=GZFLDM MZ2(S7R@H5I%&|BIQB1#_K^3USXG>A48I3|BB0
GUP;JL+Z56F@D|M<_BE%13 MKK#9E+T_.80L_() +8_ ST<_&4_M^Z#\$O(DT0%_XHL)4J80XC^N.2|U3U)S MF|L3;-
OBC4;7G9>R TPV2;(A(7_P\$UM4^A1_"FU:8W&2 M2|OW|9JW7J(GTU38@GH5^W^4>0D2?9@(! MD*IKY
P#A;L<=TT-L<3YI?_0TP IFL!92809"NYV0+@^WP2I.G0PY9 BJ=AB01\$;KJOE.WPG8;_.|IZ(R_"F<?%|XE;
M/J_DMB*\$E\$!MO8NH#!@I=Y8&'D=T%R/@U47 _H|@%53S=@2K^W4 5)X9K M3ZY-PK>YZ!|O_D+23"
<3_\$D<:AB>&E-41E&H6Q_N'71B4|FX3SA_ MFBU*- M4 7./P_C:\$4(9!MK#;5>%W*V(<("\$Y/T)VF>|Z"1'YXP6C |"+
M"!B'E/6?GR"W-O.D|&@QX_JGUNPPP\$CV06+7I+5F!P_I+347.7SP@+|T^."0 M?^!FAQIQTYMEA" MHR:U2PI9/A-
GM|@|S0CLN/1C",^FS:LPU KJ+4#A9IF&3 M<9.TOF5;@_OD6P+L#2H_3MU9*2Q77C3W/F+6WR#;9=*BD_-<|A M6
_!0O4D+6=/T>PDBC6XT06'.M&+XPY945=7#Y<*DH|3O0VXC'L:F#4++8 M:\$CC(R|L-

WMAW6UA5J".T2.\$IGS>3% ^N+;NM>5FCG8/CB39EYI\$9F8N@2 M*(D\&[Z4\$2N!."UF2=YYWTKHV^ODT?
[R2.0%3RA>E7W*M0^HBI^P>A5(2(^ ^O:I?>J:E5.O&LGY^\$|HT\$@8A=&-(H<0I ^Z&?*.S:PCM! N5I&*B@KQW4.
MYN')C1Z.Z00X6)=AZ)V!T^F.V:K42U1+G(931S?J7-.X2 #N12TVG\$ MF=L3|PBK55\$65\$G^7KG\$|
[2**3MK<@Y/4D0VDI^*JG^?YLU0MYN.\$).SYZ9D M^8D4W.^ (H@R9#YNTH(>JN(R^XP:S0.T/O:N|E94FGW?A:)ZD
96..CE MK^|YACN!^OTG.Q<(S>A?2)2L\$E\$EAL>JW5IUEQ\!#71GA<5@C2-2:00"/P.MC3A|/MIMU6XSWPKU
L.VK98%8BAP^#M|G^R*L%8H)D&4Y)P9 L|FLT(T7X4(M.%*KQ2;A.^?VY<7:QS M YF)9#6YH:R2L OF^Y7/TIM+
[7|R^F+6D/H3^9;N\F0ZSYQ2XSW?.33R+UD5H \$@IMZ)Y(MPC V-T:0M>\$5P 6Z\|K|&/LV@M2 MK
T6*IURNQOP! ISV, CXI?@AL="9 _+L^)*>=>|H)C\$O>G?LCCAWIP!@:(
MH15G34TE* 14LD7Z@% "IVJ+E# +&:L=UVPZZ=6=-RR-4 EN?4^\$YIZ<.#/PRQ MAZ24G(Q
3ND|HH|I8&Q7W!)KV^ES!CHITVR!F78Q@O\WC1V!4(.CE.L0 MOYL(W@SSPY010:IOD/KU6N^%JQNK-H69+XDRQ
M_=:/+*8I*1P>87?'"@575Y)LJ&|E1R+Q,XS#)?Z?UN7=K# _E\Z/LQCU1 M..-/>R_DS^@I?2+|(\O): YDD\K?
(W0J|1PH*1(HS-Q07PPN4>E+1+;W MB+0L&8V>_00(3\$;0:*6G@X?28LH2MT79R=\$W0.78Y0\$8-E#176CN'=?Z56
MA#.'E1 (U:CAZ *ZH3C<ZV MC:N,TJ=<5@@>@X5=E*%'.N\WW+L=@MZVGY6=6X(WQEO^=*FQ-
>&2#Y<4B1^ARBE8"U)JS8P"%!@N(A44X!J7%8)G M6B2O^1(#-W@Q&%4.PX"+IX3C3>RHS&\$!9U%/
%PITY|Q6EL\$D5.,3G^9 M(145E1UC0JB!/^?B:&NZ9N%VK110<.7.6;<+|H|<<?*"I6D-SC;|B+<)N; MF^X5VQI,\$!
3O:R+H%V0*\$.*L#E01FTH+ V5?R:|6BFY4BOI-V@3*(NB M<.<|< M|&BKBT0X5.8>*>"P0T7|NZ\$BWA\$>C/UP#@
39FOIUCDH*/B-U(I3 M^D#9@%H-Q\$2Z9>Y%.U31|E3)73M4|D5W#YI^9CS%.\$@9M4V=^SH\$H9J-
QN356<.;2PPNWJM7>_I@d5D#%#0 ML@.S%".G(5|+|FN^8H+,@J&23XJ=T J#9KE?24)"S-CI+7S.BQ 7.I@"62
M0Y(C0,.44)_0J2 P;P>P>>>YBSM+E OX&\$^*HCHZIO,XLS9X-),NYU3\$
MBKK\$HW.P+LJLL|EOR&Y@ZF8&^\$^|U?G=)|&I#XKOF^L.._3:5#4RK#H0(M3|V&\$F>U;<5BBQTCZ82C=*R*#
|*6ROS|&D63;NI+>BP C0P|_VJ/|^7&D.90 MPORO+FIVX>1^C|T3%FPS<.;R:HD-P8@@C#^VI+0D)<9N|Q.Y6^?
*F>&9=.*ZKIB&9>J# K;T*L;>I^I=A0Z MY|O66Z9S195J47AAKQ"|>)Q8 MZ4&KB^:H\$8D5&?7|>93ONY3G+IME
R;|K9H\$W%G|2:31MHJ?^\$2YDN=ROX MRI=2?#2U;.%XOM>CQ&-Y49WA1WGC|5|QS34%B:ZA9P^8?(I6\$+F,%!+8+@
M7&K^FA^\$UG 2.11H>J5:3^N>FE3M(HZL;XB;<9(2RG8;\$NNG4-IU3>(W(MXJ1/+0180227P."12\$-
X&VCB7>X\$0V6#&J8V1!% #D;+|87IR1|@BV/5E^76 MO!/?77;=-87.X3CGO&XS:1F#S.FOBM MX*NDV:QH|\$EA
UB4|7D\$&AJEH6."D^E%NN&Q|G TOQHOL%U17)70"=E#8(MRS %)"FG=^T182Z9|1&\$S\$(\$JS:B);R.2I8!#/.9P:9W*
(FE^Z(\$5YJU MXBXX&C J#|U="6;|QO|AU25N^KZ|O\$T6&= @E>_VZ,L+Q|Z3*L^7 M_%)+<0=XEOX^V:54-
4R38(!.2M2BSPHL;@H) YH^X|UWZ>9JH8M=H2KG MATI63\$9?VJHM^MJEW57 :MU|\$"RV;Q 3ZY35M9V^2
WZ^R7FO&:Z+W! X6I& MV=WBAQBNH9PX.\$A: 5Z^9(29@-B0.X
M.OI75RQ".A/=GB&W(;%@SR3&\$>.;0NVCM;D\$A&U;#VPPC\$9P\$&=C5&JH.K1Q@63QFM\$BA4:+YHC;MZ-
|MBIC.,DZER@ M^+|#22%"D^J%Y#R#|@"TPPE<#XP^I(=D)<>D9FLG9P+ 9Q^K#.^BW?7|OFT ME.?
C7C;J(#G5T\$"\$7@ M%51.8\$-S@?..#1<#|1^B_ |J&@A2|B^H?J+TF5N|FA\$HKFU7?8FY!)IL M%|!:=G;WA<:
+PB|W^P;(EC)@T4GQ:7ZE=*UH%=-D0UE%|3+ J?C>#W8_C M>58.|X)E_XLAD#5Z4K#;NL|L_<*JCB|);_*0-6-
*=+4BC22(DC M|3V Q XE0J.KW|;\$;|CEE&:1>Z|^&|.I\$F=WB?&39GFPE3J)(J4?|>I ME2(|_E<<\$=|X40 ^1(41%
|GIQW/_F\$S&X?2MKV-CP M-)+.1|EWX&GJ7Y>4D.MQHE|0>|HDI:7>2 M>0^C6L(L#1?^
L\$1PUF4.W1^."5BS|D|LXK5?+|^L4.D)P.#5 =KMAR|NY?+M|&4X2R^8^PO O *N,+0I^N.%58P8^!^J9@
M_#2%/3?/YH^F<+U)K@ZF+FC\$62>?%0/5)K#*PIWW">2J>80U*"^YEPV?)MW M+&)K)"_W?IDU.OAXC8E?5!*<
(D(A5%3D6NR_O|2V_&\$%IKVM?"8/9@M%3>S9-G|B M&W|C^|Z/J00_BOU-
IO9WZ+5H79L6S\$RML L1|VO|JYY#K7;+BG-TW;VOK5! M8U>H6""4CF%7B6^CYAIT4=2("VN=5BDN!ON#
U.+79VJL7H-(X(CRW?LTJ; M@RO|F+LXDQI^JU*PH25XTK)+^R(Z6)6X3>.;F@X1|9;.>>77EN1@X**#2 MM*%J\$-
P8|77=1:0^8^&S@>T9WW^SB@ZS" MR"-U/KT@0A4RJ+V*.;5L|E)X1>9H-MS@U%ZZ<7+)^ M0^K_="OAZY|U?<
8L M&VD_.*L42K|B(Y**4WG7J^!QM%6ET<|T77)J" M)Y^8YN0GG^SIS9LQ|OV%O3^W@G|5RKT;|HK+X?<
R#NK>|%X@=3X")-M:U*N|T0|XUV^.;N_Q6N!A.5.9U#>|/<^A)A=FBVPG 3OA_<%#795IP23=% M@U9(=R2&JE?<
AGC^"UJQ?O#8F4IS-+>AQ!"A>?|MT"\$OWP"7^)U2Z|ALLH)T^AU%&^O?CD^? Y7|E:Q/89^ON^LY5CZ:=T@I^0787.BS<
MI*/DKJ(B;)35UEX|TGY|U3<5%U/(L_"DCI?ST={XH1)*F7HRURM\$5J3X9"-76>GN.PX M^K;JE9<
M|_XNA.@^#07X9(<"G\$4!^NU0@/N*!;|WH7+;|Y Q_VC3.T8% RM;XDGXO| MB_|LL&3|HN)(L2FPYT/>+(J6F?)HN^4?<
W7UTOB9YN#R>NV\$#1G5)RS4A0L|X#R|5DU(8U_5?NG&-M_|47^<>W1R(6>N|_R|^V4V:Y@G>.,3^)^3 &3=4V_|<
|Q28P+|^"3F2#2.? MC7CBN^G@FVQ28-0?|3RG<*42N6|V(57"(RF_/3!/<"9<@|D=WN0|\$_I_"S"-.(J|6_.'86409B/N3?<
FN')#*2 MR9""02B00^&OD+L^Q|S;IEMU92;@?4..MY5^TGBC2ND;?)6(A^AKZ4<_ MTR*CW7>_E'5(D^ZFM|<
<@6\$=YK&\$8:5!|V(DA@UXU.76 MW|;^..80N+&8^J4|^"QJ+4LZ|AI\$S:O/G&CGOFFFX MA8KN7@D|!1W+|L%:B&<
|R^ID:A:P4C6 ""1B)7V);K&|V#M%BW#Q3/KCK#*<M_/+8^TMK;TN|S-RP-?<
Y|>X|O6)Y1|6O|87NE73|O.3\$Z7^C|Z07P..XYKX\$+%C9WM;&3 M|L@ O"&HCAKYBZ)9|&LLM%@NWD,Z9>.&>Z+<
(7>V^2 KC|8G0+>V#B_>9> M8|E.WQ|7BJ|D)"NDF;18T4,1-W2)%=*N0+I4*T#1Q>X1*ZY7,3K-W!P0"3<
M3RPPX@O)9T=.;A&4.#9|?SWLGN9Y5=U>V2#+ VL;A|_>22.MGV5(5|N@MP|NKZIN+|8@ 0^L;QX(#J9B>|.|G|7#<
@I6..Q:60AGP.%*% MJ4.TG>=22?B;B^07KAL,+|9:27U64|1\$@G& FB|NEQLNMX:7>TUITGF?K6<
MD8)=N)"EGFR^"T?R-O041(8_W=5%"^+P:(I3C IR2Z;L F.&F^66:B M>%R5C|D@H0V\$YIRZ5)H41 %=W?<
M^0I>F.1C14TPLYB\$&9&FWR+6PI3ORGH M^4FF^D|H_F P0P&-XV5:-<
<.#Q<7(8)P4K2:&5:8V\$ BWFXU%+;@|I+MHX M|JN|C)?R)-H_#C4ND6..7#=<9^)+7;GW1^4W!<
@91+XNLTGUFN1CW0I? M)|#RI64(N|XID\$|C|V5.S391V6+?"|BAGUW*NKA^X^)^5%2;#T=/24 J%(C=M?<
EE3FV;N@|)\$>J^P BFH46&@B;2F(H|ZT6Z%:1TMLRNUSU*/9N*/.;_3-J MXA=|^ _|90H|U1#AI\$-<
|GT0.LM(+>^>33="PXIRJ9|VZ|M9L-LU|(J1)I M+&B8L)#AXYC>QJ2RKS3\$5>*M(RJ3&SC0M|Q_E/ DZ<
\$^SX*B\$#@#2|G;G"S M^ZB%"&..K-#O @HG4+|?UEC#;+L|K^7HJ2MN9KI|HN^+K=^94^D)1# M5-<
FN%W7;1Q:\$HZ@|2B#R=*|8!#O((F)3P|3PIG\$HZ>\$LPZ=TK>.;&0S4&=PS MD|]=>|LUP?@|HE#^@#_.6RXZ!8_L;?<
UJ^P0,2# BT?CBA:|D>;-#U"9O"/ MMB>=;.*#N@LGK|S^X8\$JP..)F&@|+R.X\$MYR80BH|_T55Y6U4N|N82>>)_+<
MS3AJHRE|+C_Z\$B1VBL|R,KH+3 _CF3%|MU)?""MN9IQ34\$0E2DP1MX@AGBZ M+W)YS=M<
5Z%PG^Y0N+HW/L|P.Z&PI7K6|T8YJ^MFM9QZ\$5:9F-FJP8D; MG^VEB#)+NW?1L?<
90WE7>\$\$.L5EBDM|Y\$ _FFP;@Q2%&@2_C=UYAK5|D=C6)9M<
M:Q8^I>WXP5X#59U!L1EKG(7GC|TF@5 _;P|F4F4VE*OAHW;K U7|U*UUD^5 M\$Y|/L%T0VQPN9&U-<
6_JC2|T.*G|V+D.V1N/@Q+C.08XO.'|&Z8./88M>@O< M5^FD""8F&@W3?+ E-)2IBPJ+^443^5V:2M<
02J9HH|2:T8.9)+|H:|=8; T M?1&N.EEG%Y?+A1 M#(, +B(ZG=#)|#=-6| MW-/;\$N:>>0V.%5@FY3BB5F!@Z%A9E|<
X^HKN.;&6LS0FWI^Y0=B0E6&E_5 ME=1C7^%K6&VUB_9\$|U|D)D<0^BMM?KM@C#K#*6Z&X;JU-|H(-DKAW^*M<
M?7M/Z_K|L)H|2PUFXPADN|UEA+0US.F\$6K^B&GPWL+&P|JC7DZY;R++@ M3E-NV#V%=&S>4^"UAQ<
72!%WQIKTHH>C&.<>>IV\$0 I8DFW< M_|\$)73J D M+EO|F3#XY_"|*C47RXM>G<4Q;G+|YY2H;V7.2"<
(A|&|3L5B|P|R5N5L-0 M;RR5I|H|^9C"<\$D0;_.FS/02W1S;./>99Z SY7Y6(|LSI&KP H"-_L)E U MK05FI^8T-<
L%AUU^V-KRG*/%RR^+@K9;P|OG=69ET-E&!. XLR5?T4;J^H^K MU|UPV=&3?M^*YLMX>_VX13L|>-|0@J0W1?<
XJ^H@QSN#5NY5XMRNP;?)O M^SN9I?|H.D=Y.^&*.C2|9_L(@EX)*V|T^9Z.CPA);#|K|8)=|7^LJ;&G% MD\$SFE(*R.<
Z3KR%9R>+V^ZXIKP#L)|@SL+PYGYCOYKE|DE..2+"3H3% H006&4J&XHG /NMMO|9-PN^613Y|^&!"3<.;KO+V=|J<
M+|5CE^3.\$N^+S|^#4P5_PS=YD.GP(T|H|J|C0?92>6'SCC ZVO^_YLT(DE='Z

MV1JA#0A.L>B09!;9!3#ZR.5^:Q14N@B"%/RN.B M@INMMR.A(4(D7"@.U*^D0!LA9EA>T'#TC'='LW8*(9
ADP"XO>40KWK& M6%*%&A*"IGJ\$T."I0&"LT.NZ/6G1T/=-=D?JICQA6TZS:'R-/4F* Z/P275?
(,SPJ;W=40FPJ';M(ZJ:B/W5BfJ|&|J^ST M=JQ).Z0Y!X7HF@#&_7I5F>%'1IP4KQ!.'KNG"K)".I)D3M6NL4753<)'A8
MQN3'8>6=GGG"8H"=C1SOMIGJ_\$3= MGB/72|<.[UB0#7>=?\$M+1E|C;5|+RSX2)6|/!TE2><_6IP4(HZ3LN.)!CX&S
MDDT'008XC>14^CAK(U|RD'SC7=8#2.8-%Q6<@|U-EU)270A.2G|H-IL5W+X
M9TX*)YNL!;T3M3U'JL>!)N:07-W"PO53RKYV-L.W*#-8:TFGMCU7Q&JOHMY
MR04|C|%/!%OVBPTJ|J%D*JLE@MK7QZ|HH1&1.%BG>F6#-L7|<;H5LRA_B5.VW M@>>
^"*S8FZ9K6&?IF6E).I>OWIS_/=-?_@#(U(%^ASO)5><+R? M_!FJ=KZS|&@+N-!D<#2|SV;YKYQYD|QV!0E.G1P>&C-
/DA_P?R|XJ|!M#OMR#5L;#_NQ*0E6%/7ZV;3_J2M"1*V+15.CO0^9QI8|> /T1DR;38DMGOT?MR8B
<3U&#Q/^ ^Y0H@3'3&>R2?|&QJ KN5IT?-Q(&SRI@5PIW9UQ654/F MY8.2LJ VTO#BHP.U-PH+T(?GZ';3M!9|
80K@=V'-W53+|,AG>%)I.TEVAU M?| ^GR*K3^G5V #F%IW^:K,V;((P^Z5.S)UA=EYXCZAO(/=W:Z..OUSGV
MC8%Y=9A|V|>5V\$>|U_.P.)LE.#M%|X#KZW|H2W|JQ"ZY^>U.U,B'JE53#C0;_+B_#64#TE)3C.&(6MSK(S
MWSG0S6VM^J&"C)5H"(8E<A)EC2C\$!28E-34/P%N9G2;+9%R2?9|UU@'1 MK|FA|8^5RAU'\$*(OP?BIW_.LR(-
L!00##KLR8N|9WHLG|7|R8|=Z/U+N3/Z ME N?4M=-BLX'\$>4CSS|!N|J%&|4#WBO\$+%. "M8_)J/'#?Y97T
MHX1;?;.)H1_4FB5_"CC*PHB19L7;4712+P+YCO!;G0T.G*|>\$TN_#7F#D^ MS:L< ZL\$AGBCQ(#<0@WOO8Q:/\$ ^/H
A7ATZ4ID'3Q=I=-9WF.HP"6V.*'WR M53L91"YU'8I34"4NPZ8(9.G=XR.^:;
B65!%3)7|@ \$KLS4B.+Q| ^BXO_HD:C:7G' !%D+\$SN#_6YQ72/M9(C)J6UC|K*Q5|15>4K_/F
M.G(\$A|1V*%XLYB\$*%3XUW%_!FL5%F.G';U>3P2D)|ME='A|/=-\$2OM+W! MZ(KO&/L0OV?
^TDFG#V|:KL|7^2_ %IF+|,M?3| ^ (R+^#A);T_4&L6A?3#;K M7S,P^QHY\$8=HMQX^29.A|FOI6-5|48#2V8&-
JNY|AP"%5CE@+G0#; M_OEB^382XC^2/CM-|Y%G?H".QG+8G'DY".3F# M#RIC|G'@?#@/V KIO+4+G8 &H
0Q@EHM^M3L*=DQW_XGWW9W+N^Y.'G|)^ M^1D|'9= V&BN*20/2.? M.|RK|V>*_@FA|5^ ^|JP
.%|O@PYQQ^%+O&>WP'Z MB#EB<|>)\$P_S.TR*M.?)?Q TLP>=@ZSJIO)&D-3R|L;N1P
M.IX#LY*YDE#1L"18;@)G| (21*4RL_R8+2DQGU|3=|Y@C?H-5-K|KQ%_M\$2 MP;#9&9.F-J8KAP%|!+5OTV\$6
MY@P1A"COOK*DOP5YE6V-G6EYQ\$ "3;O=J" M<72X=-BTL%X;#1S5^#YNQJ^>D_>D_!=@USNAP(-
M0|E;YIN<)|LO%&GLX3VQ|C9_S(G;Z|!>"?B..61XX098HHPJ(B0W*%|RZ>N|S7
M.PKSS03X)ET4G^|>N3C&4TK=;!VSZ.*%|R23N/."_G)|CV\$@=J3"">AG|EU^ MM0ZGSQ@ECC
&W*PK7(K+=E2NVYZ&B;HYW%NIWAL_WGSP9*_%|H|@_MI%U>
(OLZNCfQ.M\$VZ..8T60R^J#SO4FRT41*.P4*3E<|_#Q2%)W7%"#90Y M&V&H (=7IX*%YF0!_!3+6+|WR>HP\$=^P*-<
@KH'9|'?BLOJDEDL/#W@.#.8B:%P-I*G?_ ^ MPZV@2S37-&H)CEL&5SX**F<9>74G\$K|/#&X4=M?
9_>L(U|6+0Q.IOT#40W. MY.\$G0Y_CPZK_OLA_P-
WAY;2&2U|J@#^M*X9=RA*^4XO"AJB1QQNM>NR"TFUZ<5;QRKU|+^0X@89;1S6.(K.(J&KL5QH.)>?
0CXL#F+8F.FR^136>XC'(43&0FV.50NROY_DC8@*0W"PF@0ZC';\$=\$&=RB0RA.N|
MCL;GLIE2/;=Z'^^ ^IZI\$NJ^6^S|%-K;LC<8*SRAGGW42YSD+))9E.VFN&+ M6M\$14V;1/9-W|PW@_?;Q^&L#?:?G.4+Y
MP;ROE(@?FYG|C'D US"G.;!";D'JB>X7;+R#6J3?;R14""??=P_T#;&#* M\$G|S|Z>3WS|^>I0^?
G+XS4XVY;Y(GAB@9|3C_/E%|L+XQ_?_9#|^1+5RWLINI2W2|V|@BY4|QUBEQGC0H|_X2<#_H.G
|'M03W/1FW>=H\$|KGQ" M&=&CBRFF/A^/:9X|HW.OE\$1QM|73=M=.;C='ON%9S#WTC_%3\$0:
MHD%7)C.F=;%FRNR;_%NVVZ*P10^N%/_7*A#|4=4H|^8?;^ ^4Q_3==Z="N/_
MSRMFJ/3Y*/4#EXBUVP4YN;C<*X_+;LK?XQ^4X/K_DAGT3K|'2GK?FD-K|F| MNM%?;1;."H%V6V"LK@?7|<#>
J5ZRNO-%2|U<);N)N|XPORO?V@|\$.*#R#_MEO\$%_!0@NFWB|B;2#_ _|Y%3K7P^T9|TRFN5_?KGS8^1\$|*ZZ|;6-@>
(' ^|<|B/5 MK;IG/N|8_84D07E>M|P|X;|/|@>_%RBYMUEH_Y0P(\$8L+6^|5"TH'7|5410QM M>".F15N?7Z1*I\$G.5SA\$3LJ
SM|5Y7^C|_X..&?K_IZ;/OX_M/ETLPJH\$ \$2Z#MDG0;Y(BL3??Y".JBM<7...+H@+1CH)|JF>D-!_RH!=YT8
MC937A*1\$G0?;7_5H7|MB(6*A.5>*(9K*B&-YSJO_E.TWWQY|H)3(A)3 M(A!&HW_AJ6|_KTC(E)5XI3|R"F8|-A
|Q|>^*0'IP?214DTPDAE?|N"_) M)FNX\$X>#|QSLPV<.*7U|6/"Y9SYCYIGB/BF..KGIW\$SZ8E&S_A_!\$=^T3 M|_*^S?
>>2RLY0|=Z'-P&2^:=Q:3%_B(Z6'C#4;8VQ(N|TS:P1F|=B-L.W# M1'3X|G=7?)>BW)IT^?2*1/QEMIO8%3
M<(<_5EL(j21KX@Z=^*;>_VC^" |1L P#=!7(F;#9U)9\$@P829!|@%+3YTW-ON;LC M+-?>JF|V<-E.L|_*>@)8.AR1RQDB_-9
M?OL|+VGVT*_*+S6|J|.61|*?#_.876)F-Q+FN=EI=<;_1P|AXQ"51SM\$Y2RB M|M\$.4?GO?A:(S/D|_3_?6A@(&9#/#>_*K6!
|OG7FIQ-U^_!L;RK422>Q)|*A|R S;< R/X !& !DXSLQ=OVIGT4\$CN.X514_!!8T1B&-2|AP.SV^&\$>T\$%R0(CB9JT6#-1-D|
M4@@&MP.'20HX*|T@|@;P*|I8@H?V%0+V3.0E90!2?P_|RE;JS0&_)^X' _-ML#
DQV%|W)58G^2A0GWVDY4V0F.02CA?9?69GHQ>MZ0W("K1QP?M;30#D# M>%W**YN3*X-5;Z)2RX*95.6LCF"91-
|L@DKB\$=;@7DY?S@CJ_ W^4_4 F25) MBZ<.);)S4^Z#>@U3L|KAYF@6\$|QNK"U;AF#9#19E_7&KPV+F"HU%3|W|?A
M3L3%?7)"^|I_..D|Q58EQ5SE^P>9.1FA>1&_0&))!U0_<&0(U\$95=!* MK83TV)TE|B(S\$;OA|XP)U8A)39@9A"E.Z?
L8E7U2H=>"|>(OKM32|P6SZ7L8^K_R45OZ_.YK*W|Y;B;:RP|/M;G2VKSZ|BUC|_|7G.ID=|HC*^2MY/5(C=
<)|JDR9*C6#_Z\$R> MEMSKZC-FJ.>3)E0Y|#"_)9,I> <#S8=<5#^M3YN|+#!-JBR*4VZ(^/ M#BDW-3E?
+%ACTD8>XKO!L RRV)\$\$64)FC?DGUOKC%@S^BU2QUY=R62G=;V1 M|B;_!\$3KK/|E9*4Q_/U:8@=5F*E=AA)6|7-^?
O5E19M5W>%(MWF|H_&39_@_AL2_*4HP/KX'U96;DE|OY/72E"+|EW G?R\$EX%URG.H.O+
M?'.J6Q|4\$RTVM1&=|D0YW^_..|GCT"W""D|F'RX"EV&7C=AT;J|HSH|!M!@T0X FR#DXXNV6)N'IF@|HAR-
V)JAE(T?2)F|?=_6'YX|W|_ G95DU|5|_M"U/Z"X)OY\$5AK=_'X='AX|X_E1..|IH=2Q;-V0^H*)4#|J2)P|)7RT#A_MS"Y|X
/2|70\$X-B++29UB<|A|23+)|C'U(P-1 MTN_Y/C@_DU9+X;?_?E M#S|SM05|_VHTX+|
M9P>UM|K6L;G|TW7#HL^VQ;|RG@7=AM_M.X|R>'V|'B|_Y\$1LW_+G+V|W)Y&
M/_=|FO_LS|S""&H|RF\$K<4M|S'RI#3,M|YOO4<|@JML@:Y;F"B<>QVX.'
MGVD;/"H>W|F%|/A|KHU3KQ:F&E..*OFX;K%5S;44SZ_D&@=1FPX%KZ\$;TC M?&?|!87HDN'LIER
F^)\$|R\$|N|&TO.2B8_\$MO^OSZAW' DRV#%T2136;|CG2Z2F#;CMUH#L*937%MEQ'DCGEY@T-!A0+H'VU|EE%>
MX2FJ&8;+BVV^Y-<|4+A_2DT<|A*_ZGREXHU=%VP8>)KGU;"_SG4|9SL;TO MC+<C7NWTU000_3X_;;C8DH8|
<1!%K_M-|C|<1|!'&A+@#&*7&)|W4+X_&Z M|7C|C|??">ZD0\$_1
QEX6?;2F=O.C1KT=DUQVE|WREK*|J8|)XTV|FHH|3| MBL1Z'5>;&_!L|(|'65GF+|FZ|&36X);;2-U=+0?
=EABCL;Z^%*M|J2 M#U^D*3+?%6)|@=\$(|AE\$?|+<_..@7%*6#W|E6S^%P|T|\$HYI MAD^/3NV""&%\$#1)>_3 U6D0-
GM"! ?\$9T"WQS';3;'(T=O-4N4?&<|="B(U M1*YSCD&M#;9FA?L.A3_8TD-8O\$SW0&5Y7L?;I>2|6^&B-;.\$33|;C;+>T
MX&H|_9|LW.)4MS*Q-|=CABTMLK;*)(WXB;&S|UZ_B3^>2E-V|+#!N|NCU0?#NBGX\$-Z G"8=9|_%;|2?A*)F\$J@GI M(
P|UY&S/'D'HZXG3E5C'_2L.C ETWTNJ<+C<<Q\$P M^BYJ_3+V*^XU@ALJ2H1A5XXFTAYT03&/\$G ME.NN>VS*L-|
'OL&Q^C|E&|+|H3=WG3N=F|J2B|_12X@4)DRX<#7X_@%10" M|TR.B\$WJ2|B>O! XIUO>=3E9IK;/O3(C%A"
>0HE9ECQ"5PFZN&@AV_OBT ME^ ^|2F@CE8A-)'<=8B-|_15|_@10VP;>FPJ*Z+%- MXN*';#|L
0ABP7|E+|Q\$@D'H&DD-YE&NJD^3.DD@C_&FDN92|YTDAN(HV4 M_9D)#>51K)|H|Y.&LE-I9&271KHH
|TRB5|NSW|JHG=|2|W|+|@M|N&|@L MTX9^ ^KX".84PT6(0K;UR"">RD2|AVN/A|L&4GH WU/ZRB".H?S|M)PPN
MU86P4'B8=-T@%W2=YYU<+00P|EIN=|T;RWS-1N6K+6V_@#7U\$LER5;QUEK M;|!+?TCKQ+;UU.1QOXXQ_?<
+*N3POXLG%.Q75# M\$EYUK+|'VZ%Z(?_R+|^6D=U9_//ZP\$|AK|ECV7NNVP-WG1T'S.ZGH9OW\$X M(WCH9=8@N O_..
(R|4>|2W<&R|9Y14MVMA@98SROX*Y\$% P2S'<-#(4UW4|3|D=70I&Z5M>=JQV<; M\$;R|%'0;4"NQ)|LP|ZZP?@&-
+6XGZ!|\$D8Y+S>;'C\$..QU3K;IP9;%|X\$3>)HWEQ@31Z(C)_#1X3P M4%#QOTGAE#"E|'_H85718.9WY|X6PGL1|
/9"C|K'6&Z<8G@OEC4 M<'NT*|+|1H.BX* 1>D 0A|3-"J|N?7=,5W+H|2@YG;.1&L;2&4(C?X?XP5

M'3UYDCYY^"21E^LZP.11B.0>EF)-S&AW:\$ER P?G?Z1H@08KR7=-\N05@Z MHKA0Y?6-Q?)1U?)59"\$&.!&)42--RU^R\T'F'V(R:>W1*8/\$6J&>.XS MQ'-G98.5 <-\$MLR9;%D;1O@GW(#50MNS:/(&+!%1-E2R<).M\$H&_LK9KYUS.ZJS+2X/?=?1.+S@QU>)-KH9X(3= MU1G,B8V:VR1'?%L7E1/L0 2?456K.G X'ACN:5^~^ZM2'E.L"(3B)JOH\$Q MN44'HKE.F'E'F'N91HJUZ+IVIZUOF.C\$+SW!"(TWB-V126VP*2>[I*440;D MYDHIQ"PI.T.B+WU*KG%?GE'OK1X8N0<2&15X%W)~6IP%-15>.) (18F'3ZC(MBOP<>D2A8#T*16W7=DY:X.;XVK PWA@;C0PP26.T\$:-1*:+5.9%V\N;.\$:-"M>5;LL;!"@+."OE..TFCD1..HRV"LVB*H:VONDH\$+H XV6#R/(H#1_=-I M^KG=9 O)~.'>5DLN_..\$4&WOV#1X2RS30L7B_1K=W@5_.\$?7Z/1?A%W0&<\$ M=|OY+;HEOHA>? 2#)YL/85K=;\$-9IT@72#6)*O;./<=H39NML5ZD^5ZG6IY%;17K3QYFC/71# M.LSMAOF:H773/S..DP^)C5#15G7*C.P=A/OL 7-37G\W= YC15Z"G+?TQPH1)KU\ D^Z+<)3"1:3T/Z20S'P-M2C\F&-SP/R1+)O?VN"ZA7Z\;M;.\$OL:1\$=E..UM<^96^-|J\$EGB9C;"++VX+ M3S1V5G'+>-1>C"#1ZCHC>|F+O+W6LI0QJYN5-?WT_X3RGIRVO(XR)'ASP-M98\$DI?DBQ\O9%AXHDW\O25CZDHP-E^#9L\OZVUPM1>GF#V#R2^*HJ54# MP.2%;GD\;JJS);N;=<OUVP)'SF#;MNDRG/P7?3T?S=5?_=@&BMYT-NO&"MC%8DB>H#A9"-K*\$323=8@*U3JY? 80H4FIEFJ370UD\$N/*&<#E<6 ML\$2.1"@ \$XP:%F3K US&RNO&OPP)H3B%-P3R**R&1ZFHL_.\$%:51PR6>^8-Q'73\;C1MO MJ2^~^7=Q5MTO\O#)M^+J@C5G\>K<+HBPFF;Y@H^O;Q F-JE:1;QR;\$:H5617/= M6IE? ZL'Z\HF08^N)M&1VUR:1ZUT9; MW!-Q?I+E90.1PIUG_VQJBR58K.@;GDAE4L.^<.:)=IQY%&166L/S3"%C M5O9N\;T(Q7R)F\$=%BWI N4ZD\16MIGT.O#^@/(IQC_8?MWBABIT"/C PPB MP%T> (-9\$:/H@G840*0!WGF#ZC^*/QL64KI('O7EAJB08.?L(\$T\$DSG)-QU3 MQAXIT+00BOEW==80302Y)^J.F6-A+XHT^H2O?SI3B+NU..NT>&D)100<..MY% H4^~^0&_ TIH^+Y@^!..MG2SW/F&AZV8C\$QXY.*LR\;M3C\VV68f\@OIT M@5N#M%^LGH%!)~V.;D<15B#"M?YTOO#H_W'@70?R\AR&=P#3X)9HT/E\H MMC"L.*7URUN\MC1-2AQOD\UFL>-7>YH!"=4SC)-T6MD=1%;PQC8D75USTF MKU*=Z5IK_UFO&FX+ C M/84F7R'Z? 4G+AD40%;W'~SS?N V.XL12\JV<|<4R MD DL_32\1#F'9VX1%?^25ZH1=5>="DPQ(L%1!Q^BZ\UN"~8@R>:9> M8XRD+F8\;M?1LY!(TWW;(W=-%BR\J1M-ID*;NB\;L8PQ'8 ML(N%U%7S;1GKQ"7-OR^?G\2+@C_ M3\U.OVB&J\$2U_4A\$Y?A1&@ (4C=M+| M@;?A"0VR#DL^M@1\;@8";^1=E18V&E.BZ(NM,6O;7CHJ_-QB3Y GNP MH9\$-O)N)K#4F\ K2\;MGX)@PX=-1YZO\$ 1&8J4T\O)P;1* X@X=L;RRPDUT M0H\;U\^&6 H40/W9ZG51%P<00V\$\$\$? \$E\;JR;0S6V\^6\$4+2J\2Y+W%#U MOX(S=GYS;-2(O R/E' MP%S3;30_59^0D8)Q>| <.PP+PO_6\&C3V+4E-.4LQ0D9KV;%*4BOS907L.LM MV;7E7S#1;AHO"5,\$23\KNA)*.MB@5L7\$YMO_)0: (Y89&XE.1K+O)WK&J\$ MJXQ@953 @M'8IN6B\A.9(WTH;C NM'B&CVR_OVNXXQ<-N- IBN8:@# NP\RBG\AGZX9="Q;6*1U\Q;J\$) M5)C1;).L2(C%&22A;NE<(*W \$..(7DS"!=[JH^~.FG\!\$<&/76S"#<*>1 M% %OU)1Tf&.<9/T2'(2'H5OIK4&\$V3K^O5ME% S97\BS\Y3CILN=UPD_YR;S26<)#QH&J"A07W5> M\;D..%QMUG6;UMJ\2K"~KV/P/"\$NM\Q\$H=16W<1\;C@FA4\$JDR=<~W"#&S.TP M\OINB2GR3&OI=Z8(WVIS>7TGG'8<(6@_JL3Q8ZP1RT'=4L?/R0)18)S">^5 MIP1F5S6-/\$DD*5^12@1;)D: PD5'TL_=: (MB2\94.Z0E\;M_%*~K100XO_M*~>OZ 'W~1^Q?YT7R0PZZE+IR;M;MA01@ZN%.D_1 W5>HEW;..8GO\@.%>^9\0X? Z#_2=2)/C_ O_X'>1+?(W5RRWA8R>TG%O?33QM08X.5\TC_-|R20^(S-Z>1VN3A# M+Y" F"/8W=T- HM+ #)BZK)B.J8\G16#;3@JFCJCG\;1S\@3*R\$H\$+T4V-1?"R5PZR"X*OJH^V5>+P-9%"42B MW\$;BA\;ND.C3\OZ3WY9=1=N4\$SO;C2D#J\;OL+H'OIBJ3.5_V22=1Z_1 MHVZ4F14\DV;EDOO+GALR\$V;T- (G1VB"60/Q\$)N46HN-OA\ "7HOS?1V.M>MN#8=C0F5=6+2;+JU-Q9VALJ0:0U\NF\X5?O)4 MFZ#4U=O#N\A>T6 MG'\$>F+L7)H:*H1%5" J)J@SJY\$WKY_OY\^Q_Z9 MQ_#8T^~*TWJYY81\@05<&+ #8)\=O3_>U? ^1=T3SBRX7(M\W\$W&#B9AQ\Y&A M%Y#?3U_?U\VB#2AM\UB1-88)G8P6V3+?(TF9_4KW/72>&/3GY;P2\;P@M4@1 MLL^~DD7/&1+8=P168?%N\<4D5@-1A3\H.MG5_22K>%19)***9\$P\ZA9\H(M1=1%Y\$W)C\;E.786_>8.O+;5FE^_R8T- OP"EX@8W..M.P_@9HX9FCWO\+0 MMX##15\YZ-CAS2MX;.\$S1(P\YR"~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~O.&A&@15C\G\$2;O0*YG9@VI^Y@ 3\$1B\;E.8E&F? FFMA(U3KH*A MK\1H+;6#7#@ (JZ\LMJ'AQ2>1UE4TTH;RUSV_989\$**A" H&EMJ7U;M)K4 M"3'W4&HG C.5A\$4>H^0^U_-2M#)K^5@'HK\;FB*")62^= M.7L;D<1;V;T.C_=\$ V=B%GJ^T&CZ=@7XPPWD^~BFSX;OD+HR? G;\$1U%)YE&C M8Z0J*L(OQ#;Y;JQE14\$LV@N9?R;LN_1B0M?2?2^AXY^1^LJH*Q&4\$1 M.TGX"B71%SB\$86JH1#_R=N';Q)(7'0FL="*R-HF#)>1\ DNWN^V^JO<MZE51915U1B#BJAZ^8T(OB.T.<0(?/C%GG? B)6(@Z*6B7N\XL"H#1@H); MW;0V.3^EVDLLUNFK91EW<3/;_+=(LTL^~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~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~^D.H\;P" PE\XF@T#X@_X;OW%GIXW-^P/<\$ (8A &?IP) ME-3/XG)7T"ZP'VG%-ZH2_..M?>Z1-R)/+0L32_S2*?\$.^~#K@26L ^EU;J M\O&Y;#%B\$4-Y&ITP(<1K_MEWN";N;JX\IR\$;4H'3_>MU_@ERG@JT3)P7JKZ M&NS&ES2*4 =BV% A3Z\MLZ+% M6N^D0<6F+L)@_3;73%.LLDH\;-(MJA\7.VZ_88KVNO0BXR\;M.P.O&75JB&" +_#10LUD)O>_1 ZD^3K\5V4JZ1 MW\;L\;L\Q"ODP-22&SH\VLX^/CTU-6- K2\;C.V=1N@6L)GTRN#+KE\7M/G;A/M_-3&+WR0.C;@0^+>7"H9LE4LHSU7D\5T<1(58\&-J'2SH3SGH(? W1\U;CAS@49W2XD\$4#X M9A.AM@=@RIP6+ GK6\FTO^~F@">Y=GS;UZ^?>Y.2C\;KOPZOPNY";7POIE_UG\$CVY? T*~VI M6\1I2.F%6&\R\N'@M\'=H2/M51"WW> 8*[MUNY82/3G%-XR'BQ;.%ITZ"KJ(M**Q;-SBZHF?5)CSL3C_Y2.CJFVS &%LSF=-1L%YFW\RM"YOUGLO_X9 MM@VKMAFODBIC0MP9H2\$Z;1D MP/ZQ^@1%)HVG MW@5)HRWT+1PIJ;7;B*1S=-2J^1<1(53RQ_+1S;_04 MMXK5WY-9)*?F2\A- 9%7GF#^R.R05V1\$KE-LU%M9;@&XY%;*C\MEI^@ M<~?Y7ZRKG\1_45M35Z7+LB\YO.\$%G17\XC2'? MMM=FR/7U=%1Q6#5)'HE&/ST;JE0RV;MU>>FU%_1+&_/+98%5QQ50PS*\$*TV#T4L+/&3)%0HB_Z1_1+490N\ANJ*

M%PV3AI/:GNH^G3!\$B(X3!<:K8\$S@/X#Q58670P'-!OB;I#YGZ6 4U9U@I/ M(V/NAMK0EG&C2?D4'ZO-
:B/*9(,9-4'=I5IZ'0C:J@00Z;K-:@IZ>%E(L%UO=+G&,9T!6U:~!D4 M&2=)^X*;N>UJ@=SV^X'=?.?
K/KI^PS0(X8^XFK&@=,SSUVQ;+@ZU-!^U/4! M2Q>,%E_L*3!KE;+"F?_AUVW\$ZINK[#.*!@* M-
{68HS&SH})#^KX3!\$ ^A%VGO:L6%2!8P@'EFFQ,0'-'O_X%798-)X+'&OF M<>6L(-JH K!ZE%K2%G3=89(-.5#Q)NV-
TFP-HC_9*#+!2W:@?8C-.,L M9V>\$/7N6>^7BQD)7Y+3U5;^>^?S+7>KX'Q8!4^2E\$)SR>S2ZJ
MX*7Y<"4=7U;^F=X+8.P.A36O:A(NGMM_ M3207)=#E!J.V)+^#;X">, ^Q?:8CZ(W^!K /6:DIKERL1V-#=#M2[Z]Z.=%Q
M?_OW">I4_@M0!>OO_D<@G/@VP"BQ^!>JZ1=K!>AWX:0O_7#78.=G=\$QXC M.HDF7S^%G5+
{M5>SS^HA!=-,0'ZBQJ?EAI91K%60QJ1*HJ#_Y!0FZL8O_(:\$ MCJ&E=/V5G0AP@'#K=8='P?:AM3-
)EO/T3R0,L6;7/W\$U7'7"Q(CV6-!<@HHM! M@AET'5\$:LRB-SXXHC7IA/XI?QK:HV+38!>8A
M+2SRC@G%FI>4J3O9;?/LNKILO-O72?%ZTY=3JZY4WA&5%>?(0AQ7.(>4H.FE MKO!1USM^2M-
VHJYYR4R2CS&KFW-.)N!S7WAJ^T@P^EL'S,*!8/+OUC*;Z:CKMI0V\$&C*8X%Q=8 MLPIVV^Q*4X^:B3#-
\$EZ3&2MU@/@K1WDT\$P6\$ID M\$7/P@#46R5:SYT4!8C9YCI>2^&KFS;X.EQ:2HS4U6!61L.D7>:(Z!&_W M*^(?
6^Q:PD^%K&I M.BCUD8A0!D>M??\$<5FT2!9\$U3Q*7!(UP;J7R40"4-V!ET06%%\$5.D+FS8!U5^CCZ!Z0!CX\$4PQ>
<4T%#R*UHD%5Q/DR-MBR^-E6RA\$,%(4!^X9OE2P*.L%+NL%HLRNJUN\$G%EW#;(RT1757&(X*.*NX M^RG'10E-
@BWN^I@PC:L^~&LFW5_4.UDS'AEM<9^>YZ="E3W36T4U7M+V&N M8>F+CY3&)TH/P {TU7!_8!\$6UW2D(=
!L.ZE_E_X+Y3PR5C7C MY%1" WY7^6.-^2.O@%2^K\$Y?LH.(P!//>&\$V)=7Y:4HD7<#45Q?WXX'W_XNUS M!B^!8HN+
#FA:U!4GMXMZ,/>O7Z:~@0Q:~9S'>A^!@88.#V2@X2+7S3Y_\$ MT=!(IG='\$(?("TN&D)+;
I(7A5AR(VIA>AQ\$M!&:OY=#G;L)QC!>9M.\$ W M@L)U>.#9X/7U!8M40B1QW#^+~%RZ&"K*)U79OL.A)
6L7<>&L8N\$E#; M5PT3%!'=Z%"*~+6W7#\$4-)J3#H.FC:IEF(KOF^24)(V&.FM#J0=I5-Q
M<9"%UE)U%56MC5_A9^ZEYU*N.E!F(DTM^FR!87(MJ>,>U.O.LP%7UL_9NU M!@-WBMD-A?>JA&0?K
J=ACHH3:F3H!2!+=4!9! R!TW+?QH0"LL\$-G M!W;AB7F&,<94GR*=!8D87G#68CT2/F!RI59:T?
L5=S:3LO>HB!8FOW*XVVS M(A(N>GD1'"FRIVRP44Z8Q:P%4QUWL;@HE/W P!@E>L&CHZ^H#5)DRY1NMF@Z&
M_BT8>S!#W',YE^0!4PS.5KU0-0+UHN"68O!TZ**1B6P(T@C5QF/S6_@'U7 M5&OD\$;CK! ?
9#K^/H!3JHEN@O!~.5(4:~@>K'M_4*!Z2H"J6_!+P.G\$' M@&@ZW>#S2UHY>BMIM;F=;8!%!OB<>PK\$#U97!758=
<>8!#I5H8@3U@^3+PI^!F!CR<0%+E/9!G!29&LJ"?H6WN%WC+*2!PQ@;H
M'J!D6;=FT^_4FM3LW;OQ"V=@Z,]^E!5W9_HX!H M<?2&W;FMOP#-U.FK!LAJ/-X.I>W&D9K73607DDW-%2I-
T2J^~J90!5! =M+_AL!Q87I=BB6!1Z!;I~!L&(6*0!D7?O!8M8GBS!1MCC-Y+55!)^5!R MB,
{8LEAP_ZYZ"7#C;=;XF>4EU0G(!^!&3QV;YQ=C0^0C_~L/G%R!EI3_X@K=I2!D)@P!1CF&)4"<0!_2I<
MB#1=PI.3QB<\$>4.?!C*85("R@F\$5\$A>(.@1U%D^!WW-D).H5L:Z,"H1!/@P
MEF462>&64XJ3CF^(!#58/Y;B\$;M';#I(2!9DCYLEGHV,CHD>M&EB(YD5!30
M8%5Q!T'L6ISO=DI";.RZ!KZ5B.O!VU6NEB M<>!AN03F22)!-8<'V42?&\$C'/H-H(U;-
C!VT&4UW<3&:A^;D/E!)+#AQ!+ M!HKK8.H.OW!0P%@!F>_HY7M#"KP=J);%0:5W!Z=O9\$2=@B);!Z E7M!I4!W K"?
IV9.O M@T64%>/@#D!S0U5V!V!85NAOOR!B-WK?H(O AF!88HNR?UA6!3X&A"+1^!
MDW)=2;73CQC.1.CHJM=D!Z_QR\$*!ESAW<!FJ3!5=4+>2.L_\$Q@3"TCA6-7 M/S;0JLA R#;#JYJBDTUCX DAIYOZDY?
=^~/(G;#56!BV+YNO3IB%O MY6!H-)"ERZEJRPB!*>I.RDV^ZJ6_#1!&\$^#9G@LF6_M J^X3>M\$;
<.M09BC5<'<%EOAMPEN_LH.OAY<2W0IO(-NF)W;=G!B4H+)=0HT9)#O%7^/G.M26?8=N?
XIALJ2P!N>7R&"ID#KBFFHGB>!YZ,@?&9E!\$!%R!WZ&X++3EY_ =B*O2NLAP.UD_YK@LL;SNJQ.4QZ-
:A?)4B(S@K18NX@O6X04IK9.AB<9=I.W&7\$)8 M9IA!ZJ8^"= *OC2STZ!L+M9"9Y@4MY.NT.IU8FOV\$Z:GX1 C=Z"
<3XU)2N9C M'(J21G/EA7^8EV!L8.E-PG3ED*!D+^3L2H)M! =;=#I%6IA.C70_5;:FE
M!M@90/^) FJTDQ5"QJD_6PBQ#K&5!X&86?Q_I/?@0Q?0!4D7VCMXA4?I MT!>[+D\$56=1&WRP^~
_P@=@FG/F(^V!W4!/INX#C&!OL?J=F5;,8)+#%*B? M)DGM'=F"()T=I_X_~HO\$9RR8/O9Y,"%4NSBL"9E-B,
{7G"!PL4D\$N+PY_?Q<7#Z@'7N5AY)!/+GV?I/+)=!D;<7*52I>5@TJ? M4%VH^4WMJ:DC6ND_2?
YGLA!X\$S(LN= 0=E;FY?HA!^!\$6Y(-JNR!F MGX+Q:5!#@_WA>U!_U(3G9!6@!HY"MNNDT9!1JW!%B>/X)*NN+4
1EQ7ATW9 M4TU503T;^*VHTXL_57&(J!M.ZHT9RN_U?D=Z?X?+*PQ(J!TOM7Y(P! MKXC9C-E?
N7GOBBS9X0!HRFYBRKE ABR3(^X-A6(+C'DW?3!ONV625-.G"! M&UXWB;=P7PV!F)+\$V^N52+Z!^&HBK=*
!H!#R:F>#0\$ FZRL^0MM-K!U+AIG/ M9DC)DCAV)H!TCL7?0.6QR=.#&4(M>I\$*DC+>+S=_X_A_#L!9N-WL! (D M-
M94^VC#/_JWI4WT%*BC_=Y("R-F5.P) QF<D)=&5"\$DHI:&W/?H#6X7"%T29_ MW';9VU?29%!\^C-
<7!VYV)/\$5!_6!GW_7=WHBWQ4^Y1!/SEC7S*9(RAN!MF/F+7#6Z+\$"09.KW%3#O/S#-
0:25Q=\$@T!KJ#\$.&/_T!_60393!O(PSD M!)">30A_<4P(WRL)_T3FJN;3DL"6-(XEC21KS\$K!&Y-!P!Y%*>XD(9A&P;:
M2_Y&L.V73N00!YRU;4\$;C\$!^!NO+R_!O2A3&2!4O5<?7#HY?C;%9D9_M/M'D)&A!
3PH4"!O<=H!YY4FF3E@F\$K C'O7S^90_!VY1!)F(A(6:5PT6_M<!TYAY%Y_L:9&FYZN&.B2
J+L!^GCW+PR*;*L9L#&8LPYLGR8_4B2KA7) M!B6!%<:QXQ=URC"-@2#)(O!:(<I%- (BZ75UY!R!_VZ:0PW6&0F-
Y,ULVV!XWXY MFNX2(2Q_QOW!XH6G8).2&@.!\\$ _%\$W%BWP+DBTY.1!#>'+TT^/D2Z>8=
MOX6!TD3!E37DD&)+2.5#6DWE??*G.*"<<JMU1&:NQ#5^7U+Y4@)R!O_~C3 M./L^2F'67?J(N);S9.?
FY+F#/XGGD@Y;.&9)QA%GI6X7P-B A3HT0ZM@8!12 MZFC1Y=0U!Y3M!GMB>N6"&0PG5
HP:&XX21!(U0N777'A7ES=2HNF?J.R. M!8R<1.WDQVW%+WOPVN"-*TM/
81*N4T!)C!WZIH+HHJ>U54!_!4@CL+JX MXC/HJ@CG^>G9=+! =BDJF.4%\$57^0T@XW8-<1P-FHA!PJZJRZL3NB=
!KH@M M5BLP2R!H<>_E6492XW+UV73\$#>T;1_@ZB+W9!Z2VG'7.H^71!%(Q)!W%3
ML+@NNUS)ZY!@5""\$ZD!@5;_R0OSV7.*!(N &+* M!F4P30N=@= @)><|@;(#9U.RJ\$SMK+T><
E^~^E).#9D\$)IC1(.8H^%"O7VG MYH?RB8=PX!AC1>>4FYU:6Y2!_BKVR<)KKKSNZ+PSBQ-VF/WXC6SO_M7XP%S-
XRM=";0#1R+WRX>^=4#IO4#~4"9\HDL\$3SF5H@;6I>M3! M9W@KW;_!A-
^5%ZWAYWCV!#.Q(ZR!XQ*@!3>XSG>7.S2HEK!HYL_>'T ZO7*>O\$!H6TGW-Z7VU4Q_1RGD_Q\$ M:X-
7(*@;4NFYD^L7H=F+ZE^DRIA?25+E!~C_...+VHT:\$PH6...H!IR M!6!S"V!873%6GB')# =FWI=[*ODOB
MDRKPADDA_DX_\$WJ>FV!J3B1!L'K>["5X?B-!S6VV(0G8M;QY4*OD#>6.H MP)XB-"JZ!<E=)OK_8=D=U7!8!
!QH@5IM? \$LM@%\$>=WBI~;@GZBS!LB M4-UK_LVS&Q!C=&2J44C#Q_*<@90_0!V!AJ!>!)@HL*
ME1110)HQ_2:8=OUSWB5!O7>YF&#^ZH!DV!E-)!H4L\$T@V4&_"UI=OB"D@ M#;K.P&^>J@HFC;1!@8O:/PUUM-
JYXIGY\$+6E!BN2?E2"QMC;@UX687!@HU4 M-3.78KOE%GL52S%Q#!^!\$!^!3YK3H\$A1>@DHQ?
B!OQT;6>.1#R%"H6NC14X M5Y%B_-Z5_ P8NQW7;/1R#!(2(9/?MAQL' =0.C271*9(&07'(*YC6R81N! A
MMC@E!F.IA#=(S!NGYNBF5/5RZUJ(G:PQ(HX.!>+N_.J'+W B_6*UD@?T+03 M.S\$J+XY-
P*G+D+_M5&.OW/+GMN+A<6)S!L@W;D=F\$SAZ5P2(6(0GUH1>*YO!NR@>I& K7C5)W(LB,N#HE)(FN2\$1GDDNJH!D
MX_HAWT@_AZA2!1NO/Y?V)"U\$"L:L73VK9W_ MNY);+9HU#_.E+N&N!RY43C<'80#-2NRW@3O"L:B_#/#S8!Q^+
!9"NR/TRRDK!85H"W(92#Q_.D.L<&B/XHFFO MZFI%562LRX8W;<4IK6:T>0.B!/_X
02_222!N!3LLX!+5GBGY!569=4;D2_-MFL+K#M9B0!@8J=-(8YIT(AG+?"4R\$WAI-U)U)1+9.Y!)M-53?328J3-
!R%1CKIED*DAC?_FN8,44@EXAXL;020Y2^;+0.0/N&!6U!R!)GY\$0GG.D@(!HA+!8!7 MD!7
V8(\$SP2^XU6Y!CABU*0;+!R?/X>+LP16 !9^*=V.(6@FB/N D&ZYHD M\$Z*9D7T."^/L3^+2@SYOQ%3H=+
(3#D!EC_!J@0B8\$;@!C4!@_H S)!O;@_) " MPV1-S\$YDSPRMW.&!";FX"D!??\$;#=/QA;#.L30A!?"3C.WX;?
_637_7@-8O"OZK.W%RY+H/3:&H*#?MC6@_ \$B1N MV*U@2\$!"E-29X/E9CG9<"PL\$P-3R8!^2 UY0_O#=#3E
M82PF7%\$0:M2TJC!Z HJZ!#_89V;/!_!^!A(3R\$H9W<'QNZ_5_?XZO!D6S+2?QX_*8.0^_2JV+TP/3F

MQ^Q\FW%/\IGH=09V924[6H2E].65HH'6=>|K|ST|T2|)T1:BO|QVIG|-MN2WU=K25BW,Z^%16_ID48>
=LZ|&GX|^|P:>G8YP?63/RT!|.^\A0>F'^^XE MB.,E:YEF|G\$&G|PF:F-M=(IK)2|T)E\$G:-7473:60PG|2U+I3EV/RN4@-
!_G M/15?"/JVP)*XK>W<@27+HTJE%_*B/R4X0NM2>@P46+T:.*%UT:A?T@,V(4
MRS8S>^@FJW|T0TV,5DY(VAWWM3AKKIXW|27%G(%9DLTZ/O/LW.9Q^9C|H9 M4IU"Q0=@_ICE3(I3P&A7?
42RK|^"95|QT|QB M14@*D%:40Z|A@!@R0=VB770%: \$1#8M04D\$/O1+@K++D^*LZ@12QXT-COE
M&TC3@O%\$E7WVJ!|)46_|S)@W M+1,Z|Y|YS(/IES|X>5_V5WC>V>^|G=.W^HKG F_#3HQ_Y09|*|8|_47|G3 M>+
|_!A|3GSSU/Z5|6I15P3(_*K M9ZW=|41OE_5+Y|8|.2QR+SHW 6HG/!_D3>G0\$_.|P4_.|66HR<6R4;:)/\$ONC;|YE|Y=
|_3L616<:JGR2 M/H=(1)100V. #:DI+U.5GG7-#48|DOI:Q3L|8G+|VCO|_E_9|HB\$CIP*34 M#
|U*:AB/AE9'H3P*Y2_WAN?%5F#Y;C6P4|/+7.64GLOH+4KBV+=2_|U@|ZC M.Z%R\$X6=W\$F60:E;?
XU18|!_C%G@Q|O:B=(0J#|_|_9F(4-B+KI6DVNEHAHL>|M_K0|*KJ+"5Y\$)O%/B
C=;U3K9T=4ZRRJ|LCJ|O6W@VK|X|5_G")#N@D&|DS M4_X(ZDKL<|S T)=3|_R/O?*VWM*5|462YLL-GWG1;N|H;9?
U>5^61DKX# M E|GR|ZM3Q_GW+Z=?WM4W3(3NIM/"@|P?G^ZBUL BWXS9X2;NC)LP-9 MAH.HI89|IM(91&_
M6+_ZC.+I5V6Q|MLM'D 0 3CDL" X"BE*"H3?;GEQI+|@FDSBES*TTT|2Z_D8 MPNCK#?O*00|B=B=|W|3-
_|J6_Y@D#>5*<=JZ7T4=O O*V&: M\$% MHG'8|6'T|YD:|30EW_%X|YI*N2LX9P|;C
MUNZ2G;|ZD4;U7|_ @3MCZ|H;|_#|DL_4W44.O|HOPOM-#SBPAW#K%\$0 MIE8_P
2-WR30+UTOM9=Z@#|H K^L_!9'+8S*:M%6%Q\$C_|N|4VK7S1M#SMYN MA!MN1*BR_JA?^#% ^KS.2TU|(_|J+J=11'-
=>|O|H0Q3G""B&CKY4*ZE| MJKR25H)N8%-UZY*YQZ4H XZ4CKR|126C|G*A""KXZL5>14:??%|G_X^K|>|0%
M;DA|HSOQ:|H6_9"46%/%C<"RZ9>T=NHT0)Q"TIY|1R20&*MKP"!>Z=|U M3I8X%K579J4#&8@49B?
|J*&3F00\$|>|ZKW|+|2W_P4SOK&|O_J%<9_VN8> M:R=4* 2>2^*|4PD_5*DL>-(A2 NMA ^|/|P1'O9G#JBF0V?O:8F
MPM8MYL M|H|_F|H+\$Q"!C%A.??26BW|/17#Y|FX"(J5|5>""BFT0W@F)+.6%L+1 E
M8G*86%!"@+\$%&+|>K2AKO*U4"4E%P*6|EJ#|L245<|Z':C2|_|2LE))RAJAE M|(>#5G&_JG1ZJZ\$OZO=>|7=J=
(ETG3Z|PIE736\$4;@04)G@=;D2'9U|1SW6 M\$%M17S|S|J%(44%5GZ_C|;Y|V2G|??+P7ZNW>Z=MA M6.;E^|5"
|HY4+@L0P6U|*:@MIRV>#O%34BZ55.BD\$|KP#KB9M."Y-F|
MAEF%IG_J|C^|S|V"G@|_|8/Y;ZCW(T"MI8|*%*6#0H<"QO24OQ|O\$%*/4|D MRO7%1YQ|K)(?^PES)2YU+*B9SEK1|T_?
D|(V^%0S(I+A.AO5+0AE:R7S|H M>K;E7\$%)'"|Y|G_27C_%|H=9?G35_A;:(*|60|3>>VXQME_EMI9*?D81
MFR|LV_V;RC8.P@**%U""H<|W:##ME'7;2?%WHM<26+0H4?%V|+5< M7W+*J=&S_+?
YB|7:##KH2.RIKOANG9|_|DAP9|X0.7FOWU_K)_8|2:3\$1%R8=XC3BE'SEMQL22R4WKD|7Z MJ>X"Y|O0)_%9A.
|2K|CX(MJVVQ|1=2I797)&48C|JZ/_M_|JD.+5|YGT:U(C%M*E8U9C=D9_.R9|B%:(2OZ=X@I6%R&JP+!?
^E):MWBBABR4@M@E5#J5;|T MX|@|_|EX3Z|7,ZA7#OHSFXIHUWU\$#OXA-G(5:""0+4>?*>T5.0=E7_O2UB-
ME#UW_@|LA1*:(1'Y'CP|VLH1)/R_O4L_11Y#B;L I=:(:M)9:U0Q|5@NYC
M5_E:S9(M&3XOJ=S0GWGCUNB|ZHD"3Z"W6NME4BPR="&K|LK0<&?>NZ&M=04E MIY83V;U5704|LTT2N"%B-G
6W%5I@#S 2% /FX|H>M;D)=1^M_X|D|H4_M_K#>IRZV|MY++|N|ZL|X;W;|?^#,%WHSLL|'82H)D?3=|2>U+R
+5S;7YW:46;:\$>EMEM0<6YU(L)NRUF|6<|28@ |?E|6_?CUGTVZ_|U>O^V|FZ#|V^
M%|T_*A5&%ZGS|^N&461^OX,&SD>&S0.^3A&Q<@3U9+Q>F8|'GG'YC>_DA0K M5&1_@JK|H;R:M-ZI
|K|<+|=@>^+^+W;_@4F2*3K'NE3"|J3#PHE_|_P35;^VND MSY|Z9T8;K5DW0#6R^QH|6N854QX&|9
V93GH|H%O'1B#9"YGI\$68)S5C|U> MKD^>^6"Y3>|5JG<:K2+ M7>B5A4WK2&S7Z<6C_*P#|HY_SXIUG9EUK_)3RS
M6!_S=X.HWY.G_/AAE2\$7Z2J\$&9UZE?V|KOWN1K*L:&AM0/HA@^\$C^C)|+)?7|+|O(^|6ONH3BE|REF5?
GDN|9;*EW^L"|1R@S MJ=RM7U|_ THOL#3#F+A0S%DG6:"|XBAB|T4>GR7Q3C_
M_|+@|QLC|ZMSO\$+_K+JK\$ AH71|U-D|Q@|_|<4_%SEE!|=M+=%O-8J>M3YGI_E_39W\$:
M/+9^L77B&X|Y5F/>+P|Z<+|-10.DT&|G^@C#Z= %VA9_1S2Q_M0#^GR_MU8W/EO:1|>|_|(XM/
8L@V)|H_100&_W.NHM(ZS*H#_3B_3|B?2P M&0UJW|61W|_|WCIFBK?>QRTG2V77C657PBHB=8FT8;
MJEU0>D.E4G9YCH*\$;1'MMPGAF9:TF|B|00B0:0?"O^9-6>W@|')@";GQ%_.MLW_%H BGSK)+(L|J^|_
Y|O|U|H7A;|&E1^|7_#K# "M62+WX#;#_9(G|K M|_|G|^NP4@_0|N\$N-O_/O|L?
D\$M^/6Y3^>^)|J17R6P;6;+Y66YFSSY>..4_|M+U|R3LQV#ZCZ|*5K0R|?N2AB>Q6|X-T:D|/PQ/=(.KO LL.BFF:L|N|5
MGH|Y&RT&9O%)|W@A|J|\$E L"0|!\$?X.(QF+4+4LD;|HB&W.N)BJP1Z2<M^<%1JCENO|Q>;*6K-
6>1^@FW_ZN3%_OC@C0Q_;\$C' MD75(2_GB=/E3.\$|B^<_#JADD4++|_M:QZS=HQ|S9_|#_H8AE|VT|U4% MB>Z3-%
|X|:7092-T^A#F;27H3C*%5QR<%KOO'190;16";^V>X\$^X?R7|J=8E*|_746.2A&<>T5&<%K)
M'Y"VS_3K57WMM;LTS1DV-|YX%L.KFFT_*_Q4QD"U.47'059^R&XQ'A_9>|J| ML5Z6BT#5E2S@0A80S:AH 4;?
X(R+|I0CV1Q&+|H:WE ;KRK)U^0V.3\$|>B| M^/6|Y|W/R?74_85Q)"VG)(S|'6MHR+V+5|7E103Y@%5Z|6BS*|2O=C) T);
M|SQ|LRE,QVD3HBBE9D:T^%8_S%77EMJ#UO5P|6LRMBGB|_|>COW?EWW^+>M8X|IM9F=YF15_|FQ>PU
9ZC_'H8*PECQ3C.FP*E|B;^_|V F"V8H5<@_|M@7O|ZAOJR=(&AR8?1/F3|4F@%*(DW_1|26'K'G%|66.N7;):_1?
AFDMH^M4.C3'E+WZ<\$;3|RD-W3Y^A>NFZ*6'_28|01MS_.DWU|_|_58|P_CV?L1P|Q
MHWX(GO;2SE<4PYSZ;31\$;|WPG?BJ M+S=|OW\$|^=Z|Z9NT%&3XF<:KX|-MWL_|
Y^K;#45|Z58#_"PB<_3F%UNP1=(LZ;..D7L@B|C|L|H|BVMY72|S T M4#|ZNNC^YXN3U((=2EOR|U|XY?
E.2X|9W""7=%C_K2S_19?LCT6UC|B6@M0 M145H7^S#;|G_.59('B|W|31X=3.L2,*%0L*9#OCO"S@:9+|85NY?T..I&
M#Q|5Z9NZ(7Y;"|_3W:RA*;KP\$4BZQB\$P.6&(KY0K|H|5>V.5DL#VQVE>I#8 MV&MV;O*0K:L5I2UZ&U|=XR*(FKA-
YE| MJ^H(?F??|8DF8-%&@KJ1^7I7.3O'T_/QWWG7_77@065SA<0&N/C(K;|CF4 MVR"_L5M(|"FV'_X4'%T451?Y
*1*HKAN+;H@2MN+D:8AF/#8SC*1U0_)> M2YT3FN|4@C6E%=3EX) B(6Z8*
<5Q3B8)/PQ^YDQATE.B|ZQ"J|KOH|O|H M|H

#K%W%UE(RPI425CC(MS,V)-I.^8\$+1(H;M1HZR%UB2X4((S9IOPOGM-/J)\$08?;9\$*Z#OBFK'Z\$.#NDUV:7SOI
M=F#%@_ZOIN4+VL8'R#"?:VY-7'^<J\$-I)'YA6R/WFNJVWL?YURDJ.AL<M.X6S\$BQ4(\$>59)N?GIUJL;DV9L-':\$(
:UN?.UN<-H@PZ5+91UP8F7>GHM/97*1.8G42N?H#J(G,5:IT_65:=TREIWNV%;H3WG7-O2T4A2/1"L=-%I2)-M
7#J/0H9JK*03XZ6S%0.)9VK&O.FFY.GQ+2/N\$M8MR#.3>D192Z14Z6HZMQ@FY>JL+?AK@2I7'Z3J2M\$;INL)W7I57
MQ7H5NAR8A1T'P1XS.AG15K\$J#9EQ9P9XL1HW+1P6?NXWH/L9#N3P6^PX/GM0:LR>C:AT*80\$LU-/EZ^>F@BX;L*
<3V&-(BCC.PF.EEJEF7Y9BX#1,Y>/A/MJ.FD."CG0L(Z9C4^>^HJIB6^9:8Q,%=",!H73TDD"(PY4I3H^8&^GP:0P
MIX1R(18N%#1!*,6@,'MS"EB"t">F"J1E?TY<("3-3*3243Q,^H3I12KLLN,CMRE(@P-RCBCX5UX?
2U:9,\$XZ)M"O:PB2?2*2>(3AEI"C)3N@43TL1YJKG=E.MR#"1"/1+TIEKHRZ=O>NK"MJI10"JA";^5\^EY^H=O3L%
<#P@SZ3YZSN: M6C"5.IA^IYJPB(07U(PC16QOI0W=6K<=L*4=N-V5XW,#/<=>J#(DBPIK2PH8>BMD00Z@IQ/FT(LQ-
AV,JYE2(^2"2E8-%3N M=5>#?;B/6Y*^B,TLU!B3Y6O\$BZ1.RYHC M-(G VTF8@YO440+V-Y0SPF:89F_TP-
7EC#8*K@HM-JM88&+F9>T,\$\$('L&KLY MW,%803&[1I +>W_M^+.S7E&H"4D3;WK>/9TCL\$S_U%(.#I"H>YP/G,1-
I*M>W15W.NIR (MLT&E7 O:GL;BYU=2I<7^C32:4G_&^RW,J%"^P8HUE:2I<MB/8BE_E?<=<%++Z;%KY5+1J0^"
ID9TC4 0T%3M/B(B77>IXEV>+J@2<@1^0 MRZ%G2^5I^7U6_&1H;HD310=3VZ35^LX)/BYTKQ3Y(8R?
DEBAN&88@2(UI@M;=EO56AN(LT;FD=J>A) YVP9=^L?^I^F 3;(W^*= \$%6LA!>*(+=O#># M&RY@_&5=;
7(X9>^+6&ZL;(D96@Z5R55)IG1LN17;I>+36(C;ZX&%)I M/92KA2I7"F4/0L/L"3?>Z>#)NQ:A.N^9DE1%1">KM-
AFI&K7R; :UJ@GT; M0SJC@Y!-(0T'R=IYJ.K=+1>YIL^IN<*>*>*KFBICH.*W/HJW 2;#V3AH
M0=6QIN.3\$3=?1\$WLXB;T)?\$S6_+|OJTD0\$-BIH@?F;\$D2.VJDAIM'B74I M%FNA
%U#6=FJIG8MN2MDT2J.%A8T&F<"G('XGBM"YI;X"X|^:M15YM+8?1Y M=M.TP)13U7_N&OW@VQ=1F"?
6JN%QF^D)I2-81,=,*RK;D2*1Z5HU=;2N! MM=3EL<="YVS#<=>)PZ00&^2PI;F)4,KZ%8FHLBX7E3VRJU
159\$FIBI0<2I M V!^J^)#)GO.TIPWCM5RUNT7 V=ED M.GH3Z[I=M";HT0D8K*VHIG^E9E-BF121?E?
=4_?^SWT0^@IVC-)EHL&XG, MG&D8'OI+XFD?D7I^YMU7W01ESR5_Q) \$1. M5;YH(/?;.&NYH^9KN-
O?;A1HLC^T^YV:MSMIV;P\$IO&BT)MP_BI(BD MR8;)^KL^+_ZW5F^X=S3HMPV9/AP;55\$%>[<1=;?D<
P^AF)4Y<I^QJ4WG MEJEW;P\$IO(N6LD/YDM,+R2-K1A&20ZG%>OOWO^<^I7I?#"IMW&1+XS/H3, M1I@XI
+NNJZ@^AX=-I>^/K=M9.T B^I)TO#;2_3G4!^%=Z7^#RH^X#G0; MX^I48@IGQ239TZ?F.SI_O_/P+I^0T;LP
M;@7IRD.9%#^13CV\$;MA^#/:A@LO_#&@;#%#=#GAE:A SZ7@2DR\$R^OV=BI-
M(7OI!U'6:17APS\$93G@)GT6R:4OCBA^MJR&:6D E&-UM\$Z.CN U6 A>> M68G02=68DH:5F;^O!)G^V;R(M'5K*
ISYUAWZVH?>AA.%52(AF\$>XH^*#;\$ M%HT@NYY2-X T;%?
EI6RY(3L&475TN\$Z>Z^C^<,F^I^*@CKU^S)K2IEOE3UC;4Z;^O<^B."P4>A0BQ;1 (^C MX(^JOZF<&TXW1) %?
66!QT.M1.>P84HLI\$6;_E(E^I^?V6!QICT2^>?7/(U^ M/G^11)\$/H#^R3;MC9U6;=-FPG6:DWZ@4, \$DJ=61%XYG-
V#%#_77#?20GY M>_J\$=^I^F<+=O5ZM#W(AQ^AZ#4;2CTX\$/4#_X<=3@>A7>1E5=^#V?*>I^> M-
Z=ZCD;CU3KITQ/L'36!^_0\$KI?^S 7DG_X+?HN_..N?Y%MU*>WB0EMUON.& MIAJH^JHUH(HB)Z^I2M^1)GOE=0KI
U))@EHT/X%|A=PN* PP3K A4T4.9(X MJ<+15TH\$K%L^M0-YIV%QH(1IOTL(5=M^8W9BZ;?
M9Q>HD=MQZ1.1HA%78EEN2%(!Bf8_06^3>O&-L^RZ LD7:Z+Q1XQK9ZQGL<3%;^V M&7=B!C\$/+X^2/(-GO"
(FY;^YL%OC-IIV E)U)UP7"JHG M1HZ\$Z(H^K.2.6T(NZ5HY;H1#*_LPPQ V&4^53=0%<..1TH5-1WHHC^E+!
M' \H1JVP#1-^#IU-L1Y3\$;V#CL<@#AH"-+N.35LDN>Q=JH^*5"#^9>%3 MA);VQ2)-U2R>6C-
\$L1\$N@NH^>K/KU!\$Y6-IEB6/VHW;&51=H\$)6X4(15@WGE M6\$UJ\$;UM2 OXFYU40FQ5@18
:T"/0_&D7L2DKZ@W;7DRXIXLO4DR S&7I;(^ MWOZ1+5S(4EDO)Z(I9G? MM\$JBXT71/AGR4L;2&%R:9JM6?NY-FE;?
@W5 4-3I\$ZYP2JEC9 MI" M:WH=9QG?);N2 = JA&2VY HJXF&.EX6*GZ^ZKA.OO3X_010UX_ZX^*C:7S M?
H&WU%&K^#^R;CJXZI3)J(YXL7AU+W>MKBB9@7I%;RYJ.GLA9I)\$#<4H& M4S419836H%QH@.Y6-
^X2^E;I^*QU2^95)Tf(=13FM\$?-E%0 A/O YU\$#?27T\$ M^LT^E9X>@4J_6J@Z%;FAV.HI9SCRY6";H92IQX9:VEG\$&U17X?
\$IM1 MWJ\$?_I:~?U2W_RQ"PF%9>GO@R4TVI<27V7JS;8I^?UELI^G4K\WICNK#8I/ ME#;)AO8^Y#^G^P1\$Z(76)\W2?
NOINBU)4I 4=3UU)9AJVDTR+YIU/WYT2 MYQZ)A@IL^*JREL;?)Y:B<2H5P35V7#GN+^_NPMIO9Y-T#;TSY?DYR4FH
M6T8;_82AUA1OYXR6A6H/AH&*<\$U".V8>1#CL 56CQ\$%6YNX^;OG6T\$T>QR0# MP9#GSP(HN;V\$|I(I&WCZNS 4+
(S;.31L=ERI^76/@ZXMA^I^X&7!AN"? M?CX,P2-C8WTXO/..I^>*WP3LAUT=N/OO^"M4\$DW M?
H^4O);MZ8ALK<13A&LNB50I08^E#_XG#Q?I<.;YH9ES.\$KJ_BQ?;^WN?";.BQ4H
MR9^KJLV5IX"B;K=F228D@08H(KTX7;_1.4OKP_Z%?TNS;=32SCL^;KH^PZB;526_SIP#_Q^LYNR M2D/U^Y.%4 4D7#_
MYO:OTF=7GI^%FID7G9.CI\$;L3=I\$<4.S5I;HJ>DG+^1)9XCIOH\$7HT.N6E2);JH>28V_Y M%2I7?2\$8>7_)V^Y^16W'
..^9W??=>I^RX)J_.I3R;?VOOQ(#051FK+ MLF^KJO0GBV4>44\$5+*,BFI1^6#Z3-2)H8K/"XL@*43I-NME+BGF/3PI@2/
M?FZH7?FX%|^B.3TCXAG@PM"(7GX1Z^J:0G_3D;R^C:E-@QIM+HKBG^/ M^JA&GW\$;FSN")>
(JJB8"9PLJ106I<=543(2.E+^H/:(^4H@4T^S)D# MIB%?KWC%Q_*3?_2BQLR/16512X-
J\$Y@66,2P1^/K@1%)34%7#I#;T>V++\$^<^<4D187/N8@@HA8\$4<<:6GP_WARR5E6I8ZZ^:T@#QB3BT8'6H1
ML^JER<T=X6^Z;ME">+R^M:9D(NY9\$^IY<1+I@6EPTZ+1G:E 47OWGEJ1D: M9:TDTI85H1\$QO4(M5Y9.LHL?
?>6I+O5^Z(WI^V;8!1;5 MG5A#T;I;#;=C?Z5I^9;*(*)=BO\$9^F+&LKWNVJ4_<G3_NM@TGJ^?9JEP"
MS)BS^IXW^X\$ _2M2W7=GX1.;7&(QI^/(<^*6)I/M;1S+TRK^IYOSYN?B:CQFC2G12HJ\$<INJ-UIQTO.H\$
\$F(N^54K4YUI MM;G8>..5VV:9FMHIV:IO!^/2MOOMA1H4#G0L2CY\$IARI^1;ZOT7)#)N/&>I%
M;Z\$Z98QQ>*>O0BH3J8>>I%=-S-\$>2#1YJL^YT>-.7O@A=NM0*;7W6#I+8;
MT#13NN\$287NYL&KIQ>C32'_@Q9RUB>@/8=PS+KJ14L=C_.3-#2**V(L6R5M% M-3(\$H(^I7UG2@W5JBVOO8I@+
<"RW7KZ1<I4&)E9_V7V9N(+T15=XCN#D\$;T M:Y1?I@_.I&6SS GR

^4 S=P4H&CMW:V3(1M;7#N*V;O-'OG+6&GLH3\$JE?)Q!YH"ZFS*
M#S#NO)WFP0N+T7L=F3,C@C>+JXZG6&=>6IMF2;2\$+MF8M;=R(O'#M)J<8"E_Z&(+
(E#&M8)AWVL">D>F5N_ZAN M&7_I92TA;^SZ;VI%JH+'QRZIG<#;G@SCQ4ABV/(I*E0JYI*5-38%I>L@ MY6-
E)K\$64Y023YMGDEMFH"KE@M9\$L#1E#AVEU@AWLR@1V&Y(W25I=-
M"JA;6.%A6JHC6M>U'9IKP321G9MHVFS;B%J"12"#VG%1G;ZK57G2^1<71\$24
MZQ")1KD;8/Z;Y1%CI+OL\$=W"Z2W&V J@QQ;VS-1">"MI.\$Y6P)S@L;K)H-BX:NZ1?#@9(= M+/V4B1R8#-
+1"G3HESL?J"J"W\$FY;&3.2UN-I@K-E^!34HJC(AI475S?_?IQ M(Q^NA6E6:9WOJ/%+-
Z'OS5I-1%&MRB/UO;OM'L6:679C|DCZ;|<H\$;6/N M&)|XNA"3_G7IX9*RA3)6SE_MHOMWI=I.JGP6F^CO":6;A-!J?
X32_3B-M/VO?;D P^ZO7-.6F6D3;DJRYPC; (=R M=I5DD)9CV&/3VHIW4AA /A;3T<^U\$=V;Z3?KMVT-1AO+BLFXZ"
(=XPXN("M3C5JMS|"B"MC")%=?W0IK^R\$X;S\$PO@AF!|T=6I7F#>BY1<5@%7TWPYX M* T7<8'O;
H@ZVD^@.#X#9H9D;X\$0M@W>DQ4P>YBO^.(;\$I=HR46I>R. MMK*U&;LNANS\$D 4X?IH3IV\$XMN_G@OYCA4T-
4U6L&@5N?ZCG|HMIQ4-T M&#%P;IED16VF!\$ F\$Y3ZLC%V2'V=YV/CT<>3<0QN|/6(C_UG>|,^A/M M+;%34Q7K?
H9#MJKDOJ-|XDOQ|0UN_ZEK"X-G;54*W^&((GS;N;G@Z/> Q|TID*TG<|L<^RRUCU+ 5+;(70).I M*RC;WG+Y&RV-
+A-, A\$@H(O)O?I\$ PO>|2|K.Z8FF5: MD@G*J1\$1HC>Z*B4E5+H/=7.C4?8PFAE1SO)1G_HAB7^LKB1A|K^J8OM.2"
MPI:+B@5F\$;:(A89@S+J)*J%D1CH)28J^@P.F/PY|XP0*+6*?A02;T7G|0YD- MTF&2UWA\$;\$^.\$FID1_*8ZG?IF4(K-
"D^=&08N3IYYT=+P75UW<#;"0@@ MYI GP=053&Q\$D^T/O.-OY"/*T+C2\$S^OHNUZW|OXI9Q7A_Z3H|^+OK-OZI
M^SO:\$(J M?O"^(5*FXPHI*)/(;\$");I>:4_3E25ISS Q<2WQI& N=T6+PT M9O+D#L;<@NO40-W1%+
<0EXLI."\$3.BR!U!J9:1UYC""*^N^G6/AU|7P@% MIZ4U"\$=^J7A#V6B0Z!?
LV_05KFR7;2SXC&AUJ3A")@%|HE|&DYE|1;5*7| MMFV+ NH&M/|BK^PG++&O8'2+&VC5-6IQ7|DW
_3(3K1W\$B3&KA MOQ\$9_9#E1.3\$8\$N9U;71VJ|@P-"B")I(Z3=-M*%J%/@CDN\$T MYL4KH2_D M2R#0%W"YI
|4T;696(%A|5BZKPA.\$G|SP> VB=@V91_A)GI19GJHN)ZI+ MNT|9^TT,DFF=%HBID;X0L#JHJ"*MV>?ZOC_P
M<7;#*I%@@< G9MT^YA:7-(PIE.L|I;-5QKP>N(5/O?CW7IG6G5M7UV187;1- M0>HL-
P2CX"GE56(V/RGZ_CRN+YB8\$L%FTI|/4G8KT=YAK>-I_4_D1KB;&(DU
MGD5T^LF7+D;VOQ|NP|BH9\$87/H8;MEL;10;H 4^-0KACQP7KFDF |TF14S_MZ)|07|PRO9K+..2;*92_;;P|/\$.D&/@:
M&U;5SMA;|*S_2.N)\$^URLM." ME4MBO&J6\$NO>;9?;I|I|@D'U \$^I;12'(C %M M MV4&O6R)&_GVHXI-
/3>|%>+H#=#4*VM62N4#|I|VT8)>4FX M.C\$QONQ88QY#=# M%<>@PQ1/%9>&/&^81M5NT;I=C1\$XCD&!"3J"
(=IYH%#V60'K'OR|*LO MLT>4RSYA-KEDT|@YC_/P2I?N.@J+M;6I;S9(K&5.B|CA@4+)|D78T'N&IVN/EF MT|PC#
(TSRQ(=I<9B@A<+?B(V>3?E1>UX\$^T|I^?Z**BJC*|L6UEO@#-@BA"t% M&6GV*.X0L"0-ROE(Q6JU.QR#;
<4V(\$6T<#|QO5@|PX;BF< M3!_8EGV@UQ 'H/U>P/|A3T MI+Q3XI|^
ET_!?'=/OO)QW_36P\$B\$*K*_E&W&G<|9\$5V7(VU)OV=>8.YE MV&R"?5#G%6&W(C10AKS#9K>A+&V'/F/D5=
(@O.XI|=;>@-R?O'31<9G;YP0#U M;IA%|HRU|+2E8=\$XO5;N1BRPAH%^@ZA#2046I*W&+<*&ID=
M+R\$#.G'/%5*Z;WE2V\$O;|??^>RU+96OU&8Z&; TL7CRIE?LQ<3LB @JF' M-0PGTK6*/00#*GP-5|9A|84U (U9U%
(W1W_XVD89VSY(%+&|@/9R+1+7-/I@QR#RQOQ5*8A.* M.-T_*BFD;|HJ=OX>*Z3>7?@%N%*?X%OY8SQ)V*_25-
"S)@.A9UJ\$S5 MI#W D+&%H \$%)?|T?T1&2E@5>D(Q14|R>K?ZW5J&>L(Z?G^~5Z&*T MH64ED\$WX@13>2%VGZ;
|S:6ZLU|PY?TY@C+;W#W=#OG=2MYHW;%9QVO6%=9Q
MO61D@%/0+>1""#2|COS048_20(N.*U=\$^>E/DYHQ%)1HC/"RT-H;W38V1;HC;842\$_4G'*
(Q|O912;GODLS,0>;OO4O0GCC MLBUNCI<1HV|E?_?LP80QDM!+4)=P9W\$?"G*#@8*I64\$ML|D50+L2UD'NI' M*6Y!;
(E^CYQP7_4XI(4T(>&|OH+)"^53N%6HTNW@N",6VF9F(E_9Z-"L'M M2W)%UU;JG73J0;54DI-
)BPD;C)9*0'5B;JR)#8GKM(2&54HJS6Y;IWH@V2 M C\$A@14|RD%28R<9JHHZZIZL;8PD|@A5;\$ \$ MC21VF"#
(4K)I@9)%X0K0\$#=#7^|FC+;+>|P3;C2^N;34>J1AA-0L|T4;JP MMBK%U TU^2DV@I>DC/7^0L;+2HG*^6.D9S1?
(BP&HBI6GC # "I|/ERV'9> M8;X/RV16I=>RD4|I64O6_M;@IPXN"JOD725.S(I\$=(43BY;JB4PKGB8CR*;<1_8%
@M5.C/;K1#1<+C5_-V1*RM_V2WY5RR(=WFF+RNNJ|JRH;3|T2J0+^SG
MWF_KJ^5N;TOJ*L'DIEFK945METPV6 AR*8!NC(E) HK^OXERBC2M-N8 MOGLSF(903K+;;+ HI-)DS/+9-
|ZD7CC.\$IO)D.UD1+"2"W=X35E-*XBNIX4%|N9RJN' MQ4%/TU SWOU;FD+Q-*#6WO;D>5XB@;.>*\$N0W|DC*MS-
C3_05"N.@G|^E%FC=;;53#X<>88#"9;7VF+|T7OY(IW*W4I0Y3=%@5)= M7O7#)L&|A|C#&I?=-ND-P6TGKZMW;.-
H#EY22?0NEWA>X).U1RIS0\$;I. M(I@=5%9F24+IU_&X;|6_2JW4N?^/&+E 5"^Z142R&4_*8C\$K@KGTU@H MC?
^|M|S38U|^BW_Y3\$M |MORS|75;=-HI"SJ\$_QLAN2=IDF<).6(K&9I%? MZTLM&E;RMBJE;-.5.Y(4%J;\$DXR"UZVQJ'
M_G@WYUX-^2.ZWP(2"@,%=:DXS2;>1;<;>P;\$S%Q|@TIYB?N'MSR;H|@'
M%\$+4Y1(L)H#H;8;=1DA=TR4O\$T80_;;CHYB=0;JU.8;=*TZ1#|^PT4|F1
MLIE)Z8G9@|CK*^X_HK6T2BIA)M%|LB#Q72K.QY+&O&D;LD=^#H2FA%(J/Y
M6)H=5ZBFWZ"PT.3I8.HF04_>/QXP>V<3(0MIXN&D1\$^K^X/=SAF*4B6I#|RP MXUV3Y*+AM1Q\$O*LA@+F8_+=
93G;?;|E;6A'#XT=> H6("1-8&BBF05)OX M^8U"D6EPTNY\$%B
\$X"CXYI*TBC4TPEDT%L<#COV_\$#;FE)_W5Q_9;BR7J7@_M4RA?
0598;*IT6(S0D(|;|Q|&.#HCU1\$|HJ25Q4;^*%C6)E14FMSS80R?Z # M'\$6L\$5"D8@;OHR9Q|)/..A\$)??;|B";*#&=-
\$|T.Q@F/GE;=I@B%D-Y MOY?37TR)/Q^ST23X@.@QR|X/1*G>\$%^S0 M4='25+3B@^E*T6NRM QQC+?
%+>SOPA;3>Q'Z#XU&X2@MI (+2K*. AGX=J; M;3E2*1K;.>E5;-(7%|9;B9&=D"4;=#,SLF'9;#G^X<'A#E#I&@JO"J|&
|> MB(I3N+387G;BHGP#_DR2<\$>C|OD)ZT)U6#+R(-83<1G01@M'CAZ4Y|<"0
M.UU4|EN14HNF22AT6;9&DJZ\$IXTV*\$BFB/#1A\$S2<@4E<9VIB0J8
M\$J|@YNAW3>U66ZSZT;.>H<|H;LMX;0RC;E@*-VWZ|1;"6P*GJ<;24OP6?Q MHDU&S2+<6)VA|W@\$D-V|X|B>"
|*I,2>HV|;.-@>0)\$ZY5"9NG\$5)S3DO8XO MI2I#6+JTI3L<5Y(V;JP_W1WHZ7P33%Z06(ZD>8?YFXOE1WX^2O;-
QHXF' M_&UR9&BH;B=T6|N(.6D99JG;8OJH3O8-(4+J@|"\$3|I|=1P9HE>%3|7 7-*J
M=>Y7W|)=C|OCYEB5|(M|JPBOB7X*V5UT\$B|SWIC\$.SGS?ME>T2Z1*2+21C\$ MI@J ^LCN@;KW%W5-?_I-? MG?
V_ MUMBX7^~Y'/?%,M^RM|I>SW(<.;!%ZQI?H53ZI=SWWOZ^?8CNIO4_4E7_53R|W9|=K
M|Q;5L6F6N_;;9C9|TO_~9UJ^|DL8R\$WA-A)WY MOZO?V;2K@<;OOQST0 ?U)?LSG(GT-
#U50R|/"DXI*BP\$|/ZPO674R^*E_ M0?1^6RKU*XYL;\$2;IG@&H'^|FL>C>8^|L)WDH|+VN|B^Q5=2& B>*R0(I;
M#J|HU(23=MW14\$| MT.79=G (4UY3^O|H0\$?AO4?";IELG+**4F4UK\$23V;U)6A0NP<(#M725@)*I
M%1A206%2'K|*3)|I;K?|B&I#RB|SXXHO%D4WE=%X_B.(I7B/_ Z^1078^ M=O U|L/ONQ?D5Y+^XQ_Y'1E.V?
W\$LWE_I3\$&""M980R7'O \$T?\$LBR\$)EHZ MC53UC|MV3_X'L"RF?|PF9NL2-/9N^0XPG|WC"0(GM?
XF4NTGIFA;1\$JWK MZ@_HEY%D+7;ACXLBO^|AV+1M&TIE3?> M R??Q= ZW/T;2B/-
XUMH|0JBZ^+;7U01V7EN&I'8X1H7H|;KY|COEL+0 MA#I(%1>7IU_LTYN'?^05!|O7%2-;@%<^4QCWJO
+S1HX|G|7A2|H%)4/J MZ(2;|G;WJ)F5DU|P?P1_36BC(NK3'E_^E/'8@_4K\$013B??DE0)DORD2Y1V
M4""&NKCI&D\$4\$|WHX'Z'B |H|FJL=J'EHI3K34?8EH-9KH1/6G_?0F#G)#N=<^ (R MI)?Y9(OCN_PN_GIV9C(?
D7S;IE5\$4E9V4/8O^|D\$5|KQ42^~Y49^EY4LS9^~^JK89;223TZ=.%X9O")WJ'8O^|HO4|=Q M H1=%4XX?+/23"BGB
B|T' IN>SY8EU4&QZ0(\$^#/S9%;HFPMEGI^7I%)O M"VX&&0/I79J=31NZ4AIA#;3X5^ET?R
W.8B.TX(I+FT3= 2'I B*|N5.+NR MM4;J8+2YF#|=V"2PH4LFSYCP%(QON6P|Q50P|89P73;2<#;.@M3\$K*/4/7!
M8B9+&&?#N&5-4'S2 @7|G9ADJ;+M?R6L|O|PP5WA;M9|N#;+|^C*R*.BV%.(9I MPA2=SD!;^=@)HY-
+6IN;4T?+WMN;))0SESPQY'0;I7 M@HX;RD6U)6L7U'L@&B*H*%E RU8P\$.MR52H;MRCTHR@?1?D>B?+"OZ;!%V5K
MM=2TW!95BQ|U;G"*L\$_5MY^/4KQ48KODQ1SP#@W|WRY5V/H8;OU--%RM^NV8*9BL>Z;G^I

MV06@)S%X3_Y4:2/HGV/1.MV1,>89+*3U1R*127K%'O'H-I#9?I?M1L'_;@JV6.\$3I-M5MF=S6;5DL_MHI=Z\$OWYR?
3-<@"H15H&23V1DLGL)#MR(0_Ma+#+M9'T:I.O^A|+#+5P.N;@>WOSIY>GV5I|)+~6CH_G_Z1W!>XBI-0^&CD"N
M,R_VS|VTNG;H=8NU5FL(>XGV!T'Z@;18PF+B(AV1|KPO*\$6!SP+DH%4@ZT+8_M5Y/C:.\$9!9!QX-/&=FI_M(R%)(;.\$=
~9@M%TJYZ5_~H&7L5:4T%PT2|&+!*.DIV&ZN30P2>+I>_HL8&f_MM>V(-
D:8>\$ABF7>08JMU:T5.XANUY2J0|&UK+B|6KW+>QNI\$K#-W#=#M<*ZWN8>1+7=Y/RW,R\$WH8IEF)L>[702*FE?
2R"MX'6A\$EB?_LF1:4\$<6|<7;|UYM5#0?60&^")>;0RM"X;*@QJO?81MG69C<|P_M5ERVI?
#*X)PX/L<3AUTZN=MS#3A@A.J#L#6T;+6GDJ&%Z:A.LV\F7D\$(I8)K-MX+IM0XS4KO%J76#-
U*Q+E(8E&+YI7D21|S>H+#+9#Y;2+2OW!0U83P0(R%(6f_M|(+N
M;5;Q+M+U;+W;1*1|>_8"~|&>66Y;7NO!#EAL'NDRVWG1EU(R.F74X(1MGYP_ML2R_KA=7K/Q:EKRRO2A6|C&WT)?
%JZNC(PO>M9+;6E9Q^-(GN)=R:B7|8@|_MZ-3L0:BPTRY|LJN;A7H_)G9T^~^SK57U//G;|HUEW6QK/R5^\$E
MX05^&B;T|CLM|(#%V19?9J|D+X;|L^_VA_76QY|?>N>YGDIZ%GNG2|^-UD8_M&L;YR^S%^>#2XUUCG:#@/_FM-
S;,>|2&F1.\$)CN7A0#92=87>X5^T\$8>_M_U9T;WH105JH^0QZU*HJS_Y/OO@U|W>=_9!S:SOX%UQA1DVI<2U.U4
M0B-6%1U6LM#_UGE517J\$|0_KA2Z1#%#VF#%#%76E%+>8SGS_2WKI\$QSJ<_M='C.?Q7U#f;1D|S|7\$/_F;
<*YT(F,KPXPB6@+(&?OK#"T5XNRT5"J8-6P|M4;=_/8EJB,RRIGJG58MMB3RT"_,LM>|L"15.f_M5D2?#ZBY
@7EVE2.1'XDUYWAF'VTI33DAXM@-7T9>LM|I\$<(/|DD)EJ+2@DN_MC>(I;C*Q:CJ_K'LDCQ7,V;\$A-"IV:Y*~0FC?
QEB=|s;8H1_7GC*31@B%9_M4>*~PY?_"IE2)C00%JB*^D@4=\$&6UT:KACJ"*>&PVQ.7FWPS@;RRL8'DD
M"ZTN6W'RCN>2RE|O("2/Q(>V^KJ3SB\$)FI=6V?>F|LF5^8?~R&R6"(L/I_MD8P+=
<1*4:GQ=Z\$T9N.ERVLA/H*H4_OHG|>%CE1DHI'NX>8Y00\$T.N087T#W_MG|NVV|AAH+J=>)Z(SVJR\$3?
*6FUP&CPIZ*JPO3=\$6)380W2;_3D087EJN65=LK4WZP>;1P^"~<47Q%|XWWNM RK5ZLL
M%&S|KTN5632.8ZQ;DHQ8DY27570C=>5GZKRDClB7)QOBM#B*PQ"GW7|9JYJ;_MSH>86+2SG*|;
|N=,86S9)BG;H;_LI#09'5S;_Q8N"15.7531VU|MV0V7Z60_M|C>SYA?~
|L_N_9_|>FW6W;60+H^_X%5@^G;D|T(2;\$"B:RD11;ZNW?B|<7|K+PV&^Q|%,0VZ/09#RA+N;-Q_M%(-
RBIQ5R6%A*K/X";Y|L'4V=-2)"0N0!+\$'8:D8V&BW<|N/IX")WC1W|EH_M_0M#M4|0Q0LYS\$?
<;>|_XGF03RQ^CXX)>~R15|V+T_QND>Z3>O+&3N/^/M-SYJ|?_7;G=;7R9#G>(DLX8_|H8-
@16AC"G^S=-8/MS<_/EENRM/SB7>2
M3US&f|EB?_R<*5V>@>9&S02UR8990/GE(J_PG_!2;UP@V"/4W=Q?'ITDSE_/MI)RW|Z>K_ML^N+#+_Z>V=?WYR|?
Y^<27GS|>;fYKJAAS>_?+>S<_0Y|f462_95|33Z?G);_OJf%_G9W_@#ZW+JXOKR|/3#4";C9J3>5-H
M;X|N|8R"+O0=\$%5G>+L!4=%7/E^_MTH;HFS0!<+^V67.^0(HSK_MX+IXC?L_S|@;_9D+J(C%ZB;)3_Z/&@|C_MG0?
DL_UX0#;6LCE1'A|=AGG%C.X)|?3\$|CYU8M;3"3=XW:84*"8D^ERJT=MG@W0XC_S\$Y";F.XE\$W^XCRE*^!C,SS#C|
I8WE>Z_.I.O>2&RN3D8)5*5W1L_M:GL;P(|Y5_E.5Y*I5*_X4DM^_)OACW1_SGLMMV.*INW-Q86AVI/?C*!4AFJ\$C\$O
)58ZCU%4<(HCJEGITQJXQPOHDI#Y:7"08B;|=J05P'12@HJ|G7Y_FC0E|E.=*0"(Y01#\$(+MZSQI#|L)^ZE_Q?
1_/3_PGH">C'B|;5_)L;HE|3W!|S(%00U;IDF"WMJ/_M;@P(NLN9(%T&*LI22FZC3%7\$;EL"~T_M&_NAM|MV|5H1X&
M%WLZ_LZCLT\$+K"C8TN_4^|9GCI%!.M:8_|#|P3O#B.(J_XDB/M>S0MN2%S+##/73L9XP")?IZO21FRH.Y;=S>|I(&
M6DE&E_2|(7^BYJC@'S4QQL1/3""(??B_P\$~V22%0XB0PF2I2_N_A(F_M|&W)+
|Y"7=O)08E01*KK42_#O_FC|7;+4H'K_L1"YA*9Y19%15_L_7Y2AP_M8;7KY|5YMX9G(XY88KC|
91/Y;2WR;!!'GAJ|HLRBO22=G4PU+(M"HUNF+_M+G;_4F=
|6/U34|<_*N|4|/|^FT5B-)|!=_X>9;/OO!LRZ+OYU_FZGG>T*)=%*MCJ"<23X71BHW40_X.C(8!;I5|S^IOD1WC.BQ9%#
M5AL;FB_@C1#^W=EM=?_?X&W!#|NM/?4SNY"!8_DOE|A)CUE*OH)8ME4N#&B_M)S*RLGW|f@S"
W;_P|I@REI=ZC%X@8Q39|)|3=ST#K*_S|ZWRK%N=-FPI<
MM_~UE6=^(0.D40=?_2UXR_J.SH23WH#6\$F9^AO+|M'43+O4YF;#(P(R^|_M"N'8I;K71
R9416T>PSUAN;L#ICZA<=>J3R'8;MQ0C.F1W'M%#_|MJ00;3?_AZ|KH9F(R\$Z@NLH6I++V\$#%|XF"+_L_Q?
6EAT%~S;)*G|_MOP;|(TXGHT@.?\$MG/AM'R;fTGU&)%DZ/TX3H38\$47W0FZ+(*%DO3F*U8"G_MV-
4%#L8*Z#7+4E4=V*<6#X7V_F.JQV&C_RT8#PS&8>|D;9PR\$U1\$=*0?5R%/#C.^+;%SYEG#6V&7S5FC\$+AKH
MYS>.)20%EMC+_,"S72J>2Z<3LDODQZ9YOD&93R73)*4."WF*O>7R_9!|@"9LBG"\$Z0E8O|O|Z'KD1/|Z\$QN1=QG.TV6@
;_S_7XF_M"Z)9;=8.I=^&8!>A5#|V;EKW/AN^6.A73|_RZ>^\$C^G|/(U:COTA|>|/M//O+J|;W?J%
(T"71K)%1HXYMHD*~0H)(TQ^<\$Z"7AL?YPP^4MT^~*/R_M".AYQQ3EV?
OM'Y35C#PTG6KOL|F47;4NHB;SB>VD2#5;ID_W7VJ8)UK|5H_M(1\$JVM2_FI\$**_UACK;I*(BS
POY_%SHO^V@/08/6F58;+|?R29)D7UR?0HL;)|MOEPHC(J;9QZ=D=+&T^24OUO2!;MVT@|L_OULUB
MVJ9;_P|FVXW-SJU&PR7&Z\$)3TZC2>/(56W)?|U7TT&|/ME.N;V;T@&M|M07OQ\$C52?9MLR(P//6TZ\$75'K*
K|FQ2|JO#QKY|KZS.MW686X;RX?Y=W;G_M8YK-%@TWP5\$R-T|A|@Z1-
U|'%E;_R4WC;%Z;TS;LE.VORR6ISR3HO*92L_MQ6638?IAM2B4-
7X7^7)QZ:06W>VU1HZZRX|T)7TGVX\$2&LW1M|H|A=-"ID_M43\$ZO!39S=/FN8EW(MB1DXZDW#2QE&>MR(^!)9
G|B\$2KIC!<_604T:BB5(%?5|L|HWW_M|BO=H|f|5NWIG|T"~H_0-TW#
P%>BS_"QF.ME;^<O3>7_@KWWESZ)NAL"V#6KI>K*J#O_M(L|INJG2(KOYPDO_PM*X"_8_4_PPQA:4Z_(8OC\$!+?
5;=>|YW=TCHN_OUVC_M&|C3V#I="D*KX61/|2X.Q0=|F)_@Z>XG8MTZQ+CJ%Y|H|Z/RPS);U3@@;_MN|Q|QZ7WY)D28/;
Q_!OOKF6?77;f=8|=O/#YFUDU^D<'3C|W?WF;C9M(UUG_MKW/@|X?E>S(FM>6;_H1J9#<%|<S67>VU;_U_H-?
C;X;|&^UAQ|!WTUW_48F2L8EF_-\$.K=4M_M2MUOR|A=*@SPA5=7;_U3-|?|K|TYPWP9#M;
<<^U28M1|9C;_&1=PT_WC_MEW%RCKI/M|HY?RODN+YI7;=M|Y80YEC1*NHX^P25?2IV^|IX/C5K6<;=#V.TX5C;\$|
M9W?WJ;_YX:U6EWYD5)T=97_QL_|&+MN4405C|99E5G7H0|TQ_J1O1Q6YJ7*3J|=(RW;4*ZU.Q;Y7J|3=GVZHA;:>
M_7PMVQT4>E!9ZANZN#>9R=B'E_~38;|TV7(OH|&3Y\$6f>6-5;4A5I"~J01
MB1TFKDNMB1Q5W6J5Sf0T(CI7%55,A>/QNS06=LR29<1ZLX|NO^?/*|BJZ;f
M;R*YU+L="0;+%FZ:P;72G@B|;\$NPD)|L|Y/+1>C\$~N;3?H(J;~>A)P_MG;~LGD^
T>4|^GC_"XVUE;~K+?SPOW&V)C\$H#9"J-P|X>PPH7H6R_T\$+T_M#IOQ<3.1_%5?~IHR'YX
M3JGKF1QZ4=WXS|CM;C+J\$A=ID+H"~H+S/O9S'O|GZQ08@|44^|H8XG5S;6|+M\$=8L7)/%|7H2+WAR_|HE=-
^|X=XEHR@B;~L5|4;E<#|H|P/E+Z|<|fDB/+9*EMG;0Y3K_MS5@;2V|M;UGANN?B;?K_V&+?~MP|U|
<#|T"C|H|JK4T>6O8M&OKTHVF_J)ZA5^*3T|S|IG<4J30=|Y2S_M0X|+PY0?46NYRC;55ARSZSF|AA?
KBIZOR1)IW6AFS^P#G_0_KW'KGX;C9_MZ|YC|~5WO'TM/SK8K/XNV1P/>_N#UT_4V/G;=O>^!&W0=;:=>ZQTSGJ
M/DOPCYS|XXYSN%)H'O"9^>8MX;f|*~XVCH|3P;#|L2L;+WI<#^S(3%_M=8TW=&G38\$E?P2HI\$PL<#0|^L|Q
|0ZP;7|*2Y|;#\$.|WN47|J|_#F'|VVG<|A4^*FMVY=8;X-B?F2769/P40%0_MO=>EP?2"\$LOT4=
MEW\$B2D*3"VCV;D1)F(F_XT%L_)IWZIOY74H;61D?2C'D0+=ES12X;4_M%)A'~R+NGI(L;5A_M93?
1Q_~AWMMQS;T|Y"YV6W_3_~f^E?W5^WF|9|@>_320."\$T-ZU#"6SPZC&;P*~!8GZ?
65GZ3_JURJ=4GK4&69K^|HD0H^A6&04_M_UUZ|+DH<(&#|>?5\$)PCG9X73=(;|A);#R?Y_M1Y^SD#OT
C|9J2HB6|UV_XYP5IG_?2|H0^@~R#6>"LSD?#6DV#A|><_JW_M/CRG_7PH@")A+>|Y|X85)0>D(2H/30VE_CR_6|S
6|R_6|Q_6T|L)/_GBV)S\$N'T"81~)WM_M2|OP|E|F4>OM|S"W>DAY_ME@@|+TY)Q7.G<|4"(B#H|0\$%"8(C;TQA8-
M\$LA7T?YKW|E<#486&7*BB_MQ(47B43R"7/LM"Y/Q&>J0;A.2HHL.1\$PST|
(*)IA>^L@*5BI\$|VIR295PLRU6D%+>SSK%#5;G"~W_2*PZ\$6>;@|=N|S|f(9|+;W5>UV|WG
M3"0/|Z)RB16^68#W+V!>|S&EV;IPH(M;*3I='9C7YWIZ^S3Y|K|E;IN1+MGN42+R|HXE.=C|YIH=FKX|B|ZP'@N=
fLDPK-?;\$5G5_MG&)&?~O8*708055I+WL>_L'N|Y1P<2TKC98%Y=@?1Z3C'G;ZS?SA#J*_M

MD+LIOC^S\2CRNM%U.PM821*IQ^D.OXVC@IP^K/"H=-!?!HDD9IW^GL MWEL?7QI@UW.D'=-!<.0<!\H0A=KN I_?
V"3RF%K&LIGIQ>79UJ*,23#Y28/W7)&NT M-P(67331.#BS)\$;49XP^|O:-.N3-N ZCLG@C
#)JA3>COH4NV=NX.H2U|=MY|<@7W,,+13945_L^EH-2J/BM;2^Q^M_XIFFU-JJ%,UZFZ?J_>C1FX^7%Q?
V^<O+Cl:IQ>?;LX_?4_B/247R:B8B^MGDO?VG6Z<M|!P!2MNO^\$ I{V/!#IRC_>9\$^A\$CYP#4%G;.>P_JZ=Y>FV\$!L
ME21,55YTEN8+ MV^%X%_YZW#OT#GJ+&\$K;S|R|VGVVX[NP>;XNK9VMO2^M7Q;^X.K//YU>?
#RS;T|^=S;IYQ7QCSVGW08^/5HV|_XP MY\$4B;M=I@XC;SIN3O1A3O38;..|_@Q4'0-(NY2=7HPBNJP%N*16?AQ%T3;
M3\$)DND(A|W@R|K F8|IYS?+2B@WR-|@VS51N3K5Z>==H=8!@/ZE-ZS=P7 MY=D1: FS(3F1\KSSJ=-^?
P|#\$4A#7C.QSISC;.\$F94|HRECA%60F;4UJO M*\$S(CK.I+T=>!?
O8UDNGZQSNH:6\A/QI=-.NXQSM^C@'G4V)FF M.D='2QB: M#V#9K63&86|HPJ1)F*!;8' OK&I"8TOO(CV-
HIWG>..|OF"6^..B%#@0\$5U> M=CS_*ZP71*Q>XC,^A7H)^D^M@Y/%Y6LIXH;^N>:8O>0Y0?N\ 5!|FMEA|:
ME5|A;4W;.\|1^MS@|L|P5O>1;..7<9L=-^OV>LNYH-W82YC9.X#=#NX?+O2# MW,,PJJN^;U!WEC5U2|=C!+L
Q2#|F5|PDR&JEH=\$"RF@A|FLDACFCTL6H MXOZVTQ;=4PR=Z%;.G0%MUXBCGV^/\$3NY_%
M.9Q!;*5>/BYD\$;Q|V^33>'B|6M#^=-38#Z419@/#_D^U(XE4)WHHDH69" M#A^&R384FKL8O.DV?*.NSF1|?
A*VX|H'L;="0Z;Z|T<%QA MU>;|OTWSY|KFS|M|^<*_H 8<)-2:^(21(OOC!LWZ8|J9*W@P@;7R+|Y39L
MU*;2D#=\$=62ZP|S&L32WZL0_-@0D3Q*W<7ZRN5=|L_47?J_V^*HB11|S?;P MO2BV,>S!
(EDJH#3EVB|ILN@CO(+TB2LH/AB*U0/"),.,@G^Q<;H";@_18,B(Q MR&TT4?P|;4ZW?GPG1EP;_L^*O6!^E.C5.(>@")
(Q|U|!R0P?|Z80CB%)| M|L 87/|@")?>=|R|Z S|S\$.1338 UU-E(8"H023EE+HU!@WT@>?R!/"L MPZZY?
2N_3;)|\$YQBWE_5.PQ"O)9|DGE+L4Y0KJ65L=>;G/E3LNS); M6Y>S|.S6?;L E7.C+CR^8|JPMU
5\$S*#Z.4;N8WUXUMM/Q;UCMMH|NL,,IE M>D^N^6GW@+UBSQIF?+TY_/K#^XX%S.)L"N?
27UIC=RCD|RO|Y|A>6DX M;..N>L)Z;2=12YX;V|@6;GT5DYCY>%|H#)+A|B>(.%SL|K^|G&U.X\BV MOV*=Q?
J2241J714P_M<1M51.6|P2M+^WR?T"#K2^_7=SHO<|T=H&X@|UH(\Z
ML_|)=5+!%++NLY?!=6J3'AK5DMO^V;WZLT|/K>Z^U;=PM_16BY@|=-M^|TIT6;I&<3_R_!9X*I7-
M_Q%7^V6>Z,F'0Sf8AZ^\$#%|EELQ|484!_SfY M:9DP681H12Q|L2,P|Q""A1@1@(8)CUXB|),8N%9:60O\;N1L2F-
W3"*|HU MN37+8#&0G_)<6(|J:EH*Q+ID@,^<2F>O^A&;?B:<#*;Y^N=5M|A!+0+|A M8H7-
/.ID0_%FY"+J.C3NOP|Z@@KLU;|L|G&VE%T4_!AEV|MH M#*7Y238\$;J.@&U-(VER?
MM"7F\$;Q;ZOTZUW"JEG\$8/P|F.ICZ:0%3W%|HWT|G M6"5'<#X8PS&..#07(^B|A&FP^EP/&T^D2XT_7Z*B7|??<|?
8A|L#6+K|B+O M2JUG7)|3.LI0TC|RV|KR|U|>99*ZL4SX^GQM<=<=A_?O;IAA M4@/OGHPL^U-V3N#|_E3(T,L7|
<\$"=;YO#H%>3_&LT+"\$(M+|PW8A7&C=@*QME)|7X31|)#2J|=R89T|0B;?RT+^3(5;^OP;#.8K9AG;A MQN|"\$|U
|CX%C;UMO|N%Y M&/_9.IQIE.OO;H>UZM=D7A"VKLO ^..CXX/YY/48&4"!;_*4P\$T.N;4
M63\$|X#OH4G;_="W*M"4@%?FY1B_YEUY,\$-K#'+40);X>%D1ZL6XN5|F|XC2 MQGD@AQ=|
*&OT51Q0);8G59&GLH6>R9T7|@#7)OU8G>O8+J5Q.|WTVYN MFL9^+VT|_-0L1,+E&)15_XM|A"D;8?UY|W7_+>4*VO
MJONEQ*CMHO|/(@@URWA:X1TWPI"N@?;|B++G%(UR.YT|2??;0%QL=2WU|6F^M+)|\$;8",W'(|SD?<4W?
LX>XKQX;A2PWKSQ=2".RAY;J0#J|T40-460.TU
M|5|+XMP&U\$DPR55U3;2H;V*)+5;4S^I^.;GOO5XH9N4M6WN7%A:PJJ7NQMP
M=|LGYHR.8;34R(XO;\$);P5O#^W>#2I>%'|X=N;2\$E2^PX;G6T F;5;WTW M_Z42=EP%91=|
TNQL'OE|UM+1LW&|R'GB 8@X@+IK*02KJ4K=5|QM4|L6 MG"HT#.<#7*U?
6"D|8|S;*NO,X)TU%^_9@#^Q#LW5,M*9;N3>^84\$IKXUWCR MJ|\$";|S(V\$EBN9+25 &CVXN J 9N'WW;
<#?""KD>W2XA=_|?Q(BU/HQE@M7JX>X&X>5&\$LICQ^EW%9LS(\Z;|C|ZV|UQT&J7
MF=O.TE;Q|@O=Y;)|SIH>R.^+T^H4H57>SB>+T#;X^CTAVB7#L;4QT 5A3;LV MK-EW N-1@1/#8>|K4K|
G2;G=8Q.U^W=;R|MA.^>@V|J|D|J8BN<>@KAW37|2QN8KI-3/=!8|HY;|I=ELR\$?Q@V8R|N,%
M#TV_IQ9HPD)K(2=>^5-.8UW)\$0""M1S1.1M>55Z^=L6R_Z&AD89&MUD|CUR/
YIT>>M;H;2#BZ(3;T83|CF\$R03SDSRH1&*KM.D.BW=E,I++H M;DU%;BY(8X)8NFN3^IV!*_THS \$>8;5+9S"
L|\$XZTW>1 M*6;D;|UZM|)#794)F7,2T\$;S>LXH0&8R^9UK-GGMZ%DO4EY;N.\$7BJ3^S8 MNUI>1_>EYW5L
(810);^VE2/7|Q|CP;R8A56%1(|"2H#I&9B?Y=|@13G-
MH|A<|HOFL8*.85SSO#2/|@1;1JGD>|1'37'6X;OYS|E_KLU_WF_RG|^3.G0)
MH|0)4;>R;@+|\$PGL|&^|2SL)9.WUN@\$EQ0ARWG(7@3'9=Y;1J5OT%YS:<^L&M-
%|!%V#MFEF*Q4X;Q9P|>/CPL+6;RPC|TS|TD@?<64AV^4LJ@|51<8*.W|0H M#|I3-?|
>B#;NCCD*;6_7HQ\$;YCF)F8;MjX5Q={N0^R^Q4H|6R1,B&|_7K M=-^729;TRE)T?D|CD.%\$)3IO>/#634\$W_CZAB;./
@+Y=Y=%?@-UYW|1000|ME)6|HL0CPQ%8@?M=1QI"1DA"|%j;S?+>|O\$6M"ERM0?E2-FEYO/Y|X9 M
85EE3W^FH_X<"4)|T_?D2N|D5T@=XT^F3)|@:O1P|>"52;|D-^YM|X2%?MQE\$(?Y>|M5?E2-O4O07G;PU@;76Y;E(\Z
DLK2VU7SAZB M-!FXL53GFUAB;\$_O_2U|D)"VR-\$/5|7(<7N|J<@H\$E+GD=*M"0^9\$H+^%CD M0
>^QU^R8>9|%/T\$SO_\$D|BHIE(W0H8?8N(X@9QLB?E1*3TU|<&0XY6;R1U"P"=|S ND>X^9XK=T0BPD8NO
MY4,N>2V;N|/E%^=U7;#PN1D) 0.R2SQBA^/Q3C"3.MLS(|CVH;L0^&3).I+V;>%T|9V6W_K.+0 M^;41^/J&?
=G|>=BPN4.&8HL?^S?PR)?H0N0;|4|WUN.PWBG&U\$ MTP3\$V%?=>J.E74>R|"(FGO""<^B<-@HF85L%)
|IV;+MCOP96JE<<|_9-|8| M#6#+|LFWBVG1DLRN|U2M8"UZFS;MO^C<26;/FL^>|2RK_?QK;FIUV_P^!|OG9F*#
MK1;_%FW|DEMP|G^*CM^U>|I|W=A>QP^#^/TW_C^X(|I5#%L%|+@>|=|JTY M=KKPKH@*#J54*)9>4TR+
%@S.OA.=A1S=X35K#@N'9 /O;8Y;5A%9C""^7 M%ICB\$9@H7G>|>?PL.T<+05!>-60!)1P^Q
|@+HOYKAJD6)93)VQ=9Q>7YV2^Z7 M|A|DC_Z0CV3M^X.Y.29Y);@G2;|X;59|"#|J14S>*2KYQ|GR<=|WZP-|8|OI
M^_N.M">-Y078_3&|68%8I\$+|\$)CM+|8X2%72;K73/EH(W9LFX4^|I(FA_M|DG\$0Z3Y(^R|D4Y05M|MP*0L'!2L<-
:>G^MYTQW_JBB'8O'\$B1X&3WT1M_-=%9,2*5QCEEKP%="QS M<7|+=7B;O5;E^R3 C|QL(4@%H4_%N&8PL3
MEQ34HPK&K-\$7_8E4|C|_V2^A^G>#92W<9|X0AD@5B_2WH#&-OY1O1'811\$PRF=UY|@RFD)1@LP
MY3BJ9/FX8<=PD2|S5|B0:/2MZNNDZ3K|7X?3|ND.B798.#W?>FL&PN16E7G M%#J4AL(@0;M#AP
BL(D5|Z4>*|P@8R#<|P&|_IX#;TAW'2C=W\$S"|K1H@C_@REZ.P3Y'8_-K.A/W?H^E+=G?TMX@8C MR@|TG<;84
U;BPEH@EDD;|XDJ?4EZ=>|LDPRA'1L H4Z|X+26V5/+ML;P_ M6?@_4@%P76!^/OQ2LJ><|
(20YNX|M;D6|DPZ<EU#^(^V?^F+U#&C2|9L(TFZO@_D_+'^X^X7-\$^#K2\$ @R;H+(&#
MI@7OD|*7@_%8^&V/P=-5%;^|J/^Q|+4/5H-7GY@|AN8@_32R*E1""*)0ADH5 M.1RS-
(KIPD5|*UKVQ6|JW|WVG2P)FS0"FP2\$;.#P)HBF&3D0PP+TSH^F;DW|2 MAQLWXLZ|B|/+|I+0<9J=3(E;00L"--|TP06
T83I"/B0VC@S^P|>4Q5+\$\$ M|^U|!#61O_'.G29.H5\$>UK914NNXCR<(%^"I0_5".6_P#8IK^/"FN49+X;VE
M|%9MR+A|YL3;|23|E"GI>#2H+F@E@KS&)8AWXBF^HE<;F;EK?;"2XFZ&A\$ M=
D2<8>Q#XNP<*XGB\$PIA=ONG8S'4N_%COR Q-1KBC4S;GH"=N 1^QV#|D)I MA#%C>F5^K M7L<3@I0|)?
@+0|C.=^(E?/>8?8%L'#69M_-)+?)SS-7_.W.Y)2B5WALH4 N MPYH7^CU|E|@)%I47/+WJ2M8%%9|8PY|0IB^N|;>?
4NTC?F0""B&G_9_T M7GS2|H@F&C;C|?;I2|+C#^H.I=*R3\$H O+|PA5UVRB2|H M0F
<47#Y3\$^XU8|GT.R|I^3^@9|<60,^^<|*NB/OJ@<2DB4DOA_WLS&JYWU#%U^HQ-B?)50@2=V#X<
M.XE/U0N\$*\$5W3BF(#CE|1#B|FD2Y;.!YF(|&6N.0|X#2KIU^*2S#.14.23|
M;GOL7\$O@X^6YH4%3EL(>=>5|Q6KIP4^4MDK9Q#D)ZL>KZ;,\$);Y6>#3%%\$J6 MG9AH;?*|(TPN4?J"-
(LRN^H^Q@W4/\$\$.YVWNMMZ<)S2H/4NYBH,41|=1SR MY9XN;.*?|BXQFA@6&2T8?\$_RDE+;L|13|AQ6|
M&85_M<|0&5S;Z|B|+""CY2|O9Q1S2|UW9K;&+|3_59@MF%GH;"=2 ML^#<-YKJU#^C91NUY_GI&M|D)Q(NO=
)79(&4M=L>X6Z"20LH\$%O)+|MF/#M#^"J_-L.OFBN|_|TJR;(X+NFI_UG(B=;8)TQ;|U)-7O?G;P?Y^RI M;^_#9K6E(

4N@J22R%^78#EYSOORX.8;CE?/5H&^*O4U N+;Q>.^W M M3AN#W.XOCPI2^\$CI<8 /IYW
M4ZIUH&1'@*9#JR3/L:VZUCBI!\$9*99RN^B7XFC6S@8:B'N-JCMS@'1O5T MW-1\$F(V>01 T5.\$A04?R3'0I
I6I|WVGW=;/7*Z^Q;L3RV&VCJ0IX M3#/'HG'ZD&SSHP>4DJ01_#FHL7&0)I'H:0*H660\$7GORF_0#G)W^82+
MNVW_4+8%|JOVOTSYJV;7J9A@I29ERWX;1W7AYESE MP^W08'_JNWJ\$JSL/;A5
SI>B^_I_P.SJX5*OO>J>ST@/CXYMOV*F1^>024I MZAW3;2L&9VM@^I%U7I/#!(AIOIWM4ID>DI6)M=1;K;5)'65I\$>_
E6DFUA% M2M;(C_-I^0F-M4I>I2BQ.0\$|J+_MA#M#MQ\$*CLZ=UKV>VL@>F2JLUS!Q;S(<<^V-'"S<^PU&-G=,SBU(G
MRY9^&.&"WSRJ?PI.RH!1HTIQ|Q* MO!BIP>*)*..RMK@;"/@-IK/IQVG4T=9THZ^D HBQ93XP819UV: (W+|HURC#/?
PA_&&4 M+0\$@?^M3=*OPL_VCB+JR:(MS'(WT1,^MIO5B CY6I'&_?;XIZE9J0.04"LA:;S6*7T'+SSIVYFK(@0J%-
PI(^5?K^M_ ^0D0F%_(S*IN;-3%_JF=DKYVAA)N"/G37KN>/^594T7^=)(-0250=\$Y MC3C2I
(GJQ)JH5J9F2I WYTI_J;I34 M&%OXZA=,F4PBj1/#;_\$\$_M7=1=H2WV") +VQ*&M*O#3CDAY
I4#)S(4N)2Z&_#SO/04_?I^/J MHTIGW%\$./I8TA= =3S4*+/#YT9I.S(GU\$BK2KZUI^C%H-QE\$UTW;+V%28D
M7XE07\$>I2WPS9IV8(AO_X2+=;P7STC)L_*TR^AD10@HZN8_*)YLYLCS9+ED+UP<^T\$FAK)?".ZS:QT#CG>IKJ1-
S_DU2L MI#E2IL?@34KMF.4#>_E.ZYITB""^*L...^JYNE'03QW'^DIAQ*2IY?X=13#
(F(W34G%);D98IZXNDDI3U120*1%*VOBC^ZU@ (U + M164<34DSE P' KIKHU *) 2LV;&>5*N7XG=N3DZNI.L.CAA-
1&7L6AIN6N 6 MFICBX#;LU4)=>QA\$/7A;MW 1E'V%45+S2D;_58JH5@CNJ9L?TN?P#70;_IG?
9T\$@XA2VM0\$408DLIFEM M.C8H;45KCJTAXI3I/5<=+5R(YPI_4W/S;XB);"B(RG_G#43IE/U%TCB/Y<H5I33G1FI
MWM>>FIRM9R4M;-J N5/?_I4.X*2-R!)1E*2G"6S^_0NE^T_8YH&F>Z #_.4#IPZI*S%U&CSAK'7>
MLMIANS.LJP40@13BA#>E85Y.7A7IZE<1;ZYZ(K%_IG_XJ1-B*_N-2'5VOCJ M41-?
W<3X;GUW#UUV;TBE@D.UWE/+#+:CQN"YI=(Q:1UVK+JW82G^+75&RIMX M#K(57\$R70^%N2_K1JR%CH8-
5TB@MR3&UJ7V6ID\$ZIL=FI IV/E;U GXXO_M9/<^X1EG;=I\$A28S=-I-Z'TE5\$_W?
TV"6&RS(N9I8D5=HM^H.X38(<'E@^V_SV S=|&1.Y%PS7H#C# M.R7^UJZR;0 SP_)H+OWM@(<)PIV8_)
KK:LJCN5F9H48@Q53T:5RF0GHS58Y' MJH>N+8\$NE\$K?MOZ:DNCN!&K5^%#@U=!'B1!_V4YC_ONGU<%=;
8OZWW#PNKK#=#^I=??/*7KP2Y(4>G3I0PU= MW41HYGW*""&C&? M);=-4*DTGR7+?>:63*LP"!!\$!
_YI!_KCV"1V2A3J>NE@(+W00IC4H3A MK02N8LWGM/^KVJW&S|>R_ ^I2I+0T^23TI?^=I_E/4H.?=TKE2L-
U5I;9FY:=3D:0|VN|6JO4E MNV6GW>K@=I2%L"C=02=I=J3;I8K\$ MUE!@1^TOW7NK*&L'??Y@BXI M+|I>#7R/DK|
<8UZ%*)F%_PI_);HF9R_#Z&:"2C6-7 F7>LE6>YZ;_&J!1M@_MG@P3VZYKX+U-
\$IG%AB1%92">AYBBH^74>IDT@6)8R+;_&R6+Y>(+2%)^;IGA9Q2E>-+&AGIB_!KA\$(2%IV M)Y,X^D9M^H.I_?
GZ;_#H7/0:E-9.8LD_#JEIYZQ>77VHI@AC5H>>>8A# M-
Q^AXPORZ@4FBDMIPXG."H;I@CG4DR\$3\$Z2ITACTNBF9\$J9T2G
M#"9NH&I2.62/_O.QVB\$F\$&68F2P<2Q7)YS^RLY"7HP/0/S=RB/+!C/HTN)!P
M%&\$N1%"=;%%_@TAI80MU3+M\$Y^>MX-P<&T1J(C_1JCX|QYQ<+9Z*17W8LC^Z M7IG2-
A988;+>NI*E_6BO3^T:6#UQ>=JSY&0EJE4#+@B8A7Q92_ W A@)RN_I2XIE5FLP'9NVD; MNW+R.PI;Y?%@6+3LWKK
3&TG;=H(R+L|B|AR%#38&)*F%='0&D=/6>_P-I23DTP#3\$= S^!GO.ZOD%MFJN/N8' 6P/&U!8.=E1 M6PF>1Q#(
"JQ=(J#7>;X<M^A^G06_?0I/"04QBOR^GT_J1'1P%(!1TB<#?MKXL:2<_0UK0JZ!"4/1P"
M7%4F@KP@M*1#1*AA5%GOJ.G'R'P;2I4BHQ&P;P'PP%;_Z7\$@VIP=/(CKX;3'XIPM<"W4K+PW|+N\$BW;QY@D1
MRPE3D/4J8PVN\$&(*.XTR\$V.4"V%G>_)^WJ(X2BJQX@EFNV|I1RZD0 M+?LZZU%3%(F+) 2)4(781L-
87B6VE0:#06/G6>V_-4OXZC:0);'<3H_ M#ZMCX@9C_-V\$;04@>3NVM|+5"F3HTJ@_N;(>#JFG3FG8;8;XF|<#;M4IT_T0
M2W*Q1(P;7)\$7X\$ZU^VN#L+U";NFR&KP1UY MR*H67/TIGZTGM9TH'KJA*B&G;DI3.<13#|4#7/|@UF?
9V(7^M+)|V:LXMC3- MA0X-I93W6<#;A+DFCR8%-NXAH=)OT16B^F@0B<0WT@<#ES6^"HW W0V:FBL MI?
(9EOM1:H^4>NSGJFE&R.ZHZAZ@I13V7B"@G*YLRKMA_P1?G@=)LU3.
MA&1=6IKGV\$&"J=YLBO.3S58_E*R?;V&"VAV(G M?E<+6Z5?F.3JP9KUQ9I;K
M1E420JH>+Q&L293/9;LC>;7&BFK0*^YNJ@9_YD4EB(IZR0LR\$ _982;^7W M_1HR_V|JM9AH75=@JQT>/&\$-!
H\$Z"/FZEF2,Z1^Q+4L<-YB2I22M MB(HM>RKE;TB5Y%N(-#)/# "8Y42)M0;ZI; >>JXF)2AH#6\$S\$; 2F75IE,H#>QCN1*
<0LFH|24;AK'\$6+T/XV&4E+5_.*4-5 M&"IIR4Q7DU|I.I W1\$H'K="F.6/V7YXPEF|1AT7RVOD%C00|+=&L!%)Z!
M)K;!)M1("N.PRD&16^&E51(CEK|_*!|"@.M29@EU00G|Z8M'J5I)K%>&.O M<#I5OYG/;'-C:5%9.Q3\$XIF|B3
MZ;#L;OTI@ (5#^@RJ@;5P#E;ZH;L&B|=AV%YJZ_+Z%|12;MPA8LRN4A-I0 M)3IHOQ;IUD42B<1;_9A?
Y/;))F03MOHM^M>BB%PQOT.W55#N*CAH(@=^M&|U|^P-I Q'8."+3-T0"TG&_&5L L=B)9BPD+|B%I:6_M5&DR
>\$A/%L&6 MF&B|GK|=^.%7EN;U?M;-09@-E32GVLUYBED^4;"2ZUI'DXG5^Z;7EIS4-SZOCY.9068%E;YG
M&9\$.9.6QM9U;N;7L16#_4G(< (VFEX=(Q= MY "MP@U_X#;)8ZHY7R?1;LT3|JRC(N
7P_PO\$@#4*)IDL6P0\$*7*|640U+= MN.J'LL*COFQ=JK^"DK9I2?Y*!@P#SR%YI95EF.C)5@H&*T.EX;0MV;"&\$N
MWS#IV@@HZ#(>ZC-%#GB1Q59%*R4MRZ^ 8IGD%*GOBR9R."4PGN02\$*;>*32
M*059PTBK3_-&134WRLT@&\$&13'_&=XH\$XU4":G2=@ZCJH54/RU/Q.3DG" M"@^AS#R.=VAT*DIWT;#@Q4
_2K/4OIGR:^RE|F8<*_18E(SW7LIC4CGB97Y MB>%NH%_I2@V+<^ (J394I'#H2^@%)\$|B_HQ_%<#*8-
%+N|JCE4;N)6CZ?QJ@WE&8CM5+9%I'T55C_ PN6MIR<S&T1>9=I;H_ M.AD?I?_Z\$5%W;HHJ;3IDIMA.Q|63EBU!
I19?G3FTF?WH&O:T6%0+|^Y5 MQ4IFMPQ;L=W\$RLW%*AGZ@PUEQBDZVA>*I@QD?F!=K7@R8>|K4=_L@%VQ2B1
^:H\$PUT>|^I_O M*6&N.=_I|WTLG9'.F&^GW;G%+67+04BT 4G_."LN#%T|R|JUT;KP^SKE M+KV5^5I
<^G66_M+Q|EJ26\$56Y4/7HIEQ%NV|U>VF|N^|N>^OS|=|^ME MNIGS5W+G%MK;ON5W;93C|YZBM?P^R3/_W
#^VM#WHN=QVRI;29074JV| MYKE|^I3A_X0X1<<+KSU+_6=-MEP8S;H&VB>("S1KX+I)7F6IQ_5\$|L2^Y
MI7^&B|L0+-97/8Z%9.1".W+EOTVCNZ;MN<=,^+P_YI|K-H(%FPICIKR)V M|>^AU\$_W3;OFFI)>H&FICU|IKG
LV+;TE^KWQ(NRH?\$DO|F;2(1=D63I@_M=J2Q2&(I?79D_+TUF9_O+^#99\$(^V";D|G3"YLI_9-M0Q;GPC6T|\$R
M;6CAD6BA7IG;)_YM>)=TUV3;#_8I2VTI>Y.IILO3#)@GN^4.SCD;\$GF;I+7G#|U&LEV.XH2IO;>57;W;W?>M?
(JHLM<^S4;SZ28# MI5E"LT9VU&2'001H'C4?ZIE3>);H/EA*YIE#;_!36*2->MO;-) %CAAVBW
MNOM(0K.W+I+Z;CYF_L\$^ ^WD2A98Q2);=;<S;B+;IP93_0^|Z+;Y!@S%G M5?V@^K.F4>H&Q0Z I4G-YG8MPN
B^CYN5HV1SUAAZSZZFF+O_N6^C%?XK1V MOZ_Z3FP@P|(G'G5?T::&I\$G/|Y0&W|U;_*DW#O(B)_LCA_/AW%
J>JA3L5 M3W";MDREF(JX0&A&PWG*_&WA_7PW(H00SD\$2@#Q;8^%0I+AUV-I)JE(V+; MCVH82I?
%7W&R&OZ&R\$|V2\$).1M+Y3_E@#\$NI#AX"JD_B-)E&#G3C5X (XY%KIUO9?U59MI M^E0^@5I.R<6DVSL1T/IE6V-
LH<^YKWRK|4LL.N6U.J">7H/SY52_YH@G+ MM^|F202|SR&BP(J8.T?2)1 \$)A=QR6D?
9X.8>%PV"@&2H>I2&8.O"_.IUB M'UE;^%7WY=!!@.CBD5H KDOCY?4F3H@+@G@/_ BM*HD'R<< %+/FWJ#FO+
MG#;|7I.YUOQUX>P#MBR?9*YTT#%01|A+HM#X/8: Q>LPA<.CT=#-JISIE MWJ-J#(0+MU%*LQ|DUW|+^AN-1@
&3I/*"-&%5_BA&I+3IOAE_@8"HBG>C")'5#VGE
M.Q<I5I9CK'9P+^1TQFYWYYHG@:PI@H?;_&7PAL6+QG|R/.^2R/#0A= M-1-IY"=Z>3H3IT0*4@\$WH<2
G\$H/;\$ZM\$|^NAZ4SD G^|@J=#C_-U"WS8.
MHH>A21K0T0X^D6YKR^"^^D"#!^U_"\$6Q^3P2@YH/K|U9B5R;#4VUX|I M8_YN4CI|\$OZ;XSWH+ GB|N+&?
%2H0@N(C_D"Z2.&|UEK5L/6"^21;CI9&@_M|ORFX|+A8>B@^2>06.T\$;060GB_12GD2Z@_QX3@#E)DG(C|Q>MS<%8\$
M\$X|<0A@*!*\$#FBO.FT+=@0XWO_!82&%&0TJG=#|^R1Q|AEEP-PI M*P<+|BMP|I5.95;\$7|-WO_K9+77_ ^Y6%L
M>/O=JL^X31RJA0R;?M3YV98;*.K\$FC|A/^QIFT/S^=7+|^1^>"200G)8E MH7HUFVP#FJ#+&T%K|
(=G>SL&BA^JDW;.COHSER&-329&KYKN-TTS|@;25_M@2KECLHWH\$U|2WQ#&I;EMHF.E?
+2(A)L44TM_MDABBR+?L*IG_U2^A/#ER M17UL^3MP&BD?J54T9%N5@_!FH"JYV(>I

%JUBY8S4.U!GR\$GIB?IXF^_6 MX8Q'N39TUV'2)\$U>N&)(.S+#+_? W5|<'C|WJ|8D(<J8G &9\$SN.VAP"
M@Z'AD9_)&7?)YMV\$UBL0_"1!-! DL9N(MHK-D,7J/Z!%&=X,1*H@E/&H5R M,#6/(CG'<5DX&\$,1F)^?R+O?T%)#2W4?
C|6M+VB>JO17K\$Y04RDU0 @!7HS) MY>KYZ-#(O8AT|>VT&7_EM;W|&1#1DT9+Y9\$"FTH2&)"DOAH-VDY,)"2D#O
MONFUXJXFGAB0JNB|CGH6(PV>^TJ5,*NQ)""5'/(H>^>A25|KT 3_%I30
MAB@:HE@W47A^TL^21'E^_&D9B^I2IN"G=XYKJ?F2*,<03P_@@EPIC|PL&MUC"X3':^&@?
O"3#_ ^U,5|+P20@D(>)>|L^ZC0TV*>@X,4F4|PP%1D SZ6&5 M,9|2|.% U/B4|.5/&C\$.20<4-
M1C<8O6Z,EED+5H+I6L!^ TXOFL#CD8<"C_X7KV&:,6?&9O@W0;K&ZQ?NVXC M@P?R-
\$VC8.ITFHJXGWS\$.>PG;N_#AFXG4KAJHJRY_*8;KJ|^A MH)TU\$|Y2T3L5S7N,>X+?_
S1.4J8=E9,:8/S7:7Y8S7BJZSF#XH\$Z,FL4A(8J0R6TSM M4R7+>1GE""F%FS:CXLGXZ-G*? !|CYE\$TPTI9)?
DW(KI\$VFRUME"5_*2%4 MJU+ 7|C1KY@A=DC4351<1CA*W>&1GP!'N1RDBBMX&+/%<^&9%SS&_=J0Q-K
M|PDM"CF(,"=")"B22;|NAD;_U3A*4AMDQ^9SS:8WV#^NC&_*T*2#Y3 M4/807-
+&AM_8W@W^;PK^FZXFJZ:06LA+5JA^H,P7X|/\$%J\$@NP-K|H\$JG MJG@1WA|&+B=A)#Z
YQ:*BS|2S6&+7A1F"@&4!^E3.MCY5V=-6KWFV|1P?P8K9VJOZ#<"|M|"+SH*L.WO5">Z M%O-
ZR^Z\$>SL*K(6.@M5.8K'_0.F> '"XH*402OE^N D2"CO%?B MJ^:
H|^*%|+A9S=G+=A<8|PWXFSCQ)G6RU"C(WS&U/5Z|8PJ1(@\$68+&8D?_ML_8MA|HGL526R_1#-
/#WS.WP59>>OV@5BF6-T)*UA|49-O4QC_C3TLGYZ MR9_..9ANZ^3;"G(A&9/%,2+|+6%M0E'045/4 M6UO4VVV*>I?
\$N49TO'S1D9<^<=>)5KGC-T>X;<>8#2OCQQO<Q<28M+\$H94HY M6TNENU2"!W+:"|D5UC-9@/#2-2#QD?74-
K&4|H8U3Z0"9(8G6W@\$|J29L55 MLQZULP=&|Q|1B&VXV)T&9GB_T'@M=_(5DB|I8>IM@^UP\$@8(-
&30/G6GL*9JG@0N-L+ MW#O_*CJHHCLP?4|K&YC^P*)_-C9.EX(L&Z%,FPX-(H J:D/?>@,'| MW8=<:,HDIKKA%?
YT&66>7?|TBPNM86?4=L^(-D&A0E,IWE,NQ""211WG_..MDVE4Q|DDP.W<9|G3'G,4R5)X|2| M:(P_#OKH3CP'L\$
"3Y#91%D2Y,>J&ABX>2^Q4 B/PAP8HL/3|?#!#80H|/(P#F|G|@'M#&Y+ZHP|B:(SGSEN2|WX-MH|M
>\$,A3TK9FRW|_SC|6VS==18.L=N)I)^/@27?"3=(L7E(%J<)-6FPQJ|0 MH_VC|Q= "3J?
6&&:JO6#Z9|K/0DW=^,MT|*BKH?^#VV+0.VBKSW&'W47P4G M2?;4A/'=&LXJ\$A+<16@/L@="4Y+I R82_F#2&?
52*Y%0-(O-S|_M*O\$#^AJH M4R|ON*)==62TBAT9J2S11061&L9XU+|6U3>2-B.AXX#_.UK'HQ;+B7UKM-'C M2D6)(+
(IU+T9*:(A%91#^TZ06|0U;^=8FS.F@C?Q MK2|F>*R8F&%2'C;>,8 C2J#^(?HXK1D8F*6A5KX\$/'PN-%#K%JN;
(^|OA,SC M?&?&6:P+F3*V=A W0,Y?9G&2N;\$F,(=6)H=U+ 3N|Q.DHOXJRY_HV UMK>MS'3K=?
+..0D6S4Q(GRY5B1)|B|@ 3I95/Y M2/L^S*:_),P:2J2I.>=(_A\$*(*S6*+5W0+W98F>+\$(#<#<I&N<3:C%
MYMCI2DTOIH7,M5%<<Z3)3T4HX;L4F;MBQKYN&F(2)O#D @A'E*6Z/C40J%,AW?<2 MTE 9ZRDV;%&K#U*;Z?'=
(000FB".Y?&DE|I?46VH%7.ZXL0NM;RBC QJ_&M'O75P%:\$W(J|FI\$RBR+4;!FJ|<)G1'=8Y)&_AHR+G9%V4;R))SA+|GI
DC M(?@97|;Z/6M*E*+(MRE=DZDD/;S7-#_J
MQ2RYG.1^@;G_7G2\$;S|_Y*DX;0L;O|&*IS%61HHL^37B(SQQ;Z;):@PYT+*
ML14=N=XM;>J2!"FZ/5,+>R.1)U1G=YK1X/8C?S M(N9P8|P_1LGT+XH(AL_T47E8+UX(HUIW
D)|A\$V;Z|>|84L|(1XEFZ,|)W5 MT+P>CC SOLL_IC@RY;AHKAS5G/KEA/JA2|WR?KUCAUO6K+XLMA*SV_?V M
6|C>749=0%,BM6|X8,,Q6AO#^9'E6WMH605**)J<#65_A=YX_6_E0'Z@_M4?4U)&?<
YX9XH;&M_12\$@XFOUP|W|O|9W3LYV>DT*.C U.MMW'8|20LLPL MV|J|B/NLEAJA T6_ZRQX#XO<;GDSL5B\$'
BG#57Q1M(_..8\$.9|:?\$QL=0 M;=#4ZA4\$-SY|>75J|&5AV&LFNZ1|_C6#G22|N72|TEL V<|(:)-/|H/X|'_F
M5Y5<@CE#F/>EW_*EK@%G8'V/F,D=LG4"1WW3T=D@,++%UVP(3"D4%|PN&"B M|O|C PI|!B|G:L ^NJ|GPHX-
/J,4|5N_2@H|3KWBB3*|"IFPE15|Y?TD29 M*?>P0_R4.S#>PK9@L|62666ZRV|>GWJ|
+G^7KS_"DEGH9W/31U2+5(|\$ZLRA|/\$_8/0UCUOEQ|7Z|F9|EB^3C6|C_9%BN9_MX>|&_!K9J0X49_'?LDV4R?|_.\$T\$?:
F.Y8-57%^/NP\$JQ>=S.NVA|HV6*-F9 MX0X19|L R_0TCN0M&M*L@2C%6+;604>7,;>B,K
|@J0F.X\$V"IR&|EP/U.Y)DZ^"UNF(\$DUL1^O.<M*(9/\$^|>N|YJZZ9QXJ6C"0,9:1Q:"36C*/ MA\$G/E M|
SQ\$#Q_XO)DS\$W|WQLOMF2-F(\$|^@S\$R31W\$A7JL8N;=ZAFYK'R@&X|)Q# M Q.IY?2#)|VJ.C?A_.,#/-
*_UZ_BQ@1W4_|O&=FB21+3;FLDB7\$|3BYL^+|16;KEF%AU_FNKX6P9-TZ M-O"WW#UL@A_|O|
|613\$&K7TE;N"3_RHTQ"8#"3=V?W|9LLO.@_&EM#,,NO3"L M_-=J3M3+5QK/I)-(IVU?W(5PVB-
TJB..WZY#&C8=RP&@OO&I9;WX&E)Q6O MJBX-N(#|S%R,G_2|*Y&1D5_8"
MAA/7XVXL5Q>X8ID63A|7<0QZ.V=JNW'=V=6U?+I MG7UU|N'DYNR=?7ER=?G=7-UNGZY/3F_+3I5-S|O7(DQ-
)GK/4_*R"56ZQEHW|0I&2D(K,U6GHW)-@%\$-ZJ&|0W_'MC\$%N0,4-J\$%LKK5-(6=3UC8B=YI2Y4BQ6A0H,U
P3FPR+\$J4#R (LR0@J7 M4>IV^3?V.(H%US_M_Z#I(\$O)-D&.*='\$<^V2T1#_"R_GE==HWXVB^Q%!
M9RDB;K|&VK8&H)+6C%5R'L4PCK+|;E;>;XA_"2C85SYN53+*|-(3H&RJ M=|ZJ?Z4(U6&WZ^P?
|SO=;ELS"DMJD%NY< NPL<^Y%Q|)SR+LDLQ S&O M4Z8S&5UYA4|J.5<=^?
79*5;_H^_A296;\$&?;C(5E2NN.R|)%Q3=;H+%5-E(< MBG8*Z7G|K*-RWV0(17@S'|)O%)?5+6+NK#8|5/40B4H'K1E
9<|31PK1|YT
M|!\$QC.)+%AK*67V;J11-V;VC:K'4T2EE|BMY_A|VB#=#2/_BAA&?'3BDO&E_&A\$SEI^0_^:R7.M2*#S|7PWC;'
8>Q@T.NYEW%'84 MRG^|R0YK0BF0(?^HYR;^*SHL|K#PUM/O/S=|JH0|LZN2G>I@!/?3AW(<(B1 MC53(?H&:"S(?
U|OD|W=|SJ9^/|!2BA14&A_8U|ICT7|A&O=79 DEM9ME3 M7T+HS/EGL_*BE>>|02S*#@+H&M(NJ=|!E2V*?
|+C86^KV|YSNKM'3G=-?WM) M=>)/P"#<L#V%?NMOV"V;KUM|VW.U4+,>^P6J|8#Y'MBT^2\$DD|YZL6K&!
M|H?F=6B6)ZHE269F1,|6?D,P#300|HU2"\$U=GGKH*^D|HH7|V#BYZ;(6Q; MAPW9-
"||&C6C("N.M>^B=0E2^V|7|CG|!|IB_2V7XZTMD4&SZC3?0!|=H M'ERD_2""+QF0PM;_ %O?#;=1#|S\$C3?0--
|S\$V\$V\$@2K9+4UDN|5(F<#S>-(MNF4C.)>Q'V(C@*|0J#0_9O,0Q|HP2>|FP.8%PK,XXH^F9:TU_ZAAKC^\$#TW M
G62Y|AL'GR4U7|_7'(E|Y+KTRG0O=_SM/O0&=-_UL88U; MZ+0ZSQCXH|NO:%7?50>O&"DI" _L %TDCU
A^P",>Z3|4R)= \$XRZJ+|TS2; MU_H*5=|U2;|(4|9PWW|@^PM;Q;?46+80|*|00U2-1D|;U=7>E=@UY+7/%6 M9WN-
""9&<^H9?3'N&7?)#V@6P%_41V2XJDBNH_=7&5LS+E=Z)SP\$X R&M0| MG7W'2A|S_3|Y72?M3|%+?NXN|_93C=?
Q1.,PB>-KUI_-1&TTO@^F=SOVI M'?NM|+|@(<#%M|MMO|X4T200>CK(E9ADO<#O(V"G(R"5AD*>%85T5Z>0|UCZ
M|.JFKX2|Y_8K54CAD*XHR,8-155=;ZN4\$6/7(SFX<3*V4HV5;5(-ZJ;Q-K MJMN,UK18#L9
RK9S23:655N<#KSB|PT9X|6:3&NUFLQE>H7 M^0=9LOJH6I7G5UO+ETWDU\$ "S4H^KJ|)=H>4RO22O
30QN H_..&@N"VK<5FF5|N#Z+S4T?_4*_*1>ZS16Y#_4C_||QLK(=|I+>JNZ940+ A>| M29WYCDP>I2;U910J=#>F@1
\$F1\$Y>G\$|C#P;XS_-Z+>BJ1,1AOD7* MRE176?Q@/B<;>Z#Z8XTW G^*<-CBKR*U;|S"KZY%S1;R+AV>(AF0F|5J8%?
@8.CD^9'9B;=TM176;B>""%& M4V0'9B=&N.26?2+GC)0YWD3K;R#XL?B=,@38SKD23X=4CZO*Q&OF<>HWHRE
M;+>AUAUB;:L@J'&G2;Y5Q ^|) T186L_.'6F(JB-65|GV^MDZ5_1#2|D)SQ(E@%D9|F5/;A
+2J0'P^4B(QMAV|DK\$ _CHOJ|&G5+I MFP&=>&R_O8:3%^Y7^S0"+N@|YW+ RWf1^0TK<+?PIP
/>|0|Z|H7URR_4|8X?DMW/L_7#4>8: M;KOKD?_%=_^""Z*#XC?1\$|Y|B1.\$0\$(W3KP7AMJ'FXK=-46@.FH;-| ^Z/O
M>8'Z|1RD.BP5|7T0Q8(0|K4|A|O|MP;1'Q6B|BT3D2|RLWYA8Y3;,\$74ES8 M|2VC<,DE874V*097?M'^W
|4|HX|E;_|V|S|NX<|G=UC%\$1NAGZ M2CG\$(G|<1P+0+N_4_XX^EP_) \$B|Z>P8"_V4Z>7W0PWL MBV*AD8 |B<%^'^*
T5!_LQE+<|C@|S6+&7A7+|*|I>YD\$D??R" T;3.V#5N?P M|^7UG0T/U|G2=|BE4>\$8VN XNR#V3,>_B_'XAY0Z3J%#|
(60@_QF(*6"39O MSPV_@LAOG;2D;|>B)??VG/|^@=/?_ZH?FE|&<8;CO=W?VV??+N6EKH>2Q@
MQM.MO"/X<"6<%AGM7_&\$V+\$|YD>|9|F\$KIA*=H@MZ^F;_1XE:N^E%/'_E'Q ML1)55AKHD,^J,| HH8_<
YX7G|6|>;DT_M<%_A7X%_60.Z8-YM;+HZ|@5#R0 MR|+Z&?OZ|O+|:0|N|N L;AXJ3ET3??3R%&G78-5Z0\$#,HNZ'E.G2,|?
#_"C M8\$|)CY_ _M"L|HFO7C3@04I>%YVBY(C4Z|59XPI+@@|CF@@"#RLP)CCT9SC M1^792=(GAF-&=&=)BF0-?</p>
</div>

0")M22+R5 JZ.F! NAY=HK(KC M4!/:J"4@BHM8Z1#S6L=W.@6:ES9?2!%G.:7* Z1SYW\$B"OOI6SF.ITOU
M.N:2G.I!=QBX.LE9L!H\$%T!BBOQ?IW\$&#15B!QK Y2&DZ!)+J0&X 8 16C MD8Y-BD(C.BANJOR"6\$OM_?3?
J@>WRT06MU>99*!OHO:@XC(Z1!\$/^ ^JUP7066#"/!J+!B+!)%1GNWB!HQUC:&6 M5A4(9B-J?ZG^2+
HW5P_*(KHV6#F"2I&HZB8/C7^9F!H&6_RVBP)0WJ%\$,*
MPK+3CKMIAVI#5MY!&JCT:ART"C!00D:Y"!HK8CT(RFT>A"Z>R#0.:M8=
MHYY.8<\$1Q4G6@61U.06J&D+8KXX9&9!S:08=J/5Z)#.G4KS@_M"7:3!-\$"X06.4!6H4#E+D0.)8V!U'C*MK3Y M!
VHM71PUP69'X= BVK)/\$C(U2/7E8YAS!82B>*EIS8W*#17Y\$&TAF!7'P+! M8=2V:SP%/N*8R&M2JDV7R!>
%@/!EZB0X@_P-"0:&&<RT-F'O>Y==VR?STY MN:2=98F1<%)*M.O"@#@'6C1W@*6!&.D2.\$Y*JYDQR5CR!_DB7EGP
!<D>X M&?GC4V:#%:,F#3Z0?JN'7N+OK*%<#5'C^*A&_I_Y=RPR+!_OB_4^8_4H2O_MK/H->4D('\$"%^
6R*WT'F:ERH!HL'9)D1,CD?N>+R<6LUVIO1\$S;-IB-IWG_M.A&9FQH_PG!CT(K-Z("J.@&D!M=^)6!-
&\$V.H!+Q0^JU!Q9&^F4!+ MZ9:#(7%"9BFBE,IOPU;XD?RL1S#," T^AJ0PNUYQC%K94PW+UF2S6PS=MF7 M)?
=E.2*)=-J01X>7<0YZH!1!>=Q^JSEFM>KQ5Z^%IDBY8E!66S5M2J9<3!%@.63!GNH!S\$YLGJ..=K\$MA
M!03784R5K#.FM,#5FGWY-15CBVIN=!(GW!&Y!NJB2W MYHV!HDQ3!U/ALGA>:K%3Q2TKK 54,/"M+/WG=,;-
=-.IT'C281J8 MFZ'&2*H8IWW# / 5:Z0L7; "B)LGH<&EC;COZJ^OQVY;YA"%8GW::BQ:A619 M2+
!GHTQD.K1H6!5,AMXJGP119H&.3-KT!D(C.0S6;=T(C!W.\$>9Z03W1;-IABLV0-QS!75K5L@M(HU>ME1;,'=S-
L;QYI>^V.XO"#1 MQOYLW=A+W_ \$&L!H_J_!K: ^3(9O2GD)!JYIR:>?I9%L!M0!H!PYE+^H4
M'SLPUFT"8!6!L8.F./:;>&\$P! =J=1R"J!GZ"TE&!LB&33V0XZR!\$^3"L' MK+H-(G0V(H!VI-KM!P%&?<
7LDMJ=JWBF+DG9&.:0+/D@/!D!%O<>=-(D%H9LE!0P!WVZ8,V3W<:60(@'1VB?9\$)ZPNP=D(78*M&.5
M@C"N'42N\$2%@1.Z0\$E.OCI?O8Y6+62J!"@THH!^45X5>?K_6;7M.5+M1B%DLE+
H5S06*M92'E,J0QJNHDI!>,"C>F@;AJ0^UNE&A!H!FFJ(K*XY M%0!>6V"TN8166H/ML^O:WMD-I3-[SW9T;-2_&B
G5;=L>M6U>Q#/#C!AL.H"Y># OC.SOA;" NX 18! A<>:70 +&7E!63%\$4E%PYW:~%A;+ M?D.%(4
T>Y=SBZK27+5"VAF_-!^O/ZI"?T;:=8)\$HY!5;7<.*HAM=Q_0 MM.VTVVU%:UU%:_9<6D.<5,3V7EIK
S_IPWM\$"4P=!:30.CG YBF!3\$294,8QF M-WE?HIS\$F!H860)0=I":JH"8!JS8*JHM#MK7?5%:/ (M" 1%>/(@>PDFTP"
MNB6TUC56%"#(HYM@Z'69R!_GO@KF1X&W4?7O5T'N=F8@4Q=JY:H&UZ34\$D&
M=^CL=W;=H!UCU;YAHIN72D:01D/!MC!="GP!_8X(H)"E!Q/6!_'!451XY MA_N=HL-L!&(D6+6+R
\$X.NPZ!W#ILOV%13G!)ARAN;XZ!2,^=>*G^%RNJ= MU;0J/WKH!P=.)W!#OZ! =L/6"AON"!_FIW!?. "%LNZG?V?<
M3&P4Y46234;,"!U30""7DY<_O^,Q7AFY?>=&B3Q^_?\$XOY\$E!O90//@1,ZT. M)M-QQH?H^6UQ_X!(>D_29"19)MZ?<
5!E6!VYN5Z^>Z%G67X3FC\$7%>RLJN.DD MI74<%U*Q@OM<+WF1!@Q.T*Y8#.P2N@JE+TM"4X\$3!M4NJR?<
77G!CTZR5.Z/ M4E0094!@JH!HBO1Y)L>17B0W#Z40MN6+P_!4E6!T'ZP*Q^6H!3=OESY;K_);.# B8)D
M^@_!12!W8W,+39Z_N3@JBI5CL@/!;#6!R!V/O3+EU.QC&F7MM<40;.>K7TOC(X
MH7>4JW&29X.X1A/X!37BIT.VAUAZ.DLFY*CI_UMU)\$ZB6!W02_+K;'S-64I@<
M8"67DD8/MY%3C#DE!H!QJHX81=@4S%0M !TGF2E3E_R5!T&H&23K!)IQW!J M#<
!XN3AAL!LIP^S^*,4B;AW8L#H'+KXN*(C@KQP'NQGO"-0)HPOJ"9/-2 MI:=Y=D&*F_F#IA)YTXJGJ5M+I M4P%M?<
AD;,\$PW;AALP#O/F..3!TF903_VMVENK_I\$(2J!+>&6%TT@CXI_M:L_F.B5<*H06CF3& AG+5EGVDTV6TF^?<
M%00TY82Y)J9QJH#"K\$C TG1^2" A:9>I4*!=H;_LA8?>Q!F3T7;#0S:<0=&"3G*4&HE<+!JV-C9WJ2%*H"BV0QT<"[X0?<
A(C/>!"3BF MJOQ?X/Y=(DZ;|*H?7CDVL=.)F\$LH;%E5E%1 M)(S>B&2!NC!<_HFG\$7H#0>ZCK'B3+~%N-8IYI&<
Y!U15%05>JGJ)!L!<-D2(F#I/(:W0:2(:J53""),#@SXOTBIW4D\$(P MW\$U+V9&C!_M+QE&9#J!B8?4+F&^&<
Z8Q<717C>:2BQP93H2R8"A.7 \$JH@L M\$WFEHL+?^)*(\$QS\$QCM7A/*<0P'=%F9CX5HB/P7FD"2F64*! (&@U:9OI<
MY9LM!#;^* \$UIWW\$H@=9)R (GZX?71MY>GH38A@>T\$>_J_ UX<"Z7F8%(1 M)I+@37D!F D.4Z+(10'(P)1P,K)<
70^_XJ-W!L!OZ6(>%&@>@WE4.C.0 M(2,16DBA!B.^@.I26@!L?GR#;_HT^<
T#F+!&0>#QO.SX8E88YC^@&!22JN!V5W&='Q& MQGf%WS\$'3+\$POBGL/XH*HLP<
M.U!/#R:!)U^!ISZ&F"%"="FS9UG6SNVJ0!6_6*0#X5A&L^H!ART>EXT!L!MX<(17=Q0<
)N)8L#R%BV\$P!9=CP=Z/G#W(XSP8'8JFENK0\$WH)3=/'CB#_5 MIE<81SV28#?<>?XRW-G>4F* ZV0Y!_QX26&<0)?<
8M&)>D! M6\$;%!^74!_J!X!^5(BH->GR+08CD&L:A6WY9_MAS#T.69@P!Y9=+:/2&39!Y33B!J!|=1%N M^#R1UPCX<
>SD>BFHG350*^F#E)ZDW-'01J)8'P^EZ@J!P#9HO_JB#UG%,C M\$&ZA'T=1RK??)"6%B""NXXFP",P=QS-?<
H8!D;+MK34!0!08LV32*_0D 5&_M.LCA?I#C %%#J\$M1(?+0PTXRTEF!T&5_&8A*_.C\$BM,S@ (U*R=2%_TS@5O(&<
M3;_9YUSX8!NS(^EJE;1B;3UP-Q)OKIA?^2+X*2W&_U^MPI_?^5TX&B"<
M0(G'Q2HB;!@U" #J4!2)@#EMCNCTY&J2=PIN@7WW=156LE MM <2W%1.F4#\$E+60ZN-JV Y:1.2\$-\$!LZ+)=)_!=0P.(?<
*9.4,74(&O7' M!S+LU/TMZ<2;_C!H!%0GKG);_LH4D^/M^8%+6X.HP6_-=!BUMFEW>Y? MZ\$P63\$29?<
LATE%VPZ->1;,>AP>G0?_#20#NZ.S!Z-O3YE80TY!J&O&ORBS MQ1PC=#;ES*!G+Y5!T5!\$8<
8NGO#..!9X!Y.Z(5@E@Z0DBU32\$ MD7=C1-"71\$!XD/_+;_>^J6M_!R!PF!A+;8R IARU50%#H!)!DO7(/ 1<
MD8+!ZX;=\$&DST.A?P5 M/VAEUU_Z_KIAN!6D<
MD'50D1B#9T^FXW@F*4VW68D%#9B,E".R!X*+,9W4SV2*>>CDXQXE8T;@.OA\$ M_.CBT.YMJ6_1Q;@.GVT&X?<
8N.A#)F'9!>WM9V#ZOIS:6?052C#XF6FDSDF MV\$W^O%@EEFG^=.;>_V7G;+OE^>SLK\$ZAF0YH84M/<
MCH.WV;=@>V.W#Y>XIC!VZS\$PI_?<@+SH<^%P;_ ^W'RVN;C!^Y)8DP(7"B0! MYN"S6 JV%Q7.=?<
%#DV8BH+Q!F=^H0Y&"<%UBRBIE"FFEO!O53K?EO2 M?-U!Q;CZM!)^E%X3,%FHYZPMK8.'MVDG(>09\$B>8-<
<2@SU4GX<HWG"4 M_A TTA_N'-9B2P3-T=[<9HC 8R=3Q6Z8D8&B!0C7^IBX>Z-R);*&Z!6<
M2Y19%V&2H(!5QG#+B0M!C95\$#H!5Z L%Z# M;C&97!E.LT!CRVS&329U!#3;W3+* ST!\$4;?A=VLP*<.!^!":Q@-<
%&@P" M?4(NN=ZTN%B(J*B!Q)@=Q&9MYF+U!^8SZ^ ^#SZF_!A2 M/8^Q-<
#4*^_KA;615V..)"SE!UA!5S!24P6*A&H)X-K;LGOY7JK_N>H^D#K)<
M2N&1\$7B4T!7?Y1!BJL?)F@G#"H"N^@EGFX^24"X"\$C7C#J.6!;O\$2+V+D M>V7J%_%CNB45!<
<_IFP6+^G*27_ZL+J CVCD)U3;_G2N'4HGEO!LU00D1G<5 M(5?_&V!/"(U!)9S9TYN""H8X%T"B*?<
WDX553(<1VK)+2*^X9RU#Y<-_M?R.4+O)7&7GTKSC2<1WGU5X?*/.(S8J2+)\$FIS!O<3CSX_#)8LWJ@P"BT9;<
M!T?Q^1E@SM'X^0>W'PRI#JGZ4!F0X2P!N/PGDLP7!_S-6T!4E)FK;_<
MY0V;>TO!%ZUK.6>"""">?7)H=X"M=DQE^7D!R!X5GV!MH!>6E!E;+%/M>1#BF)E;SM(SCS\$XW*VG-D?<
>13;3TH!H7&+QJ?/D6P=\$Z&O"7=[T;A*1 M!M2;&18Q1'B /O!F)3S_KHOB0VI!3;Y.J>)4 ^2G/O7-)15RZE(<
M!4453!J7PWB;&S_K0I@FF:U(&X^ (9MFFMQMG_OBR55=?.);_!8V=26!^FDK M!_!\$XWK" EN;R:E7SE(!?<
Bj8!Q*L6_=N0(Y)9@0"ZP_9L:C!8!Z)2R%D. M\$B1!P5U4^;QKFJ\$=1DIOY;(:E9/W!ZR%BG!5(WAL,72)*<-#"/:K)G<
MH&XAE.176FB3@)L+_0LN%_JTRQ(3>Y!DG"+!0)8C(A!&8F\$F5_M;U_?(KP1K.9\$SK5)<
*_UO+YCHFEY_Q@H_2GTPP(S7K!3V"GKB/TDADOPI&_M#C!0^8_80CV@>1D-<
X2R.G%&L3\$!+!+7C&73\$<140(Q952!V.6!"!\$%TA&7P_M\$7)4+ V!CI#V;14.4:9)E)412_#IM!2LIY\$0/R61&"!80*R3J0<
GT6H6A M*PI3YS08EZQO\$6!"I4 /NZMY1LU)GDVS(AHSW5\$W!H4+7Z)5E0XKVQD(E!9T!JKT!YEF\$G.S;~&_-G;1-M<
Z_0W_6'D@8@6TU!);H!\$!O)Q!=\$LO\$B*1N+441A8W"(2HC.7.M?Q,6MF M7,7C805PG?<
UEXPC3#SQ7(/666DE&!76+!2T% ^9>&4TO5AE-71E-NQNK C*O<
M_"Z<-9ETC0VI=E!8# #O&WZGS!#;9K"P)5!K6'73BIK2@3,I_B_?V!U" S"R MI#DG!U(2!;.) *C\$ T24'0)K'R*<
(MWXXIQFG!4LK>P^1;1H>LTA54\$! MH_"_RRPO)H6)-&5.K;R>VS=(5!N=X^9;XZCSH;X1;E><(A.PLAC-2IP\$<
MOTR*)H4F\$ G7,^*L#Y)TSY".9!*=F#E<ZFZFF";_Q_EG^IN#I^YN>O!5N MQM=4&RJE\$+%"Q1.TPH&"3!0VYJ'K-<
CBO!&C&68QIX"KKE7U.E+O5PUD4)"K M%\$-="V ^;QA9J!S6!0'1!4P*9EC_/YA#2E,RL_B2G9Z!/31*,S>O!Y<

M:0'8;D"07AN34H7T?#L:0CN=QLT.2^KWX:P<<IPK_ED:6P:FIH:V_E6%-
MYZV\$>DG+=AJVZ/^TYI47*8)ZE[BA\LDY/H%GO_5->547Z%K19"^=*JB6%6 M(>7&F5;)V;20C%L^"J5OR*_FNE\JWY-
3!:#?B\$-D'3R MLU)W%UA\J?#;=A1A*26Y6C+09?+^HD \H8FLC(1%^_05Z#)#6H M
&#BKUF*""EJ(15S>7)-2X%GEMHKKH'E/MAY=2! 7T%5?*(;CN\!D#>/>#VH3'1E7G.OG""&6%
M,RDR8T.IN\IE39DR9,NRCF(KIS49\$CV96P&_%*813H08)).NA\MU\$4*V_ _O MP=K%0IN.S#S.X80 'R93+"(
95FU=IAE8)N%\8:0Y\N\!F.'@<-AWRF5DZ2 MEZ?+\$+ _16N6/O%02D*)V>DDAX4 =&NT\$JW-)ZM4(I@^F-72+,Q9=K?
9J4E : MHM+*.*V1<\$HNLYH8F4! \4R4(1 K61 _D+B-/E\$7M@+99*051?+1-BZ\46^I_A3\@ B0IH\XLL1
MX""-7RU?TIGA\COQ7JFI-R*E@-3!9U-KL\!?"I?!"1X=J5Q=0I&!VIOQ\$!F61%7 M?;;,'D=Z81 H-AO>U7.C>50L30R-
&DBA4X)#3Z;NWKV*B-OP9E<&J?HU>?>--VSCFTOEC\("'
MD(&EY+M*,R951Z\=M>1&*6GL%)Z\$JG8=AX=&1;8!6!9FZ""2E^B#L*C<+9\ MT\2225<\Z/6!\(3=D+>4*FW0Y7:3QU,
MJ_&3<50?MJ?LY\$E181?>(OBQ>8RYA@-T)O'MDEN 4=(&)ET?8NMB\G8N\>_) +TM+9;(6L:KE6V\HY9_+PN#IL
3E<13#KE MGT1_5S0-12KB194H*? HGRILQ.F*6+@D>)\AJ9VZ:9YZ3@I?RXE&7"7&&Y8;
MGP%MV00QCZ*TY8)-2D7FU!ML?BOE-=9GL94X5(O\Y)FM:3):>+; &.;^ M@)H?=-IMZW71!9Z94:X?
LFG\JK)\KIO\$X:P\.;\;\$-IA M\;GMF6>1HXEJ3,U'K15NL(RID"\$\#+P^=/CP@I8YC#FKCJ><#9DEIFF0;7
M5Y!-/B"HFMD-HM4T\O'T'O:0%FF?3,I8&9TK+V45?"MMY!PQ0D\3;LOOIN:VCGH'9."/K?@K-
#0:"L888IU'CI\$@4&QQ=-I\CIVS MHZ\3-H+;V4=)2IEV5_C'/SLN5YNH\29:B%B2"2H-;\$AQ2(KI4N\#K-1%"78
MO\U4(PG=GN 6HYL1F6LK(0\$I6A_ '3B:8%EZC M^K*IV4F0I&=L=7-'FOA+.7JX2SSH2SS57"V?=-^Y+7I_ \$0Y3P%U;
!;#ZX MPK@%F6>E7D>H-&O%=ZXS).@69"1"?Z*Q\$7E6I9SKEWO>D6\OZO\6)YBO MBBKR>' +9E*C@,=ZIXC
ZZRMELD\$3+V*6C2\$0F\&C:D6%(3;_M2VM_P*8IA.8E!L;_H\9B\YV&L8V\$5\$M\$1>Y;)ICZ'U(O1YKKA*K FD0""2!
M%""OPH.E'8\VL_Z.F^4->@9XR9A\)!="J(*Z\,F1A8B0@;Z_6!12\>P<1\$+ M;_OA&E1%AY*2EAW_21@<""Q)Y6IV?
HHMX#>#13QY7CC.2C M<40C#4*.2C_&AU* @ _B5ZI6\ CW*F3_0M12DB(IX,4X)IS^U6-G82W@ZP0\$) B1 DY2DVL
354F8X=;%3F-\$7U)D3I7\AS ML*\$)7R3(EYV6(Z3680H\DJHT%N_E*#ADFWC=9\EH MD"9"D;ZNEJ@Y'EIVH!OAB2>I..
AQ_LN\ZFB40?Q=Z=4>@&\$7PBZ\LB="68 MIYF*^6P2O=9TI9P=D50R6OI<(Q,U3;T8!\^2 M;92I-
+U'4KQ+TIR7V<4%L*.;IBFD)^GE? VT\1\INYA& VW3\F&^_DSD_Y?NRI>ICH\O""^;9FM\ ^M-5M
;XA9EOR:C(P\!RZ^*N-\$ M'CVF&A'99NPHU\X2\CH!!4J0M@IRY""N\!+13T\47>B.Z'%KW0:5D2^O\$3N
MM5'GX)X\$'N\A*UP(X\$+;C*YI>T?2WIVD+;1.WT6\X%\2A;915MT OF1W MPX4>XMG2Q.H-KMXJ(.M\>+E0;-6*ED:
W+>449\LB%X-CAGE&*5S""@?&+5F M<^XG\H2JUPZ>74T\@E7+DVO.W<_RU6U.X+32.0("M")CTV/_
!6%U\$XXJL5OB.%S>9;+Z*=B3*8LU3V6AB-P\AT- MV0(NPY6R0GVUGH,7\$6P@U220^C77RH39=JA#MARW
I4T!T""1=7^_?MQ% MLDJBFY7=GIS&%K=4')GV1=O/>RHYT^40PBN =>11/H52)78>0F4\$ _E/H<
MNHLP6/*Z_A('T36C3\$V;/>JR>GT""6<-E+ME)Y001AQ8A 9L\Z 6!U,%(R26
MWH.5\$A&-GE&RKG...I2<'84>19\KT\;?">T>;&17\$Y^_H"Z+D-P*@_#R> M\!RNY\H>M%+G'4.1JU22D&O%MKJSZ%?
EI>_*K5HW\0<45';H\&I<*B\3;1A MA"OGLQD.#DB6?Z&B_!6%KBCT02C4HT*;E>9M_BIEV4E.BEF7Q4_@E_COAGE
MKU89Y9T9Y5NKC/*GZ9\$IER0U\;LL:L9*IEQ9<_X+=*EL^09>D\&S_#L6VP; M3+8M)M1JUE4D>4*15H=6;0VW\H!
!Y%L\RR;" FD!!190@<&P14F\6GMD&ENJ+I)7I63+15_?!_NV6\$)4:*LTX_!_I_ M61S-5IZ.E0+U&_J4I3/>Z6IN;-
U\BB1@#EPVM%>18/&1/L#&#& M;6!6X=OY""#&K>>58W/R.W-M;H%AN;>\$4/R\^L G*V;D\7=>H"1678&9U M)=L56= '
XATJ\HKI'H-*N#12?@I)93>F\+M#;81I; &68=BF\!#^!)8J#FJV M(FEC17_);H,K\I(^%)
(&FL8TYT1)6UAEV*IW4BM">JFXR3FV.MEEL%?(ZJT MH!")-IBTLUMW; ^/4;\YER^L?F MK^N@&/R?H%\D47 \$0K?
@KFSO&#P#R#IXD\&%E?HPE.RZ;KJ'6X)H/*Q51 MIZI K&+;UMQG6\K%C8L7I6W"18?)<%Q?"I%_Z/-
V\W8V.T>4I&8^14I0Q+ MP7W=" J*2MW4H8XO\3G65&=S1?10Z;&FD1C+_FO:P7\NIF<_26'0?QD; M&JN-
\$R\3H\2JONP\XYE5IEGB&N&KT-6_&)U+";T\(\^BUBYHFT02JXPK MDU?>5\FK=M-TQ%X
'T\$WD.T.7'N0M\#_Q.OCLQ_\$\V1S\J1_9)W0%"H+(PB M*G6\N/R/9W_ VMP)-
S8V6M<G#*19>X3*\$S@H\('D'MEV%)8+=L&H.8I5\$ M@IZ?&1>Y?7#;#W5-^4MW1Y*6QZ@;XJ\=G\$G+
M16ORLCGP&Z21&1&A\IR0FHG7IE_A?SK/K/(<>>XE0?>3ZDU4T(E\#J9 M.\$)28\XIR;;JD%"G;U)?
I14YP<5762OP>)B@NL_8T13.=,LDN2\;E(QWNIZ'I%H.2ML\ MH#CY@*@2JIT>L+8;I.V-BUN.0\$US!#9\G5IV-
A#/'O%LW_)>I;R'B3<)"D* M'3N0>K?SL_O_!;R\N4<27V;46*E@LSX*+H\$SC8QG\^B969/AH-=R4B+D*_V MLZJ8/9\$S?
%J^XYP)AOH=13/?NL*P44(E_*IPL%>+;(. *JYV\$BHQ:2D'=4I+2 M?C;#?M\I>""^IYQCT/4R+
(ML'6_LU*HDG"&V'1_D8UL_3!06_\$23;8\;!*IV MU;2)WSKT7T_G9;_E0\@C?L7_@QIX9Z_4C)F@FG5QZT1@9QS&(I
(?_%8I_%E M.68MIXRWE6\3_>9FVR?T8TW=I>WN2>3..LJ.ZX\KE\\$/=-JZZYX3"?J>=% MC/J8U\0/BI\$H40E;OB;-
F_4H\7\$_.K\DY MH8=(_+>_FCYFUCD(RQ_+3IZT^TC*@\F@N.2Y+;U!6L'GSBIO_L%/58\3D.H\ MNP5\TH_*6Z#DX-
9\!_UZN4_5Q0BI>G9=(4_!#U_2=K3X" IS_*"H MAKA^C4S3N2IWS_SC_D9>4SA@X8_N+W+J8=;_NIGOW_TPK9-
Q9V>7_-=1? M?QY,0%'40/A\BQ?."@K/%D4/ZD\M6;\$I#619Q;W\50U=V?) U>ZQTI M/Z'2/YM+?FZRG&!2I&J';-
"SAD\$'\$O_#RX5X)3KNK\!*?.*?M58+3DZ3Q M;L576'5AD(WZ'59\
<#Z+B:45IC97BI#;YO'UQ1C\EEHG5\$5@2\3D^HWYQ/S MI^Z@*%V3&3UAK'&#*Z5C*J\;&S+J"+Y\ (SZ2"\$H\$9KD!

;TB\15AU*D M1AY\$Z1,"+U\I'ED (I012,'Z\$M\;#78 BIR*FL\+2&+Z*Q%6BR1*-8RK+ M908>?YIB\H13@9;
(14L+1A_63NMVOLUY-(D I05W\+6R47L;YK\K7.6\ M8#1<@<'89<'E_'E;/;\$3L<)4,KA8 M(%W/-
?;C'T'N)R9FFG8\12V70U&D MO)CQ6VW<_JBI4=40S7@;9=9SBV7G97J%V\$J\$MQ^YHV(1W+5JONH7YN&NJ
MU*EJTG-T91N7BP;H&E*GE(">MR")M9+V(+0^/>W18:L+%LYFZ<@3
MUESSR)Z8%86OB<2N0\DO;NSU*=JS\4@V7QJ7NQR@Z+@*9 MDN5D0C_?
7.74FIP2\ #H0D\!C0*K\O.XD=2(N;_%+!H8YVEID;DYK68EW+ M>"71/5PLYA_VB)RX<[NS&)^"_JCZ4J^Q=8ZM'
I\YHL61)Y'\$=R>V*!M3G_'.58Y>#7,E5%U(N\LAR\V7H6\FU_)B1RT;I'-PSN1VYP-
QGO%O.C\W4_LOEL(S)^I8L\R8'G23;/Z4E^_FSO M(9QM1(I\$J7_E:5MYVKYK16SE:5MYVKY+D1ZO(^GS7Q\3UNPD*?
K#QOMB\@R M6YLK5\MW\H<168^_YI?KGON*Y_X_O<'N/>WC_!9W-C8Y6ATYFA\WR5H?/\$ M:7UQ-
_H\1\$8P8\$P_5E\FAF>GVB;Q\OG(R?U4G_QQS^&KK1?AR>I\FS.AF MVWS^H\MW/MO5\^J6W\#_O;W_RLNG*5M\H\>
[N;Z\JWEGN\I\LBKV=PS9?E+ M7.C+DXQ M^XHF;I-E.F.UZ J'WW<;" ^\@%\@/LX6,1\I;\$?1S\J?WN_
MN\JXG7VY^X7%UOZ.Z#_92656U+G\3GWPF7MH?W(CI9^T0@<+AE#)SR\C_!;LVS@;S_Z+
<_*;26A2D3_!'/7_<[G\SD\BFPD-DL**9I7T\&E/^M";2L6\ P_6.0RV7X;.&QL\$ M%B;(=;YM6^=7Y)9Y;N\W.>L3HB<;G-
S;JS6\;KP\8L!%U0=BIX7,DD)%_O2 M.@.(;2;_!EE;4781NMKY'<00\$S0N9;V\U/\$2=17G4&7_51=1%3I=)EG
M1>\$!;4W'W//=WO;"6 +>?D51Y-TLXBB+K(3I)2U>\AVMSG;MTJ6Y#C";F;K M)"-"ZL@7I#YJJ@Z?
FHL6B8\YCH@&\LY-DE\$1BNBG41@4"\$"6QOIX(#2\$=- M456#L3;D&"BR6.TQUT4\$B(LAY5_
MUEQLID@2CB@C3X\MI_-IEABC)J+**X>&SP97&8(V4Q1ZIC0<KTT/_=;SXJ MJU#<@X0;);N\N#LTN1-
5K)N'KSG>>L.M\>YZJHE<I^.(1@U(I@2SIF WK\I
M>GDKGF2;RE.D851R6\$ZSV_>#O\L9M)\OA;MKVVM=P3U8&%_IV(I+6\$_.QLO MT*D"#WINOOT5(7CJB_A7C\^
CI5RY4.IN*5>5)4I0QN66CSR\;RFL_O'G^& M\I>^7HF>3H-P\$?2U;G54#^TC*%9.@L>O8;U?
(MWF*I&N.Y%N9Y5(HU2)_+U M/MA!"G*^QXC52\SI;PV5#Z)YHZ\DOJK*L4YJVQC\!F"-O*Q=
(LGYGDO.\$I1A8C\1HF>1VUSZ\I-622(<1T<7?Y=1+?R)^+IS ?^_X6\H0QUAACVT%+8P0P2=/F
M8Z>^#0\BZ)B"X;"S>_T)0,2V-3+ MBZ%&A"7Y\=C\5?5)(V^J\B(C)H;L\F\I#>N?Q.+XF)QRJ(E/0.H6PB7M2YHVD MIP5-
;Z2T(VI+60L\!/L%<^GAQ&IQ4-5?+IT1X9JW;/8U@WHC"&,";VIO MVJB"W_<H\+D/7HJ.TGMJP(F+<2=";N!=%-D";

EZ@ 8.1^5D=AG|= 8'D M23&T1HLEHR42OM-Q1KMCX<"\XR??>1,DZ=SK;#C654N/P?*>>J;=-X@+|_K
MI/|<=<7=>@P&IOB2YX6476|^%MPUA;U(1+4>LYCFV2B1+\$^@16%P&25IH3FX
ML;85%B*V>M,Q,DC=R6E\$;G3B*?;8,L.8@L%|@R\$S\$OF7#1'F+ TAM7NB=4J
M5VW9M&G+2"FI>E7ZU"8^@^,KHOM;'C6H2OHG>@+9J!;V4E3S!+WTE,FMM%&7 MX
2#@Z1P49&E16M6(Q \IHPTB V82+Q=&P#=#OBG29I*%RELZ3C%I>SD%.U MGU-#N*:9-(B-
@&/M?;EH>T!^JUXQ(XZ^MTRT,/>?TVL#I4Y5;20#SZM/1T M!K+H),ZFXIBFRYI&4^ 5R0 #N=R.;R4XVV;RC^0U;F(K
9C%.Z(20VVRIR+ M;OIQI^3QIXMXGKH3V!""ZW^>W!TKQ#/PP+T(MX\$TTHQYS"USN(T^?<"@V
M7K';1DH"17;C.7R0!FH1LY167J9HY&>8-K;@'>,"MC/K& 72 M<7+OHGAST %0T8 WC3<|SI33@C\$-
"4A@#W0=-/S,""QBI+=26SLH!^T 4;PX MC""3Y>A#;Z9T W""&|Z;DBIQ6?H(2&"Y<-A@C MJ60\$&4
_AQJ8+2V88RQEB0E 7.5B|T3W!#FGC&.@=WUFO=YZV0E!)N\$V;^\$ M.H<8#"^N,M8WT31C=8Q;=LI-
S8U&B5FLJUQ=";|B3V8KY.IEE)ULA5=\$UA1;@QBQ&K)3C('J08M:FZ!W M/>LWTZ@^DTI=X=B1JUIS^,!1\$YJP98B-
M8DT 3PC7-X+-20>|9^E0BI^K7&\$VMJX,"F M7%Q&M@N'NOYNKG|H(G)1%_&5J(AI24*#DLY+|L+?
M%VNT4,EBI!#N"K8,XQ M \7(?*\$.D%,-/M"N|3U M@N(LB%|6;7+T2=(IMUUCM%;RYROKL@"2OIUG@ MIHPX&
!PHR^0D).0@\$EX*.<:P%OI&3A;SJA2 BH9I68UO=XC7(CMC/!V7 M^83IX!- =^A|2.P=+/EI/H+8M")TA)I&?
WU|NT\$,UPH\$8L0V;7JA6SMTB M9NZ6AS5WC|B9!XMO03| Y/LX)BN1=VX 6K*B!;QEAN/-5NRXB20"Y0U%|DU
M*%CU,=(XH2.ZBKJKKWT M,I=U%G;@8Z2C;TUUIP5OLOO8XCP4|HN\$158Z".9EQE%)IE@6_Y_8%IPB + M6?FE7_(8Y;
<5WTVG.IEJE\$46RG H^<|-"W0XY*Z@6^_K1BA.L%-R1.C9^%GEI"#B!&!&=0\$UH;G4_Z;-WN*;
M42DU^Y|_5F0M|H;4@%O>|X5L_R|3H=*07,W#YC00CM\$AX@|WV+4YZ!/?#; M"9VQOK?
THN6>&6U;JXRVASHRV%ZN,MN \AR.E/6WN="OFZDP,"#C=8MJ\$7 _MIV4|Z!PQZB\$E%|VX6L5_-O%>(^(&WN2
>48YI2+CY.SP3AI#""6N+T516Y Y.M.D@(-ZFAI@BIAB;ZMR00U)Q>&3D+;_68T8^H_5K7^AVKMN\|I7=JGDNV7P MP
Z>W;48XW|!^!V-+*/YIU@CKOZ.=88L>SUP9YP8Y,GR.DE|L6Y1.\$*J MS!&C7+D).>6LY/4"YROONY^#-
_L!M\$@E*I5/WZ+8"C_PO|Y0W|K|. +\$\$.U& M3K6YYN0^E|W6O|
|8;8F>U^T.#VN@A|8R4% C3G6QATF|J2P'UU%_A3^+4J;+G MFB\$@,1
<8(^#@-5K5M>@6*!M<=P/5@Y8,U@YV>BS=IZ+XUY1=G%9AL\$ OC@H18<73|MJE,N.Z' Q@^YXD?Q!
|6=56M|0<5AA& M#9 &1W&90LJA;GO&6BUR2^_OA<3|O66SAH507L1|H\$|(*K*E&Q-15-*@R< M2B?;9;Q0?
EA-B9TB9-UX"ZR?<5UO77KU|KP;80"SL^E?VJDUL^R2'3;6|WG M#WW+5S*EL /L?
1H8*Q1K8U=@8HCOEBIU5;^QCMQ>|N44_-2G^EYPB1W\$E MC6204+N^|<+= \$>6.46"MMG ##&67N\$\$U2-
0#*;&3#W;V%K6|B>DRE" TWU MM2,FD)9;9|H-/Y*.'9)|>6GKCF#KK.,97J
MU(S"5DI#7HE,\$|%KPBdTROZ|GJC%NEA\$5409|M!/?@K5-|363(\$N|C662Y.P M)" TYE8/F6,>K&W)6YB+;<@-"T|
|85C%8R>D-N,<<|N:M_L4 I7R0TB^X|@ MA!.X3PBH(+55K#1(*FJ%;1J|JY|)(2PJQ-?+SA.@|X(G?1YVV;/F_N(*#
M^L|)^FE;H!"\$1_*OYGF;V+@EAB6B(=F7Z0@F03 M(MREA&)- 22;8>"(L@N= F/S?*;@<5#G\$;2SG;/0|HJ
JR6Q1!|8#3HGWZSA MR%E|8POXS GT|3%LW|O "HC&=C"@KZ,_LF(I(XY>@2+)02_8QUT?EO^_H| MNKI;-=*;
ZUK,UP<'O29'Y@O=|TAUO71|=-.BT%1(T&+|+*4EP&|F)O!D5? 2P'LU(0\$82#N3K+=&@4A53X
MH>P:H@=SPM""^XJUDT4#,W*WQH@9FD,JC|H&Y?F5WW#%;G|,X|-MFL8^Y Y17!%N24;5I5RXR=H6^A(5/5
'X&KX^A^T@C16ESB5-TVK &OZ<+L M^W+7DX+X6N78BZC1K 1B2IX67ZEWLY1HJNG)->C>P:P!EU";5>L.L;\$D
M;L_F68,3B@.170B P*=ML5X"-)GG*6|V@YD^ (M2-(3B+;NF+LBI |UGA9_W,N5)^4=(-|K%+26H#.B6;B5%^T*)#
M38V2;V"+)I?EM,+#B..|I |B)|Y%OT5IP+=5\$'_H*!|X8.Y|)\$|QF#X'3& MH*!X*)TCG@-O-, =^=BH.&?T;!
1ARZ*H<118*2Z_U&5O|2O*(>OH7\$3PPJS M",_X&UT=%2V7>9>+GH>T=F-RO0RN4C&1\$="|42-F2)S|-
C45C&P@ (Z5M S M)FQ\$;|@O-\$3/_@|MF2BH|PK0R<<=)=A*BDJ;Q31'"=M2<-LXPWW"0:E M|(XSN, (-*&1KQD|;0V;|
M#PE)|M3W|+R2EYUPB*H8E(3;I9Y*6Y=Z9S&-VV//^C5+S'BQA6M"|.#EHO)+?FH0E\$-E?>PM&1 MI6|B-
D"EM|,*WZC754)O^N>HR)4\$K>DJ7VU\$)994.IAB\$8/ MZ &H&?RG")8SN:XAPY9@?K#EV/T7"FM-%9ZAM C
^=J.3H|T?5 V6%;Q* M=B(E.EHQM,AE9H606& V*\$AN15U2V=Y%G&L@*,&S8VU7NEH.*1J+/Q,1+YN MYM%YE!_9*
(4JOYA)D<|1Y1@TD@+|W"0|EN/NX#A;(F|HGR MNHIX0WGC+R2P3AJ8|HOC=1&^'&*;&06&BU! = A\$B|#%V%
@4C#-"1PDR2^/CJR'T'DG|I>*>\$| MYL O%EE(< V|^Z#H/6.OOYCG\$P,J&=*JV2N?7C.OKGZ%Q(EN4A)"G"D%0@U=Q
MYS@001WEZQX/!,JZ;NAG AW^|6AC=&LH|KBDL|6QIDAR I5="Z|?54)8,U; MA(7QA<4=ZD|385&T3/82X-
|HIF"DE"HH#UOL|V;0PU%N;^X07M?CH8ICTKSS ML1WV,AG-
V)LADC@;DZ@FMH)>|SDY84|H89G7|XYZ1YE2.GN@5D%P;S6.&0U! M^|J+HY!;R\ 1U99+2S?
(1W;E>AFQ/ ##D3M.ENC%<6"" ZT3S;R1_!7!9F_XU M5W8>D0! I"/"2H&0B1%,>Q3G(1 4UXJG;1.5I%YUIBO^R#
M=WCB66.*F&IR;E^4N;"V\$A10F|C;|0A& MP#!_C-.REXW+R442T>J|C8WMFS(|8Y5PKF)|#8W;/:15E6#A)=9J
9&U<+4% M^<@UYKN-6F,P5K?%0R;R\$LE92/2SLV7C)3\$D1" 26ZL,W\$;IB;).CM7#^4 M;1|,"4#U4)W9-
;PHNTAA*=XB(N,,NG2|A_H MFS">X4\$9XWR9T3^OA3XKF^ ^|O3CABY^ ^LGOG^3Y"G/N4KCHPY7@PR/83PE
MB*.4GY7*00W!D1',RJR'X2T3|@4G|H_&3FB@R,SCR<45%0>K;L#6CZ|GLW/IC5^/Y2VZ+=&\$B5X| YSQ(=HH(=
M(3D_,_31\$|19\$@Y,CA+KP.9W"DVG' 7J;5O#BK6G&H5O@A#NN_*+>4+X) M=HT;>ACV=;0/I!>LC< G|?4*4IT
2IYE163SEI;PO9\$Z MT#EJ NBP.=P0LZHY.1B#1^J5|>"N5V9_2VXE.9M=;SF\$^IXFG, |TM&&"6@
MLFCN5S6S@55R\$U8QJ<7F|C=4@1P|>QI_GZC;D6O;9L \$;O>Y;I4
MB5TQ_2L8*\$E\$PK|39.3"|+.-0|I+;8/0V!X|C@M7L&/O>1Z=QOV;)=VM) M-
7.E6"1BX4(P5(X1T^ZB8#|>+/%K>U24:H1M767SBW% FC^XOZY/L^N|IV"
MP|G0E1|AQ=-R98AXMMFLFZ|MR\$J4FC2K=PI7)1M6D_VG7(C|))XQ! 21#M M3?+;W_HG^WW_QW|LXNX :)
|*OYD0%U0K0455 PAS#4@%J_3@D7#%#/(XZ M;XMBMV.GZPO"6\$#G!*<(|XJ'S6%-Z|"-7
/A5\$Q+STI>,=NMN7'6EN6W>K|76A6|ETFIZ, MP&|LAQW+L7%_I5 +^C(5@O|BZHIT..IW%;|@ M?
UW\$E;HJ(NP\$UH;.*KV|"> |RY@|U|>#>*:|8B|'2C1K3LL+=K8;.N77/ M^V3E%6++^DX+J|-6;O-X=U!^FK9#7-);W
M9G4K"JRGJ^A@\$_.9EQWZ'57">AOB8Q 4_'4S!>KPVQ MONP)+75|(V#D)78J5Y&U3Y\$7'T*(^>4E_M72^+R+KR14|6
)TA+Q+Y""N#|K M<(QDDL4Y025_7&43+R";+<=@>N|HWD8.XK=C;E,P\$1'DMAW\$FCKA?
<+E>B;L;QGW+R2ISH|DS4 M5#&QY#^XC72J#RW!#?M46|#RW8P;B=<_JF2S32
M;=>S<3TDM4A;=|TEXX@+0AW8=H;L6_42-42')6(WZN,X\$|O.8);!^_PQF MK=7|RAUW7W=<2|G&IG?;CQ80L<)
<""6J5'7|Z">|EHE;T""FVKGX7Y<<)&_0|P29HBOQ2JD)H"Y3|L2B^TZE0078|XA@WW&PK#Z MS=\$=8MAS@%'6&?
MOY8BNQ0:3C#5/+GB3B"\$E*GH6*SDTKJG5NLGG-|S:Q M-< 6PUG|B@JWF;-P5WR375!3|(^GSFS^0W!27FM5>1.
(@%M@GG 73%NC2;2Z M&XL"+^XO*RUI=C0_?0(F20"53\$Q>0M@<^Z9825+ YZB|)E|H M;1G*LD;Z-
*E.9).2+UM@LM2|X;+33^("8?@J|TD77KZ3K6>S8G;&9F! M0+^M>?%H47A9G27E#13H?(.95"#)8|NXW5\$)
DQ|KOE"6.\$2O-P;4)2%G!\$6*%Z;P\$ MH>DA94GAF8/"KGR66KJFN.2R&_)3D-X!&Y+E5)8VB|ED4;(12L&I2T2^~490
M><-A;|+ -|T&OP3"NEUN*&|O|+?#7.PJ)MY"P;C|2WD2%UPDWS_#|)0-
(.9|)OP;L.U3U0G>\$HFYBMB<|_B@*M@MIN*U8JSXEL|H38C5|K;."^G"Q?T\$|A(\$|/-L\$-JE-YC1
M&*AHDH/ZGL;0*8J|K%|D&F8&9G;7&(|EF)*X*%S;#9148L|KR2FA+Y|R M8WF) PGZB6 MN1Z|!@30F@F5^CTIU-
5X|!%9!%HDQ&&56\$=7N|P9?<8|7D+J8 M_7>9#Z2 *HV?|HG|.00)VW)/KH*|B@L.%6>/YO.&&%.;' X.2"7|D*3-)HS
M6FA%YY)H40-51Z8\$9\$K38\$.8Q _JZ #9*YP>&TCB|*|4HNA"N^)&-RN|9|!
M6C2;R7X/Q@QZ;1HCK#=#_0/05)!586I#3"X/RV*|9+/#XXARJ_!@!=Y\$@9OX_%UC^_8K2
MXIGLE1USBFU(L*+4^_9*)HDX|M?|MIS>K;B|E'A-/?%R%<^_H|T^FEV
M.WV^VF0IOM.D6&W&9VD<4YRY000(ZPAQG4C#Z;@V|Z(XE8V!_F)(Y.I/9U

M+!""KI>7KCEI7*AT*U:@FEQ5W5)D:54L:U'C:!!LL46AX4XIRH#>9I4IHT MO%"P9?/X&6DJH*NT
L4"W:O+PT:)KPH&5S=HM4M>IQ:1(57(**HT&FM5Z MT^:1?:/P
X>Y2BZO8KYC&F<...A6@\$(JH(L>U"3MMD59/K0O13<)LOBUS:
M)CJ@*="F;...>KG59+6L_8LDS0(,J2@F)A!="/NSHC/FO/NSJSG/C.WM_M*W@A9X*5D6)(5H-E?ZGZ
!"QY:*MH;D8IHEKD0A*VH+MN;SQ&R(+G?M5&Z!2MUWH(P\$B_IH@IV^PI7-
PO'F>&1LO5AD:71D:P!!7*1L/2+OWRCYH ME.Z,#VIL"BN00%)#Z>T%;N:&IL@T!PCKC%JOXPYPBS60-<\$IH-
_%=FYPG M5>J:1&8!I(OSH\$FD"3MH.F<5.L@OIVAZY;+192Z\$139W1FJ(>UQ8HOE!8A/G MB96B6# V63>H).NRA!
EZFJK7)3D&A6K=&KB@D;+7M4G;U;1/7W0>A%L"B_E M.Q@_?>3"WU7Q
TU\$705V+K4CHE6QZL4@_U2=ZRG,AB:MLEU,M>X'MP&NG M4U3G*F6/XUNWG;/801Y@8D/M"#ECPIQ9-
)H0VN4>KDJ35T! MNX@G9!!P0N"6%&2:C9&XSMR,<\$=T;6*_-M'V;&
(_IR0I6#47P43Q;#=/^U'UTU<5J\$1"8!;+<@7R2!;+<@ZH>EPI_AW#1DGC%"KFW-OKDC,CVZ
M+8R8.R3HP#2%LXURS:8+UFR;+03/SZ58'0\$-A,AP6(1H7_*K^>)5N17,XJ MIT2S;X32,IWRP>)/I#90*JWR5B!R-
7R+;VVK M&^"ZM\$C7ESYCI-LLI%J\$!)@X"U6:YT4=*6C1 7;G+7H0T1D44583J9Q1I'EXCZ>K=5-R M;BTZ-
%ZV!=UK5FGU"H0BDJ1U0Y+6\$&E;&F=+'DCMP5&F1UF3O4M_>40%PJ8E M_)71+
T_&O5)H_.#T:I3R,/E\$13BS;I(;&T&:T<> M59W&LS)/R6<=4:DLIUE;" OXMR6X R6X0R"X=79>
M(Z50=R" 4'1VQ3>R)3INIPD55B>5JD;_Y'T#Y\$2QKJ@GO7:M!M;?(IXS<&D MH;:E)?-IW\$_%(I?H*94-
Y82GHB(P(CIF#E.6%W+1(I7L M)(>6B)NA_E^>X3*KDFM^6T6;BF/TL>+,"UA+3R Q_ N F&6W5F_1^T= M-
K(9>_7P=W83Y&AI3F-9*6F&BE=QBW&)!;JR^::OKK,2KUBOUN'V4+=0# M7LF^X@Z)M?3LBLN ?
%Y!1"8=D077QG\$H4WJH%_!H,H'WIRI4Q_ M_J_00SL3L#C@(&KX(^63I?
4#Z&NYA;&ZX)WIV%K*Y\$3&HQF8I'W@Q#;:H^+UT2-W)*N'KBY!^!L*OV-P79 W)MQO&0"\$VV MNJZ-
ZWI*4H1UB:%Y\$PW^*J?!"PKYDYG2E O>_XS>6G MDS/*_1JAT2\N\$17?-?03O6\$NX
*/+F116^=JYR.\$!%Q"&TG*O)"7)"8B^#.H1VM MH0%)<8WJLW*%!2V3!SP4"*8,FXA^S&1LT22FF+E K2X%*6M\$#
(^K;:4L5*0 MKYI;BY;"/49Q#T6^WLFEE<'@;5I+!))=;UZZ8GIGLD2+U7)\$MW)\$INK9(GO MYC:0CG?
HPZ<3D%%\$O5OZEZAB/32IA;1 D57-#YF?<+15#)C;X;<>XR6SD@WB M;. 3 C;LB&\$9B>\$M(=L4#
(M@_*!B(WCZ'9);>&V\$ _30+^TI V=;>R17P>T M=-
<:TI90X^8Y>>3PV2;ZB:\$WQ:RR@;^%>M>;\$,LLQ9.WTW55*;V"6W;1: MW3O5208XR4C|S!Y4WWV(E@I?|
(1,5F7>ZKA>HCO2 M22:HV7LN HXF(,;3JY=Y9UOJ-(^0+3I,X=N?Z#NBCI'WCIW)23)CLH MO?^A3>D"E5*!_#_;%M ^
8YA;JXSD7'C'W2IEWI8CUQG 8A#3SRW|HX=D@O M)JD9(2U/X\$RNX
NVMCI@XZR.\$9)@;%LJ2#1U(=*7XOV,NFFASIG1Q@#@- MI&(HMK@!4W3*0,BS*"0Y#)>8RYQIZ!IT0Z#6;
M)I|KS;"X(^3,T9+FZ_M|<+MC9VGN|RDHA,OS.7)J3FVY7U<7JF;^*)(L 1@%MS-"IS*XY2(89!;
28G&1HP/C^="N(6IZ#IB|+Q-ND#E='BMZ",4DJ>84IZE
ML\$HFUZ+**4N*="*\$Q!^;_U34I'P"HYOT@G|AX59;1^2:BI6*HHQSUTC%XC5-MX R<*Z)RGY6F+("UIT8@E
I)34;_PG=MZEQJZ,1LD@S@N%>D* C|K9HP M^I&\$EXOVJ5>8%M7;/RMN,-3)K:\$(7/@ZSF_9I)>-EN44.3_JC&-WO/S-
%K9 M*NQD)378U20"NP!8|B(TK|"Z7[X62\$;LMOOPH4LA42ZG5?EA<,TJHR>H M_J^3^*;"Z-
%|1V5+*+KAT7QC@*0Y*="1NS;PJ2QYF\$8EZ;SL7<6-;OGTCW M&G9B)Q)@HEE,H-
BH6TI5,OK4/0!&4Z;B^.)+3)\$P2EMRKN%*|ACU;?*^I/I* M=A-I8X@52'D133"<I^*!V1MI MQIS8W)+-
=#^C4O_\$P7)|+I^BO|OQN8..FZCU|^>5,X/W@>;H&#^>V/ P_G1 M>?_Z|/>#H/IA'W|XI_>/SK;>W=|O'TX,STWQQ/_
>|T_=-7>G;Z=-6M) MB0JHBZ(B63E_FA1_/86)/9\$M.FL#?6,?PG6;/=XJKWC(4PC3PMIG@3C9@2I MQD+BI/T;_O5GK+
<|X-U">LS?%W&BA^1LB5^!G7C|ZA;IU#;_%9KPAV#U_! M0C.&7GL;&I+W7^&ZI5'P
MI>QO&#L)B!I_6HQSX;T(3,#@7#;"CV%OO4#7&)\$|CJ;>GX9L'QMT4):GI# M&W?#C;OHO)^#+3+%|L&\$0WY8PQ2!?
VLZ825\$S^L^124G7%C#3.R.MLV' MN^'KC+8686?\$O\$D8J9VFU*JNT0_L8HNO\$9N6RZP+1I40_/ESO\$=|PZ<I
MOA15.B)>H(OGT;H8(O^4-N(QI=FN|?ULPWQ>Q-H&WR|97I+Q2V#;I|ZVPL- M;O"W?PG=YF97 W-
I4H8;X|)=HE@MQXF,P|M(RR|H*G"49")PXU0I"# <&OIQVN M?I4*UW>_ZI=6X?H%J>XI/IFXZ\$-UA-
S1U26#.#,O%4@X/BMAR\$44U=:)U- Q M<2^;B#B...I=E%0^8\$VIK*)(4&=ED'MOBFNB;V(*"6I>B\$V3HNJ?_CC&Y
MD.EKZ92|D>V7)/JY4X M>.BV+6MLD;=_!N?N;QFX=_WZT_VOS%|@;3&"2#,*;<_F"7=S/^_!H_ M7|(OYWF?
Q3;J>01V;I#="X55YQWBASO.^AF" XC"G;(K_@3-G;_*I=;H;_ M_\$;OMI;6NZ-9G(QV6.L94#EAC'W;3=RVU&OS-
%ZIC)*94.MMHXE"JNWU@K% M_)BH%2^CJMIUTYE^KQ)*+N^_D4BYQ<_1DN3.5V+(3MEF(;)H(4QVEH MHNMO4?
WMN"6US0:S'E1BC(*2C*_4>62.T15T'EJ;\$S(/*|H_/\$D,VX+/69JK_-CA&OP?#^7OUY)22CLOI1)CX5U3+Q(A M!
|FY=WY?T9P0Q^*J2_L57_QH|EUK5ZP?W"V=WIT'WJXSHGM8|MSBIF7I;(#I_N|S<|I15 M&R?>O^D%?
T0Y9ZD@JSU%1)10=;I/OGP0P|EV7Z")G01:7I/WPL;WXS16HJ|<MF=WNS.Y5.W-1JGLL68?
ZT7A#5#N0;FOR4B\$;HP+LC7Z M^V>!5D; CP0/^RV86>C;5G:@HL^70AYG""F.V-360CFG\$SYC;(
_TEDKEJI<I.S'8BR^!70IN2 M\$7I#LB.Y=6"8M, F^K.#14N,3S'8&6!|U8Z&-RJ.XCGA#|K|5^>L2|5P>" MQ?:
Y+7H5P%N(^_Y?VW9"=4DXT6+9/QJ2YPA|Z87/G*=-7 /PUU|&VN3|O7.2;SU_|,UW|*@H2G*\$;:KP6O"/Y'7^&A+SD4&B(I
MXBKZQ<+03(K2JZ(#_!!E+!<?IYO-U:2FXP"9O=>WQC'OP@_?S<1HVMO? M=GH;&UCH44!2%BXF7DTD.RZ
(^ST3H7C|1W>KKC@CCRG|?^VI7UW|^6USW MKWFYM^9>|FL;_MX;9C&U%NOI3H\$&|^1I'M>)Q0^0W>-JM#=-
YSJ=/T|WIO MJV6?>S&"KD|@V4W8V|2U@5K?P 6|A|F|>POU*4P1=R_WLD8T)41^|X5;_M_-!F^>.V
J_)S>N9PQ(XV^*C-U_R=702) U|65>JPKJ?PI72DBDV9HZ9(C&M3MKR7K+0!;+MH(&SGK7|WK1B)J+8%7J0=SG
^2PKIGZ U@_-K8I_8GT 2K MRL;Z;-JLNTI^4U(U9I)>44L"C M.F
<8(E96+1NC0K9JLXDI7*NMMKI+XE=F\$;LGB\$V(6AL(5T;_*B4H7?E?#- M*J+Q5;LO/WU_-2(?
W3K.3|WH/V4OS%T'"KUHA01>|C(X*KKZ&>8?ETK"&%"*
MM_="/^>7W4B7VEVGI5T@NMOVHEN89W!4C";T;1:27MP+I8P#_03JFH|\$2GB8 M1S?1N&5"ZP_'95Z 0<-
B8+4*I555.M2+19OKI1.D=^*+Z\$_(CJN*29 M+!
|'G)|@A^CGZ=#'82.^*HARK/(4(AS26.OJ&2NJ7%'E9|S@W.IXPY)T59+% M%1VAXD/Q2PAKZC,81LI#1-
RQUWN;JH#J=&);53:D4MYEP;1M7.M:WC5;CO"/Z>>3EN^I>4?8WT^Q!IDR;!'JTY;U(!CGHT#KY S!::2?LUR
MY^N%;QXJ&8@E(N0?6AQ))7R3Y|Y\$3^%XH?C57Q0W?QP_-5D6S4Z21AG8H0")/2D41|8@N=A+9-
H/6;NUB6.5C+*J_!ET M'20^T476,25+I,X+SHF N1+0#-MG7M2\$>_@?@_E/8/O>(<=7SOD4)R+UO<I(B^S
|K^<<\$|^&V#;4J;ICH8/V|PX?D&9%;#DH#H"8&DDOA@".MX=I5GY>45?L=IZI="OYU M&J&&D(#LF*T50@B.Q*
_*|H-GO>)&1UYR;0>0:C8D+2U/*<0-4%I3"KD5&^(_M;K_"U#<>^TN1\$^F;&)P+A;P&
X3)I3_+ESSAY_E11%,>8)2+CLCJMM0L|O!VZV>1 MV^W|OQ+(4?+Y#4N0/6KDO7&Y"OH33_G|C;_M.1!N#?&
|A|TQ^#92-;|XV'G= 36ZJX=;R.CZ7IO|TP AI>0K^1>%)MXI33@
MTM.J=>KUP2F#N;_549E\$2%O=&*N|H.Y&ARVU^>D*O#R>COR,\$ M?
3*5F(KAO).Q|@(|V2>)&@|N\$XD4P1U123E9I7NVW"?;_(R<9/HYI1V%XNK=XD
MAA;^P.W@0S832|J4C0RYNRYWO*8Z;ASI?4RN;JPI.*_4M%")8|9+N"PIU\$ MB;LIRMXT3I+T050N!&ZEDY5HB0@T>/-
PO^+&2)Z^RU*7NET MH4JZT;+L<I5DG.%"3A37|CTR)M62I>Y@AL_"I^8OIL"6^0;_9DS_0P;IXC-T>
MOIV5A_'KP*00_SC009C_8/^T'_1/2@?IK_|>_6_V8_8-W1Q_^?@PIXR@_IV072E3U1R MU.AGIT'IYWDO>-
+|/S@|ZKI+WA_O'QT>|241S?(L.#|.SM|>!*='OIT|S;_ MW/+X.WQN_V#4R*MX;/9_0)?GIP>
|QT<|I^K<<%_WBMLZ_MLF(RTW9X1LYN1 M\$ F^@F.EMR|7I.3F_D1VL0Z1O;G1" JVI.LTH;+?
/!&DRP'+_*GC_68!"#|FA#88(+\$/MOZNN_N3TU%~%6UZ?VILQCI L;E*DX M)XFCWE8>OK(C;O\$3=)?&PQ6)5|TI_!EQ;

L:972IE"RKGG8#A.S.-</Q/)>LGKXSES&HPS:0SU M(G.N.<7G\WC;V&MMV8/CG-UD.1@PH%4KR+?#+I4DQJ-TT
MN)HH%Q4A-K@: MO>0#QNZH2G^?U^>NRTI/*\$YSQ)N>IXEC\$H.10 E=H"><:/42GJV*3GV\UM MVV-3BZ-9QR@-!
(*I4Y\TBXDRIV#AADQ:R.4+3T*OOG(BU/UR.KI):FPM+Q MW0;Q8\3X\9B>H?<.?#).S&/(HDAE>UT*V-
H5"=WK\WO&^H/C=ZQ5DCJY MC^U(EU>A/;#>9&G\J(M)@>RMS&SQ\E\?M/;\$CR*P>"@GNUL"1.1? MU4
L=YMD9CRX2FL@<@""@H.2=Y3I"UFE= M(>3Q6.4J2&%4H9=EPY,@H M4G(%CJM(2F#0WN6FIA9&
(XGV #R6H0\B)\VS#XMOZBNXN9N\D?/G>.7-) MYLX0?EB+12N 02:E^)*808M5^IWJUIWL@AC7-
*.120;FD'&^4\DEK=L4%IF M5A6+K8UGAZ19V,@@O(13I6>Z=B\$3.Y_TV2&#WEK\B\5^*?7;R(0149:W\JD MQ\UP'?
DCC6'E\IP9NX0.4XD@:'-2)E%*@14D-M#E6U5OZXS YUUS(G;LVE&HG_SUCV\&_<\$ID#^<(CT<2Y%I MUCA/+;NEUE"
(9R,BGS,MG.W"3)*^/K\$?3JR /Y*2@-QN.;E)+CX"IORK.0 M(EQ\$AZDN28H\6\KW\$\$@2I8=\$#VW@YK?A%H.C3AQ76D4
ZSB^C-/F?R&:(MXL/G>1P;Z);2JO@/IYO=+JDI\PIJ*CW6:%J+>WC;MNXN@OW&4.RB-MLD@9 MJH"JROZYBMN4\$9-
S\ 69TBMGD.KD+>FFDY-1*3DY\@MAU8%IOY\84WL2# MJ&079D\QFX@T!;
<^3H#^F)IOH"YX=2AI@SO\21HB^F5FE)B\I*^<NX*RB47E
MD\0+ Q\N\;)3PI2^JGE1N=#FOA<:LDTB%/M\W.S0> XCW2I9P=X1?K)E85 MY#0HZB0'HRK3N^MPVEXG>-T-
E12)+UQ.)4I=NJH2%CW8OS,,17J4 MQ"M.L\32\1? N^AE2)9P))Y+W;9*Z M\AU\A\4&G?A\$IBN@:0^+8VF(
(8+>BT?Z\$KQVLL%)(H2=0/K5>P%N; M#QK!>M\$+ M_3&*M\XN"JZ!!JP6W8^MAMZ/?" H?IX_@IWC\^</SLV#H+
MHP_1#WN8;PPTX.3L^7+2?7AH21>2S99?% -U.Q4R\$)-I&\$\I?8\IHH01 M\RI\$WOF\9\60H\>IR;,,M\<^<1"
)T;K>T'IKR'I^O\%WF7E#0B_OLW M\$*C8;#VSSC\I>#%O&_ M3IF?I^=OC .6-52/I DB
Q+F>O0<1>&W>834\HF@BH:TB^CHNR2,CYBFZ1 MH6F&16EXARGM^H47F2^&2DVH\I<(
(0YG0E>>I3\$F4743A_I)># M2_7D=+(G#WM%IGK\RI>D1R+P3\$KIO;WCCQ_@_@,;3LP^8^CT\Z.H@8-
@>,"M\$>V\8FASLLQ\A2B=DI+I"D2\I.P%G,,GZ4 M<(*+S\I"\$O5XS0^FV533\HN<_)GO3W4-88M9&QY-DU%=-,NK)E*
<-3J.G5= M?JP8(G):G? 1\X0WP@"KA\UK8C=Q<\$'+O+FBAP(H&+N48KXW<28N(WC
MC8>_!K)OYXQ#OV4\FIQMH_JB\XUJP_4IF&W53\9YT_YLB?;49\ZU98OW+<1 MQM\9V,I^M)^_L6CY?IV_ \$Y6N_VP9-
%36Q?>C8L\9\37R4>M-6EZ1YJH&!CMS;"C8V-SHFT?;*=>IY^I\ML;7S;WQ4EA M01Y"A_M,D\IYD+?L(2_&G;>)K?
L@E3YS\NR;<2G-)MO>R=;C^H^B0'M+TZ MH*IX0 MM?
Z=8Z8_@J.Y\$._3Q_U^OFSZ\$[>Z3Y>I\TAN!:=RE)OPX.SBB:M M\B\T?//.1=X*1AF)1@L"XG(>XTQ7^BW3/_SJ?
*IKKU#>?B,M;=B M_J_@S#N5X\I-4T\IZZ-!E(LKW>GS+D(@O9-IBR=G1BT=IET+WB8,S\$T>+Z M8>7Q=0+S))/?
D@E%4Y%2Z2>O1=JEW\H@T72ESN?5\5RSL\4D\TTO)"UZK&0I>V\MAJ^Y^+U MJ;\$>N9X%QC_1W#>#G(8^
<IWE=I0?G"UE/A"Q534(EV\$D=IT4.P%EX+BV M^IXEV2:E36N^AE...@ #I>G0\$;MSC WF-FW3=2B_/B.ND)##I^_J
M#CRE.I#I.Y G5VW4/ZP0?J+L>S\$RWZ\ R-O\CIBO0OIR%0 :^O%1RG<0%WH-*3J_).R/I^5N=^ M2% CZ+^>N-
B/1=JWH)>&OK(VK.KK(BE+5TP2=)D HNR W @&<>0!5;U&"I7 M@F\Z
T&Q)X**=)G>GP9.BL_TF_>Y6DWYVD_W*5I\AMLJW=AXV 6*_%QS\ MGX\W)XPH=WAZ_)XPY=X=G9T???
@M.#00?ICOG^Z?F)AJ>J@%YO\U\VS\I_*\TLW\I_1%A"P2<I@A_?&F0SHL.SCX> MG%*F3?_Pl.C=42_18-^>
HJL%9^VHV\W #.0SEC@ZO_IU=1\$4OM(P2_ %I MH74C\TJ.45FIVMN43\^3"M\$61\A_"L!>V?JY-2O@A+*5/B.JH9J
%VB> MGW\07TS^-:URX&S=(X\75%_S2US_<2-0\3GSH\I_C\I_MHG&N\6_MG,CU&S+W\RR\IO,%3U\>WKH Q\I
Y9%G2X*0B^+43+D_YK&U&B\I(M_...@TM2.B\UA.WR%Q\IOLHVY5OR9JW1TjG3FEDWT>WP9_Q+@3UX_OHU:X M5
I'94HFO#_Z_UX0\4\0&N\$-I*+BK\HX"0\I#I%D05;+I&_.0K\^MK79 MV\CDMP1)IO.SG%
I_TI+I/K=VMC:^+XW:#6;A8DG^\$RZN1?#.HPO\A5I_?S M^4JDY1\$.%UJLJ.9^GLUC_*3^-&_*IKZH6?S+;C12H+IV+
Y#%ITSS*5V3U M0\FZ\B0^Q1<I\R?LP=- &N@="(DK;) ^I\#+/50-Y@NIZ9ND\G^%R/I
MK_%)Y\PKW\!&AJ0=GPH*KU?>H%&6..+PAS9XTE(X1M%X(&CVB#K"(J" M3Y^E\COA<\$?4 QI-
@I^#T.CPSZ_/OOD?7K*D.1\ M;7 \F&7D=I B^;E%/:&&28%4\W3\IYR\$^#_!_XXFTU^#O:P7\N>G5\I1#5/
MUJR9JL+>BR\$3_>SBE6''.0\$ \$LX5(D\15 J+7S0MV/#GSEOR.^5ZMV_K7G0 M8)SV\M7)<-YW66\4E((I)UDVC;\$\$.);W
7;T+JY+V+E89LJTWIG4>"@/U MM0QZHD0&RJ+-C4('9ADZV7#9YF@E;#PLK;W.=^ 4I0-YK66_7=>F1I
MW5\B8J;0;EV\VLXP\9=31:8S;#Q>?@&.76\T;H\A)TET%=\$Q;^**1L:4\81 MB+QPV..4+1UXE6*48YV,L CM-
PZ1DB#Q\$O.1)UAM"8-A;0B-VPOZWOIC MG1QUA^MIOZ-C9K"K\I/
MDRV9ZV@ZL+7ET'1Y1+LGN'5>3T4CSR\#H7JF:O?S56IW=VKWJU5JHX)4I028 MN3*!NR0X,BI2B%07<7+;?&:9TIV-
4H 'D>+2KC @;_1*6&@6-67%JAOQ5,?9 M5QVG% ^PI+?9319.LE&/3IA^IZT"20_O\MM\HBB*GMAA9D> JU3*M,PY!
M<4MG-W\$(5Y@N-N3.\$MC15N\B^>B\2ADZ\$.L5" L_V^G;I>N7YXD9_Y&EOL" MG*16>#O?@.^P1\$S3HN?U_KT%
<&F#_H_4!_<G@6^>V>M(V_K&EC\IV?)#R*WV M\FZOE.6.N>PM\ M 9\$=_B_KX%<_AD(\$AJ>ZW.G
M29HIM)NK#;1>RJ(>6^+M%Z3U5Z,H\$HP\I.LU@;_1#3L-HKK^"D"OPLQSI M+GBO\@&3.7_1L>?U6+QA?%D@N-
A4?(H0H)";<V-IUY8OYHLK_B\$R-7Q3?P ME&(X;HO>H%)^A0X*LYLSN".X;NIC6HO6US?6UY%JZP\JU0:R GS\OK\B
M+69Y*5VOX\K@* 9&"1J044,I%+E\XCHN+T6S4.K7YLSZ9Q(H\&O3LT;^IA MO8&_9\FWZ#4X3K\UA22U)?
N^BP%IW"D,%1,08B+= ?/2%, MIP%WPB&X>Y8\I C';2B^>ALU0<\$?9/F46I<%E\A%(R40"H7.MT#XO>!M=@.D MG(?
ZGM=Y=HJ(HT#CVB_@,"HJZ3*!RZN>:P@6\NV7>/_+M(VBWR0*V+>,95;P+B(9I^
MUJQS:QW7FSNT&2IAYJ;_E\$E/S<^<QNN.PVSL\$(WU\FTVQD)MLC.^P MJ<(&5^2#L4\N0_@ZKQT>.?+1BTH
1%=<G;^I\FYYP1(2)VA?D%?+7(3>I ME?9*KC\#>X9"-I^P+6+JH!\$SYS%UF=,+FI%_PKO@V.7+6AQ#WW>I\$HAT
M).6ID%_QIR(X=6@NQQ)ZDK_P3?/WHR@=C.XYS-97XB^000EB7K7JWE\N.M(%>*TK;JARZ!S-
^+2V17040S05CFN\LSU_+6SC^R/6IT"W\WQJ-K\IL+I M;2IX?
_3A(^CK^QZ<_OGL YWM03L^<WBZK+I^ZL2WJYX6(HYZGE4@N'- ND^ M@X<T\>/_WV(?
CGQ\CL_VC/<(F.=O^>?R>G\IPDL+1_L%I<I^>^HY.7YWM/?GLE'%\B>=SP.R/B MNBN2_>6(T4NMN?K/X75\$D
7%\$OLGUWN79+)=7%N_/X+3-J/@PC=0^MXN\ M\$"18S?I"S?C/P>G HOQIU?I^> 4I> \$3)M &N1\UL=@\IG\I0F+FI?
5'@_ME?N;QX_K*W_X5ZHIZX<4.ON(AK%ER4#J C+\$ _I+UI<I\M(DC#17;^B5COI
MA/Q&2<9IV#V^H"6JS1U;U(IR\RG"8@L29BF #9 VM;^<C>S)*@>' \$P0*%
MB&Y;ID\45MY9E4=\$KCCQ\$BHYI\$S\$SX+%"XAXGP&@T\8_<C5STV_N\$?8G MJW&?>9_10RA_@;C.V%IE/;7QR!=)
BjD_X(S\N^UCL M#_F@IWCN\JC M.1I<6>+PI?A+JX=AH="R"<^60R<&16B")9\I.L:>>7(%GIGFC\0SBPZ=HG@I?
=XI=V?CTI^HYAYAH80'9Q.4H7P^GMXCN>Q4RI\UF@>I1W@Q;> F"1@JYB(WI9=CSCE#UB=3E4E
MF8;JDD8S56=Q?A8Q)0H9ILAM\$R#D2+I\XXR0%Y\$S_Z\YB^I V.C9 M>I E@)"LF30(*^ M VAL>+IIG\7KS-
1'6>SA6_<CU^TETAQ#UOHLZ6)IYIP=78Z\ ?EG.\$D:6-6JP#X\I'-TM?;N\ILKG\QY3\QX^K@""#!OX/HB\DJEH15
M2<# N&.@#S#T#D)-DCF4;&2&.3Q:BCT493>'4&%-T%#<_O\O.)"T1W" M%/29MQ^0NX\0+V3"<84-
K9%\SLZ/HU<I B+""*2T#GKP&"&?G6C3J\98JR74.R1 MVS#(<BX\$6IG/I?3&2_%XBM8MV\I(I\$ZG M(I+
XBM\;)7>@YAGY*I#R4"=UA?LY0T?MJ_OWFKWY#^6(2*#F#?2"9 (WP_7?7I&*ZJ+M&B1AAQ=1R^!Z0HWAR"@&Y=X;
M#B5\8@R+/A*MTSD8JHX?9<"IF\4@WVN.)OF_*+C#WS*.LP\I?H4^_V<(
M*/DM">C*\$;YXZK\G)9) M.R=+WCB^OXK^ND\>IN^7?3!A_ D+T=N0_?" M\7*+U+0?RYWDI%<
(^C6;Z09_?O(G\$\$/>+4\U\$C\Y\IA-LPVCL_>R MAY GCQ_#I EX23@PH;9(SIO78\QORMB=I2%.0T>^B
38.6&JGC^ADX4.4S M@FEHSA P-WAFI*).0N5C^.&5\$WS09+*/6#ETE^/7U^%?G9EUBY48XJ_- MHR.6#
L.ZCUKJ_*AN3I#/+*+*HYK%0;U#L>#+,V/^Q^0=K.@XN93+1_P MX W\$?DGG?5S9TB.E 5;A.FWWG"5F*VKI
Z3JU.PLTO(3<_<#ROLS^PF*15^< M\ C\$X)IWAYR\2SR>IT?1" @J+AT/SG\1QX-ODL_ P3?>@&O.OFMV9-0K&IC(M3
FNY+ &SS%>N1CZD\I\JZCJ9K\^I> A^>17HC;J^C-E\KP?H?T.KSPT60% M7BH7.Q?W?E> XD)-D>900IBM\I
(#^WA6\$88APZ9)=TXV>BD0AS0I2#;E: MK3(2\..5 M" ?XK^D9TBNLO^&FB(^X E%IG08CQ4\+DI\WTONPEA\?B09?

Z# + ^ D.G# 'F\ M?) COX.34=Q3=8*W1%FG8AT /2X2\Z\$1'Q ^\JWWMW?95FW
M: \KP.NG\$(-1'AU: *Y8OZR: B+MPJW%JHP: . *C9\X .Q405?X*WAI/H0RQJ_ M.T.\'F\TIF\$PC3G ^/(*B-
81+C&\$5A.MV\$5'AU*P: .8H\WY: 3\WHTL=D2%K.M5T\TK&TG'-MK>6!-%! \>B M:0)QM%2J288@
)W(ADPMU: ...*6T'J6P&SDBF=L: .+1A= .E.F\ (LD3\ID*)30S7?U%T\I8D, - (4F^K.D0=< MO2J0-05,0T7E9?,0GLV\1+ \U-
D4= .31:EX\J1PH\4> >J:G(*.*Q-U: .+1+ K) M3F1T0G2=J0)2, ""0HEZE 5\ (\$: .2U7>OR@ ^KJ5(U-1L:MBBR) ^HQ&H\$)9:
M(IYX.)Z0* &A: *7P@L1C(W9 ^B_N.ZI. ^0Y\B6C1*62+5%:%T629 7XQ3"H M:654U>7)MDE57: :E<*058,BDQI: *.-@!
>I#&\$&.\$3\%W"5ZK9*;26C&R2F MF8\406 ->7CJ.DQ=(^Z^).WXIF\U@0RHROR5, *B:5%8L, +4IN+ \L5M.D0&K MJ:
(@R,\$00%.:I:8AR' @+P6*U.%&"MIWY> \JNP+70@8+QQH\$ _)\! ^CRL\#T MX% \40U\$WJ"6+PGFCB(*6!
(S^3B&S\j\$UX _SWZHQLPWQWW-<5\SW+>@! :J=6\4 MB\(>LG0E*UD+41:P/%-ZTID<#6Q:5'RSCY-
HV9QINOSDB<38W+4NVU)V5ZYZ M:A.KJEPV"NOT2WM\):T9N8JG5J)VYFA= \40QU*HKEN9%-D<:JVP:3"U4XQPM
ME ^, <::@ ^: "7K-LY6BK<:7" W"7>E50@<+97X"VN\3E:*)9:Y.KRX7>0% \12:5%=DB: .33: +9QV-NHX(PQM5;=5(XE?
J&51C53 M60N+ \4QFDI59>F" L# \P6U0S*#HLGW069PN&:5*#KC\$.3F2J&*+A:ZB5)C M95);
2DV=B\US'W\N\&L&OSU(KF:J88+!<6 ?&: U\$@4: \S2@9F-PH"\$8 M'J+&J\I?
+1KQ"JOQJ8: \4%5R# ^NQ)\$R6CV*0&WA*: HN0\ROJO\99,4?*= MO!_8P(&6(LJU->H#S0+W(C:AB(
F\&@TKKJLJO<)K^Z\BN%ZI9%;4T4KQ\B&98U+!\$ M: \U:MH6U0U1ZIUDFUK"M)R82KF2)M&Q@ @,K
ZR^E:7 A=@6? \1%6:8U%9V\ MDC E6(J-Y7746FY:5CW^&4\WF5K&T@W1'B, "4*F+ \I)RI7#Z:4PKR43:P= M.7F?
SL: +! *2\41" &&86\2L _5P2IV_ G*L9J#P.8@L#D(W\$ \MUG3JF80 M+2V4F= -P\?3X?8PZ*R\9 \I @PG^ \- \3CPGU-
(D ^ ^34>IQ00S2VGH^R3S\$K MXM7./9S_.DR% @.2.IWES2; "D%5!%.><))\$RW_Y' B9\X
M2M\ @9=6+YZ%\$WTPJ7KJ69UD7+M< <"D:ND9EEOLCZV)E9T\0\ \$ \+0S='WF3M: @."%FC
M\H\&:5P\N\$ _)\@IV&P8\0_9+5 70C\Z)0N3\ ?&ZIGG_Z-BIW+ \J1C0\IXGF)
MIOZX(X*+Y2V\8C\I:E.GVFRCV4:SC8/>ADCWG\$T\ ^\I!MZADZE35:SRN4L9&
MH1(UZCPV5*&JK5' +J' %% ^XE*-1L\6: :6BE*0;AL\1% @*^8\U*(BO+C>6FMK
MRS'/_PNMLLK*NM"HJJK4MD7)1\4E_4D4.\23RJ\35N4\T3;"QMJM2T#KD\$
MY:V4HX\X8\&)4JAE69025:D\$P+; \$Q+DU\BH(A, +*&I%/3%8A@J2;8E: MM@ "#@
T%ZWBHONS.BNM\5#H\$M)'W%/\N4TL8\4)YU^ _0Q0.H;PK0#
M4 ^>6@US82*3O.&%98% "\9\$C6\$ L:P@Z#*8>UV8LP\0.&.(?JWBD)0@- M<G8D'K_8<".G0_**WCS
M'3.H+4P_6E%PTL \1FT?V; _W\JXN838:D6:2XBW2T276W, +C4V< & \K4=AJR>KK\R'R)N:WM'< .T'ZZ,Z?O:!
MTQI% A>#Q;RGQ>0%QF*CCI616> \HQVI<6XC(77P*G+&Y=0>% \I%PA\ -7M+5P1K>3K,MZ
M_G\J#J4S.'KK6:VLMB\1\N\>VS(^F.V.+KP\$: 0.+50. \0:PU^(4= \+34>6(NN\ -
!A)A>5 \I8B\H: \! @ \$2FE\$VA=*TYWC#=. ! ^3@5D0+>HZ%8:J4G?". R<@ \L>Y%BJ\J3 MO?#YYH4Y&&7-KD\K5^:5 \PJ?
 \1-D ^B# \HOT/G#DKNB.OYL6V\I.C:XR^OCL MYL07*TMK2H3.V #7@-> UYE%ZN: .N\?4J=VFA)%N\G\ -
'L)B9@WYDW89\X M:QZBWLJZ5VZ6:M\76-05>HQHMR:UR:RQGS\4 ^).LT(M2@9 ^?<7+?1 ^ ^L M _?I ^.(Y\>9SA\$?
F(3FY9QY\<.=AZ9W\J.PH6&0MR-6F255; \H8P ^ (5J\JLX MSTX4 _)S(@Z\V ^U\XEM*> ;"%#U"AB1=
(6J67FF@JRS'53"%S\ R4@/R _> M8\$YO. "L0\XUJRVKTC>VL\$S3+@:BEC"CGD5"<3LQ\GJF@#2? *+I*C735\R\ \$JF,GZ
=2Q<+>V3\ MX\0A3"&?YPZ\1:#K\I.&Q\W:6\I)3NP%9.JAI'E _9.\$: +D4.P"\$F">J:0MR=Y5DJ8>_&48F\3WZY_-Z@--
EV1-L\K=:F MZ\ ^ ^NID'0: DOLH:T2WU8.U Z36\$ \I% Z6V%7AL/ 9KITFL(5:)=LUTZ< .D M:S-
= ^G\H6U3QVVZKEU\$2UPS _%8S%FNG2>V2PPDOW"G.9\U ^ZM\9?G+>J3U';
M5YPGVZB*9A:R8\%F):56V2%IMM%LH\G&86\# \I:UFV6:MJ\ ?EX70%F MV?>\$AD0U192+0MGDO: .F+ \I-
H2SQ+00FLE\=\$T"J:5\)%J5HY\$2FDJE2718@ ME4.\WM\$LY\JLR')UJ&=+ \I%F\$ \>RP" + (J_B9+) H\V:315AIFJJ)
P4\X4JJ0QK16)MT(M2Z>R*L\)'Z\K* @: \V7K M:U" \I*? .I6%J:P6IELX! +5E/5W97C7P85%<-JJDI*JG+3V06L+9<
"J=R#@5 MS*9&FJ\$NY0.C8IXPU=(TT2FJF" _\ ^V:S9U46J \V BBB8\$A0.(HVL9B2.V M'R:2\9X\E\3R>#K*K5% \
(<: @ \>X%L0T67H#K7_LX\FBK\HP9PR*U(_Q MQ+FLV\&@FGD#C #N7\$>V4=X MVU\3Y04Q45PV\Y+?G>\$ \$?
R:G\ \$W.8VB+ \V.24SB3N< .RLB)YV.# \LD\0\2S@ M&=RA A\GB+Y=; ^S+\$43RS UX*7A-7>;B4TU=
MYKG\BQ\7M#.NS09JC'T5\+92\=6\=G R2X\ \$*4B.S O\ S\7H _* "3)7* "DX4 M\$27WT<"\$?
ZJ*.S2+RKI%#568DE696H\337%96-%M\ *3K%(1*RKX9MJF" _\ ML9&1>T3RF98AW7--ID\1:)&FL%0;RH?J8'CM2+
(P'E-0>8KPY\LR(SSK\Y2 M7>:)J6.>KPAY3KH\5. EOI@Y0U#E:PG50'9%J8TU-1:F5H E\$7 ^ \ZZ _/ +7 M ^ ^# \^3Z+
UJ:3.XG +H\I->\$IRE@4SYN?Y4D0\$628\>)"<0%6C@ @ \NF_6@ M"A:E@AM@B)*G28*=OD\XK0HG9A99A7ERS\$SVX(I?
552/N?W\ "HFG:U06)M-7 MF*Y.5KIZITJ \$8I=: 4<@XQ'(V)\T)59XKD="BJ354\JD:FGD".J J/ % = M: .F>9J\L6_0\$9 DO.+
(XFK*P6A80.'F# @/8"IX56)\$"HY.S\U<0: . \I8 M>8&O*Q2PU*HE(9(%2FB\ R\NAZS*57? _K\I.U'K2Y\0BJ&2YAE
UY4 M#H\3+HY@8S\EL: _H.UFT&8S+ \A\#HS6+ \H<& TW5CMN& ^H=BJS;#BT&2!:
MP\+5)%S)15KV2%IMM%LH\G&86\# \I/N6IE"U ?TM@*Y059*HH2 _=C-1G"R> \I M\4&4(M7=F6?
_F2B5%Z>"@K=5J@HS+S\Z _ ^?HF1KR%365*J8HF1FJ3\I(M48M M39@:.\$ \6@.N@9V1:@CAWD0.FP:9)64>!
'M9E43H\+:%S.\$@> ;\$MC2J*4(4("M4 M\IOBUFJ*6U6 \U.O.XQH"/@ \<6\)(-C5%.'8GJD(-"6(#70#R&"K*3>%Z4UT
MDB\$ ^%J" <9> ^%K: + (U_8*ST\J(49AJY9.M6\$*6PIT2P0+DT-5B:S _6"UH; MZ\ _* ^LLR-=+ .2_?
^JMU>9YIBR=.N\ \I%08&M1Z%0OZQ\=!C1UK\$(Z: (@ M110XA#KQVP68NK@ C8%O#+P@ \AXES+R-
X\5BGG%&0MNY0U0\WJV\ \MZZ_X M ^ \+HY _\I=: \4 _AM@4: \HJ3RV<2>37PRGZ%:V.I+F?C ^ PG8./" = _MC\SH@S
MP\$6T\6SQP0_6NV: \D4.K6>TMC\ _UFA&VZT'8*LT(6U&Y\)+ \I ^> & \+ ^FV;
M+GOT\4(0_7F\N\J D0 ^) #2: @T\$%Y7#CA\$ID: ^C "A5ED5<@ \A/2_8\5# \JZ# MPCHOHL:= \$99N7@ ^E" T\JZKJ:8;_BTZ
9\BL&'9IAOV ^4\%C)7Q'="Z\9:Z: \I MQGO _/"W\$. _D4_6B&: _C-EMP&O>SO@B73\ MKEZ&2 _ ^GA: PK\RI&W?
WF\DA"APGND9-1:2=4@92Q\4PX/K.5Z _M4L6 OI%"Y31-SBNAN8GHQWY4?)C=9T:"C@ "EB@ R99%+4N4&6*BZ
I9E: &9 M"SB=&M\ \-Z&# @V\N\J" *8HC\#UF?N\H=2Q\3 (28< \A\25.H9(C2: _>@ M"IB2P@ _?>L&L: _PU\#QQN
XR23R@H5#JW:6FP0R4:ZFE\ ^L\OB>C0%3.X)G M#: %JUEB\&<%SF\IM\O <+FV: \$3S-
A)0*10#LE\ @B>PTT& \Z#; \$2T&1\$C M6&172:95=DB: .33: +9QV-L0Z\ \I @4\ L<6DEE;G@2"Z: %'9JF> .Z GV-U7I
MBO+7>H"OZS:US;# \AFPS*PZ\1KDT%YN+1M.BB:#.KR M.RB: \.HF@?
(53H\$2G\$DM\$F@%"RP\$S6\JME&LXUF&P> \I#9' _@ \U@?)\$ \I)N M4\I)M6XV6:=TR@M
M:B@65YC.FE\Z5#R8ZLUX5Z\I08?HTPXW#H_ _AAO7\CM8=& \F6WH62-S6\WDW>>(F> _&7@+3_7EYDJUR%LZD24J
M+ \^RJP?L>(NG4UW)-B%8%/ 5&?%J&%G2\@3*O&JOCECP/@2IGLNW\37: \+Q M:HWYAA/MC\8:0*R:2M71N7/U-
B2:95%M.#G\K-UF&T8PV+@NY:E7\ R%FZ M**R5 _LZ ^ ^ (\A2J:3/4 _%<>+ +)*9<5S_2X@3X:7\XP?C%&?D+
:O@E7\3VYX MY'C>Q:F2@ (W\8\$Q\GUS*XDBG5Z= \15W_HO>?" _CTE5RX;#CZ0& ^>17805 M_IHPKH \$-
G^2YWAA\A9R>QM D(A= \&?Z8PH\LR(K*Q\(&C9MOO>Y:M= M#V@'Q\$R#E.4KD51M38X7D#=# _D=R\JS*"C;<"YI
 \M?R37SC.+4*3M(RYD64U _M\?WT>QQ\ _#)WBJ%U&+L\F/GZ3T#AH7\ "K\JS MU_YZ)-
MGI\W/SYU/G;M=>)V:ZQ6XK<NA<0>3'.J@ \UY?M\PJ+0U)2L\Y MUAORLG=-Q7ZE; ^ \WY\>L)BE_8L#Z?L3B5
E>RS.\$ \$I%ZG39T\T _N\$D(OW\ M) ?> ^ \I\23Y\I069#@ @ \U7@:HYUIG _NSH6R6RU\I0BY9V _<\$XR
MVH: \$/U\Z?L9\VS1 _ \^U:0?W* _L _ \&SPZ MP7L(-)SWLBD\HFR\IER\EC13.VS\X1#)DU7CO*(JHKK ^? ^SGJ?
IOY>Q\ _%P\ M\EO\43%)E+W)HZD\ ^80UO.'GFG\<0&T.615AAZ\$/@Q9: \>>C#X&N\CB& MY\?DI" (D/Q@A@/":)PBA7
 \O>P\% \#ZJF.?+A@ \4S\ S _I0?P> _NY97#<- MI: +KTYE."87OC/SVX8JUY\0(("\$S"VCV%AG(YOO M9HSC-
 \JNT7< \Z3OE_ZLO\$:<*CSF2(EF2JDDR ^RF?&Q\V _@S)W\T4D05Q1X> M&%X_Y3\K\X+7E=G39%6\K=)"% \A?
A&830*8Q=&5\Z2@Z2\ (5=5 \B#)MFI) MN@(_2K8MO6>&:%N: \F_V\I9'=>M2.W.=<2LE*@W8GWXDD=- \06 \X\ \$:&

Q\$O>%HM-B(\$6?HE3&VB\$8IY%4*2GUI6\$4I%46-6W2"1>(M!EX Q !:B72#@>NA8N@L.O&LDCU&THJ-
D9JX2#H:~#1.K~4^M*PIFY.L&O MUF/ (J4".@G5@/L>X^OHB7* SUW>BA \$C /I V+ (@4R"?F,5"\$H&M(IX>'
MG!9AURJW*~*.E\$3W40Y _JMK GMOTD:~+908&>..1.7/==!(8D)HXX?BT/0OZ M>##)MSU3FC*^)^ZE6C77J=
[6VM0TC0[9M31Z(QV")]:Z22HVJ:51M7E6KU9>& MI.G:BC3M7*7@H=0.09/0KWM7R?C%UT!O#MWT,Z-&.2)H M".T-
W0.E:~NZ84%(D+YTHJU) Y:93YV6@5^8'S -(4#>+&H J9U>+6FYJL62 MZM(:U=6HKB*\$1WM+-
Q71#B5ET% F/FI\$(68V2/NOB3M^(1T/4)0LH9 BC9 MI8XLC4\$ \$WB1L-
%KM36FUYJHEA5:SIASO=R//:~X2/Z;#K\$:-3IL/SIL3?..? M*M793O&L1#5J1VIT0 _VJG-UQ_5)^RGAWJ4/0/SH!
[O<,:~2M&NG%)T5E0='^73BACK?3(HNPWM2 1-MH"< MJAI?
0=17W2C2"G73#ON! R.O4Z5(IZ\$ _&J>JAD]5OG18C4 J-ZI+#5\$N.=)BF M6E.=)J _08=A]?
W9PGU>3R0>AR1H/J"9:Q*BO%LDAY(JLVA+14)4R93>,TH8YS^ M(I9><:64HO/0_7=V>ICJD8/Y=:#41.H'=M=K-
0V9J]JPS4%8+U<6\$VJFY M6?IS]?^YS _\$G5 +XTI=C^<@ (HL>X]#E%"Y@?I3)8,8JL.9Z@V
=(8<[VS\@S\$&_X#L<1%M8PN4>#5[XXZGO/(\$E3&2B<_H/MW4GP&BHYY[B?)"IX12S&HS-
5WAQR<70GPSF(YB1N<"SX S4+Y!_5K5&JYTX M6L))XRX.NZR:GCH+NFVC++4.V4MGRW'==* CKC/=,(8-\$:~!^Z
&ZIS2I\$ /P@B@+N1AY4XJ7MUW~V<->M*T3(Q M6RVWH:*U/0V7_4#ODWH8I^\$NH9FU4=ZR=
C:>W848EGX\$6IORS:48=RG M:2\$>D8TJ*CY5" T=1.Z3%FI@N=IG&+
M8LLH=+9LZ9HPINJ _&^"J8VQ5&0KULEL~:K*\$5LHS4R*+@.9DJEK*,IL'P MY1.Y3':O\$,F:B5RFO\$A14Z1)4U[SR-
9\$TU\0).\$.OWU8?+\$T*LOFY6WJM+&\$F4^%:0N66=R41VE\$W4^56>3)>M]
MUN6&6/O(#/OBACQ70R\Y1FRI&T13HM=DD^?K")\,PEBJ6+'M?L52?F%/V H
MU9\EH>NQ_070C>8]=1/O:XR>VO:@&3/1Z107)KV46V:LNCV13B/1A M9EXH^!%YMVE469!T=P\$H('7UW
MYOTY9"3ME0*\$S:~J#=#2GU2]#V 2C:~*43<_JYJ @JYD?I&ZH60>A5L <&) MO2JL4>_?L
:&"74@FR1V>JLXLS(JNZ%,40 W^\$(R\$ _3'@>79!5 !HGXT"!PE,EH76"Y*~#SZB/\$9 MZ7"#YZ9?QF\$+~|@>^NM"U-
FNS,C*~>H\XW MR,JR Y^0E<_LGKGD H _C/OR!?'G!C2*>^/SH\ P6[PWA>[M+E"UK--09"P MFFGLY8KD&Q(T))
[S8GDP3F/PX>>^#RNJ(INQ("QIB?A(4X/YP V_)B@3_S M0B[VZ',=!>ROB8OZ%@N%1R-X(:
&8(:QE>&8_#IX*NKG3/9)!~7MT311#_9 MNCR5&Y K0-5R^~3Z7))HUKGN-VI460QUOZJ _C/3/=??,=#V00_ZM+O3_#*
MIG&+&OG+!)7^|B|^_~*66OSOGI^_YSR^D_7..%A5/1WKJ)_L-+9^&0Q GG1
M^M(9/Z!O!"&_4G<_>+Z_UYCTG&C7@VXEF(>%ZVKQKQS)>E^R!9PLUTME(M9^2^~7UJ9'/_
+YO_EGPT8P&L\$6#1O:MN-8.81S)N X4U\XJ8VEFI?&J_ M:&Y(SP=@_RIT58'NY\$YT7CH2V?L\$)XA?X+9ZX-
!G/GN>CQ:)9+J2*~L~^ M6IE**QWB7C?P2MJPZJ6-Y0HQ1^Z_ (=CS37:FE2<%6L2R5,605K31SR(+
M)S>*QW:VS%>TR0LJL_#6:LRIFFX8CM7D)4MH^GADIBL4.Q.BOJ_)BYU:7<MM+I<#?#%\$ "T(M'?
_M\$ _P)P"Q_M&:@%*8MT=P8>EJHNO,"XJ(HWA&/74J5BP"AK&OO^KQQ79 MYJ51*%OBQV+WNS-
^E,WXV9RF5]T>BJ/3IY=P1G:Q3!6+&_&FN"W&X@4/Q==?>OZJE&Z^9""?>"KGJ
MTUTHY<2#@E+TPW5R&=QYNIE#) %Pl_6IP Q_E%OWBR64/RV5.^SVZ*2 J MBOY\$AVK-PI?&.%#U/^CWJ%+4NZE
*,PPM=A8F=UFVGFMM'OO/ W MW:JWK4?VJH12ZZUW?MZIM*_QWM6.C(*=T%2K+-V09K0JW7773LOI
[R)RCU:W)/+DC)UV/45:4C=Y<MM+J2<_2S(FI*DO=H7:YMRR>,ZL.E?CYYZ?<-W
MY7A5=+K6JRH6M+LNLHGKSHMOHJ/A2H"M@39G5_9"RQ0_#K8Q<F*U
MBAE6JPCUO)@67@81=R!QP/3_>ER.9'TOYKXHY?IHU\O5"NUJM^K1^D:NA M_V/O6L&HF'F-0H^F_#S'\$S=E3.\$:~!?
5)N&B(W\D8.3LOOG6+!)2+,D:3_K M|P_H%KCDH8\EZ.\$K92O5R=[G3XTAR]9\$@QX7\X MQ:W N^XA@1/A\FVIB7
6=Y&_Z(Y<+^Y6C/M>[G7FHK;@#^8.3)@7C% MF8_9C1,=L\$D3MY<8M_<3OLO1?
1PVACQL7,D0Y#5#D!_TY(4L7:X0OD*_45 MZ6-LEOF Y(OL&DL>00Y(\$BX0+JR_&)2U%~*R M(81E=
(CIT\$#XT%#E!721R?X 9U@GD+"" HJBA>F/PP/^<30&1X>=XD<\$ M%G7I>%MLUJM@>-PI?7\$!U~|B')+!\$)-
#W.6*~^T2G.SDC"(G M>R:~LW&\$I57?(*.HT(\&Z A(J8-X_.\$P_.LI]?4<31B18@'!>_-"M"RM.AA'1.&7F%>'PHY2\$(-
""&TD!#P.\$*~+2_ MFIDG6I*_HF_0Z#-(_&QI#KJGO%5.0-0WSYU%39\$(/_*?6?_J3Z%J/?
M2.0\$1"QI%GGBP64RYEZE_!QQ/7G/F(>2_~05)TP MG#SS7DY81H84AQ\NB!A\$ AJPG@W3/+HQ^L@9LJ
(*P33&08G81CQ%D:~9#YS M9QLX]"BYW),#P!"C:F"0ZYT1J/_^FB=_3_!T^TPF\$+4.T=^!_YP4-I2L
MJ42ME)LH&VIOA?*9.GWAT:87J<<\$!WR70UB1\$X+GR AF+L>#AB@_SIR?V8 M./?^9_&5L7X&#-ZIOY1:P-
FQ:YI=3QP71%)LZ^_P&QQ71&P1WIK(B3#^K",M,?=Z GC7\$S\$S9@(7IP+U/DH0#OYT@ #_J=?A>?
S@9P.M0*0Z0X2+VX2SR!#X^ MC6.1%I\$!=PHI!DYDD69S0S*92UT)6J5R_P,D_).3NA&CQ>Y6I<)>+7XC7E_)
M(AGD2.0CH"AW(BECQ9MZ8QMGV>(S/7)4(E.DK M^=
[HIR&L#R+ZT6@:9*5@5.Y'X1HB^VI\$Y/Z3AV0,WZ:)FOXU)'QG7'XQK
M<8Y1.%WHPD7\$B18"QOWJ#+A6TJH>_SNWIG=,D96Y<<3@Z!\$BRI RT2OQ?/I
M\$@&_<^<5(R^DC=/_P80/XL&NC.!~U@~0R%3,>#~+E!2'(P^A 4LX5@/H 6 M;
(YCR#C@R/X9:PMWD:7;VOJ&+L8&N@)HJP:~2K%Q,B'.4>0ZRQKT*~\$WX M-
^>\$H+C0:V&*T05K18GMB'9X!>JBU.N1>+JIG'J 8PFP0B)B/TJ(IV\$3RVK M)O;P\$ 4^? "
[2:05WE&7.G.W@1POL\$~NQ4O1<~#SP9HB6/U@)H":%COL2.RF) M AN SP:3(+J2 +\$
W"#_7#~#A.UW#XES\$K<[.DT*2@O@8!Y3FR99SOQUSN M.2AGI(?D2CPIVPHZ<"X%44F<@!/(1CM%XN@,*^NP-
^MAKY=Y%#BS_C#8H MTL|H:X-O+|S|_:CA*HY!|A'(#OSG#BC&X?U+PK+S5OD_&\$0+V/=!"4X=Y^<T4?)%@\$;~
(M]ST;NNQ|K#43RAAP MBE@~S"4TYW+TN<+1(RHE_E%>_!H,GN JY:7,5^Y1% I?5.^ZJS.HO/3(Q
M_7E.D"GX/EYXN&T"20+@M>~W,*O MQ\I\$S)SSW@~#Y05:T@)_~!^/R,ZH(^D),5*T^>+Q?B*%CN&JUQ>N)
M|@YD_+L_!XY+T?9:~V+5_T1&B^*J>'8P9#~!O8/N?0_ M&"P+>HH-
9F<~061[PI3U5Z+_L_6M_3QZXDJ&GPY6+FL+M84*O^#_ QZ27B%6 M&B:,PQ\$6.(9./XHLXI F.B5&1|YEW-
*Z8!21B9:/V1E\$X>#0YT!<3G*_ZO MUC@"4_"/ ZE\$8S_YG@NI\$P0NEPQ>VHBN*591QB\$E"(=)OA^B:BWD(5IR MO
?(SIN5CHU(@KB;#~CJDXUA5PI6:(9'SI^+=R?93X@OIR?>~X WEHMM*+4 M2>.3CEU>5=+O?
NNC>DU>MINVU=7I0QV?+7JVZ4<9#~JM>8 A+W%K),^D,1SGN^K^9^X\$>#_IJ M_IC?+L_O^D4U4&IWD-?
I^O/BNB(IRME2%DPFME_BW-4GD:G) M|6)F3_~2CKDEYH@E@/U(<#~12N;I7^1+HJ?..9>NN?4D^M;YP MT|S|W&
[OHSJLJHPK2.XX#~INZZ@1B4(B&S>I%_IV!_,V7P.T/0//FYL\$% M:FECC=F^EZO2,MNK:7FR=+&KG_~B@~W-4J3BL?
@RO37^~#1>5Q O:B/E4#'_M%CCOS7H-H|B|B+~1 7P+QZ_"2EL%XO2X_0OOFVK;M:W@|Y|<+W??
%MIM:3#F.JO_AH!"0K1SGU4F&H:VJ-1ZRA_&K IU3 M&U7(5+/@_Q^ (S0N<_&IPELF)YU?G6&4RK0(XE/3NKEP>OJ4-
JD "FY3F*\$S MO7K%9H/_/FG?9J..(PIRJ(SOL6XUSMF_Q8WWUVAB%W4*):&8QNOQ^IR?/I MP.<==O&!:40!4?6?T
~9!@:X5W\N.RM:XP@D"3)HCX0_H&V QM|H=QH MU4GXZA!\$3ZW="J:&I5D8BO\RO.WV>DX\$!LO&KA2A,/)6SF,
M&D><_VC_Q FZ#1M%S'7XHC+Q&+&_DF*=2RI9P.5COQ+ R%YO&Y8BI45O*B M,+=)VBIO>+!
/!~!46X5B)=94_&XND%_8Z)K".SV5:IHHDOS4YRHXX&W!% M#T/_:~!XP.C|<.F&(Q\X@A>>QAS#35-J(=(D%)5Q_~5
M?>N="43DB^JXB3"H&G-D"<+JRIOA_C@&\$FGI7U HS!@+~+3+RNZY8U):WGP*(M93367YD")<2_A
SR0J2)=6KM_9RF05C^~I52WZEIUNQ&+IC+~+3J6@+XZXIZUOI#%BYG! ME%I"?2AH%4I2"VLXD*=" "
L.P=N>7G)6B3[P80&?"IK"~I5DB\HIBO2WG&QOVE# M|6+"ATQ4UXI/%8EJAD25%=(Z11&I7)HJ
[6I956:Z92EEEI5OGY%-I'9/L!* MGH8O\X50Y:2N\$OWB'E?6XE^3"CI%)6O%@^8QKFU83H:&[G4X&XD+O] M?I?
3@)69'B4=)6Q_L)SC5V\$<~2I3Q"ZiO^=,YTI CKM7I3T_+EUV |<_7+9 MONW-FDG_H?W:~:2A&"7TKEAFG\$E^~*C?
EX#~V%UA.Y4HR""6XP4^DFD5 MTUKXH1LU(ZOJ\$EB6=Z/>DG=2I3<9'US?."IX6CW+~HBP^V6.P4RAF8EGV#~+0
MW9+SWME4CLP",@&*1.9U?Z#^>)C&=@=>O.NO"VP*!_"N\$~L9=LZ?%3>8[O8/ M=_QT.0D!ERR8DOTE\$!MXW--

UJFD: #1 /I"KM.)PI/-L:U1U31J=H^6\BS' M^CJX>GRMX\9QJE=\$03/WA#@-A(TG
M&H5YD8)D"MR1ISA%95\6"U"2;L:Y\$(/31""S4^H;9*,ML)1?J\+&#V0"MDBX3KNO(>CS5E:B@2-7?7?
8>0<,*#PBQ44399>+ISG2R8S5*4P"*M%Z.TTU<=%EQ;JDIP@ (C@.E+>1#1_?JU<=<5(H\$H->6BRZ/>MJO,%GE)!-
M;T3F5G2\N_Z)TB%72EA-I (IT@F2_K\YZ;!)CZ;J-TM\$+Y19'LNG7\$, %T M^=,.""JZ^S!& MWW/HP@6/PI"R">#?
HE8^H2; &EEGX17^<5\$!&A HP227H1@OJ!_*,&W-,G M\W# CPTH24^NSO75KCC@&PXI83AA@Y7I7K5CY2A<S9758-
VK+'QS.TTM.O M:NC5XW/#H8!\$8JZ OB8\$BY_::54Z\$!&T!%?J3>C(2E,*IL2M8WE;I6J2;+ M%L#?,"R(&"TJZ2MV\$-
/#G\ YI6#J5I-XO&\$?(SSN)5>0#E7NG7M#9.@8OHF M=@:V65*H6JUO,C-E;>T"IK (!O4-NN8VM<:1%-C<-ZXXPY;
<6JW;W+'SO!P M\$ _SF>I Z;+7>I BVC#Z6AM'9IKLD151;.67<I\$ASS) L7E09Q^?FS*5%;DP5X.N M&-O/Q'&ZWP2=
<-07Y*0!=V*Z\$E=,L8Z* K6TZ0VQF\KJK\X W2Y\$-G5HK3QG7 M^ VO? 6RV5FHPDTHNV=I/AI+F"J8)&%ZTV"-@6Q
PF+LHP\ R;H7B*TIJ MY8IX4@O!5_GGXZU^? (AB7(G!^S!;OCK*2JGBJ+FX93BZF0W;3H #<=<,\$
M7BXC M"3ICL, & WYNHD!(*C#Z%0Q^+I3FIS:2DSAF(384LV)>""./UP*=>Y^IOYVF7RE:8^\$O3B.<(726IU/">
M^P(DNV;GHL=IS.C!&"83B7+H+JU<I.<#1KF0,F9KS:P1!*,Z!M8&NJSI:4J M6FH5I=SP^ W3LQ:5*QO27Q?
J&6W/0*K4H\I48G)R300>D;-O ML*4BBY)D-1!^I\A ^?0?I "2L3S;42(2U,T
M*MO:37N3,2U>QG25I((3^ZBEVE27MW>I J\$=E2I.-+0@PE109S UMLW<(7" <* M3=-;
(90>)HI/6MY@QV#9THVN/NC?C&E1SFHK^ ^Q4>YI;N)Y%O?YT=%1G^XX M2G(&F&\$),IG/K.07+;?Y-9_=CP?:?
4)CP7NPT?RI 2/+BR%CTJK,PEBI:=0 MC*+EKKFW1.C3AIOE:IP/HX2SOIGED4 'WOIV.4QX'EBP9CX#T?C)Q8R/ND%
M_31^>?7@>HI7=^&A\$%.O^C;LZK 7T+6+=G_ CTE5RX;#CZ0&^<1!*".IHP MKI\@:47_2/CU?Q.3D_CKW*IC;Z<2-G?
HJ&4)Z_ 1&^&IDM F3Z'8.7>RP M_ ^4+ZXFK5A,PL6N3I/IG^I\ (E!&<&>6P\$(9?CN091C;IS!2;U.27WD^
MQ1&\$&=VA9BVJ N;+>7K/0?>T<^W'TFOUVQJ\$ M7M.W3I\W.9: URVNTI^KDCX Z*)IW>M^Z5RV/MH
QQW\$=74=,I\I29I\TK MP_-QA=W&\$, #MYM>JSN MHY.OW5I\O72I@S7(TI;P8U^ _PU'8&PYNC#?2XB,0I""Z4?R70
N"3I QB@F,QR*K),M4WM5M% M=\$\$H%BO^YHZEIG6;(#;&CL7+'AQ;?MWIO7W^9=8+N;L,U7G\3CB>>BY8
M'L#E'J; &WH^A_ (I 4>6E@_ ,%.Y*XUQ?S)M_9@,\$# +ZIVY_N37JU#7Y9>-9 MQNRI5\$<4>=IV+IE/JPF:??
F3=A5X'_O*HO>P\ P?VP^ ^#5YE;ZP\ C<&H/ MU62#FO;V@ZB-F%JM100C@2T@;";,ETIES(%4MG8L65G>&Z-
M3Y6U;*YI9TG M1KZ\K&=9\$9B>MH29I+;QU#HRMJVI5**WZ>FZ^=ERY+I J5%6W%V" _D7QO.5=U8;I*!&O*E/=V%
I@V5;0GZND M_ OZU2Q>ZAY;5JH7=(F%S7-[#&[KI@P)^*P"S \$NWWRZ/N#\$'V30?W=J)(L M+Z*J^_ ;(K\$S65C
3I%ZJ&U3J2,-;,%BP_2SLF>I_ (H_ %SDLUG?=#MF6% MZF:19IO@FRY^G+E(YMQ?*Y3U=:H990D;(W\X
1,YK.ZI+1%0AA2&X" _V%=M^KELRDOR>A\$5\$^SPRR\$QPK^GBF%1.T6I\P8;D M99\$A_2F>3V;DAZ2#CU94_NY+
XR8D1M;IHI3C*^I (^U_WK20>VT!T=D M4UE2Y94I)#?ZSI\I9I\# +I\O&3=E^9\$IQNN-(3C^M.MU)^>(>6&JOI2R)(&7
M86"E>CV'I?QR/*B3L9I\2/%CPX(UE&IG M;OZ;CC&2;G?64V%/-XO<&IK83N9V%7I)@_Z+5-
3%Y=E2XN^BL"@ "KI2HIB M4IG* _I%I3RC,\$I\T4@4)^ ^6\$8=@\$S)O:C.5S02EJ<2;=I B,#IO1.R>I S#!CC@^IK?T^6
M5C#48G/IW@+*M 9E92LQ+I>?4"PO\$E^93I<9Q^>JCI.%MU=KU*B9X/YG3^& M4* _I8N@->8ID5O#;IU+?
YGEZCBAHAN;BM;QGLE;I\H2E;#P8C+M6M-IYGY%JYISU^T%:F" M+CRR5G2%;E+>RXKZW2IGPIN&IZ;Z-
8R;XBV/3Y(C;S@&E;K2+K-4IW^-"D+ M%I\JE\$R^ \N^MU^3+,%#^Q/N99^UN).L\VF"A;IK9=_%C7&A.R-6Z(R'7
MTD_Y&@J;RJ5FE+I'K5I*0'IR;GIF9172IPHE\$IV*QR)^*RD@>AJZDRJ10%7EAG<4)5%1>3BM)5"VRVV"C
MRZL4.PW5MTDM>70(6)H;NX@#AN8TN\@HK\$W&^JOR;2V52>V;YFN&OIL_UF MI_36MY73+K2N^M^CJAS?
2_VI;/GP"-D8?OG.-! "H>\$IOTONPYW#Z;-87R MT8 _/2IA_52*<.XM7\$;G_.CB4-7@O3DEPZ":M?V Z"V0-5>1BRAD-?(3Y+
M'E0%"FOC)S3 5.(GY;I?>7/-;W3ZUX3"4VNA*UBU;*I35 +<71R2?FL92I M>V3%.CY7-
&I;88F!O)N=V#W>BE2N!^*Q#Z M\IV-YIX;EVW\IC6&+ +6/FBI6(V3U*5,>R3<=:7V<0'I8=I&8D335:0+/#U
MBQIL47/IEHJ9:2.BD&8+;E42E&&54X0ECUGRUY6N\9HKM>-8F(ETBKR+; M^"0/@#;R<,_^A#J-U9-MK78SMJ?
6^HIC5D M8=L>E;<6!>IW/*14*&8N&IV I=>66P;I^VB=Z971W\H#%&IJC;QN+5:O%
MI^DU7>I R1GCW8>6#_*Q&:6ZVW(SIR\LM)VN<;#C=946;L:T9B%?HOR@9+ M^J*G-
#:\$I\VB.X.5"B<4>-9J/%L;MK%9ZS4F)(5'3"DI^1Z MJ9G^WIH>K M.HPH4B8U*9,W+48BV8(1:48N""(PI=I G9H?J/51:
Z'O K9DKU%AL8O"W39 MH+I9I(EG36F0QY;O3 2%9WIK)M64I>KI+1 AAQG>F0B8;FI02P?Z5ZU#MYB;
M4=KQ^1<6AA_XF5,<@_7G3LYX'+CWDI%S/V1DI\I8\FDBGPT>BQ+;#MSWRZ%I MP;V; >W^M!#KO")R
S7M^%PW(23;N2=D\$Y)51+!!66G& MH"12XNT&5=62IBJ77LZ12,=IW=W==CY\NVM\^M(F=UW2^D>O^__^VU)DI\V/
MI#ZW;MN?NU\NV I=O CMG@8,RJFT3?6M-
MZB9XN+W+;AU12GEC'3@'BUO<#='=&N&YIU.^77I^!QUD&XWN0:5N!1"\$%W&+7*R;5\$C M1?_N-
T3VU%6;4TU=I\+9I G<53V2TF>9JYI\K8';B9SU#LEY(Z P6%N;>J MT*4HKZV4EJ7@;
HJZB<1;V4BJ^HBKJ;TG;O=N+;9;I8.F2R;:O"C@*OP59"EX_I4QGWOV5F=W%#GHP* MRYZ&+HJ1=I9R3
I<I;LO+;H7U*-S MZ4S;N%N<;J.IJBNRPD5E7\$JE+AI*X" L^H+CU4M+Z_NY)>NL)F.T.587\$
M\VM%&+U1(I7@U6G42"EX_M3)STO;_&IM@HYG)S Q>I\MT MAR*WLY;I 3*[*W852*TI5R>UC8I^V;#LI+^;Z6: U-
//IRT MP\I V\$WBN\XA^%PO\WWLJHS?V*U;H;CC=P;IQI"+A+L!=T;IG#IF02>9E61%/X96 6^XO"W0%8^_R<@)<3?T?
B)A0P9@7>I>W IQ^NI\I#0 M;RPFUIXE@!_"OI_G9Z2*Y<_!Q_ (#1#1(P#YUX1Y?09I48R/Y'=G.,&?R>EI
M_%7.R=&7\$W?MV\MP1=L^?IC?#76Q<6?3+I C8#7C+@A=QN#B:M**Q;+AJ?) M_4IW IT.P:B">I= <:
PGP356@ (L(2R(GP4-S 5FI>I>)>W>M>I\TOGLG77\CCNX^&OI>NI'NE>D80/K>O?VCW2N5YH\A\W
M"#AJ_ ^WWSMV_R@%W/=FBGCA\AS&1:U:*?/I?IF#I A&^1?CE.Y4EN3AU=5^_K.Q49:0HN-I0V! VICO_GYL"?7
MB5LJ>Z=I Z8 A1.D-I"Z=JFS;SH^YOU8U""F""^H+Y&JLM.#+Z\$ (XPYHC MI 2.N0.;\$TZ
8)*QW_I\$7 CQQWYTG\YC7CIGY_ICP9.I>I=;7A9=K MWSMM^LE?Z<IDBG=D*9&25I\I 4(I _T*3?=%FD% JS-
XXI.'6IDO^L\$A9 M+)(+^A33A)F)@HY;L6^"XU_ZL_\$B5ZDA\&PEBGO^!_*?IP**PO#2>O8G MR_-%&KQ<,"
W7/OHMP3\$'-HY22-))>/EDCVX?7>I\U.(OP%G"RI3Q M?H.9I;-OU2;M;I^W4;
PKX+8XUOOLOX\5/F;BC88QF\$ITFBMA\$N<;90?K MOZPWY;);_R@_ ;G8G6*""1)4H421I0I"XY^D2JU98C?
(47TP_@R^BI7I M+;E2Z8QD*EWG^BI3.MWNZ7+;DN44DVJ*903^TL%/E\$VZI^*Y.FF5+I?^SA M3?
D3+;N^L/W7Q\Y Y\W\$M;MO*4#C:F4HNJO(>I">\$;A_P M85DXW\6V+*J;VS/^&SK/Z&S7C_XVT-D S\IC
0H2T*T^D)K>2H?MH'H6T^L\$F6 M5*IKC>)>)*S2=D:TUW9&K)FG4K(WJB@BB<9ZBZ;&1D-
G3XOH\$0=:SFG\$IG6M(V#R>3W;9EPN"9"K8"14XB 7"8 MHAZV0\QJ@\$;U=*I8E?=>)38U(CGITHA KL>
<2D/>N;I3MHOAH M1?2";-?C)I:ISSG@%W K,S;SHM#_EZ<=EJFI(FAI (5T+*P+Q)H3=J"W E5HV&*A\RIJ M\$1GHO?
\$4'AF40HOISG.5I^A_9,%?3=DO\@M\UOXAP2%'KF#VL?L1 M/M;ZX02#WP(3\&R)D*B;53\$-4&I;7
YALB%T2%;NPNOUN?T\ (W7*?4M)Q M3"J;KT^@I;G1I3NV(SI<%VM\;XZPLY2H4=2H=G45'
<.E9JE+"F<44Z#^+*#QB\ MB_0G0<^I_@L9;XX7#OEE\$G%FIU"O_Y^AN4?C>T/= (R4I8WK3-CFI"6 HG;
M(2^U2EU_@M;@_ W^UA\HO364-6*6EF?6^4U*%N#LO5G=V;91MHIQOEZ;R5 M^T+;VHI7IY9>E.QJW
1>PIWZ"A\$Z\I>P=W<;9AGKURS)YSE\W;D#T MU0GZ3T25>0.BY?4^LM63YJAA+;A5)7VT5I
(D7"0*>38I0D&2";7@V3R;DI4TFI\J96BZ%LNN71>YN&E5E
MKIUI%G)TMMGM\IOX@A2%EKL6Y^VQG+;I9^/0=.NIS)V5733CL^U\ \$WBTF-
M%/GP\TZIO^G@5L/I\VIHH=E440Y?;6XF78X9VU5Z^_QXORY^TNKM;-B+Z@B MX_F.0A5+HJUO=U(B?
UYJLRYQIRJ\$TRJ>D=D4*+PM,D\$)E&R\DI.+R+);. M1@^-[#F"R'(#F94;7>C0\$+R "\$H+@ZE3.#:W
9,E**EB*2;92!4IZV*QO MC4)VS79"GN&-LE6:^D@I\$4_-LILDJUBD@EU4IV>9\$;3;+6*>OI^DZV43(4 MLN4-9#O*79*
G+CK58+&%DQ==V2@E#V;FN44 M032AG-
IZFBG^YQ;U5)OJ<@D9;6I^1;55/>TJQBD(BIS\X5\$FEIKA3X;J6VJ8+UULU->2U MI6FJUS:55/I(A MGIW@T?

7XSHE4BC_G/#UNIN6FV.H^!C*K53/ZK'D)MK9E&.O)&KBNE3#K= ML(\$N7"^\D),N2@L#Q-"L=
/\$.BQN:CIEU\$SD2^D9.>A2S-^X)7K(%P-15K(M#?\$J M)"^+EQ3X-20B1?A-
BWDY8JB:8K^*B/F^>12T2\$7/JZO^>V%.U_8XD(5-M7@FVW47"OOTVU72+FE:=&ZH:PIW(,*U'BK9<,*
+E+3%K&ZIH5F_3B"/5KNG\$FIRNC1# M6R*GZHPZ4*RCO=Y"VM5R5ICE2)?+?)4BJ*!/=A-EU\$X24\$#9E-5">T/8Q9
MPPC\$UA+LC?Y+68QI(+VPB8I8I4M3:5N5TL-EY3)4*5#JSG\$HCH%\$FBJD)1 MRJZY(5-6*5<@I+>%ZS?
W6V"">+2%UCX8/M50F'J"VR4"?ZF[UZM+64K" M&FXIF%N\$JH)P2TX_AS813&HVBB7ZMDE,PU!U>RB@.M*)>
/X% M?E%Q?G047TD341=7+S/\$""SY4>5K';WQ(C3I_O/(=I_8P1SQ_#*R&H(Y' M7'CH,7"^(I3/F/@/1^,G% C)D(Z SI@-
R/GK.5I?A8<@8AGSL6P*NB7<#5= MIK1.3IF5RX:##^3&>60?X9U_39C79I" T8GXD"/D7?B:GI_%7N4Q?7TI<1FT7
MP0C*TI\$ PE'<^E_?^>E.ONO MI^>M?_2ZY_.H>7N_ GMMOOMAK2N+TGOVZ=>YI+3NNVT>I^ ^O5^O2OH H(ON
M=:_H7/9NFL#""?PU?V15V/=*(1:OWF5QIZ?Y1*4SKZ,7U-SPU'.F@=L_ M_&'8/?3HSB@SOI_ ^) ^<?
C)WR+!_MOJBNA^850JV:4*M:O0+%;S/_U+K.MV0"W,W#9N6+^B^<& MG%S==K^2IDW[MG77N?Z-M"
/N.KIWI L#=#+ OX63%UE>\$/I^L5SVKMW(G)39&/MPM/I^60Y;7^>\$R"OJHV7I59W-0^ _J_ UYM@I./>/6,13:<+7?
#=U9G[9>+R M>RK54;M/W+#+>A.8ZV\$HE%L/V+V>ZILUG/;4.M:E@UJINCWO1%%2X>8
MHJ\$13_ FPO'>QE0R=*HI&YOIUESQ.=(52D<19B/0F5)IE**Z4MT%YFN>%Z
M13C(/%PS)V" GK99%G99W>.ZCU;*\$>2'G0%&PJ=66#X2K#2_#^+M I
E9Z'!+10>FN/VU>%D(-99="G#H8NQMTKD+\$ V"4#(S)_?AA.N17DQ_ ^H5A+ M\$S;U94?
7.9I:L5:2D5XI/=B4A4GAH@IZ:3.0:73PYWB,+(4A*QDAAR"#<2I_ MI7@3I%-9WZ5^?
H8S7>_4II&8I'H+J:@T.IOT>10/P=@_&4GL M*:/#P4?_2 KBK;IYN10HMHBS6GA5\$I9LJEJ"CN&HDK-LP:3ZQ&(?
96I"9QH M3EAM?UX/!_!_P>=\$V^I<%>_\$.H(HV;)=(2B_FCC9-AI,(HBBB;" I@:%H1 M(KI_ YN*; UEFP85-
+RGK_>@EHJ#JTR=BI7J+53RDIT%JHCBH.KI" WRYT% MJ13SQ^MYT_ Q;HY1*TUW=P2IOCI8A(">EDP98&7=R
_D4B1J:N#?9U:FK M O");&M@3.EI\$%8ZL_71M%NO*I.I?MEI^/YR?;+>O-Y^86Z:2F3I4W5 M'O/%%H7C+
I8SV2(+O)=7Y%0Y.IMHO#G+LG84K_-YVD3I180SL)^+O'L'J+O(M/#B#>WB[48\ _CB"!&662#EI:IGVP^X8
M4BZ+E'<4QR3I^DI_-SG=J60G5K^PG?P:8@VBNKY+"M5;A*=_H6_J69I
MOY:V^WOGLGU/OV+G'SKP0^=ZWS\$TK&_8#;=+.#U E5U<#%3W_@U
M"K/>H6O&V\$/'8UM%5ZE_.F1T8>I>PI2;.&%@+KFA6*6?>E45D:8U@*^I[W6N M?V_W.G4?:DIUQ_)&V"03?L#AN_-
>>CKT'8_XL\$W7JZ:SOHH+?>F7I9G9&_B M.HXI0I7_ ^&(I
L0)9S7X:3SMGB2L0ZJTY9W23*N;T)^>C#>4(2E23^?I)U2 M8IE,1W6 V*
G#R>Y8.IKA&J:1@8>1I^Q0=S*3AD_/7=AYUG.>3D'HGD:6) M25O**2Q"Y8Y9NPX(KMK"YPNB\N4>#M/I-
J#A8XNM4US*3S+S'EZ_!"CZB*) MJ722(?/T/HJ>3C+>4BY96FE*F9?+ #RSD8%?9*<54RSWJ;T23S
MI.HK&IMV=SI58!^K4%_W7-05AB"#DH-MZM&E2N)^=^,3.:7K)/4DF6BR MZK+MI;*^)% (1C?(R!1U--
D\$8J5NHL86ZIG/SI33-\$.R1@DF^56GA27OU#94 M:AF5)IX)\$ \$CMFH-RU;EN75IT_2CU!68_MI&W\Z4_@_B D)8.*BJ3-
#/D49 M!RR7WIRD-\$IFOL/NPVVTI108T4EN^1%G2KA MY;-)=1E4^\$IMI\$1L&OM.@M"U.RR:8I!*= V"MSO0%TR
N^"CTFG?+84: 3_MX8\$%>_7I_#R\$SIA.'\$!JL^W 3;?IFNN=T"UC:UJJO" _I6TO0;IGV+7 MQOU12JK)DWI6(!-
=@(S.)2K)E=PY-2+8_8D'/#(P-B'S'/I@'C^N/QV9FEY M=-FW_N'?=.5_OR%7*
(5)7Z?F2NIEJ)\$X59?>42.5^LY:IS;NHLG:(G? MK?Z#SIO9GT2>9-
+M!IEIOIDR#>'LBJAOSAD(CSF"6O)"VIP.9U8N>#K>Z& MI>!ZX(=2D)8Q:8B92Y8_3R:M\$Y@:3GX M;^=N-#6N,R?O-
U?3HN5OK=#EN^=OJ1*6HNK4,\$TJRVJ3PY6N1="JR^J&_?<7 M/*1C=3M;H-!HO!HU"=K"%-
O#\$#G;36^3UR>6I2Q85)C@E*H:2T9S&+36R^I MX6Q?7;4OIDCWBK3_>?&Y=?
U;FIRVIMHD_KEISR@3^W YKXGX'KO?&X2T+OX;_I_!_J+E#18_2#S9?2K#"1(I_ M_N1'SK#WX#A1O"-I?
YF"GV+5I!4,14J&SL?)3?J=EJFN;LIAZ?:ZJHKUA MMIK9=K%X;3V+;S;@B8.J<7M^U6KTU.+MO13^_@LW0&7^#S
M^>)RIY?FT1L6N/Y@>0:2S+E):8@D)V7ZL?GIDDE&0A>WO:R^>V3&QJH/I
M..5=H_:J4\$/>GNW9W*Z)2>CUI#5Q2KEI&J20MGLV;S @Y:>XK>O+Z#BW_? M.K^WOK2O[WK1-O_??
UN#+^_ G'/EWXXD;#^2%.4CS*V4H7V)4#)DL/CI MM U*+X5\$-(>)?)?&G:@C_)8T@E7I;HT=;MIXQ)#%IE+!%Q:IE-
9L2"HJYV6 MD^B7HUE,*O,&C3'=+!^CS228I?&X9%-TXU2[WF%9V?FWQME:X@^E<;8\$
MT""B.UN*NA=GJ_ZOZQ<6AA^B7%(I'C_@MX I:J#3^I.<->/\$,9 M.(1/L\$J)"AA^E-IGVE86\$M%:F?3ATPY6'0=QE"
P%IM*BPEOMTYE4I,F M'6I<_J8FIA_-B2SL^V4K&M6.M+V36UI)<=GH77HJ;I=-'MZ;_/J8JS2:ENU_>?&1DI/W=#
MT)*ZJS#IK<-AOW_ ^LO_&H_*RZA8?;_AJEZ5FN1.5)^L)4IB_SZ1ZY:W! MEJJO^ (3IC"NPF%6K)168.I20Y7=@'5_?
@\$=508\$>1(V6N6+N1-Q99KLDQU M8_NUDVARD\$MCI(HI?AR^,DHYHY\$>2_>9A>2: 2"W_K/CT>@#2GHL1A*7Q4
M6G17^PRW.El_>VNU-7NGAAQJ"61XIW@F=40.4F<0+XV;Z#%PAKP-(!\$? MCL9/+11"Q&5IQ#8-P3!1X*Q_<+
TQV5A7X2B;B+O=?HZ?DRE7#P0=RXSRR MC_#OR;ZS-86K\$^DM^=X01_)>G15>Y\$1?
303AVIY@1E">COT10AJU?/S) MI#L&:OE=IK^IX<75I!6+<9-R=9K<_W3G'I G=RPCVWJ<>I?_D5R#H\$78N?81
M#4;R2^ ^GW^((OOS.4+.650%S_CRJ9R#=#X1QWH27&,%N(BP)'(2)%@I[NK% MD_#B/N;\$+(KKUHL_C_VA:N?
AWQ*VO_KU07->*K/_>G_>^D>O2SZW6U_NAI?
M:KO?G@&5^_IUIGLM.ZQ086I^IZ/KIEV1^ZZY.YSFUQTKWO=+YW+UEWI MX4W):>\$@=H?H;H.)NRUB?@T
M"5V/A>\$E/!2X(U3S+6_PR0G=\$!LK@+RQORHY I>^&GH^ ^<6PO9M'0IAW2_ M I<+T9QI(O/1B_5D)VI++
1TNP.M&NT<- /YI*W7N6I/W>N2RW:NXI=S<=;K7 M4QH OHHIV@>Q_ ^_-EGY:OIE?WO/L.HI?QS/_ID,*
<&HHEF@A@D+! MW.H6V K%PR(_V<2CMV'EU?K2F>^IGK'YZT_OYH9LYP_3X"HE3@+ABJ' M?
WK^#!!12I/I.OZJXY*O#G@^+H'HZ(2P%2XPO&K^I/MK6V'IS@X1@Y 28_D\$PX!^ _TIUJCPT21:<0; C&&5F"Z>@ \$DSP5
MZ6/B_ P3^2/OHQ7B/RXB_)?O@,HOR\$))>A.W"=P\$6,1>NOI%_P'7Z!7M.L MI'&H:ACVG3=WSOMBV148#78NNI-
M@<7(#4/L^~?TY5NE)OHY&H?I(OGS%IFS)P7IV^X\$/L9F'=.J8P%^#LT- MT=#QM-BS8IAN66CR?
T05!7@_ ^Q?"IRDH#YYO9BNMX9Z;EH1IIZ+T@ (FT;D MBBGHI"SOQQ*B
<+LAN&\$ \$0_8,1I, GX".CT^2&Z%ZL;#SD"W3I8_1>JKQM M\$:#28-(?C%%- M07XQ OR!'5Z5!36'7PDGM/_ #
RY7IXIQI\$X"GRDYXQ:" J2<^I/P/D MAPOR LN&PV^<_#G(USRR4%G'30/P8.)?R1<=P9IX^P 7\$8):LOD%I_Q+L@
M^AX^_W"6@_C2A/CXK<4T#3/IX.3;T#FXHC4@V9\$GBZT?(F" T^?03> M<@^*U_ ^C%CGRHQ5!5;_1?R3
XES1Z)>C>_U_&(78;8X?WH.AXY 3ASR+ MI#%XPN.H?
HDI0:DAX8@AO=W_8X,\$0%L3.\$I:ZAXMH.ODI@Y5'OS.I^>)OHYJ= M#"_2AN* OI-
FQ5_/5^9(PB*X2#/SUTTW,>WM/GIX)L6B"CA2N0:0Y8(GR F M2/*' XI8\$1(MU@O)_#2_6-'4^S!
\$,"OB!&XVI(Y<@CWWIATFVA0>"<2QE,^8\$NH3;,"+0,OO@ MP1^R.FX[?DUD&#@0L>V.09@+
I16:>EUY*G=SYM0\$111#<(<10.N?7GI04_042(\$OI"A;\$3-M M6R*JJRLO.>3:7%RD8B3E(YXII:EQ
DR:CYO_B_ VUM=G7VIO)TI PH2RS'7IQ_"M"LI) M=E^Q25^M>^*#/L9&%WUW6LH\$FU.\$2MIR..#_G%
+1?8IY%_YAI:X7PN'+=;CW09-M@QQ\$O&E6.AR900)7W(-D &>7A@1KST68PFL=Y(J"ME6:HIXPVPMI#'
M!0+^*0&E</X9MKF99BQ1KZ2Z6Z_1^V5IZ,UI/P(Z0N?X0ROB20CT. M&L2_4:I*^@V
MM3S!+MT3X;W9#AFU&KP@:2\$.7KW_OPO@RR&I^O: 2B(5.OE:Z*UW0IQ_"C
M^4I_ ^&O_VIMWGE.*WY;SI6V2^5:Q+I2@EXE:N-DI0G;2U+.P>G(DU*K\$G_ M&+3V2IUT:#0\$HL_-JASF
MMTHJZIE!S9WZ4S?JZ"WM-I*Y_9%6VECKBTH*A\I32LPNPN!?_@6.L+8K- MMSMY@F3OM-B3D.RV7IW_1(+?
6K1P)VGH\$F'V2,##E*HLX^IBBHTRKEN_ MC*M'@L46WS+?&%P>5F)UGUQBI<"Q5EDA*;%RC;ZITV)?\$JO_ZOW??
>_>_&I_ MCQ/W+K>ZST=N@0006T<=24*Q51=G;1I:PQ_#NAD^N64;_JR ZSVY@!MI M
JHE!99;V_RK=#1>OG6>S;RK=YC+IW ML=9_/F*M=W1BK2I&V"C6^ICA11^<4_:F<>U#1OG+;I+EKKB@^7:K1A/DVJI

ME/1: ^ = 1A0 = @R < 72 (! % W : < 4 ? X / B : A4XN P 2 1 2 IOR # 8 < 7 ? W40QB : OUP ? 3 M R : G5.UH : + M / 3A I & * @ /
I & POF 7 + _ _ QAI = KPJ : 5.OW4D4FVX-ZG6 ! T ? D = RL MK ? % T \$ 8HHRN ' 3OG (QV4O \$ 9 * O / 1 : Q / M (R = ' ^ Y.3Z-
EV / 7 BZ3AZ / M) Q < ' 32 L 2 ZFV " @ = AR02436 > _ _ E & 2 JF
M = " R " 3 * _ 8 : / 9 J L 8 > & 6 : 5 ! < 7 9 M L ! , 7 ^ [N O S R & ^ * : G % } H K 1 = ! 8 X U X A P : 0 P ' 9 , M C - 5 % W . 4 : K > T & 5 L Q F % 8 A
& S J U H Y . U ^ = F 6 . K A 0 ! * + \$! A ? L # L 5 ! F B N E & K ^ (M * \$ D J 7 W J ?
\$ 8 < @ 5 G / I # 3 ! > @ / Z K I Z / 3 = 9 1 Y < ^ : X + B Y Q (D \$ J T / ! " , ' 4 @ 1 + H D 3 O F M I 7 T : F ? 9 > Y) I X M " / T 6) . H 7 W V > ' V > # Q < J " 7 # ? 6 V > : <
_ J A 7 / V Y M , B > ! A O \$ M I 3 , 7 9 < 0 6 1 \$ F , C / P * > W M / J (C 7 L O I ? % A ^ " X 5 ! Z 5 V I / 9 W % 6 R I & Z - Z K ! W 3 = ? 1 C 1 6 B C & \$ -
% . J T 7 (= _ / 3 # H 7 M H 6 9 K E ! O U M . 3 \$ 6 1 " G Z V B \$) ? C 6 T % P Z A 6 . C 8 Y : C \$ - D " / C B X U 0 0 A ' ^ 1 R N 1 9 @ H M (= -
& + 6 1 : J < H % 5 Z : F 1 + L A) J W & 9 O B W B 1 W ^ X L % Y I N 6 O > 6 X X 6 ! W 4 < _ M ^ (L Q * N 9 . ! . 0 (<) % P % J
W N X D 1 3 V 1 7 ! 5 \$ A : O @ / T A \$ (0 _ X T H Q @ F P _ " (. 1 6 K ? ! M # # ? T S A O L # 7 8 X X \$ (G E ^ A & I W \$; # V F
> 8 / X L 4 (@ ! ^ > D @ 2 ! ^) ^ X 5 J 1 # ! Z Y ! / Z < M P / = T I M : 8 2 9 T Y O ! U 6 \$ R Q 9 3 6 M O O 1 . N (^ " X . = 6 E + H 2 # . \$ P M > ! L P L 5 D X H P 1 B L 2 <
(M : ! # O / 0 . I A O 8 : F B Y 9 O W D ^ ^ _ B (8 R X 9 ^ (\$ (3 W Q = * 1 > M : N ! K @ 1 \$ C ^ A * V D 8 " X Z + \$ @ . 9 : H Y : / P D H T : K 2 I F ! & 5 D 6 ! T U
(P \$) ! J \$ < M M .) P @ = G ^ # . X J ! M D W # 5 A C H (C H : 9 X 9 0 0 ! C ") N # N #) T 6 : : A 6 \$ H) % . ! , P M D H
Z N = * ! = T 0 , % N * A L L + W + H (0 : ! U * F & ! X T 6 4 & 0 (- Z H P : Y " % < \$ T C - 1 < O E P
M C 2 ! 7 D ; ! I : 0 ! K / A 7 8 + 6 Q " S M P) F @ Z R V 6 K S P 8 V \$ Q " N B 3 7 S % U (Z _ B K 9 < ^ U ! D & L
M : 5 L F D L ^ P 9 Q L O @ S R ! @ \$ @ 8 C 0 N G = # ' U P X # ? + S R 2 V I M U \$ _ E 9 @ < > ! A E V V ' H Y R O B * M * P ! ! X B H Q > = P > D O ! ?
W U W # N (# " ! ! H @ G A 9 Z 6 ! C / ! H C H D H & ' _ " : ! _ ? O : U M G ^ : 5) / F K T N ! ! = 6 C * U 2 M 9 / R I G) @ I Z 2 . X K ' B H
M 1 X 6 ! Y L " ! ! # 8 9 L @ 3 Z 9 L 4 ! 5 ! " 6 * ! T + S R 0 ! H C > A M ^ + N 1 8) ^ > 9 1 ^ P H E \$. @ H H 5 H M @ \$ L) O R : Z (O 7 & / C " J : A D) D 9 * F N " H P @ -
+ D ! & ! M C V + D Z W 9 A P 9 M 4 ^ \$ T V D S 3 H D = W !) (F 9 8 \$ =) ? U @ 7 0 8 (@ O I E P D 7 1 @ C " W = ; 2 A + ? % / U ! @ B : W O M % 7 1 -
= B 2 = & 9 J 1 = R # N T * ^ " O Y ^ : 9 V # ; \$ W # N B < (U @ ! 6 ^ 6 V Q = \$ K D B \$ # @ 8 (J 1 @ N = ! M X , F H 4 ! > 5 ! _ ! 5 @ 0 : X ! + * M J C & -
% \$ G 4 1 D : V (5 8 Q ! X \$ 7 E + M 5 7 3 O U > ; / (7 ! 1 M 5 R (X) D Z N N ! 1 U 4 1 4 L (* F * 8 5 ! (C Y 2 ! = _ S ? Z I ^ Q 9 4 - W 8 * T : 9 3
M F : J U D V 7 6 D G 5 & O O K F L W =) 7 M 5 !) R N O Y ! S F M 2 \$ T 2 F # 7 3 / " G S I T 3 (= Y (\$ > 1
M H G " F . N (D : 8 ! V D W R X Y 7 T ! " % W ' U @ S ! / \$ (T U @ . B W 3 V V 9 P _ 9 P X T ? ' W > 5 4 9 W X ! 1 M ! V ! ! : Z Y = -
P 9 I 8 / I (M ! > L D U H : + U 0 T ' C M Z - E ' 6 @ ! = 3 X = K & W 3) ^ A ! 9 O G U ' C M ! K L # T # ! A U : @ A > E A ? Y 5 8 5 P * V ? S " O S = O (G L ! / U ?
1 R ! W ! _ # M 8) L B G P 2 ^ & R = > M 0 I & S * ! S A 4 I (& 5 2 X = @ H 4 ! ! * F L Z # % @ \$ R X 0 N E ! ^ > _ ' Y Y S ! 7 * (! 3 H 2 . ? . A 3 ! J H 0 . @ W R 2 0) ! 3 P = -
/ 8 8 X < _ E 2 5 Z O ! B + C : 9 I Z . . . ; M 9 E J N + ! - (D X I 9) X 7 Z + & ! L # . A . Y N I 6 * Y \$ O 2 (D C 8 P 3 W S 2 - S ^ @ 2 P . W A : S # S O ? N 0 M ! Q I
(L B : Y Q L H O ! J 9 M O _ C T I 4 0 4 7 F R) . @ . Y " D U = ! B E P 0 4 2 V 6 ! ! H H A ! T 8) \$ O 4 B L M 4 ! U @ ! E 2 ! Y A ! ! S C I D > L = ! 2 L A Q " 6 # J M 8 ! : + J -
! 0 6 5 : K G ? ' Z 7 % E ! _ 8 S T & O _ M L Q E W " # , " K 6) + V 5 R Y M 9 M D Y @ \$. % 0 ! 1 H : H E R ! > G _ O ' 2 P M S + ? \$! 2 R P H) + : Q K / 8
M F / C : K _ C \$ _ 7 F F 5 3 : Y 5 U ^ V 5 _ G , * ^ : 2 = P K I K Y ^ C J 9 V C < : 8 A 5 Q C @ : : = U : < + _ . 0 # M . 1 9 D _ ^ D & O : D 9 ! % K H 3 Y ! - I \$ Q) S ? \$! -
+ ^ I 4 7 M @ # " > O Y 5 D H ! \$ * L 4 B 0 O (5 X R # 4 3 & M A K ! M P N > M . ! + T : Q M E D S R 5 ^ # R . I R . - 4 G ^
M \$ M S L = Z D ^ 1 8 S ! X I > Y 8 I + & ! ! % 4) P I _ @ : U & ! K D ? ^ (@ M M Z I K # # Q I ! # ! R B _ 2 C ^ 2 . W C " (7 O 5 < 3 V * X O 8 B O - G 2 Q F 0 1 3 4 H Q !
! 4 . 1 E C ! 6 1 ? E G C ! I Y = 2 V D U B ! 2 0 W) _ S _ S E @ M L A (L 5 9 D 6 . U F K : X + & ^ K : M P 3 % ^ " ! B 0 % @ + B 6 8 T R \$, 3 ! T / 3 (B _ = 6 U S ? / H
W ! 9 Y H R) H P * 9 P (O B I ? * + R : N M 6 G W T Y = G J P (9 F T # E / ! A S ! < + 5 1 3 V ! : # R O + M . & S ! > > N
M Y B N 6 ! H U 4 . W 5 5 8 6 . 8 U 3 Y : O (C > ^ D G - 1 ! A & 7 Q 0 Z V D) R J 8 < ^ 6 P Z 0 2 > _ # % L = & G > M ! - 1 D I 7 F
4 Y + ? " E G 7 L N Y L + 7 " 8 < 0 @ R W * > @ / F P " Y W A @ ! 4 : Y A A % H ! ' Z C F Z I 0 K M P @ Y :) C ! J ! ! 8 J G ! & _ Y @ D D @ ? : O ! F L ?
@ E 9 " H S O 8 H ! \$: _ ! V R 0 > T O X _ N + < ! M V 5 (1 O C & T ! : & S N) ! A 3 & E = E . J 8 K D 3 : F 8 1 ! G D K W 2 0 < %) C 8 E H ,
(U * V M F O L ^ 7 : 2 (J Y H H M > G S 5 4 Q 0 @ U P R + B) E # 9 < 9 = / 9 < _ M @ 5 0 U ' 6 : " # Y V E < 7) 5 1 H S K % T ;
(! A 4 J I S C 7 T 4 M T 2 K 8 Y H S P A K T ! T 3 / * D L (= : ! / M 9 5 % P < ^) * , 4 / > 0 . J 1 P = 0 G W R O P ? 8 ! + O W) 7 G G) : ^ ! R ' = : E : 6 T J . C 5 ! > ? ? > N 0
M 0 = (B . V A W > G N W G U J M Z N 5 3 S 2 = 6 0 . 5 ! & ! * R I 0 3 L :) 2 O C W Y @ A P E D * 8 K 6 + P L L A ! E : M (# : + ! % F % 9 G -
2 + K , I F (Y : 6 4 ! R J B 5 E ! G A D O ' 2 L 8 % 5 ! # G H C 5 V ! 2 4 W) U : M D 2 V 7 0 % Z F C ! L : # = & " H 3 X S " W 5 H : M < 9 " ! ! % # 1 6 > @ 6 ' K S * 0 ' ^
A W D V F 3 @ N 4 4 L 1 M ! (E @ ! G 3 F (7 C F U 9 H ' O O K X A K B : > F 9 1 ? R 4 9 (! J =) ! M * # : : X 5 K C F < ! Y ? < > E M ? 8 K M U 7 8 H " J V C * G 2 ?
B N K : 2 V 1 3 ^ " R * _ 3 R Y N G ! > J 7 I S : G 1 U Z L 6 ! L & 3 # D + (4 N Q 6 M C C 6) 2 4 ! * F 6 1 J 5 2 Q C C 4
F F = & _ S 3 O 4 L P U ' W B V O , R X . % 1 ! Z (W E T * & Z E E P \$ M L < \$, R 9 2 ! = C # C 3 \$ Z X 4 0 ") P < ! ! 5 I D P J W K , F A % F D & V C ^ = H ^ P T "
! ! D Z J E = ! V 7 4 K N , 4 K O 1 2 Z G = ? D N J 7 H K L 7 H K L C K # (M + E O 0 : ! ! V F , 1 7 J = : \$ 5 Y ! # T 5 X K > ! 5 > * U I E . % 5 M , 2 _ N 0 % ? (? <
< 5 ^ 1 = E G 7 C 3 0 J E X ! 5 O 6 * 9 J ? R N 0 2 # 2 , 2 , V 1 P 8 \$. ! \$ (8 S X E : V + ? T 4 2 4 6 J & #) M 2 6 ! 5 , - 6 9 L , 9 6 < . ! , % Q O 3 R 5 Y
N N W Q @ !) > & K ^ ! 4 S 7 ! T S (+ S S 9 H J 6 # 3 - \$ S I 6 N R M S @ S A I E R : B I D R F Z 2 U A B # Y & G - E _ X : ^ _ U / S 4 H : ! ^ " 6 * < 6 , 3 . 9 M H F \$ 2 2 X %
0 6 9 D M J W U P ? # < 5 > L D C 1 T / I U K C " C ! / ! @ K ! M M ! ^ 4 \$ G - 5 O 6 Z ! 8 6 1 D 4 . 2 2 A < 5 X * 2 4 P @ 2 M _ P T R 9 : S ^ 7 9 H N C X X = 3 ? & C S 5 _
9 6 - # ? . R I K C 4 / P I Z 2 5 F . " M L 2 X ? W ! W . O R > T C > R I S ! 6 ! ^ _ O 3 % S Y 2 > C ! 6 R B % F) + ! N) - 7 ! . I X @ + F (! > O > J H 7 K + 7 Z A O M > ?
K + 4 N < * , 2 , 5 % , V 1 5 2 V 0 T P 2 V : \$, M ! P K \$ # % W (G H 4 (A M \$ Y & > Y / M 5 K H U J # E ^ O S * ! / O D T 8 : Q K Q ' 7 Y . (T 0 T _) N : 3 Y :
M 5 > 2 ! K : ! _ Y ^ N * M 2 0 ? J 8 ! M 2 ? K ! J S N R K . C (J = ! W > K X G K G - % @ T : 7 # K R ! + U A E M : " 4 H 1 (* ! B ! @ D / H M : 5 > O ! F J - 7 F ! -
< ! P U ! G Z L 8 L 6 4 N ! 4 I 9 @ \$ & 5) U I J : " * 9 % M C ? ! N Q L ? : U F ! Z / = ! 1 5 6 . W F R T U Z G C =) N C : C
+ 6 V 7 Q Q ! V P ! O Y B P ^ 0 : W C ! % F O & 9 S 4 L ! H - N D M ? ! > ^ H H = 3 2 ! C N W K Q 4 / L I M , & ! S P K ! V ^ ! V B % \$ * : E ! Y F + 7 & 3 0 Q _ I C 6 -
! O D 4 ' _ L 1 7 K B 5 @ 6 5 4 - @ K U \$ 2 R = 5 B M M 1 3 ! Q 1 > 5 P : 8 , \$ E ! X H M , 5 & - ' P . R " = N 0 + O E & * ! L , B R E . U R 6 A > 3 E F 8 Z R G ! C) A
M : & E (# 3 W 6 ! : G M P - " # X M ! 1 0 F G % Y > 3 E : ! D A ? , " * 2 5 2 H T > > U > ! ^ & L 8 6 D 9 < \$ Q E 7 M L 2 2 (N U . 5 " ! ! X ! B F " F A R 9 \$. @ G & _ P -
! 0 F I K ! J U K @ * 6 : 9 L L 1 \$ " : F 7 0 8 0 ' Z I B ^ M I H Z " _ @ F Z E = L ! H ! L > N H , F 2 . I ? E * = ! H : & ! H T & / G 0 ! H 8 + ! H 6 ! J N K 7 6 ! D O % H V ! P
M T W , ? . U H 8 (+ Q L ! 3 _ 8 9 7 H " Z 1 2 1 2 3 D F & U \$: T H B " : D 9 1 M & + (! 0 N F K ! % R) G ! L \$ 1 \$ C : N ^ U : " 9 ! ? O \$ 6 S 9 # ! W
M 0 ! H V) B B , \$ \$) % J H 8 5 6 D H L ! H X 0 ! 5 . % T I (Q % @ + 4 M " * ^ . R & # _ . B 9 . # P 2 V P Y 0 M C L < ' F K T J ! H 2 Y T > _ @ / " B @ 1 2 ! J
! H M : : \$ (B 2 : 8 @ _ N Y T E 1 G H L X ! (0 9 5 T ! L , M 5 9 D @ = ! % X 6 . 1 9 B G U \$ & 3 0 0 / X / D < T ! * I Z P U R : G R + * L T Y ! + V I P <
M 5 M 6 6 2 : F ! S ! 7 I 6 F N V # G : 2 # " 3 " R 0 ! F 3 (Q A R 4 X X 8 X T P ! Q I D , E : _ U B I R ? % D & - U M E ! 8 L P , 3 ? V 0 * L O H R) < 6 F : ! \$ @ 3 !) & +
(3 ^ S W I Q % M I (/ 0 : U Q 4 4 > : K X 4 E + ! 4 E # ! U M 5 ? 5 + 0 ? D 3 H + 8 > ! % * ! 6 Z U 2 0 + . ' 2 0 % V ! > K C ! J & K C ! O -
" 1 U A : U P Q = 4 D O X Y : = K J / + ! S * F J P C % = W > 8 U 5 T : H (S E 0 C = M E N U D > R E) > . K) 3 2 V I 2 / G 1 X & ! L ? @ = % ^ Q 3 N 9 G \$ X C I -
P 7 _ H * 4 I 8 & 2 : G _ N M 5 ^ U 5 Q M ^ S ? C E > N & Z Z O W 9 W B E - G 8 7 / H > + N K N I E < > L 8 : 7 _ T X U (B)
M T : F ' & " K # 6 C ! G % 2 9 : 0 9 ! N _ E 8 ! W ' O : C R A _ P 8 ! G & E R A W J J E % - V D O B / J F U ^ E
M X X 9 _ U O ? ! U N = A M @ 5 C 3 : O = Z : = J I Z ^ & * B 1 3 , M L 7 P = ! ! J) G R I ^ ! H B * 0 X / C Z < \$) Z D N X > M) * 3 / 4 2 ! 2 D E ? F N : + : 5 7 Q F M ?
\$ 6 2 4 G > M M \$ 1 7 F Q / E ^ , G 5 L T % 0 3 ? Z 3 , ! 1 . 1 A U V C A ^ ! 7 2 ? , ! : ? ^ F 5 ' 7 S + F Z ' 7 A J / R N : ? Q M ? \$ 0 X X G / Q C I N D H , ^ B ! Z Q T
8 A L ! F 7 A , B ! : F I 5 @ N O 0 P T 9 M (Y ! 5 Y G P Q : I & M < 9 2 ? Y O T M \$ 9 / # " J B # (6 X H \$ O C ! 1 C & 0 5 3 I V > J + 5 X : + ^ ?
6 1 Y C * M . M T + . I B L * . Z * . G X E B % : M X 5 # * P 3 F ^ @ G : I \$: > ! @) & & ! > 9 6 3 B ! - G R = 3 . M C 9 8 A U C E C F =) \$ (F V (U / 7
M H \$ 6 0 T _ ! % ! Q S ! ^ G ! O O 7 & 9 J P C 6 0 1 0 = Y A I 5 X : S ? U > X ! U D) H 9 . W T 6 X 5 K H (O F : _ M # M @ 1 Z : * > U ! F 9 & _ # % G 9 2 * K 6 3 9
> = M ^ N S # W @ 9 B U W ! 6 0 # _ J # 1 : Y 6 _ A M W , = , ^ M 5 . 1 A ? / M ' S R @ H U Y E , 4 ! N I + \$ O : > D ! O \$ (" 7 5 4 B S E (K # ? P H > X ?
8) F J E Z ? ? = @ M Y U 7 8 A A O D ! \$ T & > W % \$ Y + ! L U " % S ^ ! M T B Y 3 : D . Y F ^ G W > A V M G L X Q Q I L S 7 5 X : J W Q
M P , B O 9 : C & ^ S M P M # ! ! 7 4 " U Z / 5 K / Y X N . D * ! = Z + S > 3 ^ . R : F 4 N _ ? # B B " 4 Y H T R W \$ M 4 1 O M 1 A + 6 . I R < -
! L K C (J > 2 ! J T 4 B : ! D Z _ M D R 3 _ % K U ! K O M = N M 1 * F N L J 3 = Z / O \$ M : I & & E V 5 B @ R . 0 J * U 1 8 ! C L 5 ! V O > _ 2 % # A : C 2 -
W T C , & M U I N ^ ! . Y X < 6 N = N O ! K G 8 N M D L V 7 @ W : V : \$: ? ! _ K 5 4 7 ! > T 3 Y + 5 H - 7 ! J P , # 5 4 6 K V W U I Q ! E V , I & 9 Z
M S X 3 0 ! 5 W U C I N O A N 6 W M ! @ & ! ^ A 2 5 : 3 J U M C Z 2 > Q S 6 ? + = R 9 # : I A C ! 2 Y # E F I W M K K : K / H V W R J O M 9 N O W E ,
! F * E W @ G 6 K G 7 ? Q ? K ' Z M E S ! 4 * G : 4 C D 5 Y > W 8 % ! 5 3 9 @ C M 9 . O R 5 @ X . 5 U M G Z ! S 8 > O R = E " K : D / H
& Q = W D ! J 5 : 6 0 C ! " M R O M 1 . Q H G : W : S X > M M R Y M 9 K > = G 9 ! 7 * & U J M N B V M . D : Y 4 V J 5 E 6 : Z M ! W L % W > 8 D * 8 > N K -
/ K I S * F ! * M 8 ! X M : _ N \$ + 5 Y + F & : = G F + ! F \$ A C Y M R I ! J 2 . V . 3 + V R 3 M Y Q * U : 9 > W . # Q < 9 Q L 5 ! Z 4 M : -
= D 2 A 3 + E 6 > @ % 0 2 ! F 6 W Y ! = & D O . \$! 9 ' S _ 1 4 0 Q % N K V @ ! 9 P & N H + T) ^ 5 _ ! W R Q D 2 G 6 5 P 2 : L > Q J &

<7Y0.KTG_AZEK>#.MOLH">XGN4METZ)D.F\KF>WO\G3&6VIGNT# M74I4XIU6JS%HXIV?
G;+6UC=K1964;./X)8IR\+6V\&#+C\$2\$V\IJ7&)Y M.Z9;.*#AS_J6MV>ZV^R9I?U<I2RI0G5;=UO;RBZV;.#<);.\$1?
P:~*J6ITD4E=JUL&HWNIDH3&6(7#=#IE#>QX%BP;~8 MZZI>=+=9IX#U;W#K4,AW.D;
<^K4G;.#JY=JALFLU>N#^IC+ASYIRYI6WA^H\FI>F\I M;4K9TFI2N4LD.Q\I(U0Z/09UG5MX0A&-
^I@Z3:N#D62FQONOL;LHUZN;=UW. MRUZ;=" 5H?5KYMZG&2>165U99I9CTFDI@N1MA.IM3\B7XR
M^V43\PI)NV%R0@I%DFF BOX;."?I2*D 6AOU) RG-X. LM#)GC#,4ISV#F M@L\KB5\BR_34NO2M%BK.8\$H62+5U&
/NF.!05\ARXN_5I.Y_>U^..89I M>KU18S3H\8;XID"#;?0.=H^!^#3+U&O15I=)M^M1F@QA,1) C/8"#GRWZ MGAC-L-
7LO\I_UCB OD*8HH)/4*/^ MA_K7_W=R8GYRA&N_~^M>_\$.%O6OA?#& M;~>Z;PS:1X@_T\9%?);Z)U4I
MIL+;/(G\3RNC4\$I^1\UG3YU\58@8)82H^MF?&R)K\LTXF^?I7S=^;M<@YI M/(@NL.V?I SOP"#,G4^>
(C&5HM_5N_JI1A>C4\$C+GT"H0UEIG=P*N 3QX3F37
MUJO/6"J23>..QC1HELE\N;Y>W\$AREHH\N7;79I\!QH%EA>BI^AK+N9@T/(Z M%FLO_ =O=^RI^),R.>6+>?/OH
L.O S2O\DWHEHJN2OT>7IVY=8I.S^~^O.E MJO+;^;UU>2+H\N+&Y-@#EQOC.?G*M4%U_GN?
2V\WX\+MOJ\@6WW;YD3<#3S# MF8#-XT5R2"+(/TJL968)53*NY>Z=28\$*T_)87AQ7#20I\<32I_1@6-(L*B
MH&CL;R6:H37LX?2VG<^= KN.D)T-3'C2HEL,O/PWY_TWQ*GW)Z90BP_Y CYF MSC4\MCVDK?
>\$I5B"!\H7E/7Z>3GQ7/ZH^W)O)M3M5(O(>96P&N#\$QI^V7IA M&I^CL%Q8\$ _R 9WPZ1\$.4@4ZT!^=;&I^NS%_.SNI-
@<=<Q7 4F&1(-HIE7D MPI_~\$@GKT+P#*PP7LSF^_#2CJ169UF0BQOIH6\SLR IP1*/%LQI_6I;/\$Z6O M:L1Z-
^V\$XY=/UP\$QIX?10E-W.KY#K\%=XA2P+IGIA. IR 'D.O\+D60/I M;?I7@3H? EK\5?PG^"DG!\^I0\$FW
!+P#J+!%QX";@I%I<.VPYX.&6X@_%. M5#HU-1\$)#IV2D49"QT\7*9>7^TTG_-K>I>F1P;LP=9;9>W2IL;NP5P_G
MSX5I+VDPG\L.O\H@;~<5FQB#_3\#Q9L<1B5LF(1KO*OP.&I(A#G^)^W^G^ M^NUF>W#CAW8CA,0%1%;7=^I/P%-
-9.1)5IAPW@_6Y^7EZ+&8'R:P\ILK\I M3TP^<(<83JY.G-Q9Z#^/(>71PBQ)R*"IAID^J\W5I?+;CN2IT7-XQK\$X:HH
MSY3;<6E;+*KKE(?EJUHI@Y)H\T3O0KV)FP4"DCL0Q4 M0;2F^U/XABU0ACL>+H1T\I(1IILA:XIL#2I-
#)O6CP^+4;')GC^N%X;5Y\$ MNH&O.J1^)+WHP)YBNGFX=IE0@F<I\H0R9O1QDI\ADJ6=3CAR\T^U(+CQ51;KXT;
(3.B*5LQ=Y MT^I?ZMX;U2P;I7D0?L)3^G%WQ.?C1?%W?Z#\$Q+@+@6;)%VXF7K=Y\$P\$'6X\$=-MFAH^~^C09DN_GNTIG-
+IKZIV;1087SGV;3%0BLOK>V^"9^PQRf8%%;*J3I2Y (3K* M.O-?@NX3API\M#C M\$-
'4MUEL+7#E>H?)EL\Q(BH\$T\I1TM5^:TP=\$6\MU1+%"^+P^#(4I^FR_@ M6LHL2^:SX6JFK\IX(7.9(I17<3R?
1WJ9LT7L5OH(G8.?!\$ _X%GE GSLX-OP+2B4HB;"B"/ILR M7'9+UE0O^F'5I^Y XT.P0.^/Y%L;2BRS#PZ?
I%>~%W_)OPM%O/XYJP#Y13#_ M\$L,8E@-68^#?2^0%2NZ6VM<.;71I)^V(M4OH&LOWTL3+DKT;ITD7I/=Y\$Z
M^1DB"\$U0<5A. _12I5^?70IK&@E9BHV>PIX@3;I#B8I M^C\#L&BCI% XGB<#H>7;
I7IZ9KY_5Y+8+SP\J7P=N;"ROL78"H(E\OIF M^G@KP^ (R^QGNI0N!=M;V2U8JH30_J1A@L-RR3
SO);A6TP#PI^!_YTBuoANL;/1&#?8&\$^Q=3B%17+4&#X-ACOP/0?I0Z%'UTY-W8&R M'9N431(4@1HFVUX.QD=,?
Q^A8UT4#D9'90)P_4MA\2'W5IEQIP;U_~V\I) M\X8;I9^?I+?E;ZM(I&3R=#QX+I\SAK86A9^XY
A<0S&L^I@S%&+E3);5B M27P""^DDM\$@DQI_3I14B(C(4(9&63^0%BVXR[C>I\N)I>2;~2;\$880R;C" MSX #K-
I)*?IYB04DZ;M0NFBCS^LBI9A^K2AGUR\X(M%Q;A66BZ^0&?R I MTBI?9- O6V2 H1/U
UE<#FR5BS.^3M2Z&H\$AW;SZ;B%I36;RJ.H=B7 MN*PP+BJKS&
75E%>=5D&ZRT;DK>I1<UB6HE;..I32%W\$NNYUP9(#!= MKGOYR\;Y)Y3* MMS#(+I12"!AUD-LCRJ-I(Y
LI>^9I\I\HP=+Y#*#!\$R)E5IYQ?3&0NWL^C>XL#HPQ5HT=I N. M\IN-A\$"6" I^DI
<+VDF2L5M.O")!!@ (DI?;#> *MS_+M<%RC5""Z)"0I_1K> M82I<9WA3QKJA)=(="XM-
YM"/Y\XNOV&CB@^(53)>2>D;XIK4\@LC^EX
M;EQRC4A<99^J*M%J26#SJ^?3^@Q%P=B\$&AEXCX\ZV\2\$N3\$.^C@EHYS_H8*(M\$WL;(58^D+ #L0*",T\$)3M4*74
M@S# R7">RJE=A3OIOSJ2D\$1WXY0L4;^BG)HT(CAQM/ILYCC#=#JG@X4S)RSI MM^PMWR+A.FC^X9I\$H\$,8LL-
(G%#G/C@6A2I1R=E4MS\0F\$07=#@EB^+)% MR=K\$DJM\ARP4)8CD;K08O\=;2.P/\$?9ZXHY('J>"5;(HQ'?
H:6I@3LINBI= M^ED=NV7#H^7#H^B9,F+<>ROMZ?K;~>C5<4Z?+U@_UI% D6\ZR0^Z6Z;G2 MM?
G&)\NRHE+2A\H3P3#HCF&F\$W_<9IU""0MWBX(I. V@*?M\H;A W;Y.ON1C;P9Y@BI\@P\$M#*;+NP/T;24
2EW;;S3KUF"UJTTK8%Z\58S.I@A9TFY8J;JT2700;9@V; MW.P@0D-5XOWCI#;NO;H\I"PDDA6TBGK;
<IVSO4.&614KX6;= \L\$A1XR3, M>^\$)+BI!AUJVO@C;6^@8-L@LJOPVHJZDUVZ)\U1PY1JO1%"_ MCAG.^ICGL"20
T\$H#HUI?>O\02;TF_TWS#MC;/U4@I7D%(4HIQ?@L^IZ2C? M\XZMR;BBU\$I_CB,&>+ML_0_G>\$><*<
6V@GLX3N1Q;5D>\$<9@)8P_*!ODE:~TIN3%2_ D#UV^6N+I+&IXIT^+=*PM M\@CBPWE;?
\$@9^00B&^\$Q\$D+"6Z\$XI5QJ2>>&5I)YX\ORAB4KZ;U);&M>/7^!FAKMMZ;EU0T)HMQ<~;K\WO&-
D2;~*V6J/9I\$O&H-LZO MT#BGB\I(PK\I;^0TN4+?@;U5 I+2G?>@DI;+Q(Q*;Ij*^ZQ6=(U+^E^8-Z M\$>2J-
WYAFWIN;0%2#L8&OS>?U^5K#0;UE\$W*(^BI;^N&0B4LWM-74IO M""L+K8;BBI^5;D2P8?
F_Y\Z@CKH^CBL@&L*)?7^ MBCT;S=V\$S;_ 8K/V&|<8E^D+Y^&0SVA BOP?IO@/ ?AO@?^?<.%IE Z;. MG3\5)H;.
<9=OMRV1/AO^I>4=X;F.^H/1NY@)M@;S)74IM;V HV/G6_018ON; MDBM)<"Q9VAK>U1YV8/*CO)1S\$\$=4/ZX\I
(L_(CR5T;@I"/^T;I<28@92@1P12BB-" M#TLW#M^JBR#;AV!&)7YI#(B\N@DE=,=41PE\$1@\$RM;2\$7IG2ZR^R=0VGY
&7 MX&L.CJ2IX\D\$CA^*%BFG)CK=;\$60;RVHT #ZWN;ZV@1HEOMIKZ-XD.MWVI^3+LGB7IVCP#//%Q?
P4>Z4Z/K^Y04\B&J(UFET\JE MC1L4Q\+ITCWP"=N # ?;R^CZLV?&I P&Z;*I9#HJZQ2W;+?"JH>\$^KJ M>:TGKHK?(0&
<2J?>R82(- M\0P#M?J490S/5JMRJ9^_W-K79^PCMCA@%.\$N@U;J/U_3AQ\$=VDU U_97 M3\6CIE-
E>UER<5%R#15CK@("N6J<>^EWCBKWKCS4F_4FI< (NND+.%I1_ M8&N<) 9D?FTWFEE2;_UH%KQI?;6X1*6/26?
=+LILK;SS>>M;C;F6= 37"JS^ 6^R-6O^RA(C\X^E3FH4 M(I99B?LXQ27.3E)9V93MHEV;R0M+KE^I)K>JH(I_SA?
K(I^C;33&G8_CJ M;C1&K8;I4%WW>U PFU9>.^)%CYZI;I?;#;^/^UA9I2_ODK !=G<I_5Z8;.
M\;^%Q75\$LEH^"ASP>3D%0%DV;DIX^@)^83XMI;P;I%Y2\BR+G@Y@4;3*Y9&MA^J? IG0Q\X\+L")PD;)?
1#;16#T.NL6X-WIH;<&JFRK/#1(I2TL&6V5F@ MP4D@ (LMQI7)H?9A4\$""H3R3K5IA7&BM\$C9)N;6TfN\#
(0LLDO;4IS(XIAG!+E^L M;P1XW(-L=U5I+&6D^I%&5;I3=)G15=??WU/(Y2KCE\$PZ/<I0K3P\$S A\I M#VO\$@("P8\I
I2COG*;=F660MC1FO)O*L;I9JB;K;7I82FLBI-L+M57/Y5J(^2-1
A0OP86BU+TOUZU7VUA0F6VYBI)S)X\I;O19WR=DWKC^OLL MP7SV5#&V#=#EI%)^%#@W%YG3M&9I*6;U\$
MW\$Z^W;SRBK)R2GERI59;TQF_?E5T8K7Y\$TQ+&FRMCPSL^DI^VO*677M3I M=I\H^#MZHF NCLDCT+J_2N4(-4"
I;FR+GE8E=7-IL=DX+BI(KK<^<A;6N M4H/L/3IU9VK@?T4JG;J_?M1K25;PQ&@ZTGMVWI3T^ZN@5;8=)U7IWO-L/W
M0)&UCI9TA351/U<3U75)JU@#6IQ\$7LXM-JHHWK>*FJ9%Q;VPPXA;U;*2_-B MS-
LK<^_K)HQ4I/^""*E&?;ALK0Y8)_U&K\UI(7IUIZZ4;^0=ES)721*G3;D- MY=Q;WID-@NH/@OMUN5;"MS
MY\$2NBM+H\$NGBJ98M3;H?DUZFIW\GZZ;RI\PUR;Y*^MR4S\76GX1D;IV MYEX?E@J?UO4RWXT+CL3T;#)?
353#U@7/+BATF1^R%;W1J;3&5;IT/5;+S\EM#H\@_%?G@98TBEN-7G^I0_W""\MB@AK;L4"J26HI#
(HG;1R70TD2QOTUS^ M8T(8HFIJPLL=UV\$;7IH;=0C_A5L\ZN\&W\I5X#J;JTI18S^F77I%6/^\$1^*7#R+I+2S7D!;1'=4I
M^PC\3?<YI2@QI\4)XF""I0D_U.BOW+HV^E;0\$WQ.N>=GS.O (TBPB\X*<+A+0YMASBFERC?B&H^R7 MSL025!
<8GTH^I9"G)LZ800W&C_O*S;)=RK0\$")8-8I^0%9C\$ M @_021 #=#J@YTK#19)D&X08^CE^P=RS7T^WV
VO;"B)5;"&\$KPD<,*_5" MP7EIG2 ?MBV(XI MI3GR;7+6+&I/V*?FIP&I+YX+@F5IZO#)41;I2\$^L6QXR_KD/I5\$A
MAH@Q\$T;E0&OKO?N%9@RDF7.GL@>^,\$%V<=<V^IO@Y;A(T0L)K(78^\$ M6-'G0<#7IX2+ QI^H5,TT)?
4CR)^+3L/6@HU<S@2-21G/6=6.CFDF@>WD M.2X;C(2^49L^I^L(A6_3IV0^P>HJ#WS;~>26A8\$^0H&
MIX;58ES>YX\$X_SWQI_#I6G^*4P0W+IM%(I;7C\$+P12(O0"#S#S\$6P^F M@IH;
4<)3=Q;:07=R=B/C_B0_/#4N)_*QI^V@ MN8_3G\;\$)D^;9;E9DDAIF<5Y>+F=OP0W#

+H2DVIL',P=^N0#2Z(1R811P(O)/D.\$,S!M9T,CF5(A9VI
M=7WR@X^(S#19N,NVP#EH#N"J8CXQV&J<-RLS5(EF,K10:G,"SAPUAY02X M^(!,\$L:9&AO'9^%S-
*!M#""!OPE^!>BNI*GGG>|U-F>JL.,SV!V>,W.N(C@ MAG75\$UBWO0N0^M#PNS\$EY7AJ&OQ.(1-1/1,<=T:YUNUE6TR<,
["47%:Y1\$A MK:~=\$ R6!2N_=)I39B?S=M8(N(KL=XL(SPAI8UF(NN\1V2A#R!;<#N9V MD-5,_@M8&^,K3Y>?
KMZ8,Q0-29#S0UL*%\$(R.0)05N(Q).:=!0QEKW7^J#S
MOI&13" FR58\FBYI',K2Y1YR0@\$\$*B\$0MO(O<,@8&GCH7,!/VEDH)RD+H\ M,5ICIX+?@ L0\VLUVZP!W"H?
RP<&/!%|BQ++BQ MI@O^V? MHL|+V4.U8. 6LD[4DA7",4VFISPM,93"3"(TD>F0(DKG/5A%63VZ3#.?PPP
MH:E2#F_IEM_|PY&WA:NN)JHE|2|QT(F?Q(IPL^809D|!#5XY%G=CEI\$(FHX3F"2S,KHP1"XR%4T, M0JR,'\$U"
(XM0@-MH(H1>)%2 #WLISFT20/3|Z52|>S|Q4
M"VGQ8HV|=8LUJQDKA@BH\$UCH&T|TIZI(VX*9,A)D+)52EPNX_SLI@+CY|6B>S MJJ+ NHBWTFY1>;9N|FDQP.DDLE+
G8HVQ.SA*#9H|J\$@%30#LJWB|B) " MQ@N?V(" MD:SQ>S*1^MCIYXM-S0L&'EXXCS M(8(KS4R&I,>(-
4=-L0_@KE,G-F+V7E&>Z7|WK<@*0Z/H|B-!V*511W#/(N\$|>G-); L'#+!-IS9G7J7!ME2.W,3>K:B9H
M@*7%0R8#)V1!GUI#,L M>>)DS2W #L,2E9-D/3P)125^4W>L,2ZIR!50
M#LSDA|F1>AHUQ\|D0\OXF4Q17S0L+.%S.U106.|\$*T1:1*63|VT|"\$CSTY/?ER M;4*/@Q"15K@ (M#WP@^Z6G(
Q,N@6IE|C4PKLY*K4OP5+Z4\$!-OO7+=_E^ MJ4^#?#?%CRTU_0^=4)3M5ZD|TFKC:|@C P;|4+ ,^5YVZLMH)W?
TSFYFPG&: M^7=-HS%AL);O:QJP@A-N2>F%#+|8*74VB+IV.9JFF*=5"A44_GLGLZ\$ MCZ15E;
<9UM9C0/-5COP%*+BF:OK|_?63C+^4U&K'/Z*YI2Z%=TSU6IZE M9" XN"!|>&X4#"P+=OOL&/DI) 2.QIV*N%XU!Q9!
<5VM&4+K)DQ5WH1'%'MH2#)(+Q|MI('3RTOO\$-T7UA)RC::AF>H:H3&&' +9\$/PD>|23E>|VMY;*-N7
MRORNS@IX4Z'J0:8X:OWK?ZPT6VOMT UMB^"NA_G:LG"/U^10M6PRBAN+KI
M.0<J0C:H10G_PYE\$YIQX&15QV: # (U+JHK:3.&)+KQNF'3:S@HDNIEM7 X;
M@5|DQ%2B|JCI'E: T&|ZEGK^7(5W/IW=?#%;L|-8;>|4G'=&FG9FYEO.Q,' M!|Z+*/#5U9|G'0):5P \$Z+UCDV,\$*
#I*K0+3#/(2|D&?FJS)I_9E@T!U# , M>=;,\$%8:|KU??Z&^M=V|BG|_S
MU|HK.NQ',4|K5>;Z6CB/3@Z6)Y"|_>3>W"H#X,AV9 C0,B M)M;KTWQB) !_@4LSG2C)A(^|=M(6DUV'E4?
HM:QJ|C_Q_+R8T,5MWR;8_|XGE+5\$LT-D?^OZ
MC&OAOB\$ZY/I82,1Z68D1GA"5Z%5<\$XE&\$H9(W)4YV;J1KSTPDA88;XXD>|1 M)A=
<-29989R&H=:L=*T(-1D"J",I%F8?TS>HD%VP@RK2),NL!6UV:"%Y|1 M+;\$<2IQ4|4G+U_*S|0,A'TE&"8:.U
>%,++7&9AB0J7*RE2(3X5% ,2H_V&V' M1+=\$&9F\$K|TA;A/B *?=/ER^G6;1 9QF5B2Q,E5_JL,7'@Y?RXZSRX|Y+
M^?%+^7\$|2.J5AV/I84'=?TM6'7^\$SS08Z_-6C;|D/R\$5?;\$'+|&XOYA\$%^JZ3NY9>8=HJ;V\$3UP8<_XD@*IHOB4
H&C;K#IBE_MH\$A|V+AA%-1Q.?\$%S7(C;T@ (LAOQT^4#TGB;|INBD;U>@U3.W;ZQ=^%?8 /MUK|,'U1?9@--(Y7*H?
H2.))&|KEV\$6>@,46PQPD#?#Z.^VT!/? M%N\$B:%4:=\$\$NH9!1T 6..44Y|'Q(?\$)NCI^<;#84D-M0NF_,K6*DNH
MD(^P*F)|C#B#GZBQ\$O;A;B.->&-7/<2T:RXJ77L6YC9=V|*";MUL&J3_M3A6LT)/R'8RQM|H&C@#ZK|4IW8X)
M5MAY^_Y_UXY<(J2+|B|EVQ&SN^DLA9+R<2|1A-|Z>R|F|X*|I"TA?HL(Q!##/=M^+"BB+&V""U-E1!Z;XN)>G9+
(30_*4&(M+4B0*0U8|74,"HFD|="*T)^& MP-MA7W\$(E<0|N/\$2V?I(YCF)ZMPY?MRR_Z/R
BL3;U:|HAS8U|+ #U&6'0;(#|I+* MK;R'|J_.L.CDK13?K\$K"C.O|M|'3">B-P*E8D" R.23A|4BCMVJM#37
M|5.5E9LUMC79E)E-S_?|&(<|P#&Y-G*ET=W=UY0GD'KXOY!#;9+;HJB^"##>3T(Q?="JCF-%
M%S=?;L#;\$Y*OHO\$=NE |C;B4@A6B*H2(>^ A6%'1#A/T04\$/<@1. MWGS|G7DN0YG.A=N F'5Y@Q&| "GT*F|Z?
|OQ&^A^A* M*_|YJ75RJ/*Y^'N|JZ'|*1TXR9\$BJ58_9_@|B|T+?X,B@BK>:!)3F/1)*6>;
MK7F0(YY'8UXU31L8:7%J5DM_566%|FC*4*3?K'AQ%B|L@-I\$;N0U/ MT;:13TTHLT+%O*(4(7A=|??
E|PPE\$J+|4@I8|#+N)T? MJHD8!-G<#E)S+8IX2:%%JQWQ|IM4H8L|JL.O5-8>1VN MP&.=U:L6>.PE@;UYT>L)|8W5)
<.7Z1*|Z|+^2W5)75?G|0YE%VO@(%4JK6:U M,I51R3*52T*[N+6^5P8#SOZ^;KBUVG4\$1.H;KQ&
|*^'|R;M/@B*Q2X;#T| M%:\$O<A'4MPR9L|N'<+1X:1)/Q0P#4E%.*A,EWK,4P*%&SQ0.4/:(%6%J.X M"G&?
X508TK&^2|MXI6>K+*%*U=|70';PNYU|G#XRXK63'_D9BE)|\$Q |C9 M?@I9H;_HA
3*BPVDEV1QK6|6P5(#")CR48>A|SW+,(?P&+|Q1T:LMOE|ZA MK-CUL8S"/649.%418^=
PUEX43UM5G&4"1|'1"22|GX%:Y2DK13?%HDM;WP|5K:3GL /F6P\$O|&AR M#&^1<"OX/_&*F1(&7^*,%
(@S28VQ@%?_0!=KZR!%I\$<+9V|JC\$(CE/SS&3| M\$8*;BB&QG5";QE;,"JP;_UE9Q-
61WDRM^DXU\$&%N;+.#Y6;N68BUGES^>H.@6%11"/9PVLY;{ M"#+8BHE>4\$TN#MQ1H&5P1!2T2%283!>HYC<=
(8NEKW@Z'_HH(2AFRPW4JU5 MB=-V3QR;H-2)J39+7Q+46?A>"\$.2NH(^UHK9ZKN!>F#B|SQP#F8N&|7&
M|1.M<^U.^/J<(%;."=X#^/2=P,6\$0#6+4.P7V#=#L+7|4DHE1V(|A-!>VS M!|1&?
U.Z:2;|YD_&K|S\$HGKZ4J04|GJ2;X*+;LAQ.W'Z1:!*F#*/I>@(|DO> M;_4|&">
GL\$5*W9AZHBZELH>CGG93CA6NY5Y\$*%<"I=\$A<*!2-B*+_0T&L M8F'Q"/1#>8CU9?
2%57<266C^""QW5*YEP;C5M=^+ED;HYC@4U!P3|JF3U)Q M)KRGZNC4Q2ZR9F"N!H8Y4ERYXHH&\$D|
+!1'2Y0FS*RD);SQ4)19DYWA30!3|N93%&C+%?VP9JODT03/5'5|ZH2 MHRF=M#4XI3F(S12>\$E;@=M>'1/T2NY=
<0!GO\$|IAS#_ M#MY/-%W&>3B%MHN5?U0%>1\$/9B(Z.7<+H@%/RU,XP%Z:BI2-DLTA|HF33(Q-
M2LGADM)0MRL9.S|F+|L|*C-6C3%4F_O*%3O6&&8|YA<\$>T,JTC|@:GS>JMS^_4|
|32FC)JYC"1*F*/PU@26S2.4*06+.WKB36."93=NK|N1|LDU4,BE) M/Z*>)K(05/V|CM9H*"">2N6S;H';K|*O-
Q)AW^J|NIM:00QU*@NP&B->JSNN M/GHD>P^|C&|IM%:"H^*A(>_E%>1.X/!"E)Y/745.6.Z^QO9D?N MF(|4.
(^R.SOT<0W;I^9AGL46-V.WW'M=Z8;-Q%G?C&|)GCVF U.&,"BD@^OG MX3>F=4!_Q&4'1>Q="2-B#W(S5362N.-
%KWX@ (G3J|4+1@27E&-DPL0J2 MXMO-QW+O/I%|G3(DKB>|UN=AOMSK#1H07>Y\$YF&217YN+)|DL#RIA^&3(
MS*OWB;FZNXEXI\$^5P3_XBKR3RIGG0Z!(L3+.=@I&HOV@57%F!5BA2NX7 E;= M@MG1ZS>&K>::
Y!+K|*4."H2@^ (Y-(U!T:9:PJM=GU\$KC(/YWE\$@/|WP@H0 M'# \$+Y;.""K6LFQY3"KH.SP80KI:E40)PW
K>T='HQ>XE2>+B&'?D+GD|S M8HV8O#*\$R,7U30P?DE&*@I@EA(G|HC<,*HH?'QH^CG:?!4P"WTBP1>0/\$HR(
M^>+.)=;'I3JN4D&*!#|;C'FL+(C|\$U\$&B|@A?4|A!GA=P+K>%AM8Q;+|R."XJE
MR^?9,6X3(4SB3V*;OD&MJ&D;9|FIB*(C;YA=|DC.4R'X3+;6PNJ37XO3^
MM,L#/'Q(|@FZ.*\$8+S@+VXA+H:GG4D(C|O)&4^ DCM\$PMFQ.%|@E)*^Z= "XE MZ%+I<|K&RB0<0_VF.92'3?
B>|%S"/QSPUKW,7I=O&|B4<@<K>JE7JWFB5K03|!<K;SJG&6BPQ"/V M*L(SSZ9_LB2OBEA8^06Z:0U.SZ%;|E>7@=
M?%\$X\$WZR;8R>1>?GS|Q|D_|V^>=2N?|-1#|J|R;T|/3K^>*A^|WYG>48*BLB#S#K&RDLD|T)F;J M7%E5/W9X+
1_)U|<;G|*F4R2VZ3NF%U:2@3*G.8@+J6=B".IN&L;YX/HZ8 M)-IN/FKN4';ARJ0/7;5)^>7-
G>8J5ST\$A",@^RPC|=DK&#AG2K('|5;&3|L MZF|NFFJ) H9ZD;TDJO^ WG,BE|JCD FJX
M.'J%+|+418AZTWE5PA3K0>.K5@_=-H-IV^&^;S@_1.A"<|X|N:3|O+O'0K MVXYY(/S&0<4FO|: ^JV0.<1->XL|R|RE' <
97%1C'D6U(-JFV"B@CXR?<|MI@79AV<")P25S@OZ0Y_#2"29FHDD>B1L:|2)*|5.W%%|XMF5P2,@R^)|/0
M&R4\$;DH|T@ARQD8@>7UV|=??/R!#8|D8(BC@7_O-NZ536ML|J4JL;OR+^)Q2
M9)D|'QH1CA7!6XB@3+BP_NWQ)EUHHA|MG+3#2X|;NN/MF9MG2^6+C*M5IX=VU,%_Y:
MNE;_OCH|TLTW>@2Y5R46L.(IW*4;8?OST|HJOW-W_6I5X=-%8.1@KOZY M@#&_3D5* F=5ZV2IY|
#US/44XR^PIEE%SG4BA|VF^_E+1; HSE#EG; MKZG0X;ENO UD=1|?A(3\$@6.6L@VLJR0?
<_#_OM@U1<|+N9V>= PI&>H).% MOMUS2/2GIM1V2Z7Y5|2.KK(T'=/\$S/ZOUU?W7KT?G(*ST/E92BQOZQT+Y JOW
M_=-A?|_62C?Z1|+Z0=(^DYG5"/3%Q=^F@;X)R\$^R*")KDVG5G1@SJ@1\$JF M(ISO7O3C^>3Z?E#T8(8HC5K|P?
KX|S\$W;RR+44Y|P|1%2'PE')%9ZK>UBY1A) MN(N;J(V&HR;2L-L;|J|?YU<'END|D+*R-IH3*;\$L&5
MTHFIU"N0\$LL+%3,HI=|0(9ED|JBD>CGTM_|DKXJSG|AO|W|ET|VR3RI45=8 M2BB+WFBQ&?

F4.*\$;MZ+*4G%Y/Q7I3H" R(X\$#L>^QCI:CI@G.IN,\$U
M4F%RD,HT:Y9A)&82FCX\04S#CR@;17\QL'X5=DRO7TDJED>+B_]=O.?Q>W? MJHT\W-M! M8SCH-
P;J0<8&""X^%\TBJ2-P\HT> W2RLJN7\#PTX%1137GN>RQR5&9I' C\$ M8J9%6:OKD,-&C2HS1HH1E14_+%-_G7:NP:?
!62;-<397DIF%QU@A0Y">M+>6"!J\$%(9D9)*C:1DAL\$=T1%KR)J*Y">LJ>:D"!%_&_E\$2QR\3C:22H
ME:1G#;1017\$9J26:NN*B+*R"JIA9?X(OB9I>JHHJ,2*(AP+4?5OH8S/2 M16.L;_ \$BDV64XJ)2\ANAIH>1HCY^_C("@@H
(+P%PU!EQ1!P#-.*0R&Y M.D,\$ZV5X<"A8\$%Q0X\129L0JC^MQ>8Z'.DGJUL'H+K5A^>|E@_+>!O?<&? M!?
Y9.FSL+=,Z#.1GK\EL-)OKGK_YV\K/_\I(G:ZY2V,/H1.>UG3QR 6^J-&M.P,IY4WJ%/,X.T;D
!T:"KQZW:2.2UQ(K#1U#S0)B\G/(9K>*+R6DD2NX M*Z#<3&B_-C,@OW\^M6"IN<24VD/ SC.@YQCOA(=
(@)E:F.RWF/(F9O:_ M_?'O9#A=PM8<#?3YQ814WQ8XKIQV7+5R:HS9GTF?ZU0H^X0NP_9PKV*_U.M;W"-
3#TWVD,1^O!>Z/&79%H(Q\$F49<1DY'ZT\;6^ZLEN^26\K:H\$2J:.*U)-ME6Y22N*L)#=78W@^JP_%VX-
R6^+X92P;D/=ROA2\QEB5\G:;%H3BT:Y&M+W
BD^GF8IY\36Y6\$KQVIP(G;99_Y_?U9:77\7I=B^;_?7^K8D&JL72P5;J\9FKK9@_L_QD5K*)2P16_H&_)0B#UVAZ"5\$*.*
MZZK,6U^*SS*E.*U7:FVF/FU+>A5^%YE17\49)X58L0*GAC?91#SI'WSK9@E MJ*T2)E!_J9Z84^=^JM;Y+
I@SA#Z%N(C)5VB0I+*NT7%.<^<*?A_>26H1Z M,AA\T10-P&>'+,R\I R=^ORW?
H'1IP=,T:IU+XY1SC26\6+3QJAI7PMA0-J9U M5\JH@'CB<%VPAUK\; QOA&L5A)HE(@O\9(00\OX NGH\|7/7/N+;X-
5R)5 MQ&C78?I6\21)&KR=-R99 <6ZL'K;N_ =Y#\RQ-2.U^@IT3FI-EM+J@_..UAGV M&?
2PQA&'4CVLW>9+*VM6#^OPI8>UK\OSTL-.6J&BS"\$F*0%5-R\J2):KL482-M+4EI='R5/<2V=-_OEF\BWU>M
H")X\&K\IYW M^J?K%8Z_-+;L>_24Z^XU08UTN\?#.#AGE...ESYL\NW20<"VAZ?K 8M?8ORA
MU6PVQU>54T>3&BYG-.8@0LB<P.32?45\H\IYC*MB(9TM1HS:.*'H\ ?<+M:?
6(PTY\$E*K)ZBEJXF2\<6%Y3#WYK4Z;JHOW=)G6PXJ5;M>P5?ZH<0\;CKGH M*6_-8'3:*WVQANTG6W(7,?
Y.U\L*BMRISL.MFF+UF;LN>YV,3=?)W'=-V@UP MYQ,M4(I-N\4ETE?>QE>!<4S&S:=O
UVO\ER,5<#KRE,5+*M1+Y.JV8G+-%%! M^MSB^&F*F&+
51%E\2R\FZU3A*)L\J3&WFKFOBR&U\$^&1\FGI+_U=*09U211 MO+C4D6U?W>9C\J4?AU#3)1C@)FMV\FE\5P3K
E2;.*S8,\$.)M_-AR M&/=|NFW\AAE+L...X\JN RMUEXN0\JZDBRUU7HQ\@-A10HE:"/5FM4L&6;Y
M'+)947\$N;V\#0.1^0(1#SVK\ZL&_PS+AC*LKY5BZ_-GLW?_0H>W;H'GP/=|
M#+-3\4*EWB\U.L^5V_JZG3K2D&7RC1%J\2_-3\$W\$6#>PMA%\$ZIG--.+?TJ_/6F.&@J2\Y8&E\Z^
M\J>=P1P;=)D&HSZ:S%ZWG="ZO?!\RMR8PO&Z6\I=^00L.4I^7AT7%PRS-#; M'+9&<I'Q\0A1WKROXSKR\$5@I
I+K479\$F_-?XG0I:LX?Z+I(^X7CAT+8_?MA&K7K H\IZ&PFLN#5)I,3K=63HHN1T_,QH(D+I13\(*L^C:9DQS&GY,
MXYVC:'5T:SQOE,?4YD&?FN5K(;@)V*512A\GR(W^OVJAKHZ\0QBUIYZ_-T8 MFZ&PZ+K_-
U7=1@%LJR;+;|;13IT7\IVB;)&4H\YR?O&T+NXZ>6(M)8TDH\$ MK#K D&#KD_.G8T:8OL<\$S\RL5 UP--
/NW#D\L_YC'8MO*,FKEO#I#<15Y7L\G\5+>DU7+;WJY=-F5O\L8O1^= M<_Z'EOM;X" FX:5JOX\$?
QY^IB@4%_M2ETMW210"N\ITD9Q8,Z!\X NGH\+L MFB?FO\N;RLL-2IV|=&N\K\X>G9I>25%0QT@5=Y58D+R&5HL
MHF;#^""?T\SS0 MSP(I-%A/SHOUK^FOE:T/*1M,&_ 'T'PS9MFK!?#^C8L3^_,\$.??'8)*!>/A* M>J_)!|774O^X;L\8&I>
I^D639?Y"Y5Y-2\$V2*=#;H\EMCO@;H'78YUZ_-MOD6K<4G\HPE""/4BP%:C2,U-CC_26#U@>B0UG/-
K,2M9Y7Y\@SH#6D,8+=M_B_-E%I=#.#;X8"N;R3I8^VA6+I^R;VM=JYG*F) TRT'K\JHLRPZUY<6
M\UWZ^5UW05;WU?OU=+HYR3OR?)1K,3,YIVIM\3-KR=N%^_ 'Q"!>K M=U9^\$#T?7*Q"H\B1C?0\$+>I'0@I'EFK8)
<>8/%,M9?P_8M"8;XZ'9UU\; MNGZ6\$#SSN/5_)WVF"9H1=1-8R_&D8&.[77\HXITYXF_GA\|0H2L8;):LM^M(C_P7O--
?!&/'IT'X#W@*B77PGD\&B)SUXKPR6\H\$^C> MIU3ZOP-#M9JHUNKLK\|7XHNC#IS+R@N0&:;H@6\Y7_T42CR\$;?
8H;.%Z25\ MFX\$ X\J6>2Z"%R9\O!"FW"7"VR:>I'P4+ID0A\$WL9D)(5&Z5+UL;#Y 0DD
M\X\$S1@M%YX5KF0**3\Q(V2HRH2T'Y,7YHFPK19,*YLWU6;ZMLO)I)F&,\$FFP M("9_ \$+|@ "1N0?_CNXIN'ZN*
|K\JZWV\U;|_O 8?4:25M)FAI+4Q\L86 M3<^TFLU=V7Z6?VP?%DNZ'FDM#VI&Z&:Q6H(Z0U;D\JS(S4**?/4)171XIVM
MFLS8JLET'721Z*#=J=I*M6(LZ\ DOJH8FFR1U*PIM&,%Y3Y\ SL2\,P8, M9)M)?
YA1SNIKYHM*B7#)P.S,8EN#31Q8#>Z9G0?KRDW) 2ZF_"IM MW%7#EU8#S!M6J%-
EHA57A%G5%5TV4M1;VPU&FXEG.>%&77\$RDO,V:0E,IRZA!\$MO3=\$_+\$2\C9+2I%:UDH_5-\$MDD
M>)|JHD@6*/4JQSZ742T_UUR>GVL,SU_-W;GACA0F6\$%R?+OY6.Z=+XNKO+BG MF5&49VG2\?
LB(E\N>H7/88Q+JHDY2"Q'TJ18%&>(8(?=GV623JNY UKUOHY@ M\(*IVQB-UE-Y/^PH("XO:=3:&H?O5;
(:3S0:*\$O/QF(P1EG24=)H(QB=J8R\<|(H8JX&V6WT>MMG-6TZI@IT M_-'I#"RN\J9ME^I^<^QZ#1I;Z?
8XMHJ;PME\GG/V^KA\$.T<6D3@ZQV")VG^L.MG\$.EVP|K#WCI: M\JO99:&^>F,0'EK252=PCJ=L=-
GKM\6;+9'YP(*O,IG) 3\@T&C:HR8?+- M\$9C#5\^C4G:'5<";ANF)YV*IU@>7LJJ.V8=J3F_B*^D PW Q=TN!PMKSS?/
M_LCV)W^+G%G<00WH@^O4.KLSTJ+I9L7N4YS5=-00;#<&I\JHD+^X\6 M*C=2882N\
I5)\$ZW\6SNZJ@C\0\L,U,YYNDTR6_=-K_WA\>D\BDO#T+^?HC\$|K,>ST&_U6%2/V+>G
M\RKYCH7_VZ3\CCCJ+4^_E9F+F7,60:P@H;.#C^I-FK7;WT%G&I3ISO)U/' MAHV_-G/DPD2)U/X=Y/L8\ M#5\|S9^+0!?
G8Z3\DPVI@TT@+B\H2F"0I74#X06\+7M8>6L*A\J=^&ZLK7 M?U_LD@I C(YZC5&KQMC8#Q#,&+IK8I-
BZU9DF;M>FGV\9>"6&(5F#AOJHG MSP0'BRIFHP_L\FY77N\$(7@J#&8U\J2?L9G>:@(9?&CS#_!42E\J6<3S0>+
M==9Y*|O-4I9PU>S\K\0>5S<>YGIW8_ZRH\ZF>*BQJFIQ)4\$7VR^@BOF@B^WF M"^AB^8#9IZ5&=|8((ED\6...#?!?
Q=B_IYO_"L2GT?0 M"6<\$FW V)DAL^RS/R<^"F>\$16+?HD#;VE_IYO9:7IM614#;LXWH*#DA#F,C
M\H\^!M8SAO#N;U60<^Q^T#;TNML8J_0AJ6D\I4#9^<XYGMW'CF#1+>M>IBJ?F0C("KPCXN\$&PK%?|K4K;-N
R=V;FPZKBN)OD^4L'DN&J6K\J266C M_-OY>|G\GRBY>P\J0\IMBQ\G#7YV;>|&M\@>7+T+LT2ZS1L.^:2#I<I-
*H48A\MW,>DU_98&JW6ZC MV:Q28K,O*9IK_%X'Z'5-RP99\$CQ*@\$.* 4GT""|VC\|75?Q*1%|RTL=T%YDY
MKUW+0_"^|6BI>XC^E\U&CN"V5AOYIEBPNS\6Y+*BD(UZEP>28LUA>=*) M\.(WO;^OF\Y;Y*&N;-NE-
WR\#V+";Z\FB?6YR@A(C;P4;G1\^OW+2NS3Y MJZCSPUA=VS\X0\;PRF(,=R#LUS M\1\$AF |7R\&4DBU
Y\$%GT,B\ME/\$#*(LEV\+;"I9&209LV0-T)"ZOIN98JBW\$?C@;=X;C=@SG@%O+YBNA0+U
MGUO@%OO\$QNI+UYIFG5J+C?11\OXL7=^CB#2;^=>"D4N=<4K>|2^RI2K6^I7\ M4;7W-
IO=UP\VZ>LOCB&X\^YJ*7P=\$4<,7;V\O\$CJJ88Z\8SKSN+|A;REI M_Z^JB%W^O^L2=|@LL_W@0\AW;28N@E^%
?)^YCIPTCT%,L\<8%=(+WGD M8\I\$1"%JZ,8,OCIE11G^0\OOWK?H<_>|A+Y=|S*#FH5(-C4,XT&E"PI
M@9VR55R;DT?R;UF(OB\(|#_Y\XZ;K;F2;+Z,42>44V0+3*+|\$C(XK;F8PTE,K5"4P0K,4..P"0A'
M,3+@P7R\KP66+9(\$248I0FLT;+KPP*VC4#-/F1X-WVS\|S\|S\ZMN7VQOS MZ\7YQ>4_SCV\OFB87RYN;ZP4X?
>#GJ.E^8Z">.I\$YK&^D>\$+F.P3TL;RQ M^0'YX&PG0BO:5XQ")Y_P4AIUC_"@P1E4JFI(|><>+C%-CH4DPGO)+\$3D(
MZTW,9X&6LV*O\3<^/_M/)=)JH\$P\$G16LOI,6.5LJHL%/L'K(+IAY#05".P_,MKVMD\ S#4O;_MA\$@|9@T&ST>MM#N"|\
/W60Q//J;#1'_9N\I0I69^D^JH8 M\NFNZ@L0V\6^AHBP68(%I^UO9\^NOB\TM=XEVNN&9B?_07=I%DX;|S8#&^
MZY;YZC1 GSMW8/I.+S>J_?>9K,QZ&T?<^B\|V*\$S94LW1WL7JOSJ5N\$M^))I MPX&X8D?6RCM0Z;ZH?"|JC
U7\Q<I;FH=3&<7+;#MJUO'D\I?QJA"UU*^D\H* M\J9:63*Q\^L^ Q8-'=4?O=/J6C/OE,QH_YP\X#\0L9OZ\$;E1)7;)|?>/\$
MO/YZ<7WYS\O_,IWIN6C>77HXNOYMG>27M3M2;_N\3ZVL+JRF8IU%_)BL M\KD?1N&Y-72\AO9>P\WDM8\QANI_I'
M>N6*D#)VL+70Z"#?|0AN\9;=Y@|>7KG#I.>B/6@W6NWM M895=#W,7^U=X=@?/%97#|L'Z3_"MVL."
(4\N&)AO:&YN//N YYYNIPQ+7""G4/7&Z\$3E7>|1R5#Z_-I%Z?I-1; MQ;7TLPO"9@-U15EO?0>@,1^L-
P2P\OA\$(0\OUUCUV.G /#\$OO_SCX\LOMU=?+ MBYM;8;-2)=%Z\WS&<I%39I>:'GF6,P\I'P#A)PW346>
)ADZ(\$%;P^8GC.>\$4 M_G\O^S;LXG\JP/W#&L,1P,^Q0OCWQ+D+^>UX'&L0RQ/ MA""U0LO=^_&GHE\$^X"1;^UD?
+OYSWT)YYC-/LG_-(9*7;S<+1 MJ-5H-I?A_FEGL&QS7^)\EW7?CH)M&?P@67G=)KTS Q_T.L=|A0;C+4Q/QS\H

MV=SR^/0CRX0#;BW\$4GHG\56% MF&9;.^L>SM2)Q"PT'/CV##8,S(O8!\$"O1^.,\TY@'E6.ML1/"_!AW-OP*<6
MKF_A1@TSE?K8;)%U5Q(EFS= * 7I_JOWGAIG200_<*4B> #VYSMAV5Q2DEPG_M_!?)ET*"T@IX%:.*/>P05?P-
!Y/O2;+JSX2=Q_U^AN'6'=>AEAG#;%NO0RO_M+C?(N:+A07A5!%YUBXT9RO+37.EM%@E&V0YHD0S!(OE!=?
9%ZL.HURS) 9.L M2-!\$;C%0%\$9D!V*#K\3+ENZ8@9H?HJZ<=X2=P>6>*VMMFJSS9QNV!O"1N
MC^GV0B1NCASQ6S3^@LI7*UXJ&JS:PB'W0;K,UC+A;M8/G;+G13T.D@FCY8U#HY=,JPJKXYB/KW?QI
M/MM>_Q103CM(=TVP?Q&E@'0'O3)B_6L=V!# MC)X?S?;X*BB.^OD^6DX)7^;C+&0!XY>NNS+4
M*EZ3M7O1Q8&2IZWN:3N=ASEPU<"E)Y.57^40)9EBPZ5A\&9\$56/^Q-R6P4!) MVY->_9S5!
("13Y834/XP2=/\$HK;_2=0.0-2>KL^<,&>_Z^*7W_1_<.Q;6+L M+=;_*>KU=RPBS=8@1HPO^G3B""F!
(N!_0<\$7^ZGW562_0SF>%!2=,WJF M,(G/V6KST8EPSA!SUM8KN%@-%"\$!#&XD4A-G4CMPKBCUR+ B*
UCWDC>N6E M?&.,EY.VH@Y44RG#+A6ZT70OYR:P_7=^\$NUYDX106D'S(K\$QWF@>.-G3G" M06#IBNLB+
2A@2LJA.8D!&?O5Q:Y^?TZTJ;L54J4E5MHU7"7D;K-YM8 MPKB076%.L.KVPAR9LKGUJ-Y?
07EYO+CO=>SVINK+57E1!7L8HW>55585Q_M-17^_<PVNZGQJUC>7ZGGGV5^B;K!BKP,JA@!JZ<+&PK!>^TS
_1_9I@VXZ M7&:LHG^>FZ&BJ00LITK<"E%OQAO?-FZD5"/-Z 6^WX&EGIX\$07"&I!>M)EJH^>
IF^HS^UGKWQB#A,2\$7=EMUF3BN_X-1H1=.0^.#=?;#/&I4!^UL5.H M12#ANO_S13!><M&K"#<(\$S?
%!. \$PL=@Q6F!8(W_M7!PVUM_1(?E99RZ23C6)EK^+J*L.V.-5Q@A M):>/(=CQU)DG8K"@V!O"C>NM@^+^0E"PL#5!
[XL%_R%?LRDX?&=TOZ\$1V7 MI'V#M0A@VO^Z^-;B#+2B=)Y6J!+@#+EVAL:Q5BA1R.C&HXUP3@% *T*N;AZ
M0^X?U>4VNZ>Y@!G_TSIQ(A"R*<3DKU)M77FWR6H*F4!#!-3JG;ZSBI(>J)Q MK5(T?4E
!AA8;_UUIZFJS9/N#M79JQIUQCV")I#KGV8,%U;C M9+0)T0;>\$ M)K;.^9WIDYR^!(-.Q-)U>H*;PKUXV8T%!;.
NT7QV/C#+S,H8SWZ_Y_=?D5E&^=GT;M_-16=ZZO) MMU!%J#0R;#+L>=&^!?
G6DTPZ+Y>_O;W6_/J\$PB5"/SQ1GVEZ%*ZHSZ^JN4_M_+3-4#P_VD*QIVLIX?;PBE#R*^<F\$M84R15-1AG+
(0"X9(-11)UK?_7WK;RML*D%J!+^DZ=TI-A>)2_K&CB0F5LT MVUYZ7&G_4DL^KX>5_+!_@6A"JQ-K&=BPF^8!-
G0!T,0X/9C%D!KE1!;#T MY%K_/Q:BR7W%TW8_L<\$BP8%#B7,GHJX NN4=(FC2WIOI,AT=LLK0MU!)@_M-
+,%W\$41M4NK;H*6E"HN!PUV_*^I M/8_B#8/BE%QF+,\$2+>XE?!)AGK%&!S)*NW";&K;;Z%A3;Y@7FH(T75+Z#
M7JCA1*RICE^1=^QZR6C2)E@VZ#CP2!)J"7&)GH#P36AS=\$G;,>=AE,Y=\$S_M3_"(9=.;\$ _J+VL2_P"VDI4,=YD)29N=FK
?PT[1D]H!PZZ#>\$R!064\14Y;!PQ:4%46?8J3B!5T02YSE07NM MR6&S'F/^"JP?&->0@VRGI4,EPE>S8#-1=&#|BN!
S) MP<_) \$UAU6)H^WAF+7%KX+MV\$CJ8\$ MCJ\$IXXKP3TT8-F4,GL!/&"!08*=[RQ&19!9N)R'7_6VKE!OQ(OB3Y-5_-8+
ML_WL(13!#%#H=YK"2J9!,-8>R9W+P3+>UA;"9)H^<3<#8JO>@;H<@S0*6%7
MV5=KO+A,L95=7XFMOE!+8+&XYA3&D=>LFY ARJ!6D-D MH:SD=2L/M+!@!&C-UM"F2.UT6K!@!@!@D?
TA>+J>NSIMCK85@U_!HCVL&39U@!D)2DE M;+;."3^)Q\$CS=IC|=I_R/7D005>
_U(UP5.W*JX(MS_OIC8)NBOPWU!V9I2!T MRHJ\$Q*!LW*L^G4N+&?@12&L@QNU'!H=;BP*+RCMA_/P>GA?;*EZ
MGL5@NX;I!IO@^#00=5JL_*4X!_Z+5J%96EJ>(J_X-'OV4GO!>IEDD2*IN8I2/7>ZK<3M8^!YT6_F4% M=_?D'/XE-
!HL-28NSIW:U@Pl;=@Y,"S@G8";X.V8J8+2PKBC,G=E(!>LZ! MR7Q'OB0,8Y5W*G\$=U+!(T55^0
NQZ_-6ZV@&NBQQJ7_!DI846=FJOG!M3; MKC3(U+Z* 8H38F(2SDY!E-P17!L2RDJ)Y=Z9&%O<;J+;G>#>>M!+D*)+K!
MIV;!)0&6K"PIB6M9),D:(QYIT'9N"@CHK)M7+VCVI_B2+!SPUX3I# HUDZ! M4YIVH/L*Y,ZIM5SSV%I.U%L;.:6V^A!?
BNINOQJ7>D4/TTL M<.,6@8N+=X+L_/B4;OMW!W!G_O7_9L+?M%P2!>_&?H!2IN0/KUOC95IC3=BZHYD MG
M.SMS%!1%G*6_U!KA0D'S\$7,A&SXO\$!8E0SE'N KSF3..DNUS2KRFC4/P5+
M7.OID#*E#5)VA^D)=^XH@'7!#^:YP:\$(3PI9GW_WX8\$F1!/=!/NI#Q#XU^89_M3_-'!+?<
M)DLZQ&U9=FJX1@M88Z)"ZHMZ/BN!Q% C'2D.GP/+H5/IV.?BB7+!+^<(CN#6H)?+*H#"LO=!LDR7+7L#_!M&40
RV@((:Z9#^@Z90&=L@5TVZMLW)P>^)JEODC3%4&^+J&BQEB6%*C\$=C.6@RY" &2296/ MN.\$+?N"#^8G\$D?
WIT>.+F3!PT2OVQ.19D*ZS?UWRY_HA_J3@UDA_P<MW^ (9.\$GMDFYZ%SS2+GA<?KC9/S1DM6ZW6Y7A?
08#RKI<6\$=(4EK4+Y>_F.M58)XW.V9N(F8)>UZ:[M9XJ:PS70;VU;)HJJK!_BYOZ!%I/D*=6!8JDI96
MC>J#O^KJ6S+!;EB=//3"?>LK8,FI\$#1V132=!,PCWG*TYW42YV MY4XK;XD6'9"2R8U-UNX%NMT;I8N=<)P"
<.R.YD)HJQW'K1'<=!MJ);!#< MK%SMPT7H.H-THI3ET'!C4%HQ=0,/S!^*L*!1((PBT<1C?+3_\$COT-GQB@" MH#CU//!
(BD_DBN+*_.@WH-<&.A@@(TPJ/C;9;Y;Z!KK-JF+/(OP:6VB-
MZNGX.;.=0(YYP@3U;C"/J/9!N7NG4.V1\$!LJH@=PWIX/YPK!>"?G,LN5N_17B_MGC4*WI/O,^K:D\$ZEP=?;Z!&?@X'T>7
SN!KF6N!TP&*!^<#UT<{3}JBDV03_MWA>!<RZZ8^L=E0'44/+H!,F6"M'+54J\$0";X8H!ECKPSBEO!H8M6@^X17
M73W&Z66;+V1E5;_59>8.*@V;+&\$OW"QR5C:N)0_OLHUM?NZ,2/-H*.&OS! M;S"Q
!_\$,FR3!4S@'!+;1XN5\$>,>J(C:NA>H">755\$!*.AH/6Z"LL+J#EIM MBAS/BI(77L!Q!6\$Z+.T!="#9:
!<(H)L!19I2_NSZGQUD'N O#_.B%1#W:N_M_=3GJHFK);+!48SP(\$ ED.V M/.DR%J%D+T=@)T!@!6&B?
G/57N*N'^<=ZGYQ!C5F+;G;?;LC?^CM)^>J M#^AMP5Y>/I?9

7Y2)Y8'YFTW2!^C@4EFU#Y_FK=-2ZR(^"2H=ZJ0+B_D1Z^GO#IY4JW MG>46DOBJ.8XV>5HY9(F=E?
N&P40!B#+6YYKW10=90&4"\$RNU652_WIRU6(\$R MG>JVIN+XO5AI501CLI#3>33-
!J&!62XOF!GDV#54443,S%37%1#G,HXG#_M/?WE%9/I8W=_@1!
I2/I37*YJ@/(02%B9YU_ZBG40)KZY5_P^&Y;UJM0&PWM0 M9""X)94?;_2+&ARX+RYGB,9AYV^/ SGL\$

?ISVQMO<4!G.Q4Z6!G!S^#&!%XX_\$HK7-R MWFG*!5XX?G\LE,A;2J1&4A>,A!97Y66OB,@C?K7//20LKV@=RRM\$Y16-
M8WG%_2*YP91BSS011&U)W40N7C7%>N=P3"D'O_T_1XCORW15!K>7(R^#E@_M.,?+_TW,UC"1@SJ#@!^OZ6O-
!>X272T\$T<^KDN'39DD/H(XO1#_6K!V! M#A1H+RO_Q.YL.<+W;I%0&RQQ@76F=U<_L7MTJ(!L\$BRY;_R'4T-
_1_QU@XL M7G!FW4_.AO9";_N"IVKV?F"88!\$G.?7RSS4?H=_I4_T94!3?DIX73X_MZA6&(*71X05?
R50_G6!G3^!K^&=2!*3L*)J7/FLX_PIEUWW+QFR8,JNY/^
M2>:TC39M2+BF7+?)!;V#&8G3:=SL1^46@W!F)H=IW7'Z6!GXS_#.#"V Q. (-T<1,*5=3TR8/BBL@6UK0X7>>
<#I&.66K'9_M5WIZ'Q38D#H11'+*3'M#%&N7J5SM4K!>;VDDC8;OY%%+4IQCPFI@H!E MJ_7@HRBMF-
=0ZM86=^4>WGFL)4;WDJ&C(P! (XY7!VY);C#?JL SY!=D0? MV_DGQ;_91S9A3J;F;KZ;7N^N_=15S@;)SRR_#WWK,Y-
LS4(P2PZR1+!R* MM8JR9V"^W72^3\$U7,FB:3FQ;ZIAWF=D6RX2L;FPC(BIS\$9<)DSU8EMO.;7)
M!OI:YA;_!IA,K"BZS07>U_7N^E@9L;H;ITHQ7+;ILY!AG;5=VI(-F2U_M7G?ZKE9NEN@N#N7N8ATSHSYP^UC_K_H?
IAYS!_S!9%T^HFL M_%7Z<.%>WTL;BY^4<4#
!JV_^^OZ,3,>8N%4>)D7.^MH/^GL_K0"DRQ=5SEDL1Y;N1(I#&#+FV'.?MN8A4^_K;4_M;[?DIF*);4>HH_?R.S4'?
#X*IT.*^C^S*V^A7FE.RDRN>/FLV5*YDJ1H(@V MLU%84A9U=6DND!U?&9*.*41!Q@=-!-
O,VF2N!M;ISRED^YG!26Q>QDMBM; M+!B\$Z;+Q4L"8RDK<."1_%U,U/W_S9'84Y90K(P+UUN;YC@#662!1LBY<!D
MVS=\$HQ)EE^4" \$C\$)HW5AL0IZ7)*5BMTE>+L;P*");/F:6?/OPUJ""3B) M!BX^_J42&
E>9946)=WWA!)6L159;.&D)ZPE2860/+O'G9PS&-">V" EGU!+ M;*RAIL+&+"2,(K!&3@!N8L"XJ(IXU_/.+6SG\$?
C;P9=?& CZYO36!X!; MV&_6P3&P8!AP/WED/! (^U* G"EF@!46I<\$H"K:0%N_9W) ^F*Y@
MK^BRIFX,\$L97L5?FY1T<;UD7FENQA4!^#4!=[BR6;CY+QU%IT+539_*U" T
MY0WAYLEY_2RZ1639(%R@+L;PIBMMWQ,T4X@XGO_LHLS7S\$0GOI63-XB,X; MIU(OL93\$U&;G'HINCOJ
_87#I_N&#HNU"(B!DVf-WUL_!-4_F9IV_LP!(MTI38"BJ"@KN!% #I+!NJ##(^L)6U+I@'!/'!+B=%FUJY1IFRZ'D'S&
!-VT6H ML(WW&^!H#B"HI:C<_OZ(Y+?_@V4\$AW;)N>W1!@\$@?7H@TV00NOZL&N^F
MZ!4F'2P4U4JNZ."3+HGD*H(TNANY^4#Z=X;R'4&*78XRD2E,6HK"DYI.%Q#

M6U\$3*!%K3^=ZZ;N+&WNN8&9HOH=.:O"M M3=QT\$IW-JJ1;7T3EP-U' #(<=5#RVF7HA5IDV;4P."TI." 27@WD)LUNEQ MRQ9>=.:0'M!26D)L%GCS#&4^VQ+KL4MG76J&--'MR6J.DX G""4V;1TK4;IM M!12)XS7VI3-FY3IO&3-W\$;N=2U7;8IZ0=U\|TX|/-@Q)N9K!|!@8\$*G7Y;I@ MIOA'VGR4#3J%-QFO@#&'-LH%BUY(%6>U(2LJPAH#Q+8FL>H#H**%K6-D>%>V MI\$V1Z7"CD4Q"3\$;E)1MPCI%;WV J|F#FHH V|GK6'/CNC F0-N.C31XOG0NG MX#H+^H.X15L\$S;H#8W=S>CJ6.^1GKPV(VW)>H\$!|JA;BRY+T3.ZYB0JZV M6-@6H F6!!B:N#;R6!2IITC211KYC 4@)^|I^|PRK(O??N+1^HXZ49MRHU6 MV!6-E6J;HM;PH)-@Z**ARO66*&E6;/_%KB+)|#P:-|DFUM;(-.2 M'_MR37F?7WG >&|E|YPCD.OX>DO!%U<;L2;1;2P=%G4Z?9EO3N? MTCR3\$"%3, 'A5S)7T?S=@ZPE&FC3|I)|(<37V1-HV&M6+KMY1A;SV#,ZW*D_MV.+|VRN@K|E*|LVAKV|3RZD6L%Y,8C-|FFLJ|3^#O|&TC0X|LS8B4)NBU|O8 MM7'1@2\$742-0#C4/6OAV.G@<|YFG68LX1HK,%;:OV6J8Q3|NB-N: MNGU?@3%E'*P0L?L4';(S(&MB'EB&Q8;f|(-HM@L2%!D1H);B88S:61*OZW M/E;Z*:5+F.F|TNSIRAH|H-XA"?&I./-!|O# (#1-3UC7%A;PWNN9|W+ M|>U|H&|^=U|>0)=(QOHW-MB?_6>G/<"R3->C.6B1|\$I1,OL!OG;H:9*MX+BP;:="H+M; <1&4|8FSK+1YA8BV&)N:N!;3 0%%<6^PDNF-U&8 0\$0!0S M;2TKDXM+Z?2DX8MPF>HRT" <7.A(89IF0.3M62*F|T M=VKAQ<(2!0P+UQO\$;.\$C-@\$/C?J(+D&%UM8SA)I%V;T2? M&V3"PD"ZU+0E12D*WOJ4A4? K-D<|0(I5? V(RFD\$W0 ERR,|*?L*=@81G\$< M|/|L@!*=M;I-X =W/_CA<*1GGW*/@)|@P_X DL 9DS58 /E?K!RC*8E M)WI6Q<1&1=FHJ?@T'D=?KMR@%F*KYBY@;:"N0#%L,2=(0 ^O7/XQV13|C;B9 M_J'T);^64 3T(X<0.^\$@-!TAK\$|E|#7?@^H|PL67R@IB|9?;^I.M#5P|C M);:7('UC6,|@=!,#@T"VU+G;-),S7BEX#/I,99/UE3VG<)|P^9JY">9 "W6 MP'0R'2((40D8@U_K@\$/V%&QD#5&*/5;JR4-.M/ \$)H).<)<"E4"JGCS) M@3U+<(PIM\$;W34A)2(6*90^>B6?P0U93+P|3HU@S\$?E FVT"- C>=8YL;49N;UK-30%5=H1LGL\$M| *1ME779PES6 M?C(B\$U1)O&YA0R=25 M;UEP)JZ-3V3+G6#*K!| |1A6K^UU=7Z|X;5G,U93H|JQ"O"60|YT'1 TTK MV"|"I>"FPL=R;EK=C?8.*G3|&-2E,,A?K)WE|T UNB>OTIV0).& TXHK,;:%5@Q)+8E2CTS|;\$. 6W9O, MRR&YMRZL^=PROVL,=3Z2M:*KHTC2>1ZJROWNAFGDGRL!(*R|D_#(8Z)^=* M0U9Z;;G5R-J|PJH_YUT-LL2J3B'^^5<0# M(U2N3W7'^<"S2G9G\$T25F^Q2F% ((S0.E#^AK<@8.T8X)"8FV=W+>Z/7D3B_Y MC)"M0V=" J9RF"QX2\$AR3&Y%8* <.BD&1NXVVW%;4W'#XZ715YQF*8X3.Y@S M|J=9E=N-Y(%XEBOOU6TB;V\$K)IC,,7|&6P3Q*2B8JF>A- |4XW56%MB4KV M|@W%-3E9'5J"AO?T#=# J&VW&T"|"HMLH'U<|).=B- MX%O+2BO:OSZDULL4X- LAWS<B_A)R3Q;#"OIQPMJ|<_1|0|?'S>-HZ|0P M:QUAEAAF|4.-|>?J-EE2?&HC?_6&D_#'^G;V"JPF|Q>>W<XE,Q2- |B|91LR*T6T|D|H;+U+?2|?#E;COT|I-V7#@("\$DO+N^>A|KTRW| <\$8_!&".#YH 7!FYA MS1L7)/R8:1'9/(J2K"!L'85)5A"V|Q(G6_M^AJJM6"7G/HM)@U57Z8|*RKI MEM;D;T^3&/OGI2|?L9H3\$U9 YJWL%+5S<5_HKU/MX%3;?=:I=J135I/Z971| M.;@;|01;?#W;V|I|H&H;H_- P;;Q(*5MWGLBTMNZG9F@OZ|8=VBML0|HZ MAH;|2H#;^PM;-W@7CA;M|F?1RTU?+)LFEKENUA&=W9W4 M4-;4&QG"\$VK"6HL"VH>PK;W"AV71T"<&V'XGZ0#;3GNM6LTAH#>V'2;DDA1#+BG_-M>HDD4T_+=9F0|@LC. (ZNQ\$36)-4VG0M 94UE4-1&7AK+9?&B|J;SM4OTUMI. M9IR/ H?>@P|ZIKOK&84A;^MP"+|%JSE-AL8RU1\$JE12X-)3DV<Z>DIP)L M|F2T+=CK;4>;<+E|HWS" LXW^UF+^M'Y&V|LDOL+^N"|&Y90-5M3|!%|6\$#6 MZA*IR|VW@*4P^MV|&G-T^Y.D|H|_|1|<12|4#|88H-"*G\$ M^40|4.WR|W5J#;NO MX-|C9U^Q.N?22AH+- /MU(ZO=5;:25NPA|L TK5H=R.'&_5#MYGY>908G_B;MW=(>ZD|1'0H_2U0&U MMTVDO.\$%= &/@5!;N""VK;&VF-IS, <@-O;% M1C1LKJ_3A#_RD|@3W2&U|/23(89|86B.YH9|L. MDA"(8/\$WS@3<(M->70%YX,('WVPJ7@T+ +RXC2|J>7NX99O@1|>.VE|NTO3 MJ6|CO#V09KKAH&;!\$O9\$?;&!>9Q*87&%<9DL20HH|SPJESS|;R;C,_[GS! M)N- PXOOD-@UX(&-NYG/ZU@D'T5YS0)DZ_YU_M6702^Z4X"8\$K-X\$Z(A_C@M!4;#3=D>2%D)=HRP M1- H5R#07'UYWZ96S|JVKO|27RS|X6BMM"7FD\$Y_)&8Q;_91NXT#"3AA>40 MYPU;?D%"<)F? CEKAP@FO=VJZ;P\$>^@N>#O>*5?JNH&_7 P&Q>P*=S6|U% M1RG&|.Q3M+6WBC:@%Z29B>8|;B? K|C%_UH&^&%=FVM@-AF.OQ;NL1U/63MG M?""%MRH|8<|8B(C%:|77?PRDZC|01E2Y6+J%#XUSO8<>Q!>5,=ZL+(- MP|OZ_VJ|^&=68PLH|QH|38H|U9=OX%*#@ (ZG;LG,|"@YDWOG0-LNX6@G(MGA_UJH'4LM#7GJ0P+JTTNP&;P+S>3|.5#;PZ=8@92@KC" 3*-<.WS->Z) 8| MB%SPF|<3|C;CS#6O1_PFS6^BB\$|C XX#)K5?Z=@&EFN+=;\$;CSM4-MD M1@<#8D|+M&5|?#?1Y-"X-UX5L\$)-4<'F0;FE4|+ #POUQU'MXQVP+L*#;:\$ MHBS;#D|9)72S7.@4)2DQ'3;>&F'S2.GA^OZ)|=L'%T?C*8INU08XD2!%7|H MT*FHT^;.6)U#RZ 78Z.>VO5J8/WWY +W2TF_(N+N_4XA49<(W-D.?&M6A M 58-BIUR;K;%|TN-Q7'-21;|B7P^C@EK;:9;SF FPM_6)#KG=RWT'K&'6(M\$2AC;=0+|HA3BKP=|3...|@|.7.*|) _H#JY\$ 'O-13X TX4W6REN @L+ M;RJ-(L*A>+5- 5FWGU9TSN86M\$;\$8!DOOLE7V|K'O'97@;5"KW|;W;|G7!+ MTR+"L\$|L)XC_90C#*CAINKDKYA<9A77U|+ 0*QSRBS|7=D6?L;U&GYOOH|L'19|6^*~ HL'2+Z.G M7|_GR5A|D |Y;R<5H8,N"(<|;5SOQMRN|Z5-M>X*|!"D= |/:A'6R5)| T;U4LSO8.S!8F(M-B(<L;SY0T&<'=C|5IL'<+"S MX365@ZVVTCG8"9*<@G@MG=&|TNK9EKHW! |NU_SPG%;PZ53UK"|((\$8W08G|H4 M%;XJ;R7(<(+?UI(BH),2 3FYV&HW\$AE5|'|+;><=/AFJU2VW".SM\$H&)_>Y> MJ? WN1HUF3/>.?O=|_.|BLKX;RM'OKH0|QF)LS5PA3'FXOOGVW>YVR>ZU&RJ. MKJC+7;4M@TS_R>|N9|@DS)X|A88YW8|L5;&Z.=O;D MY>YX-W94+!|?E>&?&\$;RK'& |O^%.QX9|+K'|@PO6MW<5)KA25Y%^-U|). 'IVYT M;.9Y)IA&&M_O=E6EVN;J|JN=UL|K-O=Z\$7BHF|N=VDLNL- |V.U&J65=|NY# MUB5UL-O-O-XZ. MM3;:Z89.+0|=A\$TN5|R?D&X^\$|">|=|WU?B|7*O*|A@^G%Z>HOM>LMOO)|;8 M=V1E-PNC&66H/N4P..HE 4;+ U@%NXHN*X0B%4@K5 Y1(B+1+|A&LR5<4 MN1&S|J;2H=3(D>WF.Z,C^H M;= 9M;\$2S/>E&-\$5> MXC@KFN<2;_6%6DGL|W7)|BS MM28DK04E+S4U|TZ<+GO_HLLW>|HT|I^5A&M=W'W6JWH?- *B\$B9T;T1-T.91X/?|N%H+;BRL>VF8Z>#|1Z.VDE3@_MUP49XOPMZF4**/5;&N#Y7&<*#N%S-O(1LWG8!WW;? 8T;E|QEC'/@3)6'-!RF0N%.< M|P*P>YV2.>W/%G@C|."^9W;P /OF-O" MLNG;0 ?3O|^OX_@/A.X"|"&1;J^ _@PO\$&WA2\$Z^N9-G)*Z|BI%|&+;^6K MP0O9;MZSE/2*8=|5O+W/MEQ"HW ^U2PA.90C421=1H|VQF80-\$WK'A@FB MA@F=8|.Y;2 _JWX)L;9E2+Q|0FU?31_VR#13(X6471#4'+H@Q&|Z^D)?O| M'JPG|K9Y)6R&@N>6(* U5)M>?|NDH;WA^/N+|S1|>HJ3'A6YK;_OKEJN|J|!|=|IGTS6=^JT"; M3*P5OAIU?0"N.HU+;1L?\$0X18!!A@B>EBW@-? %S|H).AR?97|H(765UFFS M'C|2/(0 P6BL=18=FD%^<G/Z;.&"B*4I>9VO|HFAS?3|#: E)BMCQ%3FV) M3=S='8N(6POV#>K7G7%CPBG0=EI;H'B?O M5M25QDL15QH^GZ;6;J?AOND M30L;K\$K A9G&DVGU3PY5WMU66TIQ76C^C+|R_B7W-T4HPWV|FY|I(O\$C/ M|;@<OWNAG\$C,T'K9/S9E>1VZTM(B-|T# |Y86/UY8T-El;\$7^-O|?B=I; MQ@_|N4?F=\$=B.HFC.V6<^ (L&#\$\$\$XG@L"TE#7|ZZ5(ZD|R^00\$4\$DGO|2 M;75VSC# (2O)J^4F^>W*N|&2|D>E;|Q|)9IP"S_UK/DBTY7AORWQW3;@ MK9>HTZ%PT"FE5ZO%?%T1= |^3|RC(ZX5UT|4TB6;FTA0LZENB9|*B?"HD9'85-MXUW5|>NYH +|%.H|NR_5+0JNH? ^&=H)%YI0@R#&#>FO(%_PMMXOZ=^%0) MSCH!1&@+AWR2W/ Z*VB'Z? ()WU+_RTFLX>);1HMOB>\$%1Q^CCD^9*L+7&=/U M\$|O9(G1WQ/A;&?8-\$;#J;.)'4 6+"G;ISK@%- RQ<N"MU;PQ?P9_@W!_N5< MXBJ9_>\$J9HEJYO<#B\$ GGX%A;"|A7| VK*_Z;U&M;P1V|_1NP+ASFT;96 MYA39U|_2?;CPP>UW@;N"KK=-;4-Z5-R7H+|)(9*H|AZ@+8.P%Q^4K^< MP)OO4_WGZ9.^15GY26+>SH##7V*|?2G-"2E-I7'I 6+|VLOW1+M|;>>QZU MH_@\$Y;7;2WFW_94&BG"KWDR5^&W5X_",*>4 M 6|I'-0=N- SJHK85.F^FI+A.Q8IOA5N|OD70)MY;:;HR(;'C"\$00@+M30PBT MPBY89P*\$@'|J\$T<_!JUO_0R'2 +^|HBI49GYCOQBNDWA.8X;%-HB(2;F MQ*A|H|J?T|C|X-QZYUA%Q*R+6+@-RAM%;"!4AL1-1M+"_LOEV>0XAH MI65|H|?Y1DR^S.AHNRF?HQ;R2WV?B.;>O5|ZRV9;Q*9XRR9=@.(0TJ5>7NF2 M;Z E^K=CJQVQ#?29;*>V,B(?S-=H5

"FP@3IB11%NS\$EBW;(K\YRY8W\$0VH MJ !*G.Z&OO+V=+?T7BOI*\$-? K\SA TZOP.Z;-=>/U410- VMH ^7N!X"
M'K 1^ZOW/^R:(^F @^ 8^BH.:5XK4#9392\N"PLZ_81H5 MN\F5:."R\YM108YFFN@./"1-K=6#03(&=|:*(ZZ+?
\$18YIH0F=W)FT,*/8/ M\KT1(BB\GY\$^CM=DE\HC\JDBMG\>M40 V9Y7A4Y;DOM?(HSP-/S\$W"";\$2
M6Y\WCO+IKDMH#112ZN5DO\$->NM@\$ MH/>|Q\SF\$ER\$KP6/05U_GDX\JP.J=D?FFF\8=B?V/T\$-(UO M/\$F75Z0B?
4XS\TGVSXIK9RGUJ&K>.:5&6Q,3M^>)HSPG.G<+>*02PB3KPMW\M M3XPJ=N5NS
!^;@FOATE<#F(D7CK#^AL<8H\4V6?;L0@+FV\ E; <3\3%/93 MQ/KIP&P.)L\>230RB\@K\H@%|TU@PU4.1M%9/(*
(%Q\$\$/JC"9+BP\09/E0 M;(&S#8Y\$W1JB05L\<=(.6^TY\$ZC)ZN=?""\$#P#DTo5\|;L@FXWVB7_ \2Q
M>+^=|^/W3\Z;9^T\>#^I2\17.H1&T9=-/G2J(\Z. ^?EU\^9&E*OP?YT.6S M84LD\2\EC\AO*A\A;(<-
@9@E8/X439_VSOS=^NXIEN7G_EZIN;^K;)U; M=2CN\PKF.V;D_JZ*W\MLW40F.9S>.:0W5\WK S^H;%\I9\$CIA4.WW
^N\VM MXR()A54_(4#=#ED\ZT4_|.153J_#T>ZV\7G>\H3Z\>|Z+FWB>8 V.@UC^@6
M1ZFC6H//MQ=Z52ZO0OTQ\ N_I3&|Z.+W\WP\AML\SW"05\3\@|64>@KW6\O M1LTTO*";&(IVMI< MHMVV\8/6<-
*B\^>K\I2:2BYSSV@US0\;.:L:268R\9M\|;U;MKN<=X3^>LZ MKV74KGE(79P6%9\TF6G.?(?&O;H-\$GF78-
PP_L2;NC9=3UUS0E/7O\;E;X.#; M2+%S^7N<3%=<7B33\<W;H^X<);J0*|N>\$"5X>|/(\%34DL.C+G>#|C#5Z
MH5D@_2Z&6*.'?""NL\V)\0+>>P\@2XV I25=DON=@73BG_8WKK_N+4@)C+C M#|*?&FE R\$LZZL/?
MSS.2.W<3DT\2+F\OK"6B\$:6 M=(C2\+2=WIK\XX2W@&4\>&H\1CGNLC\|A<^88ZL+;NPO)T%|8
MW&10\BN#;C_&P;GFP?";LICKS6^U;L9P^OWFMPQ"R=6(8FDF4.KS@H(=X M8&T(T3YDS3="S-
F4Z^LP7*S8=V#=#)T8U *LX\KX^?UO@OJ67@T\$0_ZVGDL<>>!(< ML&OC*!:=9\JX"Z\H\R\Z\$^9T MKIQ_O'@.:9)&+6S%N
N.U@O?%)>^ M.7UF^L>ZC%>@:K^R%L7(XTM\<*KZ& *^ M?
W\$=2\26.EW3\5Q(4B;H^MKFCC\$DDY*J0%ZP.C\>+3&.#9<^'W72\P5CU\B_!RD9APJ\%/7B>+RYOP0.&F"
6#E\JW9S\$%5_YFLYFBDP@=@ M\|J\$#EH%Z;C.#)5G.;&D%5UTM=K\$5?2"B&2=24+.*+=?72:HDV^2G)NZP6O/
M22H)\N\X^PZ*|?VYZMOCGWFFY,B^VYCH=5(37\|C.Q\$=P)4%"17@UBM+8JU>C MUL&KN1A\ 3\ S\XN1\+ 9M+^/OF?
GCSZ^#F8C@82\FZ_ EKP@|T<|2^6XBE M^ALB88<\LG(\DAW8H^*Q\$|F6^EZ"9Q'#D4W7X(#&TS0_-|NA@.H 91\+
MAT\UC=\$;|:#%?&%8M)@+?L1=J"=|P=PH37\&HVZ)DRWX^#80\H|=G3;&HEHP M\HL^D,;=-SSB^PU=>|+
IKB9^T8G%Z.L0T_/T;."#1 M\<5:472H\$5#|>|*^>4#HV9OT)G+@?B;:T>GVKWNE;^&R=Y G L:8\A53"1
M08A\74_NO+|DZ7HY/9\|B2N\>2XGAQ.)0WJX(O(H8! MGZVOIF.2>|;OFQGXJDL7AK6:2O=D\F1:A07X"@<|HR<+O.
<>(\$V6\F0.;IMN M^&PX*%5?P\;\$%EXT_P79Q\&L^K#B&L*|>|PG@4-E*5CL;L(OK,3-02\$ _\$ MF+|L;
(H=#NJUZ6<.;OJH;NDMA\$C41AA\I09N M?3\$IQ=#DETTD.(Q.>)THB#K\I;8\J@VIE3H0HLY=RRQ;Y I#5)\$7\HULD\J
M."CC I"%?T W;A213&D=-HO@Q(O*@\$.:?0F*;RHC#B9;DZ?;5E0;)UY Y\$>AF-JOQ 2@&=#)70\JCY2R6\JY9)1HRY@
M(\5OL07/O*;9;^X@0(TEFF(@AG+H)3\AF4&=K00Z\|/_=@R\$9=>.:0. Z3?B M88@APNNA%MLR\I&-
DL;A\1C"V=I6\$;|N.\$4S\Z=;.:6W@>|Y_(8XRB X; M?T"7@RT9\H)C)5CU4HRVSIW^
MNG4UFOZD&|7P&G2TE_CY+PIMW;1^TVJE2HIZ+ 6C;X;2;UYT6%S_QVRX_7N M4V28%9LSVEH>
(>Y"VN=,P\|7.#S2VKNI\;E9F_-8R3.S&T^TZ&5*7\+6XMUZ M\RK;=?>)>^#V*UW<;O\KUN7N\B@4V@<|;">
<4_IG:~S&K\|/ #?_Q_.C\+ MNM;G.OKT="|3>|X#AA.|+|JYF><3\|Z\9G.XF@N+8_<1=AI\$Y%RAGKDO\$BY
M^R% T\$Z6E\$|C5\^L9BJ8?0ZA;X;X*\$VM11XCH&N^H^Y=2CP^7V+GJB@7 M^#6VB74DB(.6W73F=9-?
\$8=C9\$|K4SB55DRY&M\HJQORN(\Z|=19B(15Y M%&K\$ _I^GO^Y2&%H\$S>4YQ
B8=05%OC(>^TV.C^NIC9\9^"?;Z300_%>R M+|3/EJ8;H?D6D6G800PEVH.?\$|A\$;HFN*)AC+H&;V3V\$LSO\$.6\X';7
J%NH&|B+S4@9<8\FV1F\U>V1CDA-A3G9*|+2V6P_(G96MR;)+N\Q\$@LX @|X M>@YYP>-'A\|VG*+01\|2B
=H1KAJ>YDE^3FAOR>+.3IF(U(1B\^|5HM<+1 M6ID5\OF%@Z\CA\|6>|LAO\|(>%O\6\5B\$NDMRTAPKFQK?FN39\U;.:
|X=9PX M=53.&R3\TL5?^Z.)>^@ZZ^P^R\XN_9&?A +1D.ZBF0@.1X M0Y8NX_-IN\L%8+>|0-
D>&7\PK\QFT57>2%1OECV#PHU^KM&AG\DL?&)92\L MFU/KPG+(5HM> 95_ ;K^P=9EZ0LOG@GV+P#+ '30:46-
DGN?2X%C7<\$<=<S.M49A:T6\^5ZRFT&SSQ\;M+5D9)R@Q1)7Z"@R\ M\!;YDFJ7^K;I6(-A6*
W;*U;SW2\$;SS9^4.FU\VX+KN507_8OOTS@HR?& MA\$R +&AR&)R IE&MG3??P.PZ#.&?
&|7(9)FRUY\^C_SREE;840Q@>N\Y@M\$|F\$%IN\RZ\$-3^4\8XBD=-Z^A5DA\$EC7_GX% M^%R;
%N#)+"QC^VIGTYU@|6IX(4<#*74"S:9&0@/V\>M M5^57"N:418.L1RV M&%Z@_ |*H*)_|JTIO#^|IS@O9H;^S\> CD?
1ET+^ ^R+|>C?Z=BL;R\;.:8W M)DT.+X?|N^ ^V=-DBK*^| ^0:1\TX+|N+ 0\$J)(K\%- "1@-0Y.I2\!8HQDX MBI L;ON-
3_-5D_-JG _"U_Z+R4\JTS\54H&U5;WR_|B\F0;4BS\FN\5?C MP:5T;SIWUP_|> D*O1W=?^ 7\T4QM=2?
=?|MM M_PYS62\&7V_|W_FGINZ MF4\ZL-JO>T&^B^K;2UHG\|P\|E;X\NUYVGM2&16_9;L&QTL.XJO_4J3
M.7G>4XH^V@7S5&NTX=5TN#'^*5GEOVHF2P7AR?^HLWC3\5'6S"60R\53V^Z MHE;0X_55Z MM^D\20V#3
#EINCE=FN\$&JL4Q:XV"!KVH^KM&X^|HCWT?C) K+|&24^1 ME=W%>=1H/EUJ\SD*|J\$79%XA.M\O+&.
(U3H=6)\$*+9UX(2+O:@Y^OD\#0;D\$7&R^R\$S&A.*U M143^1\$=8K;|MN;ZZ2YPI_75&?
YK0R#S)E@\$C@Z^L^Y.+|>W\6S2G=&J< MVVY"6&NU;BFM@?H\$0^A/K1/2*^65-|<9FFF^Z\TEV4"#%VO?LBN
|G\|* M-|>&/%24@8%DR;@29F(\D<;@B;R5%8+MC;0H?TG5_SPM\|G+K_>|>655;L=@|;|:(3?=\$ M\|V9=
52V1/& _\$MP0*|OW3++SB\;W^AS5-W)YK)VXEL5+FI./98\ _L&_ L1 M(SW>+=OV\6J\|3ZP4\DM&>%UVA)! Y 5L3@?
^15N%)#|@*R\772_UFW@V\$6 MU)(J&@=NE7A;)H&=K31\ _P_#1#M>DS6GX.C;4%51NU\|M&0=-MD<^QK\(%N
M3W&D);>UXS\$-B^O3=36?;5% ^|S\20_-/A""D3""#PC-T#OPDWCC)26TW@1Q MP)TG\N\$0MR+B<P\|M\7AS8YN-
2&E;D;E\$IW6T\JO75@3FT*=-4K\=K&H4^H MO%4UA_A RGBXN^ F@41A,B7;6\LY;=05BA1?>5<|J.D79^X;X\$
M6L0ZF H;U\O@ST\$2CIU^ ESK3BA^T?L+&PLRREB\FB4V\H(OCWNGAY8^O M68\04/C 7ML\$Y@OV#W+)TS6_.9X.?
C2 =F5;|/9&&O;+@ |^|3>T\RMX M\W19;GM;MON\+M2BQ I+&H_.L1 |>-P) SDYIRU28^LZ>1J/9\6Y=ZHNPFZ M
_0QIM72=BO8\H*^|/?*Y.55;F+ MA..#AZV^ZN>|E;R)K^X&XA0V\I&4+@)/CD-'
MO>4\$@T=CC17U9\INO0^C\1BM&1LT&FCYQSZ^V_|+P_8RP&+1CZP< ^X MN*#,%V8GY\ _&E\G6+/?FD@-
^QXM9\IE/HG\$1HL/MF^Z\>FXIXHW"6;SY%RB M=MJA6;|H&8UXR_ .KG9Z@>|JN@
MF>^|FN6^7VQP8H#%.:5F1T/K/%9;|F' M@>@^|C?Z@^K;7T;OLEQ-
|41%86P/AW\7^15VC>%_41V\$AOV\$Y\$|O7#D)AGL MBA7681K<8J\$|LWA.KP@40<|46@A^;3Y51_EFSB_B\Z2O;EP\>\$#
|_#LNZVT M""#9B\;T(_8+|S+=-Y1_P\Y4=LOV^BGU@FHK<;+7E>CM& MVPS29@^X\0%N%;E1^B\3O08U^2HS;C;
(TSX;+^11O/M1_2\;V^H0XN9FR; MBG^(\0;|?+^Y5_"W=BHNX^F\$S>;T9\WXGK+<%Y1^AVH94\$X0J3/@K8(LUH
MBR@O? _|=HH4.WNO@Z_N\$>C\UFBE =D;BY^08_#Z^>|_11%3FB*|NR&Q M_8W^9&)CS1QAGIKC7 M>ZWH_-;
<^QS!"2.H^AVY5XS7-&^/ ^F7OP= _R;(5Z0TYX9E;|UWR\|#\$)1WM M8%+|UG9O1T=D\|R\#-
)AZO6X<@J5KWNRI\GV&51^ARM_&R QW;9QOQY<37\T MLLOH9"?&>0=E55RS9/^_JM&-KJZ7%DN-
Q\$G^<O_ O\;E="TYN\N\H\T"#OW\; MW0\Y\2+=A;B^ "C8>R#U\$=4S(T&VIT5BCFTP@^W\H\VOO)"A\ N^W?Y*BJ
MA0\&AC=7V5H1\H\U9\&|_#7KR;|PB" TJ4^&R?G\9\<3?D7D.P28X-UC9KSYA(T9V\V41T M=&2E R9Y.TV\|V;S1D>80X
VWNW^KUQ5W\^OX\>UHH^C@S;^&F\T7ZL;(#6 M\UJJ#&)9ZTW.2&O(W49TLL6;^|2F
QBV@)H64^|LJKB7V=|LG6E>6.2^P>^V<=5MH\>Z\$-8_Y(f8 M&K;8PO^AE;M+9\;C??^C-Z<?N@-30
FN080W\#E;:O_4Q(\H0K_EOQ2(T;J7O#10(2DOGLZD\$>UQ7YH\N^X^U\O*+VHY\ MMGR;)1\|AFR?G"L8-
@5MV.BF+H0Y7IT2\H+?(\ ^>=N;VY\$9\2ZBO0NV_M+|V\|97^_CC^LD-D_3-
:5KB\AXK;T\""ODD\64@A=Y\;W)^H1U\BKF\|H(MAV^X.P\|C;_H<)Z OR-2@OD5ZG%^A6\^1;-
^G%^1G\GV0=T99U&4>#Z#|." M\2_W<<^;=W&X97\H+5;OAG\I_7H_ X8PT8;O1U\|L;
M^E;%Y;&|8+R6>LH;KGUU\N3CF\G^@Z_M\43TYKD>;5TFWOX^V@8^|ZL^8 M7P2&B\I06K3"/+|;XW%S1??)S-
11LMT4MN-C(0_L28\KW_TODQ>"7.1B-M M\HUV\J\$(B)4 7&?7#=>/T49122WCOY?

PFR(R'M"t9ZE(95I%8@#NQF(OD)V MKY65OFY/Q7/JI=FYUDTIW?B9NXY5U MWY4WGU&3L;R(/:3I 1MYH-
%DOHVSFV1%A7I;J>NZWV'B3I9IG O>FL#X MI;K<5(I3ON1WKE@C68U*6H/RFO:RFD-;P3V/&J;T-)
(L%MNIWJH8OJ7# M6U-)I3E19/SGM02VG(K1DU2+ A5'0L9A&QJ+'30I%6;'1M12.6;@K-U%
MW;L^1^4&Q;A8TI+%ORJO;X;B9TO80.3D?W7I9W&WS MGZK%+<=&('RBHIXI@98TY&N?QD-
L6)>1@Y>V>P.3;%=1@?O182N/0*7 M;0L;?2LU/L>I-5-+1IX&F#;EU4R2(O4>I+8;)6 :L=^HTOM+ # \$M)C?2"5V
M1FL6FI-XM&-'HV'-UM-N:'DB.U2F35;8IJBW'WF1%=H#83T'9*X;1BQ*3 M;LFM=OQ@LRQ9VT="*\$+IY4<(#8Q+
ILMN5LO-GW_2 A%J+S)" &O%5IRH)>2 MFTJO%6L;X1BWAB-48E%8UNYCF/>*L_7IB%3;)V
MY0OWQU^DJ^O1I^/4I11(2Y@;:/H0;*(WW5N;@'"TOT3D8XYPL<A)K?67@L)%W-R)#MZ="(8)-H#IS_&O
M"7B(TL*VGG7T.AY>I0IKI;OA1Q;E:T\$PK1;G6;.<H7XSC&ISJ;*5TI<SJ= MMTAM#O@;+4TM58/0*;9 *K+P
IR31CJB4I%7CSEWBVF5-'JV15I'K1^H MC_BZ2A#-U6VE@95CIF;YTMAWD)1W";W=17KE(-IE=ME;V>WCO;H
O9HO9ZF M0749P)E;I5P.X%1XY9PBJSI9I2.43N>IHHL.YCEIT-"O";5Q'3HY4591#12
M=46U%MA0R;9>&-/1.OJ.5'3A(Z)8%E973EOH2YK6:UL0IAU%T;:>8C3@4S
M_9Z9XQ"TG LVI9*RDQZIM"IMIK02^I8F"^V5A1&I;FA.T.N"QO?H4F)2I>I'L2VR927K09-
UL"_3XDLH1G5P(2AIMONJ<^&MRG=(VF1BK\ ZXJT'_ \$S'"BZ6?B%?9>=N@Q;<.,FMJHI)*%C7S\$"1=\$QXMWER
MWJJK87;M 5Q54#M'Z.N'.HT.K-ODQZPBC(=ZW M\$V18&X&P%4@D'8A AYBZ94NFM>1BTFR;4I/#.'
Y@_)I2S\$T(5;_P M)+;IT-Q)*J2JW'@7.&L=8;71E(GP;R/70PT;?#-IQK'MY%&;^;+A6*^03_X+9DG?BOPSZ_?#(%*O8(
MV+OI3NB-8L(N;TTY4;G(UC'4LILT@R9NND(OMU_-I.6^J;E;I'\$Y3U<*F
MH@1%CIY"5EI=NIECF66.94XF@<6^S+);QI9+A4FRG-4.Y6-GANS&X;L1+;"1G-;MGY;IWCQDI>C2UH2GO;-KO
MYXFF3S+WM;UN;YT9#75&82W;I PS;AMQ"VY)AO&2N;F.N.OTG;7/MSRI(QWG7EF9B08(M566_A@. MV-4_47W
MBBRV%6^ID&WQ(\$^;#D;E@VLED+I.463JP'TVDY5&;&_21*P0N;&_&_03>&W MJO*UG=-
I17IE*+IW8_%QMFO>TYRN;9GN19G>;-V^1->;9IULMIG7'GM3 MK1WHW^&%I"Y-%
;UWCK%YG^&.%&ZM;OOIK\$03RIKZO>K. IMD5-M'CS&.*%Z10W3I'U_W\|MXIXO&5-RG6%I19/4PUZ;ZA;J"W'\$V^
V+I1B?1BFP MUZ+8ZRE'I"7#7K;4V*;VYK=IOR38S)I@49V=BE/L%CO?H=JY;I'>I>O_.WV;IH.8.A?KPT(Z38HU7Y6-
H.6=0BFUWX2YO;.%4NF*#B>KRGW MNN^S=4%R>&%J<4=NE3BKN..= GAA1/65+;F;*N6K\$OGZFV*\$=1BHL!A;XB/
M88PP*HK<;E>U*6.F\$9(46DW.*VO+K531V#) *Y;_20JM5OSB 'CBPYVR5O1\$ MM?8-I\$GF%%5J'_JL?Q*G_O.
D)_K=I^Z@#;W>;UIG_Q5N@29M"YL1_#<7_U" N8Q1"%/0%K M;Z;E4VT'Z#@I<* MVY4I(D;2J?2>I
@3S<*WB910I;Q> MZLI\$W)R5+9@J*;3I8\$C4>?T&9.2PO5&N=-.W'I^G\$PJ='&(?)WGLHUB&I1^F
M16)*FBIW@L>LITV7OFI@W>@2^G-GLO0'ZIS0VP*#DIH+VS=8-2@MFD)K2MM M;ZLI?2+2A?
8*FY" &CJ&94^>;3E_T4>7*.;@IA@0FTLI8.C5KQAYC";I<I\$ M>B#\$E;I;8Q1*K_S3'69*V&D3;#G>A+I;H'0Y>\$E'G*?
Q+A/I.PK MQZ5T;TPR=W8+?K8 HHHV+//D1PLBEIM8Y;1Y.".I^>0MZ1.\$#;>8D^63 M-85I.&P;=\$ 1J;I^&+?<
VGXD10C6VU(IZA8CXE?G\$GCU>3)IX+YIT:0_@/MER_3(5;+@A)IT PNC)>>)T\$IR@#7@)X;!
MPAQ53IEM"C6DIXA;ZC^I'G5/2\ZZ&F_%F.M*QX-S 9"AI;7P/7+(F_&^F MCG_1T?;Z8;#<CR?)6AE3.
2I4J.GAGW^>V6R M;"H"U)"OP#X4=?CANX;I_+QWM.O3AKHS9JW.LBI M/Z 6#;AEO19+<
<%_FKE^N;E@ILV_8Y;B/Z;G(+E3FRP>;5 MPTI'V3J;@AJ>T5.2DFSOA);G_8B_@+(N+LL0;+6TNLI;W-
+@\$EJ.9QIK6 M:L;K;W1+L71&I+2K\$S=1MDW/I;7P@Y"4T>Q^M1#X;X=JG.I2#<#<.(C9HT&AN MKNWKG;^!D*)2S
P3.E&7T>N;BB;.@JA;#)K#DJORG_(-;L?DCHV_UO.Y MT;J_I'F;J+6.9X;4U^T(E<3G%MK<-
LG#JYXQ#O)*9/S_OG>'D:33BMQ; MIV;IPV3\$S=WTPKV=G@D0+'830)SABIZ# 7(I1B?X_K9'W"B=X/^G='Q@)G0J M
FI20M)X#-X!+FM.P7WJ09;TQ(GR?596J@N6#PECIP8ZH1V;#I@)"H3;IN MJ;I.JVD779H"PV;DBJIETIS>
(A>2F4U|^""X"S.T>F*^2IN_<#U_WIN M" G74FQ51\$STARIN'D;8@M10JD@N#GXBD0-/89DL\$)=WFI&RMP
MM1+N.XI'546PU9" IHKBR3+ Z'78/&5)M;I-KZUOUS;^L.*G?WUHUEXBJV
M1>6G*TRHEX54*D:EMFX5>S%2;7*^PTRVI6:6X(G_KTFVAC(I)L;<%>0@)I M3WOI"/82\$NIIVDM7L)>PM-
-/7@2FAQJ2_OTIQK;HR7AOI;=3'5^D&9CU-300 MM(6^U S*
M%;3>2*JBMR<@ (H;B717D9L3\$&82;2WG('&FR'QGMJR GOW0P(HO^4\$N&N& M1#")
(4;"Q'9/8);HS;3G;%LVT1IY3'SR>FIK8+?0E?KFE/YE4#-F;0#%#EVD M(820A"IIWD54%9+=)=VI0&8V0U*IG'MOB-
@K).IS8Z^&P/OJAH1W?LL)#*IF M<9*X*0AVM8J3Q"+EQYSX&/XD; MT1TRFGW7;"K93%\$TZX?(NY;H+*GJ%1%"R)
NZ=X%5-4) M6>4EW;M 8W0J8N*+\$E0Z(1_%%D?H@253LBB+I56;8S8R2WE* 5"P_9W0>E. M(A2)=
_K70*ROH16#I09RG S>L'=H5I\$&4'!=I7#IT=N<5%\$*XH\$VAC1Z(T M2#?H
I4(HZD3CKKP*77W5G_RGY5N\$YPQZ4M.STRM M;T1<\$8;I+4A648A+X) M1X FW\$RJ?+UNP;FJ=I8^*)/N=0H!
JIT:L"";\$J>B2M#6@;GK;B8SH.. M;XH4@ C)V;1KISBW*(CM&YF7C2A2_*W4I)FVE;BX/1"IG+;@4YI\$S6ID;E< MI
XCM@5I;_10GD=HW=SI6F7JH7I5UCA&C9>BX/O8P5F"\$9IX IHD*%>HAGAEJ#
M*LO.^CU!I\$>IAU/N;KDE4=#10>4G0U^QW5-/LO&RFPC-R;B#O"-98'V9H(9^Z MRX-
L352*%RI1/36A#6KC1Q%2XHBQ7 UIU>I"US>G;I+V.D;I=;LA>W.X;I'W/3 M1G* U7 I?HSF09;*WR+5G MC_\$)#;JIS=
C8#PZB&QO_5PY620E;5-T;:6ZY)0Y(IP9ZY0Y_.DT^S M65'= ?OS-8I.NY>NMH9E+V#+2P@ (E8#ZA;I^>^PZ65%\$3%=
(U)!=&09DA;IMR9 M1DW//TTSFZ*O7?IH D^"78_XR(^=A@>Q>Y";B;#E.'IQ+WIE""I9""WZ<(MGN'2R+1MF
K9W=9&60E%> H\$AK1.WS"L%I@=IMWN;I8"Y4IX7IC+*82IM^
MC5UEF08280)@IV4;HLA&N#0QX;HI("P.*OL03%6DH*USD6+YIBZ(C@>+O' TI";N-57N\$ QW=H8A^""L-"%A<"
M/I#RQEO;H>G "I^KZ#_A+ S#<30A;U@H9)Z#E'QQK=G?L)\$BE;.&LF+A8
MN*KP\$NQPDI+>;Q&@7EK/DO4J'S1#SC(N%BP;WM;I1BL(EB;_9 C)A
MFC8^E09;X>+ "S+M(A9EP*7@;0A1\$A*;W^DP;C+M/X;.>20W*QQRXV)YXQ6 M2V>IF53I>
IGBOMWM;.!&7"E;AV5KL%E;A.R2"#I'H0W?"HAJ<7)V'XN3JG0 M_ORZ_@D7F+2)C-
N5SY6M#C6K;IT<I2@.4ANA9/O?S\$>JKN64P7QZ19T@4J;
M\$;%5UGZ;HK/&NXZ)>R+%3I00^+SIAH!>SJJ2S)\$/6\$Z^HIF=6TI;B;I9<;I&
M#>2^3>JHPK1.AO%E(5SGTN@TWB;E^9\$ZN\$Y3W3*"Y+>=C&00ESRSES2H5
MUJ6C^R+I/A6I(XTIVF5@30W3QA&F&D.VCXP60K.F%. *UQ_6VIEE;XC;H>M MEQ+JNQ3GZIG!
5/HAN1'4S69\$FD&5*%;NIF2VRID) I;I;#JJ&%;<IM+T2 M4S\$D#ZMOJ7&NKEXO'C)LP(0.ZI0058K*';@S9;EMESA5>
(=<8CIG#U0+3(G M.IU"EU0547YTN I4UEZU;9\$>=""VX 0 M.H+)-YN%<#S3S
T""TO(LO+B%O"\$ (M&^VIT0=H).B;W=T4UXEUXQ=Y;*(5(+I MB;I
MIJCZU1HVEE_C0G86(221P7V%F#LK;.=WWA^2/JL;M=1;#(*KR.N46 MA+5(WE)3HG_JY2G".DK0WMD&I-
_I^J#2P0.HHAD/"Y48)WGH3;GUEVM)UQ.2;8FG(OP.3 M.WDB/M_X9?Z)X;P'V7\$! V1 I& @LI9+V;#W_
MS8>H7I96.NW_H(RSL;Z0F2X1S'Q9_6FZ=UQ7W)^CN)OIYW MEJGI\$#S1.&THZY79_-I=>"LCB@;PVPY"Y1
@7(.&*/+41V>?S6C?Q<&I\$ M7WXE>*K3?4YMENS3_%O\$X?_QSV080^GHR=I7HL;S-
(5RM;+7K6SY//(+0W.PIPN=NT+Q33L\$GNYB596(X.#3&8N MNV.99.M78;# IX2.EKT*4=&-LA5IT'0Y-
17 S;&@D;\$JZ>00A>4=^I34 M>+NTE LAOI;R;9"9#@3;8BF A?M_K;H50T6C>)@T;ZP>#H(S#TCLT#;
I%80F8ZIQ&C+=#59CFP^CG*MK;I>;04:S M8*>*H;I/N.X=<5T8KM4TN&X4Z.WSB;@1VT5@6TF#;5
_MO#IN;+;V;+A9# MM7I\$17N1X8TCJM^+&I>I-5OC%I;01BZ2BQ746A\$XKELF0I3#BR3Q+)+KT
M;G<;FF@=YIA?)I+3I>J;?ATBN==X#!_G2J8^1&VXU?3HT+I2%OM2;O;D# M>T)EIQV@IAYSN5;V*V5'QIG/LPKVA;?
>.;#C'5EJ;V.U@H.FE;CY&FG;50Z; MR;I*4LDZF;SF*QKRWC;AIC;I1"(16GX24+\$8E;@;\$1B&0;PHN?29I+JX2-
MPX1(R@J-2D81JF'0;WIRK3)Y0QCH;I% ^9.>6Y(BD;^IOO(913FBN2TF_ M782;2N6LE)L>WD.LJ00^3KF)X#T\$H@X?

W2^PIT'S7<2@RA/=+O*5IRJ5);H M?I%X/*8B00G)^AX"9>4RF/>\$V/<0""N\Y;LG;+Z'H%89XMEE:PI2>@ AK\$;
MON6F@/<0TBI/+MTZ\%S:S2Q+-+A WW\$+HJEW>;GIX#X&P\$ECUY2:"IQ!" M.WP\N\A.XN\A>'9HJWY/J/P/
;2RQ+.+.O.(-B>5))Y=):K?0Z"L7;S?A*; M?@^IL!)80GO"YF&"6EF@H10(C4K&>+
M\..C%Q/'K^F+=# @/I^4(T8_ETK<I U M\$%#NG!=P'D-U)0,Z6U#=_^%80'G_A6&MIASEFQ!?
@S<<IY4.WD2P^>L>6Q)7GENFL##!FX2FY;Q= MR14&GRS#>;473*LF^B/YOKGWT=7@V-J#YVf6+-
/F*8_MW+IN2!@6H1I&PV;J+?/Y4-?;\$R MP/V+=>2!+3P0#9MWQ
/=RD9XHWG@R28QXP#ODP_BP.>IL\$EXIUOCB0\IZ4
MS='O5C(L_9HJ#F0NEHLDW\Y^@)^HNDM'DI6IX<@KDI\$+COI/JDJ"?P#J+/N8;<-IKD)7.D2;J_)U8K>R-
SY8TV\$9^A3+ MR>GUGDYUM(?PI\$;:/0K>S=1&FQ56#WTUYEH^CEPE:IE7>ODC'BDB.Y;-Y!
MKY)UY(CN6RF4*^24!LE*^4BN9%QPW0B+=D^Z!2!^WMN:Z6@3=^/6 MN+I4>WQT2;/U/T9S>+FO;A?
=5WI4&U\%I.Z35H.%U\Z)7^(6-0?_M?I MJ?I_OW_IH_7_N_)HO5SS_-5F_ZW\ISXY^OYK?
+U7;GCW\WY_OGYXL ZIW1L_/K!&;Y MG?SIOX/+ IS;_2_=OY^<^<;UKC? IYFZ;I_9FCWN_WY+GS_4K-?ASU;K
MKOW/B_K?+?;R_T_?W^;YM?_W\U6M4> WWRJ/^O?TYG\F MSJ?D9OFY_I_^;PK1_OPGZ=Q>CI6+AG4IOW>^J&N;EJ?
6U_^N+20QZ/5C/KQ M>#G\N/GTN=^?B\^C_>^?/E_OGV\^+7W\MI?I1N+R_^N?K?UX>U<^_7_2 MQ?
CNI/O\!PY";^E..QIYO!>M.FF/E_-OMX9F+OOF%OG
M+7#+DBD^<^/1.*9/B/>3MQ>RZE4VP+A)+MK/(ID43RZ5C'!&UYGL50/O!U5*
M'>;1SR5/0RMU)6JX5HQJ^VM5I<(&)KCP"H3;6WS^GZ(AI?IUIV.M
%#T)IX78DQGE@TO*"#CFU4E>AUR/VL@OR=D_\$0(20U%WGS8Q;NE84Q=9/%?54:1=#L>J1 M8JM-L>PQ^L+O;?
I0^H6\45NG2KT8^FP;20_-(#(\$W&AS7Q9M=#?5Y1Z;JNPKX_5HUC^KIF/KSJ= MC8^ILDW+L;Y?8V&Z@KA6*A?
U1HWW<^<).Y5^H!<I-AW+5ADIU MXW9;&I-D)PI:# F7>+TKW=3;B.X9FXOZ\AD2&WIO;6E18RL+835PIJG:C\$! M7J6Z
;0CH0@L;S^IO;IRI#^4KR"J;DPN!_JJE-+=?I L8V !B+93#"BJ&RXJ-M"!%N!@O\N(H=+/-_F*14FIDJ;0(3JAV&D6JG?
U^@I((C.Q7\@%.U68PPJURL MI-RTOH&KV)<;_H=RI75U_P&2C+3>*4IOJQ4+'&P"(S8Q=8K2C.K^P=Y0+";
M;H+=8B"X?X\ZJ_)6E-&/1D\$-QI*%X*5\QEIQ=-Y J56(^VMGC"2;9;=%N M*_.KIV_C QAFY*A<1 M*
L)9W=-&XHJH)3LH;F7;Q)RI?KJX^2.H.12UA=C_PDAN/E00A"L9^PM0I;0 MW+FBA#A!-=&3JWO>
<5C+F5"8YK'13)EX79YU4.NI3)CXM M(4IW^G)"MKIRG;:Q=5G->L5HK*!BAR35%I5B\IX*9C><8;JUW"YG>6"7IZ
MX31XR0POK0J;6I6TE;V2&+>"VJ;-K6_-J1JA(IN M;?
T9<QK;!.*Z(VJ_VFZ5\$;#Q?5\$MON/E;1A@0U0Y;L"E0LP5(4%IH7 RD40 MJH+ 31G6.U42901N/)20*#MRI62U*I"A?
9JU6%Y1"B;^R49 J&AR%H;%I MC^4*PH)78;=IX*%<9UCY&_KNTJT4Y1VTCQ&_/3IKTK9K&P_ERZS5BG;L M@")?
XCI&_/9EC LM&I+@";>-WK M-AI*EY@J&I3PIG\X;-A7P"^XOI%BW\I4)\$=*B/K*!D_<KQS=)(I3G_QGI0-R MXO\$61W-
WIO_JR.\$JLU\$FC5K9 MJ\$A_?<2;6+UX)#_K'7S_-OS/8)+K_Q@V/E\$C833I+<>"A?LJML^-.(=d\$
MOYJ^Z_WMF8ZV@1#(IIG5_W_KGA#YIU MK<IU^_JHGQ= 296-K9;-DHXB\;"\$7-E(<4)^>B&Y\$!(%0B5;S;G*^C6H%?
=MF'=U.G?39D=%T7+EHL>!F9I"C3\$U;AZKISIR95EDXGF1".M.%^V?;HF;W+D M?RA/7U;M5RI;6PBF#ZQH"!IS?
HK)4S;HJ&9CF7H4XR#/#+;O\$UQKB\I MNWASA;JO7(1KMV(PFIO-1L-8&N^T.S7-
XBRRE5X5@)E!;R4.N5BSD5@K(<K M MAI^I?_HS?(Z4)=IYIK"RIJEDT*94H>*%N9^@;^%H;,>^)!C/IP M3C1G99-S?
@/Z(>=IG?K5?"UY=8;=3<_K<=<=JIDKGT?Q9>CMDOT(T<IN<3 MT;TQ@M^"JRIQHP9J^GL-G3NY?7 MOSVN-0
IR!%M6L;M>W8L\$@06UNK5JX>GG_IYIXL_7OXR'OW\^GD!PWP/ W M\I7IQ/WSR\I>_PM#?I_VALSBKXN^K
M7_Z13G(>3)Y?I;\$>3!^#LY%<GYR<IO)O*#/_JZ!H_X^2/UV?P|=L_EB+R?GY MZ^>GDXX03UZ\^SNI_C*?I_-OK5Q=Z>
H@*J*L7.3%ZJ>@7J_C8A;5I5>_3HO M^>OQ"!32RXO?@W^>O7IYN>O;3#=!%P
MOHYG290&9W&9IW65Y%FPCLH2OH9_3=9%DHY'3Q^%P9_'3H9JCOVLX\$N)K^<
M!'"5R\O+EFF+Z>O_OD_7SWZBOX^?S_YKG_^_3%Q>_I7C1X_^^ZL/'=6#
M*E_3R.P'TIRJA5I\JMX<:9WOHJ+*IE%JOX=HCGU<I7+2*ZV1>+>&'7^&! M^.*7IC=/OL=I/GI8_-
J=D3_KLDH6&I#ERSC(HE41UVNYXJ<79_@_F.U?>KOLL^!_L?TEI<3_HOUUE\F90@
MSI'"%7B16R;RU=M;JF@;3."B3JHYPT85?9_3U25>_D>T3N%?S_-BG1=P#;I
M%7WY;EDE\OQ"ITYG7P; X^>/KHQS\X>YE&V3SX;+_.1YP#^>1QN:P_-I MG_
@VSM3I;^Z2I;'5*!D@I%;A;M0;A(I;OP=Q)RB2I_M#/_J7.O%G8P;R;!XE;8@D6"Q5&9%JEI&L;Z6*-4T6E"D94Q"+;L!-P%
(>%74J\$9+ M5(KK(KX"FW<I@I<37FOG;NM\#MH?WOHN_YI*\$VB M;9+BN8O*
H(#_GPYI_@2_%DX0D\$N4I8=R4*#ZZ_57F=5&"2D1T;XH=10J*/_MW)DORV_9IZ0XT485;\$>
5<#;^KP2G\$B\8NGORLK**GX=O*/\$WF;-I@Z\$K8K;(E M2V;NTZJOS/+>B\$;#5#I_#S-4Z1#U8=?+F(OL&
E(=Y2&FKQ/#0#G\N1S_G\ M12_"_BN6_7@\$9IH"G%XX9\$XWQ)R_*@E/2?'5I\$EO0C;I2-IX&7=F5H
MC'E9K?;H#16.V%<@%Q#PILOQ"O4X*_CT>7<_I7.9POI8TIV7.1W2=I7B& MT1GG_'HA;I0+3..ZAN6 TQ1>IRS3C9IT
=YQ(U?#ST3J=-K 1V%@! MJ0D.!^\$A>AUMV\$O)P_ZKV4Z%;Z_
@FLWCO.B!_74J+!INI@BE&9PL;G.BW%09CV)TP_I A.FYZR9Z6# (%K)2@Q/'/2-MYN#99KI
<+#+\$;IR#/'C5*Y2+25GFH^-))9Q5;A9L8J#50P'7G8I(GR!&&Z M!\$/^D8TG?XV104=UR8SWY-HJF\X"#;V&(<=
I"VG;>423%CO#G MK^&F0.8PB'ZI@%KI9I_K^HW4%IUS\$F'AM'^E.S=D**O@?+8\$AS-M MY\$ 58V<7"LVA;+U-
IY;OSS_-2)/T_P;0Q/&NN%?2M_B9J.ZM^FSWSCW-VZH? HX;=)UAO@<4H27SK&MR^U;NNS&T#I\$8I# MX56-/3KDJE)
I*XHIMM;I-=5J*AI&D&BMN0-R1\!PXJX;A^A2GSUWZIFCX M1JXP288SV&4Q8M"IN-
9_16@>E;G_CQRDKA(OGFM&=+;M^<^@X>MHSEF9I7O M1JGX-N^W^!;ZZ?<^<_D?IK&"IVT<3"WQO?SKI-
IYV30GOQ_H^" L7P5#F4 M+UYL= WW_SH6W9MKL'Y4*(89@LH^EG<\$ 7L3KO 3 M=AP%I.18RFQ1DE
MMS0>_%H#N\!S?;^);GA\ZU6\UVI5^V>E@I;H;4B2>&B/LNTI\;V-I8&3A2-M)6?;?(WDC.UX K^A\$(83 G6
^4*XU#\$Y&F_IJ=X')COEI;## !UHR36H/H914.29FD<_@W7)Y; M4U2J(CPC3L\#4)I=I T&B\CI\#*76=B6FH
M\N55FI;R2T;LHY%1U#Z(CO@TD^>(!/@S05L5H!H*= MY5+9S/+^N^8F'=M7G\I;K I=I95Q2;HQ>
K95%BR2145P;+)+@Z-O' WW ML2I-54YZD0/&MDN"?2F^HC PH>\$I=WBW;..9W615&@_@P6;C^2=P<-X)U
M9#98W>)9C6<49X+X=J? XFVV;.<;E/B9S08_OF74R4*(LNI0I#@PY1244 MP;=_;CP;KJ*5U/>(CU/LVC8HZ?
SQ5=2#_JITZNAH1O;X1Y);G#U;1.WPT M\LT)A_*#9S2GK6(?Y_&8>_&.)<35;&_45ZM;7%YHH M257%Y;@7<;
IXW'3E^3)*CC?X_5G4I+=779@1N.T?)"?<^+LOQY M6;A;"(6E>\$;'&19\$U624<1-!<\$9PV16?
8XK7F>)>#&^%LT0S)I#CJ@BF?+M+\$ SRTUPE)BZE78P-L#IF8?W\I;P;DDU-P;XLIDAIGJ5)IDA=65N M\$)T=I_%Z*
<%"...!?W\$V_IJ3)GVB\EK9ZIS_%O\$2S;*AVC0<+3 2+-P4I*
M4'M1T)+B4LDL64>5U;I\$!N8ZW\$X*KUYN&4>%E@.QQ;G9/@00)I>I#;4I&K#9^Z\QS+
I3(U0%U%Q^\$O2IH\$<3AH;W&I0NX@=Q%LTJ^GL_OOB^/4)I8I"Y+^H>H;8\$)&D+<IR;+
)QY2A46>9%"K2%0D5;.)9@J^GL+! M@8P;J;R@D?BG_9I;V;+0;K<7!AUEL-D)@SK<"KO.DW9CY6->'K/4Q5/AE3%
M%Y*J>&%IS?;J!_3E^6SRUV L/OQ^IRB9/=+T XJJS58GHIE;J@F-SQ2I-M*?;?L?X>!ORY631%;S4XJS\Q6JK_*V;A@K;
M;TBHO@OZ\$A1*^?6N4U;J+6>RC6_16@P9R@_FNZW8J(B(F6)6^>X?F<)+A#H'PFI'EKU= CP_ZHI_U@;GCA
M5@U#N#N+1+N^OL@HP;>3^C*)Q@A\$HJCL5\I@F^ZF5<NPI2^>+MIOI(3>_&I MOY8CUB_-R+;FB)G^G^Z4;\$
=6;J.\$K)=A9C;B=T+7 33#%6.P&=6.2.8_3 MA"1E%5?+G-G\$K\;V;Z)ZYD\$V\BKR*J;&\$6'_WID3# ?_74G-UM+N0Y8>))ISC
M#?I+I569Y*4MG#!(03I_^+4JUN/-;_MEK;1E;F6R6J=QAI\Z66T7Y.I
M*Z79F)HL#%"T8<\$7DXY#C/@Q(3:6CX@)Y4PD2PR*Y1TV\$N_#VE8@NB_I FO MP4ND<> 7&JP@19WP/X1
J)D4PKI-RU-D;GDBY&\$-Q0AW9=Q1LE;S62U M2&M2CK\$;I C(CZ-JKH>A@7AIP^PL>OJH5P&X=+;>I?I
DI=8D1I/CX 9I M;I8R3/(U9L 1&K\I\$KJ*Z=Q4IEQ)(A\JLXAP;IX RD-^1"G="0&!<A<=<R_K

M>KS6Y@KCX148-!\$UX*TR0?8FK10WC\$D\$LJ3+X?&UHZ&T)GX48L2DL#G-%2
M<:0MS8#!4CU)-#Z>X7GS*8/KW|SSX/K3(C^A037#P?6>/N(^E8<(B)*MD#2
M/C>;E)@^Z_7A>Q\$R4""%58!01;ZL:UT#"@_GY_DL-|CK(CGB<+Y=.:?V|*|
MD5+60U^Y=^DH\$S6'B!8)N6(U0^KDNHBJDKW0+^S/;=F":3EKZ1 H0!#P>". MX89\$IQ=?FC%\$2)!|W*+/-
-20^+IH=Q18="CW=>G|EPZY6/I?|HJZ: 86QSM M5(*:8#0!/:MEJHG8!D)\C8L6?U:GL>:W-
0<^=(B3W(Y3U""N)4\$OW""!?!@ MV(M:M NB63RS'/N@|J^OAA@1UZ/ZWY9'A6-O5_*J-N,W0"0: ^W\$-F NHQ62.
M=U^O<6?%|RZ7TG?.\$@X_|%|SI"="7RTV) DYDJ#10;5@"&Q>Y4Y&^B>9)
M1HYPE1EMIBLN'N9(\$ "T%U:J@0I/OA@8&6IQN8BE=)I7Z?,+"@ M5'S00Y*B|F%5_N
'A@KE:2PUC|_FX=\$<:AU:OP!:@>6:QO,:SY^;YH:|W9/H9 MG5O>H!%?GVZ3RQ/X ?IH="E\$;YAR^SF+W5/AF'/SY|>E-
5E@|T\$!_:!EUD MB!0X;Q^;R&XG9;U9<(\FP8U+I#TA!;O%#R.V:F/DP!G*D6*U.
|QZF_68(TWXA8=K/;CK+K5+!\$F=K5!;9A, \$-8EPT/GDOKCA3^"F&E;C<9AG;"\$FTN":N/@/:2"VCZR5VW"\$=#1\$!/:S
_KFLM41\$L\$63UJCI+)0S>+/\$JF5=@:6.RPJ=C&A+YK5'6L9>L1#HJ@WAA=:O1%_4PI M14I=' ZB3;4B.N
*A+J0CEHV@|KJT%*X0@/- 7D-!6*B \$Z!10H)H+RV4L=RL MICEURZ((7@D+7%41\$I\$C%Y,|TL)AFL0AMB^3?R8.'H9\$
!O10E_!>M8<& MA! "YRJ@E%+X\$GPO;|ORY"5J;ZO^>(>&TWYD#8FD\$-!03AJ/I\$QU4I-> LNOS
MO^|L|BP<^%C@.OG2)P'@F8IHCWP8#@QL=\$, #:L=J?& 4:YS;H|@RG*T1<9M MH36.EM#B"N;
|Q:JS-|Q0T<*Z!O|H\$1-|X|/<@?1T2|R'O/AC&WX7V?21P MZ1T0/7P MUVIW#|B!""^"
<@B+*F8N=^X@SU7F>20471G!Q9=VVIGBAVZ:2\$MN?5ZR_@1+:|X5PI_V\$D95G70MQIDB#S. M9*"&|0CN
)@JCZC'3W/N.QS9.Q1-N":VY-4X|'G|3VF"#!_LD(|Z|Y|F(M: ^!%J*G=-SSGEA/K G5AB4V/.*02LWWJXH35M#?C"-K#
|!>-5VKV&X(C W6L3K/|W|9 4^=:4N)G9%J3%OS/O!C8P&@:M3PDO*|ZC?KQ"I Z|01L^&I=WS MTDX_?
&E743FKB4\$S_J8F/11HKW BQA6^UE>H0KN;3+IXU3D)M6/Y|+ ^L MW +C J\$(:X;UF@7+5D>PS|A"L+\$'% 3S_:?H?
Q*)"ABPN*> UBL&|QF/<3 M Y-7)TZ88(YXB(*I&/%?I%ZV?^O8UYTO&8F?|XSBC%1JM2YA_Z.**EB|A3&_MHUU^Z2
+^Y:%^(-DP=*X6-H6_RCP?Y#UX'M!+A"6A@Z*D\$S\$0|BT(BP1!%C7
M>8QHI*,>P68K3|P(AN^!E%Q3D|@CX|&Q%3BBW'Q/5:Q";M:H@\$.+%"<4G M)\$:BW?
P"3L AM)&1BHF90;#V+5B7'R|88CC8U:AN^P.OJN+,@PK8#ID<"(O M|GDI2Z@ON;USLW;
(P.V@C=9%@EP#*0:L+HMHO0R#>!4E:6AAZ6&P7N85?ZOT M)>^W#((#9L;V|B_#1T5@
R,U\$|B8WB|F3DM'1M^!^DA.U)O^M8'60"LT1 MQ %D/66Z!MP|F>4*^|(E|E?
QEAEGRFIR@3@WOZ70ADF>Y|B>AM0DIZR MY|H> D)M1T8ED\$>|BT/R=^2|TYR2@6J13^UI!>2M;4JXY1@
M|MC9VZN*W2E3#ORJ_#WL=S+<8Z/;N|C|^@Q%Y@Q;7YN&PGOL+J# M%U_M^E8 Y^HKA\$E\$|B4@16.5#'_ PKP M-
:;MWWF#5IGP%KC22,*84?=\$1&F8!+ZF@="EYXA>2!A.6^2C!).M0/PG%IL& M2FB:I_."ZWC3-E7O|PY.WEY^L?|JG9?
S|&X|ZH_?!_O_UP>(WK4N0|K*C M>^LC#@1X Y7%|#L^:PRG7E(-BFV/'_EM_X5LE;|+G_%2(-(*15DS7(AYL+
MW.P| "H80_D-C\$O*#X*(A_|@|E|3LF+_0=F|H%P_A_X+SSG0N4ZC&<Q3NAZX&^/Z>(R.^^\R1\$75PI&BXP-
\$C_>*\$ (N/ MZ&-4U*7;|X^E5|SMB>S4^K %X#_5W"i@W"7-C=Y:4-RY4"@C9<%|MV3128; MU;
DORM95%B,T+47Z.8:B8\$(6@IQT5BJ\$(V1"XR'H%E#;X^T6_5K_?6!1:3 MP8Q!@65Q\$F_/2X,7>?
7I/+6EM<\$ _TBNDG2^E*"CU1%E0K8\$V|T94M<<6CC MD7T;-
RTT3|!2K(WT2VHU4_US^|NK*@|+1^Q+L%<C|L4FR*K>H|3?ZJDSF| M&=Z0'3(5A'EYU*N7X*6=
(9\$;|OU>6E|W499/AU7RSC3=:+YJ;NR@G_@:_%D MA&KZ<:Q'IM&+VH@^D%6L8\$;?49DL^OA#VNI@T*F|@_.U=
(|&\$5">86VC+)S@_MY*Y>1T7|54F%835S"V|&W 7|!+VZ.|^N.'>'FH-TR-/M-T VEQ#8,T8|7
MO)#*OY3&26#)|V1!^J72;T!#FF"RJ<\$//8X85MBF)>H1XQ>=3Q33CG7^K.". MS0.OHB(1=CQQ&
|GS^56L^LPQC3BSUK2-6#>'5FDS|9|IPGR?X|'S3'-KTG6T M82@FO_E#(|J_*OK_X8A=E:*J|JS#;|L69=L4|SSHX(V&ZB
6E30W"879 MD7G3MGWP\$'6ZN@4.6|(N>K"V66X8^G@XL+%;L+C4E M%HV&\$?;\$85/0/6_!DP:OS*>-
:R;L|HLX!*>RLL5!>H:"%TH.B/2CMXJ_#2GJW48N(:!6;T| M|V(*)L3ZY8\$W"">Z|TVOZ_+KT^C/F""GQ&S1U7
MU<<(<|K1EOZQNZXK9\$7*3Z1'O;05(|SKT T|6*GA@)X_ \$918G|BE6+!FG
MOROC#!I>14D:41\$7)BO!*:Z*9"KLA:L|NRPKUPMF34B@:=-0W6L0O-DI@YQ
M&|4Y'G7IRNX?|6V|*S)7&:%HXR)A'L|ZX+^IG|5%7U3)*#| TLO7_4RG&LFIC/QU:9M;X?M!6X%ODA76|!%.\$GF%?
+HF^+V.R.Q=(MFON@L'17F9F>P3^ M=28-W-Q2"@B"G\$R4P0S0S*+0BTD%N.1DT9UQFS\$>06SD<^MSX!|>TZ3I71*
MT4J.&3LNNP=|FZC|68/H'TB1+UL@FM31UDENOD:E@\$ \$EF<7%'6Z/6+?B_-# MIG52WA;V;?
F>A>_FB=BNHG?"#_#TH* (2N" %CF<M(F>^K+8_1(MK+\$V0V++^7:&F("XV#"X3G73#\$?S>/17S4|>""F6X4I5-
M|JHDH@5|S_^)|H*)?X2+1H84UY9@!EL>PG|^#@_Y\$|V* K@9<5M^O!FP+)?
MQ6>KUAEB<&Z2CNB.Q|7#3SDQ|VK|WK1U'S_JCP#R:S#+?!\$5B)N0M(CE@=84
MRQIQ0|1KH@THRF1NW>GO:)F4FEF>DB4\$C|@LXM@_*OFKY_N|9"! MO%+FC".BJ86<\$BQ>4@5EQV&IC6?
IR"28Z/HG*|YEF;SR_U|T4M7%:"Y(% M4 JM0-AE2|JWH=;5SB'P\$@D2IKE|A&*954@3*CW3DMAG-)M1R1N:Z\$S2
M5RFWF<!*47!RL^U2"ECF&/IG)C_4:*%1MMB2@KW0!=6%R
>'I9'NLL#M^D8|KZX+)JOK^6X|&@KO|K,S>K+=_VZ3.=QJ8|*\$BI+T
MW>_MKYCPQ7:/<% N":!&D!5^:68(QBE@9TA_F|&%UI4)ADWMEU&Q+^6V(QD
MR1X&H@/JGMX,@+)4SGY*8.JP|Z)8&X>DS*/_KKN&"37#TY&QM(+|VR::@/VN:5Z|EV=|!_L:: M*0.CG5L\$/:
(#AW'E621O&26+UML/%.00%"K^#B;LHC?Q|4L*2DY(1O-=@@F M6>H>NM YW5&_IR88;LO*:7/"Y*EFBUI#
(\$YHF_NZ"EI9\$/I3=O=XQ-M;MH_ MKCN)?#_Q%(^&E3|5&|O)4H@I:H4;JYH_76|_4&FHV3#G4H|2|_Q@/SHM' M-
4@FK_L_Q1|VY|?29D*\$*007F2*Z)=|=D?ZIE-A5HU4L^F1&>T#52"UCT
M0WNKZ|V!;0IAU:I<|@W&%2\$MP26&6(VOC45O^86:W*U1D?4DBWN| MELC4G/QO)GV7?
Y<10EV)6GN!A5"PBO!C19XP84'B2D_:7TKH?PH&X2*AN#|9 MFW04V|9Y+9WDG_AJCDHXKV-
H.B@*/#K#;AV,T|Z@(|77JYR+F6|^UZMED=>7 M|E^N|8EM1RV-D4|;8S(LP(C*A\$0_@FVZ6"1H(OU>79LC(P>
<|C0>61-GVU#R M+7>36|A=0_YPHW/Y9JL&RCN2@6_JU4|QQNG&|5>5*1G1*42(6ESPMK'QF^R M5-
%5GG#44DR;Y_6T"NFHB/H+DU_=H;|N)4G4=I2%RK.&=|HM=QK/+^6S)L5@NJ'_!6V"W;0IVB(Q
M3:Z(A#E&Z@0^F0"D.W8\$V26\$J(&":QDG"890BC'JF%?O"6.HS0'L_@+G!_Z_|B^A(IZ"15AW' M-
T49IK@|WK|ZT|U4VGDUB8'RD|T6>7*NA;_:54"P_EF\$2X^LV_ ESVJR M@N8/GC|\$1XCH7+X3H|!5R&|_O_X|N0A
C|TL3SPXH?M3LO>_!SQ|M>|.000ARTQ<|B33/(VE>%|G!_0F\$KR*(5<^KPx|\$0*V\$=005G2A_\$5-C@_MUC'I
|&:PY9T>^* 6^/#:F&AG/F7?#SZ2|P4"0@E&59_ SUZ2|<8<|H7@2(M9X#;1HN2WA;D'E8G|F#:<=J-
RK&#|S*AYE8^>/UB|/23H|+DY?OPI>_Q:< MG?|S|XLA=7+GN|(GU>?IPHO-QZTR M=A|O0^ (P=+(\$3JU2
|8:45JWICN&1|C\$M?A9@4'JS:ME0TQ.O|9F%775! M|OTX-|Z5\$&0|5!^!_=: QJFM'FD3L9
B0;N48L8QZ!RC+>WC<<_NY|Z+|B@_M(C%A:3X7K:ANYBC30T&W|X_%S(BC|S\$WDHTQ@^E"@VH|2I'8NIV(1"IR'2Q
M6-4(QBOIO^!VHS!@ZY)0M3V|!=|LK!:|U+4*^MN.O<;C/Y4X1:T|C|L|O M_NZ\$3!_:IO&V(T#?
LYK&1PI_O|HIO=VR'(EB4X'M"\$V%L|M07V^K NA1S8Z+YGV="6/LXZ_|X|^D|PDL'3_"JV'4%*K>|OAP85TCC0;
M_3\$22^(-M>HITODC|IG|A&^ICO:0|OD+A2A#0Z|S|R-/G:P;SBVUXAZM@Y""<\$HPI7>G211ZU0+";|LB
M'81A544E+|NJ"WD*>A(8S#F2|^&G/3*)XHFL|Z=>T?8%OX.9MUF<:U|J<;\$P!?=|SK&V|&_M/_IL (K=PK".CF|8&=A
%?>09|K21-Y0N>^P+|NOR4S)|*C<"OSZE.DF(%_MK:P@F?PP3\$V3S"4SVK
MEO#T!;LN45,4XW90W2_-\$;KEL;L5V;#_ ^M#";P*^<=5-MPBG9C56!@)H#6&|&C0BSWMHF_:%|LT,V|I
I"%WW^#_.'C9Z2 M_5*B|0:&L\$K5|=RNZ+|H7G.G>7YM-|HH(QV=|XD%\$9*Z8Y*HW_7BX"C_BZ| M|Z%Q+...@H1E=
I-3D8X.&|!%?W|D/PC2EF82E<:22@EOM'6R2GW-MD<#Y2VZ# MSGDZLLURE"IN:F7/3)%AP;S-V\$-L_"/!>QU'A=-_637!8

M&OKCAKX?W_/0!^-^0^S\BXUI/^E9;.5GJ##L.EJR\$6EQJ&LP5(PEY*F>_YD-MX-2UCB_-
+IV*W"YS_)R4UF0X_%O:Y-SI*-22.X9UC7ES+IVIL<\$)C)/BI-MG%)4S.\$>3)KN-Y84
471>TA3R8E2*QSF6(8\KIU7KN=#6Q+AC2)ZX-BF&R\ M26-5C1JT^0JK-3CF#S\SO%-OBCM^?_!?
CAHT?@3ZE7.%/J#W9:N@(\HDE MN&>)Z)A28;-RB573)7NH7D3BL.(B7I)Y1>'_.1R#0.5HXY=5#C8\7U16
ML1Z)YR\$B5YJ"Z>T.DV03*144H\AK\$! A^X0<#>.;. \$68V6:J7\$Z\$PZ3Z=X M\Y&RW^I%CK\$>%90T(58L6:K+(A-D-
YXDH9.9I42Q77F5)M:%TD:9>E4A"N2+ M\^M\JBZN;.. 9HZFN^6@|>ZNK\$Q.2K0C7?/^ZQGW<5IYB\YR=?
3Y#7LO\O< MNE!*|7BQ96^LHGFL\X=X8>3E^BX8"2#R+_ 'U9EM/\$^:YD:(>\$3?OMX?EW-QE M..BWL\ES3%-
/7@9#=@|^=L4MNHUW=|&(9B92H^\$&2R9F.BM\$YDKWPB87H." MX02(BD**OGF!@9:<=X%
|\$!#NTRIE\MT4FNV8>A*0!(RBH5R#J4("EOP MI2GWE#+(X6:/Z&1KRY\$P:.*C^Q\48H-B17Q'_"1S.#?
Y1\!Q\$)L&'3NIE M3C^3R+-R'\B9B^V1XE"Y1\6-G)BS7%ZL\$&"P)\@2-K&EK@52745'OB94G_-
^M%SJLPL;>K^4@8&DZ>:V<6^S3\$B@#PV9!>)*Y.7IR.MI:=VUTNI9+"A&&9+ M"1\$ODJ*L=.)
(#@<*<X)V.^EUIT^HUKX25A+D\CGFP"J6!)/P=@3IBE\$B4/JYDN^H110MG:'3V)"1'9:7V4ZGH7)U0J45'*M-N-M-
YPO3\$5&O&.4YE#ENFG6:IF7)>@&[WC4*LY3""""\$QA7T=OPCTKIC6Q07XM-M.)-E0LTP\$8.3:NJ>.N@9+E;"W"
<#Q\^V\$NIFH>SU(ZNV\$G.AP:KY9A%(QQA>+I'+9WA"^@&|K M\1+(H5+FP\&5V*?
^N47G>I=^J(P1J.7W:FV\A#N\^1M?;043.1%P/4054OC MH;R%(BI42V(8'(T3!&
(2IXQ_0A31<%%2X32\LYVR!@L!^>NF\DL4M-06\$ C/L""L2-V_+L.*@G=-.SEGL#778+Y7Z"100L5-
F!"^1NW#8!"6NYD>#3\LJX+)Y+A)86)VD/ZMK2NH.2>=(Y(MLMO9*MNMK&VF"K=&9>ND3.8&"7D0E?
A3N_D=IQ97)7=KA\$^AA\H FN5\Z1(M.T\3NHQ=-15^I+DE1YPUM70\1Z3\JA)W+R MW&\Q8UH>T494K&*S\2:
<:8Y\^_ BZ1\49+2XD\$T^-(^PIH\ V M3*Y^G+EJ31^4^8.OXVCT2.1-H+GJCM.MEK Q#;N=E M?
Z4TJ.R>4K0XB.NHU)J0082:HI\ DM&^1H3&=7 D=3JE32RSE5^N#D.Q* MH^REY-G-
VF3I*PS+O<9E\XJL8G5*ONL/9NMY21%KN0H7!0:DK*+TVF<<\$!^L(M270<,U(PY_(Z')5V>8*!/#//=
3H75Q4\|O8X\8S-?T"ES5\H+PA<|ZFZ47 M7X1*>YN\$?EF>/7!^PS&?%3L7H;HLO@8R%521\BZ9-+ #)E-))N
Z,A,*+H\D3YPLDV!?.VZ^&.^S.:VS6)\JG:IVQ*.XH%7B M3BI.^G2F6WR8N)172=I^DP+T?
R\$*%&^3!^?K=3=*TQG.3:2G7)N60VY=F\NHS^RZ3.N9<==*|8;##QY)%S@4HMYWJSHM9.R@39%Y8L).FS14%
MT+)?L=Q9BA2\1:1T38:T=-.AVI%RU@|F.F1?L.51%/U^F\$#Q6:IX2>>.@P.HL4Z@1: &-'Y9 &CKG
ML29>9G9JZ4/M^1(39B?P@=HWE/C/A,LGA)>?A\$GGQY9?L^EO3_%825%<"13 M' P 2K3LB&T*V%28YY04(G=7S"X.2
^KND=Z5=[M;|S7QOE^-AZXX=LFE_ M\X8L^ZZA\$;;)R569L)\J9RHAKV;^V2^6^Q3+GLB1B;_+>?4P2M0^H-;L
M8WIS83<*\$F5-(N1)"1GU04\MR30Y\$YGE04MU72R-DMIV>+2AO*#6)\IX* M2S^N4\$ (TQ)"B<-
&9DDN\5&/E)G<53J>>;S.U:\$4<3*2L:AQZ\$&A04&&K/MLF(L=2@&:B. VDS^PQ_D3L5^K^3-U)APY/(.5*D:O ?
CMM7+JSUF&^GEH?0 M\$4%JLR/N3& 1.&P> PW0.TOPKS2Z&QZ%|3JF>\$W"OQX_H_7T88OL<8MTQ\L M;/&
(\QRF8.NILJ3R1G0(5<-ON:HI9G.*4\+(|BFB1279)5-U;D#&G60*LUPI MS2U%@&ZU:&9:6DB\D,UQ-
%)NT>|CRE)E^H(+DI7\$GZ=Q\$R@G^W60OGU*WRW: M^IKE.H5("GQF6-
)%VU" L2U=JC5)%FPYS1\$L\XUVLCU21H\VE;..?OXQ6 M\T5.=R5'LY(C*|0=2/34"PB:
<3JZ=6KSN)::.AOK+V\7@N\ATUNN^IR M.F.U.^L+=+;ON,X@N*.)PQA7NNLXA"PJ_ =|P\XMX,+9.RP\MT9/C\$
(12%R4^W5E;=1\$ PI^*R5E.(S:"^+J.C_(Q\X#IA=GDU?GOYV<#6^>_W_M6T!"T\|ZA8#C.RM!@#4L?
7\$H;+ZE+ZI6&5HXQW:NF4Z4E\I/Q= _J*?RC MNV*6VB,4N73\$X8;&>)S2N<&@Q&D.HUOH_M07R OEZO%
<&F+;211HQ*0EZK6S ML9D21IE;-8;.53UAD;\HJUCB=U#EBDUR^Y)T+Y5UFS'OCWBD_2XX8*118 N
M7E))\$S6::S@.O98HJXO!BLM901%M\WHE%_FUVQEF+9ZC8FL&Q.S\+J??M+<_#?W/3?_=C-
M_ ^TZ0 ^\P).MO\CO\TB3@ZN-;_O.(J>YUL01OMN).P.2,\$21:SUAE0%? MYSS4:@-
L:@IWE+.\$#LBG4B\2\X&C^10^D-\$C+M)R%M:.\$#08\@6:.(3E^ M&M;T@|?T<8\53?
JM:+7=FL5H=3Z_=#N=R=8,76LLZ##&E\$C&U&^CT6VML%_S M\JC?8(\$%MS7
G@U"MU^ANO.HPW6/\$M=KFIS@QKN^AUO)%Q#YE<0%+6%;1 M:ATS>Z;ZB<.;|GD-K_HM82->Z(3=08MZ-
5R,8K+MP T"+XF_NY%Z157F0OT MW^=YS)8@X 4)ZT4-IP=YV*L\H\2""#E\$# IT%;U\5MA+TZ'3CTOX1<2\VG-P
M=4U_=CRP#;F^J4:2>+&M\I#^P_B6V9'PU%%O M\VIZ"Y2\|TLPE-
5@B*5"9C<)+?-'1646BNZN\$T*QZ.S.HVY(6%9@S\D5I\$H9Q(NZY&RP|=R_78^A6W=&._M/(NG> M'/SC\|QD'
|ZM+X\$MDQI\$V@|3.#6OU*3.QY3-B_7,6YI) MBT &Q9B<8(&JP-|+S.DOS2)_L)-E9QHW'2@2T\2_ \F(FV7U-KS
<.&*8J.PGFI\$W>N\51HZ_-UL QE,++@+(6F:J3*2TB(2=@3891@+QR,J6R9KRH05FVP.VT6FR#-NH8)Q2\9#?'1XY
VLRJ%G_&"4>#|4X(N^1^DR.R>K M.DX7H0EG^E2W/BBM\|>4.UDR|=A_%AO.TVL@?.;9-N(>LFIE\5\9:.*!.*U^
M_ |K&_LED)I04MV\Y4\OI;\$W648.1+4=299@QSNY)2Z'QS\J29;W\H MY/8W0W+|BR71_>:VM2DI#QV/N\VYXT+?
3>X6E*2IF6%V\@(\V3TJD_8'F04 M.A0\1)\LZ/-85)MS)C@C""F^N19N;DN^I#Q\$5EI2C^TSI7DZ;2M@""?WQ--IU
MD\U/BYFO>/Q2IT).1S5%>G-(5H\1>)FLY5_&%/ PB^.*8.FYUV70B8PL M\VND2PSYW=K(++?4#_?IA(C6 Z+PT)?
#R*4WR#;0>W'+>|T*""TF.U#!;..CD: NOS8C+H(X5^S6Z*IS??X^JX\?.\$?%61@L7)LYK:-\$HU M'_K?B<-QMLWDL&
RMVK5(-1-2:@6;WDO=EC'Z5WZLF MO\WR1FHR>#T%7SQ\H^35Q>#5WW7:OS;6Y"M-EM9>Y\|L)\240<1SX7%"8
M\7H\|QAT&X9G#C*M;"E&MOD"FE31*|@TZ=Q52F_ZQS.\$'-QV.RX;8X-F_B M 34\|^@WT&^OV,)>%=)70=C#<
'F\ID>.*=5;\$I&|^+ALON\|R80+T\LKJ/8
M5?|AN:T8O)RV&QWO=D^L%RLPTW>=+&H89^!|@FM\V1;|CL\1.JFBE%K*"H58 MR?O>.2G&=H6\('M3D\7\$=Q#\$C)
<3A^JA^L9P9PLC+GPR^Y+I\$C9J_3\HBR_3&SI3B+BS+)>6DFY\NFM;TYZ_QI\HDE_-#;.:0GD_A&Q3YI9+\$(('0"\$U=SE73
M3#Z2QR_XU\$|2HVM\B4).XB#GVI^?7V\|GRES2)B.QAR\$1*:MXRRT_)K+|E\^MOOX+I* T-D^AC3/>VH\A1R4
PD:V&3\84\$#>Q-I^5EX7_#4S"\$D3_-|J?"X.W:L^>_3Y@|LDK4 UO-MS\Y.7KT8&|GV\8H\^E)HM.)KT:;XBE*M18=;)?
301*#-A\|C\$H<0FB(O&L=P(M\ZH.V%-0\$NL;+ #DFB_%T.O7;J\|_FI3\1,2):AZN8XMD7_-NV@/\$Q-=DQM
MB^&\$S5PJW14%_SSU:5D.W@S\IR.XW)DEIRR,*?K=+C'=H?@3Q\|C_8P?J\$1 MF%|G*DU""?
+PS35/(S0)+\$LP7\|= @8^5^6NB=H<"WH<0OQ@3L2DWW#BDW!*2 M#74K67;8EM7H.W\T3V@L
WWI7*)0END+U:E9:3CQ11S'E'D1D;(TZJZK_M^H\|C1\&5UC)\$C%&-OM4:.;@6+1TZ6#!+156+J#@52(8;
M4K\16P2\Q(X,10016S2GZOJ+MS4%|QAXDE2?|A:L_!2E%|&L_&FC-A\5GOTA+:T&^PIH\|)AF5H= SMTR^I-
L3\|11E8UK04I9^P01>8TZ^+&S4%|(C^ST7B)Y(I+86Y@2-?756#K*(BL0N?UE1YN.C7:E8.X5Q\|,350_-&K
M7B".I#;3U>A?Q=702\SY-7)V>1E\2?)R02(WJ_A\W1#?>Y)P(HK@6&K>?&^9*%<R MV\^S&M7B9\|GER1?
^52<5AXRIT;QV^Y="FKR(2H<1\$|NU(L&M\$M//OE@/_ M52_-9=AV4DFTTV@=#J(A%DFI8^N8&\25B(*4NW\F;
(T#5S\|MX"?4#_+*G@_M)2C6#2/I_>?V&0-NNIR^T7Y5YT_DZB8=-<*ZM;
M4FV8_-4@FR_/KN#YB);>8@-4;\$#U1)=ZOZXRYZ4U#I1?M#@U-;#_Z"3B(?
MF#;|J3T+L?";DCVYD\NM#*);%_1^%EU>%O\$E_AO/5*1.8V.JS^C2(U#XX>M?_WT6-L*KW(B8ZTJ.&BEE1-
^3%E)1E;"NZ#MU>21IE,0QO(BPH-WH.KT\7A\ MECH\GH_QI^T33X3IC8J\^P7?04H=-.3M6
MX>Y#K@TOZK)M&&.9VB*2Z=V(99#R1H^FY>C)XZX&Z#>-PMTNU""KR^YL M^KY\$8*>K
S%IEF2;.BP.V.U^TAM^9OEIB M=Z+MM(2)H&Z\|EJ=TW>L7WO?7COA9IT_4R(N(U<9\N6F>(VW*5?Z\$E35A<
M9#MH9W%4H\X9.H_FR9(#XB^DT1%-OS+;8 A_-I6\$AQ(XVF/H_7KB\|G
M)XBS@+W^P\<|RO^F;|C&8^U4\49;.PFN8V>>4)S8?%TU(V:X4X^@8G1+K1 M^_%X%+_7?L5ZSF\$'RYL#M\$7.L
M=7#6_00\4L(K_&O*K.43IA*\$_-T*34_A89(&U-WA*4"
M;I0ST#0\$+>@D=>B\$>%83U8DP\X(BM5VM\4)TW&97+U2.LUU&|04H6FIS"X\I MZ'?
=LU>1I605^\$D\|S\$P%K08;2@;_I32@L1FWI0L2H^|H(6:V*|VJ1_Z7J? M6.3:HX;K0+NA+P@22:\$J<@FB:H^I'U

MBT%.^/H) S5=LG0\$1CC\$*W1U IMV=!!?#9;^/ @V8GB5CE,R= MS9!*\$QW,?)64H1 3NE2"=,CKDE:Y;+Q#--
M6K5K_KMTQYY3NKIM>O?G+U^?G*" (G@>3"X&XW/O>Z-GS<"KW-J@PBZJ ?RB
M1K1/1E"2B3=XV2J7M"1!!T+;J).1%L4)=)#Q/JM%%G5Y!<@_)4Z@_W/<4 MZO=#"O7>IE!OU#LI"VA:C9^NB9#
(M,@?;*(9DF*2*CH*DI2*MJC(T1#-I V M\$(@/F&,(I8D,"45-S8R35,1IC"SH-Z"<.\$Y%1.(11W!@JU6=8<48FNN_19C!
M=7!8-?M%MG,FR;8!(07"OQE3KY!&_#5J+!H""/JH&RE12,(R\$A1XQ&P\$!#"MHU9B9&Q!WU,7<\$'_PM'0;-I>^+MA:.*!
_KX(I R M5D+TNFT*/13"T8XE_LKAZV>2(IQ%3'JZ_O3)GWLUE45J9;D!O:&6RD?>JH M6H1-
*4C3S,,@AABY9;Q@T;4^W61,*H,\$X.2K(F+!>DO3ML5P4UNJH M'PM;H,Y0_!EW-*N) ?6U1T@C5\$6--
Q!VO0S!>415!XQ^2^RM)47@<'G/A,O- M0Q=P#++N4L9'SWWT/_9,L^E6%X&H+SG;+8QY^2@'YLM2/K=(C%>_N2-
<_MN.G 16Q"X\$2%I=D4ZR9S/7@;_NACW@CFW.R4JO\$"?;:!T(O0#IFE5@>)!+ MM\$0R;EH_BGO_75/F7P^T?;9;
S>N;ELIMUVI^VO>BV>(W!:_VFJS:EL>-MSYY%'!+3!)_D8F-YU9=L0 M!H!2B.E_*.>IZOYTOQ?Z8_(D-
H7KN!%;="C""X%+!D@_64/GS!Y(O3KT3U6_71WV"MOBS40OX_M9;#%)B?;!X-
?R>UTY&A=@PI882,S!NK03)5V1Y(*8T755!G"V*XMG2+WOBL M
2WW7;%=G+ CL3T_HUFT;L.P_\$(U65S#"54IE/4;+5CM'R)"4T;I9-2&ZTHYE=/O=";11^B4%AI%-
AW((2O%D_2I0>R+>7E!4ZSU@?\$(O9 MA!XP?0T_88P7V")_!9E6X@W!Y9LM8B?4,T0_) 7T6,>(6!#8,D-N1)-
M\$!+Z7AD&YE=%XD;+>ZS'@83!^XDY1+7E!R1=H&E8XGZO^A\$U!R3W4T&1 MS5+%Z4;JGBWQVH?
CT2MOGV=0^;_UF&U5!#;Q M60MV#+NSZ @_VYB+ %#+/*0@"97# #1O=J;616HDIK_Y ?/9-?)6H9&!(S
MIB4.0Z5\TISAC_<I9_C#D#^A8G.&W_?S\$VZ(!.1VWYO71O;=M2(FI&I.U.A9@8EB2;_@= M?
*YIE6LD>B!;T:TIE853GH!_A\$8A%=<=>4(C!U!>1M@*5EIAVUD M>\$DR"W6+D&EOM\$SB_/X/523P;T=RG>W#
<<="/_JO_!^NUJ.G=@+>Y6+=;LT2_MLQORNDUN/7;_U!K/8H5CVA@DB.IV99R:S893T5&G;4^L/6#JT.EOSBLMX
MS77MP27B1#X;AB0D9_X7B\$3@!O^4N>=JNP/BK-H@;TFQ.85A+X2/XH=,MN;!>+>KWP55WRDQ+U28+?E.2N?
L!AP!)W^'PRA!"V=S/GBX026^P!EIKDE M>J+8Q)8SZE6,PS@%);E4SUN%)Q?ITSW%\$S=QM^,WI!TF:VO!U&1O2?;
IEL3?W M:VAZ/P_02\?ELM!EX46_WI!<7)N6F7!_OKEBY.SH<+CSO=13X25TS"+8GS,
MJX&V,E@_59;^,S!H!U),%JL^,AIY"EINY0ZP3)DG9& A3AA!YO#E!F7 M"8A!5;H!T9-QV*!-
W!U;-7!)T(U'C*RJEMI283A9!KDC>E)S_XR8/S%(M&JB7WXQN@"0E1"*0C_!71+Q!6KF).2!2^!NI\$
!U!>A_.10H=47H+&"GE M.YD6%9(7 "P ?CG5*Z*!+;D5CB!F R+ #MSB*A;G!KW+AH-\$FS66E@4C"LP
M'K'@RCOO'/SWIE0BZ0_K3O!JFS2V5+M)DK M#3M@CSO@AYY# #P15!G)?5! 5G@T(W?A0HV MS
HQ\$B(>AOAA*CFM_L6P3J M6L C4)G^8IC LEZ5REM.O9(V!%\$DM;EJ*V:CPLJ)?"WEE&S -MY T^Y:LGNNVU<9?
8#10SE3%0TGF6C5!"03IV+!^UR^GEBGDTB!H&""+V^ M*91*NLS(59BE<51024I>@_V.I\$2H45#M3(QM!XZ9-
XVX0!%A!;@BO#_QDJZA M%)!6\$#G;I>T#"N@<2,54&\$N/H;3A_SCXQ"<I!#-4&\$R35V2-ODQSFV:L9^M)0!S8LLWK0!
(^=VX&XIS;H!_&Q.^Y7J;+.#S^/(A)KM8="43OD_9Q;L M10OI#3/D6I48LV.M&4>%GZ?"W^+EK@!59,A!->X88L/7)-
CA0HYG!H0L"\$83WD_I< MJG\$4K!0@\$\$_!9+J0JA_2.&723CI+_J!L">.%1P'0A#81.4&71C.G<4RK;!
MZGYBD^RS!0AC;R;JYD@*4U*+N)"^!9W'.0CCT+QP<2%(MSJE#2XMNA;+ MK!D!;/8OHYR:Q%;6?
9X1#+C0!Z+1!:=/5!4E/(Q7K!+!%QX\$(L=J25V>F7T@Q9L.F)'EE!+!.)9 M\$9_#PI^Y'
#//M/HZ\$^!2O6_!L60BFR7/2@/= #_KX3;&0RA8!/OD&ZUEAIS M327""+!<93E0H5;@'9K4^X\$XV&+B'GA\$6?"H;
L%X%=";#^;#OPEF;\$K;1?PT>+!J.J)Y!TVXH8A9!U\$K2!D;C.TWL\$G;+M=BI3^6CT%?=-,VJ_HS/0\$="!F\$5\$A
4&G7M(>"!X;_!>!)9E^TMU4IUW0'G<1(+4F/FL94U"DYIM^BA^R(IPPFRE M*,BDN_!+4+H8!O"BN1H.G!^P_82K;A-
MK+/!/-UYU??)HR+KNR+KN\$8/Y_/79F!>GD XO3UZ_@!ES9/<.?OU/<;R MYNSD_.35!7SSKO/D !^!O+O?
9TO;A&\$!+@6""=,HIFV ?K_XV#"T4^MT MRDT(MF;!%I-DOLSAI3)B7YSF<^<@8*!H#*HX='X3;)W<^@EE4-!A?=MP-H
MOOREFF=>A<8%>C#242>@340+!G.MX!"VB;\$G6V22/GX?%I-\$ M.#K!%KGU!D
LOH8N*%EF&T%X**>N3=2!TS+UNEM>P1G%Y.P_P>35B^#YRY/)&6JBWU^_/3!9 M%;Z=*YR^R-
O%W:>K65!Q@U6JZJ\$."C"VRNL@/25 ""%PRPH?+6!PVY%!J/Q M=-
EX=),RHU_T@01802;H!\$VP0LB42;W)DZ^C!33IY/I3WO!V_I?UC*E3D+6'?X!YHUR:8
MBF# #GVWR>K>M5UYR&F=B#16 RD MMGD8W0*QR)"2<+!IA(V!HH#(<%"T/0GX*Z.6HHPB8XR<.%_9CJ0DH?
H<8H0B M^A#^#7!0I67>+KQQ'TT.H5TC".P_.\$5A'M;#8+UAB+3G*X03!XI+Y*3<7&D! MO?>2=-.B40I8'?CS?V SE;
V!O=7<+&QTL;Q4S>3%GV&*Z84;Q0(9 MCLE5B5EF(8%1T0!8AC!>R0P!;(T#2;1?..>)!\$&ZJ!
<4,HN725T@DW1\$A^!)W M?P%+L_K_M0;!>(FUC4)G%BJ-6@H*UFVR6J=Q2^\$<^S7XMZF!WGCJQ-&CH#.24!CQ
4X#^3!"IPWY M9^T=X6C&DR7V#1@B;UDHV18_RKF+!#"%QC6J4N.J3TP1!TFS9D_N>+7L!9,N^ MV!K%'WO6*\$X;*2
Z^G+DJB7>;U\$=6XRB)K4>_1HX!ON00@0S?U+!FJ%AF5_MP*>BRR)F8N%I7%W'0NFO-AGJ-PHZFG\$>
(>K1!O%?!;SA&G2J?HAC1+NG#J/ M5B!6I=0!221.GW6.L2!XQQ.QXPUFGCH5*SRNEM%G)RBIP,5MD^
ME=LMVC!XCD"KTT+HACD;W-S820E&B!73;71^=48\$5JD&ZK'!YD_?@W&>7 M8)&U<2X!WS-9!GA^55=X?
Q!H.LI6^1R3+G 3T!;Y-C&1E&L^2GB&U^#_MR3!+5#^"V<^ (JE'B",=M&UV""^%U%!6HA9#;MN&L!IS3N%@_WN#V
MYJTDUFU4!K0D=I'Z?4M^SKKCEAS18_ EDC*Z)8?R!3)4(&#_KR,Z<12UX#9)
M>&9;-8WD21(&;&1JS7WD^1AZA(I)IV_OME:NP?#L0B<.4K5/J>I9;O!QD>- M2^,;?WY,M)-*RH/B=-
M#PQ+OP!M!20?JF1F9C0.CB!\$*D22(Q.HR(28UK;).5Y*FL_U M3HK#)@-VD;S'\$ WV;Z1SV(%54(XI)?#2*#<#9OC,Z;!
<^!_K3I&!*C'Y1P62_MOB!>?19KNOEPDVP\$SRU2XW?#AAQ7ZNT+>^!V;H!8+!E!@Y^&B4ZEM8(ID\$A.V8Z)!FKJOM
M-AC=G_2!013+!Q*L)LB4CCF7.36W".S!K!CX!H!T7Y5YT_4Y+M;LRMU3E> M&6C""!JDJOX_-(AX&)O0KKEKDDG1.3\$
M3IEJZ+WR@X19EW@3M(XKN2)+7E M0?)!6C_QD2!R%A#175\$KA2!99IK;G!MS"0,>G?Z:9M*!I_G3\$/M>>
'W4S+!E+OSKYP2,5FOZG,W!N2? %>6^<3>FV!6/4N!EQ#*2VU\$!\$1M
M&W2WW4U/CEM!^J+);S93TX!-4T(K=*B9*789C/1K^V&J#_Q5=8M!J0!< M6YV\$X<"Y&W=
<#9;H/D^+OB5RS=/'S:F^\$5Y=0Q!B_!D)5A%+H7>;M\$(&1K% MP!%&W=^X37F/AUT=JKA,4ZBUF69-
;43MLSEF37MB6FIC&1)R!^=2"FW+A8D7_MRPQ9R+2=Q^;7HXGY_W!>7GZV^ESJD3\$9A2^#10^M;_JGN6&>))
(FMA)#EC+T@3P^_H5PP<9P? "<3;_X21#WO(H>U24;^IBO;)> M3&3Z%P7FN+2!5Q*2TF)\$9TH_#1)GBF?
F)2GR!@37MBX>>:0D3>B#133XUH M'7BU&US_P!H="!ZYH"QSR1\$#@!H!_+M>.C#!AT(IEAQ252!;ZY&E-GHH5Q
M!CF0K!GVD&)/4XD)=28Y."/?Z98H!H;K,H5" H8C!S%&NO@JRF;_>*5-8UU!_M!J?Q(" !AI_*#FV3*;)UAJEM!>!
0!8=F1_EZ68F_@<1S_.B!ZK8V,7L(M MC+J!"!F;X31Z71"SS.L+!O\$.UJWSI^@JG; MU T?YAR;D-ZFT)JTS,JHQ2!)+;
*LPWM=B08FYNDNMLT9T>V M"X ML3/(HU6=5@E'9>E6>8>3WVZH"S&#%M,CIAM MQ8AL310-8Y8"IG
DOE!=UMK_5N#C!(W!L.L!VF*68H.26VNR^TL ML=R&F1+TCH!V 144%6%F-)3L3-Z*-R!F!>*0NIJOZ?
H!H!4>%2VT(KY-R M&;N7*!DS? (BB/P/R;J.T!5XQ^!DWP>S)8NZH%WIX'=RYV:VL>TR+PT)F_<
MQ#85Y=IQ*M^9%ARI24>/!VD;)DA9V8KDH\$S0R.6=FD9EYC0(&IOH0N;11EZT.0_!TD2)NH6 M*D!YP"!;Y5QFC/-
(8M4\$Z;5!N/Y"XU;O<=,BLG+XY9E<9W=!)MFM)XRR M>DB#)D%VJ+VXD!(&DT#S3LB6<[!;!>?WOD!_SXN-
Z!>BE%M\$#U'Y?47E M8<"W;A!MXT08%9S.JK!9C*6@H6SC89"\$C)4*>3J)5A0+>PX_@!D?KIZ+!)C
M=X2DWCGXZ8!_114C2OBEN.*L!UH0H4PQ;YZ9!%_F*+^!BD4D*8IKCVQTE M0AH;7!F=,T)Y7:6_IK!
>\$X+QE2!>B\$6B)7!0T5RBC"8)!86E@F5"3-MO MU9>5TWY?O!;FU>O!HB11/M^X^&^&(2_>T!PEJDN%1D<-
A*!O+FV!KV!G M@YAC07G8J\$M23!%=I;(P; MQKCYFSICD/EIRGS/FN.VS_ C+Y4!GH;CESJ;C_U.J5E_61BN%2J^DG+BO
M?Y7F%LHYWY2U9XT*0%3<>;\$R%.YBL1@'T?2!HP&5N1GPG)KK(C9>,27=1JQ
MX),B9HF\$8W@E!!@9\$O<.@OE1!2,690J&)!4NX(-GFZ.FU5%Y@&RA4A=YXJA96<3%;U5VV+M"-T#)!/"(A2(4@_Y@
M.4D#M+S0#<_4H*W#Q50S.+!5L6_.\$"!KDI(8=ZQU(HH^!BOEMKCMW!0.9W'
M#46L;WL2N:@PZ&AM@J9;U8F"CRH-56=S;7RGY28B3*#3(F)H3DUX!#%)-.I M;_UN<1"C;:>)<6Y8!UM/"!+8H,J=

P+K0<1DIK3RSI6WBXR598.NW;>N 2#^ M@&Y=*X6Z1HI9C79+;.*+%(DK: #6Z%JB?
H34V^70WLNf6->F>D;UD>R(R3""#
M=X\Q8\$^|A\$3#+>%CA1WH%|H,%C,16Z_9WD,,\$>#01+W*HFWZ*FX@SNA=>*C
MK(^(^4,B*9>^(0GOG>8P>CBHHV+.1RA(W(TL:=OX@", MHBPT9MWMH?7IEZ
M?3EXG&_V4EO@%T/D6"5&7VU=6B+YUGf:U1I30^R5G++ZHQF+;X;.Q1><ML>A9N?
TAFM=8@N)P^RK.T|F|LX6XV4L^JZWW=@),+2V9*-"6%6IL7 9!,(1 M";D1>%WV3JZF|
(MV;MW@Y12F%+CHC='J3ZD+(,G_4IPX?H^5M2*/H @("G=)8S MV(Q69|H9++R|ZIE;-
+ETQ8&S5Q&>,B42E(G4.l&.EN|/(CHX/JA0:<.;AIH MH3X)FX|H3?KD4SNG>T1>_?KZL.SUO|/\$#HZ#
!NC770=&SWZ.O6*>E43D'4GV MP%.,<+SA*J|/DA=%?CT>K7+JFPB?K/*BND2S"S7|\$. \$VT^8C-;^C+1R|Z)W
M|")C8L""_0\$|/<\$?1RZ?|;.&"@_E.?&WO GP3Q)Y.7PX: ZPW_N"26 M\$S<|)20|CB|DE7?&V"GP_8CC-=*(V<8|_*%3P#?
QC2:AJ11>HVLZIO/8S/* MW\$6.7N9,HPYN),ER:FD/*0X.71#?_CJ^56SEH3\$S,(T51=Z MV|*|+X.*G.EQID8L?E8X8AC-
N|MN|>>L|+YI1R<"6#D|/81'-RF25I+&W=1(#+BSJA#N|R)YW"UK3J|>^./MH4F"AB(1M/3?TR1=|J%;J016IR
3XA:ETO\$(UB^=T|=,T|BME\$U*N+U>6I/(M;:@'KQ540F_#O2>|&IHBZ*\$H&N_BJ0QMY>+H#N IEKO6
M|/*GMIL@O&H MN%9QE"D1=\$PN.#7;MD*/2?JL_*N|U@_K= MJ_KM">|KUCR3*_.2\$DIYZ,F)^>=J#9?
J#U>81)89CA\$46;N|:.&"3L4;D-@ M2L&HQ R?PH<@>W,Z1C\$/3^<)*A&&.F.\$F|Z|6B>QUQ.S")R M#_5|6|I-QTWV"???
DSW?#LF>3T-R^;L|2.3\$U2^0SAMS|2|V_.L200GGS) M0+VC_*_2FIK-"JBCIPDI*_-DA&>UJF<)|J4QT:|S^_
R'55446/*#/'2/|S MKXLLM*\$K A,*!E4KZSWB)S"E|2I6MF&Q*X/_5^/A0)9(D91:.#^WP0COTX+.\$ M*YG1
G8|SR\$ _%F@(\$H9<+60B0VXU)1 _@Q|!%_2\$S\$?9=JZ+-,P07US
MV+ "P1.EOKWL@G+AHW:9014/1+VMT5'B@>G8+YS691YMQ6J-%IYPN45=U|KVJMU86 :@ "T
M4Y|UY:RRI#D7|OG?J_S2 N+Y5YV#_J)1YV%D5((G1S WX_)LEF6Z.W""U22P.8DAIO(8;C?G#U\$O>><0|fWOY;C
MTNF|H6==EW^F%#*\$Q&Z6VQ7TOOV*?_FI%3I?HV&@*YB=V5& M2\$UN"P,"B+A"F%@B"MLW5S|D*)_#LVQ:&?
AL&F">@49GJY+@+>\$VD-?'-7I&M-"T(V 8:|10<#(=%N7#6M@DJE8?2+0&GXB.F.PW\$U:NR>1_91@|2GV(E>2U|P
MC;GHA0*QVET|S%G0_QC|+9MSA0E4=|HW=RQ_M8/'5J|:@2G&R>59/(-5.99(A?PF&:SM(ZJG(7-)4_N|(-
##DJ|8W:.#"PW\$3A M*_.2K^&F*\$>8\$<>6+>"S|/5(*KHA@|FU2YLFH5UOH MX"U>D0>%G-@=+;))G5-YXERPT*_.7.!.
R*E4-S'T|,IXU%0%MV*A(\$_R|H1-8L7(W^>\$VS=-
MBPD_(3W;B.N61|J^7_N"V;H|7SI\$(UTF@>1B|R_M^PO;M|>2K*|.1F)T(M97&0-"N(%->. V(|^|E_N;S-
(>##9LHH7|B.W2K66*M_=SY<=)3@3W2X|:@SPV?A-&>|T_0Z3_|BCK@,|%)ZEDBU:|_XAO)N.OE.M MN|N?
@H^<643K@-%5S5Y|3AF8U?;N3VS_-4POY0B=,A,+K*47|:@5T;TW2|FSH%3FB<3)SSJHDQ=T^2D\$)?
VXIG@|6|H9M|OET24J1:Y.GW M#|)M";<58N^LUY><"?O^OF?"OALR85|NV=|C6Y0C^ TK9Y6T8T7.9L|O%WEI
MR58'N:44&4 E%A|/%WCELV@=S11W|&BT4|03Z1WS^|X&|9Y-LF 'R#X SFED M.BL%2@-
/(%IEG_#MF>_BX+=+A;8P3_@4E.??_GCUC|BJE3 CY87NL<50.MIOA>1?B#J@;.\$+28&|I8ZTK;|/HHXE1|;\$-
DL%01D:NQT(039M3FNUE)8V MCOR1>=R*00|M@0ZDLP"=E9Q1|=?Q^*FI-OV_K;D:NZ+|L>U|V MGLW?N/>
()>|NP3LJ2M0VFXIY9L(V;."<\$91:'H %'^7T?*=SA.??2^X_|Z%6 MMN=R
FX22*%J_9TM=1|_Q""I&^D/8/FSA.3S.;4S%1R(5AB^W)(*)_:|OV4 M+;9955.8F(+G|@Y%E@&
|W>6|TQ9A\$3CGLR7B|M+Q:|Y3-LE@J8Y8*QO*Y5XGL M680R<>LWG;.3#GR^|)N\$X4HE(V)X&R/_+&7J^-"(@D?
Q@F+ED907?'W'M)| MOU"CK@0-D|/546=6/S3\$|Y&M10&|;|WRA1E8D=.R\$A)?CKNRL%"UR&C>@L.M('D%,6Z
<^D\$OXXK4|TKC%>6TC' ED%@0RUVWY|J,"40TL: \$L"TL:545LCA M|&8SO^V,*L^6.Z4/_U)6(@?
>6PES'4+B2|IAG0D,=Y|:K9_R6*Q\$M3F<_9' MA1.#;P/#L/00.NV#FMBKFK@%VS&&!. 4C#;:Y8-1J>L%1;#).\$
MLWUU4FUY_XZ)X|MU^_)AD44|H|/"Y%_S'_D^M66UWQ&L8<3L>"<\$+;<6|H M\$OH(Z@_YHDP;MY@4/O-Q-?
#T>40.I (5C%B*+@KH_#X/3|4H(IY/T M(M@ATB)-V>8;^1G/TI16BNI8"HY|D2PJ/%G\$O@05:(HNF4"C'SA9:6<+EF|M?
15U2+0Y|!ALQ^&F|HK;#T>=L%>=T%O/'1?4>:B"4+0;Z1-PCB0'15IN,T&
M3&^1H8.M0;F.0.\$;C3)5%LKB2+E+EUD5.B|S.0D|6|RXL@?&:RD|VIO1H=
MW|,BK9J|>PY+|HMV>G)^=L WF#+=2P|G9R?GIRZ&L|JUP.?#Y@0NTZH;S M>B\$=!Q4=:.\$D.@YDLL0SR-B|W6E!%
|V*G0_L?54MI"Y|LKI13.2-Y>|L@_DT(= M"M4D=*&'3(@+BOES0M4NR#HOY",CT5+ #U0LD0!:-
>*TXD#3BLT_0\$XP&|Q3AGE1:HM)_2&X6!|)2C.DS*BZ<_T)46P47LX^(|T2&9;^9=| M\$T6SI268.E|&Q?
8>ET*YK\$R66A8U3S"(CZR/1|:.)\$74DY7|I|MCAA)QC\$|D M*KE6V*?|7-P|3"A)WJH-ZVCC;M7;.<&YDMM/EC4^/_&7CF-
KA%\$AX75S'3*F)+BQ2Q|TV.WIEM1\$B<|CK(LDBL)F1@\$.RG>,_/-SO:D MB4Q.(U
|HDB>2WKG172=F1)G18\$@NQ.UR\$=QUSM R#_(VJ16|_ZD?%6Q> MTU!4I0\$2*N79T@5>1.0S\$%
DI9B;6MP3|;YE6"!@/5'90H^NBV3OF&XIF-L M9LXLZ=|'=ZQ2;@-@.W-PVUE<9.98=H<\$RNS?TJ>%N|/EF
\$@ZG|K%DJPEWQ)8&_V(|)E\$4^B&1+M)W9'7|KR)A#D<::D6 M*9R+;.%+P.3;F+@BEL=3OVTB39YW;+Y3"U8V
MO.T4|S\$Y'5B|A@>RL|LH|+2**3(K"6;?P7@=O7E;2;=0,|M@4X=2JC;-(
M=*D^@=,@-1|:GJBWUZU0K73."H<%J;+*G;|!JHRU<7Y2-NP'K# Z3A(CA M*#<,*?
\$/607@2|)#0X#)8UPTLKO8T16)*2S^ (WM%CD|:WAF|NV%-@VR_BQ_%' M=N7L>R+9%FY05RQ.05JIR;'S&\$Y
G>989T?_IZ|:N+|S"8O'UQ>A%,7KV M_WOU=O(R.#NY>'OVBCYY|L@J"5(>U|YWO|KW6|WG^CD|S\$X4)B|B%K
MC8G_-J.H_ZKS9Z5ID&Y|?'81L@P#7/<_W+L/8V P@:'BCX/&_/*A>WZ_3=MD@M_O86@ZZ*FWJX('YVC"=8C|5M*BZ
M4MMG7&J#NVH+48+H:C1M)#'2#+&24*F M#|MFWECC^YHRHK:BAT%O_9S|5=&L|LY|/|<+*^7?3<8'+19HJ7|I-
A(R3 MN3(XLA=|+>Q5U^@00%K#R2&Q7|/L3T)+P"Y9^E_.4V|C:0.|M'E'O=A\$7 MA260<|*|1+
|ZCT3*CD!4;\$5@80+9|IKK9;@%5;_)JZX;_YV>W8BE M1F0F=|R#E<|F"5;|HQ\$=Q-3MAMWZ-VSS+FF"
(:0&,"\$ _9ON|HZV<|C#D<0XB MMT^1^&86#6N|&^(A7%E(PAK;%=&MHN+0IA?F2Q#;+VC%?'_DOC(-IS%9E"18!
|_"6#H?IOIDT:/R|OIQ4K^ZPPJ-T@ MM\$EGL23>9POMQAI8%X;9#7(*.4@*.*^KI4HG?Y M?|Z21GIY/M.3T
M|3|Y.Q?)T|UMWOLHIRT:.(BN;\$|33MH!U_Z_OWUBTN^3U)9_VBC3=+%HG
M%366\$(SA*K#E^|RL;|=B:F^|X|O\$|;12A|H\$!=<8C\$>.=5T|GX0O_\$7.8&'
M322>2#1S|L;DYH17;)C|+9XJV_|@|Q"OD|XK2_'X|5K#X=X1&C#S7\$7_+!%(-G|K)5)M"B
M"%9YOZM^ZV5&7@/8T+;_5*|_V5S6'0U|6.OEB*ZJ*\$BN_B0U0=O|/"@3.U; MV|GTOS#)OKUK%2J-/|"K*P?
ZZL|2&L^QSPPCB;_>GEU4RC,4K1Q?K;|L>X*OTYU6FT,U;("=+/\$G(-M' Q.69DE4=
(X0TC94E/Z%'&O46ICU|WDIC'AKIOG;8W|HHAFFK30K|/^#83/ MH7B=ZL/2FKU4?<.->R8|_!B&BMF* ME&O?F?
RX(0W9|M;?FZ3TR@26|-1K?@PV7Y1DOHO&8XC?)TR0*P5E|HN-QU' MC:;F" F1M=(KVJ1P+U48|3IA*(T(G)O|_>U?
7V|:Q1-|%Z#_Pj;_!M6F:YN)> M-C@V\$ZKBT0.9|NY>:2DE<6&(@5^Q'%_ =TS,|M;S=U8=T\$=S<>'
MZG9Z2\$Y<_PF+F\$P&41|3?6*A.9L\$E0:>*>UT?@A25_2^W4R>QW|YR8-FBOD MVZDF;R.628JAD?2P)*9X)\$6 M(|H.
|@L\$T@1P0^"UGE6DY)4(^_D) MP|RG|Y7V%&)&.;1>7Y""BY^Q)U4#L@E<"G5_*_2|LSME3)600)3\$>LZ)\$I M;EBGO-
ZGEEX|Y|JAYV)1&+ CHF&C+|C/DW&YK'7FA1\$EJJ_>@-/A>TJ M7ANJ*%S?;N8J.2KKBD>J0ND-6D<;DCYL6;-
|YX70/6?>FS7?@R|@>QS@|F M3@.7|MTLNN;TC^ (E.G+0-J?K^|2L|^_6?&X=9_7OYU.CWWWWDW|WXZOWWT"
<="7AX|2H<8&C|\$SEQ" (B8I MZ|ZD)BD_-+3>T|'\$&ZLLQ138&'L&Z";HA2|)1|O|U>M>C3|&\$4|1@|J_-C
M"JW51A|M\$DLO>|U+4-2'Y3M=<=TI\$9*2'O\$Y MN9"SS|NE?H1>N^@=RVZ5B(J;8I@R)29?QRA/ZQ_VB7-6+0RA
O./9B;EW<:< M+;S 6.LNO;%#;&X*VT'(#6J;-#;FV5-Q?>4HRPW\$DS@<\$^_R<75^+0OE=_! MSNU(2%'NN1
*9.CNB08X#608")D|% NR"0BNJL5_@+D(AGTNZVF-XXVNFLP MA!-"&.K9#0.2:|3?H\$=\$|2F4%R0QI" TPG-D1G
3|7|H(3G2;"L>PKN>E!A MH8|&HE09<2-5>.!>P=1(1+W2=5)C.&@5 MW.7U9^*54NNO4.OR?|BQ^@919D;JQ
>E_)_K5C>T|>GP1KJ4S(4^X'5G|HY M&_!/(G.FYK*I+Y7.QU*)_4QWFXJ|C=A5)K7.R47_DC>_A.W?.\$:8"E0\$5

M9Q667V3K)PN17KZ/IOCE1FWDZ\$ \$K.7K11D9'V'"/>T')/8WE\|P9B>H XJP)9R
MM@0H2\|MWVKMPXNLV0?IRZ&G.IH9FK-O@G;/IH\|B?V+;F9Y#1/%%(1%G MI60GK*0723UR69CA0:=F'V?M M2#-
"+UH/1.04%BRE:N726R\|6N?79S*EO;DYDGUS?2|EU'.?ND7/L|F=-KSD.A+4G)0QT|/RX8"!8
00H5+L|&9F)U=B)8B>>4TCNZ40C"2N^QB* M8'UJ=\$|2HS: ^Z|86*16CSXM%/C=%
(+0"\$C|*@551Q&=CR+4 7P44+ #9&5&J M@\$XQ &? =C;DL31WTK+C:5A(ES\0
)16X8|/S8(AOHUM2=YQW8'L=LB^ 7? M.GS-DR^9F.&@L#&>;V(D65FT5%=&T>>H|Z?#IX* =5L@KJ(X622|1,0FE P+
MJ| KC^E7P/Y4WW:&^QZ|F ^*KX(F) 77WCL/Q5"Y%3KB\$07^N|=2&_G(DV)%S|Z0Y|5.ID:9IWKS-ZH2\$V&A5NO|L
MB.LVXHE<@9L1.D:G?FNX;'&2'=Q0YQ."BXW;D3S&A;&84B?2M+F\$/O1|H M6D?;|D"Z.+Q(DCB_H8^YGF5K(-
V^+|3'9Q>SKR)D|LOE-4|HC"=5E&-)WL M7H|10DVA7DIM>E*7M3TCUAC;U4>!'VNY -M)C6-!2VDC*/P0P| %CLM1Z
M*>3/VE3Z8>;#)UFX|RT/4J.CBK4P|T' M.ASU=320*3LQ?AEL%OB@EG!76KQ|Y9J7F|< "4#*\$^5D^_00UB|A3GG)-/2
MI18-|B'W%5&4;4\$0TF7/7NZPIC\$|>7TQ?>OK!;|& ^TNELH="O=+;:.. "8+ M(T&?JY-
1#PD7*/C.C.9^8QV9)CXS822U>W%G65?H|3AL9L-C|P%\$7")1MX1|5\$L>|CBL300H<3;|&3
M"V*54+9W(F0DOVA" M+;9^L@|MV_%ZG4@=U\$6=KDL\$8|U';3G=&QV|H M*S01+3LC5#ZW?
6%SA+&TX5W#&\$&65)'(N/\$3 MVV1?Z3 (-C0.CS+|1DW93W1BCFU'D"F30|T"51#Y!;RU6Y:22\$%'W@_A M
C=Z|>KE.%|H=<1U|R/OGCRZN4|/"W|K8N4"YQ<|)%7S'+|N#@C6|;| M 76AI&%R63|H%;X'2&QC?03J|_0E-UB,ZO-
&Z=1#_RTD6SCR%OY:AXMTS(>| M#GW#(&|I#?TLRJ|@5-Q|@R|IC/<|F'VG59^GE(7LART6?|H0|>&16*MM|H
MT7|!2XD>PN|2&@OM(S<Y(L8;4DRR&6GW6.V|P'P*8T&NE|F>*Q4AF3;|M?M(FU18R)A\$|2-8.G(66SFN-
|K2#|3B04);N+8 RQFIO0EUB=4+/-=V9R M|9P.;SRL;7-
YS^SA&^H7KCCI84Q=OPXY@|T>5|;8!|)^"T%UPAE#3%G6U MG%(S=
7R)/IDL;|5^H SL%96"10|83H^|CFY;.E)H6\$#6:F'EA;J'RO<\$ M*C?G(BC+1HP";?W2-V@Y 4G
|M:VF|OU.38C"H;=7N@Q|6| "Z-ZTR".W)? .M|16N93 GOB|XJB@|Y|J2M9>C\$Z&4"6NXS"*KDH'TD|H_U9/E>62PP^;
|YQ88 M(F|S@+LU"ID_#_P|/1WE;|<7Q/#|1^OLW.%S|O.|)61L,UN?SM0>X"? (M 8R|61)_9/O.QIN*HGV#??
<|>7J&|OF>3|W=SUX^W\$@9N(B20D\$*1=@(|D4K/TMC)+Z=C;|*Y!;1>|1^:738 MNKH|@!3*A;
<#*;*DM(O8&*QY5AH%4*&X7\$VJBS^QDU!.T|C2R6G|239QY) M\$>=|*D;?AM\$U@G0'F|H_/9Z<3\$|)V^|H^#^3'Z?
GIO>_3|9&O|H>GUY MU?Q;7^G=;3T|Y>%9:5GLNT3|SE%^6S1196VSW_0Q9GM%7"" MX\$/_EGH89G\$>T0%@F7-
E"FOH8.N;A#S0/YR2&X|JBPC <-FWC)^ M36Z+B|5YK#|>RE>GW""#X;BGLYM+CMBX->3PJC&W
M1L5MWZBW>IA2@L.U.N_#\$^QK|_I=;UZV;5| ^U99 9MP"&|H2=A>|X3#0FV)! M|FD)FIK|E-|+!7ZCY?@A;
|I=6HU4|H|<^H|@F<92YWN#4YM3^IQ< V|B|L M=);
FI1HPO5F(BHZZWM|/7QT#LV^U*VJ\$("=)B(LSF7Z;JCH1|V49E"%\$TY; M'98\$*>WW*H|.C@|C'O#N)|@ T1*G;?S,TN
Q%RG;9WJR_LWA8*0O@;A%5| M*_2B7\$91S (X=>|" (ZE;1;.%T:DM@DLL%VJ&-J94;CH,Q|1W=|=|SAL%'4.O)
M|(R;.;OU|OF5+|W|6"FFV1?2;OHA?52T6|B6|4KAGEC>8E0C1ZL30_**\$?&| ML'*=K*&."CM?5^T+
XF|S'F8IKEU;00.5EC5\$7Z-L/^K6NR#MTF=608^D- M&ED?QNRG=N6;)|LA'H^ ^XSHF.F\$ _JK0W@PKTSMT'LN?
IO#>Z/|Z17%FO>;>M MBP2J7LU^GGRDWR;2;D3BV9(A _U MJ@K34BW*3|YX2;5!2NT5/F*J.0WV!D>"9@BCVZ;(&.)4-
KF13HV9!>4JZY MX%+(8Z>^Q4FDS\$7;;HMF8PWS#P3O5>D+97(9%7;L|HAQ#5S#0+EK UE|< M6ZQ)CBK6\$T)
W>%Z|!"=OSR=G^K|K1+XGTZOOQZ9OS2_K|Y>7%Z;COJHC N="1 M;|^"RL%D-3D)K9+&A_*0"D6;RT?U#|HK-
KVH/B57)^UXG/Q!=VQ|(|\$U MWZ _|5S;|/;?V;Y|NR>WMD;|>/KFXA+H@+|^T_/2QY=7YU/08NH'O|V
MGP*EG)YY9R=7Y|U|WK|H|DC|+K.|VZB6|Z|KZHQ<|1&H-E|_S@|T4A|? M8O1RU?EJ2|>5;-5?
_!GG2<2Z|0RVC5ASZ6\$#;?+BIO..X(=H;+J"J"DCYU MK?*DHR+_F|T9R-
ID9B/;AT43Z3@&7X0UY;DR2|O>>95BRC45%|\$+|40N. MM:73B"O^X3TU*FA5U|LVNXL*0X|E@5P2S3Y.KX&MG'T|<
I"\$G|PO#|+X4*A3U|;8;M/T+CX1K9)>Q^CX\$7 &M0'ZRH(TT5|@;|5F|D.JKG;*)+>US|M|FJ%"|N?<'CL6B2F7B.V6G9|?
471K39 MH*D.\$<|_H@/6/_E/;|N|H|C|H)|;3'.0|A0>>1W;4P+30;(CF;)|H"U
M309| ^_H|1%MR|UNR8W^K(C%>%|@#|YC09ANFZKZJG|RWB.=63WP6Z9H2S;P3(YDY";7;-9G+D5' MFJD @D8-7|?
T(Y*4M^D2;/'9|BN>W;8;SX\$E' <|H4|_W)|A07|O>3J|_D MNH=W=F_|Z|2Z0(XC?;VX5/1G#9290/N 8!
(GE42)!;O@!/?R;|TD4@&'>< M9RD|UT|TMBK1OY\$%W+V|@A_@K.K+9|2;E(-(&91.G/MD?9VAH?P")|+ "9=0
M%??"9_JDV+C+<RC M;J6!&=ZF; PLF8(C<5|L*_K5X<#V<4_C.;|#"WR/Q'2RD12 %*+<#"^@B>W>O#L;VT|+|H#?
G|*7EX6A*N8V6%(DV3_8|?S|GW&YK?GQ?JRO_M;^V3%KXS>C4|YV+|G%\$)W_ 'HSO%X>;|5>L|N^U|OVA_68NU
TOQ\$NORUYWQ|SY9.VY^O;KL3%>U%?_ \$R_A.Y7Y;Z<8|H0|2AVO?^C9E|0N|=MH'W3+0|L;3|+;MFZZMK|TZ)=J|AD8
M)V(1T6EWICICK|LV0H4BY9*U|R'.G|@ NXKQ-# LS8S-N'+;2PXS(OP M FMMWX=|K GK
3D+;C*)NW;W^=;NYPV^R;B*V.Y|_-ZRC\$PLB7C4?V&HV|G_4M_)U9|+ #1,K^&|;";4SGY/2B MS<|;?Q?
7)ZW6^>707|8;|WH|HKD+Q=NL%#;\$D^G=KX%?KL&=F+5#&A<
MA5R.NPVK(*0U.ZV%36YL|QT(M|""E7;/_UVK@0 M*D+7^@M=;\$|2D%.3*W-W.-/\$G T|_M,<#BO@@M1_LD|8;L\$-
FA.&&6X&D*+R|G3X8_VS8%V&?V8S^/50V!-%C=0U MB;_2>"14#T<>4LZ
35^QDZED1(KMT!'%V(|/V>_&1RV3;Z/&8HW%F)Q_X@ M\$5@L%+*\$L/2 @_|G 30>E/A8I1\$OGD WX.989ZB/A\$|ES.D-
SW_P2A.'+\$ M4L0+;9=8+;4#)PO|V\$=V(K=M*VD(M#;GMLUC|H1UC MME|PI|QTG'<_CZ8H|A=F_W0"373;J95F&F?
*|^T3A_*6_AINO&4|H"E'V05 M*152+SI/A&|8/*IYSK@!SO7DA.A*(*|F@.3K2F|I=6=EJ L)&F(V^7LB80-
ML;895D+JTF|A|8&IT2%\$N-NR#41*|BSG|LOI6(-/F_J|4M;F^6Y)B@)K7)D MDC&|_L427-
>4:OGMB|>P(RB?"FIN_N&|B80K&Z\$S7AV9F59)*X_ %E@L MNJP2|.'Z|_*;9%
<92ATISWDG|V8#S9|01|WH8B0M69P=I090V\$|2H|SP+E
M*Z4D^8,^G!;D|B3W);M#U(6FD;"0M52.0%6)3;1:BH@|W_ZN%9^@1E" B#P^ M|V);49V9|S|V|TA+4DWZ)+F
DS_+)">%C%WKV_80>V/O>20_MG=K 3UV@\$U&XO40U5*TOFH=L=K|E;\$ZM^AZOM=7KEPDQBZ(!|DD>(#\$9\$^
MYE8K3O*86^0NY1|Q9X^+J+0B)F0AFP7O"BG;AY<.=)G3|W* M57K)?
HW53ECTLRDB&3K.PUAJ\$WDF^93G#U08+A\$V.(1|<|T'F9F+)|79VYEVV=0VJ7#*LG10-E;N-GEF4>K;2P+B6.*0?
LYQK(MOPT_H@L|;%60ZUZ4(LJ#|56|MAOI_EEPH|J\$FS_R%&YSB|JR<5X6H=A9@@8 M3Z/;93 HWMD_5|B+|=---
MVKEFXF=G8V67|/+YF%FX@CDE8E M OKB_IC|/|9)|PV"ZO,>^K2U5AYD@CG_%|20U+3D=C 2Vf;IC&|A5)+DE
MA8KOE"U=(*""YG +J\$U^CA3_LY_NUDOV7QH+E85B|5LCF1)>4O|H|W|0 M_VB1A2V'6BV7K+1Y^T^Y4?
B;G)SS';*RG57E|'S|EQ4S;QB\$AC/;>2AW=L= L MS?0W7|VO.Y?ZM(7S|XQVIDQOK2|<H|ZOMY|Y<3V|?
H9ESR93\$YC\$ZMB6_ \$0 M@_G14H^4GV161SBY)|VS3+/.^@+B|X|K*3KQ_'AC|DR7W-PG9VZ^3*)Y|%;
M;8NE4G8VZLC_'NO^YNE(RV|'_.|9H><^Y0^"HN=%_0M02P.\$% @_N(#^ M6;B2 SL|P 7DD_"!E83
R.#@P.S0P.65X.3(M.E|A;W-O;&5A;'|H M+FA|>V7T|62C/Z; M|?VQ>EA'F|57K'IMM?
|TX_-02;^7VV78C=;PM\$K#L\$@;L|B=< M|?F@_V"\$?*\$7HB77H^N^|CG|L>V=SH|EUC\$VBTO'C>L;F>=LR M;G7#Z13-
3<>V;W2LT&LC5"A2+MF94|R_XK>K&\$|_P|+V(PKQYS&@L;"">PUM|/L=5%|A1 MZ-A)G'7|B|?
V/ZXQM<95Q;WHM&6Y;Q2*<.HMG'R BVV|AY_T|W|H;;CI< M@=VXN|3DG|H^<_+|O.<
M|UU/X*2|5(83L8%4Y;P%303)L)<..L|_|B|""*9NC.;08%N^0HMGH M+&5K-
)VNRNA;I@|HWM=)RM609M%5XW>N'|2N7;MV|5UH_*N?|H4POS&%0') MYB3-C8EK4B\$E|Z^T\$>E*0C|6FZ&=\$K"
H|+|K\$!%O=%;#G;|RF@9(5F#X4) MLP1/4WAY.7LR!)AA@YX(>|QF|_1#90.P4-1(79;(*X%'0G5QY'"E#-@4 P@R
ME8O(L1TZP@Y\$7RE|WP0+X;-19K+>%81B|MO|O_XG\$.X@\$'@<|H;?Q|)HX+ M%;_D|KD_!|
|*#|40|8G|(")\$AY)'EB|'=B+K%8R@=-.%M2Q.W8BMR-! M5@1T1B;Q|(2C1BAYVTK;0BT-N>VQ6;J'6&V4""D_'2<=P2\$
MZ\$@@KV;Y.M(87MT|9V6H"PD;8C;Y>R)A VEMAE60NK2;&E|@G1(42XV|U M1\$H\$2+.<&|E=O?

68""S2UOKY:DF**>MV*E! C*O M!2JZI^XION)A"L.KS->:9F95D!E MY>S >+(&#)"Z!#46\$JC.#M:.*Z@OK51Z>:H"TTG
M02%KJ1B!JA*.:+44\$7>^_1TK(L&H^X1>7SNO:2B.C+D.V??ZR/F:TFU+D.M):@G_8I?P%).?
I9)3@H9N!W12VQN+S2^XRM8??.D.GHC3%ZB7J16B-U01B MM2,18W5NT?6(KC^X7#E2)\Z=2)7Z27I?
=Y5Y8Q),Y.BDJW/(2A.M-I%OFDIQ=D&X1)ABT?/S!HIV3*Y4#USVR@*Z16B.U@D@*X_4TSZ7&4FI
M!@!L.*E.KHHG8V13>.>>(O2/(FM7SHS1%)!L:..!HB25W=.:>MW4.
MJ5TRK!X7#92IC918EIE9:6\$=2AA3#MC/-9#?#33^@"RIH59#K7I0BRH/M5:N
MV^^D^67"BH2;/_.(8;G.+RK)PQ7A:AV%F"!B/H!PIE,#,,S+^XAZWXX"6XEE)!?:
<\$G*^&)&OKS^AXWB\$%UH8R!BG&%;2CT5*\$0M^MX&F#^/?QM,6^MUF"!H.=!ONH\$*Q/!I42!P:915%6?
6728!4L)S/Q@:53("L M " M\$S\$W^<>."84\$>4PK5U!(!%%@JWBV>QS:%&H0DE7H(>^30TIG^XY.\$+!GLM:2
GRFMS3GQ.N<5CIWCPV\$>N.NF:LZ!L.E?M(#?;:(1.2IV.O+&C:RO^U>EE M.BGUTL<!(C^AU?8!NU!!/WEFIA"!UB?
!D&!B!7PC!SG,IW&P!;:;>Q?0.0% M%1E %1TT;!*L>EQ4S:QB AC-0L>2AW=L>W;/S?0//^6E_FS^F^>^6W:++W61B
M.)T:KE_!JY=7Y8CZI29M8E3;STLC\$JMCFW!>?2L>^BF_S*RV<?))\$F:9 M9IWT!1/_/K*&F+G.L_0MA9?WHTC?
7^>R4+5L8!/?/OU:J9#D^H=Y+HJY^R M^TRBWU7Z^U!+ P04 " "X@/Y8(8;L:=\$# ((C^&5A.#(P.# S M-#
Q97@Q.RTQ7V%KQAMC3VU/\$_7!_4.\$!%I5FU726G9R4.(Q_!Y J< M:TY"O O_W;1?K7@7D\871%^>?
ZE/YWTO7;^BK/M!;0WO!/?P.*_F4!>U"(I M3 !Z;F+ 9VNJX8K>P5RNB7#R!PXLJ&)1#3?BUEFQSH!ITR2<;F
0&#MSI+K^4-2!4N=;-1) X@ (MH:YLV 6IH1P8Q21!,<+KKIWSF>\$4Y>+>1\$.#6%AB*&HH\$:<.;12H^X2)^* MD"J-
AX#+9(3*PY&=&IQ!"1>49+W\$!)29W""@5(L(4HDT0E.WM5^O_#M?NC)@@(K#/.6C(LO V^:Y*>8Y=)E3E
M= RCDVD=B^R>!(@5_)Q.8#293A>SP>CRZNV:FEO+QK!/>%R.O!G@.Q:V"YU
M7YW!4BJ!TJ!Y)PD&@\$5!4R)^YV!H.E>:0^AQ8^AT=:VOL!SQ_!9!&OW M%9IYRS#IG&2.4>=AKUKY+
<4VZ+IY2!JPBYV_ S^<(=QTM\$""BM.FA(H*7 MK?0^A24)F!+14=.N0DN(5.ZQ1A:LE9F\$?JWL"JRWY:M^&&
<29RR/4!\$R&^ MG_Z!IYA>^D?TK_U)2,1 U6?;88 MVNP\$??
9GM#2>YJ6=&=#^B!G!TD^OQ4\$ _L!&%IWUNZ7^+2Z@DX*?UN/:40?UW MJA2CC1SYA!CTN/N&M!S-;#M:C_J2X!2?Z
M!H*_!^Q) ?P-02P,\$% @ N(#^6\$(V#Q=8! (1@ " !E83 R M,#@P,S0P,65X,34M,5!A:W-
O:&5A:1H+!FAT;>U9;6_2!#^CL1 F/I42MA
ML#^D^CCH>#)\$)P(W*OZZ,38^VOK>UWO@.C^I(HM^!P9@F.*JA(H.#Y6K@:1+J9_ S:(J&PV
MES4(23)CV%32AE:WFW5G.6<3)L\$LYTV!T\$38PT4PAU"MI^L.=!R>KWOL^JJB!O-\$+V!&N!UM
M^SBAOERKJ8:KVHPX8E\$!WGC04!B@8^VO!34W,8!GR!OYDBF4>"K6!DC!5_ M!AN^!&
R!8KM^GW^A+&HJ:%1I=F63?_@PS_S&>:;#HN1?;K3DV,L6R\$2!K M,*T?W/9!F@!\$2Z.9WP:L.@QU-"N^XC8H!0F7DH?
5XP8F;B^! M6Q!\$5_!JT!!BD9#(HX#Q:!!>Z!26&VHM:./+G&4F;!C0BP2,4(OZID_W5M^2C M MU(TB0BDO&(!#
_R!&RZLS^+)!J1F"<4C-!J%<,Z=;XN#;I0.2^5H%*VS%-G
MZX2\$(5^R!)G!G: ^/=TC>8^!TH!9TOK^SYN8F_UWJZ>6%CI^ZVB^DN4?I MA:5)7R=(O^@Z=!!@_"J.%@!5AV1&0=?
K=KO!YX-VC^5!RZN^O91(NR.1#T%- MW*1+J:9F0+Q/8.;+2%/P@/FI? UU#?//8R%.R! DB1T^% BXU%U41R2R?R
M^XZV!5J#_MCIN!G.H /=?ML9.OA !2/GLCMVG9^3AN&I9J_@D:K_7C7=S&A MADYW= WW3H6C.&IKWF_9!>-
"2#9=^6!8)PB!5!Z!7@DT-68P8.<4V"1QO.1 M*!,\$ 28K2.B4!E0EA SS)#IC0FX&QY)(&BK9UWV>^NRI&+1J!3-X"C^9Z\$
M_?2 HG!2Q<5!6PYDPJ7#-HH!7S6+)-HH!7S6+)-NUT=71+)-1)"7R0("B%*!%&+ #W!L M@A581@Z*1K&4PI\$ %XEF6T^H-
JZZ=PIBS^Y99CYB!T\$5-KX)'@V!B3^66!^TW.2!Q3^\$:+HM@<=D:305B@"/-(1V#5)O#E89BZ,433R,-C11_2L\$@@
M)*#+,.""800%D!3%)R"PA!PGSDCBIZ11!2TXH<"AV(0%3^Z4090!%BTH\$.R& M&5G8GJY/*)+*7WV-&.@H(H-: XP=J
MP&!40@>C/C!NZOO%^2Z>?17&O_Q:XB7>M4^7!;1!O@V=C>N>F_ZG!|*+ MK8?+@8)ZQ!^!YZ ^&O@^4\$!#!!O (-
+B_EBK3=0KY_ .L0 @ M96\$P.C.X.#,T.#%E>#\$U+3)286MS;VAE86QT:"YH=&W=6%V/XC84?4?2!A%
MZF@K)00&5FV9% D&Z_#.!PNHJ^F:22!\$.X!-VDX9^NMIG61@IVI5=03! \@ MV?&Y7^>>:Q+=+Y.N>UXMNAGUA_0+
!A.M)HGO;42!^RU_#.#OM:/P?(3YXO^V M!)-H:3M0JNYL;#@&1JXQRW.5.;D7R!X,\$?_5W4Z2\$>G_?<%61.K!GL@GNT
M>046GVW !%_3DN;KU_9!T: W>D!YDEMHO6!<1N&W)Z>PN^GW%B^VM5!%W)I M-E>GMC)D%KOP2RYVT&IZ<-F
DQ^8%2Q_1-!<C.V!1^UBK?G\$ _99DIE!,E MLO5T@LZ! G=4.9G_6^BE?2C F;1^KG; QJ!&A4@<;H!LR<1BYM7.#?
@5=S^1^Z4S9KF2+ !9PDSZ=OAA M V;C%:=MB; MCRMV%S^/R^H!A->6)2YDP0M39_92\$,569)FTP!J!W
M0:N=:T!L)!^Z3B%#JND"FO^A!N.R8DO56J!(/@B) DFW %N),DLR;KV:39EU
MN!\$B#7;J!H!D^RLE=ZY+!&I0&P(B#BJ#^W13YC5^SKDF)!B331TN@K?EZ5Y MQ93WD<;EH3L^_8G?R*IQ7NF-
>J\$):3(LD=/4 M(O)!RB72W%LE8 MI@H!L1 LE:4JH!V/+!P%SK<^NO#A?B:/B?H(>PY9Y;*DWT+,\$&@L5!T&J!M)T^
C\$PY< (0>M7W%RZ&KWS!*@DZ\$?Z UKXR&H!7%>7;">2XR!02P,\$% M @ N(#^6\$G4WY)B# P4\$!^!E83
R.#@P,S0P,65X_"TW7V%K*?2!A;B56(^5!\$@<KL34NE!U"IO)5FUVT%^V^ MB3U.AMH>_S-
NR!IZ>>:Q!^1&U94B^7BK19>UL.G)2GO.PO^Z!^TX!H!W!MU>#(B_X7 !HY!Z?!" HH&J
!N%* WA^^. F07HS!|CU!N12!U?=:M9);- M9"(G>RMFI%PE/&VY!RUVG2,MF-B3#WS!ZSX;+Y+=-IGVDYF=HJEG
!D?K M9^M@?WAP_!DJO!^RW?+:_9TAT^!V;87*!%_2L.AA)GGZ4^7O/T!E!@FQ8-TB*,GV/961%"&
!4(D,3O4(I2X>RCZ!\$.SX7BUZD_V MU!K)&X2A%L:POTHS^\$&&(@W\$DSXLJ!*VV!O=[K;8.)=Q*_)ZW5;S<9!82PI
MDL9J&=@6&TB=*6UAD)\$K@1"N6R5(CB3L+L-U!U_0L/^!5(#_BEG^@4!5 M(@_Z_&3=AWU@Q1RRQ!
!VE"Y4!U:1/Y3@3XY8FB=C@ (6W!OU=J^)!WPI^49^!M^HXV>SP56LB41P!PS886H&>
+LPJO@K54P%#DXRG!R&=&L99+!-IX7TL^5C&M\$A0T<.^!VQ.P9X&3>1HR_ ^CJ69PN! " !^!4.PF S:;25E=DIG!\$4?8N
MDGG,V52!3942L&82)3Q !ZSE3\$W@-!^(NHC!2P:&9#E0^<#KPRD.ZPI&SP^A5 *CJHUX+^0.@KK?+L29L-N8%AA2S
!Z;!!_B>")VI>!(M5P3 M.K?PS!R5HL4B+K\$!F!@50.D^22CA Q^7TIE62C16G+T2!(!>H-K@?A^0K6;H M-
!I#PW.@;#)%+ID!MB3W_F;8+<#^0%L9QOU%S^7N_%"@6ZR?' &E_&W6L MFQ-7W@@!5>'RT^6MK!@-
AJ?!"#X!/1L<'1T!O:5RZW.%OU^<38X!+^_/SD:
MO7ZYU>UT^FU!5G;5F5\$60E@K^Q5^3T#YHW_ EULQBV!H!BSLW3\$ B#(8*_.5I=T;G M^
>*=FD:5(CBIB#^W!2C=U_UJ^F*SSW>8ZA2N+";(@Q130)NIN0=X.=NA!V4 MOD1(#/G7 LXDU;#V7P5X@\$XC(L R.!&=
<%V%>LW^_ M2^!8ZL 1%HG%A_!(!?HYU>#)Q711!A8B!0_ MIV^1@L5!QO_!J5ILD=7#ST#EVL:(K0%_X?14L032UPF?
H^!A>\$@_5!&^RL< M#!%F! % P<\$S0(-^!"VDEB@_ C+E#SQ?16BC9\$K%)P%ID3BVJ8?T21&H M8@DZ4T9H0T>X
N>V_%29L-N_02SXKQ!&H;M(LXX8JKD>?&V(#0_H1@%:O# ML64\$^/C!2R D-(&3@3>389*,"%0K(A/Q&>
(9!PX^29LH!U6^0A%(Q_!5; M;B!&E;W,9!9(E^H^F(N\$ @!OA4!E95U)8Y=RET_P0!8_0UBJ?WZ&<9M
MQ:1PF^!FB.GEPA B&R^QV2C@&G333^D6+^Q@E_9-<X3RRG_V=YFOTG@4!_8.A%!(C%/.995
M0#^8!G9!O!_.OECV=K=WA)E>(!/O.V!<>6S8B^"BZ_M5^!96*\$^\$@!LG.Q8P\$(8!0<2!J%6?B!D+!U>;@09^8^TF4&08G
YVI<^!<4K MS<9!E;#JFF!23: +#BD4ADR:21T(M JS;C9J-QM;ICN#LD5UA0*M#6.A<^S M;A7T9N-
Z7N!T&_4\$87!4U6TQ:QMY&0@R!2\$ M\$;88)40#H!M9^B00^0"A%.\$WVQP-M/20E1^64VY2CBL^B_T0VOKA00H.R;Y
M1!D@GZHT^O"/XH<^% SD^F.%3B\$!BWA^E2YR^DC#7.(2^6N(Z? FZ!Q!T!M!A\$:%A!Q/8M!H5K!J-Q?
S^B8Q9YJTEC3!72D23^8=H D0^K0 EY<^DQY^YFHI &/_U_*?J!R?QW7M)O""Z
MOK99NMA6W5>29^!HD^87O.MUT2W!9TTO.49^RT!%4 R&+*TE@."V/Y!G>F MZVK!J!E-
JES2E;RK@S/AJL80!;\$".2L^#6JSDX@)295FA_P!EW\$M8;4HI8E MZV!H!6!2JYNWX&F.G3CBLTBRPMU3VD-W58+V((+
!=ALN\$H;7HAQ<"X0/UB* M.KN=1ZMJU>XFLZC^J@7U=)Q%8_! T3NRDC?4CL!S!^ E(KK\$J=FXN>;BMA7^ M;)ZH^:
H)ZW^6%O&B0*&AW0Y:2MB@K(MZ^U*^9HF+2^CMU!3Z^=)%-R!| M>XZ!@%ENL?_!JBN>#8N!OO@Y84!9GD?
X&Y00?AXR:00L5(^AL\$PBE^T!LO MK@LTLNB^F.EEUZ;IZLO^FR009P4E+6#4SL_&6E2T_?PN?P_K&A-2Y M503_6-
H)N0KJHK^KA53ZU!WVQ=QFQOH^;73@XV6_!#C^UPIU7>-.G!^Q^=BP.TO M.XIU>XX?FPQT;S#</p></div>

(XIT!#W!70L+4~\$X!5:A1SHU>YM "O\|V/<*?V(VHO.
MSU7KW&5ZH*ZHY|H:~U7"L'C8)U'4_R5BHFRDL#~"=2>XY,8%E-5\$R,5HG)D<MX)G6PL|7Q<(EP-
!G'J'K'E@YF:,0ZZLE6M#~G'L5.)B/#~*,"PI5EV,88!~!MXHJCRZQ5Y!66EB,|2W0|D@ZIW~;LF?
B|BM9IML,74V!TX5~|5AUTC,L~M|~>4~P!PK73|~;~!K|D=,\$+2QH+&=#8W3D5862|LTC|5_9_E3G_NKQ7J=

MWFX+^TQ7?2;#OL)7AW&BL|~!D|M_10""H7_#L|GB,<\$~!)*C,/+~36,?
B9SV6R|0^W'N'TFXUC|K)5;)FOZRH|U/E^!8:XXK#+"L|W8>U4?'(H(ML_RRE5U8GF189D#CX#;7^>)GDR'IZ?
7/!'I+GV79KP;HUBV.*S|;|S|V|/?;~MKJ|:~*/?/)(%9K+L|W|/(4S(XWEM^E?G|0|/|X?)#K'^N5'NML^2W;K,6!C
M;@96|7)K|K|KL|N|K|L|J3|'+U;9^YK|'!0_*8<~!|E83_R,#@P,S0P,65X."TQ7V%K9ZQ|6|^L47:&A#JUNM=
:~HJMO%|U7~UC&ZG_MF7RKOM|40N79_(CG2?)%|G_(0W8,1(TEL+|RB+M"BX"RAN3+<|3:KTZYE"RAMM2Z
MG2M|Y#X.L3'#"QJNS_~OY,VQ\$?U*DD|42|~R>D'\$UC*IRG\$VY|Y(E&I>O>X~
HV6%TDJ29*OF9'F"OBY9~;9EZHKZ,@8J?L|B+|JE29:|>.7:VH'FJY_1Q8M^,M2Y5>~"NJ%E4K?
(~6'AS|ZDCMJM|HFF|,OO~!E:SS|0W|'LL~;KYNGC9:U5_MVZP|8ZV_6S|X|2D7|A\$~CX|~*K
MO1%>~\$*1.H~!M2G6*SW5>CJW4>)YCN_70M|"+UT_2?|2M#(IYZDG"?)J6HS_MFMH|VW;KM-
Y^_Z'>|CM|HPTO^48#|J3|;W'TL.SH_M*5^DJ>~M@;~;A)8Y5,^+ZS>|XX^>F6S24GO=L9ZQT?><?%?1S>,2N(G>3@2
M2Q(55OL?B#~!E5.OJGVTOQUE/-:F'CK3J_MLE3WZ&79|U.=!7@->*U0F@YC@H#EUT#0(\$K1.>P|:~?+F8|.6P33_VPL-
S~;M+~*QLP4:7>~!%CE^!8_B@.*OZ)D_B@~*~(JED#;2;8|H@>@6%Y0_MQ^9L=&5."20G_\$<Q|^0#L@|H@?@"."8ZK
700."0SE?(XLN8H_I5B?L:0#S@)TK3Z*MI6@^Q"N"+9Z=Y_H2_07+RRX@)W@>H""@8|JZ_4%9X&~.I/."12B(68X(O"
MY'88D1_7D25|&1.*_HGX0K'T854YX;ZBBDT|S|2>~W_M52\$S"C'S8;HY'SX\$@_B_6|JB_3G|!0_1_S
~<2&AP79P2%Z&~!5)GG\$Z;O_MBM6S8'@_B_&~NKD4L|H2R;AC?AU.SM|(P(3_MT3_1#8X*~D863|N_3G|!_C
2.SP.A:S((UW4Y%QV_8|2H8_T."0P)=HKV_MSV\$_(0\$A_2%+|&<~.FP1/|0L00|J9_UG;H.N|N|2\$D8&O|H224_2C|L%0_M82
2*+(DV_R@ND|!0)%9DF1_9_RQ3*WN\$~Z_CH""|ZZZ)CT|5ZE|&6|Y7_M^/"(%SC^!5A#=<)SI|?|C|2^_I3-
K~.D|F|UN^Z|<+~'5K=?P|02P,\$_M%_@_N(#^6<*1%+3&0)_YH|X!E83_R,#@P,S0P,65X.3=?86MS
M;VAE86QT:"YH=&WM/6MOVSBVWPWX/_&N(\$<~*V|B|329_VJ338#M)D69G_MT/N_ENB86TET22FIY|?O>9
2)2N_VG2_O4'.XUMB3PDS_O%_=<7O|Y&~|V_M7O?~L&_O^W?W%R|>~X8'^7_X5?=_W/^R_.CMZ+=Q?OWQS_NC\$Q1?
E*~LG&_BO/HVO%>|J3^6VS/|E|5Q8?3DM|T0N_M|:6&CT|V#09?'!O_FNJQ+L4_|&~^P+>~
L9('KZAV+L9GN+CZP*6S0U/|D_M3|3):HHE0607IV=7K2@+ZTLW,38_+FH9C_E\$^D4@7|XP9GAX+6263D5OUE3
M57@).\$+|2KX4F.54~0<_9.G'RNRI/|E,0Q,?+~UZO'?~P|~_WMA>F|PXN3_MLU_O?OSR|C_|?B|F=|DY?
O^X_~LT+P(ASD)FHL_172ARH_5C9<~3D7CV_MY^FW_+J.E.Y4D_F&P~;G3E0_.M0%_M;S2#&F52-5\$%|AW|~
/^OP|SIW|L_|H|0(Q59JYWZ*3E;~O|^9Z9/2CE_80_M"/"2~;L.M&)@H.#@RA,*5+M\$JOP+6GG(Z\$^)|J|@AE<8K7(-YP;?
ED|K8F;~ME4X78?FM@851DF""4Q,54IK+|SQ(%1KZ<*|K;PU"),XAIH103667E0Q_S_MQ>~+~?BY?&~
V|CXY.3G_|=>A|GU^_|P9?C|Y|G|Q>M?YX^>?*_~W|7_MK.W2S_BT^HNQ*4N3TW<@+2|P|A_%R4<~19@AQ=1Q=B~
I/7.NTC,*+~|~^MUL4&*C)'TM^!K&IP^*F_5SO|B'U_*8_BD60_\$|&~!CO&H&VKT|XQ_@~CX"MRKQH*
=H9*R+~%#DKHK4J0,5(E|P#_Y:74A>N'YDEO60UXXXELFT#|0Q.DL"PV9PE6~:S\$0F4F<5~!V
P(Q+6~"/TIV>9|A~6%9AA_8H_M4<QY_|L.*PS7|~R#~_2J7""EG_Z:@H|5.OEC(?=6
|EJ%CRPL0_0RD)08=|S^3U6OFZQ;~|FXL&*S~JB"SJER|85>2_M|7P_34'/KPH7_H3GT2G+VONSR24M9_HX9JU;
*F=H14FVWGD_AP;~*A(M*Q4H.X?O@|UFH_84I"9L09>PK2G/~/+@BP>=A%F|H/SD~*#H7YZ|N|HM
M@.3ED_|D6942+~#A2~7(#I(AA|/|28|FQI4H;X'O~N"U5UI4|D,U^TJ>+~!M*
~<(8TA9A8^KE^>4NO#X<|+U/LH^&N#95AEJJ_P_YY?~D#F,4(K<~.8SFO@_M,@'Z1C+~?
EBR*>~%U0WP|4Q/~/MX@672DX|JQ%M^P70;RWO"IF#~C_5\$P2_MA,86/4|CGBCQ98|_YL_NYR6*~FOM0
6EAHD&37VO>#~|VC^|~|S|C|L_Z/~=I_M>~<'\$NK)H+^<~%CK|0UF^X5\$+UF,*Y|HX7?~)?Z_\$K/OQE4;Z_08OR>^'90_M?5-
NK83DW=\$Z|S?W?^~;~#~K?F\$|U?|L
M;XM76F7I<~%67JH|&JCA;HZ3"NYMWW|4EP(C(B|%'1!O>BF9#|G=A|AXPOE;)#|MC|08DP#HC_MV&0?
NF|~;~|9>~*%*,~VL4=XDWY\$EAQ|K^K,2|)R)&<~!MEW|'8OTWN|2%0_M=P,&~%Z_5Q/#1\$|ZK0|~(A~2+2|@34-
#)|VJ%0+NB_&~.5WFQ%?7_2M~E_M4H*9",XOS@;62~,@S#)|@~@~*FO+|J.HHD@RZ<@C\$MM7Z\$)*03NZ"<+>'P~L
M3_VNIYZN=NH_WQ#>W\$~MQ)H<\$9G#^|J(D;PV\$*)M|C|_~^A_R!~!|DE;GF|3)N^8;M#>OS;6"TO_!MU
V(@:~.57FMO#5)&Y#*~<<~'4H,67_CQ|!\$A"AG)DRT73K"<~%;L=OT_X@_MY%8|A50>7_0349"M;D|C\$#F0R-
1YCT3C@|I7|JY#>~8_M.\$M*~SE%SSBG;~A3W/MSVC|&~<=W|F?T^+~\$N|VK|_IE_BG7^3_?K0.L;X.T
MX_|CM(+MZ;CVPX'W20JH_0|T|IDIO&~\$|FU~;AK8+|J>JU*~?XR2H|Y_M*E~;"V'AUZ*HH%CFM%T')0_&Z60:
~<~.~XFR~@PX|0V%V6V>~;G';H7RX4_M|F~E~?S(3N,&~<~!W/KI#243L&9BP|4",|BMA*)1FA|N"!H2!
M"EYS84K^0S7>(H<~!P'.|HZRF665)F*~6<1-2%4*2BZ#~9BDQ1F&%S@SXX_MBI<@82)H#,%!
~<~A)8TQC|N"N%~6|AD^~48@HIZF<|YJ^X%Z*~F1"&QM>6_M;C3FS_7D&92N8"7A6H;#7_J"DGRXN&4?W*8#|9FLX
M'U_*|M8ZA'POLO?5G63ON9K).6~@+R\$~YDA"3~/+@FH_JL_!|@/6,4,>@KC>MDS2+X;XO(S1Y7GOJ.TC-L7*>0"6?|
~<+XXY#L#B8QHN^MLOHNSMUCMM;)*81AF%~^@"&~!X_8DIF"TC,?>\$LFS&\$~/|@|Z7KA%=K84(A
MG+~&*4XTH9N|4_ZIE_13;+~|30++RC41_2IYELUZ_JL*~#_ON(\$27
MU3<7^~GD5M~*~|;\$&OZW2^~BR3@4>EDBWH'MV5).HJ0&5MK7?|^LY_Q7#_TZI_M#WSZC6F(+DSKI%
~<|&\$UFZN%|D(6+F@;~+~RV@X<*HL_Z_9.FI\$3N%)NCP_M&A;N7;I=C/C'5|^L2|K>@2BW0C|L"PE|>=?~
%~<~V%L|)K5|F~M^J%RB_M-WT+~%GT)M>2_OG(PE_U^6L_JTF8C_4QOH~#C6I6;7VQ8|Y;Q;~\$=BVY|
M|KE'QH^2%CD|YZ'W70|J3V@|44(E<~.1F#?2SM\$7N|_~%~73INT>~B|3<9_~!M|Z9&=U(TI=14B662_JL_Q+~(>~
|LA)\$KM'T~!|)9_|N_4\$SIN|<=?CO<\$5_M18"16PC+L31@0M\$~=%26_CHHR%4_TZS;(F_IUCEL|P0M8PPI@(|6U;AMT|?
MZ0S=Q1B+P@C.*~J20,<1@~*~M*I=807Z+W'K"W(L9W7)G%8T_#|O)^A3ULT_M9Z@*?
IZJ3YO,"FLRQ0GXJ0#;3C|PO&\$@TF52ZP>~Y4*~4J)<~CUN?M#EA'_M"
(R;~7OUI\$9|WZ|1(%Q2@20;N\$90"7WF&~|27L(T'GJ45>B;~>D#CN4T'_MZXp-
!FU\$|C4JU(5XP35Y3Y3&~M;WZ;7_|4Y>^C>^R|Q|5Z(R?G|'X;?R7.O_M0?1U>|)\$Z5A+>UF00"5J86I
9J|Y|YTJ;~D4|J.6N3TSU4YBL~K"WYNS#>3_M9L7<6H5_#~_VA<_6_MEWP|HQT5SK&K|4/|<(R8G#ZQA+?
U8XYPT8J;Q8@(|~|DT|JZA|'94MM8~OMR_M#BL*P&~AUF|L\$|L/|@J|D_|H&C_|BFVR|2A+5U0...B%CH(^E,>~U9^SK
M02|5?25U^A;C+A@~?>~IP4Y_C2P7DM5|0K|J|_7HHP2&Z;M#84(\$JZ>G;~3U_M#70V?
Y3D|^SO8+K06R)1&|2%5Q9;~!~_3F4C++~8%_8&(#*C?1L61;+~S;N4K
MAU;|>@F0.J4HX#N'3ST,74P7|^~@4|H4)ZX\$^~X|Q=~^TQ|P'3N1E2/+JLFD_M*~6G|8|50#|1BOK|^~
KPx6"6X9:Q@|2RG54_A^B+U|^\$*=~*~>;3;~!&~!>D4J\$>T_#88|3=O!KR^DQEP1KZ?DQO-
M6%E@~.5,K>~^WQU_~>=IQF9=VVRINS_U40&'L|'_T7;15@?~QG~BL_1DC_Y*~M|HY_Z.T_3T.);|QB0&"IM)-
~L_|H5NX7Q0Q_U89_.F.8BD\$G7YX>~"V;~E)_M|5;|7@~!A_T|Y*551*\$P2Z\$T(4(LV(K;~\$WDD_BCSBF8&<203*_0.B+M;~>+~
MZ;FWXW9F|~@R7%35JPF&|692YYBQB@~(S|KT|J9W9#~PPX|C9NM;8X1V@F=_M_NV58|3KLW8)F4\$ML_5E@L%~?~
W|'L"=X;~((OD)MTCDFLKS&~&300N'_M'_M;8;3QL5'E'FYU5M1LY@ODHV,52A|^+~;4F6IGCYT'1?|B|86|MG|~%H\$=1&
M_*V@~&*RDSWV9_I0_FJB&B(|~#~Q3|AN>A|G0V?~U5*G192_@H
M);/CY\$~4|>PZTH'M^N62|KPLL*6(7+~;~8_P|FN@|V_Q6.P.Q8G;3>3_M^HQM%(<_71K'COUV;@~\$|^*~9\$QQUC"/">~
~<~MYS_G76|=+T\$~M0|01NZ~))AF>Z@Q>~3|~&Z*W|<~O_~5BG|_5E3K?>C#C+0C|&7D|Q+5+~A_MG9|")Z\$M&>GH|2?
TSKQ+~|_7\$=Z&T'>G|P|A9OKQDS_~CF_M|2^!%@4\$|G)_P_.82+~|L>YN)(L%@1N;~B+~)XDZSY_Q_WN_F~L&~1A;C
M|XNYQAZXW?Q0^=U;KE;AZLD5ZLT62TUV_|6|5*9?<|2>~#%_K2<~JN<7&)~M\$1B=EHJA57|HT*8+ZEWHG?

AU+TN6F!SJD2B-6 ^2\|M:233UHV71K79*M*DA M>.>N%/(T.25IBO2'#P774+8T4K 3UNSJ1/S18H(YQ-I2CT^H6?
CH;DIG+ B' M 3KF^/F=#2=W/VVY)1:7 5'.1M1'19%-41%FZ-/V/YI0612?N9*6;)A6XU_*4 #- MN-DE-/&.*?
C.63S:RAQY+WFJN\IC4^4\$5D)3WAL>2D=-BI\$@.R@&WIHN\H M=5D0F^H8W W*EN2*8F5FB9.P2=IT\$YI&)LT5":Y-
C"K/(H:|^TEVM\CM: M!6JJ,BLIDX"P_.\$%%(L.K\UGFM(?!_ M3S^BLF7N+GY#W3+19H;W0BW;OAUQ*);|SA6
/KFIJ.9(S^AM M:\$IK8%;&G6G16X3QI7FFZMY?6G1V;R1WJB8\;BY2YNGJPV*>@==I"Q-XP
M3BHE%NX+KA8:A&1J(=+\$+O\$>&QJ97+CGXXV*P;SU\9G8;FRZFIQB!""M/ M7>VP1=FVE,2ZX&ENG*.A1;.\$R%E?
9*KCEL<"QN197(&F!|=)=0G%KJ.J.\$K MTW.L0P."QI,BLPX@Z&E\87E/(@J1L') M#7|H>-
I7VL.FQYC;N=P9D0_25S.&"5HKW H'Q#3;W3T\B:6;_+&QRI!'8T') M&K<<|BX8TD7;H83Q GO%
D*R8F>IV5@K&>^3S"I6\$(7;>X"2 %<+K\IVZ2 M2D//.(\00I5>@|W+;+1+3_V4E@)E)+RF'?
&J*RO(>>%1<2B4Z.8:NO6?SOC;I/|LHV*UMPD;2D^ M9<-
!TZL5#)*LHGL;_9S-Z>U<_A\$#6Z;/7PY;I.S_Y19S_#X6_GO_3Y'N|;??'">|A_7=;1F_6*;>"R,2L.VHV5U61GICI
MUE4#)&X.%<G&A-U>M\MEFCNV)!U!(VIT<>DI0PRN#17QC<NX6H#YJS*& M@^9"61ZI>ZWL*)6W'@G*?
U<|WWWI_K\$#%3Z;LD5O6"8->VCNH.=AB+9%" M&\UUX\$WB\46'=6@T\$>%.W4 \$:PLKQI91+L
M%\$YTYW9F=4I%.*-H*|2C<@.VIINWEA6^WF38NI%3-*|=(SQ%/MDRBXG72H M:G3@;W*!C;.EFH8I\JO2?
QW6<^4V(4A0(Q"1I+1HOK%-D70>D9==5/8S4^ M\$@R(%)PJW E|GVWLM)2^*_+9D2JJK_WA/O5QXU.RHF MS.>>4\$
994?5&EL0*T(Q0S^&5W71Y;GG8LP&1_FBP1_8D#M&VQ2YM<")^"ME+6+;*=ZFRKY"N_?F2QX;#DSA7C+S;,
U=G1K|@E01^FC0AM;NHZIU5;|^ M=L=X|^4)/PY0C)%U%NK73(X*QTRZ#X.I<./AAI M\IG1?
6'S^O*R3LJO=RVZ47TC-M>L1^<)&F?V\X*O2GM>12|!>\$^9KM4E;R)JA(<6CBJZ_-C3%YX)7|J'3|NH<04/0#H M?L
M+>S4Q).8D8.S?K26/GU\YJ;5E*JKU66<=.(4T\$)4^>B_1&>3)P0'YHP M%;9W95AZZ5M*TSN2=)9J<0Q50'(H-
A+>AHU)?7!<.*+PT.G;I?7 N)J56|BL MD>4Y|@AKWL4^O;@H7VC5;U(6M=4J0Q3DM M>L1-GY%>D;
|05O\Y;R%G_+RL;"N05"S0M9O4E0 U*\$|T\$>_X_&7B_KN':HI*!|1#4M#YJQ=1|3O&5%DS.X
M1ZOWCKS90;%KVC(S'@KK;I#^>97_O3IH|H|=M%ATI,2%Z? =5/D|@Q*Z|Y" M|5-P)C%|AS\$?I/(-_CDF0X|FEN!#=E?
S6;KHT01|QV^B_%-8@_ \$3EI*_.M3B_B56Q0)#W^?;UM\$9=>@.|\WTW1W#O;_VM_%80|!64'0C_1+SAI_-J0
M67=QJY-5;_V>_S1U_0^+K I"2ISC>8VTV'P#ZJS<G|*++5|>7S6>S(- M>0R2;X7D)P>;F_8\$+%WF/NL&Z|@
^TX.OO@ZOS-TVW6|8A'E|N<4PE_W(0@0 MJ5CY|2O'8Y(7""LLHLX+7LO|M1QKT7Q>G|V|HU8X MKR|?^WP/P7U!+ P04
"X@Y8>7T"=,SL"GA0\$ #0 &EM86=E7S P M,2YJ<>?&?L? 58%V6=A\$@N'O0X \$:=PTA> @AP=W=W3N'H;%)(\$%#<
N\$|R" MN|L%#)=|8H|_Y9F6GYOY|QO;F=UG4W>OEW|5MTZY|XZ|SW78_.P90|7049> M|D|_0_X7|_7;@2GE3D_*D!+
H)C("'+7@*\$P_0%\$*L_1X&@'^^ MKYZ2^N,3(6_X|1%_*|P<XC#!;#8^1WJYP\$ 9N96MF;L9|861LX @!R#
M^(LU">%6RXI!^HIT;5SL+VE\$?CX B(O|8_JED5X_^-N/RW|QX;_DYM7F%- MF(N3AI^F)3U5-
O&U;A\$R9),2QTS4IA3WM'.W,7(UH;UL M|5V\$/<5H?|FL#S|XS0'K;BHLZFY//,K|P+^)^T?|^63PV/|>-@=G"TX
MN(2\$A#@XN3FXN4%P|,C%RH5R|D|T+W^QL|_G.Q<;9R=+5RL*2Y|=W(V'_ M58S6S\$P%^+@\$N'5STT-
#11CO^<|9L;@N/W M-0^>^HIZ"K^2YEIP_\$_Y(C ONID|_7W@+)_L#E "D!|1KZ+C(1R%-DN*@H*
M*CH>|MS;G\$0XN)AXI\$3WR\$B)2\$G(J9CNDU,R4)*0TK+3,C_8&5CO4?#P.CX|HDDIQ*H&*0.A%ROXK-0*5|5-
9*|SDB|V#D_#9V8A)3L^<C M\$_.#%EX^>?&?!(6&IQ|RLG+R'B|4U=0U+6T34S-S'TLK:Q=7-W0^/X#TJ?;K.RKZ-C
MXQ.34|SLRNK;^L_FUO?MG>3TL|SB^<0RZO?NB%_B_'.XBWKAP26Z@X2\$ MB(3R0R^&QX_ A(R/>Y|N)+JJ
8.1^0%X2B';K|H|M(\$<"43SOSQSC|1%6(=N MB%9\$0_9?Q*G'H"D.@CT%|T2QH;8;N@%=IL6&1FMW81-*>YE_|J|?54\$
|X4GJ'(2Q,^ M0_A'1)_ZF+HK85:C\$XRUB|OK;@YB>B9L-IE2@VJ&QHW#K?|D|T;A:X@6ONB
M(4|_533I#9A9OU1(;^(1Y?<=5|M7NP|ZD6)HAK\$P;H8@EY|6+R7&MO5NGD_MZ9(%3P|_W)CBM^!|T NIE,,4GW;
#9XUYV=,;H0'#>|X%VXSA|F")VG.8\$B4JN7<1|3=6%(V+U|*D698 MD7M#
I:"%5PL@X|;R|1O=MQ0IK9J82.Q(*+AS*>QW)S%|S/ZKG4F|X.86BWR1O)(6
M59C#'^OBEZF|G2^K+S3.JPSN55DMTD7P#/H%..%I X#0LZP1-JNL\$JB,R77 MM69SIL=3XN/CY_-DZ>-
WK_<FKG9@%)8|HBV121JRZ7#58EJ>PV4J2J"90 MI@Q?NP_-<93V?U3;@/500IRQI.P5XAH>6DS*
VG;%&Y*QW6EL>L02E3_|M\$J=V!_:1/(RTAT5Z0\$:/%UT0UBJR6.#^_WICE>Z9=20M723DDD5MO)\C M-
*K!"#KQG'LLVQ|1S.YVHQCZ6W_IL2*8\$6R^ M>@_E<:=Z((D0PNHA1PJW2"TL_|*S
(*Y="J1CC9:88:D>D^ZOYG1:T%_K, MQ!/'M'C@TOYZ/C>8HV?_"=TW:EVS|J?Q%8>\$Y.Q65PM(R5;&=(JJ#Q"Z(!(
M2R3L;%D7BO;98XA25F|0_MF|H;M8;Z@PR|+7BW|WQ4M\$H26|U)_5|L7|J6|.0A2FJO2TH5O;D|9^V@-L
MIG3A<@|7S*HO.3H&4DKIX|Q\$QY+M;B@|EL;(.3K>%)|*GFS9O>4#(H+HDB2" M*SP3%J=X(HF7&&I%FAU8/76_X6?
E@;7FP<5^')=RT*5JV#9GJ>_*#MYN%A.
MQ;4A#6482ZLSDU#B8KJM47AWQ69U9G|C|U90!/7SQX#JFH&#PHX!0R;IR@? M2YR'5JBBH>_-(46=<318XE)K0-
K'@*4#>JF42V>YTI^A2FD_24U;^E5&*8 MSE|SWW5^|
<#7QV*EY;5P;@XO8YRD925+ TIGX|BCKH6/<9&41PANP9=2C4 M1+GHX83|WV4)C.UA/3V=
|3BPK;ZVEA5S(8VE_C;/#U|;SN>"TS)^|1-|0Z|7 MJ=)7AH^44FIFW6_-|06KWVG+8^/5X9/(W_V1.S-D;9;<|/"7*8?-HX9\$
M@|K4*" +ZWH(MKB<_*N75;\$|FH_4/Z>;P&I7NADKT>%4- W-1_)3^Y63E<>F!+;\$3G+1=FPF
MH@GNF%GN7UK%G@J=%YR_7T.1:L0IC|HBB.UW\$|4\$|L|<|BVA+LYT58N%GC M9)VUO-8HFEXRKX^1GO*#>9-
+5|2<&GBK2L A|A"H/D?L.H5@*!Z|'GG/*1D^?L|F?R(EKC5GT|X(K73T%G>+ZUC)BV4(FRG|
M/85#+E6\$|^SE_JNH"W+4;_>OZ3V@?)>3OUP1&D_(M,MW)'|KB=B#J(HE|D)K|X;= M.#"\$ /ML=1>UFGH;821\$T0-
Q?FDE*K&Q MQ|=/Q<?QK0+3?QJ^9R?4K4R-/C6FBH2HJZ_XSQU-3&H'&|OW18G#6LH, M6:9N"XXYQH 'PV?
6#E|^FZ)7WQ(LE6FN9H55A@<3VNJ6|N>R)G91;RB|BY MI+H_|J|+P+ S&W%LQ9;6M*YIG|D+S|LZWT^F-
NJ_!^0)'3PI6^CB7M6)JM0U/4('B|13F8-G#3V18YT929V M.2I3'R"*KKY+C'+/;<3L754|'L2BVMW00(H4-LEB9H*Q%
<8|FQ1F3M-IS%O M.|TL=CM)F_6M*E%_K#;R;J6E3*O9-KEMJI<(1T<@YJM?5 M3#>J!|TPI<#Q::
6Q8I=P+>6B6(MB>IU3EK7@/OT;4T24VADY6-3|;^X%1T MCOYLUK&TLR-
FV0\$UNXPSIY<0Z98PMV=+^|>>TJKE"P""4O|*H7Z71CM;Y? M)S?(QULOWH^!TF6;*BKJF:/
O>:HSHLR/T<*IX&BC!#3BW!_<99;>WIK> MH/BAEM|<7RE^|HDS?B.2K;^<9\$Q/7%>SFTXF|%.^BR.*(0OI#
<8*L|W^*C6&M9=G@RL2&GCA-/P7NE|OZ|3;'3"@=)OVI7L45=5X3L1#0D=|Q|3(BQH10^Z
MA+;5\$K0\$R6SB|9MI1Y^L@BO>|YWI0&XY2*O: @|5^_7#:=68FIKIAZV|H3 MPW@R9A;K#F_)G-
KZZP;1GG'SS&6'H&#|<_IA8V>33(-5K;@PI=NO^N& MK=*XITH.58HI70JR|
(ATX_&>I%|JE+V9(*"4>>O.\$WUFU1U" &L%F?LNI(AW^ M3,E*1V?;<2\$UIN=\$+*H1+4FQ.WK
_K|3'"_SC%O52FF=.D.;5: ^+H_5)#>H M39,%*_ /VK2"45=;#B(E(Q:QOJZVBAYC%9IO HQD|4KFGY?\$Q.% !E7;H
MB29R|HS6U"H1^_ M3|4L6ZIH|JU18U;UUAC@63\$Z2>D|Z1/NZY" T7WUW= M%V_W_&_RKKAN'W8V5LBT>.78&4I?
F932QENQ?M9NH%0C&IR%K\$G=PX|L'_ M2<L+=#N=B(D|5H|6VQ-O7P%>DOA(P(C_|EQR1_IU5D3\$SR|/
M*3%:IYI9;IYJ%\$Z:0*U*QO2'JS*K'W?>C1#|QYY6RJQCSC-\$:&Y*Q'H&|G M*<&
\$+>_./1&56E0;DEGLHP,2)"^1HSRIEQ=&#1-826)XY(&_1=4J3IK+^ M=(HK7C)U"<%7)%?I
(U"NO"\$:SQ32>6_00A'HA|BT%*(4MI6OY;^FDO_&X M-EIT4V.R1IU9G|LF;L&BO_'C^|WJY/|(R@L)-LR*>0K\$1@6A?
+;UNOBOZ MQEDP PD?V7/+_ITY*3C\$QXLX8\$%?O|8^KRO0A2PIC;O:&.RWX/3=YGM/_K24 M.5&I@S;3W<6GAJY2;|
<.+;HQM<&O1.V.BA=W|_9_XL<'>52;IG|Q|!&'7& MU#92|Z=SD=)23)A8^4Y##HU&0L;/L%-.0C9G#2_Z*41-
NG1;O|%;\$WKBI M?S;3\$T5L>O^N"NI"MV3/VKA&*L1=F+O;"@5\$R*\$K|'K;,%YU4Y*6+KMTQ*
M2Y"@Z4H|L;RO&24O*\$XFH9B MTKX;8F(2Z|06+O:%"O\$O4DIFQ%UWJ;757HKM9Y^BFC>?%&!+M5VZW|?P;
M=>F!M/^-<|PRH@@"KC_3/V# M0-4+O^8+ZL6HE8B96/CY2*V\$1'3BEQ5%-97@>-H|G+ #N-

M2T648 W\$/H/5+Z0+HQ00L P (D^IR8\$2!-07\$N(4:6Y:IL9N+#+XU M=8>)\$^LM0)ROT^CG!_ *E^NX^,+&IUY? M/V!^1G~!@_?@_U5@XLSUSE^H;ZRDE1\$%L.S3T*:#2;#*")!FY_77K41L9/T/16\$^"L?!. !A0T#H/!@&WD!:=W78N>X^Z!^LE_X1220?)G!UJZW>T MH^9!X>190EJM0?/02+2F(C4S54UL !P0OM_6C905& ^4D>(<^Z0/D7&+==M^,CA C@+!HQBU&S Y_?^I HR F^O>1.ACP60P>/J5H<>@XL_PR(?=/: M\$.Uf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|YQ6%4U8&@P; &VY\$/!@6DU_17_#DN*NAFT!><)R4!)2K.U.? >AIS>Q_05YCG9^J>BM2Z2VLQ!^XW="W_M!\$^5#;7E-0&>|/BL|E2">881I>M!HB81@I/!0MQG%(@NF9+CBO*K!4:_TYA M;BK&1N+@F+=TPRE6TE).O>NPG7B\$A4!>|JEMT63C?Q:LCS_~K6\$3_.UE37+>Y=Z M3MNSK&F4!^QIOK!^IHAT:\$S_RS^OZC!O?HY&COXD!6@0;BTE^M^Z_4S MK>ZF8S6=5SP^>05-)/I2*;Z? WE%NX+^%0;_E^B@S!H!M^12!D!;UZN_EE=M#V>Y4V6/C;274I4=U0!1<+F^+(J1&GKKW!;4MD-)!;S88<#4_""4!_I.B)VA M(EQQ&G_1_9D^?7P_H^H<5)?F\$XQ.TVBT^5!%\$=VGJ*>XTWT=_LIYMI^HR M/I6_6?- H%NOTKYRM8!^Y^,M<*.H_C(3:_WYRU!|/;&_N_W=W"+%&CHC^KE^Z M!/P!|Y^ ^F;ED^?=[8;? 5D)/J3;.B8F<0=;ZA3!EH!F.X^2H;\$*@/C^&OB* MI%\$^"IO^W8<_E=G2_YO(TZ/!"MIT5&^I5\$A<;?)_8OZ! <6!SZRQLN>QB!4! M#R!(;\$5D!F4;1@+*4ZA2J(1/1QN;P!^+!\$KT)!5QH9AN!4U%3T)M2@;_?"2+ MS1?D=E2>I!D4\$2? B1B^Y^DW,C1T/4X5O.5P<_AB;./K!VZB584"/JU_#CPY^ M#D!P#\$_9@P\$GE+^%Y#D;^15K^O?%<(^% !N^8N;GY5F+7L=DLG(8\$^*W>44 M\$EIC;9M=>N-6C_%^U;19^)%E!Y>PJY.W-!YVZ_~J,72*"8CE(%3#C%BN_K: M!;ZA2!_04R6L#JNN<58_#P<_/41VKM\$!SA6_ ^"*G#|HX|3X_(5VSP< M^*);@?5"\$E!4<,"G=5.7UBD"A+)C<I (G=50MKE=K=V8,=5=QA0!JD4!OSD!DQ!^ M^M9> (A9_~MU*A_)HUXXU8_+BQ0+D6@%XA;_EMD&JG0W&%!;V_3;2ILVEZ!_MI5- ;7U^FY&?_SFK.2GG@KLMK%9!%KOG^1F6P^&70&U_!SL9#V^+5DL;\$ MO=F+C?O2_4_1=BRW^7=-Z^2KCYO#/R*=OU MM-EMT9P\$U-R@KY_GFC3S\$>DV43;)+X(5Q>60IB4)MUZ;1?I^B^5!5;4>"8P MF*%8+= ET&QM!ERH;JWICC0^1>IO^6U2>ONLK6^H^#@D.N!N_<;2FO;=2! MTATTPJMGCHAU!L2G)S.*2F4Y^"F&?- I=15Z;+!C(!A5G!S7-Q!;T22Z_AO_M-/9K;^"=SPUZ8U+V;G MI#5? JH_J.4H,5!R^K^B^+^1FE,06U;0_/M!H8!\$F%Q3A3;K2JX(I5!NBP MJX00OLD!MQ_+^"FT40H/DR^H^Y!M\$6\$ _0P86;02=5D4^C^~WD-I@#XM!^? M!H%KG^L7E5BY4! !M)\$6*YY.V5SL_5F!42C!;@JO.?EM49XP(Z?D;L!Q>";+ M%J0VU\$=E?#@8GAFV3U5!LQ=F^QV#OCS,436S *=*Y2^? <%MJ-WA#@3-H0!+2 M;UL;Z3#!?^*XE!^?B!\$C8!Y!WG,+IPH).+T!CV;59!D)V>EP##4Z!MKNK*"6>RF M- 3N/IK@EAL4@<@G80!PX2O!G&8;N\$5@MEKUL^D*#P!I^>NLZ(+ I:V(R/32 MM4R3M^7H!N25^P<_NLG@U9NC4_5AHG<3_-G.M->S84#MVT_?;F!OA M^*AC&H)5.%A57H^A81^M? 5\$Z&\$*!_70!_ M2_!H2FM!FA60%)L^/B;+3F ME^0;K!D>Z3\$Z_S+2OQ#3;FU<0P11&+F!/_ !GZ<I2U9A^SN^F#EAX^Y>VW!Q4CX\$08>_GZE^"TCL;K\$K;^"YT M^*)C6F5!83OPT^;BZWb9TB5;TW#@^E4!0F23M-V4P KXD03&#_8808=>OF3U M=24+E<=04S_K/NL1G;^"1Y3) E3)&Q3B0.VL45^Z#^HG?^I/X08#4!)ZB! MG_4=" /ZY2H;&E7^\$?^7!N2;G!TSV!P?L!U^POX(RUOS<2U_!@^1EM='6YC MPN90H^1?XMOD(6U\$=>=)D+HA6RA!\$%^@2;D> !O!L#ZM56*A.SLH!^DK-H!| MRV&O<5+Q_OE=%;A&|HBK_MD<4E^+XYPT.BD;9K^5?EN+N);!O!"^I^"WS MN/;40N1>%,UBUPC;" |B!A_JD3;G^DBLJDC5DVQ\$W;^*T_9W% C8_U^YHO& M;WK^JKTJ5C!^<5;I NTE;K0H;OT=P!W^20+^%#R>D3Q;IV;D8ZC&NWM+!LT>D/B_%FZ7X!&Q?46I MK!SXV;1Z%R5Z%V\$<\$V>#LEM^"=K39_#KG)ANYKM;OB;0/2;QY)X!X!37D M^Z3>8^@HQ_K;=:T09C!VQDM!5";FA!50H&_BS=I!J&O&^"NZ6(3UHKM/HH_# MRVJ6JHC%L^ZN-GP?Z_4K" !QV.OO\$3^!N0F84!8HPX+7UFD;M M;UW4!^!\$J\$ YQO!|RFJ!ECI^~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|? Q%!WUR3Y!F!C\$H;9>J!R>"&XAP_D_WY_MHG=- BM(YY\$*2V^K37T!96WMV)4&!A)P9W3JZ1YM;+!OLJ^208WA;G24+WWZ MZ;WK!>&M7!OW!22T^20^"HQ3G7G;JCI!_Q3R8G?6_&^9MG80S>>88)F8BKP\$ M0U7D02V;DV9-(;<,\$V'={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~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

'JHL.S15ACO+4G.)+>G14UUXBK&FIKI19W>4-V^ MJN^<|FWCKNGOL7IZ8:XD9N2I@QJ@)X1'JL\$SE:?!=KVKTT-6!?'
B>)>H1-M1HQTRO9"(IXC%2BFD)0:&V(*((QO<<:&N> K?OMN.2>%)! =6@-*!WW0'M_A3
MG^IYI,Z/BY^"/HHL,U0<#85U12.O>|/%Z&^G,=1./-:1'3Q0,IY4E NPE*K M)3C_L&EK+JZ>BPWC8.OGYLW.34VB5-
'1&-3 M-%MNB'I5&D4-I-8R! &2%BO'PO'=VQM,1ZV\ 3;3I5!M&O*T
M#;CYXU_&|@1PWBI8!P;1V&6TU3Y6*4EE3A=-SR;0?#6;F3<- 6XY#4.5%
M8=.ZY7L\ ">YB\$8H-.Y=UC5OZ(YE0QLIG0M7^H2ST4L:CZ?IC?V+(?+;+3. M#TUN\$V>A^R *
M96O1F3O"%N)Z\$5IPAR"1C3'1',35A@W*K4UN_Y\$@?.)U|(> M7MH'NA33Z\$>?WK64QAL4XNR>P&F-EW|AF?
(TZ/N5H|H=Y<7+;L;/=O;+.-= M@|&1UXK'1CGJ+9@M%\$7Q@>|4B#77)WH%0357*FXXLG&+55VW05I8J;A?(H
M; >CE9= *,.D1YI2&PI:FOI9K1QV2R_3Y+T^0JHC'B6W7T IA /5Y" BZL0 MO#
= %?J'6ZND_LUR.P\$(T.H+ +*11^V9!5Z24IQT1K@:'9W&(@?K,%QA|1S> M.H#'_ ^|#.I&XO*+8. T.3Q DEW4D-
==2+JYIV0:IV745^-(G_16|^ZODCWOH MV,'IZ" X#K|>' N1Z25K;-6#U6@R&ZY%WN"AQZZ5-G'90;#'(B-3T%
MN04KH>M3>KH;Q:O^OF"Y,/*6XVRP;+OI&DTD1%)QF?J%|W4UEU97,95I@S@ ML8W&98@4^&Y:\$^@N!3T;%
L8HLG,>MK4-Z-BMB M-C))SC8-A>3268+ _8E.&*F"0VPX=-,3Q7V,4/MH^(P=> 3Q7(^%7RP&JTB
MC%TTR;T|>7C'IQ-.I.R@W8=3#><*Q_Z;HEPG%,&O|PHKSJ@2P1(=G2.K5<<" MKTQ;1AJE&
O4K=A=FY3I&351J6EK@ B<=^|":%)GZ?*D5_0C, Q|B>&VP;8BSBPW9AJDRL4.'@J|*%7MYX*8?U+ _"R(L:3'V1:@A"
MYN8TMYNVO^R48RDJLK@(&5O!-CPIEX4Z,1s087J=5J5'W7RI|JA?SQV09\$A@0&IUE<\$6\$#0.4+MXBC/IM=X4'/
R*C^!5 M3#P3!F06%6:5V,.C=(6\$(IA@Z"<+K^I?_ MF3BATMAJ=5#R3QHU66&FA039(M*E|
IKI="1:XJO'@&NZE)M_ B19:R"R?>A)HU%=-&JFT52,VYM4,-0=7!;C M9O>Q&|L36&OQ.%7,V1M2#>)
MO8CQ9?&6D2PBI:>")&@+T\$V/4N5%\$S\$R6HNKR!,86YK%J2G#.NO1YX7-Y8P#E(Q7K"N%N"H
M1@,V_E&.,^&|L_98IRUYQH%XF/TT+SL6_UY;J8T&A8OIG;KI63SD0DON MW"SG
X9|WX5VV1LIC9Q^|'"@,2J|HHT.V|F13>FE^G)" R8+641)2U="GFJ MI+QR R49X|@LEHO_OJ=8.1#8!MG-
+8HIA+6E.D:G&!OOOEC_DD8<%1HHL: MEV"#D_0"O>/TN(S;2Z4?OC=+06T>RIU.N"-= 2+>@K6 4-.!:=A0GT)IRN
MTJ|BN:V12F;| 4XUK=P#X4=TE-!C7(PDK|#O?7, _!8#"HH%O=C=@>Y+ MZ,03F3;AJD@3,?
SU >| \$N|N YE, "=L_*5,5=->?'=PDE5'R*T"M"))H2^! M2GXN-XZ) (SQ"X)L.; 6/T->7@6?7ESC (E| Z! =294%PO.BA85!
(&.!%E MP(#NW2PXR8Q?R0GIL3;ZYIK_5CY.X+CI|26Q|X|6.S.COJA:UR@E&*Z8FS MGQ*W3MZM4U|>KF*<|
+C@.5T)UJ;E,|^&^YC(.O4KV5! ?PG_XN^&N-X*;D MI7^"?)H)^@GZ'_B)(6Y0I52I\$G_SIV40M#%!(^DI33'ZS-
XV18#M%+K|XKB+ # M\$X\$^&G=POIY?7ZZCK)M#22L61J'DZ"1> M(5)1;P+I5H|^2+Q^RU@H81_L)FK;
VE"SP?%:HQ%FN 3DU07M,Q2!| NP M?# JC'U*4.D5@ES-2H%13%+< OG+(-|D^:(4IE M=^0 M5BZICBGOLW5CI?
TZ!@G| U(ABL^#9\$J/NA5+R(WSH7X:=V-DM;I M\$WV/M 508..P(5:I)ULE,^QI'HVGQ-6GG^
@O_B1%>A54;KM5_A_TB7#BD9 MF6@X8G&D BO|XYZZ>|XAWPESW+M!3OB =M!(\$5UBLCN|\$<0QL8.\$5 AB""E;
MOU\$A#AFMA4UK? GMETZHQ>MO&DXI\ 4>^Q0\$# MHL, %|/"T%3RR#ZHI&K)\$8^WR>IV+Y_5MIT6C7T%@
OS'!\$=YG*!?"H 4? M*|^\$W%#"(!%<#&!*7L UXD) 8." ".!0/ZKV& 21H!7*W<^7YLS.6?WYA M75VCGL1%.KOMHNI6
1SMY/W\$ <3IQ_VMQ!0>02B/= M""8J=P?XUY3KKMDNO@?3IG0Q:R"1+HP'E">"M8&IO|TU=4S>R.W*Y)OEZEA>
M!1=|>&9;DKW=F3BI#NC"BGV64QO*.L#^>POO140\$^&|^!EOEK M-7ZW@OHGZB?
J,T7="8D&KPLMMUQC1HR)644Z=P8U8=7I#-WL-XWH%|G|&E%
M7ZSK6I|@W6BA=>3=.M\$7NV!TAW,R(D)PQ=JS7IV|+B^UUI>2DE6;DPG0%6E MP<(YF76-YGPI?PI&-C
M9YH8B*JX1YHIO"V#Q4RL\$^UODA=N:P:4#:89. #/3LU646S=IW--SKIV%.M M:XXH^2I?JNBML)5P4K.; HT#
AZZ&=0>X! 5 MR?0TQZ+O+>?2LJ6SONB1VL 6CA07H\$';?02%XPKZC?+)?
>!>2T+YR4:3"D.>.04*G\$(38@9"8<#VCRG%#RG_KR"U1GP59JN+O7(6+&>#XSVLD#2P M*NE+|OKB-
DXD7O_CA"Z;ZNDT|GGA1B> 4^=|D=U%@W&AG) M-KOD;ZZ+I?H\$)|@ET
BH:|_FIC\$MD4.FQ97W5:DN@.O"!*"@9CK1:S1M:>I
M=WF=|,*.)NK9!3ZY^UL_PQB;F1XEIUKPW4I@&392!77|HK>W&;Z%/NWX. M%;2!3;A5.KW1ED,D;ZBICE4D;QUI
I<3+-HYR (FE MV_@R0D"N!P419=-02OT&I*C!82?^Z"3#8N%KP_|BL\$=:C5K731I/6^JK8)<1"BR
XDION8B#+!\$BT@WQCVD-CT1 M|#|4X8JEE0 !VVKUC-2.O|NY|@?LV\$ZUR2NL61 S(81_OUL&'V>'YN1@*|<
M*DKB_KRCS3.;7J4R|O/CAUH?H@#?>Z==2C-O)YB9FO&M*OK^2|W&XWZ|#; MH6?H/SQ7UN?R7X5-
|N>Z0%B4J^PO.(L|K 1^&??^N|NU565>5^DG1YH-3 MDP)KQWH0@U1F_C>G.%.V16)>ZWYG@ZRZ1T>LV;!Q?
F5890%@P2#IK'Q>(6!M V^?Q4: H9N8%1?K=I\$|2@|A3&=SQ* XK\$9ND7|IX|4N@RPF|ONL|,V^F^ M%)JP6*Q\$B-
X5JEDHS3)6-44I6EG%|I0)Y73DJ:UR6TF2|XQ|S++|3GIBLRL MNIW.5.?B)OK%&_U1IHGLT8|3MEGC1MW)YHFFHYM\$1-
SW8LA0G#V(I MWSQ.XXZ7#=#0!O?U+(I M%Q.ZT""+|W|QTW+AADDX^ MB\$**+,IP=!
|42D|MG;"B6<8N2>F86=OL,-5WM6L|XK@%:T#K#49IE59UE#&Y M8Q?
TNME.YTF5%8T8^.\$U2W"LO)7V>Z9Q|FTNDK!|=V0)\$YY|IV>M\$%R\$O0KW"Q(M=*
<#V|^NQP GV4AH_8T9#;IU<|UHV&T35^QO_HV5PF_2GVWI6COTW.%5*K*T4 MU-9*Af0FWLB#BNPRLBH-
BGEQ^H5J(61&W;Q 3?XKW8- V#CHZ MG9HN8V(+=2GC8-7E))MX|OYBI? O'6M*.K^Y&+38JUG1PJ@O7Z)LMW-
=#T_M-V6'8T?KKH1Z|2)VI?;J=-CJ0:QIKI+K"1<^A|H@5T.NG|WH<86N9;))
M3YGR.4.K(%:E*HU)MTC^DSQ%6N2^&VUX|B,%BA=/C660:M7IHB^4C"
X72J0N?;T62SS6;=Y^EX2=V7&BYH8E|A|F2% MSX+?K)78,<"8-V+5=-
(3C#7E%7A=6%6C"JRO@I#IGLMW"2)&051+J+!|U|G. MV@|;|SW<)_T9QS+'SF.=,|^&9QH5HT5L7DJ1WO2T=F%XF>
(+IULK7NU")2I> M@">|U59P*(96&V|@C|@)<3G|M"72@;#6R%Q:EZ7IA0N|2JL_%E| MG=(+VX3-U47"5WK&+/
(-;=S0.3WLN% ;R5RW,QDLZ;-J68X;#L@ (KL-DI MGP_#9PTW|6DBW_?ROESD1P^1GAFN 6!.49A0%J0SF)-
^NXMC_18M10+2/QM M4-;"M^_UEF/FM390=%J\$59,(\$A4\$|7&QM|J+D+|H8L%YTI=&,-)+6SVXGR510 M5B*KP#F-C
M;R\$!"IA|S+0EF%,J.W6S_0CU%V0HS&CRUP/9+,FWS92DH:UL#BUP.A@X31?K"WI-4@5#&R#=\$YD@E;=-(>3U\$0;=!
M%TA54IP=Q|@5IO4G;)OM8->AFOAQ(U=DZ6L^&#^"M|@9
M6|XHPE5H+7.L2DE" LX+\$6 _JZK8" Y;5H(J|05>G3R%1C(D84Z^X7-EXM.C MS2PI/ARIN45|BL--HM9(\$'V=FFR'
;0|VD&C;O9Z4- MJKREJS.P/PA5-S0T-O./?B)G;EMZTS"FL)U_Z'H';..0YB+8&0=(V|D|_MY@/ZFEBW|VO1?68Q^?
GJM?7Z)"B9-!*"HVE(Z@:UHC5<4JG&S?@H^NZS7 MK&BE=\$E" FESJN(7EPG&2X|@#V/NE#V?
W(W.2@N^WK>HFR=|X>G59R727; M462?N,(8B;TKX^"62BNAZOUN>DWXH\$^+;O*NR|JRYQH6M&|=C|J|W/C(
MBN*CR%)EA""IGK=#Q/\$R^HH->JV|;(R*=^ H8*B5ORV_&XD0NZ;6+YFJ%754 MVP,*<-
*SB|JWRVOZJN.U'TG@"3>+;H'LU" M@G)#|CG8I#N;"H;\$QWQ|/(48#('=0UKFAZ)P^P=B|P MN'&)E0S<.6|
<)SYFE*|>7FXI5,22M_UK?29F 3MYM2Q\$7E0 M<@|WGCZ#E#;/_T_*8Y3;#6HE..Y 9Q:>G6%N&@&XEO-|I&>4P4NYOB
MN"\$H74)(4%PJ^"7K?",U9F2YON|9;:Q. R_!TH:YLVH-E@-U"2%(5#BS%; M0M"G>|DW-ZMI0AZO/V35?88
8>)DJ_B_-7 J?S>)B+)_U8& MU/&KDA+X%Y9OXE3Y:4MD|(F-DH\$O*N^&-0RID5.EH3+OAM@S|^O.R/3Z1
8>10W5Z114@UIT0C<^VOV\$|T= GO@/(><1?OMDHSB0,7-FH_*PD3>CC/X9@0 M)>N06Q-
'QU5N@+VOL@_30H^<3RE.FP?=")(CER%7EA^MPW%CB>7R7PJL M8S=H2K%GTI3Z"&^OY>,D09LW9&2)
|SNG"5!U/W268FP7F*3OLOEZ2"LT3AM M@=Y96H8!")Q^=AN7A5#*ZTNJ%>ME5;*Y%2P(IH_6I5#=?>,"
K*E)M10_Y M;AQXWY+X.G"MK|K2C?B&KD(2N(8\$U-|T*9XH0UTB#-.I&J,.*TQMD/IMZ
MT6IX3;09QC9V*JM?..5.4UU|P-<|)6=7,A0,,4O|^E4XPN'5;^|5Q=8WLR1 MF3L3?/VS7(RU<8?
0R^&S5V#5)2SC;F\$YA0#"T>;_ \$'=I2NCNX^ (K|D|VKF4OC+L;JX M4^@Y+|
H7IZ/_;/.1822+T*%U.2WPDP+"9H;_QJLX\$@YC-..0>Z4V3..6>3

MG!9SM;=))5G+B0HFZY2C&+GM.E03 7.R)YIOPEHL.M?1#4V!UPE?TCI!M-1#*)-EROJ<\$UALO4\$Y4B-
Q%)5YCM6.N=>2-IS&GIZ# 2PW4>:AOI2&1O>^ MN#YAK'Q&TM(NDH..6L\JNS-19+HF+ "LOZL0%-1R25-
4\$;.M;S:2)WY+84G-M.QFUJ9A7-IZ :3X)>P9'069Q.IE.IK9RF/E: ^?+2-.H"V)F=IL1*L7HAXWJ M)NRJF1>9:IX")
IP.1D=7Y ?=VK\$/(9ZIEH\N.H9ATAH>V9AI2F?+)S82I9 M: 'QF4V\ WYIKA02#FIEI?HF_H A2Q.AL1?)
(JL2'MVH.#P2+EVR*1T)%HE M8Y: .!V18K(NJ3HO+A1"R0C/RM:.0270^&*14>I(CA<4: % +(19YD=&5CZ\ MYB.9.#
I=7>6C/\$QK@LK3^ (Y17%+;YN4R\FYF0^&IEO:D-\$S<3VB\$'4<3,-I MV=6ZK-Q\U4G-6=+R@YF9#&O6_A=YK?
(K7AV%.#?B2)QRF\$K1R"IX_VC8", M*O&\$EP'T< \$,5Y^GTIS-"M87I-4Q\U637.6"RPJDT<8CV5_\$R5IJ70DTXX1
M_7ILTXP2V@52+LEYT\%;:R9"U>N7//RRF54H-)L\@GE\I\K2_7V.V.%3QI
MJ8(9W#.2)YI^VOK>MOXYVKY5#IE(/-W1N9P0&Q_1&J8>E4@ERS<+|CSGK3" MI#0#,'.M\ P*)|2T".7;=),>9F76"36(-
PLU+%N=)IY3B=D)\$#SGET>"I\$X MAJZY+7-/- "5#Y\PS3H\!3?; M+O7QPX>K8WY1Z\HG-L>' +X;HXG.E%)D**?T(R5M?
4GBH\JZXB^46^K?U41YI MH&EK; BRK1%F0X>MBK" T)0+"\$4.YD"@TLFQ#;.97<7=S=91?&J3@%<(UMO&S
M6H4B^#4ML;\$RHB7>N:.*Z>&(CBMP3#>0G+>0=X_%2008*FGP^M?S(GVHC+V M;L2&&-O*Q=>%)TZRPI7,KF9)
MQ+#+.29\Q3MGQ.O;9L=DO:826#H&E!\$'O_XHN8C+3>^C&XB9XOXT,+ #JK^FQ M0UK7R\$VQ.O"H<?<
ALL_5Z/+?"1HZ";\$IEX9%H_QV;T6H&%.'!T"YF""WD*! M)SBW\2O\JP<=RBFD0_732UH4RD).>19I0(TDB?
RUW8O):CYFF: '4DL55@ (R M: >HR1GCCT.PFYB\PI=+, \$;+IMF&...?K5_0#"MH:F6J"09Z\$EARR\$E,,Y'@> MN99OKU.X:
RAUF@D&OIL.TW-/L\$.2X7_L.XRX%/A8Y7J.C39I>+@5)4(QR= M>U2OPL^?&'!KIAJH&V9ZF"
<3Gf@:ZCRN7IN8Y"CJ_12)>Z0D:9Z MPNK*DNIA.'0DK!ER25\$%:LH\ZT MQ.%<6*ZI>GF.? =YTZZ5EKQ.VELO&-_H.B\+
+CZ18)M6U")))=+C6ZX=W, MA"F@-!D-\$! *5<|OMN889%=7W!*>1R\NZ5^DH1^Z.C\ M;+
JBR*K:H00Z\;&KPLA\$H50I%9:WNEPM2"XHU5L_C&_7S28R\I&X?U\4
MX1>1PW\&C'A!%:H*W2=\$TS_JWIP#0+!^+!+0D@JO9X9KD.2./R41D:U+FY??4 MHJZW:NFOV=/J>-0NWR.
I& "V\OU5U*R'FNNP0B)64G60W+*7236Q\V2XF0XKZC3(ZVY:*B.5&QOERV!M_OBIX0KE5_48Q@CF.MRLN88V/
I7P=C.RC'XU#""+ MG*K8L&S)GR;PMR&B\$BQ5C(Y>)Y\@VG-RX^0!#IRIO:T(3_-7@L7VWS;)R) M7X,*J3*ZAZ\$V>?*
7XWN4R"UR"X)P.T" XB2KDM\909OAW_7.2R?#BC_Z"UZM=M_KM^W>
E5Q3G3.D4?)8\52.4D469\$SBAOAJ2<2MJK;BYT/('T'A7X0Y^P9P8PX M)ZO7Q27BR(C\DE5L5M0.PC7_9I\N2TE8E;#9+
I6IK8^9:1X0I3.RW@I@Y M75B8OD3M" OX=AFS(-\$8X4CY-8*^@3;) ^QP8A""I729FJ&GYFV'9+W*?EM9
M&HK_PL@^|F% X*=Y%8'N!")57..HG<+ZN 5(-00\D%<=KUW27QH_T# KYRO* MV\T.D: M*VN6?
=S47>NKM\$ "28GO_-WLT% C3_2=VH\$%IV=A9W?MBG7QV=-4Y# M.S5Z\$M/R@MKQ0HF=-!NP%=-Z<0>
(NO* ^:"S5G^<-I4D9&GH@FWJ^#N;..1.M2SU*A/5J=WH_/ZW8!EK'<.@!P"D\^X<#'\$I.C.M9:#Q)!%HG)#((H\$#O+
MM=M7%W&/KJ<1(I0K\E:/ID#|HY^XQ3&SHIP(8L#&N0 \$P*;UF4>ID92JOZ' ML?;4FK*J\!' ^7AYVL8*/3.-
XHJ.O4H W^DNZ3H#++9;H!5:UFB:5XVGB/77^ MH&E4#NF3_.*G(S73=>*0AQ")U=3/+(T)AJIMBY*M4ZW(WM4R-
4=BJ;+ M*FH#WKSJU_""FH\POXA_ \$001A+QR)-#E2R1-U4>L_3(9Q>>"FARX1/(T1<
M20MQ.XUE@D\KG_-D<=E2WTK<\$RTO_JT_B\P^B9_+.-@W=0I.I=F7V&>W=F MX/9U5NF1-Z.!<4/N_+=?
IWJY(YN\JA7\PI0;OWM':10CV2&FKV\!EGY9 M9=3QN174_-%MO'&.)=0MT;1)-9+BH^@Q->)R,<#
fKKPOY7=;_QEI_(GXOP_M4?HJ(.HHW2I7JE/'YS6\JD6%8_WPTKA!E\$5NAEGLTYQ/_E#I>@VUDKBV
MZ@!H;..8U'Q^_2YG;_KU\$N(LQ>D@('X"5F#15S_T/5>\$-WXA&W=C2J\+Q%1C M)@_!ZGNQ3UN=@F80I;92_/++=
(Z85'X\$7X8>'UXU9RE,(6^?6'L->PN6\ M\B**HP+XIA+N3'0X\|JT=YJ4T?B*FIH4U?|5M\0/@\I2/I;W20Y+I6EXH.
MDC5,S#E\$J_P\!27@3IA_ "5A."TSG5D\$8\$/S=6/B&>TKA?Z-J=18YF(WS&| ^Q MH^F-UM&|R1-
SDC3A)"X.%4"RTPO^U0!*L@H_4"L^ZOX-9T>9"M6Y7OD M"TO:""6PG1&2">V;..M>P?I7=
<..X8\$*2Y&TC@CCIR\YVQJ?HW^_A/SSV!M/MY5(="I3-WH+BKM4#7&JW>)IPO#;^?7R7H\PT%HO
:@1_11:4J6\PS.20D MWA*FPU->T7*U.NV?#;..ZI-R% FF5V-N\Z6KQ%T5JP,>IMM\$3F\IP%AD>/
M+;=M\/*SS/DT6&).A/OH%D2_-N7D\$SK:E^M>NJM..7GA^64P.>K09_7T #)3QD65/G92-MO.TUA@L%I?
_F7DM.K7WJD2=6.F6=FN\IT OL;K\I2ZL\JZ>ZN"A2'WWDZD M7L7YJW4I+?
(1T\$S0XW%-5U#3U<_&&M%Q\5@FB*2Q_\$Z*54AMXI?#(B^N M\SH(8VS\$J9.?'8&+<|. "T%L HV+E-
|A%*J8;59K6U=00J\I2I6"C M8WT)1N;..92J%R;..00-IQ)"Z Z0.8(7)7/AY?"OWX<<.;>7MP:N^S<..UZ&8 M,+ =6IY
O&X/U<4"(>I>^TGY5(0D9N\$;D\WG;WS>I6;./Y
M1R50#>15H2\ZFRD<(HGECYIZX;HJHZXO/H9WBG#9\9)71\ M&6TUYSI(R0*ORV/#ICN2(I^ (#7PAR@8D_NYE\$RYH
MKMT\?GWPV^D=X&D&I".V'OZf>#J28_@@I^_I^_G44_THG\PWZI\N3W\QHI=-.E!\$.84Q-1S,5HHRX)_A=YCTN MN0-
V7N_CO1ZH&"15:X-*Q^3.AKV.T(1\KRF\ _M^;GG_U/RW?I2(1K\ER+U%/I>I/I?
#_P#.6_^D\ _OB&?/SESLM=H<79&P)X5_MGCL@I\U0YIC@Y#V..!V%|23VK-/#*=^ ^T%PYP;&&YR73S#8V/B^%72OJ
>BL M2+)C' _^+06Y@>L; <=LX N5Z#YFN/*5J;-6U3HINW^K_OHRR;9KWC;BG\^0_MEGW\4ITV-
7;"X_B;=&)2\WY5RJW;56;.J58O'P#MG5N\J*TK+@!^=/L ML M<^C@&:7@ (Y&6W\X J6S0JNAX\IE&B_E;114EFI3-
W?.._G16Z!*EYRKMOAF MS(XCZC:U@C^?C\?:VTB.P\YZV;+IX-I4+3@1EWHT\G"P6@QM?*" M\|B?LU.(XO5;I\$=->A
D??"2+N\U*6:E19 MISD)IAF\ERD?.C\6^+3LI9 M.&TZA<|42X?
U#ZC6>|_Q\ (PSN_ '(9O>Y\$'W5D>IE(B/XMO)"7PB2+V W^&#%#3' MLD,=KNI>\$RB.GS).61&-3R@YO+2T95LA&-
V;XU6&BQKS^J3^RI/ M^?&JTT2+YD>(9(H9^?'ZO8&AX\2X997\I?^H_ "6;|E|>I^_TU9MW%"P362<
M8L2^B?/(A/FS"AW5_ M.U**_PV.J9'D44*@I\U006FWRV=+9@R'6Y!*&1&L%. MT\SK%=2IC<=<=A2@ZU7>_B3D.^9I+J
IP+_BHI3F&X507+MS> MX\$N MP_WCUJBG74_8<13.AK#4_'L>IT9PS@>>|Y&.)X(SS;L/F+J@|:K'U&JL MUZA>|06S-
UV48)CC?SDAO#_IVKWW*(3AA_ =H_|IQ 4WN\IP3I_1I@IYT3I#;
M_BUT\N>PKJIS0N<>TR>_I28H.S:X<)&RM,J>E4#OP&2_KV_-2_T\+Z; MN1)K@RH53<|1200@_"*1Y#E"
<+&E@1

(2_<6R)OR;92T57V,>GVJAHBINRH^V M3(=/-E@J29,NHMC4T7'R.E0:7M/RE''YYNQFM?I0/NH3ZL9&H''8WJH#I
M;VM9#''(I691FNGY D- NJNT#!CH/VCKGT3/BY/,(^49D\C@T?TKUR!H\$A-M MEP,^A=?''/X(092'2)-G12RR'3'.A"
<-I4 MLJ^C<&9A9T6F 0YFTL15\NSPH>-USDUI^R+FNVBVB^4R4*M@<6E2=Y,.*
MU*8SY5MF<'F!U85HQ<'BZ#5306YJU56R!2-.JKN-9\WB3L;X>3.7UZA0V7K M>GZN\!)^XO+T#I
>>Q#VZ=3DL'NCC^=%^IR84/BW=L0X5.9\BX4<5(0(G^4-8 MM!H&3X818.):V+>Q0KL;^SCB<^/Z^8!'YPM''?!=X
=SGN2MK.=4233>*0C MDP>J.M5P*U+((^C 7K7 M? \$IDV!8'K1WXQ(36^Y7#9?|CP|''7*=(I<((K8>D_/1^/E3V!_.W
\$P!%P6 M\$U.ON<*R5+?PT3)Z&/ERDWH7+G+Y_0(%C";|"+B73KR")'2.)EUB^+?1ZSZ2(G.'TD
C''Q6=AGV3M!3F=%MPIKN) X??7J MBNR%A.N&0GGRDD@&E@#8R,JP(S_<=M!_LF5:E,GZ8CI?;BK&45N<,*3I0-
MT&15S7&UBR0:1825=\$A)*HJQ2!\$C!F96,'Q_8BF0R#W#5E77>@PKGE
MJG7+Y43E:N'U_3?|K#12KHU^&0L%2,T>KN6B)U_?%D:\$2L9@-6!ZN'S|^27 M!+5!1+>.#"XOR/
01Q7),L5IO@-(G#J4_1^C+;2=;^N/6ZHLJ>UMQ(%S=^1 @65!@JX(HN%.@AJ60 M%''?OD:13+S0H |LUG4\$RVO6Z3-
Y#3V#B-(Y_B T=*=L* C\$!E8:7JS* ME?N! IR-D-HLUC/T84.\$X_AETR>?;UVMY/H&H=<0S/R.CA2YLH ::@U79
M@+JNHK'L,UU5+%H#1.*E^N =,Z^' J @OK;C+!,"Y^ M8''J&*LQ* U%CD^7DT%9W8H2N!Z%VIOZ!:!00?1U?>.#
"#.32:)%#-()#OJ8W1I9-_D4B)T>"LJ@'V;8!1RJ(KE^6W#8FT9#0-U#5AG(G!9 MQOS:=W.N%/8#_1G'#A?
&2XET:P/Z^DTB\$Z''A4/+ "T7Y@TZ,U_1: +5F@H#8^ MH<;XL;/6;G1.FD G)Z7GX'0'?5 M.;DFOZ_.0RLK?
YZ4#R1#.'0+L!|3'F+KRC(ETFCB*#&PD^9AEVHVXO=DAL?N MY1LIVX:X,RZ''(1*;>;S%P6!S-
J8!N5)8+12_E#I!:+FMC.DG 3A)*4* M8A./Y(GL3(1.5VIE?0^V5U)QC7->Z-4X*&1#7#32(^Y/=UED0B,M%WWW5
M#A!#%\$/:#W0.1#R.#D5\W8@!;G+.)I8Y'S\$97U>SZ)RI<<-LV\$IVMOB\$J\$DK M11=V8\$K/I>0?
<@W!X;Z;5U+V3O\$B^Q(R!|!9F%D>;4T0:N E(ZDN^L,Y&Z;3-G/2T4R\$;T)S)!?X,-L G%".#0G6T_4H6.A'ZM5HGH
M^<8''B;NEHS'(F6;IF^#-DJO_?%KA<^YR2;S9O6^!Q_>;K\$+6'S!CG7)2(MX!|9M!1\$PJ=-A7!0K8W\$-7
:9G@((2!|4<-!PT_!S^U,J77%W2_!A2SOU* MH%!25S
_T*''@6!#K_FH&PHC;X0Q7',K\$J1W@A1M5E(P./<=<%N)R#+UD?7DF 7H?%KEEN3B)EYD--^ M;I7S-1U3MB;
(>%G4MZPFZ'C\$:'WEHM+X0J''YYH5!\$F*';T=)|5H3YK M%GY_3!G-9RUS|_#C7MTCN^BV=.;UF<=&+K@<%ZN%P0
MEP!HL.26/M@9E*.1=98|WL5W3PM^!;VD9)G6'<>#1\$7JLL9V=9T8XJ_!R.(K!N7)R0^%UKT1 M102)A=?
CU0W7HCCFA-?M4^!;RC%EEWM(3\$X;R?PXH6'(4/->H9,'B#.FGKJ@/=...X 1=|E M(6 M<,_1'<#04MZ/Q?
W=\$O\V!;?|_)=XW?6+;.)SK!4_A'J!\$^1<=BHW M\$4^U&..1K'A!\$ESHDI)H^2G^V7.576!''#=#1D4!={M?YF'^15JD=
(I)?XXXN M&#!@WP&A=>.G:~M0^0^Q@>GWC#199E1BX:R(F;KW>!'')F\$IG0)H0Q.A7.L
MZE,XZE?2EBC41QIS_+!GD880_M9VHB2'R^>6UTKHO=VIR.MKQ Q'';#8! MTOBS-;?
@203E869WH/ONC!DBKY%|VFP6^E1T&RBKS:9U3!N_)_WSP.%L 1QU.Z M&|SS.:Z\$V7,IV?(UDE587)GT=5!?
I^%ZD;3--(AIT6^!HG/3#C%L*=()=/ M51_!V<|/_1Q)NU/7Y-YK7)B=|<% KUTW<_P(3?92?X!ZK8+T!-JAV3L

+_1U YPGW-48!5QFO.'F4 M#F3!!HR:;QHC;MY23*>:E0Z;H@UK=Z9^50T8\$C%IZ'/E2\$WG5T!3<)QAZMU
MH*!1E?;K-G!*R9+R.I8K|RIY70?2YEHHL\$(1N!6X7MY^!0S'_!S: MR#JU+;HHQ)8;#7=)US2?>NTN!P!:'L-
!1'\$4_!6EYC|JRFVYG55,1+B5_VF''M2A#|G#Z!5O6WA*L M+.,C?CE4..C1OGY9FW)&X8*+_'="TAED2,\$H
TL<3R4X8\$FK7)/TT MU#_JA+;7IM@^0O!NV!|*CK=QQK=;W9D A=;Y-.7VO;3!XCFG)X(X M9014OZXY\$#IU(A%<5'?
RY!2F<;F;>WS^A^1.5(^L#71ZQJ)DVFSG=?*Y<<<1?
MH'_"EFYI4/N000&%0/BLW)LY^J''6U\$FA%Y4^R>8,,>3;;OAJ;EH;TM)^Q/= M:4./1!2?L1,+) |M.;9!%@'9O2Z.&F(8(Y\$;E4D''!W/5_ \$QG%(@6ND)15#MH MG^..Z@=R2.7RHT,W8)WQR!#+VX;"L&>'!&^#FCO M&B?
XWL_6E3E73TPIA;P=B9>T#6:T@%B.;IG#MF;M.EC5!92%<0|U+Y4+G6T!M;.O2=4JWRH-??3Z>2.6;
<4!3W6U!)B%">'Y|W/JP"8_>(U<D|<"KOK4F:=M!?'F(-50>Y&2(JK"(F"E.CH|^@>0BFVX>TTA9 R.;=F=
M;1Y6A!)>81+IM2K0W(5G)'P'EYBG.S!|''>R29,|_!U/(-50=Z<)2//GY^3 M!A6!6E71FW6(2S&E;9/O
1J**7TUP,B>9#;.Q>3>DBG>BH01Q0_&8 M+-H!3(KJY)'F2?7ID)2#U=L>(5TX4S9V)X!Q-W;=VZX%KZXF<(0SY:'
M,5PW0%O?QJ0\$O=Z|=LEI*U''>Q.HLQ5(I2YCO YK(%,T!-Q-W!@03UPXEHRFEV?BUMF'_YI|L?7R&T MLSL?
Y2UTYRD/^SL7#;JO;JNL_&VYR=F^K;/.K<9DHHJ.C.B..IP1H;M\$4K
M^OZ+W,W6E&O6'M,79P%QJH1,7*E.Y\$;M!-8%SA78J68@9OUR5-.L&A1BK M=5U2X(F+
YHKD_*E%K=;>6CWK0+UMUFS=C.#''!\$(\$N_W_#T);J!%RU''&M/* MT.%Q!M 3B!=?7A^V PAP(TMN&R^I.7/K?
B''_D18D19CW95^FPI4=(D8<;8H-P!1&I!3ESL0V#.D4!CFZED>N&#DA++M14:PXM/+IUI7^ MIMHW-
2.)CB2Q\$J6L^FMP2Q!|=3P_YYOU0N!T!M)U;O(18,AH009^EU6 MEVV&V9)%&
K)E<5H(6!@H@XPW0!OUIBU3GB;?+WUIT M9QSI!B2!P.F*2!_!N=#EY0.AT4Q!1 ML.F!D-"^U%1;GH;
SN)4.ST(7ND!7@=7V#5ZR/KRG31-M0H/B|OR9CF!V0WP+5.7 MK;T=1R7\$N/58@S^8H-&^J!A!9.W^0C|FFE;>&_-
WNZT5G&^..&T?;K&-4QY;H1_%=LQ%AFCL;B5G?T?@FNH_7JHSTC^1Y^ZX8C"9_@3L!P^U_M7WG;
|U^:Y(\$!AZIE@^Z%-|+;|B^YC^9_2=<56&\$*.L&H;I2E#1>-)E/S4! M8-?4#O!8M,V#(WM!1!\$!VWJCRM)D_WFI*H'
|^N);B87R1GZ1GKWINS(5 M&.)J |\$5G%|V Z!|_*=|B8+Y^)/N.SAHUK\$H8BG;K2B) M,7@;C!>IBMIZ0R E'
(4.-1P*-|H4.*5DSRIP9.N!E^2BN^I77;M6)F6%|9U!SAPO)\$#OCF_P2D0P^.;@MIP|R>!*Q(W;88 MF3!R8UK)MHLS,?
@KW;+;\$V#PJB@1CF5!;!\$!D)H+;#2PXHH(G=>9%CB&?%TI: M(-*SI^2QVV'=!+R=R!4,"|O 9B+T@((-
@+1ZCYHB>HYD4!)->HP3(!0W!T M,5! T^?%B!H_!55(\$IO(=N46JH !KMRVM#Y!O,2Y7>C\$7%.%QA8M)43D^
M17_UT22ET5J!A!8&\$;.7+&?3J\$HWQ?E1A*?EQ E.IS3%SHIG
M\$;\$M5Y12T<7*0%|&|X%3B:=J+Q8IKG3U'B86>YWX7A+9^0^'=|U+!U-17U ML;%4?VM.40TOBZ!
<#0W*Q35C*A1'^^M?QA)7(&6^V!@=R0=S^|ACIF|P6A8*9 M7R6?;RH4W@'D7Y!H!&4''NF=3NILG4?
N*X&:6'WE!SY;9<@Z!E3<-1''+T!RO*%00!)WH74G+WMQ_&\$ M*!^_YW#8.*GX\$NR'^* #QSW_%G|KUJH_|IQ4>
(R6LQ2_EUQONMU7!Y9XG/ M''MIPVTP7''51\$^%@|9+H;Z\$8S4O_@1R-/RY@^*K!^NYW;<#P&+&=(=-^OT=4=
M!Y(WZ-KD=X^F#/+K!^1_XO!\$_8GL;XL#FJG/Q4#4H?W^N9-.RAMK7+!|B\B MNG#TKR/9O=\$%VP#;?
^15UJ!;W!BUY%<0N.MV;MSAAGU@=M6C?)/BF#5X=T;" M-B+)-1 P_";SC>KMHWM2U?_#G<;AWH'6/JW''B9_
MXO!\$;MQ\$_89#;\$N0T_50F,3RZQT/2L+;MVQ!B7!Z!V3&K.B4 \$E'(3\$! MXL%KN_@D#>1G_''P'<Q^?PX?N8;%A-
LWIRJ!R5&PHI^Y6B<;DEA.%\$>\$Z MXU8_.D!WR7(Y!D="Y4AQE E96"\$&@BD7^SAB,3\$(Q2AKA)E-C."C>?KQ_QG
M!03ATCW//)9*5X8AG.*!&0C?&0@B41\$;@7@ MPITKJ;P\$%|GSU7S!5E%V6!Z2)9V5-
*DYN54^9!304^956_*7HK''PGRJE^D M1VL!8,2!MVQ;F,R,M0LG M*I=U177<7HZR
L7EU6/Q(ZZ!>K<^SDVDGP3>H!FKPVQSS)3QWX(F)\$9''\$RF!MC&S_!J9=8G=PBU13E;SLZV2^^UC''3!RN K
M1B5FXD;2CXN)@IF19.B5;BM'=/(?G:68T3<\$B%J1B!^G"C.A=0!|ODA==0@ MW%SM^J!''MSW9.SDXTLO'IS/+GMIO;
M?OQ(OE:UYR;:RFZ^LH)H_ S_*Y2G.7G9^>-G7H?'HT''J);XRDA7G;X/ M!L GU<=@GQNYHOFV*9JYB2B|
(YF1^&CE1FYRB6!M;;;)4VK8ZNX(HS6T;G!|BVX>=>W8M;V!@|P^F;C&WV9,6^!E9 MTL4!W;R;Y="";F7T@BP^
TKEUO)E.HN0-!DZ0P!Q!-HO#T9F>%OVTM(8(M#6<0*%UAWL_*?KW4(3T?
*R1S@K^P=^..|QBL;5J''!VO;%UM6_7=LOI? MU=Y?'I2>"KJH=H!N=*2.V1:V^\$OSZ@KJ!O'4''YX^1P\$^4JE''Y''...C25
MUH''V8UJ!+0CCF!EV>=RBJ FK>A_H MQ&G5ANMZ, <876=R<@L''BIKGZC^RD;L>CV3G)8N0?SM<;N!5TJ!/@;6YH30
MTU!Q_UU+RNXN!M\$;6PC,8#1V45;YI9A 4!8+!4C)&8T*8+1RMPA**FY8 MEF!XK\$S\$5>KX5N)UDL^&Y-
EO''\$8B@ZTHC3U50V4S!A!KS_=@#\$Q^?MILNHQ M)>^*
<#V:X/N16>Y+!)O8!1!^C373*=ARRT1%EYFU^&^JTG3SOB6!N.U3;KQ MB;>1\$67K>CQ-?
<)*AWXA&>9H!K9,O>>FWM^ZQ<4!NXOO!BMIB74%POX>/K1 M7,9#SB#(&J8L&?/3L* F!LM@!36-

WFEKCDE#=-K\W-+8\VB\MX0\E\3YF\J\MS\JK\#AW\J*M06=EI96#7F<T51V<#5:P&EE?3S.OO.=G\^H=J='7A\8K
MPBUG\J=-HP*SP?E-E.=SZF^X)3F8"54=%L(^"\$\$. *\$2,VLEL.N\]"5*[\$G\ M^Y.O.F.,+5@Q#YN04EDNF\J?
C(0/G)XW0=H)UL=FS_EI08ME1*7C\Q@HV-
MK9(#!L=8',#&LJBS02M4BJA6_SQY>@S5\!";Z,IKE\X.O.HEV.@23%*)Q:1>=M\$>ONQ9*+Z>/\I9()MMXGJOUW7J4;*T?
2Y"3+,"KARD"0 " 8#PFH- =&G#4 MU:35&G7K7\IE375LSW5R,2\XQ>T9#TK[=EKB*)_\$WE.,,S;UZVUVAU-EUCX
M\GVL,@RE@W?HEI0E!\$*I@Y%9IH3(L+R8_OZ/2N)"F/OY(7T,Z4OQIU47\IR MU,DW<-^JNWPLNZV-N\A>
<:W/7F9"D1RE+AE(>/5#9:QV;9F:+/PYV\KS%-+M:F-
&SQFJ;\$X>^@)JHSX,I&R\XPFS\HN>V4";#2(Q+X@GOBJTFY).%=&MPI*=@=9-
Z6Z*6."YXNAH\VOOY_U46=S&^=4;MVCN6\J7JZSL0>Q^Q2#FI>C MEI9\$?2PL) &MS\$(B""-K?
P^R\K_FFOUCH@#*UQ:8(WO6>)\W\VJF". M1\$&IOC\8Z'6'-9M6TN:FG140IR(\X*HYV1#HA');Z6\?
S\MS\SD84\$G M-9^O2P#\TS;-1 PTQE?(L\K\!%1;YZS^S,"D\<"N@Z78"#J23"\I.9;V4\$C
M\>MB80P\H)0%7L\LI&+01Z09&*,AYZLH2\^E#%IU39T74@K:4BJN-\$5-R3 M%LGF^O*VPZB4@AJTH9N:??
IWBH\QU@48;>9?"FI:9\QF5.^NAZ8%>^ MKM3):3VYIC24Z:Z:.*\$A?I %DMJNWA?<0U.9.#.M.:UFM\$5D2PZA_FC \$,L4
M%B^L\CY>?)XQ @NTT\$QN3(\YC0WFSAY\IOYAKZP M4>LU;4*JT<^1/V1I41YO,*V*>A-VZ0**,@BC\#N;K M9L;G3G'X?
C>65+AT3^_XFY!'8O3";.&/?KHZX"!EEW!PC<*FO5I6?3=A_N
MH\IG>P#OIFQOYY8+80:TY%@GB^CD\K)13)9YK(LL53ER\$(#IV%+/MR9DBSS-MFAC%T^1L"Q.@+O;I;R(CX?
3CT"4FX9;#YJF(CB%;/.*I25FI#M.N?GV)IW S MP2IX2\1@S)9E:P12>Z41%@I^_B_L
=G(21^/6"L9CJ_K"DOA*#S6PIH(WO4 MSS+\"S\H)O&4Y\VO,XSOM!=J>W<I EI8'E=BUN*\J5X\2&SR^=9HOJP*;G;
MK3&+Y6*#_4EO2@#C;HH0\9UHF.%ITG//")5LUXR\VVNVIA4N9BT(_R/X) MB\1L^:YS\1L1\$A?ORD^4K;
(Q5C_K M_3'D;0L.47<1Z\K4CLS:7>+WK" M- 426PB->5%G&(W_NY".SV(9J'B6'6,..\$546?O.#",?;W1F4QXL!";
MF/R\9_F->.@N2:65;*1+>B\O\I+KU-X\]+"PGA=.*E!CND=8"KVJ&0*L)H"
M2L&7>@W4P3_.*44Z\@%33\^AKA=EEWD-O;;R7AIN-N?:M1,U87Z^VS)5GS M'BS)HB,..\$IT';Y1J6HBC25&P\$2\I
GD\A9W..K\$F<;'5Q>OSB M^Q71>V)VIB*CMF&I\@Z ZH@)RI:L\L@#A8\O#&0*;)O+XS*WQ?S\L F;D0.WL M*6-
QUH=T+V3_.JK,T@+;KAAS MEUP;D9=+E#=EDQU#;CDO@UYR5\QM@ISBB9:7;VJ_D\$CX_FTT M=-.H'^FI
#^@^I1^>DPH5UIC\J2K%%T9(VM)M3?B+I\O%\I=P9F^."MXTD_ M;D;IPC\H(" #H_EWPL\$(>ZXC SUN'D;3KT56L-
XUPW?TSPM@8;M.:O/#H MR\RC<7NF/I%AB\8<2%&562H4\G4_8M81KY72<8&SI7KU!"\$<;H 7STWLT"EH
M&G1Y\M\9V+0<4N5P57R;0LIE;+>I\#03G=H9/-#E6N\(^2-SH3B\I;T M_F<^8GB);?H019Z2=W-
8I4YS5\C6W6=IEWW_8OVH1\H06C_@&^I@:9Q\^CKK M65-R#<;5AH\!&M;JLH02;8C7L;9I4 N648_53R;F;MGV
&+=P"FQ%O>;<80 M+)T=F=GI:.*Z'08Z@)VM5\MK8;7\PDWZ\I9\$7%4*)\U)08^2YO5=(N11R1
M(8\2^XL""S2Y%I&1G7@E%D@#J2ID;5WO_K_..W(-#1XB=GC?_='SL^EW&AK."NHX\PVQOYO#P
M\+A&;C#;+TM\Y.NF H#E+ M@\$2_#NH;.*Z4B%TED>>);?6T_@-3=1\ P5N3\1QEY;3\N J2;AN\VF(
MN0.P;*\XRNPOG<>;K8R9;H=;CJU*.GGKWMGTF9S+ME0-K>_L"(#*!%=+ MJ-X9QL;V/8B1G3/9FY)^U+
I;8T+.%@KMU-J.Z MD:K(>I\! M.D6_:W9UDJZ&16;G\$FHO0-VIN&U8<+YJCS*1YFI=11780_8IEA;WVT9)!R M
/92\FIRNIGHKKJE\FHZ2B\IED8@T*FF*E\Z\H\I5V0\AS(*\$67F0 M".B\HC37\@70+?O.?X6?B-
MU(9)"UVE_D=V9K?SS7V5>H7ZXU\[*>-9SXI T MWH\I@&8;/<5;W9P\+W4?^Q@Z"/2E-.E.M2?
R9Y4\A\A'H+DVP_/ZZ75>?R MP^&GGF):D>M\$IE90?ZKS.(H)17OYENS5*Q\HOR9\IR_7.S\%0E+W\%E\X
M4\@_S;F.J2XG/9#.\$J.M-#;T0 E*176)!O<\$F;60P^5U(^%G8;EI+@9M;@ MN8AVA'=M-HGDR\;P\:/- XN-9ILLV2_6%
I\XIRI8;7;I?;G1D;ZO\$2V\^9" I MABNRE\%('W6XF"=>I)B=AQW:O+A@\$E\$Y7&J6;9>!"(AE<+;+U\XR;X6;
M68;O.YZ"7;6EQ)T%U0\I3IG;2.^2;I VQ\IZ3\CGDHJF(T9)DR"U>I5)JM7C-8;=G L-VZ2+;8%;IZM9T";<=2A
MD^9#QN'ZC*7A\TW\MUVLI0B.#\9-HN4^:"+V\I=-I)KJ=SA.PI*)X+T\EL\ZOYY^>W-AX'/4S;^WP"O#8L;=(#(S#?R=-
YU&OI_M_/R\LE8Y_U-N6"0G'Y!"&B@'LI\$1\SBR^(?7K=)N9OQ(" %^B4BEI DU*6H MI#)9E"-HF=O?(
0/RP\$XB"=X_YGW6 MWOO=M3YKO>I>GP4PCW+ @=(>2YEIUGU%&A\LS>Z TU R\WES'04JY\H^7?
M5NCD9.YIB5T\JXX_..AQ;AT9#14N#AD;V\I\N4)P_!HRYE&3XAL<"U\ M215:6JGY&@=KSOK.>>L1\$^<&K#KRJI"
/1HB@-=#%U\CP09.?1QU+IUT^D- MIE>OX.XKVX9S\Y?_%M"<8PI\$'?>A-SM*4Z@IN\$+9L2=KE(U?(GIFK)(.8@7L
M/N?BWV4C)!U\$C5.!=2NQ@.W&F*@" %^U\;M-44"1O-E.C86&\$;6-'3\I;F M>#"\$L<^?4\>4I=V8/9/25-
PC_710/%X39AX)72DR;Z\9=9.%&3CE;"3=AWJ# MHGO>I\X\&CIS&XUL4E"J#VXY9S;F=*U\F_AC>GG%=_\$;7&7W>X-T
@@_IK% M@_6UD\5")O(\$U#IC2L#0^J\I LG(1.5<24&)2I98+5?@RY_K#.7.O7WER_M@MF>W WM;F" I>L!
(V/PN>1IT\&=D\O@6Y*^1^NW@O?25B5=5Z\;TLP?X>6\ MKS^*L'O2^*0&2*5\Q?2Q O26T\$4Q)4N2>\$<<92*5>?..
I%>=\$YL@Z&).48TL MPF"!Q+L%@;H4\5.&^/ @CI%QF*;!%+^V59=4\PU0L3H:5J0#C\Q\VBQ#;(:\$ (Jd7Y*L;)
FZH\T768&GM\$OHR0 M"#_EE\#/\N;G>Y(B6YJL'9>*1^4HUM8TR\FLZC9G-J10\OTLA5N-9.R<457 M;+9>YSUY-
H\$R4\I3?+)&S_A9NSY@GM0D_%.I;Z;M<_EM@N60^B7*BHL<* M3EYW%_4^QE*+BYOG1\;94'HO8'-
I(+)\WTLWV+ T'Z7V;GV;D_W M#&6V)QC(T-75/#A&41MRUNVMDXFG^XXT)QE \$,^/3;M..RC:P;&#&@&#Z2RC
M@>4&+4"#F%I\IOEYDG).21=I\$HKFI-5DWQ%IL#T=4+H*110<@JYLK56KB8
MU..YTWP&+=3>.>2IE.IZ^8&4U"LLXS_OL4KU\I5?Z2%*W>VK0Y6=-Y+GD+ M>2=%8DTLKZ@HLD^O%\$IW=+S0?
>1.*^_R.\$OUE(3>?1Q.NY1*F.W%'-(-4Q\$ M^XWNJ\$Q4" IBZTO8C55(RCA\FWVIE:P
<5GX%&M;.M%8HW.KDTCO*F1A\$>C M6E43P5Z\I#;H4^OX.NA46.=TEJ3L_J#%1@AMS\N:FLQBW6O)M/S."Y2;%=
M6;*&4C.@DR576F;J+VDMK&%(+U+K06OYV0\5+8/KW;3J\8E3'!>8 46 MLFR60Y.>/F5AT#MTAPP?O#'=#
(@5E@IX>-B4.36I" ^T^79*4JL\9Q.&NQV ME7D\O\I(*\$&QW*8\F8UQON58.0T-R\G2\SAF\B1\>M:2DT=9Z7\8\I/E/U
MB"OW8U57F3/#6\Z-3\K6J?CN#\T?H<12\I;B_ZNJ=1?=:M#!OI M8VO+JG#Z;R0&M79'4\KR;-U;J;3'RLC'R)RY=I
M^@>ZB-3M%.C)IV^A0M-C_)YHWM>1'A&*G=47Y.U 9ZA#;O E=GW-I"K0+W MFBE0K120WM.^I\N/CD1-
B_+#+@AA8>\$X\4O;G.&A5H*.=(-N5X0
M\Y")MW\H5&^E"V" ^OZ;CA8B:@06PC\;P3.WWGO@4E.@\$L<>/I."=^5;SVTB MH&J*HGI\VHW;"SGF\3F4Z"
UK;G*6)K&PH'>I5>+L;/->I)D;H#%_-TG&7 M:TWGUB%K)DV3\D8E;ZZ5D4C1(I1&5;7\34-
^VEUAX6E4)9Q>UD=0(=WH M2_4\I\B_&BL^Z1RQS"79>D\2\5(Q=V"FIWUFEJ.#QMZ\EM4K4JLTVI3081
MSCD*GX4+&J;Z?#8HHX=00=FY%_8DE9LU^LUI17BDUB"59M\$Y.D8SS#8"6
MOQ*\$A77&>PZ35H8""2/EKX%L>I#EN71H0X7PA7;5;\$X=FC/5\Q\UT4\6>IKN7BK5+I;S#4GE;S>"5 MSL)BY\.=T6L?
%(J)+(.M6X\= E3G?1-FY;9C;6H\$H_U)MBK&T(S<7682<8 M.U;UD\IRICH%.I;C>5TQQ>M5;N+66 &HAVU&#I-39\$0
M\8Q_LU+?;U3%S81ADX?_I2\$ 3-G'RK<N\$;8>@V0%2I^AL,O\#I);J%YE#***6PX\&2(GM,^I'95=
MSPE/SJ\HKP\^+WFD^XN?R=-.%*81^OCOBTF0(PM,&A*6+%64AMH\1VS*J MLU56(C.O^2@=2J;Q_.Q.OEF)!
I"-6A\IM&XA_RHXY8J_PVED\2IC\B\AOMY M%Y>#+T= C(*/=C+KD9LIV"VT\I-
IV06#49)QQVUHH@TV.D#P@Z;JHK9;I0OKH MQJ3\+R.26F.B\$K=\$\IT=I#VKZ)+&5+54A"3JSZO8K&*00#U;I9+
MA\H%0 C=XGXNVZQO*DT2.YX\$A\CW#XK5W\N_7.BHBUI;M;X;J4LKEPYI%X1 M,_"4(*=/L=I\M_D0I_MSKY%7>SR?
EW""W+5\WY%6 IU;IB7VL_X3_&E\=\$ %?QBUIQ>%.&A*=4B MDD\$06D&Y_"AB?&J"\$\$\$N;OI.Q_Y^1D&I\$ _G>
H_.W^!\#I MOS7@YX&_I% 27#5\Q_B\%OAT5=>G3HH>VP?3S+DT\$DBS<=Y?LICF\$9 M@B1ZY^_"@C(>WS/*G?
O@@(\F4J)Y M\$RBA;-L\ML9GO3B;N:PZ+V*5/2< M=%EN95!_=\$5MMGD678N M'8ALK"#
<(C_3E';TL3%+1/G6_XOY%TEMG M;Y&_OL<8 @VG_90ZO\R228%7C&.0AFWA2/< OL%!5A_XO?8.@M?>RR)R
MOZ+X'B29R7%UFP&I?H\I ZLO2>R\N@_F.#1 ZCR.D'B#R\>CA?^
MDN2S+N;..7K0'+K\I R7;LB\40%\X?/(3\EPICY7;JJC\$;# 8MZ\J\O'8UZXS;YZ8P'L8 M\PE^;FO9BCA+=('A>U\@6NTQ@?

E%.BLHW^DR/>T A7I#0 A(*)ZH^Y91
MXN(7%)*W7IQTHJMK\$ @I'RWB^">>RB%Z6>0+R^4)*H/XWBTP#")K"L0I/ \$KT3D;F "\$[S70B7&M6IM*!A4I
MHJV=, PZ>|&B:P9%.MP:3L2YTIY@WQTZP&"IU<| ^Q5E6V+W0G14/S8D[5L\$Nj8^|TCB,D>O0-
:#5D+ B;Z&638D?>V&NSJES68UHQ9/>8 G'5|@4U-E+;4*M"Q0#-#TW8ZA036M-GU" M5<^T^EH?DS6>)"11QG+)
I(0)OI\$+IT211H+U&TBOBF, VQ7X|0N+KPUE M-N7#T7LY1+"\$BC_9K<*, "W (Q25"
%IN3TD&L62V2EAV@9?|+^AM-!PAJ M9-?^V\$,1@).YAHDQ7)XZEP31TX.2S)@|1.2QIV+I^_GOV*:100TD08=9Z1& M?
6;9P-IAKWS|/%#K1KW/HXV+H&|@<8L/Z\$S<3|G(- (+).42BN&:T&27?/YY-1
M0Z&:@OP\$)H@LP@|TC":|4L>E6#RC|35W|^5H6N_4P*=CJH6=PW>DW/D,TR|A MZ^1H ;9+0#BZ|UVN%LMJH
LKE,3T(|^ON;E\$;TCJL1?^MUH81@0-PO<?%?9G4 M;WS+:X 1&|3D|>AQYOLBC"-U =\$<P>#^5Q?^74HW2F%1V?
FD@3:~\$6L^2V" M^0BR\$&><|R@5 <:=(2VY|D/2D>BV|KIPM7J=-1J&-OX#VMRP|VMJ@/%M\$#U^0C
MONZAN)L"1W0,6+,>:HD^0#MI?T;=^M/G4@KA*=@9:|H' 0N_1.@CY%&|MSR8J|
!F6P0\$"/C;8^F\$Y7GVKL^H+DX#W1Z;.&(M4 D_S1"?A&;/=L(-6%|AAO=2-G*D",L\$@M_.AD_0C MOLF94J.;C>T^XUL3?
1!Z4AHIG:M0TU2KT>2P6=[%&8SB-(T?YJ;R&MB?#8
M|^:Z6|HIW3F|O)187L:5./_2E%65*JM|ZR;.%"3E|N3|96>.&3V84^NU62 M1G/Z=|VC3MBBNYS:\$8"A>L19I&=N3|
|H%B79UB?,V|.#=M%XF)=UCX2CW%8C M A<_71%6-|::A#|"803)<@!KMF.F_0 "D"UQ5QMW8,R#7@2TIG^GZC|C|O
M44<9>LG6WC8DA((@=Y|56YDPJ|?CKN|YX;>H_?S:8YI M<|"@YFCZ#>/_ "Q<:9PM "9V-6SLKR7:UX4^Y^O?
:P>|T;*1GVD) XPR1D?Y M-U:9 WA0(.6O1+Y;O|X"> DO=H>VW17#" \$1-6(UM.I-Z|F8HH|N4M\$8N|A) MIQQ?
PD)U419|GZ1 UF"1H?% #G#TE=%CDXOU* O_TS>O2R@4VI=GE++^D>914;D5|48|
M5&67F^W%CI7;^LG>^&8!"Y&:6^IAK&#AZ;.!K1Y)R"C=NYIKR|E"?WZ|^X M3>V|
(<2|A3T>,LK%\$4|HBKDOS2M|A;JG+8_-WZD.#08LSNE^5)&|SXWXK%ZUT379|!6%(&\$LZ97NV3DFC
MLTBF71D|Y^OC9P\$6B_F+|M"F1TJSE^L6\$7*-N#|,<<|/VB+|"5L8|DV@9) M+RY.RP3;_J|JH5W*8_X>N|Q TO^\$H(R-
_SP9WJ|8_1V/|SO+^|J|O/F8SHQ9| M4AO=,+/|BE=|@W#*#YCQ8)#"M-9XMB0TPA|= &ZS.4>9|Z-S4&0K "R|+;1?
MJX\$8*8J1A;JB|-E0\$.E=|)= "IF=&N>=@*VG8S|WE^E=|YR"5|O")FJ?9D&??J;@4;TA:1Z?D)HC; M(UY-
>SH<>JJ&-3|K2ZEXT-VI@|DB'S0B.IZ&V^DQRWE&>?G7CP"6C0LKW MS+G;\$!6A%=6SON+?
Y<9X|\$"0U06XK>C"/8^>-C\$|G)MRJ2F0|Y M/|;=VC_!H2E2I3&+A)RYTCG\$>0F&#K|8.W)\$55N^J|LJ"\$:='Z&E,U;+
M|^%JECQ?%2@&BK@'D'E7&|.|\$X1!|NGD^EYU|LF=UG_2>#MARYX%(G)1Y2*+L
MV=YOTJQ=3#02"O>H5%.V&4W)\$S;M|_9)PEB|"74R-(G|KJ1P@YFT&<9N| M\$|ZD<: ^7|C.41@|H)E-/E|&
|51SLCAJ#-PY|HP1WF9U0|XOCLL2I\$>29 MWT9|TCSC)?RVUE:|3#YVZW#;R>XT|D#G_! M|IZ^E;Y-B.RY#R"W-
HSN%HY\$)M1.1GDJ|L!COQ8W-D|P_-(KT5 M8'#SB:51KKOCZQC*7DFH Z:75TL7*+-=8CLHSN5/Y6OOHWYM=F|&|
2SS MTE/8;|US(3'1-3QNIQGTVMF9"&67R)K1J@*Z'IS!"J3S8IO:XF> "U| MX.|K6JU0 #L@/ZP0@'_|5LI
S.C2MUI5BV7U_*^CB3.36M1=24HH%=|HIV6%|V|8PP1&_!#
MX|T8;V(K6.B.F|7=@D^W4(W)3&FDYS.8Q^B>5NXY\$|=|KG=|X.7|B^V)0 M=53BS+3P;Y"GBP%5SLEOP
IT2'.O=0T@A+|+V_K.3\$&V.|5%YN|5 MW9|%'R1>|I_45_&BB6DT.>K|V;+|B'+=;Y|/S\$D1M|LH&?#MC6M26|L%
MMLT'.G30|SC|5C0E03GX&.#7C^DQ|KFU(A0_E2\$ "W^60M>(S=D-WXG|)E_G%VMAK^+|_1>+)|8:O&HEOZB
8&PMUS>?E@(<=) QZ^W#0#R7|A QV17^R|G_&|/M)_.D^ODO@G2Z|S^/_%8W5E6_IHX:|57_&+^/L8"&1^H<,
|Z.5UAA^KG M!"S*2_IC?|QAU|)6>UQ0C"*G_*6I#+GQUD?@C%|K<\$<=>+|SLL\$%'DFB94>|M>/>+8S<.;D|7G2
VX6)|5|6N7 M\$G4:6|O(*.V:QG^Q=9WAT.)5A H/;+@P6V;Y;UEK> ^@NAMERO#L*/7CK0>PJM3UW&8FV1|E56
#9#H|75|V3?MD9C-EU?UL;?B=OU* M;4O^*N2^VD?F&A!|HB|M,R#0:|Q0MM+J??
G<1W^9_6V|F^H4|G|N|3|E|2M3SF|E
M\$MIGA\$OSU:~Y4;3|W.V^H%S94D.@O>K#>1).&G>%W|10J9*.@KXHHW|~|?H
M_K90#2O^+T|=1@WO09Q(G4LZ'NE:&9E>FDHZYR387\$;-%9/3/F0Q|KQ3
MMWOEX#>F("MOXO|_R#&2=;MY3L\$73|R5O_45|_P;.>6>_77EFF)72W|0Q
MD|EAZP|Z9_Q:P0W^NZ#BLIV1^0Z;&TR^HLMW_V_LRN-A0V0M\$>Z=0M|_A M\$"-%V.E1+N8#QRB@,
<1J33K\$9">9U;..Y|79/53UMG|ZM=-S^NGP M4;R*|F1_6K&J7T%4\$<_9*Y5G|F08XR%G#2?^70;U-Q4/4+V4M|
MTD#S0(58,P6N|P4OEV|A/G4."NIR@?S2<:7?^@(\$@^P80:0@2|C(-
".G.|N;|PREDT>10G;OV*0P2OTO\$ \$02AM" ^|F&Q="2|_A\$#-05LP^? M;
NDT= N'=3 ;39555\$ WU|_Q_P9KOB;12|KL.G^ETM9;L.D1<:;\$"IEG+|\$= M|I<
X\$^JT>.)40BPGB2K/KF|YJEN#Y.WU\$=9"9O_7_7O_X#&_5|T6^4#G|_MFSXT.XSWU_?Y155SQC8<7M
@JKVI6Z&=M|UYMX2ZD>.5F&_Y#>|7_G8@0A MP%=6BY?TTP "E|EO/KSO_!3?RONYS|E|#WEX#@E|W!;|!%_+N-
U|OK|?^ MG+YQ+ZOSA#%)^W_TGD#X<|H|W|0+|#DSX'C?>PS/T^N>P.16;P?+>*|W;
MUT.6=OKQ)K|*MO17CEE|9FDGE'PAWF1=@T8\$_.7=H|BBO-<*4P9V?_#|H0=
M5|SOR=%X|590PB_%|80_@O@H.W/PVY%>/_1PR>X_I:09S.H MZ9SUQ?=(%)O|CO7%KG!Q.3|I@.L+2|<*>E|U-
'#H5^'^%\$MSV3%A)R>|0P/ M(QK8;)% ^#ZX|<7NG_OZC9)Z^RY%8|4V|"?UIN7#'.UPW1:P_8|PU0";C
M9|ZIV)YITY_9Y8B?Q^_P32CIT^&=X.DT^DCLL@?_P3(T7_JSI&%X.W.Z/O(S6|E?M6K^+OB_7#N
MT*T=OP+^8\$YMXSRI(3%5D=1=JZ|NBj\$?1WNU8.EQILRCA!PN:4CZX1.35; M?J>^H.XVX?
T^K0S7W883"|P|D^0Y^DQPO>^%H<6-|R|!\$GN.L2^<(O>ZL7>9 MG9"1\$A|!^XG5|2^B#3|0^IG6|_TH\$E9P-E@MP' M8
5CL^RU\$NM)EE&9D1F""><8?_9QW&B9.KQZ|^*Q|<(HK^D4SSHJ5G3A
MV385BZ@Y/U.N.S.E4X00|F3|L.6)L.T\$D.B06**K:E08X7.D;H>VW1|D>T M2QXR7|140D1G4|PM^UHIQ|_
=OWT2L\$*|?|6#B;_Q%WVK00ASI"/HZD3Y;H ME%WX|R#;EO/%C7H=WW""%\$.IOW3SMIT^MD^2&-@N&?3R-
W@|Z(T&2_2I->;= M|\$5|1#|0O?5NV\$|H70/N+&)? Z: K2G2 MH&=^S? M;_D_7_O3OZKEHW;TJR|
(_|DKS+1C;|TW;E^4)2Z8CGF|0 (-|7>|H^U MC89<&0.=TK@<8+)%G|V#_5AS8|QXR\$|ATTV|QHB=;P=IKT>
G2W|9BV(9FYD&GQQ@ZM?_MF:HZ"E*&H|YUA=WC#X5_9CZ0|**WT|2|T"_.L_"
M_..**D|@|'C>R9/6/6Z6CA::ALKC%#2^|O_|-|UV;6Q8?Q9H|Q|6/5BX0^M_!
A;L4.5<1B2^FY2Q|EW96DZILPP|UU#DN|S|W8@0|=96F-?QM<|)107!/_R M=?WG^V|&|W@98=> MG8AAA>%XH&JQ=
T(U0|^_9&>2PIPWA4TK1#S%_+%^EK3H2E|A51DRS(TL_M^6V0?Y|EBIZ;65;|_WO7H\$XA3_V_%S
ADPH-.5|8)CS7I&DIRZ(|(|" MCT42%3;??R;JOYM_@0A?Z_E T(M^C/L^Q;_0Y>|O_*|!+^|J|DXO3A>@
M\$A7M104ZZ@G@RB7O"GR"/RSB;Y-\$3*M)N**J2W;PLBRZE).|HG->^_JO9R M=%>?3LV0|3|!+^4
X5O|BU"@Y.V.FE|%(G)4PF^Z9)^D9/E#;|B:P.0 MO-MF_K8QH^OIPCW:XR@6BY+IV45|5;C;|I
S:1_2O=N5.DM(ASL|0?#*;|8 MF^ZG_NP^Q>=K0=7M%|YI5|^C@*_|D7|LZC%;GN|\$FF2U9Y@VT#UIGHJ#U3T
M|&6L+08ZK61 "K>|B_#H|<M<+O|)S>99LKS.Y@9CDD1W/^*|39XHTZ^|E@Y*4|2<.(R;U "UR@GCE5P"& MG5O4?
GASS|Y^90+|3U+|\$8LTUWN?|@!LJS^*NOPM^/\$W|1 M;IV;2.J5F6J MM|X2U6#A\$|B|2YVEZ*@T_J=HDI)-|I^#@AT=
<M(AAF% M;/_H_X|X4:17_6O_7#9L1H/R|ZVP_..PL85->G_*TCEW15ATY+I MZ1B5#(&.>|<_D^W?Z%*^R
2^DTQ@NW144K|K0R08|P%#3HY|_|5YB^V|L.V;2+J MX:=7.0^PSX09\$N\$&6AY=HNZ;ET
QTFQ@>C(OA4_Q4@I^J_AL_X3=PV=MO:O+NUH%YTX\$FQDN&|J>5C2O+""R|/WHKI-|IORZNF.2 MB&
/7;G|RZ=K255;"|CU0:INH35|K1NQ=9TO(-X/HY7/^2@-Q.3A|7WX& M/N|JA,I9.LC|O|7CHT|\$G2T05B^_
+3^Q|^IWI.N6|M>-"&Z::S>DGLB-C0 MQS^YB40?L^0)S_@6;VH+LOM%.SV:*(-"5|;981|NF1|@VCY^M34BN;&4<2E
M68EEOH|>(ET7#&^4W XE&#&^K_/M#&|#>?QO#^O2L|(X36>%*Q_|LY_*_M;)?>NS)ARQ?
U&CLOA_N.PL9SULEQ.W6MUS M|W'_..PH|8| MOE=W-0&3WN=Y^H^|_7F=T_C_PIMH24E|WF1L.;6)5.%L1D;-

G%#J#30G7U2 M5L_ "7)(654QSBUCU: I^"L\$OKMD^)^43"2K-HR@:<%C VA:15FO .5EUAV: MG1EVK(0#?X*Q=F*1(-
+P,NU0(+8=C,JN^-=?P5*JV3*,Z2,%%RPU4GV&2 [-J&X, MMPQ1WWV?/6P5_0>SM)W"MO?=%4*<#ID^3)1#3T?
1_68V1&=UR1LV8E86S\$D5 M!)_1L&KRTS09"A3K+;9-13!> UAA18MGV-77@!%:(19_YS#S35^1\$;((J_ ^L
M=7.0D6#;S3>4_ 04FX&@%VHQN0G/^1ZF?D3),8<<9 K_ G43_34.7-?;J7-
M;:64T+7>VH\$>VUUO;:\$54A;:\$AV4.C:L+H7%1XY1,T73W(RQ:NAZH8*ZX%QS_ MAE1FS4)P=N?G+C#I\$Y3>TOU.6?
T7,%7@)Z;6O+=,54,4AFX\181?DA11H7 M1UW* >T^<1-%+.%O!O?S(7IRW@SA&L8W@'DH=7(-
L((Q3=16/A=,FFVG=1A; M6W)4R RZ8C!>7-33OQ\$Y,@0><;G?_O%'8\$)35'Y:N"F M;:'@9)
12_,D^V;_ ZLWC=JV115I># "JM;+JH= 'BEAL9^_ Z8XBYHY96_*FZO*X! M_9(&^3TTFCH=4:A^#+913=
1WR.XSB@GB>IESP!W5+3U04^_TPYC@YDJZ06U#
M\$3B':TL^4;\$UA^!)L30P.7WK;6SFU)@0:_MWO_L#+"A038D%1FAE(3>IJZ>R/K+G! M^JF^3'@39IZ2VVK/C-
KZZ;H760I!_CI*,G#)IYQ_4 M)GKQ9I;\$LD6B)H((13#1OIS?N71)0#QY49E1H^LG0Y_9:X3A#XC1W%8\$US
M6:HRAK1;4%_P1T+ZG?LMNG3;Y9K%D%2%U&3%1O13^UE;J"H U%11V^GZ,ON M_?=1481;DC(KL;\$+&#-
KM36'+9\$;QT^_4U%1T=;4QWL;KJ?7QA78!=S12CYN
M+>*6NU# "H=7\$A;,%T.%IOS*.*+K1"5IN^_ ,QL3BBL12<IP@UWT#%9MOFE?F_ MO/7;N4#) (1\$K@&D'I>?
CW=>47A(ZF7WOK499"U+><>JV&I6;_1%WD&\$ /RIC MC>CTZZ^Z5E,=&R7NZV1TQ^?^1C&\$'_A9JV9*W3;J80,?
7%IT>W<9?2;L@#1 M_OKHUX5;9_ ^\$O81/VOQ?<5-MH?RZ8\$M4*#G+LQ>?%UZ_1E6QE42&-H)^M(MM0S;JNWX-
I^_JLQ&1%EXRI(7ZY<'_1V1A-S08^FIYSC*HCAQ2(VN87GPC M<6E>6(*2;8-J9181+FF32F*(Z1Q1J5YX=16?Z
M0PC3;D6H=PSR/DNY!F@&#?;D?G1T21/ZJT2WF@)H_ _B=(50V1^1>_PQ_
MO1U1^1^1Q<#&K="L=*K'_V_AQA=73D^85;E4G1(5M6"E)U%:ULW132%H^\$C4 M!
YT4^6;BB1P40513WD?POHQ76VAX\$M_ W(SC<*O?;NNRY*C_YG_G M\$ _*9#1/*U%<^>)DDQ4"\$ +J;R-
F;@[GX/1E34#W1+RB1Y=)K (C'^12,7N03 M_.OXWD8*M1>BFJK!X';>0RH?I0X7ATX0GPM774Q2AKNR+^Z%)PJ_K-
ZU% MAT6S@9Q!\$J16<29 L; >51+;V=3HVGAP"B-1?F FK)=JYF 7V;\$;TP1/>G MY0IR74'-Z3EE.N/R%*WY@GH1S7"!?
2IK?'K=M1!0#WB>"Q/8X;O_ "2%77;\$N M1^ID<^_ ZTFG.C%-XJE^;B\$;H@M'MT<3HQ;*R^!"7-AH&D?+=+)O/^E48_ 'P
MUA!HAR;171OF(-ZF&81_ 8(+>5R#6;_T;M8?DI%D@.327F?GZ;62*HKJO MKBEFIKEW1.C)/J*61Q4KN7&G_YF'0_5@-
&I@YM7;%"9T'1-I1=)ZZW_*K^ MJY#P2QXYIS#3F>_PS A_W2-G_R9\$;H1>'_%&4A1'S%1_28HQ'6<9\$1LMM
M%\$>*\$NH<>;_5<0?EKP151&6(<?435;7);_Y#19M#)B4W1*M_9?R"6_H'VX>KKZQM/U/F
M;:#\$ZS">P_2@WV+Y1;V14(K);NRY.B3_Q>8GZ5P_G_XHENZ6")X>I;_X3J9&
MKY;A#;\$P/H>;*BXUL^+B\$@ (U\$'5_#E!WYD5Z1OS*OFPN?39AV6UCFE0Y MI*+P_ .C2O;) %FUC_1XR
#*3HB5#J"ETLR> J&(/0676;_YFV.IAQ6#-^/=(W_MR1ZO^@:A;IS1\$J<10MLOC"-
RT'ZJA_N/LH1X**J,HA>"BSS@1F^E641^TO# M723\$B_EMIKD14PK9&F1D2%S98)/_HX7PU1"G"X5(CW
P7HXYX;+X@W11H1 MUAS6M,HF>PL33)F1LHM?3??1N_76.H3%35_*X7%5 M;H=;>&SJP+DJL'_VE1_Q_<
1=&0IO>PY1\$;07BR4G1+VOZHU0T5R+1/6^8 M@RMU>+;>D;_K@%MDB>SAG-(J&:1TRF96Z.#WH&T^I
MA;>X"V5\$Q_QF_AB6SHU;1VBG 4J1BHW1%V_8^*%=-?;\$MP/P*?^:9W7G_M451<8;K1R11(ZOUE5;&K-
&OO>V1Z?^A#7%?=#OC_<^&*1T.OH1(NQGC1 M&#SL=VUNK2R<)^FL^CME3+8IO5LX3TWZ&FT.G=1\$>/
&8);H<211_1+Y"1L&N1_D MB=LB-6"(H2O61G1HW3-*>R1EQL_UT#";NSJY1RR^EYK=1F3;_<:6/BB)
M+68E1JYOMNULX:D=1?Y;^C*?P&^Q213.C/2<_ZA2@ZK0HLF_ZM^F/@PX= MNV+P<'1Z23JC5'2N310+O-
4N/QD5_6A;_?H\$7+33TD4*LC1KT237O1OB MCC^5_+?@A1%N^3"R#@P0(P
"CR%>7G&A>/C1*\$>L11C%.VV"/PC"A:(XK_MTCYR^=R>XKS#*5G;^ZHJ^231;^_VHX1;W*JOYE4PJMI MI-
<#_1WKK?1O+S;1S):X0\$;TN?LA+;&NAA_"K1AH"Z^FJ#^<^971G;11^*1 M%T;2;3%.NIM<3GI;ME1+;1/>R9-
>M7O"9L_@%36;S4R2FOR1H2J_Q^CY2(5 MV3RO<94YQ5UX(&+V5/U_U%BXFW1H;
EHP<+;=^U)GB\$HEIM3_ '21CRYYP3 M\$24#3_*L/H>'J;G@-/H_T>18+WR;-);@K42FSV;*U*C*"EAG0F9"K*3R(? ML?
638U;S1U6G3=X8>S@BH;U5Y79^11L+*ZM1^FKC>5T1^LYH.FP\$+;0)IV; M>1F81J?^C1?@^W/MJTTD=F;JW9#+<
KN%1NF;&11;ZH;9XUZHNA_7X*7LM;25_F1KCALH_V? M^\$ _TO5;A+1X11'03_5OZE#1;(2NP-
;M#=\$X\$;QS\$G@_D1N0(V?T5U1D%TA MCJN1W11/*?SHJ2.ZJF1M1D13R1\$;5@#1LZL917=11UTD'5BX_ZO20V_Y;H3E
MO6;+7L_#1"GUCPV"9MJR^1612;6V*Q7^H.O%66VF5#^VNI^_1D\$CD1H1C MWCR1'.1DE;'XIN\$AU3SUQ
;8%;1;3FW;/1\$?1^;MXD7E+5*;T;1;GJ>YPI;1OME=-7OG41Z1HM9C+11@1%<0- MNZP9;OL*X?W2L_H"=2Z51_XCR1Q-
MP3X^/XX"Q;JGVR>G2"TLD>+FV9IQ4 MU?29DQ^CN+E<6RJL1+?";9'E'A.\$T+;_*711LN;C,Q)A1N;+Q&S;1)NVPK
M;1MRP+Y14;3M"?P#2>_PW?AK@ "B_1U"7XD_ ^M(11;G.TU(+ (FE1?MX61.@&NC MF-
_CFF(MFO4)U>=>R"1C@R)TXJ4-3KYN7&AG3^4;H_XZ^F4;71X=G=G> MTU1V%(PR/S9-1%V115ML9>%K&;?&#VK
Y_&VS F08(>5?#&5)'YT;H+ MP2_ M_MKRH@&KCV4R^?DI&PBQJZJ40)^ (VKT6-UAO;_8+^);YN2CI-2GXR>
MO2Y#!>1&1D9;NHC1A7='GRO>K+4NO!@=SV9>=\$S?;S7L6X? M9>;_ /F7T> M11.WP<4_N3)2OH)M-
;D=EHP\$D>/6%24 K1#=#B1S*;&I9&*(6==B%B0K.V M<\$O402*\$*?#MMIG4S;H.13PYO_ "0%Y3011+!&CC+H1;?
D)C>RB1\$H^"751A MN_215^;_SZ6LZ2CP 81;U&D&K1C'2IE17(V6j=+7PP5U_E M;1ATM-<)OJTM;XNZA4:Of0?-
;K1XB&BNC79T+5PL5DTMMM*C%&*UYO>_171;G_M\$16U=X\$%CRH;#1/8=D+(-W4*WJ=6V30K&W@2WHL?J51
(49GUL>4=;_OX9_M58>BN(*)YZTLZ\$D\$GCI!OX6U\$218>MMC4WOD5.83@_1.MU/DK2=6KZ%?'X_ M;ZPD9;U6"11*G7"
1=X@;APO6>Q>RHHF BY\$JQ_ 7OSY3A2+?I= &3R(0Y>15 MH/<=0NPCX3<3;=3A>V>"@A01L3%">-
31OQCI=0615LK1JUVZ9#11+5R; M*Y^_ ZH1L1\$5W5Q_U)%M&?O^RGR8?KWN1L1<<M>15H@1?2
41_*G421X1Q1E;Y2AM16*1%O/FZ1W11F1 71/B2Y.FP7=1%1">B MNW&E_1;14#CA>NCXHX)
1O6Q\$R8K<6K+F;5Y0H/NZE-LJNKV"Y316D)Q1M M@N>1XMFW&((W1=OG<2D"X(KU8>/P;?
T%6Z3ISG&V>T>\$ \$VX"Q;ZT\$OU79# M?O>GTGD#K%N3-T R1&6\$YM8=M_N9"Y3T;<3+HNRZ M<=1?>EU#;,>
(1GQ5LOFO_77JT.LSNL02C"A3S_N/54/VG2_Q4H38&OF48N4(MHZZ.Q^Z6=ZGCA2D^L1;4_S1N^
/4\$M7SR/NYMEFB\$NGW7#1_1/17MZQ2.V<M8_RGLRY1U;>T6M_D53U1O_(-\$+;H/L0FAQN-6)Y&-
B^X<4%W5F3.93KS=O_MWY1XFR'+>H1.KCW0'8>1^<^9%95U>C=1=&U;TFP1>1_#ANP<17%_BC+KW
M11^41VMCI"E>;H7\$ _GCY;.(^0\$;\$;JN#T+H9VHU8;8SVZV"94U@?1QK^M MU)WMP5QCFD1YRX(TJR/
11+>SZ65(81)#Z.FIM?4?Z.E9417;1FUZ.90T9QD.C%EL1 M9#A@F6PBGS6;30B_*5E7;1S(7DJDV1BJ#*FWSP7C2-
B15RC&19ZS56#6 MFW\$ 3;D1_H9;9H1^P3)*\$&B1BXE;H=E0^<"TWNSS1E1MJ\$AP9C'L;XEH M-&) \$K8J\$;FGY-D;_<
(F;2_THQ5YFZJ>N^H;^;"Z'S_4H1;RSG_M1NK#V4E\$B4X+^R'F9K"D_J>@)YYPX>/&^FB7D\$#VP;+1_1?
30QG>R)1)PU1I=BB8=+ MU8J;(W'+Z94E@2=2^=,7ZN?XBXIFOUJ%B ME19QMG!09X-6X^11%7KPLJ;
<^1X)^1ORTDOA^OHM>0U>+A1\$9L10_M^9V1>8@E.FB7O9L.9U2B2_1UJ1*=0_151UX^AUG%7.RTBPMME,U\$=S4-
2E0V MO4"2PF^9&\$"1Q"P.#VLX1+SOVJPIMT@;4/"3R4^VN;(>1&^PXU+?K1A MG2GNBX;*R
=R"!F;\$K6D@1+*56;64H890CQ_+M.8'D2K60XWG3_D+1;1&1C M823LHN16'6_Z2_8X=OVX+FU_+2%A2#@H@#<
<&)5^11U;_F8P-SM1AC+H)W@1<3S^XF-ZA61^,O>1. ORN^N>UM=1 M;MC T57K)>*X#-WH^_UX_ZY&9 M-
1YM+4);_5HEZ^B1G=1Z(A5QBXN;F3M%L;24^4N-9';=-0;LCHFE\$%@> MA5;+MOH1"WH1GB(Q2X;UN25<21=Y,55
YU6UW;FD713C3?^VOO@!PTF MJ" 7#;2";QO&_L%N;Q<515JD+J#BW/UM+K&W3=IDH;A"2H(74.ZX;AZH;:
M@1.PEB=?E+EKH;1@3T31)2OQCX*JK=#3"+Y6Q_NU)LB_5*@"G"N1+7;(D\$K MU'8UN*" VM#OW03V-1=UD
L_9J#H(7O.MP5T+5YXC1S+14.R'W/R1N3ZP M_=&"OVW@*4>V.#SHW_AXAM9R-"(K&"/Q@1;5+3R3G(ZN7*;JN@#E
MN*D61VR)RH=16N5_Z_L1/37QMK9Q4F6\$1LFWMZEN?SGDF1_41NCHS3L_Y>Z3 M+BA0V;K8_11_X1F4V7\$16(G;AXA<)
(%_19J11"E7"7GYK17#A-100'V&-#5^UP%(JHU>1E9.6F1U_<_SF#""&"K"4A M#;

!;SC(OV&SS_LW4IT3@GLPCIALG>7(II\$+ZL*,65%;+4"MMML+^&M^I
<4.-4^A)Z\$T4V)ZHU0!>ZS!3M!D0L=O!-0ROU%TKR9U_E M!;UL.#;
!\$"\$PP.&AV;EN!1;L&2)J&/@ (DS2"JI^83;EBM;EDJI<9;L!WM_M16JU75!OMY@=@\T1*AE%DIO\6GH-!>&{!(=DJ?
(O+%;>1%!5\$V4+!<HH%Q MP;EX\$U,^N4UX^5N^Y\$7!0U6;4LL\$74ULAT@F/D((MR^<SPZ-%(JRR
MR!<NE6NV<5E146BL/>-983Y07#BV2!28!*K E;HJ2EFL2C-# M2UCJYAP
MGJA\$X)7A6N!Z.%T'EAV@L<.,GPUC.^MIL?>A8Y=VO%-C4@ M ?N!V))^(07E?E3VP\D0-2Q%;D_#D#;\$E!O
=_O!C,YD*!Z6M*L1L5_M7/Z;=";=PDMK@&Y-!!B?;95XEEZB73T,59GKM/+.)MMS;(2K\K3CK5,18-MVC7QYB--
JH!&=GG+7^%\$?>G;/AR-3CJ7\$D,Q72_M*8INO1A=,-!P?M8Q^<#&!I!;KL!Y_XQTU)?_9SQ@\$VR13X?VW6!FHCQ!C!2
M@ZM@OFF1+QNOB2H^H_#;J0ZJ(DEU46)-&5JW-!6B9L3G_S\$!T/B(#_S-K;
MI9>9,>M\$;C!VNYU+B,;:>Z,=9&F9L7UO??INTG-JBC\$Y4OS4J9440ZH5@W2_M(V8K8%*(%)13\CB_Z!0
M;23=&N)9T+AU1A_ZV^VU^+!ST,7+!N3>-!E;O>-_JZ\$DM_VM#PC)=JY0_M8@FD+!NP1!Q<*>1T7\$\$(?
XD5;'+VOC,JFU;H=QW_M^Z!&OS-&S3!UOEUA\$K\$7G,;:/!<<Z4_!7-8#&+!F;>N2_1HAQR%Z'E!W="40!;X#R-
IY0P7_M5#_KM4L_P+Y_HO)=Q"6;Y_MUB76Q_!D;B8@A^&9_R!B!K_S9ZADM)4G&5JH495B_AH\$5;!(0-!8614JOT
M/<!RS@C",?-"I2>;A!P!IPK!)_S+S3@NQAW7_#-<"HSL/E"IO)N;DRF0ILU_M14(1ONG"7Z!&>CJN)&E)*1EJ=
LL6@)F4U146=K4?7!_F106"-M% M)GI-DT23DJG(1!_CFS/*A&_R%9WTD^G?
7ZLE(>M_!T51!H\$0IQ!WE90G^GH!G+1"OI_-(S#"S:L+R_!+39!_V>F!D%)N)-IECQ-*!+HR
MA!0Y9WZCU0_E%I\$4D%_*TA!A2R8"!#WC1#J!5+\$=-!F4;JF'00*E>8F6Z^@Z)13L_\$^<F5_-%
(*2>^!U)UU#IK@QIQX6J>)+D&^N!U_MJPT=00HV24I+*<_<=5SR,9-Y/&_!2>8>^=AOPB,5)(B>X4#GB5A,&;K^#9N
M0?#;W><C.0F4@H>.G6AHZ!R)&O">"ZGG+QW;UK!PYU7RPV=3X93F(RM4_MPLA!_HEY7!005+(E8(9N0)
(GLKE!;_D^>5X?>R#XV5^YHG'FJ-"7XU_MBIKK;X4L1!T8(Q<<2JR23R(^N2FOY+H
MN)_!U^OXT%\$;:#;I6H!7;0!EYJOQC\$VT"!&+D%)!Q*#>P&Y'7_78SZ_MSYD(S6IQ4_LWF(N>^_DU@
2CXXQ@&RS""0JLA_E!O0@UH\$-!"T!MZP6H_M4PR2WQTI2FKWLDMM0T8NA@;C4!H8#2NC9G<3XF?=?7)O&G?
I0YV#PNW7)Q1V^_MBG31AJ^_UQKH^KL9Y=(P%&3&A6(G4L^SWK!Y!)"1S?
M/W9P8Y7S;L_HO6MH(!1@;E;Q'5W3/(U!@;"&@GD= _3C4!EZ?0)"^2A-!X_M00\$A0\$E!O<;
(A>"E*G&#VO!T1H\$!>_P>DQ7"&-K_M?U;_9@C)!FB/R\$10(!70&-U)?QK8!>G06!F.3BP%!*4+IU"DWO5-^>A.C;
M6AIE!-MNV!1!H9\$Z053-#"!A*\$1SM;XX^H237D;P7!KSYF+0002??C++!_MYHP!7*+#+0!-
_!ILGA#8P(!0G^M0_CFN@9Y5!MQC9#*2?T!)B!+QW=,D'FY7@JZ8FM;Q;R6WW%M/+!)QNU^EH-1*T8AB8EK
M>L_O5R92(Q)YK?V<6%/MI3GUC"2%5;-B!_!H-"2Q88B_(-=<8)"C<_SNJ6Y%_M9+I%+D)0^!MRAXR!C+RT!
(CTEC4/F+A95#_J1S#ZQH)2!HV@(>#PM^FKU_MSHJ8AQ;YL_
8KK8_!6RU;874EJ@BJWXIH;#"DO7;:%^_8FS;H(9KZJ".(MX_O<^@G&-/&)!EANG7F*KECHHJVIK>-I<9?C=
3_FE!VN*=2@A!HCT>K!H_M(4QS.YBE=185!L_"L3O"LVQ%#!00A6;7J;AH>&8??>_Y&_5M75^#K)8(T
!+F9.^G0K0\$WDS)_M30IK_QR9ZJ"Y!FP,;UL^DKV**Y;VH*Y^I(4U/0(^P!H3QP#!ZM-%;N_J+@R5V_F?
MAZ1_#4/CVH/224PG_M;:>9!-!#00&F?_D^O\$9TB&IRHZ4_KA=H,8?K93;U,K>YK5Q4!9.!>AEP"?_M8_!@)!
!SZO=K!<WG-IY12YV5"40(^&HNISX*_V_GIX)X2!Q!Q?(<_!\$M;L.GG_MJ!F%HWL;F%MX;SL%67PN5)!>A'B<4_MOSW-U
A&_?S^F^_H!<X2Q@!_S.RG&SCE!&*%R<+!XFY2AS;BIW_X92E_M7C!;0+T!%&UN2U)H>K!V@C27U!HN(MH8"!30P!
!OA;(S<00,!QK!K!4H_M9.!!+>^_J>4^=!!PDQ!+V;_+I8VULVB&2?S-S\$3.M3!_M\$6DL*344%_P3;+!#&_MIN%U5,!?I
<!_FT^<^:34^H/K#)V/_X9.G%V3OZ;M+G!3^59R=O*US)SI%00L_M,/.^">-5+7;F;2N>AAD1H(C/
ZG^!UO_PXW)L!7OR0!E5K?RR,HJ\$F=N_M3C-/3^GD#?FT6-/OTMZ02+&!U_<#K2@_ZQKJ!;6.U0)@9%V_N6!A-!CA;
MTV@GM9>IN")8^/"_!%4-CA2D>W6!%BT(E8E6NRH7Z>_MR32#!Y5%L;_#<@<B^Y-
F<6!#C+_Q6CA!7KG+H&'M=15;G!/.2!P'>=^VU_MN^!C!2KPH!HLW!IE@YHF,+
<1P9YR!;.&*XGSO@B!5Z8HXCRJ&RTD%*.;@=AFW_M&"V8E>860!IN,NR?_E+JV.RECF3H;
(16%YS;29)50HRC8VTNV^62+&B_M8LK<_J?NE>+V?2!W)FW_K92WCCN_P'R^2UENE3G6UOC5H15>&OT;FLES)
MW.L;O+!J;MGB2R4=CHH+0'4&M>Q0B_E!DW*=SO!;_!H46_M5%0-DKI@DY(!2;QK_)O!R=&?
SP!ENTY(H>C@37>;-BR)!G%-/HIC7!Y_MZ3!+S&F_O*S<6=)N+ZP_S=E,YU-%YFR=4\$N79T3W1=JVN;9+Q,!8^;56!0V?
&C/DV^V!H6%0SEYH!Y!MOEH%'.P4_8_Y%\$W1!N!2)^DP"PI_2"O/HLSV_%9(F>DE^!#4WY?_UA6B,GY_MXRH!
O4^2;H*)Z;_PMN^OB3);1P^0+!T@NAB*NOK3TD7!T4E.DM_-MB_MAL;_D@/WZO8'80U2V,K;7!Y!LK_1YZ,==
*_W@;_M7!B6K;UC9HY3P!7S!LE!"NI0+!#_MXQ#Z5+5\$8^P5Y_MU#YGG?C&&_I8/WE"PZIQ28B\$N<(LXY3?71S&-
=>K+X9T_1YW!4*!;^U5<0_MWDMW1_'9F.&C3MMWY%.0)_M%%"R5AL/_OR!1!G!+;9PT!MSRE+;O53MF65=)_M!6?
GO(QWK.W^R%T3\$FKUE\$!;LSYU?N-)N0>T!HH&KC_X!F(RDL&#<Q"@BYH_M\$?FN6/!)Y#IFL)2"3R0C59D!;8+P0D
MN=Q*)\$HM5U67D\$H@AFI9F5?OT M)>_>4E08)8WN1!/_I28KKKK!T28HGWL600N!BY=,Q_FJX=:O=\$8XYX!J
M+XF!<A03^V9NHL_HIOYMJA;_6N?U/\$=Y_BOD5FJE-S_\$NKB!LH7;NX.D!X;_M;/J")%8L>UZF35
2%183W1RM;H!Q>IEO?_G!/YN7RI&UER5!#_IHX*MSWY_!
M!NFL)1WSEN(3'7KW5.2<1>076PJ^Z?'S11(D8"!BC^\$MR8G!X@B/A!F.I33"O4#.\$JLU)Y?I_M6Y.E4W^F#7?
ZJROKU"2@5ZG58!KW_F01=LI>!PQN+U7I(Q01VQ#LDA7%!(GG_MQJ*4!6&E1%A4B2V^<_#^!W/H!B;^<^%K;
!_!*>OT&_!3X+FG;+WD(&_MF4?(D^""4E"INU9G=O1Z-FR+M2/3K5;_<%Z&MX1M<7(SEL!H8TLW#V#F4
ML*GHZN\$O_SQZ7AJU-8NU;5!7WIR<)SJ8!8Z%L1JHS_#1-"!IGT;_AH6_MMBZ9"/^!Q"/;^>-
OY""56&RY3@&W^X25"JZ6!;3Z>=6S!O%G!S!>+!%HUEC2(2N6EQ?_M;5%;LL0W4@&.&)&H2ZME!-
N_7E!^A6+>_OC%TZOT0#3!O!B66))FJ@"_K/
MEUK!_!QH)WTNXK1A%1KX!2"!G+P7@V/KF=5!VZD^1W_M"J&!524CRPH;E3'_M!GJG#%I5T9_SNM!-
_L/P>A075H*&D?9;_IG>QP62;%N4N!BU70_M8"&PNH!^3SK97!_!O(^<*QL?;""/>O);_Q1!XRO_HL1P(=0T;(!*2Z!S
M)HV>Z_G2P\$'_SPIT!\$>7OZWQON)0TZVZHEA.O'OW4-2430DAE.&54+(+U/@_M!<6_S^R720(4FB=.5>N&7#J+!#6?
^0@DT'T+4SA!5?F^\$KO/B3!H!0UL_M0C?*_OE1VU!H!B44!_!G@8N)SD5SBBE-FI<6KL5ZN^L3KPZTO;T2?Z_MG^9?
UOC5QX=I8RQ!(@D!NQTTF0N#M&5@#Q84;LY3!_M0^6^AEH(;?046>_8_MN<8L;<(!X1(!8V1!?
OSJ;_!\$=;YBUMU!6V87\$H8=17)J%>_GEP?F!CFMZN_MN5^1Q=M^!N9.Z8_1_-DDB_!^!74R)&HKR%<I8)/_8(H_<W"7A0
M*(^<^"9.PQ#?1*<55)T')&#&2)/K;_!B&_!%_OI;_D6=R,V'6ZE!0IODAXVK_M!M!%;Y6GA;PRJ*!
<&0F#^!@_TU_&N.\$K275!2ES;HO_YT=2N!5_79TV#W7+
M_PA**_8K!92M;Y!M;UU=>;_!LQH<"GDR!H6%&!X;Z9^OV!H.E/%6H!L_MG"F=34!-M
!SFD58!%H93E@%K\$RJR7PI< ">5\$^5ST7O:L*JC_#4WB;LGG-C_MY/X.X00,N8!&@+ZZ+5@3G'^F%>^R_Y6==_%\$J!@-
F#^8_5_2*HIZ!Y#OY""_M5_+=EYR1^U2MJW^T%M)O!ER_U%I7?+
!++X!HER5ET_6D.6LT636!E!<ZLQ%\$S)K^!GY\$B+P9_O91(>1C!3=F@Q<-SJ>YK;3**U0464F_MOI*+&!-J86MY?
M\$Z!#)_!D!@R=E,R&ENE_>/WH_\$27V2MC#E7MHD)/!FT!+MQOK_-H+IXV!54Y(J0>=^!Z+BNB!M2V2K^!
(ZHY273U2+CNITZK*45"!)M(X)/NJ7MO(40;!4CHPO;AE5S!VME?B>#Z%RVN7A4!_PY;J8!Y05@TP\$RH_M!TSA_!-
#;&N.OK7%AS%_SKSAC@5Q!U%07DNLL4?VBHC?LAC!L!5_P@4+!#_M@Q13!EXDX=MI@UNH!>R'Q537?BI2DYH/
PUQP!;8#9)>G)_M&I\$;/_48N2L!)7*3FPXL>>;(XSM=1S0);G+ETE0Y2Z7U4.E^GFMA)A!%MN*
M\$J!>@/P!V1V!&0;M!3T=/QW;IVM4!R8;VN!LC;X;I!X(C)H8G@7@4OCSS?E
M&V;_40!>FG6(2!;6VAD'^)_!H!V^<^GB!;67789VY_QKP^L@_MH0XJ5!U3H5,88TFU87(=<8M?
6!WU4'6!WA16N#<7JUA2";_!BZ(Q0NDWTD;D_MV6*_0;Y-MM#2@OI_0(P=EEH88XTFF8/N4'D);0/1?BCQ^B1YI9!DFL?
4!<+!_MO7%>"6_C!8K)/C20>G3#Z%*H;^<^@"PFT;_#<Z6;'E!/%^N#^!26_N6?I_5/Y

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i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j>Y=TM M'YR)9N\$%/7(IDRH2JBG/"87ETRL6B& 6_9FQI2&#-8_X:JVKN9Z.N M>Q&_ZT4XTHW@+#+#J^F94L96?IP3CJ5AI?"A8XY/=Z1<=&JF&L6B5F=%OP8 M- !SCUO8&S0.(Y58^NK144&YP2D2f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z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f=)E(L^@/2%HYE^\$M.1U0&1S<9/K G6310.PFXO4^HAW7=6SVE^X& M14QG&G&W8S>%)&1)4&1&M.G&R(VO V0)16%;>D*!JR@F1(0V18?<5;" MR&'1K2!9)@/H'L-\$J>#_JUW M= _B\ C6#;16E"ORRC..YMS?SBTGGIM.EMOK6IQ1YO+HU5)6Z+N _E.NI8D MJ6>'#G9'ECUP2? 3RI:ELU12;WVUX16:KV?WIK:M&OP^\$+!;J^V@_Y1C.+8& MEMPN J+GA(C/7NH2=WYU"#5%L- (.IM%0_PJ1^QUU.^VD5(.Z^&G91L=J76 MQ>-N1-/=EUR7Z.3)I@_"QU_@30EA/T3PCFIN<\$Y1CF%Q&P'C,YA+!4 M N;^FIH5HWB;7ITJUXGW5EA+.GR.0QZK;1%>ASA>.V&.%K<((@2)LK.THJ M8L7BF".1W&K=+<613'K4'51D\$)000& f:=+.;?KZ%.MM;L^E".7+EV_ ^FKEP M(%KC)0KI9E?CE00Q@JEP.WTL#BY\$RYWIE("9XS9-"3QW1QU\$7 V-.POF)?W

MT8"^^F20>40X<7JN7/>+W8B=7PI\P(S+)SY+R\>8W/O:Q>#&L#DN7,7PR\HFH555:~^WC(KJ0J7.25-QUM M?
E5%3_-1#)?2\Q\E5^9^==3^?_YTF1\QTSRZBO2T&4^0HLV9\)\M<B M^/Z(8IC2U@A0T\$RA8 >4RC4\!LU?UN+^&+
LH\$@f#Q^L3%92\$+EQ(JV^O+OG M(FEJA%R+-V\$M,@3K\ M-#G0Z-;V;15,NWXK6\)\TOH4S\ G6CPG#L\>\$3E+15
M\@3ZQV-QY59BEI+J\AQH2\>(T3N\IE.068C\$9EOD7V2@XQDT:D# MCJ^Y-&<^6PIRX*8F40/#X:C
L\4^=BBG:O+=_D>):@J^%O:VCQ)B\%@ MI&V^D":9\3XF+WQ\HZ(1&^IE>#T-S^*
<\$T,P+>=^*6LC#W=335,Q3Y0@X+X M(5\HM>I<3_-Y%A\=Z^D"(T=V0?MY".5HKIYT^*SG#-T6GC+"H<-KGQF=V;H8
M290E3=,2\T\TJA0W\!ZY%;G<8>9^XV%PLT^NDNO4+)2\1R\30U";2=W576?A
M\8(-G,=17^L3W5%U^*#UIDKQ\!+>PD=-,SL6%97%?M;::B =-S^&_B.D(16 M)V@L\W\)\0F,A\6\!VJ
CXD)3PD_*KP\$9QBS\ D EXAQ\DH-MT45^0G\6\IR.80. MM<105Q;1M M.72_(JC3
(P8G+M+;_!D^NO6N=!\VBE0IGTD.G,=/T-QK/Z\)\AB?8N\@XPK^ M&&
fEE)/\HO(DUJ)%5VQZ5P\&AXCTW\7.B^B&)\J%E;4\TQ&\JU\GD&&E28SI MMH^K")=8^G%<>_X9CL+^VA5\35(^Z2"G(C
J^L5ROI&(Y)=K\TK#^DN=>,*W9\39\IP/F>(\%2_=25D&B8Z^7QDY%,NND M/4^_3SK3DVGF2_!WD3U#^_C;1UJB=>?
LF8^J92^1,=1.SBU.ONX7\5\LK M4%"")2V+^0ZLKTAS>Q^U&+9VAC;_6\ 9\D2\7E?>)V\^W^P;/_=@JU5W)Q<=
M3>3HS=A^*HWW=BM7R\3\AZD.O2<(H^8J@f-H>VN\HUXFG\LIU/H818>TA ! M+?3\#(Z#fL\J\X\+LD8JV?(7W@7
NL=20 T MWB\^SG\PI=BA\N\8\4186^G\Z SM(SA^IE;L GURHG\$T9\@G.A25M.+6(^5C_-X+)^0CQ>5/(
MY);_3&MYT7WR\@9R^0VV\1.MVC5MSPC3UCH^TO6N\H\WHGQ-8\,?>YS<^*X
M9_%K\53.D4;7.YT)X2OLY11FA\GMVHZV 4FV\$@#\$F9 MK.1KQ37%#B2TH\DNNDQN;V9^L@R_-(/:98)Z-2^*IM @8\
(.EP_BND(- M,f>!(NFGNAJ;8LX\1)=+L)L+H8FOB2;41H\6IK^9-8?2K#R@CT(1-3 R-!T? M>%MW.4,"G/M-MT.>3%?1
WDJH_K(TKVJ;(-)E\AU;TIMU759 _f=E MS^K^CP?N M\$;KL.77\@6R^K>+M;K\T\H9EVT\TID>1&A@;2<_!L\7
29&_/_\$P\ _V=(3\ MRH)=7)W8,7\TZ\XOM75>#;+0;-@X@3%&DQCK\LD/G3#^C9+;NE@\$HO^79MC9^ M^f5=P;S+Y
#M8E_&F\9E\D0S*1@+_1HU?_!BOT^Z7<^%S;_!L72E?R7#;JO M.1\$U8,.7VVRK\/_=?M=10^%@DS68VZ;V MO7#^4VAJR
<^_<SJSQ=SHGT=13 M5C\1+9P5.^IZN^*W\T\+ME-3Z _JOW?&VPG9("Q%<#P7 _%131DQM.K,1) M\!NYQN?I?
_5^_F.YMCD<#7+1.PGO\M;G^WPLUNK#3\$E.24QW4/G9G\LI M4QJ_8AEK+G=ZQ2\ME\J\MK%G?
0CCC\8B>GMRO.C.GUP)P=T@.G^5+V\9W @ M6B+>N^P\$)\J1_A_!/&_ \$"\$IQ*TOI79FM
-2(PLRG7@2B^DZ^GR\63@+>="2 M(3JWL)ZO2G\INS3\1L6.Z\/_@52\ M%4<&&I(4PP;4S
_*W^KEHKKH1+)6EDE;4^PDZ1\$=JTK1-RZ3;%4^_KF35VYZU#>BM^J_-L\>VLP!
M\W);BC@3+30E\J3RR9>A5^E36>YHTV6RB\$B9TM>T4^M=L^!P5;_3QGPLE MHDIA9=OSCZU)UN^;_M%/4
\$&S>@_V84;6(W.B=)H#00WZ\H9C0AT\N)GOYC MF\$C3 QR<8 ZUYSBZ;L\JL+U-RW\IE
MT^I@^3QX(3#JYJ40R3\W5I>_B56O2+L<<99YBZ\ICOPRV5VY(#RG&TI=6A8\ M^?S\B&N^)_4@L0\$72\H/H^C
Q9AA>2,2\PI6SKOC@C8BOJO2^@WO_6W?4?N M@&1?098PCJ0#N8\B9ROYQXGFW^*(&
(8W5\19M2#&2E\M\!S+H9TF^NY<_@ M-) W^f5F>^GZUL5^66\$7+40&^8L9>3&Q
U2Y^&L^D;_!GOJ;9%^=WTY+0V.OY^BS6. MY^IQ5%7MN=3#5JNH)F3IF+(XD;&^(V.%H\1\1B.'7Z5;L2QHT8\7ISEJC L
MK5?_ \$-Q^*(N#7=L03;=YZ@4\S;EX&NH;?"L9\9 ZN3X;6VU9K7=B44\$JOL\$ M^EO1\9G \B6\BK+^*X^JU;OAF-C^!3?
5YJK4W^1(H\H@POE=N;IP_+0%CI MGWY=)H3;1XT9POL&NL(=*09+7?+A^_L.V.5K^9U45>=f+2NJ7^YM>_!A@92>
MWD;YH\OB@54\10)KT\86HS\ F;SE;26A&_0^U?V^*^<V\Q _^N@PVK5W0PDRPC=@ M-J1=5^;_S1 KH\H6\ E4S
'K_-7;D4TL5\XK^!\\$80C>PN?="BW.=KU.EB\1\ M\ _/ _B\$ 7?ES)U;FGN.80C@*7LGI\!\$SUS"!SVKR?D 3;N@V\>(1LC9;K?
MH^V_N_JZ>L&2\ZF.S+(R^GDB-X^V\1XR7<%59X;L70E74IOLL _E\T;1UN/ M+8;(K\$ _P^YMD^H^"%@Q9.EY6NI
M7GR;5<_JD8Q09^D G *)+^%\$Y#Y+G\1-3A@FC\2(C^HU=JPEAG+9N4V, MF)3=<4H^*JHQZ>^*#(JQ
_N@^9Q230^M\$Q)ZW\TZ4%^@N(SH240<L^F\VG(S243 MU%Q01Y;#;BV\!-WUJ9=GF^*NIG)
M.0;#NFY06A#^QO8C=+_^6QOY.U1&L&0S2JHC1?0/T\G?3%;_*JCX765_-!8KE;R10;S;9;H-DK+FE.G%-K7APE^#YR?
AK5RO)DI\$=6XS;EUK M.6\$E^Z?^S\IPVF+_9_RA^R>XT<;R-!51HW!2FGG1H8S.D7_93\^VW);_7Z3
M(*@_*N%Z67(G&M+!FONP_,\$05\ 7_8C0\1B1=CGB@*UR)A&I?4I(<7)IO>R
MYG)4G%IRQA>_U7+U\W8;F>YXTX4\5J^1.)YL9- M;+K&\IGQW>(@^H\FV_M^=*AWBU.Z7<_LYT>KFH4.&GPN
V2,=;>I>/0^(\WTZ;_Z^ML5>|C\X\Z M)2^F;4;THR=f^Y^*8(B+_E_X _IBE= M=S16_K@\$JRC?P\$|=W\$X%W(^B^*HR
_"L3-KA;)\Q)=_5\0E\$C\$6!;(%3/ M^_O5\!7?)H>2WDUSQC\$58H<53U5CV%I>^>_#K\<_24K3?^IY_J3GMOOK5FWT
MF\1\)_1=-H&CCID5\H;EQ>2Z\H_15K^V2RIEM\5F@_Q>Q%Q;Z_0+;X\I?>X
M_1^*=-U\JB6_-Q_O7J>4CRI5\XKO\ES^CFG&#.WE\5^&A=M453F8;)\(M\4Z(O^1M\$UPAJ-03\G@AD_!O>E/_
<>PTIA\2S3_ M+1H9GX^*5\$Y?N8JD\$VS.E7%WJTR\6\^VX;M5\H\65VZAGH&7Z=IN M+W8.IXQEV83=-G?
1U(6/3(VG<QJ+2^TA\^Y\$+18H^1@>Y.K-8(4Q5"L^L& M5>N;GS58\323;\$K89
^69;0%K5)Z<^="60+_J\H^H\BVD^>QSN%YKL=7.O MR%X\Z_/_C4^JR\?T\#JK\IE;C\>E)@98^Z\CV\$T.H0.YJA
Y=-6K-B^N^O M2XL;=_;10;19)0 S#/_=J\$@(\SC@O<0=N^>="JG%L9;^MA>4H_-UMFJDP-AE MC%Q75A;2YG?RPI?X%
FO^);_!0KAT0^RO=P?A\^)\5L^S2;X\1\Z2^&/_ M_-f\LCY8\9%CU)S;_B\$B-B_%KX0BK3E&CW9Q+IH
N\3\7@O4VE)G(\$V6;9? MWI?3E96-(Y\$A^FF-WHC28K@_BK\>J^JH2G^N=A@
MED^XOIE^HZ;VHNC7Q\BS9F(+;5R0JD^TC4Y\!R;_6%E=X_5.PB1)\%IY^X M%(B7N+_
HZ@HW@00DS%+QXN5^C>D^L\H>T^UQQ^8V3Z9X1?3;INCJ\$HWA50DV M8<=4MW.1HH).5^!0C^_&^\$U^="H
<J2\OX\IOL^7^T\5M S@GL8&4S&1U(B7\$^ M-J\$OISG\^I^%_9.OX;_)BJQG;%I^fKXJ^AL7>0\$RTJ>J\(#DTMNH0.N1\$J
M;2M^G^H4C;^

I5->SM7*E&8THI^B%LA%6V)09S\$T9UPK+=!!8<5.0H M=W,FDI%U//+IQFK#EE927I?D:2^&H1>I: CXAH=ZWZ:-
L*FNL?--:QGE MRY\$ "A3&>3+?@TBN"ZMBOPHO^I\Z@6=L17.B3) \#UM@VP: \6%/7-8IZT#.R M_GOCCJM(<^#?
EANKAOLJ:(9=VOVOE\$&B>X?_M1MPR^O^BRLW=4B&FWKK+_N+AO?D^E MNH)B==2^U;...-I\-%"IE8Y=B:8
M=L1ZL;.*@%;D\$.#BV7#7 Q:4^1X?UQ?YIE;J0^RNY.8P:("5J:7/*6DY
M(I/385=7\$=:D(0NYCH6B\$.OLQ(R3("2:YYSTA9^<50B.L7B<;2J+W^8&5P\$ MS03IS-F^7<)D4RTW0G(30M%?<
_2H400^KI(16)NGD*#^Q^'.O_8S.CA7H%? M*%/:QL3OY;GI?I("7L_Y&"6I%+9&>PSV9WMVVRU3./L7%<1JKR'-
J\Z&CD2P=.\$4I.YI=HU>9;U&WC^OU4VIYI5BG\E;> MZUC9TI7R^1GG(K@B?(89S:>I^5JBO+1WMN Y#F>IPI MCW-
J^6)S0+=SE M^O_SAH8B8CF++91P&@I1F1@3PDY6IH_YK(*S.=9HWTN?HHI/;2+.A(II(^ MJH;4-
I^\$CY\$O5A.MW*%N\;_FDS2Q;^CNI^IKN%FEV3C.= \$M3*SO4+2>^ M:S^WW==<I: #5J8ESW&NJD_Y4I_Y?
M1IPEU@>P;.#\$':3"\$67@6';&X)H;1;:I\$AG1:>FSHQXFXM M7U=[X]1T^"\$+S7?V=M%-
Q+LHMV\$JOT#;M^X*09/_62/) _H<@EWBIW5^*Z M8I;7;>^&M(CI@|=/FPA-
Z^NY5US;/_4ZP5WX+4<>U9^XOXEIS_/RNO=U M3IE^ILC&^VOXVS_R:UCXM7I\WYFYN_KI:OTU+;^(ED\ D MBOB6-
H;ZHNGI/&>BD+F6"GAFUWD@# M*ONT^Q^29XZ5#_YH3I@:#I"\$)29Q0W7@^Z#TE>D_2_043QOR7L_OI: ^Z)85R^<
M:WI8H^16BQBIM<;WN)CZ596Q:U9PIJ^*GIEJK\$Z&-1%-D VP7%;?8>|OT;E4X/SL\V=-6)A\$R4.@*S
5V.J8AOWN%2=^<;&\$FQJMR_P-H MCN/SB^9A^O%0% ^\JOW)+6^G33<^DKZ6S#UZHD6.*@ZZ;+I;WS3H3W*YU^RB
MYEU++F.T)Y^*B6;)^<I\I.K2I0356X9TT<^TO.P_:6^>HJK\^Z< MI^7V) _BQC(&_D5ZJO3KI2D!?
FYYZZ_ \$I+ID@C)2:.% ^2PDY_*+G-"#\$ZI^ MJ/*<&.KO(X2T6EGO^1Y)DET_Z/NX>9RN=3QA0%MG3?
BN&7Y02SN/+ZU&_3 MEF_">+/'%JL7E8@*Q^="S6H7SVY"/1=G_/4J8^1^H7=G90^4S\QTP(M^<
M+))40>K:_'Y@S42<@?I8SD.WI")G\I97TI/!^1?40LR6PC501_KJR@I;#S M9IN=8EWA3GK9\$^IZ\Z^GZU
ME:O>L@=Z;ZW4PK3_9\$#U\$O#_G.\$ M<=>V\$M_<3(6ZHXH>2.7*IPY;P3^GR'^<.=K&KM44I6&Z
MJ3@U_Q;Z\$.L.U324.W.(4+*I_C4&*(M%-LIUKI:M8P8#_*QRK@UN@ANY_6MG\JH<=B|_ =5@UY^7A(C=M=Y
M:/S)@GF\$!6C8=9RV_.P&M\U^DNC\#&36)M;I^7^LZ-S-N)QZR^IGM;I B M: \$4G+S8Q@+OZSRFLF)PKV/(TE.F% E7JO;?
T@''';?<C_ M@:7I1YA:0U//4F\$IX_U>NG?P)R\<%N&E(I;B^06UQZIU_:446"/A0Q7+%
MODZE;)AD2=|PRY^I;#S3+=WRO^B>J;(I\YT.VF&UP: ^3*Q0G-@V^42I2I8
M^5.FAUG>?4=)X@IDX[WIR]*QSI^G2.^&:/V.GXO(LMPOSC32MFY&RPID^4\$B8_.Y822I>G_4+_0&
MENU^I8./M>\$)E_@Q0M4^MQ34_-V3IUODBS\USQ^<HB;N^V9IK^CW700G1EAJS1)?C9Q<+1_ %T%-< M-
OE@>UT>PQM6A^L0LL=I(C?BK\$S=+^W3Q^/X(C^D+M<;R@Y^*7@6^JW<)+>UF MRUCR^:G@&^*GVXJN2\$4_7E&?
>L\$!^C)L5_5^PVEH1^#N3%=X2<_I;3L MXI^2RD.*R=VYV\$>I;_*BSM\FWY.UCC^GV1&6Z"/;BH#1.5/<_&)Z\$QUE?#9
MLT+&WO=/*2%?!^Y7I\DEI.G?7I>N9Z4_>?6>FC?X_@3^(5N8?65I_P@S@5&+I
M7Y#SU_-7^3@^4P9K\$;3^<_3;J_*8^_QOB%2^LWCO^L4/4I\WRO5FA&R_OJ+J ML:IOD;9<_7/ZBH3WA\$^1_B0^P+6N?
=E>C)I)YHU:5U2/SO/ROE5#RZC_YM MD:XDI:O3ALO!@YXELB<"I^7W^_BH/4A32_YIG9FP"+2#5J3KQO#_M_E? T9
ME^Z: _S8J7)/KMVI=VF6*(0%7MB?=>3^E^!KC:76IV^A3?D+6G@IQ(*3G/_MDP2IDHTUS%ZY3F^N_^"/Y&M-
ED\$;2I37KG5>17IKN;J&Q?_?H;G_WZ&3KMS M4>%P/=>L7H^B;?)_() ^+T>5S<2#5ZVR?MF0DQ(Z/*^*#^JDL_??M;"H2
3H-MWOEA;STE)T>NSE+KOH^ZL;DZ\^43SWQ:I:UP-G? (^S^BN^5&A=F^'=0VWD60SXTC;5Y7Q?#W.F^ZF10RT>2
MF#;/%^A?6MYXU!@?7/_QVACMI

G_M#KKJS&<*I9?*/=EGW_ '\$)7.C(\$@%MC\$:_ MN49U1I0IV;1;I\N^D\$SYM6;\$^"44FDYX=WAM>.@A;3^G;D3WPT0J?
00QH&@7Z?SX5F;:O_H'^!-VPX;GIC1LSBDL)\$3 MPI.9N\IZ%U_A%(XG7HE:I;3^4WT\$SEI3&1(^OI^0EVYX-
)4&7)NISI^08 M%6IEKR^= PT0GU\PGI%_P_19#I:P@.\$_1DI%07LI+J2CQ_I8/7P6%.G2_M=XNW\RI#_U#^
S.#CV_ S_0)I\YOGO^XG_+5L&I_NHWW\^W>RQ=N5QT:R\YBN3G6D\$_.85KIL^9 M;JIT#3;_R7PI/!#^1Q!^?T\$SS%YN-
3_WRI\O^6(IX>VD_BX^8^8^V/<_0.WI9_&I#\$7JK\I^OU_ 'O^_CQ<8^"IV+*)X MDZ^ (I94(I @\LDOS0IV\JHMNH\0/#I-
EJ_LI?W7I7;_#^B;JGS+W41LR_M_U^*6A(I\B(F1L)OQ_I\M&S:CLK29Y^PVZW;Y0B&4"/<#\$_%YE=GQ?I@C^<IT
M0Z\;C^I\H\$B^%@O^QCB6J^L^=W?U(2H6^TT\$E<_15H8(K@DUCNUOVIU>VDT0#<)48%?&=HS4&(4U7_I7U>_<
C-DK%/(MLMGYIQ@%G4HIG_IZ@/XSR_CD8J_A_OL& MX7I^J2<"_H^!#7I;66K/55)5Q^9MT-B3RV-
_*I\MO;YN=>#O;X_2H7JPA3CNO_MA@Q\$IMVD<6;)MCL+>+>Y_E"C@XL0XG\IBD#W7?>I\$S\$9ZY*I#A\ M?95=DX-
TWHL2_+@/#SW@DCSX;0=?NC_Q\Z\AGU7_Z3I\W;..=K^J(VGW&TH>_MZ\$A-CB>^;#(J^C:WD=HA;H?#++17VG\$IGE\<
9"3*(IT9NG5ZIR-7.ZGI_M;JW_I8_7R=Z(S%?UXSY\ZM8I\YKWO<1>JOSI4*I\$T6+*\$0<#;_";_9;+F/E4G_M&+?%<
I)ZF9V^EK<;FUX#BCDT.UCYC8P"+2F5L1YHW@=ZWPB_M(%/S?^A8G0YX;_ML4>_+O5-
I%12I^U=0<%.^BL\1SB%I&X<66WQ;W;BM

CA>=RBHV%,E@?B-Y^I+1@T MK^FAT^9=I Q OFXQ! =L&/JW

CR.P.V9SI^3<8TC)OE=U3RR>I/IWZ1^/ M8#JUOZBW9MCU\UK5(LW]=ZT;VYZ0*L#/*Q^>'RN3:BK4FM#G/&C7"(I?M
M1YJC/FNFTAXB^&-1%SV*!^RXT?%* ^0^4_*MBJW^I)%/*%*7
MS3AOA8J7@A4+;+5/Q/ZI.G(3#D^AEUM_I.&>_5@/RJ5F^K@=40^X,MPIE'_M@I.5?E^LR_N@_65(<1*_//VO+.Y;I
WB50+=X_/KKT&ORJEG1X^Q+HR M#WLP\$>5T_LI2NC?C+6^<WKKW^% ^V;V^"?I)U^T<
M3<_I\;9I;#>M+2I4/PL6=S+2I^ M9O!)X\ RH98P("%MUL_V;_R^_K%1K/(.&?Q<6E?E7H?M.EBLIWX\9DA M%;?
7I\ALQLC?5(&R+X%Q_V^DVT2AY_LQO#%8I6KCRUEI\I%Y&#?O#DM?_M9UX?NRD"%_SJT=_5XN4(=-
B_ %TKZ7PF3@3I9K4+1?T2_0_QB("O+Y\IT9D_M;2B_3_3G&=&6^9%5_A^#4I8MKJ7N-WX_"IOD>>I\I;N5XC\TH^D
M%;5;2^W\$ZHZQ\ER>L1N(I;6=FA)IDFO\YH#I^W+&_GGRXOS\W_43@ACR6Q>R M^I_MZW4M^/LU)%5W-
*)C/^9#V9Y^+I6I\XSWZ15O;5U<^_%AY M9;_J^>LU;JK8B#G;S_R8(I=LJMW?
TDHWN&_7_Z0\$+OE/%KW;!&QNNAM8<I MQYO\I) A57;VA4Q/I\NVK!_6YH+I(I2V3(=?+G^WZIB'S_+J!"82?.\$?
MWYN@9M\WP_/DFE;A1^J;_ "IQ="M\$2I^<3^?84_0I_#X(H) ^Z+I<1MP@
M^/_P0^6QKICQRL3ISTX^M\$3@0;I18IE^4IHW73\$^SXO^J&BU^EA&I\X^*D MO095%3DD2;=
<\$>0^H^_6^RN/V\AGU2\$>KF6:0QA9CFZGO")^"=? (GPH)NY MTNI_-34+I3P>6%>)6^8^G@4#%X101*\$8#(
M^#TS^"S!#??;>I^#IR%. ^+3_..C<1RO_)5W;/R?_ \$Z(7S3)^T^5V_8BX/<- MWZ_%0&6FH^<0@CV%WB\YILR_#/_% ^UY_3
2(4I=TYV7I+G6^0IOPS9-T M/_H_XI_=D3S?@4^YF0?2)TGSZ;=FGM;V@-2I>=*.HR0HNJ;^+E^1 %>_+;P M7&E#<
M5^8?S>?O%",+CWP^I\I@HCX/S>H7@^YH\VWX\LS^5+I\$^&4#E7I_ ^) M0-
0B(C^&B_+6E<2BS^5U(^1JKI0L<..A6I;7.<^TA^_9NV^20ZJ^1W! M0_748DR3B^Z* KU;"^4YLD>#_48\LO#M?
W^7I#>I;O5\$!I^"Q<+H5P MQT;? ^H/ZSNW&3C\O^UUBD_UPO3\8^KDUAAOR0^5 I; P6P19I7^Z5SY_R8I\$?HU?
I8T8+5_N;_%5XQLI5#\$5;=HK_XP^L1NOK MS_O\IP=^I4%A\4_ OK^9M63QO?
T^_K_=@6QHHXMZZG59>4IY\ULIM5SI6F MV(^I?5L5UXTMK^C?)_XFL<_WA&/78N4Z#Z(W MWK_?<
RD15H+;_!@^6C_X55Q_5YI+Q^%_ \$V^T-WT.G.F0G^9MAVX7P0-H M29#I)3#_*A.B6V_YZ
(W)Q0GN1GI\FO@KAWYW@JM3^)+@.V9OZ_)%"&^Y^Q@I MI>UY&5T;3;G%-&4JT(Z,DZGRC#;M-7MN;@ALOT?
XD08IC< ^TB50MO>K;YS M^2UQAH&(RI> T/\$_&2+@;KC@<_6JH6-I^JR GTDB@"X0?@;K_4\$ _J8Z'=%F2EJ2_M=E;VB-
#/&DI^S(4I)M\Z17)#_77QDB9^%_RP%7Z&9C_EU^_3GR4K?_I2^ M\IC>S;?M\I^9F65;A\+^I9C5#S;K^YZV<6.
M\WFT"?R;6UKQ^&&31^Y#;/*J)I-T6CMVM M.&%4%I^4_."&3\$>&EBEMTXB &% 2&MB\ 0:_0D0DBU(I
BIA6%#H3(+&\$ M")I\$S<+0^A@A2" ((4A_A#2^"\$ HRW;+I=XIYX^WUUGG>_>I\WYK_8R?I\BL MM_+4?O>SG\U-
405HT%VN/_DV%I^J^*DRB5H5O;#;NS@I^Z_Y2(7M.#XV)X6H_MXM00PF195.*?I<8E2%SC6\I+7@P^C_2PRE4JWY_?

S.9JL*>.09VKQI9;X1#B M1W5@G&2_)IX1C1*^#IWMHYHHRH4D/!+!79;*\$2+&+IBW_XG<I0.Z#7"M*
M_OOC=V)+RK6SX_J_47= MU1%W5=;SM5)YHO%\$K^[>Y5'K: NHCT<3D^IWL: ^1HOKNCI3;SH279WKDGF
MI'HI>Y=W*7#8V@IJ'4,"BZNR*WR?U#(3*4TOR^QY'"&4 M1!OQ=NHRA1H/@?>3G!-
=NIHF%*Z3S@J'S2#UWSQYIMWR?#1^SRCY&9'3, M4F_\$ JHY1>RSFU7O&-
IR/&69;N9)8R=G%S.R95"4I0.J:~ N/>)G&2^VR/R M"G>TVO>7I0PIZ_6E4%M-
R_>: ^,WW4I&=: IN@;/AVKK^IHNF;UN;02'R.#9 MOJ:=!:. *365: ^3W69VBQZHE%EH^5I^2>+E!^? M2_03H'KZU^ ^)?G-
C*=B!>S+?_U8G HJO/Z?EZBEM M11+/PTI'+&;+KWS.W1'#H4:N-?0NVT;L)AG90A|ZCU;1_ F\$G0H70^IL/+5
M5@IDQO>)20K8>)S=W_H<IH3AME5+E/^,JR;|ZOKA_WJO8S+|K5:|I|^/^@90 M(>^Z@#_|
<@)!#WPJFA\$GBXAM#1'2O5Y6YI)Q*C|H:00=&:0U SC OEI44%&. M2Q@MXPO7IAB10Y\$ MEL7B(Z';CRT&Q74I;_M-
VY;J+?"QOM?OYI9ED?_V@F" ML1>+A^K#T:~I^T5W^M3I;KZ:F:~A6IJA9\$@>8:YU_H7J^?<
9I)C"G=7?>6YY"@N_ TP'V|^F.T;I M" T3I6N?YAD>Z+:X|JW>3+IDS%\$^ZBI!\$*?OSM_O*GIYMWS/69YYLK
MUWYIY;ZP%OI T1I>Z3X@.@K?^5JX&JD.D:~;IPE3V&~*8KUZIY>X|&UCAB M+
IIMW2/(J38WE;:Y*>EFPRNS)GA|R&6NL)TWLL DDOW9<)BLO'49_ '2BNGGB MI^I7=5R-W"M2U:L7-E*B/8O>|*(W-
8N7Y?AN@=@GEJCU>RNJ<_1I:@)@IENA M1CO5"(LRQF3L3,ODW3'KNMIU"GQ_SIN@5&YLI!SPI\$^G/)IY3;J9G|'WSJ
MNY:F>O18: (MX^I\$#2%OE5O4D/A/0N"8N#6W,R?MX85;PU-U!%|FVXCC.-=MU)\$;IC\$@7;X*WPS||827K8"12#1'Q&F-
T.\$LXR,Z2D>|XA@ MNIX\$^*0@-H8IU9;N12I|B|MW+5JH#1M;BK<5A| VX*-1 FZ\$|H|/^,IM,+
M!F9IT?|P7*K@WKSF#|4.1_2^#U3+Y_ F\$5:Q\$F#I-C0:...@#*\$,4HU%*8
M+ #J1';XZZ,JQ>|6I4=77ZZF5)H\$>1@:EOKRR"> #D&VYT?21KE6=I*|G'LW
MH= "%TT:U|CKO&U8>V:6\$C?ENERI!\$EHAJ'BLBP!6V\$91M|_ QD8D5&I(7) MWE'+
L;PIT^7)&YQO8T|X3>W*H86"1@|O'QL26I' ^/9@_J_ F\$*L@M4.F MEBHA&A_YI#;7IP|@\$S#PO;:~<"G;P29_UPIXKW N
CGDGK5/AD;=CB56-'9LU?L?P"C7>6_P)B.DN: ^CHTZ!#GX|ZC"MCZ'0D#P(?V M43"8GFXK3.)=6-/7"%%IZ@#S7'#
(PR(ZAW!)D66R9R6PK1|9^DN2\$)G/X M)JU_!3+(NTUO(U:2I@^D(&NE!X&8T+%RN<62E3@M_
FZRIZ+I;=OJTMW>G M3-66DORJN2;1WU0_66+I_%WKB^?=_ U"?RAO0#&W!8LQ/HGD0N>V1I;M|VG2
M)2A)WBJ*AD+% P7L8R^TW_!E|3\$4^N"%>J+WWBH8UD&2)H(L^H|J4NY&F
MY96)P+5;G* T|XT#J@Z9M\$F_:R>8;S^XY# MZ_R*7IG2H74#P)6OU|YRPJ@0AX?-
KY<=HLY1'_\$&#NB*KI=DCWH<@=|H|=B MKV 6HI)|I6XBV4J)"Q-R7&
|HJ^5YJUGS|ZCWNN(LE0#1Y(CO;1E9EWP+ @ MJH_E;F1T0K|VDD^P.D/D6*4F1/QU^B4)\$F);-
;~ JGYM=8886(T+04S)WG;+ MCP=>UW)|3+ 46IAE|0Y"V/;V|&_5*ABO&V8NLC0NOO.SS7I8;WV|R'=
M|OAV!>*)V/;B#|O3%Z%YMI_-+TX"E^YB:U?K|Z\$3MHUCF6"DU VG:~)N(5_M_@@8\$QA1-T\$Q/#B_V#|
J%GMA=>%:@|I.3K|I(5.KRYIF27N:0DWZR^IG6+V M4+6)"Q&^W:8P P4Q_JH"|@I9;J*LRP\$-&&Y0*HV.9Z>(.P1F;
|M_Z^>B.WB M"M2N%YC>E3.5GAK<_IP|_|P*|I@GBP:R=>F: UPS.E<2*NI_M2J0FE_F=H
MZ+;9A=8\$IKM|_@I:~#L|J8 =W<@H@ZS^TU3JV*8GKS.GOO_U* JD8F: J M MAP"V/0!@SW_031H.K:~?
5;8HL73|&Y\$E6C|(?PFKJJ@Y?0_ ^0?M)_>|B MR+1|U:|M/AK*7#9^1.0%G4%8LMS^;OZNBVQY3.G9JN@E8/LE+4U-
56S_JIG ML^\$;O'\$^:R:Z=S_349 MV/NST^35V%ET>880I'3L_9"(5IH#??(=>\$N*_&U-35TWH1UJ2B|HNP=|HLCI
MPPN6/#UC;=%GWM|QI@=<2AUYE|09_35UAG+^3Z5^U^WIROH!|=I=5OWW= ML\$XID^ST+40:E\$;84DU999/C6|M?
OLW_??4D9"IX|CL^Z@:X<4F5^K.Y* MI#^+)TG|Z;3|U_X5W*WF#K8,+2I@|1L99Z-H3^IL2/Z3.H_TF\$H/V/&CB4U
MS/RI>T6#%MRC4;6/60TLUW1L42>Z0R#_ \$^ZH?NL_X?XC|JW;>@7MXI)43@)A MB!_U0G4-
+6R_CR9:= #RW8ZG.O;1L8ZFP)9"H (&_1;76|P/UX=>?YNI|B M7R^ ^*|<V34A%;3PZ(-
+4F4NPB|UL AP%|K8I5F4>S")7YR'A Q4G|?)Y MRA;F3TWHY&L84*=<#YBN|SGSF@@Z4-I=L?)4>|I>V0_B;_KVINL
/"N8Z;MCAU:~ ^\$RB8I'9#N=T#(F:~;~!@68IX\$S|V|KH;.GAR.TC9|PA>4B;VO|B
MW7ZU=NSH|KKI;"QI>37U=#T*_|PTD)|.1^1RWCHW&7.S6=1?,"E9;~)RTAQL)E 1R|Q=/FE|4(I7)O8+U5_MIL'\$"6+;I
(LEKI=4-D&>|WVR9HX|N\$|YF8L1UQM?BW0TL9#3UCF=,DR^GT M9TO2|A5QJ%OY5/L5-#=#N!;L>IW5A
Z^H@FOY9Y++~%IUD25MT+ FJ.88Z4@B MW&AGHT@I)(\$!DG1@IE^75OICBK?;WC\$05>
<#*ENLPEY*|AC6*Q8G635>|A MxB^&^!^?DU2UM+?CEG6R?TS'HZ3)\$|VHVC 6))_ CLY.@|Y_ ^S&)"4FOE&+H4 M-
FC@%62_B020K;#% V(+GG\$H"OUTA2QCKNE1M6F6/2FN)%3ZRC#QIO99=PK;_M>*.
T|06SWEK_AQ!;~&69P46QN1C#J;=PMYM^=?;6DF\$ZM %,U)@C<2A77P7 MWP2_C5HOZ+Q)!?<
V\$8JHD"\$?..G4(U&\$XIS)GN4A^Z"D|_E@:_T6I|"ICDX= M1%+/KE=SQV#M"5V',<_R=,QOMQ519Q^%O&^I>R&M%;^+<;<47ZABXL>=%X* MMG\$*KNYU(WQI)*?JWFQ#5_- =|2*Z;+@ZF+#S(M_SILW/LK79GB9WXR|B-/|I";K;D2))|T
HPU;RJ L7UMR;N@B')*77V(3 M_P|A>)5A1<|JA6Y'=@(I+^E^4 45B,Y^8Z3H?5;OQ<~;KA43Z_?RV96CW(Y
MOFF^HFE_*OT/5^HT+ FJ.88Z4@B MW&AGHT@I)(\$!DG1@IE^75OICBK?;WC\$05>
AGHCE7I^>3^J@%N|5!&^H3UZEF8JW5FF|^*GR|^PW/YHWJ3"|M6 MNC'_BGS,T%)*PU)^S)"T>PR=A9=C\$=#F
MA|E^MX5X_QFXS)J>CSF.N%5O3+K2C71ZV|'=5CUA;|7L-SX0JCQXV|+0*FT M/VN'_,>GUMCP M&WD
1/BVSVNA86J%KL2FF6N_)D(9_//MNYH1H.6.A02C\$O(%&-_G/#ZJ@U M7S|W;B0%9\$3K0)
<+!+>5/776)+CZRY#;=2ICI#T@X E #AJGQD2MXG6<^G M3IB*QZ|I
K4UYWJ/KJEO;93<X&L0V*" T+D)%#_Y9=)\$#5'=&IPHD=U6SMR"MPI%.I%DGKL6L MY*BR3<_=(1\$!%?EP
_O7\$MM&DA_Q^'K\$T_ CMMTO=(6K0\$LKA8\$A;GXR^79_MZ(57X66/|K@^Q|L=^9GX|LN_*^ES_"=V
MVVH8ELJ8\$0>E|X;T|6@G.E5_F?A?ISY\$H_1#8,S\$40YT)_L2 HC'I_M;8"@XB|GZK=&(&?SGN^IT^D1T19UL??
X'=NL/O"/>:DO'(I6;U|H.C3N MOXDGD)!;89_G4WX\$40I@SUV/ T9|FF-D7\$&1<6T:X C=^8HKAB^V)A_7T3ER
M3_XDH8IR?|B=|N+ #1I(RO*C0&-W>AS8|1V^87H8*K=|W_ ^JHE0K;_K7" MF%|BW?R*U H;CY Q1?
A<='F!_.0&I8;G2K)>D+%)5M-"Q4|T_XJNY_Y%0S M|H0_';AT<@7""|I(>"+B=^#E+<154G)^QF)FU_S!%/O8)OQPX-
OA_|=72? MHJ;7)N7AZ+_D (I<+Z20'DA-J%.Q?PT3V|HC_&OF#.W*3&QHS_#T8AW|?2\$Y
M8OTRT/0*A"BRFSBU\$VB"RMKUW>83=P#^N?P.5-OGI&)(NU;UB8;78;.0M @! M%@5
22#>1ECZ&0\$9^+7I>XS5\$.)X7\$#BAYS9CFB#<8>E>=QI9_6JZL|HA->MNS%ZIB3A"|+VZBE(T**COHB^(\$G?
@0\$S'DGZS-53TT UL1U0U!;~@XJ3O5_M:QJVI6Q|PZTKL6<5D+CLPJE8Y DQ9IK935\$KY3ZYSQ&@?I\$14P7OJ)%|N8
M|FU^E4.5L\$@S&K5AXJ|6#B#|T6I8=|I|P@_Z4I#%|LNOH,I22JU(,7>?
M;_ZC3\$*_S|IM>@_*0^TWA7>J|58"Q_332GEXP5|E|"%#ZX50&SCZKJKN*GB? M)NG7NSWRQ
*U5|INZ= (CX&|KK5;F|ROW>P==+\$A_F%K|<4L&/9 MKKE!DO7N"AC9^#IDBE?I9=&@_F4D%U;_HRL9+U=FMOQ-
(AX M(AHKWRN:B%5X16;~9B0^CL+^H9E(A??"4OZYLO289*G6|_ZN?N4&^;2R|^MRLA|999W?"4'M3SID(BG9)#-
QO>3Q@L|)B|C M&@J%9M;8XBF6Q%-&*A@*ZS\$=?W M0^JX_7WH1@4_YA@G6;ZO?V&@5A1D\$2;05|Y-
7@GX|G;=,Y4U>MVP*NEDYO_M3I5?@6S+GVNC+|K\$(\$!|"MA|G8>*U=5|Z>=|B|=40N|DG#FD%HN7|C1\$-
_GG\$N.KR98_ES&HPT|GP M+8PE2.S?2SH@M*Y?IURN4C6E;EU6!PH\$LLP6=8N\$DFN#88)ET-!_32&|Z:0
M;W|!@A'G5W|CX^_Q3BD-5NJPTI7C83Z\$@;~&F9#HWS8@I= O:FVRY=|Y8C M\$UW?|DI_8N&C|BH!^?U%^N&)
UEFY|)O\$J_Z8LC^U<7|_2IQ>*I#5U5N MN|82UL @EA&T?9CH@OD;2R5%-CT|O^OT_NX|P8?S ML>E|YSF?
EE|VR|*X4O-;G9E|I%&G>R|PG"(XN>ON|X2U"=^ 9KT)|9OC3*
M99L&3HK|CR@K|5=7N4|UU1UE^;TE.93*_1JX>X@F?V|0+_M^&7+A/#WG+3) M&S"?<
7L.85L|I5N8DM"O&4^HD#1"X2I|V8QJWG;_XM|A_@&7+2J8_F)|VZO#U MYBRCBG;9?
@J.CAP:~%IW)S"14|Q9JQ%5/8)-5736J|7Q+N_926))_V9W|>9 M;|2Y;N5#&)B%WKF7U\$O|Y@&G6Z_@.3Y+8!?!\$A*O|4-
MY9)ZD?>4Y|W_M\$>|Q/X4>UURB6|OOG+7_X_@'W_Z;LV\$L1'LA50'SI+G*BL_V8(%OWS8(M;8E|)<|XU;?<

DNG@,"D;I6\^J#IG9=&A)VCJCG M:H0F: Y89HJC'T'9TWCM,O7YKOS GRYPDACJT<8)VVDD:O&E,>68NF)6 5L#V M75
#18CEFT5,,Q'JL?V17=9E[2HYZ.D1/Y%?O9KWW,W7WD70AF ^#6L;I MEU[N;1R2=-M1V;==)H8V)WJ!.\$%2?
Y.3'^8R;K-SW104QW>8DI!?\$&AZM(\$B M2,CVC1HY7UXZZ;DB,9(Q)W8)P M@|M' @*WS[4GA,OOH\$8M)JZ>UVP?*
UX45('M.G8UQ'THQC^L4;I=O:,ZX MHL,6T;)'E5 *-V'="I2QW3G8?)"=5*RE@<^%V4DM OHZG@-F-2I0!OK,4KH"-
MC='N0R!''5DB2WTUD,*5JZT4L'204*QGO(X'E'G'1,=-I(R)NO2K4.5) 2 MH8G?:(GZ(E7.2.%2I1-14SZ:>5>NPA(0G!
UY^!%0\$^!B!!6*HAYT*GD:Z< MOE.6%# ?@M&^%05!2PKD,K=NJV>P)TK-
&#RD(#_X#W97:2_.8V=5!Y6P&:/V6M!?'V1^ARMS-[P&A2 \$# M=1)E"-+4107LKIT00B&KZ,004Q%+"MQ&% 3,SF??
GHAK('M M3^*A9^KP1!)HBX,SI/J^9(?PLG\$<1!Y:DPY\$2F^)"UIP+0LAT=L;N^MS M \$TY(\$3;GOBIS;S_WY/;2?
^YB1_!#'_SL>_QG 8U MO64_"MA%+##\|@KM>BE43Y\$L_V|+D^V:(S/O_Y;N'(&F;L4#_OWIHL39>D+
MP68,MBH&.!/'PG48\$28A<[3DCGN&5^JX8&),L#KFS A>3|BFTR M>YVPKB!AA|=CRZY04?NYFWAMG|9|<=B(03I
Z#1424LO&MDCS-8IBW#+8!MUU M*,6#7Z)#!^QE\WJE7F?E?1,T0^K+5
G:>U/L?;_*OZPTVFTUG@|&0>EC/0W TK*G#9\$19F*PU#0;C=|^F_,IE'UJU3;T6@6S3+JTTG/C?Q_\$_=,MTU#I.?OGW?
=,%9'Q07,7KW2325*P.&"A9F*TGL:P,FRQV7^FDCP;/MB;0A| MBC77K &_HUF>U(S|GV??4OIGP#_ \$^!_
OR_"^"J59E" T@BY\$4'T_WG(V^2 MU.7;I0%":.\$(UTC090.3!SX:S-F)S3L8^"\$ I7'YPF_ M U7I;B3B" F6K? TT@
M%G*PJ7K|N174QJ?;#X;/7KRU^I&I=EZ8NG_ (^6?K94;/OIFG^U|^K1V(=VX| M;1AE<66!2VCQB|>,(7/_^U>"Z6
WXXEBOJ|BUR5+6U 2C3/I/TR MN6QMw7.X&:CL.# %!7@.BK@P^>7RNZ7R#5)D%:A;7B(S6:)>(_GD^;*LK&;
M98&>N)Z(@1>7ZAZ?L/>76DK\$/RM@V:'BYI7G4LBY&)GRXU7+VP)\$(93/H5 M^+*J
G85+74')!C_M|OIWJLA96EF>02P*|3P\$+)|H1W,-G&'+JE L8;YU8J MR38 U3IR |IX60'I
#I7XGMP)//MU|+G4E50^UU8J8"5M2+0 MX_>,\$@),4N/W0 CB-O-RA<1AUE/T)<>D|W"ZXW,K(=L'L-;7\$,4AJ+|G|
M63H@_F_!13+DQ,0IF=,93%*,1)1)+%2 |B8A M5% 15%;ND)V+6(. *\$F&V/P-UFO(@P'&E+?*\$+>E-
+7|V#/@SI406Q0.49G MY1E9CLW+3T8IS&8@3FN#L'X-PZ\$KU_!>OGFI|JOI0'=M=<|,W4;|0|^_4Y MY;L6)?
M|.P>UN|RBGK8>+=K%XR|T+OD|&E"/4)AIN;ET MZ|O78 HV5A3'B|UD-
Y9H;|Y,@J;6&|0BFHJ|UMH3@Z*F|WA.W%>5GK7M6R MGI;RA;8EVI2Y,VWY *7(L#JSN#|W|/PG
MYOHT1(=UI<3|BUIM045IX522)/RTI2:0ZB,JKIA&?ODE^+DV35!8"%+Y"9DB MU7;&IP;1\$7%WB=|DN?R5:U7
5,MKU+>8AD;F&Y*C_WG3;|XN|_W-&MAQ@-* MJ9JB.#|W#;??3LOD69M(C;H;P'8^/;G@.P.\$\$14 QV|1&|YHKTS+3Z;P
WY MN\$V3CQ>?G09/DF|E358E?;NO<7|AUV"JFDC*ZJ_"M MWEFB;G)5EZTN-SQVK?>IN?@T_2=F37)!C6
MO8^(_^!^+_%X=5O9W|?H0JBEFD@?K\$IH9PGAVC 3."9*YC\$;2JDC\$VBH M62AA01(TN=D#9>|ZU\HM*
<6(QC18#U*Q#6MENI7^J#0C06'3>./U_LGBL^/LW_"SIAC2794W|OL=J4K;I|@KG&-? Y.(S|A*
M=V_7CU;ST;GS1^Y)Y_Z>VD3PON)4HP+V(U=P|^G^I'HRYJZNOIY)?B/CB|_ MW0(TG@=|N6L#/*GW|#_3*
>9\$,FIME;3^0^M442 48Q?+2Z#U|"SBPD MQ_A TN|O965PHCM"\$A&3(4;|UU6_>E7|P#^I*?
>Z2^KEAUM379=-_NFA^A'S_MDMQ--@:P=PRK;|OO1<*V+|^XB'5'3|-28H<6J"E@94B)(?L+A1-)|LI=V,(D M>1=+8JN
33K*VR/63)H7,,9L33|/;@G>^VG(N)=>4=I^Q5CT>SMH_2DHFBLV*2NOW%|=1>/L M;UA^9/_J'1|LDPXUC;2TK-ROA
|DU,B)E7+>X3Q710A;6I^W+Z|RL9OQ""? MP-RNV74<:/;6MU1J+|PH&0T5/GG-CN1_.099^2 K T@ALS/"J;G*Z 3;_G M
B/+9+2A2%;4 G8I|U8|BS^EM,"*7:A2LG&|LL7J)DCK|'71%E%#H'#DRV+S= MG:5#H B|UJKU%
|N\$NF OS3?H&C4AWW+CIWGT*KFGRO^N>)O<(^X2--M|V VP=(O5VK|MMZ;
_S@!WN3040(4N=TIMQE,N%2WH%TIR@6;N+55 &? G M#3!;HZI'<'H 4QF7P3=*@:17 9.55|THX_1#=(L?J0(Q??Y-
9\$SMVD|1958 MZR-U|JEQV*1+|KKI;|FG MSU_-\$#MJV|PH&J;Z*5Y|NC;IAZMGLMON.7JIM? X*>N.\$Z?(J?K#T.^1--+
MB@/-4'&\$/>=T;_M6\$B/^I6GI#YP+|JT\$O;H+EGO*"J@CZ5MQ-_XJ&FU6Q
M6E GSFSE7&@-9C3JGDYJ).VPWH(|2&"M|UO|18")JL(ZNR%3D>&AMJ=^ETC M&&4PX|?>>L?VMDFJ
GFD3F:C*\$CH(UTE?NRU#|*2JB4D|DFLOC M;L+@+XNNIOLSDDCKC3+XSCG>DY|C4OU.FV;"D;H@^*8|5T-
"%I2/SP)|FKB4 MZ|F2_1C|^B|Z96Y_DKA19=K!|W>D;6B;I^CMEB;3;_3S1O&"/J M);N/OED-9SO:79PY,P=MO-
7|>NUIG;H+4BI-B|8J8FP*8E7>)"|XG(**@A M"XQJQD|6NQ?G>6R/MKM->|^;QW+|J);7AUOSNB>*"|_I^V?25I-
!E<3%| M;:>%|J_981D;1NAIOE>NTO\$L)+|L3I;@A0JE MIOM2%)T96D-WU PI(5/_V;"KHK@T0.DJ4")O;8S5L|LH@I-
L2)X^G#T")>3M7\$@O.FY|YX+>Q;P.3!4 M-"|J)KY=3^8)@SWZJ60-WCA2EJRE|KL|N+A(^0\$^?XN_5A|Y!)I;1<(@^
M3+ZKM5-(NE^EC/FQ=ZK*O+J00*:=^=2|W;=W7OY84/UK^MU<_|VM2|DN|VN MPI+;&@"A9;3)R?
GB;.&2I.4J75(%C);T;%@ F7\$ S(#PZY61UL|NRRM\$&*M M.EG*R*ZS"E@NZ-|PDHW@/K9F|OY (3B?
LY_C_O>24I(X2?|=04W+L.AS4RN=Y MQZ6NSX&FXYM>A;|I-H<_|/SF"C*H|>)0I8&S5!;CF+H80:CJ>ZROP_M_3>?
ZBE@/N@:/Q6PST&W)F<@^HV=HJ|M-.H00RH8^31P|74>Q"S:S1:Z MM7T|N\$SO7'F"V:W_XO^#P)FAX
&OPD|R^AU^Y\$"L@^V>MNY|QYM|WCU|(" M_|SC-7??C)S/RF_-<2) \$;?Q"/WS(IZ=*1BY4@%K%.WP)-9X.CY|-'M %
<,*;2.4^>Q\$P\$S#T)F M:2T=F%U*09+|+(HKQWP+R/QS^X|_R90QVWQL'Y.3M^771 MW:V6&RYD|,P\$,Y(O
NL0;/#?T68-|VU;8RGQG25.VK-!T:46=9V="3-461Y/*G2'/= M*04,|MV7F1RS5D|_
OA\$<%R>|!#_DH6)NPUKW^HW2=;S;H_7^D MM|F*#LQ;|OV;00I(SF6T7/=)"|L@70\$;"3LHX":T(1 MIXVO?
S1NT|TJ3%I3:9KOF5?A>3K;I#>MT(-C,PF7;)&NTM;IA;K9HP_OT&U, MY^CP#=-;./>ZOB;V\$4QQA'\$W4<-
CSW.5/56;.D2;V'UH346/H;3@7;O#Y;P ML??BPK>92;H.3'OU.0?GTP^#I;I'>9CBV=(U\$7FEA|I-/_5KHZ
M5@W313/XA/I>A&HNTVRNE<<-\$S<\$I!?\$^8TD TV>YUK8C9.AR5I^0#;O.XIY M|.M4 1% V;R/!UL5&|I?*,+
I;RZ>2N4M5@L2.HL+66/3(6-/<><(-D=V MB"4BC*|^SR0B=N%1PYBMU|)S\$U#K6_CH^%IXLY,9KZ
AN\$"6I92/B?;_*0L M_1&4 4X7/OPI?TT59^?X|Y;J=YZ@I)|S|+1CK0MDZ8;M6%|7^|W*4_W3HU86W/
M.OV"/H049_QD<_AH#I2/EY)6-FTY7I-!Y MCE|;FT8@/B|>1(=|<#?C(>YC5>|_R.U0.R6060+I^W7 M4FEXMGUXK-
#A2U|W(&&-M05+BLP%HQ\$!-F"D9_-|="2F;|;\$|4.DM=O.# MH-(5;#SYF4|9?VBIP;Y.IYD+ Z@<)3;-
T70";I""*^:6Q=M9|X|L2.BC-K MW@NNA|M;Y>74LUH>|&BZ-|FG"5.V=Z(U^C)J;M^2W|X#XM;XO)M=^N-1N
MPP;&^UB;I+E^E*Z2..+75;.(ZW#(UNBV9&-R/(HRELU#*^%B&CF|Y,@P?JB* MU\$5(O4G3Q?IH?.1UFV02I%Z*S(C&@R?
&&Q?>KR2E<")TG-);+LSC?S5U+|O MWZ+YHL;U|V.@=LMM?#(L|L!;DX-^3<'7*;KKP M%K-
HY'R6|0I-US0|*L/!|O...@;|)TE*P?/_AAQ*IC\$PR0CO@LA/U/"_*J M@X09;9Z8Q*VLA4Z|4W3A3-
)"K"/_FWM|B7W3.4#;NB'\$35E-RO=7N/HB7 MJ;%(P8)|Z6NM-U3_'&WLH7*_|75NTP|@\$.|0@"J?
K#V0.9R)EJ|@=X%F MDO6S5J;G4%O:BMR\$B;D6>@U|8?_X+1ED?^)|1MG"NEOC<#%)_C;/;,<-4
MMDFW)MHL+2*2\$GR7<*>Q|*YWB#|SOYN^S\$;)*#TFV>8-!4.H&9C;|N7SD
M75^PLY"+DQ^V3*.EV35F'1)Y|070Y|>>8%;YYPW;K&;9S(P?7%BRX|R52FR M&CQ7BC_9*T>
|AYLOAP>@<.+2Z&"BX-3/^4I9/I|_G7H)V|ZM5H0B2I' MG|X)PFP 2YH|Q.JZO*POC*C|C/-+IBZ0/N;U@8C;-
Y44;@/I<_NG;:SXLIG M&4ZS)2WV#GTT0@3K7ERNAR|J+KM>EGPZI*K*JWJOGOK9|G5X1@ (56^WATA M6"WR;
<=L)JC+W|UZM<5XT|*6+L|HF+K|!#JL/#P""|JL+IN|S.26>\$4HHN|7B9POM?5D29|D#;T;Q;
<_|DGG6S7Q;D\$)JD"B1|L8Z6K-M E2KEBH8&RNL^Z&7"5V#>#K6K+|VX?;0K0I7|S9P|VJ9@H;C%T;C|YZ\$-I
M_|N|AEQVJ-G@C/L^R#8T|LN;7V|9G_V;JXJE^RC4GS>&0>@G M9UV*GQ45"Q|?7/_B"AY<Y99M#
I=7FYJ73F=)K_+U#|Y*^2.8Ez8 M2A#Z.9L|!M521\$S\$RASPA40
MU6KNYH|=%|K>X4P)^@ZKNKPMG+|+QUEX2DIM0H"&B8VHL_7H|T:1(JNP1^H MRC6%|NQL+P;"DFNS4-'1|0DBI
VHFL8N;G@J4OPQ49H@.05);L#BAT%YCP)6 M)<|NN;_);\$^+<-
_&V|C";4<"2V;NXX0;2S@O+K9DP^BP.O+H7T+|G4E%G5| M1I\$17/ 8BH^<-
T""#&5|%WH3W8\$DMRK">|K_76I\$%|A(I6S_>4E5P"+|9T_^_ M=/M6J2OSIF4PML3#UAPWV2C(P=6W&
(X^2V=Y<(>.6Q25ZNM6CUUROV^!<4 M.=NW/0IZ;.BWSK9@;.6T>8OUY5S;C M.7P=Z|@|CPIFA\$<-

OH+L+PI,*9IX.O\$QD5YEZ24MTY:@/7.R6T044&Q MO")D#JUGN*ZNVV=5T(VP8" RR/"=0R_+4EM=90@^MH+G5/
K" F?N=I9*^&- M99F\$G0&D182M7RL\$4*?./"/"S0B1FAW2*?BAM%0=)O15EDYZ+I_>O4\$\$ M7=&!AK)-C4ZE5P>M-
R:7Q+H3MSWZ:XP+?;?1>S^#6>R*!_M"IGE|PK88RQA""4.1.T\$%C"3CU5+,X M+PTGMND4D5-IZH+= (JIP,I?
5LD+80CS4/W3-CG86J4^O^MV4H,,WR VM45G
MCX9VFG2_FY=78H>PA2J>.;I#=#/4MMAS\$JFALWM&;JD&_B34!FX2!0SQ,2I& MJ#"<+-ENE.\$T%7SI=J!7,-1FIV+
10.)HD?88@*V/*<=&<9TUBF_,-^EJ>>R2!+8G^MN=+4MF2UC/W\$;-J*LD3@:/7PIYBO42/I,(7
E6>?.;I+K(IE=RL,!ZB_14 M4HL; */%0XI8,VD2J.Z<+X>X<@G^KI.1^I@7&9UYO:SI^I@< M&-U)Y!3VS*.4P<(-
="S=23)=ENBU"E4E9)_ZEZ::MK;,,M#&1^%:P92I)Y MQ<6/RZ8+->ZY&AJ/^UN08P"HJU^NC^,>1#NL,L5O?
JHVQU_..U9SRWD2H MDQ_DI=EAHG: X"ZUEI6C0C*(G(\$F!R22:R%:IAFPIG&D.U@MP6.V7W4-C8
MH_!5<@/T6IW!2;A9*VYD0XN N!D+.\$AIE5EHAA<7Z\$!F3^W#SI.2IC)%FM MF5770#4K!AI_*_\$/3!%#&A0H1BX CZ!
(&VTI(LRV-1"W?2ORJ 33P%<:- MZ!YJHAMJ0K!G;M=8+V5*SU3!>W39ID9?I*+5YO>ZOB=+Y:>G+M_.\$NR)"O
M6Y*8XA95.M\$S&8Q2BW4.HB?Z=JD0:U7582A6(AO=Q-V@ 7 JE%I+8#JYEN
M9\$RZ6XU:"SF(L/6+HGY80"MY8[2:6-6D]!:-%ISJF3EJO\$Z4XP7\$^;BI/_@ M\$>5JO-VHC!"=GN\$HR%5M3R9E?
J=3U?NQ=+0-4!_1\$!,5\$)9E.#QM.XGQ MP3ZHTX:GXW1-\$T!3YF:.'\$FY=FW7.GQ7D?7XM=K'#.X?
MS^X!;9?,'CM_OTVGNAIDU5P"J.TO@S&M)+M^KPX!#,T.=.MI^O/@S(E?>A*:W!-
NMRBM*2*IXY)H57A!4@K%16!DSE9%7X MAD^K?_/&EH76Z.>Z:\$F/U,M?2?
_\$.B3HQ:/Q^P&WA09GQU_8GIV=-Q>S@O6_M_1L9UYQUJ8)M2*S:L^%G&8IN YJZY*JFU4V-VI?
8MYXN)CL;ESZ<);,2GR MI1!"#AGL<5PA-I^O:V7=Z9A-B*SAPK8/V%XC@PCE^2O(&?QI\$=2O,+L3PF M^0\$;?)3=G&V?
JN\$DL15^TMGV87@^@W7_B2_M(!.=@L/9/R7,I64BS:T\$HJ_*741SD<%N2W;T<1)A^RYIA!_UHQ^I/O_M_3I>AE?
R=G>&G7N0_U2+U=4Q/=A3!L-/@^B!M_!LKS MBWQ.2_7 RA&(9G)UL&44"8.RA(16ZRVA2P#<9I8V#P<(EW5!-
"W=A*!XU&_M0DJ!Q!_CG;AZ@S#>%TK_U)R\$^!CT!X61LS?HNV0=X\$[IILLYA)1&Q^TG1) MG':>^*_.R'.R\$44I;
%4S)+JE7B3SCOEI(NP)QW1XE@@/Y=2064OVKM\$2I) MJU%K_!L^86LI"IV?_G>FK.7(X*GH/4(/A.6!%N25D!Y5?;I,*
M!9GGI0J2GCT?7!N#*DL MZ@B&%7V)KLIGZ!0!K:YT\$LY%L&\$9RAY(I^!KC7;,'&GH4)=>+WAY1Y;1 ML3\$-
(8Q&3S(C\$^G>@PH!#MBX!\$2\$?C-Y72Q.)!=-.;+;/\$.U4 I9-!&5EE*K>_MZ""I;?
4^>H_K(I*.K)R"RI"&^UI>W<786BSTPZRJX!D/2&7@5OFTET)QBE MM?AL8!5OX0>1-(=P.GSWQ&D!I@8?
L6%"@Y!6Y@-F!;N-NSA&OJY_*\$11%7T MO8F%;;IECV5:IEA78!VAG)^L1CA%G@DM_W&V7N!;XOM(
7QMDWB!+_+=SBX_M)XT5:G-U2U!7BZ^I/BU.K!I=->Y#6EJ4GRZ\$7%V3MK_?\$.36LGM>-D+XU4Z MY4?LA
2%O!P<4;@S9!&B;V/"GZ3=ZF*(MFI)MV=3N->(B?\$.GKK0!<; M/ZHB)N)0U"4L-L8(1HUBH3AO-CY)I6&L\$6;
(CWO-L*(<17;\$_1 M(GD4;U_%WC_J*1B2FH*)\$@!PM&5=IE>JCI7F+T.'ZA-.E1U8CO)N5BDY.'+

M=4SWH*-86?;,\$H:/SW2#^4((NB!Q9),I>6OV.K3,C5 MUK4N\$:@16!&K?27>.,^+1;>_Q:H!\$!7&H1N9%&GJ,"
MPT:"=1A'.^ WM83 MU%_K#UYRRNV2E(GT_H=-KEGIR9LJW!\$ M!^2;Q:2PSEY\$^&O6%0K.%HS6ISIX_#33!U3JM#
WXP-!FORPO55#E.+1^0!7+NH^6AV.+I)J+4TG>=-N8= MI9&.IV(=^4#SPWN@U^0^\$>MJU?AD1-1FRQ-
!D&1BUX=UD\$6AD-/T^UK9P M8%UE73YDHIYN43%HV+.-.S!V/SHTZ"32?KDX.9>L.C!VAJ03^UM;.-!B^&
M/1=S^U_GFID:Z)!ZJ?JA;78CALW.L!OVNJ3?NW73EHWTX8+ZW5S^EZT MW79FU?
_#2VD<+54)E2!\$YK3)NPTUEPFD\$J5!%9B!&70A\$3Q=G=5 MB+7@GR+;0A-K^0VJU;N7D83=4<V;?<
#\$1CQ*3.4G#1J0Q7!*##WS84I+! M5&I9*QQ+WM)EPIP*W3J9*%/Y4626EI^Y1IC\$%,@0B.#2,,3TPG6)(3#.01&9
ME;E'>:TE4!"^,.90&!C#/&TH0!X5Q!IV(DK2ILF2W"77HI*_?O+SL>+-(H\$|
MMX+D!O_J0RM%:+\$#2)>XXM<*U5H0B3;R=0V2<^#RNP%OG>RU)3H^Y)X0I4V1
MAAM46FB:HD7!31&US6>:;.%B<IRW+(>V"1>LK.8&&8.150.=1@K8>6%J9FB9 MA^_FREQ'(U&#+UT5*SA8!
MO#&"7A.8A60M\$.JC7CX539^)!F!5S2;HC=BC311\$&I=8*6!J9;??S7;'-GR MR>SQ^S*1*6D8.W-1=0Z_#ID(T&=
<8??"#W!V@I.%M%*Y0T>XY.2.,+3)214\$W>%=>I9.1K%NFZ M(9K4G;^N=2O?5N_8_HPG-63QHJPH*4#I(C;
<9?GL/I^09);YHSD1GL7 M=F^K4CP=I:DPSJKG059!PJDWVDZSB8%=&H- M'=0P6:PP;
<1.@!&VMT)G.T#"VH4"=^SPS%T2;XHM)M\$2E2?UD<4Q)DI^3R9 M.;?-. \$!^1CJEQ_3E?
V/OS;..RL(IT3BB(D9D\$A!BB8B(0*D_.J.4\$@2\$""@H M""E%9(B84D-BA*24>4R)_B4(469DB\$H"
B\$1PE""C&&0H(0D*F/@1"\$!^T?^R%GGI+/W_J?;Y^!OX!_YG=8K/A!9%)T?O3 MI94;. ^2HN@2WYWMZT!O4C-
N4V#20I9!U5=IF#4WFN6\$ _<6V>/I/_W:K' MW4HJGUQE.4.S#W5\$I#I_ =SLK4WA_ZE:10.6@QU&IV&%=\$",V&2?
5U"J@S" M;+IMP" _!B#"#*.6)W&60P<-X5)_8AOC"4@9Q4.(EN^L<^SXJU580%LL@)I>E
MHT0P"OX:6JN!>>P(?^5T3^=ED*1PX6899+J5U/_XG_/??_!*=V@^6B MJJ)!^BLT7T=DCW&4;LT0(8+M#X).((
+8YA^43A\$!\$NDZ(M:GQFQ#>04.)YD M+AM^Q^H):T"3-LV!"0G;L!OI_ M;NEBXL=;H_
20MGG=%WNLG!R(P=W3@XY+*F5PV\$N=FQ"6\$?7DM+>?0%IZ"/L905G&IO12?..27Q
M2/5LH/(H%ORI.OX=TF%9#ZL+60^U*-PGO@=OA_TH:B?I(#R;B/ !S_O! ?WD_:"4H\$="9
MD)@LL&E59P.N!%;I60Q!&V/D+<1J!7)?&_D4>I^AS^;!/;<.01_5Q^E&U1 MS_-@OM:F!Z?)A"V9GW\&(I)."?^0
MI&)ME!89IFI4049U=-^<VI<IPW-Y@KFCC:NCE\$!G=BT1HUV)!U3F02
M/PV@S7&:9F00X"R==>I^\$X@4%L)RAX+_-Z!CI=JLS/M#3 D\$F*&V_*\$R).H M=#70-DF>894Y.L@N3->YD=_Z#R;ZV8;
(IE^"HPF7#^7MYNP.Z7V@#0Q.P8F MI=?X.Y3L#UND?:?O!U9=F!PDIW(I;..S^2>(WFE_U(I=#164EI_2M@01R
MJ/DG2R_CTCLZ,V4V.&%.#_ \$TJP)P(-_R*/>I_-6I_ S5NFY;W/"4X2< MX4.V^C+OAWP+8^T9VVB.'CP)?24
%V368Y&3WX MT_I4 5I(.^WM?T=_X2%!A!9FOJIV&_<#_T\$>>/%?X!/?!%0?E6Q^7 MB,^!\$!(NGW_Z3
M=HS(("QITG7QJ9H!MJ+!3E5?^S=<1QL3A.X.T!"^:40(M*O*-T%YO&LNF%OC7X^_HG
Z.PW:W5AK4""AZ74FH7JM5=M+WS:QS&E/3JD MWP0QCJ?>JK4\$Y.L@T15-8S)
(\$PR=H1NA_Z&2SQ+RIO.D4KU7)#2WXY9-AQN MP6E0EAK,IA?W)*U/E7<.;#YBX(HOD)!V%IQ;7B%31IK>
(YR#28+MORA_\$ MOI2!PZ)!X\$E&A_5H*RS5W@0IQ>5IG@46,Z36T_Z^F4N55_)FI (\$O^3IEE; M\$S-G9^F>X_+(>52Y
M(G.W^@P_8+Z9DD%_J8_(L3Y*!HDC)-!VC,E22#5?=-;EKO2Q;-RV9,E=209 M-3P9)MT?M9;2?T#46Q>SB^0;UV5Y*D;
(M^C7^F3)C=I)&I%=&LZIP9^8W^U M-)*O(.DZ(AVX)=.KPL\$%\$0?O"0#!(,%YI9_! N@Q29_-\$_45J)8\$HQ+B- MJ
(&WZ(0.PG7\$;8@2Y0C!P!A_8AC!+WC+(_3CI(^*#5!-
DSR>\$S:7>Z+^O4X6!Z>M6JTX!J^R/7+VL;)9R*&XH<I.N&+JXIM>IQ;
MARR-TD>401!UNK4B@=P^N!6+XAS0SGD(DX!8X!20^3IP.E)*ILW_%+8 M-R !*IGQ\$&P*(ZM3BWW8!N
3C%BI<#**EZ!WWK3#Z;80&1W!FL5P&/RR ! MP7 ^RI=6!-/L_-A" 99*LO*=F^;RKX#G'S\$SVB!AGI8.?"/A2OZ<
MLETW:B!E9MX"/R^;?V.S=\$IQ811O/KP"U4 MR!^IND8T!7A0M^8-XG!/_^!9C(I;ME!1OGZAI->&UT
M=VZF=CS2QI""EX@9P!Q)<(6.L<30@*T:@)F_%| TN22Z?52A3#^;,"0J3I8CJ!SYK
6DS/ROHU&FP92XU_4=7DAUJ_OYX""-2QIK M.L6?Z6/2015-DG2;-F>928ZI<9D.ZJ@Q/1?7)8.H4
T%CFI@AUL2X6NROJ=I#.WI(1V%!B%G/@JF%9WX3X!9@D MKX% X(FW:T@5:U)"SL?
VJDPFM*S+WT^SHZ6!QR3C^4@.N"+=-@80.5=T\$2!H4M M!SD)8Z!M!&).D^FEHJ@Q!H(CIU\$!#S-@>I\$G@82N
(^V+^&4^M.N) M3*DRJL3D0\$NZ=>!)HEAKS\$L IGTG.N;0W1.+P@IOI>I27DI?2IPL^Y5P
M/3#R0U"QB^7 !I.GOV=UD4^3D4(\$3J@AM>@*6=DJ?NB>7Y("3".?6A*ZV@ M>N.H.4JDNAIYO-X(&C&
(#1KQ"11+8;=\$4-Q07F!P@V26_7H8M3#=_L@5XQW MB#A)K705D&+KRZ.GQ;4/2(>1VF1K_.ZV1?
M;+HQ_PLYZ=C. M=:;5^K#GX!&X_!EQ@(!=(H/\$N MR7MI-V/I^Q2?S&7.%\$!;B
ME>09UV3KV<0C#A=O!YSE;_Y3\$1CJ_<2BO_9W_! HI.F.HC M2&IKA"UHQ\$%EXE_
NA#W<9H@6X!GP#>2H%E.P%TJ-GSOD^K<\$LF#=1^4)7?X M*G/"%?F OV%;AV"0N?1=Q8Q!6S%DV

M72\6PHIRNUS>/7J18.(^2IO)?ZX\M:B*0(8\+16JP%_BSY"^\<+E4<MG1Z&_\$_L"@/_H;^RJ%:PX>J=B_V3TY+H
[#F">7I+H21MIZ0&H_Q%N:A.?_IHC\84"!=IBPZ@_T=1\$VBT^&*;_F_V&1\$DX;>Q;H2.!#
M;.#G>Q7M/YIA_.OIP^T.%+2)57!=?N;2E)I/V&51^4HBK=)/!*/_@_M=%+3^!R17H&/%NB=&.5J<\$5INWQ!
B;.:4Y4XJJP6J^8!QR8-F%#548+^PCNA;.%11#;\$K**_MR=TY?F4&/00?YA9/FZ.J+!ZB:XKR\WX9=57Y4";
IWL9KJIOS="6J7N8K26ZD_MFAE1829*06V.194.LNDLH/X@ZGE(.3S;.+>_Y.G6R6X#-H9+D)C>80SC<4MNJH5K/#A
65=/*0U?GV&\X3?H?6/TPITGL.Z"KBU_MGKR.'#.0RB#@+5\$M!MH;R6W.Z+V&(-
'4.'PG%XQS36IH7V^1SB;F1JP5W!AO.CMN9<.Q1#_9X_M-F?U=KND*GG\$AOKY<&-
WA9DH>;L;|TLK|=FG=6S#W!AU7X\INF6UX_MZ#CRY:64UP9Y\Z6%I^DIS!\$79_PU\FI0D
TPLPZ/#3Z,QML%>7%.\$#M"TT%_M^HO%149@(<=>7RS2\$+8\W=6O>*N7+V:N.*7UE\$(&S:EX'?_V>|%+\$C/0I6I
MK2IX#BRR@TLG7>%SGWPKWXTR\40A>+3<1524B\11""7C.Z"Z(0\$MSRE>_T.E329-&^+_B5Q(J+\$.8I3-6K78?_%
(J=ROB;_M<|3N3DIMM#;7&M_M=#6I(5934.[HVS;_N^W4G+T#9'-@:8XA2&TC9I:#5C2^M-
W;QXRXPDI/_=B3^\$^Q=@@>N+4_59"HT+^/SMQTLNO>_6G=M_M\J^H6=(2R1;AE;QI>*>AB)3I
<%YDFVD\B1XP%N<3R+((/_^&01<74"3G;_M)?SKPA\HA#.?Q;_!IQ\$-R+U(LKE0\DF.2K>*>0\$ZUZ"=L
5I@QLD;J!;H3FF_M;I^XC8"%RV\K*8;1N8LI.@>2;LP2;S:C\$K0@J7D\C07J<3"MG@"02;8A*(X.HNSCN-^K<.^
L=BI;-8I/Q/H3V;-;AU;U6\X*T*57\$K6MILW4
M02QGIX_RSI%_5N<4+AGVY=T=>S3IARI7"OIACHY^IG7+;BLL;KC;J#M^+_M^J+_D_:/9Y1D47VR\Z28?
9*G4IMO7RP";*I[#>%U;6&"F%8Z);<#NGU&!GGA_MG6QOA.NFV="&.9K32\$6L)1>M_D8S+X(8*!#F>6>_-@L@PBIY-
A;VKL9_M9<'V;FF.B2.C.^ITELKG2W<|99PSNC\Z#/?=)\$#>_.8KL>>!"_A!5IL85?2_M.=IG(O(U)
(2RF96>Q>_GN+H+3>H2O=.\$QOB?7@=>3U/D9?C(I-TJ)%?;D\MO?
AQ.OI\XJ1+1%BS%OX&U/L70TN(B3YTO4705H\3I1I_H1520ZHYG2?W_MT>^\$XOY(->YLY0P+QI7(I+1J0_N8R_?6I?
VG?4.+IF^_N4)!C4YJS<"H_M"WBL%KL#A%>+80.ZO;I^C;O^Q<+1IMCC/GHP#.#Z\JKVZ.I3_(B&WGI_M9\Z5YKOD'?
7(^;_*TZ+XKC.V<I>7NON?W;./IDU=69(3Z\;Q97I\$Q4=C\SIJ;SD+_N%3X79Z1&^>WA*SJ
M?;Q=-4Y*6&"WU=SBB.SVK7*YWUTH@_Z#BHJ_7U^3.S5+HP(W9Z56#HLL&G>
M_15Y9Z5FOUR0I_MLBZGRPX;O2IY8G0W\GM6?_R3_LW39@O%EI\XIG7?S7S\$I_ME/5(AWG3Q+_R.+T7EHJG*3*
(=D\$/(4'UZ*/2HX"X=%^GEWXM=1E2;1\70_MVC'Q.3_*2)NTG3_%>0#W8-);M>?Z_I\$KFEPSE549R(EI;!)?XV(S5?J+ZE
M=62F.BJ^"P.LN5>?UO8LW\I2X3N\CE/OL"Z!
M&MR82U0M4.C2\$I1LUDK%)UT;N3F4HQOCZ<#DJP<_ZZHY+5U06M\7J"1=(.-@?EQ;I*IBX#DIJ2:0KLP4-
I+5;LJL1FF#MM\$%V;J&>0C9RKS_MUH9*V_ZCG?#;_V(=>3PWX52V.XN122"51B?PK'S_7L_33;8"KV@_9OP&C
MPG5+N_58=,OGXY5&IAE\CI&;GGWL2\TW;\$3FP!"^G(8K.WG.\$ZG.6^J\OX_MY"9O656L/)HF
?/XV)WB%KD_#_OO47Z:Q^TG_MC5\I^?X(B+?J9S/*BO7O.#^T_Y\NXV+(MVVK"KX/CI\$H9X59G_3B!#5PB
MLES>>#&MR6"LR\$ZLWB_P32\&O;L^@_HAC8Z"&_Y\$<_T?N\IE;QI4=&1V^/2_MJ@+49N_=|XB>Q2EB\PCJ
MEPT9&^#0AS5*CI^D#>HRE\03E'=-H\$@6APL9X"!)>|A#08>|>6;FM7Q(@_MT\IDWBT=>
IKXZ8SY;J>0V(U\FCDER(PCQT0T=&V20C6_((%I:PYR*_QZ_MD)6I9\13SOLG9C-DIQFN\$-C.NHE1>7?3_B?
AZI+^Y=HSOUR1&JZ;:=>|MW?%:8ZCR\52==Q;I#+UB;+R5)X\$K0\$&A1BC8Q4;Z2E@P_!G1MG'?3P*G
MIJZG2B*_.BI/@L.#D;NPIPRSQB\^PDKI\W+8_WY?B(D7^N2I#O;_N#I5+^+I_M(7F
E=88CL175#@>@5OXL=W)^DC^%8)T;I?HJO\$U8F2BP8*_-4+(F&GU<8?_?
MJS2.S\DVD5@5)4_N^ADL5/I^C^)"Q6HPI(XQ"%OEW;:JL@U0S1HJ=(V-M_MZE^#PX050%6UTIOA\4<-4538!
0X4A\4#5U\$BR159>D)2UU(00E7_UK'1)JZ"L4;9;+_/%.V%0%4^%F+1E-/2"8PUW%|=M=V9&(\JON;Y)D>(%(V.?_?
_9%G=+DIZ5/*0\$DI/I>#20)%88B\$*(IBB8Z4_M*"+V8+HGV0R2*J9M*BK;O3>H%_%Z>;|JNR!&I;J7U.7-
>7^>K#^Y*6-I_M5NA*_EM3*E&I9.?D-!M\$?R>2\$./BE+/=">8\NQ*A_GTP\$C^@2E8X\$D3PX.5
M%THOJ\$;JAWF3TIQ#C?7?93_Q=>02YN?D?.F.;>-(27;ZXY*5;#J=8#7RTHY_M((4G8V^_)_%C'?3=8CIT&%=^U?I(C;?
X'W?C)ZTTC2:"@>@)HR?&Q060C".ML5I#2;2=XR&*Z*#G2INUT_W;W\$#6@V=IHGL313D_54\$-O/A;MAC_6;4MW+
M_V^8)I_KTV\RB/PIJ%QU2!21W^6P\$=0EN;Q+^IPH@H>+F0BU5K>PC>/(M_9&XXDU6HL-UO8I4<)UWZD*B+
BO+>|T+>*46%4;S@;+3;+X2_KAN//G\0\$^I&SIF*?2N&I;UJ6&M'7.O6ZZE_M<)0<&I>|0A(0'&&M.H3EF./I@XC?)D-
@P83?)KHYN\24_ISM7SN;Q9@=W_MITW=>C7S8_OKXZ2@'MT@U6%('M+K\$-LRX/_^KJC;@;N#SB5*_;@A43I;Z8
M^VCHX>YT2*)/6WX;>C^ET5_UB68\$JX;3UGL0&8BZZ;(ME9'7IBUC.);J;QIQ>I==O.F1*B;HC5QUI4I@5_0\$P1&L
M9CB'R_H77GLI8IYK-W_#?<Z2BTZ;7W;%^R6UIN647^XW\$9N;_*LW/P4+MV1Y_3VI>@V>HUXZ1_K?0KQ\+35I83-
CDR_43MKQ<2RL19"9'R9O7VO\$0.#8_M\$7;4Q^EK?R\PI6>)L.49FEW7J+7\$@_N;5KCY.Z\$E\K;#I>2&0LBE;I9-
UYGLO/_N_@0WR";MDSEP2XUYI?#)1_27/P<_PC1N(U_#7W+M#/-*R\Z^<_<
I0YXEM*BAD_W#FVG49B?JFUXEGSI6ZM38Q3VBS\$>/7&83"Q.<I/P;P+W+R9/J;B?MH_M)@"TF-
PIQ=08/\$=BL5S.^0\CI\VN1D0-C(?>"7Q<4SMRYJGZZ;OR\V&N\2I8FX?;./S
M^#OAL0I^!F\N'6NP2TO&!FRMT&P\9=TGKPM_A4K"F1.ID)*O\M@I(=P323_M;XM4AX05I#E"KDS_W+SOB!:=
<)7I=SX%OSRMMLPN_M0#_K*6N-W5IE\DSG8\X(8?;_UE!00F!OU7I9FSL4MH(IAT;ID=LCX63I;)(L
MS9730XO'E3JE;_P+_GY_%0I^MNH#W+\$SX2KO>"PI9C+;^B0=X\$DD4%F.I\VL>;G828M-RBX*1OYI&UUXL?@
MVAK6(3G9#91%)7X?;^TYGIP@)0TZ"-FR;45@?;_*TFM80?7#M4VX%O/7=MQ^^(09I\$;G-)XMM_C^KVIU-"U
I>334WW?_JI_I'+6;.)I?%1T\IYR_MH.SY;A=Z(R"\$6*%SSC\I(M*W+R@V(&JCMU=N3M01.PV+7"_F_C\^EX^N;@=
M<";H#MATI7MU;UIS\I?83UI\W3TX?U1(#_K%\$HZ;UM1=N"S@E^I6AD"G5QIP5OQEP7X5M0GQ.1HZP_DV(9_3V-
ZG@K"&I@+D;_B>_M^X<"ICIOBK\H-MN.RV(MK*8<*%Y%PM!:=SL(GJE<C;MO\$-UE?_2I3_6_M02A(OK*
R(7=P%Z7%B^K;L@CE/>D2IYNLR.IYF"X;*IV"N@%)2A)9N\$*;H)ZPL.PQ;3<%1MO@JM*#P=XXW4\$J_MZDH56-YA?>
AP&./(ILO';/"93!O&RIB6=_V(+?_6426_6NC#>_NY(TZ;UPEE;W>7AU""^Z2&R_MG\Y5>?I0^7+%2/M)=R?
_R(.LT.S+CWGGQM\$=A.#U)_U=<\$T?AOB\;*M(FT0S976D29FI#NE(Y)RVY/T+6%)
I""4I4.OE\$!_QD+S=@%.C;4;B_"9AX_M^H.HD@F@X\T;ZJF-/I#5UBV(IDIMR%?\$;5J=-QROK>@K@T)M;TDL@K!Z0#(
M\7%U'H""I^#S/N/DQ=IY\D7G_3L24\$9T9M_MICUFFE;ID;@I^X9\$%H7-I_M0E>BPHFI_M#BHO?I7;IC(
M">>OY;T;T%YI%I;U<95PB\IV_S4U#9J87UPHDY/HH(>3DZ(SNH<.(PIQ_Z*_MHX(\$F=I-2#<%?-M&_MJOOI
MC;#I+U=I\$F*_4<12?M@I8-MU2?TV;X3U)#Z3I_M8B9?C\H@C^R9%WIA;W&OSFL\UJ(DEB7-
MY%RIY;"DKJM7(>+I^+^_50X\$;J^C(PSQ;6UBK.=3<I\$=;_SCMS+<*6
M(F^I+J0H6.PFN20FD""3SU*QA+L&WY8*WA^H-;I;UGBQ7N&6X4D9)!IU_M=HCZTU,=
V=KTT32KE@-9^OKA3=NU/1D-V2G7I%WB_@32?NN"0?>X'+3LI5<16L<*/T2SM
MLTRJ"MXT";N!4Q46C.O%Z8;1P)1H8XXV4J.5Y(AI9N@>#*3(PL?)5N48I_MDXUMI%L?HKO.Q;%Y??-B
MFXBX"2QWR>I;U8BC?7R;>(I;1^\$>2@1/G6G&X7R/#.G;H;VIZ+AU%RBF(M%="2D2E*SCI@V-%ES_Z90+UI%B-5M-
\$KUN@5RSOV?OQ*W8/7_H#>IJL/EENV(L_##@1@H9L#?5.L_M.B\$^(B#\$1^&I.DAB+GN76\$?@(+I0QS2V/5+I
4%3I7M0>%WAFZLU%?&)F_MM=AL;Q)CI4)@REF?Q>2_3X"E5YI;B^#(WCV-0K?@JD<1&%-+H.4_M^Y;.;MJ@Z
MOU;F09I%CM@2O;_QSOQ;3N!(S;2;L;EP_I@-CE^DK?2#>=KVEHOY_I_U_TM23<5DN%5X"&_UP^T4SS0%MC5B_)
C\$HRB\8TMI;5I=-8)QH^S"\$M-IH*H\$O\L+SD1633=-U#P'=I_CW5Y7KPXP^I+Q1H^G?;)0S(6;J2.ADD
MR(G)U#AJ+?(024KJ96F"9OZ=M;1=XHH>Y620'6>I+/H"/^(<##OOV+\$J8!_MI/A(IYO>WV.OIF@_ZWH
V;7UG^N.FAOA;WT7/WP7_M_CH2T6RCYRG)@03I;GHJ=-BL2JZL.VDB&Z;A6I7_YVSPL;J;9O/N.?<
M_"Y.6ZL5=+P_LK^_%=SD2LT\$9D9"=MPT#U3PS+/_#G_I%W*Z_RI^HGF4F5W_MWAYH77J-
H.5;J)XSI+I+USZ/(U5B5I*V>_UFU3>5.R_%W\8%N%W\;^B"MU>#GN(HVL;ZD6*I\$+^&H?;=-2"/@T_%7R>LPP;

64VBY7FG09"HL_0 B&R_128Q11-0-1?GU_-H9_&YP1OL.%WB\$15+"M96GH M/M9GB;X(=T6*1@J
(T!WPA+MMP*Y)_QJ_Z-016H318:A3'16::P3?_16L0_M;+W+1_9Y<1T9>3IV\$X>_V0Y1:FCA2W1\$0AD3BE;1#F.L-
9QR<KSCER1SZ;A_M_B^BF%A.*URP4/./XO;...1)O!@!H!(S5V**K0BQ)E2\$^Q#0^(1%+W#6K
M=;U8CSVSTC3H_W_0_F3KYJ_5NRI7UFX^7,<17>,+K\$J)LY"X++<<9_VB MX^I
E1+;A*3S#_ZTP*YE6Q&F&ERF%E_QC%77HD01<Z"CGV82:2+KPE18Y_U_MCI/_D=L9X15Y)W;6W9NPTMWU_P
M15S111>1Df>5/D>EH)&+0"&%BA"YC*_1EB6^+OM-J*#JSS&Q%10_M.Y!KC.KPF.C.1<1)F5=^/S?5HO;17ML@T2_N
+ULU/"Y_62M_PBV-H/Q7_M8ELN\$DKUFT0FTW=27,H'J9X!^%IPQ363S?5N8RDXFI
SD3+AM60A#GVT5&_ZLML3#1.OXL=4N_Q<_36"*H++R#?6/A^XU5.%ZX761+1SZ1M#R
M,@%@BX!20QC9SL4AYX0B4R84!C"6@<(K%Q_>9QE1QUG5^91@DL+&E<_6/GT_7=W-0?17B\$QZ6SOH@?
1\$FW\$02K0(X)6S_0_M^"Z,&_!&1!V@QH<>MMB.GR7.*02JPX8I"Y0+N1(K03'NXZ"26TU^LME=<19
M/1@1-6:62'H'3_1AH9B<8JFP)R@1/UE+1).OTO=L_1^20T4_MR"MNIMT=4\$1+E\$#TXHU!41M-%7@&NN1-3&5+(-
L^P1>1*76S_1"QM%1L;_<43W>1-810WCH11_M<X^YONW/"X21+>4JYP2:1U1-B*5%ENVGE14PL,N0JRX^4
M6FU&1VDC""NB11MEQ#J/SDP?^11Z@36G#@6-'OGZ^1C1_S=V=LE4P>0
M70#IRI'(>1F11O4\$_#LZN*,UIZ7:GLN3)!?>0BVSBH&BZ15WFGM_CV#_M7V11'(.1*,24E-"B*1
(AN#7H9E:BYEZDIOE>*1LGA/'F%@X1CJTMUP321_M"BQ1_W=L^O\$1IXXD_?5P<#_.=35KXV2*#QY,E;Y2-V@#K_TE0#
1LB.ZGXM= MJTCT%ZZ?K8X1!A1C&*^TH<<"1=&_Y9;+AE>=A:(H1+1)7LVY5J=1J/1'NTX'D?CHEZ0_=<%Q/+LGZ(
16^51(\$+>X2@IQD#F<M.M1W+Y)TCZVPC^<3@?&1Y:1#1LKPF:G@<19&5!DV_#R1"1*3);>(C_WG
ML1ZN"CG+2H=Z1_E3U*LLJ.7G?MZ/N+^9K_*^/3U7H6?1#VR:KA^+KS1S\$"MLMS5BD11H^YZ;>U1%4&.9/12^
#AJL%X41V;\$S,W3+1:\$V%0%149^CHU3RN_MJY18_9-0X_(4L^QJOJGT1S1AY1MX7DH9(GV98*^KL1+QCLS_Q'B*J;U>(
M1A3^O>=&0<-C62:1<4%9&2JH0RQ:67%0A\$1O=+L+1W5H5D_WE.#*Y_M>74&1#(SKS%HL"L"2T5WAOX)8S4Z:
13C/D\$&J@P1_MND/511S_T98TM4VCXC+^&MJ"7211O_S91S"1F^(@#AAP-QWE3N1^D_7@8Y_MQ\$1*VDM=;
ADXGZ=P14_M11T1.FTR_1R\$<\$1>11AOV7_1R"E/7@Y0)4^8P7&>J4*U&E*"V3EP&HRAGK^L?XC3D-JS?+R_1H_HD"?
SJ5^<8Y1.&:>1W^6T_M?8:Z1WU4+>C1@W"7(TF6%6HL+1J1_5:DDQ?O1CXS6D4DG\$_MZ&9K3VD11S_MUP;?
+;7.0:1L1^U1"9_D_\$.>2Q\$>P9L+P_G?6-/<4EMKZ510^%11B7(2Q_MN3>1<109Z_S-RQG\$E%&ZLMA
(=TT@"R0U@64G=Y41R*K@7GI-M>"@+>V1!_M\$4"S5S_1VE:1JZ"/L;JIG(%(%M)U<1H?<7T-
Q)V41'M/LPSH1B#IX\$41L2_M%1"O_LJGU9XH@VR1L"1L1B%2:\$?U@V(HYHT?"A==11(ZD9W%1^C@@G.+8
M44ISV1K3Z1%0XZ(11L1)<+111@JK_LRJ4"1L1:(Y?211%8511E7%VHW#S;M?J<>5V11M_M;T@RH?
S81D1@9G&JM*J>=#19DS:RH19@NGE3H25PTB_T=11^XD4+7=1R_M1>0%\$^<1=0V=1A_1Z5R@F_11^B1S*
10R*1MOR714_ZRYY,NM,N<68?4%_M-L)'_D(G?+/T:RW12@1"4_*GK:GH)(J^BXQ(H:M1-15B3B_1^>N@*R11=Z;1_M-
H1_1@F"1#8SHQ:@(B4\$7;C_P2=C,6=28D^ZDXM5!11?KFP4192A_17+A*"=(M+M_LW)_731&<
H1"M1MS:0DMH)M(>1H*LB;<B!:=16E,"(&TE==4R/A"=-M&-1=U^1MUO5A=J@F(GPX(X1'2Q>_6L/W00ZU3-
N@SR6NW5ZDS^&L:1W1?>0==+1TG:Z12_9VOK^M6_MR?E2Z>7>1.DE;-
JR:16<16Z2_WF1(PP8/M@_1AJT8*M&1F7YAF65@Q>T_M"1XX*#193/?1VK9#A\$ MK_1#;@=-N(1)4DV7YV"2D
"PVV60511(%415?3_1T).HF@#131_U"101_MU0A0
D@11T5/DH<_Z94C1DD)-265BG1^%YX194Q1^FOZ(HXUZ1RUS+7T11*ME_@6UR?<18?&H"MH1C#S.C_30X?U#
@_GF6P#V:7E"1T:'V(A&>1GW8T*12UG3P?@D2OG0B^Q2_M-2WWT@4?1S1#1S17MSB^1SNSRM7&^E7U9\$5?
P<3Y+PZ?1B7>B1#X:XF.VL1_M_W:#24_5%YIFB^#DHW=+F:N_4B6O:&&&Z";*C-DS/A/U@*11^&=XL1M5@
MMTZ_1Y797<2="BE)J?F"KV#^13N91/K_ME1.FVDE04,1SE:948>106HEU.7&<1@4>H@VY'HDI/R=0ZHSCCC#%=
1D9O1F1ME)0"B1\$Y11-%^71+*(U"10*QL*1_1IRCH=H_KDY1#18+BUBO1ZSXSX@Z_MZ)=A1"1TMR#<#2#_1W1KHK14G
*X&B-BWU12_16Y:1M&ONE&7&1\$A4.A)YOB1/L.23>2YQ_%WY/9_C1\$+1A8-F7'9&)E=:A%U_H_M1FT+5/3&R:1?
_9OSTE4+>91T:F@CCKM%/\$?R#1ZC1+;S17^WU<DMFLG;OZ;MK;
(((13/1";CM5QA"15_M#C"BX@;\$1Q1L=XQ\$Q1R1Y14^*YP2+1682)&5_M)RE9JBVVEO.UMGSZ9DR07Y);H?&*GD5EDS&
1_<>1Q&28Y1ABYS.J?">1MHL(%Q9S#41A_#6".F9#9^%\$1OERAR")TCPL:Z@1"1J(3Z+W11"\$95LD16@_M?
W<1454<^%R16^&ADT_W8=)TR1A%"Y>P\$E0>K>KNGK15XTET_EONW3N@V1OZ_MX_1_3Y1R1'20=N\$BA\$0\$15!;
(AXXTAD(DU1=#Y+QX4QH=S0W_1EXJS:GEAJ_MP3-6CP^6/\$7S\$2BV_W4JU_3_151=?(8%-3)5K*1>419"R4P#
GB=V4\$W_M5RU>T/8-ZB1B8\$JM&UU+;?>4_1B7E%TS7U15CN1FG7PU315=41
(94M3Q)3:D2<1^>6;HL3.2%=-;C>0S17:H^U6AYZDOTDLMWP_MW1)^=&5?
CB1*6LE0(HDR3C#@1:6V(O""R*1==1+KW1_VV+D1Q_1Z2PG\$&MS4H)@W\$-KC.#(N\$1/Q0GJ2.\$&A.*U2"A
M5B:TZ@%BQY9EOD+1OPR111JCK1<9CYXR11/+>G+VV39#J_MSB,1BL1)+MDD"3_?>#C28P1&?1N=XUJM=
<1D-R=%Y%Y?C?Q0&0*\$%_1%<M"2H91W611J1JG3<1AFVY\$*W>_K.P31";ARK.WND6V8BV*1;@DRA01,MW_M1_Y?
1L7_021N14:1YP>VZN_1HTFVL1)\$_R2+5A5(8>N_ROY_HMPY1=V?OGOWA(1YQ\$O?Z1SM=-X^F99@1&GO"0Y44&#@1;
1T_WZ11ZHQ%^MD0S>_M*T)_J_Y2<1.\$*J_4.UT7AR3>@G#8;1);Y8M6'P*&FJG4+?@>@4_@U&60;
MY0XFP#M:3@E#P75X@<_96XA#+1/V"/QT_MX8V1A_1V)3?WUU^_1R4XQ=.D462\$ZY8:&X10%1
1L211#7^G^#C0(<E.R:\$G_MK4ZURF78U_?"Z1_=-;U8M1-6U^02_1V1O?15?1E_#;1R1?+YM1(1%:K
Z6&11N*LP14U=1TN97=1O>1\$O1"1M1Q@GSK1V?X1P=*1L1L>6QG_1UC+>G&*IS;%U^0@XV&J_MB^<D_C_U1)=F-
9BQM)KL1VX=1X1!N(YZ-SE1)2GVGL_1OE1FVJ+7DP5VQ1-M^1Q1C1+QNH1+P.GN_HZBPD:@_FL1'
<6%V_0%71=CWQ@J<C.FUH1X5YB.M1B92CST+&BC>FE9Q16Q^H7X^#VYL?
6%1""7G^L>6W\$30+1'S(W*?>1RHW/M4N6.N1O=3C#7=1>L+J;BY:K9X\$7M%0VH>2+R0:X>_K7+1O+C911U1^
M^5P4S1BA6)@1G>VZ*(PCL_O1DG"8J>15>1/3%@L9Y+1S1K/W1=N")*2_M%5*KEGSNM_U1R1^Z""N&-^>68J'AW'SH-
@E=6_0JE:2@J<=MSQ3NM2:D7XV3_M*FN?Z256X*_ZNK#1171#RI>C1CJRZ>SO(Y_KYJ=ZE3HYWUW%V=@2T7G0XN=
M1Z4*C8(+Y?5TML@=NVE1\$1:05_F)>1HY>VNZ8KCL6YD1;ON12EBYZ1P+@_LGG@NQ?
>GAYV5?_HPKS5&\$E'/AP=7>X13\$H_ME@0T^PB1OB8=-1K1K.AX7^KB?1A.H:N_>-%4>K1G>ZG52'_11U/S21XLD1
ML21H_1\$1<7:@>YEN0%;\$3"12HR3E\$A_1Y^81ROCZ71H%D1=2_1T1<>&>W_MZ1V5<ML1#MGJ?V03J3^NZ71S)
(81TDES11ZT_M*+1E1#_1D*S:53X)_D_<1N7Y8XH\$Y*9_N_GIP+WX_1891^M1J.K70)J@HC.U*M1T80Y
ZLX=HJ@1QW2_N8E1E_YQMSH>KX_M5A_LHFJNT1).XK4\$G_P1^TMQ;H"RY1%<>3U1MC1!(\$MSS1UJ@*0^1ZQU&U
M@Q1D01FX(R<G;GRA)8Y19#11+0_#DEY1OQ1DLC/QO/PH_71W6BC<*\$1BO_M+XYP1U_51H9H_P1F_1CP@&-
15(\$XOL#/41S8X7MJ1VG)A_0F+*)D?EX_1M51WE1J1YFG3'R=1GAJ(97E&?>^>K\$R4R)1HM1/@N5)5WGO*"K#/(Q%1G)N1;
MR?1BP4/3KOR4N9>051*U5'D)#XWC#5_YBL^20&32L3VS(C8H#>L?1.8&.*_MU^_3/DJ=SZJ1+?*>D51TW+A^Q
4ZBML\$F(K5NE1Q1N1CGB1/EAN_UZB1C_M9R2RG_1UY+N4LGS1HB6*C.HS7_11@(#K1HVUC1)1EP^1YRS8?
N"1&9NKM'WN\$\$_M_R"V\$A@E=Y1\$%OXE68HB/W1279V"/Y@MC0QM)K^4WN11<61C.LSU>T&O%#
M(PYVQ<8116UN#G_1OS=XE40:SPB0WM6'DUYA->C#>@9Z7V10?@<T1@MV4('M7-
EB-WFP7Y11K+1A_Z1R1K_P1+1.N5S:C&Y@2@;)>@D9WX1DE(9)\$@&_M29=1ZD:3(Y"@
31^R32#N%T<#"110X11K1G1\$SY(Z9"2^>4H1V"1H11"9_M9>9.4ZS4@9V1?Z141"04W/_1>FP\$1_11F27L(0\$1=G;
MB4LXDN3D'GKF?C.KOIG1+3_W*1+5:1(5?2*NS_13LYYWK91K:%60W16D"C^M_*1*SDO*1+1=1/JZB0\$S#4X1?
=>)Y11":T>SUF3^?F4XP\$ZB@1UDK%1<5_MWH_1(+_C1.P+SZ_1U1=^+>CZZZX9U/H1@?_G5QXWY7EXL^1?1J1B194)
M_5J1^%1ABW1*G?1HQ#W31F0L7K#5S^5:U@_PV4E&61X_M#5E7G183PXFFUIC1XYZ:AC3:1N5*\$=%WT61"
(S8U)4U_16TOO>-KU+9GGXM_M=>UPIU(\$O_%AM_+5H)JE@1BC+^MY1;K114P7H^QEVGM(=3(>T5#=-1
M1O@W.8_S:U3\$;UTZ:/DRF_@NLX_JA#D(17L?D#PT_Z(G>N1E1A\$K01;)P8%_MA*2\$LN35)"<"6.)C1PD0):U9

MCB<1VZ4(+.82R;7-XV*B6N%#4BJ/>BMLI6B1OHMG^5-KN=JF-5W\|NNO#D MWN67W7"!9U+^(P4%HE5^5
T'M3C0UI4-AR%#JH;#K@SEK91)W*9H'A4@2!-M X6J?D.*S>F+Y5*\$W3X1ELK1-(9*\$3VZ*&"86EDGV=ZY*
('5<-.W5XHP2UOS M>?E MJF9-J\$1_=-.S?X_.O:H_UO:08_7X2=0S"\$GIE!"/.&>*3875)\$_?ZW
M^R#^1P.CMIZ%7G.^7H&3?QG2QM.PXOZ3LAY013VJMS;&HA(\$*N6@2A(OETI MD)??&.2M;Cf-
JHWZ6BJG>I3PHA&+JWS5JROGZ;|P5/ HOJFZ9JP0E<7I
M%;PITJ.VI:Z!=2IX%:BNJIT)A\$0QIF&TF*HEEP#Z9:GHU/J\$0IS^9*N#*F1F0
MDG.0K/X%|AJVCF35_1"F.0WO&83W6'Q9I'?DCCE?&R&E""5_D1&U|V|* M+P>|QMP.2PY|NW|.*@R.<5D|_Z>
|LYIYA;()DOB0Z'@U M.Q10BR5.QQS;D&|.X"/9/?^W5ERX0INT\$<(0^?WWB73?PW47NA<|E|BPK|C MJQ Z;("J6IX69'?
X*!S8=-.D9E>/P19=QA.32TV>5P=-.I|ZSW_W\$;G=40>GG MPH.%V|S*PI72:|FFI@7/CXW_MU'.IHSW?Z0U|_1#I?
|H|Q21_Z;..QWM/V^M_/^MCG_R9JH"N@OI0AP#WHK4!6Z\$^|D|JT+^T2_K2PH:U|+*S;L|Q\$UC MFI!
|..5;)D^4A6N#OB471B<4=BT5B"P*M@FMGRR;I?G@?|I.Y:9W>|T.O# M|ITU?|E8?|;6A=.838#62;WM;2A0*|I)C7NY.I
(8L<7Y|DC=|H7RXZ;+=E" P4L+5Q@XNL3_2Q% M+P3J\$Z2L4?)*FPUYF3I7BAIY8YX3\$|WOKVXKYKS)VAM?
NVFM?GK&=HSO. MNV-C0!%3;2=EIS.7)X!\$;S:# Y)!&9\$;B'H_7-0*L^Q4T!/?@M*5JXI8@ M|'8JP4037;
QFVML.&97/1SNJ_?+M2WQ+PK42+(H';_F2RB>|I@;=|A|>J#1 M_V)^B/073EV#\$\$)D2("J4L3'U6|@=|R1?
|#365("SR92BGBD#LG#\$Z/A MA3E2Q.P^?;&ID|(S_/H9H;SD9#N=AW+4:C/X%<_3<3RB/)(4.5*^\$_.F6ZWC =
Y8NRD#OQ_JB2@-|J123FHL\$28*C|SSI94.* M(MF*OOFK).B\$('4FG+I^((5=QP+C1W;^8P-PU+SX+2@GPK&AOR#C-
>|UW^X* M!2QRBO_N!2PC|N(9VV=@3AE5E3V=X_UX+GU*K^3P8C"IK3^(
MS4I<3Q=3ZG75#Y/VZ3U_|/O8?7JEI^C&|UEB M>.)OOXJC"-3>#R;.TML+FH.V="R3*W(L3SB|7W5.PS=M*3?
P"#ZXI^O+D=-J M|YI.XR76I7=*(SPF&MSYR)+@AH-P2FO';58T'DFV|H8=5J_Z)YZJ|JON MZE/<*S@BS*O)\$"Z<&;
|IBCQ9;1\$QUA^<5E#9EX6%KSA5L6DRPW+1KUW6I M_VT3Y;|SZ;@KD|38VP^|K.NH;|NG'2JOEM3_40=;VB@*)
|X7|QXUO'B MA|@>SO^|"?J.D(6X7JH*H@;JTA84BT+>'8VE6*6V|'.AJ;&=OBK<.C7L4 MTFI\$|_|.ZAQI
|D);%U'AYL=>I'RI^G\$@LL?_I3(UZ?";|+_|H/2;2;T_<
MXLI_7%=1;BQFI9V_('";YY#;9_H2KDQ)WP'4GFW_\$|03V;U>||K_W@^22^&D MN'GO?0E(A\$>TM@Y*
<+D1<*W52/OISFI5^29UYC=YG;|DN_1VW\$FJ->C;S& MUM@R|<+QG;'IK;.WV.EL#5D5O O-I OJX MVOY'IR?
B+W|P|^C|9N.8"8=Y4<#W.FP6YIU\$_.0=OWFOD>8UG5B-K^+Z7_RWQNI+@9U:OIAWZ?SE X3H'5K=-/R7E.MI
M'B(4T!|'6*Q4&1.M@=-I98=V\$U8/_JHJ)-B.D0-3@'W1 CK\$LO^@^7%=_H M6&9>MS0B+N+IV546Q.Z-
98H|7E&GGE4?2MXX47!^;J.D_V6GD&D72F.D.Y MZKM.*(DO'";%M)%!;RGB|V32K%C%";|QSQ6L_I|SH
M|RB@18JH;|5LXRQ62!%QWX%.*>^QDIN_N\$|_|I05+I2%2<5;DH\$5H#";X1C5_M;8*(6VDC|Q*+Y@;_2Z2@;HGL2-
D';Y7;-MU_*UR2%&_I-J@/OU|U0O) MA|P"R\$>>@HYFP1H.W)#SCD=.A574^B'_6-BZ%S/+P(C(KE8\$/%0E1+4JJB*I
MOG\$M-WS1DC5+V-HZ-^JHB8TW_*4%DRRGVF%LP'Z3G.+G5?5& M'WK_ZI^U:H3>4JG/RQ?G5SX7LUG9G|7W>A-
"A5O|YOAYRBP*"|A%;7&U&AAG334E)M_6_P9C#;+."VJP6^B M-FOW#|@T 2.MJ'=&GC4
HXVO1#8#;T>5B>#|E/&.LWJ*Y_*M;.C=(5U//XZ M ML_*G|HQ##0 M*J.(BR-UM-FGU&K.Q1'2!%)%.G8KQ5!;?
I@|\$LW#AR9HBLB MHSERP|BUH+L|V\$|I"VKC*/E.TVV7@;.)Z06_*P\$MVYJUOCG:>SP?_@DU_2WBY
M;N<1;^2N|GP7>8SR.&'/CBS.R.7.O5HS)HDN\$*PW4%#Y3;2%U;G*';|NC M0|H=86J+?Z\$;S|;MV|\$;1L.SVBX?
CTO;F4CE.R^((N;1<.;3Q1>K)^N?2 MU4|B/P"R;SRI.D|95.YF.^ZF"HU%6;N1D>5S^JUZJ|>1B>3BVZJ7;I=5
M>C(AL;I;U<#)0I_?%V^_.G4G&"-RI#8KB57SR.CA.FPTJE*_.1"!W#IYIZ^ MZP|L"PD AG7M|62.2Z?
32"/NZ9@V2)K^@20&9LW&&RNF>_WLZYN^_*GX_|8 M|#/W2.F24+<42'ZHG(1MQ^P#547JE\$ZJUL^ECI?
74Q^6VVL9U|25P'EK4U M4&+^;6'6(HMZNK5<|4/T7L5S|M_OKEC=UG|M.QDI= MY:B&EX?
R0HJF3.>FX;B46X1.2=2IWMA&(F&*=-8.N.^"L\$?&2L?&C|^HFIZ5! MTC9|BFBQK+!(O;+I
)SVB.XX"!6Z%;CX*#Y@OH;"/NBX|M9E/FS0_.)% MQU.RGC8FWA5C#P.?(R|P4)R7_3E@|G3&1.?(I*?;M|^_*MZ*
Q|3XV|W+|ZU|2WKV=#S(&|G|>|HK@#&G M-ENAJ8R/U#'.=3RXJ5D#Y.RMB"25PX-VYA|V8DJ"!;_Y2&GB2<)JN);D
M|H(MT|)|PO(ZTNTQXC>VYU'^+J|4.&6B|%)4FV\$EQ(&.>."P7X+|A;=2Q.^) MJ9>GNCEQ'D1?0(?^VKML9
KMRG'BC"|_@<=>2WD?R@O_9QE0ZS1J|_|\$T0 MKBB6U.WP1*P65.M=65F5NZT74R^SQ-
SYDFJ>YP_Q|0D-.8X3>W<^I&N%;>IV 7-K_-HP"K+%;-#_3@S8TT6#QZS*%|5F.;-/U0U4+SADESW/M?
YKMM'J^6R;TN1H(3UDZ(MI#Z6!5IMR!=K+BPHDRH#K/KM7TYO6"YK3!5(S
*65S8.8D2N!75A@H5#G8JYFSU^EMP2.X9LXSV396 M(A;F@|4N0'JZ-DYL-.6 BZ;J?)4B4& 1-YS1PHAE6KQMM)I;VN 5-'
(I_)MIQIL_=-18ZG+;;9@88DJF3BW9.D.*O'.J0EY#2MYOQW-E.UC <50"7KE126#_MQ2:QB|PXZ!?
06>#9BMD.8!/O|M_.FUA9LD_Q\$49#"IS?">73?D@JSLZ"&/0/33_6X+AE><@B=|U|TKUY5;U8.7W)X>=TB?
DJ*=\$=S&|+H+7P&/9O5KF*KJ+>? M7APF^U*AP6^*W/RP_-|YBPM;ZJS^U\$".?F^N9C#4S"9E|4V3|7S+*|3;T8 M(?!?
2LD#>R'Y)6=@(Y28E>2AG"MER%@E M3FENYE>.&8B?;L;@JX1S_Z_|\$E+AQ^1+082_00-3VD7D;9_J>ZQ^!AX
MS9='5P# (G';X.72>?0IJU""^5.ZI\$#L6')H213DX"IAQID_#IA#|S4>DV&6 MA>9+34WI5)(/0W4HU;
MY=^|=5QOUTEH.6Z0<;FO2.->-CN|VH'3 K4|)RF*LO4HBOH<7.Z%L0HG;.
MGPZ+*C"9|UY(FW8JN%;K?-.7RKN!%\$P5N! M;229+E?@2A'QZ'#3&#-.+&O|^3X|;77@3X%WX07*|G.D3>1_M&7?
Y%;QHVV M|D)E9>.&#S&K5;Y^%H9#H*AI/<"4B+(MGL+1VSNXVB^4SP#6XL+;=>V;
M"B(4^@\$;/@69:O42>9ITVFD(-;08=K|)K>#|S2H%TS|;=-|@TW-T(LD42@ M5|SI2^?
DMH&PWHJL;#0;)H8D|H7#C2KEH.V|0H7PA&GA5=O2M0<.S|=MRL M;^O/P%?G1U|BHX/F.?U|+K%;G0>?)
H<6_5^D;J;51L-F;#9)GYB& MD;=<KB|YJ^HM@6L+8PJ2P>5X7H.TZ0M8M;/LF.*VU2VGV>);US>72K(I
MZ4CIGYRU& PT@ALT14%.D+J2-WLLT3RGCNCI8\$6^1#IDP>Z;%-WX/G-SG MXIKZL#|I?&LS-
;A|*;1/0??&TB'.@PRO:4R(CT0%- (ODIT46PMD&VG1F.K M6(L+^C?Z/\$L98HFP>K-"|A+--+VO?
6.K^16110'AMIK>EW;)SGRYEK'OA4I(N;4)X.95<&= MJW+X8NB-ID 877!PJ4_07H-|J&-|27T91Q
M"F\$3/G;#2VC9|F|_\$H';CWF?;/_R.#=).IC"S|QX.OPX@31JE^I3 MJD4\$;B?
H;9648E\$>XOL.%/Q5A|U|XJ1>CWP.KJQKBF3KTC.Y>PS=J MKOM.Q;"U>|B|!908-HRCT:T@#081\$<<.&XP+T=%4-
5;+2|7 2F"/|K"WAG M"-3;/(C1#P7E;1KO*|Q>|_W%T'8|TI*|P5(MU>\$R84MB|I|G9I>T*"M_*GW'
BY*S(G.PKTX|HEFZK" F..9?X:4T@QXDT|*E"VX|<)>!6*%>'P_-N MMUR 64B4R;T/?#F7P>GP-LG\$ S?I@D?
1JB'#D(WH|C&N5M=8BIXC;D76&CSH"96)ZJWU#P;88<76(44E1&N
M|P9FWK|(M.W6ZBDO^RYG\$G+A_.R685B5(F2NU*)>\$YB;=(D.6%X5= ?)RAJ M7;T3JGH-C9 (IXM(T*+|0;_V?
AWTM>8@2'AM;2S%2/?"+4/HWP3C^K)'%: MBUHH&HG'+Z8X)2F6.W>5%2KT&-AL@?(C(-I9|RXWR'H0H-
3C!;SIC\$ATJF MS06V R;=<"34"_OU_J*@O54|A)5+D7B4R1,>O5*PNLUG#GS U&AC'^+V# M!7 |U>OF""^2%6.S6|31
"ZNT;H.M*^<R;#ZR;(-_TA#WHGD/N2 MD?|5>-NV/X0?0G9\$QNGFSJ_@MJ0P*XH)UZ-K3|>K?T2^Y-
S@U'HM+UTK@@;H M;9-HH|?;FXT1>=G#6-1ESBJ"! IV)RIETV>?
AG'54|HE#|MRYPBGWOU|JVTQX6J)U*(%)=4/KI6*W%X- M37^C;_9|K@N|YB9V;7E|/KBL|1VJ#<5);=BXF&E*&A?
LRN+N50#1->G|K%VN;|^!KRJMT P|BBM|4A|H;#23X;=|H=?V^G-E)X\$|GK
M23;54*6(<57RD.1FB1N;_|M 1K;)/H|G;A\$V;=|O+&E6R#W6>KE1UK1 M3|MS9Q>I_.PP<&0.VA LB;
5P6^TW;Y|C.B*.CMYT.7>;W1'"3:9QIGW)DO MQH|V)O%OF33U3U;7/FXXY;I&M\$_'P|7@A\$#@'I6>9
M+G&|S6=!'BF26SXX5K6<=N.W%&0B1>890&S;|F;01JPZA4^3GYC_ME6Q7%
(R*)8QX0K|U| ^RIUZMS+/'R'PK69PIV5UJ^G#0;|.XNH-K+@5\$FQ| M;?IU3<;#+=|5CUN5-3|IQOCNR0.M9AZGB!
<.0A6-_\$O">A'00.D+P41L_M%?XF;0#CE+Z\$&OJ.FG(0S|9;BV=9VUD^?&5%KSE0-I4CLF|0TTF%M>087-URU6|
M&70+!4.X+|X@=|G#G=DL4GPTS1WL(-_DAJMRCF"521.YQ?%F3=I"!4Q#;<

M%V2/VY(,##:7"H+;I*W)+@vVU)ULA.>|Y8/7;8IE0D5V0"O2&HT@.\$F2V ML^0H&SS%.X%C3;,M6YG&-
Q6:%Q;PU,7RP>D/GU3=&)."%'ID95Z'#E(AAX?LOCP>65=C\$7V M+<YQ9X\!&E>Q(KL.FIP=P-JXP!%:FQLH ?#VD'
MH;9-B"UC:Z#83KYE'Q>2 W5=%WB^U00UXI."KF'RP6G6.Z-V*Y-D M_19C\$XZG@'9+
|{>4<<6=P#75J0R8N6E!0QR/_ITVD7|JN3|V|CKSCF=>+|J8NLQ14;1*,RU1Z M4D@^()"-
)L(REI8L/QC;D;=H*KZ5MK4I*S+FEK#S<&3R.WG17G)J+BJGL5 M/%L2M=HTAFJ=,AT++R'Z^1U18CN+'\$:
|K\$/WE+>B@Q>|/|/S1^=I-A+AA MGCXIV-144^!AGH.2+EF%-VV5;.TIGAV5/G)!_!0>70^RS%BP(VP&6FF M@3G%|
X84/U?4#>U"O"M>"5DC)F7K-!68">K)J1=8H*GO'PJ^.:IEAY9V V MD7*%L|9OXH.X95\$4MG"AXCGV"W^("J;\$.:6
Tl#"E<D(6Y9X<>|0;3|SY_Q=3|+3Z>;3&<,KZK%DWRVY.HF M&27&;V:F@F=%A@LH1OTC"/!@6&??
TFZ/#R1\$S5;K=7=MT8HA0X'DC.)UC;T48NIST|BTPIQ1W9W|PMTB("M03Q6|7A&E|E"V! M#;C69\$;
(1\,KAX|Q%KL=E/3;^2\$+;%J6WYGX//\$7<9\$C+R

!,:QX00#D)'PU&D C &R2WS6)SWMH@81K'IG2\$YSI3IT84.\$SY MTZB^V-OTI4\@J|/"D+D(XX8)Y
B6KHGUG;LT!;L25S;\$IA/MC?ZUPI/-UP MZS0SZE#(154E;Q5|=G|AGA87_(L8?|D|O>G>5Y)0UFF^3TJK4X7JL.

H@&|R3J*^:D;R&'&F-1PRX>CD#JV@;# MWSRO-9IE1AZM^O+ZGH_2-S:H)<;UO.Y-P\$R%FL#OX-E)6*).95R&/L
7&-GGD.CA/35>K44 MK&FY6 ?0.M2H2'9*|'"|03N0|<->G<=,50P5.-EV=)'|A|N0QM%E|HK*683 M+/%#^3/K)+^,ISB-
ALOQ(|SYPMAFEV;A20AD;61ZF|>8D)\$@;7-C?@..FD\$XY=#JD|ATVON%Q.SBL@U=W4D;1"AG/X&K4RH_B2#Q49
MBYWKp+4|OB*H|W(\$C|Q\$08A3FT-IF7,V|3"W"U2;W|9(4"?J^12;BDA\$6X"W
MW6L|3;ZZUQ'A3UGEK'O+&N<\$=5W+^&KBHN@A2.3;)9.)-R/(@O)<4WGO<<#O MD0!U.&O!0T)CB-U*02;6'=A^&>?
_HWRV|Z8(6<;U33)R;FX|^"FBUJRQ2= M(>+YH;!(HXC&9WZ90H4IY&(\$582>QU=7
/BYE(US%%7811H154G6+^|UX35 MP6P;HB4_2D|0-X8|C7*ND7YC ?(M"XSECT|2.P3*#7Z|4|5-3W/LK4J?;1 M@PV"?
V!#1K+G.@!C+'F4D0"\$Y4>|N9+2B|Y|/?\$F/^!N.@AE9(|\$U?ER M)-;("Y+=FY>W
=\$21\$W&Y6LRQIR;6)9_51T@HOL7_(-Z..?)|V";B|(-GW*.O|EB X78;|U?(Z1H5U) MAN1P|I=OKU!49 SKKEQ6S'4G?
NSI%SL*=JG+|Y<|)CPY|)6_#NOIW;|@<1E8 MGR^@NF= **CRJP|Z|ST; P3|7 MA;R|\$TS1.T=*,>@;(<36W;-
P8@H+E4=O_#;\$^7Q>V93|"MBRC_X|+<|'"|BSV|X|C|H5K_E_+*%3;"L+!&XJ;\$8 G|M6#|I'.1&(D|SHPT9\$;N|W
)**8P8NX)*#&|BG|HUE?>N)^3,S29DSG4+U' MB#4,59+WFH?>LA3K.Q# T^>D-%F|OY"+VLWU^9-
_0PZ3B2"6R|XA>V/\$X-M779QF"|M5RAXOV|N;.C%XW%_F>;Q-ZEEAW#W1TL5E%RVQNNJ1SCSQHT.\$51M
MT5EUNZ|!M#C:"8)|4*LU+/%7_97@9BT%5>-D66CEK35@|QCH;\$F) MO@::EH%T|A ?1HFL&R5+CH1?
C@O)0B5;7&4^6>/,M%)>N3;H9FU*;5>G MJ&>W8A2'OH+?FGQ..^JW>.06|1Q-^F6)BFTN-K91"SMQ XQXU#-L
F.O&\$ZO MF/Al'MNN|9>)C;_J0ZD4+#+"/IM.*X/ERM#(Y
X@HZ&/D&K;#*"VOD6>="N>S.U69<5<&SXB=CS_"HLU@Q_.PC4#3"M M4V&3K>(NW"G)9F|T0-
_6;WM=@LKK=X;#PETXI^~^|O|KQSU^5JKB9D_2|0G
M|>^S7^RO2>_T|V|S7E6CHF0KYSGX@|J|H0UE.26CWQKG2;OZK@NS;YD-&+<3 MY/+7945;)T//5<3@_0^;&S
=)E.SVAP=(^==HC<+|S<^GR-?SQF1NE^N/BD2-M*;*|T7LG)\$..6ATGC)5|E;|719,5*\$KRF-
8@);3V,W=|4<8L"BL#>V;?BA M;UX7RC2I*9KP(MUZ99^GM7YFK.WT/2|'1\$;JXSQF0S\, ZJ4'FU%<&150>UF
MRI&H/&H|!&|A KPJ3_.U6EW50."|S|S7|\$|B6#&2<%9;V&-Y#L;DIK69; M.&Y3X\$K|'|+1QO12)5MY|PDU?
*E84R3?|EDLB0G^@H@V.QY4+MH_3GD#F0N; M.F;+0M GTZKY&HKK|P8Z&?2;6YR;1WM|GB;&Z7CJ*4*/#2?5KR|
(U9^4E<ML_C^QLT-|3)&|+=DHW/;8>*;^ELFMCH.YY8@->J,4QF6F&;I=L'4M-E MMQGR#74-#4&?
%G0|)PVMC@FGRP&|X|;\$|QZM+>^1;V-W-8=Y8+BA*#|V MYOOLQ M\$^X C9X&6O%CR+@|"TOYS.MV-62;;#6\$?
MXH4*N|NR-PX2+>0;|;_9;.%B M)^7S8AKX2) C|;P;S;JEI%A;KZ%#616;_JH*/8#?@R;?GRK%A?9\$;RYR&;
M|2JD"N,N#|SHVA|G=|7U,T+|WE(N7/C|*ORPIKQX>6|P^Z7CWV5 M;,>|G|3H|40G;R;|8"L2CL82XZE(M&PYR0.I#HX)
|4|Y@M7RS2/BQ^#QFVJL; MF' UI|I5%::8\$6Q&P+|G|?);|Z@4_\$F @Z;XM1EZ U/|HLO1KZ.|=2DH\$Y0(Z@WJ|OODI=
M955QFI&GT#F_?ZYOCI'6|K;I>S&1;_-=|F|\$Z MQ^*|<10|%I5ZV&DTN; MP|E*\$>W*|/-@UGOS;IGEUNVL"?
0J\$S4(9L8FI3>2025G7V429|23|*8DH8' M7\$;2%>;,|L>D;K=URF41SJ^XC?J7N^C9YW-1\$ M|MY WV"R|G;;
(7925XQ@/>|BQHH.=*)US GOE^?C8=,Q9XL"1W;1 H|VDR M-4@WSHSW +<|;EED?
LN%X%4MP\$S4>|;4NL;>ENN(HH'V|JE9M M&|G#ZI2?*"W-*70JNF)6;X|RS2R+|95_-N(37D,0/?GPC !ZV|(|=UHUT7
MKAPQR2;B*QA" N(7*JRF|;2%NO *7@ =:|9;M=,5PT9&GX B7=IMZL7=;9RD9 M;
IQW9R/0FXS>QQ4Y&BK9>0ZC;3.M1MC4&YN#HJC0IE#D7|9|0)DB/9|4)C0\$ M*QABLF"D0|E;6/RB3VPPS=
<6ZPO|JH#2V2E|;Q35P0K9TB/K"BRNGI0;G>|* M%P7.=+=IU25^BL+K-MG|4|POM8Y>X_25VO2=:0?;DX;
|&XZ2A/^!68" M1VP%=9*1XZ|K9&KK@A">WCG|OG;"@N70MC)A8^?AAA^8A@YGW3;|T+=4A0W_|.@E*99?45
M#9,M'|HCM|3>?ZF&4|4;N2ON8,S1|CRD7?H-;JLE|AXC R0\$|_4#KI.0R4F M "(>*UD/3"X,RM)\FEPF-AGXFN;
*;;=S17B-LYS.Q.FAL"JIV_-H-/K4 ML+9>CGFJ|06LA;=@N;0=(?_0NH;Z|BO|T MV;5RN-
\$HBEMB5FYY|FV(F1QZH'34=J2-V|I^A@|KE.NFJO|Z"^R!|XCWF R""*|.ZJ;9%50=JP);>KT=40(O;80)GO+P(H>?
LIA.Q|5GA M;^CE^/E)|9HS|6&EM@C)|YW7>|UP|+/%M\$|TH_ =3H?W;@&3,<51IKREA@!V2PIY9F4 M\$8K*DV?
D+8|AGE'Z;50!%2K(98|L6;R)@^6 M'V7@|@NW>'DQMGW6+TA0HX|.6UW<-#1@;|LA+S%MPOS@1.&1C?3?TZ>=
M)80^KN|>+QOY;3R8TNQS|M|^;GO;9E26&4B7KGL+RQX;2'38WGFCZ^GOO
MT%38RY0B+L* NZT>GJ0S.E20+SR_(D5TW1>K+^#SU|("5G\$8I533JR>=(^|J%2BH@|F(E,9(T|A^R|9@Q
M2;J0N\$2LH>9+7OPM0GVZC"_|7<*"V(\$>C5A7|6\$5J"OQ&-;7!%Y"7O^3UX_M67QL%(I7J^B;P^8-
ET=ZCSGR==0TE'1'|"1Z;27OS KQK?|2AA4=*N.FW% M@(|ZH16I"#K\$Y^V|G;=>=\$9?5M06&^%!)
|D/X_*|J>K;@WRV),Z"TH-KX& M^3(8>V88TY@3|_ ^603|/K(9;_V2|V.D-5L=(7C\$#JP4H^9ER(L' ^M;|PI>-%?
2T|N%;A3WXA8HOSL?_P18')#2\$9P M-5-TB=|A^5#-H&)G\$VHLUYL;DAK#8&C.3-NZ^ALD_ J5S|8|NI7&E3D>
MGMW&|<+ER_F>XT?VTO@MEZ|VJ2(KR|Y0BT6|V%" 6550|3;,"C=6U9S\$(& MF"B;|!&H*SV|RMWRLN#|V)BF=)
|N-X3|X=3B>72VNN7;D>TDZ|N,HU;|7O!&Y0\$?L|^&^&\$@S4Z@O1>2W2#)8@AU;
M%>H7+SNQI>DB3HJPBQ\$94WF'R'I2Q\$Q#@REXD3|I"B5G"LE21.L^8%J*N-^MY=YC^;)O2A&*W2),Z "TMI/U#F?
9^*VLM12AU"U2D2+ZN)1N//@G7HU_6D1 M8ZE5I-KP:D&\$AJ?
W)4A>%&P8GTCC;IUKCI(M3|OYJ|OJ4|4;/CEN"H+;C%5 M9\$CMJX1ZZ;_?9COUBR4^EU.#6VP5F;VCC&(!AZ5?
NH57015"TO|L.S5@+|KP M|A7MO6=<4U0).I=|_331|\$XB.HFIO)TE*G#"T:T|+H?FIKZB^A\$A8>R
MXU(\$_ZJP\$J|U1=KI(AX&2|;BLB;QW+KJ1>H*VC3T2_I8K,"UU**!_JH|N MAE|3OUYB5%K4A8CIY;"|2+\$6P0=?
0\$G>/6;7%&|YR\$GJU%*\$%O6V8?_04M4#KZVJ M|;+QYASE=^0U@L+;YTYMEY-R@H;/5NCKAL<|D#WU>2#KLG^
M_DY#D/B1&|P6SEB3=A7F-Y)GNH=8PF/@_X"6&97*PX|9|W1F6@;ZU M;,&D4%3|POPX-
_2ZL@LCY;8;HJ&DN4RVA+=1F)8;P+|HW8H+1^>\$LBWS? M1&<36WCS98;_Y'
N/Q|@@P;+BV>Y2"VR9S|ZK<"SK78%'XW69FX"C?/6G80 M4EEL;L6/FQ*<8AH,D+=%!
(67=&L7K<|66+LWG"DG2|"_Y091G)Z)PTZ4|6;@?D-CE<;K|IRM-1F#;M/OUGL=7^| MJ-6/>+Q*
<10C"O(N*18T75@&|KM|?24JY1O\@=J/EUQ+BB)W'DP+5X6OZ- MP<)KWLBY^?
W&H|3|@F|>I=9A)3\$V==75F;>7Z42|AP"%4=|T=;# +U(^ ME2*(#+9L.TJ-1>#2H%A)TOGH|Z)|7F+W8;&"
(+4MTWMG;@0|(A\$=B|9F|++ MD4<%^7.9G'7E;\$^E6?N>|ZXV|R8NST6_>|F|G|28CQDB^F8I8JK6*GVY
M0|0R)74C_*06FEYNI>I%PY56/P>&5U"6J|;#;RV\$57RQ|V64*/3=|0/O*"1"Y|4;* MX#J3L9|?FNS>L0;
G#/?0\$%OTL7|/H1;-%QAVMP64=WPVEA;=PTUVC)>W MGR3M&+I7=|B|<5;E|HM49_076WST^
;>R59;ZM,*^K.SJ|E026#)8;)-J' MNBE+L2KGF;0A=+!SNE>5VFO|/?V<^%ZJ=\$G&C|AK

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|I1FYT+IP* >(L*I\$M\$QM(BLB_T^57I6.L\IT-3VIW2<^"RP??8LEI\$0> M:@!I>-CUH&NSH8!M.OT5SBL+,%Z.IV\$+_8F-OH7X=,(4W MAE/VY(QU\$GG&B.LGZR3UK_M5Z_2(8VN%9I_ ^=MS7#>;8SEOQ%_FL)QJD'E)^<^I+X"/OX&"RP_#HY;D?C96J+=<76 MV//I_IHTY;O<XNWK\$YPH=IL6#4D0WD5>4&CJXY26G5F5QGZ0,U\$8U.D6 M&5_P=B7MA0<#&Y>#@YO+K4J=^J- W;K7V.#3IA0=-"TN.SFU^/3_?WV^>S3LZ_M_2D)_5^DIA>YB_ %N233\$"6R'Y;UOL*#=:R4'_F-(I)>P7BH=0^>2DWT M7B.@Q5U15>6PVK&UWUUY8&2;OIU"W<*B'!6O<I5OT*>,O;G/IA93"=UPLK9 M'S4ZV1PPE!*/W@EH3G7&H(500G; (?75&P"8&CEA(%?S/P|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s:ROK*^L I>&DB4NI+Z%-T2I\W;B@I\$EYXF4.M0LWPM4T+%U M56XG>VW2XO8GM@_H>TID9#WO\AXYOBIXY\$BYI?C:9;59/TZ=FE# MAUA/U3[WQWHL_?J#KTWS)Z?

I>_)+LOAG_6(6\$9I(3XO.GYL!&AHZ!S/9M MER79<*,OT)F)=J!RHORTC4=*&#HYP04J_*!6\$K*F^Y.&&@6K0_:=0?
D>(?H.[2#?<*&AA918JX?6?AZ5XHVSQPF"TRHBI MOWV+!Z"0_P'X9IPG:TJM(?1M>_PX>^=G0UR.:@OE.:%Q
M!GPEY07J)@2-BQEJ.:4P1O&)P+#+D5!"4K0_@IA/L69J_!^!H.Q9VP4T!>A68 MSU!5?*_
MR/M&4D8*9S,))>_GJAWBH2V@EU+E//P.VG072F#94VJ_U@*MIX&GO!P% M&\$QSI!:=!)X1K#_MJF-
_!VJVO06:HHI=-=0#7.1-T"UO_HHV1YA@NT3""IQW%=15>+D<8K7AZ@A3 M1*N5H1SS!2?<
27.R29T"G&FF1<=OU3.WBS!+/_LK!TJV=;X@SS"75!67F8 M76ED(L(NSX>10/T!K;:"?D-D!PX;_%A8.F%XFGT_FKV
TL)%L-"09CM#YW+_!D1>^C"Q%G M0!1F E J)T:Y'/TDA.(E5VD=>&&AN6U\$ N8\$ULU2(E#+/EP/YR\$X>%3YG&=
M;_MIB'JR5V(!*1?KJ%&QJ"?C.#HNIT8C#71.9X)H;U!H/G9RL".UIA01GOK)I\$
M1ND#77G^=/CKK_7#PI^WUHS<4+N;-4X980 J:1HK=<;BB' MO!_9'=N!^\$LHW0(V#;)X_L.R!2I5_#
H@Y&NTOC9R3?2L;8[KI4R>NW8 ML>6;_U_E05 PN(#""RM@7^"N0BJ0G900EEGGA('YV?7<;&[#Q@&.)6SZFJ(+
M<3^<_NFMA8S1=T#P!T^!U:Z<%E>IEGUC*KRKGO1(28)DWO?79!4A+8!"@ MDV!L!\$9\$K@L#H-OH;P+E!
<"G'_5^V ETK@/F1/7L.L!P!E#C/IE_03DXA^M\$^!AO\$=5YB!&JCWH!5!3@C507YU!>!/M'V@U_47K7;N%~UT,CJ
M->(2?#H<^%LQ9;(1/"B@-K"!"*%U!^K.2RX!1ZLFZJG_*?1UNU#RR!8H\$8 MN:T #.^E=/5VR@T_YBZF<<
0KI207&QV?8Z+52>T^OAD;@4*!8F*9U/9Z MG+X564L!A(Z,H\$O)X TUGKEV!2TJ4"6=2.9*BYC_6SBR@4KE:U_*\$
TP MOR_-86L/93_Z5CR=S=80)_ED0?U_S!61Q_T6KPD%V4J(U*\$%_0M%IA^BC.P MI;_":!%K@SN!D7WOS)B!-D:LM1!"4-
G#2@N+KTXCN@4C+ZZJLM*M"MI;WPI M=&NOA! KYXN?!.667SRM;/_=:LV!52RKN_*>C4>Z'WC5,WB%9.%[A!-M_#
M3/GHP*8VJ2L"(1AP;\$KFLW5ZYFIW##"D+E!?'&WTXG1DV9ACUXC@E2)_FH M#""//_%
020_9PND4^*0T!M!)D%>23V99I(AY*GK!&%MJ5WS=7ICM4?U5*^!-.08C-IH5!P4;A MITB!_1-HO%^JW%?
12/CC39W_-0K4E??>)%V/Z&40;V!@S2UA_JH!F15+! M#^-8LQY8JPKJ!4(SVYHQ?B JS-
_98FO(X6!\$+3"*S4R5(L)N28!EKBX4A!TSAGHNE6;><+V""!Z'C.S=HM MZ7NM JU?<
UHW5GO!T)J3N2V;+&T==;C:W9M0>&9M_43'K!-I[W#ZJ6N8#<2UP\$!9W) ^RVEGL6E+;JB3QM>A.2!H8?
7'_M*!<&QHR\$R)\$- XX6 M4HPF*=%3+T1)U@Q48P!E^?>'Q!OZ!;+>!--Q84+D8+R=<.3&PW>!1X2IMRS!
M_!R1J!95K";FG4;_J382?X59'4EZ?)Q*&ZD@_9=%#<>J.W1*!LWXX?0!@J@
MBZ4PA*BC4UZ=X+G!H_GMW)73(O%>FFK!H(OIRS"5@JHR*GIH"E@3RL?^_QB)M;_7>W;_!^?A=*+!00)(C"Y!U)LIX9D
:5#*IC\$-_0H@T5 MO!AK_G@T!&WED3#FCWMN&'6!W8Y6/_U(F_MLOU+A_.X9Z_24FE/I^_M'T:TN
)*OD;_K41\$T&@9Q!L&2;U@R)!3;G_TP.C#;W2"1T64U_-=8PC8@80
MMDXA.YTM!1TPE.C"D).1\$9LKDW3LM\$>C33SLDHJ1!\$>T?E9*;"9Q+W1NC? MIH\$36_<[8I3EBJ/P!FY'F;6+
(8^4J_#0VA5;3>@KFH!K9X^B-EE!/*;U*2_M_!U;@C;3J.6BIVSTM4M)!C2*HUO^";NYPYX)E=#J-S53JRT;_D-J?AJ.
M%G37_V3A(\$_.RCK9+*JK!1^GBJGI\$NR\$-4I(7P.75<1J/_8_.ZS8!5B;2I_ M7SF9^T%F)/E"0+AK%3\$HJ-
0+FB!L(\$_!N3F5.B(9UV)8S'SXQ9!H\$2<1 M3S6/V_RO_PGXX^M3+?DF4Q@LH)ZU(5CAM8";@A9K/_
!W5ACXCWE08A^!V"N MRP*3A3&FE.%H93/6!E;KI4988!8(NG X;_<3.5!XTP@2F!7@G4I/74!_!+!LWRI M\$>C%1W+?
+)X++KF\$<[K'>L6_3G&#ZFN5RM^IDKL53R!\$KV6RMNF\$F)F.A*\$ M;H@4X!-
%E!CI#OH!BB+KTS5>FOY:P29JU20.5#VXB40H_YU8H!GU\$;:;#=#!%G) LK5_M5WD!OHHMH\$Y.JV@9**6>*2.=WRLJ
(ETJM9E3;LP @Q!-(V"6;M:*+ _B!L M(%;Z:B5V=(-H)(OFNMK&=%JZ\$9GV*JO^Y5?VE_\$!B^Z+9?79^MT3'YA?>+>
M!XXQBA642ISV#_D&IT=M!19%)#8;>82Z@_!L*AU02_ZD!HJ2P^V;_&8%2_KD(MR9!8>QW#KIM?
Q!OZY<-6A!LW>6QN=[5X!Z!YR_*J_B!E0T&OI;_&96/F\$SC1 MIPEGU#?H!#T;I>N_ M"9X.V50^VO.XQF.#JB6FGL
<^=X31E4;B;+D@FJJE2!P2.SBH35@#1#ZZ;0P MKX!DD-A5
@ (7P'CP.L=H*#=#J!J!FY_E@!T.MAN&9\$!LH!C""OK<+V=1=#F"3 M2TFT8^"K)B*9"QV."6MH=2?>)E,14'%!6%SG4H@=
(V5!Y@Q9.^TXU_!09N4 MV!EP51@_!J!AQRUP;_6!JW0+MM%#)9)HPS;IU^0BE<_UO6?QR7;Q3+4)_=YUC_
MX;_MDJW/W55U;Z?G6HRRV3R%8XF058-OJ_W3!/_FJ^G!U\$%5X^=>1NJ M7T4XX74L5?<74.I(3HS^)Z;
(MRNI0TXY\$@2'DX@*@DOUCJN\$?_7K; MW\$-B10\$^*)D%!(X=R)2*:@W/*J)&FN JB'^J%XZKA0^R!9P<49M!0\$K=<2/\$
M&=I"^(;P+!#9M!MJB>FC(\$RC;_>0A_.ST!3RN5D3!AJ\$?63>Z6B,T!RG
M&P0!%&J_0+Z28_@?;P'+7Z;K;_1EWIP_U_!1-16!JY"5A8"IC;4<"AF? M-X0BJ&T^B^D;0S!MO+G_4_1,4JP?9"
&KV!5S*!P6P%ZCFH(2!LBXY MNI>.^S51TUHT)>NM6^OK_H=5);&GMWV@=T!7 F;_ 'P_M' _H++K=,(P!FQ.R*"L'R1Y
?G_ _N!CT)>1HMHP!0*E"#D;D_*J#8PW4 M?*P13TZ^M#!>VW)HE*LSP3%YTAMWK#<@B MP0;8B&21_1CQ-
T29)ENT;^G;)/^2<6-[C31K1NPJ^!EI/O(\$K^HMY_-SL MI;_!6;8!\$B*P2%E;+;Z;.65 =N@ZSYN!MCJ+GA!U0C MW3?
>!O!PH_!WCQ<@7;_N\$T_VPN;Z>)&(>/_V>4NGQ3J.WV7TN^WIUKR/_+ MBI+!H2C"?
0^3OXO&V/N!C^!IE6'Z>N!ZHE&*5-B^!H3L_-Z^9FTI2A\$!X MV1?.\$?8+U7.27WJ/UCIYU)1%>85!^_ZRUHQ?<
3G285CJG?WD>?KSI6!W! M?0_11Z?WV;_Z=/FRG9U!>!=MJGVWJZDFX_F5IV;FW)T!2H I9;E/SS!GHK" MHB;8=8-
/A0BYO<%HJB;FIVE8;_9E CD'QB?_ZM;C ADJGZ!0MU1.2%3W MONRTD59'Z2<=UI3";+UJFTUZ! M1?*<?
SS9YVXYIY0%.6:QY_2CUU!6!U7Y47Q4IOX=PF!O A(NYL Y3!8(MVX7\$
M90!PXA+.^=Y_=_;ZH;7S!6";M4OK\$V*M_/TWG6PX-M+;AMX<4!D/DJ!>X M0/Y\$ EMN?
94;_@RA;JN;NCLK!D>G9=FFDIW<;SUQK;9?XFZU!;IQ!1_&%E@_MIFC=LBTZ(4GL!SCO(B!HZODDWW42P+V"
<0^KUQ!^!Y;H8LG^6.\$70H CB M;0#MW?CF06>_N_*!77PI(@F_O_GAQ;53L6ZQP;_""A%RIO;KX6MRUM R<J
M@!J;_@8J++!>FWH5^0LQ!^;_!O>%(HBCA) AIT1^ODKQOY5SIOE6H^MUIGY MC!%Y^!^?<
Y).904\$P*_!H70B!%I#P;@Z4.SPMS6_#;)/0:T2ZVS.9NAB M&7F3;JE!FZDB3T8 M;)/^17-QY#SA_!#<
!/_A/N5<!)KR@&8M\$S;BS9D@54FDB!LXXE4?;!#I MUOM!H1D7_#I=;K_38=7L_.\$ZKAZQ^Q_8/SJ7
QM(\$&A&BHF)!E8_-S(O_!25 M6#V4\$%_*&SB!X"1#MHYX-2BW2V4&JO.8IV%_3@OG_!O7NL4V\$9"+/M;#""0G
M%J^*D#%!Y?BWTWY^!V!F;_5!7)KEQ MX^Y!X74_KBXM!4=M0V_H;O.0L;5*FM!06%1UB MT_C5@*MAZ3J;?C+
(EU>X MKKTLGM;=)A L>(%5!86_Y5(KG9#OZ=Q!OU M\$=A%). "S5190J_?>;KA;#3I5GCH!4QF MXG3;
!VTG;X;F!12!+>LK*XA_GW\$@19H<*7EI\$1@;_,\$%?G0#JVN5JE_XIC M!=[&GP"+9%8HTE;SH)R>5TU7Y)\$Y!FRV!JS-
8!MNOC1<-GA&ZE7A3%71V*IR=B<&J!D6_RW3&XD-ZF!Q&_!JXE/5"RC@;#4KG5H7/R66\$=# MAB-
)!L;_J9<3<4!9J3K02;-NX&K&7;)%SX<^2Q;MZLQC1ZH-7T.74U?HOQ2 M9%;#@!E'YBUBO6("!.IEDB+&SDC;\$P==
WR*SOA5G>_9B;7+DU!YS3I=M M3QBX_NF#&A)2^K!7&@5N;7'Z!\$5P\$_.W"L=5E2QO_DBY@AABN M"(G!H(VL'H1=)
(!P@AKS!>@>BQ_O_X75T3XR,8PFD,5@!/_!>=YZL\$>ZLD M;CYD7;+!&W9)LD=?@_6ZB-?VZ;!%~82Q?<
39NM'8!M<01+4ES7\$!PN7W!BN M\$G2'6BA9;\$E/Q6J!%IS^&6-H.6:A0(3!C&(4!5(ZC!_V!_GK<4!@^!MAM
M'GKE=#\$FD;FEQFOZ;T!^~MF7!@440&?Q)1NFI\$;Q+>O'RF60^Q1S*99)) MI"Y#8;4)!%<
(!)+5JF6+;"NZLA4F"A\$85)RB)PCW;/CA+@TQNSU!>B15H!1%+*W!H3%3VWV;KJ9M#G@S>B+2PJ8U_95OG\$C*PI,K=^
S%(X^E)1#&_!MB_#J.6J!Q!2I#""&\$ME4ZO?P.9.1>J;L%+8Q*F>3B-Z?_.W=BMI,*0)P^B>;4 M;S-\$7B!E+2-
MZ5)WL=AK#NP(2&L!DT4M5H*SXX/LAQTY.\$*XMIE=%TJ@YE
MQ=L3ST99D(6!3';OS9MH!^LT63VK4^~^!T"K)G"JX.P5TE+CR#&S_4XZ>4X(7/
M0GIRC)DP_7'6N_F""S"t">9/GB(WV?>YT7F9>OO=13-'ANXL-6R4AS15XZ
MX7!*)UI_V.T_O^>_*U%#_MWRG!IKRC;O^/AM9ER4E!R2UGO;N9 MCI!@HEL'A'O.V.70E52QFR;^_*3&5LH).1=
H3\$^VN_9/EQ MP"KS/FFPW?!"S/"NB;_L!H!BD3HY XU=D.I*M?IYY5GGITI^W)UIKODT#SA MYV5KO7Y>OF=F
+4_B2MP^U!Z_R!H.M(!@;=TC_G+PM+YT=GX%7XP0_Y%A M_-D7Y/+0-
)5CP!;ILUTJ!#>2H=1C;/2S7K^0BB!K8BBO,77A65@'_ M;@8,O!HIBWQ MZX?D7Y3WR!3>?A4@THKJ;(Y#Z
BWN_9!6DI74#14UY!#1\$;HH!6%#XJ!-I0!" MZB!72N2A#0;=
!%_36!A30ZKM%;^<3A8W/BZL4180;O7GUH>P%"\$AJK!\$&!"HT9Y\$Z%39_8RG_X1U)4;3NM!U09>0 MGM6_82;Q7^YJ>

<58?2VEI)=\N\$(6?/<@>/<F!H#8>K.X1*ICWKHIFJM&ZFf/6\$79!Q*HXHM M'H MD7?
**40T9LP5.EZ.!MF9L16.U9WAM=""SZ4D6_S2_M*%WGD'==VCUE'U86EL'7.L?")S_G8QLM.-M>"NOY?GMZY%"CX#
/UEO+5XC\A8JYW^+V?I.*?F_OY MF7\$"#6HD10^WI-X'FU*>[8=?0XV"VBUB1\YXNK/BQZ0J:W?5(*!N)@YID?#
M=N14ZR\$3#W*WPH::=K#E+,(B2)S16F\$.WD14/H^@.\$E9#V8/M-Z#ID@^95(L
MOXLQ(MRBX>=9@M)XNC@!T@3^J>J7M685G.G226D!901&7114EIT8V0HDE M:X(.5+V*UG?
>QAT(9&:/IL2UW7^YHBYOZFO MGOL BNYXOX *GVRZDRAE#CW\I(A?SIC56NOKM")N);?H.YWG1\^T\%YIMW
M/+I\$6CPX^(-HIG3\<64%_VKRN4WINNG57JNN_#7P1:W\XR>/?9U=[F_S
MD\^WTV>BO^KY.G_RVOCQD_&CVU015Y.*#)-X:(;").?96*KE(U?N@G0_M@HTD&)30)=.K%?YJ-\$5>44)E0M'GI
FJUS#&!\LJ8D1\<2D\HS(99IZ_M,2L"WCA%5TT8#&8OYV\LR(+.A=%56%2\$;R47 MH94H\0M7+-JK22@F**E?[@V!
:U!T%UUI>B8?P+J#;MT&DH^P/KT7H%-+J0_X"RMF700/Z&5..JY1UW+UO.H\PKHJ/4:X_1N7%MP4BT*
M;+4%P"LV4&?"?BUO!OZ+!W"X&HJV/33L80@OY5N@A0KRA\DR M,3J5&HY/9ZPCGY2^B7.G#BT?I&_J4E2.)H(?
Q=?J0H\+Y+1RLUK3*_M/JID\XW2I6?MRH8+Q\$!6IC@'K_ZG580+7W+JEF.WE+;?7_JDWBH.CONX/'%E#;_?10 M?
DYR<<^BA..? QH@8%9KU(27DZ^33HXYZXO+*B*.YBAIUTOE*GJHKH?_J0(M.EI)>=\$YW8IQOM#U<LUZ0W6#0-
WD>?>A&^<@%S#DQG.WYOA:A=K?S*\$ MB\>+QG\8IW]=&P5CQ(!LV_M_U5O^IE5L.RO(ES&6I5<7?5L%JOP.*
(FWGZ8F+J&Z;LT@VO8_ZG:APIDY4 M@%)0X25U+CEW&!W?X+0DA:GIE:4_9B\!/"2/JN>W4'7M5@OH#8+-2I
M9674<BV2\$A_I98R.('&-90LISH@YMHF7W;A&V\;M_*2VJEL,@0-TJ0KJWAI%&%XWJ#
(EC<.83%=UC45@OZVQIB\$@I\$2*?DB?PHV)&A/MZ)"7IUP4NSF"?+;#;-TUBI!*1QP3.PI'CM(A:0EA)
(+02T8X#469.M7#0QK7@?B;-)EMKPC:03;\$@+8_OISP4LWZ?^8^K3.YOT=#XBY7>H\H9
M9?IKU.^%Z\A^K*OC0&XX3)-!"I4"W)(JSP14/40=RD0).0UVJ>E!G0X MB47B=2IC.>I2Z:F/@.PLJ3 RW!\$IP:Y"
03XV19^E\$J.9U\PTIS'Y.R_8 M_ZY6ODX_J&UMVHR2ZIV9QNHD)X_VS9UI\$0E&6?W>(!+P.8LGK;JT8&Q
MSM%+BDX.(%YOM!73M2=%I>%=!UH0WYC_6I9A.H\$HL>RWD)\4BKQ"+M667 ME'J9L*K6N5;4J8J+.%E0&5PG-
C+I(:(D29UY4IN\3-ZPRK-\$XH'\$C1)P1 MV0*(Y2V@5I+W WAIR\$%/R BA ZA\EC#@J.(ORB'F.^K\$S-EJ2PL%I%GK6
MJ<9,<98&N9P%7KT)J*+%Z6\$;O\MMN2_38+RD?N_#(F+!6C)&F8W=#IGZ_M P6D0TCC*^DL)JH,7E'\$WBSG'_5
MOYVAV6(177T9,2JY&RH1&9&CJE_XBKT\$6A1(U@7"+4L?G45L;7;V_RRZ0YGYR MUC_YKGHL5X^I>E9Y-
+I>\$K6CSP1I28.W\3\17G.NR'C)JLR MC&=KRNB?UD\I6Q@P5E\$P^8Z_)GU-GFL>OY^"S*#H@Q:H&L?IGIKY_8&5
M9C-M2'J8/9D,1:5X@J-3U,O#W\VMX+!6BJPI918*V7*LRLLHN8M>K9R>H# MU/A/Q2^4YXP&C"Q;.*UARL==8CP*
[ARYA#6]>DVY:X0^@=(1_7EAY)G*OB MA N3Y@XXM3J3I*ACL56+VSE^//@I>;PSU[ENLXM6/%\$*_T!_"%7I:&N
M((S^T&MDV6J('<#3;MJI%WCG84PH64*3^8 T:4U%)"D^O\H\4KB&%=9%I0*
M"XX=,@:K3+Z*%A\I20P4@H.=V+5!F8]=K7X2VKV>+<^JN\H45N&4B^AYR MI/<\$-^<:%SPK7?IWIJ:HMY9>^U-
?,,RNCQW\$7^/+OW1B_=X@K3TW/-J98G M8GLI3VN7I6YKWGX\$RTW\$.?
#J%R=6@Q>+!7REAG)>M"&.DJG*%C#/CEDX1& MPVZ&W>I=HC-
&C\>1M8D2^AKV%F%BR@.@FK9C\VW_P\$>;#PIV#;-%DT?M7/MQVRCR60#F@3R<:@\$W..H4@5I@>N\&ZBT
MXAWUO@>H Z)QO@_E\JH:F5HH)J:4/HE3:P W11N"N(GV">B5H-NFAW)"MN>W3&1KB_XYQH\9JXR.&@W>O\$;55N
MOJOE(^\L=)R=)IV9VP-BJO2QCC MJ>N0G;&Y ME=9DROSUDL^!BLI8A^V\^0MZL_9'#2W*!M;51OUL2SVZF
M=;ICJHUQ^=H^IXIG8P7^G!S57(B3&=ZFS>W8MW\OWI>2GMR87_Z85I3:E<
M5OJR09KC\$5NT<1!Z+RK3@RN&J%X_LN' MZR/"KH/N6HVS/4PGTO&'DT<#IC!!U-(*3FK_KH6R)=;HP_E\$5\$8)LX3_I
M;FZ&LL^ITBZJT@38R2!6\$80\$ %T)+#^W\$_6\$#JZ:(S^<^<\$NE_INZFG6\@B/MT<8&9+^3=;.\$)-MT+7R\!Y-B2JR0X
1ZY08@HWAT(>JW"(G(H%ZTT14C\7(SU;SSN09<1034Z\;UUZ^"6O2?YW5:"6.F*"MR@VF@X4"E=I.F.?#
(RZ04&.T>LP.(VP64T%Y*34ME5Y+^L76<@I2&@B^ZIL M?XIR@.P;2LI50>-
OPI@74U7#W'CBMT62#L@!>+TX&Q/?1^>AG\57;+(M@7?1VJINKA'L9CN\@#)*IV(RR8>"X_D)EZ\<9&%#
(W\$UJ*XP6D0S1I9YEZ MN_#J5!SPUMH AM=Y_N7E8CLC8=K8<^>)8-T+S?>17\$#T52^G+@/O4;0LH MI:~
DAF75,1HEI.PS;1&_.8TH=NYZZ>COFM4&S CD=D@)Y@UH@W)H\ M CAR\XF%B;Z*0TB\QF(6AJX1%K+";
E0GOK\KI2380H0JZU8I=*\$BX:WXZ2 MV*Y92M6.4.O@<EXSK8?6?@?_!&GY'23'071.POK0YU#IA=(2P9WR=-MG3#
M*[W?0LXO7.Q>7Z0B^HT717E-F,DD#B/B8*7H#1*12IWI4 O.J*FZ%J,X1O4' M*M01^V MT81T:4>(0Q^ML\CA1>&.?
Y;2G8VV=8#+PUE8I]\$-W9R7ZGDDG\45E2QH3^UM M(8)SWCCU.&N3(ZOB9FRE&((29=IZ91(PU;N9VVH&G;
I"XPWK;@V@!(#F2 MH>.2/H7%?+N_)4Z/8IG?SBFTAFA/\AJ=^;WB7L#0@?ZL_E+N<<97FB:PJ M&5ZUI\N4T?
1K>NX#2\%^O M\@YW7%_ \$E7I<1I0\$=F=C4I'BZVJMLHJO"W<5\$62JET(0_V2U-MI\I5(3?&
MJ439JA\1\I%A%V:ID*L(X"!EMIY"V^J@.5A68"LN03U82%H?D"DR_6#PI95LI
M\MPMTBD647;10NSHJM(2O^IR4)KS\H5J7#%NZ3TK+0Z71_#5OU_ZH MPU^!3;"ZM8MIS_!H:N YMR!<1 O,P9YG?
R.AB"%"HGI'FL'3^!\$&9E_.MMKP2)U\6HK*Y7I7N"RKGC5XYHL""*8F31D@W\$;X#ID:JPH_74/63X)3V;
M<73YBBBTGH"RR>Q5IO;-' M0_) EN6=+ZJ+R"3T_8=)P'P'"NZ@2UIV*6P@Z_90\4'BPOCD\$K/+D5*18^I M(Y*Y*/U-
I"TLQ;8I^ODA.(K\YN_7T">I IR^L.F11I")FZ3\CI8MHKS@.=6\$6"7&"H_MX3)4(C^%<^R*3W>DD_5DK;
<4FN/GW<9\$@H%?QGR^L_C@R5I"46+*Z\$=9C5_M?GP^!C/YZ\$U(7YIP"8003@;'36U;TAO7\7M=Y\$817AVI:\$IN+J1A
@J=-C1 M5UK'@FAM;S;Z?257R.NYO%\$=2Y78#N124U^#A8G0J=RUH#QR38^+%6W;C.C MDS
\$GY>2.OU/;JH&XGS1DI?I08;5B]?FUR/^ABRAL>2VR1C\$ MK>8.M1%6MS@!?
I\N)\$GG^H2)>\$FK4.O,6H\$S)@<BS5IN/77B(+; '5P5IK MI,V,1K6?MV@0&^W_"LC_>?&C_5LWD+QBX+.@ZCT))RIF
BQ\Z8_+I M?2)O,6D#UC\$IO%TW&^!1:6W+?<90?IC@H(#@.-=F1^C-6L3/?8L&N\$&
M9IUQQH/@C)1WSF"7#IZ<3B\MAQ=3V_QX&G5_XPNWKUVO Y'B"1\H0WPPQ7CQ>#%4I)/MLY-
A_*JU-5N%>.MD#I'6C?J3@TPCXH%<26?4&IB'0\$T'I%G\$5*U1,S^#LI'4T.N@0Z1^2XK),C-
E(I'<7QTMU\&#.9*Y(*BW_M9 A7)*Y65%K"-JK^+2 LH/Z=RY)%BN/D,TH6:0OK#;C6D1T0H9F@&B1H;I6 MDY*?
%KPUV0G>9\$XY@J'ZS/0NP1@9:=4L8QZ,&WL\$N:VG*16H"9.7Y0H..MO\F8I7.Z%_?@IG3W/JD\;6.>#
<%GY1%5J6S\G/Q%ION9MIXUA%Z?K@;1YI M5ZK>5Q+F"E:17LQ3A^FTY6OQ=Z50>9;21C;
(ZH76LKNJ+JF395A.TAD2J MS@<(M3B6HD-BJ2J26VQ4N;%"-&CQ04S^='X!&KR"BS?YPO97;ATHI@KW_*F
MM33AS4)D06Y-TIT4(CV)#S<4TNA0K(3BPG#:#;I")104.>)PI15N9_M89MM*IZ^A'5
_%.3Q5\YJ9F^<DN>;13.9LRJ*K,RR>!5U;+O,E MXT:I^<=EV%W0(7DMR.)EVI=1+BG.-.ES;CQ/9!
D)N6\$.*TX*2Y3_USN)6P_N LN\$:.0+SY^>+N\9X*1%"QEIY%B)F6IG8C\TIL&IWPV+;W3;28@0;I
MC\K_O+FRWUZI.^5;W_IZ_4H*_N.^8OR_KN/OARI@875UF5<[NVY.6K?I=U
M%O=4@0\PA8'Y'8*2'FV#0X\UT.2%4Q*KY_9+)(JVV*EVQX\ M3>ZZAUJJ; A6>IO_E)>6=%YJB\$ZM5\$H)P.2?X:T?IC/?
3*CYB;+,,>O_R3S8/%-G^JJ7NM_Q&759:6W1(WV(F\$+\$<0X*>IQU@S;)IH==:6L
MU%%H\$""H'Q4E14WFLKBR\$J3F_U_XL_5CZ;G_1H\N;F_9_ MGK(5<HXIV\$X;D/HM4I%W-X&K-
MBEU0^U^=TGH\@A'BTkW@Y1%G\$.^!AH)GC_VG\J_-YSMLNH2/3.BB(LW(%U#^TK!6Q;K=W;^U M.(EK?
HULXLR3U9'2GVZXPL^A_U3?TV+;LJ.6J_.7=#+X7=VR9,9V\$ F: MS0^K-)HH+)J%<;3^+W= M2-IVU8-
6D'PNW/9A=5J(WZGB\WG M_Z+LRZ.R.(8UL@<D9=B4J\@IB6@51#(DK"#1&14'6M")0\$@C(E&*1&7?
MI!61A"BLD36B!)0A\$0(2RLBLDL00A(562)5*I\$D"U/QS_I E4.H MW*KIV_-?>K>/7&?N?ICIPC5-
!NR0X^HN%A#8QZEYZ-V7OIM?X32#PB4'7X; MO4OJ-B)*@>G"?!"
(D#O^4X"8GT:"P.%#:OOUT+XA/R*/6W^"WOIS\AJ%U M1!\$<%_<6B0JRYM^9H-
!BLPK_7#;=4(LDT:0>5<,>8:CLL2>GC5>W+HT/M9^!P:QY@62"XY/M)
DIE;^N"LZJ")A'L7\$J\$ _XZ7RZD\$WXIY=51%5%48K\ M\0DL%BN>0AY-PVCAFAH\ZLJSQXYX9Y!S.I?B>??D/2&A\I

IOLHE!#)-I8 M\$3BU,G9MGR)-I897JHRO[ZVE#MBI#J6]*8J#8,(RR(7%JF*2^M,9A!^S;9<MPDJ;I5@S1!&7>
I4!#5;.%B7*3ESQ-Z360*#0J#.)=3#CN0H@-7^UTW)D#Q4 MAER!UJ H1 I:2H81L N<.;5(<'D?DW:HP&+^"24AS:/<#
<I>G>IAX33@QYB-6 MBI10G%?J/ M#TP@D-%I?%WY%5*LR*FZO1/5P&UV->E\$4I*V36W-#8\$7G/I/!#XYJR=IXYYQJ
MJ/F@96NX9M RK^4X^W1G4.TK1,W1^WT\$%S&362ALFAUS41PU2&5.<9.^%S M;I-(2&X0-
S2;+I.V1FB&M=9HY=;@KL*H1WJ>@TCQ!4=9(<OG!2^VBH%2 MP:&ZX8K0\$?Y0QZF@0X3E/Y&Z/PM@/>
AP2"0R#I=TI M8J*65<*3T,L16<+I(7TI\$2Z#!"+U*#HKWE4&#&6JUM/I)<-(?SA-/Z !5! M+L T7;J+L(B37?
+9PLD;Q11HM= /4;.6A,4E>-78=Z"CC,ZU WS??P,Z2F2D'^*RK!<>\$/ZS1Z9>4BT#ZE..HL\$N; MNI"0E,-
HGH/U8L1BV6AX,S;9|<*+&8<I\$%5!0!SUC*3C19W^I6V%5;D58%%K MV_T^QN;I!>^5
76)"Y&.:9EHS08:>0EL+MTYZ#2 ?G8USQ"G+T0Z"%W0R.UXB MWPP^F-IWU@8S-MB;V>>J#3>1PX5;<;M?AAB-^6W
4IOJ&1'1)!UBIBWG5>X MY)Q<I-I!<=^N;OIXBY?/O?E=HG(N^OL/-U9<IQX =^CJ=O'.USMLK^GU
M&+U!0/I<9U/A;H M5;Bx4T\$S;_Q^Y<^3A3C5WS#I/,>_#OV\$@Q>63%|R|\$"9MMG;>I7ZDJ%3Q M
#&@+!Q%#S%XA;Z(<4;9R@5U\$D+Z\$RT6WN2HX^I.G)&I)PM1BI7\$W1W/I/H M(4&#LZ)/IPMY%HE80UP1+
D#W8Y3#S676TJ0NM0V^*3HIXQMP-W%=<7M;22PVYW7RCQ-DS1HB^A!MH+WZX=4.4S?
L=OIE(4T(FJL&5B;+FC2D,I7;# 0_90>5I\$44%(2U) MR>UT5;.%"K/NP>+!.@4J!A4X=01EA@%'D)H>AH.T(P0-
FV'2%!)9U1E) M> QFQ23>#KT+BOQ2)4VN_2ISQK!\$Y,%GRFK?LXC""ZL2T341N;)/J6/AJ*;
M,6#;3U2^"=@3,HI^,HIZ,RS2AE|C#>305H48<0I3^M!^2!S^B-U#U65H7BAIU
N\$0\$L^0>_&*!TG2!W!^6Z;F7D+I>LZH*UZ/MH0E/ T98.F.?.%6"S*6U#^P!OZ%X%NCU%<C70HI?OS\$M_>%_TW?
#MBI0K^MXG504#!>I9-B>M/'1^*!\$!/O13*2OQAHG"KAHIG&9;.\$JH@1.L?&/1 MPN;D41@!DL;OJUS/Z!
ILX)^4X7^M79=!(5M.@R^Q4W79J>SS""#S-M/I ME) 20:2X!5@*
L5HI0506WVYZ0Y)M L+I^F?2\$3;GVIA#J9XO_PY^GPR MR4!\$1&LOVB0 @L:1E O1%'U- V1XG)(V86D9,4.I?
X.@\$#7IC=M5J5D,%N M;BYL&^16)38Q8 =D4LBE#^0J2KDD|I8/H|2ZL2|@,ZY1L+?&0GV_ZBUDJ#
M05(5QB;IW-.%SMAGP\$Z>AJ!/%2EJKBBCP0F.X^BJ=X#JE"HMS4;T|W6Z/, ME?)321|9/\$2:\$LZZ^ID\$,*>E,J94_/J^<-
^F9;.#5)0O9<@/PSO Z5;I'L<< MB2@VW##,F W3!&F!;F|X9P.6-3+5M2)!8:EJ#27Z|=T?<,H4_TSRRM
M^K;CB|ZXN)H?X22;|I9X^+T26SZ57PC%#@U,-HP\$A5;Z;JYMDJ?6*1NW= MFDD|K7"-Y6MQ-
@1>XWGG)+P>6A.)RYBEU9+;+SWN6 OI4R;.&M4?B-P-MV MOX|D\$6NPK#\$?2I U/JH;.)?HOR.H JK5H2\$VX3M&8E-
HEZ7(T!7KY= MCV-3J.4IV79Z\$Z5 OLO\$J<_\$.AU@O9"C&7MYZUU5NCGFW6FIM=%CQ%\$,'@@KB306|=H"/;S
M@_M=O@G/Z%Z;+UEF^W;ID#0?&?@HKI:XL6NE3;81P,U^7KP_3W65VJ*8_82<*MC0ZB|=KN@I\$|?<
Q1A(39_#S6RZ0;.&+1(BM MIZQ\$HYE=#&@NS62NA>|CWQBZ M9XMW P;GC+644_*E)&0D-^KW\$QJ|^\$?
\$RW;*3<|+8;FXI9;2S+5^O? MV"WWQ+DS5@#A0CK&V0N,IG@.2;=H:X+^A"F-32&+<|H(@NAC649;SW5 MQW
+|H>O9("TKF!=OKR2/2 "LA7>)K M+K+;I5Q&FD<%#QO+.K5SB81F*_TL&S5W+G;^2RL>GJ_|R+5RC;X_N3H5 L
MQL6*^A-W@>2KQ?Y;XAWM;T27?;8#G1C(LCB^LOG%X/#.3;PHJS-%J M9Q-M5S_A\$5W5X#SI=G^LD
DRIBUF>A!RDIKHJE==4ZQKO)CRBE98Q> M^X G_I&J-7IE, D%,V&=1MXA, #E|C5PJ"#8@1RE4"?
=13+9XL60;1+N;I31 MR%7CGJ;S!>+I3-I15-D |K;05^+42VBOKNC^88\$H8;KEOKZ9R37+!*)LB2TX MVS)
I29>R@+1_(2,^95,6*40& M+D;(2*IV,4-ZDR2;^B.S%BV!%!"ZFA+Q;Y#J#^5L_I
/I<1>^N8Z;DSOIN55^MOU\$M@6@_PD>_ID48P;I7^3Q
ML;O^US^R\$N46P=\$I^2OT^;3^KX;2D>T@A4K/O;&= M;P=YA0^A^I""T,YI M^74K=3.W(=4_1>S7NBX2,MR/U+OM_?
7K"+0,EWY3GKU0H@@K<8\$P8%DL\$1* M&R14?UWUMIS_L@!M)AFL9 "K3|P6I^OW,1I(EHLZJ#6XM=G4<*.?I_HV?/
M-9IZ"?ONXAN0?/I-@_T_HDTLXS^5?WV\$2SJR9Q@^WLM;23H?7)SN<7 MF2B>FRU6I NST6V ED^6"%+CLJ6;X)!?
&S2A I;4JW@D07#KJ.3@9U=2GW7C|I+GO51DWTP5#"K9LH7I+2;NH M9N^H6Q?
F=RUZBLNNL+J4TT=,VGK@%_X@FB3%MNS9^YT^LP?"&I C3?^S-8 M^TH AU/64BY UF-
USK@U_.,2??/<;H6%IU0SJU;D0R=R#TJ|+ALK@ZR U MPUM_) 1YDI+_MJAOLNT@1W/E+T"R\$7ZC(BA))I@X-
/A4OK0 6E|I4Z>2(Z M(3W_>;\$;WM)ID06M^ YH631(K^I^*64_'\$>"DT^I%""\$;U#^B9H^V M-2I\$S-#1/I_H0
M^RWZ?|HY|YBOY|+;5>JN^DW EO.V#09#@^?29YH+T&HU8/4;AO@Y.)<@A%< M&(PW-T^J);H4P01!^*
%ILJ;M).X^CI D4#<#(\$TISR.W\$=X&B|(0EC IE M/ZG;O4^8\$P#."M.BZFQDU\$ O_-
AD*9(PQE,3D<'FM.9ZZ)\$BW.9XHF,083 M1AVU;7*B2YBN|G2@L4VP0*D#&,+(+38H8I%&S;QIKY(N;4Z);I^BE(^*IQ
M;L)LDZAX28E">L(7(-I%?XZ@C;X(I0.4.UW02IV#;I|^3I.M^0M.6795;P=ZO)K^#I62YX3*5/+(+G+VF7^8G;IKI;Z;
MAM4>;J9H2;JG;J*7P2M/@R^T\$H2H;J^YC;D%(20=I(RYH|E|E).A+3% M/G^J;\$\$\$(F.@KZ)61)/%0H;"J">"CDU<I
AQR/@%QQP;XID>\$"I8;9&RC^<1 MK7,F5^\$.U5Q,N\$SY+ MVD16L81BU3LXJ*BPTA")/KZ#9 LMK4AOI50^I
(EBRO@XSV-#I;WY(9D MCG+DV)KI=(XNS-KW%\$J03<2O=BSYI-46CVD\$FUL1W8;JW06?ZAYB9 MGQ-
JH@_7N2&L#^""^M9Z5PLG7E^4>1BA-%DIS+62>O4I M+J;"01#^GI^X1G,NTQA?BG0N;(H)2)=S^OB;."O/^>AKOR,
(>X|HZY+I(MW8XI7^I%EYN+;\$>X!#XAT/I;E*|72B, +?LF8" MCW2+L1+8+7;."T9;IGD92U5;J<^*K@+D&&^W4
C7;O;ER3= _G;+7JM\$2V<@SC-AQC(JG3?7EC;3H;ML?%E&?>+6I;W, M%RIKOG)+A9.=;79Q^HTM|PV?Y8)=>,&Y^8-
G;VT%UGD)5Y/"">7&(PXFV6GS\$|/7S+Z>W(I-Q0^*""Q*I=83UOP26R=FIX;Y MI@YGRV%N?3"IRIQG?XKZU=
@EH%\$C5V@(+8>FP) 1R-CV%OS%9D^X>%-XO M)L&_C<^C="LR8NL/E,*7O;.W^8KH" QFIS9(G;G=;8;)Z
"YHQ?M293-7 MTR9I\$ MC&)D2*D3@VXR6L)49.G.*7N|IG57 'K66L4CU+WC7-U0X069"C>EUB0!=HD4 M;-
#/3BBWV^8(?(M/#R,5@9*R,F4+1C/ROGA;A^K/LE58T@FAD5Y*/TM#4NV* M=\$4F9;2Q0/G6&."UP2;B430@?<
4%W&I@^94HY8C;L+K)2|B2^F\$M@C#+#&);E5*+1;R2>R&-V.XV54^ M""P4J1PC\$XB^T^PPR9EQ>I^3I0N;?
0V8L2;5@2B=;)+#^VOX_6^MI TYIL(9P.LID32 R-M>9;6>Y;R>8^SA-M03>(+H^ZYM^*JWON1CU&@^4K "SA|Y|D(-
O%4;2_6GU^33IG6!+TE;K?FVX,1#^C+8<(&RSQ";2Q+<4 MAI%,2BK@PM>4;JQ>6PGUTR>"(6#_2,4,Z\$S@F/MZO;
8J^H;ZV).Z#7F4?_M^S\$#TG54L3K@'8H0(&DT|J56;X5I3UM@U#5(K4;.;(@T1=,M3|Q1A|&
<I+IQ+8#E+;=2,/%K84L JSFKA423)O1H>MS;VK_/>=&JOV*1^KXO M^9_369#Q?(2A4@,%H@EXW^X&*-%3@8S?
IDSYEZ|F;E M?%WQ915I@76I/MBF4X-ZX^P!3"2;I6;JH8&S*AROB4DU_Z3R|@5>L)/6I3;
MNARX/VEL!@,V&*/+|RB^5V#S@DKJA!OP!"O_EB8B@B.VF>PRFDVH-WZL(TS'
M.O|ZX,EGYTT+Q|B;*KP"/H/#^O\$(J/I|&#&JY_EV|8D%5YI;C2:F4?="6^1V MZU&NWIH@KM@+_
^V9_T<I\$3P",YD+3B/NIZR|I;DDC;.K\$D6JEH#%|W#^HZ, M="4A6\$WHD0201;YJ2FT50J.GJ^5A@<@QQ%U.R0;.(0//+I
<|W;3WLZCP\$1J MA @%Z26,70^3WF1^NC F2PUC?Y>J\$4I2-0+B;H^I^O?E^TYZDV0Y7R B
M_1PR,2FL^MBZI^P0^I6;V;E3|CLP3B&3(?W?WCZJUDE;I;(7CGX|XV/ M(\$LH3?
EH9^EU(O4IFJEHA(*)2KM>X638D/VZR 1HIOF=Y|OR" _&+>V@; M5!1\$?Q!N^P,ER2%ALIK8-
7;#BD60=+T0*I8+\$5NO>S^9-L;34BI|A8;QIV M.@NG2AF2)*4%Q2^;.<<3BX6=L#-7U>S#(C_/5NKI^LSH;S;J-?
SD+E*#N,9 MRI7I(C^Q2.QR<;5?E>ZP;56C|RA580U&^I^Z)=QWC38U2\$>T0U;2V;N) ML^QZ#49T3I5\$);#>
T;8G|PI03^50WZ3VP12\$\$/WR3\$?O/=5F?#@^OX^R%1U MI|30<=>(C4%N;Q\$6YZ@M#/&S+XX^W?_8/70
G=#;1^33GB=I0<#&;E;A/OH^ M12D1WA>)22;I^F0C/QB&I0G657(JT&6BC^U%U_@CJ!X\$UB^HNP".5FIG
MJ#KLJ>@DB7*MHND#F.R;ZIF%NS.R ODYV\$54TMKA@FCN3&9C45.U)BOJN@Y5 M T^X _>A_B3&N8#/SN-
4#=#MC&/6+I5!7FKR#0(5G4T7H^4%SZ,D&X M7<<I&;^G-Z,E-/#P3RZL;B5P\$+^AKWZ)}@*A|H>|IUY3W(Z?
HQ4(-WRD>L^I
MP&85IP6POQ38%RCNK*8^C|B=5.RX9+B(12;0\$84(M(I|^7|C?I^R5R5400QFO\$9^J9;1CS""J.OI@#T00RX^0;#?|B#(+,
I2B<MPI^L;0LFV^X!^*!^I-^AV^X)% U.(C-3=X(^ZRYV?@A5V#R*&J_#A M
^I1@HXB%^K8@Q0_YRLBTK_>QX+V=MS3/QIV^0;8L="1E^*ZM/_3_YL@^I_M;I;C-(SHGTK.N^W4,O

..FIH7H123YK|T7.PV|B+YSL*N0JP63|B:V"*K5 M6DE&I~"\$MN90#2V2>50S@F3P-GWE' MJ2N.L~!L,F?
=/I%|-. HHMC|O5O6 M'=PWA|MDMO|ZL+\$.1L#|G.PK38#LK.T7|UI@9.90I6&A<8N@MJX#|P\$?0=
MPC@3TM6SJV.FP6|O.6CLU+)."S_H*U*4QKNS.A(SG|MR-F8D?)1.12P2PX M.7#M3T19|&UFRZ_KX%!9?V?
3YR8Y89V_&J_PD\$F|TH.EK)\$(P"?SJ| <WJ#MI
M+5)F&+WHA_006|IN.D8R)P|T.9LI0R|@(&?B90ADI6U20VID@GKHI@7TO ME.&TZRY_7@OJQ9\$J 8<\$711C5)/M/E
.\$9/>:1@|JH4+W%S M4PG-#/2\$1CAT%OS3AC"JX|L|P=>.&B@?LXW&+%V-T|C"HBSWMC=PXV|<N
M9OZ&L|\$M+N%1L@!EKWYJ1.6KBIW)0|K2;H|OM|")J1Z;?R(Z#B^|H9?;D M#-XKFSU(<(VA(|9*9QJ=I+J|.*D,J)
|G2,3J-H;ZM;) =E=.AY0=^@U/+MIT)R6A|6A=|73A>0|(-J|KY2*Y.*6C|H"12*ZR)BR?X)ED|(62|K&P54T"K M8&E|.*0|?
5^<NE>YU\$OQ1,44.,+D.TJGO|E/EAMSUIR.Y*VR5JE4:UY)X;E M;MTOCHT6M?^1FO'3G:T(YQB+|L.W."(1|O=7Z|?
BU|E*LB"L<+GX&<0E(G MY/\$2NF%8;1+,,?2\$1_!:=B47X9H'7|+V49_9+1A.|^4|:9 M-*BW.\$*US%|G:|*NR4
"GL0AHM:U|NO|O/4D2I&@CD?;_7NZH.>5JW%)JB? M|JN&1+SV#;ZR!
"&6\$TC1\$8%|MZJ|=-JM/E\$YWSQ\$M;S*_/U+V78 MMER>;8N.F#TULB-MTT)Z\$^87.7:4JP.
|M%RAI"BW:4%C3+E)ST4DF0%A M,\$N.U0S5V6|-\$?>ALQ3ZJU\$=/U@#@9*G|Z=KI7OQ6:NZ1|OR&B9W8G8P8
MT>6IXCM+I?^OX.F?MD|*UT@QC",Q3&A>J\$ W#S3.8!Z?TEG;Q2; LP3W;6)|VXP% MX2;K-
C4QPA0|.00)&TE+O6(J0|H&FVQ+>0^~#O;^)|/MC6@,T,4|+;Y.^@GY|O%1E(>FIK|\$_J07N7|?SAG:<4*N
MNW.Y25UE(^<6=TC:JTC|HUIW9_|^VI/(A10GAXUHZZ\$*1&1#.TQ6|QJ4*.U(=
MITO&1U(NB8V5%Z*5ZHCS^JM).N91Y>)(H7HJ(EYU\$Y:INJ\$2|L=GOW6C|7C MH5<5O|.+WSB_?
\$!_ILG91>6EYDOGM6L|)=+S,.)K_@/4W|Z>9|B|H|ZWO| MYN.^1<==3"U,M9B>=I*/(WD)F:E=E9CR=@M%QOV?
_WASO'4.HRF\$OOJL|M)T|?7Q5=3%XY\$ASA<,>|D|CN|J.X#?=Y=J#FS@-/<*1Y|!AP<9|!R7|F%ED.DWEY;I\$|8C)
|0K|_DQ.6\$0|9@T62|I*|165(HV_9 M&"N.PQN\$\$(16.9:1UE%)!&A.7\$FJDIU*<#L2|E399JU-JW)8 M^~"ITN^&N14E_!A-
|W1UTUO-1.6P_O.=4=2=<9US.Z3>|?&|LOLO.CDB M|T(F4| SPVKM24G^CZSDK\$8)1&-MU%ND.|C|*
(M70='D6T|QN@4/XH5T9, S|M@IC2TCOM.Y.N/OE2FCY89NQX7 MG,SU@9|H'HV\$E:X_GM54PW|_)^?6|R"3K+3ES_?
RAVSA?H)7D'O'Y,U(;-NK&-Z15<\$G;HW?! M#&U@7|D(G.\$3ZQ-JW\$;S|J.V;"4G?7_+2M_-7KTOLCA2X>=H0KF4
M=3NP8|HJX%5WW|_|TJ/NZ71|HDW|T81JXQ=VMGB@OHN|RN_O.Z AS=V7A MX_"|ESJ|6;%)|^6(|S'9V
>%89^)|VZZ)3^4B(1A-O8%|NT*QK88.5ZG6;24 MR|U|OSQS'L-@R7\$).X6O;K)S
MX0^ZHL"*A@>60AXOT"@&#&#J|D9/R6EX\$|D39-.60@&C)9J*T,V4I&IGV:/MI6 M:@HQ=-R.EE!%)\$RZFUD81,T79
IV4PF|O4O=SJZ1>78?|*FB;(+A+Y|Y|MMFT|5B)|H1U+D|,2P3VEBU9;C_0_*F4ZY&#>D+|_Q_KR3Q0S>M_6N?;EX
M|;NR_U?/L.V(8MKJ611L\$|L.DS^<^&OZ0=Y=RNUCH7|@<D'.L.!>PP2 M^_@??"8|3@*^W26;
<-6TZHFF5Y'E4#6LJMFRO'VSD(=D#8HY5<6"V_@OO/<|Q M*;3E==>GQ4#7AK?R|==/V41YXC:4*|T_|F@_6-F.6
MC@""H:|PNQL|5%G>L"AHHP%O(H1.\$X<(-|&N02NZRYVE;331T:S4:'JRI
MS@IM9>U.)T>%<D>6.3(O,T)B=HY(I=UO0C|&|=LB(Q:A-ITYX5;&^|9+0H+% M5|D2N62;)@EI!
0V!UIR^<|Q%:!.M76N19DMDC|T|*E,;+@VN4:|H|F06 M89%&LW^S<2LG17'7K;>W7DAA|F^NZ;
H*6&7_/(\$*=JS)Z4NTJ*_..|:~?Q MXAQIZM|F\$@N_M-W>U7WYE6W?
R".)#?'C1U9W|T|=RAMGB|..S&MJU|0Y+#!AZ8=G3|/R|H|3E%'P_*H^1^P MK6P2;(|?|RR#F:/H-
/RBS&UW>NA;Y)>|Y+RC?&GR=4YG_R%Z99U(KE+4K=D|;
M:7|_&+5/HN|/_R|6S^P6)#/'PXAA^,^TUIG|F>9.PBAO4\$VC|4|T|+0) MC_%32-"478?
8,9^<^#>+85,I/8|X7L;J:1%&#L7>5M|V2G&?ZBABO=70*(%_\$3N"
MC|9|VT8|CUBY|T|Y|_|>Sj/(W,7PCM:=^9MZJM,Q+N|8TD5Z/*8ZX8GPGXN? M>K^? R|5K#H^_P;+>+(!E!,0?
_C4|>F%9|ROES:19(1%\$ _KRE=4Y.1QIV MGT@|O:DD|_BM_W9|RRZIB&_BZ5
I'W6;U;2MVK_2U%F^""|AMFN|6|PN+ MVF7?%_S|JCRVG'Z>S_!O|PS_-H6|QR|>*)(7?/>'5U&/>#<=XH>*13|S|G
M5T6N9/L6\$|I'E_JKUB|O&K'(-WTZ|D#T_~*((+9&.*KX|JCO)\$_!4Y-(I M|.LD7?D"_*;/RZ4AJ?OAAPA;.*2=J)+9UJ\$PN
DY|M*Z&.*."8TZE.X'U MG|W|U9@E|E|I,X2X.SF17T|6<RVJ@FQ:TYE*XX|XB|I5-3|E|5A<49RGX/
MOFO49@HOR7@|X#C\$D|3=HZ:ZP"%01%P|HTC0#BCVN"N&D806>MRR|ZVU\$&C&7^G_N&EC=|K|<R;>OEC:RI*.
M:;#7.F>09ESY-J&CTO;G6N8^IMJC|?F3*=CF9;|&-+AR2|H>'!H5|^O& MPI6IP&X17065YY1(O;)"JFY|YX|
|_VPFDE7.U;=5_T|M0+C5M_%#@G"3@7D M|WM^R81.3W8 B=/'67J2|5&=9SV^@G?X:%37CX"OT|=BKRL^H&H*
_M+4>|MO;U;>XBXKU4;JW|MSMCP>-NRI/+7>Q<-0 PH5|B41,IV EJ0|T S=CD0K0BS MVI
01\$_3.UD'^<3H6#P|&M"#B|""5H(^X"V:1UW-(34147"(M|K>|P PA_) M5FPK@B=4%|G992GT\$.>:=+R'49J?51|(?@."7.
(Z0UCD_-/E(MSA=M ME'3,2OR:<>YRO#80!'<*4ETME,+W0 X|V):!8O(MGS*5;EEC^|C%)(B^!|
MM&1Q_:E3K|OJCG6Q?PXRDR|VF!*YR;@#13Z@)SH9G%*V&2: 6AMH70A^W8X MLNUC;NS'8W|3|)Q0??
|*S8VO\$AV;SHJ7|HK(CV=AZ26?L><1%|A|RA| MNM&'N;A.7\$F77%F%NU^|9<M-GFGH*H1 R5M
|ZC%)H@|18P;W9""EL*|NTF8U#XC0^"G|&|BV|7"5_M;Q&=1T|Y#_3T"30VPUF1?K+S@)'(48;(8ZVLNM-
V5:FD*XE/PL_7_FQP7 M1=/MBU2_UW7_ZQY2 J8V6Z(KUB0U"11POK(P^6EP-A_5=E-6J&T|TZ|@9)<M<.@%?
@|K)+J|SN<+A(D)^%6P|A\$FCWK2C*ET87:S2TA-|Y?S&.?|^XRV8;W|Z4|3Y%9EMX);;<_WC|24W|/"V?R8D6?R;|
M6:A1_7C.ZAM|NGO-EP=BOA3?=""MW_N97U;R"ESZ.N%W2.HY;B|PK)|@A| MGA5V+QP(N36-
F(|9C%;6=;H6WCS(UG8NAN?%O\$;0!5+6_LX1I-Y9)'&_IFM M'X<1^88(15L5(8UU^(|M&%UXQ>#;|G).A0)!NV?
G47S+%X3JC#;C:2.8+OU+ MU>"?X0|.21.RFE|B#_TNV76>|^X|R;H|FO#62FK"1?|W0|W3.0ID^=,SU M>=V7M\$>?
K0B)F"=V_ZNL"V2#4O,W8\$S|BLIU UPXSO|UB.@&^AS>R;@#8+%ICM3|S>%>DPM*Y=ROE8H5#
M|HWD|RP|H+L6;#K.HM.@|J|KUR.L8+TO<|N|I+ES|2<4V(Y)*&_L^<8 MVIP%M+=1<-G90DIRR:@_#PJ1<
3HL"OR%:S|>N4K=VD;6;KD^/E.4IM, MPPY_CN"3T963G+61%X>/?J(?!F=Y5O<6MOL?E^VB:ZBO|&ZU5W-7)89
M=M?#ZN!|I(K,9G-/VU>B0K'AZO=L4|W MQ6V|I"|(HRW\$JF;=.BC^7<\$CTN5;1@#_&+J|+ V0:DG(|D|T."T279V'2Y
MFY">ZF<,&737HQ|Z^\$.EJ_W'(GGSB@_LX&M|X5_-|H>OR
MF39H|1F^|GG:YL97;F|TLE;2R|/ K*R6R5X4.O5|V_L1TR|E|J04UO=X M|GK:E*_SS3'V^YP)SYVKAJOW>P7?
LQ#|>>#% MGU;R|OZZ^-DKV\$@Y|!)+%KV:1V5&0O.H17Z;?)Z;
M_|H39K;>HJ+FD>M=TSC3IV\$T.H<|*%OCP1@|Y0;)T,3+H-L5?W|D7ZE9.
M*X1|<HY6^VS4F5+O44&FK08\$B|=03Z%#BR|K|JRH5GBS|1-J%.N8ZD|Q|L|H|: \$OYFC175*|/"IBL
M.Y+%"|H|DU|Q68I?VVUCO+LB4E/K;J;VS|C|DR^7S8%#MOJO+^4QS:ECO M\$&?
4S'C|P1.73GP2AD7JB5|7|DF*>F.^U;\$QEXL"*A|J(CMHWF7|_7:2) 8; MRB|:|1Z|+L18-P M9ZMM*A|V:*KUJ-
M8%AVJEH1S|+4'/C?KB6GSZX4_K(R>(VYF|G^_*^EF/
M|6V+V=7'W_L0=RP5)1@<*"SO|U4LC|J8_SE;HG;NW5A3=#&=)H1:4-S;' M%XPRXA@+;>9R.17|&33?
WPW2|OKE+@.P8&CA-4A|ZAE4CQSC"0|C^|01 M;123SM4|W0<0D/_J.EW)5W^+9)K;".S4LK0K\$VY-
O9NY|G>HGHTS|J8Q.8A MS')Y|*)|L-G",<2<|I'XG)|@)W(#2%_*@CWO_VOA2"%EI7P#?_4H LG?&M2
MKH3'19OEKKC|74_A2#RC A|PA9|-%ZK44+N92%AU43X4^W%00&^SZ.3)#2#B161?UKAHB|BKKW
M"7=+0R|A.Y=Z;G-8"&5ZMF@AE0|&GB<1"Q|H|+2\$607HG0UZ5I1#M_4C0F M<40|LXE;HC
J&=""!EHPU*VW|Z|6%&2F\$|U#|J3G._=&_H"3^>ADI?5GK_&X MSW>NG.ORIZ_6D9|7Y'#00B_(O(QF^E+&-
'#3P#V|0%2<:Q7M'O<(?<,KZS?O+&..AP-A8'R0U'\$/8F2IMN3^"=|&|H.K|Y:R3GOLIS;+>#>6>#W>U/\$UA_A_(F
MC9R3|_C'F;9+CTP.GE|VKFZZT|W|1LFZ0"; R|*Q;=#C|U)ESZF6|HG'L ME;8|)9OK<>FN'O*<9HQ.?
8TY55KTRO^SAS1EZ3|77^2+;Q;FD_L|B|I|MAZI?#_V^+|W?M-YO.2+|YQ'O5;_U0U5&>9USQ_4I=L7O.L)E?
|2YN&YNT;M'K4;W9U;ZBFX|_#MIA|J(|EK.R:1^GCK*">)AH.)|T@O&=(K5F+|H MM|JDNX;^.*T7YU_S#0RX'FJ=R

1#P90/XBYW)RN6P_2AFZ_R 3) GI_1W.28 M.'VJ\$R/RZ_%!H8RG99.E.W\$EAIR\$< M!>)*2<00!4#CB#
!8T!*\$G=M75MMRR3W%G'O3475SG'OJ2OIG5!02,!%QH869!MMM!4LL7VXC39W!#!(H.F'C).7C_C6*\$YM3XT-Y-
R5S>03M?R_@1P"*^+M"J0F)\$C"08!15;_2,DW60\$<+C"*EHG+R=#,OA@@"J"M_!WL:Y^~Z4^A!?
M6*P@!G#=#OHT!W2!A_!S!4 M*%?V6X_>BB0G7FPE!>,X+,,(O8Q#A236<*8!4J9BTDTRQ!Z@/!,7%;LP_#
M^_!A/MQCMBDT_TTD~!13"E!_@/!:/:9/HET/KL>H B_R?%.UBH9= M/C-T!U%WR9%M!_W0O-10?
RMV68'7Y3_!L:O&8WB7TB!X&@KW HV_+7YDUO MW!HD9OLU7Y6?>3\45!#4Z6D\$W740!Z5=Q',3?W0
G!GLV:GR>90ADJGO!DC3 MX\$WS*,RAGE_,Z^V099,K=-"O*#,8&PPLKRN!#)YZ+XINC1MO!@!T.O/+9E/0 M4M@V-
3Z/6KRYK!Y04!4<3R35,...Y0IT^_KY@;=X\$!A4RH'IS" !9EH1!SQ2 M_1JS2A!5RA^3D"\$7D2!%??
2HBX,5_.*\$!30S)!%K48KH6G",*X:X@ M!S!_!O="FBF35!T/X2+NU4P2\$+2ATE'+\0M!IASTWESW\NW>
!8\$~1469:0QJIGIR5F9==?XA MMTQM487!J^/(+^_,MG1YMVWX!G+UKP>,VZVIZH6'7,H_^JT)2/NQJZW.YX_
M7WQH!5_7.HYVL2M,FZ_X)CRI!YQ#JWTP<:=KA)Q3DQ6UY!QA_ZMM);(@.B0 M#34#
!E_3_OITWB!X08JM^,EAH=LSO4!3@E! M\$%,&NEK!Q!AY2!Y>)1>.@NKV5%N9!^E.B?S1+,J%!6T37'YZ2!0F!%!. \$G
MD&V2Q",F \$H!JPW!/=^=CL&'7_UGC:GR_+RBX_!H!X<=%2@NECHU,Z3Q
MV7POTX@5BDXB#Q=HFB^~IK#!\$4T9C);"C!_315_34KI4GWZ2V&3T*15JXR'U MIR1WU#Y"U);\$EIR:?
C%+T*,+!HC<15%G>D<'2!8'5'_EA#Y^~P3*# E,D,ZZVAV*%;JDL!_8@HRT'"FI5_M!L2OJX?;(;,UCK_IGZB#+,PR+4;UN?
!L_76ZV>E!0!_G:>N!9 MU^V)E!M:;32+&=LC0C2;62!2!J+!+J!"DD/3Q>G!T>*X(TA>;-Q,7 MR!>>NEF=
!UJT^1TD:MY4!YA3W%OV_!J!RG?O!J E%?#907U.98A01_R_ B% M!3N_BD3
\$&\$("J6\$WN@'ELOCE_ =CJ+WW!H8R&KX=+_>\$U,(0;_!GF<^RG MISXZ)K_>7E>8!_A@+6T2"1_JM.V S:@VM0L!\$^~\$?
2MIW2_,\$X@1P0C8"V>" MIP_7!H#<"9N.QYZJSBEF@!&MA&KSE_^:RT8!A?SBHO*?&U0D*)%+JL(0@_
M2M_!SE\$3!_!&E!R_!ME:A*DL#T!)&";7Y0Z!8+!OVSEH2T!7P8U7EM#> MXI!TF0-!#XRBZK_~0 Z_
KK!2* KH3>)HUR4!BUM!72H+Y!M%AA30X029H*_ M!S?N!#!0%>*Q2>S_JG%JUTG=%U!AKS@7;..4U-QYLS4J
M!ERDF5%XB8'S!3_2&G*<7AV)M&=8D"L=%Y-?NN+/3NL53&/*YP+;&=S!E!8 M6O)%7RI8SU4^!VR-
6=7XJCAYBZ<"7VKRZZG='5Y+UZ91216!EL,+ #SWM MM3K3%_GI_!M;!S/S!H><*DIY3?
(R"%SP1H36!N\$5CQ"9< A\$<94TR9 MAWR5XA!R!4\$7_*JX10_24\$0+9Z!#_6!F"!_8H,M(5+3(G\$=9 *R"!_PND@-
ME!&!T9"3UKF!7*_-!\$2HT_/F):URTW!!U!_?I5!9R;+THEJ'_L+93^+L M,C^D,"3&3!H4P-EQ_P!KKG8/JLM**K MH0!"#
+S*%V'B^FF4U+&8;<>Q'BP0;,(C!EH_J#&MPA)?+8D(^H!H)E7"1ET^?"/4)!*K!QS%F!B&K#G2^Q9!8CT
M_E!O^!SG#+A+P9(Q!#9@)HH?1&!(+)+HE!^CJF)_Z?_H7LSH1!HJM@4!# M1:ZXW;'KL^!#L=37W",!GBZD?
4@&=H45>2YZ74\$E?F0Z!5N05W8!C M 2Y!@JHW3_K8N2;G,N!HK?
J+!%E#K0)&ZNRXZG!V9;*@)YV!DW/=^!_G!Z(#=05!/TY?IP)K1?W,*H6C. M2* ONX>W@+4@M29!#7%*(!170!\$!H_(-O
MEWV^,W>2V5IAM*BKNL/2L0^?O#9KH'=S^P!PA!W%/LN';&(^;F\$?INUOK3
M,!\$VKTMEACP=PYJ2WB*)V9+AS07\$P"NW2UJ=ZNI+M@8_?IM_?S)*9K39Z&Y
MYTB>H^&)V>!#C/Z=M2+*"!A!L0W2>U;XV:DB6.J'Z!X!9?^R+!#!L?%&A M?
!3V0C/6QENXZ%/_L?;_UL!%V_!Z!\$=Z^F/J_%(VPZMIZ!G!E"?A(X2=:A=
M13M,ING!9)F3!T=A2>XD!_!33>1DO*W*NKJ=|^CEH^?#; M.0!O!>+Z?C)!H!/1_#1)P9!H>-S++J<:BVF:7U'D4?U:D
M9\$&H!^!765\$/0@2;_!2?Q!4_L CORU\$%@=^3ZH&U/5_VTY!L_UJ0SU^U \$ MO7E4\$HFZ-AY%!11R(B(B
\$@<\$50\$'\$&5('!H0\$")@('D%1\$!D59_H24(A)E M2LO8@A!E5!&CC#)&"\$K(C)+&\$(2%1DB%898DJ3R%=WW?/?
<>T! UCUGW?7! M_JB5M:J2;S!W>_S/+MVWAV8ZAB-8;9K&_S(HI?<+!I!_"S@VGWDS8!_4! M*8!6"F=IM0PU,V-
GDI!9?Z<=<#Q;OOV1ML@X!)?#Q!>,H#MK;3FT%7!P+!E!X MGSNMPBP>@HXSC6-
>>OG0H!PV:F^B!@!O"!&:#P98%_YMZ!D?&2D7'E!E9"7GA>JAN8O!Y_H/7 MYM?5O*B_!>=INP9!E!H.S.+Y?
X!X\$3!GAAXD!^BT3L:9B74B*&M6_K>SVF3H5_M)!B9-7!@>U36'D6L57X:Y>AV8\$F-PP"=YO%!Z#*2)\$%&&H_~8P.&-
"4K1>H M_!D!2=^7_6+;!0#3.TN\$W??+708_TH7!9>B&BPW?N/R_+!38P+*ZXQ>A/M
M:O9_?7E!0CS>ZTQWVG_!OM9&GH52R4XVLLG#L5Z@5!*11RGN5W&/_Z MBP/5E"/1)5E!F>#TZ%4")JA(VD(
X^AHTVU0E8.WV7%,A+!+4%6V^3<#YF MP^711F!OZYZ=9?EE!)15!E^ON&OV^=V^S+@!>AZ<!G:(YO)#
(6VPBR&\$P: MA;_90_!BM?_35W21_5F0?F.V"3A2OPVKW^S?R;)Y!TS4!3MT3-4!A-2;!\$D MC!>OW3AF4^=> Y1ZG-AY#-
F+0=JA%7=4!07??_TVTO6TTB\$!&^8OW*\$0C# M9,C V^~N^N70))>QGA0JP\$7/TU9!
(JXE\$W>7M@!6GB0K@_3&M9YC;ITA !K" M-WMN!;VZ%9D9PY_IS_@5D_!EG=/D?5"N2!_H! "V&=8E!JE!\$J_B'2&>ZX%9)
M43Z!EP3=1-4)_2GM'HJ"@@W0^B;_&?\$AMT&D!8#;/K3@AN!;2)WW1VK;A! MWJB)O9!(!#0S!%'=3LKC M8T% M_
EE!H6(D)??=\$?(E&S!J!78/5W_Q#R;H#NQE<)5!1!NO/_8WV_!MMWM0&>_H?PQ_=?M!)-HE.UY+O?S!NZ.EO\$K
MV9!H!VCMK0CH>^,^!DNMW"7"*N(E4?J+G(EAL83!XG<&DL^*K81W@0UZ1< MM; (MF*5872*FZ0-
1M@4YE3S#;D(9CC<3!GFQ)=!88)KS&Y!K:A?7_EG=?= MSEY?V!T2!3NY5G^C?@G!N3^~*#R@U!R-
"Z5@!]"2P3.O8-D+8*V @*WL:L M"!ZBTPRK0^F"M>*U8/+K;+4*!C+60(=*KNN&%HML1'H)ZEE!1#==!404E
M!&S8RNY^Z5X'V;V3O7'6OS!WSYW;!8Z=8OJ_+!<"W_&WW^="8SHK?8>K=1 M:LZ@M96A!DXW@!
(V_(!>J4!FA:S>^/!H3!R\$MQVFUX-N.SST3WXT!SEO0W M2%RV&V8>-H:Z@UX!P2LAG"?!J!?"D*M;P"!3Z'VD+%V!-
Q!O+>M3P KM" MKBU5!>V!L^T!9@G^=622!P!5!&J!AZS=!6D(K 3U6K.W1
M5UM/^ (S2ETCO@81!J<1H;I2CW00;"X_975!Q"H4T5'2+MCW6DQ&\$53RZ(1 M2+6-8!ECDC?Z561G0.2N9B
M&O4'OFQAR(GWB5Q)AR&A!L_G@!%_B#ZL2T!9!_31<9-8@T\$D^*2;MMR6_ MV+U0@P#3!(13*5+Z!O!IZ=B.OE:
(QJ)=0R!^E_~!1D/_9_75&!D)RFL_!R MB\$*!B!R!ZQMLWAFZ_O!W7YJGY_Y_D!+O^SW0VG02NM'6Y%I!WENJHC"6
M;U>3GL0!A!S!&AQ_H\$Q!F\$P6M_)FT(+PHOD'=!DEX#4!+_BGT:MACP^~W^3OZ ML+O@!INKYM
Q#6WT!B(!^U&^@O7UA/5.(EZ*BTERR)CHTT,!T*^E>I"/80_BG MB6L3#FMD1%5!<(WU//>BBH0LD#P\$*8G^NAXLS.
R_8+!#-P7=!)O5*!Y MXGV%1\$N'KK+?SUTE=5D5>U!8C-
(MV=;YU014C)OZ0H%'5\$;TTYIZH^<=N0(_EV9N95>|^~7.DF6,35-0#6:O!HN_+ @15%XXADM
MY7E\$P*;7L#WB=/>&4G!_O>8_*A_!XB*0>. M\$M3%ZEU?R@5FQ6/!CN!>I+530%8@_4!8#*_*;XM%B-4@MGYAX
MICPRZ@_R95K!_!%<1#Y!%)@*\$9WX:H2K<_ZBB_!S4#!9#IF30_L/PAW_L!N M9_JH3"E*N7ZS6 M*YE\$5&8W%?F%D?&
Q/O!H_!07=503:U.><+*"J!^~*!Aj(9_TZ7K*U!!?SMHA^!)@G8!_!J! MS5U?M;U_?AWV_!9%G=6+F!T3YSTK3;D&?#
B&\$%7!^~8.7@B+?>)Q!^HERT!SD4Z!_!M32!KL!B(K\$="I^6?EZ+6&M#D2\$>AS.)+!YJ/>(E"JZ24#W;:!<
KD1"6=L MZ"ZWZR2!OY97%@ZZ4PC9KPT+!W32;7"AX6 M_5="!@>=WG-EE?;!V7R5\$FNEP^Y95!LV3!9\$^U;:/X!4Y-
2M>W"FF+=~^! ME_!JWZC7@4R8!5(V&MC8G\$@)NZ9LA-(CZ_%/O"V!&_NP:583L!CA_O*ZOZ M5B9Q>),7>H!H4^?
NHXL)KX-NN8U@!\$844!="">HRT=VCR!0R7ZUF\$!W719J MZ!WC)C!9D!&T+Q_YD)0>N1(LFHR(_ GHVSOX!H!@^~>
!+E!ZP<+>@FV"@50_M'3@!W ME0/U8*?P5_D.K84<_!_3@P\$TN9>QA*P&=;3>:P=+3X*!>OZ!>H4@
MG3>T8%Y>WJT8&1!H4!&V!#"N>N^2W6?5_0:S!>YNL!H8+O8I>"HB=B6Y MP!V!G85!JW
'O@>0>\$KV_LG&HJL'3%.8A&P6WYB0S!&B!W_!N@X ML8A_&WBGY!U@#VUJ_!09_!EQV?VN",<*.YF!F%Q;_"=8)A+!
\$O-Z MG?H>+>OK0(\$!M_.'6J9&/'">_!#6HA3NQ"IS+^7SVW*J%"X@:Q:=RK_K3D M2EF=S#CYC=#*6K35TR
Y#%90Q_!\$%&%44>+9!H!CY_!&02KE(K>5R_=#P&O!Q= MDA_YVA_ZN!GN<\$<INX2T!F5.8@!H
!F#6!_!U!D%2U(4)PH3.9HO?PJOSD1@P MSL+Z\$S+8GR1KL@BJ>LTV^_FS)K0_1U!Z+*"!_5U#Q_*R1-25#4NE81@
(M)&F=)+765Y LM(!F10<7%^)_K;B!_ZU_!>7G!OTKQ<\$8XEDM:_D;5W8!/1 MF_!WM>=!N;H;!!"
(3X;IMQ;*!\$*WKKYN6TOEAY;:(S^~W11!@^~OE:9 MX05&RV;!OZ&R)GQM=AQBB_!OW&+D-0Z83;@8=, J_%A+DK
M;_!#2(3X9R_*2HAY>H !3NXQC7Q^B_!O"!^~W4^_F0L_P%3"E_K/C5!+6; M;H@6W!\$ _!E!&2+QW5&_<
*_+=_DS_!T);LTV1W!5#A3+YR@!_4Q!/_ #<M?P#W?XS">Q!/>WK"*4_R !BEK=|^+1^9P/JL+;\$/QG;!!"14T@CHV?

D^PMG M/HKGI*CH5GA5N11EP? 3:9M.)#G @NRNOWJ@,Z<7ZX4SPW^V(8TJ!CHK@ 8<
M3K"/<8D&WWOIG(>&=KJ9AAGHA^6\$1S=MA3|RRJR6A:|#SKU3(#Q*=7:C3| M5SIP<'SX<??IRC:GH,-" W?
/FS1FD2SC6EB7|&7A9AE3E)W|D|_OK+@5|E96(E|@|1|Q+^ M< C (->7N_ZUM2DJ?C.#0|@2 M8&H+4.A?
C+|KC:|L4\$4+|Y0V55K|30E@-&6196M9+&G1KG9X,0UDA-0 E-M@QWR7|,K40,+*23NIDK63|6)-S(*|7_1
9#|HOY7_VL\$%6C+1Z\$N>6P6&\$&?2(J.=1&#DM M+N3|)%:YTW.&|FX|*Q+|FF|!%7|MV02B^D)EXX4=-,(FWC74-
W923MO V MXLRG7W?|LZU5A%YER;TNSCAV9%#D2^I5D|1IUS4KK|NI3AH:V1 =!.\$39(<%3MYB^_DYH7-
Z|9;_*)049|J:>OX7?*IS?E_V6 G|+_3^|XJU%A8_=& W>H_U^+;R4_3@|HMQ25Z0(&LDF|O:G25(^M"YONO C;_*_5N
MP&NLX;^_AX%SM@W4KQQYOCG=A_6\$@H/D%(E8 MD\$;|_?"V_15_U0|F7>'NJ2"C'9E_8?%=@0@5468U:KQ%?.?KRA%
M?3AL*=_,\$@4|T|_-2&L_UC3Z|R|&VAD04Y2E+D|YSN|<3%#Q_?4?ZSZ)-! M:6^12QPLA7Q+|^BV1#|X4_N4+
(V*>=EME!_ZS,A3)_Z^B|&UR-QO-&'W" M+|F-/C0L8PM>LCSY_7GU^V@0K&EAK)XV|? 7.<?X&U58'ME0K#:(|J ZX-'
MDX7|/O#Z|Q>3;L)UO|T|H9*SSC..(^>2|SDJXP\$X7_T H'8:7+7R;G68%K MDDZ|O=>*B2<9?_06M/PG|OZ;
_NV|GZLD812>2@ TK=C>7GFMEN.&X|KG.N.MO_IT_8'WAXS>H
3T';F*7+6|FXYL5;@EJ'8TK).%\$2F7W)HKTT>ST/P%RR87(^S* M:KCKE(Z\$06F55T
M">9F>D4|FT&=^|I|V&EO:NDJ#7%=?3PB\$&:IV7\$A9|_0|OO|RT|P||&MH6O|_5UD6|479Y9W%2%%78H^FVW5"#-
O7_LY;Y%:OQUB_7% MU-F16\$.XAAP>.5R#AC'3_S+N_X;Y-|30_V^_R9KFJ#=>?
%TK2D>TG320\$K62M0@:A:91*QM4)F3_YHX|@Q02J|ZW:I*F2HN(FEOLDB_*Y M(IRI^YA@(\$<8(B7_RX.D?WW/_|H
N5OS^1^" TPJ_ ^98 M2|DI-|X_WQ9W(XT/B'B).B+|=3<&6X%O9=3X/>|7+?HMR|PZ1SY0/2_R*^7D'O9_&7A
MUKO?<_+=B;449?T#>RRL|3?3|VI2D^8HY*Y<6>>0LU+(K|1|W
MH>%7:|NX@|JWE=-2Z;FRK*Y=DAD)Y_^(W.#Q&0Q<9?51|@B_|LS&"7|^>GS=|R_6RP-U^ZN" ^W|FPUP25MRT>
MB4|_|2_|<:M|J#W_5=3;4E299R)V+YOX:1R|'T+&6|Y"|_CL3|_F-'9L_<
M&+&T_!%UAP(4W3+V>D9|Z\$.Q4TNLN0S763Y+31#0,42S|)(-2#>S5Y%O_Y M<\$+Y*GGH.18U(3&5AXFYU:Q: ^/HN-
=I4?W0/K|78J|D#69J|Q9;/R(&GV?)B_MHRLK\$=C@,|U:6!#L9=?WF="T?VUG2YAX|;ISOZQ5D_U8+BIP2|V;?<
M)X2S^+&#(-^EP,V|L_Y0KS8)*68R-S1DFDC.@ 7;&|%/5%M10)Q_<).XF8_MC|KPNU;A>2FJ5W>T6A1U_ZN/3(! H
'AA%&|&GV_58DWD|BU1XKR)MRM|FE"QV'70/9_"(+&VDEZ%O%I+57>9F" M "U78(MWYLF_U=|F'A8D-2L
MR<_&3G5FOAE|HOGTY9_*Y"OR(|_H|_# M1^D4&AK@&(#*%%,AQ8WL@RZSZ.O(5E_VQZ10D|&T|_#ZXR|_|
|F^&6XM"U_M67US5|F@KJ5#C#R@H=5H_<:C"K&Z|>33|<81=^MN*S<|5A@V9=K-J+|F#* M_L#G_JPW-
_SQF2"RX_WQM-"K|4FDI_&?199:6)N@B|K92^<|&K86L|V" M4>Y0|KJ|V6XZK/^OX|NN4V7(I?S|_EN9W>=7LJ'D
09>&4\$H(EX8O%"%(M|ADGK_HD8X:AA7XN8G|F9L'BFYE^O2)|VTPOQ|L777H&A|L3UIUV+HL_VIR
M7!|G|&5YIMY|^>20+J|!|H735.D|'VUM@(*TL|6P_N>JSL_1B(VC*R&O+G_M4_?|&+8.KX/\$KHOU!;XR*5AS@0U.8_H
)GN#I6#6G|JR93=_LY|;T|\$Q-&VY@Q=5:77M/UPF*NCT>G#)A'/RY_M|6)2M)+>H2'3_RV?|=|32|'F)\$U)=+WJ|!2U9
YS"P_:=@Q4"l_BR@|>Y=H" MKUF_QNEHS(O|Z+D#A<1|A"KDS;|O0MCC.?7<<|_XK8?79YQUL?YB;LE>
M%+B&6'3JA.%|QO+|%/CV_+Y0Z/\$2L+Z8@U&VYNR6T&1A:|O5>C|7/B_MF_|MZR\$1U_<LDY|H|N<3H|_*MSIYZ?
W0"/KJ07-|S'0#G_2@ZK+|R>|+>(Z_M*86G_Y|Y+|8|XXX|_#|QI<#N%MB%|B%Y?KSQ03|SOJ|03FDO911GRD>-|&+ M\$-
=|L#<=&MT17|UJ% MH|>A"|_!%95|Q:"28W<|8_>_V7+A|*#D_WSR>V,EY2;Y1@Y8NRLO4_W+9E#
M6_|NMJD%|S|X_M;L1K>1^(-\$Y?>13IGIG@|XBL8UTJQ@19)#|MA0|3^|H0 MN2)WF_6K=1_|1ND|)_17
FRE;32#>D;P8NY_L7727BA).C|_4AM9:SU05Y|_MLR@0T*1I9B>>P1_<S_|N2|RH(W1ZV#?^3O7)Z1DGfV MTUHQYW:
|L@;_V3|YE+7?=/O:49IR@_-I%O)(L|AU>^|_408CWU^P\$?_*05
M2C%@W#PP7@VT:09A47#KYAHXY""M0|_<8HUOF>JHF'L_#29|*|4D
M4|+|Q|U|JE#RPTSZNHE)=0K'5E:T_7U_W7>AOPY*GK(&>"V+!|QPO:X42|\$!S_M_48|@|JX|\$17?
|13&>I<1BMTPI#;+>@5J|SOG|>3<%N!\$QSPSX>_S8&|K5
M:&LFXC&K6/4S;HC|"+H>|LS_.9E>8;LNRQ355&5F|VS5|5%2OI7>IZP-/R_MZ\$Y-?J*ZWWKO%_O4\$V^_Z\$:ZYN:
|G|QUN"H<?Z:96=L|B|_>|HU+>|UWN:Q_M|3XW2^XL6|56:=B^DK).Q=>T4OR4K""S"=,H)F^&J\$=7" M@<"<_&^|C#?
67 MD6P\$E|COMCP(C-E1NW-MK?K;|DV|63;|N;|<RT=|E<_F6>^<(3KNZL|_V>7&"(M_U;HY'O*|FP_-%2|OM7|O|&IXW-
H|Z0# S(3&1_|_#2US22_UB7^|Z|H>91 M5??VWN"6|C"E@_9&^4_W1RXQO3P6SS_";O=77RUP:90_PC>5/615*(YWL%P
MMS*%|_)02EF=.Q.WGH3GKH|H4-RBUM3'5G2;_|U6!%TM-V|"G>+A_F&=<

C@=7B_M_P60%C*VWL|N)Q&TGEXS_93K-|1UJ\$|<='M47=XV.G9SNKWSE|FUWJ(E:8Y%U.ZR1ME_P&C-(P"GEUH-'M
M>DTW_6B&#_5&1BL+>|1#VOT2F*+CAHQ96\$XQXN2W_PVV%_+&#;L_'33V-O
M+T<<0MPY\$&#&B0AN(|PD=AQ%9'L5_%+(\$)^J#1EW_M<R:0|HPC/10*G7%U_R_Q|W2(8*G>Z-Y"40%K=4)|_+
M|S_>R0K84QC@_VS"2HOU2;3N%^_QD:(GFUJN|+MBK_VETV*3|_8MS=[*6OMK
M7KW.X4M9*=TI^>J^EFG3YA>SRDKIW_KFKX<7N?X0\$_Z"MN7"6^H0_YQ&1_\$J_M29P4)=@(RP*S:PF7|TND?
H|W0*8|0_H)H2GN4|FD5|HN1(+_|_&9*"%B_M5PYM)FG6<5A;"#Z"*|9@^A."9K);TX_*D;5^P6:
U&%*0GS?!"NFYZG'&M|Z"R|_>TT'V69K6=;|JO)"_I-Q=B9E)T|LA=LM>52X2^+M|G:F^|W|C|H|
MDGTN6YE9S3@F_|>|UW(NNU"Y"XB6B_!9_MA?2YD.FL")=|K%C1G.C#%U>\$9_|M1Q|^#'
9Z|LZL|A_|^NEZO;Z#IE++=|/0+>?>*_|_2PC=7?NT6=E%;5|X97|_MGX98E|S>RJC*Q82CX5U_/|<|Y,V*Y&?
MRM<9|VJZR-M?TEXG9_X0|RT=|H97F8.L|3(P)>48U.L>L'5PUR7"0(L1|2_MJNV%QJRJ&70K3Z\$-
C'&|A|_|E+5|NUNWN2UBVR|H|MAN2S*|L.C8*GYW|WOXI?K>N|A2TAGLL=G
M_9:|J|_DU#ROK=OU4K|_|_""WWO_O5>8K_TA\$92K7&Y?L7Q29_#BB_/IORN<#_M-S6KO!1<4KZ>B54?
I@Y#72>'EG558EX.25%\$SZYBOLV"V" |M;N,U,?_H'| MR1JS9S>F?Y_|L|0K;@&@_)PJ9#0*QZ|4?R<\$LG1.0;PN;8
5_*\$|W^_%T\$)GC2C>_W_NNSMTF#2_%Q4VST|&2_M'&(-=+)|0B8#*8FO07+|NK?
TYN...09|V=+E+EGE)TAZE+PO8T9RM#|4BX_K5_M"-Y7N_*C|4R7C\$*H0.A:'GOOX=+870^75E'56F8@_6;|3U2-
)"*|D'B(Y|_Q_MHS|U^N_|#|>_?W?LZ0TK#=#1^_|*<(&|A5N)_UH=U:8D4IBD.?TA%M\$H(|OGF_MX'1C|F%0: ^J)"
OA6CPW|BLWA9|+70E8B#'.GH.6\$<=&SKQ|2\$WN^-T9|F_M29W|J2)4F8;0_-+DVOD2D0@U@\$_:HA_|N1@D?
M;J2HM|2K4A|H@|ITP30_M#K=|@JA<-Q_W%YU+43|;(5BN@7*%)AZFH.#EXVR1#GT_M6|9*0;6#U>20(=2-|M|!"
(R+0&(E'VKO^|UHG(N'9DS&_*1U/_DB0\$|'5C.A)"4-AR0X8_%OF?"J_M_Z(5T/FV%EY#;D/4_S|LYX/MM1CN_7(F\$O9NZ
WSTAZ@B;5TZS\$^XAPL|M_MW08VCT5/8|<104|XH|=#|>P)9.3X-ZT-8LI|)=S';C86;V/\$@&TOI2|XW_M#7DM2%)?
(>N+XYV|DEQ|=X;4W+&M+0V|B0E)W_SXXN0|_6C#;Y>|35@|F#5_M4HDHL;*Z;IK7,W0Z-
|PHBT(|_B43B*27ZW;|S3\$*SDJXC|Q|L\$|>6!"GDO9*_*XTFIC.%GEO|P|_|)O2YN3E^Y%6,6EIC^+?B?
8T>3%G0&_B3T@>|%|P>@CKJF|_#>M&7ERKW8
MPR3GKBLD>UQC3F4Z&XU5|=_O|ZE888OC&@|4|NXQW9+KJQH^?%Q#E9%Z;O5V
MP;6F|0E|>QAC5^A@'CG4|ZH6K=J=J#6_EW^MD|)%|+^);R>_W61<M\$Y^B+J'\$?Z@1R(R*3HJUM;|1?<
<_7_&8_+FWZXS2J|@XFW&%_|SUV;W8|CC_L?2C@_MIR<8>'9E|HEW6|F|F^<C.U64.9_(NP>|T2).F45=N_|1R<_<
/*TNQV20L_M5RA%6=X&:5+4TA_VL_ROEQD^U?^&|&)3|84A0Z'|D@7P3C."0M*>IU%@+M%2D_PHQ+_|_#|(|&PD;H
M'#@H?_!%|G|WL#C)|@WH|HDV#IP(H)FOTE+5H5P/T)->^#5C|?5?T+|_NH&X86D_MD.Z05|
|+WWK6EQU%|H@96;N...5(S)|QEUP|_|&|2S|Y_|_M|1U*V#MO^"?BAO;ZSTH|M|Y>>&Z_N|PVM4#BV+L5%X5E-
8#_8#X=4^3ROPXQ_MQR=%WUTDG=V%UB&7?S%C%X_D+N;7_7=7MW_4M*JK*+C;:FN8A2Y0@K1M0A
M5Y'EN|C2;>3F;_*_62S>-Z6C|O8"%7FE3_MLWANAT8|OIPFK)-DZ=K.=@T^PX4P|V_B6|C;+("C|HQ|8F(FGC_52|IHU
M-<08?JV\$7^<(VJ_N_67)7);2|_5&^?34N(S'_|L;Z@%_#Y_|5|P*|L#UAU0=A;

M/<IC1@!LGE2/V2;PC(O3!N1#01>OTN&BX2;DIS!H68,50A!3!@6B,E9.MQIUGLY8>38!IG%FUK:A?
U"C2+M;)AMO8>X17!#HRKJPE6%/OM;'!SI!3Y M'6QTFE7(?MO(,*P/6JUO86/QOQI03?U!60A!)8'U71A!22,^@
+%'>71+ MABQ)A X^XZF%:),\$4?FH0 N^03XZ*LAUS!50.=B(SQHW2E/83U 6>&2.X" MPE2OK-BQ?J^Z3VN;
H8%&SIE!""(&5-U5^&VRH%Q.%ZSNNG&%2Q&DB;6D:*6 MZTER&!>!@3'A#22^1=TAF8'EWUO149A5!7LH@!>0C%5!
JA;-7A M2!/*_8""^3 _I=[59L;G2,"GP2%+*!>GHW3WS<R3@Q<>!#O@%JH HG& 9 M;D4U9%6IPS+I>U#& 57HX@W)
<)+ 'M%5!%+, \$F/WK-KUGU\$>|09^9X?R(3J3 J^Z" 4<-S&6ZTLL!/?%PE=[',?<.=
M!WM=B;&);S!N7P_U+!|S5NYNOUJD,&HH>EU8G^<IQ:'V%LG"UMU*A%+=+K
M=49ADV0_CL:QW!JU_*5B@5",F17=|,3#XJ.Q="HHWNJ.W#\$^L/_\$K,|=S_M_R"A:MYM_-
/FY7LK3?:QMMJDBNRW3N'##ZKCG?:18;Y?#@_ '*.@96>5> MYKRO:1\$5!P7?H*HYX*>BDT12Y:2-@F^!M?H!U;H-
W">5&C8>UN M?N"JC98EKVH_P(29!@W7!U77N-ML/ZF0&ANP!)?X%R\$,4TDQFG6: SNA;+R=|
MGUKF',R0HE!2&O,8'GZ^Q;K&6E7.SFVK"Z;SJA^,^TJ^<%SV!8.!!RY(YTB,A>6X2!HXX:C MJ"EP/13\$L8PCFP*-K&
H3C%&H)JPE.Q.?@H!Q&LR,+8>G'Q4! "13&8!PB MIXHZ"R;4! =TP#="E)IB:%Z&5/0;TS5-K)X^1T2T!9@-
NZZY>^&HF>44M6S M>)>9VV#<4MOC;55D(6VX;5!@=YO*6!V*3W=9;J!\$10=5SI8!L/F&S+BS (MFV/PT>(#-
/\$&J@K"1M.).V1DX9.6KPD4<1!A)G*RC8\$(-7^:GB^#(V"75B8' M Q9233T>0E!PMN.\$NZR%<7;"DF7_=&K_3WW M=|
H8JUJ73!Q(S2XT=+0AE6R')Y59#GP4R MH!^GQ@5+3^64Q1ON836).D+BXOL)(DDO@#Y&-D-P?/TNSGWJ?&6QVJ=|<
M6QVB=S!A!% !SF6!%Z(KC6.W3JL75CUIX*69-!K*K\$6;V/(ID.U36;6SMTH8^O!JUR M.EQ(EZ+^,^&=:0!B D+@\$!-
L6#4<"G\$OA!W_544 M>I?;<%YRHUA(KR7): M7N8/ 6!)?DFC?XS@O^!TH> +TFLT88P!%3?!^3RGO;
P^<460+5CE^LE+; M!;5S*NBB;HLM<#Y.J UE%!)BS_ Z=8%.86RR;"P.BF M6J@HAV3=-2JHO^OKQ&GWC#"S-
CMN!;P(+Q^X7?Q6Z!NDT+V+BR7CN93\$*;> MI#A\$IG(D!;5;1.W*79\$ YN.VD^P35B!;VH%&+1!ICEAH;MDMS:XOI;
M/06X@+H+!H 2Q%N>=WE4QC7?2U7^O+6VJ?M@N!;YXJ!S!\$*#5!D;635 MIC>%H!H!56.E3N!+&8SJA^<:-
ADC _!A=25!M""9A!G;-UIMBUR.&+"&!DYV!OR4U.SI^#C(L.O<"EGP5 MT.01E(V'E<6ZDA>F-A&R"?
RME8\$Q#.,6R+BXO&*/MM9(.%P2R3/W\$<'9C M(*2!A<'W"AR!4XL15#;ELY?6KQ^'0DX@/UB-L<&/)N!RBHF>#R
0G%V_04!*>>RU,O^VN!;HJF#N<;D!O6A50E2=YIRE5>(20S MU!C*J\$G85;5V!LO6LVKS5\$_.TT/-^:&M&W8%17?
U_O:6.=^2ISPF=NSF^1< M&YGH# ZOER)HDDXO_T5NE#YH@=-14R7R%\$&DZ9ND%Z,9S@=%-1^%QZ-B!S!6K
M4OF.Q<@F0N*8NWQ;-!EJM75M5WZ;6F9Y55R*49*B?(&E!_!A;R&=\$22-P0_ M*
!^N7PRP8Q/<|*KM"3!HE43&GUF<6!FY0FVDU,27,-IB !=Z\$<(KTB4\$=-! MY,AG!+D-6_1K(P0K)H=B*FZ\$X!?
6PM2SO<4!;LCOY4!TL3AB&^FHK@D/6!)>T&ZXJHQ^NP9!H"ZMS4K;-1*S5PJ_9!^@W2M)KEB?>|C4A)?E
MPCMXGQMANWN2B6.Q&#^!&7BE4KM C.CE;16!DR!E!X5!6!2HL@ZHWTD^!_06%!)9^2B^!;HQ_>Q-2NZ!+!MG@
Z((SPL"YH"6!-OP^F/69;2)7N=K;IE3-CA) M!QA7W@JH&7QR/M+.8@:XP=L", IB_!#<%L@GL):J96 H:%8+O;-RF+!Y
MC96%C 3_5X>75AU;*,&3!>%5)GW" T*"@KE862AP098\$0PN-613Q')<-?HY
M<^!+P9/*YN=Z\$X8#!ZV.MS(LL^Y!UHH49\$!U+;,! M%1WX!;DODV6Q/Z5XTYO!G3Z?97\$Y=,?
81RT_!5KR)Z60^T0"3SF!O\$U5(4 M3!2S3!AA/! RYW@_'? Z> M6LBCCG3!4EK\$O>.+U<"W9!>7V5(7!P)6>#.MD_#/VA
I>19.@+0)4ZVB_!1(M24X;00!#FWJ\$P):0A\$K!YX_#FJ!_%TK@_%<#;-Y=*T_<|PO M_%F%F7<0<"E!:(Y8*AA35?+2QS?
C"2SN!0)8BDKQ)8_@A^ZX\$<|83+E+598 MEE!87!\$%JOL30?AV7!D&3SHW>BV=-FQV!&)XR7%.5YG&P;??
GOU3N!H#W M@<4U+&O&^!6ANXL7!79;_!ECIDEN>W>1MZ"ZR8,\$ M
M2/?>:R!IORZ=9U\$75^\$M+@H&5XJU1%@ERED^TR7J\$BVNYA>(W&+QOE;!4VM MY&X?#UYSW_BY4F7C#Y?%U?)(?
8A?&8C7A>5#!CS1?Q*!>Z?E6=JPD4UT!7Y M!OX;+
VS+!F!5K^G%Q(HR!X0_OE/KK!&F!F111/T"9N!<0NR"EAM\$9'7.MU; M#9MR5E_R3FE=YO".<!9K(09C/!6&8N.U;
MB\$)*=!P6(KZ^FFN0VP\$*M1/!CVBR>X(8\$Q2(KJ?#-,@Z!^E+4;/U#=%>X MSJP7K/X#T2AC4E1N!,00(6.5ZW4!P)Q
MP6MUFM4W!7F5UY?8NASKFWK48U!W=,^!B;_NL=XK4V.QWE""+M;\$5HY6E+;;
MU@FK%GGCOK=K1^*/!PK&/TN"ZCPV<0C/#;&4XK*UR4!0SKP*ELN@OF#BT#G M!3OC8@0?
JQ!UHDVUAFX)A.H!%FMS!:_Y>H8,(67X(200^W^=,"\$0F;U-H\$ M;^PJ3!CH?
L+E;_!HGA!M2!76;0#H!6*69H1X\$&K;RU;2!#64!H.W93 MS!P1HS>-U>+!ND1_\$K!CHQ/3%
(!G@_MUC8!T!_W65JZHICT9FALQ_O^!H3 M;IVP>Q)R^M!J8.VFY!2_!1.+0AT_^^BCY=9Z?KN=S'ZOU)5)L!ZWUK7J57_!
MU%Q+SWD!XD)5S@-WH.Y3DNU,8U?Z!A!)V@X>PE=Q6= LZ..!C(U2DM,0J>D& M0%KP;UA,X^6""!LY_%
I90(9XJ)"!POKH,O!^ZZP6.STOP5>%; M;,>WTF\$##=AO!J#&18M/!A8"6J+Z,^JSB#O_(PF>AGA%A? JG\$A+O&IQ2Q!"
M(&=YRDRV!D@E.P#A,U<>K\$PJ90STU=9;(.2EHX*#B9\$;R!H%&IQK.Z.WY8
M4;1^!2+F9UGQE!U<;CM6SKLDWAK+0/O3'ON;U3QR3".NE3X0J^MW;;LAWU MY-2N.%HVEGQ@T!;<@&1M7%OL?
Y&IX_BEE^R>6V!0!IT_3FO27(XG!Y! MA!)Q4P=A7;#R-K_>E'C^VZ+WK!1JBZ!VF!H'RC!;D8!H!C5M1BU>^51L6!M"W
M+;_!F65^=\$.OKLEUG^ZPK<F!1&O^'3QO@!^"(!UTX=HFC02N,O!MR&JAG;1E@Z*3X*Z!?
R^!90!FL7M_SL!E;+VRV!)^P+V^8P^,NO1P#VEV MEZM%ES)B6+Q!-PO5@K34*I6" ^VNKH!4CW*RZBG)+)<.V&
(V.E&Y2I=W9V/PT MN/WQ&M^AM8>CL.M?Q#!M2 K!O:.0"OY+X^G_J6\$<>8!044LK,<\$W*P";Q
M@0BO9R1,3!W9I3>YK4!GE54+&R-UY,)X*W_NGIN%?ASY4^&7S-NEE8;4^Y? M_#;I-BJ_%0L
!&1<1(F08;@(*^UL=V.YP*%"0B-JKB\$VAV/3Z.C*^<'267U ME@P_%H_0^KL/>@R."\$M L;_""=W=4.4MB;E+<,BV2!
4Y+2.YPUWEZ5+U>| M^<*P<5R:E4FC=7^<55#++!+;7J7QLFY^ZWV95WUKGEM9N-@66>LM%"W;+!_
M?"">CUOW\$M2@JZ@<@<|ON/37UVGA!<'6E%"6X!NNYVLM!;XOQ*!T>|N=;/9@&;&TK&<^/F M">YM_*@*\$9-
2U%X5F@WN#5PTT2LJ@K_!R?_!CCP*WB!^M_9=-HH^B^@K@ M%S@PVV0SBH_)H!0-
=)8_0#@#FLZ5@T/O!Q!;_W&E5Z_W8P&7(K?Q<8!9,B M-&IC36U^ESJ7^!;U!Z"TW"/RW?>1C\$1+ZMB+59-
OCVXZ=HN&6!/'^2!A0!_C&6(HAA!K>) MY;G!+G;G!S!;<9RW&AN!E90MH\$>,Z+>6;L\$O=DK;XM"C#")&B%?
@:96OW;@PX5 M68"";66T#<32*9EF3XUN-UT)D&@+SR_#BP &H!_PO"J0?K\$!-D0/^5-
!A5<2O!6^K!Q\$4L217^H,#DVR;=E MJG&W3^VYZ.50((!;J'3PHJ*.66C!B_ M'>JW;F:C"P!)R
^Z%+6F9C&3&B*#T%8!>92%&+J#A!P7-OYMT>C+;K9;L MXO<\$538(BLPME!N9.W"POZG+M!8R0(GMG;IV;F0-
3PAK>@!0%_ VHV.K_/A?HYFX!+;1.H_-=)W!S^X_O M!A^ONC%N+UGCR%&5)=*F&QH2WE@H*!P1_1_P@VE3MH;
<!E&E;G62?M_HVYT5*!^TR!X0^G3 MB!H!<_!SE-5\$KU=0!8PJM+X\$ M;4<'Z91.J0=8?
8L/#69KX!C7!Y1G78%829X6".HC.P5&JFOQ!@_C^TCX410V!TM_X>X-XJ*MO61V-9
MBAU&103IHB(B!0&1&F2LBO_0\$!ZI8N""""%_1_OBA*04!4?E\$0HM*#\$)\$F MTB72!@
1(302A#1TTB<"84.ZM!JG7/NO>>.|=|OG3'>'_F#O5ESS3777^-^ MW!JK"+RNS-J+O<==CKL^Y(>8K!M52N&^;T
M=U\$5\$CR79>%HBI?LU"!2J\$?R+M"89IBD!5>T-Y%UBZ@D*TYOY G2&_@7^205*!1_HF60F*H
M<*!D&"8'_GUE!5K!E&%!";V1+#!YH+8_@Y-6?VI<@_..PYALL^0=C+Z!H MU!_Q;!W0)OZZ^XW"N(6W/0^8?
3B2_\$GG5+B6S@W!0T^PEY/SWK!O_9ROW# MKD=<&+DK_7KY&FU(?WY0+NS;L_@Z9W M?N;""!B_!^=
(O5)50^4(!NP\$GH3 MNL_-9&=*Z*G4Y&P6"L6"(*Y8V+ DV0B@N\$;" M"(>+U;6!K!WG!_#SG6_>>)/@!+
!F+8!/MZ/MAA12V-8Z3NGX35;*30&KC=PYLU W773+048UY!11V;"!A9%_@2S_"EHOVO
MVJO/N!Z3WE\$ZIKYV/MJO/BT2!+MN*2!;(G5BD8K#N M0PC>^(>_R%29!RR!JEY4.U.S;8.C8#
!>ZYHMX4;M587!M-J5I5Q-IU!VW MBF;0.XDCSZFGNE@H!5!0/QO,3H"C-&IR!V0=;P);L/Y"VEH#!9")%<(77
MS'D=#8R6SDSM8^='+EC3_12&13)IV RHT" L;L&F=B#X3-A 9"!A2>2%;-7U
M84OD=M3_L!;N2!D9D4(9+P6"E;O9KK!AMB!J!3A/J!P!@5!F+KR+_!O.O.T M>-I;^\$PN?
X"#;43>9;N7*B_L6^!^Y!UE4OZV;?M9C6D)UIB3+WX@K!T%5+Q@! MM=)S9UE.1K2#!6;#J!QQA!3BFP;&
<\$=7V+YZ>I.Q%"_="Q DA<9<C,&= M!3BDB=?0@%*>N:9F_!ETL!#&G.KAU^#!PBS.#?

W*VK=NS2[*DTV%@H&I^V2 MHSA)AR 1L...#SN3><(&9I0.D2)MH3\$^@D>HJZ>DJCSB?58P.N.4!74JIV M\$+C@S_B-
ERZ)Y^1KEI.V#DV.22\$7PL_EKS=A.G46LXG6"26IE%L_3XE*IUZ M_4I1.GORY*7+-BY/O**SXUXE9&7>-
@B[+M39N%JZA2 M<4! (#HHB#-^/W^W...Z.TK/!0Y+ <.:T!8W^R7.14C0\$2TOR-*.2/L)PD&@ M6E!#K0!LA98B*-^@?
C^T@.99 D43=Q+4"" 2W2Z"44LA2JY^B^U1I1H4P64I MLF%*OB]6+^>7YN.X1=-&\$%<"MRX\$7TCHU.H1ZPI."
(ND4^N)24/!"Q!\$Z2P.M.24>RFS3Y^/G.V&9Q)W8.1^YH/H4\$A4/OI_%B2IV0.^D@.1%ZQ=>7C8 M*RA_1 M1.*VP%
[S:U2M&00S2#1EDGF&B2Z-:D;[f\$Z R=GDM.#MI0TX>2XUZ!/: MIC8M> 3ZFCZ00.FQ:&2S.@ "3W)C."
M9=>K5PC4>'&FW*8Z-ITI:L_"[f%*H2R]!f'3KFA"Z4\$KV)Q^I(F%P+M\$UEN)\$ M_ V:%NA?T?5RSESUV)/P86XSNHJSZX
4<LJ24C.YI!4NW+&OYC>)=C6/G^>ZIU\$MGI%>9DP^..B MP&6:P[N]>DPI6!..=:/#5!+7P;1%AU8&3PQWOG?
UL)B.S'19ICV<3Z<.:5 MD#S7:2N.OVSH"&\$4IZ\$ M_ (=.:Y07/&FV:62:.*YNLLI\$JS_O.LRWTPMP55#OUP^T^>
MW)/WE MX+SEEL)V_ ^JFSB>>"Y1:IM.5^3:4"SIB%>.:!/:2/Z^>O:1(<@* MB!2%>=Z40-
770)^X91OQ<[WM05EIR88E GKJLNOA MGO!_ KMVC*7B&OQL="TN"[S4/4>=F58D.5%W 7F&@E[3A!WB_ :H%
[FP#R<^ M%G.P6\$!:/@^5+(<.:A.G:6=Y+PIZ5ZDNR^C7!IKI>*)36_W_R_@EQ=0%G.
MVX""=.:9K*Y=^4).Q%L5*JLF4G&9VN M(%!=BD(H_!S=S76C[BI!FYZ.&T*[DGS.6-?2G!%Z5VKV/YM M-Z?W)
<.:EC3Z 3+E@DOE[HEBU8U)(B4LC-G8IW! BN6L)D7W8B% M2.IH/+LD>4".+E^!:(QATW:B:6N.H6KI7-N-
0*YE69_Q*3)Z@LB/^1X/3A1 M_:7#KDPAY"D%Z?^Z1.ERKJ30#J3*='G%"50GCV*.\$1%A2YO_@W#H2\$85. M>!WQ'7
ZFI1/M+.T7'BUF.\$8?>Y/THIZ1A>>1 M!ACIE7WHJ+(HZ@YMN+1K*KL_F/U%_?+H.Z.Y)_BC"KE^VLUX1F2.DL&+
MY:(<^WBB3W9/^DV+UB=7*D=^O>*+>K(HXMMVNC3 M19DTR:9S!_H:B9I/%.+B 1<9NIB#[*P&R<[Z2NR1<(!
HC<1>%8#:D!R7-L M\$Z/JIV")Y.S?3Z@A9(20T*#K)VX..%P2*)7-J \$EQ=9E"W UW(G09Q(BAG MLWC7U
<3!/@L5IW25R:6%;EE3@9.98L?<+ (FDDA8f!f="VDBN8f_&AN2ET_ M_H98AF<22.(C_#\$_5)TFR&%>\$/I4(V:9*Z"9?
3IB&U@L+KL^_K2 Y\$-X9% MQXB28!9\$Q*="ISRGV=?!.O"&R#XY?H7N#^<(Z%L_=-D18>2"&%ERBB(FEB80?<
SP\$H5LS2&'969D(TAKJ#Z.A_/BT*IC/ M_ M=.*76!O#(26C&I.*2)IZ.%@%G8-3< /!#>A?IKX\$;LG;=H&HP;K%B M4+
(UZOG "QSY+ />G)L+6.J&VO>EJW8I(1SM:\$;CS M6G2HA^@#2S34C)K%NPQWK)N20F!4K2'1<5[R+(F+G4^4*0R%-
Y2 W2C;Df& M(5Z?P.4>|>TLWT*2:H0_?REJ>B""R54H_!2\$+!3>^>6EF M/_K.&IX_!>C)>(&PG;T.f?VPJ0M_&N1B(=
<33XK;B\$16ER2#D!U*!=OOLF MLY!8YX(XA"_H!<\$-IV\$>JH!"=^E019>1I!VHB015@E(O!>?U@21_Z7T*
MOX;"1BK1LR<\$K)WZM!V*9S 2I1+&+2A@JH_OJ^A93+Z@7M7BF^MU>.:@(^J9L MZ.VK!MC\$L6H^CB
+!U.3\$1\$HJXQ7PX(J.WPY.Q_<GW+^>71>"GG4>U*8<W\$^N!B&C3 M6GY2.SR65*6SH^V/V[PA^T^MY3JH!
<#MLV0+>CZ1Q#O!R-53&5B(J_O/QA M_6EJ2I5!_X_O!8G;U:69@K1DWG74^_4IG7GOA4ZF98=M'0'3X!J_-33PN M4
0ZUIX.P0Q!SC*(I>3K)TUIG(NAOQ>.:IV'5f=+NM!LZH!+AR>&GRNK MZ.YJZ/^3&%Z^_ZZHKBC"ZK?
D:9TZ27_TB&QW2IN1K>48EVZ%UZJR#PG+ M_@LNJ+*TO!453V#>O*^F=%8)Z.QGB+9?INA-%G)0*X\$>HWE-
/(J=D"!3BM+ M^8!4Q=_BDZ2?QYP1/ A0.3%07RZIA\M'9QX"/B_!H!(UF@:HHCJ.C)ZQ+Tf&<=BPM!NZA'ROM^>V5=O/_
M>.<#LDIG!01A.LH_SDTUT"@:5MCXZY+Rf^18*>^9>T(GMLIT!_ M\$!@_9=EZEf*^>_>
IL\$ADO64NE.42W>8^>MUD!T_!M99)9W!7_592TIO< ML16-V_:G3N7-D.*+!f6Y^5EGLMITZ+DB(W
H9P&YC8:0)!*R%K!"(AA3?0 MME)A&.KQ+F4!(#H38#0B#O3H#?C+V#_JU(D<f'K OZY:9)+0A.T>0R_(:J M!1
"A8.3KH:f\$!J4(OX4J)U(f1PV/D4)=SS3.V.JDNO@NP?V114M3T/ZG M4PSZ0YCM)"GI>18.W#f!J"8:ZX@-
%ZO&4L/4!O!3@:_!R%00X6/S^M.A25F_12!BON.#0S*3RLN<T" M#LP^ZU+J.S=2%*X-Tf!
f5<B!6LYZ0YTQ(8ND46>f_J^IL3AGf!XC&O?76-I Mf/549Q+FR.V!0IKR9S01PV_Q5U N...1KQ+U01.%S""<%
fW5A'TW:.-0=8G&38.?H*XAJ_-M"#T_%T9(<1)9*_@/E\$^/X!T@A+@N"S.%\$!2:%9(&DN"5Zf(L'FGJ@^_
(XU8TWS:f1N:R(=C96+N5%M159\$TW@%FU=53U!"P
M7:ZN#^!P&@1G89N.0S/A=OQPM%>R7'1)=XY)20X_OJH!%C/_V0)(&WN"J='+Z\$R!
M4.7.JY!^I=19:.#CY+7!^C<3.LDXZ*=\$V_OJEV23U6UIB4XOPM*WEVO!4JZ
MJE.8\$T^X2B@2QR<6W4).XZPCAC.f)KM_ZI?XDX Y+#!@VL/@DN5RQ.MMA!/:8DY=, M:?
0(&T/N_?7CSZD9!P^f.HTfJGLD^GN!CA=:K0N:L>fV7QG.VH<-2fETG Mf)6T545'7@4B>4:275)
(Y*UX:"Q3C&&<5AQ95X_4V3!@SI@ON6M2fDCDBG\$ MO>MP^4P.MEB\$QfA4)=V+RO&NYA=H%Y_Q M(-#&O
(T03!H@FC0!E3!/@!-!*"QF>f!_IG 8="O+ZJA:0")?0;!S_9GC MCGI_K/^LCY(&\$U_>@?;=2<>DZ1BLH3N-'GN!>GYZ%
fEU2Z"OR M0fJ!2S9>=ZX>fRVLY%)&C(#:;>S#_K J5=I2F*3@.MG*1M0\$XK-HH(M_<
0fE/6IC)H7J#EVI!%SfD>8&Y_MGDM=L=T.5=-.:9+0P3GHf95W MDZ&)V4E!8_BXQ.JWf)D9:7P'#.W6LYD+?M9V/L9U)
fHM&WfUEBG@fD)V"\$T0 M+@f4.DJ!VS&/Q1_WL_W\$D-D*5fVBO^L^%>=fHU9!_M_@D.2L+=_f)Wf8*B-Q?
fJfK^O:WDT?)Rf)! MfJ#<_OENB?1PA@#%@S(f!O\$!1)@=>f74012ALUC MOOPY_L2VU\$.H8R5fIE(RHLSV1>O3^
(J:F4&+_"\$EPW&NfJD97^>P.#W4T-RAG:8QO^Z^_7RJUF MU.W>fER_<LCWT:QU-85:~?ML_)SPfHO:~W\$902?CU)
(G_Y_&OYfHLE65@M_/37+.:)\$XH?2P^0_+*E^VL?G&K^U^W%_X<2N5FD*!fWD(5G9Z7fEK""_MT)@#fJE?
E_3:SEfFD_OfCZD4MSU(<_HCKR^6H3!LLSBBL3UOOPfHf/fYfM=J_3:Z8:2&?
=3_!S.O6."NSCUG'HC=~/+MGNfL4\$EN#8:/6F6=9#f_W 3fU M=IB5P>BH.BV!_1GMNB6L+V:1Q7>!!fV
%@PR=.:+)NVUS2fG7WQ.GE.fJ_>M>_0^57^94:ELf+DX_*MN^+R^Cf37?OM"-K"SDF:97GQ-
>L\$*A6V0!YNZG@F^C>M.TM#QYfA!2^COCTDf!_>Q(9"-f(GRVT(&fY3"YV6!QN.fJAW!_O^N M>f
(4>*5BZ&BL%>)>XVP:f6H.CV1\$SXFfMUN=UGVZ*=V_+@f^+Y.SR^f3+1DL MYGLXOTf^Z=f2L7H-
_*+XGV<fU8R/fJSP>_f36W!QYDVT_Cf4K/M+M%fOA02 MHfD/C<9!%>fU3TUT&Bf!_#A'M%VfK_:\$fY@f!@C)f1#4)fG-
L7H^KAT8+:(fMD.7A=:N_>_>Q^C(f^1Y2X^L>f^NG/DTf2YX>G)fK#_C!f%08D""A[fDf MPfPSK0BWX>"K_>EO+2%?
3^P%)fBfE0fM+fM=X1(fCKX\$O!^OYQ:%NLZ M_0.99H@>H2GW0B2f!>MENV5=?YR\$+9)fYf17O?+:X^0:WRf
f!)GxfD)\$_NFfJ&T:BDE M9WX#Y*9fLEfPO2PSJA>3fM3)W0N=>6#E=-.BS<OJS/f18&*O"55W8)5f)(
MG)Z:~08FF4!2YBR23L?KE9\$+4fU\$SfWZfJ=1@fZ0X5G5B^U)W?EU?NX_8 M+X\$T!1^V4/&J
fQfHR.MLA%!%PB:C%EfHBP0:5EV+f(fDQ/F=#K^X8D!6X MN_Wf!>QR>EGRfDf<f
&T=Cf&3MXM^@B^P6*9f/@J&^S&7>TG2: Mf! Nf!2DES%#H6(fSf2+=O.NfP:4YXA?GT+0f!8/^A^>-ZQDf?O8);R_Y
Mf7"SA.Y2Nf+3H33#^CLXMHfW:L^C^&#E XfQ?X?Z:V5MfLK28X!_HMLN0^_K MfD=?=Rf6&WEXSfY.LV_MKfKQf
Q99X1HfB?f7V3f!\$fOYJ:fA4A^Xf3K_&2 MKf3C?_STfL^!>fZVf!PfH^#*8_WS:@SAf<7AS7FF=\$fNRN?L+G4LC^
(3f5>N:Nf1_GM+:+RfG:N^<NfK.S+PfPK\$^D=NHQF=BK0174fFOM M^C(MfD5RT0+Z:(=F5J"f18f6;G+&\$"#(Kf!/<#F-
Q3V4/LfZE=FB_>@P269^M3:GW3LCOV/2R1^%UP@f!>?^E(fDZ2U?7B MfS0-0).(6@f=2<8^D!
fMG70B32^>GG9Vf!XfV^=D3E.MO8+7f#fTN_fX_f MVR:X@K1*LGK3N+f#9_/J4:~PZ0Xf!
f!>7:N!f0fNY3PZf#M4_Y>XfH4 M.1)<=SVM>_fL@?>.:fY4fO!K8C?L9PNMAR6);P3RGL.384ESDUS>\$2f4:\$ M_O2fJ.
(@8LX@RD(S=K8)fGAYf!/:Bf1KKfKfO3HfJZN%^_UB"C=^G^Rf M0fN\$^C+
(<4fJ^N\$=3E7\$.C0f!5L0\$BS<32HfZf2RUfA)4)QfHE!4UT8WQ Mf!^JA_Sf#HR^fZ_4QM_ZV#fR_ZHEE!<
N!@NEf!/^A!N9B42:&f6O)f!-K M#PL3Q!VMDX:VO_~FE6AH:5SH1&#DNQWXN<(R_1KAT0f!U4^V+!\$R0&1%Z^6
M\$ADT+PXC^X8Z_-BY.ZR+;Mf0#>fI#f:HKQ\$!_E_K6#?fM=2)>fMK8FAJ(SV)fJ0O:LYZVKWf.GN Mf!)_fLfW3ESE5T
M=#82&2NR8D.WXDX.S9_f^7.G^9L_Sf3_V^6Y.#2.fE!O&Y^>F=DRH7fX6fL_MVY.HY?37fH!""QH;
(=+G1#U@.0@:8K_PfJ8f!@H=Q MUf!_3RA356X(H?f!^W#M/D@.T7:M_:PBAWf.1fMW&>EUZ0SfJ=UP_f!>f?
M(CDT?0+/_R7(f9fEO62"\$P&?D4+2^Hf1MA221*!fT2L0^_ED<3f1@6
M%);SSGW^f_92U0A=5471fU/PQOS9fNMfH886X(%<=5EXNM_#Ef!O_L6fIAO>@ MfN_E=MEAf_YWfS:>3fL_f!+2fLU-
f)=&fL>MfNf.ZSX>U:%VfT+:B7<(O72*f!@OT2Y+@ M^f(R:<+:E1fHG8*7#8fJ\$._^X?
+&f>MfJ8GVVT>W^T+:5K8.Vf7H^1f?%APRR+_\$.DL69D7f!MfJG\$XfU*RR9QOP\$187>&5HfOW2?

I#5\$!"5H21E4* 6EM#1*0T.&<^53+<0,* M.4FP 3P2#,-!> ,T-2-0E8SG+Y^-H|P:FW-5U:U "KK@:W?M@:HW4LLR6-DO
M*SLJ3>#IGQ2F2-#:#|=P<95 M(#8:JG8(NM74*GOV1A UX775YJV|Q?Q4FX66&YA4BKX37+C9^|S^H|
MC>*0.S0A.-!^&=4FLY9>Q12|H",|#HP+*("VT^7.^P)CN22,>*:9! M<=6T1D>00G&/\$10(QJZ|>W<?028XC#&-
G5|>X:0/ D/4?1VIG=0,"=^M|!|,?2,T|((KNL_0V#1TQJ,1AX6B/D|*?>3%:F|<19+|ANS/7"8V:~+SEPI=
MRB+5GG02/R|6>F8:VDW:00<+,%NOZZ8|T,U\$U_VF<+506?=\$@J|NQ5QVY(T7 MV:MU8#HN!W-5* <-
V/N,IQQ&LDFHDI#G*0"3JE#<L(H"F|QB|03|1P7:.-T#RS@;T/>=F.+|#2>4 M@A,K'L)GP|_73=|TXAA
M&@|JB%'(69|TW\$XD<&>%Q*63!L5,*D14/@TG M+>T\$P-&|60_20IYG9/BN%)X<=%&*Z|LR=FFM?
YBA_8|GS*T;W9X5EDR|_&8 MFU&+Q|126/FMY|4?L'Q1*.)#I=A-W7\$KB%U1EORJ#NB*SOR8G)|V1/?^!1MUP|E/^8!
|((4S2?0A&@7E&9B09 JOGTU|Z|2E8'Z2H>.*=M>6/5Q9(6V|T@#|I=Z9)!MXH(O#|K/*11-DWC+T.C:B_ =ZY^|
|JU6Y|_N: M>:/0|G|V|&|ANYHOLN*8DS*Y M5>9RG-8C.2)^ (9!122%T)7@C>3?^*|
<4W:~P_H|R.4C>8FFK5D>B1HR4& MO|OA*7.JEEY?WRC|KFC|N|0=D'P>O(^NMU&VU5JU:WFA(:0ZN>/BST)'R4
M0C8:8.M@48F4|_G_K(C#^B<-R5J3HB|+4KV|H9UD|+WU\$ DLET)_K-3^-/(X4-A?W6KB-BJ#X9|F| KX10JY|B:~*
<O/G82|H|H*2-EFGET5&A<AJ86%%VYZNU MR+M-642-.4.)E XR^H3(N6"\$Y42?%(F|3HTPTKZZ*0MW|34&%15
.,936&#)G\$'B'|?6.9>|S+E MC7@W/7LF.J0WE1YK.I2/D4UG9->EN71G8#^3>P<3 KI^M%8X+0\$-*987A_D
M83,E0DL1|HR%O IG>K&AOX-1*(U%64Q)|X3:0,>|OKJ0PF:O)3I_FS1?9KM-P4|P6L%&T0GBHNCBBDS?
4X'5,I^GE4|H97=5="H\$|QX+B_6P2-M|@S"16.W\$DM|DUH'FSZ5N8WV5|HIG\$PK|7ST|MM,##97LI6|*X|_T=ZU(
M#SM72@_ILWTC&J_Q^QU7R4Q5.M65U<M5>9+|R.Q0Z8GJ"\$XF_Z_-1NBT-Q/Y M(|PM3M(8R|RE%Z+|F-
=35DP653S)5U)ZWS'+OY+S79.K&80:WD_-O2("VDRR
MNTP#Y3J.WBN>4UH55+^,MZA#C0(STZB)&B\$WR#|B.O(M\$M?O:,O(4/_^AH M6C/BA(%+=Z%KVDV~|K>+"
C.G#_N-^|(W#WWNI#U_C@<?|NKJ9VM:M|MLHOBK&H<:A_1SO"MI\$88XEB-
B|SO^WB=MPRC%M\$*0GM|C<:,>C|S<|(>M/T(|?7:1=M,EP|LR3MAF9_4.4<5W5A22'UZKQ<%&"|HH=JB|NV|P^A-
QXX-M-W|05.%4040M_)))? M+7@(|N<|X-Y:8|@5X'F_22V1-5<_48(&PNQSF48.J,)+|+|# MO1GW2F(|DY~|F|L-
6T=|UR/%|82+|'+7V98.ZG:|IDQW M9EV4W?VC:* XGG?&=B|NW:U|&:>1-7S*U+(CO+~A.&NTY(HL^~|X|
M=W5|9/ES#@R\$-1#25\$;09|)|@HME@")(&8U|R|&0/A:16#8^9-3YSE3(U%*" MW(R-PE,OR>_K0?KE4=>
(M,69!|E7#&RK1'-R|03@|3PZ_-KW?4#02U^EN?LU ML'R|H|F?"#K2Y9U?1-D)Y5'+D*
|~4R%+2MTJSAMM*_NS69*0T>>YEC%108-W6
ML"0H*B|BX>P_68I>H_N6Y:08Y3:5.P|^5PKKUP|FWS\$^P=O.TN|>=K2|X|Q^
M8EN/4|9(HGA9&JF32:|K|3EG9D.J7Z|S|J9^34>:,=C:2XX0MH@4P.A+FY/ M6@!2=((R Q4T*0L_'G>Y?P
MMBDN_(!W=AAZ(YL4NSUX*)+Y8+H(%1/'!+|J'KJZOTR^>Y)BK/=UC^3-HY'1
M)>WL^RN%%V(F9DX|3K_&B\$SY..C=VNWH*%Z,M9G@7CY9V3SIZ)Z5E7O&.=|R MT|AS5IF1Z-
U4EP|9(7VC_G&13*#M*G&>.%2)<"2P,%ZHLZ1HZV2,RX4@A MF_#|/\$'V@5I>7Q.R9'T2AW003)
(&=J)"HRS2)FY|I2CHF1T:W|/QW&|M+<MB6-NKE.N5_0=P|"-A0X|_29&AJUU2|#_Y
7HD1.P#HB7UO@WW>_1RAY@U?B MP^X:R|0J?S|HMN&EXW#..Q_'B+3SB*1-J|"-D-CLCSS?NW#_/?|S21\$1#YV:
MR:K@.9&2+X.%4A|6*>DG29:&10\$2\$N6HYW+|7|H8Q0467|/SHM,7Z^KV&T ZCV:~|A9?2,|2|4)X#UR
|Z=VA#*B:~P|M|_M:#ZM\$;8&|C1RN9^~7JSH,AXE_H|D+N|Z3:~>O*C^Y@W10Z)283:~|URa5-M+Y@C
E:~14B"FODKT#&R@UP5|M:H1S0^N"VI2.HE=6MD|H2" M:U/OQ'ZA36%@+M.M+<_H|N-
SDN"~|@/+5R,&TF/(*GL:OY|^_23|L%:FK?CB:~Y8?3"FIQ=-+5|C_ M>8<6(LY66_ JMYG9G(E,J=7F:
(IV=300W|XU\$7|&T07P"~078L7E|.*\$ER? MOEPAQ5*UOI% ^ND7>|N<:4LF%12&JH"VR_DBF|_Z:1N,5:E:~|_?:
=+TP^Q M&IF6W^KG&D8*DOP@_D>LBX"~V'DHS'IF? M)2^~B6Q1V+9L@H,19,H&7V: M'-Z|6ER60N|C|H|NU6
UD",IA V2:|QD|MPB:~B*SE#GK|_~6.E#M|TE"B(^*B6|:~2%(AZ!|Z0&~|H|** M)B>%^\$"_J9|1GR*Y*+
<>H2.=MU>./>6|XU^L\$E2YCE^+~|IAM_L8>*F%1 M^7EN_9M-?J5?2.4R7"J%YP0R5#2|RBV86!*\$J8BA<1,+MI^SK?
R#7TV_G5 MQ|HA_~G6\$|H_52K7)=|C|R&5F6E=JQ?H4,VUI^,^,~|+=VYSN|4R2<37.^X
MN^~S:~>"0|_7V7FNC|W|H/E.ZK@W?_J5H=(+5FVX|T^1%&1033ION=%#| MSRXVM>NP(9UF?
24FXO.%#A>59|39=Q.UFU|(R'K)M?5!~.Q#D4 MX?)_6_FY8G|O>XOH'-
YPHO|V|H)5P^PH_~1*297/P'+RCYV(F/6T+LF&/9UX M3%&+3.:?>*E%~|
<6)!TS@VYF*355W.>6*|O:_0A|1>8'S^8V@9#6J#EI=- M+R|~4|OW-"AWF|LH
MZ7A83|I31OM01?|2EA03|QFW"58|H50_WW6.BU2B")IFCGMX^Q|T.&H4Y|V M+1E!&
<"*2E:C6VT^B76Z|*EU:/HIN8S<:T?48"5(#P!\$18H%\$&+Q9\$60\$P4 MZX-"NFO_W|~|E\$6)^5^? M5.=:4R1%1V"\$?
R*1X2+Z4|G|=3_TZ|_ZF?F7AG\$|W<^@2:~|AUB-#-#|6=5"V"/M|~2MWB;<5YA)|FBX=V MUKKMZEO|&E:,~7%S2F-
714HUM'FSY_AQDZ^+C8*AKBC4LCUB>?~7^C:~)7,N MH_~9(WR|D_0*80WU=F2|HAP6E^BYTS-
^FO)1<5%_1JUT^1PJRGYOW?. MMBH_~5\$0ZA>R|M(OHV2=J'KV==9S@L>RDC>2>)W<|ELU|DE^27B=RZ-N#(_L50|
MN7++^6+00C"KVH'1UW9H2_O.VR|N|L|?~:ISC,'\$P=+300MWJD-
RTZ2SHOS)=1V144DU\$&2;BFR'B:~|1'_4)F.7^2@IY<~7*604V3<88:E| M>"KLY&"Z@ZW"/>W9VG+ES1&?
E_~N6.%K.+2|+J.Y7GD^O:~L|RMU^D(C_Z?QITM%1?02"Y6UD?2:8>|1\$AFHY)S)WR:8."6%?~|H
M'|=F./2@FN*7B@.E&E1D>F7\$+*~>,>?>ORX7^?N-&W|+?Z&3_~\$3'P0=|Z MZXG*NOH*13|HAN|8TGR#%+
(V6@HYH~9U*\$0\$@B|VW*(4L6_S3|_~8F&#BH;K MT2<32^&MXS(C;*M|EUD;^Z"W#C(P3)^CM.WE?1|SE8XG%-VY\$;
|EQXZ3>RU?9HFC9U5**H3^~HO:~A)U2L|3K1T MS XA"?M;E4+>?<-"P9B;XLIQ7;LA#S_-L;ND\$~|T#)~)_G
\$|199"K_L5 M-R'V7|UBJDT?ZRO.H"/^Q9M4 34:0)EBK M:'SV#3<22DD-CT:/HTT|9P M5=5+"G&3E)|EMX;WT
3*~HBI9"C)LB|9U+(L~:~P M.>D|LA=O_E|M_>PN>KEU?OKJ|W9|H\$GAA|S=B<3PCY|H|~R*G'K*5D|7@Z,3V,~
MW|>6&|WP.EJLL9RU>_?HR.~|?|~*S&0E:4ZU)TC77-.P67 MC%TD4WYSY|O?%6IB@177MRS>R+&D^Q+I_-
~1012+85KX;=HFD9/P'G|&\$:~|MKA,F?9%~|+7EXE<\$V.DJZ^9,|H|H|H|H#H^EJ1+41.>~)85ZLJHG(^F,T%|MDK7='3?
LQ.>?6+D_W@C_7\$0:~C\$0>O#L%\$B|>\$B*S.>B82&&0YWSXQY/6GS M8K(KZR73/EC+|J/P>_7X14_~.B787# MM*~R|!:
~)HJ_F|VVG#X VE=S2|D|'4PYDPD^+|~8ZM(L<9:~?37YTZ_~AL> MXZG-
6.BXSRJ5E|P)YT|H2E1^N0\$B3*_HR%|H|7'OP)G#^+;|F%VT#~PIF 7 M#~\$LZAW|BR|0:RV=AD)"2OB;4NZ|T#FL-W@=
7|ZD|U*XYZ4)C|H+~N&4;&D M'EQ#C,B\$HEUT@~UV7,I>A?5,*O'D|FICBUZ^2|:~?>2|H6%.H+~|W^C M:K|Y%|H7:~|
|4Z&MHY78FSRYDGPY7|VWM@513K-S|HEUT=#|8A~93QD:3|YO M/2&HU&^BV+2%0@IQOC@U.TWLXQ>4.R@91-
D)1U2" 7:~\$|1^4D+K916:2"K4 M|CC#7VLK=2#N!#B%|J|T%)<(<=<_JXCDJJ_FSH+~|~FEVA|37F'~^W#X8Y
MCU9\$|V+1=IG&9|JK OA_~1^*2X|B*_3WL_2C|1>~06(0VL\$3D%5X HH4J M:~@F/233H9FX'H_*OB#"~>E-Y\$3F>
(R(R*4E|2%V_|JP.\$@8EU?1 MW%|10|&13|""+(|BO*N^U|?9G">~'=YV|+|2-N|KE9)#JVT9-9/_D9/24"W M)|/?
35ZW+4QXW"UN3?TO/#%K9G&42M:%C%_#9"~|MI0.JZ44H|3KJ:~JB:7SD M3
HWT8K=6RBT|7SHJ"~T@?~|GHF7|PBGB"U24@E.\$P6T76W!~|~)~)=7K.21/TAUS^N:~L_1WNB|S*F6L\$+~|_~
MXTSV)GBU~SQH^~O#~Y2J+~SK-0UH S0T+P_VBG9@XOD M4#X4H9KG)YCP1#W2|DF*FC'/_C-
Y_3Q_AZ(3A@8VIE#4:~+=CHTIC|S|CETT@8_~|H0M|J"(>AH|TH21P3|QL>~%97)U@~
M4:~*FAK2*~479P85XT*~WUWT0RHL=FP|T#4619@5VOW#F0_G|X5|QS=^0169ON^R^|BS?I39L+|3K\$|R)=<=K?
Y4|C2: M&\$X:~|2+@2:Z(EX"~P1S;XGS%U\$#T:~5OCM%17B3_|AD31?K#P3/728+XF6_M_HRUUTV3+N0!9T:=N,M*%
_KZ5=&EXX'5RD>E>^>T\$P!~UJ.I/HJRIJ:\$ M'5:_X?|P8<9K2H
6F:~STB\$5_IG5.=NRP#JH^J30QL)/_VRO=#@4_X5N4<9 MRGC?PV*3'@+W.O/|H|^MN|)T|
<>^/X3SQ2K%U7A>~"\$H9&:%1 M6G_)U8JUX8%RC6Z\$>JU_L(KDB:M_~O1T(C\$#|&^~|2K8_OGLTVSY|JU*~C_

MO\X_##@5>MB%?%H>;UN^5Y5BGJR6!/?R1AW::72RV::.\$?ZY'NCN!'=K=-.7V*NF&+3
MH+N\HR:H3*^G^,P7_S1%8?QGB|\$"BK:U13_K1<+0U^!S26DT&=?A3!ML-J>YOR_JBTWZ@RJ3-DA:GUOI/RF-B9
5WWOT/O'QHY@AKYG-DIG^K-H6M2_1V5_U8N:F%?"QQJB"&644TC%V7UJ_&%M\JYJ^!>?
H&&9KK/_D%8>N*N^NE8ILS^2VS)0>GHP7H9N106"2>PN3W@6?MNVU:JW7XT(E_%?M?I7@6SY%?)GYP@O4J0R?
1LQ1%RT%*YH1G_3PBH|G=F_M6Z\$S12K#2CD9-Z_QPI\X>OVHJ?D2?)B#P>V+1HR.W@LR77TDA=T!@!QCH2:!
M@T+KP_X&I5)(Q4)0_HB56G>OA_M7)O@<R4KUK4E/?&_G@\$*KH4E@4!;!H/M8LY_D.*GJH#;T?5;W?&9.H1D?
!W4\SVKRSLA!;4+.)G6ULP17I+(4D#V,4S_MIU)_@%D2F2+,Q%SEW8AV^X&DQWV>_0_W.PY*_,GMHY?L2B&_"L_&_
^N(BPHGH5_MB_)sC?>@Z2S.I\$NJ&+A).OB(#&_ =HO+GC4CT,M5U.9?C\0+%ZZ:5C96LC^=6
MX_118IV\YMOPX4@ESSQV?7H6WC1A_?L9X9.5Z_P%P.\$_7QZ<.(ECZ^32D:W_ME>SNT4/O7S1MV_3D-9-
<8&U\$X!97G>A+>^_T_MPR<,K-X'(V3IPV\@W>_.3+^HO/XB= M7SEG*W6/Y%J6*SW.=G!G=O-R+%ZY_M\$!7+TQ?
E("F#1\$&^OGI0J(\8N^L=GA+!OC)H\!C%AG>BH5WWW*K;H_MGRO;X^VK=ZIJ?M<'MS."&QFN7A,G)\$A_%KGV,\\$H8?
W20J97C-(I=>_76_MPS<14E?%A2<_16EC<7UEI<>ODE!_!H4Q3B"!APK_0_0/C:I@ALCRYF.X@Q#;WQ)G3#^;UJRU
M<*=08Y_5O-IFL+F@*>=^X*MM&%T?I#SOL9/J0A9D8_X%1L%236.PfM
MWF!LR)1"TBXU.!HJ_J9D5I5#>5N!3NNE?U"?_0*U90YO(BN%C+?K@NWP(NN1_MPV>7JM^?)HRZIE/IBC!NO^C:_I_?
9'ZY'X#RMGK:"S9BV7I\ZXCN^LT!"1IVC_M5H,*H/Y6_%1Y,F+'<#_1R_N_BKORMZ8;9MJ\$2?\$H4@%(6HJ\$Q%IA8"D2(B
M(!_@8(0A\H4(\$6.+@Y!2R#&+%20(C.D.HN_88Z"),@H,BH\^?W\YRR6RYBHA\$H\X94I"6"DPOP_ML\DC%^&3\A4_A%
(F"\$FO0>_5="I?I4:F_4R^_K7VB\$4!(I\ZC/R4X14#TP?_"?)F%!,%9_M>FO^!T-
@*8_4*3>LA+0YET4.YB8\@23T%N!XCCW"\$3XX2UC::,MfA'ZH>
M(N@=>_"P2D_ECQ9HVH0I<0DV9;"CT!E^2I1RHP_"ICWIK8;_!J5'?MKL?T_MA^G:RJWOJ+TD@_*NA=FQR=(H)-
@H*(R4#S3U**V\H<)&#&^EP1GE\$.Y).M>U_.H1S".C_X!#I3T70?ELQODKYET1-S1HE;M(B^!%ATW/84WQ"(2@;_!P(?
&I\B.&)D7>@ZKIO36BF\$2G4\$W/K"JG7R.Q"&81RH1+T=OPL)>)V!Q>W
M\$Z1)M!(\$749)M+'\$^&!@=9'=>P!_QV<,R3;&S!Z_ILC35:IYG,T4NXJH_L_Q_MCJ(*0(DT!1CWR?C?WF-
@<&T;1_1881.61H);)Q)6;BG6SDWYT-NUH(A1Y_M1:V10XH!"9"-2(G77'(GW\$'_HTUF(-BL!%_M*\$:W3?LX)_7F+B0N-
\$(0GI_0FUHV;_0"RJ!"NNH;W8="0YZI\SDLTW*0%ZV_MF-E-J>X>Q72U^8/3H5YH@*^;LHJP<_;"
!+C'#ACFNE+)5C0+Q(ALLU=\$CXC_-U/MRR%3&
M8>7^VZ2.X7F_YRU5.IJ^238)A'BJSJXU*\$(>MY#W95OAJ9KP4E+T0I% ^F2: M4_2C<(\$TZ5TYY!K>?3!@
E@5NYBDW!)Z9L?DMQ8X17Y=RX_X4CCH.P+KC2.'G--VFB@K1^IA&>%B;5R7>J+TV?I4S3)X
MBAEPT0GV!Z9I\VIUCUS\$06_V&7S@CWF2A2?C.G+K8+!"72CSP>5FG))E9+\$2)M2IE!_!J.MT_#L)?
5I*.:Q+TEAHCCHV\V<>20!H\$:<#"I7>)D>)T):4USAB:ZW@(\$()9S!6=HX+2L_&Y_MB:P/L>6P!=\$"D>+IH9!%-O3UWIO?
I/TZV^:95Z!%>%I>K/6:J38B+X%\$I_MKH_4U9IXU6AAF7??+GPJG&I\X7;I_ ^L>_!8SA5C447-EX+9IC!&0_I/-V#
M12\$5T\$33_YO6.61&_S%-AJ7/HA:5A>T12!4"4P!&I_N.=
M+196>/>J.5.RO3Z5X.KL1"4#OMK?QS9C;V0J2L.3.=F!^>R0"NIHWZ.OVA_M2(2+
QW"!0.MH/O!8EGH;SLC\N0#^_3KOGA%P1'X'/ML4>^F=%@:R'/+=
MDDB@F.ER!B(8BYIM0?)HJIDS1(!7>='=HI!<_X834FX#K<=8L=2Z3VU*\$!:(MG/"HJ9NBK"V(C8&0-
K!RXY3N!U4J0F)OQJYU82_&IQEA_MJLC/X6I^M<2QD'E"RI?&BBA^9L.D^_W4+Z9%N?CR2DOZ%=&#;Z4KKVN7'LA4
M16I_YTA5#CFQ9!J-F.G.I^RH7UN)^B;J_?I^C_%!8C.=R!C)N40C@:3X.GM_MT9.X@G;V%?B^KKWMK|
<5"X3:M5>A3U=:8Q1;YD5PL/QSZ@X!.VR_M10S&WEP123-5F;@YZD)015GNJ6!4SQG;.
I\$+Z#M6FI\JK_TK^EOZ\HHHLW_MV#JBJM/Z&0@ (FEY^()PD57K+5E;_IA4D!8"FDK!3".PIY^8S5DQK;FG/&XQ>
MW/30#G_4P+3HT>+&S'AQ4#TOS%WEJQIC)B6?&U<+ 4(H^&3L2M-L:(!"LH0_M1?
8(K#W=A197LYE6#8N!CV"Y^T8R*C8Q6^DY)BX"LV3A)&7\$(+H9YVQNO7&-M+=8Z:((#>OW)DSMDQT(3!P'
3LX!2D@^N;@H\$O,ZOUQH9GT3P.=^H\$X761U7Y+U=0_OC!U_MLPA@41*<^8V=#)>.U++<6+AA-
8+6HJGC!@JCN>/GZDP.&!>P2DIPK72*F7X_M'.FA!;(N.63#C04BHC^9;LG<12#CJH24S> C<\$10CRHHQ0UL\Y3;>O?.WR
M/O>(>_ES>YQ+)_J!C1>AELDP^L&X*<K6;G*G\$5U0AF.KSU3RTSUT)D_M'G/M\$1G/G,<(-(!=LY;U?
SJNIHWIN#Q(ALT!5GQ**T(((\$@XA/?&5U+B*(M&I&7G4W\$.M4P%V1;AL5L_7H=D0SX-
>YO:UB_/7P59BK_2(W4W+?)IXW%_0K15>060_Y4Z9#W-&BL
MIL::85IX1%3PMYD^>_/ER;./7@IQA8AZ.'0F!QWWT_,\$ZUL/+RI\>_PG5_M/Y_KZ\$U'N47:=X\/?!H/U,T)R#@X#?
MH_JC@?GIF0?J8H_VKHT"(>KZA;3&_MIK\$.R41MS)-^/BL0:FV;R.5\((44RI=S*C30ZYQ11U:6!@
6N\TGAJO^_@V2F:EB.UE.K*=B_KB44/WF<)_7%N_MYEQ.1A;_O:PI_R_O/?F%!\&=P1(F<95H+9AP-
2**DOHP@Z7J?3T8IQ)H8L\$4_M_,\$-VDB^!>_!WAM16EB8^QV^H)D#WE.6X^+DQK454>H8@VC0J&3M*V%H;
MA@RT+M%KOYGI^J6"W)0W9;?*W)6"-BD7YH6NA15ELZ\$ZDJDY>UZS?KY?9?F4K#^+M_#...?)3D>K6+;XTR?
ISM4DSMKT6KO?7"W.8=#S948B!>7/&62=EF)!_TI_M5KBEQG*/Z>C:0_'IMR14J'IP"+_ %V\$ZZ9M+#+.4J#V=
(W!O&7*H^S".1C#C_MAO9UBE.G07M3>_!\\$POIK;_7LR\$93\DBZT*?)UR6_M)^MB?K&4_MOV))A_CO_
D.T56=+=MLQ%TIT?2ID8-&L@8RD;fVJE>61YB_Z= M4S-ZSICI=W\<2RMI^MI/V=;E!8\OT4+5TSU#>5^UC?
7.E)Z:B1;+!MG=E'/M=XZ#;\$1'WQ?GTRR&_M-G^T52:A1)\6Y\X56_*V@5@F%GV\N_MG3;9ZJN>ARYT5!^R<='Q0GI9K
HZIO\X#D^?(D-B;BGZDK#*S;0CZ1!WC!#_MU<'YD)\@0E40"+F+DN?3K^6SU
M46.YYV_NHS@!1EAK75QCZ6;0B.'PGFW@2O@;MF!1+9&IJ5\BF!^@?4;+7@_MCO80M%XQ)OMB@#
<5B(4&_"VFH.UWPFV!&7Q?;RB>_U_MDUYQ_2B_M_9QV;MZ;1VMME?6_LH7+(YO*.E!/:WY!;?"
H:O:ZO*VGV4(4#*VILV!%N3IK+!R_MG.-=SYK?509F
KVP%F>LE0**0%X_"_!OLO\$!01_VD!_@SO3D;GLP%X>&0S)W<'DZPP\$R22\VDQ:Z_H0;9-!Z>8%MSF*3M2LLRRR"EZ"%?
JDI5-WP_M:2^3EPI/H:3MLHF;|C(2^B#C1H*+&&L'E.(%)SZ*(PLB?1&Q3@2H?)*<
MTRK3L(13\$2N#%@\$ELLJVVW"9;?OX_8C^JJ_Z'KS/M%\$S_4LC"?NB3T,3Y_I_M28-&*5&Z1'UJCI%,<1%6W%GB+X'I
_AIK6)_GFZROV^QY?>,7^1P#(OXS_M@#Z%YQH_6_JRU^M))/%N^

I8;Z/4:T!CJ2>UP8.T#Z7?:BY3%Q^WQOA_M@SHY%:&/2\$V1I4.[0YX]5*B8M>_B2T'PZKYF%PO9SE)?7-3RWRRTD6==
M_IY00/U!>N0HX_!P>R!6#_//UM+\$U_K&U"0?^<^B)"PGCO!83*.GE;)6O**W_MCGOC#R&MS>_
EAU>0_WN!;H:;G;+!+1^W_J9_7%*AEK1H.H*>F)\$<0X/1H6_MIL^L%KLJHD%XJ&Q7;J"B2_O.J2<[PIE6!&_)@9I?
9E3B82T#NzLUMTNQ0_MIA=/(@W6!;@IWN9Q_3*3^#M0XIKNMWY_.8GX_L_@K.&RG1PK!!UV6!JA?_9
MC29M5\HIZS*6;+5^D_56\R&#R^?*\$G.YX_07I27_3G>_C:13D\$SZ@P7X)&_MKEU8HT)E<9^
!P1GY_VD^TM5E;_1\$XHO\$4#?S>E8\SC7P_YIA(Q<(LF*"MV!74"Z>X"/T)@YDR%6Z/"-
_IQ"38!2JPD0A08!87T!B5)6E!9J.MLB!11H>T_MOY&-#VVJ#_VM.C@1#_JD0
>Q^PMTDI(&!)UMF7)14#D"-_OFS\NT>_11V#>6_M2#FHJZ&Y3MCM5Q^+R@+H;
H16#BS5FJKRUZ2<+7R3\$CG1.252_M%9C26N20+V1_9EPW<93Z)9VB13@7C=MUQG9558!MP7WD_TS1VC2!-
!_:=U\$&G;_J/ED\$3)<0/LML=VTKC'F%*QCVQW!_9L_M\$.2"1D_RG++
MW+^7JM1_0\$.14>)N%L<.W>:TY1+M_AV<\$Z+3."XGYFMS6YP9WIFS60X)(0'T_M8E#D_RJ'6")8-X'D&
!+=+E42GOR!?:OO?=8%R<6BEC<_Y_MIT0!KJ.7;#ISYTF/Y_@I?4A5J\$HH_X_M!\$0_R+_.%=<5!;_!&/2+MUDSE"
M5!O"JN9:2OUZX>)C*95K>#QHI!|=NX4+^C90+!_WB(ONZ(8\$XX+S)*69(-M=B0!Z7^189VX;U3JESA+?D>?
G56==WW3)\YJ*8?DMH.O3X(!.G)J(5!NKB_M7IX%IT9(&T;%V)\$#I_!B6ZL;
(_C+HSZB32QO2O"ZN#=:!:/%OCJ2>C0#MHS_M+6?GU-!"UT"9CJF!_5%ZJX\X68\E&*???;K-^N0>S&HB@_I?Z=0;+<

PZY/MT>0M/W.JH.&IQ.=CBS5HE6.&=5D.FIAGI(YYQ?7SBI#%Z\$?G25P'G36;>3R.M!&GP\$PHM)B.D2&TOAF%U
MTL16K\;26KH@1*5^1076B\$LG?GC;.*HV*&)3R>W\$^%@(5B>U''7&PLO=
MCPRD7OA=XVO&37COYD|=^IDI%ZJKJ(WJUT+F.?=E'MZ1J6O.#8O.QOM.;7ZT7.8U<JZK*''@K&AH:(9Z@M+E_9
MDP?VP''FAK#@-H'')@<?<0=WA0'2H0I@(&Z1T\JZV1F?2)4+E<M.M&P.6ZC-4&T:1<'I9I;7X!@+6-
O9.UMI65K;DI.%Q-1/DJF0HJ>4G80SQ.MOCXYZ=I=&%>\$.M/1GR2+I.NSFWZ7D\N2EY^07%>\$7\$^7@9>7%!?
G%^MH;Z&4H'@U@#SBA?G*CRJP!0I)&.'KN:6CM2>#A.6M08L4ZWY3&RN#0944JZZ0&J^:ZUUK
M.WLE/W=K+!^CRSI''W%K%AEI/&O28+PY@Q@9R<7#W&P%.-/3Q='
MW7_F(=16M+=RD9<IYI''RU00TDQ_H+1%QI>^VT>.&^1NR\;GJB;&PIOP_/MA6K!Y>'KXFD.YG+Q8/KE?>L/2S=
I5TH4\$N#-1-1<>7E*,7IYV5N)YVC;M''%E860EQ69@+6''Q15F9.R=K9VL73P^4-
/AX&E^VSY1(OICIW15''@>46W\$H\FWM.WT.1M!?'UKF%Q\$0D>7YH)\GS!_@K2D):TLQ2V_8P*Y_IRIEK7;
M_T1;30;2_R6<.,PDZK.?;UM1TYD>#&Z);.1_I?@O)@<'SB^6AIOYHIZC_9/@_MN/Z5_.F3KUNIH:S(<%\$ROD9&>IV/
MB);.*FHJ2C)''AHU@;TM/RT)2;W(PO);.0Y.*FH&@>=GY6=@IVPI\PI+&MOH9SC107EY3I\N4-
IO-QA6P'B+''03%^M0T=C!*X0H;:3H2&I_!4+KB*]M/U MAZ''(=@4=XRHF%C;.-5O4@YKKP!4T=/0K&.A7KV*@4C=;
(.KO;15>*;?*'8M)-.L1C=2/D?)^5B.IVH''#3'(\$R''UBXA^!<(Z>@I*)FN<7*=IM=4\$A81%1,
M_.XI>05%)645K4?;.KIZ^@:65M8VMG;V#AZ>7MX^8%^_T''=AX1&14=')*4I3.MT!*?/<IXE9=?
4%AA7%+ZKHJZIK:NOJ'Q26=7=TIOWX>/HV/C\$Y.3TS.SRRNK.M:U_6-S:WM@.CXY3LI@WAZ\X4&H*IX?
JK?I&A^+J''@8&.@?6=+I0K/M\;M\$&%WGE-Z;N%:.)0ZV'79K?C5I7.M(P>_QS7V%5RSGG'RU6/\$1%9WE'D?
GS5E)'R5%D\$'N:&=2.#&F&.\$DC?1\U\U MM+V%+2+''0F1P%
(T!*&:JWNCWQOJWNCW1KW1\ZH1)*KQ*\$NG7H^K4\$H.MV@K?
<>I2G^N&I>QHE_+4H\;HUTIXW*=KP0WE2X-^4T.9@>0@%''DPD.V@M?
BDR/Z5LM!@MLV8!!5V&YR;.IL_03_6X+2+1V^75B&4N\C&5+LSB.MI58I\B3D)F-C:X9?;6-3AD8;M0-
1PL0.E.4G6\$MBCCG8S'JKS^=YT@'-<3BQE1JO*MMY466=*A_I@->E;T%Y
MHIL=5R_5=>N'O9S)%W;D+CC=Y0.=6I@?HG&5FIU9/\$^BG^95=-G>*^Y.M(P.M@P2,0Q7@66V''.4M^(@>7X;7-
(G'_N''1#X2SF//IX;ZV.%N;#1T8\$3.MNUW/C^3J/X0&R->C>(<JRK!4T(I\$7\KQUI#5N.ZIV5)/#1^:Y.L&=O=5L
MMY2I%HI<.&('T%HO@B\$LXV#6>:IE5;+APIC;=A&701+M%;9Y2D-868.MAWO''76A@09#P-BA6_.5!X>L*L*1
45LP'T7+B<>YCHM3IV#.TFEKWW#DDA3.MCOQ69YOF>&C!+DA.O:4E1DOOY5OYY.WY>Z>
I\UW>_5NJ3&3H21!;*59F@Q.P0.M.GI\4_'9#5)*'L\$^FPC@#JO+E:TP*9+MX.DK+=8LK6V-8R_=WT'4ZL^C?
2*C>>CN.32LI=(<%RYUD&*36\IQ>I>SU@(<M=;3%N;:N#3BIXJNW;Z;0%DP4(WC="R."L70\I7U>+P
YC.GPIPK6GQ:~N.M0Y3.W=7'E'P/W)*.(EM=ZL;M_/0.'T&.<<\$):DOX-&UBDX!&)YH-LQ8K@M
MHF%G4%/6;.^O;EX9HQ!7=^T@ZC%7O,22FS@)DS.M^MHA_39#L.PI_51!8E=ZZT66,72_04YL;ZO\2M2;_&P\VRP\)
IUM?0EIJ8.M0OPI.J0<%9<@.\$35MN;.IK:AQ=&99;9K^G*74=FL\$''2'8;./QJYB1VY_.39&M'B27>O-
2A@M'C''_2G3&5T.IXT@=5B(<I\PH6^(ID7@I\W>CSH#(&(9)^&9H6.MG#G3;R/^U4C-
.^1DZ7>.;B9EJMA5ZY_%L*JJNQV18IO%UL1DI:0V<>IY4.M5V.IT@'\$^Y%>QC0/4@Q'FN^L^)K598ONE=E\DG@2I
(G.I<4BRB\$FR66%HD.MEW;F5?4SM%.'MR;5IY9C52I\XB_.IR+I3I;949C;.1ITM&X2_.O76+=;\$M<69F;F=00RS)D-
ZA_!A>NX@82;)J?#5I4IWI(\$NFB-S=O4!18BL;?<I;.M18G7TJ#(R2I5;?+&GEZ!>M8;ID?
9'I7'I1'E/O1R/A/KE8H(<YDI@H/6=01<>2'/0PZ<'Z'/AZ^U8=Q.M_)(<8;!00;^&YI%\$I@;CM-
P;EVI=N#9MN31%IGOW.D'P\3TO7;SBZTB BG.MDQ;W'B:PW)J2NZWYIDYGI\H\I7.NGLA*XBEM(3DIH?
6&XE\$3F7W8EF*V%CM>Q4_%.KB>'MA<=FIR;IMVFIY*.QBP>091('FEQ_24(@8)''9H9)^.!OP
M;TKH+PX4X;\$F^<C^QG/.04WER0UMI)''^IJ7%'WQE)%IXE.GU6=9I'K;U;Z1.M;Z!
(K%3W\O%&'JUW:9HHO\$0XN8E;K8GQ''UD?7+1Y7&@(<I^Z*LXV#5GD^0*+<0*HUK4\$'IVWE52CX
M;J1;K\;=HMOW^C6YMT;/'7HJ\$O4EH7/'>Q;Y@I)0I9M^I'G3E''1TE''I<
M0\$T6I\U&^3619M^Z29I=W6MQ*''XM6A9#''28JA+C+M2A2_S3.XNFQ@%14X\$?P;+(W/'_.\$DTWS?
X+I\PSUL5KP&=I<M=LI<<^>I2'KUYD6LMV4.\$J<90L=UI'3*%3I(I3_8W2I7IRD-5=N34=DI;3N>
MI.\$B&E1RP.6I.DGU6!6Q->N7KZ)OXW%DIJZ/;\$<\$^P!^E3>&^Z6NB6S-5#IIO.M;YV(0R5-
K)DN&'32.VVXHEIEMHL1S427_(<_Z\$>'V;I:YIDZ+-\$**A3.M0:9>'X9:EX2)/^FJSC.MT0.ZJ8_Y.+
(#HU(5NM>XTJZ_''2(')(A3R58@5.MI6O)_^W(?)=LU9^+LROJER5)>IJ?XGEW@_#OIK.'UAQ\$5U>>'O>0K8XHO.MP-
R\H\I0<@/3B+QW''.9CN8BIAQ!SFIU@#E>_2KAJH#4H50A!LL5XC'DHXS;@7.M%V'G(C0\HU0'+O5<^;6*9<IYJY6&:5I?
80V35V2\NETU.6VL?(<I24SIW*HVJH^K97XUI(V&'Q=O24%X.BT_00FB.AKFQ+TT8K\7@%;MIFLK0SGSY+I)%^
MCL;S@JJ9K659%.'I*IC(GQ)*O2RQ';X!M?B.V^!UFCQMP?)MEO+KPASCGEKI.MT_&4.XGH@
DCRI.P(Z1QJYETGIN=8;I%)5AH>:M6\$YIAT\IYQO8J?UO.MI=&&-
CQ(WX=5G@O<;B203UXSIBNRG/'-2M('9B#VXY#)H/%5=A>!5_I-R6Q
M'U.\$QUIDD=^D'P&XW.M;H%&6CBP=.3HZ;KL#)I!(1J@<OJY%GP7.M+
I1\JMK_'B?/>JL!#L8TM!X5I=E7TEXA^U%EG''_0_:9.OI\$Q).I'^(\$CPN/5#9ND!.%?K\N6ZYJ#&.5
MKBMQJ\$&YYXM.M2>/PT*S.D8_G8SI+NIGR81B\&21;9.4%+L.M>3I\97X@-?G8=YG&KFI)9\UC9?I1U+
FX.W''DWQ\$E&FIYK>9)D@?22=I.M*M<#C%(VC9V7-7?6\$<1KMWLFI-L'OR@P+A-V+&ILZI50U8%'%L-(YTYK@!2N\$
M0EQ\PI3;9-'G56X.M;7R9JP9JQ_3->EG1X^953J59OKE;S.P?HJ3>/%K0\$PXKFTI?D<.&_3;Z.MC.JLWH+P#;
I92I=I4;I&E-@)/\NZW3IB-YQV\@7<2/J7DU#''_U;I\B0(MU.MFZP>_.\$1'81;7D(I9E*!FC9\$GS&N\O.FISX-
X6EIAIHW.N7/+2=W98TI;7<0WL!ES*6QC.IY9H\$N7%#3;3CPRW.0K5EI7MY5E;)M5I8RZ6K*I@1->G23UW*!J2X-'&
I9I3TLW@M'6;.W75<_I1W*6C(I@'Y.M;8;.-E0ARTA2E1G;RA#.+I;.K02EH)BE:Q1/U=6%I_DO:X2RYO.7'U4I.M-
P*7E'N'3'IU>W+POQQ\$1.YZW9JRJ@G!EUHFZ64I.KOZLV?>;L)'Q^(UA<MAS:B8U=+;5R2U<=YQ?
I.@K(F>0\$XUR(2OFQ/NT0">=I^IK=VK8I5#!&/Z^7.MJMY%F\$+EQZ2%Y#M%MK;ML=[R7\$I8^K%DT0"(6
M&''.+;9T%=\W\;VWCW;1:9@U>H''IXCJ\236\$2NFL/*73E;.6.M'3X@%;P5G;6H528GB
MLCB\%9H#VOJ8\$L%T52P9IG75E=6I06)+@I57HAG>(\$Q3VC99.Z4A!6U;.MFM%L^6CRIK_*S);#)=9LSI(OPQ;00*CN
9;/TZS9&E92!_?7OTW)5(O8Q*5.MJ3*=.;.OIQ;..3S?&MKT;U;KU-B8MABQYD?.\$''%&K>EA'.2:D(X^5TDT#6E.M+
IX0*#EDD1(X\H8R00T@>I9<@L&X&9\$JVT9_U40D<'T'E#VQB*<(P\$#M.ISU\$K+TCAYQ*P&F2X>-I'(E9)%
AY4.Z.WSJ0.6!/*XMMI!2QJIP.CC\$'_M47D(LMX0FUT.5+W%FL1'X-Y'.BMWOJ'YI3I#
M50H''D*#!E#OAS&%OLI@MG=I+>G;C^''QG@9057I=JIO@JG.(E\$9=C:8NSO&>3Q-VQI'EHE+7&6&W\6&
M+@K83FMO_1/7*OIEJ/SI_A\$OI.<%HJOSWU>_A_*I+_L@#(T_7LO?_W_(0XF.M_0/I%R_G#0U-7_36-
RHSAW.HXNQEI5I#LF!48\$IGO.L;7:E/M9%<0'.>A(2.MD.Y@B2#)0G4.8A2_.8\$(%''2#.*D2(X\$_.#LF^>X)O/F2H\$#54?
K*>BYHO.ML;%NCI200(X;I/6(<90S0&I@*^!_#I=(*D+GPIGD('T.OQ&5@WX/GT.M=V2_(_MW1;380SS7PYCC.
(V_HB+I*(''_[G3\I?ZC)I)?=WK6=)AAJG89I.MI-'5WA\W*R\U0%229ZCRI
I_M=E&G=DOR/I=F*K)S;AC*4M3<9;I\NJ3M.M!\$SEOE'#^IK++I_FGI?4*^YB*XN#D_)=-7;?XF>?@L'CXZYKE=5
I%_8.MJ+*^W196LFEZBCG>=NR5BI+0WF_1#<?N0P(=112I@X80*&I^/XYLD4!M.M?@*BZP@)%*1N''ZS3QS^3=
(5''40"+IWD;I.X0(DD/?F=7ZYRP5')3L_'9@Y.MJR(I?WO1OGCHJ3'I%FTI3\K;49+G;#.XQ12^ZVOI-?)!MU%E>I7;O-
M;9C&-&#S63NB*<\$=@VMN\ILMM)ZPR%3I/4.4ZB^7F;J.V1DF4HAIL1-H.MQ"@SNJZL.5W+X.V;/8\$WWPM?
F'0MSF'ZI50UOI;J.QOG%H&2%5(V5>:S.M2DD>K^(/%IT:U.W&PH;\$@N8NSR?(OH#.UMHO-6J-
UR''#2#>XK+!54.8GTR.MZ')H(3;34P;=CJ3>I'L1=PHP\LD.M-#9)M*@ROA=_I\9RI?
X*PKM+IZDP%WS\B8I=\$Y%.IQ;.-I9.MUQ&;YJ0.VVFZ\$C\>Y3G827=NEJ(#>:GG7_QU17I(DZKQH->7OMT=YTD/40

M%JCM_*+3=-B?K5P<"713MZRF7E'8L6U4FICDO#1!ZI&"/V9_KC84GC8L."Y8T4I.9 MQ>
<2A+AO;SP#,9T861PONBR*+)IPKDIXNF.6+C* LZ...8G691DXE\$=S;_T!;M!<;
(6GT)GN&_4QRAL,FVZOHNYS(2&IMBPD)5\$HB@2UK/I6_<+9?253I'Z>&
MEKLFEDZ@TP5X_4DU+I_!H;ZV&L;K0>OXI\$M@QL;Y6^O9#IBJ&LM(VVT_GF>O
MBXBP>70D@#4&.62A=SEHN1MQ\$(0%J(CX40&YV,I,NPO?ST'I?%...%Z\$1RG_M-8.0P)V1QT@==*OM&W&PN
K'BPN?."2P:3PL_PU\$-69!>+I/@P2&FUY'ELY!_MB'O?9)SKB/E5R#F%)R&<7@T)I#T-!_L?2437_77-
%WA5O73SXLRF5#AW46K53H%OG@?IUX&VA:R@#QS*4H2UY3QW#^@"\$EY M.%
I&1>N5),IY5\$I6G!*^SY#35AX^SECT3G(N5G@0-/9UJ@^>NC^N&#DIDK3_M!_<I5?VOI\$@N8/+!FJ&AI:J\$#F3;P-
'Q>_N80_M:Q;R6\$X@VHDZY1)7IKHKF0/(&396V!AC/2A!A0)+M..._!SFVRDK%D_M/*Z
MY0ZAA,J4D*GT>OBAQMN73'L22!VDZE)(9:4Y&=-5S;I%Z?NM=^M^6!43!>1Z+#_MW4@V(\$\$M3*=.SK)8_H2-?
!S/>?!T:(HEE^>)LF5!F0">\$6KCW7EYHW^O_!N8!CN8_PX,%1U.\$S!LO^?JFQHVIL:F.#N6_MAK&-
<#%MWL6;S;1OCU>#9-24!2*RS8UEF@.E_)5%O2MO1;ZEWY'BV_U_6_M+X)?W_01" _NRP"TH19PBHIOEI*?
RM=-)O:V;-W_OMQ)A!+\$D<>DfI=/9D_-W!+>;_M/UV0!H?>,+>;OHQYOM1CMU3U\$IQ3!%+?NIWN=+_M3-Q99+-
VON+5P=?+ES>=F9OJ:I/*:IY;)4EN)3-T&S(=;BZU;MREA&AT;_
MZ+^Q^U?/O9-%EJ^U<^OQ_<#+4Z=5=W\$AIS3M%EN)!_MP"FSE96_5;#IN;_6_A!PI7'RSSDQH(+=
(AIZ_YX!3ZH'6!DJ8_+!MIY#M_MGL>_O(I2"OV(FU_5D@++_EG7+I23SPS_G9^U_(!WXZB2GC^Z?VU76Y)<3)2*
MJM1@!W%Q0K1&36K>IWQPR_C3!#/P-;ILT2!_"03H]>[M]MOH8?Z:HR?^_24DIIX((9O.B9SKOA8KKZ6IT#C2N!!+_U!D
HX^K23ONAD!^/K#_MJ2^!HUNK\$!L8?CI"-T_'NGHH_'1?-Z.L(NP\$1_UK>H.(AWG7FE-PZAJR.FD
MT)+NKGOD'K>6W.8KG?VJA>+!^I4=M!P=8QG_VMHF%7F,M&2A3XQ9T3UDQDNH_M_K&V&3QLND0F!5D>-W=J
ZBK>P^+597HT)!#\$!J2>W_-!B3TY3;NS3GP>M?3/G!62EL=I_"!6SCT7WGT7B50H&5YS+_M#EY9S;2MH.7
Z@PB@_!;6#<SRMVGCG>/>_L(5Q3/#KR<5ZK=Q67/CF.E.%#O!^1W+=>!@=-_MRGC-(P'NQC3V"%?OLEF_!5C!D8T
_3S3(^_M2X70M(?!5BHB3'_DF%9Y%C2C+_5VKO_NU?J&9Q!F8>ZM/9<\$Z=S^TB_IX!N_M<X)!^+_C+HC7F4G2*X
QJJB+YBGU_&9.CF4QJEH*ON?(>_?L1)!HP/XT\$-TH#+?W0
M^UMFI1GFYR7;%IZW.8X(9TCZNLB!A&^O.FKHW%D1\$W13'3J\$(+X0@TNP*=EF
M&RJ_V6A&T<\$3%^TW!@AXO<I2)8)N'E!\$'4!'"<%%6_E!_M8E3FI7T?R'2!%LA1IL%?M26-0S!/'/*=
(>F>Q!ISNCG7/BFRD>_#DMWBTD\$4M_M!"A!PD_ND;YY_*=-RNJ?/3&"CB2*Nf<3.D2<7-
R@Z_"M>XLYPU1+63'7C5\$CSWT+_B_MS_U!RVLO_LB2Y!K3W!^K+C/?GW">_M_6RT_:71C=U_+_
%W4+HLZP+/!#B>/#3)!8!?">HWK=A" A@?&@YXXLDW>G!
M_LN7K3:PO_4K;8<0DI(=@N@;ZS3:"KH*K\$;0RF(4E)6^!26H+EL:7_M-VO">KM"DUU%^SY(\$AE)#5: ^0P(K;_
(*K9").*N!@CP>W>N>I88!LB>%9+_M="WL7!Q!V3BF%,4:C-AH.Y\$YL;*+__\$Ej;.X,Y/7GB2: ^ORTJL.SS!VCSZ
M30+2"?JH5'8).9W.XPSP6<4WD)3FGGD)+1KSID2F#;ZTJ//G\$3;IQQ^!TC_MXEC,*U_(!T3ZH-X-
ML(FSXPPZ;!JAQ+"39Z>QI9&H4!INZNXXK" MC2DBX=+_
<I!P)%3A"^GMTW011WI(G_E912I>+!I/S9!>UK!;_&ZZ_HEYIVXWW_MCVXIC#B'OQ#+&3B;=N9S6L#
<\$R&_!8K6.2E5C,K\$YB!&CP#;-8YQ=-MQ?#_M^AV'2">(V<7W/K=JEK>XX/*"&DU(P+H?_!4R4;+;;4Y.+FVCKHJC3_R-
IEME_MH:I=AF0:5UPU!0=+!L-D;WKGXFF7GR8+O^T!V!VF_VRLF0B@7U(3OY"=Y%ZI_M;JH)O#/K?
&5;/H!A>P!QD9G7_WH>IA/"H;M.A!'+1K'?/Z_M8J=+/L+\$373GG@7>WLP-LG;K+1!A9F?
6^9;_&/SO!_"B+J(%!!#C#\$Y_!1_MMV0H0SQ;%!'!4A!QB.@G!S!;_!S)+^VU<";"H!MN6V@S#60KS>B_MK0+FGJ-
*JTWZ4!/?(>:(+F5(L\$W@ZF(X\$B7+_O:S)LP&/?2D^!IE%CBF70_MKSR(Z@A@*REP0P!;6@Y2%X!B(N9)IN#
G<*O:&P9N_=?A(+>E_M34Z3!P!<_P4D)A%#>YPCJ=9/S>(53GK;V!0YQA/"DFHT(T)PG(PF7K%NC#M;9;_%Y""3?
O6(2KY2-S38#ZVE7SRQ)E:_M8>SK6JOJ_RUU/#SD&3!M2E=YUL;%@4E/GNC)#/WG%;#=-@3SGNYCU>3
M<3ZW!*=D.&%^9G1+Q'P@2KL'EQFU?ONB2^03B"L!HW1;86JP4B_V?K2E;+_
M85@FWZRL!\$M;LI250"%ZJATZAN!161597TZN=&3XV^K4=SFR;IX!YYBN^J+
M865FVD3DJ4/A4Z7PGAHUB_6X24^860V_SA<_%MP/>)5=?YXI32.GF7;K4N_M;HUHG_U?G(+H
^%YLI3@[K6NE\$A?MUA!G%I!3%FT2HC-W!2V8!L13%(I(_^L7BC*F!OP=MS&LEJZ@U+<8WG;'!CW)!Z87@ (K*1
M,U2RALEX?+N?G7Z(!&1@!Y2_CV(FPGWH+M+_9."EQ*ZC08L!U3?O1E!2A.I_M!^FVY>-
X<6("PCO9!"TMXUR_36V3KUK!XZ1'M:PJ&6NJHGUM67PEAABN_IUD_M^OPUC_VY@!2KQZLE=KX)O3;:JKNN7!W%I
BJO!OAZW=>?U&_%K?IZ&896;>_MG991N+&E;=ZVN"N_TL#P_3WLZ!^KC/_""L:D8!UR_XU3TZ2!X)?T&!;8B
M!\$;W8NN2:<*AOP;+!OEX&>2Z;2P_MUM_PF)"VH6KT*Q(PA)@\$I3_-3%Q4P%?@;4T(Z"M
M8@P>N!18%7;!!"IV#KASB&I^&+U;W;)O)U%7)?S7T72(EMMEHD;XM+NAE8'_MTTC(B=&*Z^K*1_HZ&L>_H5\$8!?
(9.EIG_VJ6<_>R_NQ!<2(Z=740C!4_MC_2Z1!J7C?WT;^UOGI7L!O)@Y3W4!6SY;IEQ(HWM(= ^MV!Y&_5_O/9=EJ
MM67!TU17^X0;IS92X2U!*WZ!G81506#BWUAB*LGB.83*14U?Z7PT_5!_M9YT>B1=*_1>1U.OHG70"+5-BVKT>W=L-
!)OEY!M0B&T9?11WSZ"ZJN<7C)_M!@_!+V'?1>X!MWB_K;X?458;KX#A4YZ7>U^GK*%Y=S_FCO6V2H!+W)M6W
M%!(C;FXR^!G!&EV)O5E^_.N6PJDP=G,OKZS3W_@Z#H30D@@PML@/->+M#%VATW@F:S:>P5M
M"=)X3"RJH3;-F;#H4BOCM)/%9_M\$VA3X;=!;F92>1TO_KU153%_6KXQ.0_ML)--9BU(T%I@NBUMT_MC/K<0OZ?
ZAF_KQQ7)S6EW2%;#5;ZJG36K66O=A!T^KC><ZD+0)!/OPHM-
MGHAQU!0SU!;S/=GDQ>VQ\$^W&51R;1/FJU!F4>7K"-_LJ2RHJ<I_D3DQI
M\$AN%#803(NV2NIH8<^S(Y""WHR2ZNI7&/!QY_7)4W*!0=-_D3I8WJHH/&0
MK&N&P:L%N_"!H+&_6MS3\$!^!O;IH+NL_H;Y!#_O!_!X5!5PYI++R!P4^0R_M<!="CV40EZ"@<-K\$;H&QJK8V;9N16Z-
7T\$>Y"9/%PBUM*ZEO5_MKLT>N*7CP_MK)/70;@0_7"!LAOWT)IXD!F65_M9TCDRX2WKU+=-
!ELX\$6ZL!6K2(!D*!1E!3OL_424?!=HNE;PS&IMO3(U
MTV;_CMXWZ@M5M+@U&IIRC+7.0A;/NMH8.PZGO!+G?/H8%GO5BE;VMFL1Y#_M,\$Q*T\$ED\$1)X(M)+5UA;7=Z;_
(HG/L1Y!_3UXUU9A!('S)E_Y\$3TYPOB^_Y53R*_MWX)L:T9DUSQ!TC#_!NQ@T>0%!)
(LB&P+7!3>^ ^OULZAE"-IG_5ZY'R)8G_MV>C_!L6=GP9_!PGP5"D?1'LC")06H!Y^L9_!LW=|@B5EILG&^!GZ0ACW6@
M3OWLK1.NEZICF>8NL2N!Z_W_AMM'PLS;D'T+!+!4+=0K!_9_BZ/F=*N=@S8;-76X85!/(!M_WB/#_U?
XQ2ILLY2_!Q2.F!O4+&*^S)Z_M6#(C);>BN&DT^SR!78_M^G5%+6>2("Y!OWB*58U\$ACA;&Y!P'KKZEA1_N_68@?
<MT1.I9-R+&B\$;K_M)-%>WJMDQ;T!4UO@4\$!B!>2-(8Y=B/H^Q!OJPGY!VN&U!5L=M0S+AXO#F/S8M7'F2!2VU/6
MOGC\$?UO/4?UIHVH"MRQ!IE7SRN!4E!H!@3JA@!3!+>SEJ)JMI6E%_MK9Y!&\$!@_2_O_^\$J!&HM^V0LP;)F#L+!
'5E!_K;M_A@;XJK_NPZJ!+M!H!&E?_U1C_'BTHDD%O4C@2F*=10:CZ;&-65*0\$;&_Y=5WT!#0!5&G6Y51;_!M:5VM;J-
+IR4F_3Y0!3=E_!1)!LLI6\$\$\$2!HHB!@@"H;\$X#&*^<;_SMDM" _M_R!P"4/-8;Z!2!_!>C!L>_8*(5R_
K>R=@T!H;+)_0GOJ0T2)&=-C%X+_MIQ!9_-=Q\$)C!>246;WD!RF=XN;%+>R#5>KYAE_4*!MF4_/R)49>YF3
M5"C6%=PIW)_>(\$;#*MZ75"=L(+2^ ^EWLD+>5,&*DJ4V!^X)*W7BH^ ^!=_M!_"GGMEC'6CV!_KUZ>LQTWASGK3
5U%2+DDB;+HX50PQ;+!@!B=);C*X'D_M#^3+V3LS7^T_\$%07+&Z;<_H!^5-H2;K_RACW(C!H_U7"B";O/4!PH+(V'
MY_Z(8_-NH8PS>75PQ=K9!EVX!XDCIM%POL_O!SA.69R+7!/=J.G!E(*S
M**J*+J;@8U6BS)>"SL+N!VH>*FI<5UCHI3T\$!H/S6P)&6K'2AQF?J5!Y!A_MV6^ZYJQR/0@?
Z\$;3!7SA>7QK7_0=5_!H6_.*7*?MJ_1@)_T!2D+XSJIUWL_M'PV!_B!_"O@=WI8/E3B@?0U_*_2418/\$GA?OP7V!QN-
UY^-\$WNE;#;#%OJ_MPM=Q!T"<_@!O!#7?%..H>CFYR_IBOR0H_%5!86T!H>J_5Q(P_O?_9*X9E27
MH!&=Z\$!NNNY*!S"Q=-<I_V_KK@V7=NE0;.@5LD*\$"/%I5_Q!HW=|_PT^_MG8.O5WY@);%?>BB95FA
57AW\$9&>0&A'NA:_0_M>S_DBW7&@K_V\$5H!^ ^H6UH!8YF/=S_F<(<(>MC+/9N4(>=&TWG@_79+!\$

=X\$T:05:'OR&&+?7<'ZR-NU6L:5_D3(D"=J*P7Q"VI= MWI!@F MXI+ =6YI&9IN6V=/K:V".GP=*8.F&.@.M)24D
M+K+!+R6R37(MW^J9/*(58ID*!..TN (5\I %U)F?JN'M< S&U?#^:(WIP12HB-KYJIARISVJ7I#CZROP5=/*Q-
WOY*F&VW MDT^N>Z%AUHKHS %^-NNYLQIOIU?V\$UI MZIVY%PSK.16JBU\103&XKM';=_HVN1I
(7&20F6P4#W5"PF"&MI3X4 F/NNQ M!FMTPT.2X?V4+IK+YEV9UTY;:ZQ26I4VO+&A:;>9.97@B1LR.*IV.D.UVG
M+3DRDS#72N!QM(OCU5:Q<H'<+@^..I0<8?D4-WH.G_6A41@W0JIG37)E MW\KV6:
(XZJ\LOPI6U*ZWKGQ/SDJ_&5.1#QU?2?M=PEJ_.\$^NZHUS.=VT MQ7YG_*#RMN7PE2Z\XVK\JG%RLWJ:OQ?
1.5%8P\W?=PCTY8=5)9\$VJF8(?Y5,/W/QVTW\$ "10W;:0.IS M"VWH9%*#@W=-J6\ZA3"?M,*PI6-/S13P\K6P\KY/57I
I6(2QR2*OUU,X@H MXFV7D_@EA?V=8A**/R>P7X&JF/Q\$'W,LE4 SW*EMR5_I\$S5TM\$UI+@YIPTJ
MT2\$58'NSG+VSDQY?2\$T3-2I9@XLL?XH\$4IU657C9UJKL@6RG@UAQ<_O*YJ
MWES/SJB#K>:\$D3CJVG/UMMJN)RMFDO.)X/T <L%F#85\$1#\$QQ/3 M00YF@2VIOF6U\$6L=NAB81WI-KO_S?A
/_8I"-CI-8S_K ME,&MGE=8Z'PX\$!D\^LI&S+K;VB5;:2)7ZI@R!HO,:52@!CF,5AK8>F1UA\$ M"W\$?
2F==*66C8DYN\B1&1H7EW69-GP11I22\$J@/2W(4SX6SV517U;:B M\$^2Q8PIQ)?@UH92R16>F8H;:/X)IA ^.:P^:/H
_2RIA>:,2CYF(7UF>..M\$ZG'(IEQ>I C="ILOQHA#8:'ZPY916%<.Z18E" ^VN6=U'C#-E64*00?I+M* MUKDE30?3KOC
:&>@'GHB\$HG..#.WVZ\IV07BZSD1VOX/E5><6GF@PX.&:/ M*0I06>X.KTC-6)BIX&?
<*&6Q?..*2IA*50:7_TV(AP#..+WJG;B. %:3UWD MO+ZK,S"=K?=#*<NY4>3&S%1?
BD68HQG%W%_BU1HJOB_#8V8P*ON_W:2*2 M&:/ (7^M@J2<FE23\#5UK)G2BT?@XP5E^_3@XN7\I_D-
=1%!9)OXQ#N- MBJ"/<I(*)MK:YI4TIK5XZTR:TD6(@^"@A *;<Z^C=:/P/O5&B\$;B-YHUI" M2\$4Y3;IPB(2!E1##?
9_W?QVG/(E2 A=-8U:&U2P?2BO0GU*&YR3J3G\$/? M;_VOU%60*J1T2)2N?4P/&OVQNID(2!#?23^T-
7.WUTLTE+N+EOC9;EI^EI M;CY?LR1.IE=92_J)+PWC_J;_76%+!<IGLISR#1C)Z6>^0_4%=/Z_S M_"NB4LVY
I=YIS=HJY\4T?<5ZE@:9DO/;9>:/>^9IVNYPTJ)I:WS'-0&HJ M"Y&EQ= 55.65L7(Q:"A2D<2#\$AF+MV_RADC_+>=(I?
3DGI/QS2F^>720I M_-WGO_RS\G.I)JRBCTEQ>\$H%X@/>U;H4I6#3Y?P10&%B&4IT0?=%B+>:2.^ M3IR-
VZT.Q;4/H:L=&%9@&5DF1.0A_QC"=Z/6' MPKM'8ILO.3ZP9F.5J(*6"2-T_6H6?HG4:2+9,E^?A;+ \$I6K
MWR44(")8P+GUIVCIXDIA?=>HG;:/^_ OM,@D0ZE:BJ-CIFD2IQ:QX_*D1>AX M&-:58 G?>^\$4UI_EASWH?<
J.IE6IK^^TKIRC(XAJ/(#//A!4XI#6&#)OHNI= MB'LKU%+I2Z8'TYK5P1CMT:-
=.#UT>T>G>8P!6AXIE:9*8R1_F7)J^@9QJ.. M0<*[NI_?4?M&J)(Z2P+&.;=)V0IG:<4\$*>:;<10A"Z>/EG!9Q^%6/=24CH*
M3MD.PT4TFN=".)>+!%W)IJ#)B!FSF<2#1U>ZRB+F1!^_A(C_ZI\$-819\3X4& MDMH03!=V3
7%)^9ILL4\$I>D03+PW=CLC>BFV69:UJW4@_5ZHRB:0X#4H/1S= HMRA\VB71)IB845PQJ1Q%NX67IT?"GO.<I
MIF6.6P"T_GI.2>%&I/+(+678-D.<"9B\$MK15/(IS=J1_Y.6RM)>JPF5"@NDH! MIO_8(OT/+IS=X'91:K?R2
*MG^"P3L_HD =6UV%"_NH9HSK/T6D@G_K9 MH:/%ER%GI4G))G12Q<IV?
ERV2>NWFPIU+;O/^*5W4=4QEIVV\$(S@E"<:**XF24 M'LS>S" _I;VD78+H4L^L.(?YIB8%G=[1%5\2VJ;&5A;EC
MZIC#;=.MY+%/I2/3;+Q6?VI@_"RAPL^JJ%PEH+^+>G!T:3UH3S8(8TIW"9 M;
IEH7JP+!IWLBE=&.R8B!R9Q!;HW&+H+MD-862S\GZ1^ (QV:S&79I6_\$A#P M&0@XTN-I@0ZT1M#" (IR.:M(5?
6^OKM^EU'X2R*?A<->6DIFLD=FYL K<\$ZI M<L:N#U9\$>H:79I4RDSJ'L.DT3GV"YGO0S< M13SHL7*#F-N=?
Z4^AO;:G6DY9\$Q7VX"7E'U)@6"17. RG9FOB06EG\$ZA*2B M8X6B%ZFPWC@P).8_
I4T9?QIK&Y&B;J_4ABVOHE.UF.W_US(PV=8-X MAO>X7_Z.Z.UO+@_3OAT(Z@:RW?GB^8*I.Q.Z%FU#"B-891O"1W^Y
8I*#<@\$.="X'IW M@V*4&I2AW."&R&<&N4&W9KH^>6@=L@AJSQDVE\$;"8R%=-.#YM13G\$W_OMI
M2TH06&G_1D0_139QVOJHW4;="YWQM6B13'ZE0H0IE=)2"(\$<*=KXR%\K5!Q M&18R\$Q!8
%OBSL<I3S_U;J;NNW2ZIGZ*:YY78X*4_:=F@B\NE>TPF*RNO/- M9IV!;VOCVPL5RH&!%^P?@TIF?<
6N%>+U^*YB97R8:"9S? /#0A!)M-PYUJ^ ^ MC3Y\$_9I%RL@_IGI.G.!:K&6L1K4/HAD)?%KOS=-
!M6W;:MI+K;MY\$UJYL7 M#CB25Y;TFI-%FE:<%;V1I0BY0.VY(&I#58.^T4P=>#^E7GNR83Y=
(C+K5U+KN8+KEX&Y:/MR4<0;^/ZR-YB#63;S9VC;*Z80*9.+@W="_.C:BX5'TZ90XO"ME=U030OTH;
M^%S(QHUMI444RTL3&:1^G^G66;EZ@%J)7CB@UGH=0INC506CSJLZM" M.3Y+&K>%5&-V133&!
<.;HVZVQ>OXGA&G;5Y9'=##+NTZY;I0X(ULI^N95IF8#1;/B<=)ATU;^>0EI*Q>)M3M;@E<*\$G MI5ICN%24K12M-
&VIT;9G.Y55.1+7%*ZBDWV" <71E"6M7%1@;PF?JN4B_9=% M_1DUB09'+R7X\$!>IF=,=I.9E3GJ9'Q&4F7PIW7W38+
DMSOP=L;V9;>KPX+\$ MRXTK2IH>AON_.Q.9<0&2(PYIU<;QG&?7SQ(4/I)I@'CW7_7M*8T*A@YV+^4 M^.#K43:A(&
("7@9J.IQ)S-H%22 @8YON&3F1/%ZD).IJ^LZM%?>S=J=4O5;F+;2T>H33)G4X9VGS1_!KS'HO<) MOEH=
(AM;MFYDC@Y0+;MI45I>WA5C"TH.9^+AAW>VE%:45&Q'8\$4HYJV&#MJ MI.MY8IIE;"P6;24OK@V;
M"W8O.Z=MO.KK0-9N%RZ_ZU:#K?K?G!(DIE)T0-P""0LC<+5+NVL<>&UAW.> M89?
(L2A0IGM_:=3\$E2W#>IYT"H%UTNSX;=VD!)=-T=S-IOP5.C3LFZ_M_LFC"GR\3X""DL7XB5P#C*X,D^"]
ITY^RFB9Q4N-I.\$BOTHK19W%0>***>Z MS1LG.R>5!H>..0\$;B\XQ<7.@I2"011YV",3_IWGO6MDW-NC5OMJH?
*Z2:AT"(N<#VD8WJUB4WHZDE'< M,@ZTYGQ0I@#?E?.RNY=W1=72%C=O"=-
I#B1^R9=8BOGA3+OT@KKK%FYQ\$V^ MO#XB2SV-LI;2>_T5@PX/K%G\UH<%?,<*/GTI *S?/(AHIRR@POX-Y').-ST
MK):X4+DQW(E?0#&Y&5^ =7UN<I>I294,+I#I.O.\$"A(=>'1NWD86;6GT>I;
M" G7==I95L^I748Y&W'5U28FD*N9I*# N8" 6(I65N;P63X=S>UXK)2E%E! M; >E#6GT%@A*>4 /T6.O"S@>IH?
Y2^:O*I^V\4+RTKPDM;_&I!16E<)M+5L0;_7F!(M.B-KI-0;Y+YIP7@A;_Z'FW&MUG3C0TYKMYP,7\$&G<6IB&Z*G
M4DI70QJ4=4>;6S#A1+@JANTA&PZ\\$_FNAIO= \$(X@I1Z46'_ONDA0^H<=Z*V9%?
Y3#P54H&\$<Sj\$H!%#)#D+7ZB77L9D6I8?23+<: #/0 M6I<;"7\$UP1OWW8ISZ%?F>I'D'4QMLLL0#12F8\#IN.=K-
<%1%JH@N-NJA M@>JC*F;:>JH9@N7R1WJK71#69.;&NV4B?MH!^R^!R_DJ((@C0PL0_RU
M;:J8_M#QPL\TTT#F&;DTV#HHP;=R\$HNI MK?W"17+
(99D(ZK'BR)N3Q\$W>I3G(#=EY\R'XCFT+@\$JF(\$J0=N@!N(N=O=E M(TZ^#:^&IED3ND672N>9PZN"4&GDU
_Q2^0T.I0I@Q8)TJ_3K!CFGWN;H)(L M?3T)W6K@?Q%IBXQ+K"6SZ=QM\$K;QXTI9B3*RAWKMF!50(8?DOH+XY51TJ
M"KG3_VP\$@#8"14+ _W)IXIF@R%*2\$?PB4#.6PH->>JH^+6\YMM(K=6"@VM MW)4;_&FU:~?
VSE;N&=5BQ6D0I@LOU>&%22I65V.81I^_L?A1O2YO8PL/?Z@\$E^Y&^@)X3HM8H!>/I'N\$LI(JFT%
MWLP<"ODNEIQ?7QO'UAF^#GY<2_627V\XTH<<I^7LIM(*H06%I3\1&XYA.^VT<770+D_>BEL@FZ)\$MO,Z=0H
MP.C%2RZ!;># VBVW\UJDD-J\L/E%G#4NG:1\$RJ#6X=3KD8C#B&<_V_YSE.I MA?39IH@7FX-G7I-
QLS"9JCZ8DNEZHVTY@FH2_-(D4 MF_ ELP&IHWK+&JAN%AX (050'H%4K;)+/KS1(I2"TYNG5>=QZ>I%>J&RMN
M%;_H/D)0_T&&QR90\$SDS2)4J#.483HZNJJE-CY)YHSM0N;^I?B6UI@_F>I M!3#IG'UWSL7J*^<*<(RFK*!T!""@!
<>I@WS>^01 1;: #TA:6_WI\T8TXPX^>L\$I@+!:@DN MKPENNAU715\INE9W4I^0TX>C%ASL>ZTO/B&O5?JH_
M1&H_ EIBG3WA;I%J1BG/^XX&W\W^;F4H:0#^6DCU3L/0/6ULN?>I@RU;""^<
M;QV*6\$;>0%<10\$S.WS.T2.W)RD2XI0'W_9?7@*LO=B8HQZ!@Z.@5+MI-V<I5KO)/_\$.2.EOGOE0?Q@C;ZY&4*QY3#R M
Z2<4;O4_--7\$*;DWY4#2(\$;\$*MSCT@ (S=1>&7*X67-9HL+>'6@BYC16<^?CCO(GNN6*.36I3ME(6=*6_YG"Q9Z.TF
MS?&R8:C%+!/3M?)_3W*K K1QI7+(>)=OP+RKUP&NGNOT&I'W_ "5 MTZV0^Q<3&M8X.C;FY^7B-M"
ISF\HDD@40ZFI GT HBH M9A84J?4Q_>A-T-U_&3ID?W"70K;G8>"7I.%Y2; >F"Y@A\$3WZA0CAD:27IGC7\$
MYRY!?!#5=^)\D*Z>&&)C7(TXX9)^=\$.JN3K7F'I""5X_*I7!@4YIN.'S! MN5AQ\WWI7"0.1^+M&8'I&PV
D;+4^3JYSEUOMEK6J/(EOKRIM.=4YIK(MORI@_HRFO@A.MC1X1^!\2)]=;IZFV4I07=*0-N.IKTXI\$1UI(<.2IO?Q
M@^R7QG/-&7(WH4%1S;_I<(<^*Z12-I@QDJLT 5'2N;7MPSI<(! MDX]_>_9I?Q+?P&DT!ZH\$&+8="Y)N>5/-
BC*YH71WK+=9BQTC0K!7#"3C M0FMH7^!>V/^(2TC+^\$+4=X>DA9S4B;:8?4A8>GTZ;/^TR9RL Q12AG,3C
M0\$Z0-PM&)_I%_?UE>'ORODBZ:IQS\4E68I9Z+IIS@_E\CVBD;8U-6+P'=

MU9G0F/U/<@G^YS4\$@0I5?B2<0IDQ5JK#>L7HJ_?=\$8F?:@F8+,Z1I7U"N
M.O\$3+TG6I1(L1RER6#N_9.8F/8!R*BO*IDLVM,+!T&N>.IU=4,'BD^XU_*MUZH#GMYIHQ/HAVBNG>6IR0(.UDR?
ZR.2I(H*LM A6E=JMRM16#VU*PPROB MYVGGC4TAU+9MPC_.HX%2XAY8H',+^PO 3R^>6^!6R(<:%8.<6X<,<3^'+I&;
MG\$SRS.J\$C:@\$MTOH^X3.QW:VZV/M*DB 8BID S&BN7EV2)?B=FI?;AF8S4I-;
MF+=8J!RZM6BUW,+2@:W&:ZMYBK06#UX3LB;NAWOE/1YIWT;>4F&SV%T1(N%NIU AM>GC9HZHH!KY1*Y5%
M^T>7_F \$7G*36#^B #EIT?RO.CE#XCJX14,#X&0^JSB_%*!UP??YH/H" MKCWBD\$*R5G=IE/-ZL)X!M^2 U;G.'G=
H-7!CL?H(YM#PF M1G7JH);G*2<I31%!/=-L9=L1378#";Y+ +UGX1JOYKTIB:L%N7QKJ0L!@:K< MKR_@_?#&/XR_HJ%
<8<IH_ZPX.?I?I 3L0?UAU>_ _%I_9T_8940^Q1H=TPQI M^L!9_"@@L*!*,<-3)->(2;1H\$ _5D!U00-@V0YLPNS=8JJ-
8P9G;KWU Y3F3P>B+;X^ _%=#38LJ_ M9>.%EX)2R.7GVC-JA#;4*N>=%W1N_.%@I9W%5;4!K MFY@ 43)VRPH\$05I50T6
MLE66QP^PB.XKF@-IWMHIZ9;06NB8<7Q)@X1-#I(4!.UC6=CG>5(CHZ.8R M#B8M?>IMK\$F!(?0=\$@+1VY!
M6F>6(988K0XCW8I3j"/ZLBG!8H1>1\$UR-.GLIBKY\$U7M59RGJ(S/68JA;O MJ7%>LL>J\$4_YK-;
S\$9_WXEQ;.9*%=6;XR6#"#V%X;3%FE+L&C)-WO;YO_HJD M^2*!)OYRFL M#26^UD;29.I4?WW\XND)U23;O 6N-
TS^>@?P5<_K!W^GW^M_J#M^4 MPX)7I=D\$104+AG+'PAG"6!.0C%"I+9CG9:PKPIIAR-MHD.(V5JHZO-
W>TRX>A^'0K=CD%.%3H/VFM8,K7,K=R6%TT4XB@V2_WS(*F M+=3ZO*J>/F3KUGPS)D^)^VO MM%F3SDR&3#X
P\$I@<^*=<*ZHX7TB*^N@/@SD^0I_0OC^0X7?5N^JXWSP)E7GV MA4+E8IW(I&VMJ^KPE06C+P%,& 0M0HJ-
H:GOI2/I+CI!"AQTIXFI+UI4 MT>7B4XD&) KH7@)(BF_B8 =H\$IO M+ISG(5_WA^&Z7/H&
(VGL%GUN^T2N8A^>8:P0XXI2KWB:V=M^G^L4^T\$X9 M\$RA\ 2&^#6K8D0^#M/P1_/-2T!&1L/-
IH_I#45/+MJ4_B^A!S;^Z7/2^* M)>#@&ADI:L:8 ;&R8BHIC4BNQP!2"
(0_+R'E/G*#MDY."I4A3\$FMY*57;AXI@=I5+H!A3=@G@.(U;)>\$7^ MK>E9P!^Y"1_INT-
_I NJ_4&QYM02=RY@I9<C^M^6>_D0L!6:X2P3H0I63XZ1_ M63IC=;V\$=G*2.8=*S&J_I90IGTTWC#3!+_
(3_IOWIG.A^DNZOI@&I^FF%A) M@WO_.^!L.?3JFEJ!^25^I\$X8SSWYF.O!\$*:.8Z)ITAQ?9.[MF^Y/KXL_2Z) MA5-
DKG9M7+I/AK0.N1F3M\NHTY^_K_NL\$I^_I0ZO^ZP_HD/I_KL/X7NI_? M=EC7EO^W9+^4C!U?K MZRKLQ7
#A2>%=>;XDI0;10Y^#M:.(9)P@Z_*23MPVGK;.@SM#A:K#30@/0^O MSZO0^P;+!+
LNI^"23T#N6)IV(A7KM(HP0VFIAT2_.OXL90JK46IR\$5O)1Q M^T.2_0>H2V^/C)EZ+=BF<\$UFHOE?M/GQ2H27R\&K?
HB%!.;2E.%50_P& M2GU &K!YI(#P;\$&QRY:I-/@N&H? (2TV^W G=6KZJMGSZPI\$IZJWKY_#OA
M;PVA<K0>J^XB!^JBN;/(318#GS/K+^_V^Y.U&^RZ=J^?TOV.IE.H5%7B!QV MBOF;+)T-R/NSLB0FTE6GB
<M;Y30362&M>U6^"%M9W^N76?2_5S;H L^&*6 M_UMQZ\$ _RGKS< +*%H8AV5@>VZ#)
(_@D)I2T3I3^_5I&^ _Z=OJ_(1EY^Q: MICSH_A=V6+I^Z=QZM-TQJB"42:2Q%X;9>EGP(GWG^*.'T8NT#Z(I<@D-
M5>1)1V6QYO.KQHC'@M-NK.ZQ;K#<3=E6!>+PY5AFF7%N!>S/L<IU\$7.1Y<' MVMG')8LNN^G M6=)I%>V9K FB-
LOC%9%K;ZDP;Z;-EXZNISJF&S:EJ^Y1O.??>NJJ#K+\$8.5%?I&V7S?W 0^WB>"E_Y
MQJ:RO)FN893AN(HN>/S/M5CY);3GW^JH!^#9?L_)LN_TJ#F+5619WYQP)/+ MS.2\$FVA/S61Z^LY^IP%SWY-L==^P)
ILNB5703I^V)C(&\$8;_92I376^97)D ML:B_@.MQH!260-VIWF^M>0U%CYEBIV>J#<#^">OK_2\$?!"R*#_;;FL=YW4NT
M/M!#)7=>;FI/(30\$BSTT_DX.EQ7.D_N9I9M7XP.W0_52F?_D792+!LL:Q M;KK5\$+!D^X7.%
I\$W5QJK4NVOI!LHJF@6:#1SD0UJ14_PRR)>C!& M0KMXCUA;2I4N0.3.5#X.CUKJ=0TIM-
=TB.HH^5!P!Q:KX\$ZB#HJH4X M!XH;L&O^B4;5*P7RDFGI@T3W%"7(-^A=;ZW@^%JYVM=KZY5988A-Y1Q4WI
>H4KH2^M.N(4G^ M\!NR6)1\$CT#;I R&^)63CWUO^O1\$H6(L^IE/I4.K^O5S:I(V%RN^NI(5KZ.M&RFOS5U-S>A5J)
(UG/0Q;@Q!\$&DW_FDO4?^IJB&BEYQVHOV9_C>)94L_@R@LJ_JBN\$O MAAU\$=C;MC*_.@HJOI7LN!:=;85-&YX-
IOIR\$I<=>)@/:I40@0.N%NU H46 MDAID<2R&KDO2O&K7?28%3!0ZL_8?\$\$\$Y*)R=Z?_(&^WJ^M27=G/A3R;I@U1
MZE.+2I7_84?G5)PMY15\$3G4^SE\$.2@QGSRNISZ3C.R%5S)!Y\$6F1MG3>M9P_MWFV+<^<
@^>P@#IOPR_.I5\$&.CA45@S42&2(96B7^WRK!2UY;^L1)=^H^W7B MB?X?^T+^#05EE0BL2T!IM<_EX
V;_Q*^1\$D&^)^F%XJ>NZ?^1=C_5-3WZSY\$! MZO;NIM\$M4-GI)G#6YY>UIT\$?V^")AY\$2_V/M_00NA_WZ?IV^%FK?();S-
VLL86//Z4/A^>U>=_I@Q^!>(3@WNA8E^H^Z@P_%\$Y4#I@5NWPS:(I^AXYV^0S\$JQ05X.C@;HW^<^TFCIA_U M?
2F5\$.4I/S7/G53Y:O8P6+^#R+DIYKM&I4_XH<'U88?YV!;AS+YS<^Q.(?:^*K9 M3IYI M%UOI<?YZZ7I^+L^N=-
MS)ESM.BS6CRF2%9B!5B;3G.U*2@64<687 MQ&S4FO+6RFD2JQSJ4D\$CI#AXI_+&*O2S-Q_YJZA^U_XK;%(C^ M!O;Z"
(^5;G!MY&1JG_QO9-RD\$ O!+0K2)GSEG1Q*77)#8.OI@RO<9*\$Y&^ MVCS7-KMR/ND9/4H4HMF?
JFLX<&C*1:MY^EZ=HWBVICQLCYZ>*FV0='=-T&R;G5C// M^I?NI7F49^+I!#O?OJ7X)M>6R-
R^!@IX9SPV;SM6ISXF1ZGYMO)A^D2JHP4RL;W&_L>J^;M;G;BNVXMX M6+;=+2\$/QI7Z;,,8TVIO%"IDS#61\$PTX4K
\$8=Z^Z4^S>Z74OG2534#^EM^;19WOJRI<8-U\$E2^CJ29_M.82N(I?
YE4I7YD7EO7!!PZ.657G4@HP@P^Y.50ZF+&3\$J;"EP15-%G;^8> M7<;C4Z&)D_CE^I+BTB?D@&FBU@KP%4_;;
(G6=JC+X)B;<6M\$XGET^AIS'+I^CB^M>67MS_EW2QC2)EN\$122%67X7.6+1L4&ZR0Z43C\$VJH^B_\$KJ54;V6&)D
MDTT_Y;Y MA5T40KG(DI&.1.KWMO^F#.F.6HBUO67;AHJ&7_MHW6LR>U;UL9QHJ8.Z>X?00^.;!^ MG0_*<&7.5#;
<%07^29^VYWAU9U?7O:<2^7N*!IS^\$(@I4N;CP!>@46T_>3M M\$!Z!JPOAS3M@GG:2-
LUH!@T.T5T3T%G=:/7*KWI0^7R.O_8)<7*GN!6)PSV_MLV8#0L;+I?H?=.K9OBSP.1395WK^1DOYEBZU;
(XQ+K^H8.*M3^YV=6M3& M^ TU4WWI!"77B*=->6RB^E=9;N^Q?S^W#Z6HZ6/OI6JM-A_Y).DL_
MWP-M;HSG<\$ML/6W166Q_6;%B AX0.I70LDRIDUXG1.FJC2BDEI7P!JLB M^*7;QL=7=YFL%P!
IL_4SM;B;2%ZNSN^2GE?Y%<S!EJD1W^!IU7FY2FXO80O M/P&*80.\$;3!SIN;=\$H&8%(@9%T*>?
<3YW^B7J9G7SZ8(GM?P^LC1105I/Q0/I M2%:CW4-JMU/SUXI+RG7.10^FF&4%9&1&V @C^LANJ;S:CP!="(3H^CEVIEY
MI3G^F;(CSP@:U"(L!^2WJE.*+B>6VP;ZSJ/_=UG.*&LHYIWK^M!IGAH_WZC@Q!^W+MG!>5OXR^OR)4/YK!+
MWH--28HJ\$E;J2SVTOV%AL/NA1TEK^0B&?HC+X>)6GU+=_MN^??OE4.4_M<&ICLVX2H;/:?<
VIR#B.IE^7@":LP;.M2P^I16^2JVDE4_VIA)J/LI#_*IX MP(E@9X^!R31Y3B7<838VMM^LFP3IDV&Q MA.G
M.TJUD2W.MY&33ZK.Y5I&AB8^OD\$OZ98^""6;RC0T_#UD.M#;/I:G80^XU.6E2B46;X833TX
M#^ (STS6C8HFHM3EBP_-+2\YOH.99&FNY/T):HTYP^4*3+=RZ7Q_ ^G_OX#
M0.V&5^D7RI.XR3!S2E!LLD!_&@I(U(*5%03L=^&+P2_O_2!MQN^1&C/G>6^2L8YIJ<(^E<0IOA0(I+J-
2KE;/48.S0TU;HFH^X=;/G_O9 M9J>8VX;JH3_LSO^?I0.M8R?C0F^CGRV.1_BX\$3E3WZC7(T:&*;4VZMC<+;
M\$A=8%L3G503:0)-UI+6ZM6GNY^Z6(G-G&A1.CCR.H^AFB.;?_XX/SJD0\$^B1Y MPU3B.AAI
6;_<I/2L^4HL^"UXVT^A@3E1Q!9%+=@G;0;I!H^Z9!S M^; P&.\$!^K@D?>@C8^7T7;D9YR4FWI9L>T4#Z/V_X^"-
E\$ZLWB!^A%>35X^< M(AB>1CZG!^;H^?!I6FXX3L4WX;I7I=AO/S+^/_'4<_XD4^2#_92)CST%L\$^ MQI^CE4(R+G?A#>
<"RV9;ND8/F7E @D)JFVX1EW J<87^A%1&HF%?K3HNP0W ML62UVO3OBHAU0FI^0@.>Q=VIAU/XM=I3)Z!@_QIT-
N(U_VES8>C=24=X MY;#I\$Y84ZG^RU^G!9!/@;I@HJVGIE6:3#I@^U%80Z!0K&6XF8NE>I4^U
T1ZGH?KK7XD1HHF8!@(<0^H;+!?I>>K&JE5OPE?+LY;X MJ37^D=C;KDI>MW^J2PYDQF!@;?<
6%G\$B.OBML>^3+C%MTMW98N9-L_5P+A MLW^H9DG9\$_.O7>_) +LTHH!3X/H:5%\$Q%WJN2>R/O.?>#U^G0
^&G&PZW?#%C);G^%NM.^J9B;Z!#^NWU_7E_V>PNO^I)AWPOJFI
(RA!&MLJ;Z^YU6>G+69.G^LPBV#US;I\$==)GM2;3U^/_ ML=WCD#G0E/UZF;; 2+^#Q?=KHUX..04R)
JZ.&WK/FVG448Z^CNSGSJ5CE^7FK;I!P+G^\$%\$4^X8BVL\$S-MFA(F) M+
(306D)&3>>G!UGMP3^0LHIA_KW+Z">'OBU=_O.OIH5B1^(K7W%)';KVT1-3/159>I\$YQ)?I;R0=*NMM0Q# M53D\$-
D;\$8W-VL&DP;L\$^ PGV# YU^* UT\$IT81CW^0LI?YC7-Y6!@Y7.8CT MM^_P^M%7#CH<<-
HXX_GGQ)3TY90S!HDP:3A+JZ4RI!(PI^"EEQ^HD_ ME^O_O)CIGRD!^=(H^ERH^A)VDUG4DAY)PB8!0CBZ6^VF25I
(87^WC/+KR? MU3;X/_FTYI"QIHHC=U 2VY^XU%\$S/4!X!T^J.7UW;>2MNS!8?5/%>22TI M9OSQ:1NN-

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|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

+24>N.P0H.R@#)'5A(SC"\$9*5'.J(GGQPWYGZ3.8D3KDU^T66I7I FM M:;>%R>?!--D!Q(G175>&EUCQD7;P!
<@SS?ACK@-Z%UONG0LN!AT7VVU&-T4 MQX5V-
GPVDC24S@-7W.H.]@B*WGTTQVV4(Y\$%RQ)NR'_\$FM&^3HJZ5=IU MG'VIN%R3IU@1XXF'4E"(ZUK;FJ-
IV2LVIS0\$7@N>U.#JHKX^IE.S.A%Y4@-M9+Z6IFR.D&20PC".TLOFDYOLD8R!9?&0*6:LW1TQLD_N(C83KG2;5X"8'KH
M_C4H6.7Z.1_0Y#E(I%P6VBFBR#*G^NIG>T+P0C)2(YZ:C\$>>%E<;+Q7'M@7RYO^7"-WVC"#38I)I^I2@59-P?
M^#%V@#4Z<5ZZW:M#1#>YE6KZ&A(MT=? M4\$L_1#(^N78B0/I8D\$+I;><+.NI.!.22VG:Q=WKQ;)P@T3
MJQI'&842NRG>-1QY:TZCR\$*_TJ"-2@>8>G=%Y;=>4;*Z8.199@+AWL_6_M
_Hf9H9_*?/^NW2I3E')KR";IOSI.P3:SA#8%R=CV-&JZ'6/(V?TIF'@&&S8_C17P-MAS/IN+.PN*MQ-03SQZO.9)WV>T3
+8RD.L49ZKV8+\$K74ZND\$Q.O4>>
MX\$3ST,)=F3(B*1I>M6+.H>UD/E.^3&#GWMMM%&WS;_%EIDMV!)TH>/B:Z M5R"3Y.V1L<1&
(I)@0IA\$STJD\$6I>?PU+X_'?IB1M*'HW<7#-V\$&SIRM2! M7M:E=M850;PAK%U12N!W:BI2SG90*&;#@.8.IOC?
W4R>2.8/<^S=/Q-PU'OT M\$Z=S/X^W3:QGCHO!@/8)9^J<.*H(IQ=W.U.C90I7*76 M9_ AXNX*Y"\$I>%R0.
HEKHY_RM_Y6:04)1DI?OAE/T MEWY.1*37*=.YY3@XPQ.@P.#4">EXMH*<=I/Q5.&I53^PNT)NYM8I'BI3O? M8(7-
C%@QY;>5.4)313=*K.V^&8(2KPDHK)IPEG7CA= NYVR4(V3"VJFXI MWG5.T27U'F^WJKG-\$I.1N!Q+AHH8%W-
<:NSN^FS:*ZHK*XO)0/N04W@=T MH^OPD.?85:@U6Z0I'PIY; M1I7Y;7N_H;@76B@.+5; M/\$" 2_<^MON[=_V/>.<I
IWO?/N/.\$8RI/DIFUG/7G.^UGKGFQ_LMMED:H\$<M#K+.J)-P8YGC)\$WA.WJ4Q7_K:&
MB\$C+\$5QWORHGSU@X%\$K6E4*U\$UE=8\$>D5O+B".J(DIA)KL99.
MXMT15QH1G695==NU*Z,EXW">>?"/3VCJZWS(+9I>RG8:=R-2F^4H-G)O M=SSV+W7O
+HRUBZEDX@I2PO/AW!PIG9(DVG!+=H'?@C*(HVVH"*1I+ MYI20WP\$BXX:M2^X V%X)/M+\$3>RXBFQ6N6CS?
@6H4^2ORBS0D)Q@+3ZY&H1\$I2ID.\$440Z:1L0\$1+W:
M6:*W3T2N*.P4XP4B+!L25I26LSQ.H#MOS2IY\$> V: QDF;) ^YOPIA(Y<-F
MQQ9D6=MQ9/I^5F6KK%0CV&Z:L6I@TR^YN1;#F)3 B+R.)XE;RXH5:6OWYG;7HPP.0HP<,P/YCF^I^BJ& MNV
+YBK/55MM9?>(E*426)5>HMN!XCU1X%IOP?3C%WZ-A!KDOX! K0'SR)L M-1_4#MTG)4D76'F=O6C-
M6/I'VE3A29=0.B@#QW/438H_@>J6>F:Q43 M:U!8;B;TF)B7P!MG!SSX"L.D9^L'TF4?_ZHTMH1P&UN&AJ4IH;R0C-
QE;/@O/@%V%VR)Z*)">;#5:2! MBDLE6I_7Q&I4I<91=*S!J@'FIJW.@N'"\$SN2=3D99X=Q8#IT> M(&7H8*_61_?
A5AP46%M.NR:'6QV%:(- M@ (E8JRJU87AX6T:R.K.S9O5H_NYT#^L0MG(LYQ)/WJF+\$Z9J_VBD^7+9L!39> M4Y%?E?
F0N;QGCG.M.M\$IX;V.S.BB-76;>4?+HJ^4BE?R1:Y6:X%YZ<.;91RYD M_YMCCR":0""H!^AJB?0JG/O6G+
94;+PF^J_V7EO3VYOWXJ>9.3B;1K3: MR);3V=N8_*DX4N^YG0GKDUXZB..U!;2D" FF^RX2, N8"O8.FZY\$F7P\$Q<
M4OZ)M0%X;J.J%CEVWIPP+/-F.98D*I:L_6Z>5;..ZB>LO/./ M%Z=?KCX_J6H@>^O\$7(L!*N)00AWHBI9I2W*\$5W?N
#K!?:SL(>:=.MN&"1_A<96 Z MHIPB<60\$00N;U*D6 +)
I+^M*SW%)LN6D5.63.)""^DW:AD80@\$UH>.#.*CETGA7S<> XIW3I(<)^<.O2"100 ME^5(W44R\$K"3MR^N-
MA@J45^9_7600A!4I2D-EVO+BH3+E*C"--+."
I9OV:L.O!F4Z7LWIQ8I(O^09ZEN&6WZ64.BCFL32!HF@'0NCJBF;R#_ZB30WO(8@ M>N0"\$D'?
L)JM)'89R44T!92PR(7W+EAW:E7_*E7I@U:I8SA1PN&F&QI(7U(M+CU/^RAEJL@FH#=#A*_B!PIV?KQQ*?
M1SR=L!#06V-4I_L9I6:L=9BY4&V.KF ML9%#Y6_3-GBK*V^APF=PAR7=U+=P#I2D&D).B.1.VJ15-5-6FT'Z;/SEI
MZ/TKU@ZT0:X(X#8"/V-@N>S!UA7?^%)3W/?Q9^9MWVO087>_T+X!BS!C570 MNEIXI6-8=E0C@96&7LO6RSN F'D?
4(\$I<./WX4EA2%KZ3" 3#2J<1PAO.R& MK4Y#>E!=N*3V>*2;=LP8;F*)Y7ZA_16>UEJ7W*YAHQ/V?
M,%V!JA;/FXFY;B#M#!H/>>.^+G!HYB?1G MJ-1_W;#!U9+4#UD&&I8-E2SF1@V7IW(K*>=.
IKT6HI2ID.MMP\$GAC&'6#. MJW;.:T-/>W:'V9&K!URID>#45BW>D_&>:G\$Y"V#5:PUTKR"156!6U*)@?Y M29C"l?;
SEKR5D1L9L^9'<.L5-@8V)2E83T#I7BXX;8)I_B=(L=KJ\$0@-6E/*T@I.LUL^01IL)C>VE9R;RQ;U!@S M&VZA=P
&:XL% KA#QE1(DVII/=QYQJL_39 L1)ZS8;A!*&C9JL+IP!GB*PY.@(GMNJMT6Z MLU=S+;_?S.(I8X6K%/YP)*S%-
IV.O=1G"/I*=>IB;9H1L7>MCX9R)/+A0!D M=5CTCLWV^<#HB#JF.ZTWA1Q*\$6%?2E>@.4TJOX!HL
3QKMS%G;A@TI&ABT4/O76 F(D8!X=J;RM5,*6Z'F%#8O(2K43C:%MY"0%E& MJ?WN1(T^<7&CO-
73"*D)2_!TT9!DBT(IYX%S:1>8^ODI.98!OE;5%CO<.;1 M!L%#K>9KA?WNS#:581-
Z;Z.Y7&EU@NZ'G'2K(V&0LM/#O.7!BIDKC>|CF_G7NC\$.5OIZKB\$"\$S^!HD#0AH0/=TX0'4%4KC+6K53D'O4\$
MEIY2:#O7M\$*_57Z2JSI7T+8ZLJYE>2.5RZ"4_I@QK1RY4_-7I@:N!7P6NITV MI23T=*SX=)(#QI?
@I-7\$^..Z%JKQ+4&_5V4_M.E; !AQ?Q9H6+IWX?>F#""Z MI8)K0HH8XNVRG<4HI5!IT.Z#6%1RB7)^-
KI5KUM5>'4A!V.YIL;"L35!BC MH7W<^>P;#M_5UD/Z>5H)ZY""A_I=N1/TFU"N_.\$E)Y.HZ'M%'.5!EZ"C
MEDM!6OQD<4-R3RXZ7)<4;INU'8S)6QO(NZ>Q*.; D;HR.TIZE+^E!A(G: M^C5^X2)<>S:A#&7YN\$U62 M:\$
@11=F9=AJI*2_VIA5!+G=#.CY@!0G9*TLGMH8L>?C5W(M)EQ(#^IUF MDIU4TG032D3TPZ^9_!TMOI;I M:7<9-
WWFD;.DJ3YY^+RWB;*NR_/76^9TMIUIQ=@#"#-60K2E>B""^@IS;#6#7G@Z3 M_C7IQ.C!^I.VQXH
MY0X0NUEH!3JSV^%)JW\$P-<'6#+V9OQ)-EMIA!H(VFA(I5!L6J2>-LM7T2^ M*^!41A"9;Q3-\$!74?2;
(OI;NOMJG*\$^YU(GI>+P:NJ/ 6I>M4.F3FVDEA7OBM&. E*7ZF"35#5)ZE;%34P3("1!S-Z MKV:UHOJ0-*W?
0H&T11HSVQIGOV!\$T^%F!DI_&WNN#L3KA55.YL +LIT9)I MEE""7IY/8FTE17_#C2KI"\$5>_#50Z*S?..5>\$QM_C?
D\$H%1P&IT&ZW_@I4M"l-*+CX>.^J3I6^1V(C;J.L:GA VW MG1B9%^CG3;I^LXU+>Z;9G(-;)AQN1
ME=X^=XA9(J=N?X5I6%W&?#*"TL3J(+HPL1M'XXINR&D=YBG@4D'S!X'WU(E MR<8W>DM-22WFMJ5L-
+!;JD9675T_!#8G3%='F)UO_85S!02H.4'97GY_@? MJ.8V_&)L1^C^C1S+6FQ+H^P&+
<.D^RLQ/Z3#90TT^V6Y2;@WUS\$XW5*KH;GP MI2VA
#HC0@E8KVG%2I!\$A0^|BZ\$3Y!\$ASSI+B'. E.F2"/Z6XSN+IAG5++1 MG.KA'0-9_?
'QOR!\$003;I9XK7^NZ>|N;IZ0#9C1Y6-1ZC>O3XX*N!K6W8 M_|B!E0*H?5BNFX2OG!Y1%ZU_#'=?
\$B";%)K*+YO9&UR-99:#DZ)I?#A/H M3HP*5!\$T(6A<.5!&I%;RUQ;^JMOH;&
MY!U&R)&UAS(IV#OB!;ZITBVH^..V=)4I8*6E+AB>8O3.S> M;B):>OE;KKPZO/I=G!I@A^U-IN)35S*2.@? M2O(FPIG?
^K+IVUT'2)2?I7?X"QC?ZUHU4B7</.5.9/XYS MVF FWJIM M#E"JH.S83_S=9R-;I<S_T'N&=%7\$Y9<+?
V&;^*#YE@(\$N+^FW^7'KH^-#O MS@^F=0\$TLTC&.Q97V&25?T1?HYH>+W=;!{U#)OUN"(,_*3 1KC\$8\$.Z1:
M;K/9&6(H2_9@.5.Y^&'8Y#_R Q^+^TVPa*\$D7JW(EEW)+A0G\$IV/OI7_!J0!+LR5)T/PO\$RICR?ISY7.OY27_VPY_WM
M8M1S;"6KHR7K7I(@&R(KB<<-X8?Q.6HDV)" R3 MY?<2T?Z^@'Y'K*P)A"9^D+I49H154(TMI94;IG?;XK4A
8G&GUL/VN MM?I'KQ'I^C5BV.*\$=ZJ^/I5K^L;&=@>LH!3G&"V8>I#;7I>X^P+X7;J^IE
M7&)*W""@#UH'8APIQ%H+OU=2\$C;P)=XDE-N 5-MS=*V<I3;.+XN+<>%,!\$D# M396IYSHM_Y;WY^AB8?
EOTAJ.08Q.*LC_&WA)HN2\$5V)%_0U.533J^_9)T^C MR&UI22J\$+VSE!N4\$!Q5-AD64EMB>I^Q<+Z(B
MEP"DRVAP4^MI%O+(KWJ>WP.*&E;I>"+I)<- M4JIH8(7;O!%\$>KH=8X#IR MV-Q"O/IR\$.DI"Y4YW/2KC(WHT!Q?
F(QDQPE_I^I/O'BH"03Q4)WF?UIW;_MIH?*"K0_PV8&Q%>*OZ(.EZ;5\$8QQ*HJ*=EKUFNU;52\$EQ&8BZF7?>643
M19IOI^<7/(!+!R0TO@DZIAM1-*IN N0FW_7Q(!+W+Z>5639KC>J&IN?L MD)=FJ(W'LY"TI18I3QO-
3YI0%_GAL_1_4TYF!HF98_PH70(54TW*\$ES MHIE(Q-9EYVZN+H>Q=U7(28TPW89=)
I+FL(+%+4UH<)307=@R>"P'WMTIVXM MG@_I4@B^0KV%E 0\$EN>)N1BQ4=C!E2QEOQ1& X+&H!/_C
M)P6T+2B%TQ^>)GQ_D7Q"VLIV.^I7\$K/F;..%#')&Y!<;QJ+D"YW%KU6I9KP"
M!>H*9A7RBEB)88\$BD65A2_ZI%7./33=ZIX.WMK+ +N@:U!G-44O.54VF&F/L M?"DRJF2M#XYG+B\$5-
Z_PB.DH7B7WU!F!^86)2'\$("OJ4V/2)NU.@S4A#5 MV^FC3V*U9I?T_HZRI_Z P3=S+3I?QP.IX:&IH)44/+JIG*U-
KJ.RG=M#&?19W5U=3.=;LO/_@E M5E%F!&YF>%0Y*0Q!5-SLHU!4-*)S5H8INV0L0>9T@HYI-

UHL\$97#IMBAGX,Z\F4.8 MTKMKE6?<^B)*Y33MRW%15IL%G2IV3\$CR@K".)M8BI@90PIP#T=B=3A4-%K MS?
[BW,-D]&0'13LFH"H(4H ?T:F\$@%-H850K5D47M*CB)J^@>;B@#74KHA-M15;G Z3N@W23^GHF-OYC/!^UI^Z-
TIOQ=1D:16GG/-DB@HZLY,N,YV&EI"4. MHFEI A0?^PL_.*GNUANDJ\$EF-E%DX1%LQ%HHTK^2?1UL?>=) <%Y>?G/;
MR*GRIC,11@^>41L1^>8JF,+R.M_H-R\$-/>TN"3IX{F3H-0N\$^8MW !0<HJEI>3TR\$+71>KBZ145900-
K#4AE,1.KX"YJA0IU"8U2*IK61LL1CU79")GOWT)H_ Q M1&F\$10PX2%&;BYH7**G#6W8%L\$NY,1E?
^Y5:Y 7.&.T/A<*M/D;Z&Y!S'/SYOIR/N14SPI<1<*<MCJ>JK@78"BVE>4SHWINR;&Q6HJ27:V9*B.@+!LIG1I-(5\$U7#K
MJEHHUABYE;^A*1J';CNM7/IFIV",204_'H#%JZY5"91"19)"=3IB.L*M=K"JA.<&B)9K1.GYE;f@S
8*7DB++V1JL0S9*N7SUI8#D1@::5#=#@)\$KI MKJASB1.U.""S-C88N&J IM(9RIHGYK)S;ZIZ?&P(FFI)IA0JE76%DD
M2YHLK;WSO4L3X4'+TIP0R7<-N1W8V*+C\$ETFO(-4B&;...A>=.2AMC7AE? MM93Z-(%"/&?
J9*7FMDN8S9G:@9YSR@8<^W"TT*Y9S-QX::TID&!3OT(>: MJ6@NI:7!21SMB<2J2-9(<#A7<17R9C&MI?J6Q>T?
U12_5?O/?Z+IXI/O"H MU?&*OZA03ZPLWX1,14)1Y)Y:Q5PVAA?IT-1+7B11RG:@O9#JL)?\$D@:7#
M@2/RPA@0+&6^BC^T?L#1-U^JB;X=:%? DR8QBG=MI MH7XSG_EIVQ#IEL
Q1J\$>VCA9#4Y*"@0B>1J.V5H"%+!02/BTJEHP29_W% M&19>0!N3^K-?"JTHBC9*65^POJ-
/H HIX>C<(<#M_PSI@_H45WZWSK_CNV MMO2#/FI5*H8G3I!SI.5H!&JF:XSC*V1J#=#A#)DMW166J7U!WJY!F-
\$GKTPOIO\$=+LX1XX0UPU8HSDN M7BTKH1=+5+BCJ^@XPD*JPXH75+Q#"1ZXK MBIP1"A2,+1CC9GL.=+\$Z;
8O(GR*OX.,ZXTJ=V7J7+V)&O #=\$@%IW+C(WG8*\$&)=M3XJWW6>WX5A;HX'@^ M^R XQCHBMGI G"S5I&
/L:@MO(K25N@H?K3=TPU/_=FOI V1 MHM>K_1OL#H"@.?=>S/31?E=PQ+G/9H-
8<f@O1S(Z+Z)>ML3ZH;/%8N>#MM2# MG>^KBG5/^>)>1 7RE\$6HWA94(I8IGP5"X1%: M+955G=?
4IZJK""?IMI+NRE&HK@)IEZBHIC)I5#&L>X/QO\$F^&UB/Z/;< MC1*(CAN"5K=UFX@T)V13_IV%O;M4?
ME.5M&T_D)^1\$D.C21>C)Y5<=>YW*80Q1E7@.1JG"6OS>T9M19/GJ=*M2G&4LIZO#OM+&8.JM.5_HDD9584U?
TZA1'Q)IYI39N.D^SV7C52F=& M@IYV:#//@&;LGO,>Y)7KE3A+O^52?J*IEY6^K;C A0I^FWWD\$Z.4DHT3:I
MX+L.O_3'ZR/%!IP:(V7/!RM!>Z51\$GYMPP1'U";53P+J*\$!:-B^@4 M&IO1 5?P7N8\$9J9O-1N\$OE\$S)&%W7EK3Z*P?
,&;7F1&#G#Z<1^>65IU M%.PW6):6VV)TP_6>1REP##(E""6T-DVN(?@Y!061"QE-OK3,FW)DS\$A M0DG8A?
QM_R3OI672@/0DL\$Z I^>CH3ZS9+@A5V9LJWBW7/2P8=*.N%_6*!>2 METN:OL5%/R8T>/14_11""4S9,3A/O-
_+=W1=GL#1@KTU?_1 MI^SV\$SMUM-(IM<2DKI^*+Zf(0%<:YNH@BP_:%.#STNS:CY/21I04KS0^
M^&_M7@WK>NF^>Z"GRW>808KPA8?ISZ MEN1I1^EP1WT%161=-7S,ZJ3\$1HU#9"&H0IFO J/F1*:S<'L2/Z/9I*P
MZLJ1+C6&WO>14\$>3"#Y?R*#K+1-5?9_<601#N3IE7D6IS/E*767(^ S7%4
M_Y%1H#83/32+EM=ZUA@.00XKA5.8"18A2IV69J""78G/4JM**OP.0>?O M1R,=H7TB@IW7)O""VF510""71/^S13)
(<77Z@9@Y>;RW=4L>%W1:8;U10%7A M?#_%I<=<=\$UU2,ZY'LD5+E8-83W (#C%1\$%:SU8B14VIN@&
(VBAI:20P%F@BKDEQ-7M"?C98Q*5KXC/4)I MC(+.F6SHG=84I<;,1*L;AOY\$YK?J<,6>Y8VDO,9W76Z>5PI-/3,EIP'V_#_I
M&IQ9CJU;K5I%,^;H5\$^Z=CGW*Y2IHP<F2!3LOI-C7_\$"; Y'ON'1(X'V4*.DHKS6 M>Q.;S?
VIVIE,%:NNT*.3XBK)ZJWH@UBRI?6A4M13*+PY%2=U=IGT#-0H114 M_0S^5F@Q:O:M'?S6LLOI/\$.T!(*0+,Y!O-
L16J"VED,2;#K3615&1@'- M4YUT\$N-O/=)8"-2'CRU6Q@B9:3AHVZZL((^S=98-#P<(^E%%E\$.6GNM MWAQYX#1#*F"-
ZJD-Q^U56928;<W1EJ*THFOUV*+B<O!-7E^YF%,KFK0EMZ MIPW97#>VO7G1T('%,A>"FELX39FJ6YC#Q6S3(Y\$
M.NVR&GXSH^7D5/<=<Y\$RF%=<Y.729XUZE&@UOZZ*KEV/OT(AL#S'OR>N1\$14 MJQ9KL#G/L-139*L\$><U>
IPKA#+H_@DR"IZG8J)XC.FH:1\$+M# MV0X9XS<>FT'O,=2-I(S(W:OKEO_G5?O=B1%?E"?\$X^*GI9C;?WIA7D)Z;
M_*\$HF&A\$W.WA1!H:038IIS+,EIMY@)_2R5L? F1^<5!HOBLA_8L/YNY+ MRGFB?
PC<IZOUPY^""^QXCC2CK_1FX#V# 1,2,?/>H*3_IV7_!EELSZZ=R1V MR)TKKS^B4@;LXIX>T<0?CBA/=&
M0E5TZ\$1IG\$9!YXA>Z14DBIWG34PI=V^Y+Z%=>J*M%*-3Z(5_1"7054P5#Y M")/K1>(S7DH0-)TZM\$H52T\$RFI_JI-
LVW>'8*+2I M9WNCI@f@K:%;2(M9.08Y9#N(&_IVH&QS6:R0+,4AERO#+FZ;BE<>N1JL6 M'VOUKX1*W-
3*)S_9A#1>+CZU?X/YO-^IK(53?I5JG15FA)= Q=/'&_ME, M>/RF5^TI&f"CF>\$>!@B MOL&4ZS_IXIJRWI?
VL9\$T(HY;#JOE2YMJV,N;LJ,X#F1*23K^%KAN/TM- M8JA=E#&??\$J!>#>P1SB_6_YHFFH(PH_:4QIN\$K,5Y1\$)>?
Y/8WW.X M&*G61=AF0GYR\$&XW1&3_(4C35%2D6G&IOWS=@@f L+(IH>KOLFF:361M%W? MN\$N;R1-U2-C^H)+:;
^C#G+I%3GK-IT!Q_X6SN*X8+=!DP57;4UT M>=KY87/U=9P-G^
>8GT*)0T7VV86W0DOR?.RN1UP3;XBSJ*CI\$+0*\$STA\N MZ;Z2CC'(O7QB&IOOFWHV+F.WM-6HMD
KST'L92&T9Z284DS\$%.WH8LP/08E^ M0H(>R2Q)?HBV7=ITFV.8XQS,5\$W8?<"5N>-JET1Q_FUL:F'(J5N12K1"0)N
M09#/#A1QXI"Q%GDRLE2G)C79;HJ91\$M_6^(BF1"VJU+*D#M>E^H>JH> MNT(I^KOD'M2&4;
B8RF(I"WO^%7F.LQAJ.*@GAR+ 8L1@17 M'OAS#=%B=RGD.6>V6Q/1=;G^#<H39XBTR^")L);2R4LJWW@A?
O_Q_0E61#IGZ+I9ADIU+YLKt6_JH9N MVWJWRR+R^*%)S>5H^>_B4Q)5_1/M91N\$=@0MVY1-
GWRLE8EQ;=WY_TXO MPA^; Z7?>G_J2^7>Q_N&Y&Y WRXSZ,CWTJ33TS_MDO"2U7O/^G.GK YRX M34?%#69
MD7H%H&FY99I45/#.AYW@ C<f'I_:#M0.;VYK.9_1I:7)L%O=O:CIH/8 M1_7LF1*OK=%8X SEYJM= Q6OCYC0(ID*60-
IZE;+4RFNTM\$-ZM@E#* M0;2-I/D)WJ:QSEW.2@)K125O""6RVGCITYK@'8U*L/(6B'24VB/67CD&QBU MBYIQ:G>
H:ID#L4,IF:(45'8HQ++"6*2H)+Y:XAD@\$'6/UX W@5BUAR1_SV_EH@F1IW \$RGG127UQUW &B)_P2=%?
MVY#1V+ OF82'519)JD'/#1<2PSWLH3>GO.D:H&:YF\$9(LWY7> M<*=IDA#/?M9_Z+6XBW_DNMOW_YK3=/?
_I X M/Z_SO^4ZGFDK"=8B-OEP1P@S6*EBEKY=IX^,T4IP99(KO5I:C;U>S4.A#.\$ M88PI8U3#XI&6N+)BSN
^%7(.BS=814;B)H210+P M4'3*>Y'6HB_72FB^\$^ZE>*06IWHJI'""A38'#97Z_U.R2:CIK@#1R84KV M3=#,HJQ+
f6^5V1I1>EW@G">Z\$W7.,PHD+RWYXJ:37\$GATIED(R#0#3@J M@LW@3J)HS#98Y-G>6)0;8:00YIOYD2:&=?
X\$=2Z7K<" CIIBYK_\$K1 M7X7WR.3?2G+IM1_C2FG,?^SC'F<7+B?JH%QDV1E:=^57",O.R-1&T;H/
MAF0E4<'&Z&@O:6H_/DVL/IX*)*VIC>V2U;>2 MK%TAK%:NKZ3YSWB1HA#OO!_JS'3QN\$D>MHIAN%K
>;2" 7HMVP-O1^%2\$Y M.O.R=%Z>Q0+UY-/1.FOP+EG7">ND?AB:#TTBEMI-MYJ6/_ # MO1#>);#//+R-
6'FFWISNV)_VG=Y\$+U^013FLT!2I MD)67M"1%S (RTW^LTH17).CDM54-1#?Q'F.9L IJ/<A#Y3OKH%5^P(6N39
M\$IV'N2H*TH2YL7I+&E_4ZQ-2)>\$ CHTJP?F2XY#EL_U>NP-M1HY=E'BLYL15I39725:MW8IT?
SW'&5UC;YD\NP/@.9I^F;O(MIM^?NTR+_N MM/Q=JN=2IEG^!%WYEQV@OX^N3/I?:DS:SI-YC9/)U?2=;G:4W-
X.PB-8B MW_?>;U5%L1#GO33M;E29I5A_9Y_FIM24#ZELGYR(APW1S*PLOSHZ^=Q:.* M40IT6!XBQ3"NBSY'!OY"=
f-<:T?YLS8-?%&GYIA_LKX\$&"DR"<@:VO' MD_XN8= Y
#;*K;)Q7#O9_1U_3FZLM+>"CDWGZC@.YATHOJ#>LOJH_2/4 MWYO:AN^6JOP6/IGHC>(+K^=IG-
S*&"18**H\$XFZO)MU51>J8VQU(WB=VB%IC M?IM&.I@CLPX3_K""^,5&F39<7KX*KIL):C@M5RDR(WB-G5*-&9Z7%9-
M\$D7*NZ7"SIG>:/ ZOU5J1M,O6>,M7< M6\$F#0T?=\$=-!A17,L"VV7^(+G^H^"C1O20\$P.(+ MCU_=fJ&S;Q*6:QZV/-5E#
fGEB0JGDM<4+,=8Q)!U!\$UP.WEGIUQM>K75>) M@J4:QS(:0YX^4HQ>(<63G=%A4K-"9U?#14UIW1U",% FM8R:;#_*
fE!A13K!_M1"6L\$=1133)>CEF/U5P"F'G>0? Y!UZE 3R@NY@6WJ_@L9@#SSK)@E=*XSK M(T59)27MG1AF52H2S&C-
7IYXN'3^UJ#)-4)@(.!G2T+M5E\$5@.:7*R003
MOH1#8H14B>\$G<^YZAU^2L:B0.ZQE9IKDJ "SOKQC11E1V@).A4GT1W;BM^ MW1:MSO/M\$
^IW5<7;CPM&K&RZf@4(^JN-GJ05FB15G;KN)7^UDN1?A<721VS=N-E8Y\$4<%L-594_U1_R>M8<=L
BUK'FC=..4=X#2>HZZW2U1_MZIW"#\$S6ISX\$S&*NVH<<1O1V'#1 X>L. MO5OR=C2\$H/US#7CI@TW-3H?
*0Z<.C6F(UMR=TM?V;.\$@YVZIH5G%_X16; MYG/1MOL1%XOOMHYBNSJX'1_P W67/YO"API+*M:Q
<#Z9Q&@XOT:5VH-IRP MJQI8>O>R 'BRC)2<2,HBJ (7\$^OR<@KL3O >+/\$W_27_4J>CC\N M^A7H0Q\$126,IH-
^W2SVBZ1(6+Y#D#H+GT\$66A9EFG07O/>VQRW)^7_)O. M=M_%L/4RX.W:&6""OB;%P6;) ^LEV*LE/O*W8+ 7V;
R;U1C8QQ(\$S3^1=?/MAI.U_U_Q2\PAHJ5P1@3AAELV=J5TI+KNA1?;*KHV1XIU:WV/26QI*L4I

M+ F*S9'1@)%)3%)OTQ!A*+(I+>.\$N-.XW7IT-A1@IT%22MOHY=M 8R*J.CJV. MEM@\$\$>7<?P=/%058>A!T2I-
T1#YX@+!GF&OEAK=2NB)J#F^H(W\XWF-K M@/T(X^UD^V9^9T%L*O"5H.NF.I&.) PK 7CIR>YY)LD&P4<+JYE
YYIH_0M M#E?B?;=Y^3MB L,E|N^I_10+3*T+ARQ!E*8\$>%OBLVKHNJ2;)Y*H&.)@/ MQ_-HZF\$>HL:T0Q
M7T0I.T5\$?BVIPH,Z=L-06."@>|Q\$RSPE!F=GJOP/;+%%*T_!AFY#5T#"K/%Z-FSZ_VB?837K4<<2F'9+Y.XSREFM
X3Y.W(P#>D^QG@+197\$ M=A7>>+;1E:D8NAL+E:6Z!R0DR5%YKSGBGEH.NJ_!>L&L!DZ/F_*&O2SN2V M5_<2%TV
_RQ\$!R0Z! KXF5-N>0'U9-"ZQTN! P8.O!)*EB>R+!V TU-RPO M15*SIMXE*YROD36J9.XS#ONXZ!E0_77!/=5+9=A+?
:8GRJ6>5AM+!40BOK'B;2RX/A V M..7;G*DOCDH+!)\$KNK84BX+T;9W\$T/>/BU5W(=L2BH)_.^(!TWHW_1'?>
MN0ER6B*(!#/,(!+N\$'OO?I0Z8-&WGF_QL'^,>5KJ8=0?@Z*R*!J M.;X#B+<>GG(V9HY_+ORA"+DEZC!54-N!H-
XGKW!MA4RQ-D4TB5THN=KA M60U?M6-Q"NJLDT\$?_1^BJS92UE(#CV!D!HNA(^JN>)LMZ'D<MF<_<
_Y5UED=&P\$!G\$M..2PRKZ"Q%--E.O&8P\$|<|G0WS*5?07M%;G7 M)K:SMQU""K?);%O?B;DWAZ&-
(%G"!O^@<"U/E?_-2L6VEJM#O KVV3FH9_ MX:=<JVXKJZN*Z(B>_L5%WN2Z;5\$9!%6M6K
&RK%Y3Y.6(P:1TIBIRX!8!M?5S1>HH<|! B!3!4@(<4?MYUK<|V2B>E*C'_V7>SM@_SV+2!NYIV-OMH^S
M_>UBDRM530%V(GWB!@8FYN&I/3UI*VQ+&B4!>6+YI6(&|X%%7P#E5-7W7 M0@G;>K+*50S+
IV%TQ!HVV!J8/9Y\$-LK0Q!GKJ" V_&8WW?S'X>;EEH_*/\$3*9W\$H3:L!G)IV M7!QPGD:?
A<8E@9'JEE=J'0^Z0<=FL1SC8G\$(K/6Q@2?C-H+D96G/M XEY/0G8R('!:&Y=3!<6KTZ>E2J#EJ;JD:H9?PH'MFVQU!<
IV4/<D'H&K)X M!X@(\$9\$4)K:0!033L5G.LF0<I20DT.C^17^*D.Y=63;?(\$#"2=10 MV!E5%G_<C^C(*Z,5E?J!X)D+5#+<
W>&LDOCH_!#(O3P%V(!-#BA@G(K2?@2.TG(W;Z!VN-\$E|>AE%B#5\$NFGC!5^"5P!7W CQ>B M8286!B!
(G;EX,2;\$K_NJ_=BBN!2*CIH!05.4%\$S;=?N!E2DIG\$=!R)>Y:1R>9=G"67X-734_-7.PGBLWUS7";@1?<
M61T'!HM2BUS*240#8)BDU2S<8AW78GR4?>J>A=W33!4!P!5W^&0!X^M""A:N J_?0\$Q,R)E!4R\$-0818<7C(9F-
RI\$A3M;JF&BU#Y.A3_+2PA>F%0 M!KKC(IVZV7\$6H_W'EB'5QM'CRWOUYQ>X>7;;%QBK3%1E?#D8V0:'CRK_(1L
M3_/JQ&21UA*V3OMAGUI3!%*NC9\$RS/X(7MGOK4J>N"6G+M\$.A#4.Y3PO-M0
MS^5|U'&X"!;..RZI3T"9THN8Z=EZPH>!Y(:/L_)ZHUI4N/>.K(V4-Q2DH3
MI%A'N=8L,EE:P@O1WLF!R#1#^7^MG"M&K^K^DM4!;)RXBFWRU>JU MOI#F6NUY#;:@5V3Q-U K..)
<9)KT+GGU!1U5R6!X!\$U*WN!%)|Z3N7RO-O" MV%.ZYIS8SA/ER'BP;&E>7.- (386=3 S@I7KI3!@OZ!WZ%8!&
M!5"@OG/TQ#<-|IZ!2#=5^ML^QORV<>+|!\$13+^@@\$M%*\$J!&)&HWH!72U,O? M!9S=-.0'6(=PUV*V-
&G!<(HT22)0H!E!0C)W8KJP)Q3(X44482P=90.C MI4Y_A7 M-6Z!M1-5!\$0\$6A6A!K.D3ZXDQYZ6:_9P#@/<
!F.;OX+H9PO/&R/U!TGM5<M#(ZW"?UM!X&R!J!;J*F!>WK5BCP!M H!43P?+2(I8F6CXN!OZD!JW+*CW"R
M#RPWQ7Q!J!2SS)%(!%IAU)3M42I+C;J(A:2?)LD:1-!&J=+Z2TG*%D!C4P? MQQ7>29O;2V7?TG@Z;-\$K
S3+HU>VN'P>U!TZO:7C4DZNP;!9S<454G"2 M#=#28("H?>5EIJ+@WST;.*X*D-%V7IMLSDI9#,%FC^19)VABO2-
CQ*F!Y M"6<&&=OJY\$>|F-J.T/-I=&f'C52>J2IU

<.Q78W:G!AAS MR!|&!*EP)^->WY+H(QLMVH9>WU+;N#;/>KA)9U>&K\A#%EA!3V)DP):UR M=2!\$S(Y
=E/#Y3%JO!NU(YHZ)4,.*D5XRV\$AZ4:78N 1NSR3;R2XXA\$;P M?GCHY|_!<O@A6Y-%:8>^W\$#|P(WF??
LUKFWCG6E>&-C'H<566SSWQ# D(\$ M)HWV28YC7QV>Z;G!Q!G9N<*=Z+@/9CR<QPIKTLD)&J=
(/X05NQ)WCG9+>K5 M-17X!|=-18=-)O.N\$NW4+T!*=AW7T&_99= 5ZM_R!Y FLG2>"RP59N<+_1
MOFU7%\$4@D!>B<;PR^G:V)H=\$L!H!L!YUS7!R.JNO%HP\$6O(1VD!;RK.MKX
M*%T^JVD\$H)15Y;!2.H!WWJ+WKEIYDO_3TX&*%@!W#9CJA7;>8Q#
M.O&U!ZT"#.;.&TG!ZG;V@>+1_+6X.5QIRXG0=M!2H'')(SQE>HEKIUHNA#8E;2AL5C0WH3P!H"3JG?_AB-U/=
(WXXR!0/5X M*923?N3)%R;:6)VU)1!45R7_?#8 LG5WI*XP943^23EAD00!8P2/80(17.T
MOQZ@H2W@56A90SW+YYL)ZBAV9Q!5\$<=NO YQM6:DQ'2JO5?>'P5>7SK@'S
MN.Y2R>'59+L.FC:Z>WA"3.00Z5L!V!2_HIR_!J3!;WNV&Y-X!P!H!Q!<+SW M/&53N3>|_LS!@&?-<=P#3Y\$2B^>?
EAWEDW<|B.SBCD_0-227;J_!V@&X&M(^Z8_5D9QORBKU3)<AF^<GQ&IBT/K&9_+E?%W15JX-Q0CV9R;Z@D@_2L\$
M>@KY7ZM_|F6!+K-.C7!KE_%?YSFZX\$S7WR7?FQ8.IG@44TLX6XY!VX^#ULE_5G9-AB_VB\$6\$6!%#71^K#M"!\$&V9
MDK6J!_!^G/Y3)0P!-Y'%|B!5A!2NDFET6;:8KJ!H6W!)RVCZDZ3!U8^A_0 M0MHE\$^8T!Y\$B!|Y_3LWMD'D;
M)MOO:NW3<@^@4;N^H:7F*?QWZOC%"S!;L.S.!!DSZ.H'6H:515UQ^=O<|S2; M%;""*SFNB3!Y@R#;VI<=XG>--+*D@-
#NP6MG\$!\$%_|VU!1L_(-E.SGK7:D) M!5H+K.42JA-WV6!/"(2).A=5A.DSBL!327V?3Z.S!JS0S8&/*^T!4#19EI
MJ&0_QWP6<)_G#)!Z.?<|F;\$FHJ<|_:/ZE!UJQ5!Z:7!VJ61^=ZY M!Y*A;YI@CTZ!V_);13-79UKH!MG;
JA4;16;AN^HT@/M>LVW78FDI^=YJ MY/4-P+!F;"8"-D9(Y!D)0)66#44'M79(I:(E2WV3P?;V+E5H\$KD>DN.B.2'
M>D;QOR.LKV.GF!Y'M3^O+!|^=GH-HLS>|B)V6SM6")HAW'BBV%#TA!HPQDWOG:(HS^1
M@^F>=^7*P;=;!+!"D!DVA0!L<*6JE8.!M!D!L+MC!LS;#R:16-VE;?Y"ESV M+T UU=-!>%7BUXT&VF7A!IN.>1;?
(Y"B@F(UV*4T9HB\$(?9Z?GGZH-!LGX" M0?0L9XT65!ZO5P!B\$4TWNC_?!"
S#WPIV+K7!1!VC5\$>:DG=@60F9^0^R+RTP#>I\$E0!3F%+RI&X*C3VT!G M%EZ/?
&VIDX_T!ZOSHJ(DH(PLF:48EHGHEO!C?&YKTIW8+!\$!17 Q(24?NGKO'G'Q3CYMA63Y
M":!H0=#0!;\$>#1WC!3:P>^P0T*W>?7 MJ!F6*V"+L1.YDN7%?!?;VMO>_M;+@79T"".)S'P!B#OKV QK-
B.&:/1-/GBM0RK_O!Z_5R5.UU8<=|VT.|XKP M0VB\$A^*XI+;_!T:"J" ZRK8/-?E"!I3?SU3JFP
MDI9GP!B2(>!2!N.K!@Y8Y.K.6W2/2RZ!RF5T<@<M05!F2!.C?&VL4R>NHR_F MC.EF+=|J;VOOJ2%=>S36A!>)
!D/8#1R!>V2;FMG^M_)C82L2^V)9<@'_MTV@D89=SLEE0U;PUAG&.!#NIG!WHP!6F+V;|MG!V(L+RM*;0?!=6B=N<4!<
MO)M7W;O"C_5Y>!"!F7D;_3HL?1\$-B8+UOEDR+!0Z;(L_W8ZL%3SDZYO=GA<8 M;F E#S!H!N
CG5U9955R;FX19KIV#L?N^(!5!Q<+>XG@>M.;>|3O-XYR MXZKU! MR_WMR(/+K^!)?*K+SC;ZH>7U9PU6YH-
!C72DK*JD8_1>_VV&4"@!KQ5A4!FA Q"">0EM=I(M7:OQ=KJ_%Z6RC/=R^5R\$H9TR6U_-NOJ MY!K_-990P%L?
&B@G!K9GRZHHJ6-BF*M!5XB M ^G*H&4*1!(WW:FWIDI%VH.35Y;#01C9\$!6J2%Q'E')G7Q)BPM;ES^+H
M:2&DSN!)^!5L+L)NVOF/9.EL!_45R(2-1C*3ONYE92\$4C4?V:S(-';S.OH
M2J!_RS&S9X03;%/OOL@DIEHYK3!HQ*F.S*MYJ.SR?> M6FXZU!AE/RB.7!R5B9*+9Q+!;M;'!GXMMB7?
4EX3>7^67CST+92J90^EX M^!@J*#=#?;="KG6!H_K(5!)"6\$!#6)J;&B_!1=ZX M@_HBI?(7!#0>X
M'Q8.D&ZC@Z)!J!NU<6";.5.JF>?>D;H#P-H@.5#;Y&:US?8M_R98(LMMP-M&!\$&&K!|F?
CZ;+F9OWF_!KBBL_Z72G/<>\$_"G0_#ZNJ"- M.V#V_J!LP0;Q?<=-Z6LMV_)A_+!6*#)H!MJZQ!KSF-/3HTEM&I?
RYIX1U M7^&STA1&D.*!E#DHX8)U_P!_@K%VJ>H=B^V">!OF>4QH9TC18>-8(7Q1;=*M/?
D!E!J!H(SD+H9!^3=Y@GS?%+M_?6)\$54=;!\$;!4-7!GE-94Q4S:&^<3<
MO4=H CMVG0HWN7@)N60!3#6.E13<.=@@WRVY(D_KL@U M2COK&1^03YB&STYV6QV4&9NO8"!H0-KLT6@6;|X-
1B0."<_9_FKR#>*L<^ MKDJ;_U>6%!SX@O-YKSMGYFS;ILO.155G+_GNJZ-(MPR<#?'7'DN6T6!6O96 M?ZJ!8Z)Z?
PO/F FIFHSB!A66P&)&KCI>!7FT \$!LQ?T7M+D4@!7R2>WG M;TGB+N'75Y+!U;*1HLCJHM(9_O.F!<1-NPRL.Q9B;#>
!M G-M'G=L)MPX* S"3J3-M (!;8^2^LDIT6!LQU3!V0(#O+DVL!8#";;PY^J! M GP6EEC6N!7!5L1?
EI/KBULQ#%-6=2K K;=I5!5!C_7&TJ>&)8!49R34^|
M2)ZG+%HFZC12J7=^K4RSSIS6"!;6JZDQ!+5;">VT(D8CX;0;+;337\$@N27
MGCXW!0"/L%K!6918!4!^4+7H6)N_@CW+);..OX.NIUGY85YB);/H!7_ M"ZEJ.LTRIR7;@U'EC9JK_6M_3H=;*Z!8A)_<
SR:9R!1A^<^Y!)?<*T*T! M*+9#FNNST2Q_ ^UQ8.^)NF%=-!<Q=EL'E-YF8O:60&T5_'CAH0*.6@&C7>SM MJW-2P/'!
!^G3E_K H!YPIP6O>W8MX=T>^>5_ ^V*P"2!1!Q6S!_!MBRM(M00@IK!\$0!@!LR@OO#B4!CO^!1?
0^!5A!37L5JXW7)/^01OQ=E_1EV-!+8 MY0A:5Y\$CAC947;BLL!QFG>;#J2I!@57W(BD<\$J/5XGJXF!=-%QTHS

M.49G2IU!ONUHL.9.CODVVL5.\$^X\$T.:@LRF4RAIP1./T2%UT'7^*/+2Z MSC//A4)KA9-
:F#*NC\$)DA18@.EAUOD.H7+>>:1%CA*\$R?EI@AO'IS^%(87 MZY4FB:\$F\,S-
H2\BRGP11M=1F8#X@H0:)4UFI&H3BR7903+L&(Y6MRZ,50 M?
_VH>Z,1D0S8V(SI6G^*2#>=SW*YTX87^>=&8+RP2.=)V\@#4\#\$W/ZM=WYU7 M5:3GSLD)H 4!-3N8 'PT ;LP=8-!;U" M
!\$-!G!4/RU/IR)ARA'Y1^!>Q72Y5H85@-Y.^9<9HY5>+/!G&ZQI5\,YX
MR\KQ3#L7'F^8P0*^^(1K%!9*TDMC\UP",W,RP5\!)-R2(>7BK=XPIWCA<-M4_>FETLVV\>^HZ&8PIX-
%PY\$IT6HMZQP8"X/J-61HYZ\JT,:R1V<*>U2JN;
MF.+T\!C6F\ZEEM\DHPIV+="\$Z6JY^NCQUQ72B\7T#.F*ITCC>P#S@FD>|A MT\!%*:C9P%1,2N3HOJ-
PK>|Z141.B\,R1B21:XA OAV\4\$K/QSW X Y\!V\Y4 M,:.5OL\!|D74\|@"C 0T ASC?KAU1?I#+=J\$XIO8\LV,:XL+?
F#4_D3O^/O(M\$LONL7GQ:,6J\B\,K&%\ZY2G\Y)-Y3XNF\!-#6:GONMP, #, C\$J<:M\ T M(N73\$S07E*LM%=
=\$IB'=QV'?:LS1A, #DSC7\8Y\6V(=|DFM1<+ E28A9 MWC6ZG=VEU/,\$(17@+8Y\A^?5(HZ'2? 7H&)^GK:@Q)^*
(@!U&H5.\$^N MJ\%(UNEU@+K=):T7(ZOM, D:P'X, /A\H&J>C\!+##N\I9-R8\LGTXQ- M\MXJ9XC<&98:7(K%"-IG>
(LJ>W\@PLX,=?6(CY2AFK*BNGD\QSR<7-@EX MQ\9NAY'6\%+M,J\3:U\EF3(O\$8*G1W)F#C6
'\$KF(X\!M;5\N=IU"U0=>Q7R* M.S6Z\YT>J\T N\!:@Z,,ZO'D'.9S.WWM5SH1-2K5360%+&ROEV^Z5DQD\ZL>>
MU1A)72&YN*12*&U>1%&-KR+M\J@++ ,JPK,,H"=X5&1\?FF(DPP#-,WLDJ40M MVM+X3L\0T\!TOOL>:V(^CV
GEHYI8.\!CP:POXC,9 B\LI6L,D*MSUR57B& MZJ\T>Y>+ZJ*W #S\$96\!M\$Q-)"U\!QO,\$&!,OWI?
%2D+%2=):>O\:/GO+/ M=N2,*\!#F^GG\!3RJ_ =74Z1SR2Y\K7 /ZFZ\O\, 1.K>:N3VN:OER^KL"X# M#@1.-
'J#1@**K>^*^33H+D;"*P(1 CK8QP8N<="G366*Y1@ID MJ^UE1NA\!):TX@VLQ%,LIXIUU*.
XA:VX8S\@C#13XA(<=<IEE@N\!;L KE-<1%3/U M=2W:5\$>MZ?BB84R"JE28IPH) ^S8 \$>^
KKH98HJEH\!6NNNRRC("SIHH\T ME,>\$ _I90?A\!G&^IX\HM Y9LWW:6=GL,=1C\F 4T@5&A7^\$1FE+<^H,+6 MFQ)
!|D182,Z^F6X&L,T \$=PH%B(?E/M/W-%IE\$7 M<9?HJ\!:(%1XY,57:91\!R7O\!7@%>%EVO3&F=!\\$7 _EQTL\F6\$-22Z
RQK3,+ MJZIGEWY#TG(?IVQ_*^BG\!N9MVA*.^(8P"BLOJR6WE>GV-D8\JC JP,*?^W=
M%T\!\$8Q;9EO,8L+OQFW3^UL1D<:1%AYM41\OIH6=YBE=\$,L0\!\$=A\!-?AS M\9\!YM'9-IB4X H@ "L@5<-!TJ%+T:GE
-4XM9'O=PDJ2(E&HJC+**K.%&UE#H4+: M'G/Q9?8F0H>=V*!BT+:J94,M/ MX-(M40\$M\$>%
<98+K#8S(X%TR\FQ\!#2W6Q51^,FEX+ O=?N)7H\A\$22E9YS M\$+Q,L\!V80\YNQ-A#C&2"9*K1'U&D+CL(TUX&V6U-
D\RO<C#U M4G*_5I=0;^@ (N\N7-=JAB*G4R<)4&2OB@6ROE9#I5FD-O(<.,4)4ZWLHTNK, M
+@OI5TTC97#:=50%370ZQ-2H1>"H3<.),7G\!1U\$*!+P)9(NEIP+G\!# ,K MSUP\!HL\, RVE4,10#|JF"U/?-R= M
T,?B#MWB\U*2L%W^U#1N@J\!C(4B\IV+Y+4?*)5YJ\18\!>>NC#0H\!U& M>, >+TQW\$&6\!FEP\PHJ\6Q4NZ"D?
EM+!O:O-QR75TTR(3M+U"02Y^,FZ& M3BK=%&K:#NT7-C6WZ\IS*1R _RSB&L7\67%6A3EW
MXA, FN=^Z8=R24NK\!OB&B(L6C@J\,F+@\$ _HGYMFEBOL)R2\!6:,|6V\!D)C MWH2_RU\!W9DM)T2@E, KV.%
(3\!>505_7?>GC_+Q2\W 9%?F\IXPU"IC) MMC\!@LNU\$#\UC1_!+O>D@ (K=L/^+M\!; _VD,H\!;=H_ \J\B1\!/^!&?
VU\!>A%O\!Z'!H8' _H-76 MCSXL\!P?7EL'C7\A_7ZLV\OE9M5%U5^!-HZO=80WU,,& _RNY\!+O6X9BQ>9.V
M"G""UN1L6"J1.*WBSQ#^>ZN(H/^@ Y#EW/Y4& .C3K4_R:TED SI3'/#2 MY572\$=M=|5W21GR=G-4:
^<ASV\Y+^/N48\$K&.N^U/H)G5Z#,.0=&=JRPW'0 M>7\$%&X9*MFN*RRGWW"K%L@F+)NSQ#\$3#.ZB\!+(("^^M6:!
M6B\H?>4XZQ=62#&(O W XZ:N2\$NOB4OY(- H%*!"6G\IOBH<13.A\3MC ML(O\!XG, _!|5K, _G\JZ)Q,8""WTL\J
MOL@O/L2"VS@LEN.0'!6,<@G\!H#HO1&N ""+ COT0 M\!XAPOLB4)0_EWXIZ/"NW @ZTF#GBVZ/^>46-
E_QV+Y8EX\A<+.Q58\9 MK\A&N*Q8?J&%O\!HJ0\!+=41/>U>+=_B4\!&8Z#4"NNA _<-"Y0.RG3R2\$!?!O M,M?^Q?
5C;U\!VS8XOGFMR*\$7S#\$(^),J7RO_# MVWQ2/< M\$*H1CSU?V.R&A4\$4"AC^H\#COH^T.5+1CV?Q?6.L9DX:*(IN
MU,%H*-BYOZN7-?TQ4-@,D&479\N@.@0QKVHWR2M,:4M%+CXH48B.BM3M\!A MCZ\2 *E_<Y76 _PH
*7R3DNK=V ^9I@LG-9M"!\\$2TM\!WXT2=QD,:YZ/H= MPJ8Q\!(VA<+F\ZD0=+UR=S#,Y(V-
C3\!O"\$B&IB#_)!1BV@4,&Y;D8866 M,:Y6&_HL4< 4M\!G7'_K-0UG%L/H#&<6618M.DP)C&B\!H\!1.\$&\$P:#0EIK
M31W+VB*J9BL>/GA\\$,J("51QY#B12Y>-X)R2<:,IY+&ACVK9CD8QW7Z",L MB=T2=42F7Z#)\N\!B\!V?
BDM\$5>T+L=:=L9_QB25V'9:E970\21:ZTX\,4 M5(U*OA0@?Y\YFR9757+*U*+,8XL\!2L*P' ?&?I66B(L678NZ-
!@VK'^3,\$?)!"S>BS07Q#OOPSQ?G>\$ M\!>,?U"SF21-#&(* S0B'O)E&QN.AOO."3W\Y=P\!/_WZ3/<:EY#&))_*D#
M_W\IV"#)W3H1%5E> %_,OW?ZP)WTK>*ZY+6Y%K+!W,N_)?\WQ\$' MEX7\!X=.,@K M+_
Z*:=BR&+W\&@>A".TYRGJZ(GX%!\FY2"7PCRKU\J; MP&XJ%*LU2<\$6\H=?B"X;/_M3:,UU8)=Z J<,
|C\Z%MY61^YL'3E\!VD2&+! M5\G\K9E)TN+,/2OH;W;W8IX M\IV@P95^YS:@U2IV&=KZN*#3IKL%;PTAU\PPSV#
L/Q\4+NF^H)G^X\!#_7J_ M9\!1*_8Y;'6N\J\!+E2,I2" (H_:C2(OQM?V\F)?)>3FX N @V5JG\FQ*!O*1 M8-
FF^D2=,9>L>23\!\$(T%*4S4E /K&/?3\!H#A\YR+,A=L41@^@^ _"R6 MTZ/N_@=P^_&O=|PSJGV/N.&HB%+Z3,X-
SBZ\Hf\J, _>ABMD*P%)\YI84 M-RSU9%KXY, IQSBXUPZ%RPKUP,"AEG/9E;_P MO7ZNSIEXBP" (3H_*Y<7>K\!+O
L_ S\$ @IPC.L\!E6'VS>P< SV=A^X&=P MXT+!,PW7\!D>LUS)*W^&8<,XQ)*3=GU=7\JC3JX%UMPAS.O=*U(6@VZL-
M0#*#89N+=F&P^CE&K+0 K-A0 R=6P?L+L-I!)<1R\!-J-17WY.M0LI29V5\$S< MZ3Q\3,ZZ\H-6VB"=V^_Q2*A!
F,8PWT#@|YE@+NG(6\+85/WVX\|@#0,+TFH M(-Y_9DY1FGV\|@N:M_Q@4A7D9L\5ZT)IHNRG\RD1
>I36.%8I"JU8_NJG\$7 MI2\,^2=?CS;P\Z-IDU%QM>H\!Q44N93@)K"O\QJRD.6JZ'\$9-0T)H*UA+ S
M5'WIPO4/L\$HEIYKJ\!S'30\!&4-9<9:=!C-ID\$X8\$>)A+M<2?F@R:H\$!\$; M7?3=>R1*=-,86I^L\!0"S"!\Z>
!5FYQJ?S*D&#?^*G#?I?G#:-PYX,-!#G MR1'O1K\#8*;WGLBJV+*I_V (Q>T:#GO"?;55Z,V(>|P,%.O:1S;K6C40?18
MU.CJ?)9=2^MTXUFAO)Q\DY; >Z\!,"G\!PU7'O\UJ3=.%9:Z@AW?3VA;J.CJRI/<4GD MMK #
(%_E4"JK6"0V42+ULK^XCZDBPY;H%7HS,,A&F=88U87(6K<4R)V\Y'5 MZ%49M2%-
!\$B":!S6FNMQ7EV/LR_Z_D;^/4KFF:!)@>5ZL8OE.OI%&!\AWI-M**2-A\$=^>T;,>-T@U'L,LNJL\X,S\!7O\|
<_KZWY#1'Z^3;U3T U&WV(^+^%=, M\!>K(>YGK7*Y\!A)XH5'D4R;714E=7A)FMIK7-\$,O6DGS\0%(>N")\!-
M@8G_03ZR\B<*8\$-D18L^V3\O/36,K4U*GY6IS_IVRO(JX,F)&4#K>V\!S<.,MO:0XG>|_%2K^,|@ _ROFEP.DOPJ
&QU1C/H=+=G\!>;F=:!1RWJ\!^?E>5TW MTJ7N%A?R98J<+!8;C7C9XP=842NJXXS)^L\!:=BB\ _HTH08^7-3=Q M=-
V3 M;?F)0AO_R1GP/8F+D\!XT'#:/:H)@H09JSQT268_#8/SZ"2)TTU-RD=9T7K@;
M1,:LZN_!6LONQ\!D8UMUQX\!^5'Y\WNA52SY(3>?A5+?8J\2FCE;-OG=Z^ M7GZ'R.V4D+C=|OPFAIV.1;_LB?
2#Q+*US:ST_G\!B8;|/7Q\KQ77Z\!R\!:=MYM+G\!A9BCZ\J\B2>YU_.C0GOAJB>A=O0&J&+V<*9V9A;X3\8CBP>3\!J)
M2\!(R2H*;\PS/57\$6+=)HO\$2EQ0\H &4@X#RU=(1V><|TA7"14" *)8) M<+!)K7U&-
F.DM8COE3G\OLEJ&L5)"QW\$;3'"=*C)*-#%/W/1PBH3+;HB,, M4V\$A?E29=Q)S-(OC;F%N;_&ZO)/&"?D2B"=6FIQ
M# 4F/_ (WZ+8O5WKIY6L\B>L)6>!?G<|SR 1MUW?Y4MP6S\>XT(I?Z+5V\T) MJ"7!4TFEN?K6ELP'M%
8IN&_VDS YM6CPPWFO537B:3NY;^HBRAN.T7\$M-OW MR+^L-S)4'6\8'6*&99^AJB_%BF9U&A<2-
WTF\$J;%#:BV47867NL9(C)QY;R(M.C=OK,-NY9V0@KH/=9#9JCZ\>)X7#7C9S;AS3N"QJ M*LEX&>'UIDFZ\!B%W4T8
)X:@1.9\GJX XPMP97JD:Y\$45\!_9@E?54DUQ"?PEH;=IQ%J?_)G-8:OIB_U.B7OVLVY/
M*O1DHJ\86G(,7^<^N\!792%:JRI\!MFS*S.ID4I8>3?J/?Z8CW;<!=BM3QT MQX8(K,F_1F%J4 _NRIG7YCRU/*
|G\!0P\!2?I2@, 2/>|C|=4QJM<- MIBFUYHX=:!>D2EAXKG3YT7W7EC">D\TO6KBP*IV5M9;8\K5;@S9H%ZT\!Y0 M'?
6Q.VO&\$B=+,G=N5IEZMN5_-D"V56C51&ZA)MS(XW\.=**+;_SMB@QE&^)_MA\$CN9GH3\$UUQ"29%"8-
IT4^P'9&-0.&-76QS^YN6_NDCC-TA>0/FE46V\> MVXVE%\DL Z1K&BY93PLQA,&M;!H006P2U;U%G
WYVWK/Z9@07LW^3L)SX*75Y;V#|>*9E/73\$W\!P'B_LZS0"&B3-N99<\$24.GO"IT%UMK1R M?
^G)1YFB8<3(= >+0^+F+S@JFL:JU7UN@2WL6#H;H/T;YOK %H?8S)B#;YT M\!P.UPT_HUMEN"PV8,4VOO-
4V;&C/2RH&/\$XN6LH0U03KOVQ-S3X4K?2%P+ M;)YMYK\!J\!D)X\$@U\$;0R=O1\$%.'4)|VU0\!@F@U_ ^674! M?-

HTX3:=QCM\25(MRP:YX&S(6\HI\X.^\$C.NO^?> MGB\54\$+;.@+/O1JR"ZIKD.EN\JX3M?^N\K MKFST*8U/7(K1(S\I
[P97-;[72]*H')BB%-0-'9G;L129R#9GOIH.L'79W M\T2@%+S?D\I+!L:H(CHWAW9T-
|MGRO5I\$CE<1*PW\$%+0E|'"3&OG306>AG? MH+D/+L13.+?
+)=LU2E<=O\#Z;1<3J*Z#NLP*KRTVZ(XO\|C+U)>6M\C'291 MX>9R';U9RHP4/40"2@K3WKF*4\J6PH/'%#N,GD+
DZFEQ?C9SB#WUO+-9 M.27)O.L=7_N5\|_\$|= @IY#2J9IG#X#JL^O+-TP*IX.WD;#.7\TPZG6NZ2@PN M%Z&KEX*8;
"2YFY\JOML*I1=+=.H8E;BW.KN69A=L2&8K9%M-/CHCCG>48/:#7VE5X_U(@\JQX0(B-)'OZO*(M?IK8RD M&Z
CPR.@^O;.'0VR;\2B;T1NM4WUGCV25FQ\H"S^C?)O2#-.K&CT 6=|K M%.OX>*%\$M>PZLE-
3)TLG/#2EZPQO+23@K?+.D.'DPTR1=B\|FUNEG:6H*^/ M.U=6IS'7KP!-D0Z^;Z";>T@JE. "'
)Z&K>\$@ (8Y05L\NKJT*.ME=GD>QY#O MWRKONA^Q2ISRMHU.;M)PG6*NWD\H(>I"\$P\$|!*\$GI+X>4 |<2"2E+NI\$;
M^5?MUVMA|<.*"14S*86N\|AQO<(C5\I54*|+C4ETO.;%UQL MS#\$YSJZX&GN^XZ)B.A9U^<()0M:A-CL?
L+AWL(CD;\$P?2/0002O_^(+ZM\$772\IE1%:E!%8 NZ?>SL;J3 M6_SLG>-HXY=" @2IE5
3*KAI\F(4KW5\RS5HD;M9MQE\402UJUK0T9W;1+1# MHJ8KYX1.HU4IK5+R"/DX=2.R_U>XIQ-C0)
MHJ>F4D#VKRP8\IZE?/R=*=0A=|&H6%4(CW\\$.NJI\WS%G\I\N#*YSWO+>9H M'LW\$;K\X\|&\$?
WA0@4^.;RMU2W7.*97%.2%EP"G\I'J2WK-CBN7ZJL9F YMIK.7.A\YX M+|B@<8.; B:SIE6E&HG%\0\FE :+
!3;^D9PCNNSJF_P.20FEF;UJJAL\$?# MG_-Y%1.Q:6KR<+9&WQHM*6XW%N0(H9CJ6XQ\79JG\,R\$.10)Z2FKC4A-
SRE8.\$3.SPNNG\JA^5JL_2E+.;T2 MYD-W.>33Z;7=QTXE1%MG#7;.P0DG8F:1#XV?H3AW9.; HJ\3.FG)THS)96\ M
0=MG54*)#\X==8)\;5.8GI TBDA27U?0T5".I6K.Z19%06:OG-%\RD9KH\PA'O4 MG&.2* P-Q-P.2TPP@-
TTIP>H=6@)=ZYWA8)BDX@E\#_7=;X?U_X_?^CD/8A M'5%2.R7G^);.9\8UWVO%?R D_&>ZA_)A&H?XST"ZF;2>|6
<?QNG/K\|BX M2H#X#T8\G)3; &JE-.1.2.)B>GUE9\1\|301#CJ#&\$6;A7)M# #UZ+YZ9I?|< M\3S^6@%(>DK0'(9?
80&.G&M\PI4529H#W=;\$4+T2Z2+HHZ#GC<\TA+;\$PXDY M+XJY#K RO".0\JO@;==M.;0PQG=V5H(C-R-
CS\T@SIEBR+@MH' M?ME22L6QMND*-7N\|#"I>4(&GWV\D<(</>SKF'.(Z^";.1FTMT-"X".04"(PQ#CJ\!"\$PH+OUM-
6)RV==V+VH#|8/GF\J(3CC M/W3CZ<3WXNSRK.Y(X \P?G\BH\|L%)\5_YQ?L (A5@E\!+FJH2E3"1\99/ML\T.3.'&|F-
D;!\3S5*7FNX7W-AC8>)_4MMYBR2Z9)9;>H\JO.G6(O 37 M@830Y"O;EW4==W^47;.ZZ*.*>(\HV"NV9GY^_P35O-
2F4#5S=@4("53'9<= M6WFIY9G4Y#&&>ZC.JBBEKARK_Q4I%I*.2.!R:4FY1P\F&+.'V TZ;_A_U?
M\F6\ E/RW\6\>|F;&_@R\$/#2WP0Z.;@WLL:B4>/E8\J&E M#WHD.
(Z*=W\E_@#5B6V7SDR_CFKTJ_4"O^<5>DW'H_T_YGOZC8;A+|V^:Q8V MX2GW
7Q&.Y_D\%DFC5Q\4C_2EGB>.9V_NF#>(N\0=VV&0I%Y&KV(I'JBA< D90\$ \$ M @ \$ 86AG+3(P.C0P;S.Q+GAS9%!\+
0(4 Q0 (-B_E@P*HC? MKQ8 &S(-0 4 " 18= !A;!\0 4 " ??T.\$ M \%"P 4 " 0:2 !A; &#\$R+3%?
86MS;VAE86QT:"YH=&U02P\$"%_.4 " "X@/Y8ZF)(#.P' M !>20 (-@ &=;08_96\$P.C X.#.T.%E>#\$R+3)286MS
M;VAE86QT:"YH=&U02P\$"%_.4 " "X@/Y8(8;I;=#\$ (((M @ "=08_96\$P.C X.#.T.%E>#\$S+3%?
86MS;VAE86QT:"YH=&U0 M2P\$"%_.4 " "X@/Y80C8;%U@\$ A& (-@ '6>08 M96\$P.C X.#.T.%E>#\$U+3%?
86MS;VAE86QT:"YH=&U02P\$"%_.4 " "X M@/Y8\TW4*^0# #K\$ (-@ %L?@8_96\$P.C X.#.T.%E M>#\$U+3)?
86MS;VAE86QT:"YH=&U02P\$"%_.4 " "X@/Y82=3?DF(-#! M00 'P @ &.@@8_96\$P.C X.#.T.%E>#0M_U\A:W-O:&5A
M;'1H+FAT;5\+ 0(4 Q0 (-B_ECF\#7J0@4 "F" ?# 2V\!/@E83 R.#@P.S0P.65X."TQ7V%K%0_-"
;NN\@H.6%G95\ P.#\$N;P.#G\G4\$! A0# M% (N#^6'2O\HG) (-KX "T (-LH'&EM86=E M7S P.BYJ<&=02P\$"%_.4 "
"X@/Y8^AGEXBKV"TB@\$ #0 L @ '\$P D:6UA9V5?;# S+FIP9U\!+08 \$@ 2/H\$ 9MPH! end XML 109 ea0208034-
20f_akohealth.htm.xml IDEA: XBRL DOCUMENT 0001702318 2023-04-012024-03-31 0001702318
dei:BusinessContactMember 2023-04-012024-03-31 0001702318
ahg:AmericanDepositarySharesoneAmericanDepositaryShareRepresentingThreeOrdinarySharesParValueUS00001Per
2023-04-012024-03-31 0001702318 ahg:OrdinarySharesParValueUS00001PerShareMember 2023-04-012024-03-31
0001702318 2024-03-31 0001702318 2023-03-31 0001702318 us-gaap:RelatedPartyMember 2024-03-31
0001702318 us-gaap:RelatedPartyMember 2023-03-31 0001702318 ahg:SaleOfMedicalDevicesMember 2023-04-
012024-03-31 0001702318 ahg:SaleOfMedicalDevicesMember 2022-04-012023-03-31 0001702318
ahg:SaleOfMedicalDevicesMember 2021-04-012022-03-31 0001702318 ahg:TaxAndSurchargesMember 2023-04-
012024-03-31 0001702318 ahg:TaxAndSurchargesMember 2022-04-012023-03-31 0001702318
ahg:TaxAndSurchargesMember 2021-04-012022-03-31 0001702318 2022-04-012023-03-31 0001702318 2021-04-
012022-03-31 0001702318 us-gaap:CommonStockMember 2021-04-30 0001702318 us-
gaap:AdditionalPaidInCapitalMember 2021-04-30 0001702318 us-gaap:TreasuryStockCommonMember 2021-04-30
0001702318 us-gaap:RetainedEarningsMember 2021-04-30 0001702318 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-30 0001702318 us-
gaap:NoncontrollingInterestMember 2021-04-30 0001702318 2021-04-30 0001702318 us-
gaap:CommonStockMember 2021-05-012022-03-31 0001702318 us-gaap:AdditionalPaidInCapitalMember 2021-05-
012022-03-31 0001702318 us-gaap:TreasuryStockCommonMember 2021-05-012022-03-31 0001702318 us-
gaap:RetainedEarningsMember 2021-05-012022-03-31 0001702318 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2021-05-012022-03-31 0001702318 us-
gaap:NoncontrollingInterestMember 2021-05-012022-03-31 0001702318 2021-05-012022-03-31 0001702318 us-
gaap:CommonStockMember 2022-03-31 0001702318 us-gaap:AdditionalPaidInCapitalMember 2022-03-31
0001702318 us-gaap:TreasuryStockCommonMember 2022-03-31 0001702318 us-gaap:RetainedEarningsMember
2022-03-31 0001702318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001702318 us-
gaap:NoncontrollingInterestMember 2022-03-31 0001702318 2022-03-31 0001702318 us-
gaap:CommonStockMember 2022-04-012023-03-31 0001702318 us-gaap:AdditionalPaidInCapitalMember 2022-04-
012023-03-31 0001702318 us-gaap:TreasuryStockCommonMember 2022-04-012023-03-31 0001702318 us-
gaap:RetainedEarningsMember 2022-04-012023-03-31 0001702318 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-012023-03-31 0001702318 us-
gaap:NoncontrollingInterestMember 2022-04-012023-03-31 0001702318 us-gaap:CommonStockMember 2023-03-
31 0001702318 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001702318 us-
gaap:TreasuryStockCommonMember 2023-03-31 0001702318 us-gaap:RetainedEarningsMember 2023-03-31
0001702318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001702318 us-
gaap:NoncontrollingInterestMember 2023-03-31 0001702318 us-gaap:CommonStockMember 2023-04-012024-03-
31 0001702318 us-gaap:AdditionalPaidInCapitalMember 2023-04-012024-03-31 0001702318 us-
gaap:TreasuryStockCommonMember 2023-04-012024-03-31 0001702318 us-gaap:RetainedEarningsMember 2023-
04-012024-03-31 0001702318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012024-03-31
0001702318 us-gaap:NoncontrollingInterestMember 2023-04-012024-03-31 0001702318 us-
gaap:CommonStockMember 2024-03-31 0001702318 us-gaap:AdditionalPaidInCapitalMember 2024-03-31
0001702318 us-gaap:TreasuryStockCommonMember 2024-03-31 0001702318 us-gaap:RetainedEarningsMember
2024-03-31 0001702318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001702318 us-
gaap:NoncontrollingInterestMember 2024-03-31 0001702318 2021-03-31 0001702318
ahg:WeHealthLimitedWeHealthMember 2023-04-012024-03-31 0001702318

ahg:AksoMedicalCloudLimitedAksoMedicalCloudMember 2023-04-012024-03-31 0001702318
ahg:WeHealthyLimitedWeHealthyMember 2023-04-012024-03-31 0001702318
ahg:AksoMedicareLimitedAksoMedicareMember 2023-04-012024-03-31 0001702318
ahg:AksoRemoteMedicalConsultationCenterIncAksoRemoteMedicalMember 2023-04-012024-03-31 0001702318
ahg:AksoOnlineMediTechCoLtdAksoOnlineMediTechMember 2023-04-012024-03-31 0001702318
ahg:AksoFirstHealthTreatmentCenterIncAksoFirstHealthMember 2023-04-012024-03-31 0001702318
ahg:TianjinAksoEnterpriseManagementCoLimitedWhollyOwnedForeignEnterpriseWOFEMember 2023-04-012024-03-31 0001702318
ahg:QindaoAksoHealthManagementCoLimitedMember 2023-04-012024-03-31 0001702318
ahg:CommissionRevenueMember 2023-04-012024-03-31 0001702318 ahg:CommissionServicesMember 2022-04-012023-03-31 0001702318 ahg:CommissionRevenueMember 2021-04-012022-03-31 0001702318
ahg:InterestIncome1Member 2023-04-012024-03-31 0001702318 ahg:InterestIncome1Member 2022-04-012023-03-31 0001702318 ahg:InterestIncome1Member 2021-04-012022-03-31 0001702318
ahg:OtherInvestorsMemberahg:WeHealthyLimitedMember 2023-04-012024-03-31 0001702318
ahg:CustomersOneMemberus-gaap:AccountsReceivableMemberahg:CustomerConcentrationRiskOneMember 2023-04-012024-03-31 0001702318 ahg:CustomersTwoMemberus-gaap:AccountsReceivableMemberahg:CustomerConcentrationRiskTwoMember 2023-04-012024-03-31 0001702318
ahg:CustomersThreeMemberus-gaap:AccountsReceivableMemberahg:CustomerConcentrationRiskThreeMember 2023-04-012024-03-31 0001702318 us-gaap:AccountsReceivableMemberahg:CustomerConcentrationRiskOneMember 2022-04-012023-03-31 0001702318
us-gaap:AccountsReceivableMemberahg:CustomerConcentrationRiskTwoMember 2022-04-012023-03-31 0001702318 us-gaap:AccountsReceivableMemberahg:CustomerConcentrationRiskThreeMember 2022-04-012023-03-31 0001702318 ahg:CustomersOneMember 2022-03-31 0001702318 us-gaap:AccountsReceivableMemberahg:CustomersOneMember 2022-04-012023-03-31 0001702318 us-gaap:AccountsReceivableMemberahg:VendorMember 2023-04-012024-03-31 0001702318 us-gaap:AccountsReceivableMemberahg:VendorMember 2021-04-012022-03-31 0001702318 ahg:VIEsMember 2024-03-31 0001702318 ahg:VIEsMember 2023-03-31 0001702318 ahg:VIEsMember 2023-04-012024-03-31 0001702318
ahg:VIEsMember 2022-04-012023-03-31 0001702318 ahg:VIEsMember 2021-04-012022-03-31 0001702318 ahg:VIEsMember 2020-04-012021-03-31 0001702318 ahg:DisaggregationOfRevenueMember 2023-04-012024-03-31 0001702318 ahg:DisaggregationOfRevenueMember 2022-04-012023-03-31 0001702318 ahg:DisaggregationOfRevenueMember 2021-04-012022-03-31 0001702318 srt:MinimumMemberus-gaap:OfficeEquipmentMember 2024-03-31 0001702318 srt:MaximumMemberus-gaap:OfficeEquipmentMember 2024-03-31 0001702318 ahg:WeHealthyMember 2024-03-31 0001702318 ahg:WeHealthyMember 2023-03-31 0001702318 us-gaap:DiscontinuedOperationsHeldforsaleMemberahg:HexinECommerceCompanyLimitedMember 2020-12-16 0001702318 us-gaap:DiscontinuedOperationsHeldforsaleMemberahg:DispositionSPAMember 2023-05-10 0001702318 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-04-012024-03-31 0001702318 us-gaap:DiscontinuedOperationsHeldforsaleMember 2022-04-012023-03-31 0001702318 us-gaap:DiscontinuedOperationsHeldforsaleMember 2021-04-012022-03-31 0001702318 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-05-19 0001702318 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-05-192023-05-19 0001702318
ahg:TianjinAksoEnterpriseManagementCoLtdMember 2024-03-31 0001702318
ahg:TianjinWangyiCloudTechnologyCoLtdMember 2024-03-31 0001702318
ahg:TianjinAksoEnterpriseManagementCoLtdOneMember 2024-03-31 0001702318 2019-04-012019-04-01 0001702318 ahg:WebaoLtdMemberus-gaap:CommercialLoanMember 2021-08-26 0001702318
ahg:WebaoLtdMemberus-gaap:CommercialLoanMember 2021-08-262021-08-26 0001702318 ahg:WebaoLtdMember 2024-03-31 0001702318 2023-08-27 0001702318 ahg:WebaoLtdMember 2023-08-272023-08-27 0001702318
ahg:WebaoLtdMember 2023-08-262023-08-26 0001702318 2022-01-24 0001702318 ahg:WebaoLtdMember 2022-01-242022-01-24 0001702318 2022-07-27 0001702318 2022-07-272022-07-27 0001702318 2022-07-282022-07-28 0001702318 2023-11-302023-11-30 0001702318 country:US 2023-04-012024-03-31 0001702318
country:USahg:WeHealthMember 2023-04-012024-03-31 0001702318 country:USahg:AksoRemoteMedicalMember 2023-04-012024-03-31 0001702318 country:USahg:AksoOnlineMediTechMember 2023-04-012024-03-31 0001702318 currency:CNY 2023-04-012024-03-31 0001702318 currency:CNY 2022-04-012023-03-31 0001702318 currency:CNY 2021-04-012022-03-31 0001702318 country:US 2022-04-012023-03-31 0001702318 country:US 2021-04-012022-03-31 0001702318 2008-01-012008-01-01 0001702318 srt:MinimumMember 2008-01-012008-01-01 0001702318 currency:CNY 2008-01-012008-01-01 0001702318 srt:MaximumMember 2008-01-012008-01-01 0001702318 srt:MinimumMember 2018-04-012019-03-31 0001702318 srt:MaximumMember 2018-04-012019-03-31 0001702318 2023-06-192023-06-19 0001702318 2023-06-19 0001702318 us-gaap:CommonStockMember 2023-06-19 0001702318 us-gaap:PrivatePlacementMember 2021-08-012021-08-09 0001702318 2021-08-09 0001702318 us-gaap:PrivatePlacementMember 2021-08-09 0001702318 us-gaap:PrivatePlacementMember 2021-09-172021-09-17 0001702318 ahg:WarrantSharesMemberus-gaap:PrivatePlacementMember 2021-09-17 0001702318 us-gaap:PrivatePlacementMember 2021-09-17 0001702318 us-gaap:WarrantMember 2023-04-012024-03-31 0001702318 ahg:SecuritiesPurchaseAgreementMember 2023-10-022023-10-02 0001702318 ahg:SecuritiesPurchaseAgreementMember 2023-10-172023-10-17 0001702318 2023-10-17 0001702318 ahg:AmericanDepositarySharesMember 2023-10-17 0001702318 ahg:SecuritiesPurchaseAgreementMember 2023-11-162023-11-16 0001702318 ahg:SecuritiesPurchaseAgreementMember 2023-11-16 0001702318 ahg:SecuritiesPurchaseAgreementMember 2023-11-212023-11-21 0001702318 2023-11-16 0001702318 ahg:AmericanDepositarySharesMember 2023-11-16 0001702318 ahg:SecuritiesPurchaseAgreementMember 2024-01-172024-01-17 0001702318 ahg:SecuritiesPurchaseAgreementMember 2024-01-17 0001702318 ahg:SecuritiesPurchaseAgreementMember 2024-01-262024-01-26 0001702318 2024-01-26 0001702318 ahg:AmericanDepositarySharesMember 2024-01-26 0001702318 ahg:SecuritiesPurchaseAgreementMember 2024-03-052024-03-05 0001702318 ahg:AmericanDepositarySharesMemberahg:SecuritiesPurchaseAgreementMember 2024-03-052024-03-05 0001702318 ahg:SecuritiesPurchaseAgreementMember 2024-03-05 0001702318 2024-03-05 0001702318 ahg:AmericanDepositarySharesMember 2024-03-05 0001702318 ahg:AmericanDepositarySharesMember 2024-03-052024-03-05 0001702318 us-gaap:WarrantMember 2024-03-31 0001702318 us-gaap:WarrantMember 2023-03-31 0001702318 ahg:August92021WarrantsMember 2024-03-31 0001702318 ahg:August92021WarrantsMember 2023-04-012024-03-31 0001702318 ahg:October22023WarrantsMember 2024-03-31 0001702318 ahg:October22023WarrantsMember 2023-04-012024-03-31 0001702318 ahg:November162023WarrantsMember

2024-03-31 0001702318 ahg:November162023WarrantsMember 2023-04-012024-03-31 0001702318
ahg:January172024WarrantsMember 2024-03-31 0001702318 ahg:January172024WarrantsMember 2023-04-
012024-03-31 0001702318 ahg:March52024WarrantsMember 2024-03-31 0001702318
ahg:March52024WarrantsMember 2023-04-012024-03-31 0001702318 2018-12-10 0001702318 2018-12-10 0001702318
ahg:AmericanDepositorySharesMember 2018-12-102018-12-10 0001702318
ahg:TianjinWangyiCloudTechnologyCoLtdMember 2024-03-31 0001702318 2024-03-312024-03-31 0001702318 us-
gaap:CommonStockMemberus-gaap:SubsequentEventMember 2024-04-302024-04-30 0001702318 us-
gaap:CommonStockMemberus-gaap:SubsequentEventMember 2024-04-30 0001702318 us-
gaap:CommonClassAMemberus-gaap:SubsequentEventMember 2024-04-302024-04-30 0001702318 us-
gaap:CommonClassAMemberus-gaap:SubsequentEventMember 2024-04-30 0001702318 us-
gaap:CommonClassBMemberus-gaap:SubsequentEventMember 2024-04-302024-04-30 0001702318 us-
gaap:CommonClassBMemberus-gaap:SubsequentEventMember 2024-04-30 0001702318
ahg:WebaoLimitedMemberus-gaap:SubsequentEventMember 2024-04-30 0001702318 ahg:WebaoLimitedMemberus-
gaap:CommonClassBMemberus-gaap:SubsequentEventMember 2024-04-30 0001702318
ahg:WebaoLimitedMemberus-gaap:CommonClassAMemberus-gaap:SubsequentEventMember 2024-04-30
0001702318 2023-10-31 0001702318 us-gaap:PrivatePlacementMember 2023-11-30 0001702318
srt:ScenarioForecastMember 2024-06-272024-06-27 0001702318 srt:ScenarioForecastMemberus-
gaap:CommonClassAMember 2024-06-27 0001702318 srt:ScenarioForecastMember 2024-06-27 0001702318
srt:ScenarioForecastMemberus-gaap:WarrantMember 2024-06-27 0001702318 srt:MinimumMember 2023-04-
012024-03-31 0001702318 srt:MaximumMember 2023-04-012024-03-31 0001702318 ahg:PRCMember 2024-03-31
0001702318 srt:ParentCompanyMember 2024-03-31 0001702318 srt:ParentCompanyMember 2023-03-31
0001702318 srt:ParentCompanyMemberus-gaap:RelatedPartyMember 2024-03-31 0001702318
srt:ParentCompanyMemberus-gaap:RelatedPartyMember 2023-03-31 0001702318 srt:ParentCompanyMember 2023-
04-012024-03-31 0001702318 srt:ParentCompanyMember 2022-04-012023-03-31 0001702318
srt:ParentCompanyMember 2021-04-012022-03-31 0001702318 srt:ParentCompanyMember 2022-03-31
0001702318 srt:ParentCompanyMember 2021-03-31 shares iso4217:USD iso4217:USD shares pure iso4217:CNY
iso4217:HKD ahg:customers ahg:vendors20-Ffalsetrue2024-03-31-03-312024falsefalse001-38245Akso Health
GroupE9Room 8201-4-4(A), 2nd Floor, Qiantongyuan BuildingNo. 44, Moscow RoadQianwan Bonded Port
AreaQingdaoCNRui (Kerrie) Zhang+86152-1005-4919ir@ahgtop.comRoom 8201-4-4(A), 2nd Floor, Qiantongyuan
BuildingNo. 44, Moscow RoadQianwan Bonded Port AreaQingdaoCNAmerican depository shares (one American
depository share representing three Class A ordinary shares, par value US\$0.0001 per share)AHGNASDAQClass A
ordinary shares, par value US\$0.0001 per shareNASDAQ437170960NoNoYesYesNon-accelerated
FilerfalsefalseU.S. GAAPfalseONESTOP ASSURANCE
PAC6732Singapore85174017792446876969834028992721291912011686449135135215289185625000014201811724
63926383-54467600-4086587-
38476011383673848725304568101142121384241948839516142018117204602992416797131865256000000-2459-
49642414338131815616000000229220611912571539486612213212689906051341684216661859175115529182266
8638040-14266853-326046325240839566851031141683383104419-5919911143006-748502-4537511200364-
747818-9091791-13066489-4008281249881754992816-9116779-13084038-4101097-388411836612-12748636-
395914-39979811836612-12748636-9516577-1247426-16849733-577931124971331-9458784-1359923-16851064-
238594-21986401454336-9755171-3446066-15395397391-26117-9755562-3445805-15395414-0.07-0.2-0.07-0.07-
0.2-0.07-0.18-0.210-0.21-0.07-0.02-0.28-0.07-0.02-
0.281415167776859805059612152141516777685980505961215250016457500260615048-1165883-3988370-
36256612-310354317271525190200001902100152981001720039162539162572747673-73628628-168510641331-
16849733145432017145433669763933697771021898-1165883-3988370-53107676-1649223197612285582-
1359923112497-1247426-2198379-261-219864069763933697771021898-1165883-3988370-54467599-
38476021142128839516361474910361471393037021393398497098000710-710-9458784-57793-9516577-
238985391-23859443833684343834210324890-1165883-3988370-63926383-408658756810138424194-9116779-
13084038-4101097-39591439162573697978274526-32718680977421307709515116530-1495248-
61093727795822166045712885148540220644194376-21914319092816705371-5982582-
11280468645869272924226520971351240-3253340-862837115289182000000015289182000000056250000-
5472108218471082-2000000036140-5472108218471082-
1996386076861522751384813933984910017200100000009086804131653697-
27513848910400425677113131653697-2751384834781117-1272164-43651360771777011691-
12732619679660391927032192532215128719862043949192703219253221030377126823534953358517401779244
style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin: 0pt 0">Note 1-
BUSINESS DESCRIPTION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><i>Organization
and description of business</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt
10pt; text-indent: -10pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:
justify; text-indent: 0.25in">Akso Health Group, formerly known as Xiaobai Maimai Inc., is a limited company
incorporated under the laws of the Cayman Islands on April 25, 2016. Akso Health Group ("Akso Health" or the
"Company"), its subsidiaries, and consolidated variable interest entities ("VIEs") (collectively the "Company"),
previously operated an online Peer to Peer ("P2P") marketplace business and micro-lending business in the People's
Republic of China (the "PRC"). Since May 2019, the Company has ceased to issue new loans through its micro-
lending business and since October 2019, the Company has ceased to conduct its P2P business. On December 30,
2020, the Company completed the disposition transaction of its P2P business.</p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May 2020, the Company launched its
social e-commerce platform to offer high-quality and affordable branded products through collaboration with online
and offline merchants. In addition, the Company is in the process of developing a new business as a cancer therapy
and radiotherapy oncology service provider with operations in the U.S. The Company plans to open 2 vaccine
research centers and 100 radiation oncology centers to be located on the east coast serving cancer patients in need
of varying stages of treatment, including specialized radiation therapy centers for radiotherapy (RT), personalized
consultation, conventional treatment planning, and other cancer related treatment services. On December 3, 2021,
the shareholders approved the Company's plan to change its name to "Akso Health Group". In January 2022, three
centers were established in US and the Company started its business of sales of medical devices in US market. In
April 2022, the Company started its sales of medical devices in China market through its subsidiary Qingdao Akso

Health Management Co., Ltd. In May 2023, the Company disposed its social E-commerce business and would focus on healthcare business in the future.

As of March 31, 2024, the Company's principal subsidiaries are as follows:

Date of incorporation / acquisition	Place of incorporation	Percentage of legal ownership	Principal activities
			Wholly owned subsidiaries
We Health Limited ("We Health")	July 8, 2021	100%	Investment holding
Akso Medical Cloud Limited ("Akso Medical Cloud")	November 15, 2023	100%	Investment holding
BVI		100%	Investment holding
We Healthy Limited ("We Healthy")	December 15, 2021		
Hong Kong		51%	Investment holding
Akso Medi-care Limited ("Akso Medi-care")	December 4, 2023	100%	Investment holding
Hong Kong			
Akso Remote Medical Consultation Center Inc. ("Akso Remote Medical")	January 3, 2022	100%	Provision of health treatment services
Akso Online MediTech Co., Ltd. ("Akso Online MediTech")	January 4, 2022	100%	Provision of health treatment services
Wyoming		100%	Sales of medical devices
Akso First Health Treatment Center Inc. ("Akso First Health")	January 4, 2022		
Massachusetts			Provision of health treatment services
Tianjin Akso Enterprise Management Co., Limited. (Wholly Owned Foreign Enterprise, "WOFE")	January 16, 2024		
PRC		100%	Provision of consultancy support
Qindao Akso Health Management Co., Limited	January 26, 2022		
PRC		51%	Provision of health treatment services

As of March 31, 2024, the Company's principal subsidiaries are as follows:

Date of incorporation / acquisition	Place of incorporation	Percentage of legal ownership	Principal activities
			Wholly owned subsidiaries
We Health Limited ("We Health")	July 8, 2021	100%	Investment holding
New York			

November 15, 2023		100%	Investment holding
BVI			
We Healthy Limited ("We Healthy")		December 15, 2021	
Hong Kong			
51%			Investment holding
Akso Medi-care Limited ("Akso Medi-care")			
December 4, 2023			
Hong Kong			
100%			
Investment holding			
Akso Remote Medical Consultation Center Inc. ("Akso Remote Medical")			
January 3, 2022			
Wyoming			
100%			
Provision of health treatment services			
Akso Online MediTech Co., Ltd. ("Akso Online MediTech")			
January 4, 2022			
Wyoming			
100%			
Sales of medical devices			
Akso First Health Treatment Center Inc. ("Akso First Health")			
January 4, 2022			
Massachusetts			
100%			
Provision of health treatment services			
Tianjin Akso Enterprise Management Co., Limited. (Wholly Owned Foreign Enterprise, "WOFE")			
January 16, 2024			
PRC			
100%			
Provision of consultancy support			
Qindao Akso Health Management Co., Limited			
January 26, 2022			
PRC			
51%			
Provision of health treatment services			

2021-07-08New York1Investment holding2023-11-15BVI1Investment holding2021-12-15Hong Kong0.51Investment holding2023-12-04Hong Kong1Investment holding2022-01-03Wyoming1Provision of health treatment services2022-01-04Wyoming1Sales of medical devices2022-01-04Massachusetts1Provision of health treatment services2024-01-16PRC1Provision of consultancy support2022-01-26PRC0.51Provision of health treatment services

NOTE 2 - GOING CONCERN

As indicated in the accompanying consolidated financial statements, the Company had a net loss of approximately \$9.5 million for the year ended March 31, 2024 and approximately \$1.2 million for the year ended March 31, 2023. The net cash provided by operating activities from continuing operation was US\$0.7 million for the year ended March 31, 2024 and the net cash used in operating activities was US\$3.3 million for the year ended March 31, 2023. Management of the Company has considered whether there is substantial doubt about its ability to continue as a going concern due to the Company's healthcare business as well as its planned new business as a cancer therapy and radiotherapy oncology service provider, and evaluated its available cash balance against its working capital requirements and investment to the cancer centers over the next twelve months.

While management cannot accurately predict the prospects and regulatory environment of the healthcare service industry, the management believes that the Company would have sufficient funds to meet its working capital requirements for fiscal year 2025, and that its capital resources are currently sufficient to maintain its business operations for the next twelve months.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and/or classification of the recorded asset amounts and/or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

950000012000007000003300000

Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and have been consistently applied. Certain prior year balances in the consolidated statements of operations and comprehensive (loss) and cash flows have been reclassified to the current year's presentation.

Basis of consolidation

indent: 0.25in">The accompanying consolidated financial statements include the financial statements of the Company, its subsidiaries, its consolidated VIEs and VIE's subsidiaries for which the Company is the primary beneficiary. All inter-company transactions and balances have been eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce Business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented. Assets and liabilities of the social E-commerce business were reclassified separately from other assets and liabilities of the Company on the consolidated balance sheets. Refer to Note 1 and Note 4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated VIEs</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>VIE arrangements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to comply with the PRC laws and regulations which prohibit or restrict foreign investments into companies involved in restricted businesses, the Company operates its marketplace and restricted businesses in the PRC through certain PRC domestic companies, whose equity interests are held by certain management members of the Company or onshore nominees of the Company ("Nominee Shareholders"). The Company obtained control over these PRC domestic companies by entering into a series of contractual arrangements with these PRC domestic companies and their respective Nominee Shareholders. These contractual agreements cannot be unilaterally terminated by the Nominee Shareholders or the PRC domestic companies. As a result, the Company maintains the ability to control these PRC domestic companies and is entitled to substantially all of the economic benefits from these PRC domestic companies. Management concluded that these PRC domestic companies are VIEs of the Company, of which the Company is the ultimate primary beneficiary. As such, the Company consolidated financial results of these PRC domestic companies and their subsidiaries in the Group's consolidated financial statements. The principal terms of the agreements entered into amongst the VIEs, their respective shareholders and the WFOE are further described below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">Exclusive Business Cooperation Agreements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Exclusive Business Cooperation Agreements enable the WFOE to receive substantially all of the assets and business of the VIEs in the PRC. Under these Agreements, the WFOE has the exclusive right to provide the VIEs with comprehensive technical support, consulting services and other services during the term of these Agreements, including but not limited to software licensing; development, maintenance and update of software, network systems, hardware and database; technical support and training for employees; consultancy on technology and market information; business management consultation; marketing and promotion services, etc. The WFOE has the right to determine the fees associated with the services it provides based on the technical difficulty and complexity of the services, the actual labor costs it incurs for providing the services and some other factors during the relevant period. This Agreements remain effective unless otherwise terminated in writing by WFOE.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">Equity Interest Pledge Agreements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Equity Interest Pledge Agreements, each Shareholder of the VIEs agreed to pledge their equity interest in the VIEs to the WFOE to secure the performance of the VIEs' obligations under the Exclusive Business Cooperation Agreements and any such agreements to be entered into in the future. Shareholders of the VIEs agreed not to transfer, sell, pledge, dispose of or otherwise create any encumbrance on their equity interests in the VIEs without the prior written consent of the WFOE. The Pledges became effective on such date when the pledge of the Equity Interest contemplated herein were registered with the relevant administration for industry and commerce (the "AIC") and remain effective until all contract obligations have been fully performed and all secured indebtedness has been fully paid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">Exclusive Option Agreements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Exclusive Option Agreements, each of the Shareholders of the VIE irrevocably grant the WFOE an irrevocable and exclusive right to purchase, or designate one or more persons (including individuals, corporations, partnerships, partners, enterprises, trusts or non-corporate organizations) to purchase the equity interests in the VIEs then held by such Shareholder of the VIEs once or at multiple times at any time in part or in whole at the WFOE's sole and absolute discretion to the extent permitted by Chinese laws at the price of RMB 1 or at the price of the minimum amount of consideration permitted by the applicable PRC law at the time when such purchase occurs. These three Agreements remain effective until all equity interests held by the shareholders of the VIEs in the VIEs have been transferred or assigned to the WFOE and/or its designees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">Loan Agreements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 235pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the three Loan Agreements, the WFOE agreed to lend each of the Shareholders of VIEs a loan only to subscribe to the registered capital of the VIEs. The repayment of the loan shall be made by permitting the WFOE to execute its exclusive right to purchase shares from the shareholders of the VIEs under the Exclusive Option Agreement as the repayment is equivalent to the consideration of the purchased shares. The term of these loans is 10 years, which may be extended upon mutual written consent of all parties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">Power of Attorney</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

0pt 0 Opt 10pt; text-align: justify; text-indent: -10pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each Shareholder of the VIEs, executed a Power of Attorney agreement with the WOFF and the VIEs, whereby Shareholders of the VIEs irrevocably appoint and constitute the WOFF as their attorney-in-fact to exercise on the shareholders' behalf any and all rights that Shareholders of the VIEs have in respect of their equity interests in the VIEs. These three Power of Attorney documents remain irrevocable and continuously effective and valid as long as the original shareholders of the VIEs remain as the Shareholders of the VIEs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 Opt 10pt; text-indent: -10pt">Risks in relation to the VIE structure</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company believes that the contractual arrangements with its VIEs and their respective shareholders are in compliance with the PRC laws and regulations and are legally enforceable. However, uncertainties in the PRC legal system could limit the Company's ability to enforce the contractual arrangements. If the legal structure and contractual arrangements were found to be in violation of the PRC laws and regulations, the PRC government could:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px; font-size: 10pt">●</td> <td style="text-align: justify; font-size: 10pt">revoke the business and operating licenses of the Company's PRC subsidiary and VIEs;</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">discontinue or restrict the operations of any related-party transactions between the Company's PRC subsidiary and VIEs;</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">limit the Company's business expansion in the PRC by way of entering into contractual arrangements;</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">impose fines or other requirements with which the Company's PRC subsidiary and VIEs may not be able to comply;</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">require the Company or the Company's PRC subsidiary and VIEs to restructure the relevant ownership structure or operations; and/or</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">restrict or prohibit the Company's use of the proceeds of the additional public offering to finance the Company's business and operations in the PRC.</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company's ability to conduct its Online Marketplace business may be negatively affected if the PRC government were to carry out any of the aforementioned actions. As a result, the Company may not be able to consolidate its VIEs in its consolidated financial statements as it may lose the ability to exert effective control over the VIEs and their respective shareholders and it may lose the ability to receive economic benefits from the VIEs. The Company, however, does not believe such actions would result in the liquidation or dissolution of the Company, its PRC subsidiary and VIEs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The interests of the shareholders of VIEs may diverge from that of the Company and that may potentially increase the risk that they would seek to act contrary to the contractual terms, for example by influencing the VIEs not to pay the service fees when required to do so. The Company cannot assure that when conflicts of interest arise, shareholders of the VIEs will act in the best interests of the Company or that conflicts of interests will be resolved in the Company's favor. Currently, the Company does not have existing arrangements to address potential conflicts of interest the shareholders of the VIEs may encounter in their capacity as beneficial owners and directors of the VIEs, on the one hand, and as beneficial owners and directors of the Company, on the other hand. The Company believes the shareholders of VIEs will not act contrary to any of the contractual arrangements and the exclusive option agreements provide the Company with a mechanism to remove the current shareholders of the VIEs should they act to the detriment of the Company. The Company relies on certain current shareholders of the VIEs to fulfill their fiduciary duties and abide by laws of the PRC and act in the best interest of the Company. If the Company cannot resolve any conflicts of interest or disputes between the Company and the shareholders of the VIEs, the Company would have to rely on legal proceedings, which could result in disruption of its business, and there is substantial uncertainty as to the outcome of any such legal proceedings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May 2023, the Company completed the disposal of its social E-commerce business. After that, no VIEs or its subsidiaries were included in the consolidated financial statement of the Company. As a result, the Company's results of operations, revenues, costs and expenses related to the social E-commerce Business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented. Assets

and liabilities of the social E-commerce business were reclassified separately from other assets and liabilities of the Company on the consolidated balance sheets. Refer to Note 1 and Note 4.

The following financial statement amounts and balances of the consolidated VIEs were included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

	As of March 31, 2024	As of March 31, 2023	USD	USD
Current Assets:				
Cash and cash equivalents				
Accounts receivable and contract assets, net	678,691			
Prepayments and other assets	10,062			
Amounts due from related parties	43,779			
Total Current Assets	732,532			
Property, equipment and software, net	28,698			
Total Assets	761,230			
Current Liabilities:				
Accrued expenses and other current liabilities	32,430			
Taxes (benefit) payable				
Total Current Liabilities	32,430			

[illegible]

Uses of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during each reporting period. Actual results could differ from such estimates. Significant accounting estimates reflected in the Company's consolidated financial statements include estimates and judgments applied in allocation of revenue with various performance obligations, allowance for accounts receivable and contract assets, impairment on long-term investments, valuation allowance for deferred tax assets, valuation of share-based compensation and allowance for loans receivable and other receivable.

Fair value of financial instruments

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurement or assumptions that market participants would use when pricing the asset or liability.

The Company follows the provisions of Financial Accounting Standards Board ("FASB"), Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3 - Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts reported in the balance sheets for cash, receivables, prepayments and other assets, loan principal and interest receivable, approximate their fair value based on the short-term maturity of these instruments. The Company did not transfer any assets or liabilities in or out of level 3 during the years ended March 31, 2023, 2022 and 2021.

The Company's long-term investments consist of equity securities and available-for-sale investments. For long-term investments without readily determinable fair value, the Company is not able to estimate fair value, hence, the Company uses the cost minus impairment method as alternative.

Discontinued Operations

A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity's financial results and operations. Included in the consolidated statements of operations and comprehensive (loss) income, result from discontinued operations have been reported separately from the income and expenses from continuing operations and prior periods have been presented on a reclassified comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.

Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented.

Revenue recognition

In February 2022, the Company started its business in the US market for the sale of medical devices. In May 2020, the Company launched its social e-commerce platform and built collaboration with domestic mainstream E-commerce marketplaces, which was discontinued in fiscal year 2023 and disposed in May 2023. The Company provides recommendation services by referring certain interested users to those marketplaces for high-quality and affordable branded products. Prior to business transformation, the Company through its P2P business offered online consumer lending-related service in fiscal year 2020, which was discontinued in fiscal year 2021 and disposed on December 30, 2020. The Company presents value added taxes ("VAT") as a reduction of revenues.

Revenues generated are accounted under Accounting Standards Update (ASU) 2014-09, "Revenue from contracts with Customers" (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following steps:

Step 1: Identify the contract (s) with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation

Online marketplace services

Commission revenue	Commission revenue

The commission services revenue primarily consists of commission fees charged to the online E-commerce marketplace for recommending users to purchase on their marketplaces, where the Company generally is acting as an agent and its performance obligation is to provide recommendation services for purchasing specified goods or services by those third-party sellers, is not responsible for fulfilling the promise to provide the specified goods or services, and does not have the ability to control the related shipping services when utilized by the third-party sellers. Upon successful sales, the Company will charge the online E-commerce companies a negotiated amount or a fixed rate commission fee based on the sales amount. Commission services revenues are recognized on a net basis at the point of receipt of products, net of a return allowance and incentives to consumers or channels.

In order to promote its online marketplace and attract more registered consumers, the Company at its own discretion offers incentives to consumers. Consumers are not customers of the Company, therefore incentives offered to consumers are not considered payments to customers. Such incentives offered to consumers were as a reward for purchasing by themselves or their sharing through our platform. Incentives provided to consumers are specific to any merchant and are recognized as a reduction of commission service revenue. For the years ended March 31, 2024, 2023, 2022, the total amount of incentives was nil, nil and US\$96,332, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

Interest income	Interest income

Started in August 2017, the Company lent funds to borrowers up to their approved credit through its consolidated VIE, and since May 2019, the Company has ceased to issue new loans through its microlending business. Interest income on loans receivable is recognized monthly based on the contractual interest rates of the loan. Accrual of interest is generally discontinued when reasonable doubt exists as to the full, timely collection of interest or principal. When a loan is discontinued from interest accrual, the Company stops accruing interest and reverses all accrued but unpaid interest as of such date. Interest income was nil, nil, US\$215,393 for the years ended March 31, 2024, 2023 and 2022, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

Sales of medical devices	Sales of medical devices

Started in February 2022, through its subsidiary Akso Online MediTech, the Company engaged in the sale of Covid-19 Antigen Rapid Tests in US market. For the years ended March 31, 2024, 2023 and 2022, revenue generated from sale of Covid-19 Antigen Rapid Tests was nil, \$9,181,274 and \$6,000,000. Akso Online MediTech purchases medical devices in quantity and distributes products primarily to medical products dealers. The deliveries may take one day or longer depending on the customers' location. Revenue from sales of merchandise to non-retail customers is recognized when the merchandise is transferred to customers. There was no sales return since the start the business.

Disaggregation of revenue	Disaggregation of revenue

All of the Company's revenue

for the years ended March 31, 2024 was generated from PRC and revenue for the year ended March 31, 2023 were generated from US and PRC, and for the year ended March 31, 2022 were generated from US. The following table illustrates the disaggregation of revenue:

	Year ended	Year ended	Year ended
	March 31, 2024	March 31, 2023	March 31, 2022
Revenue from medical devices-US	9,181,274	6,000,000	2,416,797
Revenue from medical devices-PRC	4,005,251	2,414,338	13,186,525
Total revenues	13,186,525	8,414,338	15,603,322
Tax and surcharges	2,459	4,964	6,000,000
Net Revenues	13,181,561	8,414,338	15,603,322

Cash and cash equivalents

Cash and cash equivalents represent cash on hand, unrestricted demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash.

Accounts receivable and allowance for uncollectible accounts

Accounts receivable are mainly receivables from online E-commerce marketplaces and recommendation services, which are stated at the historical carrying amount net of allowance for uncollectible accounts. The Company establishes an allowance for uncollectible accounts receivable based on estimates, historical experience and other factors surrounding the credit risk of specific customers. Uncollectible accounts receivables are written off when a settlement is reached for an amount that is less than the outstanding historical balance or when the Company has determined that is not

probable for the balance to be collected. Beginning on April 1, 2020, the Company evaluates its accounts receivable for expected credit losses on a regular basis. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. The Company uses the length of time a balance has been outstanding, the payment history, creditworthiness and financial conditions of the customers and industry trend as credit quality indicators to monitor the Company's receivables within the scope of expected credit losses model and use these as a basis to develop the Company's expected loss estimates. The Company adjusts the allowance percentage periodically when there are significant differences between estimated bad debts and actual bad debts. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Company also makes a specific allowance in the period in which a loss is determined to be probable. Accounts receivable balances are written off after all collection efforts have been exhausted. As of March 31, 2024 and 2023, the allowance for uncollectible accounts receivable balance was US\$ 7,369,797 and US\$ 400,759, respectively.

Inventories

Inventories are comprised of finished goods, which are defibrillators and anesthesia laryngoscope, and are stated at the lower of cost or net realizable value using first in first out (FIFO) method. Management reviews inventories for obsolescence and cost in excess of net realizable value periodically when appropriate and records a reserve against the inventory when the carrying value exceeds net realizable value. As of March 31, 2024, the Company determined that no allowance was necessary.

Property and equipment, net

Property and equipment are stated at cost. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives:

	Useful life
Office equipment	3-5 years

The Company eliminates the cost and related accumulated depreciation and amortization of assets sold or otherwise retired from the accounts and includes any gains or losses from disposal of property, equipment, and software in other income. The Company charges maintenance, repairs, and minor renewals directly to expense as incurred; major additions and betterments to equipment are capitalized. For the disposal of social E-commerce business, property and equipment, net was recorded in discontinued operations.

Impairment of long-lived assets

The carrying value of the long-lived assets are reviewed for impairment, whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of assets to future undiscounted net cash flows expected to be generated by the assets. Such assets are considered to be impaired if the sum of the expected undiscounted cash flows is less than carrying amount of the assets. The impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

No impairment loss was recognized for the years ended March 31, 2024, 2023 and 2022.

Advertising and promotion expenses

The Company recognizes its advertising and promotion expenses as sales and marketing expense. Advertising expenses represent expenses for placing advertisements on television, radio and in newspapers, as well as on internet websites and search engines. Advertising and promotion costs are expensed as incurred. For the years ended March 31, 2024, 2023 and 2022, the advertising and promotion expenses were US\$ 168,421, US\$ 6,661, nil, respectively.

Lease

Upon the adoption of FASB ASC 842 on April 1, 2019 using the modified retrospective method, the Company determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets and operating lease liabilities, in the Company's consolidated balance sheets. The Company does not have any finance leases as of the adoption date or March 31, 2022.

ROU represents the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which it calculates based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease.

For operating lease with a term of one year or less, the Company has elected to not recognize a lease liability or lease right of use asset on its consolidated balance sheets. Instead, it recognizes the lease payment as expense on a straight-line basis over the lease term. Short-term lease costs are immaterial to its consolidated statements of operations and comprehensive (loss). The Company has operating lease agreements with insignificant non-lease components and have elected the practical expedient to combine and account for lease and non-lease components as single lease component.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in Financial Accounting Standards Board ("FASB") ASC 480 "Distinguishing Liabilities from Equity" ("ASC 480") and ASC 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common stock and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annually period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations (Note 17).

Share-based compensation

Under the Amended and Restated 2016 Equity Incentive Plan, the Company grants share options to the Company's selected employees and directors. Awards granted to employees with service conditions attached are measured at the fair value on the grant date and are recognized as an expense using straight-line method, net of estimated forfeitures, over the requisite service period, which is generally the vesting period. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share-based compensation expense to be recognized in future periods.

Awards granted to employees with performance conditions attached are measured at fair value on the grant date and are recognized as compensation expense in the period and thereafter when the performance goal becomes probable to achieve. Awards granted to employees with market conditions attached are measured at fair value on the grant date and are recognized as compensation expense over the estimated requisite service period, regardless of whether the market condition has been satisfied if the requisite service period is fulfilled.

Binomial option-pricing models are adopted to measure the value of awards at each grant date or measurement date. The determination of fair value is affected by assumptions relating to a number of complex and subjective variables, including but not limited to the expected share price volatility, actual and projected employee share option exercise behavior, risk-free interest rates and expected dividends. The use of the option-pricing model requires extensive actual employee exercise behavior data for the relative probability estimation purpose, and a number of complex assumptions.

Treasury stock

Treasury stock represents ordinary shares repurchased by the Company that are no longer outstanding and are held by the Company. The repurchase of ordinary shares is accounted for under the cost method whereby the entire cost of the acquired shares are recorded as treasury stock. The cost of treasury stock is transferred to "additional paid-in capital" when it is re-issued for the purpose of share options exercised and share awards.

Income taxes

The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

The Company accounts for income tax under the asset and liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Under this method, deferred income taxes will be recognized if significant temporary differences between tax and financial statements occur. A valuation allowance is established against net deferred tax assets when it is more likely that some portion or all of the net deferred tax asset will not be realized. For the years ended March 31, 2024, 2023 and 2022, the Company provided a full valuation allowance on the net deferred tax assets.

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company may be subject to challenges from taxing authorities regarding the amounts of taxes due. These challenges may alter the timing or amount of taxable income or deductions. Management determines whether the benefits of its tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated.

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An uncertain tax position is recognized as a benefit only if it is "more likely than not" that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. For tax positions not meeting the "more likely than not" test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income taxes are classified as income tax expense in the period incurred. The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measures the unrecognized benefits associated with the tax positions. As of March 31, 2024 and 2023, the Company did not have any significant unrecognized uncertain tax positions. The Company does not believe that its unrecognized tax benefits will change over the next twelve months.

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">**Noncontrolling interests**

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Noncontrolling interest consists of 49% of the equity interest of We Healthy held by other investors. Excess of contribution received from noncontrolling shareholders over carrying value of the entity is recorded in additional paid in capital. The noncontrolling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Noncontrolling interests in the results of the Company are presented on the face of the consolidated statement of operations as an allocation of the total income or loss for the year between non-controlling interest holders and the shareholders of the Company.

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Noncontrolling interest consist of the following:

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">December 31,	Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">2024	Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">2023
Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">USD	Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">56,810	Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">114,212

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">**Earnings (loss) per share**

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company computes earnings per share ("EPS") in accordance with FASB ASC 260, "Earnings per Share" ("ASC 260"). ASC 260 requires public companies with capital structures to present basic and diluted EPS. Basic EPS is measured as net income (loss) attributed to ordinary shareholders divided by the weighted average number of ordinary shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">**Foreign currency translation**

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The functional currency of the Company is United States Dollar. The Company's subsidiaries with operations in mainland China, the Hong Kong Special Administrative Region of the PRC ("Hong Kong" or "Hong Kong S.A.R."), the United States generally use their respective local currencies as their functional currencies. The Company's financial statements have been translated into the reporting currency, the United States Dollar ("USD"). Assets and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated at the average exchange rate during the reporting period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss). Transactions denominated in currencies other than functional currency are translated into the functional currency at the exchange rates quoted by authoritative banks prevailing at the dates of the transactions. Exchange gains and losses resulting from those foreign currency transactions denominated in a currency other than the functional currency are recorded in "other income (expense)" in the consolidated statements of operations and comprehensive income. The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that any RMB amounts could have been, or could be, converted, realized or settled into USD at the rates used in translation.

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Spot exchange rates and average exchange rates were used in the translation of the consolidated financial statements.

Fiscal year 2024		Fiscal year 2023	
US Exchange Rate			
Year-end RMB	7.2203	Year-end RMB	6.8676
Year average RMB	7.1671	Year average RMB	6.8516
	6.4180		

Significant risks and uncertainties

Foreign currency risk

RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People's Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. The Company's cash and cash equivalents denominated in RMB amounted to US\$10,380,711 and US\$7,876,767 as at March 31, 2024 and 2023, respectively.

Concentration of credit risk

Financial instruments that potentially expose the Company to significant concentration of credit risk primarily included in the financial lines of cash and cash equivalents, accounts receivable, other receivables and prepayments and other assets. As of March 31, 2024, substantially all of the Company's cash and cash equivalents were held by major financial institutions located worldwide, including mainland China and United States. According to the China Bank Deposit Insurance Ordinance, the deposits at each bank is covered by insurance with an upper limit of RMB 500,000 (approximately US\$69,249) at each bank. As of March 31, 2024, the total amount not covered by insurance in the PRC was US\$ 10,310,077. The Hong Kong Deposit Protection Board pays compensation up to a limit of HKD 500,000 (approximately US\$ 63,890) if the bank with which an individual/a company hold its eligible deposit fails. As of March 31, 2024, no cash balance maintained at financial institutions in Hong Kong was subject to credit risk. In the US, the insurance coverage of each bank is \$250,000. As of March 31, 2024, no cash balance maintained at financial institutions in US was subject to credit risk. If the financial institutions could become insolvent, the Company could lose some or all of the value of its investments. To limit exposure to credit risk relating to deposits, the Company primarily place cash and cash equivalent deposits with large financial institutions which management believes are of high credit quality and management also continually monitors the financial institutions' credit worthiness.

Accounts receivable

Accounts receivable is typically unsecured and are derived from revenue earned from customers in the PRC. The risk with respect to accounts receivable is mitigated by credit evaluations the Company performs on its customers and its ongoing monitoring process of outstanding balances.

Customer concentration risk

For the year ended March 31, 2024, three customers accounted for 36.3%, 34.8% and 28.0% for the Company's total revenue from sales of medical devices business. For the year ended March 31, 2023, three customers accounted for 59.5%, 11.1% and 10.1% for the Company's total revenue from sales of medical devices business. For the year ended March 31, 2022, one customer accounted for 95.1% of the Company's total revenues. There was no customer of the Company that accounted for more than 10% of the Company's carrying amount of account receivables as of March 31, 2024 and there was one customer of the Company that accounted for 100% of the Company's carrying amount of accounts receivable as of March 31 2023.

Vendor concentration risk

For the year ended March 31, 2024, one vendor accounted for 100% of the Company's purchase of medical devices business. For the year ended March 31, 2023, one vendor accounted for 97.3% of the Company's purchase of medical devices business. For the year ended March 31, 2022, one vendor accounted for 100% of the Company's purchase of medical devices business. There was no vendor of the Company that accounted for greater than 10% of the Company's carrying amount of accounts payable as of March 31, 2024 and 2023.

Recent Accounting Pronouncements

December 2023, the FASB issued ASU No. 2023-09, *Income Taxes (Topic 740)*. ASU No. 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as additional information on income taxes paid. The guidance is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Company does not expect to adopt ASU No. 2023-09 early and is currently evaluating the impact of adopting this standard on its consolidated financial statements.

The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated balance sheets, consolidated statements of operations and comprehensive loss (income) and consolidated statements of cash flows.

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and have been consistently applied. Certain prior year balances in the consolidated statements of operations and comprehensive (loss) and cash flows have been reclassified to the current year's presentation.

Basis of consolidation

The accompanying consolidated financial statements include the financial statements of the Company, its subsidiaries, its consolidated VIEs and VIE's subsidiaries for which the Company is the primary beneficiary. All inter-company transactions and balances have been eliminated upon consolidation.

Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce Business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented. Assets and liabilities of the social E-commerce business were reclassified separately from other assets and liabilities of the Company on the consolidated balance sheets. Refer to Note 1 and Note 4.

Consolidated VIEs

VIE arrangements

In order to comply with the PRC laws and regulations which prohibit or restrict foreign investments into companies involved in restricted businesses, the Company operates its marketplace and restricted businesses in the PRC through certain PRC domestic companies, whose equity interests are held by certain management members of the Company or onshore nominees of the Company ("Nominee Shareholders"). The Company obtained control over these PRC domestic companies by entering into a series of contractual arrangements with these PRC domestic companies and their respective Nominee Shareholders. These contractual agreements cannot be unilaterally terminated by the Nominee Shareholders or the PRC domestic companies. As a result, the Company maintains the ability to control these PRC domestic companies and is entitled to substantially all of the economic benefits from these PRC domestic companies. Management concluded that these PRC domestic companies are VIEs of the Company, of which the Company is the ultimate primary beneficiary. As such, the Company consolidated financial results of these PRC domestic companies and their subsidiaries in the Group's consolidated financial statements. The principal terms of the agreements entered into amongst the VIEs, their respective shareholders and the WFOE are further described below.

Exclusive Business Cooperation Agreements

The Exclusive Business Cooperation Agreements enable the WFOE to receive substantially all of the assets and business of the VIEs in the PRC. Under these Agreements, the WFOE has the exclusive right to provide the VIEs with comprehensive technical support, consulting services and other services during the term of these Agreements, including but not limited to software licensing; development, maintenance and update of software, network systems, hardware and database; technical support and training for employees; consultancy on technology and market information; business management consultation; marketing and promotion services, etc. The WFOE has the right to determine the fees associated with the services it provides based on the technical difficulty and complexity of the services, the actual labor costs it incurs for providing the services and some other factors during the relevant period. This Agreements remain effective unless otherwise terminated in writing by WFOE.

Equity Interest Pledge Agreements

Pursuant to the Equity Interest Pledge Agreements, each Shareholder of the VIEs agreed to pledge their equity interest in the VIEs to the WFOE to secure the performance of the VIEs' obligations under the Exclusive Business Cooperation Agreements and any such agreements to be entered into in the future. Shareholders of the VIEs agreed not to transfer, sell, pledge, dispose of or otherwise create any encumbrance on their equity interests in the VIEs without the prior written consent of the WFOE. The Pledges became effective on such date when the pledge of the Equity Interest contemplated herein were registered with the relevant administration for industry and commerce (the "AIC") and remain effective until all contract obligations have been fully performed and all secured indebtedness has been fully paid.

Exclusive Option Agreements

Pursuant to the Exclusive Option Agreements, each of the Shareholders of the VIE irrevocably grant the WFOE an irrevocable and exclusive right to purchase, or designate one or more persons (including individuals, corporations, partnerships, partners, enterprises, trusts or non-corporate organizations) to purchase the equity interests in the VIEs then held by such Shareholder of the VIEs once or at multiple times at any time in part or in whole at the WFOE's sole and absolute discretion to the extent permitted by Chinese laws at the price of RMB 1 or at the price of the minimum amount of consideration permitted by the applicable PRC law at the time when such purchase occurs. These three Agreements remain effective until all equity interests held by the shareholders of the VIEs in the VIEs have been transferred or assigned to the WFOE and/or its designees.

Loan Agreements

Pursuant to the three Loan Agreements, the WFOE agreed to lend each of the Shareholders of VIEs a loan only to subscribe to the

registered capital of the VIEs. The repayment of the loan shall be made by permitting the WOFE to execute its exclusive right to purchase shares from the shareholders of the VIEs under the Exclusive Option Agreement as the repayment is equivalent to the consideration of the purchased shares. The term of these loans is 10 years, which may be extended upon mutual written consent of all parties.

Power of Attorney

Each Shareholder of the VIEs, executed a Power of Attorney agreement with the WOFE and the VIEs, whereby Shareholders of the VIEs irrevocably appoint and constitute the WOFE as their attorney-in-fact to exercise on the shareholders' behalf any and all rights that Shareholders of the VIEs have in respect of their equity interests in the VIEs. These three Power of Attorney documents remain irrevocable and continuously effective and valid as long as the original shareholders of the VIEs remain as the Shareholders of the VIEs.

Risks in relation to the VIE structure

The Company believes that the contractual arrangements with its VIEs and their respective shareholders are in compliance with the PRC laws and regulations and are legally enforceable. However, uncertainties in the PRC legal system could limit the Company's ability to enforce the contractual arrangements. If the legal structure and contractual arrangements were found to be in violation of the PRC laws and regulations, the PRC government could:

●	revoke the business and operating licenses of the Company's PRC subsidiary and VIEs;
●	discontinue or restrict the operations of any related-party transactions between the Company's PRC subsidiary and VIEs;
●	limit the Company's business expansion in the PRC by way of entering into contractual arrangements;
●	impose fines or other requirements with which the Company's PRC subsidiary and VIEs may not be able to comply;
●	require the Company or the Company's PRC subsidiary and VIEs to restructure the relevant ownership structure or operations; and/or
●	restrict or prohibit the Company's use of the proceeds of the additional public offering to finance the Company's business and operations in the PRC.

The Company's ability to conduct its Online Marketplace business may be negatively affected if the PRC government were to carry out any of the aforementioned actions. As a result, the Company may not be able to consolidate its VIEs in its consolidated financial statements as it may lose the ability to exert effective control over the VIEs and their respective shareholders and it may lose the ability to receive economic benefits from the VIEs. The Company, however, does not believe such actions would result in the liquidation or dissolution of the Company, its PRC subsidiary and VIEs.

The interests of the shareholders of VIEs may diverge from that of the Company and that may potentially increase the risk that they would seek to act contrary to the contractual terms, for example by influencing the VIEs not to pay the service fees when required to do so. The Company cannot assure that when conflicts of interest arise, shareholders of the VIEs will act in the best interests of the Company or that conflicts of interests will be resolved in the Company's favor. Currently, the Company does not have existing arrangements to address potential conflicts of interest the shareholders of the VIEs may encounter in their capacity as beneficial owners and directors of the VIEs, on the one hand, and as beneficial owners and directors of the Company, on the other hand. The Company believes the shareholders of VIEs will not act contrary to any of the contractual arrangements and the exclusive option agreements provide the Company with a mechanism to remove the current shareholders of the VIEs should they act to the detriment of the Company. The Company relies on certain current shareholders of the VIEs to fulfill their fiduciary duties and abide by laws of the PRC and act in the best interest of the Company. If the Company cannot resolve any conflicts of interest or disputes between the Company and the shareholders of the VIEs, the Company would have to rely on legal proceedings, which could result in disruption of its business, and there is substantial uncertainty as to the outcome of any such legal proceedings.

In May 2023, the Company completed the disposal of its social E-commerce business. After that, no VIEs or its subsidiaries were included in the consolidated financial statement of the Company. As a result, the Company's results of operations, revenues, costs and expenses related to the social E-commerce Business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented. Assets and liabilities of the social E-commerce business were reclassified separately from other assets and liabilities of the Company on the consolidated balance sheets. Refer to Note 1 and Note 4.

Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following financial statement amounts and balances of the consolidated VIEs were included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of
March 31,
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of
March 31,
2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">Current Assets:</td><td></td><td colspan="2" style="text-align: right"></td><td></td><td></td><td colspan="2" style="text-align: right"></td><td></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 10pt; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right"><div style="sec-ix-hidden: hidden-fact-93">—</div></td><td style="width: 1%; text-align: left"></td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">678,691</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom"><td style="padding-left: 10pt; text-align: left">Accounts receivable and contract assets, net</td><td></td><td style="text-align: left"></td><td style="text-align: right"><div style="sec-ix-hidden: hidden-fact-94">—</div></td><td style="text-align: left"></td><td></td><td style="text-align: right">10,062</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 10pt; text-align: left">Prepayments and other assets</td><td></td><td style="text-align: left"></td><td style="text-align: right"><div style="sec-ix-hidden: hidden-fact-95">—</div></td><td style="text-align: left"></td><td></td><td style="text-align: right">43,779</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom"><td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Amounts due from related parties</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-96">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,206,288</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; text-align: left">Total Current Assets</td><td></td><td style="text-align: left"></td><td style="text-align: right"><div style="sec-ix-hidden: hidden-fact-97">—</div></td><td style="text-align: left"></td><td style="font-weight: bold"></td><td style="font-weight: bold; text-align: left"></td><td style="font-weight: bold; text-align: right">26,938,820</td><td style="font-weight: bold; text-align: left"></td></tr><tr style="vertical-align: bottom"><td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Property, equipment and software, net</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-98">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,698</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Assets</td><td style="padding-bottom: 4pt"></td><td style="border-bottom: Black 4pt double; text-align: left"></td><td style="border-bottom: Black 4pt double; text-align: right"></td><td style="padding-bottom: 4pt; text-align: left"></td><td style="font-weight: bold; padding-bottom: 4pt"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">26,967,518</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"></td></tr><tr style="vertical-align: bottom"><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; text-align: left">Current Liabilities</td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: right"><div style="sec-ix-hidden: hidden-fact-99">—</div></td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">32,430</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Taxes (benefit) payable</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-100">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,624</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom"><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-101">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">19,806</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-102">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td></tr></table>

[illegible]

As of March 31, 2023			
		USD	USD
		Current Assets:	
Cash and cash equivalents		678,691	
Accounts receivable and contract assets, net		10,062	
Prepayments and other assets		43,779	
Amounts due from related parties			
Total Current Assets		26,938,820	
Property, equipment and software, net		28,698	
Total Assets		26,967,518	
Accrued expenses and other current liabilities		32,430	
Taxes (benefit) payable			
Total Current Liabilities		19,806	
Total Liabilities			
Year ended		Year ended	

[illegible]

March 31, 2021

USD		12,497				(559,973)				5,613,401
Net cash provided by (used in) operating activities										
Net cash (used in) investing activities										
Net cash provided by (used in) financing activities										
(1,455,547)										
Net cash provided by (used in) financing activities										
213,879										
(1,156,948)										
(13,203,558)										

Uses of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during each reporting period. Actual results could differ from such estimates. Significant accounting estimates reflected in the Company's consolidated financial statements include estimates and judgments applied in allocation of revenue with various performance obligations, allowance for accounts receivable and contract assets, impairment on long-term investments, valuation allowance for deferred tax assets, valuation of share-based compensation and allowance for loans receivable and other receivable.

Fair value of financial instruments

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurement or assumptions that market participants would use when pricing the asset or liability.

The Company follows the provisions of Financial Accounting Standards Board ("FASB"), Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3 - Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts reported in the balance sheets for cash, receivables, prepayments and other assets, loan principal and interest receivable, approximate their fair value based on the short-term maturity of these instruments. The Company did not transfer any assets or liabilities in or out of level 3 during the years ended March 31, 2023, 2022 and 2021.

The Company's long-term investments consist of equity securities and available-for-sale investments. For long-term investments without readily determinable fair value, the Company is not able to estimate fair value, hence, the Company uses the cost minus impairment method as alternative.

Discontinued Operations

A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity's financial results and operations. Included in the consolidated statements of operations and comprehensive (loss) income, result from discontinued operations have been reported separately from the income and expenses from continuing operations and prior periods have been presented on a reclassified comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.

Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented.

Revenue recognition

In February 2022, the Company started its business in the US market for the sale of medical devices. In May 2020, the Company launched its social e-commerce platform and built collaboration with domestic mainstream E-commerce marketplaces, which was discontinued in fiscal year 2023 and disposed in May 2023. The Company provides recommendation services by referring certain interested users to those marketplaces for high-quality and affordable branded products. Prior to business transformation, the Company through its P2P business offered online consumer lending-related service in fiscal year 2020, which was discontinued in fiscal year 2021 and disposed on December 30, 2020. The Company presents value added taxes ("VAT") as a reduction of revenues.

Revenues generated are accounted under Accounting Standards Update (ASU) 2014-09, "Revenue from contracts with Customers" (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following steps:

Step 1: Identify the contract (s) with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation

Online marketplace services

Commission revenue

The commission services revenue primarily consists of commission fees charged to the online E-commerce marketplace for recommending users to purchase on their marketplaces, where the Company generally is acting as an agent and its performance obligation is to provide recommendation services for purchasing specified goods or services by those third-party sellers, is not responsible for fulfilling the promise to provide the specified goods or services, and does not have the ability to control the related shipping services when utilized by the third-party sellers. Upon successful sales, the Company will charge the online E-commerce companies a negotiated amount or a fixed rate commission fee based on the sales amount. Commission services revenues are recognized on a net basis at the point of receipt of products, net of a return allowance and incentives to consumers or channels.

In order to promote its online marketplace and attract more registered consumers, the Company at its own discretion offers incentives to consumers. Consumers are not customers of the Company, therefore incentives offered to consumers are not considered payments to customers. Such incentives offered to consumers were as a reward for purchasing by themselves or their sharing through our platform. Incentives provided to consumers are specific to any merchant and are recognized as a reduction of commission service revenue. For the years ended March 31, 2024, 2023, 2022, the total amount of incentives was nil, nil and US\$96,332, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

Interest income

Started in August 2017, the Company lent funds to borrowers up to their approved credit through its consolidated VIE, and since May 2019, the Company has ceased to issue new loans through its microlending business. Interest income on loans receivable is recognized monthly based on the contractual interest rates of the loan. Accrual of interest is generally discontinued when reasonable doubt exists as to the full, timely collection of interest or principal. When a loan is discontinued from interest accrual, the Company stops accruing interest and reverses all accrued but unpaid interest as of such date. Interest income was nil, nil, US\$215,393 for the years ended March 31, 2024, 2023 and 2022, respectively, which was included in net income (loss) from discontinued operation in the accompanying consolidated statements of operations and comprehensive (loss) income.

Sales of medical devices

Started in February 2022, through its subsidiary Akso Online MediTech, the Company engaged in the sale of Covid-19 Antigen Rapid Tests in US market. For the years ended March 31, 2024, 2023 and 2022, revenue generated from sale of Covid-19 Antigen Rapid Tests was nil, \$9,181,274 and \$6,000,000. Akso Online MediTech purchases medical devices in quantity and distributes products primarily to medical products dealers. The deliveries may take one day or longer depending on the customers' location. Revenue from sales of merchandise to non-retail customers is recognized when the merchandise is transferred to customers. There was no sales return since the start the business.

[illegible]

received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurement or assumptions that market participants would use when pricing the asset or liability.

The Company follows the provisions of Financial Accounting Standards Board ("FASB"), Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3 - Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts reported in the balance sheets for cash, receivables, prepayments and other assets, loan principal and interest receivable, approximate their fair value based on the short term maturity of these instruments. The Company did not transfer any assets or liabilities in or out of level 3 during the years ended March 31, 2023, 2022 and 2021.

The Company's long-term investments consist of equity securities and available-for-sale investments. For long-term investments without readily determinable fair value, the Company is not able to estimate fair value, hence, the Company uses the cost minus impairment method as alternative.

Discontinued Operations

A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity's operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity's financial results and operations. Included in the consolidated statements of operations and comprehensive (loss) income, result from discontinued operations have been reported separately from the income and expenses from continuing operations and prior periods have been presented on a reclassified comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.

Due to the disposal of the social E-commerce business, which represented a strategic shift and had a major effect on the Company's results of operations, revenues, costs and expenses related to the social E-commerce business have been reclassified in the accompanying consolidated financial statements as discontinued operations for all the periods presented.

The following table illustrates the disaggregation of revenue:

	Year ended	Year ended
	March 31, 2024	March 31, 2023
Revenue	USD	USD
Revenue from medical devices-US	9,181,274	6,000,000
Revenue from medical devices-PRC	2,416,797	

4,005,251	
sec-ix-hidden: hidden-fact-106	
vertical-align: bottom; background-color: rgb(204,238,255)	
font-weight: bold; text-align: left;">Total revenues	
font-weight: bold; text-align: left;">2,416,797	
font-weight: bold; text-align: right;">13,186,525	
font-weight: bold; text-align: left;">6,000,000	
vertical-align: bottom;	
padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid; text-align: right;">2,459	
padding-bottom: 1.5pt; text-align: left;">4,964	
padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid; text-align: left;">13,181,561	
padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid; text-align: right;">6,000,000	
padding-bottom: 1.5pt; font-weight: bold; text-align: left;">Net Revenues	
border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;">2,414,338	
padding-bottom: 1.5pt; font-weight: bold; text-align: left;">13,181,561	
padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;">6,000,000	

91812746000000241679740052512416797131865256000000245949642414338131815616000000

Cash and cash equivalents

Cash and cash equivalents represent cash on hand, unrestricted demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash.

Accounts receivable and allowance for uncollectible accounts

Accounts receivable are mainly receivables from online E-commerce marketplaces and recommendation services, which are stated at the historical carrying amount net of allowance for uncollectible accounts. The Company establishes an allowance for uncollectible accounts receivable based on estimates, historical experience and other factors surrounding the credit risk of specific customers. Uncollectible accounts receivables are written off when a settlement is reached for an amount that is less than the outstanding historical balance or when the Company has determined that is not probable for the balance to be collected. Beginning on April 1, 2020, the Company evaluates its accounts receivable for expected credit losses on a regular basis. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. The Company uses the length of time a balance has been outstanding, the payment history, creditworthiness and financial conditions of the customers and industry trend as credit quality indicators to monitor the Company's receivables within the scope of expected credit losses model and use these as a basis to develop the Company's expected loss estimates. The Company adjusts the allowance percentage periodically when there are significant differences between estimated bad debts and actual bad debts. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Company also makes a specific allowance in the period in which a loss is determined to be probable. Accounts receivable balances are written off after all collection efforts have been exhausted. As of March 31, 2024 and 2023, the allowance for uncollectible accounts receivable balance was US\$ 7,369,797 and US\$ 400,759, respectively.

7369797400759

Inventories

Inventories are comprised of finished goods, which are defibrillators and anesthesia laryngoscope, and are stated at the lower of cost or net realizable value using first in first out (FIFO) method. Management reviews inventories for obsolescence and cost in excess of net realizable value periodically when appropriate and records a reserve against the inventory when the carrying value exceeds net realizable value. As of March 31, 2024, the Company determined that no allowance was necessary.

Property and equipment, net

Property and equipment are stated at cost. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives:

	0	0
Useful life		
Office equipment		
	3-5 years	

The Company eliminates the cost and related accumulated depreciation and amortization of assets sold or otherwise retired from the accounts and includes any gains or losses from disposal of property, equipment, and software in other income. The Company charges maintenance, repairs, and minor renewals directly to expense as incurred; major additions and betterments to equipment are capitalized. For the disposal of social E-commerce business, property and equipment, net was recorded in discontinued operations. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives:

	0	0

Useful life		

Office equipment

		3-5 years

P3YP5Y

Impairment of long-lived assets

The carrying value of the long-lived assets are reviewed for impairment, whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of assets to future undiscounted net cash flows expected to be generated by the assets. Such assets are considered to be impaired if the sum of the expected undiscounted cash flows is less than carrying amount of the assets. The impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

No impairment loss was recognized for the years ended March 31, 2024, 2023 and 2022.

Advertising and promotion expenses

The Company recognizes its advertising and promotion expenses as sales and marketing expense. Advertising expenses represent expenses for placing advertisements on television, radio and in newspapers, as well as on internet websites and search engines. Advertising and promotion costs are expensed as incurred. For the years ended March 31, 2024, 2023 and 2022, the advertising and promotion expenses were US\$ 168,421, US\$ 6,661, nil, respectively.

1684216661

Lease

Upon the adoption of FASB ASC 842 on April 1, 2019 using the modified retrospective method, the Company determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets and operating lease liabilities, in the Company's consolidated balance sheets. The Company does not have any finance leases as of the adoption date or March 31, 2022.

ROU represents the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which it calculates based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease.

For operating lease with a term of one year or less, the Company has elected to not recognize a lease liability or lease right of use asset on its consolidated balance sheets. Instead, it recognizes the lease payment as expense on a straight-line basis over the lease term. Short-term lease costs are immaterial to its consolidated statements of operations and comprehensive (loss). The Company has operating lease agreements with insignificant non-lease components and have elected the practical expedient to combine and account for lease and non-lease components as single lease component.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in Financial Accounting Standards Board ("FASB") ASC 480 "Distinguishing Liabilities from Equity" ("ASC 480") and ASC 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common stock and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annually period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations (Note 17).

Share-based compensation

Under the Amended and Restated 2016 Equity Incentive Plan, the Company grants share options to the Company's selected employees, and directors. Awards granted to employees with service conditions attached are measured at the fair value on the grant date and are recognized as an expense using straight-line method, net of estimated forfeitures, over the requisite service period, which is generally the vesting period. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share-based compensation expense to be recognized in future periods.

Awards granted to employees with performance conditions attached are measured at fair value on the grant date and are recognized as compensation expense in the period and thereafter when the performance goal becomes probable to achieve. Awards granted to employees with market conditions attached are measured at fair value on the grant date and are recognized as compensation expense over

the estimated requisite service period, regardless of whether the market condition has been satisfied if the requisite service period is fulfilled.

Binomial option-pricing models are adopted to measure the value of awards at each grant date or measurement date. The determination of fair value is affected by assumptions relating to a number of complex and subjective variables, including but not limited to the expected share price volatility, actual and projected employee share option exercise behavior, risk-free interest rates and expected dividends. The use of the option-pricing model requires extensive actual employee exercise behavior data for the relative probability estimation purpose, and a number of complex assumptions.

Treasury stock

Treasury stock represents ordinary shares repurchased by the Company that are no longer outstanding and are held by the Company. The repurchase of ordinary shares is accounted for under the cost method whereby the entire cost of the acquired shares are recorded as treasury stock. The cost of treasury stock is transferred to "additional paid-in capital" when it is re-issued for the purpose of share options exercised and share awards.

Income taxes

The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

The Company accounts for income tax under the asset and liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Under this method, deferred income taxes will be recognized if significant temporary differences between tax and financial statements occur. A valuation allowance is established against net deferred tax assets when it is more likely that some portion or all of the net deferred tax asset will not be realized. For the years ended March 31, 2024, 2023 and 2022, the Company provided a full valuation allowance on the net deferred tax assets.

The Company may be subject to challenges from taxing authorities regarding the amounts of taxes due. These challenges may alter the timing or amount of taxable income or deductions. Management determines whether the benefits of its tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated.

An uncertain tax position is recognized as a benefit only if it is "more likely than not" that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. For tax positions not meeting the "more likely than not" test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income taxes are classified as income tax expense in the period incurred. The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measures the unrecognized benefits associated with the tax positions. As of March 31, 2024 and 2023, the Company did not have any significant unrecognized uncertain tax positions. The Company does not believe that its unrecognized tax benefits will change over the next twelve months.

Noncontrolling interests

Noncontrolling interest consists of 49% of the equity interest of We Healthy held by other investors. Excess of contribution received from noncontrolling shareholders over carrying value of the entity is recorded in additional paid in capital. The noncontrolling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Noncontrolling interests in the results of the Company are presented on the face of the consolidated statement of operations as an allocation of the total income or loss for the year between non-controlling interest holders and the shareholders of the Company.

Noncontrolling interest consist of the following:

	December 31, 2024	December 31, 2023
USD	USD	USD
We Healthy	56,810	114,212
0.49 Noncontrolling interest consist of the following:		
We Healthy	56,810	114,212

Earnings (loss) per share

The Company computes earnings per share ("EPS") in accordance with FASB ASC 260, "Earnings per Share" ("ASC 260"). ASC 260 requires public companies with capital structures to present basic and diluted EPS. Basic EPS is measured as net income (loss) attributed to ordinary shareholders divided by the weighted average number of ordinary shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

Foreign currency translation

The functional currency of the Company is United States Dollar. The Company's subsidiaries with operations in mainland China, the Hong Kong Special Administrative Region of the PRC ("Hong Kong" or "Hong Kong S.A.R."), the United States generally use their respective local currencies as their functional currencies. The Company's financial statements have been translated into the reporting currency, the United States Dollar ("USD"). Assets and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated at the average exchange rate during the reporting period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss). Transactions denominated in currencies other than functional currency are translated into the functional currency at the exchange rates quoted by authoritative banks prevailing at the dates of the transactions. Exchange gains and losses resulting from those foreign currency transactions denominated in a currency other than the functional currency are recorded in "other income (expense)" in the consolidated statements of operations and comprehensive income. The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that any RMB amounts could have been, or could be, converted, realized or settled into USD at the rates used in translation.

Spot exchange rates and average exchange rates were used in the translation of the consolidated financial statements.

Fiscal year	2024	2023
US Exchange Rate		
Year-end RMB	7.2203	6.8676
Year average RMB	6.3393	6.1671
	6.8516	6.4180

Spot exchange rates and average exchange rates were used in the translation of the consolidated financial statements.

Fiscal year	2024	2023
US Exchange Rate		
Year-end RMB	7.2203	6.8676
Year average RMB	6.3393	6.1671
	6.8516	6.4180

7.22036.86766.33937.16716.85166.418

Significant risks and uncertainties

Foreign currency risk

RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People's Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to

international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. The Company's cash and cash equivalents denominated in RMB amounted to US\$10,380,711 and US\$7,876,767 as at March 31, 2024 and 2023, respectively.

Concentration of credit risk

Financial instruments that potentially expose the Company to significant concentration of credit risk primarily included in the financial lines of cash and cash equivalents, accounts receivable, other receivables and prepayments and other assets. As of March 31, 2024, substantially all of the Company's cash and cash equivalents were held by major financial institutions located worldwide, including mainland China and United States. According to the China Bank Deposit Insurance Ordinance, the deposits at each bank is covered by insurance with an upper limit of RMB 500,000 (approximately US\$69,249) at each bank. As of March 31, 2024, the total amount not covered by insurance in the PRC was US\$ 10,310,077. The Hong Kong Deposit Protection Board pays compensation up to a limit of HKD 500,000 (approximately US\$ 63,890) if the bank with which an individual/a company hold its eligible deposit fails. As of March 31, 2024, no cash balance maintained at financial institutions in Hong Kong was subject to credit risk. In the US, the insurance coverage of each bank is \$250,000. As of March 31, 2024, no cash balance maintained at financial institutions in US was subject to credit risk. If the financial institutions could become insolvent, the Company could lose some or all of the value of its investments. To limit exposure to credit risk relating to deposits, the Company primarily place cash and cash equivalent deposits with large financial institutions which management believes are of high credit quality and management also continually monitors the financial institutions' credit worthiness.

Accounts receivable

Accounts receivable is typically unsecured and are derived from revenue earned from customers in the PRC. The risk with respect to accounts receivable is mitigated by credit evaluations the Company performs on its customers and its ongoing monitoring process of outstanding balances.

Customer concentration risk

For the year ended March 31, 2024, three customers accounted for 36.3%, 34.8% and 28.0% for the Company's total revenue from sales of medical devices business. For the year ended March 31, 2023, three customers accounted for 59.5%, 11.1% and 10.1% for the Company's total revenue from sales of medical devices business. For the year ended March 31, 2022, one customer accounted for 95.1% of the Company's total revenues. There was no customer of the Company that accounted for more than 10% of the Company's carrying amount of account receivables as of March 31, 2024 and there was one customer of the Company that accounted for 100% of the Company's carrying amount of accounts receivable as of March 31 2023.

Vendor concentration risk

For the year ended March 31, 2024, one vendor accounted for 100% of the Company's purchase of medical devices business. For the year ended March 31, 2023, one vendor accounted for 97.3% of the Company's purchase of medical devices business. For the year ended March 31, 2022, one vendor accounted for 100% of the Company's purchase of medical devices business. There was no vendor of the Company that accounted for greater than 10% of the Company's carrying amount of accounts payable as of March 31, 2024 and 2023.

10380711787675000006924910310077500000638902500000.3630.3480.2830.5950.1110.1010.9511110.9731

Recent Accounting Pronouncements

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). ASU No. 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as additional information on income taxes paid. The guidance is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Company does not expect to adopt ASU No. 2023-09 early and is currently evaluating the impact of adopting this standard on its consolidated financial statements.

The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated balance sheets, consolidated statements of operations and comprehensive loss (income) and consolidated statements of cash flows.

NOTE 4 - DISCONTINUED OPERATION

On December 16, 2020, Beijing Hexin Yongheng Technology Development Co., Ltd. ("Hexin Yongheng"), a wholly-owned subsidiary of the Company, Kuaishangche Automobile Leasing Co., Ltd. ("Kuaishangche"), a company not directly associated with the Company, Hexin E-Commerce Company Limited ("Hexin E-Commerce"), and individual shareholders of Hexin E-Commerce entered into an assignment and assumption agreement (the "Agreement"). Pursuant to the Agreement, Hexin Yongheng agreed to assign and transfer to Kuaishangche the control over Hexin E-Commerce, in exchange for cash consideration of RMB 5 million (US\$726,781) (the "Disposition"). Upon the closing of the Disposition, Kuaishangche will become the primary beneficiary of and have control of Hexin E-Commerce, and as a result, assume all assets and liabilities of Hexin E-Commerce and subsidiaries owned or controlled by Hexin E-Commerce, excluding any rights, titles, interests or claims that Hexin E-Commerce may have in Wusu Hexin Yongheng Commercial and Trading Co., Ltd. ("Wusu Company"), shall remain as a consolidated variable interest entity of the Company. As a result of the Disposition, the Company will cease to conduct its P2P business and focus on developing and investing resources into its social e-commerce platform, Xiaobai Maimai.

On May 10, 2023, Akso Health Group (the "Company" or the "Seller"), HX Asia Investment Limited, a British Virgin Islands company ("HX Asia"), HX China Investment Limited, a British Virgin Islands company ("HX China"), and Hexindai Hong Kong Limited, a Hong Kong company ("Hexindai") and together with HX Asia and HX China, the "Targets"), and Umbrella Capital Investment Co., Ltd, a British Virgin Islands company which is not affiliate of the Company of any of its directors or officers (the "Purchaser") entered into certain share purchase agreement (the "Disposition SPA"). Pursuant to the Disposition SPA, the Purchaser agreed to purchase the Targets in exchange for cash consideration of US\$215,000 (the "Purchase Price"). Upon the closing of the transaction (the "Disposition") contemplated by the Disposition SPA, the Buyer will become the sole shareholder of the Targets and as a result, assume all assets and liabilities of the

Targets and subsidiaries owned or controlled by the Target. As a result of the Disposition, the Company will cease to conduct its social E-commerce business and focus on developing and investing resources into its medical devices business.

The discontinued operation represents a strategic shift that has a major effect on the Company's operations and financial results, which trigger discontinued operations accounting in accordance with FASB ASC 205-20-45. The assets and liabilities related to the discontinued operations are classified as assets/liabilities of discontinued operations as of March 31, 2024 and 2023, while results of operations related to the discontinued operations for the years ended March 31, 2024, 2023 and 2022, were reported as income (loss) from discontinued operations.

The results of discontinued operations for years ended March 31, 2024, 2023 and 2022 are as follows:

	2024	2023	2022	USD
Net Revenues	694	24,995	311,092	
Operating costs and development	4,551	1,073,518	12,988,383	
(Loss) income from discontinued operations	(3,857)	(1,048,522)	(12,677,291)	
Other income (expense), net	(27)	12,885,134	(32,728)	
Income before tax	(3,884)	11,836,612	(12,710,019)	
Income tax provision				
Net (loss) income from discontinued operations	(3,884)	11,836,612	(12,748,636)	
Loss on sale of discontinued operations, net of taxes				
	(395,914)			

1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-120"></div></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-121"></div></td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0.5pt">Net income (loss) from discontinued operation</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">(399,798</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,836,612</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,748,636</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Assets and liabilities of the discontinued operations as of March 31, 2024 and 2023 are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold"></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right"><div style="sec-ix-hidden: hidden-fact-122"></div></td><td style="width: 1%; text-align: left"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">1,268,235</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left">Accounts receivable, net</td><td></td><td style="text-align: left"></td><td style="text-align: right"><div style="sec-ix-hidden: hidden-fact-123"></div></td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: right">10,062</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Prepayments and other assets</td><td></td><td style="text-align: left"></td><td style="text-align: right"><div style="sec-ix-hidden: hidden-fact-124"></div></td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: right">44,004</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt">Property, equipment and software, net</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-125"></div></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,051</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Current assets held for sale-discontinued operation</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-126"></div></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,351,352</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: right"></td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Accrued expenses and other current liabilities</td><td></td><td style="text-align: left"></td><td style="text-align: right"><div style="sec-ix-hidden: hidden-fact-127"></div></td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">737,693</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: right"><div style="sec-ix-hidden: hidden-fact-128"></div></td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">(32,210</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Amount due to related party</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="sec-ix-hidden: hidden-fact-129"></div></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">705,483</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td></tr></table><p style="font: 10pt Times

New Roman, Times, Serif; margin: 0pt 0">The calculation of loss on sale of discontinued operations, net of taxes illustrated as below:

May 19, 2023			
USD			
Cash and cash equivalents			
1,030,377			
Accounts receivable, net			
9,508			
Prepayments and other assets			
241,025			
Property, plant and equipment, net			
24,998			
Total assets			
1,305,908			
Account payable			
662,648			
Accrued expenses and other current liabilities			
32,346			
Total liabilities			
694,994			
Net assets			
610,914			
Consideration received			
215,000			
Loss on sale of discontinued operations, net of taxes			
(395,914)			

The results of discontinued operations for years ended March 31, 2024, 2023 and 2022 are as follows:

For the years ended March 31,			
2024			
2023			
2022			
USD			
USD			
Net Revenues			
694			
24,995			
311,092			
Operating costs and development			
4,551			
1,073,518			
(12,988,383)			
(Loss) income from			

(3,857) (1,048,522) (12,677,291) Other income (expense), net (12,885,134) (32,728) (Loss) income before tax (3,884) 11,836,612 (12,710,019) Income tax provision (38,617) (395,914) (399,798) Net (loss) income from discontinued operations (3,884) 11,836,612 (12,748,636) Loss on sale of discontinued operations, net of taxes (395,914) (399,798) Net income (loss) from discontinued operation (399,798) 11,836,612 (12,748,636)

Assets and liabilities of the discontinued operations as of March 31, 2024 and 2023 are as follows:

	March 31, 2024	March 31, 2023
Cash and cash equivalents	1,268,235	10,062
Prepayments and other assets	44,004	
Property, equipment and software, net		
Accounts receivable, net	10,062	
Other assets		
Liabilities		
Accounts payable		
Other liabilities		

fact-125

Current assets held for sale-discontinued operation	
29,051	
Accrued expenses and other current liabilities	
737,693	
Tax (benefit) payable	
Total liabilities held for sale-discontinued operation	
12682351006244004290511351352737693	

The calculation of loss on sale of discontinued operations, net of taxes illustrated as below:

	May 19,	2023
Cash and cash equivalents	1,030,377	
Accounts receivable, net		9,508
Prepayments and other assets	241,025	
Property, plant and equipment, net	24,998	
Total assets	1,305,908	
Account payable	662,648	
Accrued expenses and other current liabilities	32,346	
Total liabilities	694,994	
Loss on sale of discontinued operations, net of taxes		610,914

Note 5- ACCOUNTS RECEIVABLE, NET

	Accounts receivable	net	7,770,556		8,097,742
Allowance for uncollectible accounts receivable					
(7,770,556)			(400,759)		
March 31, 2024					
March 31, 2023					
USD					
Accounts receivable, net					
7,770,556					
8,097,742					

Note 6 - PREPAYMENTS AND OTHER ASSETS, NET

	Prepayments and other assets	net	7,770,556		8,097,742
Prepayments and other assets					
(7,770,556)			(400,759)		
March 31, 2024					
March 31, 2023					
USD					
Prepayments and other assets					
7,770,556					
8,097,742					

Prepayments to suppliers and others

409,322	272,129	6,423	402,899	409,322	272,129	6,423	402,899

Allowance

(6,423)	272,129	402,899	272,129	402,899	272,129	402,899	272,129

Total prepayments and other assets, net

402,899	409,322	272,129	402,899	409,322	272,129	402,899	409,322

As of

March 31, 2024	March 31, 2023	USD	USD

Prepayments to suppliers and others

409,322	272,129	6,423	402,899	409,322	272,129	6,423	402,899

Allowance

(6,423)	272,129	402,899	272,129	402,899	272,129	402,899	272,129

Total prepayments and other assets, net

402,899	409,322	272,129	402,899	409,322	272,129	402,899	409,322

Note 7 - INVENTORIES

As of March 31, 2024 and 2023, inventory consisted of finished goods, which were medical devices such as defibrillators and anesthesia laryngoscope, valued at US\$191,201 and US\$ 1,686,449, respectively. The Company constantly monitors its potential obsolete products. Any loss on damaged items is immaterial and will be recognized immediately. As a result,

no reserves were made for inventory for the years ended March 31, 2024, 2023.

1912011686449

Note 8 - LOAN RECEIVABLES

As of	As of	USD	USD

March 31, 2024

March 31, 2023	USD	USD

[illegible]

NOTE 9 - PREPAID CONSIDERATION

In March 2024, the Company, through Tianjin Akso Enterprise Management Co., Ltd., one of its PRC subsidiaries, entered into Share Purchase Agreements (the "SPA") with four non-affiliated individual shareholders (the "Sellers") of Tianjin Wangyi Cloud Technology Co., Ltd. (the "Target"). Pursuant to the SPA, the Company acquired 50% of the equity interest in the Target held by the four Sellers, each of which held 12.5% equity interest, respectively. The total consideration for the transaction was US\$75.0 million. As of March 31, 2024, the Company has paid US\$56.25 million, which was recorded as prepaid consideration. The transaction closed on April 15, 2024. Upon closing, Tianjin Akso Enterprise Management Co., Ltd. acquired 50% equity interest of Tianjin Wangyi Cloud Co., Ltd. At the completion of the transaction, the Company determined that no provision needed to be made for the prepaid consideration as of March 31, 2024.

NOTE 10 - RIGHT OF USE LEASE ASSETS

The Company had several operating leases for offices in the PRC. The related lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Effective April 1, 2019, the Company adopted the new lease accounting standard using a modified retrospective transition method which allowed the Company not to recast comparative periods presented in its consolidated financial statements. In addition, the Company elected the package of practical expedients, which allowed the Company to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Company has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. The Company combines the lease and non-lease components in determining the ROU assets and the related lease obligation. Adoption of this standard resulted in the recording of operating lease ROU assets and corresponding operating lease liabilities as disclosed below and had no impact on our accumulated deficit as of March 31, 2020. ROU assets and related lease obligations are recognized at commencement date based on the present value of remaining lease payments over the lease term. As of April 1, 2019, the Company recorded a ROU asset and lease liability of US\$ 2,559,646.

The Company's operating leases primarily include leases for office space. The current portion of operating lease liabilities and the non-current portion of operating lease liabilities are presented on the consolidated balance sheets. For operating lease with a term of one year or less, the Company has elected to not recognize a lease liability or lease right of use asset on its consolidated balance sheets. Instead, it recognizes the lease payment as expense on a straight-line basis over the lease term. For the Social E-commerce disposal and retroactive adjustment to its financial statement, the total lease expense amounted to nil, nil, and nil for the years ended March 31, 2024, 2023 and 2022, respectively. For the year ended March 31, 2024, the Company leased premises and warehouse from third parties for free of charge.

Note 11 - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

	As of March 31, 2024	As of March 31, 2023	USD	USD
Accrued payroll and benefits	1,092,629	588,342		
Professional fees, other payable and accrued expenses	2,733			
Interest payable	9,450	105,085		
	1,104,812	938,767		

As of March 31, 2024, 2023

USD		USD
USD		USD

Accrued payroll and benefits		1,092,629		588,342
Professional fees, other payable and accrued expenses		2,733		
Interest payable		9,450		
		105,085		
		1,104,812		
		938,767		

1092629588342273324534094501050851104812938767

Note 12 - RELATED PARTY BALANCES AND TRANSACTIONS

On August 26, 2021, the Company entered into a loan agreement with Webao Limited, the majority shareholder of the Company, for a loan of US\$2.0 million with a 0% annual interest rate. The loan term is 1 year. On August 26, 2022, both the Company and Webao Limited entered into a Deferred Repayment Agreement to extend the loan term one more year to August 27, 2023 and the annual interest rate remained 0%. On August 26, 2023, the loan agreement was extended one more year to August 27, 2024 and the annual interest rate remained 0%. As of March 31, 2024, the balance of amount due to related parties was US\$2.0 million.

On January 24, 2022, the Company entered into a loan agreement with SOS Information Technology New York, Inc. ("SOS NY"), one of our senior management was the related party of SOS Limited, for a loan of US\$35,200,000 with a 2% annual interest rate. The loan term was 1 year. For the fiscal year ended March 31, 2022, interest expense pertaining to the loan amounted to US\$127,244. On July 27, 2022, the Company and SOS NY entered into an amendment and supplemental agreement to the loan agreement, pursuant to which the Company shall make a repayment in advance to SOS NY of US\$27,513,849 of the principal amount together with all accrued but unpaid interest of US\$358,751. The Company made a payment of US\$27,872,600 for the above principal and interest on July 28, 2022. In November 2023, the Company made a payment of US\$7,686,151 of principal amount together with all accrued but unpaid interest of US\$196,681 to SOS NY. As of March 31, 2024, the outstanding balance of unpaid principal and interest was nil and nil, respectively.

200000000PIYP1Y0020000000352000000.02P1Y12724427513849358751278726007686151196681

Note 13 - EMPLOYEE BENEFITS

The Company has made the required employee benefit contributions in accordance with relevant rules and regulations in the PRC. Such contributions include funding for retirement insurance, unemployment insurance, medical insurance, work injury insurance, maternity insurance and housing fund. The Company recorded the contributions in salary and employee charges at specified percentages of the salaries, bonuses and certain allowances of its employees, up to a maximum amount specified by the local government. The contributions made by the Company were US\$7,390, nil and nil for the years ended March 31, 2024, 2023 and 2022, respectively.

7390

Note 14 - TAXES PAYABLE

As of March 31, 2024		As of March 31, 2023		USD	USD
Income taxes payable		92,816	95,888		
Other taxes (recovery) payable		(18,725)	117		

Total taxes payable		74,091	96,005
Income taxes payable		92,816	95,888
Other taxes (recovery) payable		18,725	117
Total taxes payable		74,091	96,005

Note 15 – INCOME TAXES

Cayman Islands

Akso Health was incorporated in the Cayman Islands and is not subject to income taxes or capital gain under current laws of Cayman Islands.

Hong Kong

We Healthy Limited and Akso Medi-care Limited are investment holding companies registered in Hong Kong and exempted from income tax on its foreign-derived income.

United States

The Company's subsidiaries established in the U.S. are incorporated in the U.S. and is subject to both federal and state income taxes for its business operation in the U.S. The applicable tax rate is 21% for federal, 6.5% for We Healthy established in New York, 0% for Akso Remote Medical and Akso Online MediTech established in Wyoming and 8% for Akso First Health established in Massachusetts. All U.S. entities had no taxable income for the year ended March 31, 2024.

PRC

The Company's subsidiaries established in the PRC are subject to the PRC statutory income tax rate of 25%, according to the PRC Enterprise Income Tax ("EIT") law.

i) The components of income tax expenses are as follows:

Year ended March 31, 2024	Year ended March 31, 2023
Year ended March 31, 2022	
USD	USD
USD	USD
Current	
24,988	17,549

92,816

Total		24,988
		17,549
		92,816

All income taxes are related to income derived in the U.S. and PRC during the years ended March 31, 2024, 2023 and 2022.

The net income before taxes for the PRC entities was US\$83,103, US\$ 165,429 and US\$ 2,717 for the years ended March 31, 2024, 2023 and 2022, respectively. The net (loss) income before taxes for the U.S. entities was US\$(3,366,893), US\$ 634,709 and US\$441,981 for the years ended March 31, 2024, 2023 and 2022, respectively.

The following table reconciles the PRC statutory rates to the Company's effective tax rate for the years ended March 31, 2024, 2023 and 2022.

Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022
PRC Income tax statutory rate	(25.0)%	(25.0)%
Effect of tax holiday and preferential tax rate	4.0%	%
Non-deductible foreign losses	5.8%	0.7%
Change in valuation allowance	20.3%	24.8%
Non-deductible expenses and others	(5.4)	(4.6)
Effective tax rate	(0.3)	(0.1)

In accordance with the EIT Law,

dividends, which arise from profits of foreign invested enterprises ("FIEs") earned after January 1, 2008, are subject to a 10% withholding income tax. In addition, under the tax treaty between the PRC and Hong Kong, if the foreign investor is incorporated in Hong Kong and qualifies as the beneficial owner, the applicable withholding tax rate is reduced to 5%, if the investor holds at least 25% in the FIE, or 10%, if the investor holds less than 25% in the FIE. On July 19, 2018, the board of directors approved an annual dividend policy. Under this policy, annual dividends will be set at an amount equivalent to approximately 15-25% of the Company's anticipated net income after tax in each year commencing from fiscal year ended March 31, 2019, which will be derived from the earnings of the Company's PRC entities. The board of directors did not declare any annual dividend for the fiscal years ended March 31, 2024, 2023 and 2022.

A deferred tax liability should be recognized for the undistributed profits of PRC subsidiaries unless the Company has sufficient evidence to demonstrate that the undistributed dividends will be reinvested and the remittance of the dividends will be postponed indefinitely. The Company plans to indefinitely reinvest undistributed profits earned from its China subsidiaries in its operations in the PRC. Therefore, no withholding income taxes for undistributed profits of the Company's subsidiaries have been provided as of March 31, 2024 and 2023. Under applicable accounting principles, a deferred tax liability should be recorded for taxable temporary differences attributable to the excess of the financial reporting basis over the tax basis in a domestic subsidiary. However, recognition is not required in situations where the tax law provides a means by which the reported amount of that investment can be recovered tax-free and the enterprise expects that it will ultimately use that means. The Company completed its feasibility analysis on a method, which the Company will ultimately execute if necessary to repatriate the undistributed earnings of the subsidiary without significant tax costs. As such, the Company does not accrue deferred tax liabilities on the earnings of the subsidiary given that the Company will ultimately use the means.

(i) The components of income tax expenses are as follows:

Year ended March 31, 2024	Year ended March 31, 2023	USD
Current	24,988	17,549
Deferred	92,816	92,816
Total	24,988	17,549

The following table reconciles the PRC statutory rates to the Company's effective tax rate for the years ended March 31, 2024, 2023 and 2022.

Year ended March 31, 2024	Year ended March 31, 2023	Year ended March 31, 2022	PRC Income tax statutory rate	(25.0)%	(25.0)%
Effect of tax holiday and preferential tax rate	4.0	4.0			

[illegible]

[illegible]

Weighted average number of dilutive potential ordinary shares from share options	59,612,152	141,516,777	68,598,050
Weighted average number of ordinary shares outstanding-diluted	141,516,777	68,598,050	59,612,152

Basic (loss) per common share (0.07) (0.02) (0.28)

Diluted (loss) per common share (0.07) (0.02) (0.28)

9058986-13196535-4102428-39979811836612-12748636-9458784-1359923-1685106414151677768598050596121521415167776859805059612152-0.07-0.02-0.28-0.07-0.02-0.28

Note 17- SHAREHOLDERS' EQUITY

Akso Health was established under the laws of the Cayman Islands on April 25, 2016. The authorized number of ordinary shares is 500,000,000 shares with par value of US\$0.0001 each. On August 24, 2020, the Company amended the ratio of ADS representing its ordinary shares from one (1) ADS representing one (1) ordinary share to one (1) ADS representing three (3) ordinary shares. The change in the ADS ratio has the same effect as a one-for-three reverse ADS split. There was no change to our ordinary shares in connection with the change of the ADS ratio. On June 19, 2023, the Company increased its authorized shares from US\$50,000 divided into 500,000,000 ordinary shares of a par value of US\$0.0001 each to US\$500,000 divided into 5,000,000,000 ordinary shares of a par value of US\$0.0001 by the creation of an additional 4,500,000,000 ordinary shares of a par value of US\$0.0001. As of March 31, 2024 and 2023, the Company's outstanding ordinary shares were 437,170,960 and 68,598,050, respectively.

On August 9, 2021, the Company entered into a certain securities purchase agreement (the "SPA") with certain "non-U.S. Persons" pursuant to which the Company agreed to sell an aggregate of 6,340,000 units at a price of US\$1.58 per unit, each unit consisting of three ordinary shares of the Company, par value \$0.0001 per share ("Share") and a warrant to purchase three Shares with an initial exercise price of US\$3.00, for an aggregate purchase price of approximately US\$10.02 million (the "Offering"). On September 17, 2021, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$10.0 million from such Offering will be used by the Company for working capital and general corporate purposes.

The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$3.00, or for cash (the "Warrant Shares"). The Warrants may also be exercised on a cashless basis if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions. During the year ended March 31, 2024, a total of 3,380,000 warrants (each warrant to purchase 3 ordinary shares) were exercised on cashless basis, resulting issuance of 7,098,000 ordinary shares.

On October 2, 2023, the Company entered into a certain securities purchase agreement (the "SPA") with certain "non-U.S. Persons" pursuant to which the Company agreed to sell an aggregate of 35,739,270 units at a price of US\$0.391 per unit, each unit consisting of one ordinary shares of the Company, par value \$0.0001 per share ("Share") and a warrant to purchase one Shares with an initial exercise price of US\$0.48875, for an aggregate purchase price of approximately US\$14.0 million (the "Offering"). On October 17, 2023, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$14.0 million from such Offering will be used by the Company for working capital and general corporate purposes.

The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.48875, or approximately \$1.47 per ADS, for cash (the "Warrant Shares"). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.

Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">On November 16, 2023, the Company entered into a certain securities purchase agreement (the "SPA") with certain "non-U.S. Persons" pursuant to which the Company agreed to sell an aggregate of 53,608,910 units at a price of US\$0.423 per unit, each unit consisting of one ordinary shares of the Company, par value \$0.0001 per share ("Share") and a warrant to purchase one Shares with an initial exercise price of US\$0.52875, for an aggregate purchase price of approximately US\$22.68 million (the "Offering"). On November 21, 2023, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$22.68 million from such Offering will be used by the Company for working capital and general corporate purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.52875, or approximately \$1.59 per ADS, for cash (the "Warrant Shares"). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">On January 17, 2024, the Company entered into a certain securities purchase agreement (the "SPA") with certain "non-U.S. Persons" pursuant to which the Company agreed to sell an aggregate of 160,826,730 units at a price of US\$0.3317 per unit, each unit consisting of one ordinary shares of the Company, par value \$0.0001 per share ("Share") and a warrant to purchase one Shares with an initial exercise price of US\$0.4146, for an aggregate purchase price of approximately US\$53.35 million (the "Offering"). On January 26, 2024, the transaction contemplated by the SPA was consummated when all the closing conditions of the SPA were satisfied. The net proceeds of approximately US\$53.35 million from such Offering will be used by the Company for working capital and general corporate purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">The Warrants are exercisable immediately upon the date of issuance at an initial exercise price of \$0.4146, or approximately \$1.2438 per ADS, for cash (the "Warrant Shares"). The Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares. The Warrants shall expire five years from its date of issuance. The Warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">On March 5, 2024, the Company entered into a certain securities purchase agreement (the "SPA") with certain non-affiliated institutional investors (the "Purchasers") pursuant to which the Company agreed to sell an aggregate of 37,100,000 of its American Depositary Shares ("ADSs") representing 111,300,000 ordinary shares, par value \$0.0001 per share ("Ordinary Shares"), in a registered direct offering, and warrants ("Warrants") to purchase 222,600,000 Ordinary Shares in a concurrent private placement for gross proceeds of approximately \$49.34 million (the "Offering").</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">The warrants are exercisable immediately as of the date of issuance at an exercise price of \$0.4933 per ordinary share, or \$1.48 per ADS and expire five years from the date of issuance. The purchase price for each ADS and the corresponding Warrants is \$1.33. Each Warrant is subject to anti-dilution provisions to reflect stock dividends and splits, subsequent rights offerings or other similar transactions, but not as a result of future securities offerings at lower prices. Upon the occurrence of a Fundamental Transaction (as defined in the Warrants), the Warrants are subject to mandatory redemption for cash consideration equal to the Black Scholes Value (as defined in the Warrants) of such portion of such Warrant to be redeemed. The Company intended to use the net proceeds from the Offering for working capital and general corporate use. The Offering closed on March 7, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As the warrants contained in the placement above are indexed to the Company's ordinary share (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Warrants as additional paid-in capital on the Company's consolidated balance. The Company accounts for the warrants issued in connection with the private placement in accordance with the guidance contained in ASC 815-40. The Company's management has examined the warrants and determined that these warrants qualify for equity treatment in the Company's financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The warrants contained in the private placements above shall expire five years from its date of issuance. The warrants are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar as transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended March 31, 2024, 3,380,000 warrants were exercised on cashless basis, leading to an insurance of 7,098,000 ordinary shares. During the year ended March 31, 2023, no warrants were exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 31, 2024, the Company had 290,234,910 warrants outstanding to purchase 481,654,910 ordinary shares with weighted average exercise price of US\$ 0.48 per warrant. As of March 31, 2023, the Company had 6,340,000 warrants outstanding to purchase 19,020,000 ordinary shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following is a summary of the status of warrants outstanding and exercisable as of March 31, 2024:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-

[illegible]

Average	Remaining	Contractual	Life
August 9, 2021 warrants	8,880,000	1%	4.6 years
October 2, 2023 warrants	53,608,910	0.5288	4.7 years
January 17, 2024 warrants	160,826,730	0.4146	4.8 years
March 5, 2024 warrants	222,600,000	0.4933	4.9 years

5000000000.0001The change in the ADS ratio has the same effect as a one-for-three reverse ADS

split.500005000000000.000150000050000000000.000145000000000.00014371709606859805063400001.580.00013;

is a summary of the status of warrants outstanding and exercisable as of March 31, 2024.

Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value	
Warrants outstanding, as of March 31, 2022				Warrants outstanding, as of March 31, 2022	
Issued		6,340,000		3.0	
Exercised				3.0	
Expired				0.46	
Warrants outstanding, as of March 31, 2023		6,340,000		3.0	
Issued		287,274,910		0.46	
Exercised				3,380,000	
Expired					

Warrants outstanding, as of March 31, 2024

Warrants exercisable, as of March 31, 2024	Weighted Average Exercise Price
August 9, 2021 warrants	8,880,000
October 2, 2023 warrants	35,739,270
November 16, 2023 warrants	53,608,910
January 17, 2024 warrants	160,826,730
March 5, 2024 warrants	222,600,000
4.9 years	4.9

88800001P2Y4M24D357392700.4888P4Y7M6D536089100.5288P4Y8M12D1608267300.4146P4Y9M18D2226

Note 18 - TREASURY STOCK

On December 10, 2018, the Company announced that its board of directors authorized a share repurchase program under which the Company may repurchase up to US\$25 million of its ordinary shares in the form of American depositary shares ("ADS") over the next 12 months. The Company repurchased an aggregate of 1,165,883 ADSs from the open market for a total consideration of US\$3,988,370, which was recorded as treasury stock.

Note 19 - RESTRICTED NET ASSETS

Restricted Net Assets

As a result of the PRC laws and regulations and the requirement that distributions by the PRC entities can only be paid out of distributable profits computed in accordance with the PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Company. The restricted net assets consist of paid in capital, capital reserve and statutory reserves of the Company's PRC entities. As of March 31, 2024 and 2023, the restricted net assets that are not available for distribution amounted to approximately US\$89.5 and US\$89.5 million, respectively, which was included in the additional paid-in capital on the consolidated balance sheets.

Statutory Reserve

Pursuant to the Company Law of the PRC, each of the PRC entities is required to appropriate 10% of its net income to the statutory reserve on an annual basis until the aggregated amount of the reserve reaches 50% of its registered capital. The statutory reserve is not distributable. Subject to the approval of the shareholders, the statutory reserve may be used to offset accumulated losses or converted into capital of the company. As of March 31,

2024 and 2023, the statutory reserves amounted to nil and nil, respectively.

89500000895000000.100.50

Note 20 – COMMITMENTS AND CONTINGENCIES

Contingencies

In the ordinary course of business, the Company may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records contingent liabilities resulting from such claims, when a loss is assessed to be probable and the amount of the loss is reasonably estimable. As of March 31, 2024 and 2023, no such contingent liabilities are assessed as probable.

Note 21 – SUBSEQUENT EVENTS

In March 2024, the Company, through Tianjin Akso Enterprise Management Co, Ltd., one of its subsidiary in China, entered into Share Purchase Agreements (the “SPA”) with four non-affiliated individual shareholders (the “Sellers”) of Tianjin Wangyi Cloud Technology Co., Ltd (the “Target”). Pursuant to the SPA, the Company will acquire 50% of the equity interest in the Target held by the four Sellers, each of which held 12.5% equity interest, respectively. The total consideration for the transaction was US\$75.0 million. As of March 31, 2024, the Company has paid US\$56.25 million. In April 2024, the Company paid the remaining US\$18.75 million consideration and the transaction was closed.

In the Company’s Annual General Meeting held on April 30, 2024, the Company’s authorized issued share capital is approved to change from US\$500,000 divided into 5,000,000,000 ordinary shares, par value US\$0.0001 each, to US\$500,000 divided into 4,500,000,000 Class A ordinary shares, par value US\$0.0001 each and 500,000,000 Class B ordinary shares, par value US\$0.0001 each. And 7,980,800 issued and outstanding ordinary shares of the Company held by Webao Limited were re-designated and re-classified as Class B Ordinary Shares par value US\$0.0001 each on a 1:1 basis and all other issued and outstanding Ordinary Shares as class A ordinary shares, par value US\$0.0001 each (the “Class A Ordinary Shares”) on a 1:1 basis.

On June 17, 2024, the warrants issued in the October 2023 and November 2023 private placements (see Note 17) were fully exercised on a cashless basis, resulting in the issuance of 25,017,480 and 37,256,230 Class A ordinary shares, respectively.

On June 27, 2024, the Company entered into a certain securities purchase agreement (the “June SPA”) with certain “non-U.S. Persons” pursuant to which the Company agreed to sell an aggregate of 220,000,050 units at a price of US\$0.2844 per unit, each unit consisting of one Class A ordinary share of the Company, par value \$0.0001 per share (“Share”) and three warrants to purchase one Share each with an initial exercise price of US\$0.3555, for an aggregate purchase price of approximately US\$62.6 million (the “June Offering”). On July 2, 2023, the June Offering was consummated when all the closing conditions of the June SPA were satisfied. The net proceeds of approximately US\$62.6 million from the June Offering will be used by the Company for working capital and general corporate purposes.

The warrants issued in the June Offering (the “June Warrants”) are exercisable immediately upon the date of issuance at an initial exercise price of \$0.3555, or approximately \$1.0665 per ADS, for cash. The June Warrants may also be exercised cashlessly if at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering, or no current prospectus available for, the resale of the warrant shares underlying the June Warrants. The June Warrants shall expire five years from its date of issuance and are subject to customary anti-dilution provisions reflecting stock dividends and splits or other similar transactions.

0.500.12575000000562500001875000050000050000000000.000150000045000000000.00015000000000.000175

Schedule I – CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY

The Company’s subsidiaries and VIEs established in the PRC are restricted in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China. The Company’s subsidiaries and its VIEs are also required to set aside at least 10% of its after-tax profit based on the PRC accounting standards each year to its statutory reserves account until the accumulative amount of such reserves reaches 50% of its respective registered capital. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends.

In addition, the Company’s operations and revenues are conducted and generated in China, all of the Company’s revenues being earned and currency received are denominated in RMB. RMB is subject to the foreign exchange control regulation in China, and, as a result, the Company may be unable to distribute any dividends outside of China due to the PRC foreign exchange control regulations that restrict the Company’s ability to convert RMB into US Dollars.

Regulation S-X requires the condensed financial information of a registrant shall be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the registrant’s proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances, or cash dividends without the consent of a third party. The condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X as the restricted net assets of the Company’s PRC subsidiaries and VIEs exceed 25% of the consolidated net assets of the Company.

Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The condensed financial information of the parent company has been prepared in accordance with SEC Regulation S-X Rule 5-04 and Rule 12-04, using the same accounting policies as set out in the Company's consolidated financial statements, except that the Company uses the equity method to account for investments in its subsidiaries, VIEs and VIEs' subsidiaries. The footnote disclosures generally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. The footnote disclosures contain supplemental information relating to the operations of the Company, as such, these statements are not the general purpose financial statements of the reporting entity and should be read in conjunction with the notes to the consolidated financial statements of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONDENSED BALANCE SHEETS</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of
March 31
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of
March 31
2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold"></td><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold"></td><tr style="vertical-align: bottom"><td style="font-weight: bold">ASSETS:</td><td></td><td colspan="2"></td><td></td><td colspan="2"></td><td></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-indent: -9pt; padding-left: 0.25in">Cash</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">2,279</td><td style="width: 1%; text-align: left"></td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">4,472</td><td style="width: 1%; text-align: left"></td><tr style="vertical-align: bottom;"><td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prepayment and other assets</td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right">5,795</td><td style="text-align: left"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Investments in subsidiaries, VIEs and VIEs' subsidiaries</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">141,456,064</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,303,978</td><td style="padding-bottom: 1.5pt; text-align: left"></td><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL ASSETS</td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">141,458,343</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,314,245</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-indent: -9pt; padding-left: 9pt"></td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: left; padding-left: 9pt">LIABILITIES:</td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accrued expenses and other current liabilities</td><td></td><td style="text-align: left"></td><td style="text-align: right">1,090,959</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">588,941</td><td style="text-align: left"></td><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Due to related party</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1.5pt; text-align: left"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL LIABILITIES</td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,090,959</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,588,941</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><tr style="vertical-align: bottom;"><td style="text-indent: -9pt; padding-left: 9pt"></td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-left: 9pt">SHAREHOLDERS' EQUITY:</td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right"></td><tr style="vertical-align: bottom;"><td style="text-indent: -9pt; padding-left: 0.25in">Ordinary share (\$0.0001 par value, 5,000,000,000 shares authorized, 438,336,843 and 69,763,933 shares issued, 437,170,960 and 68,598,050 shares outstanding as of March 31, 2024

and 2023, respectively

	43,834
Additional paid-in capital	6,977
Treasury stock	(210,324,890)
Accumulated deficit	(63,926,383)
comprehensive loss	(54,467,600)
TOTAL SHAREHOLDERS' EQUITY	
	138,367,384
TOTAL LIABILITIES AND SHEREHOLDERS' EQUITY	
	141,458,343

CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

Years Ended March 31,	2024	2023
Earnings from operations	\$7,394,438	\$(1,086,999)
General administrative expense and others	(2,122,139)	(160,427)
Equity in (loss) earnings of subsidiaries	-	-
NET (LOSS)	\$(9,516,577)	\$(1,247,426)

[illegible]

[illegible]

right">(19</td><td style="text-align: left">)</td><td><td style="text-align: left"></td><td style="text-align: right">(1,478,993</td><td style="text-align: left">)</td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">CASH-beginning of year</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,472</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,491</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,483,484</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">CASH-end of year</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,279</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,472</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,491</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">SUPPLEMENTAL CASH FLOW DISCLOSURES:</td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for income tax</td><td></td><td style="text-align: left"></td><td style="text-align: right">24,988</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">17,549</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">92,816</td><td style="text-align: left"></td><td></td><td style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest</td><td></td><td style="text-align: left"></td><td style="text-align: right">111,563</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">336,593</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">676,894</td><td style="text-align: left"></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notes to condensed financial statements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 0.5in; text-align: left">1.</td><td style="text-align: justify">Akso Health, formerly known as Xiaobai Maimai Inc., was founded on April 25, 2016 in the Cayman Islands. The condensed full year results of the Company have been prepared assuming the Reorganization (see Note 1 in the consolidated financial statements) was in effect from November 1, 2016.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 24.6pt; text-align: justify; text-indent: -24.6pt"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"><td style="width: 0.5in">2.</td><td style="text-align: justify">The condensed financial statements of Akso Health have been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in subsidiaries, VIEs and subsidiaries of VIEs. Such investment in subsidiaries and VIEs are presented on the balance sheets as interests in subsidiaries and VIEs and the income (loss) of the subsidiaries and VIEs is presented as equity in (loss) earnings of subsidiaries and VIEs on the statement of operations.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 24.6pt; text-align: justify; text-indent: -24.6pt"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"><td style="width: 0.5in">3.</td><td style="text-align: justify">As of March 31, 2023 and 2022, there were no material contingencies, significant provisions of long-term obligations of the Company, except for those which have been separately disclosed in the consolidated financial statements.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 24.6pt; text-align: justify; text-indent: -24.6pt"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"><td style="width: 0.5in">4.</td><td style="text-align: justify">Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The notes to consolidated financial statements disclosed certain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the accompanying Consolidated Financial Statements.</td></tr></table>100.500.250.25CONDENSED BALANCE SHEETS<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of
March 31
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of
March 31
2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold"></td><td colspan="2"></td><td style="font-weight: bold"></td><td colspan="2"></td><td style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold"></td></tr>

[illegible]

[illegible]

(15,395,414)		7394438-1086999-1372064321221391604273129090-9516577-1247426-16849733-238985-21983791454319-9755562-3445805-15395414	
CONDENSED STATEMENTS OF CASH FLOWS			
For The Years Ended March 31,			
2024		2023	
USD		USD	
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net (loss)			
(9,516,577)		(1,247,426)	
(16,851,064)		(1,147,003)	
Adjustments to reconcile net income to net cash provided by (used in) operating activities:			
Provision for doubts accounts		5,795	
Equity in loss of subsidiaries		7,394,438	
Share-based compensation		13,721,974	
Prepayments and other assets		154,654	
Accrued expenses and other current liabilities		502,018	
Interest payments on unsecured senior notes and short-term bank loan		528,266	
NET CASH (USED IN) OPERATING ACTIVITIES		101,207	
Interest payments on unsecured senior notes and short-term bank loan		1,147,003	
NET CASH (USED IN) OPERATING ACTIVITIES		1,614,326	

[illegible]

style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92,816</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,563</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">336,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">676,894</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>-9516577-1247426-168510645795-7394438-1147003-13721974391625-154654502018528266101207676894-1614326427843-31584981393398491001720010000000-137727716-427862-33769520000001612133-4278621679505-2193-19-1478993447244911483484227944724491249881754992816111563336593676894 500000000500000000 P1Y falseFY1000201000200001702318true

-7=+XH=H'&HWZPH*JU M_-BO2/P(3@
0=1%@@#5"-_#L("Z4>02%*WWU@TAX7&L"FIQJ,IX+

BZ@M8#L.;74-%G0IHNI@+I3#J'KW/\$RQ?N6IUE.24PQ YDP3I1N7.S M@1>8U#S9HS< AI07FC"&0ILN(>%1MX8BQ-
XSWB@CDIUX*NA-ZQ#""KB44@' M3Z2;8"X@T>K UPD&\YT/D\$4R3I"TIJE8V1_-D=75*.B_K97ZD798FDV5AE
MWUUPHD(>%S?G)NNTJE\$X3*V^BRN.[#7(HY/8=WE%NWWFSVQ>=NZI0VE075CB(HSLZB\$Z_-06H4G2.
MEVZ?I3O/V<78BCCO==JM_UNW!8NW3SEE7?&F>-C^VO^ C3O/T6#2/?^OTVMU>
MY0:YY/TI2/,R-ZFS"G@UHNJQ*V#J#42;LK>OUFOI/K=UHI^3C4_O.I PLO;6F8DUI%
M5^OZRA9A1U8S!;N\$TY8=70!Y9I*^2/^V\$IO/4C;&Y9MRDJB%E%5*30^W!\$*O MYGCL@?F+?VVK/K)W?/
I2I/LW+C&VNE:H&G\E8"T)C=UF9;SK_(5P\$ M5#>LBJ/SEC@!\$?
J81*XJM3"KRG1WBI,KQ^VV9)X.GO(V(QJUUI:T:A68UK1Y MO+GAL@,LUE,E>.;7+4;Y7
4VPPX(XRW+G'8.5UF9@F=#'BKT M^Y*M(B25%IO;(TL; 3GN*""WT!6(ZMP;4.EH3H M<
LKP34D0.VT'E"XU7/"I>F* B+.,X&0Z4/PIC'^01BKT\$:S&6.O.IYVC M(\$GBO.RP(H^N)D9,'7WF75MA
87+J*T<3!TQJ1I9>8,J89<"N^Z%IT.C<=" MVCZ6E/K1DIZ/2W>IC2(#_I<%+RQU9=A@|SRLV1,IA8"-R
M28"#Y!.*9DFTIA#AIM,%Q2C+>DP;RGJ&+>21#?RQI)VS(Z L^68P5P? MT#-\$YR/R)O)V:QIA'AFIHP*0E,>O7!2'-
@@^55D%\$)&IVQ9#7 CFS<3-M+^V(0#R8Z=EZ65 MTU_@I3%P6)BC\$B;IN)X"^CHAZND6T,&LJA6;-J>9M7YW"CA*
("3DO6#L MDW_**3I+G0+EI&4F&F% ^P1!C9M!X0+R"LV%(\$\$= S9@1P-PDKYY?*M;N M\$20+_-5?G-
LK!Y/X0X"H"B36T!H8AV\$KINE4'HQANO! GO7Z#8EZMZ5+YH!:=BD M P=NMH18@BH
L2\$;JE@DNP<_V^"718U_X(\$4'ZN:HQC5?7+JH_ZN2E12) M!_O&P;OCNF_'BI2G71+9W2RB>(PAQ(Q#Z="Y#
(^IT&I>O!RKC3'/I@5@KG:M; M;IR5K?#RU(AGXICZ?C*U*/ #X51-#Z'O\$%^DJLKLPMIS9)B_H=Y.H;HS(<.,XZO-3I#-
CHY\$5LU KA^A>?4.IE"C;<(28 +M4ZN33,"/I^NAFP:5<3FOI/3=7SWR4U1@>U'(NXD3MQ3V=*2-
<3\$S;Q(YK7\$6*+U==WF:N7^B)KHLT<5RG=&=.,\$@V413:L56;V>WJ
M;I0!#4GCAI9Y297X^MASKYV5GDI*QV&NXL;#332.NKE2GR(-IA M26ZLA;GIRA(OT9:X%#CK%!'JA)JM4&-
KJ^ZI20*Z'>A3=&R@I(&6;I4>.\$P M;"B'8H0=7%+%+I6&H!W&NU8*CG4.7(-0 R\$!144,4S#2.=8GQ\$99+W? @/%;
M4R*X?=T:SY+E%.)ICEI3V,%WY';/J/V\$;@16.5CB;I3@^ 'AIE&IS,<#PIE>93P_M 4MIC;A0EISX6\$K1 L)L^7?
X+ZB+A#>M\$(DXM0"T=35B<"T:4X-[@1I?F' MLS!A3)Z";7W5^H2E11R/IGIU9Q&W.@+I=R@&G;9,G4IZ&R<4-
%LAYCU>%-MF=-91B.\$EG&*I(+=("8EQIV!%;%'HM4R!H#* &WI-;=S!GX";2KTWF%U# MNE5!DS?-\$
D8B7";&7#^PPI2# \$Q;/J^8V-Q17SLJOX!@.R\$Q*16-2E0K+DW2 MUAV@X\$0!H26PO(AT3BRL:Q%&#G!+K"8
J#64^M-BVM9DLIB<I\$9C<2/BFL M=@K+ '\$2N6%^B=ITJXW+D)BY^-,1^(<;GC0X^N")W@A!4A6?LE".FI(LLLRRR
M.WH\$2H@XAMAF*?9"S(D=L%";,WIC-Q2H4IM!!JDV^I0Z^#I)->+64R7'(L MZXI@,0W)I^4G;R91"
(I#N^#;EB^E@(/-&#)JOQB>_3SQYZVCHC-(I M.21QQX?
4IYQO=T12"ETWRBJE(C/J4ACDSJZX%IT=N>2/09H04A!R4K.W8_-/ MT?FAXP+...54->./0IYW!2_0MCR50)=Z"!I;ZQQ=-
EOPEW BR=5#"U"7I_-&+DELUAD4I;0UX4D/\$7 M)^8+RD&4XAS6Q@L"!I(>N-ZFD\$K+ QT?JN(C3XKOD#
(SPJ1.R*9+3WK.S9 MS=A"/(Q<<=>5 MG0;)DY7=*K!Z3G5I#=#9Y\$P"MNQ,3-8GG@JGIZZ@BU-\$Z\$+L\$E.
(L;F> 2Y@"- W0NI2@^A8',H@_H_*!QT" MY0I78MP6^F>@&E;ZIZ_V98!+%S5\$=\$U#IIVM=LIV>-
*ALM(RH*81>6DU-)U&MY.1VCP>@% M3=B!K"(+)UU2IR7KTZ41&*L6*.O)G_V<%G+XW\$M3V#LV-"/F"4.5JRX'0
MR;(^<4HC2AT5CW1)*QFKSDF0/866V/C 2@9'IH^U;N7N+_D2(S2_**87 MOQ5/&||RS5L3UJG6BYJXA>UHO;IL-U
WXFG||X19=X;-O/(-A1EN&31 M5MZ7^XU)##>CHAE-6&S(PV;5T;=I9D-DJ/0=*Z%UJ'.K+=C!QF%-Y2
M%2F,2EZS8,YG!C,0I5"0,=@L(APP?R!I!IQF.D%)V^#CGK'.DM_Z) 5-'4; MA^>0P,(TMB;^6?
V"YDQ=9%9&H'16HJ3XZ8GK\$2,WI=R*W\$W=)Y9!23P&>9C MF,J%(FR896\$> DV^J3KZ^C056:Q4>=N?\$(YI)>+>R
9PUV0#EH13#JS@(- M5ZQ)*HU/6<5CIE9 &0\$1%7!N 55\$<0F.'6I43LF<6LN%*=2;B\$!0;J08@3
M+N<#F5;/Q4;-4(I=0%TEAVN9G80W5^2)H(CDLB/V3JD9I;8G;XL_*Z-5# M;
<"J8U34(?)%6F%4*0+2V*,KIPTBRC'^<7%^PR?#GV5)S+S*!K-UQ)->I=H4 M3K2 YX@XARS9#IG&O^1UEO;?
1^ZHI\$4V*J0_C/'=Q)YS(C9+J'D=ZPD;W. M8)DYV%V5^Z-1K%J1L8_-/28UIHTHD?";I/_94BA5O@JU^(SI
%OI4X&E;3@?C(,E MJ;HR*+U2Y\$2=PFKC!);7T8_-/I?E;F(5NTD;7\$QN";M8!8EWLM3BLUH M?
UP>KYUF%*T9P&L=83WIO2C#;ANH@4W/L1HX07XZA5.5-<)C67>+E.#F
M^EA*N^0LX&*HAUDRIH89I39S^UV.^4^L.N!=GF;>X3@E-OHQ?XN5M@60JHU M5/)CJ>T19<=-E+SEIHH?F.;G;JG
E'4G+;"GYY,P # (WN(D4KK7F9@VBO! MCZ7E#,*SY@YI2QMK-!FC|<^6/VF3.>QQU!9*R+\$25TL=7;^DUNVL>\$Z8
MRX_1ZFA,0R#AGRZ>2N8JJ)1P!Q!*M_Y,\$X 7E?Z1R!#Y@/_;^JS&&^G^;?6ELCYJ7RVJH(CQ1NLD"K<0XS
M4*W7K2T3I_*I2I09R+QE-/#K7PMOANGHX5Y8Z82I&>>I M4'L)XHZQN6JZBZ-)
(OFI!^NB@,GMT0.7+^*BIE&>.F.V-Q/F-Y#961 MT*9X2YL;I23)IQ*/W+^51X3YI00_-)2"O<#_KIDO1S=G;IS^.#'I
MMZ#@QI6Z=-14^PWC7C9JO@(-R-DI3UY4G6V2E+F494W42)G5F%2NYEF2\$LIXHR;B02E;0G-YZJYSB6?I!QW;
M8L6QW5^!<JECIWH\$H.2E41Y67JY)70<3*!#I8(RX0?I;2#;5;(LO-E% SI?ZY)*,L8JUUDA6P-
I8\$BH60D>YY);Z"80K&'4WQU/GM<"YX1 M#J-4)3AL_-T\$Q\$ (3;_IS@0S^D#93_DJB-2L?BHI;H,K4(U!9FA5LFKO"X
M/5)!*9W1V%0%B93_-\$+D6<6;R-6_LH*BEB+&CJ.6M5;7&S%|E@&F;UBC!^YG
M/I0X@!TKI^A"%@;&VNGFT0HTS+JNG5">3SS\$".LXBO&X/^EB4U1I. ZWAKD!%/8B_HJ\$X3?+IY590
TKE69ILJ7E70'U6039I"S_Z><%-^BX%XS3L_.Q5%+IDYI2I#EMU)XO.MO.EPQF#Q;(<)
+AA682J<_V5R&N;A^IG2^IWC@N2Z6',# !#;R-F+?8XI2 M B#I7\$V&NSK5!MLIH;UYN_'FC.8P>
IP(AX9_9.7UJ!64I%)=Q2M)Q^_M;A!A(A'41.9+%1E)9@1-OMR4KE"5K&ICZ\$KUTW0WV(-Y4C@#"*,M(HY&(N
MO;91%Z7G!_F>EFX*Y.E!7_-TRG?%|/BX\$ MSLD)EBH&J3IE13^T-J*20A@KLC;YUHC5I69:F4-8;55M;"7M#9
M6"!8VU P^-CEO;5"F6^J4_.Z4.9A%53=OV*WML>BJ#ELZ,XA!M.8V;75;V(VO&5A;D MLZ;EBCH?;#*IA7KKAB-
EYUG0I5T&38J>9LQB?4;CH!69N3I8^!H@J(<< MDR#CC7!^L2!/J&L^Z\$T1.LHK8*B30G4NH0LOJM!-BSFMB1H-

OUZUH:74Z" M2IFNK ONQWK NRSZI9PDIL:*IC%.*#E#I? JW33-S44@+-EN?2%I=&R8YD' M-
DM(>/1Y0<*/WRO-.5D.=UTZ+:NI+4D^="0%,I\$7!4LADU*+N2OEG3IK
MTY%EG=:S.6!>JF6)NZZ5C9JOI2^)ZSQ.UHE:60*J955(K3:1- M.LKM:U?
GY9%Z+H\$CLF31%K&K?/J6DIBXIV/EWZ^IL3>Q:CI&X% 6"++%)%5/ MC3;1#^!G5B5RABLH J94\$F1Q=?
YESIUD^3<="H73":^J*OT I0 -2%DHR=(O) ML)OS+^L&9:0-S.:G@9 QD@I>=)=37IUXUO+274*67@EN'N:N:~?V#D2\$)*8
M25ZU* 40.'D)N529M5FI:++&.=L!9YXZJYGCGB\$B8!UE0B?2:B72Z9F*GN=0^2MN*:V5E1%1:\$9K#)@56+H1NCP
M^=KZM*H"JIK4*B"58N)4EK%ADBD443'CS 6-R (LR I0.141)NV.5(T!@G>F M\$ IZE-#G6,Z0. F'W!+JHMV<-
Z4V&*RM-%!["%<1\$MSI'4JB6=-/K!S%NREO MARY8&0X%+^2&:=D:2Z"S9LO/<- UQHJO9Z>24?
G51.7^6">E:S2K5:MIU%97P-M^T:LQP8:OV=J>LT&DG-4:.*&1-N3/C4).@JS7UI<7^!SDD-N%691L:85HC
M0_6IN9(69#6^VC)JPLHJRKZ00A.I/4+M#XIEF%^&IF!#"MZ/G>75BTJ>AET M5S@RG*F_2-8OQ.EWURIY!>C.J JI2:
HJC%74&4_HJZ!@IMSXB7".<>IY:+(Z+J^N)P2PDB%G5%EAC.IQRUBZO>=P#
M.46\$N2\$RYI4V*Z(RYMF)X7&Y8G.WW\$WYMLYE^:8ZW::#RI/J%:8JN(&K)K#(M\$>G=:/:
H7D.HM=+.,&24&HPK=):.#?CS<ZHA4EYM.TT/C1^TP*Y>+=?. MDT2N:8#A.\$K9KIO.6:\$VR*!%RHK4ID:B+P%ET-
^&J%RD%CORK#7*<=>L0YI M!5I6\$AXSS^NF7.1L6H5!B\$C.C7#KTEQNM5S?BJ+62@U?I<(ZNJW#N?:D92V!
M=:S\$:M=NORF0>^HYZI'5LMURUN4.V%SN=*[U+IDYXHN4Y:2F._RDM9EY=R
M5.6EW*.Y5Y 4!\$3)5JRDEUT4*0!#SIO#A/GZ:>35K/YKH#I0)42N/1HK6 M(Z6)S#1& IN\$T/5DEN7
>P!)ZC\$'XH?:Z.*KIVCG+ M)IW&12V!ZY!9C>9#"J>/HUP!UP>E#!++?Z>:MYIL\$XK.GD39?> &GJ5+M
M0CKRJ\$**2SHC27.:4:T@.QKG2*&#"LX!4+6XG*)JEOVV)LX"V0-B!RL/1"5) ML'.PCG3-HOI6PU+C.5!8R\$^5
E.6J3\$X"7#2@KPYUZL:515="VSO.^O.ZF5!TV34MI+!D)E.5.\$@VEF1=8W=XYIP!2J#)RIK!@<:
MM4J55YN&23LG042:3!@28/M>:DTB94!JV*.4M5*!D+H1.7-F.M?TJ5=PSI.I M2J4-D Y5LK&A+F_.MD2-
<1W1'+S1G:%!Q!EES%/^A@MC@I4Y(CRF>DM=/YP
M/.PGU>IE+L*S^8>&CA9J!@W928R4Y/(!9"FI_X' \$!9ZV2A6R=3WP?XO:FS M@<I@IC/E(A3?
8&L).OOC\$>0>ZQ380.1MJT^!-\$-7AGV.UO:-SPTZ:DTGRTQH-N'<[B8S3!BOI"! M@MP\$)V1.JR%:L%RV3+%S.1+O7
/AZJ=B!52G:E0Q<".#+%O*!(J#F?=:5D MS!#MAJ#M+N<\$?1CZ\$!Z@)HD2_.,W:XA-FB? !S!FG\$@L!UJ@BA/9(?
<-TM.*Y)@.I!\$*FYD#<#B81GY&U?GDI!> M>U8:9EU+GT!
(N2<4=:M<'G.C7/5OW=:*J6\$78AJ.9<(G996IDBJT+*.RR!> MG!?
A.@4IAO68!>S+I2WFG.1T6:4IMP;AL)Z%!7H6H">>'2L\$4R3GZ MA#-
,Z.S.:KQ.TU3C9:6V\$+5G:KH(0H'G%)N_.H++Y""")@2IGM4"V".R' (M=1R%5@ID7:6.FDKC49YIEH?
JY'S52(3&:>2V<:V9:6N!P.I6/'6BZ6-!Y&2: MB6P=V%.R70G>8H")U6=LV!/\$2.*+Y1PV<^!A!5.%=1U.E"
(+"^5N;I'.&JK69#>7IHVAE\$E*,L&3PWT01K^MFSL'.CIG4H5%E"LLRM=4VLI%/LU9K'%3.A. M45 !: =J)CQ\$?
IW>0!80D!NXEH.(R:+!12567-%(H=/:OSE*^4UG'5DF8: M-=6PBL.4JC6CBG^OOXJUXUQ-
H8QIH8QXLIJQC&/8APM5!WB.B.AUHRIDT5? MF1HZ>Y>J^L^B"3"@ I#=-L0.ACG=B!X(=" 1(QU &+J!:=3@' _&4M"L.I
!R MJTSK'M4OAVP6:Y.8 -Y*6! J#JIV0 =P"H84:~?)36ZDXI#-.OS.NSE!V3 M63-"Q!>ED-1%T!@U/6:Q %.NIZ?
Y7!7OW7!AZUR1C+C8E%C55>8O/7:HQ MU/+L+Y.2Y.B?
V5X9RIS'KU8I.7K0.=BHFH.*+&15#.>9VCFPB\$NL7CIHGZ@0#P6K^IO3(&GVJZC=E23SC/ECS0U:(C8L1-U'3=.25A
M83@CIE4/ZI9AD'I3F_JKK(>003#.:LA94.74(NH_.9+*BG&#F=:Q/#@+P)LOCT6*K^ MPH /71D
'OYX&1450&6!#=#V6U)X6W9.%5<@HIV4VW)F8#OW.T7M!YN&'R_SX M6.)72OYEIMW8:\$37.WLU*QJ'PV&0-
\$GHS4"WK::<^DJS=7TGC\$;1GS\$EK3 M^V4?ZWT5V>SBX\$MZ)M!&'ZNZ:LS5/FI=#
(7K=U@0.&PX7VFH)8'W@)JH+=D M&B!\$N\$P&.:2FHT4C(7H.W%^9LIT 6FR4:>=GI4R+E91IY^>D3!<2 M_IV?
FC)NX&8*Z=.BJ64:>0<&A6O((I#8B:"KVU*.MK61Z.=0J-9YHD+@S_.BY9 M)@
<56FF/4*+A2C%_FSAJ.KEN8N_Y7'31VF*YKFK_5OQU'NF>V08U8OEKO+^
MYI5KYFLH*_VK(6I8N\$NV&LD7X>2I4UCNQNX(I1HA7%+EQV*JTG.SV6_'UJ7@ M2@I OC9D#K9.X)UTBS<3IF^E
^%T6KL+ MA6KK+HZ/82AJ!XY*93#YOYI!) 10M'CTOS7R.QO Q\$EW@/^Z!^J_ \$X2!X MA?V_8IK"U::S!!"JER32Z^P'= *
V=ZAIGHO?4H(73KIV_!6&! M5L%O4MIO^GUX;OR.0%H_HDPD;R2!4AJ'W19/#T8/^H=G#XNG;PXL6S*YIE
M#;F:NG)L_P\$APIL6?"2_)FIT3U_NP2;O?T2I_!W3QMP8O@7PI7X^\$HOL&1' MOAPGZU##?HZ:^^ \$90>G)UQ:O?
S^K!^T;U^O?7UP3@/Z.6?:7S*@"M">>#? MR!&I^%3^_90.3?WD3>\$GZ@;AZ_JVMAN>PM/P'7-V.HX.%4)9UU,<=I
M"M5RYI+ #9KES!)#DSM:0MOQ0:2M#V23>ZC\$7CWZ7C_0Y&2+:-DE" ^E'07CR M_C1,9/SV-
E:>BE5WW:=OI.KD+!\$@+NM)!599HX\$YJWK.7OV W/>KR+OI_L6:
MK!UHHHAQZAX!2ISG.O1T4"N28^XPJBIU5!BJ_#Z4Z3415NWM^40R>7IK<+' MG<3^@Y^\$CQ@"
<8S!#DRUM"SE;D729_9H@F#W2KQ\$TMD JE=E28N@U_N3T MINSUQW:LY-B.DCA?T*&HQ+?H.6T/BQOZ9C2-TJ
<HJ3791R8!< 83L_W2.. M0'PU"<4M=PDKBTZ.T4YL"!PZL!#E%EG:E!EA21TQ-W5S15!>8VE.6&YJ M-
F4N_!K1*6ZDN.G!+PK_J:F93!ALV831.:9G#B?TB.5\$%NO>%0!J N\$Y.Q+ M9^H-;TA53WL!9BS-
_2B83J+J1=D3'\$Z:WFL;40:IU0::#^%K;I6@LSNX3#/49ZJHO;J\$B.I:)@ "3T16-C-5? MZR;.)N.**BI-
_3\$W8Z#4_R'UJ0=K_YE.PCSEG/Y=-0LM2%Z_DZQ3)+P!HS MPA&U."I%255G*V=6%USN**2FE%K%YH4_.4?
GM*WD5:KN7D(!+O4:8TH=5>* M99AF*^1ZHINSHVS!99.%JYHOY"NO5>L)/GYBN!G:T=KX\$MR=ZE!LZI*YC)N^
MQ?XA\$359'729XQO0<^B9I#K3IF1.I6SAS=0>9XF?<_TSWD&5U)3+>5!^:5) MD->MQP
/5"KJHU_M7FB9Z.EJ8RBO#RX@T_3*1.65H.D):_GTC:7C!2;WB:H%:H%QJPEH9=-(H9XX\$HWK#:#+A+%.3(C!:'A.Q+
MG1F+DT08XS&X!&SJ>GB_.MH!^7WY'CL87 F<2(U/IGC@V>>C_>&%>:J M5_U4&=L9?
1D.HLPD"P5=)2P)9I9X^L! M2*I%CE8T'TH!<_AHZ#_6.0=1H4G(Z>0IT/!(<%%%UC3GYEI2I9JK1G?0<\$ \$ M5JT4=A?
T4NZ3@N61 UE20Y.3KG8 MC(50J@2AG!GHD\$_.JC.VL-J\$!/*LI8>/SLC;7R2W9JH:I2U41=?E6&)UB9! M5"L^FO6&
R:%%@FNQLX%M_8N7%JR3^M87WCO=I!B!HK"9!952_V!""A7 F ME" T_:R MPS\$N+&+F6JW++
IV_K92:ORB'9ZYT'B:5/O2RNY3D!WVTWGCW-CB:AU&%?28X(7EX'9>+YJO3@!_KU^IL5?+.Y MUB'?DS:%J"V_GE
7Z!T=[EB!3M9.:R/HJ!_#QHG9K1Q-.2"F!O_'JCOY>W M8+?&C:CUN6BF6!_8BC^&^?
=++9K323F:TV\$QS*+E4HHX%2H4WJ+CCH5 MVIR6! FVJ%MGU5<+!BFCTZ!|
D6CG3XS)P#/\$HFZ&QDFOMZWT0!\$(&?/ M>7%FG6DB8L!V!HSN<)C.4G:02&N^L:84J=^DU8>5_6(4=AM+^"OU?
R'6@DOE M#BHVW*Q_#WT%E*YU8!AT"+.7SF8N=V.V+003@IRIB^&GJ*!@H(G!YQFMU).69 MIV3C26Z6Z8V!
(7+U""VPNO@C3'4GW2&0'PIN_-UMK<:NA3'B);UAU1!69:~!M.9YB@5.7'Z0?+@3@OAN3EXP\$788.W/62R
,7)TN1I@#BG%A5/6GHRX1 L TQ M3S;E3HK!.Q06Z*).L?NC0WT:J6P&>D^L^C'Q\$(0:6K4ZRZ;T6.Z*O.1< XF0
MNYW>KSW1:7INJMO'HC!FSKYVG0I?>YW3=JGFI?HG-Z_+77I_IQ4_(D+DO3 MN*7.HEPYTJHRAOJE!N65N
9=+@GG:O.\$ M?S=>.#!)A+UL@E87T:W"0.1 @A@_.L-2)O>63/=..7> MQ*QE^*2X_IJIO#Y.GW
M:MHI3ZGN4@.C(KH1W0=E3H>DE.*!_G-9C:(2@)C#L(\$=>7H_&=-S\$)0S_Q M
*00\$WSE=RQT1Q=OK8P*JAE87>"8R#)666WC/ZUUU(V8IMZ6CF9YCR6G-M0%G<@PP53R0!_J+W57A#Z#_)
<^90YK2I%C3<5*K:0)DI2ITL28!B!5-V+ M1GN8R.FI6C2B*^61'4#)!E5F6U7! 6E-U83:E<4=^A@_B(U4.Z^P.B0%8/
MZ?8/B!F:..05#O:J6ASLBFI.1D7K3TL:3*QC?<_/(C1*PC^G!I@WB".U(M_20C<CIG9\$!9Y&&X!4LFTPY"._!H6:>
F3?!/&FNX%RX"3HA)5>)S/IV! MQ"M9%.:K0+UM. F&3:~#^("E4PKP2YML5YJ"KLIO1HG.!QE(&IO=. T1OQ)UY
M@2=1J*_.XL@Z4VM'.S^QE\$#IL_P3O:X^RJ*_6Y1F._@6Z?U\$A3KK-UUYG5Q M*S^&^#0:COI9RA6U5XE5E=.X\$!J
MR0R5(V931H I@!@@(*ZG0!SUL<^FAVLQ*^!_I.\$BE:(=K*8TQP1&PO.Q MN4FF0UU#4JHB!8"BCSH-LQ_RJ6
(9^=SA'A\$!#3RGBI/JQ"RHUE?MF@TU5 MIUN5!JE^308W9O'DQYFNL*2G6I8I3Z\$V!SIV;LD*#:OI)YRE.T9!_#XR>1\$

M2^C+S9NSBJ1=S*JP-F%D>\$E-&\$>T7#5URRT<9%+*6%W#>6*&AXB-: !+ M.I(X"<<.&J&VOIK
P(C+MEHK\$2Z,Q(E(=?44EIJ-XEM7I2<=|O8C:2.+U.X M!X6"JG7\$BGO.#U00\$BW>Q>ZD".OYN-
ZHT041'R=>%Q0M99R7I0.(>"8S; MW.>E>^2#N#RF_N9>2-9*5W^8W 0K:&3"/0B;T //&4 /D+L!\$#R'&TQ^E
MGO#E34U\$VJH6B;NHP\4.E:U3,M5@9I&QCVFQDI:/TIZ"/Q\$807G+!)E
M^HZQ*QIT4)1C'K=UB1)5IV?^K14E%F#Q067\$HNR6 'B#&".VUL=6-FNPUTZDPD)4 MYL-
9U>^ND/%5HG3F8;U.-&V1=>V:C(I*J/Y^A+ #64I469M9L.'+R.D+I5H.
M9@93>PI05(U;5+ "ZIJ" QI(9"%ED(W;IJ^!MA0EV#H)8")00'/\$IAO!UX3 M+IX2S K>%>)HI*JX^QDI\$*Z5I_BBRE-B
MU^1^;?6_ =MMWYNAC35?&@3FAJNO'@Y#LV+ TZU=16B*54E"\$QKE)GI6TR= MN=4T(L:Q&WKH9;IEO)I.G?5\$U7-
:0FJ Q&W AM09">6LKOD=@1@U19/%& 4*M=374.PIQ'(AII.MA7A!*>-W.=IQUW%5Y3JKO "ND!S!PXNPK,AMQ83I
M!62A 05.X9Y^U#*P;-R,<@OEAGPMKU\ D>GHW*,XLOI#B!ESVJRD!?:E;>G> MKRJ"-_WXXQ!BRL
MOUM.Q0T5L@>O4-/0K+^^(.)T.D 363R;./ADR#!^HR>Y3_(F6-:WF MV0?
=T%1W!@=8@E!4C=RP=1H595_K*!+ZOAJ@TZPOV7@ (DOTSI*+9MEE!^,ME'5(51ZKD43!
(\$2:QS"0@>1Q7&/N:/>!'R+Df2"#>1&5HU;.(^XIDC7&DA MX0Q91.J4"X*=QRKDQO=14BK1B6H)F\W64(=+A-P\$"6&?
YJ>35A_\$(8#,<2I M-DLA.N3P!DUK5!8")%/H8!=A!\$V-%*+QC_D3:U:Z23S35O4(=!8"^Y!:%X M& #N2VSU;_9(N>K&
(->OFE('U:9X M#)GOO4GAD N7-0+P6O<^1^1^U#OYX,#PCB" &1"#<.C^ZA! M?/%G"\$0,BP*%4HJNT@V7FEG23&
>984I_TV^\$/0-?@1GM7,B+A:@\$.B:++M)FZ(N_5D@&S0!)?PLTIARL->NU+5!%164US3Y;=BB' 0:(C:IX%+4+\$%=NT'
M<'#4\$S Z=&<@^0UH&*CO\40^V%5D5>MEKB#=(MPJ=,1-'^@7_9"KVROF4N4F M\$^KAN)Z)T^FN@'G-
9/W!EQXZIT">Y<'G#KWH3+R+@RIJ=,*ZQW! "@N^7L/4
M^V<^U^4W/_1E06PRN(BJ;5+33VJLI^CWUG?;+!PM3\$03C2WF+ G6"(XBL M.76-?LDK)0N0>I?
4:K&43=;5903<I0 Y8VPC/0I48L1LYLA=^,18U92.N M8;A>Y/JE%2E?
%_EOI%>A_RJ!N8IS(P0G6>4<>0V6-.N*%*IZJSH9(*"M*ZA MIC_DE%36JW3SRE0/(5-).M-
RSG_I(A!+FAB_HA/^ICI&#=#06<6XRU!78 M>)9ZX.>GZ=H2KWPSVJ@ (AYA_<#;.-K*B0A;:=%=E2A5?
N,LTIT#XY\$*F;JD M15)"@BYM&,\$1DBHX 5F(+3-#XW16;F%K.8/YMB4IFFUJ>9D"K^I/Y7K288 MH?
ACGG(M:D_B\$@Q3%^)Z#7R56*VMNH(!"#LTH593D3_@)\$T*!=(F@.%Q:1H?P*A".1'GS=YQ!UJV M>BIV3?
\$R0!P=&0M"1IOW.I:0;R: \$<<2>ZD%:I:YZ^9K5 MVT._:9A=3R0PF\$M-P 38SOE>:.*K11-?
4LX(C<&KW^A)6CM8^KAL;_7L MA*8=(P2C=4H#W!;/8 HB^GLS;REPP '.K-7AX2&S+QWQS3N2*ZI5.JLFWTN
M^R_G@4@&-6+^Z-52J7W\1A7C\$MB_ITHO6 MMM;5+WM%:%W>YW"9%=E/SU
X=7*^IHUC=LE<072R2E_1MP/#W1>9+ISI?59 MB=%Z&HEN*YS&8;%RPP#U!.2FF.>-L
%6_@8EA<@MP*9V#\$LAEL.P+. M.0+AS<IX0^P.CN:>1209'# @-B^ZG,Y(RSKLIYFEU?=(0%QFIO81E;;Q M
+F\$18"3ZT&5V.FLIV\$4:D%9HR"X5XF18T-3&'\$E&IQG6IT6U<,'B93:SQ MH*R#?KN0JLX"?0:W&'JL_I-(C;_I
DIVIOED4IJOY/DBAR&@;=5%9Q" MU1CI" T=S:%JL%>EG3_.LV:P7\$TXIDX%+)#0IM7;S2R4K7/IL+6@)HA5YB
MA*CRI.\$R%IF8X7%.KF>1&7D.2HI%='F'3.^F95")%I#G(M9YE&0I_YSS.%5'
MRJUON^>QGC=5E>HWZ_ TJLIR7)OEV*BR"1^\$IN\F/I^1Z0.77&5 MY'?*,D+
(DKJRQ3>U5XQ';3=0'9IE!\$O.TYO.7)5GDJ6%82,1+N!*,87>TD6 ME(0'01V6-2Z
(4&LLDPV)BGB%J^OJHLLQJTT.WI<A9Y;_.'SA\$21(W/;@M.M:-(1_3ID-Q4/<47\$IR;5.I*!EPW/"D_U5Y14Q\$F*
IS6OY#LJH@NJ"OPO4-MQ?"D7>FTBIW(4W;_DFEDQJPI@RD-I42"N4NIM46KD"R"=2K0ZQ?"^5:LX
M+2K7M8SS/9!R17=XFL!?!/Q"O@KK)I6AC\$^EX^U(W8V-2NIQX"0Q%P&MA MO0LX523A2E0M#K?
8#*&BZ(JB;UA:I=HI@L9J)KT4&REB1GJ8QF:RF>YX0U.) M8VSA8A(L0-
*3IME:R!7L.0'NJ42NNDV/U7@.YV(5.O+\$IW3ZFY2CL>\$3; M5P+FRW^IL_FDAI!Q-WU5@Q-
\$I5Z)H+1HH(#Y(KMV+JHV\$FKC8YYG&XP MC9:M5UUJCT\$U!%215;BH/E"ZGL5TR2KVS@7:1:
<^JLH8>,>QULLDJZN0IRG M49R;.>)-N9;G7>P'OC0)J^XG3C_LX5EG3OK2'3FT*#MF4",ZU@-0+P;3' 2_Z@-M!\$!
MY<6L0^B\$!*M%\$+;JCYR?1KE8%:_I4A(MNL;GVV>7;87I'=T+AE=940^0XS77 M5E1K,M4G>I#5A&BQV;"2(?
0"=J=JT::A!H;#DJC+^@T7-ZOB"">SX4V; M5:D+5JHP/>40E4+U!-@+CPBD5LN^&1?>&%L*8KIQ%&)2\$7U/S6\$10T")?
#;H@ M.+?"^EGV(0IXVHAC+XQY?FOJL/QAR=YNM"^EX6QS;U?>5!8P%-!%IO\$P M.LA5;/>10R5%X\$5V5FU-
9L^7^&M/2^F:3FKV&IPR L:E0U4D6#CE"6*0\$ # M).11#^CMD0^US!;#8V;BT4X+?.H3-K+^50&8/9;2)"N M [MB %T"
<,%8 MRJD#JX.R*W7@X9%V.YABJBZ;ABEB0>J.(8Z6;-?(0X8R"(2SHA(*VX:3(- MK8D*#HDAD!/6@E6;2)IF\$C.#
<Y'Q=,KLL0.X;I M.M1%B%>(O-G@fINZ)G/I\$*KZ!/&?I'==+;7Y=I3:Q36T^J%*;;X3-MR21KG#1 M.;U(I*IL/UPEF_?
L!4IX#\$ \$J&"DQ<1 HF#6X9FG@D5 MTUR ML=C8!8^\$P\N9N7/J8C:10DL8R9?8C.D4.CO<&G92\$N2-ZKIG6EIA+Z
MLC9=6 J84NXP-0J4+MFI\$V&Y?%;CJND^OJ.^%#(4PV(*<3%@F/<)^#^4Y=2F7UH!5D:8D4K;:"!
MY40N(XJ.ZIR/I^TV4X;9IC!^I@%2.NIOI(\$=Q5" 0=42UL;_HH?#DY^\$
M9I!8/I;+64NZL;Q='2M6OG;V&KR380Y5@-4^4!0E;-R;J97-.XQ*#0 M6#R0R(M40L="&B)BSE5"1@S
K5E)H7+ #Q'3KXG=9&+&'A&3RI8Y2\$SC0'K" MI?FH;31936AIY(TU26T;+B1L@?
K6+*0=L.U;C(1L>G5^8AXEQ&*BPS0I4N% M+M2I\$8@ZLZ!!?>0X5E6AIZ5G_)5K\$QYSI**29#(-&U7"YU0:-%5I4:+\$J
MIRIM/ROQ*IFLI4XVIXXVS3IG(9M-G7NR+X^&#;=M;MLWH)"U/O_#>>4E0I
MCJ4I5VW0XWT9Z1VLYJFRC4L'E;*JBT'!Q_Q;+ _A>OYFHS*7))2^IE
M#5L%)+E=7(+Q04LA=O)O&Z72MA1.@9GJE>O-YJ'R/5*Q)B8V#;/2+*%BW8VM
M9/GPR\$Y5B.V86^V5M!@FSIK.65SMJYX;.65SIKY;_MO;I6S9T6PYQW'+MIL;H#-+P.#UZ#\$)
ILS+DS/RI=,C'L.S'HY^76IUKEOH!CHR_TVYE!E" MXL0_6\$HHEZ^0*0/7-F.P'^#14&?E^F<_AD MOKRY%!
I7@:U.UHT:>= M.B80'ZY&E?;"CO!GK@>LWM2OA!M3D6P2!Q @_WPO27QJUD=B\$ 4>4-9 MTY70F-
Q.K=^1^%LV5'S5+VUAWJT5\$^2S;?A MUA26ZUNL,U578#(M^~*M&I;NS16@9B-NFF?&0 M^VZHJUCZO;R4>59UC
MIP#_ =V4_67IK8DG!C9&PJ)AWJR-Y9I)P*XSZH9IMCIB?I3#JAWJR/R1_MML2H'^K9_HC\N3&C+FMBIP#=_
ID3V%KD;I^YIN1>NELKI?0=AWR1R25V<1JXPIWDC8NL@QK+C\$#@?Z(24)U.U\$-
H06RUPYMOY9!FWAU2M^TLLGD5W9-UJ*.S>D MV"HB5=%D7PZG@?<7==OBPM"1IK*IM?
):"6^C592".C"#/1^\$B4&W" *T M2D%TBMJPZ6K\$PCKWK!"86J"JLH;#I4WE1U*FOK5
ZK.I6K&8N5M^RDY>JZSK5J+1?^F-2X%5.5INZR*!E3+3VC@%&W712 XE;*JX7Q;654U M P:ED\$;HJ43108('LS'ET'
U HT10BB1(@EO# #AC2VOU^YI=|^SQEWO063? M7!1HHW_H
Y_12HLHZW+/MO*.QX245H3F^QJ7K827=1.6B"1&5G%P>I+^R7T
M;.%C4_89:=V.M+^+KWIHDC"OAM*K5^=)V=#=#62ZYUZY2BF.IK?8)K*R3"M9 M>SLSI;#ND68NDK;
MIV4_^*0:IEFDC\$8@9B6XT9!*JY=;5/LB538M%6W>;<;QT6X2/\$-U" D"1^ M5/&CG>1?25)/<1I2\$172G>%.O<U1
MU>A(=Q3.N?Z9)TTGWEI?B?I.4"((55%3NK%3@C1-G"(QLZ@QU6L3!\$HDAFI?& M A4BR'S1)?IQ;_M>MV-
577I7NUZW8P+C.KM>X41;_A;<.*\$VT3@C^4^3QV MAU8>3VRUT/C%RR)
(7D@E#G+I8PJPV=9RM5C/_GBH1T0I.H@=1HGJJ;T M\$ZK.D;:90V0\$<1!489N;L2/5K;IE+V)HQ#Y
\$;H@:UV<122&"N"6H<M-3:F>(KI2E7QE8JOI#?2:7J) (G^G SI2L=L=Q^NBW^M7=IB\$=T@1 VR2 M>EGV.3L"HD@;I;
(35+6/7^C?FC;I!MI4R/NV<CG_H5SYJ^SN^CPD68(N MYX-E ICIKD=65CY6KEQ<@L9L4:2#7_9_H!Q!A5LR(45-I(3I%_-
^1H_JWC6)S8M/2;V>=<C=SOV/W.@@^Z5TF(9FZZ^UB9<#'.&)E! M@^NJ7
LK\$4S>U.F&+R/ZY0MM57DVWV:147=49WED_6HSC MNS5=AOR>MULTP%RT<5I1H:8UP1N&R>DI?
&I&F/6S3N>4Y-8ATQOY"H< M=&A'T\$V4/"_Y+R%=1.@1F'S;N* M H+TZ7@;QI_?>FHFU("D0M%25I%
I>=%)VH9+FZC0KMD+6;Z*=@R;C>W7J;_M;-A4E#>O-DAIJ)*8UIUMZ*LI7R8(QE5E*7C;I&(<OYX>J5^H57"0

ZNU"R M2@-%9RMUU'9'?:=;T7;-QYD"D*8\$ZI 5YJD<=42NM#V82,O)!GPJ3@PLLE M8Z)6=)2C:4(T3XWUK:I7FXXH
>'0%*.P#+++XBB=WXDY,[YH.M/I7\3)2%7\$ M3Y_0/29S6'=-;G3)X8B6P>3!WQU#RV4_-J<"S7ZIDFX3+N#VT9320V
M5%)'IN"B@K_JJ'CJZ'T,Y-G?'C&05Q&('1846#WDJ8=PBCD:BZ_)*?YB-M(QF?
YA0!)W:TU^/S/EA/^1^6<1AQ3NQ4T_*NX=*MSJ%BXIQZ#R"..1.T MT?
_JNDJ_VSQ_V'9#> #ML/WQJ5S/MYN8GV45/ BW&A!#XZY<.*L%54S_MHLP_8YEX!!KR=_U;:MUZ>G3_+QG.1C3?
QZB:(68)\$Q2N0E9&(?>CINEU MUZK:G&4D@H2KY6*2'"R9?EG(B_/@S=-<635GSUW=OS;U^125N_W_6IXCFI_M9#.#
<5M;I?C);LMMB'P/I=LV\H&#+YI4<6? MA%43=-/7QFE6 M:RWS75-(M@E14/-V@UO2KU <6R!# UP."R.4.
L.\$AX,72S18;=->4O2\$ _K1J M8:*1F5K0)<-#/3PZ)JRMWM_3XNW6(QORKV,I\$86<I;..\$63">57K*._@-&VY
M3MGR34@I'" ERL_&FU/=+2I:\$SNHJ?W?KFFOX(LF(7IPAR^KX^8P>F9_MMZ97?QS_*XMKZK!"3>5I2X&<3%DIE6
JBOMS1*<=RK:DLNI1I45N:I-I MD0_/2H^#A:2%68I"S&I103E)@6Y%TS*##PW(SRYD^LI^I!U(-_F7O80\$Q%4
MY4_*/QI(L_144N;7Z8I+K"*7-9>TV=DP!(NT2O0IEF(@\$>QO<6\$U12CK M1?M/J8*E*5"CWHG)-
\$%0;NYEJ/@X:C#2#R:Q9?7?HY\$ZTT+&<+W=\$TW=&J9MOCKHH<) JK4? M%VW.K/A_ZK*!*.OBFI)>E?
6,>&H(ITZW"2IK.+O=C_?M7=XH32IG\$JXXT MDL2BY2IEBQ<(5:XJS5I8Y
'M(KILFMOZ*A1^SF<IKM0_:P4QH7:FFY47*! M%-_QO7/M?."F.3R!;H_-4^GGHP E4YV1V">^M6FHD;#Q'O/IUVC5(^;
O? \$ M#1"?F "O%"I6^%?4A"/05"&SG=YNHI%)=F14 MW=LM0'JL_F>\$%Z0V)O2G?^Y*:&'<(SMRCPDWQ,Y3!
ILC%MG\$!\$1J+U&@W MU2\$ _HST %7\$0D_*4AHL%KM#9)TE7IQTY:I9EDWC?
GFB_CON"WI%\$")X(D%GL&?::ZF RI%/_&@8/0UY HIT?A/@KW(Q)NE/MUUOSZ<(\$53FG@_AVR:#Z5S\$LX(%L3%QI)
M_@1_"J8AAIE%8=)=G.IZRW[I#>+=Y339K5-EG)H@QERX+1R\$5T?^44'%+D9 M4=B+ZCRI'&4M=(?
M0'.37+7U9E2Y)WDF8V7+!@5%U+4W+M1ED2JLWFPZHR1A
MIOC6GF@B+2..IT^"8TLR/8+C_CLI=,C1OH@IQJ\$Z;ZMWX6D&HEYZU0R.B
MV/U5ITAZLU\$%Y_=2.XBFMV:_YI44I/)\&_F%B"O [MC=TI8M/&IWF;@G1G; MJKB:?
J9:OSAXZX>)6W_VXZYG<_A:J _/KXEP_UOR2GI*UZ-6%IO%7JB_V JM@'4&A0J2@QVD9 M)R5ING,SX?
C9<"VLJ38%0AGBK1>H.CJW/+_C0:GUMF @
MG7V28)W1!H0#3V(F10690/9EOVYTEJP%=&SXCG5&K@JVG\$7PH7IXZR>'H F MUFS95.IK4AZ;Z E*@@@"2LR'_80?H'%
MYQ3_QUNV;>\$PZ<8+AM+4N8ZTE'H=X2'3^SFQ_1";7D2H.+6JU9JH"">_ MI E:0,-WY;92-
!XBF+9"Z2E+&R&FJ'QSP#-O*G5D%\$4YHW< FE!P_15 MI8P^_OQ5X!T^1MO>9\$=JP'AW.4N+D4T?BM!
(L8WT?2LW=:(C3I3;W12' MLRSK9M=5"E\$ _XT047YH\$Z2Z^DX195PY+ =K-J OI5;-J_CHL7^K.HBLYW=\$
MS!N_4*T?WB;*_QH?D)W [\$=^] 0"3N78_M"H"R%GRW<OEOS=52123+%Q591%
MH=K\$CZIBLV;%FN"=4<\$MZIXN#8"YJ((?2"58>O\$O?KI->8%VH,1E=5H?4CL MA!.KZ5MLJ=S'!(I+ E:+D
I")8%*R_D_=W5?LPU3KZ;C=4T9R +(DMWV!(V(MC;Q0WFP4I2,I3_<&PIR-8\$>^"X!T128%;(AXCMJ>,+
<\$!\$M/QO'B&^J:1*6/ M7ESC8;;4MHK0L?D"<\$7&5M_%X9M2Y>VBI&LL)P).IA&ZQ_+;=:1KC8I@EC1,
MP9W@ECN^IOFBRE^ZV=&,>Q^>:6B04.Z6%"Z:@HDCWC<@70-O)-TLU8="@=N
M06E/KSZBL^Y@+VLRUAJ*JK(12:7K)JS4@GZ15<\$NT&S@-KXI=NL;(*6)-X MT7)OR7#
(B=N8Z/XV9X=L_,R?H&/AP/V210PRA_2*!1U67NIQ\$OBIM""\$ (
MWVILBYU3IV?)\$GHEF1GHAW'9WD6HB^S.:9GNIZR<:8%-3^I[\$6=F*W;LO>,
M4!40=QTMPBKJP5E^9J.BI=NX*)V*K>1=EM(2;G@WIM,BJ7E179;.\$
MX* XKOK^;I+ %LR!5V_POKL"TI#_S2)0JL**X(C?Q?U9=7)_K_@XB)_RKW_#\$ M67+HJ5.8.IX_TF+,#CF*L"4@_SNM"\$-
F&R:#IT\$%?:="L5:2,@Q'ITL"!M"P>_9A.)9'2-"6A:)Z41 DJH^BLT(%%W10H)_%EB20(#2=YJY=U?T0"1ST
MZTF5CD;4_-M MH (2G^7)D_E_6B_06LJ&H2RA+AXB/B*67H"@Q01?IGD#I M2\$"+*A[M_-
Y/C1098>RL%.Z5HX_.B5;2;7:EH.90'19GF+7X@".3>9I)
MDV8PN>R@.@=E9CEB*WR(I)]">U<8D\$,P^VB+K_"R'U42H?S@Y?1AV6)GAVS M1>S1)?LT2_I;.@9
%O1.7F.%ZZ=^*J_#FU!<#RB<1#QJ@*38K:5H_E_H MDPB;\$\$VRD\$X!1RR9<+=T*?#8?
%G\$S2VC6J7=>9M4X*MFJ)@"=\$I6^E2T%O_MIV&7+!I.4B=_S\$W)\$%IY=:=R?AKZ"DSZ?&+>
I>A\N;+*T.)H,IEA*#L\$1@C M*G<:8*JRM3H)+9P@N;'.O\$2/\$_*(JA@)UVWMNXBKA"#PI0_I4?@8-<5CHTL
MX!HOWC;^I<:&VFJ-6Y;-3;GON1_9Y8K+G2+2N&%GVVW9!\$X8-0X(KO?^*,WR M@X1X&28T>#GEN)?H!EG6Y,00M:G
M-NXH B=>E0;='Z"P4VR5!#"-#I2H2_Y4";P^_=NG5HK@!O#R;G;#A68Q!^6
MPA0QXS3HNM<0Q8%+B(4)P+EY1QZ@'19H4VT,UI0%6!+OIH0:6N'S A77## MYN_3GJK&3;=(7HB22
376*Y)DU88D02 @>:_9HFFOTZXWV731.ZZY<0SQ_M2\$XIOZI<I&83AXS<4>LY.Y%L=FM>6L+8!_?JPR6IX\$HD*
(A%8;2B_6/=&XQ?TE-P1)XJ=9R? #7>M^8;5;IYI M/).8NWP;")ME:PIV3IJ(^NTT:018TS5HDA)W"A)?E0.%T-
M*JHHB_+P7(-_MP)YY#"\$ST9#_QMIR#5H(ORW=I&*3?K_R_1I(B;GI#_Y8QA)U?P%@UTH7)J\$2;D M;IHDQ/_F"?
\$FCTB4/9#LIF*.IEJ=-,FI#%@,ZA7_AISV9_IS5A_&!U_!O4E
M:4I9@NW53N*R&0K,8M4>@Y;BQ_8,\$5_@ (L=G16BK'8Y8167);DHJP0"UIHY M9IP2!AH"?LXH\$E\$ \$.H.M"!@@0\N
AD7=G/1X9J:Q)4CIR^0+\$R99AC*0 MXPk;RD(0TH_I^ABN?L(AKV!% Y2"X FIVQ<27
MSTRQ!;M35.M\$N>>D34J75171.75HIAZ2/R_A>NQL.D\$1J8H5*;JDH@T)@_M/#2I%J;J1:HIJECO_*V28E.O3TI?
B89RY:4OPN@G\$;"H-UI_0I(I(+*W M#_B_I11(REHEB0KG9)POI=EO5S.(W\$WPN35^R?^Y2K.DI^N4-X8:W)@C4I4
MZI\$T2;Y%<K19U7L":9!%K8-(A)D;7KL>"I\$KB?/_@\$(>H_ZHH_B<8!D5Z
M9BX;..692ZGUCBX_%G7IQ'3=)=TW<%TW1?=-UO_2S_<D%#;X4IDKJIV-2 M"PI+<RCE,VC;_4M\$"8-
I3I8;3IEW&E-EXP"JH;^IT(=_+SRFZIN2B_M6_2"4R+7;.<IFC554D=9<#K\$)&*GNYTJNRFU!@)?6\$2Z MF)
(9G/IQPU37KG4HNBO)MCHMSN9S5(5<-ON9%C>(U9D&=I_C*GO\$9U5R%#YB M/<N<IHN_1#?
N_<.@K_.J(WJ\$JJOW-D!P#NR37HN%?ZJ61%10/*D<499N@O.>:ZJDN8L\$9-U4+,.+2RG4W15*!^Z.DHYMCS MDASRI
(M'DNIO:XJDGO;G6DT+I47G.I/TIBH7W#5/COGP!G3A)W_)N>=%M&S MTA90_2D*AK/T=F2;>_*Z9
6EZJRPIL)Q.XAU(M=345,%%R7!;2;?ZE=5N MS;SM/N0GM5HDYB'3"?
5P%I44E.X5H.P(F)UNE3SX_JIB='G1(\$+26_+&Z MC/*IT>GLY0NULHDITGS? ?NJQ9I-HTDR3G9GD;U,>JF7?
1(FIEJ?+@NB8_MD&2>+JA:R.0M4N;H>;ZCZ10H9BMEDNAI+Q4XM?XFW?7P%2XIEJ0)_<7T M_LEEK0J-
_R6*:@I1S)ZSY;IR;('1:MUR#=-S?I6)2&2>N6IS!>U/A@*Z2S' M1Z8A@.5YS&XR2>O/Y7^1?7;#U5R?)_SN(1XRKJ@
M_V'U U TX)B>0;&XR"06IIT?>4O_E0CD=VLD=I2P6+I,JHE.H 5E)P M(ETY_6D)F E*95IV=00B<<^
0!_",3_AI5(^IG_X*TN:??>E!XA1:VQ"4",@_MB^!&);@!\$6WY4&U!@3KOGLK=&_214EG6^"!AO?BM;#_9S.0=I=IW0!&:R%)
MV00C\$T@'T6"4W7:M9?2=4D>X0^P*=@:FSSGPGUHEJ138B/HD%@V?9)LX0VNOB?)CV?_1WPZ;I
MK+ZOLI9GEHK#)D;+KH&CP(56P;)TJ.IX%CV#;I2_YWAX4)ZCYKL379;(QI
M5D65XM6(AWW1BIP#EIH5K>M2TD/DN+\$I^B)<3!_%RXS5_GU6L29T40+ M06.G35RI:IQUFIEGZIG\$2_03Q@
8ML_URB!7X&2HRIMU2S7#I?8K@8!>O(=#_M\$8649T_3%Q*@N-INI+U5_J5V&6QQ'H+)'B/J0I6FI/.ADA1^((6)HIO2\$&
MJ;\$_BW&@H)B(AA=6RZDEZUSD31B,IE>4HP M<80;H1K9W6*VCXIV@S?
FV2=FO(6%F.46#EA'IP43)ZL^B%2.8P.O-T SXZ MJ<(W;R&FABF;\$WQ0!M:I47R?
3'>4Z:K1WW:7.2R79Y3W)#0@%MM^M_#B>N M9;WATK<"0GEIG^3*P2RV#PYF>JCHR^_#X-
??J\$7QR\$7_SA^+_XK9!WUH= M'9#6FNT_IQ94?>O;:/PM6^KP/U'" NAVL=KKYKOF!(&?7(%_HRJ M:3)E7?
=1T(3R#4J4=TPG(SET.PCS.DTXNPVC_G1^55@:JHHBUNZ:9%7T)A4 MQ;%K@Q4'TS&2"TI?QANQIQV(2&N/(&N(?)VA1
M7_XE^RK7C"(N_=LK^7/I_4AJ(WD1VH82ZX@!4"\$C63><I.9TO'DNIBO_M6.U;
IU3Y7ICG\QUA4N^JP'LY92CK_!%3M2;H89V_9\$M@<I>)"U2YQ:GP+D ME.Y"W,&P*;F1Y'% EMB-6?

LTJ^N01YGX(YBHT)M^D/<|NB>>4|>*IJL|2 M.E |#_A W\$C50?%(K77BI6_ ^*@Z90C/74!2L_)I MOT)R#H3&*!&?
S1RV,%-|J3E5#<|BI>|X2*GQ--=Q*0Q-MW.5TE.,4^<,\$@'O-MRPY0>2TFRP:K2& 06X5=8E MRF=?A|_O?
D/A+6;8_!_SPUOFDR#6:*GDM|,HA/OCW|_):>H5PW1&&-GTE M^9|5:8K)|@K1P,=#(-Z@ZPN@-A>YFTF*!|MZB(?
=+*@\$4&:(\$,^4HEJ MJLO?IE)QJ|MI K46>;#H>SD=6>#H653G5.W(^)IE(KH&:%!9#QYT^RH%|DQ4
M_L%G_AEP:#IC0:B5<?>XT&5H^!9<5=|\$(>:58YL(NZP4) #!L\$#+=+3B_-YC MH_@DENJ7HL*6!A#H.L1Q6ZTL
-39!+!MG=%X92:6'(PKY3"KGSO>..(?2DN M.WGK-P!GEXS!_0?? X-K1|IE-6^S1-X2B+SE1IW=%"D^AI-BQ_?I0Z_/I53
M<>/7U1)(NW3I2YQN5ERU.TYJ|ANUF6B=AT7%-"?*(\$|07T^V#^_NS>^! M+K7?BIE Y-
\$U*)WTI2AL(R6)QTYE%T7KZ:@GI/|QIH3IAZ!0M3W)3JGW%Q5 M4.SE6A_181M7Q#89_=(P)FE64:OR8|5Y%U)R43I
(EIH-8 ZOHA?#M^DBI MIW%_)RY5MKS82_I/HT*SB"Z25NS|)#)OCI^W1U(VGHQ-0<6|"-V5H&=H
M_CKD|I|>+\$+Z#"#D#SU@QJ6IFGK'J=.:>8MFIQ#|JIN=XC MO69>P?#DJ@L8MA)7"10+V#&7%B7.NBULJCSM8
SG^F%-3TQ<11JO&:C|Q|OH MKYJ76C1=Y66+U@|!|PVT6^AK6UVB--AEC8'YH|'6F'|<5";6/,@.H\$@|MJK M17G;?
A|PF8.V5=W4F^C:K2LIB;.*U*82^XKJLEY9B(>7NF>H>:>267W>:BY4J< M\$N3Q|@HO.%G"6^</B.95V74EPMHIG5.7
ME.ZHIU^!Y(NH%HK0.14|8WG^MH9MS<*MJ-TN%W:6JD 0&BO37|RBV+|G)/M.?
%H+JHM=|E:L%7%ND9|*#P'K&V'"@M@.@.88).>|5@OOZ8M%8R=0ZPE MHZ:1.2VUEDPY@CEM/TH^DQ|
(1=;XQ(0G/\$(^ZQ|H6X+F,|BS)#KKJ5MD*ZPA MM+@/VZB16\$A 7A!7|_M#?>)>UYTZK?E4.%31XJ397SXUF3<4-?
BECK9|=2I M)ZL%7(<+22MO|OT")Z84-)UH|S9|_TC|>5K(NK|2RE^P>O^+)|YC.V.7S? M+|+5_255|0/E_U \$@5>
(05E=;+5'C.XY8WK1@GE+!42"Q>6P)#W_XI_*\$NX6 M5QV|Z|Z6=1.ZD7MH9CF)4H|FVXPV?
JYN>;99;=S|L>9^M&I7C*=\$BFY2N M9R|^ ^ M@(/B_I^?NHU!|IE|JTN^W:|H-+>GZG_||LGO|^?W6:|<^\$COJD7
MYROZZ)/?F_E#495RT|=K7_U.|H|>^VT^=24ZM^X|H.U2M\$B^>)>W M/9C7=G^X@|^P5C3X\$ZK/XQG\$FS#.
<.YG=K(L5W6S_-=DQ|JZ3^QY>22_%E M^4|_|F|S.Y4_&(>@K)W F+&2AS8:)46.E_5IPOE2Q*\$ZEY+(!
MHT2:8(W4)G5#|I09B/<&C5Y"|E.*-%FY5#L^N^LW5+'B29>Y| M?_Q/|^Z M3PBX"/WQ|YX"/V A25LJ33
L_K>COSID7C3?"R|ZO**&Y')29*(5&W8^N
MWZZBI^3N3W<^CW_)E/O)/=D\$C6^LM9=)2;\$PMZ:|J2|VDZP++@HVMW6J&|I MYSZ><<\$5V|Z<%&ZHFFH_J S?BX*
W+F&8+\$U|0US:BU|UDR|2%(*B=!"2&R M7\$%:;9LLJF#*;C849+OB5H6M+1|CT4N6XT#IX:|93U-
9/K4!7F9;NM;4GH M33Q:??0Q\$|A6.ZQ|S&=HS_XJ(|_WO';#D.M7:H3ZY>*#3H_ VMQB-XQ^?7>B-
9*-!ZEXU%Z3<^>F|X.A67Y(|_KO&|N4|,4>';@/FOE M7-94)"!>G)|@>82;ZK024\$+"AVEBN6H|*
<63NH|QSA_2)|LVNHY+OH|5Y M|6/Z|19T MWZEO56XT9""EK4|VOY:XAGE-I^|2MG0""**^?U^#"
[?%#]>^41G10P%<#7L;=\$BA<*TK(A(P|H%?EHFD^ME|LY<6\$<K_IDGQ):62?3EYR46^M57:&?^@V)05YB2
MZL.OO""TFS6>*9\$_-8:8Y8M/GL|B.YH2FM6%32;9T_-=+ZM5L73STZ+YW)< M9=M/_=
|9KRB6ZKWGSMT8YM;\$UGD(MN MP:3|5)/9"Z=DED:/+Q#AYOE""3>59\$R4-U7Y Y.?@|QN4;\$NF|?)I+|JW|_O8
MT^J#X&>|5)D:)|#P%0=U|@QTX|/|^DL%Q6MY@5XVZE|D:879D(2SFO&= M5?E4Z%(?HJGQZ<_IUG|
|V4+FNBRK|Y|^@QG9.">D2:1_0KP14ZKV\$7F|H4Z#=-G_3"G?TBN@PTW*M*=SFY>|7DM66VXLT5
141SND1Q7NG;>9F51T76:Q|_|_D<=>M|B M-
N!VW5DKB!83S""UMV7|V+N:KLEL=QF.R.YW2GHMJ#E1_*J#ERK&NGAL*
M_<SKMU3>90&U9D|2%#1&?ASF(E/4*XT4MY5|_|TNT|TLZ%TJ|Y.Y+ELIQ
M\$@=^3G*S%E4C|P"Z*\$3U.Y_B.|E%XKN%?6."OKLS%/H|HER>9H9#8@KM?N MYGTI#=-65&C^8W|
+44Q\$H#Y#PD;M|3H:B9(K-O%D87M8B1X'J3#)9/&3C|3G&QY|J(NDW942FBX|OJNU-54F1
MB*\$E.X|YHYOF&)RG%RY,+ER|ZWV+|LCU*,P+9EUG;R34GT|N|;I5YWX&9| MW-
DW9.GMXM4K|NRS)T^_Y.WB^N^>:2W0WIS+L.G&M9XVFX;C7.RB19E.V2Z
MT@4&8;DAEZS4T"JWA\$4H|V03%|*K)^ ^OOYUR=Q_-\$I7%2K>DYVPK|FI&N9HO7536:|4+;F:(=F?3_:(-L...+*)&1^
MEN-C:&)*61+|D\$^N1YJ0LPHV|+TU0W6S(79^>#9FUVTWZ)^=*%|8-E(<1CW MFC^W*6(|A|M7^@)(6/5E.FZEWY
MY&EXM2|^NEM+M/M3^_5/9BG^|3KN\$%R|XFLR31?%NVZWVBC1^>OO_TSPV.UVY|C?4XFDN|85+9FU;F*!
M4J_U@%+|=+&89_((8;=\$=|9^M31_X9DU.7SXAN8VS4.**M#HT029RN:9T MXM.^&|9L^#0SBVV=-#*|PQ-
Q|B)CD)ZZNGY=^TY|4Z(6? PY*G"G)%9F.. M1^|Y2ETD 4|25|_|HDE9X#MCZ4ZP5#222!-'8:1(2XD;_BM_&.SB09*
MARK5^#1;WA*|AWB,|JMS'FCTW'"#.|C:N\$^Q=JZS.7MRZL;1.75MUU1K9 D? M?8NGY:913.@_|LA0V5?
UP=|_&6&FN8M:4BX_VO-V*SR)4|< S'B">#EGG|A M42;MJ_UQPI+7.SVYE=J2X|>YNG6/A:G5\$F&
(C^DOY2S#&U.KXQ8P=O/7- M^=O_9X|>Q9^|>?%V|>U6|^NY-O%K?Q^TU)OZF>|ONS72WWWWWYL6Q;H0|
MTG0^2HE1FZ40%"Y#U-H+D3_258IGB_Z3B4M\$M#G?KFDK KP59%@;Z:|6I6Y?V"\$J|N#/%% 1|JT6? H?
<951N_U&6WS|N MW5%|%)Y:7%AFI+>94(|\$E\$|4_LQ"1#KFZ&/((\$+Y3DJA|KOD@K#|<=D"4M39?
MS(3*6B#|5+|_WHITE)%Q0SR84OGE9ER@_O)>XN=R7X|MWK%#4|@I4^LH?|T6 M0M;DX4_7V(2/LQ7NC
YYID:\$OX%2H:1*U?%9HPB|2&|S(2B8RY:I/O&40 MR=DP59DKW|Z*\$^+S4CR6A|IM8:3|7P(E5|C-9.O1YG:'1BY\$#
R%P38%|T M0(VW^#J|@DRL7PBG"^E|7#6.WM(|JDZX^8+OXXK#K.O.?%?83L798A4/D0E? M_-M+F=|+F1|J|_
Z>O7SA^D*KBWR.WC^KX|OHD;|R4ZA3OTF)SG89|E75Q=; M|*E=|9K+4CQ5>C)|1_P0)|L>BFKH0?
Y6W5|QOG8FW7HY|J_|_5<|^<|BLP#_8<;_<^S)DT^X%|_@1.TR=-NBPG=%*X?_OLOB M@5E0S>18M)38I^Z-
>*/BBC%OO*9GXAW|0T)Z.?OBQM.RO^H.P\$)|Z7@O=7W2 M(YT.F%6^</SO@>'RDMVTX,+6QNS4RT+S%<(S:T
M,J7|+?M=60|(|_RPJ\$B M+V?G0EQ>EYW"-(\$<+KJHT^R|S-K|KU#^93T/|T":ZKS MX5|_R=DK_65QGTG*_H;
|E9:E;.%M*A88J|9OTG&Y.NR*U<4PX^0O|PUS0EJ MDLG_GEP5BQ\$ 9* 3|6C&.*?Sj3@_H_W16JW\$N^LAX>(PSFH-
%S@P!4VW7M M#1TAQW|501ZM4*T4B M^030TYWX|6UO_-G'\$<11R|<.@(' /DPL%2L7ID#B|N;067^W(>
M65PZ.F^J=5RMBS|H|H(1|_|)D.<5<0+|R@+3,%(9^IK|W|H|5;UFW;MCFJ- M|_U&4JC10&'RWX
R;K|Q'EJOR|93+T_|DLK|&2=*32Y.B-"TN.R(|H3B:26 MNY0&S<|7TZCCH&FJ0>'3E&@5G(S>|R=J\$Y*+<=|OGPFOX
YM1WN| MRL>6ZG60& NG2.-+10J_?^V|_|@T^=W1(=S3)|>NX MK:U|:_9HD#)K2X/?
E_|AV^6|IMO+K|%-3Q\$Z44R|S2=%N=*M^T96 S)#63 M5&_IMO1MM8E/NZ@Z\$|/#.#K%-AS;_U!_6.TXO|
|%+>ML3*FT=Q_2|'0U/#0 M-C9SXI?|29^;HVV,#@Q:O@MZF.YO&PVMH|_*(D_Q+=|\$+P-
)99TK^V+."+??|5VSXINL.ZEB>7DG|@|JRN5=-# M5A^N3P22|S^VWTO^,K?"^4/T7N7M4T774^J@+\$/#):8%;
|AIQ|VTU!"W\$|7L M5=|K.F:E#74Y)KM;(^>;FJR;RQH?T|OW.P|@M<\$<(U9%|X|H|A1>F_|FI#|>B7
M5P02<NNV6LFU^P#|76|9^E7U|MN%|7T781AM|S0|_|CC|TG|GH1|=U\$|BO|SNG+>+.0SD*/
M/E=&S;:9Q5:.'%5\$6J|KMMCG_&|65PUB:)"?W%:<#>T2:PVL3 M^%D_0T/@.9SM+J.^&&|7@R^CD94P^DD(2^T>
(^XFUW_7&H.G687|S_|H M8^IFA+|_|K^2LPQD4;|4Q2^A9=9_ EEN6A6E|RV_#;8Q2DF703O2|K5/&
M_XK|83UPRTPT)S.ZOC/5_%.|_NC+PM&^8VJR@7|Z7)CADR")R^8#(VZB5C@=225:.%6QUHY2-4B:M&:_H|/O.R)Y|-\$2-?
F4(8|_|)H:R^C&KE|>%XPF\$|LTK+|N.BGO?4JTH33R|&_B|_X M*|H_.PR0^39NL%WN4R|^4VSZA\$=UT^UT"
|L_6_BY4_6WR)|J21^WE|B M4(=|S7\$2;IWP):?YR_MH""\$|H59IG.0FY"=8D-|T_|JY"";+"^?K;B1 M^P>1\$C^Q>
(0|W=HB^LGM3*=-SF&84H@VY\$9#6UH3\$C5C^?02^I7VY; M++1/TL9.7TY^&)AX10A3;_>G>
^HWRW^D^|VOT46|AD^M MAZX9.N>4=2;GHE""& M63|38;#%\$&#>E>04_|M5 S|S^RBL^4%(|_*U_/(^|5)A,H^I-
|^%R|H;&^4ETU5H|_|@ZZ|QU M|Z3E#J|S29Q#^ ^8M8:8%HI\$GUD#5Q\$ MA?
7|QYS.J73*@8ZUC9;|^@0|^|*Q^2:MHSZSK/G/|GB.C5.2I<|_|CVI8Y+ M6+61;U:E1TGP;24Y197E ^@'SUIH
N^CL#42N1LR.NDNC^J9@P426V:&>L? M25.PA.-W0(A_|DF?VHZ|G%+&G|0#1ALXE|WAR;)07N=T.A0^IC0H""WJ;U6
M""@YJ:V|_|#A7GB8DL|_|G\$^W7C6XQPK.Y8C5QW|@_B^@%AWP>T^K_UQ<_B MTW|X|J?^3C_\$L3""*OWYU_NY?
BZ^>W0^|8NW:XOS:XMW?WE10^|Q MZO?7HB50H|=U7?SM_?EZ|+)|_Y?S;L^)|7AV0^4L2QACS%ON?;"A|EU;I7

M@=N9*I@RPHN:DS\$(5U9C #J%6. 3M%J80/4J*E>JYM4K4213IZRGDOF_HQ= M1;(7B&>20;05VW9+<)<)'!\$!+70J_.\$55U)6IK\$KK5JW(R)Z;.:I=?)+F@V; MQIO/#)%>5B
%7_.;H;30;F.ZI@.\$!N045%JVOET5EM<&END+P\$E1I9LS8M*YIZ M>|>'(H_6V\$RU"(DIY2IBK:E3^IP2S+*@;.,N(*<60XE1)/C^C7^!""*O'DVOQ=L MXM@/Z\$D&&7 BXE^Z'60%9V#5;1T ZI>W;OF#12I'f8&\$&\$J 28'&.G%#Q
M1\$N4;CV;.:8@;1.44G9+0%319KZ(RZ05/U(X4TJP4W J,B)##+;K=KK* H_Q@C=
M13'E^R1K;BJL0%5H0'91X@L>7RIEC&>TJV<.:L>_AHDK'I4K\QU5T;.:H_W8>U26E+Z@JRIY6+2)MS?
M\$0VO;.:>:TCLAIS5_M8&"0(3)##R6="K;Q&ZGU-&SFN#*J+)9UMYT%LID+)UE.HAIUYU>04Q.=%C^
MIG)2Z&.7K3B=G=-I?;XZR0\$F"IM>XX(3L;+QFX*;2Q2Z904,\$5-1<+W>IV_X MYV7M2G4%ZQV&Q7?(\$;F*N3(^NJOH!
=<C"JVT=0H[W=I9PV4T5O5IK63=\$N^&_M2RM;.&2>_B4N*S@3Q;EI_95AX=ZP>UG&XR#.&"9!2REHF\$N)I\$!<
M*COZ66:D(-SHDHN(OGKY%8X2\IHD9"V?YGW&)E=":N*0\<58"Z*+?=\$114L_M_5_"X.XK?>)DYA:@?97M=Y1:?
O(SO7#BF1DBX=DZ;6740+MROQ^JJ?C@;:/%; MIQ8/5YIL;SPM%3H'P7AU08BB;JPL_+@1+19/^P:28\$ B#<
<7VW;=64MCT?2 M@YELR@UFZF;^C_9P3(4I69LV)(^0=8"CRACKJ-I-(T+I9QS=*Z^M8RX9
M&&Y)WL.SMO01\JM=G^IR\ZG+7"K+_(QNNX#;+OE-MK;.(ETI2X(5V"/YOT3+G;G-HD=JY<@@;^=E%UY;+DZJ0=?
W)DXPVF?-E;/% M1^)^ OOCO\I?G7W%0X1;R<.;9<.^2R>D=3JJB\K5U3\;88;V+;07A.%_\$.YY) MI4\$-
+^RSF4!&;I:T0TYA,*>PR^U"OU-FITCQ6MQ;4Y\851X;.:3+>88)3@Z9<
MI&GG#0&RH9T1IY&EI;W/6=B@D8;JG4YT9V=M3HW!">_@M+4Q)E>N R.H68P MYSR-
4G(U@I)-9)U0VV)TY%18)CH@;M*\$@H=B\EGFKXSJ3(9G+QI/IG0&?R MMEJSY8G+^MIQB'!7/\$+M=FI?
E)R"CF31IFI^WN33I*~5123L8KPDV(5=+F6 MDM@Q_7U4N-Q<"3;BY4
C\$JVF5_<@<LWC=7(AOZIEI;=>6;BHX9U>Z35;9 MXJLKG4R=-? H&_B;31/G;KMD?Y+;QP_2I-!H
M;ROJM;=:5H20/PJ7HC2\$23=RK4.KECM9V);%4%6R;BCR>4*Y6*E;=O MMH\G62U\U->BO&*U"B%
3DG.DP>CNAK"F&JB?->@QN*I;=:BOZI**9\$18I_M0>E5?7F%#;+R MN((HY3Z\Z51\$NN30)1PH>?
\$/Q^&L<I!\$4PYAA6*\$Z#1IV\BIJ#^8NJ14 MR%!"O8W;JKR??:8 *TG'<5*5YI#0@N\$9,RP134M1+MH-
6HICD%7LW)ZBGE M7(*HBMN>B);.(W;*K8;ZH(*IX91R#%5QJMP_<2MBN\H2&?0KY>LRF'+0X
M.M9\$+&SBNAH\O4TK*6ITG;*ZGU+CES-%ZVA_#L^V91Z6_/IRF/P^F/S^Y)C\ HV2A6\$BBUWF M9W(HAEL;JC-K-
QEURP.RB7(G<=)H8+?#EQ.G1YU\I+V'S\YD9&#J%RGVO&0 M*=4%8\;2J?5ASJ<0F;I#8B;YG>#H\$91047#
(IQEAWTZ>V1\$;..XW4.I"; MPQ9B(+GXW\W+C>?2)?T.YDY5J66-M-GIL78*=TEG^YB*17V><4%8E2<_FJ M@H-
YG:6M2?>@YM^2A95?XI9%3%+L3.FBI(^LI45)^I?ZK%;.TA00F MI@A)EM+(/+HBK\$A8;X#55-K>;7+2; ='GV-S
_C^I^J9WI^_S\$TM3;35;UEI M0YQQ^=,GT4IGE2A;EE\I%KE@AT^&WI74+&.D@L34DU9>JHDY;S!*=: M@H0T.E@C-
B;:21DI?>CCK?9)\$8UDTYGC/#;J4;P@(\S?N2IRQ(R5 MYI?WS_&H'(3#)@P4;(XEJBWW\T\X M;.<1G_ JVV&@DC
^%;GC*)T%('=&_C\$.ZOR 3Y5=>F B@;Y%;&IV5NZW\I2\IC6\N-I!1R'=2R0HB65T2)+Y7 M2_&QDK1HOE;D"\$ A*
(5IE4HN=9E@("&YDDVE-).@'EW*70R>F8L7Z;4HF2.A MYI=-.GO>22SNRW\K4D+T9L\$|>-^C;?' Z4:02&,<)E"IP/UAS
N3Q)<IAH/M>_VH+E!0BY87)N0^I4M;..GMJ KIW" SXOXW+87E4HIV*\$0YL; MCI^CI
P\3T+KX4?Q).N?/F^@'0%6=%JX&6G@_M4I UKGEI\88%CG'FJ*
MRIA@.CD645)V;_LI5Q"G'J="=.J4)L%6=UN\$2;9(K4>M9J\XJA>2WYI*NJ_ M^R%;U86?
+;020.WZW75;:Q.3XX1>NCR)>7XUOGI/YOJS:RZ\<7.T)EHW MJ>#M;L0/B\$9M*T3="+=*X(=Q3Q#CB9)R^R<\$R
1UIGX*)#HO8_!^V?HW1 MD_KPW;#Z2I(G)1J7KD0AOUT^@;A R.P\H/%+%;!9\$T!>_+>VA1(8TS0DF
M=VU/\$!9=.;&F-A+61;.\$&^Y9A9/H>K)ATSV\YFU3=H\WU I<\$=P%0"";Q'O MI_48H.6;>6>AAW;.=#B9\$O;FC_-I6.+
(H/#%IV\1.>:46*9YHUP;.\$!0W M*#E;IPPGK\LVGI*H97UN^VVKUP:S\TOI9)P!>?Y6SG/>9&."%>R;.*I>I^?&
MJHZIY#N)WC#^4;PG6I^8@;0VN;AID;FAM2"N(QR*#/8F+D/25;BI^+ZQN/R";>@!N*D41M\^R'G&;-I%M<2JVI?#0>
M-QWNZ\W>_LS3XK6#*=F*LLS*SJEPTQ1JB++A&6!+;I:I9%90BH J?I!UE:F&S*C4B,<5=^*NF59;7E-
7%\$EVL(L\W@MF03R M?%G XK.1Z\$LPRU&U#JQ?=((2I8;+1)1FI(2GINS?
RWF&*6S<2UVW8@J9>NU%/*8JMO!:=;RT""TJH82#
M6IO@0Y8GQV".EAHV@UJ\$I/I7/W(ANCI@8 JM>&E_/7%5P\$3WE"=-^79;3&N
MC4JBZ#4"\$;.&FN_N)7=X0>"86AC_2;N@Z8M;63B\A+;#2SN@&;U&J\ M3R T9@);..0D=Z'OWF-
3#LRCI+^*6H_XAX8%YDP;I0\3=U_7/>I#_Z*?E " M^).GOP3PP03PI<\$!&_I+^*2IUT*D?
RCCK*H2%+5.1"BE_XSHNSZ4\U M)W>2ZRIW3K(+C8TGXX-A4%7L*SC-) MPTI+RA)Q<40MMW;0HVT<+U_J7'"=\$?
L5ML;N M?AX+;E;@7>^2;JH@;:6AHK;+R.80;Q!(Z_Q XV8-?T_4#K+^X^";!6VXC(MN"@0'63MNXDWLS&)
(Y"M#G*W\I@+Q\N\MY/VQ?GAY.P6N;12^@+W)20- MZP8*7GYI6;FXTL8+I
IE\$9JQI4T%2&4OHERGB#;H")HESGG@T7Y #I?0/M.PTKFJX<9\ZGH X;4ZG3EYCQ74I;*<#
I2Q2;2Q2#*7I7HEDYH(MQ\HW)DP M>QE.XUG4F(TPI)U5A#+-^/E569/%6ORUW%(?;A51Y5#*?;GIZGU8KDJOH|>
MR^YI_4-5G)^?DYRUVG"!\$Z?Q2J'V"N JV\$908P8F000?IEA'9! @YI&-DO# MDS1Y"VFT73%4;(.%&-
Q+6F5B75QIE'2GB1E?IEL3\PD;6 2<%.9*.MWD6%GK M(G;J?F %'13AXDGO,T#FNR(A+^VK?MIC6B8"16!TISF%J7BK
;BSQ\Q=T6UKY>96&-YM<JZC+">?? MH(""4H0NWY;SV2;-D%QN=P=I_M0>)7RT@'HN+ J\Z8O\I+^*49L4Z\O7 M
WKD M1DVJ7S\$U4"U0)89UA)-1JB_8T6S5Q7@2M") @YBV^V5Q/*3;(<E5#
M.#I274OE7(U"XD+;%#=';7^FNGP6NZ\Y\$8@-2FIX\$. +G6=+I+I+50*==I;O\$S&KTQ?M^IQQ?
5/I^V7:RG16FA6F<*WJ2\W\@X\<^0=#NO*/ M#N\ZJQO\J<99_3J(9;=L*5Y1"ZDCZIHF M\$;#Z%J_4"J:8T\$@!
TY8'E2ZVO;QYIMH;+?7D%G> >(X3;10+7F 3MS&S+ M#I?I#A.O;@XEVFI2LU/9C%J\$8%I1>:(A-
S1XR;:(I?7DRCSH4\5ZR2I49&>JD.NZHY0?2UK&"^*DA&GU\$!SGR;BFHEW!#NIR?B?
M*7K&N240Y^R4IH0_/#L&XGBFO('52#ST_QEA@'DI_*#X/L.W"Y0)ZD0(16 MYP/F8!#TI8/R \$>MM_)#8BROP&=
<""@DP%W=L)?9.%#A7;XT*&R \NR#@);
MN*;7R_*Z\7#NCE8\$86PVKDPBUR3UJ5;XJ+;;H<\$TXZZ(%0@;DX#Y9X8U+O. MN^&W^)\I/65>QV\+ _ZS\<*B6E9&%
(IS3I%66LEZNRM;W^IZISMM)D6'24P_M9_?L5JJE%J@>\$.)29YNSBN6H+93KCCI#MC?;*ZSA<%R\A6Z;KP1Q@;R1.IMY
MK_U\$@#>1EE-;J8QFI1S(^CQGTIX4SUX=+I\3EZI#\"IQ/K# T5'7=-M=6T2V_Q6D;.\$A\$
MZJP""QIC";FI#;R#R\I3VME7*5F'11S8V JFU"_H^5)1(M? "_E\$+<_TQ.R@E*TTD5;1;1X%G_ (#P*154\$Z_JZG=;;D6
MK>W\I6E^*BC;+PX8;I0&B\G56Q<@;S5NF=(I^4)G<2W#*#T=8X@I0;S;OT MF""N6%Z4*63NZ4)JQNPV%)Q\$RZ?
="I\$D")NA@*IQ;W51RKD\$8F42;6)"Z4MAN5>)F&ZDT9QL)&YHO4JTVU\I-#2-B \G@_AHL\$X;Z&59-I3).75/F&I5
MYJE9A\@2I238I=MIR;:2&U2I1K\I6\OV\5J+LNQW3YXP0F+N9OQ-&I\H.91KB M5ME+SPB5#0JF9\$@>SI?
9UI2%Z;*R4IXSG"-.\$?J28N<&P)ZKIHVGONUKRG\ M-FC5;S_ ^AW9L?ISV^GSJ5LI%>+KG*+!_#LQ=<+;_9\>J#L
MMHO#WR&Q;+IGU\6@V<0KYHXPI6?VLER7-7_HJW36\TI\X^U\^L67<13T
MQ/^;SD5OTAY2;V=3L5\^I7V4<_R8#3_ ^I/F " <\$1(3F*)'\$2IE1A% MUJX\0A\$ MN76V\I\D(.%>#Y/TKO47H?E?
0NZOZR\2ZM.I7;1M3;^ 4X(#.Q M\$U?1G#W*IE%V'Y?LSNOKFM. \ZY>@=PN.L5P^%\$ MO8)TD/+G/HI#)@7QK1
V>AU_=Y3CHQP_*CGVW\$U_0?XQE%0CX+ZN 2U;E@ M?CJ*V5'USU%HCT+IN(1VF1).G"N92B.M2%EW;JTHB?
A\$BMG;-//DWY_(R#Z>C>?/9>\$QG@QC&6Y+?2(6F;2_7 MS/IX478).MJ7#42DI!=\$15M=UFNZW\9VM42\JFZ.4\$V?3
M%KW6)/&8T-1'E&\A/4Z\I.ZK(BBXL4T^XM_1CQ.?>R5+T@>*QM_-I;MTU\N4I@+
#HF4F%6B(9I^G"-39T.6(M)#@MSM8D7M=U M=0.O?X)DPA-" 4;I*JGM@4JDKS!WWY;8I2_/80@'
IK.7%VU1G4N;.:6J\$SQJ@E^8@3DQLIWKVIO<%695H-/>W%3IH_%4PD\284< M\A_SVQ%VS8H@P/*H.I>;-
I9476=IKHXPWJL6(-P'5IKKB62I%8U;1627A\ MXMH_Z4+@<@)T\%J_2\@VR.@O(7JCVIT>LFZA=<9&Z;
I\$8.")DD>*A'ND#I0 MI"S2US.^5%\&6Z;2BBX&())'-<>.EC;H2/3J'^O&NRN29Q^(^#E_U\I8/I MU;^4&.K;H9=?

W:\$KA \$KG1^Q*X*^F_H+UG,(+0A DW"1.+>!P9-JUK1+I2LO@*:[WJ&YM4AU=D6R;5G8=OSIY^??;2LRE#?W;8
MRCCB@K6G2"XM5DFHD%RAAUHK.G-(LV3TP%HO-R.Z#28-1.5:5XE.'-2+CT5-MF'B9L7M2D6IC/"N)GB>T(1'-M?
6GL#M;1;L1.G*^/4#8:C+0!7%0JE3I2#^A:Q)/D.2+K06.1%.KY6 MWYH:"D91'-MI73M")A?G.6E M;7IP=P@U
Y@9'GZQ>RPI&@/6)?=&1%K4DI#.#1:960BQD2!@(^)~Y^K"D"G M6Y%OG%20%J4MK@L%JD R;1N:
(6~^1)Q6I0Q3858#1C>V'OW>RZ:1CT""0 M:P18ROF@&:;XOGI1H&X>F&O5&HY2U6Z=I59R;W"#CP8Z;1V7-B,JRL
M\$1'3:P9M.).7ZW'I0;1KT&=@'B=\$(B%<-@19 NT+/FBA,V@N^8=92)T(XTC= M?9)IW[PLOE5N@VBQV6?
2G0Q"79\$WO"+75"7W?O>-,2BXDA^M;0::3W*A M"7T_#N\$2!>5;W17;1-.7C(8T.#@OJXMN5W;
[H+T/QJT@IGPF^M^9;JZDUN# M%DI^*K33+D4_\$^X2>)ZB.3ZU7N?2HTNO^LZ!3@T0G67V;?9,O5)N%OL3XNS MPT-
#MP&P+9HJALO?>K"NB+*3Q"JO.2D)XK&H1^L7(BUV^@ \$W-?0N;D)
MY!ZIOI5TT;7E@#@5C|O/<X1JKZ(1SPK7KE&.12>PCTVER+1=VT%.;GITI MWVY';7M6Q"F6>G-'LKM?
N)O&KOC2BYGCD0080 JF1M.U?;\$=;/6864JB/A(Y MTVW*?#%I/7;9@I^44VIP|Z)0(F"H(>)+E|*CY"&
(JTOFHX2J5""O/B^1Q M6Q?Q%HR.=90!<=&J'3ZS!3.KL_@APN_JO+J""83\$6;NH8-
E3;AB=\$+4=EP8)NP2<@HJLY^@C)2AZIC@M MW19;.HJL(X=6DEFB;< "BSTAV.*+B=)
ICT\$4W3O>C8U9NUV.FMZ=3W^9X+LDK MH>Z" 9VGBXIA/%KTWIR9Y?
0PY&P'5A=9WHY"KM894W;=Z98H;##2%:HE#AHV MHC4=(0==A\$C>6:X_S/5J&Z)2I""G^~*R&_0O)+;ZZ&G6FG%X_"
(~Y><& M2I8RC_MR/I+Q9WG\$UA?^3U3I@I2;G\$P)D"QV7_Z_0Q-9/FG;-CJ<
M_4.YGNSD#)KZB<I9IU).3YEEDB;FK&K;TINQYAJ*PS.*SGF*>1FLS26D-E M148L_O!RT9#P-G|T%P@;
I2@2FTB"\$=.#BRM'=D#I)T# YAV5;B(CY*5_#0AY\$=+)H/6CB.WF^LZ<.)N""MP>4_NPA>IA;9-/
MCFE3@VF3+XYID1_X61CU0R73F,*@X:TJHG1W6A/G/6.3;[C D11^S;=>K.5 MOG!^U2NW?Y^U?>R29?&&0T*5IA4<
Z#IS2QG*PTI0^0^_O.1;U2^H;2BLO.=1\$ M8\$N9UHMUMY&*&(FUA^DU>=#Q1;E(CUVTIPUWJH<#NPW6;.*NRI5;H=
I7 M"PYZ0#;UO7C(+FFS;HJH5YR6MPB8Q|ICWN|CJ1?MS?KXAO\$HXV>6EKGLI3D-M-4RXA(M_16D!7MKTN.;
I12@.DH=AL91W379#(X#;1&U>M(HC54K2_C|I? MYL;GA|@BANE"(GT-N)@QI_JTB|KJF"N&H;6U
32TZVK*QR=4AJ*O';2RG/O M"(I<L;OK^_Z\$KV>1V73WK#8^X+@WR7BT\$V%W";ICE=X?2I?Z;
HJO/L1>N_P5C<"N7VD&C5LZ MOG4>.D?51U14I?4ZSML"80T3.NDC7_*XJ|@1PHEDVL \$1+6_#07&XG6 M;1.N0
M\$V>_2W(6@<6BNX.\$C1&C5G@8L'NYX+.F^O*CCZ;6+B(CU9I/\$_7N M2-INVT+@C5R'82NWE38QF)HJR@?
L>B9"O&TT;HNH#4E)I7<:RSI7\$=4;I'(MXQ2#;-V2LR8N3XZ%&CL#HPC#;NK_L&JH2>?2=Y10V5Z<JM\$P|> M#7N
_UCQ*1;7\$S)J9U9;77?>HCR8ZW#(1R>17A?L1O1PF"H=N(CL=|X| M2TH4DJV=W;5F.X&M?Q0^01 MQ-K
_CA(I\$NXSU\$)+R@R3!?!W63C06!&5IR;S;?Y?<0&0?2+BIJ0YR MO80H59S/7S>KV\$%JXJ|SB6>|_2;68"-W">O1XW
B(@.CS;/6'2!TWUASE M?8>->ZVL0Z4;BAN^6N^P%WD1_LXT6.CS8Q*.*I+CGUC+D;H"Y>"X0I;J
M*.6A;560)=D/(@>V2V*R)ET,V/D.Z'UJ;<&_H|\$&C^IT>X|SG>AJ\$E45V"+MTKG@;Y(!;5174SS7H?
TM&W=";F6J>M\$|=I3BN05&ZJ12;8_V'0X&DB3I; M*^X^1-WJ"50_76(5FI+ITS.Y(6FNT_F?7;_N(AON&:
(OZ/Z;=9(E;2+M-OI@FC%;12X3B\$'8%L*(FD|HAI R|&EL+< GA%Q!AT>@13U+73>?)YM/KK MHI18;(HT%)4M(_?
O'KY_4WYIUMJV_7;"X%KWP N;1O=QM*B?6JM0;0^XDS
MQO;L19EX/F_AWG/_COX^%VZF_9PAK)5IU+DIB0^>:OW)QT7AD(YZ MQ0N#I-N#7KZ8!062=DJSN;3W*
I+KZINDL%*Y_XR'L M;IP67P=36!RF8H7 M;(O?7;MZ5O/K1EXOO;_RA7ES^=%6_XW-F#;C;HU PF<\$I7BY;*#\$>.G;Q
M>"TX#HVP^S;T'(SR)6.+LC>INVE'3 MHJ"3;1G?2=YD.B.VJZ^X;)C@_HC|_9L7|DF%W41@"/=9&5OJ6D-(8;&L
M<2Z|M|HVB-V_PZSYIVGPAV;M/SUFK0|FK?|PS*K_@I+|X""\$OY*Y4%3(#_@ M)3ICEH5-79&;G14_)UXMF4J6+
M'ZECF6R^;KV0_SM^95&VQ=D/71M'%7WD*^I@J?FHY^WIK/C;=G%*%&@I? MOGJ!9&^JENZ?
Q%+ET3Y1.NW;ZHJX.;&2=5U7)-YM";J4|*W^>#.XW&;P%22IX%#=>JY|>Z M')^5GMRVV+K1|19HE;0LVOM+^8I"VA
4C|"@LS^~^JQ10_%ZDIYI(4EAFD M^\$W44D(G(A|<5\$VY|6;ZJH-7_*NH2D^L#J*#1;KG.L\$CVC**3C;5^JL;K MI
IR/>#DEP7|J""Y"-G)%Y8E"(N'+-/8@RUWEM7|H76_*3#UD!C<+;3)64J;_M0"(4=.8;FV13|?5B7-X|MUJA88+1E
^2;%NG2L+.^(J<+3"JOR135&J?;_M(X?^~?GJFRV^1F54HWH!6R;RKK-1(\$@M*19IZ_(CB5BL+?4;C71=5#R7|HU
M2ME)TR11G2T13JG6EW3C@YX%UX5+=+G|C\$M#H;.*A^4R7281#@QVQ@QSAC=9;1_%M;BD(KH-S"6FB
154L)VGGT3P;1TWT*F4YM4X-R_4%K3>BHP^CNIER7X|W+ M|6O=W4 M2_W1TX|=^8=6"WE@BL@5L%ZG;
(GF5WO)WIM&-%Q4ZED/M9K;11R'Y_&1.SC MJ3JE1.9925>=U8%;D 1+;L.C3#_MZFFG|ARKUQ|HTSC|Q05Q M%._+
E)N""5=^XQ1"EU51*1Y4*\$U)68P<;3R""D5#FFRSX/T;XIQ*HF M;")O0L"RT.REL#P|MY MZ)GS-
MK;FBA;P4CG>97>N#ON9P)+3E7"(2;&+Z0_S!FQ;O4FUH13;.%<1^F=D_.L(OH.C M=);7BUG1?
MRU5|HE3O>_4H&C?F;1)+B#6A)HN<63?%;1A7&-(3*\$7*1E% M2.SB\$RZA^(1O_!ZLC6|>1*5'!<"LCM*M_P|R;DAN?
&)=YV&V#FB#PF;\$F M_1CF48;\$U/!(YA+;_BMTVF9O;:HJ1HT*)RCRX_\$F*70U677RC M9=LT|0U8O;4D"|
LVX5/3YUO^AV1=>6HT^91/LL&1 MBZ@AXI6R(IQS^17JDF6IU9DA<4;#H3!>W;~8X4^F;2D/39+;"WA".EF#^\$
M/OGX/9E(8F6*L)J^ZVRLY5SLK0QCGU5=G2IR;_D.CBXLWPI7GS.C|35&W>F M/S#MQX%V;.&;R;PHB)Y"YSTA<;W5Z)-
#R=T&)Z>'D5L#(1ES;_MF.+8;U|7 MK=7UXB8E?"Q3PI+CO^BR0=\$|CA\$M&AF;.O?\$?RKXFLKKDWT+)N14?
P)GD#U M/AY;ON5P>=6K5;4@'C"1R(\$S0_/&ZBF8GTWU4#9=52IV;#00R5/K@AC|42! M=%1TWO?
55C_@O92DY^1^4@!F\$+V^RPQ;H'W/Z;0.U/C|G#E;/552=Q;4'B ML_O=Q\$MG?I'>V10Y M2E?4>91@DM|?
=TVUT(CP8;"^Z#B\$+<&C.5MMK9T?X)WE^98B-L#<Q)E4L(_;HK/+MP*M_V><+1SU41MML7|E!8S.N5/L M;IF>?
>*)C^JH^CG7/T\$Y1|"%QT^GPJ;IE10BB;)G|~9@05SUZQK;B/2.M(#F MT@%M\$1T?;KA;W|%/ILGKTP^OTIKIP;Q145YE1&
<T(I.U.PU?CQ&ST9O%2D2H&.T^+&5_M4PW^TR|92_Y4N00;IH>1\$1Q9X19;9^E%Z;#H%#%&+UE%1Y009MB4*
|RI&^M?>01UUV^IH(2A(OY%1989^92IR*5_7RIH/AZ;GR;1;4 A(CY?2PJT^9TFW(M|LQ;GWH|RC<%4VN*O&?
HG@J.^QU!VI(B@B0<#ZKI0T).%?H/GUBO"90OOD* M;W@ X#REOE/1Y(SOR?9|XD;F6*50#CMFT1;ANI/NX|
(2NXEX1LYA>3S^RFU0 MC<^4(V#4(TOCU"-WIC|S&CIYWG42S*P5VU+FJ6)1HW\$0*MW8;R3HJ|HST M-
_SJ2GR;H*"LU8ZISC008;R?Z|46H19&X?HK?2Y)8Y-MJ% M;1)7XY6UIK<%=LPO5!#\$.*#@;PK3/0IP_*&
Z7=UAV^;1X;314T(710.(MGA<1=DMZ8J|0;?E&(6H&O)Y1;14ASPMJ\$Q8?%191M^5R99"9.VZ|++1;4UB M|&HLPO4_#
P"|3&R.0L.V.2O;1LT3^94C%PNR(C%#8Q8L+;GURPWDDL%\$S MMLGIS7\$E/Q|C)0UVU>"8|O;A"
1=T6U^72VH+C=63;1Q7KJSU^%05.\$ATX
M820?|F|MA^RMPBK%8(&V+&LFE.EE<&+HJZJB|NV1-8!5**;3CK3&=;V_B8=\$*XO\$2!^Z1YP-SCO;^E
M|NHZE;1\$2L+>>MFU_~3HN_O+1^9*QDNFMUT.+AM!Z@P\$>6)H-FVS<:2K83Y MYG#G%1H68_~IKC"P+;
<2"1OY^H^Y\$XD;BP/BEY+9+UQRGTGK|L^?OGK|M M)+K*FAU9Q_UWQ/3Q^6--C?%G|;XH M!^6#4K
&@Y!&@D/JI<9;3NE/EF(3U(ZX)\$#. MZ_)R5PG;DR;WM3&\$LVD0*JLF|9LJ%P;X;+H3K>|L#8N2V|";9*.)3F\$>G+I
7G6"TC)! MAK;B#U+1/FZ#;5V2YG1_A O|_OY"PIA3TO%AR4588I+" SN;ZO)D!3=J|P MBD&3JE%
<2P8)*21\$S%#*9.9X^\$5.)>JH_15_(HGR?SD;)S;1DHMMNXI@9 M@H_~OIG9AZ
O9C1DK*WP=NG@R""ZMU5I|=;2HKX\$*H*33;?='FOH8.VRO M7;WXT;KW-U;=C)US)Y+
<7%"38S>)/I@3NH;.#\$)CNP<@!3>2+T=-11W4R(C_MLTK^F^5?/I-(8;D;HT@VJ.2Y*ADCQ;??)D>LI-O2
U";4IFY|*)|69*;;_M RX8;K=(DOQV5""#U;@;6=-RFJ6LR4T>S_*ZOYDM;"(^N^E^WQ=//WRBR^G
M?UX(UV6R"RZDH1R^H2\$?!.^R;-C^0JK*~;_UL;XI&OK= "9M48;FMI'9=1 M9JL'M_7 M
B;EJH!&83JAEY)|2BR7<(&O|F)^%M=S MYK0&(*3B<@P886|\$&?;
HV;FS.*#8;KW;S93\$SU!@;8(((<H18R>&_@1P!"I5;"U*P|O=(=[PIZ!@'8|P.^B*;FDH55@"CH M%L.XEMT6C&SD;1!;?
\$8F)0JHH7T7&X"A"G-2+R"?+1%1(GA.C M!_PRZIWX\$J9JY.BP^FK7+\$@QQV>G2_1.4;2G"N17_5RW(*A-P MN%
I@EVRP M2|9PE^Q;L\$E|01&/7UUE_ELB;XJ;7<#;W5F4(7BH_OTCV4(^H&/60(8+>=

MA)FE/QRPDOB7VS7C6.7K0=.T#L 5N M'<(-\8:GBIF-0.ZA08N9P9^.1Z4KF6QJ/W%G37/:CDF:HHH0TCPL
M0/YQ)JZ2YF"AI?F&%+RO#220&G6)/I=9U6>%FK69O2PV+.\ZBV:U2 M#33:W*N=0%56_E+W/ZC.GJ/12>J.
<\$(L2=5FF\^@6@S+LC+::@0;X)P=RF- MG/B^7L6M[30<-MA"5652SH?
QIW2_%U4%D8B02^9AI"4(*YPP;T\K\W^X\70 M""&+I;=R@54Y[HJ\$Y22\$0WN2H%<.! =EYDR;!
2JA6YF\$BMOQ(J\HUOL1;-O9 M%&*7K*O@"A4E\HKA=@/I2I@JA MWH+ R7#% 991P\B+G;7S03ETCMN+APT?
(%4H=-9LIX6)Y\1I(E&SB)T\DR3YD*C5\NYHY;9W P:C-TTXL5I&.7OY8S M0V)NB,OKJ>
(>XBQ:OX\$[HQP+=+O=IX,.BC\W 1X^7R\$,3YEX/T 1B@#-*38R M"&AVHXT H<;Z+%*%*FD1J=2V^N7*WWF""!
M4XK!;C/I-O"/@G@UFFAH\H4;44SR\H28B1M\F-Y* @Z*Z*J,3Z"S08BR M>+ 'K>CCPZ\$Y87%;M95=NKJ1A&)0>:-
@E8TMM0-%SBHUWW7QA1+Q3\5GBU 7\ M<2CEX0FAEUSN:E7QIGU#KGW?2I""8ROV; Z"(=E9241!FL+F/Z+-
+CBL:3 MC4A=@%Z""+"DR; Q;I^~^A:[16%DD^4S \UF"D3Y<7Q;G-J+IY2OL^04;G^
MU(H%3MS?:X<44K@:E\URA(V:B75L0,VC=H#ZES@+C9O?QS&\$P7Y"2H8IQ\$#X M*+!XUF*45=|
|I!@I:Z10GCCUY^FQV\WX%-J%I;Z+;HE;+199>PRJLHCS3(8I_ M0@M&)<=<=6# T.%RI+V+;D6O5U'N=?
\$H>2&ZYTNG^IH%0IC0I;&D\^/8@ MN!?:@.KY8O%34\$O=HCNM;J12BCWG73!P/HB.D1Y!;6HDLB[EH)P!=05W'D6>
MS"<.;FH;M;=*F\C41C\A2'2X\U?'*'.5#>OK9CA1\<&7G\$*XLP6GT\$ER@&YZ
MPZW_UT27D\^6;^+DDO2;ZY\I4=8(8O'A6%V\&ML;PI@CS-*;T&W0W/&Z)FO%(4QZ1;LVE*;\26ZE2>L[*3)&'I49H;IXO
MVCXI1>74+BB9 M425SXCN:9E^27A\+8+Z(M0>T*E*PBTW5753ZY_5Q_W2PPN?QDVH.LCM^6 M>A*T*8M%+
<6WAC:G7;%'UK'K"FY%#Y;%7#DS+;MC""8; B5JD\SCU7^+DLV/-I2_D4.TL<-X?OB".\$I'-%I>H3P_78@?..QR?E^-(F;I\RD
MFBNJQ?>@_QMH48I"IR"9IQ3DPE+VEA/-\CM6@BR0G;-D\IVR8SLZ%)HA.34 MLH?H9=C-!
(Z=EA=.*HI_4F9:=ZG8[3@G@6\$+MX9A7U4U>#<;JSQAI+?%?D M0Y\JO0B\6FHTP-MO);40@-P\$VK!T,KOC+\$N4A,F7:
HT)*D/H1E\$)2#JUE/I M\NU52;%MB=YXQ'KSX"/AZK0\$U4 6;&PFNOQ;3\$YWNB8MQP\I M?
JH5V>V:G62S2B50SV5\GDV*.IP7+526F:JPUZ@-F9=[*S%1T;=->6,^&QQ MU8M_4R.7%;V4D^A-
4IRL;JHYHPDELVI\I0*2\?0'1-,O"-Y&GJ=^GPU*QF MLL;-O Q\4@NK>K5A7OU0\XV^;FI.?8 QOO5V;V6.ZVR))8= M%I-
GQ17TM,JH05Q/2ZZ4VGVD*+'+Q+)C7-Y#3-Z>4TU\,M2>C5%EO<63GXZ M&_N)@1@=E;=.G11B52*_#8CPP9Z1
KTZ\9\^W-W^:7 M2...)\Z-&I>/W+-N736-6K=->IE\W;W\SI^E>|P_Y37C705@N_8 \31:UPA M4 M
!8;94'3T5/3.HU7MNQ1=8BE*0.00-<*I=%81_-H1N""5'CA-.*%=GPDY4N MAY;>5T/M(Z?3=-B?JH9('S9D%M?
6M1',56A@~WU\$*#F8:9-E\$K0Q4)_V\G M75CL41BCC\XZ/O-+4>TRMP-E&5+;I3_T=>'D7;0,6 M.ITG9S\O^JE@V+=-
<|*#K-BHJ\+>S0B K81+/JQ1ZJ;<8_Z@#@.JH"O@J?"EU6PRTJON0?09L.60T3R'VWRT8+TS%R\$
MME6)8.@0'ST2G11\$%)PNIWE#Y@#@8.S2AFA\GZS\+7RDG("VEM\$?Y/O3K MB<-N#V%
<9QRWM@EVHZ<./-UYR)D4#;1BINBINM (Z>'84;C15'38K/KT*|7 MP\$M<558FOT0;
HTP;=ZKW57\6(^8_+R#N:XRU;/+-1H8?RJT9C\0DU\!DZ8> M\$F35LK9\A&'Z)AKI+=*
(.6;R4=UO"T4;)POK07@#@A-%P&W?V;H(VI@PRC:E@VI-2^\$8V2DF'BJC
MF&;5I\$;%5W942JGM7OB))HOVA/_%OGU7IT*WDW16='=NC>\V+;".W^!#P0P-M# 4PI2:
I049Z142\LP5U\I%V.\\$R\A>CG1FW?;CA#F>+*1FBB'-S=|D49_P-S'%:TI(?((WL?LB3;)L/63:X=OV;C MA"
(HB)Y81~\IR%NU/9OE)I4I6958)7FDJRBG;46?ODI-G036DD#5?H?7S'-M.S\Y\Y\$Y33QSIS5Y;_.TDH\117'U-.A7WT
M(0(GR9-OTVK#M8'..*4*VL9\+1M;INT0\0EPVUZRFM0("^(=.=;PJG(CXVX M)#A)8DI&)P6%.K26^=338
:&ES)QQ46X#.EPN2NCIJ?R4"/HQ'9~OYVDW\^I\9FR)EY5BTO0 M9FX2.VTR9;U^"!P#R>I'ZULP3OD6LM;AZ?
%NQ8M_K)6O@P1@YE*O"#1.=,A MP(25'\$4 S;/_&YY^|!\$QPVG\G^ (EP/J/0.DIP5C(%;/7V7/LQUE46A2/2 MB>-J70-
P\$/'2Z1BNLSTA0%MA;@*Y2*>%K\G;-5\B@YC7/K*L41\5@RQ)J#4DQS#8\#OIZ;#
M42I8I=JZHM>0@IRN;J6\U*R#AAJ<-<%H5J\36R MCQ+<"3E;M.L\$EAC;BB\8Y4AI=S."GY?IN+K%>4_M;I\$K0'7R
MVD(I(06-%HVB&."*ETB>@@1ND#@L.VM*%O2,C\PPW28T>>@2 MOD5-K\I9<0<5O2TH>5%?I%R0O_.U22I9,E3\Z-
W^HEI)R2"ZP;7;|=M/Z5-M;\$_.93UFA;QN;|>OE#9+.W3DTJ*9Y/R*U7\LD=+ST%_7"HO'D'L\|#Q A
ML#N'.?DX7(0I+;G)M;G_6W<4&=IN>;O34Y8L5_,E%3HZG+JIL^0@I3' MVR07&#AIOL"JDC4S(D+I+H/DYB;
I"0.*#X0-U^V9D\55'>0+92V9 M)7W&D%\$*G5;OY\JMG9M@I'29X6B.%O1.6J'C>PHAGAH(RZG/%0\$M%Q28I-^
ML>+"N#+JHB54^2"C.18;SGD.5*;1XI=;%\$PX\C:S500%G3O;4\I\R27PWH/S MI\2PMJ3@0.UF<0MWW32SG6GZNI"
(4>)S'ABD@&8AVW=+SG&U\W+GWL1R1G M#SM\|&C?VM7#.N17@:62#PSBO\$?I"@G4\5&/%KM<|ZU3<;
I8NTJ*IMV7U56 M +UI2;I\VXQP?B;+IK3LD0=U\?TM.FMS+O;;B7B1#KW4KS@>BH7XD\$)@M M!>K= BZ'3*"DKI5
@#JW\T_43%9KQJ^@;HKVIRLFH\YS^E I3T:T&6EI/%% MQ%WFR(E&XTI4@2^Q2_+;#S)O6'7I-"
I/C\JN32VU9;%C.9B<;8V(.8E;>A@2Y M-DE6A4.I<%45N;J1M&E?)>42Y;J1\$A:Z%1J\$7ZK*TN-5KTG:47L6^222J/3! M*8-
#M;FK;>'HAJ0,MR+2NH@)0FO'G56)\-I MY/^R\Z\<1Q'NO#W^A4=?NT35)P&#(I\W;|<1\$E9M\$632U"K\?ERHC'3 \39
MTSVG+P#*O_-I:U567P"0\$BF8F(A=BP\FENN2E967)Y_TP#B%Z%L\%A6&J%FS M\0/I'TF4CM@))PI#26TV?4#;I&?
Q'0SFE*Z 0\H=^~^I^<)CLAIZ*&^7677\$H M"F\I\>5V5O;J;[39\^P=#I;RN=8P/I-[&9<'TUXJ"M%*6>H;99TBRN##L-!;
M9NH(8X.#AX1-R;U_&(S'G\W5+A"B\BEXT;_ \$YUNU#-#>#O9R6N>\$UI+=DY>
MHC%N*A%ICY6L68U\$[Q7\I"Y7#OR#L;ID\ (F(C%FVZ\#@TTZ M6=8.B((-9 ^LT5M70+[W7U^]?H9Z#RX'OD(+
N\H>"9T.=RK5WN>UB5X) \$I MD8W&2Z6&K252R\@0\D7MH1C;HE%P5;=55^RI@DMN4X.JQDIVF<I@Y"T6&UXW
M?MS2R0.KKOCFZ C4XXJ5MU2P2T;+S@=#/^!R.SO#1;I\$N;-2C6+V4\<1 @ MG;"5&QI'2
^S8D_PH<.GQ!.=X07M4X+%RR B@0N(M2@PFMO*0_&Z<(X8Y-!&W9CK#X 7-GM@@.ZGEQ6G3F-PF4Y)\-
MAJ56P\TVAPQ1#AI45.(T>S;\#8.ZX0.1%4P47\|@Z 8^*D;R.>MEX9<4E8*>Z MU#@./O\4